primaryid,drugname,pt,outc_cod
160821476,Infliximab,Skin infection,OT
160821476,Infliximab,Sinusitis,OT
160821476,Infliximab,Pain,OT
160821476,Infliximab,Off label use,OT
160821476,Infliximab,Joint swelling,OT
160821476,Infliximab,Incorrect dose administered,OT
160821476,Infliximab,Hypertension,OT
160821476,Infliximab,Gait disturbance,OT
160821476,Infliximab,Condition aggravated,OT
160821476,Infliximab,Bronchitis,OT
160821476,Infliximab,Blood pressure increased,OT
160821476,Infliximab,Blood pressure fluctuation,OT
160821476,Infliximab,Animal bite,OT
160821476,Infliximab,Abdominal abscess,OT
160821476,Infliximab,Skin infection,OT
160821476,Infliximab,Sinusitis,OT
160821476,Infliximab,Pain,OT
160821476,Infliximab,Off label use,OT
160821476,Infliximab,Joint swelling,OT
160821476,Infliximab,Incorrect dose administered,OT
160821476,Infliximab,Hypertension,OT
160821476,Infliximab,Gait disturbance,OT
160821476,Infliximab,Condition aggravated,OT
160821476,Infliximab,Bronchitis,OT
160821476,Infliximab,Blood pressure increased,OT
160821476,Infliximab,Blood pressure fluctuation,OT
160821476,Infliximab,Animal bite,OT
160821476,Infliximab,Abdominal abscess,OT
160821476,Infliximab,Skin infection,OT
160821476,Infliximab,Sinusitis,OT
160821476,Infliximab,Pain,OT
160821476,Infliximab,Off label use,OT
160821476,Infliximab,Joint swelling,OT
160821476,Infliximab,Incorrect dose administered,OT
160821476,Infliximab,Hypertension,OT
160821476,Infliximab,Gait disturbance,OT
160821476,Infliximab,Condition aggravated,OT
160821476,Infliximab,Bronchitis,OT
160821476,Infliximab,Blood pressure increased,OT
160821476,Infliximab,Blood pressure fluctuation,OT
160821476,Infliximab,Animal bite,OT
160821476,Infliximab,Abdominal abscess,OT
160821476,Infliximab,Skin infection,OT
160821476,Infliximab,Sinusitis,OT
160821476,Infliximab,Pain,OT
160821476,Infliximab,Off label use,OT
160821476,Infliximab,Joint swelling,OT
160821476,Infliximab,Incorrect dose administered,OT
160821476,Infliximab,Hypertension,OT
160821476,Infliximab,Gait disturbance,OT
160821476,Infliximab,Condition aggravated,OT
160821476,Infliximab,Bronchitis,OT
160821476,Infliximab,Blood pressure increased,OT
160821476,Infliximab,Blood pressure fluctuation,OT
160821476,Infliximab,Animal bite,OT
160821476,Infliximab,Abdominal abscess,OT
166888634,Infliximab,Weight increased,OT
166888634,Infliximab,Urticaria,OT
166888634,Infliximab,Tracheobronchitis,OT
166888634,Infliximab,Rhinorrhoea,OT
166888634,Infliximab,Rectal haemorrhage,OT
166888634,Infliximab,Pyrexia,OT
166888634,Infliximab,Productive cough,OT
166888634,Infliximab,Product use issue,OT
166888634,Infliximab,Oropharyngeal pain,OT
166888634,Infliximab,Off label use,OT
166888634,Infliximab,Nasopharyngitis,OT
166888634,Infliximab,Nasal congestion,OT
166888634,Infliximab,Malaise,OT
166888634,Infliximab,Labyrinthitis,OT
166888634,Infliximab,Influenza,OT
166888634,Infliximab,Heart rate increased,OT
166888634,Infliximab,Headache,OT
166888634,Infliximab,Haemoglobin decreased,OT
166888634,Infliximab,Faeces soft,OT
166888634,Infliximab,Erythema,OT
166888634,Infliximab,Ecchymosis,OT
166888634,Infliximab,Dyspnoea,OT
166888634,Infliximab,Drug ineffective,OT
166888634,Infliximab,Diarrhoea,OT
166888634,Infliximab,Cough,OT
166888634,Infliximab,Condition aggravated,OT
166888634,Infliximab,COVID-19,OT
166888634,Infliximab,Blood pressure increased,OT
166888634,Infliximab,Blood pressure fluctuation,OT
166888634,Infliximab,Weight increased,OT
166888634,Infliximab,Urticaria,OT
166888634,Infliximab,Tracheobronchitis,OT
166888634,Infliximab,Rhinorrhoea,OT
166888634,Infliximab,Rectal haemorrhage,OT
166888634,Infliximab,Pyrexia,OT
166888634,Infliximab,Productive cough,OT
166888634,Infliximab,Product use issue,OT
166888634,Infliximab,Oropharyngeal pain,OT
166888634,Infliximab,Off label use,OT
166888634,Infliximab,Nasopharyngitis,OT
166888634,Infliximab,Nasal congestion,OT
166888634,Infliximab,Malaise,OT
166888634,Infliximab,Labyrinthitis,OT
166888634,Infliximab,Influenza,OT
166888634,Infliximab,Heart rate increased,OT
166888634,Infliximab,Headache,OT
166888634,Infliximab,Haemoglobin decreased,OT
166888634,Infliximab,Faeces soft,OT
166888634,Infliximab,Erythema,OT
166888634,Infliximab,Ecchymosis,OT
166888634,Infliximab,Dyspnoea,OT
166888634,Infliximab,Drug ineffective,OT
166888634,Infliximab,Diarrhoea,OT
166888634,Infliximab,Cough,OT
166888634,Infliximab,Condition aggravated,OT
166888634,Infliximab,COVID-19,OT
166888634,Infliximab,Blood pressure increased,OT
166888634,Infliximab,Blood pressure fluctuation,OT
166924285,Infliximab,Toothache,OT
166924285,Infliximab,Therapeutic response shortened,OT
166924285,Infliximab,Skin disorder,OT
166924285,Infliximab,Rash papular,OT
166924285,Infliximab,Rash,OT
166924285,Infliximab,Product use issue,OT
166924285,Infliximab,Pain in extremity,OT
166924285,Infliximab,Off label use,OT
166924285,Infliximab,Nervousness,OT
166924285,Infliximab,Muscle swelling,OT
166924285,Infliximab,Liver function test increased,OT
166924285,Infliximab,Limb injury,OT
166924285,Infliximab,Intentional product use issue,OT
166924285,Infliximab,Incorrect dose administered,OT
166924285,Infliximab,Inappropriate schedule of product administration,OT
166924285,Infliximab,Hepatitis C,OT
166924285,Infliximab,Heart rate irregular,OT
166924285,Infliximab,Heart rate increased,OT
166924285,Infliximab,Headache,OT
166924285,Infliximab,Fatigue,OT
166924285,Infliximab,Fall,OT
166924285,Infliximab,Drug level decreased,OT
166924285,Infliximab,Drug ineffective,OT
166924285,Infliximab,Condition aggravated,OT
166924285,Infliximab,Burning sensation,OT
166924285,Infliximab,Bone swelling,OT
166924285,Infliximab,Blood pressure fluctuation,OT
166924285,Infliximab,Abdominal pain,OT
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Respiratory failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Pharyngitis,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Haemorrhoids,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Disease recurrence,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Cardiac failure,HO
167830657,Infliximab BS for I.V. Infusion100 mg [NK],Back pain,HO
168388644,Infliximab,Treatment failure,OT
168388644,Infliximab,Pneumonia,OT
168388644,Infliximab,Off label use,OT
168388644,Infliximab,Joint swelling,OT
168388644,Infliximab,Hypersensitivity,OT
168388644,Infliximab,Drug ineffective,OT
168388644,Infliximab,Contraindicated product administered,OT
168388644,Infliximab,C-reactive protein increased,OT
168879615,Infliximab,Weight increased,HO
168879615,Infliximab,Vomiting,HO
168879615,Infliximab,Urinary tract infection,HO
168879615,Infliximab,Somnolence,HO
168879615,Infliximab,Pain in extremity,HO
168879615,Infliximab,Pain,HO
168879615,Infliximab,Off label use,HO
168879615,Infliximab,Nerve compression,HO
168879615,Infliximab,Nausea,HO
168879615,Infliximab,Nasopharyngitis,HO
168879615,Infliximab,Malaise,HO
168879615,Infliximab,Incorrect dose administered,HO
168879615,Infliximab,Inappropriate schedule of product administration,HO
168879615,Infliximab,Hunger,HO
168879615,Infliximab,Heart rate irregular,HO
168879615,Infliximab,Feeling abnormal,HO
168879615,Infliximab,Fear of injection,HO
168879615,Infliximab,Fatigue,HO
168879615,Infliximab,Drug ineffective,HO
168879615,Infliximab,Depression,HO
168879615,Infliximab,Condition aggravated,HO
168879615,Infliximab,Blood pressure fluctuation,HO
168879615,Infliximab,Arthralgia,HO
168879615,Infliximab,Anxiety,HO
174110964,Infliximab,Sinusitis,HO
174110964,Infliximab,Rhinorrhoea,HO
174110964,Infliximab,Nasopharyngitis,HO
174110964,Infliximab,Nasal congestion,HO
174110964,Infliximab,Maternal exposure during pregnancy,HO
174110964,Infliximab,Malaise,HO
174110964,Infliximab,Iron deficiency,HO
174110964,Infliximab,Inappropriate schedule of product administration,HO
174110964,Infliximab,Hypersomnia,HO
174110964,Infliximab,Headache,HO
174110964,Infliximab,Fatigue,HO
174110964,Infliximab,Cough,HO
174110964,Infliximab,Condition aggravated,HO
174110964,Infliximab,Colitis ulcerative,HO
174110964,Infliximab,Chest pain,HO
174110964,Infliximab,Anaemia,HO
174779382,Infliximab,Therapeutic product effect incomplete,OT
174779382,Infliximab,Pyrexia,OT
174779382,Infliximab,Product use issue,OT
174779382,Infliximab,Off label use,OT
174779382,Infliximab,Nausea,OT
174779382,Infliximab,Migraine,OT
174779382,Infliximab,Haematochezia,OT
174779382,Infliximab,Feeling abnormal,OT
174779382,Infliximab,Fatigue,OT
174779382,Infliximab,Condition aggravated,OT
176209023,Infliximab,Tremor,OT
176209023,Infliximab,Therapeutic response shortened,OT
176209023,Infliximab,Sputum discoloured,OT
176209023,Infliximab,Sinusitis,OT
176209023,Infliximab,Rhinorrhoea,OT
176209023,Infliximab,Pulmonary congestion,OT
176209023,Infliximab,Productive cough,OT
176209023,Infliximab,Off label use,OT
176209023,Infliximab,Nausea,OT
176209023,Infliximab,Nasopharyngitis,OT
176209023,Infliximab,Nasal congestion,OT
176209023,Infliximab,Muscular weakness,OT
176209023,Infliximab,Malaise,OT
176209023,Infliximab,Jaundice,OT
176209023,Infliximab,Intentional product use issue,OT
176209023,Infliximab,Influenza,OT
176209023,Infliximab,Inappropriate schedule of product administration,OT
176209023,Infliximab,Hyperhidrosis,OT
176209023,Infliximab,Hot flush,OT
176209023,Infliximab,Headache,OT
176209023,Infliximab,Gastroenteritis,OT
176209023,Infliximab,Fibromyalgia,OT
176209023,Infliximab,Feeling hot,OT
176209023,Infliximab,Fatigue,OT
176209023,Infliximab,Dizziness,OT
176209023,Infliximab,Discomfort,OT
176209023,Infliximab,Decreased appetite,OT
176209023,Infliximab,Condition aggravated,OT
176209023,Infliximab,Body temperature decreased,OT
176209023,Infliximab,Blood pressure fluctuation,OT
176209023,Infliximab,Arthralgia,OT
176209023,Infliximab,Tremor,OT
176209023,Infliximab,Therapeutic response shortened,OT
176209023,Infliximab,Sputum discoloured,OT
176209023,Infliximab,Sinusitis,OT
176209023,Infliximab,Rhinorrhoea,OT
176209023,Infliximab,Pulmonary congestion,OT
176209023,Infliximab,Productive cough,OT
176209023,Infliximab,Off label use,OT
176209023,Infliximab,Nausea,OT
176209023,Infliximab,Nasopharyngitis,OT
176209023,Infliximab,Nasal congestion,OT
176209023,Infliximab,Muscular weakness,OT
176209023,Infliximab,Malaise,OT
176209023,Infliximab,Jaundice,OT
176209023,Infliximab,Intentional product use issue,OT
176209023,Infliximab,Influenza,OT
176209023,Infliximab,Inappropriate schedule of product administration,OT
176209023,Infliximab,Hyperhidrosis,OT
176209023,Infliximab,Hot flush,OT
176209023,Infliximab,Headache,OT
176209023,Infliximab,Gastroenteritis,OT
176209023,Infliximab,Fibromyalgia,OT
176209023,Infliximab,Feeling hot,OT
176209023,Infliximab,Fatigue,OT
176209023,Infliximab,Dizziness,OT
176209023,Infliximab,Discomfort,OT
176209023,Infliximab,Decreased appetite,OT
176209023,Infliximab,Condition aggravated,OT
176209023,Infliximab,Body temperature decreased,OT
176209023,Infliximab,Blood pressure fluctuation,OT
176209023,Infliximab,Arthralgia,OT
176327455,Infliximab,Weight decreased,OT
176327455,Infliximab,Vomiting,OT
176327455,Infliximab,Rectal haemorrhage,OT
176327455,Infliximab,Product use issue,OT
176327455,Infliximab,Off label use,OT
176327455,Infliximab,Neutrophil count increased,OT
176327455,Infliximab,Nausea,OT
176327455,Infliximab,Nasopharyngitis,OT
176327455,Infliximab,Monocyte count increased,OT
176327455,Infliximab,Malaise,OT
176327455,Infliximab,Loss of consciousness,OT
176327455,Infliximab,Intentional product use issue,OT
176327455,Infliximab,Incorrect dose administered,OT
176327455,Infliximab,Inappropriate schedule of product administration,OT
176327455,Infliximab,Hyperhidrosis,OT
176327455,Infliximab,Heart rate decreased,OT
176327455,Infliximab,Gastrointestinal inflammation,OT
176327455,Infliximab,Feeding disorder,OT
176327455,Infliximab,Faecal calprotectin increased,OT
176327455,Infliximab,Dyspnoea,OT
176327455,Infliximab,Diarrhoea,OT
176327455,Infliximab,Condition aggravated,OT
176327455,Infliximab,C-reactive protein increased,OT
176327455,Infliximab,Arthralgia,OT
176327455,Infliximab,Anal fissure,OT
176327455,Infliximab,Abdominal pain,OT
176327455,Infliximab,Weight decreased,OT
176327455,Infliximab,Vomiting,OT
176327455,Infliximab,Rectal haemorrhage,OT
176327455,Infliximab,Product use issue,OT
176327455,Infliximab,Off label use,OT
176327455,Infliximab,Neutrophil count increased,OT
176327455,Infliximab,Nausea,OT
176327455,Infliximab,Nasopharyngitis,OT
176327455,Infliximab,Monocyte count increased,OT
176327455,Infliximab,Malaise,OT
176327455,Infliximab,Loss of consciousness,OT
176327455,Infliximab,Intentional product use issue,OT
176327455,Infliximab,Incorrect dose administered,OT
176327455,Infliximab,Inappropriate schedule of product administration,OT
176327455,Infliximab,Hyperhidrosis,OT
176327455,Infliximab,Heart rate decreased,OT
176327455,Infliximab,Gastrointestinal inflammation,OT
176327455,Infliximab,Feeding disorder,OT
176327455,Infliximab,Faecal calprotectin increased,OT
176327455,Infliximab,Dyspnoea,OT
176327455,Infliximab,Diarrhoea,OT
176327455,Infliximab,Condition aggravated,OT
176327455,Infliximab,C-reactive protein increased,OT
176327455,Infliximab,Arthralgia,OT
176327455,Infliximab,Anal fissure,OT
176327455,Infliximab,Abdominal pain,OT
176327455,Infliximab,Weight decreased,OT
176327455,Infliximab,Vomiting,OT
176327455,Infliximab,Rectal haemorrhage,OT
176327455,Infliximab,Product use issue,OT
176327455,Infliximab,Off label use,OT
176327455,Infliximab,Neutrophil count increased,OT
176327455,Infliximab,Nausea,OT
176327455,Infliximab,Nasopharyngitis,OT
176327455,Infliximab,Monocyte count increased,OT
176327455,Infliximab,Malaise,OT
176327455,Infliximab,Loss of consciousness,OT
176327455,Infliximab,Intentional product use issue,OT
176327455,Infliximab,Incorrect dose administered,OT
176327455,Infliximab,Inappropriate schedule of product administration,OT
176327455,Infliximab,Hyperhidrosis,OT
176327455,Infliximab,Heart rate decreased,OT
176327455,Infliximab,Gastrointestinal inflammation,OT
176327455,Infliximab,Feeding disorder,OT
176327455,Infliximab,Faecal calprotectin increased,OT
176327455,Infliximab,Dyspnoea,OT
176327455,Infliximab,Diarrhoea,OT
176327455,Infliximab,Condition aggravated,OT
176327455,Infliximab,C-reactive protein increased,OT
176327455,Infliximab,Arthralgia,OT
176327455,Infliximab,Anal fissure,OT
176327455,Infliximab,Abdominal pain,OT
177298515,Infliximab,Weight increased,HO
177298515,Infliximab,Weight increased,OT
177298515,Infliximab,Product use issue,HO
177298515,Infliximab,Product use issue,OT
177298515,Infliximab,Off label use,HO
177298515,Infliximab,Off label use,OT
177298515,Infliximab,Malaise,HO
177298515,Infliximab,Malaise,OT
177298515,Infliximab,Intentional product use issue,HO
177298515,Infliximab,Intentional product use issue,OT
177298515,Infliximab,Inappropriate schedule of product administration,HO
177298515,Infliximab,Inappropriate schedule of product administration,OT
177298515,Infliximab,Heart rate irregular,HO
177298515,Infliximab,Heart rate irregular,OT
177298515,Infliximab,Heart rate decreased,HO
177298515,Infliximab,Heart rate decreased,OT
177298515,Infliximab,Fall,HO
177298515,Infliximab,Fall,OT
177298515,Infliximab,Drug ineffective,HO
177298515,Infliximab,Drug ineffective,OT
177298515,Infliximab,Condition aggravated,HO
177298515,Infliximab,Condition aggravated,OT
177298515,Infliximab,Blood pressure fluctuation,HO
177298515,Infliximab,Blood pressure fluctuation,OT
177298515,Infliximab,Weight increased,HO
177298515,Infliximab,Weight increased,OT
177298515,Infliximab,Product use issue,HO
177298515,Infliximab,Product use issue,OT
177298515,Infliximab,Off label use,HO
177298515,Infliximab,Off label use,OT
177298515,Infliximab,Malaise,HO
177298515,Infliximab,Malaise,OT
177298515,Infliximab,Intentional product use issue,HO
177298515,Infliximab,Intentional product use issue,OT
177298515,Infliximab,Inappropriate schedule of product administration,HO
177298515,Infliximab,Inappropriate schedule of product administration,OT
177298515,Infliximab,Heart rate irregular,HO
177298515,Infliximab,Heart rate irregular,OT
177298515,Infliximab,Heart rate decreased,HO
177298515,Infliximab,Heart rate decreased,OT
177298515,Infliximab,Fall,HO
177298515,Infliximab,Fall,OT
177298515,Infliximab,Drug ineffective,HO
177298515,Infliximab,Drug ineffective,OT
177298515,Infliximab,Condition aggravated,HO
177298515,Infliximab,Condition aggravated,OT
177298515,Infliximab,Blood pressure fluctuation,HO
177298515,Infliximab,Blood pressure fluctuation,OT
177838103,Infliximab,Weight increased,OT
177838103,Infliximab,Weight decreased,OT
177838103,Infliximab,Rectal haemorrhage,OT
177838103,Infliximab,Rash,OT
177838103,Infliximab,Off label use,OT
177838103,Infliximab,Malaise,OT
177838103,Infliximab,Intentional product use issue,OT
177838103,Infliximab,Inappropriate schedule of product administration,OT
177838103,Infliximab,Illness,OT
177838103,Infliximab,Hypoaesthesia,OT
177838103,Infliximab,Hot flush,OT
177838103,Infliximab,Heart rate decreased,OT
177838103,Infliximab,Headache,OT
177838103,Infliximab,Fear of injection,OT
177838103,Infliximab,Erythema,OT
177838103,Infliximab,Condition aggravated,OT
177838103,Infliximab,Chest discomfort,OT
177838103,Infliximab,Body temperature increased,OT
177838103,Infliximab,Body temperature fluctuation,OT
177838103,Infliximab,Arthralgia,OT
178259114,Infliximab,Tremor,OT
178259114,Infliximab,Tooth disorder,OT
178259114,Infliximab,Syncope,OT
178259114,Infliximab,Suicidal ideation,OT
178259114,Infliximab,Sinusitis,OT
178259114,Infliximab,Respiration abnormal,OT
178259114,Infliximab,Presyncope,OT
178259114,Infliximab,Poor venous access,OT
178259114,Infliximab,Pain in jaw,OT
178259114,Infliximab,Pain,OT
178259114,Infliximab,Off label use,OT
178259114,Infliximab,Neurogenic shock,OT
178259114,Infliximab,Nervousness,OT
178259114,Infliximab,Nausea,OT
178259114,Infliximab,Nasopharyngitis,OT
178259114,Infliximab,Malaise,OT
178259114,Infliximab,Intentional product use issue,OT
178259114,Infliximab,Insomnia,OT
178259114,Infliximab,Infusion site pain,OT
178259114,Infliximab,Infusion site extravasation,OT
178259114,Infliximab,Influenza,OT
178259114,Infliximab,Inappropriate schedule of product administration,OT
178259114,Infliximab,Hypoacusis,OT
178259114,Infliximab,Hyperhidrosis,OT
178259114,Infliximab,Heart rate irregular,OT
178259114,Infliximab,Headache,OT
178259114,Infliximab,Feeling of body temperature change,OT
178259114,Infliximab,Fear of injection,OT
178259114,Infliximab,Fatigue,OT
178259114,Infliximab,Eustachian tube dysfunction,OT
178259114,Infliximab,Erythema,OT
178259114,Infliximab,Enteritis,OT
178259114,Infliximab,Eating disorder,OT
178259114,Infliximab,Ear pain,OT
178259114,Infliximab,Ear infection,OT
178259114,Infliximab,Ear discomfort,OT
178259114,Infliximab,Dyspnoea,OT
178259114,Infliximab,Drug specific antibody present,OT
178259114,Infliximab,Drug ineffective,OT
178259114,Infliximab,Dizziness,OT
178259114,Infliximab,Cough,OT
178259114,Infliximab,Confusional state,OT
178259114,Infliximab,Cognitive disorder,OT
178259114,Infliximab,Chills,OT
178259114,Infliximab,Burning sensation,OT
178259114,Infliximab,Bronchitis,OT
178259114,Infliximab,Body temperature increased,OT
178259114,Infliximab,Blood pressure fluctuation,OT
178259114,Infliximab,Blood pressure diastolic decreased,OT
178259114,Infliximab,Blood pressure decreased,OT
178259114,Infliximab,Balance disorder,OT
178259114,Infliximab,Arrhythmia,OT
178259114,Infliximab,Anxiety,OT
178259114,Infliximab,Anger,OT
178259114,Infliximab,Abnormal behaviour,OT
178259114,Infliximab,Abdominal pain,OT
178259114,Infliximab,Tremor,OT
178259114,Infliximab,Tooth disorder,OT
178259114,Infliximab,Syncope,OT
178259114,Infliximab,Suicidal ideation,OT
178259114,Infliximab,Sinusitis,OT
178259114,Infliximab,Respiration abnormal,OT
178259114,Infliximab,Presyncope,OT
178259114,Infliximab,Poor venous access,OT
178259114,Infliximab,Pain in jaw,OT
178259114,Infliximab,Pain,OT
178259114,Infliximab,Off label use,OT
178259114,Infliximab,Neurogenic shock,OT
178259114,Infliximab,Nervousness,OT
178259114,Infliximab,Nausea,OT
178259114,Infliximab,Nasopharyngitis,OT
178259114,Infliximab,Malaise,OT
178259114,Infliximab,Intentional product use issue,OT
178259114,Infliximab,Insomnia,OT
178259114,Infliximab,Infusion site pain,OT
178259114,Infliximab,Infusion site extravasation,OT
178259114,Infliximab,Influenza,OT
178259114,Infliximab,Inappropriate schedule of product administration,OT
178259114,Infliximab,Hypoacusis,OT
178259114,Infliximab,Hyperhidrosis,OT
178259114,Infliximab,Heart rate irregular,OT
178259114,Infliximab,Headache,OT
178259114,Infliximab,Feeling of body temperature change,OT
178259114,Infliximab,Fear of injection,OT
178259114,Infliximab,Fatigue,OT
178259114,Infliximab,Eustachian tube dysfunction,OT
178259114,Infliximab,Erythema,OT
178259114,Infliximab,Enteritis,OT
178259114,Infliximab,Eating disorder,OT
178259114,Infliximab,Ear pain,OT
178259114,Infliximab,Ear infection,OT
178259114,Infliximab,Ear discomfort,OT
178259114,Infliximab,Dyspnoea,OT
178259114,Infliximab,Drug specific antibody present,OT
178259114,Infliximab,Drug ineffective,OT
178259114,Infliximab,Dizziness,OT
178259114,Infliximab,Cough,OT
178259114,Infliximab,Confusional state,OT
178259114,Infliximab,Cognitive disorder,OT
178259114,Infliximab,Chills,OT
178259114,Infliximab,Burning sensation,OT
178259114,Infliximab,Bronchitis,OT
178259114,Infliximab,Body temperature increased,OT
178259114,Infliximab,Blood pressure fluctuation,OT
178259114,Infliximab,Blood pressure diastolic decreased,OT
178259114,Infliximab,Blood pressure decreased,OT
178259114,Infliximab,Balance disorder,OT
178259114,Infliximab,Arrhythmia,OT
178259114,Infliximab,Anxiety,OT
178259114,Infliximab,Anger,OT
178259114,Infliximab,Abnormal behaviour,OT
178259114,Infliximab,Abdominal pain,OT
1836411911,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
1836411911,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
1836411911,Infliximab Pfizer (Unknown),Frequent bowel movements,HO
1836411911,Infliximab Pfizer (Unknown),Frequent bowel movements,OT
1836411911,Infliximab Pfizer (Unknown),Decreased activity,HO
1836411911,Infliximab Pfizer (Unknown),Decreased activity,OT
1836411911,Infliximab Pfizer (Unknown),Colitis ulcerative,HO
1836411911,Infliximab Pfizer (Unknown),Colitis ulcerative,OT
1836411911,Infliximab Pfizer (Unknown),Colitis,HO
1836411911,Infliximab Pfizer (Unknown),Colitis,OT
183977842,Infliximab,Weight increased,OT
183977842,Infliximab,Visual impairment,OT
183977842,Infliximab,Underdose,OT
183977842,Infliximab,Off label use,OT
183977842,Infliximab,Nausea,OT
183977842,Infliximab,Nasopharyngitis,OT
183977842,Infliximab,Malaise,OT
183977842,Infliximab,Incorrect dose administered,OT
183977842,Infliximab,Inappropriate schedule of product administration,OT
183977842,Infliximab,Heart rate irregular,OT
183977842,Infliximab,Flushing,OT
183977842,Infliximab,Dizziness,OT
183977842,Infliximab,Diarrhoea,OT
183977842,Infliximab,Chest discomfort,OT
183977842,Infliximab,Abdominal pain,OT
183977842,Infliximab,Abdominal discomfort,OT
184124853,Infliximab,Weight increased,OT
184124853,Infliximab,Product use issue,OT
184124853,Infliximab,Pelvic inflammatory disease,OT
184124853,Infliximab,Off label use,OT
184124853,Infliximab,Intentional product use issue,OT
184124853,Infliximab,Condition aggravated,OT
184124853,Infliximab,Abscess,OT
184443804,Infliximab,Therapeutic response unexpected,OT
184443804,Infliximab,Off label use,OT
184443804,Infliximab,Intentional product misuse,OT
184443804,Infliximab,Drug ineffective,OT
184443804,Infliximab,Crohn's disease,OT
184582062,Infliximab,Interstitial lung disease,OT
187078282,Infliximab,Weight increased,OT
187078282,Infliximab,Weight decreased,OT
187078282,Infliximab,Off label use,OT
187078282,Infliximab,Lower gastrointestinal haemorrhage,OT
187078282,Infliximab,Intentional product use issue,OT
187078282,Infliximab,Fatigue,OT
187078282,Infliximab,Diarrhoea,OT
187078282,Infliximab,Condition aggravated,OT
187078282,Infliximab,Blood pressure increased,OT
187078282,Infliximab,Blood pressure fluctuation,OT
187078282,Infliximab,Abdominal pain,OT
187078282,Infliximab,Weight increased,OT
187078282,Infliximab,Weight decreased,OT
187078282,Infliximab,Off label use,OT
187078282,Infliximab,Lower gastrointestinal haemorrhage,OT
187078282,Infliximab,Intentional product use issue,OT
187078282,Infliximab,Fatigue,OT
187078282,Infliximab,Diarrhoea,OT
187078282,Infliximab,Condition aggravated,OT
187078282,Infliximab,Blood pressure increased,OT
187078282,Infliximab,Blood pressure fluctuation,OT
187078282,Infliximab,Abdominal pain,OT
187122602,Infliximab,Weight decreased,OT
187122602,Infliximab,Urticaria,OT
187122602,Infliximab,Pruritus,OT
187122602,Infliximab,Product use issue,OT
187122602,Infliximab,Off label use,OT
187122602,Infliximab,Inappropriate schedule of product administration,OT
187122602,Infliximab,Heart rate irregular,OT
187122602,Infliximab,Heart rate decreased,OT
187122602,Infliximab,Bronchitis,OT
187122602,Infliximab,Body temperature decreased,OT
187122602,Infliximab,Blood pressure increased,OT
187122602,Infliximab,Blood pressure fluctuation,OT
187122602,Infliximab,Weight decreased,OT
187122602,Infliximab,Urticaria,OT
187122602,Infliximab,Pruritus,OT
187122602,Infliximab,Product use issue,OT
187122602,Infliximab,Off label use,OT
187122602,Infliximab,Inappropriate schedule of product administration,OT
187122602,Infliximab,Heart rate irregular,OT
187122602,Infliximab,Heart rate decreased,OT
187122602,Infliximab,Bronchitis,OT
187122602,Infliximab,Body temperature decreased,OT
187122602,Infliximab,Blood pressure increased,OT
187122602,Infliximab,Blood pressure fluctuation,OT
192629842,Infliximab,Throat irritation,OT
192629842,Infliximab,Swollen tongue,OT
192629842,Infliximab,Lethargy,OT
192629842,Infliximab,Inappropriate schedule of product administration,OT
192629842,Infliximab,Headache,OT
192629842,Infliximab,Arthralgia,OT
193812362,Infliximab,Off label use,OT
193812362,Infliximab,Nephrolithiasis,OT
193812362,Infliximab,Intentional product use issue,OT
193812362,Infliximab,Inappropriate schedule of product administration,OT
193812362,Infliximab,Foot fracture,OT
193812362,Infliximab,Abdominal pain,OT
195010281,Infliximab,Drug ineffective,NULL
195024531,Infliximab,Syncope,OT
195578211,Infliximab,Type 2 diabetes mellitus,OT
195578211,Infliximab,Off label use,OT
195578211,Infliximab,Neoplasm malignant,OT
195578211,Infliximab,Intentional product use issue,OT
195578211,Infliximab,Condition aggravated,OT
195578211,Infliximab,COVID-19,OT
195578211,Infliximab,Blood pressure increased,OT
195578211,Infliximab,Type 2 diabetes mellitus,OT
195578211,Infliximab,Off label use,OT
195578211,Infliximab,Neoplasm malignant,OT
195578211,Infliximab,Intentional product use issue,OT
195578211,Infliximab,Condition aggravated,OT
195578211,Infliximab,COVID-19,OT
195578211,Infliximab,Blood pressure increased,OT
195856161,Infliximab,Vomiting,OT
195856161,Infliximab,Visual impairment,OT
195856161,Infliximab,Rectal haemorrhage,OT
195856161,Infliximab,Pyrexia,OT
195856161,Infliximab,Nausea,OT
195856161,Infliximab,Mucous stools,OT
195856161,Infliximab,Haematochezia,OT
195856161,Infliximab,Faecal volume decreased,OT
195856161,Infliximab,Constipation,OT
195856161,Infliximab,Blindness,OT
195856161,Infliximab,Abdominal pain,OT
195856161,Infliximab,Abdominal distension,OT
195856161,Infliximab,Vomiting,OT
195856161,Infliximab,Visual impairment,OT
195856161,Infliximab,Rectal haemorrhage,OT
195856161,Infliximab,Pyrexia,OT
195856161,Infliximab,Nausea,OT
195856161,Infliximab,Mucous stools,OT
195856161,Infliximab,Haematochezia,OT
195856161,Infliximab,Faecal volume decreased,OT
195856161,Infliximab,Constipation,OT
195856161,Infliximab,Blindness,OT
195856161,Infliximab,Abdominal pain,OT
195856161,Infliximab,Abdominal distension,OT
195856161,Infliximab,Vomiting,OT
195856161,Infliximab,Visual impairment,OT
195856161,Infliximab,Rectal haemorrhage,OT
195856161,Infliximab,Pyrexia,OT
195856161,Infliximab,Nausea,OT
195856161,Infliximab,Mucous stools,OT
195856161,Infliximab,Haematochezia,OT
195856161,Infliximab,Faecal volume decreased,OT
195856161,Infliximab,Constipation,OT
195856161,Infliximab,Blindness,OT
195856161,Infliximab,Abdominal pain,OT
195856161,Infliximab,Abdominal distension,OT
196149991,Infliximab,Weight increased,OT
196149991,Infliximab,Weight decreased,OT
196149991,Infliximab,Urticaria,OT
196149991,Infliximab,Tonsillitis,OT
196149991,Infliximab,Skin plaque,OT
196149991,Infliximab,Pruritus,OT
196149991,Infliximab,Off label use,OT
196149991,Infliximab,Nasopharyngitis,OT
196149991,Infliximab,Erythema,OT
196149991,Infliximab,Drug specific antibody present,OT
196149991,Infliximab,Drug level abnormal,OT
196149991,Infliximab,Cough,OT
196149991,Infliximab,Condition aggravated,OT
196149991,Infliximab,Asymptomatic COVID-19,OT
196149991,Infliximab,Anaemia,OT
196149991,Infliximab,Weight increased,OT
196149991,Infliximab,Weight decreased,OT
196149991,Infliximab,Urticaria,OT
196149991,Infliximab,Tonsillitis,OT
196149991,Infliximab,Skin plaque,OT
196149991,Infliximab,Pruritus,OT
196149991,Infliximab,Off label use,OT
196149991,Infliximab,Nasopharyngitis,OT
196149991,Infliximab,Erythema,OT
196149991,Infliximab,Drug specific antibody present,OT
196149991,Infliximab,Drug level abnormal,OT
196149991,Infliximab,Cough,OT
196149991,Infliximab,Condition aggravated,OT
196149991,Infliximab,Asymptomatic COVID-19,OT
196149991,Infliximab,Anaemia,OT
196664362,Infliximab,Therapy non-responder,HO
196664362,Infliximab,Therapy non-responder,OT
196664362,Infliximab,Pyrexia,HO
196664362,Infliximab,Pyrexia,OT
196664362,Infliximab,Product use in unapproved indication,HO
196664362,Infliximab,Product use in unapproved indication,OT
196664362,Infliximab,Pneumonia,HO
196664362,Infliximab,Pneumonia,OT
196664362,Infliximab,Off label use,HO
196664362,Infliximab,Off label use,OT
196664362,Infliximab,Musculoskeletal pain,HO
196664362,Infliximab,Musculoskeletal pain,OT
196664362,Infliximab,Drug hypersensitivity,HO
196664362,Infliximab,Drug hypersensitivity,OT
196664362,Infliximab,Autoimmune hepatitis,HO
196664362,Infliximab,Autoimmune hepatitis,OT
196664362,Infliximab,Therapy non-responder,HO
196664362,Infliximab,Therapy non-responder,OT
196664362,Infliximab,Pyrexia,HO
196664362,Infliximab,Pyrexia,OT
196664362,Infliximab,Product use in unapproved indication,HO
196664362,Infliximab,Product use in unapproved indication,OT
196664362,Infliximab,Pneumonia,HO
196664362,Infliximab,Pneumonia,OT
196664362,Infliximab,Off label use,HO
196664362,Infliximab,Off label use,OT
196664362,Infliximab,Musculoskeletal pain,HO
196664362,Infliximab,Musculoskeletal pain,OT
196664362,Infliximab,Drug hypersensitivity,HO
196664362,Infliximab,Drug hypersensitivity,OT
196664362,Infliximab,Autoimmune hepatitis,HO
196664362,Infliximab,Autoimmune hepatitis,OT
196780872,Infliximab (Unknown),Underdose,OT
196780872,Infliximab (Unknown),Joint swelling,OT
197323861,Infliximab,Off label use,HO
197323861,Infliximab,Off label use,OT
197323861,Infliximab,Leukoencephalopathy,HO
197323861,Infliximab,Leukoencephalopathy,OT
197323861,Infliximab,Enlarged cerebral perivascular spaces,HO
197323861,Infliximab,Enlarged cerebral perivascular spaces,OT
197323861,Infliximab,Coronary artery stenosis,HO
197323861,Infliximab,Coronary artery stenosis,OT
197323861,Infliximab,Cerebral microhaemorrhage,HO
197323861,Infliximab,Cerebral microhaemorrhage,OT
197323861,Infliximab,Cardiac perfusion defect,HO
197323861,Infliximab,Cardiac perfusion defect,OT
197323861,Infliximab,Off label use,HO
197323861,Infliximab,Off label use,OT
197323861,Infliximab,Leukoencephalopathy,HO
197323861,Infliximab,Leukoencephalopathy,OT
197323861,Infliximab,Enlarged cerebral perivascular spaces,HO
197323861,Infliximab,Enlarged cerebral perivascular spaces,OT
197323861,Infliximab,Coronary artery stenosis,HO
197323861,Infliximab,Coronary artery stenosis,OT
197323861,Infliximab,Cerebral microhaemorrhage,HO
197323861,Infliximab,Cerebral microhaemorrhage,OT
197323861,Infliximab,Cardiac perfusion defect,HO
197323861,Infliximab,Cardiac perfusion defect,OT
197417941,Infliximab,Product use issue,OT
197417941,Infliximab,Loss of therapeutic response,OT
197417941,Infliximab,Colitis ulcerative,OT
197535051,Infliximab,Therapeutic response shortened,OT
197535051,Infliximab,Off label use,OT
197535051,Infliximab,Fatigue,OT
197535051,Infliximab,Disease recurrence,OT
197535051,Infliximab,Crohn's disease,OT
197535051,Infliximab,Condition aggravated,OT
197535051,Infliximab,Blood pressure increased,OT
197535051,Infliximab,Abdominal distension,OT
197576191,Infliximab,Weight increased,OT
197576191,Infliximab,Visual impairment,OT
197576191,Infliximab,Oxygen saturation decreased,OT
197576191,Infliximab,Off label use,OT
197576191,Infliximab,Intentional product use issue,OT
197576191,Infliximab,Hypotension,OT
197576191,Infliximab,Hypoaesthesia,OT
197576191,Infliximab,Haemorrhage,OT
197576191,Infliximab,Feeling hot,OT
197576191,Infliximab,Erythema,OT
197576191,Infliximab,Drug specific antibody present,OT
197576191,Infliximab,Drug level decreased,OT
197576191,Infliximab,Dizziness,OT
197576191,Infliximab,Blood pressure fluctuation,OT
197718001,Infliximab,Wrong technique in product usage process,HO
197718001,Infliximab,Wrong technique in product usage process,OT
197718001,Infliximab,Weight increased,HO
197718001,Infliximab,Weight increased,OT
197718001,Infliximab,Throat tightness,HO
197718001,Infliximab,Throat tightness,OT
197718001,Infliximab,Therapeutic product effect incomplete,HO
197718001,Infliximab,Therapeutic product effect incomplete,OT
197718001,Infliximab,Rash erythematous,HO
197718001,Infliximab,Rash erythematous,OT
197718001,Infliximab,Quality of life decreased,HO
197718001,Infliximab,Quality of life decreased,OT
197718001,Infliximab,Pruritus,HO
197718001,Infliximab,Pruritus,OT
197718001,Infliximab,Mucous stools,HO
197718001,Infliximab,Mucous stools,OT
197718001,Infliximab,Incorrect drug administration rate,HO
197718001,Infliximab,Incorrect drug administration rate,OT
197718001,Infliximab,Haematochezia,HO
197718001,Infliximab,Haematochezia,OT
197718001,Infliximab,Fatigue,HO
197718001,Infliximab,Fatigue,OT
197718001,Infliximab,Dysphonia,HO
197718001,Infliximab,Dysphonia,OT
197718001,Infliximab,Constipation,HO
197718001,Infliximab,Constipation,OT
197718001,Infliximab,Condition aggravated,HO
197718001,Infliximab,Condition aggravated,OT
197718001,Infliximab,Back pain,HO
197718001,Infliximab,Back pain,OT
197718001,Infliximab,Anal incontinence,HO
197718001,Infliximab,Anal incontinence,OT
197718001,Infliximab,Abdominal pain lower,HO
197718001,Infliximab,Abdominal pain lower,OT
197718001,Infliximab,Abdominal pain,HO
197718001,Infliximab,Abdominal pain,OT
198089151,Infliximab,Vomiting,OT
198089151,Infliximab,Pyrexia,OT
198089151,Infliximab,Overdose,OT
198089151,Infliximab,Off label use,OT
198089151,Infliximab,Hepatocellular carcinoma,OT
198089151,Infliximab,Diarrhoea,OT
198286451,Infliximab,Ileus,HO
198286451,Infliximab,Ileus,OT
198397791,Infliximab,Off label use,OT
198397791,Infliximab,Intentional product use issue,OT
198397791,Infliximab,Eyelid cyst,OT
198397791,Infliximab,Cardiac disorder,OT
198623071,Infliximab,Rhinorrhoea,OT
198623071,Infliximab,Off label use,OT
198623071,Infliximab,Cough,OT
198623071,Infliximab,COVID-19,OT
198643851,Infliximab,Weight increased,OT
198643851,Infliximab,Incorrect dose administered,OT
198729641,Infliximab,Weight increased,OT
198729641,Infliximab,Otitis externa,OT
198729641,Infliximab,Off label use,OT
198729641,Infliximab,Intentional product use issue,OT
198729641,Infliximab,Injury associated with device,OT
198729641,Infliximab,Condition aggravated,OT
198729641,Infliximab,Blood pressure increased,OT
198729641,Infliximab,Arthralgia,OT
198882081,Infliximab (Unknown),Subcorneal pustular dermatosis,NULL
198894331,Infliximab,Skin reaction,HO
198894331,Infliximab,Pyrexia,HO
198894331,Infliximab,Pruritus,HO
198894331,Infliximab,Poor venous access,HO
198894331,Infliximab,Off label use,HO
198894331,Infliximab,Malaise,HO
198894331,Infliximab,Intestinal fistula,HO
198894331,Infliximab,Intentional product use issue,HO
198894331,Infliximab,Inappropriate schedule of product administration,HO
198894331,Infliximab,Heart rate increased,HO
198894331,Infliximab,Condition aggravated,HO
198894331,Infliximab,Body temperature fluctuation,HO
198894331,Infliximab,Blood pressure diastolic increased,HO
198894331,Infliximab,Skin reaction,HO
198894331,Infliximab,Pyrexia,HO
198894331,Infliximab,Pruritus,HO
198894331,Infliximab,Poor venous access,HO
198894331,Infliximab,Off label use,HO
198894331,Infliximab,Malaise,HO
198894331,Infliximab,Intestinal fistula,HO
198894331,Infliximab,Intentional product use issue,HO
198894331,Infliximab,Inappropriate schedule of product administration,HO
198894331,Infliximab,Heart rate increased,HO
198894331,Infliximab,Condition aggravated,HO
198894331,Infliximab,Body temperature fluctuation,HO
198894331,Infliximab,Blood pressure diastolic increased,HO
1311836434,Infliximab Pfizer (Unknown),Urticaria,HO
1311836434,Infliximab Pfizer (Unknown),Urticaria,DS
1311836434,Infliximab Pfizer (Unknown),Urticaria,OT
1311836434,Infliximab Pfizer (Unknown),Ulcer,HO
1311836434,Infliximab Pfizer (Unknown),Ulcer,DS
1311836434,Infliximab Pfizer (Unknown),Ulcer,OT
1311836434,Infliximab Pfizer (Unknown),Treatment failure,HO
1311836434,Infliximab Pfizer (Unknown),Treatment failure,DS
1311836434,Infliximab Pfizer (Unknown),Treatment failure,OT
1311836434,Infliximab Pfizer (Unknown),Tongue disorder,HO
1311836434,Infliximab Pfizer (Unknown),Tongue disorder,DS
1311836434,Infliximab Pfizer (Unknown),Tongue disorder,OT
1311836434,Infliximab Pfizer (Unknown),Therapy non-responder,HO
1311836434,Infliximab Pfizer (Unknown),Therapy non-responder,DS
1311836434,Infliximab Pfizer (Unknown),Therapy non-responder,OT
1311836434,Infliximab Pfizer (Unknown),Therapeutic response decreased,HO
1311836434,Infliximab Pfizer (Unknown),Therapeutic response decreased,DS
1311836434,Infliximab Pfizer (Unknown),Therapeutic response decreased,OT
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,DS
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,HO
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,DS
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,OT
1311836434,Infliximab Pfizer (Unknown),Tenosynovitis,HO
1311836434,Infliximab Pfizer (Unknown),Tenosynovitis,DS
1311836434,Infliximab Pfizer (Unknown),Tenosynovitis,OT
1311836434,Infliximab Pfizer (Unknown),Tendonitis,HO
1311836434,Infliximab Pfizer (Unknown),Tendonitis,DS
1311836434,Infliximab Pfizer (Unknown),Tendonitis,OT
1311836434,Infliximab Pfizer (Unknown),Synovitis,HO
1311836434,Infliximab Pfizer (Unknown),Synovitis,DS
1311836434,Infliximab Pfizer (Unknown),Synovitis,OT
1311836434,Infliximab Pfizer (Unknown),Skin ulcer,HO
1311836434,Infliximab Pfizer (Unknown),Skin ulcer,DS
1311836434,Infliximab Pfizer (Unknown),Skin ulcer,OT
1311836434,Infliximab Pfizer (Unknown),Skin necrosis,HO
1311836434,Infliximab Pfizer (Unknown),Skin necrosis,DS
1311836434,Infliximab Pfizer (Unknown),Skin necrosis,OT
1311836434,Infliximab Pfizer (Unknown),Rheumatoid nodule,HO
1311836434,Infliximab Pfizer (Unknown),Rheumatoid nodule,DS
1311836434,Infliximab Pfizer (Unknown),Rheumatoid nodule,OT
1311836434,Infliximab Pfizer (Unknown),Rheumatoid lung,HO
1311836434,Infliximab Pfizer (Unknown),Rheumatoid lung,DS
1311836434,Infliximab Pfizer (Unknown),Rheumatoid lung,OT
1311836434,Infliximab Pfizer (Unknown),Rheumatoid arthritis,HO
1311836434,Infliximab Pfizer (Unknown),Rheumatoid arthritis,DS
1311836434,Infliximab Pfizer (Unknown),Rheumatoid arthritis,OT
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,HO
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,DS
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,OT
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,HO
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,DS
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,OT
1311836434,Infliximab Pfizer (Unknown),Rash pruritic,HO
1311836434,Infliximab Pfizer (Unknown),Rash pruritic,DS
1311836434,Infliximab Pfizer (Unknown),Rash pruritic,OT
1311836434,Infliximab Pfizer (Unknown),Rash,HO
1311836434,Infliximab Pfizer (Unknown),Rash,DS
1311836434,Infliximab Pfizer (Unknown),Rash,OT
1311836434,Infliximab Pfizer (Unknown),Pulmonary fibrosis,HO
1311836434,Infliximab Pfizer (Unknown),Pulmonary fibrosis,DS
1311836434,Infliximab Pfizer (Unknown),Pulmonary fibrosis,OT
1311836434,Infliximab Pfizer (Unknown),Psoriatic arthropathy,HO
1311836434,Infliximab Pfizer (Unknown),Psoriatic arthropathy,DS
1311836434,Infliximab Pfizer (Unknown),Psoriatic arthropathy,OT
1311836434,Infliximab Pfizer (Unknown),Product use issue,HO
1311836434,Infliximab Pfizer (Unknown),Product use issue,DS
1311836434,Infliximab Pfizer (Unknown),Product use issue,OT
1311836434,Infliximab Pfizer (Unknown),Peripheral swelling,HO
1311836434,Infliximab Pfizer (Unknown),Peripheral swelling,DS
1311836434,Infliximab Pfizer (Unknown),Peripheral swelling,OT
1311836434,Infliximab Pfizer (Unknown),Panniculitis,HO
1311836434,Infliximab Pfizer (Unknown),Panniculitis,DS
1311836434,Infliximab Pfizer (Unknown),Panniculitis,OT
1311836434,Infliximab Pfizer (Unknown),Pain,HO
1311836434,Infliximab Pfizer (Unknown),Pain,DS
1311836434,Infliximab Pfizer (Unknown),Pain,OT
1311836434,Infliximab Pfizer (Unknown),Overdose,HO
1311836434,Infliximab Pfizer (Unknown),Overdose,DS
1311836434,Infliximab Pfizer (Unknown),Overdose,OT
1311836434,Infliximab Pfizer (Unknown),Osteomyelitis,HO
1311836434,Infliximab Pfizer (Unknown),Osteomyelitis,DS
1311836434,Infliximab Pfizer (Unknown),Osteomyelitis,OT
1311836434,Infliximab Pfizer (Unknown),Off label use,HO
1311836434,Infliximab Pfizer (Unknown),Off label use,DS
1311836434,Infliximab Pfizer (Unknown),Off label use,OT
1311836434,Infliximab Pfizer (Unknown),Nausea,HO
1311836434,Infliximab Pfizer (Unknown),Nausea,DS
1311836434,Infliximab Pfizer (Unknown),Nausea,OT
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,HO
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,DS
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,OT
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal disorder,HO
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal disorder,DS
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal disorder,OT
1311836434,Infliximab Pfizer (Unknown),Mobility decreased,HO
1311836434,Infliximab Pfizer (Unknown),Mobility decreased,DS
1311836434,Infliximab Pfizer (Unknown),Mobility decreased,OT
1311836434,Infliximab Pfizer (Unknown),Malaise,HO
1311836434,Infliximab Pfizer (Unknown),Malaise,DS
1311836434,Infliximab Pfizer (Unknown),Malaise,OT
1311836434,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,HO
1311836434,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,DS
1311836434,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,OT
1311836434,Infliximab Pfizer (Unknown),Joint swelling,HO
1311836434,Infliximab Pfizer (Unknown),Joint swelling,DS
1311836434,Infliximab Pfizer (Unknown),Joint swelling,OT
1311836434,Infliximab Pfizer (Unknown),Joint injury,HO
1311836434,Infliximab Pfizer (Unknown),Joint injury,DS
1311836434,Infliximab Pfizer (Unknown),Joint injury,OT
1311836434,Infliximab Pfizer (Unknown),Insomnia,HO
1311836434,Infliximab Pfizer (Unknown),Insomnia,DS
1311836434,Infliximab Pfizer (Unknown),Insomnia,OT
1311836434,Infliximab Pfizer (Unknown),Infusion related reaction,HO
1311836434,Infliximab Pfizer (Unknown),Infusion related reaction,DS
1311836434,Infliximab Pfizer (Unknown),Infusion related reaction,OT
1311836434,Infliximab Pfizer (Unknown),Inflammation,HO
1311836434,Infliximab Pfizer (Unknown),Inflammation,DS
1311836434,Infliximab Pfizer (Unknown),Inflammation,OT
1311836434,Infliximab Pfizer (Unknown),Hypertension,HO
1311836434,Infliximab Pfizer (Unknown),Hypertension,DS
1311836434,Infliximab Pfizer (Unknown),Hypertension,OT
1311836434,Infliximab Pfizer (Unknown),Hypercalcaemia,HO
1311836434,Infliximab Pfizer (Unknown),Hypercalcaemia,DS
1311836434,Infliximab Pfizer (Unknown),Hypercalcaemia,OT
1311836434,Infliximab Pfizer (Unknown),Headache,HO
1311836434,Infliximab Pfizer (Unknown),Headache,DS
1311836434,Infliximab Pfizer (Unknown),Headache,OT
1311836434,Infliximab Pfizer (Unknown),Granuloma skin,HO
1311836434,Infliximab Pfizer (Unknown),Granuloma skin,DS
1311836434,Infliximab Pfizer (Unknown),Granuloma skin,OT
1311836434,Infliximab Pfizer (Unknown),Granuloma,HO
1311836434,Infliximab Pfizer (Unknown),Granuloma,DS
1311836434,Infliximab Pfizer (Unknown),Granuloma,OT
1311836434,Infliximab Pfizer (Unknown),General physical health deterioration,HO
1311836434,Infliximab Pfizer (Unknown),General physical health deterioration,DS
1311836434,Infliximab Pfizer (Unknown),General physical health deterioration,OT
1311836434,Infliximab Pfizer (Unknown),Gastric disorder,HO
1311836434,Infliximab Pfizer (Unknown),Gastric disorder,DS
1311836434,Infliximab Pfizer (Unknown),Gastric disorder,OT
1311836434,Infliximab Pfizer (Unknown),Fear of injection,HO
1311836434,Infliximab Pfizer (Unknown),Fear of injection,DS
1311836434,Infliximab Pfizer (Unknown),Fear of injection,OT
1311836434,Infliximab Pfizer (Unknown),Fatigue,HO
1311836434,Infliximab Pfizer (Unknown),Fatigue,DS
1311836434,Infliximab Pfizer (Unknown),Fatigue,OT
1311836434,Infliximab Pfizer (Unknown),Erythema,HO
1311836434,Infliximab Pfizer (Unknown),Erythema,DS
1311836434,Infliximab Pfizer (Unknown),Erythema,OT
1311836434,Infliximab Pfizer (Unknown),Enthesopathy,HO
1311836434,Infliximab Pfizer (Unknown),Enthesopathy,DS
1311836434,Infliximab Pfizer (Unknown),Enthesopathy,OT
1311836434,Infliximab Pfizer (Unknown),Drug tolerance decreased,HO
1311836434,Infliximab Pfizer (Unknown),Drug tolerance decreased,DS
1311836434,Infliximab Pfizer (Unknown),Drug tolerance decreased,OT
1311836434,Infliximab Pfizer (Unknown),Drug tolerance,HO
1311836434,Infliximab Pfizer (Unknown),Drug tolerance,DS
1311836434,Infliximab Pfizer (Unknown),Drug tolerance,OT
1311836434,Infliximab Pfizer (Unknown),Drug intolerance,HO
1311836434,Infliximab Pfizer (Unknown),Drug intolerance,DS
1311836434,Infliximab Pfizer (Unknown),Drug intolerance,OT
1311836434,Infliximab Pfizer (Unknown),Drug ineffective,HO
1311836434,Infliximab Pfizer (Unknown),Drug ineffective,DS
1311836434,Infliximab Pfizer (Unknown),Drug ineffective,OT
1311836434,Infliximab Pfizer (Unknown),Drug hypersensitivity,HO
1311836434,Infliximab Pfizer (Unknown),Drug hypersensitivity,DS
1311836434,Infliximab Pfizer (Unknown),Drug hypersensitivity,OT
1311836434,Infliximab Pfizer (Unknown),Drug eruption,HO
1311836434,Infliximab Pfizer (Unknown),Drug eruption,DS
1311836434,Infliximab Pfizer (Unknown),Drug eruption,OT
1311836434,Infliximab Pfizer (Unknown),Diarrhoea,HO
1311836434,Infliximab Pfizer (Unknown),Diarrhoea,DS
1311836434,Infliximab Pfizer (Unknown),Diarrhoea,OT
1311836434,Infliximab Pfizer (Unknown),Decreased appetite,HO
1311836434,Infliximab Pfizer (Unknown),Decreased appetite,DS
1311836434,Infliximab Pfizer (Unknown),Decreased appetite,OT
1311836434,Infliximab Pfizer (Unknown),Contraindicated product administered,HO
1311836434,Infliximab Pfizer (Unknown),Contraindicated product administered,DS
1311836434,Infliximab Pfizer (Unknown),Contraindicated product administered,OT
1311836434,Infliximab Pfizer (Unknown),Condition aggravated,HO
1311836434,Infliximab Pfizer (Unknown),Condition aggravated,DS
1311836434,Infliximab Pfizer (Unknown),Condition aggravated,OT
1311836434,Infliximab Pfizer (Unknown),C-reactive protein increased,HO
1311836434,Infliximab Pfizer (Unknown),C-reactive protein increased,DS
1311836434,Infliximab Pfizer (Unknown),C-reactive protein increased,OT
1311836434,Infliximab Pfizer (Unknown),C-reactive protein abnormal,HO
1311836434,Infliximab Pfizer (Unknown),C-reactive protein abnormal,DS
1311836434,Infliximab Pfizer (Unknown),C-reactive protein abnormal,OT
1311836434,Infliximab Pfizer (Unknown),Blood pressure systolic increased,HO
1311836434,Infliximab Pfizer (Unknown),Blood pressure systolic increased,DS
1311836434,Infliximab Pfizer (Unknown),Blood pressure systolic increased,OT
1311836434,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,HO
1311836434,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,DS
1311836434,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,OT
1311836434,Infliximab Pfizer (Unknown),Blood creatinine increased,HO
1311836434,Infliximab Pfizer (Unknown),Blood creatinine increased,DS
1311836434,Infliximab Pfizer (Unknown),Blood creatinine increased,OT
1311836434,Infliximab Pfizer (Unknown),Basal cell carcinoma,HO
1311836434,Infliximab Pfizer (Unknown),Basal cell carcinoma,DS
1311836434,Infliximab Pfizer (Unknown),Basal cell carcinoma,OT
1311836434,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,HO
1311836434,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,DS
1311836434,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,OT
1311836434,Infliximab Pfizer (Unknown),Arthropathy,HO
1311836434,Infliximab Pfizer (Unknown),Arthropathy,DS
1311836434,Infliximab Pfizer (Unknown),Arthropathy,OT
1311836434,Infliximab Pfizer (Unknown),Arthritis,HO
1311836434,Infliximab Pfizer (Unknown),Arthritis,DS
1311836434,Infliximab Pfizer (Unknown),Arthritis,OT
1311836434,Infliximab Pfizer (Unknown),Arthralgia,HO
1311836434,Infliximab Pfizer (Unknown),Arthralgia,DS
1311836434,Infliximab Pfizer (Unknown),Arthralgia,OT
1311836434,Infliximab Pfizer (Unknown),Alopecia,HO
1311836434,Infliximab Pfizer (Unknown),Alopecia,DS
1311836434,Infliximab Pfizer (Unknown),Alopecia,OT
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,HO
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,DS
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,OT
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,HO
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,DS
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,OT
1311836434,Infliximab Pfizer (Unknown),Abdominal discomfort,HO
1311836434,Infliximab Pfizer (Unknown),Abdominal discomfort,DS
1311836434,Infliximab Pfizer (Unknown),Abdominal discomfort,OT
1311836434,Infliximab Pfizer (Unknown),Urticaria,HO
1311836434,Infliximab Pfizer (Unknown),Urticaria,DS
1311836434,Infliximab Pfizer (Unknown),Urticaria,OT
1311836434,Infliximab Pfizer (Unknown),Ulcer,HO
1311836434,Infliximab Pfizer (Unknown),Ulcer,DS
1311836434,Infliximab Pfizer (Unknown),Ulcer,OT
1311836434,Infliximab Pfizer (Unknown),Treatment failure,HO
1311836434,Infliximab Pfizer (Unknown),Treatment failure,DS
1311836434,Infliximab Pfizer (Unknown),Treatment failure,OT
1311836434,Infliximab Pfizer (Unknown),Tongue disorder,HO
1311836434,Infliximab Pfizer (Unknown),Tongue disorder,DS
1311836434,Infliximab Pfizer (Unknown),Tongue disorder,OT
1311836434,Infliximab Pfizer (Unknown),Therapy non-responder,HO
1311836434,Infliximab Pfizer (Unknown),Therapy non-responder,DS
1311836434,Infliximab Pfizer (Unknown),Therapy non-responder,OT
1311836434,Infliximab Pfizer (Unknown),Therapeutic response decreased,HO
1311836434,Infliximab Pfizer (Unknown),Therapeutic response decreased,DS
1311836434,Infliximab Pfizer (Unknown),Therapeutic response decreased,OT
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,DS
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,HO
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,DS
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,OT
1311836434,Infliximab Pfizer (Unknown),Tenosynovitis,HO
1311836434,Infliximab Pfizer (Unknown),Tenosynovitis,DS
1311836434,Infliximab Pfizer (Unknown),Tenosynovitis,OT
1311836434,Infliximab Pfizer (Unknown),Tendonitis,HO
1311836434,Infliximab Pfizer (Unknown),Tendonitis,DS
1311836434,Infliximab Pfizer (Unknown),Tendonitis,OT
1311836434,Infliximab Pfizer (Unknown),Synovitis,HO
1311836434,Infliximab Pfizer (Unknown),Synovitis,DS
1311836434,Infliximab Pfizer (Unknown),Synovitis,OT
1311836434,Infliximab Pfizer (Unknown),Skin ulcer,HO
1311836434,Infliximab Pfizer (Unknown),Skin ulcer,DS
1311836434,Infliximab Pfizer (Unknown),Skin ulcer,OT
1311836434,Infliximab Pfizer (Unknown),Skin necrosis,HO
1311836434,Infliximab Pfizer (Unknown),Skin necrosis,DS
1311836434,Infliximab Pfizer (Unknown),Skin necrosis,OT
1311836434,Infliximab Pfizer (Unknown),Rheumatoid nodule,HO
1311836434,Infliximab Pfizer (Unknown),Rheumatoid nodule,DS
1311836434,Infliximab Pfizer (Unknown),Rheumatoid nodule,OT
1311836434,Infliximab Pfizer (Unknown),Rheumatoid lung,HO
1311836434,Infliximab Pfizer (Unknown),Rheumatoid lung,DS
1311836434,Infliximab Pfizer (Unknown),Rheumatoid lung,OT
1311836434,Infliximab Pfizer (Unknown),Rheumatoid arthritis,HO
1311836434,Infliximab Pfizer (Unknown),Rheumatoid arthritis,DS
1311836434,Infliximab Pfizer (Unknown),Rheumatoid arthritis,OT
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,HO
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,DS
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,OT
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,HO
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,DS
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,OT
1311836434,Infliximab Pfizer (Unknown),Rash pruritic,HO
1311836434,Infliximab Pfizer (Unknown),Rash pruritic,DS
1311836434,Infliximab Pfizer (Unknown),Rash pruritic,OT
1311836434,Infliximab Pfizer (Unknown),Rash,HO
1311836434,Infliximab Pfizer (Unknown),Rash,DS
1311836434,Infliximab Pfizer (Unknown),Rash,OT
1311836434,Infliximab Pfizer (Unknown),Pulmonary fibrosis,HO
1311836434,Infliximab Pfizer (Unknown),Pulmonary fibrosis,DS
1311836434,Infliximab Pfizer (Unknown),Pulmonary fibrosis,OT
1311836434,Infliximab Pfizer (Unknown),Psoriatic arthropathy,HO
1311836434,Infliximab Pfizer (Unknown),Psoriatic arthropathy,DS
1311836434,Infliximab Pfizer (Unknown),Psoriatic arthropathy,OT
1311836434,Infliximab Pfizer (Unknown),Product use issue,HO
1311836434,Infliximab Pfizer (Unknown),Product use issue,DS
1311836434,Infliximab Pfizer (Unknown),Product use issue,OT
1311836434,Infliximab Pfizer (Unknown),Peripheral swelling,HO
1311836434,Infliximab Pfizer (Unknown),Peripheral swelling,DS
1311836434,Infliximab Pfizer (Unknown),Peripheral swelling,OT
1311836434,Infliximab Pfizer (Unknown),Panniculitis,HO
1311836434,Infliximab Pfizer (Unknown),Panniculitis,DS
1311836434,Infliximab Pfizer (Unknown),Panniculitis,OT
1311836434,Infliximab Pfizer (Unknown),Pain,HO
1311836434,Infliximab Pfizer (Unknown),Pain,DS
1311836434,Infliximab Pfizer (Unknown),Pain,OT
1311836434,Infliximab Pfizer (Unknown),Overdose,HO
1311836434,Infliximab Pfizer (Unknown),Overdose,DS
1311836434,Infliximab Pfizer (Unknown),Overdose,OT
1311836434,Infliximab Pfizer (Unknown),Osteomyelitis,HO
1311836434,Infliximab Pfizer (Unknown),Osteomyelitis,DS
1311836434,Infliximab Pfizer (Unknown),Osteomyelitis,OT
1311836434,Infliximab Pfizer (Unknown),Off label use,HO
1311836434,Infliximab Pfizer (Unknown),Off label use,DS
1311836434,Infliximab Pfizer (Unknown),Off label use,OT
1311836434,Infliximab Pfizer (Unknown),Nausea,HO
1311836434,Infliximab Pfizer (Unknown),Nausea,DS
1311836434,Infliximab Pfizer (Unknown),Nausea,OT
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,HO
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,DS
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,OT
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal disorder,HO
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal disorder,DS
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal disorder,OT
1311836434,Infliximab Pfizer (Unknown),Mobility decreased,HO
1311836434,Infliximab Pfizer (Unknown),Mobility decreased,DS
1311836434,Infliximab Pfizer (Unknown),Mobility decreased,OT
1311836434,Infliximab Pfizer (Unknown),Malaise,HO
1311836434,Infliximab Pfizer (Unknown),Malaise,DS
1311836434,Infliximab Pfizer (Unknown),Malaise,OT
1311836434,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,HO
1311836434,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,DS
1311836434,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,OT
1311836434,Infliximab Pfizer (Unknown),Joint swelling,HO
1311836434,Infliximab Pfizer (Unknown),Joint swelling,DS
1311836434,Infliximab Pfizer (Unknown),Joint swelling,OT
1311836434,Infliximab Pfizer (Unknown),Joint injury,HO
1311836434,Infliximab Pfizer (Unknown),Joint injury,DS
1311836434,Infliximab Pfizer (Unknown),Joint injury,OT
1311836434,Infliximab Pfizer (Unknown),Insomnia,HO
1311836434,Infliximab Pfizer (Unknown),Insomnia,DS
1311836434,Infliximab Pfizer (Unknown),Insomnia,OT
1311836434,Infliximab Pfizer (Unknown),Infusion related reaction,HO
1311836434,Infliximab Pfizer (Unknown),Infusion related reaction,DS
1311836434,Infliximab Pfizer (Unknown),Infusion related reaction,OT
1311836434,Infliximab Pfizer (Unknown),Inflammation,HO
1311836434,Infliximab Pfizer (Unknown),Inflammation,DS
1311836434,Infliximab Pfizer (Unknown),Inflammation,OT
1311836434,Infliximab Pfizer (Unknown),Hypertension,HO
1311836434,Infliximab Pfizer (Unknown),Hypertension,DS
1311836434,Infliximab Pfizer (Unknown),Hypertension,OT
1311836434,Infliximab Pfizer (Unknown),Hypercalcaemia,HO
1311836434,Infliximab Pfizer (Unknown),Hypercalcaemia,DS
1311836434,Infliximab Pfizer (Unknown),Hypercalcaemia,OT
1311836434,Infliximab Pfizer (Unknown),Headache,HO
1311836434,Infliximab Pfizer (Unknown),Headache,DS
1311836434,Infliximab Pfizer (Unknown),Headache,OT
1311836434,Infliximab Pfizer (Unknown),Granuloma skin,HO
1311836434,Infliximab Pfizer (Unknown),Granuloma skin,DS
1311836434,Infliximab Pfizer (Unknown),Granuloma skin,OT
1311836434,Infliximab Pfizer (Unknown),Granuloma,HO
1311836434,Infliximab Pfizer (Unknown),Granuloma,DS
1311836434,Infliximab Pfizer (Unknown),Granuloma,OT
1311836434,Infliximab Pfizer (Unknown),General physical health deterioration,HO
1311836434,Infliximab Pfizer (Unknown),General physical health deterioration,DS
1311836434,Infliximab Pfizer (Unknown),General physical health deterioration,OT
1311836434,Infliximab Pfizer (Unknown),Gastric disorder,HO
1311836434,Infliximab Pfizer (Unknown),Gastric disorder,DS
1311836434,Infliximab Pfizer (Unknown),Gastric disorder,OT
1311836434,Infliximab Pfizer (Unknown),Fear of injection,HO
1311836434,Infliximab Pfizer (Unknown),Fear of injection,DS
1311836434,Infliximab Pfizer (Unknown),Fear of injection,OT
1311836434,Infliximab Pfizer (Unknown),Fatigue,HO
1311836434,Infliximab Pfizer (Unknown),Fatigue,DS
1311836434,Infliximab Pfizer (Unknown),Fatigue,OT
1311836434,Infliximab Pfizer (Unknown),Erythema,HO
1311836434,Infliximab Pfizer (Unknown),Erythema,DS
1311836434,Infliximab Pfizer (Unknown),Erythema,OT
1311836434,Infliximab Pfizer (Unknown),Enthesopathy,HO
1311836434,Infliximab Pfizer (Unknown),Enthesopathy,DS
1311836434,Infliximab Pfizer (Unknown),Enthesopathy,OT
1311836434,Infliximab Pfizer (Unknown),Drug tolerance decreased,HO
1311836434,Infliximab Pfizer (Unknown),Drug tolerance decreased,DS
1311836434,Infliximab Pfizer (Unknown),Drug tolerance decreased,OT
1311836434,Infliximab Pfizer (Unknown),Drug tolerance,HO
1311836434,Infliximab Pfizer (Unknown),Drug tolerance,DS
1311836434,Infliximab Pfizer (Unknown),Drug tolerance,OT
1311836434,Infliximab Pfizer (Unknown),Drug intolerance,HO
1311836434,Infliximab Pfizer (Unknown),Drug intolerance,DS
1311836434,Infliximab Pfizer (Unknown),Drug intolerance,OT
1311836434,Infliximab Pfizer (Unknown),Drug ineffective,HO
1311836434,Infliximab Pfizer (Unknown),Drug ineffective,DS
1311836434,Infliximab Pfizer (Unknown),Drug ineffective,OT
1311836434,Infliximab Pfizer (Unknown),Drug hypersensitivity,HO
1311836434,Infliximab Pfizer (Unknown),Drug hypersensitivity,DS
1311836434,Infliximab Pfizer (Unknown),Drug hypersensitivity,OT
1311836434,Infliximab Pfizer (Unknown),Drug eruption,HO
1311836434,Infliximab Pfizer (Unknown),Drug eruption,DS
1311836434,Infliximab Pfizer (Unknown),Drug eruption,OT
1311836434,Infliximab Pfizer (Unknown),Diarrhoea,HO
1311836434,Infliximab Pfizer (Unknown),Diarrhoea,DS
1311836434,Infliximab Pfizer (Unknown),Diarrhoea,OT
1311836434,Infliximab Pfizer (Unknown),Decreased appetite,HO
1311836434,Infliximab Pfizer (Unknown),Decreased appetite,DS
1311836434,Infliximab Pfizer (Unknown),Decreased appetite,OT
1311836434,Infliximab Pfizer (Unknown),Contraindicated product administered,HO
1311836434,Infliximab Pfizer (Unknown),Contraindicated product administered,DS
1311836434,Infliximab Pfizer (Unknown),Contraindicated product administered,OT
1311836434,Infliximab Pfizer (Unknown),Condition aggravated,HO
1311836434,Infliximab Pfizer (Unknown),Condition aggravated,DS
1311836434,Infliximab Pfizer (Unknown),Condition aggravated,OT
1311836434,Infliximab Pfizer (Unknown),C-reactive protein increased,HO
1311836434,Infliximab Pfizer (Unknown),C-reactive protein increased,DS
1311836434,Infliximab Pfizer (Unknown),C-reactive protein increased,OT
1311836434,Infliximab Pfizer (Unknown),C-reactive protein abnormal,HO
1311836434,Infliximab Pfizer (Unknown),C-reactive protein abnormal,DS
1311836434,Infliximab Pfizer (Unknown),C-reactive protein abnormal,OT
1311836434,Infliximab Pfizer (Unknown),Blood pressure systolic increased,HO
1311836434,Infliximab Pfizer (Unknown),Blood pressure systolic increased,DS
1311836434,Infliximab Pfizer (Unknown),Blood pressure systolic increased,OT
1311836434,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,HO
1311836434,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,DS
1311836434,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,OT
1311836434,Infliximab Pfizer (Unknown),Blood creatinine increased,HO
1311836434,Infliximab Pfizer (Unknown),Blood creatinine increased,DS
1311836434,Infliximab Pfizer (Unknown),Blood creatinine increased,OT
1311836434,Infliximab Pfizer (Unknown),Basal cell carcinoma,HO
1311836434,Infliximab Pfizer (Unknown),Basal cell carcinoma,DS
1311836434,Infliximab Pfizer (Unknown),Basal cell carcinoma,OT
1311836434,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,HO
1311836434,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,DS
1311836434,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,OT
1311836434,Infliximab Pfizer (Unknown),Arthropathy,HO
1311836434,Infliximab Pfizer (Unknown),Arthropathy,DS
1311836434,Infliximab Pfizer (Unknown),Arthropathy,OT
1311836434,Infliximab Pfizer (Unknown),Arthritis,HO
1311836434,Infliximab Pfizer (Unknown),Arthritis,DS
1311836434,Infliximab Pfizer (Unknown),Arthritis,OT
1311836434,Infliximab Pfizer (Unknown),Arthralgia,HO
1311836434,Infliximab Pfizer (Unknown),Arthralgia,DS
1311836434,Infliximab Pfizer (Unknown),Arthralgia,OT
1311836434,Infliximab Pfizer (Unknown),Alopecia,HO
1311836434,Infliximab Pfizer (Unknown),Alopecia,DS
1311836434,Infliximab Pfizer (Unknown),Alopecia,OT
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,HO
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,DS
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,OT
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,HO
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,DS
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,OT
1311836434,Infliximab Pfizer (Unknown),Abdominal discomfort,HO
1311836434,Infliximab Pfizer (Unknown),Abdominal discomfort,DS
1311836434,Infliximab Pfizer (Unknown),Abdominal discomfort,OT
1311836434,Infliximab Pfizer (Unknown),Urticaria,HO
1311836434,Infliximab Pfizer (Unknown),Urticaria,DS
1311836434,Infliximab Pfizer (Unknown),Urticaria,OT
1311836434,Infliximab Pfizer (Unknown),Ulcer,HO
1311836434,Infliximab Pfizer (Unknown),Ulcer,DS
1311836434,Infliximab Pfizer (Unknown),Ulcer,OT
1311836434,Infliximab Pfizer (Unknown),Treatment failure,HO
1311836434,Infliximab Pfizer (Unknown),Treatment failure,DS
1311836434,Infliximab Pfizer (Unknown),Treatment failure,OT
1311836434,Infliximab Pfizer (Unknown),Tongue disorder,HO
1311836434,Infliximab Pfizer (Unknown),Tongue disorder,DS
1311836434,Infliximab Pfizer (Unknown),Tongue disorder,OT
1311836434,Infliximab Pfizer (Unknown),Therapy non-responder,HO
1311836434,Infliximab Pfizer (Unknown),Therapy non-responder,DS
1311836434,Infliximab Pfizer (Unknown),Therapy non-responder,OT
1311836434,Infliximab Pfizer (Unknown),Therapeutic response decreased,HO
1311836434,Infliximab Pfizer (Unknown),Therapeutic response decreased,DS
1311836434,Infliximab Pfizer (Unknown),Therapeutic response decreased,OT
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,DS
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,HO
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,DS
1311836434,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,OT
1311836434,Infliximab Pfizer (Unknown),Tenosynovitis,HO
1311836434,Infliximab Pfizer (Unknown),Tenosynovitis,DS
1311836434,Infliximab Pfizer (Unknown),Tenosynovitis,OT
1311836434,Infliximab Pfizer (Unknown),Tendonitis,HO
1311836434,Infliximab Pfizer (Unknown),Tendonitis,DS
1311836434,Infliximab Pfizer (Unknown),Tendonitis,OT
1311836434,Infliximab Pfizer (Unknown),Synovitis,HO
1311836434,Infliximab Pfizer (Unknown),Synovitis,DS
1311836434,Infliximab Pfizer (Unknown),Synovitis,OT
1311836434,Infliximab Pfizer (Unknown),Skin ulcer,HO
1311836434,Infliximab Pfizer (Unknown),Skin ulcer,DS
1311836434,Infliximab Pfizer (Unknown),Skin ulcer,OT
1311836434,Infliximab Pfizer (Unknown),Skin necrosis,HO
1311836434,Infliximab Pfizer (Unknown),Skin necrosis,DS
1311836434,Infliximab Pfizer (Unknown),Skin necrosis,OT
1311836434,Infliximab Pfizer (Unknown),Rheumatoid nodule,HO
1311836434,Infliximab Pfizer (Unknown),Rheumatoid nodule,DS
1311836434,Infliximab Pfizer (Unknown),Rheumatoid nodule,OT
1311836434,Infliximab Pfizer (Unknown),Rheumatoid lung,HO
1311836434,Infliximab Pfizer (Unknown),Rheumatoid lung,DS
1311836434,Infliximab Pfizer (Unknown),Rheumatoid lung,OT
1311836434,Infliximab Pfizer (Unknown),Rheumatoid arthritis,HO
1311836434,Infliximab Pfizer (Unknown),Rheumatoid arthritis,DS
1311836434,Infliximab Pfizer (Unknown),Rheumatoid arthritis,OT
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,HO
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,DS
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,OT
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,HO
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,DS
1311836434,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,OT
1311836434,Infliximab Pfizer (Unknown),Rash pruritic,HO
1311836434,Infliximab Pfizer (Unknown),Rash pruritic,DS
1311836434,Infliximab Pfizer (Unknown),Rash pruritic,OT
1311836434,Infliximab Pfizer (Unknown),Rash,HO
1311836434,Infliximab Pfizer (Unknown),Rash,DS
1311836434,Infliximab Pfizer (Unknown),Rash,OT
1311836434,Infliximab Pfizer (Unknown),Pulmonary fibrosis,HO
1311836434,Infliximab Pfizer (Unknown),Pulmonary fibrosis,DS
1311836434,Infliximab Pfizer (Unknown),Pulmonary fibrosis,OT
1311836434,Infliximab Pfizer (Unknown),Psoriatic arthropathy,HO
1311836434,Infliximab Pfizer (Unknown),Psoriatic arthropathy,DS
1311836434,Infliximab Pfizer (Unknown),Psoriatic arthropathy,OT
1311836434,Infliximab Pfizer (Unknown),Product use issue,HO
1311836434,Infliximab Pfizer (Unknown),Product use issue,DS
1311836434,Infliximab Pfizer (Unknown),Product use issue,OT
1311836434,Infliximab Pfizer (Unknown),Peripheral swelling,HO
1311836434,Infliximab Pfizer (Unknown),Peripheral swelling,DS
1311836434,Infliximab Pfizer (Unknown),Peripheral swelling,OT
1311836434,Infliximab Pfizer (Unknown),Panniculitis,HO
1311836434,Infliximab Pfizer (Unknown),Panniculitis,DS
1311836434,Infliximab Pfizer (Unknown),Panniculitis,OT
1311836434,Infliximab Pfizer (Unknown),Pain,HO
1311836434,Infliximab Pfizer (Unknown),Pain,DS
1311836434,Infliximab Pfizer (Unknown),Pain,OT
1311836434,Infliximab Pfizer (Unknown),Overdose,HO
1311836434,Infliximab Pfizer (Unknown),Overdose,DS
1311836434,Infliximab Pfizer (Unknown),Overdose,OT
1311836434,Infliximab Pfizer (Unknown),Osteomyelitis,HO
1311836434,Infliximab Pfizer (Unknown),Osteomyelitis,DS
1311836434,Infliximab Pfizer (Unknown),Osteomyelitis,OT
1311836434,Infliximab Pfizer (Unknown),Off label use,HO
1311836434,Infliximab Pfizer (Unknown),Off label use,DS
1311836434,Infliximab Pfizer (Unknown),Off label use,OT
1311836434,Infliximab Pfizer (Unknown),Nausea,HO
1311836434,Infliximab Pfizer (Unknown),Nausea,DS
1311836434,Infliximab Pfizer (Unknown),Nausea,OT
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,HO
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,DS
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,OT
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal disorder,HO
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal disorder,DS
1311836434,Infliximab Pfizer (Unknown),Musculoskeletal disorder,OT
1311836434,Infliximab Pfizer (Unknown),Mobility decreased,HO
1311836434,Infliximab Pfizer (Unknown),Mobility decreased,DS
1311836434,Infliximab Pfizer (Unknown),Mobility decreased,OT
1311836434,Infliximab Pfizer (Unknown),Malaise,HO
1311836434,Infliximab Pfizer (Unknown),Malaise,DS
1311836434,Infliximab Pfizer (Unknown),Malaise,OT
1311836434,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,HO
1311836434,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,DS
1311836434,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,OT
1311836434,Infliximab Pfizer (Unknown),Joint swelling,HO
1311836434,Infliximab Pfizer (Unknown),Joint swelling,DS
1311836434,Infliximab Pfizer (Unknown),Joint swelling,OT
1311836434,Infliximab Pfizer (Unknown),Joint injury,HO
1311836434,Infliximab Pfizer (Unknown),Joint injury,DS
1311836434,Infliximab Pfizer (Unknown),Joint injury,OT
1311836434,Infliximab Pfizer (Unknown),Insomnia,HO
1311836434,Infliximab Pfizer (Unknown),Insomnia,DS
1311836434,Infliximab Pfizer (Unknown),Insomnia,OT
1311836434,Infliximab Pfizer (Unknown),Infusion related reaction,HO
1311836434,Infliximab Pfizer (Unknown),Infusion related reaction,DS
1311836434,Infliximab Pfizer (Unknown),Infusion related reaction,OT
1311836434,Infliximab Pfizer (Unknown),Inflammation,HO
1311836434,Infliximab Pfizer (Unknown),Inflammation,DS
1311836434,Infliximab Pfizer (Unknown),Inflammation,OT
1311836434,Infliximab Pfizer (Unknown),Hypertension,HO
1311836434,Infliximab Pfizer (Unknown),Hypertension,DS
1311836434,Infliximab Pfizer (Unknown),Hypertension,OT
1311836434,Infliximab Pfizer (Unknown),Hypercalcaemia,HO
1311836434,Infliximab Pfizer (Unknown),Hypercalcaemia,DS
1311836434,Infliximab Pfizer (Unknown),Hypercalcaemia,OT
1311836434,Infliximab Pfizer (Unknown),Headache,HO
1311836434,Infliximab Pfizer (Unknown),Headache,DS
1311836434,Infliximab Pfizer (Unknown),Headache,OT
1311836434,Infliximab Pfizer (Unknown),Granuloma skin,HO
1311836434,Infliximab Pfizer (Unknown),Granuloma skin,DS
1311836434,Infliximab Pfizer (Unknown),Granuloma skin,OT
1311836434,Infliximab Pfizer (Unknown),Granuloma,HO
1311836434,Infliximab Pfizer (Unknown),Granuloma,DS
1311836434,Infliximab Pfizer (Unknown),Granuloma,OT
1311836434,Infliximab Pfizer (Unknown),General physical health deterioration,HO
1311836434,Infliximab Pfizer (Unknown),General physical health deterioration,DS
1311836434,Infliximab Pfizer (Unknown),General physical health deterioration,OT
1311836434,Infliximab Pfizer (Unknown),Gastric disorder,HO
1311836434,Infliximab Pfizer (Unknown),Gastric disorder,DS
1311836434,Infliximab Pfizer (Unknown),Gastric disorder,OT
1311836434,Infliximab Pfizer (Unknown),Fear of injection,HO
1311836434,Infliximab Pfizer (Unknown),Fear of injection,DS
1311836434,Infliximab Pfizer (Unknown),Fear of injection,OT
1311836434,Infliximab Pfizer (Unknown),Fatigue,HO
1311836434,Infliximab Pfizer (Unknown),Fatigue,DS
1311836434,Infliximab Pfizer (Unknown),Fatigue,OT
1311836434,Infliximab Pfizer (Unknown),Erythema,HO
1311836434,Infliximab Pfizer (Unknown),Erythema,DS
1311836434,Infliximab Pfizer (Unknown),Erythema,OT
1311836434,Infliximab Pfizer (Unknown),Enthesopathy,HO
1311836434,Infliximab Pfizer (Unknown),Enthesopathy,DS
1311836434,Infliximab Pfizer (Unknown),Enthesopathy,OT
1311836434,Infliximab Pfizer (Unknown),Drug tolerance decreased,HO
1311836434,Infliximab Pfizer (Unknown),Drug tolerance decreased,DS
1311836434,Infliximab Pfizer (Unknown),Drug tolerance decreased,OT
1311836434,Infliximab Pfizer (Unknown),Drug tolerance,HO
1311836434,Infliximab Pfizer (Unknown),Drug tolerance,DS
1311836434,Infliximab Pfizer (Unknown),Drug tolerance,OT
1311836434,Infliximab Pfizer (Unknown),Drug intolerance,HO
1311836434,Infliximab Pfizer (Unknown),Drug intolerance,DS
1311836434,Infliximab Pfizer (Unknown),Drug intolerance,OT
1311836434,Infliximab Pfizer (Unknown),Drug ineffective,HO
1311836434,Infliximab Pfizer (Unknown),Drug ineffective,DS
1311836434,Infliximab Pfizer (Unknown),Drug ineffective,OT
1311836434,Infliximab Pfizer (Unknown),Drug hypersensitivity,HO
1311836434,Infliximab Pfizer (Unknown),Drug hypersensitivity,DS
1311836434,Infliximab Pfizer (Unknown),Drug hypersensitivity,OT
1311836434,Infliximab Pfizer (Unknown),Drug eruption,HO
1311836434,Infliximab Pfizer (Unknown),Drug eruption,DS
1311836434,Infliximab Pfizer (Unknown),Drug eruption,OT
1311836434,Infliximab Pfizer (Unknown),Diarrhoea,HO
1311836434,Infliximab Pfizer (Unknown),Diarrhoea,DS
1311836434,Infliximab Pfizer (Unknown),Diarrhoea,OT
1311836434,Infliximab Pfizer (Unknown),Decreased appetite,HO
1311836434,Infliximab Pfizer (Unknown),Decreased appetite,DS
1311836434,Infliximab Pfizer (Unknown),Decreased appetite,OT
1311836434,Infliximab Pfizer (Unknown),Contraindicated product administered,HO
1311836434,Infliximab Pfizer (Unknown),Contraindicated product administered,DS
1311836434,Infliximab Pfizer (Unknown),Contraindicated product administered,OT
1311836434,Infliximab Pfizer (Unknown),Condition aggravated,HO
1311836434,Infliximab Pfizer (Unknown),Condition aggravated,DS
1311836434,Infliximab Pfizer (Unknown),Condition aggravated,OT
1311836434,Infliximab Pfizer (Unknown),C-reactive protein increased,HO
1311836434,Infliximab Pfizer (Unknown),C-reactive protein increased,DS
1311836434,Infliximab Pfizer (Unknown),C-reactive protein increased,OT
1311836434,Infliximab Pfizer (Unknown),C-reactive protein abnormal,HO
1311836434,Infliximab Pfizer (Unknown),C-reactive protein abnormal,DS
1311836434,Infliximab Pfizer (Unknown),C-reactive protein abnormal,OT
1311836434,Infliximab Pfizer (Unknown),Blood pressure systolic increased,HO
1311836434,Infliximab Pfizer (Unknown),Blood pressure systolic increased,DS
1311836434,Infliximab Pfizer (Unknown),Blood pressure systolic increased,OT
1311836434,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,HO
1311836434,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,DS
1311836434,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,OT
1311836434,Infliximab Pfizer (Unknown),Blood creatinine increased,HO
1311836434,Infliximab Pfizer (Unknown),Blood creatinine increased,DS
1311836434,Infliximab Pfizer (Unknown),Blood creatinine increased,OT
1311836434,Infliximab Pfizer (Unknown),Basal cell carcinoma,HO
1311836434,Infliximab Pfizer (Unknown),Basal cell carcinoma,DS
1311836434,Infliximab Pfizer (Unknown),Basal cell carcinoma,OT
1311836434,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,HO
1311836434,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,DS
1311836434,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,OT
1311836434,Infliximab Pfizer (Unknown),Arthropathy,HO
1311836434,Infliximab Pfizer (Unknown),Arthropathy,DS
1311836434,Infliximab Pfizer (Unknown),Arthropathy,OT
1311836434,Infliximab Pfizer (Unknown),Arthritis,HO
1311836434,Infliximab Pfizer (Unknown),Arthritis,DS
1311836434,Infliximab Pfizer (Unknown),Arthritis,OT
1311836434,Infliximab Pfizer (Unknown),Arthralgia,HO
1311836434,Infliximab Pfizer (Unknown),Arthralgia,DS
1311836434,Infliximab Pfizer (Unknown),Arthralgia,OT
1311836434,Infliximab Pfizer (Unknown),Alopecia,HO
1311836434,Infliximab Pfizer (Unknown),Alopecia,DS
1311836434,Infliximab Pfizer (Unknown),Alopecia,OT
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,HO
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,DS
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,OT
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,HO
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,DS
1311836434,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,OT
1311836434,Infliximab Pfizer (Unknown),Abdominal discomfort,HO
1311836434,Infliximab Pfizer (Unknown),Abdominal discomfort,DS
1311836434,Infliximab Pfizer (Unknown),Abdominal discomfort,OT
154592797,Infliximab Pfizer (Unknown),Swelling,OT
154592797,Infliximab Pfizer (Unknown),Subcutaneous abscess,OT
154592797,Infliximab Pfizer (Unknown),Skin warm,OT
154592797,Infliximab Pfizer (Unknown),Rash,OT
154592797,Infliximab Pfizer (Unknown),Purulent discharge,OT
154592797,Infliximab Pfizer (Unknown),Pain,OT
154592797,Infliximab Pfizer (Unknown),Joint swelling,OT
154592797,Infliximab Pfizer (Unknown),Exposure during pregnancy,OT
154592797,Infliximab Pfizer (Unknown),Arthropod bite,OT
154592797,Infliximab Pfizer (Unknown),Abdominal pain upper,OT
164803343,Infliximab,Weight increased,OT
164803343,Infliximab,Off label use,OT
164803343,Infliximab,Flushing,OT
164803343,Infliximab,Drug ineffective,OT
164803343,Infliximab,Weight increased,OT
164803343,Infliximab,Off label use,OT
164803343,Infliximab,Flushing,OT
164803343,Infliximab,Drug ineffective,OT
164955535,Infliximab,Wound,OT
164955535,Infliximab,Weight increased,OT
164955535,Infliximab,Uveitis,OT
164955535,Infliximab,Skin lesion,OT
164955535,Infliximab,Skin exfoliation,OT
164955535,Infliximab,Rheumatoid arthritis,OT
164955535,Infliximab,Pyrexia,OT
164955535,Infliximab,Peripheral swelling,OT
164955535,Infliximab,Periorbital swelling,OT
164955535,Infliximab,Off label use,OT
164955535,Infliximab,Neoplasm progression,OT
164955535,Infliximab,Nasopharyngitis,OT
164955535,Infliximab,Musculoskeletal stiffness,OT
164955535,Infliximab,Mouth ulceration,OT
164955535,Infliximab,Malaise,OT
164955535,Infliximab,Intentional product use issue,OT
164955535,Infliximab,Inappropriate schedule of product administration,OT
164955535,Infliximab,Impaired healing,OT
164955535,Infliximab,Hyperphagia,OT
164955535,Infliximab,Heart rate decreased,OT
164955535,Infliximab,Gait disturbance,OT
164955535,Infliximab,Fistula,OT
164955535,Infliximab,Dry skin,OT
164955535,Infliximab,Condition aggravated,OT
164955535,Infliximab,Blood pressure increased,OT
164955535,Infliximab,Blood pressure decreased,OT
164955535,Infliximab,Arthralgia,OT
164955535,Infliximab,Aphthous ulcer,OT
164955535,Infliximab,Anal fissure,OT
164955535,Infliximab,Alopecia,OT
164955535,Infliximab,Acne,OT
164955535,Infliximab,Abdominal discomfort,OT
164955535,Infliximab,Wound,OT
164955535,Infliximab,Weight increased,OT
164955535,Infliximab,Uveitis,OT
164955535,Infliximab,Skin lesion,OT
164955535,Infliximab,Skin exfoliation,OT
164955535,Infliximab,Rheumatoid arthritis,OT
164955535,Infliximab,Pyrexia,OT
164955535,Infliximab,Peripheral swelling,OT
164955535,Infliximab,Periorbital swelling,OT
164955535,Infliximab,Off label use,OT
164955535,Infliximab,Neoplasm progression,OT
164955535,Infliximab,Nasopharyngitis,OT
164955535,Infliximab,Musculoskeletal stiffness,OT
164955535,Infliximab,Mouth ulceration,OT
164955535,Infliximab,Malaise,OT
164955535,Infliximab,Intentional product use issue,OT
164955535,Infliximab,Inappropriate schedule of product administration,OT
164955535,Infliximab,Impaired healing,OT
164955535,Infliximab,Hyperphagia,OT
164955535,Infliximab,Heart rate decreased,OT
164955535,Infliximab,Gait disturbance,OT
164955535,Infliximab,Fistula,OT
164955535,Infliximab,Dry skin,OT
164955535,Infliximab,Condition aggravated,OT
164955535,Infliximab,Blood pressure increased,OT
164955535,Infliximab,Blood pressure decreased,OT
164955535,Infliximab,Arthralgia,OT
164955535,Infliximab,Aphthous ulcer,OT
164955535,Infliximab,Anal fissure,OT
164955535,Infliximab,Alopecia,OT
164955535,Infliximab,Acne,OT
164955535,Infliximab,Abdominal discomfort,OT
165679744,Infliximab,Visual impairment,OT
165679744,Infliximab,Viral infection,OT
165679744,Infliximab,Urticaria,OT
165679744,Infliximab,Therapeutic product effect incomplete,OT
165679744,Infliximab,Tendon pain,OT
165679744,Infliximab,Skin plaque,OT
165679744,Infliximab,Rhinorrhoea,OT
165679744,Infliximab,Renal disorder,OT
165679744,Infliximab,Rectal haemorrhage,OT
165679744,Infliximab,Rash,OT
165679744,Infliximab,Pyrexia,OT
165679744,Infliximab,Psoriasis,OT
165679744,Infliximab,Product use issue,OT
165679744,Infliximab,Off label use,OT
165679744,Infliximab,Nausea,OT
165679744,Infliximab,Liver disorder,OT
165679744,Infliximab,Intentional product use issue,OT
165679744,Infliximab,Influenza,OT
165679744,Infliximab,Headache,OT
165679744,Infliximab,Head discomfort,OT
165679744,Infliximab,Haematochezia,OT
165679744,Infliximab,Fistula,OT
165679744,Infliximab,Fatigue,OT
165679744,Infliximab,Erythema,OT
165679744,Infliximab,Drug specific antibody present,OT
165679744,Infliximab,Drug level below therapeutic,OT
165679744,Infliximab,Cough,OT
165679744,Infliximab,Condition aggravated,OT
165679744,Infliximab,Blood pressure increased,OT
165679744,Infliximab,Blood pressure fluctuation,OT
165679744,Infliximab,Asthenia,OT
165679744,Infliximab,Arthralgia,OT
165679744,Infliximab,Anorectal discomfort,OT
165679744,Infliximab,Anal pruritus,OT
165679744,Infliximab,Anal fissure,OT
165679744,Infliximab,Visual impairment,OT
165679744,Infliximab,Viral infection,OT
165679744,Infliximab,Urticaria,OT
165679744,Infliximab,Therapeutic product effect incomplete,OT
165679744,Infliximab,Tendon pain,OT
165679744,Infliximab,Skin plaque,OT
165679744,Infliximab,Rhinorrhoea,OT
165679744,Infliximab,Renal disorder,OT
165679744,Infliximab,Rectal haemorrhage,OT
165679744,Infliximab,Rash,OT
165679744,Infliximab,Pyrexia,OT
165679744,Infliximab,Psoriasis,OT
165679744,Infliximab,Product use issue,OT
165679744,Infliximab,Off label use,OT
165679744,Infliximab,Nausea,OT
165679744,Infliximab,Liver disorder,OT
165679744,Infliximab,Intentional product use issue,OT
165679744,Infliximab,Influenza,OT
165679744,Infliximab,Headache,OT
165679744,Infliximab,Head discomfort,OT
165679744,Infliximab,Haematochezia,OT
165679744,Infliximab,Fistula,OT
165679744,Infliximab,Fatigue,OT
165679744,Infliximab,Erythema,OT
165679744,Infliximab,Drug specific antibody present,OT
165679744,Infliximab,Drug level below therapeutic,OT
165679744,Infliximab,Cough,OT
165679744,Infliximab,Condition aggravated,OT
165679744,Infliximab,Blood pressure increased,OT
165679744,Infliximab,Blood pressure fluctuation,OT
165679744,Infliximab,Asthenia,OT
165679744,Infliximab,Arthralgia,OT
165679744,Infliximab,Anorectal discomfort,OT
165679744,Infliximab,Anal pruritus,OT
165679744,Infliximab,Anal fissure,OT
168305724,Infliximab,Therapeutic response shortened,OT
168305724,Infliximab,Therapeutic product effect incomplete,OT
168305724,Infliximab,Therapeutic product effect decreased,OT
168305724,Infliximab,Product use issue,OT
168305724,Infliximab,Pain,OT
168305724,Infliximab,Oropharyngeal pain,OT
168305724,Infliximab,Off label use,OT
168305724,Infliximab,Intentional product use issue,OT
168305724,Infliximab,Insomnia,OT
168305724,Infliximab,Inappropriate schedule of product administration,OT
168305724,Infliximab,Heart rate decreased,OT
168305724,Infliximab,Chest pain,OT
168305724,Infliximab,Blood pressure systolic increased,OT
168305724,Infliximab,Blood pressure increased,OT
168305724,Infliximab,Blood pressure fluctuation,OT
168305724,Infliximab,Blood pressure diastolic decreased,OT
168305724,Infliximab,Asphyxia,OT
168305724,Infliximab,Therapeutic response shortened,OT
168305724,Infliximab,Therapeutic product effect incomplete,OT
168305724,Infliximab,Therapeutic product effect decreased,OT
168305724,Infliximab,Product use issue,OT
168305724,Infliximab,Pain,OT
168305724,Infliximab,Oropharyngeal pain,OT
168305724,Infliximab,Off label use,OT
168305724,Infliximab,Intentional product use issue,OT
168305724,Infliximab,Insomnia,OT
168305724,Infliximab,Inappropriate schedule of product administration,OT
168305724,Infliximab,Heart rate decreased,OT
168305724,Infliximab,Chest pain,OT
168305724,Infliximab,Blood pressure systolic increased,OT
168305724,Infliximab,Blood pressure increased,OT
168305724,Infliximab,Blood pressure fluctuation,OT
168305724,Infliximab,Blood pressure diastolic decreased,OT
168305724,Infliximab,Asphyxia,OT
168305724,Infliximab,Therapeutic response shortened,OT
168305724,Infliximab,Therapeutic product effect incomplete,OT
168305724,Infliximab,Therapeutic product effect decreased,OT
168305724,Infliximab,Product use issue,OT
168305724,Infliximab,Pain,OT
168305724,Infliximab,Oropharyngeal pain,OT
168305724,Infliximab,Off label use,OT
168305724,Infliximab,Intentional product use issue,OT
168305724,Infliximab,Insomnia,OT
168305724,Infliximab,Inappropriate schedule of product administration,OT
168305724,Infliximab,Heart rate decreased,OT
168305724,Infliximab,Chest pain,OT
168305724,Infliximab,Blood pressure systolic increased,OT
168305724,Infliximab,Blood pressure increased,OT
168305724,Infliximab,Blood pressure fluctuation,OT
168305724,Infliximab,Blood pressure diastolic decreased,OT
168305724,Infliximab,Asphyxia,OT
173131773,Infliximab,Vogt-Koyanagi-Harada disease,OT
173131773,Infliximab,Product use in unapproved indication,OT
173131773,Infliximab,Off label use,OT
173131773,Infliximab,Drug effective for unapproved indication,OT
173131773,Infliximab,Condition aggravated,OT
173865485,Infliximab,Weight decreased,HO
173865485,Infliximab,Weight decreased,OT
173865485,Infliximab,Urinary tract infection,HO
173865485,Infliximab,Urinary tract infection,OT
173865485,Infliximab,Therapeutic product effect incomplete,HO
173865485,Infliximab,Therapeutic product effect incomplete,OT
173865485,Infliximab,Tachycardia,HO
173865485,Infliximab,Tachycardia,OT
173865485,Infliximab,Rhinorrhoea,HO
173865485,Infliximab,Rhinorrhoea,OT
173865485,Infliximab,Respiratory tract infection,HO
173865485,Infliximab,Respiratory tract infection,OT
173865485,Infliximab,Pulmonary mass,HO
173865485,Infliximab,Pulmonary mass,OT
173865485,Infliximab,Productive cough,HO
173865485,Infliximab,Productive cough,OT
173865485,Infliximab,Product use issue,HO
173865485,Infliximab,Product use issue,OT
173865485,Infliximab,Product dose omission issue,HO
173865485,Infliximab,Product dose omission issue,OT
173865485,Infliximab,Poor venous access,HO
173865485,Infliximab,Poor venous access,OT
173865485,Infliximab,Pain,HO
173865485,Infliximab,Pain,OT
173865485,Infliximab,Off label use,HO
173865485,Infliximab,Off label use,OT
173865485,Infliximab,Nasopharyngitis,HO
173865485,Infliximab,Nasopharyngitis,OT
173865485,Infliximab,Myalgia,HO
173865485,Infliximab,Myalgia,OT
173865485,Infliximab,Muscle spasms,HO
173865485,Infliximab,Muscle spasms,OT
173865485,Infliximab,Lung neoplasm malignant,HO
173865485,Infliximab,Lung neoplasm malignant,OT
173865485,Infliximab,Intentional product use issue,HO
173865485,Infliximab,Intentional product use issue,OT
173865485,Infliximab,Insomnia,HO
173865485,Infliximab,Insomnia,OT
173865485,Infliximab,Incorrect dose administered,HO
173865485,Infliximab,Incorrect dose administered,OT
173865485,Infliximab,Inappropriate schedule of product administration,HO
173865485,Infliximab,Inappropriate schedule of product administration,OT
173865485,Infliximab,Hyperhidrosis,HO
173865485,Infliximab,Hyperhidrosis,OT
173865485,Infliximab,Hepatic steatosis,HO
173865485,Infliximab,Hepatic steatosis,OT
173865485,Infliximab,Hepatic lesion,HO
173865485,Infliximab,Hepatic lesion,OT
173865485,Infliximab,Heart rate increased,HO
173865485,Infliximab,Heart rate increased,OT
173865485,Infliximab,Gastritis,HO
173865485,Infliximab,Gastritis,OT
173865485,Infliximab,Feeding disorder,HO
173865485,Infliximab,Feeding disorder,OT
173865485,Infliximab,Fatigue,HO
173865485,Infliximab,Fatigue,OT
173865485,Infliximab,Emotional distress,HO
173865485,Infliximab,Emotional distress,OT
173865485,Infliximab,Bronchitis,HO
173865485,Infliximab,Bronchitis,OT
173865485,Infliximab,Body temperature increased,HO
173865485,Infliximab,Body temperature increased,OT
173865485,Infliximab,Blood pressure fluctuation,HO
173865485,Infliximab,Blood pressure fluctuation,OT
173865485,Infliximab,Back pain,HO
173865485,Infliximab,Back pain,OT
173865485,Infliximab,Anaemia,HO
173865485,Infliximab,Anaemia,OT
173865485,Infliximab,Weight decreased,HO
173865485,Infliximab,Weight decreased,OT
173865485,Infliximab,Urinary tract infection,HO
173865485,Infliximab,Urinary tract infection,OT
173865485,Infliximab,Therapeutic product effect incomplete,HO
173865485,Infliximab,Therapeutic product effect incomplete,OT
173865485,Infliximab,Tachycardia,HO
173865485,Infliximab,Tachycardia,OT
173865485,Infliximab,Rhinorrhoea,HO
173865485,Infliximab,Rhinorrhoea,OT
173865485,Infliximab,Respiratory tract infection,HO
173865485,Infliximab,Respiratory tract infection,OT
173865485,Infliximab,Pulmonary mass,HO
173865485,Infliximab,Pulmonary mass,OT
173865485,Infliximab,Productive cough,HO
173865485,Infliximab,Productive cough,OT
173865485,Infliximab,Product use issue,HO
173865485,Infliximab,Product use issue,OT
173865485,Infliximab,Product dose omission issue,HO
173865485,Infliximab,Product dose omission issue,OT
173865485,Infliximab,Poor venous access,HO
173865485,Infliximab,Poor venous access,OT
173865485,Infliximab,Pain,HO
173865485,Infliximab,Pain,OT
173865485,Infliximab,Off label use,HO
173865485,Infliximab,Off label use,OT
173865485,Infliximab,Nasopharyngitis,HO
173865485,Infliximab,Nasopharyngitis,OT
173865485,Infliximab,Myalgia,HO
173865485,Infliximab,Myalgia,OT
173865485,Infliximab,Muscle spasms,HO
173865485,Infliximab,Muscle spasms,OT
173865485,Infliximab,Lung neoplasm malignant,HO
173865485,Infliximab,Lung neoplasm malignant,OT
173865485,Infliximab,Intentional product use issue,HO
173865485,Infliximab,Intentional product use issue,OT
173865485,Infliximab,Insomnia,HO
173865485,Infliximab,Insomnia,OT
173865485,Infliximab,Incorrect dose administered,HO
173865485,Infliximab,Incorrect dose administered,OT
173865485,Infliximab,Inappropriate schedule of product administration,HO
173865485,Infliximab,Inappropriate schedule of product administration,OT
173865485,Infliximab,Hyperhidrosis,HO
173865485,Infliximab,Hyperhidrosis,OT
173865485,Infliximab,Hepatic steatosis,HO
173865485,Infliximab,Hepatic steatosis,OT
173865485,Infliximab,Hepatic lesion,HO
173865485,Infliximab,Hepatic lesion,OT
173865485,Infliximab,Heart rate increased,HO
173865485,Infliximab,Heart rate increased,OT
173865485,Infliximab,Gastritis,HO
173865485,Infliximab,Gastritis,OT
173865485,Infliximab,Feeding disorder,HO
173865485,Infliximab,Feeding disorder,OT
173865485,Infliximab,Fatigue,HO
173865485,Infliximab,Fatigue,OT
173865485,Infliximab,Emotional distress,HO
173865485,Infliximab,Emotional distress,OT
173865485,Infliximab,Bronchitis,HO
173865485,Infliximab,Bronchitis,OT
173865485,Infliximab,Body temperature increased,HO
173865485,Infliximab,Body temperature increased,OT
173865485,Infliximab,Blood pressure fluctuation,HO
173865485,Infliximab,Blood pressure fluctuation,OT
173865485,Infliximab,Back pain,HO
173865485,Infliximab,Back pain,OT
173865485,Infliximab,Anaemia,HO
173865485,Infliximab,Anaemia,OT
175333663,Infliximab,Weight decreased,HO
175333663,Infliximab,Urinary tract infection,HO
175333663,Infliximab,Off label use,HO
175333663,Infliximab,Myalgia,HO
175333663,Infliximab,Inappropriate schedule of product administration,HO
175333663,Infliximab,Heart rate irregular,HO
175333663,Infliximab,Cystitis,HO
175333663,Infliximab,Arthralgia,HO
176266463,Infliximab,Weight increased,OT
176266463,Infliximab,Weight decreased,OT
176266463,Infliximab,Rheumatoid arthritis,OT
176266463,Infliximab,Pyoderma gangrenosum,OT
176266463,Infliximab,Off label use,OT
176266463,Infliximab,Joint swelling,OT
176266463,Infliximab,Intentional product use issue,OT
176266463,Infliximab,Incorrect dose administered,OT
176266463,Infliximab,Inappropriate schedule of product administration,OT
176266463,Infliximab,Fatigue,OT
176266463,Infliximab,Erythema nodosum,OT
176266463,Infliximab,Dysgraphia,OT
176266463,Infliximab,Condition aggravated,OT
176266463,Infliximab,Blood pressure increased,OT
176266463,Infliximab,Blood pressure fluctuation,OT
176266463,Infliximab,Arthralgia,OT
176266463,Infliximab,Aphthous ulcer,OT
176266463,Infliximab,Anal fissure,OT
176266463,Infliximab,Abscess,OT
176266463,Infliximab,Abdominal pain,OT
176266463,Infliximab,Weight increased,OT
176266463,Infliximab,Weight decreased,OT
176266463,Infliximab,Rheumatoid arthritis,OT
176266463,Infliximab,Pyoderma gangrenosum,OT
176266463,Infliximab,Off label use,OT
176266463,Infliximab,Joint swelling,OT
176266463,Infliximab,Intentional product use issue,OT
176266463,Infliximab,Incorrect dose administered,OT
176266463,Infliximab,Inappropriate schedule of product administration,OT
176266463,Infliximab,Fatigue,OT
176266463,Infliximab,Erythema nodosum,OT
176266463,Infliximab,Dysgraphia,OT
176266463,Infliximab,Condition aggravated,OT
176266463,Infliximab,Blood pressure increased,OT
176266463,Infliximab,Blood pressure fluctuation,OT
176266463,Infliximab,Arthralgia,OT
176266463,Infliximab,Aphthous ulcer,OT
176266463,Infliximab,Anal fissure,OT
176266463,Infliximab,Abscess,OT
176266463,Infliximab,Abdominal pain,OT
176403552,Infliximab,Off label use,OT
176403552,Infliximab,Haematochezia,OT
176403552,Infliximab,Condition aggravated,OT
176594615,Infliximab,Weight increased,OT
176594615,Infliximab,Uveitis,OT
176594615,Infliximab,Pain in extremity,OT
176594615,Infliximab,Off label use,OT
176594615,Infliximab,Nasopharyngitis,OT
176594615,Infliximab,Influenza,OT
176594615,Infliximab,Increased appetite,OT
176594615,Infliximab,Dyspnoea,OT
176594615,Infliximab,Condition aggravated,OT
176594615,Infliximab,Chills,OT
176594615,Infliximab,Blood pressure increased,OT
176594615,Infliximab,Blood pressure fluctuation,OT
176594615,Infliximab,Arthralgia,OT
176594615,Infliximab,Alcohol intolerance,OT
176594615,Infliximab,Weight increased,OT
176594615,Infliximab,Uveitis,OT
176594615,Infliximab,Pain in extremity,OT
176594615,Infliximab,Off label use,OT
176594615,Infliximab,Nasopharyngitis,OT
176594615,Infliximab,Influenza,OT
176594615,Infliximab,Increased appetite,OT
176594615,Infliximab,Dyspnoea,OT
176594615,Infliximab,Condition aggravated,OT
176594615,Infliximab,Chills,OT
176594615,Infliximab,Blood pressure increased,OT
176594615,Infliximab,Blood pressure fluctuation,OT
176594615,Infliximab,Arthralgia,OT
176594615,Infliximab,Alcohol intolerance,OT
176594615,Infliximab,Weight increased,OT
176594615,Infliximab,Uveitis,OT
176594615,Infliximab,Pain in extremity,OT
176594615,Infliximab,Off label use,OT
176594615,Infliximab,Nasopharyngitis,OT
176594615,Infliximab,Influenza,OT
176594615,Infliximab,Increased appetite,OT
176594615,Infliximab,Dyspnoea,OT
176594615,Infliximab,Condition aggravated,OT
176594615,Infliximab,Chills,OT
176594615,Infliximab,Blood pressure increased,OT
176594615,Infliximab,Blood pressure fluctuation,OT
176594615,Infliximab,Arthralgia,OT
176594615,Infliximab,Alcohol intolerance,OT
176886813,Infliximab,Weight decreased,OT
176886813,Infliximab,Therapeutic product effect incomplete,OT
176886813,Infliximab,Proctalgia,OT
176886813,Infliximab,Off label use,OT
176886813,Infliximab,Intentional product use issue,OT
176886813,Infliximab,Infected dermal cyst,OT
176886813,Infliximab,Inappropriate schedule of product administration,OT
176886813,Infliximab,Heart rate decreased,OT
176886813,Infliximab,Faecal calprotectin increased,OT
176886813,Infliximab,Extra dose administered,OT
176886813,Infliximab,Drug level below therapeutic,OT
176886813,Infliximab,Condition aggravated,OT
176886813,Infliximab,C-reactive protein increased,OT
176886813,Infliximab,Arthralgia,OT
176886813,Infliximab,Anorectal discomfort,OT
176886813,Infliximab,Anal fistula,OT
177061843,Infliximab,Therapeutic response shortened,OT
177061843,Infliximab,Stress,OT
177061843,Infliximab,Sinusitis,OT
177061843,Infliximab,Sinonasal obstruction,OT
177061843,Infliximab,Rhinorrhoea,OT
177061843,Infliximab,Off label use,OT
177061843,Infliximab,Nasopharyngitis,OT
177061843,Infliximab,Migraine,OT
177061843,Infliximab,Infection,OT
177061843,Infliximab,Incorrect dose administered,OT
177061843,Infliximab,Inappropriate schedule of product administration,OT
177061843,Infliximab,Fatigue,OT
177061843,Infliximab,Epistaxis,OT
177061843,Infliximab,Dyspnoea,OT
177061843,Infliximab,Drug level increased,OT
177061843,Infliximab,Condition aggravated,OT
177061843,Infliximab,Blood pressure increased,OT
177061843,Infliximab,Blood pressure fluctuation,OT
177061843,Infliximab,Therapeutic response shortened,OT
177061843,Infliximab,Stress,OT
177061843,Infliximab,Sinusitis,OT
177061843,Infliximab,Sinonasal obstruction,OT
177061843,Infliximab,Rhinorrhoea,OT
177061843,Infliximab,Off label use,OT
177061843,Infliximab,Nasopharyngitis,OT
177061843,Infliximab,Migraine,OT
177061843,Infliximab,Infection,OT
177061843,Infliximab,Incorrect dose administered,OT
177061843,Infliximab,Inappropriate schedule of product administration,OT
177061843,Infliximab,Fatigue,OT
177061843,Infliximab,Epistaxis,OT
177061843,Infliximab,Dyspnoea,OT
177061843,Infliximab,Drug level increased,OT
177061843,Infliximab,Condition aggravated,OT
177061843,Infliximab,Blood pressure increased,OT
177061843,Infliximab,Blood pressure fluctuation,OT
177178673,Infliximab,Weight increased,HO
177178673,Infliximab,Weight increased,OT
177178673,Infliximab,Off label use,HO
177178673,Infliximab,Off label use,OT
177178673,Infliximab,Intentional product use issue,HO
177178673,Infliximab,Intentional product use issue,OT
177178673,Infliximab,Inappropriate schedule of product administration,HO
177178673,Infliximab,Inappropriate schedule of product administration,OT
177178673,Infliximab,Condition aggravated,HO
177178673,Infliximab,Condition aggravated,OT
177178673,Infliximab,Cerebrovascular accident,HO
177178673,Infliximab,Cerebrovascular accident,OT
177254815,Infliximab,Weight increased,OT
177254815,Infliximab,Weight decreased,OT
177254815,Infliximab,Vomiting,OT
177254815,Infliximab,Skin discolouration,OT
177254815,Infliximab,Off label use,OT
177254815,Infliximab,Nausea,OT
177254815,Infliximab,Malaise,OT
177254815,Infliximab,Intentional product use issue,OT
177254815,Infliximab,Incorrect dose administered,OT
177254815,Infliximab,Inappropriate schedule of product administration,OT
177254815,Infliximab,Hot flush,OT
177254815,Infliximab,Food intolerance,OT
177254815,Infliximab,Feeling hot,OT
177254815,Infliximab,Fatigue,OT
177254815,Infliximab,Eye discharge,OT
177254815,Infliximab,Erythema,OT
177254815,Infliximab,Decreased appetite,OT
177254815,Infliximab,Cough,OT
177254815,Infliximab,Breast pain,OT
177254815,Infliximab,Blood pressure increased,OT
177254815,Infliximab,Angina pectoris,OT
177254815,Infliximab,Abdominal pain upper,OT
177254815,Infliximab,Abdominal pain,OT
178016963,Infliximab,Weight increased,OT
178016963,Infliximab,Tooth abscess,OT
178016963,Infliximab,Therapeutic product effect incomplete,OT
178016963,Infliximab,Rash,OT
178016963,Infliximab,Product use issue,OT
178016963,Infliximab,Off label use,OT
178016963,Infliximab,Nausea,OT
178016963,Infliximab,Intestinal obstruction,OT
178016963,Infliximab,Intentional product use issue,OT
178016963,Infliximab,Infusion related reaction,OT
178016963,Infliximab,Hypotension,OT
178016963,Infliximab,Flushing,OT
178016963,Infliximab,Feeling hot,OT
178016963,Infliximab,Condition aggravated,OT
178016963,Infliximab,Chest discomfort,OT
178016963,Infliximab,Body temperature fluctuation,OT
178016963,Infliximab,Body temperature decreased,OT
178016963,Infliximab,Blood pressure fluctuation,OT
178016963,Infliximab,Weight increased,OT
178016963,Infliximab,Tooth abscess,OT
178016963,Infliximab,Therapeutic product effect incomplete,OT
178016963,Infliximab,Rash,OT
178016963,Infliximab,Product use issue,OT
178016963,Infliximab,Off label use,OT
178016963,Infliximab,Nausea,OT
178016963,Infliximab,Intestinal obstruction,OT
178016963,Infliximab,Intentional product use issue,OT
178016963,Infliximab,Infusion related reaction,OT
178016963,Infliximab,Hypotension,OT
178016963,Infliximab,Flushing,OT
178016963,Infliximab,Feeling hot,OT
178016963,Infliximab,Condition aggravated,OT
178016963,Infliximab,Chest discomfort,OT
178016963,Infliximab,Body temperature fluctuation,OT
178016963,Infliximab,Body temperature decreased,OT
178016963,Infliximab,Blood pressure fluctuation,OT
184111874,Infliximab,Weight increased,HO
184111874,Infliximab,Pyrexia,HO
184111874,Infliximab,Off label use,HO
184111874,Infliximab,Nasopharyngitis,HO
184111874,Infliximab,Heart rate irregular,HO
184111874,Infliximab,Dehydration,HO
184111874,Infliximab,Condition aggravated,HO
184111874,Infliximab,Blood pressure increased,HO
184111874,Infliximab,Blood pressure fluctuation,HO
184111874,Infliximab,Weight increased,HO
184111874,Infliximab,Pyrexia,HO
184111874,Infliximab,Off label use,HO
184111874,Infliximab,Nasopharyngitis,HO
184111874,Infliximab,Heart rate irregular,HO
184111874,Infliximab,Dehydration,HO
184111874,Infliximab,Condition aggravated,HO
184111874,Infliximab,Blood pressure increased,HO
184111874,Infliximab,Blood pressure fluctuation,HO
184564913,Infliximab,Weight increased,OT
184564913,Infliximab,Weight decreased,OT
184564913,Infliximab,Pain,OT
184564913,Infliximab,Nasopharyngitis,OT
184564913,Infliximab,Nasal disorder,OT
184564913,Infliximab,Inappropriate schedule of product administration,OT
184564913,Infliximab,Cough,OT
184564913,Infliximab,Abdominal distension,OT
184747544,Infliximab,Therapeutic product effect incomplete,OT
184747544,Infliximab,Product use issue,OT
184747544,Infliximab,Poor venous access,OT
184747544,Infliximab,Off label use,OT
184747544,Infliximab,Malaise,OT
184747544,Infliximab,Intentional product use issue,OT
184747544,Infliximab,Inappropriate schedule of product administration,OT
184747544,Infliximab,Illness,OT
184747544,Infliximab,Hypertension,OT
184747544,Infliximab,Hyperhidrosis,OT
184747544,Infliximab,Fatigue,OT
184747544,Infliximab,Condition aggravated,OT
184747544,Infliximab,Blood pressure fluctuation,OT
184747544,Infliximab,Blood pressure diastolic decreased,OT
184747544,Infliximab,Blood pressure decreased,OT
184747544,Infliximab,Arthralgia,OT
184747544,Infliximab,Therapeutic product effect incomplete,OT
184747544,Infliximab,Product use issue,OT
184747544,Infliximab,Poor venous access,OT
184747544,Infliximab,Off label use,OT
184747544,Infliximab,Malaise,OT
184747544,Infliximab,Intentional product use issue,OT
184747544,Infliximab,Inappropriate schedule of product administration,OT
184747544,Infliximab,Illness,OT
184747544,Infliximab,Hypertension,OT
184747544,Infliximab,Hyperhidrosis,OT
184747544,Infliximab,Fatigue,OT
184747544,Infliximab,Condition aggravated,OT
184747544,Infliximab,Blood pressure fluctuation,OT
184747544,Infliximab,Blood pressure diastolic decreased,OT
184747544,Infliximab,Blood pressure decreased,OT
184747544,Infliximab,Arthralgia,OT
184866693,Infliximab,Weight decreased,OT
184866693,Infliximab,Taste disorder,OT
184866693,Infliximab,Tachycardia,OT
184866693,Infliximab,Stress,OT
184866693,Infliximab,Sinus polyp,OT
184866693,Infliximab,Rib fracture,OT
184866693,Infliximab,Respiratory disorder,OT
184866693,Infliximab,Pyrexia,OT
184866693,Infliximab,Psoriasis,OT
184866693,Infliximab,Productive cough,OT
184866693,Infliximab,Parosmia,OT
184866693,Infliximab,Pain,OT
184866693,Infliximab,Off label use,OT
184866693,Infliximab,Nasopharyngitis,OT
184866693,Infliximab,Nasal polyps,OT
184866693,Infliximab,Nasal congestion,OT
184866693,Infliximab,Musculoskeletal chest pain,OT
184866693,Infliximab,Migraine with aura,OT
184866693,Infliximab,Malaise,OT
184866693,Infliximab,Intentional product use issue,OT
184866693,Infliximab,Influenza,OT
184866693,Infliximab,Inappropriate schedule of product administration,OT
184866693,Infliximab,Hypotension,OT
184866693,Infliximab,Hypersensitivity,OT
184866693,Infliximab,Heart rate decreased,OT
184866693,Infliximab,Headache,OT
184866693,Infliximab,Full blood count abnormal,OT
184866693,Infliximab,Fatigue,OT
184866693,Infliximab,Extrasystoles,OT
184866693,Infliximab,Dyspnoea,OT
184866693,Infliximab,Dizziness,OT
184866693,Infliximab,Dehydration,OT
184866693,Infliximab,Cough,OT
184866693,Infliximab,Condition aggravated,OT
184866693,Infliximab,COVID-19,OT
184866693,Infliximab,Burning sensation,OT
184866693,Infliximab,Bronchitis,OT
184866693,Infliximab,Blood pressure increased,OT
184866693,Infliximab,Blood pressure fluctuation,OT
184866693,Infliximab,Anxiety,OT
184866693,Infliximab,Abdominal pain upper,OT
184916094,Infliximab,Skin mass,HO
184916094,Infliximab,Skin discolouration,HO
184916094,Infliximab,Pyrexia,HO
184916094,Infliximab,Pancreatitis,HO
184916094,Infliximab,Malaise,HO
184916094,Infliximab,Inflammatory bowel disease,HO
184916094,Infliximab,Feeling cold,HO
184916094,Infliximab,Condition aggravated,HO
184916094,Infliximab,Adrenal disorder,HO
184916094,Infliximab,Abdominal pain,HO
184916094,Infliximab,Skin mass,HO
184916094,Infliximab,Skin discolouration,HO
184916094,Infliximab,Pyrexia,HO
184916094,Infliximab,Pancreatitis,HO
184916094,Infliximab,Malaise,HO
184916094,Infliximab,Inflammatory bowel disease,HO
184916094,Infliximab,Feeling cold,HO
184916094,Infliximab,Condition aggravated,HO
184916094,Infliximab,Adrenal disorder,HO
184916094,Infliximab,Abdominal pain,HO
184996652,Infliximab,Weight increased,OT
184996652,Infliximab,Therapeutic response shortened,OT
184996652,Infliximab,Rectal polyp,OT
184996652,Infliximab,Pseudopolyposis,OT
184996652,Infliximab,Product use issue,OT
184996652,Infliximab,Pelvic pain,OT
184996652,Infliximab,Oropharyngeal pain,OT
184996652,Infliximab,Off label use,OT
184996652,Infliximab,Nasal congestion,OT
184996652,Infliximab,Muscular weakness,OT
184996652,Infliximab,Intentional product use issue,OT
184996652,Infliximab,Infusion site pain,OT
184996652,Infliximab,Heart rate increased,OT
184996652,Infliximab,Haemorrhoids,OT
184996652,Infliximab,Fatigue,OT
184996652,Infliximab,Drug level above therapeutic,OT
184996652,Infliximab,Drug ineffective,OT
184996652,Infliximab,Condition aggravated,OT
184996652,Infliximab,Blood pressure increased,OT
184996652,Infliximab,Abdominal distension,OT
184996652,Infliximab,Weight increased,OT
184996652,Infliximab,Therapeutic response shortened,OT
184996652,Infliximab,Rectal polyp,OT
184996652,Infliximab,Pseudopolyposis,OT
184996652,Infliximab,Product use issue,OT
184996652,Infliximab,Pelvic pain,OT
184996652,Infliximab,Oropharyngeal pain,OT
184996652,Infliximab,Off label use,OT
184996652,Infliximab,Nasal congestion,OT
184996652,Infliximab,Muscular weakness,OT
184996652,Infliximab,Intentional product use issue,OT
184996652,Infliximab,Infusion site pain,OT
184996652,Infliximab,Heart rate increased,OT
184996652,Infliximab,Haemorrhoids,OT
184996652,Infliximab,Fatigue,OT
184996652,Infliximab,Drug level above therapeutic,OT
184996652,Infliximab,Drug ineffective,OT
184996652,Infliximab,Condition aggravated,OT
184996652,Infliximab,Blood pressure increased,OT
184996652,Infliximab,Abdominal distension,OT
185127572,Infliximab,Weight decreased,OT
185127572,Infliximab,Weight decreased,HO
185127572,Infliximab,Therapeutic response shortened,OT
185127572,Infliximab,Therapeutic response shortened,HO
185127572,Infliximab,Product use issue,OT
185127572,Infliximab,Product use issue,HO
185127572,Infliximab,Pancreatitis,OT
185127572,Infliximab,Pancreatitis,HO
185127572,Infliximab,Off label use,OT
185127572,Infliximab,Off label use,HO
185127572,Infliximab,Intentional product use issue,OT
185127572,Infliximab,Intentional product use issue,HO
185127572,Infliximab,Inappropriate schedule of product administration,OT
185127572,Infliximab,Inappropriate schedule of product administration,HO
185127572,Infliximab,Heart rate decreased,OT
185127572,Infliximab,Heart rate decreased,HO
185127572,Infliximab,Faecal calprotectin increased,OT
185127572,Infliximab,Faecal calprotectin increased,HO
185127572,Infliximab,Disease recurrence,OT
185127572,Infliximab,Disease recurrence,HO
185127572,Infliximab,Condition aggravated,OT
185127572,Infliximab,Condition aggravated,HO
185127572,Infliximab,Blood pressure increased,OT
185127572,Infliximab,Blood pressure increased,HO
185127572,Infliximab,Back pain,OT
185127572,Infliximab,Back pain,HO
185451852,Infliximab,Weight increased,HO
185451852,Infliximab,Weight increased,OT
185451852,Infliximab,Therapeutic product effect incomplete,HO
185451852,Infliximab,Therapeutic product effect incomplete,OT
185451852,Infliximab,Skin cancer,HO
185451852,Infliximab,Skin cancer,OT
185451852,Infliximab,Product use issue,HO
185451852,Infliximab,Product use issue,OT
185451852,Infliximab,Off label use,HO
185451852,Infliximab,Off label use,OT
185451852,Infliximab,Nausea,HO
185451852,Infliximab,Nausea,OT
185451852,Infliximab,Intestinal obstruction,HO
185451852,Infliximab,Intestinal obstruction,OT
185451852,Infliximab,Intentional product use issue,HO
185451852,Infliximab,Intentional product use issue,OT
185451852,Infliximab,Gastrointestinal pain,HO
185451852,Infliximab,Gastrointestinal pain,OT
185451852,Infliximab,Fistula discharge,HO
185451852,Infliximab,Fistula discharge,OT
185451852,Infliximab,Drug level decreased,HO
185451852,Infliximab,Drug level decreased,OT
185451852,Infliximab,Condition aggravated,HO
185451852,Infliximab,Condition aggravated,OT
185451852,Infliximab,Back pain,HO
185451852,Infliximab,Back pain,OT
185451852,Infliximab,Axial spondyloarthritis,HO
185451852,Infliximab,Axial spondyloarthritis,OT
185451852,Infliximab,Atrial fibrillation,HO
185451852,Infliximab,Atrial fibrillation,OT
185451852,Infliximab,Weight increased,HO
185451852,Infliximab,Weight increased,OT
185451852,Infliximab,Therapeutic product effect incomplete,HO
185451852,Infliximab,Therapeutic product effect incomplete,OT
185451852,Infliximab,Skin cancer,HO
185451852,Infliximab,Skin cancer,OT
185451852,Infliximab,Product use issue,HO
185451852,Infliximab,Product use issue,OT
185451852,Infliximab,Off label use,HO
185451852,Infliximab,Off label use,OT
185451852,Infliximab,Nausea,HO
185451852,Infliximab,Nausea,OT
185451852,Infliximab,Intestinal obstruction,HO
185451852,Infliximab,Intestinal obstruction,OT
185451852,Infliximab,Intentional product use issue,HO
185451852,Infliximab,Intentional product use issue,OT
185451852,Infliximab,Gastrointestinal pain,HO
185451852,Infliximab,Gastrointestinal pain,OT
185451852,Infliximab,Fistula discharge,HO
185451852,Infliximab,Fistula discharge,OT
185451852,Infliximab,Drug level decreased,HO
185451852,Infliximab,Drug level decreased,OT
185451852,Infliximab,Condition aggravated,HO
185451852,Infliximab,Condition aggravated,OT
185451852,Infliximab,Back pain,HO
185451852,Infliximab,Back pain,OT
185451852,Infliximab,Axial spondyloarthritis,HO
185451852,Infliximab,Axial spondyloarthritis,OT
185451852,Infliximab,Atrial fibrillation,HO
185451852,Infliximab,Atrial fibrillation,OT
185543502,Infliximab,Postoperative wound infection,OT
185543502,Infliximab,Postoperative wound infection,HO
185543502,Infliximab,Off label use,OT
185543502,Infliximab,Off label use,HO
185543502,Infliximab,Malaise,OT
185543502,Infliximab,Malaise,HO
185543502,Infliximab,Inappropriate schedule of product administration,OT
185543502,Infliximab,Inappropriate schedule of product administration,HO
185543502,Infliximab,Gastritis,OT
185543502,Infliximab,Gastritis,HO
185543502,Infliximab,Crohn's disease,OT
185543502,Infliximab,Crohn's disease,HO
185543502,Infliximab,Cough,OT
185543502,Infliximab,Cough,HO
188914542,Infliximab,Product use issue,OT
188914542,Infliximab,Off label use,OT
188914542,Infliximab,Inappropriate schedule of product administration,OT
188914542,Infliximab,Heart rate irregular,OT
188914542,Infliximab,Blood pressure increased,OT
188914542,Infliximab,Blood pressure fluctuation,OT
190284823,Infliximab,Rectal haemorrhage,HO
190284823,Infliximab,Rectal haemorrhage,OT
190284823,Infliximab,Frequent bowel movements,HO
190284823,Infliximab,Frequent bowel movements,OT
190284823,Infliximab,Decreased activity,HO
190284823,Infliximab,Decreased activity,OT
190284823,Infliximab,Colitis ulcerative,HO
190284823,Infliximab,Colitis ulcerative,OT
190284823,Infliximab,Colitis,HO
190284823,Infliximab,Colitis,OT
190284823,Infliximab,Rectal haemorrhage,HO
190284823,Infliximab,Rectal haemorrhage,OT
190284823,Infliximab,Frequent bowel movements,HO
190284823,Infliximab,Frequent bowel movements,OT
190284823,Infliximab,Decreased activity,HO
190284823,Infliximab,Decreased activity,OT
190284823,Infliximab,Colitis ulcerative,HO
190284823,Infliximab,Colitis ulcerative,OT
190284823,Infliximab,Colitis,HO
190284823,Infliximab,Colitis,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
190669982,Infliximab Pfizer (Unknown),Weight increased,OT
190669982,Infliximab Pfizer (Unknown),Weight increased,HO
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
190669982,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,HO
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,OT
190669982,Infliximab Pfizer (Unknown),Rectal haemorrhage,HO
190669982,Infliximab Pfizer (Unknown),Off label use,OT
190669982,Infliximab Pfizer (Unknown),Off label use,HO
190669982,Infliximab Pfizer (Unknown),Nausea,OT
190669982,Infliximab Pfizer (Unknown),Nausea,HO
190669982,Infliximab Pfizer (Unknown),Faeces soft,OT
190669982,Infliximab Pfizer (Unknown),Faeces soft,HO
190669982,Infliximab Pfizer (Unknown),Drug level decreased,OT
190669982,Infliximab Pfizer (Unknown),Drug level decreased,HO
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,OT
190669982,Infliximab Pfizer (Unknown),Drug level above therapeutic,HO
190669982,Infliximab Pfizer (Unknown),Dizziness,OT
190669982,Infliximab Pfizer (Unknown),Dizziness,HO
190669982,Infliximab Pfizer (Unknown),Diarrhoea,OT
190669982,Infliximab Pfizer (Unknown),Diarrhoea,HO
194303772,Infliximab,Optic neuritis,OT
194303772,Infliximab,Off label use,OT
194303772,Infliximab,Optic neuritis,OT
194303772,Infliximab,Off label use,OT
195024541,Infliximab,Ventricular septal defect,OT
195024541,Infliximab,Inappropriate schedule of product administration,OT
196098511,Infliximab Hospira,Post procedural complication,DE
196575211,Infliximab,Off label use,OT
196575211,Infliximab,Haemorrhage,OT
196575211,Infliximab,Discomfort,OT
196575211,Infliximab,Contusion,OT
196575211,Infliximab,Off label use,OT
196575211,Infliximab,Haemorrhage,OT
196575211,Infliximab,Discomfort,OT
196575211,Infliximab,Contusion,OT
196662362,Infliximab BS for I.V. Infusion100 mg [NK],Sinusitis aspergillus,HO
196662362,Infliximab BS for I.V. Infusion100 mg [NK],Sinusitis aspergillus,OT
196662362,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
196662362,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,OT
196662362,Infliximab BS for I.V. Infusion100 mg [NK],Sinusitis aspergillus,HO
196662362,Infliximab BS for I.V. Infusion100 mg [NK],Sinusitis aspergillus,OT
196662362,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,HO
196662362,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,OT
196775901,Infliximab,Urinary tract infection,OT
196775901,Infliximab,Off label use,OT
196775901,Infliximab,Intentional product use issue,OT
196775901,Infliximab,Condition aggravated,OT
197023872,Infliximab,Therapeutic product effect decreased,OT
197023872,Infliximab,Paradoxical psoriasis,OT
197023872,Infliximab,Off label use,OT
197023872,Infliximab,Crohn's disease,OT
197023872,Infliximab,Therapeutic product effect decreased,OT
197023872,Infliximab,Paradoxical psoriasis,OT
197023872,Infliximab,Off label use,OT
197023872,Infliximab,Crohn's disease,OT
197023872,Infliximab,Therapeutic product effect decreased,OT
197023872,Infliximab,Paradoxical psoriasis,OT
197023872,Infliximab,Off label use,OT
197023872,Infliximab,Crohn's disease,OT
197023872,Infliximab,Therapeutic product effect decreased,OT
197023872,Infliximab,Paradoxical psoriasis,OT
197023872,Infliximab,Off label use,OT
197023872,Infliximab,Crohn's disease,OT
197066891,Infliximab Pfizer (Unknown),Treatment failure,OT
197066891,Infliximab Pfizer (Unknown),Treatment failure,HO
197066891,Infliximab Pfizer (Unknown),Colitis ulcerative,OT
197066891,Infliximab Pfizer (Unknown),Colitis ulcerative,HO
197147621,Infliximab (Unknown),Serositis,HO
197147621,Infliximab (Unknown),Serositis,OT
197147621,Infliximab (Unknown),Pneumonia mycoplasmal,HO
197147621,Infliximab (Unknown),Pneumonia mycoplasmal,OT
197147621,Infliximab (Unknown),Pleural effusion,HO
197147621,Infliximab (Unknown),Pleural effusion,OT
197147621,Infliximab (Unknown),Pericarditis,HO
197147621,Infliximab (Unknown),Pericarditis,OT
197147621,Infliximab (Unknown),Off label use,HO
197147621,Infliximab (Unknown),Off label use,OT
197147621,Infliximab (Unknown),Lupus-like syndrome,HO
197147621,Infliximab (Unknown),Lupus-like syndrome,OT
197147621,Infliximab (Unknown),Serositis,HO
197147621,Infliximab (Unknown),Serositis,OT
197147621,Infliximab (Unknown),Pneumonia mycoplasmal,HO
197147621,Infliximab (Unknown),Pneumonia mycoplasmal,OT
197147621,Infliximab (Unknown),Pleural effusion,HO
197147621,Infliximab (Unknown),Pleural effusion,OT
197147621,Infliximab (Unknown),Pericarditis,HO
197147621,Infliximab (Unknown),Pericarditis,OT
197147621,Infliximab (Unknown),Off label use,HO
197147621,Infliximab (Unknown),Off label use,OT
197147621,Infliximab (Unknown),Lupus-like syndrome,HO
197147621,Infliximab (Unknown),Lupus-like syndrome,OT
197942751,Infliximab,Urinary tract infection,OT
197942751,Infliximab,Pyelonephritis,OT
197942751,Infliximab,Metastatic cutaneous Crohn's disease,OT
197942751,Infliximab,Loss of therapeutic response,OT
197942751,Infliximab,Intestinal obstruction,OT
197942751,Infliximab,Crohn's disease,OT
197996671,Infliximab,Skin laceration,OT
197996671,Infliximab,Scab,OT
197996671,Infliximab,Road traffic accident,OT
197996671,Infliximab,Off label use,OT
197996671,Infliximab,Myalgia,OT
197996671,Infliximab,Eye haemorrhage,OT
197996671,Infliximab,Concussion,OT
198029871,Infliximab,Drug ineffective,OT
198323951,Infliximab,Drug ineffective,OT
198795651,Infliximab (Unknown),Treatment failure,NULL
198795651,Infliximab (Unknown),Inflammation,NULL
198849491,Infliximab,Sepsis,DE
198849491,Infliximab,Off label use,DE
198851421,Infliximab (Unknown),Off label use,NULL
198851421,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198988671,Infliximab,Wrong product administered,HO
198988671,Infliximab,Wrong product administered,OT
198988671,Infliximab,Weight decreased,HO
198988671,Infliximab,Weight decreased,OT
198988671,Infliximab,Product contamination,HO
198988671,Infliximab,Product contamination,OT
198988671,Infliximab,Poor quality product administered,HO
198988671,Infliximab,Poor quality product administered,OT
198988671,Infliximab,Off label use,HO
198988671,Infliximab,Off label use,OT
198988671,Infliximab,Nausea,HO
198988671,Infliximab,Nausea,OT
198988671,Infliximab,Melaena,HO
198988671,Infliximab,Melaena,OT
198988671,Infliximab,Intentional product use issue,HO
198988671,Infliximab,Intentional product use issue,OT
198988671,Infliximab,Inappropriate schedule of product administration,HO
198988671,Infliximab,Inappropriate schedule of product administration,OT
198988671,Infliximab,Constipation,HO
198988671,Infliximab,Constipation,OT
198988671,Infliximab,Body temperature decreased,HO
198988671,Infliximab,Body temperature decreased,OT
198988671,Infliximab,Blood pressure fluctuation,HO
198988671,Infliximab,Blood pressure fluctuation,OT
198988671,Infliximab,Abdominal distension,HO
198988671,Infliximab,Abdominal distension,OT
160735425,Infliximab,Treatment failure,OT
160735425,Infliximab,Synovitis,OT
160735425,Infliximab,Rheumatoid arthritis,OT
160735425,Infliximab,Product use issue,OT
160735425,Infliximab,Nervous system disorder,OT
160735425,Infliximab,Nausea,OT
160735425,Infliximab,Joint arthroplasty,OT
160735425,Infliximab,Hypersensitivity,OT
160735425,Infliximab,Drug intolerance,OT
160735425,Infliximab,Drug ineffective,OT
160735425,Infliximab,Drug hypersensitivity,OT
160735425,Infliximab,Condition aggravated,OT
160735425,Infliximab,Arthropathy,OT
160735425,Infliximab,Amnesia,OT
160735425,Infliximab,Treatment failure,OT
160735425,Infliximab,Synovitis,OT
160735425,Infliximab,Rheumatoid arthritis,OT
160735425,Infliximab,Product use issue,OT
160735425,Infliximab,Nervous system disorder,OT
160735425,Infliximab,Nausea,OT
160735425,Infliximab,Joint arthroplasty,OT
160735425,Infliximab,Hypersensitivity,OT
160735425,Infliximab,Drug intolerance,OT
160735425,Infliximab,Drug ineffective,OT
160735425,Infliximab,Drug hypersensitivity,OT
160735425,Infliximab,Condition aggravated,OT
160735425,Infliximab,Arthropathy,OT
160735425,Infliximab,Amnesia,OT
160799174,Infliximab,Wound,DE
160799174,Infliximab,Wound,HO
160799174,Infliximab,Wound,OT
160799174,Infliximab,Weight increased,DE
160799174,Infliximab,Weight increased,HO
160799174,Infliximab,Weight increased,OT
160799174,Infliximab,Weight decreased,DE
160799174,Infliximab,Weight decreased,HO
160799174,Infliximab,Weight decreased,OT
160799174,Infliximab,Therapeutic product effect incomplete,DE
160799174,Infliximab,Therapeutic product effect incomplete,HO
160799174,Infliximab,Therapeutic product effect incomplete,OT
160799174,Infliximab,Sputum discoloured,DE
160799174,Infliximab,Sputum discoloured,HO
160799174,Infliximab,Sputum discoloured,OT
160799174,Infliximab,Poor venous access,DE
160799174,Infliximab,Poor venous access,HO
160799174,Infliximab,Poor venous access,OT
160799174,Infliximab,Osteomyelitis,DE
160799174,Infliximab,Osteomyelitis,HO
160799174,Infliximab,Osteomyelitis,OT
160799174,Infliximab,Oropharyngeal pain,DE
160799174,Infliximab,Oropharyngeal pain,HO
160799174,Infliximab,Oropharyngeal pain,OT
160799174,Infliximab,Off label use,DE
160799174,Infliximab,Off label use,HO
160799174,Infliximab,Off label use,OT
160799174,Infliximab,Musculoskeletal pain,DE
160799174,Infliximab,Musculoskeletal pain,HO
160799174,Infliximab,Musculoskeletal pain,OT
160799174,Infliximab,Malaise,DE
160799174,Infliximab,Malaise,HO
160799174,Infliximab,Malaise,OT
160799174,Infliximab,Lung disorder,DE
160799174,Infliximab,Lung disorder,HO
160799174,Infliximab,Lung disorder,OT
160799174,Infliximab,Kidney congestion,DE
160799174,Infliximab,Kidney congestion,HO
160799174,Infliximab,Kidney congestion,OT
160799174,Infliximab,Intestinal obstruction,DE
160799174,Infliximab,Intestinal obstruction,HO
160799174,Infliximab,Intestinal obstruction,OT
160799174,Infliximab,Intentional product use issue,DE
160799174,Infliximab,Intentional product use issue,HO
160799174,Infliximab,Intentional product use issue,OT
160799174,Infliximab,Influenza,DE
160799174,Infliximab,Influenza,HO
160799174,Infliximab,Influenza,OT
160799174,Infliximab,Hypertension,DE
160799174,Infliximab,Hypertension,HO
160799174,Infliximab,Hypertension,OT
160799174,Infliximab,Haemoglobin decreased,DE
160799174,Infliximab,Haemoglobin decreased,HO
160799174,Infliximab,Haemoglobin decreased,OT
160799174,Infliximab,Cough,DE
160799174,Infliximab,Cough,HO
160799174,Infliximab,Cough,OT
160799174,Infliximab,Constipation,DE
160799174,Infliximab,Constipation,HO
160799174,Infliximab,Constipation,OT
160799174,Infliximab,Condition aggravated,DE
160799174,Infliximab,Condition aggravated,HO
160799174,Infliximab,Condition aggravated,OT
160799174,Infliximab,Chronic kidney disease,DE
160799174,Infliximab,Chronic kidney disease,HO
160799174,Infliximab,Chronic kidney disease,OT
160799174,Infliximab,Cellulitis,DE
160799174,Infliximab,Cellulitis,HO
160799174,Infliximab,Cellulitis,OT
160799174,Infliximab,Cataract,DE
160799174,Infliximab,Cataract,HO
160799174,Infliximab,Cataract,OT
160799174,Infliximab,COVID-19,DE
160799174,Infliximab,COVID-19,HO
160799174,Infliximab,COVID-19,OT
160799174,Infliximab,Blood pressure increased,DE
160799174,Infliximab,Blood pressure increased,HO
160799174,Infliximab,Blood pressure increased,OT
160799174,Infliximab,Blood pressure fluctuation,DE
160799174,Infliximab,Blood pressure fluctuation,HO
160799174,Infliximab,Blood pressure fluctuation,OT
160799174,Infliximab,Bladder obstruction,DE
160799174,Infliximab,Bladder obstruction,HO
160799174,Infliximab,Bladder obstruction,OT
160799174,Infliximab,Arthralgia,DE
160799174,Infliximab,Arthralgia,HO
160799174,Infliximab,Arthralgia,OT
160799174,Infliximab,Abnormal faeces,DE
160799174,Infliximab,Abnormal faeces,HO
160799174,Infliximab,Abnormal faeces,OT
160799174,Infliximab,Abdominal pain,DE
160799174,Infliximab,Abdominal pain,HO
160799174,Infliximab,Abdominal pain,OT
160799174,Infliximab,Wound,DE
160799174,Infliximab,Wound,HO
160799174,Infliximab,Wound,OT
160799174,Infliximab,Weight increased,DE
160799174,Infliximab,Weight increased,HO
160799174,Infliximab,Weight increased,OT
160799174,Infliximab,Weight decreased,DE
160799174,Infliximab,Weight decreased,HO
160799174,Infliximab,Weight decreased,OT
160799174,Infliximab,Therapeutic product effect incomplete,DE
160799174,Infliximab,Therapeutic product effect incomplete,HO
160799174,Infliximab,Therapeutic product effect incomplete,OT
160799174,Infliximab,Sputum discoloured,DE
160799174,Infliximab,Sputum discoloured,HO
160799174,Infliximab,Sputum discoloured,OT
160799174,Infliximab,Poor venous access,DE
160799174,Infliximab,Poor venous access,HO
160799174,Infliximab,Poor venous access,OT
160799174,Infliximab,Osteomyelitis,DE
160799174,Infliximab,Osteomyelitis,HO
160799174,Infliximab,Osteomyelitis,OT
160799174,Infliximab,Oropharyngeal pain,DE
160799174,Infliximab,Oropharyngeal pain,HO
160799174,Infliximab,Oropharyngeal pain,OT
160799174,Infliximab,Off label use,DE
160799174,Infliximab,Off label use,HO
160799174,Infliximab,Off label use,OT
160799174,Infliximab,Musculoskeletal pain,DE
160799174,Infliximab,Musculoskeletal pain,HO
160799174,Infliximab,Musculoskeletal pain,OT
160799174,Infliximab,Malaise,DE
160799174,Infliximab,Malaise,HO
160799174,Infliximab,Malaise,OT
160799174,Infliximab,Lung disorder,DE
160799174,Infliximab,Lung disorder,HO
160799174,Infliximab,Lung disorder,OT
160799174,Infliximab,Kidney congestion,DE
160799174,Infliximab,Kidney congestion,HO
160799174,Infliximab,Kidney congestion,OT
160799174,Infliximab,Intestinal obstruction,DE
160799174,Infliximab,Intestinal obstruction,HO
160799174,Infliximab,Intestinal obstruction,OT
160799174,Infliximab,Intentional product use issue,DE
160799174,Infliximab,Intentional product use issue,HO
160799174,Infliximab,Intentional product use issue,OT
160799174,Infliximab,Influenza,DE
160799174,Infliximab,Influenza,HO
160799174,Infliximab,Influenza,OT
160799174,Infliximab,Hypertension,DE
160799174,Infliximab,Hypertension,HO
160799174,Infliximab,Hypertension,OT
160799174,Infliximab,Haemoglobin decreased,DE
160799174,Infliximab,Haemoglobin decreased,HO
160799174,Infliximab,Haemoglobin decreased,OT
160799174,Infliximab,Cough,DE
160799174,Infliximab,Cough,HO
160799174,Infliximab,Cough,OT
160799174,Infliximab,Constipation,DE
160799174,Infliximab,Constipation,HO
160799174,Infliximab,Constipation,OT
160799174,Infliximab,Condition aggravated,DE
160799174,Infliximab,Condition aggravated,HO
160799174,Infliximab,Condition aggravated,OT
160799174,Infliximab,Chronic kidney disease,DE
160799174,Infliximab,Chronic kidney disease,HO
160799174,Infliximab,Chronic kidney disease,OT
160799174,Infliximab,Cellulitis,DE
160799174,Infliximab,Cellulitis,HO
160799174,Infliximab,Cellulitis,OT
160799174,Infliximab,Cataract,DE
160799174,Infliximab,Cataract,HO
160799174,Infliximab,Cataract,OT
160799174,Infliximab,COVID-19,DE
160799174,Infliximab,COVID-19,HO
160799174,Infliximab,COVID-19,OT
160799174,Infliximab,Blood pressure increased,DE
160799174,Infliximab,Blood pressure increased,HO
160799174,Infliximab,Blood pressure increased,OT
160799174,Infliximab,Blood pressure fluctuation,DE
160799174,Infliximab,Blood pressure fluctuation,HO
160799174,Infliximab,Blood pressure fluctuation,OT
160799174,Infliximab,Bladder obstruction,DE
160799174,Infliximab,Bladder obstruction,HO
160799174,Infliximab,Bladder obstruction,OT
160799174,Infliximab,Arthralgia,DE
160799174,Infliximab,Arthralgia,HO
160799174,Infliximab,Arthralgia,OT
160799174,Infliximab,Abnormal faeces,DE
160799174,Infliximab,Abnormal faeces,HO
160799174,Infliximab,Abnormal faeces,OT
160799174,Infliximab,Abdominal pain,DE
160799174,Infliximab,Abdominal pain,HO
160799174,Infliximab,Abdominal pain,OT
164779503,Infliximab,Therapeutic product effect delayed,OT
164779503,Infliximab,Product use issue,OT
164779503,Infliximab,Poor venous access,OT
164779503,Infliximab,Off label use,OT
164779503,Infliximab,Nausea,OT
164779503,Infliximab,Nasopharyngitis,OT
164779503,Infliximab,Maternal exposure during pregnancy,OT
164779503,Infliximab,Inappropriate schedule of product administration,OT
164779503,Infliximab,Feeling hot,OT
164779503,Infliximab,Facial pain,OT
164779503,Infliximab,Erythema,OT
164779503,Infliximab,Dyspnoea,OT
164779503,Infliximab,Drug level below therapeutic,OT
164779503,Infliximab,Cough,OT
164779503,Infliximab,Condition aggravated,OT
164779503,Infliximab,Colitis,OT
164779503,Infliximab,Chest discomfort,OT
164779503,Infliximab,Blood pressure fluctuation,OT
164779503,Infliximab,Anaemia,OT
168860463,Infliximab,Weight increased,OT
168860463,Infliximab,Sensitivity to weather change,OT
168860463,Infliximab,Rash pruritic,OT
168860463,Infliximab,Rash erythematous,OT
168860463,Infliximab,Rash,OT
168860463,Infliximab,Productive cough,OT
168860463,Infliximab,Primary biliary cholangitis,OT
168860463,Infliximab,Pain in extremity,OT
168860463,Infliximab,Off label use,OT
168860463,Infliximab,Nephrolithiasis,OT
168860463,Infliximab,Nasopharyngitis,OT
168860463,Infliximab,Malaise,OT
168860463,Infliximab,Lymphadenopathy,OT
168860463,Infliximab,Loss of personal independence in daily activities,OT
168860463,Infliximab,Intentional product use issue,OT
168860463,Infliximab,Inappropriate schedule of product administration,OT
168860463,Infliximab,Hepatic enzyme increased,OT
168860463,Infliximab,Heart rate irregular,OT
168860463,Infliximab,Heart rate decreased,OT
168860463,Infliximab,Frequent bowel movements,OT
168860463,Infliximab,Fatigue,OT
168860463,Infliximab,Drug ineffective,OT
168860463,Infliximab,Condition aggravated,OT
168860463,Infliximab,Bowel movement irregularity,OT
168860463,Infliximab,Arthralgia,OT
168860463,Infliximab,Abdominal pain,OT
175723223,Infliximab,Tonsillitis streptococcal,OT
175723223,Infliximab,Pus in stool,OT
175723223,Infliximab,Pruritus,OT
175723223,Infliximab,Pain,OT
175723223,Infliximab,Off label use,OT
175723223,Infliximab,Intentional product use issue,OT
175723223,Infliximab,Insomnia,OT
175723223,Infliximab,Inappropriate schedule of product administration,OT
175723223,Infliximab,Hypokinesia,OT
175723223,Infliximab,Fatigue,OT
175723223,Infliximab,Drug ineffective,OT
175723223,Infliximab,Cough,OT
175723223,Infliximab,Condition aggravated,OT
175723223,Infliximab,Blood pressure decreased,OT
175723223,Infliximab,Acne,OT
175723223,Infliximab,Abdominal pain,OT
175723223,Infliximab,Tonsillitis streptococcal,OT
175723223,Infliximab,Pus in stool,OT
175723223,Infliximab,Pruritus,OT
175723223,Infliximab,Pain,OT
175723223,Infliximab,Off label use,OT
175723223,Infliximab,Intentional product use issue,OT
175723223,Infliximab,Insomnia,OT
175723223,Infliximab,Inappropriate schedule of product administration,OT
175723223,Infliximab,Hypokinesia,OT
175723223,Infliximab,Fatigue,OT
175723223,Infliximab,Drug ineffective,OT
175723223,Infliximab,Cough,OT
175723223,Infliximab,Condition aggravated,OT
175723223,Infliximab,Blood pressure decreased,OT
175723223,Infliximab,Acne,OT
175723223,Infliximab,Abdominal pain,OT
175723223,Infliximab,Tonsillitis streptococcal,OT
175723223,Infliximab,Pus in stool,OT
175723223,Infliximab,Pruritus,OT
175723223,Infliximab,Pain,OT
175723223,Infliximab,Off label use,OT
175723223,Infliximab,Intentional product use issue,OT
175723223,Infliximab,Insomnia,OT
175723223,Infliximab,Inappropriate schedule of product administration,OT
175723223,Infliximab,Hypokinesia,OT
175723223,Infliximab,Fatigue,OT
175723223,Infliximab,Drug ineffective,OT
175723223,Infliximab,Cough,OT
175723223,Infliximab,Condition aggravated,OT
175723223,Infliximab,Blood pressure decreased,OT
175723223,Infliximab,Acne,OT
175723223,Infliximab,Abdominal pain,OT
176178665,Infliximab,Wound infection,OT
176178665,Infliximab,Vomiting,OT
176178665,Infliximab,Urinary tract infection,OT
176178665,Infliximab,Sputum discoloured,OT
176178665,Infliximab,Skin plaque,OT
176178665,Infliximab,Rhinorrhoea,OT
176178665,Infliximab,Productive cough,OT
176178665,Infliximab,Product use issue,OT
176178665,Infliximab,Pain in extremity,OT
176178665,Infliximab,Oropharyngeal pain,OT
176178665,Infliximab,Off label use,OT
176178665,Infliximab,Nasopharyngitis,OT
176178665,Infliximab,Nasal congestion,OT
176178665,Infliximab,Intentional product use issue,OT
176178665,Infliximab,Injury,OT
176178665,Infliximab,Inappropriate schedule of product administration,OT
176178665,Infliximab,Impaired healing,OT
176178665,Infliximab,Hypertension,OT
176178665,Infliximab,Heart rate irregular,OT
176178665,Infliximab,Heart rate decreased,OT
176178665,Infliximab,Food poisoning,OT
176178665,Infliximab,Fatigue,OT
176178665,Infliximab,Eczema,OT
176178665,Infliximab,Diarrhoea,OT
176178665,Infliximab,Dermatitis psoriasiform,OT
176178665,Infliximab,Conjunctivitis,OT
176178665,Infliximab,Body temperature fluctuation,OT
176178665,Infliximab,Arthralgia,OT
176178665,Infliximab,Alopecia,OT
176179204,Infliximab,Wound haemorrhage,OT
176179204,Infliximab,Weight decreased,OT
176179204,Infliximab,Therapeutic product effect incomplete,OT
176179204,Infliximab,Swelling,OT
176179204,Infliximab,Stress,OT
176179204,Infliximab,Stab wound,OT
176179204,Infliximab,Skin lesion,OT
176179204,Infliximab,Sinusitis,OT
176179204,Infliximab,Pruritus,OT
176179204,Infliximab,Product use issue,OT
176179204,Infliximab,Off label use,OT
176179204,Infliximab,Nausea,OT
176179204,Infliximab,Nasopharyngitis,OT
176179204,Infliximab,Malaise,OT
176179204,Infliximab,Intentional product use issue,OT
176179204,Infliximab,Insomnia,OT
176179204,Infliximab,Injection site extravasation,OT
176179204,Infliximab,Inappropriate schedule of product administration,OT
176179204,Infliximab,Illness,OT
176179204,Infliximab,Heart rate irregular,OT
176179204,Infliximab,Heart rate increased,OT
176179204,Infliximab,Heart rate decreased,OT
176179204,Infliximab,Fatigue,OT
176179204,Infliximab,Erythema,OT
176179204,Infliximab,Eczema,OT
176179204,Infliximab,Dry skin,OT
176179204,Infliximab,Condition aggravated,OT
176179204,Infliximab,Blood pressure increased,OT
176179204,Infliximab,Blood pressure fluctuation,OT
176179204,Infliximab,Attention deficit hyperactivity disorder,OT
176179204,Infliximab,Anxiety,OT
176179204,Infliximab,Angina pectoris,OT
176179204,Infliximab,Abdominal pain upper,OT
176179204,Infliximab,Abdominal pain,OT
176474835,Infliximab,Vomiting,OT
176474835,Infliximab,Tooth disorder,OT
176474835,Infliximab,Tooth abscess,OT
176474835,Infliximab,Therapeutic response shortened,OT
176474835,Infliximab,Rhinorrhoea,OT
176474835,Infliximab,Pyrexia,OT
176474835,Infliximab,Pruritus,OT
176474835,Infliximab,Pain,OT
176474835,Infliximab,Oropharyngeal pain,OT
176474835,Infliximab,Off label use,OT
176474835,Infliximab,Nasopharyngitis,OT
176474835,Infliximab,Nasal congestion,OT
176474835,Infliximab,Intentional product use issue,OT
176474835,Infliximab,Influenza like illness,OT
176474835,Infliximab,Headache,OT
176474835,Infliximab,Gingival swelling,OT
176474835,Infliximab,Feeding disorder,OT
176474835,Infliximab,Drug ineffective,OT
176474835,Infliximab,Diarrhoea,OT
176474835,Infliximab,Condition aggravated,OT
176474835,Infliximab,Body temperature increased,OT
176474835,Infliximab,Asthenia,OT
176474835,Infliximab,Abdominal pain upper,OT
176474835,Infliximab,Abdominal pain,OT
176474835,Infliximab,Vomiting,OT
176474835,Infliximab,Tooth disorder,OT
176474835,Infliximab,Tooth abscess,OT
176474835,Infliximab,Therapeutic response shortened,OT
176474835,Infliximab,Rhinorrhoea,OT
176474835,Infliximab,Pyrexia,OT
176474835,Infliximab,Pruritus,OT
176474835,Infliximab,Pain,OT
176474835,Infliximab,Oropharyngeal pain,OT
176474835,Infliximab,Off label use,OT
176474835,Infliximab,Nasopharyngitis,OT
176474835,Infliximab,Nasal congestion,OT
176474835,Infliximab,Intentional product use issue,OT
176474835,Infliximab,Influenza like illness,OT
176474835,Infliximab,Headache,OT
176474835,Infliximab,Gingival swelling,OT
176474835,Infliximab,Feeding disorder,OT
176474835,Infliximab,Drug ineffective,OT
176474835,Infliximab,Diarrhoea,OT
176474835,Infliximab,Condition aggravated,OT
176474835,Infliximab,Body temperature increased,OT
176474835,Infliximab,Asthenia,OT
176474835,Infliximab,Abdominal pain upper,OT
176474835,Infliximab,Abdominal pain,OT
176617454,Infliximab,Underdose,OT
176617454,Infliximab,Tonsillitis,OT
176617454,Infliximab,Staphylococcal infection,OT
176617454,Infliximab,Psoriasis,OT
176617454,Infliximab,Pharyngitis,OT
176617454,Infliximab,Off label use,OT
176617454,Infliximab,Myalgia,OT
176617454,Infliximab,Intentional product use issue,OT
176617454,Infliximab,Inappropriate schedule of product administration,OT
176617454,Infliximab,Hepatic enzyme increased,OT
176617454,Infliximab,Heart rate decreased,OT
176617454,Infliximab,Asthenia,OT
176617454,Infliximab,Underdose,OT
176617454,Infliximab,Tonsillitis,OT
176617454,Infliximab,Staphylococcal infection,OT
176617454,Infliximab,Psoriasis,OT
176617454,Infliximab,Pharyngitis,OT
176617454,Infliximab,Off label use,OT
176617454,Infliximab,Myalgia,OT
176617454,Infliximab,Intentional product use issue,OT
176617454,Infliximab,Inappropriate schedule of product administration,OT
176617454,Infliximab,Hepatic enzyme increased,OT
176617454,Infliximab,Heart rate decreased,OT
176617454,Infliximab,Asthenia,OT
176942813,Infliximab,Urinary tract infection,HO
176942813,Infliximab,Urinary tract infection,OT
176942813,Infliximab,Off label use,HO
176942813,Infliximab,Off label use,OT
176942813,Infliximab,Loss of consciousness,HO
176942813,Infliximab,Loss of consciousness,OT
176942813,Infliximab,Intentional product use issue,HO
176942813,Infliximab,Intentional product use issue,OT
176942813,Infliximab,Inappropriate schedule of product administration,HO
176942813,Infliximab,Inappropriate schedule of product administration,OT
176942813,Infliximab,Blood pressure increased,HO
176942813,Infliximab,Blood pressure increased,OT
176942813,Infliximab,Blood pressure fluctuation,HO
176942813,Infliximab,Blood pressure fluctuation,OT
177305984,Infliximab,Weight increased,OT
177305984,Infliximab,Off label use,OT
177305984,Infliximab,Malaise,OT
177305984,Infliximab,Infusion site extravasation,OT
177305984,Infliximab,Heart rate irregular,OT
177305984,Infliximab,Fatigue,OT
177305984,Infliximab,Drug level below therapeutic,OT
177305984,Infliximab,Drug level above therapeutic,OT
177305984,Infliximab,Diarrhoea,OT
177305984,Infliximab,Condition aggravated,OT
177305984,Infliximab,Appetite disorder,OT
177305984,Infliximab,Abdominal pain,OT
177305984,Infliximab,Weight increased,OT
177305984,Infliximab,Off label use,OT
177305984,Infliximab,Malaise,OT
177305984,Infliximab,Infusion site extravasation,OT
177305984,Infliximab,Heart rate irregular,OT
177305984,Infliximab,Fatigue,OT
177305984,Infliximab,Drug level below therapeutic,OT
177305984,Infliximab,Drug level above therapeutic,OT
177305984,Infliximab,Diarrhoea,OT
177305984,Infliximab,Condition aggravated,OT
177305984,Infliximab,Appetite disorder,OT
177305984,Infliximab,Abdominal pain,OT
177552053,Infliximab,Vision blurred,OT
177552053,Infliximab,Therapeutic product effect incomplete,OT
177552053,Infliximab,Rhinorrhoea,OT
177552053,Infliximab,Respiratory tract congestion,OT
177552053,Infliximab,Product use issue,OT
177552053,Infliximab,Pain,OT
177552053,Infliximab,Off label use,OT
177552053,Infliximab,Malaise,OT
177552053,Infliximab,Iritis,OT
177552053,Infliximab,Intentional product use issue,OT
177552053,Infliximab,Inguinal hernia,OT
177552053,Infliximab,Inappropriate schedule of product administration,OT
177552053,Infliximab,Hypersomnia,OT
177552053,Infliximab,Eye pain,OT
177552053,Infliximab,Cough,OT
177552053,Infliximab,Condition aggravated,OT
177566743,Infliximab,Vomiting,OT
177566743,Infliximab,Toothache,OT
177566743,Infliximab,Tooth infection,OT
177566743,Infliximab,Therapeutic response shortened,OT
177566743,Infliximab,Swelling,OT
177566743,Infliximab,Sensitivity to weather change,OT
177566743,Infliximab,Red cell distribution width increased,OT
177566743,Infliximab,Platelet count increased,OT
177566743,Infliximab,Oxygen saturation decreased,OT
177566743,Infliximab,Off label use,OT
177566743,Infliximab,Oedema peripheral,OT
177566743,Infliximab,Nausea,OT
177566743,Infliximab,Intentional product use issue,OT
177566743,Infliximab,Infusion site swelling,OT
177566743,Infliximab,Infusion site extravasation,OT
177566743,Infliximab,Incorrect dose administered,OT
177566743,Infliximab,Hypertension,OT
177566743,Infliximab,Heart rate decreased,OT
177566743,Infliximab,Headache,OT
177566743,Infliximab,Eye haemorrhage,OT
177566743,Infliximab,Drug specific antibody present,OT
177566743,Infliximab,Drug level below therapeutic,OT
177566743,Infliximab,Drug ineffective,OT
177566743,Infliximab,Condition aggravated,OT
177566743,Infliximab,Blood pressure fluctuation,OT
177566743,Infliximab,Blood pressure diastolic decreased,OT
177566743,Infliximab,Arthralgia,OT
177566743,Infliximab,Aphthous ulcer,OT
177566743,Infliximab,Abdominal distension,OT
177566743,Infliximab,Abdominal discomfort,OT
177566743,Infliximab,Vomiting,OT
177566743,Infliximab,Toothache,OT
177566743,Infliximab,Tooth infection,OT
177566743,Infliximab,Therapeutic response shortened,OT
177566743,Infliximab,Swelling,OT
177566743,Infliximab,Sensitivity to weather change,OT
177566743,Infliximab,Red cell distribution width increased,OT
177566743,Infliximab,Platelet count increased,OT
177566743,Infliximab,Oxygen saturation decreased,OT
177566743,Infliximab,Off label use,OT
177566743,Infliximab,Oedema peripheral,OT
177566743,Infliximab,Nausea,OT
177566743,Infliximab,Intentional product use issue,OT
177566743,Infliximab,Infusion site swelling,OT
177566743,Infliximab,Infusion site extravasation,OT
177566743,Infliximab,Incorrect dose administered,OT
177566743,Infliximab,Hypertension,OT
177566743,Infliximab,Heart rate decreased,OT
177566743,Infliximab,Headache,OT
177566743,Infliximab,Eye haemorrhage,OT
177566743,Infliximab,Drug specific antibody present,OT
177566743,Infliximab,Drug level below therapeutic,OT
177566743,Infliximab,Drug ineffective,OT
177566743,Infliximab,Condition aggravated,OT
177566743,Infliximab,Blood pressure fluctuation,OT
177566743,Infliximab,Blood pressure diastolic decreased,OT
177566743,Infliximab,Arthralgia,OT
177566743,Infliximab,Aphthous ulcer,OT
177566743,Infliximab,Abdominal distension,OT
177566743,Infliximab,Abdominal discomfort,OT
177871304,Infliximab,Weight decreased,OT
177871304,Infliximab,Rhinorrhoea,OT
177871304,Infliximab,Off label use,OT
177871304,Infliximab,Neurogenic shock,OT
177871304,Infliximab,Nasopharyngitis,OT
177871304,Infliximab,Intentional product use issue,OT
177871304,Infliximab,Heart rate decreased,OT
177871304,Infliximab,Blood pressure increased,OT
177871304,Infliximab,Blood pressure fluctuation,OT
177871304,Infliximab,Weight decreased,OT
177871304,Infliximab,Rhinorrhoea,OT
177871304,Infliximab,Off label use,OT
177871304,Infliximab,Neurogenic shock,OT
177871304,Infliximab,Nasopharyngitis,OT
177871304,Infliximab,Intentional product use issue,OT
177871304,Infliximab,Heart rate decreased,OT
177871304,Infliximab,Blood pressure increased,OT
177871304,Infliximab,Blood pressure fluctuation,OT
184571522,Infliximab,Throat tightness,OT
184571522,Infliximab,Product use issue,OT
184571522,Infliximab,Pain,OT
184571522,Infliximab,Off label use,OT
184571522,Infliximab,Nasopharyngitis,OT
184571522,Infliximab,Intentional product use issue,OT
184571522,Infliximab,Hot flush,OT
184571522,Infliximab,Herpes zoster,OT
184571522,Infliximab,Heart rate decreased,OT
184571522,Infliximab,Haemorrhoidal haemorrhage,OT
184571522,Infliximab,Haemorrhage,OT
184571522,Infliximab,Haemoglobin decreased,OT
184571522,Infliximab,Fatigue,OT
184571522,Infliximab,Faecal calprotectin increased,OT
184571522,Infliximab,Erythema,OT
184571522,Infliximab,Drug ineffective,OT
184571522,Infliximab,Cough,OT
184571522,Infliximab,Condition aggravated,OT
184571522,Infliximab,Blood pressure fluctuation,OT
184571522,Infliximab,Blood pressure diastolic decreased,OT
184571522,Infliximab,Blood pressure decreased,OT
184693353,Infliximab,Weight decreased,HO
184693353,Infliximab,Weight decreased,OT
184693353,Infliximab,Transient ischaemic attack,HO
184693353,Infliximab,Transient ischaemic attack,OT
184693353,Infliximab,Stress,HO
184693353,Infliximab,Stress,OT
184693353,Infliximab,Pallor,HO
184693353,Infliximab,Pallor,OT
184693353,Infliximab,Off label use,HO
184693353,Infliximab,Off label use,OT
184693353,Infliximab,Inappropriate schedule of product administration,HO
184693353,Infliximab,Inappropriate schedule of product administration,OT
184693353,Infliximab,Hypotension,HO
184693353,Infliximab,Hypotension,OT
184693353,Infliximab,Heart rate increased,HO
184693353,Infliximab,Heart rate increased,OT
184693353,Infliximab,Feeling cold,HO
184693353,Infliximab,Feeling cold,OT
184693353,Infliximab,Feeling abnormal,HO
184693353,Infliximab,Feeling abnormal,OT
184693353,Infliximab,Fatigue,HO
184693353,Infliximab,Fatigue,OT
184693353,Infliximab,Facial wasting,HO
184693353,Infliximab,Facial wasting,OT
184693353,Infliximab,Dizziness,HO
184693353,Infliximab,Dizziness,OT
184693353,Infliximab,Condition aggravated,HO
184693353,Infliximab,Condition aggravated,OT
184693353,Infliximab,Blood pressure decreased,HO
184693353,Infliximab,Blood pressure decreased,OT
184693353,Infliximab,Atrial fibrillation,HO
184693353,Infliximab,Atrial fibrillation,OT
184782822,Infliximab,Weight increased,OT
184782822,Infliximab,Weight decreased,OT
184782822,Infliximab,Therapeutic response shortened,OT
184782822,Infliximab,Rash,OT
184782822,Infliximab,Product use issue,OT
184782822,Infliximab,Off label use,OT
184782822,Infliximab,Mouth ulceration,OT
184782822,Infliximab,Intentional product use issue,OT
184782822,Infliximab,Condition aggravated,OT
184782822,Infliximab,Body temperature decreased,OT
184782822,Infliximab,Blood pressure increased,OT
184782822,Infliximab,Blood pressure fluctuation,OT
185353352,Infliximab,Weight increased,OT
185353352,Infliximab,Therapeutic product effect incomplete,OT
185353352,Infliximab,Rhinorrhoea,OT
185353352,Infliximab,Off label use,OT
185353352,Infliximab,Nasopharyngitis,OT
185353352,Infliximab,Intervertebral disc degeneration,OT
185353352,Infliximab,Intentional product use issue,OT
185353352,Infliximab,Inappropriate schedule of product administration,OT
185353352,Infliximab,Hyperhidrosis,OT
185353352,Infliximab,Headache,OT
185353352,Infliximab,Functional gastrointestinal disorder,OT
185353352,Infliximab,Drug level decreased,OT
185353352,Infliximab,Condition aggravated,OT
185353352,Infliximab,Body temperature fluctuation,OT
185353352,Infliximab,Blood pressure increased,OT
185353352,Infliximab,Blood pressure fluctuation,OT
185353352,Infliximab,Back pain,OT
185353352,Infliximab,Weight increased,OT
185353352,Infliximab,Therapeutic product effect incomplete,OT
185353352,Infliximab,Rhinorrhoea,OT
185353352,Infliximab,Off label use,OT
185353352,Infliximab,Nasopharyngitis,OT
185353352,Infliximab,Intervertebral disc degeneration,OT
185353352,Infliximab,Intentional product use issue,OT
185353352,Infliximab,Inappropriate schedule of product administration,OT
185353352,Infliximab,Hyperhidrosis,OT
185353352,Infliximab,Headache,OT
185353352,Infliximab,Functional gastrointestinal disorder,OT
185353352,Infliximab,Drug level decreased,OT
185353352,Infliximab,Condition aggravated,OT
185353352,Infliximab,Body temperature fluctuation,OT
185353352,Infliximab,Blood pressure increased,OT
185353352,Infliximab,Blood pressure fluctuation,OT
185353352,Infliximab,Back pain,OT
185550113,Infliximab,Treatment failure,OT
185550113,Infliximab,Salmonellosis,OT
185550113,Infliximab,Product use issue,OT
185550113,Infliximab,Off label use,OT
185550113,Infliximab,Intentional product use issue,OT
185550113,Infliximab,Hot flush,OT
185550113,Infliximab,Heart rate decreased,OT
185550113,Infliximab,Haemorrhage,OT
185550113,Infliximab,Feeling hot,OT
185550113,Infliximab,Feeding disorder,OT
185550113,Infliximab,Fatigue,OT
185550113,Infliximab,Drug specific antibody present,OT
185550113,Infliximab,Drug level increased,OT
185550113,Infliximab,Drug level decreased,OT
185550113,Infliximab,Drug ineffective,OT
185550113,Infliximab,Diarrhoea,OT
185550113,Infliximab,Decreased appetite,OT
185550113,Infliximab,Condition aggravated,OT
185550113,Infliximab,Abdominal pain,OT
185550113,Infliximab,Treatment failure,OT
185550113,Infliximab,Salmonellosis,OT
185550113,Infliximab,Product use issue,OT
185550113,Infliximab,Off label use,OT
185550113,Infliximab,Intentional product use issue,OT
185550113,Infliximab,Hot flush,OT
185550113,Infliximab,Heart rate decreased,OT
185550113,Infliximab,Haemorrhage,OT
185550113,Infliximab,Feeling hot,OT
185550113,Infliximab,Feeding disorder,OT
185550113,Infliximab,Fatigue,OT
185550113,Infliximab,Drug specific antibody present,OT
185550113,Infliximab,Drug level increased,OT
185550113,Infliximab,Drug level decreased,OT
185550113,Infliximab,Drug ineffective,OT
185550113,Infliximab,Diarrhoea,OT
185550113,Infliximab,Decreased appetite,OT
185550113,Infliximab,Condition aggravated,OT
185550113,Infliximab,Abdominal pain,OT
185915152,Infliximab,Weight increased,OT
185915152,Infliximab,Weight increased,HO
185915152,Infliximab,Vomiting,OT
185915152,Infliximab,Vomiting,HO
185915152,Infliximab,Sinus pain,OT
185915152,Infliximab,Sinus pain,HO
185915152,Infliximab,Product dose omission in error,OT
185915152,Infliximab,Product dose omission in error,HO
185915152,Infliximab,Off label use,OT
185915152,Infliximab,Off label use,HO
185915152,Infliximab,Migraine,OT
185915152,Infliximab,Migraine,HO
185915152,Infliximab,Maternal exposure during pregnancy,OT
185915152,Infliximab,Maternal exposure during pregnancy,HO
185915152,Infliximab,Intentional product use issue,OT
185915152,Infliximab,Intentional product use issue,HO
185915152,Infliximab,Inappropriate schedule of product administration,OT
185915152,Infliximab,Inappropriate schedule of product administration,HO
185915152,Infliximab,Headache,OT
185915152,Infliximab,Headache,HO
185915152,Infliximab,Crohn's disease,OT
185915152,Infliximab,Crohn's disease,HO
185915152,Infliximab,Constipation,OT
185915152,Infliximab,Constipation,HO
185915152,Infliximab,Condition aggravated,OT
185915152,Infliximab,Condition aggravated,HO
185915152,Infliximab,COVID-19,OT
185915152,Infliximab,COVID-19,HO
185915152,Infliximab,Anaemia,OT
185915152,Infliximab,Anaemia,HO
185915152,Infliximab,Abdominal pain,OT
185915152,Infliximab,Abdominal pain,HO
189207952,Infliximab (Unknown),Sialoadenitis,OT
189207952,Infliximab (Unknown),Sialoadenitis,HO
189207952,Infliximab (Unknown),Noninfective sialoadenitis,OT
189207952,Infliximab (Unknown),Noninfective sialoadenitis,HO
189207952,Infliximab (Unknown),Localised oedema,OT
189207952,Infliximab (Unknown),Localised oedema,HO
189207952,Infliximab (Unknown),Drug level decreased,OT
189207952,Infliximab (Unknown),Drug level decreased,HO
189207952,Infliximab (Unknown),Disease progression,OT
189207952,Infliximab (Unknown),Disease progression,HO
189207952,Infliximab (Unknown),Crohn's disease,OT
189207952,Infliximab (Unknown),Crohn's disease,HO
189207952,Infliximab (Unknown),Abdominal pain,OT
189207952,Infliximab (Unknown),Abdominal pain,HO
189543432,Infliximab,Hodgkin's disease,OT
191348602,Infliximab,Rash pruritic,OT
191348602,Infliximab,Purpura,OT
191348602,Infliximab,Product use issue,OT
191348602,Infliximab,Off label use,OT
191348602,Infliximab,Liver injury,OT
191348602,Infliximab,Intentional product use issue,OT
191348602,Infliximab,Hepatic steatosis,OT
191348602,Infliximab,Drug-induced liver injury,OT
191348602,Infliximab,Alcoholic liver disease,OT
191348602,Infliximab,Rash pruritic,OT
191348602,Infliximab,Purpura,OT
191348602,Infliximab,Product use issue,OT
191348602,Infliximab,Off label use,OT
191348602,Infliximab,Liver injury,OT
191348602,Infliximab,Intentional product use issue,OT
191348602,Infliximab,Hepatic steatosis,OT
191348602,Infliximab,Drug-induced liver injury,OT
191348602,Infliximab,Alcoholic liver disease,OT
191864782,Infliximab,Weight increased,OT
191864782,Infliximab,Nausea,OT
191864782,Infliximab,Incorrect dose administered,OT
191864782,Infliximab,Fatigue,OT
191864782,Infliximab,Drug level below therapeutic,OT
191864782,Infliximab,Blood pressure diastolic increased,OT
191864782,Infliximab,Weight increased,OT
191864782,Infliximab,Nausea,OT
191864782,Infliximab,Incorrect dose administered,OT
191864782,Infliximab,Fatigue,OT
191864782,Infliximab,Drug level below therapeutic,OT
191864782,Infliximab,Blood pressure diastolic increased,OT
192571502,Infliximab,Therapeutic response shortened,OT
192571502,Infliximab,Therapeutic product effect incomplete,OT
192571502,Infliximab,Product use issue,OT
192571502,Infliximab,Off label use,OT
192571502,Infliximab,Malaise,OT
192571502,Infliximab,Intentional product use issue,OT
192571502,Infliximab,Heart rate decreased,OT
192571502,Infliximab,Drug specific antibody present,OT
192571502,Infliximab,Drug level decreased,OT
192571502,Infliximab,Drug level below therapeutic,OT
192571502,Infliximab,Condition aggravated,OT
192709792,Infliximab,Weight decreased,OT
192709792,Infliximab,Pain,OT
192709792,Infliximab,Off label use,OT
192709792,Infliximab,Nausea,OT
192709792,Infliximab,Intentional product use issue,OT
192709792,Infliximab,Illness,OT
192709792,Infliximab,Flank pain,OT
192709792,Infliximab,Feeling abnormal,OT
192709792,Infliximab,Fatigue,OT
192709792,Infliximab,Emotional disorder,OT
192709792,Infliximab,Dizziness,OT
192709792,Infliximab,Disturbance in attention,OT
192709792,Infliximab,Depressed mood,OT
192709792,Infliximab,Decreased appetite,OT
192709792,Infliximab,Condition aggravated,OT
192709792,Infliximab,Blood pressure increased,OT
192709792,Infliximab,Blood pressure diastolic increased,OT
192709792,Infliximab,Back pain,OT
192709792,Infliximab,Asthenia,OT
192709792,Infliximab,Abdominal pain,OT
192709792,Infliximab,Weight decreased,OT
192709792,Infliximab,Pain,OT
192709792,Infliximab,Off label use,OT
192709792,Infliximab,Nausea,OT
192709792,Infliximab,Intentional product use issue,OT
192709792,Infliximab,Illness,OT
192709792,Infliximab,Flank pain,OT
192709792,Infliximab,Feeling abnormal,OT
192709792,Infliximab,Fatigue,OT
192709792,Infliximab,Emotional disorder,OT
192709792,Infliximab,Dizziness,OT
192709792,Infliximab,Disturbance in attention,OT
192709792,Infliximab,Depressed mood,OT
192709792,Infliximab,Decreased appetite,OT
192709792,Infliximab,Condition aggravated,OT
192709792,Infliximab,Blood pressure increased,OT
192709792,Infliximab,Blood pressure diastolic increased,OT
192709792,Infliximab,Back pain,OT
192709792,Infliximab,Asthenia,OT
192709792,Infliximab,Abdominal pain,OT
194061392,Infliximab,Wound,OT
194061392,Infliximab,Urinary tract infection,OT
194061392,Infliximab,Folliculitis,OT
194061392,Infliximab,Condition aggravated,OT
194061392,Infliximab,Abscess limb,OT
194855661,Infliximab (Unknown),Thrombosis,OT
194855661,Infliximab (Unknown),Rash,OT
194855661,Infliximab (Unknown),Mood swings,OT
194855661,Infliximab (Unknown),Local reaction,OT
194855661,Infliximab (Unknown),Infection,OT
194855661,Infliximab (Unknown),Hypersensitivity,OT
194985771,Infliximab,Stomal hernia,OT
194985771,Infliximab,Stomal hernia,HO
194985771,Infliximab,Postoperative abscess,OT
194985771,Infliximab,Postoperative abscess,HO
194985771,Infliximab,Post procedural complication,OT
194985771,Infliximab,Post procedural complication,HO
194985771,Infliximab,Inappropriate schedule of product administration,OT
194985771,Infliximab,Inappropriate schedule of product administration,HO
194985771,Infliximab,Condition aggravated,OT
194985771,Infliximab,Condition aggravated,HO
195025532,Infliximab,Tubulointerstitial nephritis,HO
195025532,Infliximab,Tubulointerstitial nephritis,OT
195025532,Infliximab,Product use issue,HO
195025532,Infliximab,Product use issue,OT
195025532,Infliximab,Product use in unapproved indication,HO
195025532,Infliximab,Product use in unapproved indication,OT
195025532,Infliximab,Off label use,HO
195025532,Infliximab,Off label use,OT
195025532,Infliximab,Labelled drug-disease interaction medication error,HO
195025532,Infliximab,Labelled drug-disease interaction medication error,OT
195025532,Infliximab,Inflammatory bowel disease,HO
195025532,Infliximab,Inflammatory bowel disease,OT
195025532,Infliximab,Haematuria,HO
195025532,Infliximab,Haematuria,OT
195025532,Infliximab,Drug resistance,HO
195025532,Infliximab,Drug resistance,OT
195025532,Infliximab,Contraindicated product administered,HO
195025532,Infliximab,Contraindicated product administered,OT
195025532,Infliximab,Acute kidney injury,HO
195025532,Infliximab,Acute kidney injury,OT
195025871,Infliximab,Off label use,OT
195025871,Infliximab,Crohn's disease,OT
195025871,Infliximab,Contraindicated product administered,OT
195203081,Infliximab,Chest pain,LT
195222671,Infliximab,Dyspnoea,HO
195222671,Infliximab,Dyspnoea,OT
195222671,Infliximab,Bundle branch block,HO
195222671,Infliximab,Bundle branch block,OT
195222671,Infliximab,Arrhythmia,HO
195222671,Infliximab,Arrhythmia,OT
195722772,Infliximab,Psoriasis,OT
195722772,Infliximab,Migraine,OT
195722772,Infliximab,Hypertension,OT
195722772,Infliximab,Endometriosis,OT
195722772,Infliximab,Drug specific antibody,OT
195722772,Infliximab,Drug intolerance,OT
195722772,Infliximab,Drug ineffective,OT
195722772,Infliximab,Depression,OT
195722772,Infliximab,Chronic kidney disease,OT
195722772,Infliximab,Asthma,OT
195722772,Infliximab,Arthritis,OT
196076552,Infliximab (Unknown),Sebaceous hyperplasia,OT
196076552,Infliximab (Unknown),Colitis ulcerative,OT
196076552,Infliximab (Unknown),Sebaceous hyperplasia,OT
196076552,Infliximab (Unknown),Colitis ulcerative,OT
196076552,Infliximab (Unknown),Sebaceous hyperplasia,OT
196076552,Infliximab (Unknown),Colitis ulcerative,OT
196076552,Infliximab (Unknown),Sebaceous hyperplasia,OT
196076552,Infliximab (Unknown),Colitis ulcerative,OT
196239981,Infliximab,Vulvovaginal injury,OT
196239981,Infliximab,Off label use,OT
196239981,Infliximab,Maternal exposure during pregnancy,OT
196239981,Infliximab,Intentional product use issue,OT
196239981,Infliximab,Delivery,OT
196240071,Infliximab,Skin lesion,HO
196240071,Infliximab,Rash,HO
196240071,Infliximab,Pain,HO
196240071,Infliximab,Off label use,HO
196240071,Infliximab,Intentional product use issue,HO
196240071,Infliximab,Drug specific antibody present,HO
196240071,Infliximab,Arthralgia,HO
196573961,Infliximab,Weight increased,OT
196573961,Infliximab,Viral infection,OT
196573961,Infliximab,Sneezing,OT
196573961,Infliximab,Sinus congestion,OT
196573961,Infliximab,Rhinitis allergic,OT
196573961,Infliximab,Renal disorder,OT
196573961,Infliximab,Pyrexia,OT
196573961,Infliximab,Paranasal sinus discomfort,OT
196573961,Infliximab,Oropharyngeal pain,OT
196573961,Infliximab,Off label use,OT
196573961,Infliximab,Nasopharyngitis,OT
196573961,Infliximab,Nasal discomfort,OT
196573961,Infliximab,Malaise,OT
196573961,Infliximab,Intentional product use issue,OT
196573961,Infliximab,Increased appetite,OT
196573961,Infliximab,Incorrect dose administered,OT
196573961,Infliximab,Inappropriate schedule of product administration,OT
196573961,Infliximab,Headache,OT
196573961,Infliximab,Fatigue,OT
196573961,Infliximab,Dyspnoea,OT
196573961,Infliximab,Diarrhoea,OT
196573961,Infliximab,Cough,OT
196573961,Infliximab,Condition aggravated,OT
196573961,Infliximab,Chills,OT
196573961,Infliximab,Chest discomfort,OT
196573961,Infliximab,Cardiac disorder,OT
196573961,Infliximab,COVID-19,OT
196573961,Infliximab,Blood pressure increased,OT
196783951,Infliximab,Weight increased,OT
196783951,Infliximab,Weight increased,HO
196783951,Infliximab,Faecal calprotectin increased,OT
196783951,Infliximab,Faecal calprotectin increased,HO
196783951,Infliximab,Crohn's disease,OT
196783951,Infliximab,Crohn's disease,HO
196783951,Infliximab,Condition aggravated,OT
196783951,Infliximab,Condition aggravated,HO
196806131,Infliximab,Product use issue,OT
196806131,Infliximab,Off label use,OT
196806131,Infliximab,Malaise,OT
196806131,Infliximab,Intentional product use issue,OT
196806131,Infliximab,Inappropriate schedule of product administration,OT
196806131,Infliximab,Heart rate decreased,OT
196806131,Infliximab,Drug level below therapeutic,OT
196806131,Infliximab,Condition aggravated,OT
196842741,Infliximab,Respiration abnormal,OT
196842741,Infliximab,Product use issue,OT
196842741,Infliximab,Paraesthesia,OT
196842741,Infliximab,Pain,OT
196842741,Infliximab,Off label use,OT
196842741,Infliximab,Nephrolithiasis,OT
196842741,Infliximab,Incorrect dose administered,OT
196842741,Infliximab,Inappropriate schedule of product administration,OT
196842741,Infliximab,Heart rate irregular,OT
196842741,Infliximab,Disease recurrence,OT
196842741,Infliximab,Diarrhoea,OT
196842741,Infliximab,Abdominal discomfort,OT
197058511,Infliximab,Tooth disorder,OT
197058511,Infliximab,Therapeutic response shortened,OT
197058511,Infliximab,Therapeutic response delayed,OT
197058511,Infliximab,Off label use,OT
197058511,Infliximab,Incorrect dose administered,OT
197058511,Infliximab,Inappropriate schedule of product administration,OT
197058511,Infliximab,Hyperventilation,OT
197058511,Infliximab,Faecal calprotectin increased,OT
197058511,Infliximab,Crohn's disease,OT
197102411,Infliximab,Product dose omission issue,OT
197102411,Infliximab,Pneumonia,OT
197102411,Infliximab,Pain,OT
197102411,Infliximab,Nasopharyngitis,OT
197102411,Infliximab,Malignant melanoma,OT
197102411,Infliximab,Inappropriate schedule of product administration,OT
197102411,Infliximab,Impaired healing,OT
197102411,Infliximab,Heart rate increased,OT
197102411,Infliximab,Fungal infection,OT
197102411,Infliximab,Feeling of body temperature change,OT
197102411,Infliximab,Fatigue,OT
197102411,Infliximab,Cough,OT
197102411,Infliximab,Chills,OT
197102411,Infliximab,Product dose omission issue,OT
197102411,Infliximab,Pneumonia,OT
197102411,Infliximab,Pain,OT
197102411,Infliximab,Nasopharyngitis,OT
197102411,Infliximab,Malignant melanoma,OT
197102411,Infliximab,Inappropriate schedule of product administration,OT
197102411,Infliximab,Impaired healing,OT
197102411,Infliximab,Heart rate increased,OT
197102411,Infliximab,Fungal infection,OT
197102411,Infliximab,Feeling of body temperature change,OT
197102411,Infliximab,Fatigue,OT
197102411,Infliximab,Cough,OT
197102411,Infliximab,Chills,OT
197184381,Infliximab,Type I hypersensitivity,HO
197184381,Infliximab,Type I hypersensitivity,LT
197184381,Infliximab,Throat irritation,HO
197184381,Infliximab,Throat irritation,LT
197184381,Infliximab,Therapeutic product effect incomplete,HO
197184381,Infliximab,Therapeutic product effect incomplete,LT
197184381,Infliximab,Hypersensitivity,HO
197184381,Infliximab,Hypersensitivity,LT
197184381,Infliximab,Dyspnoea,HO
197184381,Infliximab,Dyspnoea,LT
197184381,Infliximab,Drug specific antibody present,HO
197184381,Infliximab,Drug specific antibody present,LT
197184381,Infliximab,Drug level abnormal,HO
197184381,Infliximab,Drug level abnormal,LT
197184381,Infliximab,Drug intolerance,HO
197184381,Infliximab,Drug intolerance,LT
197184381,Infliximab,Anxiety,HO
197184381,Infliximab,Anxiety,LT
197184381,Infliximab,Anaphylactic reaction,HO
197184381,Infliximab,Anaphylactic reaction,LT
197184381,Infliximab,Abdominal pain,HO
197184381,Infliximab,Abdominal pain,LT
197184381,Infliximab,Type I hypersensitivity,HO
197184381,Infliximab,Type I hypersensitivity,LT
197184381,Infliximab,Throat irritation,HO
197184381,Infliximab,Throat irritation,LT
197184381,Infliximab,Therapeutic product effect incomplete,HO
197184381,Infliximab,Therapeutic product effect incomplete,LT
197184381,Infliximab,Hypersensitivity,HO
197184381,Infliximab,Hypersensitivity,LT
197184381,Infliximab,Dyspnoea,HO
197184381,Infliximab,Dyspnoea,LT
197184381,Infliximab,Drug specific antibody present,HO
197184381,Infliximab,Drug specific antibody present,LT
197184381,Infliximab,Drug level abnormal,HO
197184381,Infliximab,Drug level abnormal,LT
197184381,Infliximab,Drug intolerance,HO
197184381,Infliximab,Drug intolerance,LT
197184381,Infliximab,Anxiety,HO
197184381,Infliximab,Anxiety,LT
197184381,Infliximab,Anaphylactic reaction,HO
197184381,Infliximab,Anaphylactic reaction,LT
197184381,Infliximab,Abdominal pain,HO
197184381,Infliximab,Abdominal pain,LT
197291841,Infliximab Pfizer (Unknown),Weight increased,OT
197291841,Infliximab Pfizer (Unknown),Furuncle,OT
197291841,Infliximab Pfizer (Unknown),Escherichia infection,OT
197291841,Infliximab Pfizer (Unknown),Drug ineffective,OT
197291841,Infliximab Pfizer (Unknown),Cushingoid,OT
197291841,Infliximab Pfizer (Unknown),Colitis ulcerative,OT
197291841,Infliximab Pfizer (Unknown),Central obesity,OT
197291841,Infliximab Pfizer (Unknown),Cellulitis,OT
197291841,Infliximab Pfizer (Unknown),Cataract,OT
197291841,Infliximab Pfizer (Unknown),Bacterial vulvovaginitis,OT
197291841,Infliximab Pfizer (Unknown),Bacillus infection,OT
197603041,Infliximab,Product use issue,HO
197603041,Infliximab,Product use issue,OT
197603041,Infliximab,Off label use,HO
197603041,Infliximab,Off label use,OT
197603041,Infliximab,Nausea,HO
197603041,Infliximab,Nausea,OT
197603041,Infliximab,Intentional product use issue,HO
197603041,Infliximab,Intentional product use issue,OT
197603041,Infliximab,Haematemesis,HO
197603041,Infliximab,Haematemesis,OT
197603041,Infliximab,Gastrooesophageal reflux disease,HO
197603041,Infliximab,Gastrooesophageal reflux disease,OT
197603041,Infliximab,Fatigue,HO
197603041,Infliximab,Fatigue,OT
197603041,Infliximab,Drug level above therapeutic,HO
197603041,Infliximab,Drug level above therapeutic,OT
197603041,Infliximab,Diarrhoea haemorrhagic,HO
197603041,Infliximab,Diarrhoea haemorrhagic,OT
197603041,Infliximab,Condition aggravated,HO
197603041,Infliximab,Condition aggravated,OT
197603041,Infliximab,Blood pressure increased,HO
197603041,Infliximab,Blood pressure increased,OT
198054311,Infliximab,Vision blurred,OT
198054311,Infliximab,Rash,OT
198054311,Infliximab,Pruritus,OT
198054311,Infliximab,Myalgia,OT
198054311,Infliximab,Insomnia,OT
198054311,Infliximab,Headache,OT
198054311,Infliximab,Haematochezia,OT
198054311,Infliximab,Frequent bowel movements,OT
198054311,Infliximab,Drug hypersensitivity,OT
198054311,Infliximab,Blood pressure increased,OT
198054311,Infliximab,Arthralgia,OT
198054311,Infliximab,Alopecia,OT
198056601,Infliximab,Viral infection,OT
198056601,Infliximab,Tonsillar hypertrophy,OT
198056601,Infliximab,Synovial cyst,OT
198056601,Infliximab,Oropharyngeal discomfort,OT
198056601,Infliximab,Off label use,OT
198056601,Infliximab,Inflammatory bowel disease,OT
198056601,Infliximab,Inappropriate schedule of product administration,OT
198056601,Infliximab,Headache,OT
198056601,Infliximab,Foreign body in throat,OT
198056601,Infliximab,Dysphagia,OT
198056601,Infliximab,Drug ineffective,OT
198056601,Infliximab,Cough,OT
198056601,Infliximab,Condition aggravated,OT
198056601,Infliximab,Body temperature decreased,OT
198056601,Infliximab,Blood pressure fluctuation,OT
198056601,Infliximab,Arthralgia,OT
198109011,Infliximab,Rash,HO
198109011,Infliximab,Rash,OT
198109011,Infliximab,Off label use,HO
198109011,Infliximab,Off label use,OT
198109011,Infliximab,Myocardial infarction,HO
198109011,Infliximab,Myocardial infarction,OT
198109011,Infliximab,Herpes zoster,HO
198109011,Infliximab,Herpes zoster,OT
198367341,Infliximab,Immune reconstitution inflammatory syndrome,OT
198367341,Infliximab,Hepatitis B reactivation,OT
198708291,Infliximab,Vasculitis,OT
198708291,Infliximab,Takayasu's arteritis,OT
198708291,Infliximab,Posterior reversible encephalopathy syndrome,OT
198708291,Infliximab,Pain in extremity,OT
198708291,Infliximab,Osteonecrosis,OT
198708291,Infliximab,Off label use,OT
198708291,Infliximab,Obesity,OT
198708291,Infliximab,Neck pain,OT
198708291,Infliximab,Maternal exposure during pregnancy,OT
198708291,Infliximab,Malaise,OT
198708291,Infliximab,Intentional product use issue,OT
198708291,Infliximab,Fatigue,OT
198708291,Infliximab,C-reactive protein increased,OT
198708291,Infliximab,Bone density decreased,OT
198708291,Infliximab,Arthralgia,OT
198708291,Infliximab,Aortic dissection,OT
198843941,Infliximab,Sepsis,DE
198843941,Infliximab,Off label use,DE
198912911,Infliximab,Product use issue,DE
198912911,Infliximab,Off label use,DE
198912911,Infliximab,Death,DE
198988571,Infliximab,Rash,OT
198988571,Infliximab,Pruritus,OT
198988571,Infliximab,Off label use,OT
198988571,Infliximab,Inappropriate schedule of product administration,OT
198988571,Infliximab,Head discomfort,OT
198988571,Infliximab,Erythema,OT
198988571,Infliximab,Drug ineffective,OT
198988571,Infliximab,Condition aggravated,OT
198988571,Infliximab,Chest discomfort,OT
198988571,Infliximab,Burning sensation,OT
198988571,Infliximab,Arthralgia,OT
198988571,Infliximab,Anal fistula,OT
198988571,Infliximab,Anal fissure,OT
160647757,Infliximab,Throat irritation,OT
160647757,Infliximab,Therapeutic product effect incomplete,OT
160647757,Infliximab,Sciatic nerve neuropathy,OT
160647757,Infliximab,Pyrexia,OT
160647757,Infliximab,Product use issue,OT
160647757,Infliximab,Paraesthesia,OT
160647757,Infliximab,Pain in extremity,OT
160647757,Infliximab,Oxygen saturation abnormal,OT
160647757,Infliximab,Oropharyngeal pain,OT
160647757,Infliximab,Off label use,OT
160647757,Infliximab,Ligament sprain,OT
160647757,Infliximab,Intentional product use issue,OT
160647757,Infliximab,Inappropriate schedule of product administration,OT
160647757,Infliximab,Hypertension,OT
160647757,Infliximab,Heart rate irregular,OT
160647757,Infliximab,Fracture,OT
160647757,Infliximab,Fall,OT
160647757,Infliximab,Electric shock sensation,OT
160647757,Infliximab,Dysphagia,OT
160647757,Infliximab,Dry throat,OT
160647757,Infliximab,Cough,OT
160647757,Infliximab,Condition aggravated,OT
160647757,Infliximab,Carpal tunnel syndrome,OT
160647757,Infliximab,Blood pressure fluctuation,OT
160647757,Infliximab,Arthralgia,OT
160647757,Infliximab,Abdominal pain,OT
166888744,Infliximab,Urinary tract infection,HO
166888744,Infliximab,Urinary tract infection,OT
166888744,Infliximab,Swelling face,HO
166888744,Infliximab,Swelling face,OT
166888744,Infliximab,Product use issue,HO
166888744,Infliximab,Product use issue,OT
166888744,Infliximab,Peripheral swelling,HO
166888744,Infliximab,Peripheral swelling,OT
166888744,Infliximab,Off label use,HO
166888744,Infliximab,Off label use,OT
166888744,Infliximab,Nephrolithiasis,HO
166888744,Infliximab,Nephrolithiasis,OT
166888744,Infliximab,Intentional product use issue,HO
166888744,Infliximab,Intentional product use issue,OT
166888744,Infliximab,Infusion site extravasation,HO
166888744,Infliximab,Infusion site extravasation,OT
166888744,Infliximab,Headache,HO
166888744,Infliximab,Headache,OT
166888744,Infliximab,Blood pressure fluctuation,HO
166888744,Infliximab,Blood pressure fluctuation,OT
166888744,Infliximab,Urinary tract infection,HO
166888744,Infliximab,Urinary tract infection,OT
166888744,Infliximab,Swelling face,HO
166888744,Infliximab,Swelling face,OT
166888744,Infliximab,Product use issue,HO
166888744,Infliximab,Product use issue,OT
166888744,Infliximab,Peripheral swelling,HO
166888744,Infliximab,Peripheral swelling,OT
166888744,Infliximab,Off label use,HO
166888744,Infliximab,Off label use,OT
166888744,Infliximab,Nephrolithiasis,HO
166888744,Infliximab,Nephrolithiasis,OT
166888744,Infliximab,Intentional product use issue,HO
166888744,Infliximab,Intentional product use issue,OT
166888744,Infliximab,Infusion site extravasation,HO
166888744,Infliximab,Infusion site extravasation,OT
166888744,Infliximab,Headache,HO
166888744,Infliximab,Headache,OT
166888744,Infliximab,Blood pressure fluctuation,HO
166888744,Infliximab,Blood pressure fluctuation,OT
166888744,Infliximab,Urinary tract infection,HO
166888744,Infliximab,Urinary tract infection,OT
166888744,Infliximab,Swelling face,HO
166888744,Infliximab,Swelling face,OT
166888744,Infliximab,Product use issue,HO
166888744,Infliximab,Product use issue,OT
166888744,Infliximab,Peripheral swelling,HO
166888744,Infliximab,Peripheral swelling,OT
166888744,Infliximab,Off label use,HO
166888744,Infliximab,Off label use,OT
166888744,Infliximab,Nephrolithiasis,HO
166888744,Infliximab,Nephrolithiasis,OT
166888744,Infliximab,Intentional product use issue,HO
166888744,Infliximab,Intentional product use issue,OT
166888744,Infliximab,Infusion site extravasation,HO
166888744,Infliximab,Infusion site extravasation,OT
166888744,Infliximab,Headache,HO
166888744,Infliximab,Headache,OT
166888744,Infliximab,Blood pressure fluctuation,HO
166888744,Infliximab,Blood pressure fluctuation,OT
166888744,Infliximab,Urinary tract infection,HO
166888744,Infliximab,Urinary tract infection,OT
166888744,Infliximab,Swelling face,HO
166888744,Infliximab,Swelling face,OT
166888744,Infliximab,Product use issue,HO
166888744,Infliximab,Product use issue,OT
166888744,Infliximab,Peripheral swelling,HO
166888744,Infliximab,Peripheral swelling,OT
166888744,Infliximab,Off label use,HO
166888744,Infliximab,Off label use,OT
166888744,Infliximab,Nephrolithiasis,HO
166888744,Infliximab,Nephrolithiasis,OT
166888744,Infliximab,Intentional product use issue,HO
166888744,Infliximab,Intentional product use issue,OT
166888744,Infliximab,Infusion site extravasation,HO
166888744,Infliximab,Infusion site extravasation,OT
166888744,Infliximab,Headache,HO
166888744,Infliximab,Headache,OT
166888744,Infliximab,Blood pressure fluctuation,HO
166888744,Infliximab,Blood pressure fluctuation,OT
176527363,Infliximab,Weight increased,HO
176527363,Infliximab,Weight increased,OT
176527363,Infliximab,Therapeutic response shortened,HO
176527363,Infliximab,Therapeutic response shortened,OT
176527363,Infliximab,Rash macular,HO
176527363,Infliximab,Rash macular,OT
176527363,Infliximab,Product use issue,HO
176527363,Infliximab,Product use issue,OT
176527363,Infliximab,Pneumonia,HO
176527363,Infliximab,Pneumonia,OT
176527363,Infliximab,Off label use,HO
176527363,Infliximab,Off label use,OT
176527363,Infliximab,Intentional product use issue,HO
176527363,Infliximab,Intentional product use issue,OT
176527363,Infliximab,Increased appetite,HO
176527363,Infliximab,Increased appetite,OT
176527363,Infliximab,Inappropriate schedule of product administration,HO
176527363,Infliximab,Inappropriate schedule of product administration,OT
176527363,Infliximab,Faecal calprotectin increased,HO
176527363,Infliximab,Faecal calprotectin increased,OT
176527363,Infliximab,Drug level below therapeutic,HO
176527363,Infliximab,Drug level below therapeutic,OT
176527363,Infliximab,Drug level above therapeutic,HO
176527363,Infliximab,Drug level above therapeutic,OT
176527363,Infliximab,Condition aggravated,HO
176527363,Infliximab,Condition aggravated,OT
176527363,Infliximab,Body temperature increased,HO
176527363,Infliximab,Body temperature increased,OT
176527363,Infliximab,Body temperature decreased,HO
176527363,Infliximab,Body temperature decreased,OT
176527363,Infliximab,Blood pressure increased,HO
176527363,Infliximab,Blood pressure increased,OT
176527363,Infliximab,Blood pressure fluctuation,HO
176527363,Infliximab,Blood pressure fluctuation,OT
176527363,Infliximab,Arthralgia,HO
176527363,Infliximab,Arthralgia,OT
176625255,Infliximab,Vein disorder,OT
176625255,Infliximab,Rash,OT
176625255,Infliximab,Psoriasis,OT
176625255,Infliximab,Pruritus,OT
176625255,Infliximab,Poor venous access,OT
176625255,Infliximab,Palpitations,OT
176625255,Infliximab,Off label use,OT
176625255,Infliximab,Nasopharyngitis,OT
176625255,Infliximab,Meniscus injury,OT
176625255,Infliximab,Infusion site discomfort,OT
176625255,Infliximab,Inappropriate schedule of product administration,OT
176625255,Infliximab,Heart rate irregular,OT
176625255,Infliximab,Heart rate decreased,OT
176625255,Infliximab,Haemoglobin decreased,OT
176625255,Infliximab,Eczema,OT
176625255,Infliximab,Condition aggravated,OT
176625255,Infliximab,Cellulitis,OT
176625255,Infliximab,Breast mass,OT
176625255,Infliximab,Arthralgia,OT
176808384,Infliximab,Renal failure,HO
176808384,Infliximab,Off label use,HO
176808384,Infliximab,Hypertension,HO
176808384,Infliximab,Heart rate irregular,HO
176808384,Infliximab,Heart rate increased,HO
176808384,Infliximab,Dyslipidaemia,HO
176808384,Infliximab,Drug ineffective,HO
176808384,Infliximab,Condition aggravated,HO
176808384,Infliximab,Blood pressure increased,HO
176808384,Infliximab,Blood pressure fluctuation,HO
176808384,Infliximab,Renal failure,HO
176808384,Infliximab,Off label use,HO
176808384,Infliximab,Hypertension,HO
176808384,Infliximab,Heart rate irregular,HO
176808384,Infliximab,Heart rate increased,HO
176808384,Infliximab,Dyslipidaemia,HO
176808384,Infliximab,Drug ineffective,HO
176808384,Infliximab,Condition aggravated,HO
176808384,Infliximab,Blood pressure increased,HO
176808384,Infliximab,Blood pressure fluctuation,HO
176895942,Infliximab,Weight decreased,OT
176895942,Infliximab,Weight decreased,HO
176895942,Infliximab,Off label use,OT
176895942,Infliximab,Off label use,HO
176895942,Infliximab,Nephrolithiasis,OT
176895942,Infliximab,Nephrolithiasis,HO
176895942,Infliximab,Intentional product use issue,OT
176895942,Infliximab,Intentional product use issue,HO
176895942,Infliximab,Influenza,OT
176895942,Infliximab,Influenza,HO
176895942,Infliximab,Heart rate decreased,OT
176895942,Infliximab,Heart rate decreased,HO
176895942,Infliximab,Haematochezia,OT
176895942,Infliximab,Haematochezia,HO
176895942,Infliximab,Blood pressure fluctuation,OT
176895942,Infliximab,Blood pressure fluctuation,HO
176895942,Infliximab,Weight decreased,OT
176895942,Infliximab,Weight decreased,HO
176895942,Infliximab,Off label use,OT
176895942,Infliximab,Off label use,HO
176895942,Infliximab,Nephrolithiasis,OT
176895942,Infliximab,Nephrolithiasis,HO
176895942,Infliximab,Intentional product use issue,OT
176895942,Infliximab,Intentional product use issue,HO
176895942,Infliximab,Influenza,OT
176895942,Infliximab,Influenza,HO
176895942,Infliximab,Heart rate decreased,OT
176895942,Infliximab,Heart rate decreased,HO
176895942,Infliximab,Haematochezia,OT
176895942,Infliximab,Haematochezia,HO
176895942,Infliximab,Blood pressure fluctuation,OT
176895942,Infliximab,Blood pressure fluctuation,HO
177078673,Infliximab,Weight decreased,OT
177078673,Infliximab,Urticaria,OT
177078673,Infliximab,Sinusitis,OT
177078673,Infliximab,Pruritus,OT
177078673,Infliximab,Nasopharyngitis,OT
177078673,Infliximab,Infusion related reaction,OT
177078673,Infliximab,Fistula,OT
177078673,Infliximab,Eczema,OT
177078673,Infliximab,Ear infection,OT
177078673,Infliximab,Condition aggravated,OT
177078673,Infliximab,Weight decreased,OT
177078673,Infliximab,Urticaria,OT
177078673,Infliximab,Sinusitis,OT
177078673,Infliximab,Pruritus,OT
177078673,Infliximab,Nasopharyngitis,OT
177078673,Infliximab,Infusion related reaction,OT
177078673,Infliximab,Fistula,OT
177078673,Infliximab,Eczema,OT
177078673,Infliximab,Ear infection,OT
177078673,Infliximab,Condition aggravated,OT
177172883,Infliximab,Weight increased,OT
177172883,Infliximab,Off label use,OT
177172883,Infliximab,Intentional product use issue,OT
177172883,Infliximab,Inflammatory marker increased,OT
177172883,Infliximab,Inappropriate schedule of product administration,OT
177172883,Infliximab,Heart rate decreased,OT
177172883,Infliximab,Faecal calprotectin increased,OT
177172883,Infliximab,Drug level below therapeutic,OT
177172883,Infliximab,Drug level above therapeutic,OT
177172883,Infliximab,Condition aggravated,OT
178669633,Infliximab,Weight increased,OT
178669633,Infliximab,Weight decreased,OT
178669633,Infliximab,Pain,OT
178669633,Infliximab,Off label use,OT
178669633,Infliximab,Intentional product use issue,OT
178669633,Infliximab,Inappropriate schedule of product administration,OT
178669633,Infliximab,Hypertension,OT
178669633,Infliximab,Headache,OT
178669633,Infliximab,Fatigue,OT
178669633,Infliximab,Cerebrospinal fluid leakage,OT
178669633,Infliximab,Body temperature decreased,OT
178669633,Infliximab,Blood pressure fluctuation,OT
178669633,Infliximab,Weight increased,OT
178669633,Infliximab,Weight decreased,OT
178669633,Infliximab,Pain,OT
178669633,Infliximab,Off label use,OT
178669633,Infliximab,Intentional product use issue,OT
178669633,Infliximab,Inappropriate schedule of product administration,OT
178669633,Infliximab,Hypertension,OT
178669633,Infliximab,Headache,OT
178669633,Infliximab,Fatigue,OT
178669633,Infliximab,Cerebrospinal fluid leakage,OT
178669633,Infliximab,Body temperature decreased,OT
178669633,Infliximab,Blood pressure fluctuation,OT
178669633,Infliximab,Weight increased,OT
178669633,Infliximab,Weight decreased,OT
178669633,Infliximab,Pain,OT
178669633,Infliximab,Off label use,OT
178669633,Infliximab,Intentional product use issue,OT
178669633,Infliximab,Inappropriate schedule of product administration,OT
178669633,Infliximab,Hypertension,OT
178669633,Infliximab,Headache,OT
178669633,Infliximab,Fatigue,OT
178669633,Infliximab,Cerebrospinal fluid leakage,OT
178669633,Infliximab,Body temperature decreased,OT
178669633,Infliximab,Blood pressure fluctuation,OT
182838353,Infliximab,Vertigo,OT
182838353,Infliximab,Tachycardia,OT
182838353,Infliximab,Rhinitis,OT
182838353,Infliximab,Pulmonary congestion,OT
182838353,Infliximab,Pollakiuria,OT
182838353,Infliximab,Pallor,OT
182838353,Infliximab,Off label use,OT
182838353,Infliximab,Nervousness,OT
182838353,Infliximab,Nausea,OT
182838353,Infliximab,Intentional product use issue,OT
182838353,Infliximab,Inguinal hernia,OT
182838353,Infliximab,Infusion related reaction,OT
182838353,Infliximab,Inappropriate schedule of product administration,OT
182838353,Infliximab,Heart rate irregular,OT
182838353,Infliximab,Dyspnoea,OT
182838353,Infliximab,Dizziness,OT
182838353,Infliximab,Diarrhoea,OT
182838353,Infliximab,Chills,OT
182838353,Infliximab,Blood pressure fluctuation,OT
182838353,Infliximab,Anxiety,OT
183463053,Infliximab,Rash,OT
183463053,Infliximab,Off label use,OT
183463053,Infliximab,Nausea,OT
183463053,Infliximab,Lower respiratory tract infection,OT
183463053,Infliximab,Inappropriate schedule of product administration,OT
183463053,Infliximab,Dyshidrotic eczema,OT
183463053,Infliximab,Drug level decreased,OT
183463053,Infliximab,Cellulitis,OT
183463053,Infliximab,Blood pressure fluctuation,OT
183463053,Infliximab,Blood pressure decreased,OT
183463053,Infliximab,Abdominal pain lower,OT
183463053,Infliximab,Abdominal pain,OT
183825882,Infliximab,Off label use,OT
183825882,Infliximab,Mucous stools,OT
183825882,Infliximab,Inappropriate schedule of product administration,OT
183825882,Infliximab,Haematochezia,OT
183825882,Infliximab,Feeding disorder,OT
183825882,Infliximab,Drug level above therapeutic,OT
183825882,Infliximab,Drug ineffective,OT
183825882,Infliximab,Condition aggravated,OT
183825882,Infliximab,Abdominal pain,OT
183825882,Infliximab,Abdominal discomfort,OT
183928753,Infliximab,Weight increased,OT
183928753,Infliximab,Weight increased,HO
183928753,Infliximab,Weight fluctuation,OT
183928753,Infliximab,Weight fluctuation,HO
183928753,Infliximab,Weight decreased,OT
183928753,Infliximab,Weight decreased,HO
183928753,Infliximab,Tooth disorder,OT
183928753,Infliximab,Tooth disorder,HO
183928753,Infliximab,Pruritus,OT
183928753,Infliximab,Pruritus,HO
183928753,Infliximab,Musculoskeletal stiffness,OT
183928753,Infliximab,Musculoskeletal stiffness,HO
183928753,Infliximab,Muscle twitching,OT
183928753,Infliximab,Muscle twitching,HO
183928753,Infliximab,Malaise,OT
183928753,Infliximab,Malaise,HO
183928753,Infliximab,Heart rate decreased,OT
183928753,Infliximab,Heart rate decreased,HO
183928753,Infliximab,Diarrhoea,OT
183928753,Infliximab,Diarrhoea,HO
183928753,Infliximab,Condition aggravated,OT
183928753,Infliximab,Condition aggravated,HO
183928753,Infliximab,Cardiac disorder,OT
183928753,Infliximab,Cardiac disorder,HO
183928753,Infliximab,Body temperature decreased,OT
183928753,Infliximab,Body temperature decreased,HO
183928753,Infliximab,Blood pressure increased,OT
183928753,Infliximab,Blood pressure increased,HO
183928753,Infliximab,Blood pressure fluctuation,OT
183928753,Infliximab,Blood pressure fluctuation,HO
183928753,Infliximab,Blood pressure decreased,OT
183928753,Infliximab,Blood pressure decreased,HO
183928753,Infliximab,Weight increased,OT
183928753,Infliximab,Weight increased,HO
183928753,Infliximab,Weight fluctuation,OT
183928753,Infliximab,Weight fluctuation,HO
183928753,Infliximab,Weight decreased,OT
183928753,Infliximab,Weight decreased,HO
183928753,Infliximab,Tooth disorder,OT
183928753,Infliximab,Tooth disorder,HO
183928753,Infliximab,Pruritus,OT
183928753,Infliximab,Pruritus,HO
183928753,Infliximab,Musculoskeletal stiffness,OT
183928753,Infliximab,Musculoskeletal stiffness,HO
183928753,Infliximab,Muscle twitching,OT
183928753,Infliximab,Muscle twitching,HO
183928753,Infliximab,Malaise,OT
183928753,Infliximab,Malaise,HO
183928753,Infliximab,Heart rate decreased,OT
183928753,Infliximab,Heart rate decreased,HO
183928753,Infliximab,Diarrhoea,OT
183928753,Infliximab,Diarrhoea,HO
183928753,Infliximab,Condition aggravated,OT
183928753,Infliximab,Condition aggravated,HO
183928753,Infliximab,Cardiac disorder,OT
183928753,Infliximab,Cardiac disorder,HO
183928753,Infliximab,Body temperature decreased,OT
183928753,Infliximab,Body temperature decreased,HO
183928753,Infliximab,Blood pressure increased,OT
183928753,Infliximab,Blood pressure increased,HO
183928753,Infliximab,Blood pressure fluctuation,OT
183928753,Infliximab,Blood pressure fluctuation,HO
183928753,Infliximab,Blood pressure decreased,OT
183928753,Infliximab,Blood pressure decreased,HO
184180162,Infliximab,Weight increased,OT
184180162,Infliximab,Therapeutic product effect incomplete,OT
184180162,Infliximab,Swelling,OT
184180162,Infliximab,Skin laceration,OT
184180162,Infliximab,Product use issue,OT
184180162,Infliximab,Off label use,OT
184180162,Infliximab,Nasopharyngitis,OT
184180162,Infliximab,Mucosal disorder,OT
184180162,Infliximab,Malaise,OT
184180162,Infliximab,Heart rate increased,OT
184180162,Infliximab,Gastroenteritis viral,OT
184180162,Infliximab,Eye infection,OT
184180162,Infliximab,Drug level above therapeutic,OT
184180162,Infliximab,Dermal cyst,OT
184180162,Infliximab,Cough,OT
184180162,Infliximab,Condition aggravated,OT
184180162,Infliximab,Blood pressure systolic increased,OT
184180162,Infliximab,Blepharitis,OT
184599303,Infliximab,Weight increased,OT
184599303,Infliximab,Weight decreased,OT
184599303,Infliximab,Product use issue,OT
184599303,Infliximab,Off label use,OT
184599303,Infliximab,Intentional product use issue,OT
184599303,Infliximab,Inappropriate schedule of product administration,OT
184599303,Infliximab,Heart rate decreased,OT
184599303,Infliximab,Condition aggravated,OT
184599303,Infliximab,Bronchitis bacterial,OT
184599303,Infliximab,Blood pressure increased,OT
184599303,Infliximab,Blood pressure fluctuation,OT
184599303,Infliximab,Weight increased,OT
184599303,Infliximab,Weight decreased,OT
184599303,Infliximab,Product use issue,OT
184599303,Infliximab,Off label use,OT
184599303,Infliximab,Intentional product use issue,OT
184599303,Infliximab,Inappropriate schedule of product administration,OT
184599303,Infliximab,Heart rate decreased,OT
184599303,Infliximab,Condition aggravated,OT
184599303,Infliximab,Bronchitis bacterial,OT
184599303,Infliximab,Blood pressure increased,OT
184599303,Infliximab,Blood pressure fluctuation,OT
184745573,Infliximab,Vision blurred,OT
184745573,Infliximab,Tremor,OT
184745573,Infliximab,Therapeutic product effect incomplete,OT
184745573,Infliximab,Seasonal allergy,OT
184745573,Infliximab,Product use issue,OT
184745573,Infliximab,Palpitations,OT
184745573,Infliximab,Oropharyngeal pain,OT
184745573,Infliximab,Off label use,OT
184745573,Infliximab,Nausea,OT
184745573,Infliximab,Musculoskeletal pain,OT
184745573,Infliximab,Lacrimation increased,OT
184745573,Infliximab,Intentional product use issue,OT
184745573,Infliximab,Inappropriate schedule of product administration,OT
184745573,Infliximab,Hypotension,OT
184745573,Infliximab,Hunger,OT
184745573,Infliximab,Hot flush,OT
184745573,Infliximab,Headache,OT
184745573,Infliximab,Feeling hot,OT
184745573,Infliximab,Fatigue,OT
184745573,Infliximab,Erythema,OT
184745573,Infliximab,Dyspnoea,OT
184745573,Infliximab,Drug ineffective,OT
184745573,Infliximab,Dizziness,OT
184745573,Infliximab,Disturbance in attention,OT
184745573,Infliximab,Decreased appetite,OT
184745573,Infliximab,COVID-19,OT
184745573,Infliximab,Body temperature increased,OT
184745573,Infliximab,Arthralgia,OT
184745573,Infliximab,Anxiety,OT
184745573,Infliximab,Amnesia,OT
184782743,Infliximab,Visual impairment,OT
184782743,Infliximab,Urinary tract infection,OT
184782743,Infliximab,Tissue infiltration,OT
184782743,Infliximab,Throat tightness,OT
184782743,Infliximab,Secretion discharge,OT
184782743,Infliximab,Pyrexia,OT
184782743,Infliximab,Productive cough,OT
184782743,Infliximab,Product dose omission issue,OT
184782743,Infliximab,Panic reaction,OT
184782743,Infliximab,Palatal ulcer,OT
184782743,Infliximab,Pain,OT
184782743,Infliximab,Osteoarthritis,OT
184782743,Infliximab,Off label use,OT
184782743,Infliximab,Oedema mucosal,OT
184782743,Infliximab,Nausea,OT
184782743,Infliximab,Movement disorder,OT
184782743,Infliximab,Mouth ulceration,OT
184782743,Infliximab,Migraine,OT
184782743,Infliximab,Localised infection,OT
184782743,Infliximab,Intermittent claudication,OT
184782743,Infliximab,Intentional product use issue,OT
184782743,Infliximab,Insomnia,OT
184782743,Infliximab,Inflammation,OT
184782743,Infliximab,Incorrect dose administered,OT
184782743,Infliximab,Inappropriate schedule of product administration,OT
184782743,Infliximab,Heart rate increased,OT
184782743,Infliximab,Fracture displacement,OT
184782743,Infliximab,Foot fracture,OT
184782743,Infliximab,Dyspnoea,OT
184782743,Infliximab,Discomfort,OT
184782743,Infliximab,Diarrhoea,OT
184782743,Infliximab,Condition aggravated,OT
184782743,Infliximab,Burning sensation,OT
184782743,Infliximab,Blood pressure increased,OT
184782743,Infliximab,Blood pressure fluctuation,OT
184782743,Infliximab,Bacterial vaginosis,OT
184782743,Infliximab,Arthralgia,OT
184782743,Infliximab,Aphthous ulcer,OT
184782743,Infliximab,Abdominal pain upper,OT
184858332,Infliximab,Vomiting,OT
184858332,Infliximab,Therapeutic response shortened,OT
184858332,Infliximab,Therapeutic product effect decreased,OT
184858332,Infliximab,Pyrexia,OT
184858332,Infliximab,Productive cough,OT
184858332,Infliximab,Product use issue,OT
184858332,Infliximab,Poor quality sleep,OT
184858332,Infliximab,Pharyngitis streptococcal,OT
184858332,Infliximab,Oropharyngeal pain,OT
184858332,Infliximab,Off label use,OT
184858332,Infliximab,Nausea,OT
184858332,Infliximab,Nasal congestion,OT
184858332,Infliximab,Migraine,OT
184858332,Infliximab,Lymphadenopathy,OT
184858332,Infliximab,Intentional product use issue,OT
184858332,Infliximab,Inappropriate schedule of product administration,OT
184858332,Infliximab,Haematochezia,OT
184858332,Infliximab,Fatigue,OT
184858332,Infliximab,Faecal calprotectin increased,OT
184858332,Infliximab,Drug level below therapeutic,OT
184858332,Infliximab,Diarrhoea,OT
184858332,Infliximab,Depression,OT
184858332,Infliximab,Cough,OT
184858332,Infliximab,Condition aggravated,OT
184858332,Infliximab,Apathy,OT
184858332,Infliximab,Anal fissure,OT
184858332,Infliximab,Vomiting,OT
184858332,Infliximab,Therapeutic response shortened,OT
184858332,Infliximab,Therapeutic product effect decreased,OT
184858332,Infliximab,Pyrexia,OT
184858332,Infliximab,Productive cough,OT
184858332,Infliximab,Product use issue,OT
184858332,Infliximab,Poor quality sleep,OT
184858332,Infliximab,Pharyngitis streptococcal,OT
184858332,Infliximab,Oropharyngeal pain,OT
184858332,Infliximab,Off label use,OT
184858332,Infliximab,Nausea,OT
184858332,Infliximab,Nasal congestion,OT
184858332,Infliximab,Migraine,OT
184858332,Infliximab,Lymphadenopathy,OT
184858332,Infliximab,Intentional product use issue,OT
184858332,Infliximab,Inappropriate schedule of product administration,OT
184858332,Infliximab,Haematochezia,OT
184858332,Infliximab,Fatigue,OT
184858332,Infliximab,Faecal calprotectin increased,OT
184858332,Infliximab,Drug level below therapeutic,OT
184858332,Infliximab,Diarrhoea,OT
184858332,Infliximab,Depression,OT
184858332,Infliximab,Cough,OT
184858332,Infliximab,Condition aggravated,OT
184858332,Infliximab,Apathy,OT
184858332,Infliximab,Anal fissure,OT
184937563,Infliximab,Weight increased,OT
184937563,Infliximab,Off label use,OT
184937563,Infliximab,Intentional product use issue,OT
184937563,Infliximab,Hypertension,OT
184937563,Infliximab,Ear infection,OT
184937563,Infliximab,Blood pressure increased,OT
184937563,Infliximab,Blood pressure fluctuation,OT
184937563,Infliximab,Ankylosing spondylitis,OT
184937563,Infliximab,Weight increased,OT
184937563,Infliximab,Off label use,OT
184937563,Infliximab,Intentional product use issue,OT
184937563,Infliximab,Hypertension,OT
184937563,Infliximab,Ear infection,OT
184937563,Infliximab,Blood pressure increased,OT
184937563,Infliximab,Blood pressure fluctuation,OT
184937563,Infliximab,Ankylosing spondylitis,OT
185026753,Infliximab,Weight decreased,OT
185026753,Infliximab,Neoplasm malignant,OT
185026753,Infliximab,Inappropriate schedule of product administration,OT
185026753,Infliximab,Weight decreased,OT
185026753,Infliximab,Neoplasm malignant,OT
185026753,Infliximab,Inappropriate schedule of product administration,OT
187016902,Infliximab,Weight increased,OT
187016902,Infliximab,Somnolence,OT
187016902,Infliximab,Pallor,OT
187016902,Infliximab,Off label use,OT
187016902,Infliximab,Malaise,OT
187016902,Infliximab,Intentional product use issue,OT
187016902,Infliximab,Incorrect dose administered,OT
187016902,Infliximab,Inappropriate schedule of product administration,OT
187016902,Infliximab,Heart rate irregular,OT
187016902,Infliximab,Heart rate decreased,OT
187016902,Infliximab,Haemoglobin decreased,OT
187016902,Infliximab,Haematemesis,OT
187016902,Infliximab,Frequent bowel movements,OT
187016902,Infliximab,Feeling drunk,OT
187016902,Infliximab,Feeling abnormal,OT
187016902,Infliximab,Dizziness,OT
187016902,Infliximab,Decreased appetite,OT
187016902,Infliximab,Condition aggravated,OT
187016902,Infliximab,Blood pressure increased,OT
187016902,Infliximab,Blood pressure fluctuation,OT
187016902,Infliximab,Blood pressure diastolic decreased,OT
187016902,Infliximab,Weight increased,OT
187016902,Infliximab,Somnolence,OT
187016902,Infliximab,Pallor,OT
187016902,Infliximab,Off label use,OT
187016902,Infliximab,Malaise,OT
187016902,Infliximab,Intentional product use issue,OT
187016902,Infliximab,Incorrect dose administered,OT
187016902,Infliximab,Inappropriate schedule of product administration,OT
187016902,Infliximab,Heart rate irregular,OT
187016902,Infliximab,Heart rate decreased,OT
187016902,Infliximab,Haemoglobin decreased,OT
187016902,Infliximab,Haematemesis,OT
187016902,Infliximab,Frequent bowel movements,OT
187016902,Infliximab,Feeling drunk,OT
187016902,Infliximab,Feeling abnormal,OT
187016902,Infliximab,Dizziness,OT
187016902,Infliximab,Decreased appetite,OT
187016902,Infliximab,Condition aggravated,OT
187016902,Infliximab,Blood pressure increased,OT
187016902,Infliximab,Blood pressure fluctuation,OT
187016902,Infliximab,Blood pressure diastolic decreased,OT
192711472,Infliximab,Sinusitis,OT
192711472,Infliximab,Off label use,OT
192711472,Infliximab,Nasopharyngitis,OT
192711472,Infliximab,Nasal congestion,OT
192711472,Infliximab,Lower respiratory tract infection,OT
192711472,Infliximab,Heart rate decreased,OT
192711472,Infliximab,Headache,OT
192711472,Infliximab,Bronchitis bacterial,OT
192711472,Infliximab,Bronchitis,OT
193820982,Infliximab,Off label use,OT
193820982,Infliximab,Maternal exposure during pregnancy,OT
193820982,Infliximab,Drug ineffective,OT
193820982,Infliximab,Crohn's disease,OT
193820982,Infliximab,Off label use,OT
193820982,Infliximab,Maternal exposure during pregnancy,OT
193820982,Infliximab,Drug ineffective,OT
193820982,Infliximab,Crohn's disease,OT
194980131,Infliximab,Product use issue,OT
194980131,Infliximab,Product use issue,HO
194980131,Infliximab,Off label use,OT
194980131,Infliximab,Off label use,HO
194980131,Infliximab,Intentional product use issue,OT
194980131,Infliximab,Intentional product use issue,HO
194980131,Infliximab,Fatigue,OT
194980131,Infliximab,Fatigue,HO
194980131,Infliximab,Condition aggravated,OT
194980131,Infliximab,Condition aggravated,HO
194980131,Infliximab,COVID-19,OT
194980131,Infliximab,COVID-19,HO
195028981,Infliximab Hospira,Takayasu's arteritis,OT
195041511,Infliximab,Pulmonary pain,HO
195041511,Infliximab,Pneumonia,HO
195041511,Infliximab,Fatigue,HO
195177261,Infliximab (Unknown),Pulmonary embolism,OT
195177261,Infliximab (Unknown),Cardiac ventricular thrombosis,OT
195665562,Infliximab,Small intestinal obstruction,HO
195665562,Infliximab,Small intestinal obstruction,OT
196071473,Infliximab,Intentional product use issue,HO
196071473,Infliximab,Diarrhoea,HO
196071473,Infliximab,Intentional product use issue,HO
196071473,Infliximab,Diarrhoea,HO
196282361,Infliximab Hospira,Septic shock,DE
196282361,Infliximab Hospira,Off label use,DE
196282361,Infliximab Hospira,Endocarditis bacterial,DE
196526521,Infliximab,Weight increased,OT
196526521,Infliximab,Off label use,OT
196526521,Infliximab,Intestinal ulcer,OT
196526521,Infliximab,Incorrect dose administered,OT
196526521,Infliximab,Condition aggravated,OT
196526521,Infliximab,Blood pressure increased,OT
197042371,Infliximab,Weight decreased,OT
197042371,Infliximab,Off label use,OT
197042371,Infliximab,Intentional product use issue,OT
197042371,Infliximab,Haemolysis,OT
197042371,Infliximab,Feeling hot,OT
197042371,Infliximab,Blood pressure increased,OT
197061961,Infliximab,Premature baby,OT
197061961,Infliximab,Low birth weight baby,OT
197061961,Infliximab,Foetal exposure during pregnancy,OT
197239481,Infliximab,Pneumonia mycoplasmal,HO
197239481,Infliximab,Pleural effusion,HO
197239481,Infliximab,Pericarditis lupus,HO
197239481,Infliximab,Off label use,HO
197239481,Infliximab,Lupus pleurisy,HO
197239481,Infliximab,Drug specific antibody present,HO
197239481,Infliximab,Drug level abnormal,HO
197239481,Infliximab,Pneumonia mycoplasmal,HO
197239481,Infliximab,Pleural effusion,HO
197239481,Infliximab,Pericarditis lupus,HO
197239481,Infliximab,Off label use,HO
197239481,Infliximab,Lupus pleurisy,HO
197239481,Infliximab,Drug specific antibody present,HO
197239481,Infliximab,Drug level abnormal,HO
197407211,Infliximab,Weight decreased,HO
197407211,Infliximab,Throat tightness,HO
197407211,Infliximab,Sensation of foreign body,HO
197407211,Infliximab,Oropharyngeal pain,HO
197407211,Infliximab,Off label use,HO
197407211,Infliximab,Neck pain,HO
197407211,Infliximab,Inappropriate schedule of product administration,HO
197407211,Infliximab,Feeling hot,HO
197407211,Infliximab,Dysphagia,HO
197407211,Infliximab,Drug ineffective,HO
197407211,Infliximab,Condition aggravated,HO
197407211,Infliximab,Chest pain,HO
197512781,Infliximab,Weight increased,OT
197512781,Infliximab,Therapeutic response shortened,OT
197512781,Infliximab,Rectal haemorrhage,OT
197512781,Infliximab,Product use issue,OT
197512781,Infliximab,Off label use,OT
197512781,Infliximab,Intentional product use issue,OT
197512781,Infliximab,Inflammation,OT
197512781,Infliximab,Inappropriate schedule of product administration,OT
197512781,Infliximab,Condition aggravated,OT
197512781,Infliximab,Blood pressure increased,OT
197942661,Infliximab,Vomiting,OT
197942661,Infliximab,Vomiting,HO
197942661,Infliximab,Product use issue,OT
197942661,Infliximab,Product use issue,HO
197942661,Infliximab,Off label use,OT
197942661,Infliximab,Off label use,HO
197942661,Infliximab,Non-alcoholic steatohepatitis,OT
197942661,Infliximab,Non-alcoholic steatohepatitis,HO
197942661,Infliximab,Liver injury,OT
197942661,Infliximab,Liver injury,HO
197942661,Infliximab,Intentional product use issue,OT
197942661,Infliximab,Intentional product use issue,HO
197942661,Infliximab,Infusion site discolouration,OT
197942661,Infliximab,Infusion site discolouration,HO
197942661,Infliximab,Hepatic enzyme increased,OT
197942661,Infliximab,Hepatic enzyme increased,HO
197942661,Infliximab,Blood pressure increased,OT
197942661,Infliximab,Blood pressure increased,HO
197942661,Infliximab,Biliary colic,OT
197942661,Infliximab,Biliary colic,HO
197942661,Infliximab,Bile duct stone,OT
197942661,Infliximab,Bile duct stone,HO
197942661,Infliximab,Alanine aminotransferase increased,OT
197942661,Infliximab,Alanine aminotransferase increased,HO
197942661,Infliximab,Abdominal pain upper,OT
197942661,Infliximab,Abdominal pain upper,HO
197942661,Infliximab,Abdominal pain,OT
197942661,Infliximab,Abdominal pain,HO
197942661,Infliximab,Abdominal distension,OT
197942661,Infliximab,Abdominal distension,HO
197995761,Infliximab,Steroid diabetes,OT
197995761,Infliximab,Product use in unapproved indication,OT
197995761,Infliximab,Chronic kidney disease,OT
198078611,Infliximab,Fistula discharge,HO
198078611,Infliximab,Diarrhoea,HO
198078611,Infliximab,Condition aggravated,HO
198108691,Infliximab,Weight decreased,HO
198108691,Infliximab,Sleep deficit,HO
198108691,Infliximab,Gastrointestinal obstruction,HO
198108691,Infliximab,Condition aggravated,HO
198108691,Infliximab,Arthralgia,HO
198237751,Infliximab,Therapeutic product effect incomplete,HO
198237751,Infliximab,Tenderness,HO
198237751,Infliximab,Peripheral swelling,HO
198237751,Infliximab,Pain,HO
198237751,Infliximab,Musculoskeletal stiffness,HO
198237751,Infliximab,Joint swelling,HO
198237751,Infliximab,Inappropriate schedule of product administration,HO
198237751,Infliximab,General physical health deterioration,HO
198237751,Infliximab,Gait disturbance,HO
198237751,Infliximab,Fatigue,HO
198237751,Infliximab,Dyspnoea,HO
198237751,Infliximab,Discomfort,HO
198237751,Infliximab,Burning sensation,HO
198237751,Infliximab,Asthenia,HO
198237751,Infliximab,Arthralgia,HO
198237751,Infliximab,Therapeutic product effect incomplete,HO
198237751,Infliximab,Tenderness,HO
198237751,Infliximab,Peripheral swelling,HO
198237751,Infliximab,Pain,HO
198237751,Infliximab,Musculoskeletal stiffness,HO
198237751,Infliximab,Joint swelling,HO
198237751,Infliximab,Inappropriate schedule of product administration,HO
198237751,Infliximab,General physical health deterioration,HO
198237751,Infliximab,Gait disturbance,HO
198237751,Infliximab,Fatigue,HO
198237751,Infliximab,Dyspnoea,HO
198237751,Infliximab,Discomfort,HO
198237751,Infliximab,Burning sensation,HO
198237751,Infliximab,Asthenia,HO
198237751,Infliximab,Arthralgia,HO
198394851,Infliximab,Weight decreased,OT
198394851,Infliximab,Sneezing,OT
198394851,Infliximab,Sinus congestion,OT
198394851,Infliximab,Rhinorrhoea,OT
198394851,Infliximab,Oropharyngeal pain,OT
198394851,Infliximab,Off label use,OT
198394851,Infliximab,Nasopharyngitis,OT
198394851,Infliximab,Nasal congestion,OT
198394851,Infliximab,Heart rate irregular,OT
198394851,Infliximab,Headache,OT
198394851,Infliximab,Condition aggravated,OT
198394851,Infliximab,Blood test abnormal,OT
198394851,Infliximab,Arthralgia,OT
198697201,Infliximab,Weight decreased,OT
198697201,Infliximab,Vitamin D decreased,OT
198697201,Infliximab,Pyoderma gangrenosum,OT
198697201,Infliximab,Headache,OT
198697201,Infliximab,Erythema nodosum,OT
198697201,Infliximab,Anal fissure,OT
198794781,Infliximab (Unknown),Off label use,NULL
198794781,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198912941,Infliximab,Product use in unapproved indication,DE
198912941,Infliximab,Death,DE
199052221,Infliximab,Rash macular,OT
199052221,Infliximab,Rash,OT
199052221,Infliximab,Psoriasis,OT
199052221,Infliximab,Off label use,OT
199052221,Infliximab,Malaise,OT
199052221,Infliximab,Intentional product use issue,OT
199052221,Infliximab,Heart rate decreased,OT
199052221,Infliximab,Dizziness,OT
199052221,Infliximab,Condition aggravated,OT
199052221,Infliximab,Clostridium difficile infection,OT
199052221,Infliximab,Blood pressure fluctuation,OT
199052221,Infliximab,Amenorrhoea,OT
199052221,Infliximab,Alopecia,OT
199064151,Infliximab,Urticaria,OT
199064151,Infliximab,Thrombosis,OT
199064151,Infliximab,Rash,OT
199064151,Infliximab,Pruritus,OT
199064151,Infliximab,Pain of skin,OT
199064151,Infliximab,Oedema peripheral,OT
199064151,Infliximab,Feeling hot,OT
199064151,Infliximab,Erythema,OT
199064151,Infliximab,Dyspnoea,OT
199064151,Infliximab,Blood pressure fluctuation,OT
199064151,Infliximab,Abdominal hernia,OT
1570794320,Infliximab Pfizer (Unknown),Transplant rejection,LT
1570794320,Infliximab Pfizer (Unknown),Transplant rejection,OT
1570794320,Infliximab Pfizer (Unknown),Transplant dysfunction,LT
1570794320,Infliximab Pfizer (Unknown),Transplant dysfunction,OT
1570794320,Infliximab Pfizer (Unknown),"Sleep disorder due to general medical condition, insomnia type",LT
1570794320,Infliximab Pfizer (Unknown),"Sleep disorder due to general medical condition, insomnia type",OT
1570794320,Infliximab Pfizer (Unknown),Rheumatoid arthritis,LT
1570794320,Infliximab Pfizer (Unknown),Rheumatoid arthritis,OT
1570794320,Infliximab Pfizer (Unknown),Product use issue,LT
1570794320,Infliximab Pfizer (Unknown),Product use issue,OT
1570794320,Infliximab Pfizer (Unknown),Pneumonia,LT
1570794320,Infliximab Pfizer (Unknown),Pneumonia,OT
1570794320,Infliximab Pfizer (Unknown),Pain,LT
1570794320,Infliximab Pfizer (Unknown),Pain,OT
1570794320,Infliximab Pfizer (Unknown),Overdose,LT
1570794320,Infliximab Pfizer (Unknown),Overdose,OT
1570794320,Infliximab Pfizer (Unknown),Ovarian cyst,LT
1570794320,Infliximab Pfizer (Unknown),Ovarian cyst,OT
1570794320,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,LT
1570794320,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,OT
1570794320,Infliximab Pfizer (Unknown),Liver function test abnormal,LT
1570794320,Infliximab Pfizer (Unknown),Liver function test abnormal,OT
1570794320,Infliximab Pfizer (Unknown),Incorrect route of product administration,LT
1570794320,Infliximab Pfizer (Unknown),Incorrect route of product administration,OT
1570794320,Infliximab Pfizer (Unknown),Drug ineffective,LT
1570794320,Infliximab Pfizer (Unknown),Drug ineffective,OT
1570794320,Infliximab Pfizer (Unknown),Condition aggravated,LT
1570794320,Infliximab Pfizer (Unknown),Condition aggravated,OT
1570794320,Infliximab Pfizer (Unknown),Alopecia,LT
1570794320,Infliximab Pfizer (Unknown),Alopecia,OT
1570794320,Infliximab Pfizer (Unknown),Acne,LT
1570794320,Infliximab Pfizer (Unknown),Acne,OT
160821545,Infliximab,Vomiting,OT
160821545,Infliximab,Vomiting,HO
160821545,Infliximab,Stoma obstruction,OT
160821545,Infliximab,Stoma obstruction,HO
160821545,Infliximab,Product use issue,OT
160821545,Infliximab,Product use issue,HO
160821545,Infliximab,Poor venous access,OT
160821545,Infliximab,Poor venous access,HO
160821545,Infliximab,Off label use,OT
160821545,Infliximab,Off label use,HO
160821545,Infliximab,Nausea,OT
160821545,Infliximab,Nausea,HO
160821545,Infliximab,Muscle spasms,OT
160821545,Infliximab,Muscle spasms,HO
160821545,Infliximab,Malaise,OT
160821545,Infliximab,Malaise,HO
160821545,Infliximab,Intentional product use issue,OT
160821545,Infliximab,Intentional product use issue,HO
160821545,Infliximab,Incorrect dose administered,OT
160821545,Infliximab,Incorrect dose administered,HO
160821545,Infliximab,Inappropriate schedule of product administration,OT
160821545,Infliximab,Inappropriate schedule of product administration,HO
160821545,Infliximab,Hyperchlorhydria,OT
160821545,Infliximab,Hyperchlorhydria,HO
160821545,Infliximab,Hot flush,OT
160821545,Infliximab,Hot flush,HO
160821545,Infliximab,Haemolysis,OT
160821545,Infliximab,Haemolysis,HO
160821545,Infliximab,Food poisoning,OT
160821545,Infliximab,Food poisoning,HO
160821545,Infliximab,Feeling abnormal,OT
160821545,Infliximab,Feeling abnormal,HO
160821545,Infliximab,Fatigue,OT
160821545,Infliximab,Fatigue,HO
160821545,Infliximab,Drug ineffective,OT
160821545,Infliximab,Drug ineffective,HO
160821545,Infliximab,Dizziness,OT
160821545,Infliximab,Dizziness,HO
160821545,Infliximab,Dehydration,OT
160821545,Infliximab,Dehydration,HO
160821545,Infliximab,Constipation,OT
160821545,Infliximab,Constipation,HO
160821545,Infliximab,Condition aggravated,OT
160821545,Infliximab,Condition aggravated,HO
160821545,Infliximab,Body temperature decreased,OT
160821545,Infliximab,Body temperature decreased,HO
160821545,Infliximab,Asthenia,OT
160821545,Infliximab,Asthenia,HO
160821545,Infliximab,Anal incontinence,OT
160821545,Infliximab,Anal incontinence,HO
160821545,Infliximab,Abdominal pain upper,OT
160821545,Infliximab,Abdominal pain upper,HO
160821545,Infliximab,Abdominal hernia,OT
160821545,Infliximab,Abdominal hernia,HO
160821545,Infliximab,Vomiting,OT
160821545,Infliximab,Vomiting,HO
160821545,Infliximab,Stoma obstruction,OT
160821545,Infliximab,Stoma obstruction,HO
160821545,Infliximab,Product use issue,OT
160821545,Infliximab,Product use issue,HO
160821545,Infliximab,Poor venous access,OT
160821545,Infliximab,Poor venous access,HO
160821545,Infliximab,Off label use,OT
160821545,Infliximab,Off label use,HO
160821545,Infliximab,Nausea,OT
160821545,Infliximab,Nausea,HO
160821545,Infliximab,Muscle spasms,OT
160821545,Infliximab,Muscle spasms,HO
160821545,Infliximab,Malaise,OT
160821545,Infliximab,Malaise,HO
160821545,Infliximab,Intentional product use issue,OT
160821545,Infliximab,Intentional product use issue,HO
160821545,Infliximab,Incorrect dose administered,OT
160821545,Infliximab,Incorrect dose administered,HO
160821545,Infliximab,Inappropriate schedule of product administration,OT
160821545,Infliximab,Inappropriate schedule of product administration,HO
160821545,Infliximab,Hyperchlorhydria,OT
160821545,Infliximab,Hyperchlorhydria,HO
160821545,Infliximab,Hot flush,OT
160821545,Infliximab,Hot flush,HO
160821545,Infliximab,Haemolysis,OT
160821545,Infliximab,Haemolysis,HO
160821545,Infliximab,Food poisoning,OT
160821545,Infliximab,Food poisoning,HO
160821545,Infliximab,Feeling abnormal,OT
160821545,Infliximab,Feeling abnormal,HO
160821545,Infliximab,Fatigue,OT
160821545,Infliximab,Fatigue,HO
160821545,Infliximab,Drug ineffective,OT
160821545,Infliximab,Drug ineffective,HO
160821545,Infliximab,Dizziness,OT
160821545,Infliximab,Dizziness,HO
160821545,Infliximab,Dehydration,OT
160821545,Infliximab,Dehydration,HO
160821545,Infliximab,Constipation,OT
160821545,Infliximab,Constipation,HO
160821545,Infliximab,Condition aggravated,OT
160821545,Infliximab,Condition aggravated,HO
160821545,Infliximab,Body temperature decreased,OT
160821545,Infliximab,Body temperature decreased,HO
160821545,Infliximab,Asthenia,OT
160821545,Infliximab,Asthenia,HO
160821545,Infliximab,Anal incontinence,OT
160821545,Infliximab,Anal incontinence,HO
160821545,Infliximab,Abdominal pain upper,OT
160821545,Infliximab,Abdominal pain upper,HO
160821545,Infliximab,Abdominal hernia,OT
160821545,Infliximab,Abdominal hernia,HO
160821545,Infliximab,Vomiting,OT
160821545,Infliximab,Vomiting,HO
160821545,Infliximab,Stoma obstruction,OT
160821545,Infliximab,Stoma obstruction,HO
160821545,Infliximab,Product use issue,OT
160821545,Infliximab,Product use issue,HO
160821545,Infliximab,Poor venous access,OT
160821545,Infliximab,Poor venous access,HO
160821545,Infliximab,Off label use,OT
160821545,Infliximab,Off label use,HO
160821545,Infliximab,Nausea,OT
160821545,Infliximab,Nausea,HO
160821545,Infliximab,Muscle spasms,OT
160821545,Infliximab,Muscle spasms,HO
160821545,Infliximab,Malaise,OT
160821545,Infliximab,Malaise,HO
160821545,Infliximab,Intentional product use issue,OT
160821545,Infliximab,Intentional product use issue,HO
160821545,Infliximab,Incorrect dose administered,OT
160821545,Infliximab,Incorrect dose administered,HO
160821545,Infliximab,Inappropriate schedule of product administration,OT
160821545,Infliximab,Inappropriate schedule of product administration,HO
160821545,Infliximab,Hyperchlorhydria,OT
160821545,Infliximab,Hyperchlorhydria,HO
160821545,Infliximab,Hot flush,OT
160821545,Infliximab,Hot flush,HO
160821545,Infliximab,Haemolysis,OT
160821545,Infliximab,Haemolysis,HO
160821545,Infliximab,Food poisoning,OT
160821545,Infliximab,Food poisoning,HO
160821545,Infliximab,Feeling abnormal,OT
160821545,Infliximab,Feeling abnormal,HO
160821545,Infliximab,Fatigue,OT
160821545,Infliximab,Fatigue,HO
160821545,Infliximab,Drug ineffective,OT
160821545,Infliximab,Drug ineffective,HO
160821545,Infliximab,Dizziness,OT
160821545,Infliximab,Dizziness,HO
160821545,Infliximab,Dehydration,OT
160821545,Infliximab,Dehydration,HO
160821545,Infliximab,Constipation,OT
160821545,Infliximab,Constipation,HO
160821545,Infliximab,Condition aggravated,OT
160821545,Infliximab,Condition aggravated,HO
160821545,Infliximab,Body temperature decreased,OT
160821545,Infliximab,Body temperature decreased,HO
160821545,Infliximab,Asthenia,OT
160821545,Infliximab,Asthenia,HO
160821545,Infliximab,Anal incontinence,OT
160821545,Infliximab,Anal incontinence,HO
160821545,Infliximab,Abdominal pain upper,OT
160821545,Infliximab,Abdominal pain upper,HO
160821545,Infliximab,Abdominal hernia,OT
160821545,Infliximab,Abdominal hernia,HO
175199134,Infliximab,Weight decreased,OT
175199134,Infliximab,Respiratory tract congestion,OT
175199134,Infliximab,Pruritus,OT
175199134,Infliximab,Product use issue,OT
175199134,Infliximab,Prescribed overdose,OT
175199134,Infliximab,Oxygen saturation decreased,OT
175199134,Infliximab,Off label use,OT
175199134,Infliximab,Nasopharyngitis,OT
175199134,Infliximab,Nasal congestion,OT
175199134,Infliximab,Maternal exposure during pregnancy,OT
175199134,Infliximab,Lethargy,OT
175199134,Infliximab,Irregular breathing,OT
175199134,Infliximab,Intentional product use issue,OT
175199134,Infliximab,Hypertension,OT
175199134,Infliximab,Heart rate irregular,OT
175199134,Infliximab,Headache,OT
175199134,Infliximab,Haematochezia,OT
175199134,Infliximab,Drug ineffective,OT
175199134,Infliximab,Condition aggravated,OT
175199134,Infliximab,Body temperature fluctuation,OT
175199134,Infliximab,Blood pressure fluctuation,OT
175199134,Infliximab,Blood pressure diastolic decreased,OT
175199134,Infliximab,Weight decreased,OT
175199134,Infliximab,Respiratory tract congestion,OT
175199134,Infliximab,Pruritus,OT
175199134,Infliximab,Product use issue,OT
175199134,Infliximab,Prescribed overdose,OT
175199134,Infliximab,Oxygen saturation decreased,OT
175199134,Infliximab,Off label use,OT
175199134,Infliximab,Nasopharyngitis,OT
175199134,Infliximab,Nasal congestion,OT
175199134,Infliximab,Maternal exposure during pregnancy,OT
175199134,Infliximab,Lethargy,OT
175199134,Infliximab,Irregular breathing,OT
175199134,Infliximab,Intentional product use issue,OT
175199134,Infliximab,Hypertension,OT
175199134,Infliximab,Heart rate irregular,OT
175199134,Infliximab,Headache,OT
175199134,Infliximab,Haematochezia,OT
175199134,Infliximab,Drug ineffective,OT
175199134,Infliximab,Condition aggravated,OT
175199134,Infliximab,Body temperature fluctuation,OT
175199134,Infliximab,Blood pressure fluctuation,OT
175199134,Infliximab,Blood pressure diastolic decreased,OT
175483354,Infliximab,Tooth infection,OT
175483354,Infliximab,Tooth abscess,OT
175483354,Infliximab,Syncope,OT
175483354,Infliximab,Pallor,OT
175483354,Infliximab,Off label use,OT
175483354,Infliximab,Malaise,OT
175483354,Infliximab,Intentional product use issue,OT
175483354,Infliximab,Hyperhidrosis,OT
175483354,Infliximab,Heart rate irregular,OT
175483354,Infliximab,Drug level above therapeutic,OT
175483354,Infliximab,Drug ineffective,OT
175483354,Infliximab,Dizziness,OT
175483354,Infliximab,Condition aggravated,OT
175483354,Infliximab,Blood pressure fluctuation,OT
176033533,Infliximab,Weight increased,OT
176033533,Infliximab,Weight decreased,OT
176033533,Infliximab,SARS-CoV-2 test positive,OT
176033533,Infliximab,Pyrexia,OT
176033533,Infliximab,Product use issue,OT
176033533,Infliximab,Off label use,OT
176033533,Infliximab,Nausea,OT
176033533,Infliximab,Maternal exposure during pregnancy,OT
176033533,Infliximab,Malaise,OT
176033533,Infliximab,Inappropriate schedule of product administration,OT
176033533,Infliximab,Headache,OT
176033533,Infliximab,Fatigue,OT
176033533,Infliximab,Expired product administered,OT
176033533,Infliximab,Dyspnoea,OT
176033533,Infliximab,Diarrhoea haemorrhagic,OT
176033533,Infliximab,Diarrhoea,OT
176033533,Infliximab,Depressed level of consciousness,OT
176033533,Infliximab,Condition aggravated,OT
176033533,Infliximab,Abortion,OT
176033533,Infliximab,Abdominal pain,OT
176545154,Infliximab,Weight decreased,OT
176545154,Infliximab,Off label use,OT
176545154,Infliximab,Malaise,OT
176545154,Infliximab,Intentional product use issue,OT
176545154,Infliximab,Inappropriate schedule of product administration,OT
176545154,Infliximab,Heart rate decreased,OT
176545154,Infliximab,Heart rate abnormal,OT
176545154,Infliximab,Blood pressure increased,OT
176545154,Infliximab,Blood pressure fluctuation,OT
176564735,Infliximab,Weight increased,OT
176564735,Infliximab,Weight decreased,OT
176564735,Infliximab,Stoma site haemorrhage,OT
176564735,Infliximab,Product use issue,OT
176564735,Infliximab,Off label use,OT
176564735,Infliximab,Intentional product use issue,OT
176564735,Infliximab,Hernia,OT
176564735,Infliximab,Drug level above therapeutic,OT
176564735,Infliximab,Contusion,OT
176564735,Infliximab,Condition aggravated,OT
176564735,Infliximab,Blood pressure increased,OT
176564735,Infliximab,Blood pressure fluctuation,OT
176564735,Infliximab,Blood pressure decreased,OT
176564735,Infliximab,Arthralgia,OT
176564735,Infliximab,Abdominal pain lower,OT
176564735,Infliximab,Weight increased,OT
176564735,Infliximab,Weight decreased,OT
176564735,Infliximab,Stoma site haemorrhage,OT
176564735,Infliximab,Product use issue,OT
176564735,Infliximab,Off label use,OT
176564735,Infliximab,Intentional product use issue,OT
176564735,Infliximab,Hernia,OT
176564735,Infliximab,Drug level above therapeutic,OT
176564735,Infliximab,Contusion,OT
176564735,Infliximab,Condition aggravated,OT
176564735,Infliximab,Blood pressure increased,OT
176564735,Infliximab,Blood pressure fluctuation,OT
176564735,Infliximab,Blood pressure decreased,OT
176564735,Infliximab,Arthralgia,OT
176564735,Infliximab,Abdominal pain lower,OT
176857843,Infliximab,Somnolence,OT
176857843,Infliximab,Pathogen resistance,OT
176857843,Infliximab,Oropharyngeal pain,OT
176857843,Infliximab,Nausea,OT
176857843,Infliximab,Migraine,OT
176857843,Infliximab,Inappropriate schedule of product administration,OT
176857843,Infliximab,Headache,OT
176857843,Infliximab,Disorientation,OT
176857843,Infliximab,Cough,OT
176857843,Infliximab,Chills,OT
176857843,Infliximab,Body temperature increased,OT
176857843,Infliximab,Body temperature fluctuation,OT
176857843,Infliximab,Blood pressure fluctuation,OT
176857843,Infliximab,Abdominal discomfort,OT
177025604,Infliximab,Vertigo,OT
177025604,Infliximab,Spinal fracture,OT
177025604,Infliximab,Skin plaque,OT
177025604,Infliximab,Sinusitis,OT
177025604,Infliximab,Rhinorrhoea,OT
177025604,Infliximab,Pyrexia,OT
177025604,Infliximab,Productive cough,OT
177025604,Infliximab,Product use issue,OT
177025604,Infliximab,Poor venous access,OT
177025604,Infliximab,Peripheral coldness,OT
177025604,Infliximab,Pain in extremity,OT
177025604,Infliximab,Oropharyngeal pain,OT
177025604,Infliximab,Off label use,OT
177025604,Infliximab,Nasopharyngitis,OT
177025604,Infliximab,Nasal congestion,OT
177025604,Infliximab,Musculoskeletal stiffness,OT
177025604,Infliximab,Malaise,OT
177025604,Infliximab,Laryngitis,OT
177025604,Infliximab,Joint injury,OT
177025604,Infliximab,Intentional product use issue,OT
177025604,Infliximab,Intentional dose omission,OT
177025604,Infliximab,Inappropriate schedule of product administration,OT
177025604,Infliximab,Headache,OT
177025604,Infliximab,Fall,OT
177025604,Infliximab,Eye irritation,OT
177025604,Infliximab,Dysphonia,OT
177025604,Infliximab,Cough,OT
177025604,Infliximab,Condition aggravated,OT
177025604,Infliximab,Bronchitis,OT
177025604,Infliximab,Blood pressure fluctuation,OT
177025604,Infliximab,Back pain,OT
177025604,Infliximab,Arthralgia,OT
177025733,Infliximab,Off label use,OT
177025733,Infliximab,Intentional product use issue,OT
177025733,Infliximab,Incorrect dose administered,OT
177025733,Infliximab,Hypotension,OT
177025733,Infliximab,Heart rate decreased,OT
177025733,Infliximab,Condition aggravated,OT
177025733,Infliximab,Blood pressure fluctuation,OT
177717963,Infliximab,Weight increased,HO
177717963,Infliximab,Weight increased,OT
177717963,Infliximab,Pyoderma gangrenosum,HO
177717963,Infliximab,Pyoderma gangrenosum,OT
177717963,Infliximab,Product use issue,HO
177717963,Infliximab,Product use issue,OT
177717963,Infliximab,Poor venous access,HO
177717963,Infliximab,Poor venous access,OT
177717963,Infliximab,Pancreatic disorder,HO
177717963,Infliximab,Pancreatic disorder,OT
177717963,Infliximab,Pain in extremity,HO
177717963,Infliximab,Pain in extremity,OT
177717963,Infliximab,Oxygen saturation abnormal,HO
177717963,Infliximab,Oxygen saturation abnormal,OT
177717963,Infliximab,Off label use,HO
177717963,Infliximab,Off label use,OT
177717963,Infliximab,Neck pain,HO
177717963,Infliximab,Neck pain,OT
177717963,Infliximab,Intentional product use issue,HO
177717963,Infliximab,Intentional product use issue,OT
177717963,Infliximab,Drug ineffective,HO
177717963,Infliximab,Drug ineffective,OT
177717963,Infliximab,Dactylitis,HO
177717963,Infliximab,Dactylitis,OT
177717963,Infliximab,Condition aggravated,HO
177717963,Infliximab,Condition aggravated,OT
177717963,Infliximab,Chest pain,HO
177717963,Infliximab,Chest pain,OT
177717963,Infliximab,Bursitis,HO
177717963,Infliximab,Bursitis,OT
180333044,Infliximab,Vomiting,OT
180333044,Infliximab,Vomiting,HO
180333044,Infliximab,Vaginal flatulence,OT
180333044,Infliximab,Vaginal flatulence,HO
180333044,Infliximab,Vaginal discharge,OT
180333044,Infliximab,Vaginal discharge,HO
180333044,Infliximab,Urinary tract infection,OT
180333044,Infliximab,Urinary tract infection,HO
180333044,Infliximab,Somnolence,OT
180333044,Infliximab,Somnolence,HO
180333044,Infliximab,Skin plaque,OT
180333044,Infliximab,Skin plaque,HO
180333044,Infliximab,Skin cancer,OT
180333044,Infliximab,Skin cancer,HO
180333044,Infliximab,Pruritus,OT
180333044,Infliximab,Pruritus,HO
180333044,Infliximab,Post procedural infection,OT
180333044,Infliximab,Post procedural infection,HO
180333044,Infliximab,Poor quality sleep,OT
180333044,Infliximab,Poor quality sleep,HO
180333044,Infliximab,Phlebitis,OT
180333044,Infliximab,Phlebitis,HO
180333044,Infliximab,Oropharyngeal pain,OT
180333044,Infliximab,Oropharyngeal pain,HO
180333044,Infliximab,Off label use,OT
180333044,Infliximab,Off label use,HO
180333044,Infliximab,Nausea,OT
180333044,Infliximab,Nausea,HO
180333044,Infliximab,Nasopharyngitis,OT
180333044,Infliximab,Nasopharyngitis,HO
180333044,Infliximab,Myalgia,OT
180333044,Infliximab,Myalgia,HO
180333044,Infliximab,Loss of consciousness,OT
180333044,Infliximab,Loss of consciousness,HO
180333044,Infliximab,Intentional product use issue,OT
180333044,Infliximab,Intentional product use issue,HO
180333044,Infliximab,Injection site pain,OT
180333044,Infliximab,Injection site pain,HO
180333044,Infliximab,Inappropriate schedule of product administration,OT
180333044,Infliximab,Inappropriate schedule of product administration,HO
180333044,Infliximab,Impaired healing,OT
180333044,Infliximab,Impaired healing,HO
180333044,Infliximab,Heart rate decreased,OT
180333044,Infliximab,Heart rate decreased,HO
180333044,Infliximab,Headache,OT
180333044,Infliximab,Headache,HO
180333044,Infliximab,Foot deformity,OT
180333044,Infliximab,Foot deformity,HO
180333044,Infliximab,Feeling hot,OT
180333044,Infliximab,Feeling hot,HO
180333044,Infliximab,Feeling cold,OT
180333044,Infliximab,Feeling cold,HO
180333044,Infliximab,Fatigue,OT
180333044,Infliximab,Fatigue,HO
180333044,Infliximab,Fall,OT
180333044,Infliximab,Fall,HO
180333044,Infliximab,Facial paralysis,OT
180333044,Infliximab,Facial paralysis,HO
180333044,Infliximab,Ecchymosis,OT
180333044,Infliximab,Ecchymosis,HO
180333044,Infliximab,Dyspnoea,OT
180333044,Infliximab,Dyspnoea,HO
180333044,Infliximab,Dysphonia,OT
180333044,Infliximab,Dysphonia,HO
180333044,Infliximab,Dysgeusia,OT
180333044,Infliximab,Dysgeusia,HO
180333044,Infliximab,Decreased appetite,OT
180333044,Infliximab,Decreased appetite,HO
180333044,Infliximab,Cystitis,OT
180333044,Infliximab,Cystitis,HO
180333044,Infliximab,Cough,OT
180333044,Infliximab,Cough,HO
180333044,Infliximab,Cholelithiasis,OT
180333044,Infliximab,Cholelithiasis,HO
180333044,Infliximab,Cerebrovascular accident,OT
180333044,Infliximab,Cerebrovascular accident,HO
180333044,Infliximab,Cerebral thrombosis,OT
180333044,Infliximab,Cerebral thrombosis,HO
180333044,Infliximab,Cataract,OT
180333044,Infliximab,Cataract,HO
180333044,Infliximab,Bronchitis,OT
180333044,Infliximab,Bronchitis,HO
180333044,Infliximab,Blood pressure increased,OT
180333044,Infliximab,Blood pressure increased,HO
180333044,Infliximab,Blood pressure fluctuation,OT
180333044,Infliximab,Blood pressure fluctuation,HO
180333044,Infliximab,Back pain,OT
180333044,Infliximab,Back pain,HO
180333044,Infliximab,Arrhythmia,OT
180333044,Infliximab,Arrhythmia,HO
180333044,Infliximab,Alopecia,OT
180333044,Infliximab,Alopecia,HO
180333044,Infliximab,Ageusia,OT
180333044,Infliximab,Ageusia,HO
180333044,Infliximab,Acne,OT
180333044,Infliximab,Acne,HO
180333044,Infliximab,Abdominal pain,OT
180333044,Infliximab,Abdominal pain,HO
180333044,Infliximab,Vomiting,OT
180333044,Infliximab,Vomiting,HO
180333044,Infliximab,Vaginal flatulence,OT
180333044,Infliximab,Vaginal flatulence,HO
180333044,Infliximab,Vaginal discharge,OT
180333044,Infliximab,Vaginal discharge,HO
180333044,Infliximab,Urinary tract infection,OT
180333044,Infliximab,Urinary tract infection,HO
180333044,Infliximab,Somnolence,OT
180333044,Infliximab,Somnolence,HO
180333044,Infliximab,Skin plaque,OT
180333044,Infliximab,Skin plaque,HO
180333044,Infliximab,Skin cancer,OT
180333044,Infliximab,Skin cancer,HO
180333044,Infliximab,Pruritus,OT
180333044,Infliximab,Pruritus,HO
180333044,Infliximab,Post procedural infection,OT
180333044,Infliximab,Post procedural infection,HO
180333044,Infliximab,Poor quality sleep,OT
180333044,Infliximab,Poor quality sleep,HO
180333044,Infliximab,Phlebitis,OT
180333044,Infliximab,Phlebitis,HO
180333044,Infliximab,Oropharyngeal pain,OT
180333044,Infliximab,Oropharyngeal pain,HO
180333044,Infliximab,Off label use,OT
180333044,Infliximab,Off label use,HO
180333044,Infliximab,Nausea,OT
180333044,Infliximab,Nausea,HO
180333044,Infliximab,Nasopharyngitis,OT
180333044,Infliximab,Nasopharyngitis,HO
180333044,Infliximab,Myalgia,OT
180333044,Infliximab,Myalgia,HO
180333044,Infliximab,Loss of consciousness,OT
180333044,Infliximab,Loss of consciousness,HO
180333044,Infliximab,Intentional product use issue,OT
180333044,Infliximab,Intentional product use issue,HO
180333044,Infliximab,Injection site pain,OT
180333044,Infliximab,Injection site pain,HO
180333044,Infliximab,Inappropriate schedule of product administration,OT
180333044,Infliximab,Inappropriate schedule of product administration,HO
180333044,Infliximab,Impaired healing,OT
180333044,Infliximab,Impaired healing,HO
180333044,Infliximab,Heart rate decreased,OT
180333044,Infliximab,Heart rate decreased,HO
180333044,Infliximab,Headache,OT
180333044,Infliximab,Headache,HO
180333044,Infliximab,Foot deformity,OT
180333044,Infliximab,Foot deformity,HO
180333044,Infliximab,Feeling hot,OT
180333044,Infliximab,Feeling hot,HO
180333044,Infliximab,Feeling cold,OT
180333044,Infliximab,Feeling cold,HO
180333044,Infliximab,Fatigue,OT
180333044,Infliximab,Fatigue,HO
180333044,Infliximab,Fall,OT
180333044,Infliximab,Fall,HO
180333044,Infliximab,Facial paralysis,OT
180333044,Infliximab,Facial paralysis,HO
180333044,Infliximab,Ecchymosis,OT
180333044,Infliximab,Ecchymosis,HO
180333044,Infliximab,Dyspnoea,OT
180333044,Infliximab,Dyspnoea,HO
180333044,Infliximab,Dysphonia,OT
180333044,Infliximab,Dysphonia,HO
180333044,Infliximab,Dysgeusia,OT
180333044,Infliximab,Dysgeusia,HO
180333044,Infliximab,Decreased appetite,OT
180333044,Infliximab,Decreased appetite,HO
180333044,Infliximab,Cystitis,OT
180333044,Infliximab,Cystitis,HO
180333044,Infliximab,Cough,OT
180333044,Infliximab,Cough,HO
180333044,Infliximab,Cholelithiasis,OT
180333044,Infliximab,Cholelithiasis,HO
180333044,Infliximab,Cerebrovascular accident,OT
180333044,Infliximab,Cerebrovascular accident,HO
180333044,Infliximab,Cerebral thrombosis,OT
180333044,Infliximab,Cerebral thrombosis,HO
180333044,Infliximab,Cataract,OT
180333044,Infliximab,Cataract,HO
180333044,Infliximab,Bronchitis,OT
180333044,Infliximab,Bronchitis,HO
180333044,Infliximab,Blood pressure increased,OT
180333044,Infliximab,Blood pressure increased,HO
180333044,Infliximab,Blood pressure fluctuation,OT
180333044,Infliximab,Blood pressure fluctuation,HO
180333044,Infliximab,Back pain,OT
180333044,Infliximab,Back pain,HO
180333044,Infliximab,Arrhythmia,OT
180333044,Infliximab,Arrhythmia,HO
180333044,Infliximab,Alopecia,OT
180333044,Infliximab,Alopecia,HO
180333044,Infliximab,Ageusia,OT
180333044,Infliximab,Ageusia,HO
180333044,Infliximab,Acne,OT
180333044,Infliximab,Acne,HO
180333044,Infliximab,Abdominal pain,OT
180333044,Infliximab,Abdominal pain,HO
183978252,Infliximab,Weight increased,OT
183978252,Infliximab,Off label use,OT
183978252,Infliximab,Impaired quality of life,OT
183978252,Infliximab,Condition aggravated,OT
184111962,Infliximab,Weight decreased,OT
184111962,Infliximab,Uveitis,OT
184111962,Infliximab,Serum ferritin decreased,OT
184111962,Infliximab,Productive cough,OT
184111962,Infliximab,Off label use,OT
184111962,Infliximab,Malaise,OT
184111962,Infliximab,Irritable bowel syndrome,OT
184111962,Infliximab,Intentional product use issue,OT
184111962,Infliximab,Inappropriate schedule of product administration,OT
184111962,Infliximab,Feeding disorder,OT
184111962,Infliximab,Eye inflammation,OT
184111962,Infliximab,Cough,OT
184111962,Infliximab,Condition aggravated,OT
184111962,Infliximab,Blood pressure diastolic increased,OT
184111962,Infliximab,Blood pressure diastolic decreased,OT
184111962,Infliximab,Arrhythmia,OT
184111962,Infliximab,Weight decreased,OT
184111962,Infliximab,Uveitis,OT
184111962,Infliximab,Serum ferritin decreased,OT
184111962,Infliximab,Productive cough,OT
184111962,Infliximab,Off label use,OT
184111962,Infliximab,Malaise,OT
184111962,Infliximab,Irritable bowel syndrome,OT
184111962,Infliximab,Intentional product use issue,OT
184111962,Infliximab,Inappropriate schedule of product administration,OT
184111962,Infliximab,Feeding disorder,OT
184111962,Infliximab,Eye inflammation,OT
184111962,Infliximab,Cough,OT
184111962,Infliximab,Condition aggravated,OT
184111962,Infliximab,Blood pressure diastolic increased,OT
184111962,Infliximab,Blood pressure diastolic decreased,OT
184111962,Infliximab,Arrhythmia,OT
184211564,Infliximab,Off label use,OT
184211564,Infliximab,Lipoma,OT
184211564,Infliximab,Intentional product use issue,OT
184211564,Infliximab,Inappropriate schedule of product administration,OT
184211564,Infliximab,Hypertension,OT
184211564,Infliximab,Heart rate irregular,OT
184211564,Infliximab,Faecal calprotectin increased,OT
184211564,Infliximab,Dyspnoea,OT
184211564,Infliximab,Drug ineffective,OT
184211564,Infliximab,Condition aggravated,OT
184211564,Infliximab,Body temperature decreased,OT
184211564,Infliximab,Blood pressure fluctuation,OT
184211564,Infliximab,Off label use,OT
184211564,Infliximab,Lipoma,OT
184211564,Infliximab,Intentional product use issue,OT
184211564,Infliximab,Inappropriate schedule of product administration,OT
184211564,Infliximab,Hypertension,OT
184211564,Infliximab,Heart rate irregular,OT
184211564,Infliximab,Faecal calprotectin increased,OT
184211564,Infliximab,Dyspnoea,OT
184211564,Infliximab,Drug ineffective,OT
184211564,Infliximab,Condition aggravated,OT
184211564,Infliximab,Body temperature decreased,OT
184211564,Infliximab,Blood pressure fluctuation,OT
184330923,Infliximab,Therapeutic response shortened,HO
184330923,Infliximab,Pyrexia,HO
184330923,Infliximab,Product use issue,HO
184330923,Infliximab,Oropharyngeal pain,HO
184330923,Infliximab,Off label use,HO
184330923,Infliximab,Intentional product use issue,HO
184330923,Infliximab,Infusion site warmth,HO
184330923,Infliximab,Incorrect dose administered,HO
184330923,Infliximab,Feeling of body temperature change,HO
184330923,Infliximab,Cubital tunnel syndrome,HO
184330923,Infliximab,Condition aggravated,HO
184330923,Infliximab,Cold sweat,HO
184330923,Infliximab,Blood pressure increased,HO
184330923,Infliximab,Administration site warmth,HO
184330923,Infliximab,Therapeutic response shortened,HO
184330923,Infliximab,Pyrexia,HO
184330923,Infliximab,Product use issue,HO
184330923,Infliximab,Oropharyngeal pain,HO
184330923,Infliximab,Off label use,HO
184330923,Infliximab,Intentional product use issue,HO
184330923,Infliximab,Infusion site warmth,HO
184330923,Infliximab,Incorrect dose administered,HO
184330923,Infliximab,Feeling of body temperature change,HO
184330923,Infliximab,Cubital tunnel syndrome,HO
184330923,Infliximab,Condition aggravated,HO
184330923,Infliximab,Cold sweat,HO
184330923,Infliximab,Blood pressure increased,HO
184330923,Infliximab,Administration site warmth,HO
184364482,Infliximab,Weight increased,OT
184364482,Infliximab,Weight decreased,OT
184364482,Infliximab,Loss of therapeutic response,OT
184364482,Infliximab,Incorrect dosage administered,OT
184364482,Infliximab,Inappropriate schedule of product administration,OT
184364482,Infliximab,Hypertension,OT
184364482,Infliximab,Heart rate irregular,OT
184364482,Infliximab,Haematochezia,OT
184364482,Infliximab,Fatigue,OT
184364482,Infliximab,Faecal calprotectin increased,OT
184364482,Infliximab,Dyspnoea,OT
184364482,Infliximab,Blood pressure fluctuation,OT
184364482,Infliximab,Asthenia,OT
184747284,Infliximab,Oropharyngeal pain,OT
184747284,Infliximab,Off label use,OT
184747284,Infliximab,Nephrolithiasis,OT
184747284,Infliximab,Nasopharyngitis,OT
184747284,Infliximab,Lethargy,OT
184747284,Infliximab,Kidney infection,OT
184747284,Infliximab,Intentional product use issue,OT
184747284,Infliximab,Inappropriate schedule of product administration,OT
184747284,Infliximab,Heart rate decreased,OT
184747284,Infliximab,Headache,OT
184747284,Infliximab,Haematochezia,OT
184747284,Infliximab,Frequent bowel movements,OT
184747284,Infliximab,Drug ineffective,OT
184747284,Infliximab,Depressed mood,OT
184747284,Infliximab,Condition aggravated,OT
184747284,Infliximab,Body temperature decreased,OT
184747284,Infliximab,Blood pressure fluctuation,OT
184747284,Infliximab,Arthralgia,OT
184747284,Infliximab,Oropharyngeal pain,OT
184747284,Infliximab,Off label use,OT
184747284,Infliximab,Nephrolithiasis,OT
184747284,Infliximab,Nasopharyngitis,OT
184747284,Infliximab,Lethargy,OT
184747284,Infliximab,Kidney infection,OT
184747284,Infliximab,Intentional product use issue,OT
184747284,Infliximab,Inappropriate schedule of product administration,OT
184747284,Infliximab,Heart rate decreased,OT
184747284,Infliximab,Headache,OT
184747284,Infliximab,Haematochezia,OT
184747284,Infliximab,Frequent bowel movements,OT
184747284,Infliximab,Drug ineffective,OT
184747284,Infliximab,Depressed mood,OT
184747284,Infliximab,Condition aggravated,OT
184747284,Infliximab,Body temperature decreased,OT
184747284,Infliximab,Blood pressure fluctuation,OT
184747284,Infliximab,Arthralgia,OT
184916063,Infliximab,Off label use,OT
184916063,Infliximab,Intentional product use issue,OT
184916063,Infliximab,Inappropriate schedule of product administration,OT
184916063,Infliximab,Drug specific antibody,OT
184916063,Infliximab,Condition aggravated,OT
184916063,Infliximab,Off label use,OT
184916063,Infliximab,Intentional product use issue,OT
184916063,Infliximab,Inappropriate schedule of product administration,OT
184916063,Infliximab,Drug specific antibody,OT
184916063,Infliximab,Condition aggravated,OT
185046423,Infliximab,Off label use,OT
185046423,Infliximab,Malaise,OT
185046423,Infliximab,Intentional product use issue,OT
185046423,Infliximab,Infusion related reaction,OT
185046423,Infliximab,Heart rate increased,OT
185046423,Infliximab,Heart rate decreased,OT
185046423,Infliximab,Dizziness,OT
185046423,Infliximab,Body temperature increased,OT
185046423,Infliximab,Body temperature decreased,OT
185046423,Infliximab,Blood pressure increased,OT
185046423,Infliximab,Blood pressure diastolic increased,OT
185046423,Infliximab,Blood pressure decreased,OT
185046423,Infliximab,Arthralgia,OT
185046423,Infliximab,Abdominal pain,OT
185459892,Infliximab,Vulvovaginal mycotic infection,HO
185459892,Infliximab,Vulvovaginal mycotic infection,OT
185459892,Infliximab,Vomiting,HO
185459892,Infliximab,Vomiting,OT
185459892,Infliximab,Vision blurred,HO
185459892,Infliximab,Vision blurred,OT
185459892,Infliximab,Vascular access complication,HO
185459892,Infliximab,Vascular access complication,OT
185459892,Infliximab,Tooth abscess,HO
185459892,Infliximab,Tooth abscess,OT
185459892,Infliximab,Therapeutic product effect incomplete,HO
185459892,Infliximab,Therapeutic product effect incomplete,OT
185459892,Infliximab,Sleep disorder,HO
185459892,Infliximab,Sleep disorder,OT
185459892,Infliximab,Rib fracture,HO
185459892,Infliximab,Rib fracture,OT
185459892,Infliximab,Respiratory tract congestion,HO
185459892,Infliximab,Respiratory tract congestion,OT
185459892,Infliximab,Pyrexia,HO
185459892,Infliximab,Pyrexia,OT
185459892,Infliximab,Pyoderma gangrenosum,HO
185459892,Infliximab,Pyoderma gangrenosum,OT
185459892,Infliximab,Productive cough,HO
185459892,Infliximab,Productive cough,OT
185459892,Infliximab,Product use issue,HO
185459892,Infliximab,Product use issue,OT
185459892,Infliximab,Product dose omission issue,HO
185459892,Infliximab,Product dose omission issue,OT
185459892,Infliximab,Poor venous access,HO
185459892,Infliximab,Poor venous access,OT
185459892,Infliximab,Pneumonia,HO
185459892,Infliximab,Pneumonia,OT
185459892,Infliximab,Pleurisy,HO
185459892,Infliximab,Pleurisy,OT
185459892,Infliximab,Painful respiration,HO
185459892,Infliximab,Painful respiration,OT
185459892,Infliximab,Pain,HO
185459892,Infliximab,Pain,OT
185459892,Infliximab,Oropharyngeal pain,HO
185459892,Infliximab,Oropharyngeal pain,OT
185459892,Infliximab,Off label use,HO
185459892,Infliximab,Off label use,OT
185459892,Infliximab,Necrosis,HO
185459892,Infliximab,Necrosis,OT
185459892,Infliximab,Nausea,HO
185459892,Infliximab,Nausea,OT
185459892,Infliximab,Muscle spasms,HO
185459892,Infliximab,Muscle spasms,OT
185459892,Infliximab,Movement disorder,HO
185459892,Infliximab,Movement disorder,OT
185459892,Infliximab,Mouth haemorrhage,HO
185459892,Infliximab,Mouth haemorrhage,OT
185459892,Infliximab,Migraine,HO
185459892,Infliximab,Migraine,OT
185459892,Infliximab,Menopause,HO
185459892,Infliximab,Menopause,OT
185459892,Infliximab,Malaise,HO
185459892,Infliximab,Malaise,OT
185459892,Infliximab,Intestinal obstruction,HO
185459892,Infliximab,Intestinal obstruction,OT
185459892,Infliximab,Infusion site extravasation,HO
185459892,Infliximab,Infusion site extravasation,OT
185459892,Infliximab,Infusion site bruising,HO
185459892,Infliximab,Infusion site bruising,OT
185459892,Infliximab,Inappropriate schedule of product administration,HO
185459892,Infliximab,Inappropriate schedule of product administration,OT
185459892,Infliximab,Illness,HO
185459892,Infliximab,Illness,OT
185459892,Infliximab,Haemorrhage,HO
185459892,Infliximab,Haemorrhage,OT
185459892,Infliximab,Haematemesis,HO
185459892,Infliximab,Haematemesis,OT
185459892,Infliximab,Glaucoma,HO
185459892,Infliximab,Glaucoma,OT
185459892,Infliximab,Fluid intake reduced,HO
185459892,Infliximab,Fluid intake reduced,OT
185459892,Infliximab,Fatigue,HO
185459892,Infliximab,Fatigue,OT
185459892,Infliximab,Fall,HO
185459892,Infliximab,Fall,OT
185459892,Infliximab,Eye infection,HO
185459892,Infliximab,Eye infection,OT
185459892,Infliximab,Erythema nodosum,HO
185459892,Infliximab,Erythema nodosum,OT
185459892,Infliximab,Epistaxis,HO
185459892,Infliximab,Epistaxis,OT
185459892,Infliximab,Emotional disorder,HO
185459892,Infliximab,Emotional disorder,OT
185459892,Infliximab,Ear infection,HO
185459892,Infliximab,Ear infection,OT
185459892,Infliximab,Dyspnoea,HO
185459892,Infliximab,Dyspnoea,OT
185459892,Infliximab,Diplopia,HO
185459892,Infliximab,Diplopia,OT
185459892,Infliximab,Dehydration,HO
185459892,Infliximab,Dehydration,OT
185459892,Infliximab,Decreased appetite,HO
185459892,Infliximab,Decreased appetite,OT
185459892,Infliximab,Cystitis,HO
185459892,Infliximab,Cystitis,OT
185459892,Infliximab,Conjunctivitis,HO
185459892,Infliximab,Conjunctivitis,OT
185459892,Infliximab,Condition aggravated,HO
185459892,Infliximab,Condition aggravated,OT
185459892,Infliximab,Chills,HO
185459892,Infliximab,Chills,OT
185459892,Infliximab,Chest pain,HO
185459892,Infliximab,Chest pain,OT
185459892,Infliximab,Blood pressure decreased,HO
185459892,Infliximab,Blood pressure decreased,OT
185459892,Infliximab,Asthenia,HO
185459892,Infliximab,Asthenia,OT
185459892,Infliximab,Arthralgia,HO
185459892,Infliximab,Arthralgia,OT
185459892,Infliximab,Aphthous ulcer,HO
185459892,Infliximab,Aphthous ulcer,OT
185459892,Infliximab,Anal fissure,HO
185459892,Infliximab,Anal fissure,OT
185459892,Infliximab,Anaemia,HO
185459892,Infliximab,Anaemia,OT
185459892,Infliximab,Abscess oral,HO
185459892,Infliximab,Abscess oral,OT
185459892,Infliximab,Abdominal distension,HO
185459892,Infliximab,Abdominal distension,OT
185459892,Infliximab,Abdominal discomfort,HO
185459892,Infliximab,Abdominal discomfort,OT
185459892,Infliximab,Vulvovaginal mycotic infection,HO
185459892,Infliximab,Vulvovaginal mycotic infection,OT
185459892,Infliximab,Vomiting,HO
185459892,Infliximab,Vomiting,OT
185459892,Infliximab,Vision blurred,HO
185459892,Infliximab,Vision blurred,OT
185459892,Infliximab,Vascular access complication,HO
185459892,Infliximab,Vascular access complication,OT
185459892,Infliximab,Tooth abscess,HO
185459892,Infliximab,Tooth abscess,OT
185459892,Infliximab,Therapeutic product effect incomplete,HO
185459892,Infliximab,Therapeutic product effect incomplete,OT
185459892,Infliximab,Sleep disorder,HO
185459892,Infliximab,Sleep disorder,OT
185459892,Infliximab,Rib fracture,HO
185459892,Infliximab,Rib fracture,OT
185459892,Infliximab,Respiratory tract congestion,HO
185459892,Infliximab,Respiratory tract congestion,OT
185459892,Infliximab,Pyrexia,HO
185459892,Infliximab,Pyrexia,OT
185459892,Infliximab,Pyoderma gangrenosum,HO
185459892,Infliximab,Pyoderma gangrenosum,OT
185459892,Infliximab,Productive cough,HO
185459892,Infliximab,Productive cough,OT
185459892,Infliximab,Product use issue,HO
185459892,Infliximab,Product use issue,OT
185459892,Infliximab,Product dose omission issue,HO
185459892,Infliximab,Product dose omission issue,OT
185459892,Infliximab,Poor venous access,HO
185459892,Infliximab,Poor venous access,OT
185459892,Infliximab,Pneumonia,HO
185459892,Infliximab,Pneumonia,OT
185459892,Infliximab,Pleurisy,HO
185459892,Infliximab,Pleurisy,OT
185459892,Infliximab,Painful respiration,HO
185459892,Infliximab,Painful respiration,OT
185459892,Infliximab,Pain,HO
185459892,Infliximab,Pain,OT
185459892,Infliximab,Oropharyngeal pain,HO
185459892,Infliximab,Oropharyngeal pain,OT
185459892,Infliximab,Off label use,HO
185459892,Infliximab,Off label use,OT
185459892,Infliximab,Necrosis,HO
185459892,Infliximab,Necrosis,OT
185459892,Infliximab,Nausea,HO
185459892,Infliximab,Nausea,OT
185459892,Infliximab,Muscle spasms,HO
185459892,Infliximab,Muscle spasms,OT
185459892,Infliximab,Movement disorder,HO
185459892,Infliximab,Movement disorder,OT
185459892,Infliximab,Mouth haemorrhage,HO
185459892,Infliximab,Mouth haemorrhage,OT
185459892,Infliximab,Migraine,HO
185459892,Infliximab,Migraine,OT
185459892,Infliximab,Menopause,HO
185459892,Infliximab,Menopause,OT
185459892,Infliximab,Malaise,HO
185459892,Infliximab,Malaise,OT
185459892,Infliximab,Intestinal obstruction,HO
185459892,Infliximab,Intestinal obstruction,OT
185459892,Infliximab,Infusion site extravasation,HO
185459892,Infliximab,Infusion site extravasation,OT
185459892,Infliximab,Infusion site bruising,HO
185459892,Infliximab,Infusion site bruising,OT
185459892,Infliximab,Inappropriate schedule of product administration,HO
185459892,Infliximab,Inappropriate schedule of product administration,OT
185459892,Infliximab,Illness,HO
185459892,Infliximab,Illness,OT
185459892,Infliximab,Haemorrhage,HO
185459892,Infliximab,Haemorrhage,OT
185459892,Infliximab,Haematemesis,HO
185459892,Infliximab,Haematemesis,OT
185459892,Infliximab,Glaucoma,HO
185459892,Infliximab,Glaucoma,OT
185459892,Infliximab,Fluid intake reduced,HO
185459892,Infliximab,Fluid intake reduced,OT
185459892,Infliximab,Fatigue,HO
185459892,Infliximab,Fatigue,OT
185459892,Infliximab,Fall,HO
185459892,Infliximab,Fall,OT
185459892,Infliximab,Eye infection,HO
185459892,Infliximab,Eye infection,OT
185459892,Infliximab,Erythema nodosum,HO
185459892,Infliximab,Erythema nodosum,OT
185459892,Infliximab,Epistaxis,HO
185459892,Infliximab,Epistaxis,OT
185459892,Infliximab,Emotional disorder,HO
185459892,Infliximab,Emotional disorder,OT
185459892,Infliximab,Ear infection,HO
185459892,Infliximab,Ear infection,OT
185459892,Infliximab,Dyspnoea,HO
185459892,Infliximab,Dyspnoea,OT
185459892,Infliximab,Diplopia,HO
185459892,Infliximab,Diplopia,OT
185459892,Infliximab,Dehydration,HO
185459892,Infliximab,Dehydration,OT
185459892,Infliximab,Decreased appetite,HO
185459892,Infliximab,Decreased appetite,OT
185459892,Infliximab,Cystitis,HO
185459892,Infliximab,Cystitis,OT
185459892,Infliximab,Conjunctivitis,HO
185459892,Infliximab,Conjunctivitis,OT
185459892,Infliximab,Condition aggravated,HO
185459892,Infliximab,Condition aggravated,OT
185459892,Infliximab,Chills,HO
185459892,Infliximab,Chills,OT
185459892,Infliximab,Chest pain,HO
185459892,Infliximab,Chest pain,OT
185459892,Infliximab,Blood pressure decreased,HO
185459892,Infliximab,Blood pressure decreased,OT
185459892,Infliximab,Asthenia,HO
185459892,Infliximab,Asthenia,OT
185459892,Infliximab,Arthralgia,HO
185459892,Infliximab,Arthralgia,OT
185459892,Infliximab,Aphthous ulcer,HO
185459892,Infliximab,Aphthous ulcer,OT
185459892,Infliximab,Anal fissure,HO
185459892,Infliximab,Anal fissure,OT
185459892,Infliximab,Anaemia,HO
185459892,Infliximab,Anaemia,OT
185459892,Infliximab,Abscess oral,HO
185459892,Infliximab,Abscess oral,OT
185459892,Infliximab,Abdominal distension,HO
185459892,Infliximab,Abdominal distension,OT
185459892,Infliximab,Abdominal discomfort,HO
185459892,Infliximab,Abdominal discomfort,OT
185459892,Infliximab,Vulvovaginal mycotic infection,HO
185459892,Infliximab,Vulvovaginal mycotic infection,OT
185459892,Infliximab,Vomiting,HO
185459892,Infliximab,Vomiting,OT
185459892,Infliximab,Vision blurred,HO
185459892,Infliximab,Vision blurred,OT
185459892,Infliximab,Vascular access complication,HO
185459892,Infliximab,Vascular access complication,OT
185459892,Infliximab,Tooth abscess,HO
185459892,Infliximab,Tooth abscess,OT
185459892,Infliximab,Therapeutic product effect incomplete,HO
185459892,Infliximab,Therapeutic product effect incomplete,OT
185459892,Infliximab,Sleep disorder,HO
185459892,Infliximab,Sleep disorder,OT
185459892,Infliximab,Rib fracture,HO
185459892,Infliximab,Rib fracture,OT
185459892,Infliximab,Respiratory tract congestion,HO
185459892,Infliximab,Respiratory tract congestion,OT
185459892,Infliximab,Pyrexia,HO
185459892,Infliximab,Pyrexia,OT
185459892,Infliximab,Pyoderma gangrenosum,HO
185459892,Infliximab,Pyoderma gangrenosum,OT
185459892,Infliximab,Productive cough,HO
185459892,Infliximab,Productive cough,OT
185459892,Infliximab,Product use issue,HO
185459892,Infliximab,Product use issue,OT
185459892,Infliximab,Product dose omission issue,HO
185459892,Infliximab,Product dose omission issue,OT
185459892,Infliximab,Poor venous access,HO
185459892,Infliximab,Poor venous access,OT
185459892,Infliximab,Pneumonia,HO
185459892,Infliximab,Pneumonia,OT
185459892,Infliximab,Pleurisy,HO
185459892,Infliximab,Pleurisy,OT
185459892,Infliximab,Painful respiration,HO
185459892,Infliximab,Painful respiration,OT
185459892,Infliximab,Pain,HO
185459892,Infliximab,Pain,OT
185459892,Infliximab,Oropharyngeal pain,HO
185459892,Infliximab,Oropharyngeal pain,OT
185459892,Infliximab,Off label use,HO
185459892,Infliximab,Off label use,OT
185459892,Infliximab,Necrosis,HO
185459892,Infliximab,Necrosis,OT
185459892,Infliximab,Nausea,HO
185459892,Infliximab,Nausea,OT
185459892,Infliximab,Muscle spasms,HO
185459892,Infliximab,Muscle spasms,OT
185459892,Infliximab,Movement disorder,HO
185459892,Infliximab,Movement disorder,OT
185459892,Infliximab,Mouth haemorrhage,HO
185459892,Infliximab,Mouth haemorrhage,OT
185459892,Infliximab,Migraine,HO
185459892,Infliximab,Migraine,OT
185459892,Infliximab,Menopause,HO
185459892,Infliximab,Menopause,OT
185459892,Infliximab,Malaise,HO
185459892,Infliximab,Malaise,OT
185459892,Infliximab,Intestinal obstruction,HO
185459892,Infliximab,Intestinal obstruction,OT
185459892,Infliximab,Infusion site extravasation,HO
185459892,Infliximab,Infusion site extravasation,OT
185459892,Infliximab,Infusion site bruising,HO
185459892,Infliximab,Infusion site bruising,OT
185459892,Infliximab,Inappropriate schedule of product administration,HO
185459892,Infliximab,Inappropriate schedule of product administration,OT
185459892,Infliximab,Illness,HO
185459892,Infliximab,Illness,OT
185459892,Infliximab,Haemorrhage,HO
185459892,Infliximab,Haemorrhage,OT
185459892,Infliximab,Haematemesis,HO
185459892,Infliximab,Haematemesis,OT
185459892,Infliximab,Glaucoma,HO
185459892,Infliximab,Glaucoma,OT
185459892,Infliximab,Fluid intake reduced,HO
185459892,Infliximab,Fluid intake reduced,OT
185459892,Infliximab,Fatigue,HO
185459892,Infliximab,Fatigue,OT
185459892,Infliximab,Fall,HO
185459892,Infliximab,Fall,OT
185459892,Infliximab,Eye infection,HO
185459892,Infliximab,Eye infection,OT
185459892,Infliximab,Erythema nodosum,HO
185459892,Infliximab,Erythema nodosum,OT
185459892,Infliximab,Epistaxis,HO
185459892,Infliximab,Epistaxis,OT
185459892,Infliximab,Emotional disorder,HO
185459892,Infliximab,Emotional disorder,OT
185459892,Infliximab,Ear infection,HO
185459892,Infliximab,Ear infection,OT
185459892,Infliximab,Dyspnoea,HO
185459892,Infliximab,Dyspnoea,OT
185459892,Infliximab,Diplopia,HO
185459892,Infliximab,Diplopia,OT
185459892,Infliximab,Dehydration,HO
185459892,Infliximab,Dehydration,OT
185459892,Infliximab,Decreased appetite,HO
185459892,Infliximab,Decreased appetite,OT
185459892,Infliximab,Cystitis,HO
185459892,Infliximab,Cystitis,OT
185459892,Infliximab,Conjunctivitis,HO
185459892,Infliximab,Conjunctivitis,OT
185459892,Infliximab,Condition aggravated,HO
185459892,Infliximab,Condition aggravated,OT
185459892,Infliximab,Chills,HO
185459892,Infliximab,Chills,OT
185459892,Infliximab,Chest pain,HO
185459892,Infliximab,Chest pain,OT
185459892,Infliximab,Blood pressure decreased,HO
185459892,Infliximab,Blood pressure decreased,OT
185459892,Infliximab,Asthenia,HO
185459892,Infliximab,Asthenia,OT
185459892,Infliximab,Arthralgia,HO
185459892,Infliximab,Arthralgia,OT
185459892,Infliximab,Aphthous ulcer,HO
185459892,Infliximab,Aphthous ulcer,OT
185459892,Infliximab,Anal fissure,HO
185459892,Infliximab,Anal fissure,OT
185459892,Infliximab,Anaemia,HO
185459892,Infliximab,Anaemia,OT
185459892,Infliximab,Abscess oral,HO
185459892,Infliximab,Abscess oral,OT
185459892,Infliximab,Abdominal distension,HO
185459892,Infliximab,Abdominal distension,OT
185459892,Infliximab,Abdominal discomfort,HO
185459892,Infliximab,Abdominal discomfort,OT
185602293,Infliximab,Thrombosis,OT
185602293,Infliximab,Thrombosis,HO
185602293,Infliximab,Therapeutic response shortened,OT
185602293,Infliximab,Therapeutic response shortened,HO
185602293,Infliximab,Sputum discoloured,OT
185602293,Infliximab,Sputum discoloured,HO
185602293,Infliximab,Scar pain,OT
185602293,Infliximab,Scar pain,HO
185602293,Infliximab,Rhinorrhoea,OT
185602293,Infliximab,Rhinorrhoea,HO
185602293,Infliximab,Procedural pain,OT
185602293,Infliximab,Procedural pain,HO
185602293,Infliximab,Painful respiration,OT
185602293,Infliximab,Painful respiration,HO
185602293,Infliximab,Oropharyngeal pain,OT
185602293,Infliximab,Oropharyngeal pain,HO
185602293,Infliximab,Off label use,OT
185602293,Infliximab,Off label use,HO
185602293,Infliximab,Nasopharyngitis,OT
185602293,Infliximab,Nasopharyngitis,HO
185602293,Infliximab,Myalgia,OT
185602293,Infliximab,Myalgia,HO
185602293,Infliximab,Intestinal obstruction,OT
185602293,Infliximab,Intestinal obstruction,HO
185602293,Infliximab,Insomnia,OT
185602293,Infliximab,Insomnia,HO
185602293,Infliximab,Inappropriate schedule of product administration,OT
185602293,Infliximab,Inappropriate schedule of product administration,HO
185602293,Infliximab,Hypertension,OT
185602293,Infliximab,Hypertension,HO
185602293,Infliximab,Heart rate decreased,OT
185602293,Infliximab,Heart rate decreased,HO
185602293,Infliximab,Headache,OT
185602293,Infliximab,Headache,HO
185602293,Infliximab,Fatigue,OT
185602293,Infliximab,Fatigue,HO
185602293,Infliximab,Cough,OT
185602293,Infliximab,Cough,HO
185602293,Infliximab,Condition aggravated,OT
185602293,Infliximab,Condition aggravated,HO
185602293,Infliximab,Body temperature fluctuation,OT
185602293,Infliximab,Body temperature fluctuation,HO
185602293,Infliximab,Body temperature decreased,OT
185602293,Infliximab,Body temperature decreased,HO
185602293,Infliximab,Blood pressure increased,OT
185602293,Infliximab,Blood pressure increased,HO
185602293,Infliximab,Blood pressure fluctuation,OT
185602293,Infliximab,Blood pressure fluctuation,HO
185602293,Infliximab,Arthralgia,OT
185602293,Infliximab,Arthralgia,HO
185602293,Infliximab,Anxiety,OT
185602293,Infliximab,Anxiety,HO
185602293,Infliximab,Abnormal faeces,OT
185602293,Infliximab,Abnormal faeces,HO
185602293,Infliximab,Abdominal pain,OT
185602293,Infliximab,Abdominal pain,HO
185602293,Infliximab,Abdominal distension,OT
185602293,Infliximab,Abdominal distension,HO
189543372,Infliximab,Hodgkin's disease,OT
190756133,Infliximab (Unknown),Off label use,OT
190756133,Infliximab (Unknown),Off label use,HO
190756133,Infliximab (Unknown),Large intestine perforation,OT
190756133,Infliximab (Unknown),Large intestine perforation,HO
190756133,Infliximab (Unknown),Ileostomy,OT
190756133,Infliximab (Unknown),Ileostomy,HO
190756133,Infliximab (Unknown),Histoplasmosis disseminated,OT
190756133,Infliximab (Unknown),Histoplasmosis disseminated,HO
190756133,Infliximab (Unknown),Colectomy,OT
190756133,Infliximab (Unknown),Colectomy,HO
192763707,Infliximab (Unknown),Polychondritis,OT
192763707,Infliximab (Unknown),Off label use,OT
192763707,Infliximab (Unknown),Auricular chondritis,OT
192763707,Infliximab (Unknown),Polychondritis,OT
192763707,Infliximab (Unknown),Off label use,OT
192763707,Infliximab (Unknown),Auricular chondritis,OT
192850232,Infliximab,Weight increased,OT
192850232,Infliximab,Pain,OT
192850232,Infliximab,Inappropriate schedule of product administration,OT
192850232,Infliximab,Enterocutaneous fistula,OT
192850232,Infliximab,Drug level decreased,OT
193588232,Infliximab,Weight decreased,OT
193588232,Infliximab,Systemic lupus erythematosus,OT
193588232,Infliximab,Paraesthesia,OT
193588232,Infliximab,Off label use,OT
193588232,Infliximab,Intentional product use issue,OT
193588232,Infliximab,Hypoaesthesia,OT
193588232,Infliximab,Headache,OT
193588232,Infliximab,Fatigue,OT
193588232,Infliximab,Arthralgia,OT
195011483,Infliximab (Unknown),Pneumonia,DE
195011483,Infliximab (Unknown),Off label use,DE
195011483,Infliximab (Unknown),Drug ineffective for unapproved indication,DE
195112191,Infliximab (Unknown),Suicidal ideation,OT
195112191,Infliximab (Unknown),Off label use,OT
196105671,Infliximab,Weight decreased,OT
196105671,Infliximab,Vertigo,OT
196105671,Infliximab,Tremor,OT
196105671,Infliximab,Skin disorder,OT
196105671,Infliximab,Skin cancer,OT
196105671,Infliximab,Sensitive skin,OT
196105671,Infliximab,Papule,OT
196105671,Infliximab,Off label use,OT
196105671,Infliximab,Nausea,OT
196105671,Infliximab,Muscular weakness,OT
196105671,Infliximab,Limb discomfort,OT
196105671,Infliximab,Intentional product use issue,OT
196105671,Infliximab,Inappropriate schedule of product administration,OT
196105671,Infliximab,Herpes zoster,OT
196105671,Infliximab,Heart rate decreased,OT
196105671,Infliximab,Fall,OT
196105671,Infliximab,Decreased appetite,OT
196105671,Infliximab,Confusional state,OT
196105671,Infliximab,Condition aggravated,OT
196105671,Infliximab,Chills,OT
196105671,Infliximab,Body temperature decreased,OT
196105671,Infliximab,Blood pressure increased,OT
196105671,Infliximab,Blood pressure fluctuation,OT
196105671,Infliximab,Balance disorder,OT
196105671,Infliximab,Anxiety,OT
196105671,Infliximab,Anal incontinence,OT
196105671,Infliximab,Acne,OT
196105671,Infliximab,Abdominal pain lower,OT
196264841,Infliximab,Immune reconstitution inflammatory syndrome,OT
196264841,Infliximab,Hepatitis B reactivation,OT
196867681,Infliximab,Weight increased,HO
196867681,Infliximab,Vomiting,HO
196867681,Infliximab,Off label use,HO
196867681,Infliximab,Nausea,HO
196867681,Infliximab,Maternal exposure during pregnancy,HO
196867681,Infliximab,Malaise,HO
196867681,Infliximab,Headache,HO
196867681,Infliximab,Gastrointestinal disorder,HO
197053191,Infliximab,Therapeutic product effect incomplete,OT
197053191,Infliximab,Penile pain,OT
197053191,Infliximab,Penile contusion,OT
197053191,Infliximab,Off label use,OT
197053191,Infliximab,Intentional product use issue,OT
197163671,Infliximab,Premature baby,OT
197163671,Infliximab,Low birth weight baby,OT
197163671,Infliximab,Foetal exposure during pregnancy,OT
197163671,Infliximab,COVID-19,OT
197166351,Infliximab,Wound,HO
197166351,Infliximab,Weight decreased,HO
197166351,Infliximab,Therapeutic product effect incomplete,HO
197166351,Infliximab,Oropharyngeal pain,HO
197166351,Infliximab,Off label use,HO
197166351,Infliximab,Nasopharyngitis,HO
197166351,Infliximab,Nasal congestion,HO
197166351,Infliximab,Loss of personal independence in daily activities,HO
197166351,Infliximab,Intentional product use issue,HO
197166351,Infliximab,Inappropriate schedule of product administration,HO
197166351,Infliximab,Cyst,HO
197166351,Infliximab,Cough,HO
197166351,Infliximab,Condition aggravated,HO
197166351,Infliximab,Blood pressure systolic increased,HO
197166351,Infliximab,Blood pressure fluctuation,HO
197792181,Infliximab,Urticaria,OT
197792181,Infliximab,Throat irritation,OT
197792181,Infliximab,Rash erythematous,OT
197792181,Infliximab,Rash,OT
197792181,Infliximab,Pruritus,OT
197792181,Infliximab,Poor venous access,OT
197792181,Infliximab,Pain,OT
197792181,Infliximab,Inappropriate schedule of product administration,OT
197792181,Infliximab,Hypersensitivity,OT
197792181,Infliximab,Fatigue,OT
197792181,Infliximab,Condition aggravated,OT
197792181,Infliximab,Blood pressure fluctuation,OT
197792181,Infliximab,Arthralgia,OT
198214191,Infliximab,Stress,OT
198214191,Infliximab,Rhinorrhoea,OT
198214191,Infliximab,Rash,OT
198214191,Infliximab,Oropharyngeal pain,OT
198214191,Infliximab,Oral disorder,OT
198214191,Infliximab,Off label use,OT
198214191,Infliximab,Nasal congestion,OT
198214191,Infliximab,Mouth ulceration,OT
198214191,Infliximab,Intentional product use issue,OT
198214191,Infliximab,Incorrect dose administered,OT
198214191,Infliximab,Inappropriate schedule of product administration,OT
198214191,Infliximab,Headache,OT
198214191,Infliximab,Faeces soft,OT
198214191,Infliximab,Drug level increased,OT
198214191,Infliximab,Blood pressure systolic increased,OT
198214191,Infliximab,Abdominal pain upper,OT
198214191,Infliximab,Abdominal distension,OT
198395041,Infliximab,Rectal haemorrhage,OT
198395041,Infliximab,Frequent bowel movements,OT
198395041,Infliximab,Condition aggravated,OT
198395041,Infliximab,Abdominal pain,OT
198663911,Infliximab,Off label use,OT
198663911,Infliximab,Joint injury,OT
198663911,Infliximab,Intentional product use issue,OT
198663911,Infliximab,Inappropriate schedule of product administration,OT
198663911,Infliximab,Condition aggravated,OT
198663911,Infliximab,Blood pressure increased,OT
198663911,Infliximab,Arthralgia,OT
198781281,Infliximab (Unknown),Rash,NULL
198781281,Infliximab (Unknown),Off label use,NULL
198781281,Infliximab (Unknown),Drug effective for unapproved indication,NULL
164922306,Infliximab,White blood cell count increased,OT
164922306,Infliximab,Weight increased,OT
164922306,Infliximab,Weight decreased,OT
164922306,Infliximab,Vomiting,OT
164922306,Infliximab,Vitamin D decreased,OT
164922306,Infliximab,Ulcer,OT
164922306,Infliximab,Therapeutic product effect incomplete,OT
164922306,Infliximab,Small intestine ulcer,OT
164922306,Infliximab,Small intestinal obstruction,OT
164922306,Infliximab,Serum ferritin decreased,OT
164922306,Infliximab,Red cell distribution width increased,OT
164922306,Infliximab,Red blood cell count decreased,OT
164922306,Infliximab,Product use issue,OT
164922306,Infliximab,Platelet count increased,OT
164922306,Infliximab,Oropharyngeal pain,OT
164922306,Infliximab,Off label use,OT
164922306,Infliximab,Neutrophil count increased,OT
164922306,Infliximab,Nasopharyngitis,OT
164922306,Infliximab,Nasal congestion,OT
164922306,Infliximab,Monocyte count increased,OT
164922306,Infliximab,Mean cell volume decreased,OT
164922306,Infliximab,Mean cell haemoglobin decreased,OT
164922306,Infliximab,Mean cell haemoglobin concentration decreased,OT
164922306,Infliximab,Malaise,OT
164922306,Infliximab,Iron deficiency,OT
164922306,Infliximab,Intestinal obstruction,OT
164922306,Infliximab,Inflammatory bowel disease,OT
164922306,Infliximab,Inappropriate schedule of product administration,OT
164922306,Infliximab,Hypokalaemia,OT
164922306,Infliximab,Heart rate increased,OT
164922306,Infliximab,Heart rate decreased,OT
164922306,Infliximab,Haemoglobin decreased,OT
164922306,Infliximab,Haematocrit decreased,OT
164922306,Infliximab,Feeling cold,OT
164922306,Infliximab,Fatigue,OT
164922306,Infliximab,Faecal calprotectin increased,OT
164922306,Infliximab,Drug level decreased,OT
164922306,Infliximab,Drug level above therapeutic,OT
164922306,Infliximab,Condition aggravated,OT
164922306,Infliximab,C-reactive protein increased,OT
164922306,Infliximab,Abdominal pain,OT
164922306,Infliximab,White blood cell count increased,OT
164922306,Infliximab,Weight increased,OT
164922306,Infliximab,Weight decreased,OT
164922306,Infliximab,Vomiting,OT
164922306,Infliximab,Vitamin D decreased,OT
164922306,Infliximab,Ulcer,OT
164922306,Infliximab,Therapeutic product effect incomplete,OT
164922306,Infliximab,Small intestine ulcer,OT
164922306,Infliximab,Small intestinal obstruction,OT
164922306,Infliximab,Serum ferritin decreased,OT
164922306,Infliximab,Red cell distribution width increased,OT
164922306,Infliximab,Red blood cell count decreased,OT
164922306,Infliximab,Product use issue,OT
164922306,Infliximab,Platelet count increased,OT
164922306,Infliximab,Oropharyngeal pain,OT
164922306,Infliximab,Off label use,OT
164922306,Infliximab,Neutrophil count increased,OT
164922306,Infliximab,Nasopharyngitis,OT
164922306,Infliximab,Nasal congestion,OT
164922306,Infliximab,Monocyte count increased,OT
164922306,Infliximab,Mean cell volume decreased,OT
164922306,Infliximab,Mean cell haemoglobin decreased,OT
164922306,Infliximab,Mean cell haemoglobin concentration decreased,OT
164922306,Infliximab,Malaise,OT
164922306,Infliximab,Iron deficiency,OT
164922306,Infliximab,Intestinal obstruction,OT
164922306,Infliximab,Inflammatory bowel disease,OT
164922306,Infliximab,Inappropriate schedule of product administration,OT
164922306,Infliximab,Hypokalaemia,OT
164922306,Infliximab,Heart rate increased,OT
164922306,Infliximab,Heart rate decreased,OT
164922306,Infliximab,Haemoglobin decreased,OT
164922306,Infliximab,Haematocrit decreased,OT
164922306,Infliximab,Feeling cold,OT
164922306,Infliximab,Fatigue,OT
164922306,Infliximab,Faecal calprotectin increased,OT
164922306,Infliximab,Drug level decreased,OT
164922306,Infliximab,Drug level above therapeutic,OT
164922306,Infliximab,Condition aggravated,OT
164922306,Infliximab,C-reactive protein increased,OT
164922306,Infliximab,Abdominal pain,OT
164991695,Infliximab,Rheumatoid arthritis,OT
164991695,Infliximab,Product use issue,OT
164991695,Infliximab,Off label use,OT
164991695,Infliximab,Incorrect dose administered,OT
164991695,Infliximab,Inappropriate schedule of product administration,OT
164991695,Infliximab,Drug ineffective,OT
164991695,Infliximab,Condition aggravated,OT
164991695,Infliximab,Body temperature fluctuation,OT
164991695,Infliximab,Body temperature decreased,OT
164991695,Infliximab,Blood pressure increased,OT
164991695,Infliximab,Blood pressure fluctuation,OT
164991695,Infliximab,Rheumatoid arthritis,OT
164991695,Infliximab,Product use issue,OT
164991695,Infliximab,Off label use,OT
164991695,Infliximab,Incorrect dose administered,OT
164991695,Infliximab,Inappropriate schedule of product administration,OT
164991695,Infliximab,Drug ineffective,OT
164991695,Infliximab,Condition aggravated,OT
164991695,Infliximab,Body temperature fluctuation,OT
164991695,Infliximab,Body temperature decreased,OT
164991695,Infliximab,Blood pressure increased,OT
164991695,Infliximab,Blood pressure fluctuation,OT
165217248,Infliximab,White blood cell count decreased,OT
165217248,Infliximab,White blood cell count decreased,HO
165217248,Infliximab,Product use issue,OT
165217248,Infliximab,Product use issue,HO
165217248,Infliximab,Platelet count decreased,OT
165217248,Infliximab,Platelet count decreased,HO
165217248,Infliximab,Off label use,OT
165217248,Infliximab,Off label use,HO
165217248,Infliximab,Ocular hyperaemia,OT
165217248,Infliximab,Ocular hyperaemia,HO
165217248,Infliximab,Malaise,OT
165217248,Infliximab,Malaise,HO
165217248,Infliximab,Intentional product use issue,OT
165217248,Infliximab,Intentional product use issue,HO
165217248,Infliximab,Illness,OT
165217248,Infliximab,Illness,HO
165217248,Infliximab,Hyperkeratosis,OT
165217248,Infliximab,Hyperkeratosis,HO
165217248,Infliximab,Heart rate irregular,OT
165217248,Infliximab,Heart rate irregular,HO
165217248,Infliximab,Heart rate decreased,OT
165217248,Infliximab,Heart rate decreased,HO
165217248,Infliximab,Haematocrit increased,OT
165217248,Infliximab,Haematocrit increased,HO
165217248,Infliximab,Haematochezia,OT
165217248,Infliximab,Haematochezia,HO
165217248,Infliximab,Dizziness,OT
165217248,Infliximab,Dizziness,HO
165217248,Infliximab,Constipation,OT
165217248,Infliximab,Constipation,HO
165217248,Infliximab,Conjunctival hyperaemia,OT
165217248,Infliximab,Conjunctival hyperaemia,HO
165217248,Infliximab,Condition aggravated,OT
165217248,Infliximab,Condition aggravated,HO
165217248,Infliximab,Circumstance or information capable of leading to medication error,OT
165217248,Infliximab,Circumstance or information capable of leading to medication error,HO
165217248,Infliximab,Chills,OT
165217248,Infliximab,Chills,HO
165217248,Infliximab,Chest discomfort,OT
165217248,Infliximab,Chest discomfort,HO
165217248,Infliximab,Cataract,OT
165217248,Infliximab,Cataract,HO
165217248,Infliximab,Body temperature fluctuation,OT
165217248,Infliximab,Body temperature fluctuation,HO
165217248,Infliximab,Blood pressure increased,OT
165217248,Infliximab,Blood pressure increased,HO
165217248,Infliximab,Blood pressure fluctuation,OT
165217248,Infliximab,Blood pressure fluctuation,HO
165217248,Infliximab,Anaemia,OT
165217248,Infliximab,Anaemia,HO
165217248,Infliximab,Abdominal pain,OT
165217248,Infliximab,Abdominal pain,HO
165217248,Infliximab,White blood cell count decreased,OT
165217248,Infliximab,White blood cell count decreased,HO
165217248,Infliximab,Product use issue,OT
165217248,Infliximab,Product use issue,HO
165217248,Infliximab,Platelet count decreased,OT
165217248,Infliximab,Platelet count decreased,HO
165217248,Infliximab,Off label use,OT
165217248,Infliximab,Off label use,HO
165217248,Infliximab,Ocular hyperaemia,OT
165217248,Infliximab,Ocular hyperaemia,HO
165217248,Infliximab,Malaise,OT
165217248,Infliximab,Malaise,HO
165217248,Infliximab,Intentional product use issue,OT
165217248,Infliximab,Intentional product use issue,HO
165217248,Infliximab,Illness,OT
165217248,Infliximab,Illness,HO
165217248,Infliximab,Hyperkeratosis,OT
165217248,Infliximab,Hyperkeratosis,HO
165217248,Infliximab,Heart rate irregular,OT
165217248,Infliximab,Heart rate irregular,HO
165217248,Infliximab,Heart rate decreased,OT
165217248,Infliximab,Heart rate decreased,HO
165217248,Infliximab,Haematocrit increased,OT
165217248,Infliximab,Haematocrit increased,HO
165217248,Infliximab,Haematochezia,OT
165217248,Infliximab,Haematochezia,HO
165217248,Infliximab,Dizziness,OT
165217248,Infliximab,Dizziness,HO
165217248,Infliximab,Constipation,OT
165217248,Infliximab,Constipation,HO
165217248,Infliximab,Conjunctival hyperaemia,OT
165217248,Infliximab,Conjunctival hyperaemia,HO
165217248,Infliximab,Condition aggravated,OT
165217248,Infliximab,Condition aggravated,HO
165217248,Infliximab,Circumstance or information capable of leading to medication error,OT
165217248,Infliximab,Circumstance or information capable of leading to medication error,HO
165217248,Infliximab,Chills,OT
165217248,Infliximab,Chills,HO
165217248,Infliximab,Chest discomfort,OT
165217248,Infliximab,Chest discomfort,HO
165217248,Infliximab,Cataract,OT
165217248,Infliximab,Cataract,HO
165217248,Infliximab,Body temperature fluctuation,OT
165217248,Infliximab,Body temperature fluctuation,HO
165217248,Infliximab,Blood pressure increased,OT
165217248,Infliximab,Blood pressure increased,HO
165217248,Infliximab,Blood pressure fluctuation,OT
165217248,Infliximab,Blood pressure fluctuation,HO
165217248,Infliximab,Anaemia,OT
165217248,Infliximab,Anaemia,HO
165217248,Infliximab,Abdominal pain,OT
165217248,Infliximab,Abdominal pain,HO
165217248,Infliximab,White blood cell count decreased,OT
165217248,Infliximab,White blood cell count decreased,HO
165217248,Infliximab,Product use issue,OT
165217248,Infliximab,Product use issue,HO
165217248,Infliximab,Platelet count decreased,OT
165217248,Infliximab,Platelet count decreased,HO
165217248,Infliximab,Off label use,OT
165217248,Infliximab,Off label use,HO
165217248,Infliximab,Ocular hyperaemia,OT
165217248,Infliximab,Ocular hyperaemia,HO
165217248,Infliximab,Malaise,OT
165217248,Infliximab,Malaise,HO
165217248,Infliximab,Intentional product use issue,OT
165217248,Infliximab,Intentional product use issue,HO
165217248,Infliximab,Illness,OT
165217248,Infliximab,Illness,HO
165217248,Infliximab,Hyperkeratosis,OT
165217248,Infliximab,Hyperkeratosis,HO
165217248,Infliximab,Heart rate irregular,OT
165217248,Infliximab,Heart rate irregular,HO
165217248,Infliximab,Heart rate decreased,OT
165217248,Infliximab,Heart rate decreased,HO
165217248,Infliximab,Haematocrit increased,OT
165217248,Infliximab,Haematocrit increased,HO
165217248,Infliximab,Haematochezia,OT
165217248,Infliximab,Haematochezia,HO
165217248,Infliximab,Dizziness,OT
165217248,Infliximab,Dizziness,HO
165217248,Infliximab,Constipation,OT
165217248,Infliximab,Constipation,HO
165217248,Infliximab,Conjunctival hyperaemia,OT
165217248,Infliximab,Conjunctival hyperaemia,HO
165217248,Infliximab,Condition aggravated,OT
165217248,Infliximab,Condition aggravated,HO
165217248,Infliximab,Circumstance or information capable of leading to medication error,OT
165217248,Infliximab,Circumstance or information capable of leading to medication error,HO
165217248,Infliximab,Chills,OT
165217248,Infliximab,Chills,HO
165217248,Infliximab,Chest discomfort,OT
165217248,Infliximab,Chest discomfort,HO
165217248,Infliximab,Cataract,OT
165217248,Infliximab,Cataract,HO
165217248,Infliximab,Body temperature fluctuation,OT
165217248,Infliximab,Body temperature fluctuation,HO
165217248,Infliximab,Blood pressure increased,OT
165217248,Infliximab,Blood pressure increased,HO
165217248,Infliximab,Blood pressure fluctuation,OT
165217248,Infliximab,Blood pressure fluctuation,HO
165217248,Infliximab,Anaemia,OT
165217248,Infliximab,Anaemia,HO
165217248,Infliximab,Abdominal pain,OT
165217248,Infliximab,Abdominal pain,HO
166670012,Infliximab,Vanishing bile duct syndrome,HO
166670012,Infliximab,Hepatic failure,HO
166898736,Infliximab,Treatment failure,OT
166898736,Infliximab,Synovitis,OT
166898736,Infliximab,Rheumatoid arthritis,OT
166898736,Infliximab,Red blood cell sedimentation rate increased,OT
166898736,Infliximab,Pain,OT
166898736,Infliximab,Off label use,OT
166898736,Infliximab,Nausea,OT
166898736,Infliximab,Malaise,OT
166898736,Infliximab,Liver disorder,OT
166898736,Infliximab,Joint injury,OT
166898736,Infliximab,Inflammation,OT
166898736,Infliximab,Headache,OT
166898736,Infliximab,Fatigue,OT
166898736,Infliximab,Fall,OT
166898736,Infliximab,Drug use disorder,OT
166898736,Infliximab,Drug intolerance,OT
166898736,Infliximab,Drug ineffective,OT
166898736,Infliximab,Drug dependence,OT
166898736,Infliximab,Diarrhoea,OT
166898736,Infliximab,Depression,OT
166898736,Infliximab,Contraindicated product administered,OT
166898736,Infliximab,Asthenia,OT
166898736,Infliximab,Aspartate aminotransferase increased,OT
166898736,Infliximab,Arthralgia,OT
166898736,Infliximab,Anxiety,OT
166898736,Infliximab,Anticipatory anxiety,OT
166898736,Infliximab,Alopecia,OT
166898736,Infliximab,Alanine aminotransferase increased,OT
166898736,Infliximab,Adverse drug reaction,OT
166898736,Infliximab,Abdominal pain upper,OT
175534842,Infliximab,Sinusitis,HO
175534842,Infliximab,Rhinorrhoea,HO
175534842,Infliximab,Pruritus,HO
175534842,Infliximab,Paraesthesia,HO
175534842,Infliximab,Off label use,HO
175534842,Infliximab,Nasal congestion,HO
175534842,Infliximab,Myalgia,HO
175534842,Infliximab,Muscular weakness,HO
175534842,Infliximab,Muscle disorder,HO
175534842,Infliximab,Limb discomfort,HO
175534842,Infliximab,Lacrimation increased,HO
175534842,Infliximab,Intentional product use issue,HO
175534842,Infliximab,Inappropriate schedule of product administration,HO
175534842,Infliximab,Hypoaesthesia,HO
175534842,Infliximab,Hepatic enzyme increased,HO
175534842,Infliximab,Heart rate decreased,HO
175534842,Infliximab,Drug level decreased,HO
175534842,Infliximab,Drug hypersensitivity,HO
175534842,Infliximab,Condition aggravated,HO
175534842,Infliximab,Arthropathy,HO
175534842,Infliximab,Arthralgia,HO
175534842,Infliximab,Sinusitis,HO
175534842,Infliximab,Rhinorrhoea,HO
175534842,Infliximab,Pruritus,HO
175534842,Infliximab,Paraesthesia,HO
175534842,Infliximab,Off label use,HO
175534842,Infliximab,Nasal congestion,HO
175534842,Infliximab,Myalgia,HO
175534842,Infliximab,Muscular weakness,HO
175534842,Infliximab,Muscle disorder,HO
175534842,Infliximab,Limb discomfort,HO
175534842,Infliximab,Lacrimation increased,HO
175534842,Infliximab,Intentional product use issue,HO
175534842,Infliximab,Inappropriate schedule of product administration,HO
175534842,Infliximab,Hypoaesthesia,HO
175534842,Infliximab,Hepatic enzyme increased,HO
175534842,Infliximab,Heart rate decreased,HO
175534842,Infliximab,Drug level decreased,HO
175534842,Infliximab,Drug hypersensitivity,HO
175534842,Infliximab,Condition aggravated,HO
175534842,Infliximab,Arthropathy,HO
175534842,Infliximab,Arthralgia,HO
176032563,Infliximab,Product use issue,OT
176032563,Infliximab,Product use issue,HO
176032563,Infliximab,Proctalgia,OT
176032563,Infliximab,Proctalgia,HO
176032563,Infliximab,Osteoarthritis,OT
176032563,Infliximab,Osteoarthritis,HO
176032563,Infliximab,Off label use,OT
176032563,Infliximab,Off label use,HO
176032563,Infliximab,Malaise,OT
176032563,Infliximab,Malaise,HO
176032563,Infliximab,Intentional product use issue,OT
176032563,Infliximab,Intentional product use issue,HO
176032563,Infliximab,Incorrect product administration duration,OT
176032563,Infliximab,Incorrect product administration duration,HO
176032563,Infliximab,Incorrect dose administered,OT
176032563,Infliximab,Incorrect dose administered,HO
176032563,Infliximab,Inappropriate schedule of product administration,OT
176032563,Infliximab,Inappropriate schedule of product administration,HO
176032563,Infliximab,Heart rate decreased,OT
176032563,Infliximab,Heart rate decreased,HO
176032563,Infliximab,Haemorrhage,OT
176032563,Infliximab,Haemorrhage,HO
176032563,Infliximab,Drug specific antibody present,OT
176032563,Infliximab,Drug specific antibody present,HO
176032563,Infliximab,Condition aggravated,OT
176032563,Infliximab,Condition aggravated,HO
176032563,Infliximab,Blood pressure increased,OT
176032563,Infliximab,Blood pressure increased,HO
176032563,Infliximab,Blood pressure fluctuation,OT
176032563,Infliximab,Blood pressure fluctuation,HO
176032563,Infliximab,Anal abscess,OT
176032563,Infliximab,Anal abscess,HO
176053714,Infliximab,Weight decreased,HO
176053714,Infliximab,Weight decreased,OT
176053714,Infliximab,Off label use,HO
176053714,Infliximab,Off label use,OT
176053714,Infliximab,Intestinal obstruction,HO
176053714,Infliximab,Intestinal obstruction,OT
176053714,Infliximab,Intentional product use issue,HO
176053714,Infliximab,Intentional product use issue,OT
176053714,Infliximab,Incorrect dose administered,HO
176053714,Infliximab,Incorrect dose administered,OT
176053714,Infliximab,Inappropriate schedule of product administration,HO
176053714,Infliximab,Inappropriate schedule of product administration,OT
176053714,Infliximab,Condition aggravated,HO
176053714,Infliximab,Condition aggravated,OT
176053714,Infliximab,Weight decreased,HO
176053714,Infliximab,Weight decreased,OT
176053714,Infliximab,Off label use,HO
176053714,Infliximab,Off label use,OT
176053714,Infliximab,Intestinal obstruction,HO
176053714,Infliximab,Intestinal obstruction,OT
176053714,Infliximab,Intentional product use issue,HO
176053714,Infliximab,Intentional product use issue,OT
176053714,Infliximab,Incorrect dose administered,HO
176053714,Infliximab,Incorrect dose administered,OT
176053714,Infliximab,Inappropriate schedule of product administration,HO
176053714,Infliximab,Inappropriate schedule of product administration,OT
176053714,Infliximab,Condition aggravated,HO
176053714,Infliximab,Condition aggravated,OT
176117353,Infliximab,Weight increased,OT
176117353,Infliximab,Heart rate irregular,OT
176117353,Infliximab,Haemorrhage,OT
176117353,Infliximab,Fistula,OT
176117353,Infliximab,Blood pressure fluctuation,OT
176117353,Infliximab,Blood pressure decreased,OT
176117353,Infliximab,Weight increased,OT
176117353,Infliximab,Heart rate irregular,OT
176117353,Infliximab,Haemorrhage,OT
176117353,Infliximab,Fistula,OT
176117353,Infliximab,Blood pressure fluctuation,OT
176117353,Infliximab,Blood pressure decreased,OT
176117353,Infliximab,Weight increased,OT
176117353,Infliximab,Heart rate irregular,OT
176117353,Infliximab,Haemorrhage,OT
176117353,Infliximab,Fistula,OT
176117353,Infliximab,Blood pressure fluctuation,OT
176117353,Infliximab,Blood pressure decreased,OT
176239713,Infliximab,Weight increased,HO
176239713,Infliximab,Weight increased,OT
176239713,Infliximab,Weight decreased,HO
176239713,Infliximab,Weight decreased,OT
176239713,Infliximab,Tooth disorder,HO
176239713,Infliximab,Tooth disorder,OT
176239713,Infliximab,Therapeutic response shortened,HO
176239713,Infliximab,Therapeutic response shortened,OT
176239713,Infliximab,Rhinorrhoea,HO
176239713,Infliximab,Rhinorrhoea,OT
176239713,Infliximab,Pyrexia,HO
176239713,Infliximab,Pyrexia,OT
176239713,Infliximab,Product use issue,HO
176239713,Infliximab,Product use issue,OT
176239713,Infliximab,Paraesthesia,HO
176239713,Infliximab,Paraesthesia,OT
176239713,Infliximab,Panic reaction,HO
176239713,Infliximab,Panic reaction,OT
176239713,Infliximab,Pain in jaw,HO
176239713,Infliximab,Pain in jaw,OT
176239713,Infliximab,Pain in extremity,HO
176239713,Infliximab,Pain in extremity,OT
176239713,Infliximab,Pain,HO
176239713,Infliximab,Pain,OT
176239713,Infliximab,Oxygen saturation decreased,HO
176239713,Infliximab,Oxygen saturation decreased,OT
176239713,Infliximab,Oropharyngeal pain,HO
176239713,Infliximab,Oropharyngeal pain,OT
176239713,Infliximab,Oral infection,HO
176239713,Infliximab,Oral infection,OT
176239713,Infliximab,Off label use,HO
176239713,Infliximab,Off label use,OT
176239713,Infliximab,Neck injury,HO
176239713,Infliximab,Neck injury,OT
176239713,Infliximab,Migraine,HO
176239713,Infliximab,Migraine,OT
176239713,Infliximab,Malaise,HO
176239713,Infliximab,Malaise,OT
176239713,Infliximab,Localised infection,HO
176239713,Infliximab,Localised infection,OT
176239713,Infliximab,Jaw disorder,HO
176239713,Infliximab,Jaw disorder,OT
176239713,Infliximab,Irritable bowel syndrome,HO
176239713,Infliximab,Irritable bowel syndrome,OT
176239713,Infliximab,Intentional product use issue,HO
176239713,Infliximab,Intentional product use issue,OT
176239713,Infliximab,Injection site extravasation,HO
176239713,Infliximab,Injection site extravasation,OT
176239713,Infliximab,Influenza like illness,HO
176239713,Infliximab,Influenza like illness,OT
176239713,Infliximab,Inappropriate schedule of product administration,HO
176239713,Infliximab,Inappropriate schedule of product administration,OT
176239713,Infliximab,Heart rate decreased,HO
176239713,Infliximab,Heart rate decreased,OT
176239713,Infliximab,Headache,HO
176239713,Infliximab,Headache,OT
176239713,Infliximab,Food intolerance,HO
176239713,Infliximab,Food intolerance,OT
176239713,Infliximab,Feeding disorder,HO
176239713,Infliximab,Feeding disorder,OT
176239713,Infliximab,Fatigue,HO
176239713,Infliximab,Fatigue,OT
176239713,Infliximab,Faecal calprotectin increased,HO
176239713,Infliximab,Faecal calprotectin increased,OT
176239713,Infliximab,Cough,HO
176239713,Infliximab,Cough,OT
176239713,Infliximab,Contusion,HO
176239713,Infliximab,Contusion,OT
176239713,Infliximab,Constipation,HO
176239713,Infliximab,Constipation,OT
176239713,Infliximab,Condition aggravated,HO
176239713,Infliximab,Condition aggravated,OT
176239713,Infliximab,Chapped lips,HO
176239713,Infliximab,Chapped lips,OT
176239713,Infliximab,Breath odour,HO
176239713,Infliximab,Breath odour,OT
176239713,Infliximab,Back pain,HO
176239713,Infliximab,Back pain,OT
176239713,Infliximab,Back injury,HO
176239713,Infliximab,Back injury,OT
176239713,Infliximab,Arthritis,HO
176239713,Infliximab,Arthritis,OT
176239713,Infliximab,Aphonia,HO
176239713,Infliximab,Aphonia,OT
176239713,Infliximab,Anxiety,HO
176239713,Infliximab,Anxiety,OT
176282253,Infliximab,Therapeutic response shortened,OT
176282253,Infliximab,Therapeutic response shortened,HO
176282253,Infliximab,Off label use,OT
176282253,Infliximab,Off label use,HO
176282253,Infliximab,Musculoskeletal stiffness,OT
176282253,Infliximab,Musculoskeletal stiffness,HO
176282253,Infliximab,Musculoskeletal pain,OT
176282253,Infliximab,Musculoskeletal pain,HO
176282253,Infliximab,Intestinal obstruction,OT
176282253,Infliximab,Intestinal obstruction,HO
176282253,Infliximab,Intentional product use issue,OT
176282253,Infliximab,Intentional product use issue,HO
176282253,Infliximab,Hot flush,OT
176282253,Infliximab,Hot flush,HO
176282253,Infliximab,Heart rate irregular,OT
176282253,Infliximab,Heart rate irregular,HO
176282253,Infliximab,Headache,OT
176282253,Infliximab,Headache,HO
176282253,Infliximab,Haemorrhage,OT
176282253,Infliximab,Haemorrhage,HO
176282253,Infliximab,Fatigue,OT
176282253,Infliximab,Fatigue,HO
176282253,Infliximab,Dizziness,OT
176282253,Infliximab,Dizziness,HO
176282253,Infliximab,Condition aggravated,OT
176282253,Infliximab,Condition aggravated,HO
176282253,Infliximab,Cold sweat,OT
176282253,Infliximab,Cold sweat,HO
176282253,Infliximab,Blood pressure fluctuation,OT
176282253,Infliximab,Blood pressure fluctuation,HO
176282253,Infliximab,Arthralgia,OT
176282253,Infliximab,Arthralgia,HO
176669123,Infliximab,Weight increased,OT
176669123,Infliximab,Therapeutic response shortened,OT
176669123,Infliximab,Therapeutic product effect decreased,OT
176669123,Infliximab,Sneezing,OT
176669123,Infliximab,Sinus disorder,OT
176669123,Infliximab,Rectal haemorrhage,OT
176669123,Infliximab,Product use issue,OT
176669123,Infliximab,Off label use,OT
176669123,Infliximab,Nausea,OT
176669123,Infliximab,Intentional product use issue,OT
176669123,Infliximab,Insomnia,OT
176669123,Infliximab,Incorrect dosage administered,OT
176669123,Infliximab,Inappropriate schedule of product administration,OT
176669123,Infliximab,Food poisoning,OT
176669123,Infliximab,Fatigue,OT
176669123,Infliximab,Drug level below therapeutic,OT
176669123,Infliximab,Dizziness,OT
176669123,Infliximab,Decreased appetite,OT
176669123,Infliximab,Cough,OT
176669123,Infliximab,Condition aggravated,OT
176669123,Infliximab,Bronchitis,OT
176669123,Infliximab,Blood pressure fluctuation,OT
176669123,Infliximab,Blood pressure diastolic increased,OT
176669123,Infliximab,Weight increased,OT
176669123,Infliximab,Therapeutic response shortened,OT
176669123,Infliximab,Therapeutic product effect decreased,OT
176669123,Infliximab,Sneezing,OT
176669123,Infliximab,Sinus disorder,OT
176669123,Infliximab,Rectal haemorrhage,OT
176669123,Infliximab,Product use issue,OT
176669123,Infliximab,Off label use,OT
176669123,Infliximab,Nausea,OT
176669123,Infliximab,Intentional product use issue,OT
176669123,Infliximab,Insomnia,OT
176669123,Infliximab,Incorrect dosage administered,OT
176669123,Infliximab,Inappropriate schedule of product administration,OT
176669123,Infliximab,Food poisoning,OT
176669123,Infliximab,Fatigue,OT
176669123,Infliximab,Drug level below therapeutic,OT
176669123,Infliximab,Dizziness,OT
176669123,Infliximab,Decreased appetite,OT
176669123,Infliximab,Cough,OT
176669123,Infliximab,Condition aggravated,OT
176669123,Infliximab,Bronchitis,OT
176669123,Infliximab,Blood pressure fluctuation,OT
176669123,Infliximab,Blood pressure diastolic increased,OT
177816954,Infliximab,Vomiting,OT
177816954,Infliximab,Therapeutic product effect incomplete,OT
177816954,Infliximab,Product use issue,OT
177816954,Infliximab,Prescribed overdose,OT
177816954,Infliximab,Off label use,OT
177816954,Infliximab,Intentional product use issue,OT
177816954,Infliximab,Inappropriate schedule of product administration,OT
177816954,Infliximab,Heart rate decreased,OT
177816954,Infliximab,Gastroenteritis,OT
177816954,Infliximab,Diarrhoea,OT
177816954,Infliximab,Condition aggravated,OT
179561834,Infliximab,Rhinorrhoea,OT
179561834,Infliximab,Pyrexia,OT
179561834,Infliximab,Oxygen saturation decreased,OT
179561834,Infliximab,Oropharyngeal pain,OT
179561834,Infliximab,Ocular hyperaemia,OT
179561834,Infliximab,Nasopharyngitis,OT
179561834,Infliximab,Malaise,OT
179561834,Infliximab,Lacrimation increased,OT
179561834,Infliximab,Inappropriate schedule of product administration,OT
179561834,Infliximab,Illness,OT
179561834,Infliximab,Cough,OT
179561834,Infliximab,Condition aggravated,OT
179561834,Infliximab,Cataract,OT
179561834,Infliximab,Blood pressure fluctuation,OT
179561834,Infliximab,Rhinorrhoea,OT
179561834,Infliximab,Pyrexia,OT
179561834,Infliximab,Oxygen saturation decreased,OT
179561834,Infliximab,Oropharyngeal pain,OT
179561834,Infliximab,Ocular hyperaemia,OT
179561834,Infliximab,Nasopharyngitis,OT
179561834,Infliximab,Malaise,OT
179561834,Infliximab,Lacrimation increased,OT
179561834,Infliximab,Inappropriate schedule of product administration,OT
179561834,Infliximab,Illness,OT
179561834,Infliximab,Cough,OT
179561834,Infliximab,Condition aggravated,OT
179561834,Infliximab,Cataract,OT
179561834,Infliximab,Blood pressure fluctuation,OT
182971662,Infliximab,Weight increased,OT
182971662,Infliximab,Weight decreased,OT
182971662,Infliximab,Therapeutic response shortened,OT
182971662,Infliximab,Product use issue,OT
182971662,Infliximab,Poor venous access,OT
182971662,Infliximab,Off label use,OT
182971662,Infliximab,Intentional product use issue,OT
182971662,Infliximab,Dehydration,OT
182971662,Infliximab,Condition aggravated,OT
182971662,Infliximab,Blood pressure decreased,OT
182971662,Infliximab,Weight increased,OT
182971662,Infliximab,Weight decreased,OT
182971662,Infliximab,Therapeutic response shortened,OT
182971662,Infliximab,Product use issue,OT
182971662,Infliximab,Poor venous access,OT
182971662,Infliximab,Off label use,OT
182971662,Infliximab,Intentional product use issue,OT
182971662,Infliximab,Dehydration,OT
182971662,Infliximab,Condition aggravated,OT
182971662,Infliximab,Blood pressure decreased,OT
184040902,Infliximab,Transaminases increased,HO
184040902,Infliximab,Transaminases increased,OT
184040902,Infliximab,Therapeutic response shortened,HO
184040902,Infliximab,Therapeutic response shortened,OT
184040902,Infliximab,Pneumonia,HO
184040902,Infliximab,Pneumonia,OT
184040902,Infliximab,Pain,HO
184040902,Infliximab,Pain,OT
184040902,Infliximab,Off label use,HO
184040902,Infliximab,Off label use,OT
184040902,Infliximab,Incorrect dose administered,HO
184040902,Infliximab,Incorrect dose administered,OT
184040902,Infliximab,Heart rate irregular,HO
184040902,Infliximab,Heart rate irregular,OT
184040902,Infliximab,Heart rate decreased,HO
184040902,Infliximab,Heart rate decreased,OT
184040902,Infliximab,Flushing,HO
184040902,Infliximab,Flushing,OT
184040902,Infliximab,Feeling hot,HO
184040902,Infliximab,Feeling hot,OT
184040902,Infliximab,Dyspnoea,HO
184040902,Infliximab,Dyspnoea,OT
184040902,Infliximab,Dizziness,HO
184040902,Infliximab,Dizziness,OT
184040902,Infliximab,Body mass index increased,HO
184040902,Infliximab,Body mass index increased,OT
184040902,Infliximab,Blood pressure increased,HO
184040902,Infliximab,Blood pressure increased,OT
184040902,Infliximab,Blood pressure fluctuation,HO
184040902,Infliximab,Blood pressure fluctuation,OT
184040902,Infliximab,Atrial fibrillation,HO
184040902,Infliximab,Atrial fibrillation,OT
184040902,Infliximab,Transaminases increased,HO
184040902,Infliximab,Transaminases increased,OT
184040902,Infliximab,Therapeutic response shortened,HO
184040902,Infliximab,Therapeutic response shortened,OT
184040902,Infliximab,Pneumonia,HO
184040902,Infliximab,Pneumonia,OT
184040902,Infliximab,Pain,HO
184040902,Infliximab,Pain,OT
184040902,Infliximab,Off label use,HO
184040902,Infliximab,Off label use,OT
184040902,Infliximab,Incorrect dose administered,HO
184040902,Infliximab,Incorrect dose administered,OT
184040902,Infliximab,Heart rate irregular,HO
184040902,Infliximab,Heart rate irregular,OT
184040902,Infliximab,Heart rate decreased,HO
184040902,Infliximab,Heart rate decreased,OT
184040902,Infliximab,Flushing,HO
184040902,Infliximab,Flushing,OT
184040902,Infliximab,Feeling hot,HO
184040902,Infliximab,Feeling hot,OT
184040902,Infliximab,Dyspnoea,HO
184040902,Infliximab,Dyspnoea,OT
184040902,Infliximab,Dizziness,HO
184040902,Infliximab,Dizziness,OT
184040902,Infliximab,Body mass index increased,HO
184040902,Infliximab,Body mass index increased,OT
184040902,Infliximab,Blood pressure increased,HO
184040902,Infliximab,Blood pressure increased,OT
184040902,Infliximab,Blood pressure fluctuation,HO
184040902,Infliximab,Blood pressure fluctuation,OT
184040902,Infliximab,Atrial fibrillation,HO
184040902,Infliximab,Atrial fibrillation,OT
184040902,Infliximab,Transaminases increased,HO
184040902,Infliximab,Transaminases increased,OT
184040902,Infliximab,Therapeutic response shortened,HO
184040902,Infliximab,Therapeutic response shortened,OT
184040902,Infliximab,Pneumonia,HO
184040902,Infliximab,Pneumonia,OT
184040902,Infliximab,Pain,HO
184040902,Infliximab,Pain,OT
184040902,Infliximab,Off label use,HO
184040902,Infliximab,Off label use,OT
184040902,Infliximab,Incorrect dose administered,HO
184040902,Infliximab,Incorrect dose administered,OT
184040902,Infliximab,Heart rate irregular,HO
184040902,Infliximab,Heart rate irregular,OT
184040902,Infliximab,Heart rate decreased,HO
184040902,Infliximab,Heart rate decreased,OT
184040902,Infliximab,Flushing,HO
184040902,Infliximab,Flushing,OT
184040902,Infliximab,Feeling hot,HO
184040902,Infliximab,Feeling hot,OT
184040902,Infliximab,Dyspnoea,HO
184040902,Infliximab,Dyspnoea,OT
184040902,Infliximab,Dizziness,HO
184040902,Infliximab,Dizziness,OT
184040902,Infliximab,Body mass index increased,HO
184040902,Infliximab,Body mass index increased,OT
184040902,Infliximab,Blood pressure increased,HO
184040902,Infliximab,Blood pressure increased,OT
184040902,Infliximab,Blood pressure fluctuation,HO
184040902,Infliximab,Blood pressure fluctuation,OT
184040902,Infliximab,Atrial fibrillation,HO
184040902,Infliximab,Atrial fibrillation,OT
184581882,Infliximab,Interstitial lung disease,OT
185279852,Infliximab,Weight decreased,OT
185279852,Infliximab,Therapeutic product effect incomplete,OT
185279852,Infliximab,Skin infection,OT
185279852,Infliximab,Product use issue,OT
185279852,Infliximab,Off label use,OT
185279852,Infliximab,Nausea,OT
185279852,Infliximab,Injection site paraesthesia,OT
185279852,Infliximab,Incorrect dose administered,OT
185279852,Infliximab,Inappropriate schedule of product administration,OT
185279852,Infliximab,Fatigue,OT
185279852,Infliximab,Condition aggravated,OT
185279852,Infliximab,COVID-19,OT
185279852,Infliximab,Bone pain,OT
185279852,Infliximab,Blood pressure systolic increased,OT
185279852,Infliximab,Blood pressure fluctuation,OT
185279852,Infliximab,Arthralgia,OT
185279852,Infliximab,Weight decreased,OT
185279852,Infliximab,Therapeutic product effect incomplete,OT
185279852,Infliximab,Skin infection,OT
185279852,Infliximab,Product use issue,OT
185279852,Infliximab,Off label use,OT
185279852,Infliximab,Nausea,OT
185279852,Infliximab,Injection site paraesthesia,OT
185279852,Infliximab,Incorrect dose administered,OT
185279852,Infliximab,Inappropriate schedule of product administration,OT
185279852,Infliximab,Fatigue,OT
185279852,Infliximab,Condition aggravated,OT
185279852,Infliximab,COVID-19,OT
185279852,Infliximab,Bone pain,OT
185279852,Infliximab,Blood pressure systolic increased,OT
185279852,Infliximab,Blood pressure fluctuation,OT
185279852,Infliximab,Arthralgia,OT
185353603,Infliximab,Weight increased,OT
185353603,Infliximab,Off label use,OT
185353603,Infliximab,Intentional product use issue,OT
185353603,Infliximab,Injection site extravasation,OT
185353603,Infliximab,Heart rate irregular,OT
185353603,Infliximab,Heart rate decreased,OT
185353603,Infliximab,Body temperature decreased,OT
185353603,Infliximab,Blood pressure increased,OT
185353603,Infliximab,Blood pressure fluctuation,OT
191820272,Infliximab,Renal colic,OT
191820272,Infliximab,Off label use,OT
191820272,Infliximab,Nephrolithiasis,OT
191820272,Infliximab,Ear infection,OT
193812282,Infliximab,Wound infection,OT
193812282,Infliximab,Wound complication,OT
193812282,Infliximab,Toothache,OT
193812282,Infliximab,Skin wound,OT
193812282,Infliximab,Scab,OT
193812282,Infliximab,Rash,OT
193812282,Infliximab,Pruritus,OT
193812282,Infliximab,Peripheral swelling,OT
193812282,Infliximab,Oropharyngeal pain,OT
193812282,Infliximab,Oral bacterial infection,OT
193812282,Infliximab,Off label use,OT
193812282,Infliximab,Muscular weakness,OT
193812282,Infliximab,Heart rate irregular,OT
193812282,Infliximab,Fatigue,OT
193812282,Infliximab,Erythema,OT
193812282,Infliximab,Drug level below therapeutic,OT
193812282,Infliximab,Condition aggravated,OT
193812282,Infliximab,Blood pressure increased,OT
193812282,Infliximab,Blood pressure fluctuation,OT
193812282,Infliximab,Back pain,OT
193812282,Infliximab,Arthralgia,OT
193812282,Infliximab,Acne,OT
194845911,Infliximab (Unknown),Loss of therapeutic response,OT
194845911,Infliximab (Unknown),Crohn's disease,OT
194845911,Infliximab (Unknown),Loss of therapeutic response,OT
194845911,Infliximab (Unknown),Crohn's disease,OT
194859481,Infliximab,Tooth disorder,OT
194859481,Infliximab,Therapeutic product effect incomplete,OT
194859481,Infliximab,Product use issue,OT
194859481,Infliximab,Off label use,OT
194973101,Infliximab Pfizer (Unknown),Angioedema,OT
195010822,Infliximab (Unknown),Dyspnoea,OT
195010822,Infliximab (Unknown),Dyspnoea,HO
195010822,Infliximab (Unknown),Bundle branch block,OT
195010822,Infliximab (Unknown),Bundle branch block,HO
195010822,Infliximab (Unknown),Arrhythmia,OT
195010822,Infliximab (Unknown),Arrhythmia,HO
195032151,Infliximab,Interstitial lung disease,OT
195032151,Infliximab,Interstitial lung disease,DE
195032151,Infliximab,Condition aggravated,OT
195032151,Infliximab,Condition aggravated,DE
196123651,Infliximab,Maternal exposure during pregnancy,OT
196123651,Infliximab,Live birth,OT
196123651,Infliximab,Cholestasis of pregnancy,OT
196123651,Infliximab,Cholestasis,OT
196518172,Infliximab,Therapeutic response shortened,OT
196518172,Infliximab,Sinusitis,OT
196518172,Infliximab,Off label use,OT
196518172,Infliximab,Intentional product use issue,OT
196518172,Infliximab,Dermatitis,OT
196518172,Infliximab,Cough,OT
196518172,Infliximab,Condition aggravated,OT
196518172,Infliximab,Arthralgia,OT
196518172,Infliximab,Therapeutic response shortened,OT
196518172,Infliximab,Sinusitis,OT
196518172,Infliximab,Off label use,OT
196518172,Infliximab,Intentional product use issue,OT
196518172,Infliximab,Dermatitis,OT
196518172,Infliximab,Cough,OT
196518172,Infliximab,Condition aggravated,OT
196518172,Infliximab,Arthralgia,OT
197660721,Infliximab BS for I.V. Infusion100 mg [NK],Lung adenocarcinoma,OT
197685272,Infliximab,Pulmonary tuberculosis,OT
197685272,Infliximab,Product use in unapproved indication,OT
197685272,Infliximab,Off label use,OT
197685272,Infliximab,Pulmonary tuberculosis,OT
197685272,Infliximab,Product use in unapproved indication,OT
197685272,Infliximab,Off label use,OT
198167451,Infliximab,Pleural effusion,OT
198167451,Infliximab,Pericardial effusion,OT
198167451,Infliximab,Disseminated tuberculosis,OT
198201741,Infliximab,Immune reconstitution inflammatory syndrome,OT
198201741,Infliximab,Hepatitis B reactivation,OT
198683581,Infliximab,Wound,OT
198683581,Infliximab,Type 2 diabetes mellitus,OT
198683581,Infliximab,Treatment failure,OT
198683581,Infliximab,Therapeutic product effect decreased,OT
198683581,Infliximab,Systemic lupus erythematosus,OT
198683581,Infliximab,Synovitis,OT
198683581,Infliximab,Swollen joint count increased,OT
198683581,Infliximab,Swelling,OT
198683581,Infliximab,Rheumatoid factor positive,OT
198683581,Infliximab,Rheumatoid arthritis,OT
198683581,Infliximab,Rheumatic fever,OT
198683581,Infliximab,Rash,OT
198683581,Infliximab,Pericarditis,OT
198683581,Infliximab,Pemphigus,OT
198683581,Infliximab,Pain,OT
198683581,Infliximab,Musculoskeletal stiffness,OT
198683581,Infliximab,Mobility decreased,OT
198683581,Infliximab,Maternal exposure during pregnancy,OT
198683581,Infliximab,Malaise,OT
198683581,Infliximab,Joint swelling,OT
198683581,Infliximab,Infusion related reaction,OT
198683581,Infliximab,Hypoaesthesia,OT
198683581,Infliximab,Hypertension,OT
198683581,Infliximab,Hypersensitivity,OT
198683581,Infliximab,Hepatic enzyme increased,OT
198683581,Infliximab,Headache,OT
198683581,Infliximab,Hand deformity,OT
198683581,Infliximab,Glossodynia,OT
198683581,Infliximab,General physical health deterioration,OT
198683581,Infliximab,Fatigue,OT
198683581,Infliximab,Drug intolerance,OT
198683581,Infliximab,Drug ineffective,OT
198683581,Infliximab,Discomfort,OT
198683581,Infliximab,Decreased appetite,OT
198683581,Infliximab,Condition aggravated,OT
198683581,Infliximab,Blood cholesterol increased,OT
198683581,Infliximab,Arthropathy,OT
198683581,Infliximab,Arthralgia,OT
198683581,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
198683581,Infliximab,Alopecia,OT
198683581,Infliximab,Abdominal discomfort,OT
198752591,Infliximab Pfizer (Unknown),Stress,OT
198752591,Infliximab Pfizer (Unknown),Stress,HO
198752591,Infliximab Pfizer (Unknown),Resting tremor,OT
198752591,Infliximab Pfizer (Unknown),Resting tremor,HO
198752591,Infliximab Pfizer (Unknown),Pyrexia,OT
198752591,Infliximab Pfizer (Unknown),Pyrexia,HO
198752591,Infliximab Pfizer (Unknown),Product use issue,OT
198752591,Infliximab Pfizer (Unknown),Product use issue,HO
198752591,Infliximab Pfizer (Unknown),Off label use,OT
198752591,Infliximab Pfizer (Unknown),Off label use,HO
198752591,Infliximab Pfizer (Unknown),Hyperhidrosis,OT
198752591,Infliximab Pfizer (Unknown),Hyperhidrosis,HO
198752591,Infliximab Pfizer (Unknown),Faecal calprotectin increased,OT
198752591,Infliximab Pfizer (Unknown),Faecal calprotectin increased,HO
198752591,Infliximab Pfizer (Unknown),Extra dose administered,OT
198752591,Infliximab Pfizer (Unknown),Extra dose administered,HO
198752591,Infliximab Pfizer (Unknown),Colitis ulcerative,OT
198752591,Infliximab Pfizer (Unknown),Colitis ulcerative,HO
198752591,Infliximab Pfizer (Unknown),C-reactive protein increased,OT
198752591,Infliximab Pfizer (Unknown),C-reactive protein increased,HO
198752591,Infliximab Pfizer (Unknown),Asthenia,OT
198752591,Infliximab Pfizer (Unknown),Asthenia,HO
198752591,Infliximab Pfizer (Unknown),Stress,OT
198752591,Infliximab Pfizer (Unknown),Stress,HO
198752591,Infliximab Pfizer (Unknown),Resting tremor,OT
198752591,Infliximab Pfizer (Unknown),Resting tremor,HO
198752591,Infliximab Pfizer (Unknown),Pyrexia,OT
198752591,Infliximab Pfizer (Unknown),Pyrexia,HO
198752591,Infliximab Pfizer (Unknown),Product use issue,OT
198752591,Infliximab Pfizer (Unknown),Product use issue,HO
198752591,Infliximab Pfizer (Unknown),Off label use,OT
198752591,Infliximab Pfizer (Unknown),Off label use,HO
198752591,Infliximab Pfizer (Unknown),Hyperhidrosis,OT
198752591,Infliximab Pfizer (Unknown),Hyperhidrosis,HO
198752591,Infliximab Pfizer (Unknown),Faecal calprotectin increased,OT
198752591,Infliximab Pfizer (Unknown),Faecal calprotectin increased,HO
198752591,Infliximab Pfizer (Unknown),Extra dose administered,OT
198752591,Infliximab Pfizer (Unknown),Extra dose administered,HO
198752591,Infliximab Pfizer (Unknown),Colitis ulcerative,OT
198752591,Infliximab Pfizer (Unknown),Colitis ulcerative,HO
198752591,Infliximab Pfizer (Unknown),C-reactive protein increased,OT
198752591,Infliximab Pfizer (Unknown),C-reactive protein increased,HO
198752591,Infliximab Pfizer (Unknown),Asthenia,OT
198752591,Infliximab Pfizer (Unknown),Asthenia,HO
198752591,Infliximab Pfizer (Unknown),Stress,OT
198752591,Infliximab Pfizer (Unknown),Stress,HO
198752591,Infliximab Pfizer (Unknown),Resting tremor,OT
198752591,Infliximab Pfizer (Unknown),Resting tremor,HO
198752591,Infliximab Pfizer (Unknown),Pyrexia,OT
198752591,Infliximab Pfizer (Unknown),Pyrexia,HO
198752591,Infliximab Pfizer (Unknown),Product use issue,OT
198752591,Infliximab Pfizer (Unknown),Product use issue,HO
198752591,Infliximab Pfizer (Unknown),Off label use,OT
198752591,Infliximab Pfizer (Unknown),Off label use,HO
198752591,Infliximab Pfizer (Unknown),Hyperhidrosis,OT
198752591,Infliximab Pfizer (Unknown),Hyperhidrosis,HO
198752591,Infliximab Pfizer (Unknown),Faecal calprotectin increased,OT
198752591,Infliximab Pfizer (Unknown),Faecal calprotectin increased,HO
198752591,Infliximab Pfizer (Unknown),Extra dose administered,OT
198752591,Infliximab Pfizer (Unknown),Extra dose administered,HO
198752591,Infliximab Pfizer (Unknown),Colitis ulcerative,OT
198752591,Infliximab Pfizer (Unknown),Colitis ulcerative,HO
198752591,Infliximab Pfizer (Unknown),C-reactive protein increased,OT
198752591,Infliximab Pfizer (Unknown),C-reactive protein increased,HO
198752591,Infliximab Pfizer (Unknown),Asthenia,OT
198752591,Infliximab Pfizer (Unknown),Asthenia,HO
198786111,Infliximab (Unknown),Off label use,NULL
198850741,Infliximab (Unknown),Off label use,NULL
198850741,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198866101,Infliximab (Unknown),Off label use,NULL
198866101,Infliximab (Unknown),Off label use,NULL
198881881,Infliximab (Unknown),Off label use,NULL
198881881,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198912921,Infliximab,Drug ineffective for unapproved indication,DE
198912921,Infliximab,Death,DE
198962221,Infliximab,Somnolence,OT
198962221,Infliximab,Off label use,OT
198962221,Infliximab,Inappropriate schedule of product administration,OT
198962221,Infliximab,Condition aggravated,OT
199027031,Infliximab,Weight fluctuation,OT
199027031,Infliximab,Oxygen saturation decreased,OT
199027031,Infliximab,Off label use,OT
199027031,Infliximab,Intentional product use issue,OT
199027031,Infliximab,Hypertension,OT
199027031,Infliximab,Condition aggravated,OT
199027031,Infliximab,Arthralgia,OT
160716887,Infliximab,Rash,OT
160716887,Infliximab,Pruritus,OT
160716887,Infliximab,Product use issue,OT
160716887,Infliximab,Photosensitivity reaction,OT
160716887,Infliximab,Off label use,OT
160716887,Infliximab,Ocular hyperaemia,OT
160716887,Infliximab,Myalgia,OT
160716887,Infliximab,Muscle spasms,OT
160716887,Infliximab,Intentional product use issue,OT
160716887,Infliximab,Hot flush,OT
160716887,Infliximab,Eye pain,OT
160716887,Infliximab,Drug level decreased,OT
160716887,Infliximab,Condition aggravated,OT
160716887,Infliximab,Blood pressure diastolic decreased,OT
160716887,Infliximab,Blood pressure decreased,OT
160716887,Infliximab,Anal fistula,OT
160716887,Infliximab,Anal abscess,OT
160716887,Infliximab,Rash,OT
160716887,Infliximab,Pruritus,OT
160716887,Infliximab,Product use issue,OT
160716887,Infliximab,Photosensitivity reaction,OT
160716887,Infliximab,Off label use,OT
160716887,Infliximab,Ocular hyperaemia,OT
160716887,Infliximab,Myalgia,OT
160716887,Infliximab,Muscle spasms,OT
160716887,Infliximab,Intentional product use issue,OT
160716887,Infliximab,Hot flush,OT
160716887,Infliximab,Eye pain,OT
160716887,Infliximab,Drug level decreased,OT
160716887,Infliximab,Condition aggravated,OT
160716887,Infliximab,Blood pressure diastolic decreased,OT
160716887,Infliximab,Blood pressure decreased,OT
160716887,Infliximab,Anal fistula,OT
160716887,Infliximab,Anal abscess,OT
160716887,Infliximab,Rash,OT
160716887,Infliximab,Pruritus,OT
160716887,Infliximab,Product use issue,OT
160716887,Infliximab,Photosensitivity reaction,OT
160716887,Infliximab,Off label use,OT
160716887,Infliximab,Ocular hyperaemia,OT
160716887,Infliximab,Myalgia,OT
160716887,Infliximab,Muscle spasms,OT
160716887,Infliximab,Intentional product use issue,OT
160716887,Infliximab,Hot flush,OT
160716887,Infliximab,Eye pain,OT
160716887,Infliximab,Drug level decreased,OT
160716887,Infliximab,Condition aggravated,OT
160716887,Infliximab,Blood pressure diastolic decreased,OT
160716887,Infliximab,Blood pressure decreased,OT
160716887,Infliximab,Anal fistula,OT
160716887,Infliximab,Anal abscess,OT
160716887,Infliximab,Rash,OT
160716887,Infliximab,Pruritus,OT
160716887,Infliximab,Product use issue,OT
160716887,Infliximab,Photosensitivity reaction,OT
160716887,Infliximab,Off label use,OT
160716887,Infliximab,Ocular hyperaemia,OT
160716887,Infliximab,Myalgia,OT
160716887,Infliximab,Muscle spasms,OT
160716887,Infliximab,Intentional product use issue,OT
160716887,Infliximab,Hot flush,OT
160716887,Infliximab,Eye pain,OT
160716887,Infliximab,Drug level decreased,OT
160716887,Infliximab,Condition aggravated,OT
160716887,Infliximab,Blood pressure diastolic decreased,OT
160716887,Infliximab,Blood pressure decreased,OT
160716887,Infliximab,Anal fistula,OT
160716887,Infliximab,Anal abscess,OT
160716887,Infliximab,Rash,OT
160716887,Infliximab,Pruritus,OT
160716887,Infliximab,Product use issue,OT
160716887,Infliximab,Photosensitivity reaction,OT
160716887,Infliximab,Off label use,OT
160716887,Infliximab,Ocular hyperaemia,OT
160716887,Infliximab,Myalgia,OT
160716887,Infliximab,Muscle spasms,OT
160716887,Infliximab,Intentional product use issue,OT
160716887,Infliximab,Hot flush,OT
160716887,Infliximab,Eye pain,OT
160716887,Infliximab,Drug level decreased,OT
160716887,Infliximab,Condition aggravated,OT
160716887,Infliximab,Blood pressure diastolic decreased,OT
160716887,Infliximab,Blood pressure decreased,OT
160716887,Infliximab,Anal fistula,OT
160716887,Infliximab,Anal abscess,OT
160798965,Infliximab,Vomiting,OT
160798965,Infliximab,Syncope,OT
160798965,Infliximab,Rash,OT
160798965,Infliximab,Product use issue,OT
160798965,Infliximab,Off label use,OT
160798965,Infliximab,Nausea,OT
160798965,Infliximab,Mycobacterium tuberculosis complex test positive,OT
160798965,Infliximab,Lethargy,OT
160798965,Infliximab,Hypoaesthesia,OT
160798965,Infliximab,Headache,OT
160798965,Infliximab,Haemorrhoids,OT
160798965,Infliximab,Gallbladder disorder,OT
160798965,Infliximab,Fall,OT
160798965,Infliximab,Eczema,OT
160798965,Infliximab,Dizziness,OT
160798965,Infliximab,Diarrhoea,OT
160798965,Infliximab,Bronchitis,OT
160798965,Infliximab,Blood pressure systolic increased,OT
160798965,Infliximab,Blood pressure fluctuation,OT
160798965,Infliximab,Back pain,OT
160798965,Infliximab,Arthralgia,OT
160798965,Infliximab,Abdominal pain upper,OT
160798985,Infliximab,Weight decreased,HO
160798985,Infliximab,Weight decreased,OT
160798985,Infliximab,Uveitis,HO
160798985,Infliximab,Uveitis,OT
160798985,Infliximab,Thrombosis,HO
160798985,Infliximab,Thrombosis,OT
160798985,Infliximab,Red blood cell morphology abnormal,HO
160798985,Infliximab,Red blood cell morphology abnormal,OT
160798985,Infliximab,Product use issue,HO
160798985,Infliximab,Product use issue,OT
160798985,Infliximab,Pneumonia,HO
160798985,Infliximab,Pneumonia,OT
160798985,Infliximab,Pain in extremity,HO
160798985,Infliximab,Pain in extremity,OT
160798985,Infliximab,Off label use,HO
160798985,Infliximab,Off label use,OT
160798985,Infliximab,Nephritis,HO
160798985,Infliximab,Nephritis,OT
160798985,Infliximab,Intentional product use issue,HO
160798985,Infliximab,Intentional product use issue,OT
160798985,Infliximab,Inappropriate schedule of product administration,HO
160798985,Infliximab,Inappropriate schedule of product administration,OT
160798985,Infliximab,Heart rate decreased,HO
160798985,Infliximab,Heart rate decreased,OT
160798985,Infliximab,Fatigue,HO
160798985,Infliximab,Fatigue,OT
160798985,Infliximab,Drug ineffective,HO
160798985,Infliximab,Drug ineffective,OT
160798985,Infliximab,Condition aggravated,HO
160798985,Infliximab,Condition aggravated,OT
160798985,Infliximab,Blood pressure fluctuation,HO
160798985,Infliximab,Blood pressure fluctuation,OT
160798985,Infliximab,Blood pressure diastolic decreased,HO
160798985,Infliximab,Blood pressure diastolic decreased,OT
160798985,Infliximab,Arterial occlusive disease,HO
160798985,Infliximab,Arterial occlusive disease,OT
160798985,Infliximab,Weight decreased,HO
160798985,Infliximab,Weight decreased,OT
160798985,Infliximab,Uveitis,HO
160798985,Infliximab,Uveitis,OT
160798985,Infliximab,Thrombosis,HO
160798985,Infliximab,Thrombosis,OT
160798985,Infliximab,Red blood cell morphology abnormal,HO
160798985,Infliximab,Red blood cell morphology abnormal,OT
160798985,Infliximab,Product use issue,HO
160798985,Infliximab,Product use issue,OT
160798985,Infliximab,Pneumonia,HO
160798985,Infliximab,Pneumonia,OT
160798985,Infliximab,Pain in extremity,HO
160798985,Infliximab,Pain in extremity,OT
160798985,Infliximab,Off label use,HO
160798985,Infliximab,Off label use,OT
160798985,Infliximab,Nephritis,HO
160798985,Infliximab,Nephritis,OT
160798985,Infliximab,Intentional product use issue,HO
160798985,Infliximab,Intentional product use issue,OT
160798985,Infliximab,Inappropriate schedule of product administration,HO
160798985,Infliximab,Inappropriate schedule of product administration,OT
160798985,Infliximab,Heart rate decreased,HO
160798985,Infliximab,Heart rate decreased,OT
160798985,Infliximab,Fatigue,HO
160798985,Infliximab,Fatigue,OT
160798985,Infliximab,Drug ineffective,HO
160798985,Infliximab,Drug ineffective,OT
160798985,Infliximab,Condition aggravated,HO
160798985,Infliximab,Condition aggravated,OT
160798985,Infliximab,Blood pressure fluctuation,HO
160798985,Infliximab,Blood pressure fluctuation,OT
160798985,Infliximab,Blood pressure diastolic decreased,HO
160798985,Infliximab,Blood pressure diastolic decreased,OT
160798985,Infliximab,Arterial occlusive disease,HO
160798985,Infliximab,Arterial occlusive disease,OT
160798985,Infliximab,Weight decreased,HO
160798985,Infliximab,Weight decreased,OT
160798985,Infliximab,Uveitis,HO
160798985,Infliximab,Uveitis,OT
160798985,Infliximab,Thrombosis,HO
160798985,Infliximab,Thrombosis,OT
160798985,Infliximab,Red blood cell morphology abnormal,HO
160798985,Infliximab,Red blood cell morphology abnormal,OT
160798985,Infliximab,Product use issue,HO
160798985,Infliximab,Product use issue,OT
160798985,Infliximab,Pneumonia,HO
160798985,Infliximab,Pneumonia,OT
160798985,Infliximab,Pain in extremity,HO
160798985,Infliximab,Pain in extremity,OT
160798985,Infliximab,Off label use,HO
160798985,Infliximab,Off label use,OT
160798985,Infliximab,Nephritis,HO
160798985,Infliximab,Nephritis,OT
160798985,Infliximab,Intentional product use issue,HO
160798985,Infliximab,Intentional product use issue,OT
160798985,Infliximab,Inappropriate schedule of product administration,HO
160798985,Infliximab,Inappropriate schedule of product administration,OT
160798985,Infliximab,Heart rate decreased,HO
160798985,Infliximab,Heart rate decreased,OT
160798985,Infliximab,Fatigue,HO
160798985,Infliximab,Fatigue,OT
160798985,Infliximab,Drug ineffective,HO
160798985,Infliximab,Drug ineffective,OT
160798985,Infliximab,Condition aggravated,HO
160798985,Infliximab,Condition aggravated,OT
160798985,Infliximab,Blood pressure fluctuation,HO
160798985,Infliximab,Blood pressure fluctuation,OT
160798985,Infliximab,Blood pressure diastolic decreased,HO
160798985,Infliximab,Blood pressure diastolic decreased,OT
160798985,Infliximab,Arterial occlusive disease,HO
160798985,Infliximab,Arterial occlusive disease,OT
166826914,Infliximab,Weight increased,OT
166826914,Infliximab,Urticaria,OT
166826914,Infliximab,Therapeutic product effect incomplete,OT
166826914,Infliximab,Product use issue,OT
166826914,Infliximab,Pneumonia,OT
166826914,Infliximab,Off label use,OT
166826914,Infliximab,Nasopharyngitis,OT
166826914,Infliximab,Malaise,OT
166826914,Infliximab,Intentional product use issue,OT
166826914,Infliximab,Inappropriate schedule of product administration,OT
166826914,Infliximab,Heart rate irregular,OT
166826914,Infliximab,Drug level below therapeutic,OT
166826914,Infliximab,Drug ineffective,OT
166826914,Infliximab,Blood pressure decreased,OT
166826914,Infliximab,Anal fistula,OT
166843713,Infliximab,Weight increased,OT
166843713,Infliximab,Therapeutic response shortened,OT
166843713,Infliximab,Respiratory tract infection,OT
166843713,Infliximab,Productive cough,OT
166843713,Infliximab,Product use issue,OT
166843713,Infliximab,Pneumonia,OT
166843713,Infliximab,Off label use,OT
166843713,Infliximab,Malaise,OT
166843713,Infliximab,Lower respiratory tract infection,OT
166843713,Infliximab,Limb injury,OT
166843713,Infliximab,Induration,OT
166843713,Infliximab,Incorrect dose administered,OT
166843713,Infliximab,Inappropriate schedule of product administration,OT
166843713,Infliximab,Erythema,OT
166843713,Infliximab,Body temperature fluctuation,OT
166843713,Infliximab,Blood pressure fluctuation,OT
166916755,Infliximab,Pyrexia,OT
166916755,Infliximab,Product use issue,OT
166916755,Infliximab,Oropharyngeal pain,OT
166916755,Infliximab,Off label use,OT
166916755,Infliximab,Nasopharyngitis,OT
166916755,Infliximab,Nasal congestion,OT
166916755,Infliximab,Lower respiratory tract infection,OT
166916755,Infliximab,Influenza,OT
166916755,Infliximab,Incorrect dose administered,OT
166916755,Infliximab,Inappropriate schedule of product administration,OT
166916755,Infliximab,Heart rate irregular,OT
166916755,Infliximab,Heart rate decreased,OT
166916755,Infliximab,Headache,OT
166916755,Infliximab,Drug level decreased,OT
166916755,Infliximab,Cough,OT
166916755,Infliximab,Condition aggravated,OT
166916755,Infliximab,Chills,OT
166916755,Infliximab,Blood pressure diastolic decreased,OT
166916755,Infliximab,Pyrexia,OT
166916755,Infliximab,Product use issue,OT
166916755,Infliximab,Oropharyngeal pain,OT
166916755,Infliximab,Off label use,OT
166916755,Infliximab,Nasopharyngitis,OT
166916755,Infliximab,Nasal congestion,OT
166916755,Infliximab,Lower respiratory tract infection,OT
166916755,Infliximab,Influenza,OT
166916755,Infliximab,Incorrect dose administered,OT
166916755,Infliximab,Inappropriate schedule of product administration,OT
166916755,Infliximab,Heart rate irregular,OT
166916755,Infliximab,Heart rate decreased,OT
166916755,Infliximab,Headache,OT
166916755,Infliximab,Drug level decreased,OT
166916755,Infliximab,Cough,OT
166916755,Infliximab,Condition aggravated,OT
166916755,Infliximab,Chills,OT
166916755,Infliximab,Blood pressure diastolic decreased,OT
168259103,Infliximab,Weight decreased,OT
168259103,Infliximab,Suspected COVID-19,OT
168259103,Infliximab,Pseudopolyposis,OT
168259103,Infliximab,Polyp,OT
168259103,Infliximab,Off label use,OT
168259103,Infliximab,Intestinal mass,OT
168259103,Infliximab,Intentional dose omission,OT
168259103,Infliximab,Inappropriate schedule of product administration,OT
168259103,Infliximab,Heart rate decreased,OT
168259103,Infliximab,Haematochezia,OT
168259103,Infliximab,Fatigue,OT
168259103,Infliximab,Drug specific antibody present,OT
168259103,Infliximab,Drug level below therapeutic,OT
168259103,Infliximab,Drug ineffective,OT
168259103,Infliximab,Decreased appetite,OT
168259103,Infliximab,Blood pressure increased,OT
168259103,Infliximab,Blood pressure fluctuation,OT
168259103,Infliximab,Abdominal pain,OT
168259103,Infliximab,Weight decreased,OT
168259103,Infliximab,Suspected COVID-19,OT
168259103,Infliximab,Pseudopolyposis,OT
168259103,Infliximab,Polyp,OT
168259103,Infliximab,Off label use,OT
168259103,Infliximab,Intestinal mass,OT
168259103,Infliximab,Intentional dose omission,OT
168259103,Infliximab,Inappropriate schedule of product administration,OT
168259103,Infliximab,Heart rate decreased,OT
168259103,Infliximab,Haematochezia,OT
168259103,Infliximab,Fatigue,OT
168259103,Infliximab,Drug specific antibody present,OT
168259103,Infliximab,Drug level below therapeutic,OT
168259103,Infliximab,Drug ineffective,OT
168259103,Infliximab,Decreased appetite,OT
168259103,Infliximab,Blood pressure increased,OT
168259103,Infliximab,Blood pressure fluctuation,OT
168259103,Infliximab,Abdominal pain,OT
168386404,Infliximab,Onychomycosis,DS
168386404,Infliximab,Onychomycosis,HO
168386404,Infliximab,Onychomycosis,OT
168386404,Infliximab,Onychomadesis,DS
168386404,Infliximab,Onychomadesis,HO
168386404,Infliximab,Onychomadesis,OT
168386404,Infliximab,Off label use,DS
168386404,Infliximab,Off label use,HO
168386404,Infliximab,Off label use,OT
168386404,Infliximab,Nail disorder,DS
168386404,Infliximab,Nail disorder,HO
168386404,Infliximab,Nail disorder,OT
168386404,Infliximab,Musculoskeletal stiffness,DS
168386404,Infliximab,Musculoskeletal stiffness,HO
168386404,Infliximab,Musculoskeletal stiffness,OT
168386404,Infliximab,Movement disorder,DS
168386404,Infliximab,Movement disorder,HO
168386404,Infliximab,Movement disorder,OT
168386404,Infliximab,Loss of personal independence in daily activities,DS
168386404,Infliximab,Loss of personal independence in daily activities,HO
168386404,Infliximab,Loss of personal independence in daily activities,OT
168386404,Infliximab,Joint swelling,DS
168386404,Infliximab,Joint swelling,HO
168386404,Infliximab,Joint swelling,OT
168386404,Infliximab,Injection site reaction,DS
168386404,Infliximab,Injection site reaction,HO
168386404,Infliximab,Injection site reaction,OT
168386404,Infliximab,Headache,DS
168386404,Infliximab,Headache,HO
168386404,Infliximab,Headache,OT
168386404,Infliximab,Grip strength decreased,DS
168386404,Infliximab,Grip strength decreased,HO
168386404,Infliximab,Grip strength decreased,OT
168386404,Infliximab,Gait disturbance,DS
168386404,Infliximab,Gait disturbance,HO
168386404,Infliximab,Gait disturbance,OT
168386404,Infliximab,Fatigue,DS
168386404,Infliximab,Fatigue,HO
168386404,Infliximab,Fatigue,OT
168386404,Infliximab,Drug ineffective,DS
168386404,Infliximab,Drug ineffective,HO
168386404,Infliximab,Drug ineffective,OT
168386404,Infliximab,Contraindicated product administered,DS
168386404,Infliximab,Contraindicated product administered,HO
168386404,Infliximab,Contraindicated product administered,OT
168386404,Infliximab,Coeliac disease,DS
168386404,Infliximab,Coeliac disease,HO
168386404,Infliximab,Coeliac disease,OT
168386404,Infliximab,Arthropathy,DS
168386404,Infliximab,Arthropathy,HO
168386404,Infliximab,Arthropathy,OT
168386404,Infliximab,Arthralgia,DS
168386404,Infliximab,Arthralgia,HO
168386404,Infliximab,Arthralgia,OT
168386404,Infliximab,Abdominal discomfort,DS
168386404,Infliximab,Abdominal discomfort,HO
168386404,Infliximab,Abdominal discomfort,OT
174222143,Infliximab,Urticaria,OT
174222143,Infliximab,Rash,OT
174222143,Infliximab,Pruritus,OT
174222143,Infliximab,Product use issue,OT
174222143,Infliximab,Off label use,OT
174222143,Infliximab,Infusion related reaction,OT
174222143,Infliximab,Inappropriate schedule of product administration,OT
174222143,Infliximab,Heart rate decreased,OT
174222143,Infliximab,Condition aggravated,OT
174222143,Infliximab,Blood pressure increased,OT
174222143,Infliximab,Blood pressure diastolic increased,OT
174222143,Infliximab,Urticaria,OT
174222143,Infliximab,Rash,OT
174222143,Infliximab,Pruritus,OT
174222143,Infliximab,Product use issue,OT
174222143,Infliximab,Off label use,OT
174222143,Infliximab,Infusion related reaction,OT
174222143,Infliximab,Inappropriate schedule of product administration,OT
174222143,Infliximab,Heart rate decreased,OT
174222143,Infliximab,Condition aggravated,OT
174222143,Infliximab,Blood pressure increased,OT
174222143,Infliximab,Blood pressure diastolic increased,OT
174957133,Infliximab,Weight decreased,OT
174957133,Infliximab,Off label use,OT
174957133,Infliximab,Iron deficiency anaemia,OT
174957133,Infliximab,Gastrointestinal ulcer,OT
174957133,Infliximab,Faecal calprotectin increased,OT
174957133,Infliximab,Drug level increased,OT
174957133,Infliximab,Drug level decreased,OT
174957133,Infliximab,Drug level above therapeutic,OT
174957133,Infliximab,Dehydration,OT
174957133,Infliximab,Condition aggravated,OT
174957133,Infliximab,Blood pressure diastolic decreased,OT
174957133,Infliximab,Arthralgia,OT
174957133,Infliximab,Weight decreased,OT
174957133,Infliximab,Off label use,OT
174957133,Infliximab,Iron deficiency anaemia,OT
174957133,Infliximab,Gastrointestinal ulcer,OT
174957133,Infliximab,Faecal calprotectin increased,OT
174957133,Infliximab,Drug level increased,OT
174957133,Infliximab,Drug level decreased,OT
174957133,Infliximab,Drug level above therapeutic,OT
174957133,Infliximab,Dehydration,OT
174957133,Infliximab,Condition aggravated,OT
174957133,Infliximab,Blood pressure diastolic decreased,OT
174957133,Infliximab,Arthralgia,OT
174957133,Infliximab,Weight decreased,OT
174957133,Infliximab,Off label use,OT
174957133,Infliximab,Iron deficiency anaemia,OT
174957133,Infliximab,Gastrointestinal ulcer,OT
174957133,Infliximab,Faecal calprotectin increased,OT
174957133,Infliximab,Drug level increased,OT
174957133,Infliximab,Drug level decreased,OT
174957133,Infliximab,Drug level above therapeutic,OT
174957133,Infliximab,Dehydration,OT
174957133,Infliximab,Condition aggravated,OT
174957133,Infliximab,Blood pressure diastolic decreased,OT
174957133,Infliximab,Arthralgia,OT
174957133,Infliximab,Weight decreased,OT
174957133,Infliximab,Off label use,OT
174957133,Infliximab,Iron deficiency anaemia,OT
174957133,Infliximab,Gastrointestinal ulcer,OT
174957133,Infliximab,Faecal calprotectin increased,OT
174957133,Infliximab,Drug level increased,OT
174957133,Infliximab,Drug level decreased,OT
174957133,Infliximab,Drug level above therapeutic,OT
174957133,Infliximab,Dehydration,OT
174957133,Infliximab,Condition aggravated,OT
174957133,Infliximab,Blood pressure diastolic decreased,OT
174957133,Infliximab,Arthralgia,OT
175262083,Infliximab,Treatment failure,OT
175262083,Infliximab,Tooth infection,OT
175262083,Infliximab,Red blood cell count decreased,OT
175262083,Infliximab,Pseudopolyp,OT
175262083,Infliximab,Off label use,OT
175262083,Infliximab,Mean cell volume increased,OT
175262083,Infliximab,Mean cell haemoglobin concentration increased,OT
175262083,Infliximab,Inappropriate schedule of product administration,OT
175262083,Infliximab,Heart rate irregular,OT
175262083,Infliximab,Heart rate decreased,OT
175262083,Infliximab,Drug specific antibody present,OT
175262083,Infliximab,Drug level above therapeutic,OT
175262083,Infliximab,Drug ineffective,OT
175262083,Infliximab,Condition aggravated,OT
175262083,Infliximab,Clostridium difficile infection,OT
175262083,Infliximab,Blood pressure systolic increased,OT
175262083,Infliximab,Blood pressure fluctuation,OT
175262083,Infliximab,Treatment failure,OT
175262083,Infliximab,Tooth infection,OT
175262083,Infliximab,Red blood cell count decreased,OT
175262083,Infliximab,Pseudopolyp,OT
175262083,Infliximab,Off label use,OT
175262083,Infliximab,Mean cell volume increased,OT
175262083,Infliximab,Mean cell haemoglobin concentration increased,OT
175262083,Infliximab,Inappropriate schedule of product administration,OT
175262083,Infliximab,Heart rate irregular,OT
175262083,Infliximab,Heart rate decreased,OT
175262083,Infliximab,Drug specific antibody present,OT
175262083,Infliximab,Drug level above therapeutic,OT
175262083,Infliximab,Drug ineffective,OT
175262083,Infliximab,Condition aggravated,OT
175262083,Infliximab,Clostridium difficile infection,OT
175262083,Infliximab,Blood pressure systolic increased,OT
175262083,Infliximab,Blood pressure fluctuation,OT
175489145,Infliximab,Weight increased,OT
175489145,Infliximab,Pruritus,OT
175489145,Infliximab,Product use issue,OT
175489145,Infliximab,Off label use,OT
175489145,Infliximab,Intentional product use issue,OT
175489145,Infliximab,Inappropriate schedule of product administration,OT
175489145,Infliximab,Heart rate irregular,OT
175489145,Infliximab,Fatigue,OT
175489145,Infliximab,Condition aggravated,OT
175489145,Infliximab,Blood pressure increased,OT
175489145,Infliximab,Blood pressure fluctuation,OT
175489145,Infliximab,Arthralgia,OT
175489145,Infliximab,Acne,OT
175489145,Infliximab,Abscess limb,OT
175847373,Infliximab,Weight increased,OT
175847373,Infliximab,Product use issue,OT
175847373,Infliximab,Off label use,OT
175847373,Infliximab,Intentional product use issue,OT
175847373,Infliximab,Incorrect dose administered,OT
175847373,Infliximab,Inappropriate schedule of product administration,OT
175847373,Infliximab,Dyspepsia,OT
175847373,Infliximab,Blood pressure decreased,OT
175847373,Infliximab,Anal fissure,OT
175847373,Infliximab,Abdominal pain,OT
176169964,Infliximab,Weight decreased,HO
176169964,Infliximab,Weight decreased,OT
176169964,Infliximab,Stoma complication,HO
176169964,Infliximab,Stoma complication,OT
176169964,Infliximab,Procedural pain,HO
176169964,Infliximab,Procedural pain,OT
176169964,Infliximab,Peritonitis,HO
176169964,Infliximab,Peritonitis,OT
176169964,Infliximab,Off label use,HO
176169964,Infliximab,Off label use,OT
176169964,Infliximab,Muscle rupture,HO
176169964,Infliximab,Muscle rupture,OT
176169964,Infliximab,Joint swelling,HO
176169964,Infliximab,Joint swelling,OT
176169964,Infliximab,Intentional product use issue,HO
176169964,Infliximab,Intentional product use issue,OT
176169964,Infliximab,Inappropriate schedule of product administration,HO
176169964,Infliximab,Inappropriate schedule of product administration,OT
176169964,Infliximab,Hernia,HO
176169964,Infliximab,Hernia,OT
176169964,Infliximab,Cough,HO
176169964,Infliximab,Cough,OT
176169964,Infliximab,Arthralgia,HO
176169964,Infliximab,Arthralgia,OT
176169964,Infliximab,Abdominal pain,HO
176169964,Infliximab,Abdominal pain,OT
176169964,Infliximab,Weight decreased,HO
176169964,Infliximab,Weight decreased,OT
176169964,Infliximab,Stoma complication,HO
176169964,Infliximab,Stoma complication,OT
176169964,Infliximab,Procedural pain,HO
176169964,Infliximab,Procedural pain,OT
176169964,Infliximab,Peritonitis,HO
176169964,Infliximab,Peritonitis,OT
176169964,Infliximab,Off label use,HO
176169964,Infliximab,Off label use,OT
176169964,Infliximab,Muscle rupture,HO
176169964,Infliximab,Muscle rupture,OT
176169964,Infliximab,Joint swelling,HO
176169964,Infliximab,Joint swelling,OT
176169964,Infliximab,Intentional product use issue,HO
176169964,Infliximab,Intentional product use issue,OT
176169964,Infliximab,Inappropriate schedule of product administration,HO
176169964,Infliximab,Inappropriate schedule of product administration,OT
176169964,Infliximab,Hernia,HO
176169964,Infliximab,Hernia,OT
176169964,Infliximab,Cough,HO
176169964,Infliximab,Cough,OT
176169964,Infliximab,Arthralgia,HO
176169964,Infliximab,Arthralgia,OT
176169964,Infliximab,Abdominal pain,HO
176169964,Infliximab,Abdominal pain,OT
176392885,Infliximab,Rectal haemorrhage,OT
176392885,Infliximab,Product use issue,OT
176392885,Infliximab,Off label use,OT
176392885,Infliximab,Nasopharyngitis,OT
176392885,Infliximab,Nasal congestion,OT
176392885,Infliximab,Intentional product use issue,OT
176392885,Infliximab,Inappropriate schedule of product administration,OT
176392885,Infliximab,Drug level below therapeutic,OT
176392885,Infliximab,Condition aggravated,OT
176392885,Infliximab,Blood pressure increased,OT
176392885,Infliximab,Blood pressure fluctuation,OT
176392885,Infliximab,Rectal haemorrhage,OT
176392885,Infliximab,Product use issue,OT
176392885,Infliximab,Off label use,OT
176392885,Infliximab,Nasopharyngitis,OT
176392885,Infliximab,Nasal congestion,OT
176392885,Infliximab,Intentional product use issue,OT
176392885,Infliximab,Inappropriate schedule of product administration,OT
176392885,Infliximab,Drug level below therapeutic,OT
176392885,Infliximab,Condition aggravated,OT
176392885,Infliximab,Blood pressure increased,OT
176392885,Infliximab,Blood pressure fluctuation,OT
178255874,Infliximab,Weight increased,OT
178255874,Infliximab,Weight increased,HO
178255874,Infliximab,Weight decreased,OT
178255874,Infliximab,Weight decreased,HO
178255874,Infliximab,Skin lesion,OT
178255874,Infliximab,Skin lesion,HO
178255874,Infliximab,Polyp,OT
178255874,Infliximab,Polyp,HO
178255874,Infliximab,Photophobia,OT
178255874,Infliximab,Photophobia,HO
178255874,Infliximab,Pain in extremity,OT
178255874,Infliximab,Pain in extremity,HO
178255874,Infliximab,Pain,OT
178255874,Infliximab,Pain,HO
178255874,Infliximab,Oxygen saturation decreased,OT
178255874,Infliximab,Oxygen saturation decreased,HO
178255874,Infliximab,Off label use,OT
178255874,Infliximab,Off label use,HO
178255874,Infliximab,Neck pain,OT
178255874,Infliximab,Neck pain,HO
178255874,Infliximab,Mobility decreased,OT
178255874,Infliximab,Mobility decreased,HO
178255874,Infliximab,Memory impairment,OT
178255874,Infliximab,Memory impairment,HO
178255874,Infliximab,Large intestine perforation,OT
178255874,Infliximab,Large intestine perforation,HO
178255874,Infliximab,Intentional product use issue,OT
178255874,Infliximab,Intentional product use issue,HO
178255874,Infliximab,Incorrect dose administered,OT
178255874,Infliximab,Incorrect dose administered,HO
178255874,Infliximab,Hypotension,OT
178255874,Infliximab,Hypotension,HO
178255874,Infliximab,Head injury,OT
178255874,Infliximab,Head injury,HO
178255874,Infliximab,Gait disturbance,OT
178255874,Infliximab,Gait disturbance,HO
178255874,Infliximab,Fall,OT
178255874,Infliximab,Fall,HO
178255874,Infliximab,Drug level increased,OT
178255874,Infliximab,Drug level increased,HO
178255874,Infliximab,Crohn's disease,OT
178255874,Infliximab,Crohn's disease,HO
178255874,Infliximab,Confusional state,OT
178255874,Infliximab,Confusional state,HO
178255874,Infliximab,Condition aggravated,OT
178255874,Infliximab,Condition aggravated,HO
178255874,Infliximab,Cervical vertebral fracture,OT
178255874,Infliximab,Cervical vertebral fracture,HO
178255874,Infliximab,Catheter site inflammation,OT
178255874,Infliximab,Catheter site inflammation,HO
178255874,Infliximab,Catheter site erythema,OT
178255874,Infliximab,Catheter site erythema,HO
178255874,Infliximab,Cataract,OT
178255874,Infliximab,Cataract,HO
178255874,Infliximab,Blood pressure systolic increased,OT
178255874,Infliximab,Blood pressure systolic increased,HO
178255874,Infliximab,Blood pressure fluctuation,OT
178255874,Infliximab,Blood pressure fluctuation,HO
178255874,Infliximab,Atelectasis,OT
178255874,Infliximab,Atelectasis,HO
178255874,Infliximab,Arthralgia,OT
178255874,Infliximab,Arthralgia,HO
178255874,Infliximab,Arrhythmia,OT
178255874,Infliximab,Arrhythmia,HO
178255874,Infliximab,Weight increased,OT
178255874,Infliximab,Weight increased,HO
178255874,Infliximab,Weight decreased,OT
178255874,Infliximab,Weight decreased,HO
178255874,Infliximab,Skin lesion,OT
178255874,Infliximab,Skin lesion,HO
178255874,Infliximab,Polyp,OT
178255874,Infliximab,Polyp,HO
178255874,Infliximab,Photophobia,OT
178255874,Infliximab,Photophobia,HO
178255874,Infliximab,Pain in extremity,OT
178255874,Infliximab,Pain in extremity,HO
178255874,Infliximab,Pain,OT
178255874,Infliximab,Pain,HO
178255874,Infliximab,Oxygen saturation decreased,OT
178255874,Infliximab,Oxygen saturation decreased,HO
178255874,Infliximab,Off label use,OT
178255874,Infliximab,Off label use,HO
178255874,Infliximab,Neck pain,OT
178255874,Infliximab,Neck pain,HO
178255874,Infliximab,Mobility decreased,OT
178255874,Infliximab,Mobility decreased,HO
178255874,Infliximab,Memory impairment,OT
178255874,Infliximab,Memory impairment,HO
178255874,Infliximab,Large intestine perforation,OT
178255874,Infliximab,Large intestine perforation,HO
178255874,Infliximab,Intentional product use issue,OT
178255874,Infliximab,Intentional product use issue,HO
178255874,Infliximab,Incorrect dose administered,OT
178255874,Infliximab,Incorrect dose administered,HO
178255874,Infliximab,Hypotension,OT
178255874,Infliximab,Hypotension,HO
178255874,Infliximab,Head injury,OT
178255874,Infliximab,Head injury,HO
178255874,Infliximab,Gait disturbance,OT
178255874,Infliximab,Gait disturbance,HO
178255874,Infliximab,Fall,OT
178255874,Infliximab,Fall,HO
178255874,Infliximab,Drug level increased,OT
178255874,Infliximab,Drug level increased,HO
178255874,Infliximab,Crohn's disease,OT
178255874,Infliximab,Crohn's disease,HO
178255874,Infliximab,Confusional state,OT
178255874,Infliximab,Confusional state,HO
178255874,Infliximab,Condition aggravated,OT
178255874,Infliximab,Condition aggravated,HO
178255874,Infliximab,Cervical vertebral fracture,OT
178255874,Infliximab,Cervical vertebral fracture,HO
178255874,Infliximab,Catheter site inflammation,OT
178255874,Infliximab,Catheter site inflammation,HO
178255874,Infliximab,Catheter site erythema,OT
178255874,Infliximab,Catheter site erythema,HO
178255874,Infliximab,Cataract,OT
178255874,Infliximab,Cataract,HO
178255874,Infliximab,Blood pressure systolic increased,OT
178255874,Infliximab,Blood pressure systolic increased,HO
178255874,Infliximab,Blood pressure fluctuation,OT
178255874,Infliximab,Blood pressure fluctuation,HO
178255874,Infliximab,Atelectasis,OT
178255874,Infliximab,Atelectasis,HO
178255874,Infliximab,Arthralgia,OT
178255874,Infliximab,Arthralgia,HO
178255874,Infliximab,Arrhythmia,OT
178255874,Infliximab,Arrhythmia,HO
178516273,Infliximab,Weight increased,OT
178516273,Infliximab,Therapeutic product effect incomplete,OT
178516273,Infliximab,Rectal haemorrhage,OT
178516273,Infliximab,Proctalgia,OT
178516273,Infliximab,Off label use,OT
178516273,Infliximab,Intentional product use issue,OT
178516273,Infliximab,Fistula discharge,OT
178516273,Infliximab,Enterocutaneous fistula,OT
178516273,Infliximab,Condition aggravated,OT
178516273,Infliximab,Blood pressure diastolic decreased,OT
178516273,Infliximab,Arthralgia,OT
178516273,Infliximab,Anal fistula,OT
178516273,Infliximab,Abortion spontaneous,OT
184329743,Infliximab,Respiratory rate increased,HO
184329743,Infliximab,Respiratory rate increased,OT
184329743,Infliximab,Off label use,HO
184329743,Infliximab,Off label use,OT
184329743,Infliximab,Inappropriate schedule of product administration,HO
184329743,Infliximab,Inappropriate schedule of product administration,OT
184329743,Infliximab,Illness,HO
184329743,Infliximab,Illness,OT
184329743,Infliximab,Heart rate decreased,HO
184329743,Infliximab,Heart rate decreased,OT
184329743,Infliximab,Dyspnoea,HO
184329743,Infliximab,Dyspnoea,OT
184329743,Infliximab,Blood pressure fluctuation,HO
184329743,Infliximab,Blood pressure fluctuation,OT
184329743,Infliximab,Asthenia,HO
184329743,Infliximab,Asthenia,OT
184329743,Infliximab,Respiratory rate increased,HO
184329743,Infliximab,Respiratory rate increased,OT
184329743,Infliximab,Off label use,HO
184329743,Infliximab,Off label use,OT
184329743,Infliximab,Inappropriate schedule of product administration,HO
184329743,Infliximab,Inappropriate schedule of product administration,OT
184329743,Infliximab,Illness,HO
184329743,Infliximab,Illness,OT
184329743,Infliximab,Heart rate decreased,HO
184329743,Infliximab,Heart rate decreased,OT
184329743,Infliximab,Dyspnoea,HO
184329743,Infliximab,Dyspnoea,OT
184329743,Infliximab,Blood pressure fluctuation,HO
184329743,Infliximab,Blood pressure fluctuation,OT
184329743,Infliximab,Asthenia,HO
184329743,Infliximab,Asthenia,OT
185202913,Infliximab,Off label use,OT
185202913,Infliximab,Intentional product use issue,OT
185202913,Infliximab,Incorrect dose administered,OT
185202913,Infliximab,Hypotension,OT
185202913,Infliximab,Fistula,OT
185202913,Infliximab,Drug level decreased,OT
185202913,Infliximab,Drug level below therapeutic,OT
185202913,Infliximab,Diarrhoea haemorrhagic,OT
185202913,Infliximab,Condition aggravated,OT
185202913,Infliximab,Body temperature decreased,OT
185202913,Infliximab,Arthralgia,OT
185202913,Infliximab,Aphthous ulcer,OT
185550023,Infliximab,Pyoderma gangrenosum,OT
185550023,Infliximab,Off label use,OT
185550023,Infliximab,Intentional product use issue,OT
185550023,Infliximab,Inappropriate schedule of product administration,OT
192448814,Infliximab,Iron deficiency anaemia,OT
192448814,Infliximab,Iron deficiency anaemia,HO
192448814,Infliximab,Ileus,OT
192448814,Infliximab,Ileus,HO
192980474,Infliximab (Unknown),Subcutaneous abscess,HO
192980474,Infliximab (Unknown),Iron deficiency,HO
192980474,Infliximab (Unknown),Abscess limb,HO
192980474,Infliximab (Unknown),Subcutaneous abscess,HO
192980474,Infliximab (Unknown),Iron deficiency,HO
192980474,Infliximab (Unknown),Abscess limb,HO
193944852,Infliximab,Wrong technique in product usage process,OT
193944852,Infliximab,Weight increased,OT
193944852,Infliximab,Off label use,OT
193944852,Infliximab,Intestinal obstruction,OT
193944852,Infliximab,Intentional product use issue,OT
193944852,Infliximab,Incorrect dose administered,OT
193944852,Infliximab,Faecal calprotectin increased,OT
193944852,Infliximab,Drug level decreased,OT
193944852,Infliximab,Blood pressure increased,OT
193944852,Infliximab,Blood pressure fluctuation,OT
194543982,Infliximab,Premature labour,OT
194543982,Infliximab,Premature baby,OT
194543982,Infliximab,Off label use,OT
194543982,Infliximab,Maternal exposure during pregnancy,OT
194543982,Infliximab,Gestational diabetes,OT
194543982,Infliximab,Foetal exposure during pregnancy,OT
194543982,Infliximab,Premature labour,OT
194543982,Infliximab,Premature baby,OT
194543982,Infliximab,Off label use,OT
194543982,Infliximab,Maternal exposure during pregnancy,OT
194543982,Infliximab,Gestational diabetes,OT
194543982,Infliximab,Foetal exposure during pregnancy,OT
195706111,Infliximab,Takayasu's arteritis,OT
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Pyrexia,HO
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Pyrexia,OT
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Infection,HO
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Infection,OT
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Endocarditis,HO
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Endocarditis,OT
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Diabetic complication,HO
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Diabetic complication,OT
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Cerebral infarction,HO
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Cerebral infarction,OT
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Pyrexia,HO
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Pyrexia,OT
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Infection,HO
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Infection,OT
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Endocarditis,HO
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Endocarditis,OT
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Diabetic complication,HO
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Diabetic complication,OT
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Cerebral infarction,HO
195904041,Infliximab BS for I.V. Infusion100 mg [NK],Cerebral infarction,OT
195947311,Infliximab,Sinusitis,OT
195947311,Infliximab,Secretion discharge,OT
195947311,Infliximab,Seasonal allergy,OT
195947311,Infliximab,Pyrexia,OT
195947311,Infliximab,Pharyngitis streptococcal,OT
195947311,Infliximab,Peripheral swelling,OT
195947311,Infliximab,Nausea,OT
195947311,Infliximab,Nasal discharge discolouration,OT
195947311,Infliximab,Musculoskeletal chest pain,OT
195947311,Infliximab,Malaise,OT
195947311,Infliximab,Joint swelling,OT
195947311,Infliximab,Hypokinesia,OT
195947311,Infliximab,Hot flush,OT
195947311,Infliximab,Headache,OT
195947311,Infliximab,Gait inability,OT
195947311,Infliximab,Fatigue,OT
195947311,Infliximab,Erythema,OT
195947311,Infliximab,Dysstasia,OT
195947311,Infliximab,Decreased appetite,OT
195947311,Infliximab,Chest pain,OT
195947311,Infliximab,Back pain,OT
195947311,Infliximab,Arthralgia,OT
195947311,Infliximab,Abdominal pain upper,OT
196150451,Infliximab,Weight decreased,OT
196150451,Infliximab,Hypertension,OT
196820321,Infliximab,Drug level below therapeutic,HO
196820321,Infliximab,Drug level below therapeutic,OT
196820321,Infliximab,Drug ineffective,HO
196820321,Infliximab,Drug ineffective,OT
196820321,Infliximab,Colitis ulcerative,HO
196820321,Infliximab,Colitis ulcerative,OT
196820931,Infliximab,Off label use,HO
196820931,Infliximab,Off label use,OT
196820931,Infliximab,Myalgia,HO
196820931,Infliximab,Myalgia,OT
196820931,Infliximab,Mesenteritis,HO
196820931,Infliximab,Mesenteritis,OT
196820931,Infliximab,Intestinal obstruction,HO
196820931,Infliximab,Intestinal obstruction,OT
196820931,Infliximab,Head discomfort,HO
196820931,Infliximab,Head discomfort,OT
196820931,Infliximab,Feeling abnormal,HO
196820931,Infliximab,Feeling abnormal,OT
196820931,Infliximab,Erythema,HO
196820931,Infliximab,Erythema,OT
196820931,Infliximab,Chest pain,HO
196820931,Infliximab,Chest pain,OT
196820931,Infliximab,Blood pressure increased,HO
196820931,Infliximab,Blood pressure increased,OT
196820931,Infliximab,Arthralgia,HO
196820931,Infliximab,Arthralgia,OT
196820931,Infliximab,Abdominal adhesions,HO
196820931,Infliximab,Abdominal adhesions,OT
196943473,Infliximab (Unknown),Viral infection,DE
196943473,Infliximab (Unknown),Viral infection,HO
196943473,Infliximab (Unknown),Viral infection,OT
196943473,Infliximab (Unknown),Stomatitis,DE
196943473,Infliximab (Unknown),Stomatitis,HO
196943473,Infliximab (Unknown),Stomatitis,OT
196943473,Infliximab (Unknown),Rebound effect,DE
196943473,Infliximab (Unknown),Rebound effect,HO
196943473,Infliximab (Unknown),Rebound effect,OT
196943473,Infliximab (Unknown),Product use in unapproved indication,DE
196943473,Infliximab (Unknown),Product use in unapproved indication,HO
196943473,Infliximab (Unknown),Product use in unapproved indication,OT
196943473,Infliximab (Unknown),Oral fungal infection,DE
196943473,Infliximab (Unknown),Oral fungal infection,HO
196943473,Infliximab (Unknown),Oral fungal infection,OT
196943473,Infliximab (Unknown),Opportunistic infection,DE
196943473,Infliximab (Unknown),Opportunistic infection,HO
196943473,Infliximab (Unknown),Opportunistic infection,OT
196943473,Infliximab (Unknown),Off label use,DE
196943473,Infliximab (Unknown),Off label use,HO
196943473,Infliximab (Unknown),Off label use,OT
196943473,Infliximab (Unknown),Immune system disorder,DE
196943473,Infliximab (Unknown),Immune system disorder,HO
196943473,Infliximab (Unknown),Immune system disorder,OT
196943473,Infliximab (Unknown),Erysipelas,DE
196943473,Infliximab (Unknown),Erysipelas,HO
196943473,Infliximab (Unknown),Erysipelas,OT
196943473,Infliximab (Unknown),Dry eye,DE
196943473,Infliximab (Unknown),Dry eye,HO
196943473,Infliximab (Unknown),Dry eye,OT
196943473,Infliximab (Unknown),Dermatitis,DE
196943473,Infliximab (Unknown),Dermatitis,HO
196943473,Infliximab (Unknown),Dermatitis,OT
196943473,Infliximab (Unknown),Death,DE
196943473,Infliximab (Unknown),Death,HO
196943473,Infliximab (Unknown),Death,OT
196943473,Infliximab (Unknown),Bronchopulmonary aspergillosis,DE
196943473,Infliximab (Unknown),Bronchopulmonary aspergillosis,HO
196943473,Infliximab (Unknown),Bronchopulmonary aspergillosis,OT
196943473,Infliximab (Unknown),Bacteraemia,DE
196943473,Infliximab (Unknown),Bacteraemia,HO
196943473,Infliximab (Unknown),Bacteraemia,OT
196943473,Infliximab (Unknown),Viral infection,DE
196943473,Infliximab (Unknown),Viral infection,HO
196943473,Infliximab (Unknown),Viral infection,OT
196943473,Infliximab (Unknown),Stomatitis,DE
196943473,Infliximab (Unknown),Stomatitis,HO
196943473,Infliximab (Unknown),Stomatitis,OT
196943473,Infliximab (Unknown),Rebound effect,DE
196943473,Infliximab (Unknown),Rebound effect,HO
196943473,Infliximab (Unknown),Rebound effect,OT
196943473,Infliximab (Unknown),Product use in unapproved indication,DE
196943473,Infliximab (Unknown),Product use in unapproved indication,HO
196943473,Infliximab (Unknown),Product use in unapproved indication,OT
196943473,Infliximab (Unknown),Oral fungal infection,DE
196943473,Infliximab (Unknown),Oral fungal infection,HO
196943473,Infliximab (Unknown),Oral fungal infection,OT
196943473,Infliximab (Unknown),Opportunistic infection,DE
196943473,Infliximab (Unknown),Opportunistic infection,HO
196943473,Infliximab (Unknown),Opportunistic infection,OT
196943473,Infliximab (Unknown),Off label use,DE
196943473,Infliximab (Unknown),Off label use,HO
196943473,Infliximab (Unknown),Off label use,OT
196943473,Infliximab (Unknown),Immune system disorder,DE
196943473,Infliximab (Unknown),Immune system disorder,HO
196943473,Infliximab (Unknown),Immune system disorder,OT
196943473,Infliximab (Unknown),Erysipelas,DE
196943473,Infliximab (Unknown),Erysipelas,HO
196943473,Infliximab (Unknown),Erysipelas,OT
196943473,Infliximab (Unknown),Dry eye,DE
196943473,Infliximab (Unknown),Dry eye,HO
196943473,Infliximab (Unknown),Dry eye,OT
196943473,Infliximab (Unknown),Dermatitis,DE
196943473,Infliximab (Unknown),Dermatitis,HO
196943473,Infliximab (Unknown),Dermatitis,OT
196943473,Infliximab (Unknown),Death,DE
196943473,Infliximab (Unknown),Death,HO
196943473,Infliximab (Unknown),Death,OT
196943473,Infliximab (Unknown),Bronchopulmonary aspergillosis,DE
196943473,Infliximab (Unknown),Bronchopulmonary aspergillosis,HO
196943473,Infliximab (Unknown),Bronchopulmonary aspergillosis,OT
196943473,Infliximab (Unknown),Bacteraemia,DE
196943473,Infliximab (Unknown),Bacteraemia,HO
196943473,Infliximab (Unknown),Bacteraemia,OT
196943473,Infliximab (Unknown),Viral infection,DE
196943473,Infliximab (Unknown),Viral infection,HO
196943473,Infliximab (Unknown),Viral infection,OT
196943473,Infliximab (Unknown),Stomatitis,DE
196943473,Infliximab (Unknown),Stomatitis,HO
196943473,Infliximab (Unknown),Stomatitis,OT
196943473,Infliximab (Unknown),Rebound effect,DE
196943473,Infliximab (Unknown),Rebound effect,HO
196943473,Infliximab (Unknown),Rebound effect,OT
196943473,Infliximab (Unknown),Product use in unapproved indication,DE
196943473,Infliximab (Unknown),Product use in unapproved indication,HO
196943473,Infliximab (Unknown),Product use in unapproved indication,OT
196943473,Infliximab (Unknown),Oral fungal infection,DE
196943473,Infliximab (Unknown),Oral fungal infection,HO
196943473,Infliximab (Unknown),Oral fungal infection,OT
196943473,Infliximab (Unknown),Opportunistic infection,DE
196943473,Infliximab (Unknown),Opportunistic infection,HO
196943473,Infliximab (Unknown),Opportunistic infection,OT
196943473,Infliximab (Unknown),Off label use,DE
196943473,Infliximab (Unknown),Off label use,HO
196943473,Infliximab (Unknown),Off label use,OT
196943473,Infliximab (Unknown),Immune system disorder,DE
196943473,Infliximab (Unknown),Immune system disorder,HO
196943473,Infliximab (Unknown),Immune system disorder,OT
196943473,Infliximab (Unknown),Erysipelas,DE
196943473,Infliximab (Unknown),Erysipelas,HO
196943473,Infliximab (Unknown),Erysipelas,OT
196943473,Infliximab (Unknown),Dry eye,DE
196943473,Infliximab (Unknown),Dry eye,HO
196943473,Infliximab (Unknown),Dry eye,OT
196943473,Infliximab (Unknown),Dermatitis,DE
196943473,Infliximab (Unknown),Dermatitis,HO
196943473,Infliximab (Unknown),Dermatitis,OT
196943473,Infliximab (Unknown),Death,DE
196943473,Infliximab (Unknown),Death,HO
196943473,Infliximab (Unknown),Death,OT
196943473,Infliximab (Unknown),Bronchopulmonary aspergillosis,DE
196943473,Infliximab (Unknown),Bronchopulmonary aspergillosis,HO
196943473,Infliximab (Unknown),Bronchopulmonary aspergillosis,OT
196943473,Infliximab (Unknown),Bacteraemia,DE
196943473,Infliximab (Unknown),Bacteraemia,HO
196943473,Infliximab (Unknown),Bacteraemia,OT
196943473,Infliximab (Unknown),Viral infection,DE
196943473,Infliximab (Unknown),Viral infection,HO
196943473,Infliximab (Unknown),Viral infection,OT
196943473,Infliximab (Unknown),Stomatitis,DE
196943473,Infliximab (Unknown),Stomatitis,HO
196943473,Infliximab (Unknown),Stomatitis,OT
196943473,Infliximab (Unknown),Rebound effect,DE
196943473,Infliximab (Unknown),Rebound effect,HO
196943473,Infliximab (Unknown),Rebound effect,OT
196943473,Infliximab (Unknown),Product use in unapproved indication,DE
196943473,Infliximab (Unknown),Product use in unapproved indication,HO
196943473,Infliximab (Unknown),Product use in unapproved indication,OT
196943473,Infliximab (Unknown),Oral fungal infection,DE
196943473,Infliximab (Unknown),Oral fungal infection,HO
196943473,Infliximab (Unknown),Oral fungal infection,OT
196943473,Infliximab (Unknown),Opportunistic infection,DE
196943473,Infliximab (Unknown),Opportunistic infection,HO
196943473,Infliximab (Unknown),Opportunistic infection,OT
196943473,Infliximab (Unknown),Off label use,DE
196943473,Infliximab (Unknown),Off label use,HO
196943473,Infliximab (Unknown),Off label use,OT
196943473,Infliximab (Unknown),Immune system disorder,DE
196943473,Infliximab (Unknown),Immune system disorder,HO
196943473,Infliximab (Unknown),Immune system disorder,OT
196943473,Infliximab (Unknown),Erysipelas,DE
196943473,Infliximab (Unknown),Erysipelas,HO
196943473,Infliximab (Unknown),Erysipelas,OT
196943473,Infliximab (Unknown),Dry eye,DE
196943473,Infliximab (Unknown),Dry eye,HO
196943473,Infliximab (Unknown),Dry eye,OT
196943473,Infliximab (Unknown),Dermatitis,DE
196943473,Infliximab (Unknown),Dermatitis,HO
196943473,Infliximab (Unknown),Dermatitis,OT
196943473,Infliximab (Unknown),Death,DE
196943473,Infliximab (Unknown),Death,HO
196943473,Infliximab (Unknown),Death,OT
196943473,Infliximab (Unknown),Bronchopulmonary aspergillosis,DE
196943473,Infliximab (Unknown),Bronchopulmonary aspergillosis,HO
196943473,Infliximab (Unknown),Bronchopulmonary aspergillosis,OT
196943473,Infliximab (Unknown),Bacteraemia,DE
196943473,Infliximab (Unknown),Bacteraemia,HO
196943473,Infliximab (Unknown),Bacteraemia,OT
196992891,Infliximab,Product use issue,OT
196992891,Infliximab,Off label use,OT
196992891,Infliximab,Intentional product use issue,OT
196992891,Infliximab,Heart rate decreased,OT
196992891,Infliximab,Headache,OT
196992891,Infliximab,Dizziness,OT
196992891,Infliximab,Condition aggravated,OT
196992891,Infliximab,Blood pressure decreased,OT
197060731,Infliximab (Unknown),Tenosynovitis,OT
197060731,Infliximab (Unknown),Rheumatoid arthritis,OT
197060731,Infliximab (Unknown),Pulmonary fibrosis,OT
197060731,Infliximab (Unknown),Lung disorder,OT
197060731,Infliximab (Unknown),Interstitial lung disease,OT
197060731,Infliximab (Unknown),Dyspnoea,OT
197060731,Infliximab (Unknown),Cyanosis,OT
197060731,Infliximab (Unknown),Cough,OT
197060731,Infliximab (Unknown),Bronchiectasis,OT
197100111,Infliximab,Small intestinal obstruction,OT
197100111,Infliximab,Small intestinal obstruction,HO
197100111,Infliximab,Off label use,OT
197100111,Infliximab,Off label use,HO
197100111,Infliximab,Nasopharyngitis,OT
197100111,Infliximab,Nasopharyngitis,HO
197100111,Infliximab,Nasal congestion,OT
197100111,Infliximab,Nasal congestion,HO
197100111,Infliximab,Intentional product use issue,OT
197100111,Infliximab,Intentional product use issue,HO
197100111,Infliximab,Cough,OT
197100111,Infliximab,Cough,HO
197100111,Infliximab,Blood pressure decreased,OT
197100111,Infliximab,Blood pressure decreased,HO
197456941,Infliximab,Pyrexia,HO
197456941,Infliximab,Pneumonia,HO
197456941,Infliximab,Pain in extremity,HO
197456941,Infliximab,Off label use,HO
197456941,Infliximab,Intentional product use issue,HO
197456941,Infliximab,Bone pain,HO
197456941,Infliximab,Arthralgia,HO
197996291,Infliximab,Weight increased,OT
197996291,Infliximab,Weight decreased,OT
197996291,Infliximab,Off label use,OT
197996291,Infliximab,Heart rate decreased,OT
197996291,Infliximab,Condition aggravated,OT
198078581,Infliximab,Weight fluctuation,OT
198078581,Infliximab,Spherocytic anaemia,OT
198078581,Infliximab,Product use issue,OT
198078581,Infliximab,Off label use,OT
198078581,Infliximab,Inappropriate schedule of product administration,OT
198078581,Infliximab,Heart rate decreased,OT
198078581,Infliximab,Drug level above therapeutic,OT
198078581,Infliximab,Condition aggravated,OT
198078581,Infliximab,Anal fissure,OT
198078581,Infliximab,Anal abscess,OT
198283221,Infliximab,Hernia,HO
198283221,Infliximab,Hernia,OT
198294221,Infliximab,Weight decreased,OT
198294221,Infliximab,Tonsillitis,OT
198294221,Infliximab,Sinusitis,OT
198294221,Infliximab,Off label use,OT
198294221,Infliximab,Intentional product use issue,OT
198294221,Infliximab,Inappropriate schedule of product administration,OT
198294221,Infliximab,Exposure to SARS-CoV-2,OT
198297332,Infliximab,Therapy non-responder,OT
198618451,Infliximab,Off label use,OT
198618451,Infliximab,Condition aggravated,OT
198618451,Infliximab,Off label use,OT
198618451,Infliximab,Condition aggravated,OT
198657571,Infliximab,Drug ineffective,OT
198781551,Infliximab (Unknown),Urinary tract infection,NULL
198781551,Infliximab (Unknown),Off label use,NULL
198781551,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198988181,Infliximab,Off label use,OT
198988181,Infliximab,Off label use,HO
198988181,Infliximab,Inappropriate schedule of product administration,OT
198988181,Infliximab,Inappropriate schedule of product administration,HO
198988181,Infliximab,Haemoglobin decreased,OT
198988181,Infliximab,Haemoglobin decreased,HO
198988181,Infliximab,Condition aggravated,OT
198988181,Infliximab,Condition aggravated,HO
198988181,Infliximab,Cerebrovascular accident,OT
198988181,Infliximab,Cerebrovascular accident,HO
160798128,Infliximab,Urticaria,HO
160798128,Infliximab,Urticaria,OT
160798128,Infliximab,Urticaria,DS
160798128,Infliximab,Ulcer,HO
160798128,Infliximab,Ulcer,OT
160798128,Infliximab,Ulcer,DS
160798128,Infliximab,Treatment failure,HO
160798128,Infliximab,Treatment failure,OT
160798128,Infliximab,Treatment failure,DS
160798128,Infliximab,Tongue disorder,HO
160798128,Infliximab,Tongue disorder,OT
160798128,Infliximab,Tongue disorder,DS
160798128,Infliximab,Therapy non-responder,HO
160798128,Infliximab,Therapy non-responder,OT
160798128,Infliximab,Therapy non-responder,DS
160798128,Infliximab,Tenosynovitis,HO
160798128,Infliximab,Tenosynovitis,OT
160798128,Infliximab,Tenosynovitis,DS
160798128,Infliximab,Tendonitis,HO
160798128,Infliximab,Tendonitis,OT
160798128,Infliximab,Tendonitis,DS
160798128,Infliximab,Synovitis,HO
160798128,Infliximab,Synovitis,OT
160798128,Infliximab,Synovitis,DS
160798128,Infliximab,Skin ulcer,HO
160798128,Infliximab,Skin ulcer,OT
160798128,Infliximab,Skin ulcer,DS
160798128,Infliximab,Skin necrosis,HO
160798128,Infliximab,Skin necrosis,OT
160798128,Infliximab,Skin necrosis,DS
160798128,Infliximab,Rheumatoid nodule,HO
160798128,Infliximab,Rheumatoid nodule,OT
160798128,Infliximab,Rheumatoid nodule,DS
160798128,Infliximab,Rheumatoid arthritis,HO
160798128,Infliximab,Rheumatoid arthritis,OT
160798128,Infliximab,Rheumatoid arthritis,DS
160798128,Infliximab,Red blood cell sedimentation rate increased,HO
160798128,Infliximab,Red blood cell sedimentation rate increased,OT
160798128,Infliximab,Red blood cell sedimentation rate increased,DS
160798128,Infliximab,Red blood cell sedimentation rate,HO
160798128,Infliximab,Red blood cell sedimentation rate,OT
160798128,Infliximab,Red blood cell sedimentation rate,DS
160798128,Infliximab,Rash pruritic,HO
160798128,Infliximab,Rash pruritic,OT
160798128,Infliximab,Rash pruritic,DS
160798128,Infliximab,Rash,HO
160798128,Infliximab,Rash,OT
160798128,Infliximab,Rash,DS
160798128,Infliximab,Pulmonary fibrosis,HO
160798128,Infliximab,Pulmonary fibrosis,OT
160798128,Infliximab,Pulmonary fibrosis,DS
160798128,Infliximab,Psoriatic arthropathy,HO
160798128,Infliximab,Psoriatic arthropathy,OT
160798128,Infliximab,Psoriatic arthropathy,DS
160798128,Infliximab,Product use issue,HO
160798128,Infliximab,Product use issue,OT
160798128,Infliximab,Product use issue,DS
160798128,Infliximab,Peripheral swelling,HO
160798128,Infliximab,Peripheral swelling,OT
160798128,Infliximab,Peripheral swelling,DS
160798128,Infliximab,Panniculitis,HO
160798128,Infliximab,Panniculitis,OT
160798128,Infliximab,Panniculitis,DS
160798128,Infliximab,Pain,HO
160798128,Infliximab,Pain,OT
160798128,Infliximab,Pain,DS
160798128,Infliximab,Off label use,HO
160798128,Infliximab,Off label use,OT
160798128,Infliximab,Off label use,DS
160798128,Infliximab,Nausea,HO
160798128,Infliximab,Nausea,OT
160798128,Infliximab,Nausea,DS
160798128,Infliximab,Musculoskeletal stiffness,HO
160798128,Infliximab,Musculoskeletal stiffness,OT
160798128,Infliximab,Musculoskeletal stiffness,DS
160798128,Infliximab,Loss of personal independence in daily activities,HO
160798128,Infliximab,Loss of personal independence in daily activities,OT
160798128,Infliximab,Loss of personal independence in daily activities,DS
160798128,Infliximab,Joint swelling,HO
160798128,Infliximab,Joint swelling,OT
160798128,Infliximab,Joint swelling,DS
160798128,Infliximab,Joint injury,HO
160798128,Infliximab,Joint injury,OT
160798128,Infliximab,Joint injury,DS
160798128,Infliximab,Insomnia,HO
160798128,Infliximab,Insomnia,OT
160798128,Infliximab,Insomnia,DS
160798128,Infliximab,Infusion related reaction,HO
160798128,Infliximab,Infusion related reaction,OT
160798128,Infliximab,Infusion related reaction,DS
160798128,Infliximab,Inflammation,HO
160798128,Infliximab,Inflammation,OT
160798128,Infliximab,Inflammation,DS
160798128,Infliximab,Incorrect route of product administration,HO
160798128,Infliximab,Incorrect route of product administration,OT
160798128,Infliximab,Incorrect route of product administration,DS
160798128,Infliximab,Hypertension,HO
160798128,Infliximab,Hypertension,OT
160798128,Infliximab,Hypertension,DS
160798128,Infliximab,Hypersensitivity,HO
160798128,Infliximab,Hypersensitivity,OT
160798128,Infliximab,Hypersensitivity,DS
160798128,Infliximab,Hypercalcaemia,HO
160798128,Infliximab,Hypercalcaemia,OT
160798128,Infliximab,Hypercalcaemia,DS
160798128,Infliximab,Headache,HO
160798128,Infliximab,Headache,OT
160798128,Infliximab,Headache,DS
160798128,Infliximab,Granuloma skin,HO
160798128,Infliximab,Granuloma skin,OT
160798128,Infliximab,Granuloma skin,DS
160798128,Infliximab,General physical health deterioration,HO
160798128,Infliximab,General physical health deterioration,OT
160798128,Infliximab,General physical health deterioration,DS
160798128,Infliximab,Fear of injection,HO
160798128,Infliximab,Fear of injection,OT
160798128,Infliximab,Fear of injection,DS
160798128,Infliximab,Fatigue,HO
160798128,Infliximab,Fatigue,OT
160798128,Infliximab,Fatigue,DS
160798128,Infliximab,Erythema,HO
160798128,Infliximab,Erythema,OT
160798128,Infliximab,Erythema,DS
160798128,Infliximab,Enthesopathy,HO
160798128,Infliximab,Enthesopathy,OT
160798128,Infliximab,Enthesopathy,DS
160798128,Infliximab,Drug intolerance,HO
160798128,Infliximab,Drug intolerance,OT
160798128,Infliximab,Drug intolerance,DS
160798128,Infliximab,Drug ineffective,HO
160798128,Infliximab,Drug ineffective,OT
160798128,Infliximab,Drug ineffective,DS
160798128,Infliximab,Drug hypersensitivity,HO
160798128,Infliximab,Drug hypersensitivity,OT
160798128,Infliximab,Drug hypersensitivity,DS
160798128,Infliximab,Drug eruption,HO
160798128,Infliximab,Drug eruption,OT
160798128,Infliximab,Drug eruption,DS
160798128,Infliximab,Diarrhoea,HO
160798128,Infliximab,Diarrhoea,OT
160798128,Infliximab,Diarrhoea,DS
160798128,Infliximab,Decreased appetite,HO
160798128,Infliximab,Decreased appetite,OT
160798128,Infliximab,Decreased appetite,DS
160798128,Infliximab,Contraindicated product administered,HO
160798128,Infliximab,Contraindicated product administered,OT
160798128,Infliximab,Contraindicated product administered,DS
160798128,Infliximab,C-reactive protein increased,HO
160798128,Infliximab,C-reactive protein increased,OT
160798128,Infliximab,C-reactive protein increased,DS
160798128,Infliximab,C-reactive protein abnormal,HO
160798128,Infliximab,C-reactive protein abnormal,OT
160798128,Infliximab,C-reactive protein abnormal,DS
160798128,Infliximab,Blood pressure systolic increased,HO
160798128,Infliximab,Blood pressure systolic increased,OT
160798128,Infliximab,Blood pressure systolic increased,DS
160798128,Infliximab,Blood parathyroid hormone decreased,HO
160798128,Infliximab,Blood parathyroid hormone decreased,OT
160798128,Infliximab,Blood parathyroid hormone decreased,DS
160798128,Infliximab,Blood creatinine increased,HO
160798128,Infliximab,Blood creatinine increased,OT
160798128,Infliximab,Blood creatinine increased,DS
160798128,Infliximab,Basal cell carcinoma,HO
160798128,Infliximab,Basal cell carcinoma,OT
160798128,Infliximab,Basal cell carcinoma,DS
160798128,Infliximab,Aspartate aminotransferase increased,HO
160798128,Infliximab,Aspartate aminotransferase increased,OT
160798128,Infliximab,Aspartate aminotransferase increased,DS
160798128,Infliximab,Arthropathy,HO
160798128,Infliximab,Arthropathy,OT
160798128,Infliximab,Arthropathy,DS
160798128,Infliximab,Arthritis,HO
160798128,Infliximab,Arthritis,OT
160798128,Infliximab,Arthritis,DS
160798128,Infliximab,Arthralgia,HO
160798128,Infliximab,Arthralgia,OT
160798128,Infliximab,Arthralgia,DS
160798128,Infliximab,Alanine aminotransferase increased,HO
160798128,Infliximab,Alanine aminotransferase increased,OT
160798128,Infliximab,Alanine aminotransferase increased,DS
160798128,Infliximab,Alanine aminotransferase abnormal,HO
160798128,Infliximab,Alanine aminotransferase abnormal,OT
160798128,Infliximab,Alanine aminotransferase abnormal,DS
160798128,Infliximab,Abdominal discomfort,HO
160798128,Infliximab,Abdominal discomfort,OT
160798128,Infliximab,Abdominal discomfort,DS
160798128,Infliximab,Urticaria,HO
160798128,Infliximab,Urticaria,OT
160798128,Infliximab,Urticaria,DS
160798128,Infliximab,Ulcer,HO
160798128,Infliximab,Ulcer,OT
160798128,Infliximab,Ulcer,DS
160798128,Infliximab,Treatment failure,HO
160798128,Infliximab,Treatment failure,OT
160798128,Infliximab,Treatment failure,DS
160798128,Infliximab,Tongue disorder,HO
160798128,Infliximab,Tongue disorder,OT
160798128,Infliximab,Tongue disorder,DS
160798128,Infliximab,Therapy non-responder,HO
160798128,Infliximab,Therapy non-responder,OT
160798128,Infliximab,Therapy non-responder,DS
160798128,Infliximab,Tenosynovitis,HO
160798128,Infliximab,Tenosynovitis,OT
160798128,Infliximab,Tenosynovitis,DS
160798128,Infliximab,Tendonitis,HO
160798128,Infliximab,Tendonitis,OT
160798128,Infliximab,Tendonitis,DS
160798128,Infliximab,Synovitis,HO
160798128,Infliximab,Synovitis,OT
160798128,Infliximab,Synovitis,DS
160798128,Infliximab,Skin ulcer,HO
160798128,Infliximab,Skin ulcer,OT
160798128,Infliximab,Skin ulcer,DS
160798128,Infliximab,Skin necrosis,HO
160798128,Infliximab,Skin necrosis,OT
160798128,Infliximab,Skin necrosis,DS
160798128,Infliximab,Rheumatoid nodule,HO
160798128,Infliximab,Rheumatoid nodule,OT
160798128,Infliximab,Rheumatoid nodule,DS
160798128,Infliximab,Rheumatoid arthritis,HO
160798128,Infliximab,Rheumatoid arthritis,OT
160798128,Infliximab,Rheumatoid arthritis,DS
160798128,Infliximab,Red blood cell sedimentation rate increased,HO
160798128,Infliximab,Red blood cell sedimentation rate increased,OT
160798128,Infliximab,Red blood cell sedimentation rate increased,DS
160798128,Infliximab,Red blood cell sedimentation rate,HO
160798128,Infliximab,Red blood cell sedimentation rate,OT
160798128,Infliximab,Red blood cell sedimentation rate,DS
160798128,Infliximab,Rash pruritic,HO
160798128,Infliximab,Rash pruritic,OT
160798128,Infliximab,Rash pruritic,DS
160798128,Infliximab,Rash,HO
160798128,Infliximab,Rash,OT
160798128,Infliximab,Rash,DS
160798128,Infliximab,Pulmonary fibrosis,HO
160798128,Infliximab,Pulmonary fibrosis,OT
160798128,Infliximab,Pulmonary fibrosis,DS
160798128,Infliximab,Psoriatic arthropathy,HO
160798128,Infliximab,Psoriatic arthropathy,OT
160798128,Infliximab,Psoriatic arthropathy,DS
160798128,Infliximab,Product use issue,HO
160798128,Infliximab,Product use issue,OT
160798128,Infliximab,Product use issue,DS
160798128,Infliximab,Peripheral swelling,HO
160798128,Infliximab,Peripheral swelling,OT
160798128,Infliximab,Peripheral swelling,DS
160798128,Infliximab,Panniculitis,HO
160798128,Infliximab,Panniculitis,OT
160798128,Infliximab,Panniculitis,DS
160798128,Infliximab,Pain,HO
160798128,Infliximab,Pain,OT
160798128,Infliximab,Pain,DS
160798128,Infliximab,Off label use,HO
160798128,Infliximab,Off label use,OT
160798128,Infliximab,Off label use,DS
160798128,Infliximab,Nausea,HO
160798128,Infliximab,Nausea,OT
160798128,Infliximab,Nausea,DS
160798128,Infliximab,Musculoskeletal stiffness,HO
160798128,Infliximab,Musculoskeletal stiffness,OT
160798128,Infliximab,Musculoskeletal stiffness,DS
160798128,Infliximab,Loss of personal independence in daily activities,HO
160798128,Infliximab,Loss of personal independence in daily activities,OT
160798128,Infliximab,Loss of personal independence in daily activities,DS
160798128,Infliximab,Joint swelling,HO
160798128,Infliximab,Joint swelling,OT
160798128,Infliximab,Joint swelling,DS
160798128,Infliximab,Joint injury,HO
160798128,Infliximab,Joint injury,OT
160798128,Infliximab,Joint injury,DS
160798128,Infliximab,Insomnia,HO
160798128,Infliximab,Insomnia,OT
160798128,Infliximab,Insomnia,DS
160798128,Infliximab,Infusion related reaction,HO
160798128,Infliximab,Infusion related reaction,OT
160798128,Infliximab,Infusion related reaction,DS
160798128,Infliximab,Inflammation,HO
160798128,Infliximab,Inflammation,OT
160798128,Infliximab,Inflammation,DS
160798128,Infliximab,Incorrect route of product administration,HO
160798128,Infliximab,Incorrect route of product administration,OT
160798128,Infliximab,Incorrect route of product administration,DS
160798128,Infliximab,Hypertension,HO
160798128,Infliximab,Hypertension,OT
160798128,Infliximab,Hypertension,DS
160798128,Infliximab,Hypersensitivity,HO
160798128,Infliximab,Hypersensitivity,OT
160798128,Infliximab,Hypersensitivity,DS
160798128,Infliximab,Hypercalcaemia,HO
160798128,Infliximab,Hypercalcaemia,OT
160798128,Infliximab,Hypercalcaemia,DS
160798128,Infliximab,Headache,HO
160798128,Infliximab,Headache,OT
160798128,Infliximab,Headache,DS
160798128,Infliximab,Granuloma skin,HO
160798128,Infliximab,Granuloma skin,OT
160798128,Infliximab,Granuloma skin,DS
160798128,Infliximab,General physical health deterioration,HO
160798128,Infliximab,General physical health deterioration,OT
160798128,Infliximab,General physical health deterioration,DS
160798128,Infliximab,Fear of injection,HO
160798128,Infliximab,Fear of injection,OT
160798128,Infliximab,Fear of injection,DS
160798128,Infliximab,Fatigue,HO
160798128,Infliximab,Fatigue,OT
160798128,Infliximab,Fatigue,DS
160798128,Infliximab,Erythema,HO
160798128,Infliximab,Erythema,OT
160798128,Infliximab,Erythema,DS
160798128,Infliximab,Enthesopathy,HO
160798128,Infliximab,Enthesopathy,OT
160798128,Infliximab,Enthesopathy,DS
160798128,Infliximab,Drug intolerance,HO
160798128,Infliximab,Drug intolerance,OT
160798128,Infliximab,Drug intolerance,DS
160798128,Infliximab,Drug ineffective,HO
160798128,Infliximab,Drug ineffective,OT
160798128,Infliximab,Drug ineffective,DS
160798128,Infliximab,Drug hypersensitivity,HO
160798128,Infliximab,Drug hypersensitivity,OT
160798128,Infliximab,Drug hypersensitivity,DS
160798128,Infliximab,Drug eruption,HO
160798128,Infliximab,Drug eruption,OT
160798128,Infliximab,Drug eruption,DS
160798128,Infliximab,Diarrhoea,HO
160798128,Infliximab,Diarrhoea,OT
160798128,Infliximab,Diarrhoea,DS
160798128,Infliximab,Decreased appetite,HO
160798128,Infliximab,Decreased appetite,OT
160798128,Infliximab,Decreased appetite,DS
160798128,Infliximab,Contraindicated product administered,HO
160798128,Infliximab,Contraindicated product administered,OT
160798128,Infliximab,Contraindicated product administered,DS
160798128,Infliximab,C-reactive protein increased,HO
160798128,Infliximab,C-reactive protein increased,OT
160798128,Infliximab,C-reactive protein increased,DS
160798128,Infliximab,C-reactive protein abnormal,HO
160798128,Infliximab,C-reactive protein abnormal,OT
160798128,Infliximab,C-reactive protein abnormal,DS
160798128,Infliximab,Blood pressure systolic increased,HO
160798128,Infliximab,Blood pressure systolic increased,OT
160798128,Infliximab,Blood pressure systolic increased,DS
160798128,Infliximab,Blood parathyroid hormone decreased,HO
160798128,Infliximab,Blood parathyroid hormone decreased,OT
160798128,Infliximab,Blood parathyroid hormone decreased,DS
160798128,Infliximab,Blood creatinine increased,HO
160798128,Infliximab,Blood creatinine increased,OT
160798128,Infliximab,Blood creatinine increased,DS
160798128,Infliximab,Basal cell carcinoma,HO
160798128,Infliximab,Basal cell carcinoma,OT
160798128,Infliximab,Basal cell carcinoma,DS
160798128,Infliximab,Aspartate aminotransferase increased,HO
160798128,Infliximab,Aspartate aminotransferase increased,OT
160798128,Infliximab,Aspartate aminotransferase increased,DS
160798128,Infliximab,Arthropathy,HO
160798128,Infliximab,Arthropathy,OT
160798128,Infliximab,Arthropathy,DS
160798128,Infliximab,Arthritis,HO
160798128,Infliximab,Arthritis,OT
160798128,Infliximab,Arthritis,DS
160798128,Infliximab,Arthralgia,HO
160798128,Infliximab,Arthralgia,OT
160798128,Infliximab,Arthralgia,DS
160798128,Infliximab,Alanine aminotransferase increased,HO
160798128,Infliximab,Alanine aminotransferase increased,OT
160798128,Infliximab,Alanine aminotransferase increased,DS
160798128,Infliximab,Alanine aminotransferase abnormal,HO
160798128,Infliximab,Alanine aminotransferase abnormal,OT
160798128,Infliximab,Alanine aminotransferase abnormal,DS
160798128,Infliximab,Abdominal discomfort,HO
160798128,Infliximab,Abdominal discomfort,OT
160798128,Infliximab,Abdominal discomfort,DS
160798128,Infliximab,Urticaria,HO
160798128,Infliximab,Urticaria,OT
160798128,Infliximab,Urticaria,DS
160798128,Infliximab,Ulcer,HO
160798128,Infliximab,Ulcer,OT
160798128,Infliximab,Ulcer,DS
160798128,Infliximab,Treatment failure,HO
160798128,Infliximab,Treatment failure,OT
160798128,Infliximab,Treatment failure,DS
160798128,Infliximab,Tongue disorder,HO
160798128,Infliximab,Tongue disorder,OT
160798128,Infliximab,Tongue disorder,DS
160798128,Infliximab,Therapy non-responder,HO
160798128,Infliximab,Therapy non-responder,OT
160798128,Infliximab,Therapy non-responder,DS
160798128,Infliximab,Tenosynovitis,HO
160798128,Infliximab,Tenosynovitis,OT
160798128,Infliximab,Tenosynovitis,DS
160798128,Infliximab,Tendonitis,HO
160798128,Infliximab,Tendonitis,OT
160798128,Infliximab,Tendonitis,DS
160798128,Infliximab,Synovitis,HO
160798128,Infliximab,Synovitis,OT
160798128,Infliximab,Synovitis,DS
160798128,Infliximab,Skin ulcer,HO
160798128,Infliximab,Skin ulcer,OT
160798128,Infliximab,Skin ulcer,DS
160798128,Infliximab,Skin necrosis,HO
160798128,Infliximab,Skin necrosis,OT
160798128,Infliximab,Skin necrosis,DS
160798128,Infliximab,Rheumatoid nodule,HO
160798128,Infliximab,Rheumatoid nodule,OT
160798128,Infliximab,Rheumatoid nodule,DS
160798128,Infliximab,Rheumatoid arthritis,HO
160798128,Infliximab,Rheumatoid arthritis,OT
160798128,Infliximab,Rheumatoid arthritis,DS
160798128,Infliximab,Red blood cell sedimentation rate increased,HO
160798128,Infliximab,Red blood cell sedimentation rate increased,OT
160798128,Infliximab,Red blood cell sedimentation rate increased,DS
160798128,Infliximab,Red blood cell sedimentation rate,HO
160798128,Infliximab,Red blood cell sedimentation rate,OT
160798128,Infliximab,Red blood cell sedimentation rate,DS
160798128,Infliximab,Rash pruritic,HO
160798128,Infliximab,Rash pruritic,OT
160798128,Infliximab,Rash pruritic,DS
160798128,Infliximab,Rash,HO
160798128,Infliximab,Rash,OT
160798128,Infliximab,Rash,DS
160798128,Infliximab,Pulmonary fibrosis,HO
160798128,Infliximab,Pulmonary fibrosis,OT
160798128,Infliximab,Pulmonary fibrosis,DS
160798128,Infliximab,Psoriatic arthropathy,HO
160798128,Infliximab,Psoriatic arthropathy,OT
160798128,Infliximab,Psoriatic arthropathy,DS
160798128,Infliximab,Product use issue,HO
160798128,Infliximab,Product use issue,OT
160798128,Infliximab,Product use issue,DS
160798128,Infliximab,Peripheral swelling,HO
160798128,Infliximab,Peripheral swelling,OT
160798128,Infliximab,Peripheral swelling,DS
160798128,Infliximab,Panniculitis,HO
160798128,Infliximab,Panniculitis,OT
160798128,Infliximab,Panniculitis,DS
160798128,Infliximab,Pain,HO
160798128,Infliximab,Pain,OT
160798128,Infliximab,Pain,DS
160798128,Infliximab,Off label use,HO
160798128,Infliximab,Off label use,OT
160798128,Infliximab,Off label use,DS
160798128,Infliximab,Nausea,HO
160798128,Infliximab,Nausea,OT
160798128,Infliximab,Nausea,DS
160798128,Infliximab,Musculoskeletal stiffness,HO
160798128,Infliximab,Musculoskeletal stiffness,OT
160798128,Infliximab,Musculoskeletal stiffness,DS
160798128,Infliximab,Loss of personal independence in daily activities,HO
160798128,Infliximab,Loss of personal independence in daily activities,OT
160798128,Infliximab,Loss of personal independence in daily activities,DS
160798128,Infliximab,Joint swelling,HO
160798128,Infliximab,Joint swelling,OT
160798128,Infliximab,Joint swelling,DS
160798128,Infliximab,Joint injury,HO
160798128,Infliximab,Joint injury,OT
160798128,Infliximab,Joint injury,DS
160798128,Infliximab,Insomnia,HO
160798128,Infliximab,Insomnia,OT
160798128,Infliximab,Insomnia,DS
160798128,Infliximab,Infusion related reaction,HO
160798128,Infliximab,Infusion related reaction,OT
160798128,Infliximab,Infusion related reaction,DS
160798128,Infliximab,Inflammation,HO
160798128,Infliximab,Inflammation,OT
160798128,Infliximab,Inflammation,DS
160798128,Infliximab,Incorrect route of product administration,HO
160798128,Infliximab,Incorrect route of product administration,OT
160798128,Infliximab,Incorrect route of product administration,DS
160798128,Infliximab,Hypertension,HO
160798128,Infliximab,Hypertension,OT
160798128,Infliximab,Hypertension,DS
160798128,Infliximab,Hypersensitivity,HO
160798128,Infliximab,Hypersensitivity,OT
160798128,Infliximab,Hypersensitivity,DS
160798128,Infliximab,Hypercalcaemia,HO
160798128,Infliximab,Hypercalcaemia,OT
160798128,Infliximab,Hypercalcaemia,DS
160798128,Infliximab,Headache,HO
160798128,Infliximab,Headache,OT
160798128,Infliximab,Headache,DS
160798128,Infliximab,Granuloma skin,HO
160798128,Infliximab,Granuloma skin,OT
160798128,Infliximab,Granuloma skin,DS
160798128,Infliximab,General physical health deterioration,HO
160798128,Infliximab,General physical health deterioration,OT
160798128,Infliximab,General physical health deterioration,DS
160798128,Infliximab,Fear of injection,HO
160798128,Infliximab,Fear of injection,OT
160798128,Infliximab,Fear of injection,DS
160798128,Infliximab,Fatigue,HO
160798128,Infliximab,Fatigue,OT
160798128,Infliximab,Fatigue,DS
160798128,Infliximab,Erythema,HO
160798128,Infliximab,Erythema,OT
160798128,Infliximab,Erythema,DS
160798128,Infliximab,Enthesopathy,HO
160798128,Infliximab,Enthesopathy,OT
160798128,Infliximab,Enthesopathy,DS
160798128,Infliximab,Drug intolerance,HO
160798128,Infliximab,Drug intolerance,OT
160798128,Infliximab,Drug intolerance,DS
160798128,Infliximab,Drug ineffective,HO
160798128,Infliximab,Drug ineffective,OT
160798128,Infliximab,Drug ineffective,DS
160798128,Infliximab,Drug hypersensitivity,HO
160798128,Infliximab,Drug hypersensitivity,OT
160798128,Infliximab,Drug hypersensitivity,DS
160798128,Infliximab,Drug eruption,HO
160798128,Infliximab,Drug eruption,OT
160798128,Infliximab,Drug eruption,DS
160798128,Infliximab,Diarrhoea,HO
160798128,Infliximab,Diarrhoea,OT
160798128,Infliximab,Diarrhoea,DS
160798128,Infliximab,Decreased appetite,HO
160798128,Infliximab,Decreased appetite,OT
160798128,Infliximab,Decreased appetite,DS
160798128,Infliximab,Contraindicated product administered,HO
160798128,Infliximab,Contraindicated product administered,OT
160798128,Infliximab,Contraindicated product administered,DS
160798128,Infliximab,C-reactive protein increased,HO
160798128,Infliximab,C-reactive protein increased,OT
160798128,Infliximab,C-reactive protein increased,DS
160798128,Infliximab,C-reactive protein abnormal,HO
160798128,Infliximab,C-reactive protein abnormal,OT
160798128,Infliximab,C-reactive protein abnormal,DS
160798128,Infliximab,Blood pressure systolic increased,HO
160798128,Infliximab,Blood pressure systolic increased,OT
160798128,Infliximab,Blood pressure systolic increased,DS
160798128,Infliximab,Blood parathyroid hormone decreased,HO
160798128,Infliximab,Blood parathyroid hormone decreased,OT
160798128,Infliximab,Blood parathyroid hormone decreased,DS
160798128,Infliximab,Blood creatinine increased,HO
160798128,Infliximab,Blood creatinine increased,OT
160798128,Infliximab,Blood creatinine increased,DS
160798128,Infliximab,Basal cell carcinoma,HO
160798128,Infliximab,Basal cell carcinoma,OT
160798128,Infliximab,Basal cell carcinoma,DS
160798128,Infliximab,Aspartate aminotransferase increased,HO
160798128,Infliximab,Aspartate aminotransferase increased,OT
160798128,Infliximab,Aspartate aminotransferase increased,DS
160798128,Infliximab,Arthropathy,HO
160798128,Infliximab,Arthropathy,OT
160798128,Infliximab,Arthropathy,DS
160798128,Infliximab,Arthritis,HO
160798128,Infliximab,Arthritis,OT
160798128,Infliximab,Arthritis,DS
160798128,Infliximab,Arthralgia,HO
160798128,Infliximab,Arthralgia,OT
160798128,Infliximab,Arthralgia,DS
160798128,Infliximab,Alanine aminotransferase increased,HO
160798128,Infliximab,Alanine aminotransferase increased,OT
160798128,Infliximab,Alanine aminotransferase increased,DS
160798128,Infliximab,Alanine aminotransferase abnormal,HO
160798128,Infliximab,Alanine aminotransferase abnormal,OT
160798128,Infliximab,Alanine aminotransferase abnormal,DS
160798128,Infliximab,Abdominal discomfort,HO
160798128,Infliximab,Abdominal discomfort,OT
160798128,Infliximab,Abdominal discomfort,DS
160798128,Infliximab,Urticaria,HO
160798128,Infliximab,Urticaria,OT
160798128,Infliximab,Urticaria,DS
160798128,Infliximab,Ulcer,HO
160798128,Infliximab,Ulcer,OT
160798128,Infliximab,Ulcer,DS
160798128,Infliximab,Treatment failure,HO
160798128,Infliximab,Treatment failure,OT
160798128,Infliximab,Treatment failure,DS
160798128,Infliximab,Tongue disorder,HO
160798128,Infliximab,Tongue disorder,OT
160798128,Infliximab,Tongue disorder,DS
160798128,Infliximab,Therapy non-responder,HO
160798128,Infliximab,Therapy non-responder,OT
160798128,Infliximab,Therapy non-responder,DS
160798128,Infliximab,Tenosynovitis,HO
160798128,Infliximab,Tenosynovitis,OT
160798128,Infliximab,Tenosynovitis,DS
160798128,Infliximab,Tendonitis,HO
160798128,Infliximab,Tendonitis,OT
160798128,Infliximab,Tendonitis,DS
160798128,Infliximab,Synovitis,HO
160798128,Infliximab,Synovitis,OT
160798128,Infliximab,Synovitis,DS
160798128,Infliximab,Skin ulcer,HO
160798128,Infliximab,Skin ulcer,OT
160798128,Infliximab,Skin ulcer,DS
160798128,Infliximab,Skin necrosis,HO
160798128,Infliximab,Skin necrosis,OT
160798128,Infliximab,Skin necrosis,DS
160798128,Infliximab,Rheumatoid nodule,HO
160798128,Infliximab,Rheumatoid nodule,OT
160798128,Infliximab,Rheumatoid nodule,DS
160798128,Infliximab,Rheumatoid arthritis,HO
160798128,Infliximab,Rheumatoid arthritis,OT
160798128,Infliximab,Rheumatoid arthritis,DS
160798128,Infliximab,Red blood cell sedimentation rate increased,HO
160798128,Infliximab,Red blood cell sedimentation rate increased,OT
160798128,Infliximab,Red blood cell sedimentation rate increased,DS
160798128,Infliximab,Red blood cell sedimentation rate,HO
160798128,Infliximab,Red blood cell sedimentation rate,OT
160798128,Infliximab,Red blood cell sedimentation rate,DS
160798128,Infliximab,Rash pruritic,HO
160798128,Infliximab,Rash pruritic,OT
160798128,Infliximab,Rash pruritic,DS
160798128,Infliximab,Rash,HO
160798128,Infliximab,Rash,OT
160798128,Infliximab,Rash,DS
160798128,Infliximab,Pulmonary fibrosis,HO
160798128,Infliximab,Pulmonary fibrosis,OT
160798128,Infliximab,Pulmonary fibrosis,DS
160798128,Infliximab,Psoriatic arthropathy,HO
160798128,Infliximab,Psoriatic arthropathy,OT
160798128,Infliximab,Psoriatic arthropathy,DS
160798128,Infliximab,Product use issue,HO
160798128,Infliximab,Product use issue,OT
160798128,Infliximab,Product use issue,DS
160798128,Infliximab,Peripheral swelling,HO
160798128,Infliximab,Peripheral swelling,OT
160798128,Infliximab,Peripheral swelling,DS
160798128,Infliximab,Panniculitis,HO
160798128,Infliximab,Panniculitis,OT
160798128,Infliximab,Panniculitis,DS
160798128,Infliximab,Pain,HO
160798128,Infliximab,Pain,OT
160798128,Infliximab,Pain,DS
160798128,Infliximab,Off label use,HO
160798128,Infliximab,Off label use,OT
160798128,Infliximab,Off label use,DS
160798128,Infliximab,Nausea,HO
160798128,Infliximab,Nausea,OT
160798128,Infliximab,Nausea,DS
160798128,Infliximab,Musculoskeletal stiffness,HO
160798128,Infliximab,Musculoskeletal stiffness,OT
160798128,Infliximab,Musculoskeletal stiffness,DS
160798128,Infliximab,Loss of personal independence in daily activities,HO
160798128,Infliximab,Loss of personal independence in daily activities,OT
160798128,Infliximab,Loss of personal independence in daily activities,DS
160798128,Infliximab,Joint swelling,HO
160798128,Infliximab,Joint swelling,OT
160798128,Infliximab,Joint swelling,DS
160798128,Infliximab,Joint injury,HO
160798128,Infliximab,Joint injury,OT
160798128,Infliximab,Joint injury,DS
160798128,Infliximab,Insomnia,HO
160798128,Infliximab,Insomnia,OT
160798128,Infliximab,Insomnia,DS
160798128,Infliximab,Infusion related reaction,HO
160798128,Infliximab,Infusion related reaction,OT
160798128,Infliximab,Infusion related reaction,DS
160798128,Infliximab,Inflammation,HO
160798128,Infliximab,Inflammation,OT
160798128,Infliximab,Inflammation,DS
160798128,Infliximab,Incorrect route of product administration,HO
160798128,Infliximab,Incorrect route of product administration,OT
160798128,Infliximab,Incorrect route of product administration,DS
160798128,Infliximab,Hypertension,HO
160798128,Infliximab,Hypertension,OT
160798128,Infliximab,Hypertension,DS
160798128,Infliximab,Hypersensitivity,HO
160798128,Infliximab,Hypersensitivity,OT
160798128,Infliximab,Hypersensitivity,DS
160798128,Infliximab,Hypercalcaemia,HO
160798128,Infliximab,Hypercalcaemia,OT
160798128,Infliximab,Hypercalcaemia,DS
160798128,Infliximab,Headache,HO
160798128,Infliximab,Headache,OT
160798128,Infliximab,Headache,DS
160798128,Infliximab,Granuloma skin,HO
160798128,Infliximab,Granuloma skin,OT
160798128,Infliximab,Granuloma skin,DS
160798128,Infliximab,General physical health deterioration,HO
160798128,Infliximab,General physical health deterioration,OT
160798128,Infliximab,General physical health deterioration,DS
160798128,Infliximab,Fear of injection,HO
160798128,Infliximab,Fear of injection,OT
160798128,Infliximab,Fear of injection,DS
160798128,Infliximab,Fatigue,HO
160798128,Infliximab,Fatigue,OT
160798128,Infliximab,Fatigue,DS
160798128,Infliximab,Erythema,HO
160798128,Infliximab,Erythema,OT
160798128,Infliximab,Erythema,DS
160798128,Infliximab,Enthesopathy,HO
160798128,Infliximab,Enthesopathy,OT
160798128,Infliximab,Enthesopathy,DS
160798128,Infliximab,Drug intolerance,HO
160798128,Infliximab,Drug intolerance,OT
160798128,Infliximab,Drug intolerance,DS
160798128,Infliximab,Drug ineffective,HO
160798128,Infliximab,Drug ineffective,OT
160798128,Infliximab,Drug ineffective,DS
160798128,Infliximab,Drug hypersensitivity,HO
160798128,Infliximab,Drug hypersensitivity,OT
160798128,Infliximab,Drug hypersensitivity,DS
160798128,Infliximab,Drug eruption,HO
160798128,Infliximab,Drug eruption,OT
160798128,Infliximab,Drug eruption,DS
160798128,Infliximab,Diarrhoea,HO
160798128,Infliximab,Diarrhoea,OT
160798128,Infliximab,Diarrhoea,DS
160798128,Infliximab,Decreased appetite,HO
160798128,Infliximab,Decreased appetite,OT
160798128,Infliximab,Decreased appetite,DS
160798128,Infliximab,Contraindicated product administered,HO
160798128,Infliximab,Contraindicated product administered,OT
160798128,Infliximab,Contraindicated product administered,DS
160798128,Infliximab,C-reactive protein increased,HO
160798128,Infliximab,C-reactive protein increased,OT
160798128,Infliximab,C-reactive protein increased,DS
160798128,Infliximab,C-reactive protein abnormal,HO
160798128,Infliximab,C-reactive protein abnormal,OT
160798128,Infliximab,C-reactive protein abnormal,DS
160798128,Infliximab,Blood pressure systolic increased,HO
160798128,Infliximab,Blood pressure systolic increased,OT
160798128,Infliximab,Blood pressure systolic increased,DS
160798128,Infliximab,Blood parathyroid hormone decreased,HO
160798128,Infliximab,Blood parathyroid hormone decreased,OT
160798128,Infliximab,Blood parathyroid hormone decreased,DS
160798128,Infliximab,Blood creatinine increased,HO
160798128,Infliximab,Blood creatinine increased,OT
160798128,Infliximab,Blood creatinine increased,DS
160798128,Infliximab,Basal cell carcinoma,HO
160798128,Infliximab,Basal cell carcinoma,OT
160798128,Infliximab,Basal cell carcinoma,DS
160798128,Infliximab,Aspartate aminotransferase increased,HO
160798128,Infliximab,Aspartate aminotransferase increased,OT
160798128,Infliximab,Aspartate aminotransferase increased,DS
160798128,Infliximab,Arthropathy,HO
160798128,Infliximab,Arthropathy,OT
160798128,Infliximab,Arthropathy,DS
160798128,Infliximab,Arthritis,HO
160798128,Infliximab,Arthritis,OT
160798128,Infliximab,Arthritis,DS
160798128,Infliximab,Arthralgia,HO
160798128,Infliximab,Arthralgia,OT
160798128,Infliximab,Arthralgia,DS
160798128,Infliximab,Alanine aminotransferase increased,HO
160798128,Infliximab,Alanine aminotransferase increased,OT
160798128,Infliximab,Alanine aminotransferase increased,DS
160798128,Infliximab,Alanine aminotransferase abnormal,HO
160798128,Infliximab,Alanine aminotransferase abnormal,OT
160798128,Infliximab,Alanine aminotransferase abnormal,DS
160798128,Infliximab,Abdominal discomfort,HO
160798128,Infliximab,Abdominal discomfort,OT
160798128,Infliximab,Abdominal discomfort,DS
160798128,Infliximab,Urticaria,HO
160798128,Infliximab,Urticaria,OT
160798128,Infliximab,Urticaria,DS
160798128,Infliximab,Ulcer,HO
160798128,Infliximab,Ulcer,OT
160798128,Infliximab,Ulcer,DS
160798128,Infliximab,Treatment failure,HO
160798128,Infliximab,Treatment failure,OT
160798128,Infliximab,Treatment failure,DS
160798128,Infliximab,Tongue disorder,HO
160798128,Infliximab,Tongue disorder,OT
160798128,Infliximab,Tongue disorder,DS
160798128,Infliximab,Therapy non-responder,HO
160798128,Infliximab,Therapy non-responder,OT
160798128,Infliximab,Therapy non-responder,DS
160798128,Infliximab,Tenosynovitis,HO
160798128,Infliximab,Tenosynovitis,OT
160798128,Infliximab,Tenosynovitis,DS
160798128,Infliximab,Tendonitis,HO
160798128,Infliximab,Tendonitis,OT
160798128,Infliximab,Tendonitis,DS
160798128,Infliximab,Synovitis,HO
160798128,Infliximab,Synovitis,OT
160798128,Infliximab,Synovitis,DS
160798128,Infliximab,Skin ulcer,HO
160798128,Infliximab,Skin ulcer,OT
160798128,Infliximab,Skin ulcer,DS
160798128,Infliximab,Skin necrosis,HO
160798128,Infliximab,Skin necrosis,OT
160798128,Infliximab,Skin necrosis,DS
160798128,Infliximab,Rheumatoid nodule,HO
160798128,Infliximab,Rheumatoid nodule,OT
160798128,Infliximab,Rheumatoid nodule,DS
160798128,Infliximab,Rheumatoid arthritis,HO
160798128,Infliximab,Rheumatoid arthritis,OT
160798128,Infliximab,Rheumatoid arthritis,DS
160798128,Infliximab,Red blood cell sedimentation rate increased,HO
160798128,Infliximab,Red blood cell sedimentation rate increased,OT
160798128,Infliximab,Red blood cell sedimentation rate increased,DS
160798128,Infliximab,Red blood cell sedimentation rate,HO
160798128,Infliximab,Red blood cell sedimentation rate,OT
160798128,Infliximab,Red blood cell sedimentation rate,DS
160798128,Infliximab,Rash pruritic,HO
160798128,Infliximab,Rash pruritic,OT
160798128,Infliximab,Rash pruritic,DS
160798128,Infliximab,Rash,HO
160798128,Infliximab,Rash,OT
160798128,Infliximab,Rash,DS
160798128,Infliximab,Pulmonary fibrosis,HO
160798128,Infliximab,Pulmonary fibrosis,OT
160798128,Infliximab,Pulmonary fibrosis,DS
160798128,Infliximab,Psoriatic arthropathy,HO
160798128,Infliximab,Psoriatic arthropathy,OT
160798128,Infliximab,Psoriatic arthropathy,DS
160798128,Infliximab,Product use issue,HO
160798128,Infliximab,Product use issue,OT
160798128,Infliximab,Product use issue,DS
160798128,Infliximab,Peripheral swelling,HO
160798128,Infliximab,Peripheral swelling,OT
160798128,Infliximab,Peripheral swelling,DS
160798128,Infliximab,Panniculitis,HO
160798128,Infliximab,Panniculitis,OT
160798128,Infliximab,Panniculitis,DS
160798128,Infliximab,Pain,HO
160798128,Infliximab,Pain,OT
160798128,Infliximab,Pain,DS
160798128,Infliximab,Off label use,HO
160798128,Infliximab,Off label use,OT
160798128,Infliximab,Off label use,DS
160798128,Infliximab,Nausea,HO
160798128,Infliximab,Nausea,OT
160798128,Infliximab,Nausea,DS
160798128,Infliximab,Musculoskeletal stiffness,HO
160798128,Infliximab,Musculoskeletal stiffness,OT
160798128,Infliximab,Musculoskeletal stiffness,DS
160798128,Infliximab,Loss of personal independence in daily activities,HO
160798128,Infliximab,Loss of personal independence in daily activities,OT
160798128,Infliximab,Loss of personal independence in daily activities,DS
160798128,Infliximab,Joint swelling,HO
160798128,Infliximab,Joint swelling,OT
160798128,Infliximab,Joint swelling,DS
160798128,Infliximab,Joint injury,HO
160798128,Infliximab,Joint injury,OT
160798128,Infliximab,Joint injury,DS
160798128,Infliximab,Insomnia,HO
160798128,Infliximab,Insomnia,OT
160798128,Infliximab,Insomnia,DS
160798128,Infliximab,Infusion related reaction,HO
160798128,Infliximab,Infusion related reaction,OT
160798128,Infliximab,Infusion related reaction,DS
160798128,Infliximab,Inflammation,HO
160798128,Infliximab,Inflammation,OT
160798128,Infliximab,Inflammation,DS
160798128,Infliximab,Incorrect route of product administration,HO
160798128,Infliximab,Incorrect route of product administration,OT
160798128,Infliximab,Incorrect route of product administration,DS
160798128,Infliximab,Hypertension,HO
160798128,Infliximab,Hypertension,OT
160798128,Infliximab,Hypertension,DS
160798128,Infliximab,Hypersensitivity,HO
160798128,Infliximab,Hypersensitivity,OT
160798128,Infliximab,Hypersensitivity,DS
160798128,Infliximab,Hypercalcaemia,HO
160798128,Infliximab,Hypercalcaemia,OT
160798128,Infliximab,Hypercalcaemia,DS
160798128,Infliximab,Headache,HO
160798128,Infliximab,Headache,OT
160798128,Infliximab,Headache,DS
160798128,Infliximab,Granuloma skin,HO
160798128,Infliximab,Granuloma skin,OT
160798128,Infliximab,Granuloma skin,DS
160798128,Infliximab,General physical health deterioration,HO
160798128,Infliximab,General physical health deterioration,OT
160798128,Infliximab,General physical health deterioration,DS
160798128,Infliximab,Fear of injection,HO
160798128,Infliximab,Fear of injection,OT
160798128,Infliximab,Fear of injection,DS
160798128,Infliximab,Fatigue,HO
160798128,Infliximab,Fatigue,OT
160798128,Infliximab,Fatigue,DS
160798128,Infliximab,Erythema,HO
160798128,Infliximab,Erythema,OT
160798128,Infliximab,Erythema,DS
160798128,Infliximab,Enthesopathy,HO
160798128,Infliximab,Enthesopathy,OT
160798128,Infliximab,Enthesopathy,DS
160798128,Infliximab,Drug intolerance,HO
160798128,Infliximab,Drug intolerance,OT
160798128,Infliximab,Drug intolerance,DS
160798128,Infliximab,Drug ineffective,HO
160798128,Infliximab,Drug ineffective,OT
160798128,Infliximab,Drug ineffective,DS
160798128,Infliximab,Drug hypersensitivity,HO
160798128,Infliximab,Drug hypersensitivity,OT
160798128,Infliximab,Drug hypersensitivity,DS
160798128,Infliximab,Drug eruption,HO
160798128,Infliximab,Drug eruption,OT
160798128,Infliximab,Drug eruption,DS
160798128,Infliximab,Diarrhoea,HO
160798128,Infliximab,Diarrhoea,OT
160798128,Infliximab,Diarrhoea,DS
160798128,Infliximab,Decreased appetite,HO
160798128,Infliximab,Decreased appetite,OT
160798128,Infliximab,Decreased appetite,DS
160798128,Infliximab,Contraindicated product administered,HO
160798128,Infliximab,Contraindicated product administered,OT
160798128,Infliximab,Contraindicated product administered,DS
160798128,Infliximab,C-reactive protein increased,HO
160798128,Infliximab,C-reactive protein increased,OT
160798128,Infliximab,C-reactive protein increased,DS
160798128,Infliximab,C-reactive protein abnormal,HO
160798128,Infliximab,C-reactive protein abnormal,OT
160798128,Infliximab,C-reactive protein abnormal,DS
160798128,Infliximab,Blood pressure systolic increased,HO
160798128,Infliximab,Blood pressure systolic increased,OT
160798128,Infliximab,Blood pressure systolic increased,DS
160798128,Infliximab,Blood parathyroid hormone decreased,HO
160798128,Infliximab,Blood parathyroid hormone decreased,OT
160798128,Infliximab,Blood parathyroid hormone decreased,DS
160798128,Infliximab,Blood creatinine increased,HO
160798128,Infliximab,Blood creatinine increased,OT
160798128,Infliximab,Blood creatinine increased,DS
160798128,Infliximab,Basal cell carcinoma,HO
160798128,Infliximab,Basal cell carcinoma,OT
160798128,Infliximab,Basal cell carcinoma,DS
160798128,Infliximab,Aspartate aminotransferase increased,HO
160798128,Infliximab,Aspartate aminotransferase increased,OT
160798128,Infliximab,Aspartate aminotransferase increased,DS
160798128,Infliximab,Arthropathy,HO
160798128,Infliximab,Arthropathy,OT
160798128,Infliximab,Arthropathy,DS
160798128,Infliximab,Arthritis,HO
160798128,Infliximab,Arthritis,OT
160798128,Infliximab,Arthritis,DS
160798128,Infliximab,Arthralgia,HO
160798128,Infliximab,Arthralgia,OT
160798128,Infliximab,Arthralgia,DS
160798128,Infliximab,Alanine aminotransferase increased,HO
160798128,Infliximab,Alanine aminotransferase increased,OT
160798128,Infliximab,Alanine aminotransferase increased,DS
160798128,Infliximab,Alanine aminotransferase abnormal,HO
160798128,Infliximab,Alanine aminotransferase abnormal,OT
160798128,Infliximab,Alanine aminotransferase abnormal,DS
160798128,Infliximab,Abdominal discomfort,HO
160798128,Infliximab,Abdominal discomfort,OT
160798128,Infliximab,Abdominal discomfort,DS
160799045,Infliximab,Weight increased,OT
160799045,Infliximab,Weight decreased,OT
160799045,Infliximab,Therapeutic response shortened,OT
160799045,Infliximab,Respiratory tract congestion,OT
160799045,Infliximab,Red blood cell count decreased,OT
160799045,Infliximab,Product use issue,OT
160799045,Infliximab,Poor venous access,OT
160799045,Infliximab,Off label use,OT
160799045,Infliximab,Nasopharyngitis,OT
160799045,Infliximab,Mean cell haemoglobin increased,OT
160799045,Infliximab,Intentional product use issue,OT
160799045,Infliximab,Incorrect dose administered,OT
160799045,Infliximab,Cough,OT
160799045,Infliximab,Condition aggravated,OT
160799045,Infliximab,Weight increased,OT
160799045,Infliximab,Weight decreased,OT
160799045,Infliximab,Therapeutic response shortened,OT
160799045,Infliximab,Respiratory tract congestion,OT
160799045,Infliximab,Red blood cell count decreased,OT
160799045,Infliximab,Product use issue,OT
160799045,Infliximab,Poor venous access,OT
160799045,Infliximab,Off label use,OT
160799045,Infliximab,Nasopharyngitis,OT
160799045,Infliximab,Mean cell haemoglobin increased,OT
160799045,Infliximab,Intentional product use issue,OT
160799045,Infliximab,Incorrect dose administered,OT
160799045,Infliximab,Cough,OT
160799045,Infliximab,Condition aggravated,OT
160799673,Infliximab,Synovitis,OT
160799673,Infliximab,Red blood cell sedimentation rate increased,OT
160799673,Infliximab,Pain,OT
160799673,Infliximab,Malaise,OT
160799673,Infliximab,Joint injury,OT
160799673,Infliximab,Inflammation,OT
160799673,Infliximab,Headache,OT
160799673,Infliximab,Fatigue,OT
160799673,Infliximab,Fall,OT
160799673,Infliximab,Drug use disorder,OT
160799673,Infliximab,Drug ineffective,OT
160799673,Infliximab,Drug dependence,OT
160799673,Infliximab,Depression,OT
160799673,Infliximab,Asthenia,OT
160799673,Infliximab,Anxiety,OT
160799673,Infliximab,Alopecia,OT
160799673,Infliximab,Abdominal pain upper,OT
160821737,Infliximab,Weight increased,HO
160821737,Infliximab,Weight increased,OT
160821737,Infliximab,Weight decreased,HO
160821737,Infliximab,Weight decreased,OT
160821737,Infliximab,Tremor,HO
160821737,Infliximab,Tremor,OT
160821737,Infliximab,Somnolence,HO
160821737,Infliximab,Somnolence,OT
160821737,Infliximab,Product use issue,HO
160821737,Infliximab,Product use issue,OT
160821737,Infliximab,Pain,HO
160821737,Infliximab,Pain,OT
160821737,Infliximab,Off label use,HO
160821737,Infliximab,Off label use,OT
160821737,Infliximab,Myalgia,HO
160821737,Infliximab,Myalgia,OT
160821737,Infliximab,Intentional product use issue,HO
160821737,Infliximab,Intentional product use issue,OT
160821737,Infliximab,Inguinal hernia,HO
160821737,Infliximab,Inguinal hernia,OT
160821737,Infliximab,Increased appetite,HO
160821737,Infliximab,Increased appetite,OT
160821737,Infliximab,Incorrect dose administered,HO
160821737,Infliximab,Incorrect dose administered,OT
160821737,Infliximab,Heart rate irregular,HO
160821737,Infliximab,Heart rate irregular,OT
160821737,Infliximab,Heart rate decreased,HO
160821737,Infliximab,Heart rate decreased,OT
160821737,Infliximab,Headache,HO
160821737,Infliximab,Headache,OT
160821737,Infliximab,Gait disturbance,HO
160821737,Infliximab,Gait disturbance,OT
160821737,Infliximab,Fatigue,HO
160821737,Infliximab,Fatigue,OT
160821737,Infliximab,Condition aggravated,HO
160821737,Infliximab,Condition aggravated,OT
160821737,Infliximab,Chest pain,HO
160821737,Infliximab,Chest pain,OT
160821737,Infliximab,Blood pressure increased,HO
160821737,Infliximab,Blood pressure increased,OT
160821737,Infliximab,Blood pressure fluctuation,HO
160821737,Infliximab,Blood pressure fluctuation,OT
160821737,Infliximab,Arthralgia,HO
160821737,Infliximab,Arthralgia,OT
160852015,Infliximab,White coat hypertension,OT
160852015,Infliximab,Weight increased,OT
160852015,Infliximab,Vision blurred,OT
160852015,Infliximab,Social anxiety disorder,OT
160852015,Infliximab,Pharyngeal swelling,OT
160852015,Infliximab,Pharyngeal oedema,OT
160852015,Infliximab,Pain,OT
160852015,Infliximab,Oral candidiasis,OT
160852015,Infliximab,Off label use,OT
160852015,Infliximab,Memory impairment,OT
160852015,Infliximab,Intentional product use issue,OT
160852015,Infliximab,Hypertension,OT
160852015,Infliximab,Fungal oesophagitis,OT
160852015,Infliximab,Fatigue,OT
160852015,Infliximab,Condition aggravated,OT
160852015,Infliximab,Blood pressure increased,OT
160852015,Infliximab,Blood pressure fluctuation,OT
160852015,Infliximab,Asthenia,OT
160852015,Infliximab,Anxiety,OT
160852015,Infliximab,White coat hypertension,OT
160852015,Infliximab,Weight increased,OT
160852015,Infliximab,Vision blurred,OT
160852015,Infliximab,Social anxiety disorder,OT
160852015,Infliximab,Pharyngeal swelling,OT
160852015,Infliximab,Pharyngeal oedema,OT
160852015,Infliximab,Pain,OT
160852015,Infliximab,Oral candidiasis,OT
160852015,Infliximab,Off label use,OT
160852015,Infliximab,Memory impairment,OT
160852015,Infliximab,Intentional product use issue,OT
160852015,Infliximab,Hypertension,OT
160852015,Infliximab,Fungal oesophagitis,OT
160852015,Infliximab,Fatigue,OT
160852015,Infliximab,Condition aggravated,OT
160852015,Infliximab,Blood pressure increased,OT
160852015,Infliximab,Blood pressure fluctuation,OT
160852015,Infliximab,Asthenia,OT
160852015,Infliximab,Anxiety,OT
160852015,Infliximab,White coat hypertension,OT
160852015,Infliximab,Weight increased,OT
160852015,Infliximab,Vision blurred,OT
160852015,Infliximab,Social anxiety disorder,OT
160852015,Infliximab,Pharyngeal swelling,OT
160852015,Infliximab,Pharyngeal oedema,OT
160852015,Infliximab,Pain,OT
160852015,Infliximab,Oral candidiasis,OT
160852015,Infliximab,Off label use,OT
160852015,Infliximab,Memory impairment,OT
160852015,Infliximab,Intentional product use issue,OT
160852015,Infliximab,Hypertension,OT
160852015,Infliximab,Fungal oesophagitis,OT
160852015,Infliximab,Fatigue,OT
160852015,Infliximab,Condition aggravated,OT
160852015,Infliximab,Blood pressure increased,OT
160852015,Infliximab,Blood pressure fluctuation,OT
160852015,Infliximab,Asthenia,OT
160852015,Infliximab,Anxiety,OT
160963734,Infliximab,Weight increased,OT
160963734,Infliximab,Weight increased,HO
160963734,Infliximab,Weight decreased,OT
160963734,Infliximab,Weight decreased,HO
160963734,Infliximab,Vomiting,OT
160963734,Infliximab,Vomiting,HO
160963734,Infliximab,Vein rupture,OT
160963734,Infliximab,Vein rupture,HO
160963734,Infliximab,Renal impairment,OT
160963734,Infliximab,Renal impairment,HO
160963734,Infliximab,Pyrexia,OT
160963734,Infliximab,Pyrexia,HO
160963734,Infliximab,Poor venous access,OT
160963734,Infliximab,Poor venous access,HO
160963734,Infliximab,Pain in extremity,OT
160963734,Infliximab,Pain in extremity,HO
160963734,Infliximab,Off label use,OT
160963734,Infliximab,Off label use,HO
160963734,Infliximab,Nervousness,OT
160963734,Infliximab,Nervousness,HO
160963734,Infliximab,Nausea,OT
160963734,Infliximab,Nausea,HO
160963734,Infliximab,Musculoskeletal pain,OT
160963734,Infliximab,Musculoskeletal pain,HO
160963734,Infliximab,Mood altered,OT
160963734,Infliximab,Mood altered,HO
160963734,Infliximab,Malaise,OT
160963734,Infliximab,Malaise,HO
160963734,Infliximab,Lip swelling,OT
160963734,Infliximab,Lip swelling,HO
160963734,Infliximab,Injection site haemorrhage,OT
160963734,Infliximab,Injection site haemorrhage,HO
160963734,Infliximab,Incorrect dose administered,OT
160963734,Infliximab,Incorrect dose administered,HO
160963734,Infliximab,Inappropriate schedule of product administration,OT
160963734,Infliximab,Inappropriate schedule of product administration,HO
160963734,Infliximab,Fatigue,OT
160963734,Infliximab,Fatigue,HO
160963734,Infliximab,Erythema,OT
160963734,Infliximab,Erythema,HO
160963734,Infliximab,Drug ineffective,OT
160963734,Infliximab,Drug ineffective,HO
160963734,Infliximab,Drug hypersensitivity,OT
160963734,Infliximab,Drug hypersensitivity,HO
160963734,Infliximab,Discomfort,OT
160963734,Infliximab,Discomfort,HO
160963734,Infliximab,Diarrhoea,OT
160963734,Infliximab,Diarrhoea,HO
160963734,Infliximab,Condition aggravated,OT
160963734,Infliximab,Condition aggravated,HO
160963734,Infliximab,Body temperature increased,OT
160963734,Infliximab,Body temperature increased,HO
160963734,Infliximab,Blood pressure increased,OT
160963734,Infliximab,Blood pressure increased,HO
160963734,Infliximab,Blood pressure fluctuation,OT
160963734,Infliximab,Blood pressure fluctuation,HO
160963734,Infliximab,Arthralgia,OT
160963734,Infliximab,Arthralgia,HO
160963734,Infliximab,Anxiety,OT
160963734,Infliximab,Anxiety,HO
160963734,Infliximab,Anaemia,OT
160963734,Infliximab,Anaemia,HO
160963734,Infliximab,Abdominal pain,OT
160963734,Infliximab,Abdominal pain,HO
160963734,Infliximab,Weight increased,OT
160963734,Infliximab,Weight increased,HO
160963734,Infliximab,Weight decreased,OT
160963734,Infliximab,Weight decreased,HO
160963734,Infliximab,Vomiting,OT
160963734,Infliximab,Vomiting,HO
160963734,Infliximab,Vein rupture,OT
160963734,Infliximab,Vein rupture,HO
160963734,Infliximab,Renal impairment,OT
160963734,Infliximab,Renal impairment,HO
160963734,Infliximab,Pyrexia,OT
160963734,Infliximab,Pyrexia,HO
160963734,Infliximab,Poor venous access,OT
160963734,Infliximab,Poor venous access,HO
160963734,Infliximab,Pain in extremity,OT
160963734,Infliximab,Pain in extremity,HO
160963734,Infliximab,Off label use,OT
160963734,Infliximab,Off label use,HO
160963734,Infliximab,Nervousness,OT
160963734,Infliximab,Nervousness,HO
160963734,Infliximab,Nausea,OT
160963734,Infliximab,Nausea,HO
160963734,Infliximab,Musculoskeletal pain,OT
160963734,Infliximab,Musculoskeletal pain,HO
160963734,Infliximab,Mood altered,OT
160963734,Infliximab,Mood altered,HO
160963734,Infliximab,Malaise,OT
160963734,Infliximab,Malaise,HO
160963734,Infliximab,Lip swelling,OT
160963734,Infliximab,Lip swelling,HO
160963734,Infliximab,Injection site haemorrhage,OT
160963734,Infliximab,Injection site haemorrhage,HO
160963734,Infliximab,Incorrect dose administered,OT
160963734,Infliximab,Incorrect dose administered,HO
160963734,Infliximab,Inappropriate schedule of product administration,OT
160963734,Infliximab,Inappropriate schedule of product administration,HO
160963734,Infliximab,Fatigue,OT
160963734,Infliximab,Fatigue,HO
160963734,Infliximab,Erythema,OT
160963734,Infliximab,Erythema,HO
160963734,Infliximab,Drug ineffective,OT
160963734,Infliximab,Drug ineffective,HO
160963734,Infliximab,Drug hypersensitivity,OT
160963734,Infliximab,Drug hypersensitivity,HO
160963734,Infliximab,Discomfort,OT
160963734,Infliximab,Discomfort,HO
160963734,Infliximab,Diarrhoea,OT
160963734,Infliximab,Diarrhoea,HO
160963734,Infliximab,Condition aggravated,OT
160963734,Infliximab,Condition aggravated,HO
160963734,Infliximab,Body temperature increased,OT
160963734,Infliximab,Body temperature increased,HO
160963734,Infliximab,Blood pressure increased,OT
160963734,Infliximab,Blood pressure increased,HO
160963734,Infliximab,Blood pressure fluctuation,OT
160963734,Infliximab,Blood pressure fluctuation,HO
160963734,Infliximab,Arthralgia,OT
160963734,Infliximab,Arthralgia,HO
160963734,Infliximab,Anxiety,OT
160963734,Infliximab,Anxiety,HO
160963734,Infliximab,Anaemia,OT
160963734,Infliximab,Anaemia,HO
160963734,Infliximab,Abdominal pain,OT
160963734,Infliximab,Abdominal pain,HO
165632266,Infliximab,Wheezing,OT
165632266,Infliximab,Weight decreased,OT
165632266,Infliximab,Product use issue,OT
165632266,Infliximab,Pneumonia,OT
165632266,Infliximab,Off label use,OT
165632266,Infliximab,Lower respiratory tract infection,OT
165632266,Infliximab,Incorrect dose administered,OT
165632266,Infliximab,Inappropriate schedule of product administration,OT
165632266,Infliximab,Heart rate irregular,OT
165632266,Infliximab,Heart rate decreased,OT
165632266,Infliximab,Dyspnoea,OT
165632266,Infliximab,Condition aggravated,OT
165632266,Infliximab,Body temperature fluctuation,OT
165632266,Infliximab,Body temperature decreased,OT
165632266,Infliximab,Blood pressure fluctuation,OT
165632266,Infliximab,Abdominal distension,OT
165632266,Infliximab,Wheezing,OT
165632266,Infliximab,Weight decreased,OT
165632266,Infliximab,Product use issue,OT
165632266,Infliximab,Pneumonia,OT
165632266,Infliximab,Off label use,OT
165632266,Infliximab,Lower respiratory tract infection,OT
165632266,Infliximab,Incorrect dose administered,OT
165632266,Infliximab,Inappropriate schedule of product administration,OT
165632266,Infliximab,Heart rate irregular,OT
165632266,Infliximab,Heart rate decreased,OT
165632266,Infliximab,Dyspnoea,OT
165632266,Infliximab,Condition aggravated,OT
165632266,Infliximab,Body temperature fluctuation,OT
165632266,Infliximab,Body temperature decreased,OT
165632266,Infliximab,Blood pressure fluctuation,OT
165632266,Infliximab,Abdominal distension,OT
168917404,Infliximab,Therapeutic response shortened,OT
168917404,Infliximab,Pyrexia,OT
168917404,Infliximab,Off label use,OT
168917404,Infliximab,Malaise,OT
168917404,Infliximab,Intentional product use issue,OT
168917404,Infliximab,Influenza,OT
168917404,Infliximab,Inappropriate schedule of product administration,OT
168917404,Infliximab,Illness,OT
168917404,Infliximab,Heart rate decreased,OT
168917404,Infliximab,Haemoglobin decreased,OT
168917404,Infliximab,Condition aggravated,OT
168917404,Infliximab,Blood pressure fluctuation,OT
168917404,Infliximab,Therapeutic response shortened,OT
168917404,Infliximab,Pyrexia,OT
168917404,Infliximab,Off label use,OT
168917404,Infliximab,Malaise,OT
168917404,Infliximab,Intentional product use issue,OT
168917404,Infliximab,Influenza,OT
168917404,Infliximab,Inappropriate schedule of product administration,OT
168917404,Infliximab,Illness,OT
168917404,Infliximab,Heart rate decreased,OT
168917404,Infliximab,Haemoglobin decreased,OT
168917404,Infliximab,Condition aggravated,OT
168917404,Infliximab,Blood pressure fluctuation,OT
172383265,Infliximab,Weight increased,OT
172383265,Infliximab,Weight decreased,OT
172383265,Infliximab,Therapeutic response unexpected,OT
172383265,Infliximab,Therapeutic product effect incomplete,OT
172383265,Infliximab,Suspected COVID-19,OT
172383265,Infliximab,Rheumatoid arthritis,OT
172383265,Infliximab,Restlessness,OT
172383265,Infliximab,Rash,OT
172383265,Infliximab,Pyrexia,OT
172383265,Infliximab,Product use issue,OT
172383265,Infliximab,Oxygen saturation decreased,OT
172383265,Infliximab,Oropharyngeal pain,OT
172383265,Infliximab,Off label use,OT
172383265,Infliximab,Nausea,OT
172383265,Infliximab,Malaise,OT
172383265,Infliximab,Loss of personal independence in daily activities,OT
172383265,Infliximab,Joint warmth,OT
172383265,Infliximab,Joint swelling,OT
172383265,Infliximab,Joint injury,OT
172383265,Infliximab,Intentional product use issue,OT
172383265,Infliximab,Influenza,OT
172383265,Infliximab,Infection,OT
172383265,Infliximab,Inappropriate schedule of product administration,OT
172383265,Infliximab,Hypertension,OT
172383265,Infliximab,Heart rate increased,OT
172383265,Infliximab,Erythema,OT
172383265,Infliximab,Dizziness,OT
172383265,Infliximab,Discomfort,OT
172383265,Infliximab,Cellulitis,OT
172383265,Infliximab,Bursitis,OT
172383265,Infliximab,Blood pressure increased,OT
172383265,Infliximab,Blood pressure fluctuation,OT
172383265,Infliximab,Arthralgia,OT
172383265,Infliximab,Anxiety,OT
173865364,Infliximab,Off label use,HO
173865364,Infliximab,Off label use,OT
173865364,Infliximab,Inappropriate schedule of product administration,HO
173865364,Infliximab,Inappropriate schedule of product administration,OT
173865364,Infliximab,Heart rate decreased,HO
173865364,Infliximab,Heart rate decreased,OT
173865364,Infliximab,Gastrointestinal disorder,HO
173865364,Infliximab,Gastrointestinal disorder,OT
173865364,Infliximab,Drug ineffective,HO
173865364,Infliximab,Drug ineffective,OT
173865364,Infliximab,Condition aggravated,HO
173865364,Infliximab,Condition aggravated,OT
173865364,Infliximab,Blood pressure systolic increased,HO
173865364,Infliximab,Blood pressure systolic increased,OT
173865364,Infliximab,Off label use,HO
173865364,Infliximab,Off label use,OT
173865364,Infliximab,Inappropriate schedule of product administration,HO
173865364,Infliximab,Inappropriate schedule of product administration,OT
173865364,Infliximab,Heart rate decreased,HO
173865364,Infliximab,Heart rate decreased,OT
173865364,Infliximab,Gastrointestinal disorder,HO
173865364,Infliximab,Gastrointestinal disorder,OT
173865364,Infliximab,Drug ineffective,HO
173865364,Infliximab,Drug ineffective,OT
173865364,Infliximab,Condition aggravated,HO
173865364,Infliximab,Condition aggravated,OT
173865364,Infliximab,Blood pressure systolic increased,HO
173865364,Infliximab,Blood pressure systolic increased,OT
176353665,Infliximab,Road traffic accident,OT
176353665,Infliximab,Respiratory tract infection,OT
176353665,Infliximab,Product use issue,OT
176353665,Infliximab,Off label use,OT
176353665,Infliximab,Myalgia,OT
176353665,Infliximab,Ligament sprain,OT
176353665,Infliximab,Ligament pain,OT
176353665,Infliximab,Intentional product use issue,OT
176353665,Infliximab,Influenza,OT
176353665,Infliximab,Inappropriate schedule of product administration,OT
176353665,Infliximab,Hypertension,OT
176353665,Infliximab,Heart rate decreased,OT
176353665,Infliximab,Fall,OT
176353665,Infliximab,Drug ineffective,OT
176353665,Infliximab,Catheter site extravasation,OT
176353665,Infliximab,Blood pressure fluctuation,OT
176353665,Infliximab,Administration site irritation,OT
176353665,Infliximab,Road traffic accident,OT
176353665,Infliximab,Respiratory tract infection,OT
176353665,Infliximab,Product use issue,OT
176353665,Infliximab,Off label use,OT
176353665,Infliximab,Myalgia,OT
176353665,Infliximab,Ligament sprain,OT
176353665,Infliximab,Ligament pain,OT
176353665,Infliximab,Intentional product use issue,OT
176353665,Infliximab,Influenza,OT
176353665,Infliximab,Inappropriate schedule of product administration,OT
176353665,Infliximab,Hypertension,OT
176353665,Infliximab,Heart rate decreased,OT
176353665,Infliximab,Fall,OT
176353665,Infliximab,Drug ineffective,OT
176353665,Infliximab,Catheter site extravasation,OT
176353665,Infliximab,Blood pressure fluctuation,OT
176353665,Infliximab,Administration site irritation,OT
176564533,Infliximab,Wound,OT
176564533,Infliximab,Viral infection,OT
176564533,Infliximab,Vaginal infection,OT
176564533,Infliximab,Urinary tract infection,OT
176564533,Infliximab,Therapeutic response shortened,OT
176564533,Infliximab,Sinusitis,OT
176564533,Infliximab,Secretion discharge,OT
176564533,Infliximab,Seasonal allergy,OT
176564533,Infliximab,Rhinorrhoea,OT
176564533,Infliximab,Red blood cell sedimentation rate increased,OT
176564533,Infliximab,Pyrexia,OT
176564533,Infliximab,Productive cough,OT
176564533,Infliximab,Product prescribing error,OT
176564533,Infliximab,Plicated tongue,OT
176564533,Infliximab,Pharyngitis streptococcal,OT
176564533,Infliximab,Oropharyngeal pain,OT
176564533,Infliximab,Off label use,OT
176564533,Infliximab,Nasopharyngitis,OT
176564533,Infliximab,Nasal discomfort,OT
176564533,Infliximab,Nasal congestion,OT
176564533,Infliximab,Musculoskeletal pain,OT
176564533,Infliximab,Iron deficiency anaemia,OT
176564533,Infliximab,Intentional product use issue,OT
176564533,Infliximab,Influenza,OT
176564533,Infliximab,Increased upper airway secretion,OT
176564533,Infliximab,Inappropriate schedule of product administration,OT
176564533,Infliximab,Immune system disorder,OT
176564533,Infliximab,Hepatic pain,OT
176564533,Infliximab,Heart rate irregular,OT
176564533,Infliximab,Heart rate increased,OT
176564533,Infliximab,General physical health deterioration,OT
176564533,Infliximab,Fatigue,OT
176564533,Infliximab,Epistaxis,OT
176564533,Infliximab,Drug specific antibody present,OT
176564533,Infliximab,Drug level above therapeutic,OT
176564533,Infliximab,Decreased activity,OT
176564533,Infliximab,Crohn's disease,OT
176564533,Infliximab,Cough,OT
176564533,Infliximab,Condition aggravated,OT
176564533,Infliximab,C-reactive protein increased,OT
176564533,Infliximab,Body temperature fluctuation,OT
176564533,Infliximab,Body temperature decreased,OT
176564533,Infliximab,Blood pressure fluctuation,OT
176564533,Infliximab,Blood pressure diastolic increased,OT
176564533,Infliximab,Blood iron decreased,OT
176564533,Infliximab,Anal fistula,OT
176564533,Infliximab,Anal abscess,OT
176564533,Infliximab,Abscess,OT
176564533,Infliximab,Abdominal pain,OT
177623144,Infliximab,Weight increased,OT
177623144,Infliximab,Weight increased,HO
177623144,Infliximab,Vessel perforation,OT
177623144,Infliximab,Vessel perforation,HO
177623144,Infliximab,Vein rupture,OT
177623144,Infliximab,Vein rupture,HO
177623144,Infliximab,Therapeutic product effect incomplete,OT
177623144,Infliximab,Therapeutic product effect incomplete,HO
177623144,Infliximab,Spinal stenosis,OT
177623144,Infliximab,Spinal stenosis,HO
177623144,Infliximab,Product use issue,OT
177623144,Infliximab,Product use issue,HO
177623144,Infliximab,Ophthalmic herpes zoster,OT
177623144,Infliximab,Ophthalmic herpes zoster,HO
177623144,Infliximab,Off label use,OT
177623144,Infliximab,Off label use,HO
177623144,Infliximab,Intentional product use issue,OT
177623144,Infliximab,Intentional product use issue,HO
177623144,Infliximab,Inappropriate schedule of product administration,OT
177623144,Infliximab,Inappropriate schedule of product administration,HO
177623144,Infliximab,Herpes zoster oticus,OT
177623144,Infliximab,Herpes zoster oticus,HO
177623144,Infliximab,Herpes zoster,OT
177623144,Infliximab,Herpes zoster,HO
177623144,Infliximab,C-reactive protein increased,OT
177623144,Infliximab,C-reactive protein increased,HO
177623144,Infliximab,Blood pressure systolic increased,OT
177623144,Infliximab,Blood pressure systolic increased,HO
177623144,Infliximab,Blood pressure diastolic decreased,OT
177623144,Infliximab,Blood pressure diastolic decreased,HO
177623144,Infliximab,Aortic valve disease,OT
177623144,Infliximab,Aortic valve disease,HO
177623144,Infliximab,Weight increased,OT
177623144,Infliximab,Weight increased,HO
177623144,Infliximab,Vessel perforation,OT
177623144,Infliximab,Vessel perforation,HO
177623144,Infliximab,Vein rupture,OT
177623144,Infliximab,Vein rupture,HO
177623144,Infliximab,Therapeutic product effect incomplete,OT
177623144,Infliximab,Therapeutic product effect incomplete,HO
177623144,Infliximab,Spinal stenosis,OT
177623144,Infliximab,Spinal stenosis,HO
177623144,Infliximab,Product use issue,OT
177623144,Infliximab,Product use issue,HO
177623144,Infliximab,Ophthalmic herpes zoster,OT
177623144,Infliximab,Ophthalmic herpes zoster,HO
177623144,Infliximab,Off label use,OT
177623144,Infliximab,Off label use,HO
177623144,Infliximab,Intentional product use issue,OT
177623144,Infliximab,Intentional product use issue,HO
177623144,Infliximab,Inappropriate schedule of product administration,OT
177623144,Infliximab,Inappropriate schedule of product administration,HO
177623144,Infliximab,Herpes zoster oticus,OT
177623144,Infliximab,Herpes zoster oticus,HO
177623144,Infliximab,Herpes zoster,OT
177623144,Infliximab,Herpes zoster,HO
177623144,Infliximab,C-reactive protein increased,OT
177623144,Infliximab,C-reactive protein increased,HO
177623144,Infliximab,Blood pressure systolic increased,OT
177623144,Infliximab,Blood pressure systolic increased,HO
177623144,Infliximab,Blood pressure diastolic decreased,OT
177623144,Infliximab,Blood pressure diastolic decreased,HO
177623144,Infliximab,Aortic valve disease,OT
177623144,Infliximab,Aortic valve disease,HO
178161384,Infliximab,Wrist fracture,HO
178161384,Infliximab,Wrist fracture,OT
178161384,Infliximab,Stomatitis,HO
178161384,Infliximab,Stomatitis,OT
178161384,Infliximab,Rash papular,HO
178161384,Infliximab,Rash papular,OT
178161384,Infliximab,Pruritus,HO
178161384,Infliximab,Pruritus,OT
178161384,Infliximab,Off label use,HO
178161384,Infliximab,Off label use,OT
178161384,Infliximab,Mouth ulceration,HO
178161384,Infliximab,Mouth ulceration,OT
178161384,Infliximab,Infusion related reaction,HO
178161384,Infliximab,Infusion related reaction,OT
178161384,Infliximab,Incorrect dose administered,HO
178161384,Infliximab,Incorrect dose administered,OT
178161384,Infliximab,Inappropriate schedule of product administration,HO
178161384,Infliximab,Inappropriate schedule of product administration,OT
178161384,Infliximab,Hypertension,HO
178161384,Infliximab,Hypertension,OT
178161384,Infliximab,Gastrointestinal infection,HO
178161384,Infliximab,Gastrointestinal infection,OT
178161384,Infliximab,Fall,HO
178161384,Infliximab,Fall,OT
178161384,Infliximab,Erythema,HO
178161384,Infliximab,Erythema,OT
178161384,Infliximab,Dyspnoea,HO
178161384,Infliximab,Dyspnoea,OT
178161384,Infliximab,Drug specific antibody present,HO
178161384,Infliximab,Drug specific antibody present,OT
178161384,Infliximab,Drug level decreased,HO
178161384,Infliximab,Drug level decreased,OT
178161384,Infliximab,Drug level below therapeutic,HO
178161384,Infliximab,Drug level below therapeutic,OT
178161384,Infliximab,Drug ineffective,HO
178161384,Infliximab,Drug ineffective,OT
178161384,Infliximab,Dizziness,HO
178161384,Infliximab,Dizziness,OT
178161384,Infliximab,Condition aggravated,HO
178161384,Infliximab,Condition aggravated,OT
178161384,Infliximab,Blood pressure increased,HO
178161384,Infliximab,Blood pressure increased,OT
178161384,Infliximab,Blood pressure fluctuation,HO
178161384,Infliximab,Blood pressure fluctuation,OT
178161384,Infliximab,Abdominal pain upper,HO
178161384,Infliximab,Abdominal pain upper,OT
178161384,Infliximab,Wrist fracture,HO
178161384,Infliximab,Wrist fracture,OT
178161384,Infliximab,Stomatitis,HO
178161384,Infliximab,Stomatitis,OT
178161384,Infliximab,Rash papular,HO
178161384,Infliximab,Rash papular,OT
178161384,Infliximab,Pruritus,HO
178161384,Infliximab,Pruritus,OT
178161384,Infliximab,Off label use,HO
178161384,Infliximab,Off label use,OT
178161384,Infliximab,Mouth ulceration,HO
178161384,Infliximab,Mouth ulceration,OT
178161384,Infliximab,Infusion related reaction,HO
178161384,Infliximab,Infusion related reaction,OT
178161384,Infliximab,Incorrect dose administered,HO
178161384,Infliximab,Incorrect dose administered,OT
178161384,Infliximab,Inappropriate schedule of product administration,HO
178161384,Infliximab,Inappropriate schedule of product administration,OT
178161384,Infliximab,Hypertension,HO
178161384,Infliximab,Hypertension,OT
178161384,Infliximab,Gastrointestinal infection,HO
178161384,Infliximab,Gastrointestinal infection,OT
178161384,Infliximab,Fall,HO
178161384,Infliximab,Fall,OT
178161384,Infliximab,Erythema,HO
178161384,Infliximab,Erythema,OT
178161384,Infliximab,Dyspnoea,HO
178161384,Infliximab,Dyspnoea,OT
178161384,Infliximab,Drug specific antibody present,HO
178161384,Infliximab,Drug specific antibody present,OT
178161384,Infliximab,Drug level decreased,HO
178161384,Infliximab,Drug level decreased,OT
178161384,Infliximab,Drug level below therapeutic,HO
178161384,Infliximab,Drug level below therapeutic,OT
178161384,Infliximab,Drug ineffective,HO
178161384,Infliximab,Drug ineffective,OT
178161384,Infliximab,Dizziness,HO
178161384,Infliximab,Dizziness,OT
178161384,Infliximab,Condition aggravated,HO
178161384,Infliximab,Condition aggravated,OT
178161384,Infliximab,Blood pressure increased,HO
178161384,Infliximab,Blood pressure increased,OT
178161384,Infliximab,Blood pressure fluctuation,HO
178161384,Infliximab,Blood pressure fluctuation,OT
178161384,Infliximab,Abdominal pain upper,HO
178161384,Infliximab,Abdominal pain upper,OT
181741319,Infliximab Pfizer (Unknown),Wound,OT
181741319,Infliximab Pfizer (Unknown),Visual impairment,OT
181741319,Infliximab Pfizer (Unknown),Treatment failure,OT
181741319,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
181741319,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,OT
181741319,Infliximab Pfizer (Unknown),Systemic lupus erythematosus,OT
181741319,Infliximab Pfizer (Unknown),Synovitis,OT
181741319,Infliximab Pfizer (Unknown),Rheumatoid factor positive,OT
181741319,Infliximab Pfizer (Unknown),Rheumatoid arthritis,OT
181741319,Infliximab Pfizer (Unknown),Retinitis,OT
181741319,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,OT
181741319,Infliximab Pfizer (Unknown),Rash,OT
181741319,Infliximab Pfizer (Unknown),Product use issue,OT
181741319,Infliximab Pfizer (Unknown),Product use in unapproved indication,OT
181741319,Infliximab Pfizer (Unknown),Pneumonia,OT
181741319,Infliximab Pfizer (Unknown),Pericarditis,OT
181741319,Infliximab Pfizer (Unknown),Pemphigus,OT
181741319,Infliximab Pfizer (Unknown),Pain in extremity,OT
181741319,Infliximab Pfizer (Unknown),Pain,OT
181741319,Infliximab Pfizer (Unknown),Osteoporosis,OT
181741319,Infliximab Pfizer (Unknown),Osteoarthritis,OT
181741319,Infliximab Pfizer (Unknown),Off label use,OT
181741319,Infliximab Pfizer (Unknown),Oedema peripheral,OT
181741319,Infliximab Pfizer (Unknown),Nausea,OT
181741319,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,OT
181741319,Infliximab Pfizer (Unknown),Mobility decreased,OT
181741319,Infliximab Pfizer (Unknown),Malaise,OT
181741319,Infliximab Pfizer (Unknown),Lupus-like syndrome,OT
181741319,Infliximab Pfizer (Unknown),Laryngitis,OT
181741319,Infliximab Pfizer (Unknown),Joint swelling,OT
181741319,Infliximab Pfizer (Unknown),Joint stiffness,OT
181741319,Infliximab Pfizer (Unknown),Joint dislocation,OT
181741319,Infliximab Pfizer (Unknown),Infusion related reaction,OT
181741319,Infliximab Pfizer (Unknown),Infection,OT
181741319,Infliximab Pfizer (Unknown),Hypoaesthesia,OT
181741319,Infliximab Pfizer (Unknown),Hypersensitivity,OT
181741319,Infliximab Pfizer (Unknown),Hepatic enzyme increased,OT
181741319,Infliximab Pfizer (Unknown),Hepatic cirrhosis,OT
181741319,Infliximab Pfizer (Unknown),Headache,OT
181741319,Infliximab Pfizer (Unknown),Hand deformity,OT
181741319,Infliximab Pfizer (Unknown),Glossodynia,OT
181741319,Infliximab Pfizer (Unknown),General physical health deterioration,OT
181741319,Infliximab Pfizer (Unknown),Foot deformity,OT
181741319,Infliximab Pfizer (Unknown),Fatigue,OT
181741319,Infliximab Pfizer (Unknown),Exposure during pregnancy,OT
181741319,Infliximab Pfizer (Unknown),Exostosis,OT
181741319,Infliximab Pfizer (Unknown),Ear infection,OT
181741319,Infliximab Pfizer (Unknown),Drug intolerance,OT
181741319,Infliximab Pfizer (Unknown),Drug ineffective,OT
181741319,Infliximab Pfizer (Unknown),Drug hypersensitivity,OT
181741319,Infliximab Pfizer (Unknown),Dizziness,OT
181741319,Infliximab Pfizer (Unknown),Discomfort,OT
181741319,Infliximab Pfizer (Unknown),Decreased appetite,OT
181741319,Infliximab Pfizer (Unknown),Crohn's disease,OT
181741319,Infliximab Pfizer (Unknown),Contraindicated product administered,OT
181741319,Infliximab Pfizer (Unknown),Condition aggravated,OT
181741319,Infliximab Pfizer (Unknown),C-reactive protein increased,OT
181741319,Infliximab Pfizer (Unknown),Bone erosion,OT
181741319,Infliximab Pfizer (Unknown),Arthritis,OT
181741319,Infliximab Pfizer (Unknown),Arthralgia,OT
181741319,Infliximab Pfizer (Unknown),Anti-cyclic citrullinated peptide antibody positive,OT
181741319,Infliximab Pfizer (Unknown),Alopecia,OT
181741319,Infliximab Pfizer (Unknown),Abdominal discomfort,OT
181741319,Infliximab Pfizer (Unknown),Wound,OT
181741319,Infliximab Pfizer (Unknown),Visual impairment,OT
181741319,Infliximab Pfizer (Unknown),Treatment failure,OT
181741319,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
181741319,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,OT
181741319,Infliximab Pfizer (Unknown),Systemic lupus erythematosus,OT
181741319,Infliximab Pfizer (Unknown),Synovitis,OT
181741319,Infliximab Pfizer (Unknown),Rheumatoid factor positive,OT
181741319,Infliximab Pfizer (Unknown),Rheumatoid arthritis,OT
181741319,Infliximab Pfizer (Unknown),Retinitis,OT
181741319,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,OT
181741319,Infliximab Pfizer (Unknown),Rash,OT
181741319,Infliximab Pfizer (Unknown),Product use issue,OT
181741319,Infliximab Pfizer (Unknown),Product use in unapproved indication,OT
181741319,Infliximab Pfizer (Unknown),Pneumonia,OT
181741319,Infliximab Pfizer (Unknown),Pericarditis,OT
181741319,Infliximab Pfizer (Unknown),Pemphigus,OT
181741319,Infliximab Pfizer (Unknown),Pain in extremity,OT
181741319,Infliximab Pfizer (Unknown),Pain,OT
181741319,Infliximab Pfizer (Unknown),Osteoporosis,OT
181741319,Infliximab Pfizer (Unknown),Osteoarthritis,OT
181741319,Infliximab Pfizer (Unknown),Off label use,OT
181741319,Infliximab Pfizer (Unknown),Oedema peripheral,OT
181741319,Infliximab Pfizer (Unknown),Nausea,OT
181741319,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,OT
181741319,Infliximab Pfizer (Unknown),Mobility decreased,OT
181741319,Infliximab Pfizer (Unknown),Malaise,OT
181741319,Infliximab Pfizer (Unknown),Lupus-like syndrome,OT
181741319,Infliximab Pfizer (Unknown),Laryngitis,OT
181741319,Infliximab Pfizer (Unknown),Joint swelling,OT
181741319,Infliximab Pfizer (Unknown),Joint stiffness,OT
181741319,Infliximab Pfizer (Unknown),Joint dislocation,OT
181741319,Infliximab Pfizer (Unknown),Infusion related reaction,OT
181741319,Infliximab Pfizer (Unknown),Infection,OT
181741319,Infliximab Pfizer (Unknown),Hypoaesthesia,OT
181741319,Infliximab Pfizer (Unknown),Hypersensitivity,OT
181741319,Infliximab Pfizer (Unknown),Hepatic enzyme increased,OT
181741319,Infliximab Pfizer (Unknown),Hepatic cirrhosis,OT
181741319,Infliximab Pfizer (Unknown),Headache,OT
181741319,Infliximab Pfizer (Unknown),Hand deformity,OT
181741319,Infliximab Pfizer (Unknown),Glossodynia,OT
181741319,Infliximab Pfizer (Unknown),General physical health deterioration,OT
181741319,Infliximab Pfizer (Unknown),Foot deformity,OT
181741319,Infliximab Pfizer (Unknown),Fatigue,OT
181741319,Infliximab Pfizer (Unknown),Exposure during pregnancy,OT
181741319,Infliximab Pfizer (Unknown),Exostosis,OT
181741319,Infliximab Pfizer (Unknown),Ear infection,OT
181741319,Infliximab Pfizer (Unknown),Drug intolerance,OT
181741319,Infliximab Pfizer (Unknown),Drug ineffective,OT
181741319,Infliximab Pfizer (Unknown),Drug hypersensitivity,OT
181741319,Infliximab Pfizer (Unknown),Dizziness,OT
181741319,Infliximab Pfizer (Unknown),Discomfort,OT
181741319,Infliximab Pfizer (Unknown),Decreased appetite,OT
181741319,Infliximab Pfizer (Unknown),Crohn's disease,OT
181741319,Infliximab Pfizer (Unknown),Contraindicated product administered,OT
181741319,Infliximab Pfizer (Unknown),Condition aggravated,OT
181741319,Infliximab Pfizer (Unknown),C-reactive protein increased,OT
181741319,Infliximab Pfizer (Unknown),Bone erosion,OT
181741319,Infliximab Pfizer (Unknown),Arthritis,OT
181741319,Infliximab Pfizer (Unknown),Arthralgia,OT
181741319,Infliximab Pfizer (Unknown),Anti-cyclic citrullinated peptide antibody positive,OT
181741319,Infliximab Pfizer (Unknown),Alopecia,OT
181741319,Infliximab Pfizer (Unknown),Abdominal discomfort,OT
181741319,Infliximab Pfizer (Unknown),Wound,OT
181741319,Infliximab Pfizer (Unknown),Visual impairment,OT
181741319,Infliximab Pfizer (Unknown),Treatment failure,OT
181741319,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
181741319,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,OT
181741319,Infliximab Pfizer (Unknown),Systemic lupus erythematosus,OT
181741319,Infliximab Pfizer (Unknown),Synovitis,OT
181741319,Infliximab Pfizer (Unknown),Rheumatoid factor positive,OT
181741319,Infliximab Pfizer (Unknown),Rheumatoid arthritis,OT
181741319,Infliximab Pfizer (Unknown),Retinitis,OT
181741319,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,OT
181741319,Infliximab Pfizer (Unknown),Rash,OT
181741319,Infliximab Pfizer (Unknown),Product use issue,OT
181741319,Infliximab Pfizer (Unknown),Product use in unapproved indication,OT
181741319,Infliximab Pfizer (Unknown),Pneumonia,OT
181741319,Infliximab Pfizer (Unknown),Pericarditis,OT
181741319,Infliximab Pfizer (Unknown),Pemphigus,OT
181741319,Infliximab Pfizer (Unknown),Pain in extremity,OT
181741319,Infliximab Pfizer (Unknown),Pain,OT
181741319,Infliximab Pfizer (Unknown),Osteoporosis,OT
181741319,Infliximab Pfizer (Unknown),Osteoarthritis,OT
181741319,Infliximab Pfizer (Unknown),Off label use,OT
181741319,Infliximab Pfizer (Unknown),Oedema peripheral,OT
181741319,Infliximab Pfizer (Unknown),Nausea,OT
181741319,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,OT
181741319,Infliximab Pfizer (Unknown),Mobility decreased,OT
181741319,Infliximab Pfizer (Unknown),Malaise,OT
181741319,Infliximab Pfizer (Unknown),Lupus-like syndrome,OT
181741319,Infliximab Pfizer (Unknown),Laryngitis,OT
181741319,Infliximab Pfizer (Unknown),Joint swelling,OT
181741319,Infliximab Pfizer (Unknown),Joint stiffness,OT
181741319,Infliximab Pfizer (Unknown),Joint dislocation,OT
181741319,Infliximab Pfizer (Unknown),Infusion related reaction,OT
181741319,Infliximab Pfizer (Unknown),Infection,OT
181741319,Infliximab Pfizer (Unknown),Hypoaesthesia,OT
181741319,Infliximab Pfizer (Unknown),Hypersensitivity,OT
181741319,Infliximab Pfizer (Unknown),Hepatic enzyme increased,OT
181741319,Infliximab Pfizer (Unknown),Hepatic cirrhosis,OT
181741319,Infliximab Pfizer (Unknown),Headache,OT
181741319,Infliximab Pfizer (Unknown),Hand deformity,OT
181741319,Infliximab Pfizer (Unknown),Glossodynia,OT
181741319,Infliximab Pfizer (Unknown),General physical health deterioration,OT
181741319,Infliximab Pfizer (Unknown),Foot deformity,OT
181741319,Infliximab Pfizer (Unknown),Fatigue,OT
181741319,Infliximab Pfizer (Unknown),Exposure during pregnancy,OT
181741319,Infliximab Pfizer (Unknown),Exostosis,OT
181741319,Infliximab Pfizer (Unknown),Ear infection,OT
181741319,Infliximab Pfizer (Unknown),Drug intolerance,OT
181741319,Infliximab Pfizer (Unknown),Drug ineffective,OT
181741319,Infliximab Pfizer (Unknown),Drug hypersensitivity,OT
181741319,Infliximab Pfizer (Unknown),Dizziness,OT
181741319,Infliximab Pfizer (Unknown),Discomfort,OT
181741319,Infliximab Pfizer (Unknown),Decreased appetite,OT
181741319,Infliximab Pfizer (Unknown),Crohn's disease,OT
181741319,Infliximab Pfizer (Unknown),Contraindicated product administered,OT
181741319,Infliximab Pfizer (Unknown),Condition aggravated,OT
181741319,Infliximab Pfizer (Unknown),C-reactive protein increased,OT
181741319,Infliximab Pfizer (Unknown),Bone erosion,OT
181741319,Infliximab Pfizer (Unknown),Arthritis,OT
181741319,Infliximab Pfizer (Unknown),Arthralgia,OT
181741319,Infliximab Pfizer (Unknown),Anti-cyclic citrullinated peptide antibody positive,OT
181741319,Infliximab Pfizer (Unknown),Alopecia,OT
181741319,Infliximab Pfizer (Unknown),Abdominal discomfort,OT
181741319,Infliximab Pfizer (Unknown),Wound,OT
181741319,Infliximab Pfizer (Unknown),Visual impairment,OT
181741319,Infliximab Pfizer (Unknown),Treatment failure,OT
181741319,Infliximab Pfizer (Unknown),Therapeutic product effect incomplete,OT
181741319,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,OT
181741319,Infliximab Pfizer (Unknown),Systemic lupus erythematosus,OT
181741319,Infliximab Pfizer (Unknown),Synovitis,OT
181741319,Infliximab Pfizer (Unknown),Rheumatoid factor positive,OT
181741319,Infliximab Pfizer (Unknown),Rheumatoid arthritis,OT
181741319,Infliximab Pfizer (Unknown),Retinitis,OT
181741319,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,OT
181741319,Infliximab Pfizer (Unknown),Rash,OT
181741319,Infliximab Pfizer (Unknown),Product use issue,OT
181741319,Infliximab Pfizer (Unknown),Product use in unapproved indication,OT
181741319,Infliximab Pfizer (Unknown),Pneumonia,OT
181741319,Infliximab Pfizer (Unknown),Pericarditis,OT
181741319,Infliximab Pfizer (Unknown),Pemphigus,OT
181741319,Infliximab Pfizer (Unknown),Pain in extremity,OT
181741319,Infliximab Pfizer (Unknown),Pain,OT
181741319,Infliximab Pfizer (Unknown),Osteoporosis,OT
181741319,Infliximab Pfizer (Unknown),Osteoarthritis,OT
181741319,Infliximab Pfizer (Unknown),Off label use,OT
181741319,Infliximab Pfizer (Unknown),Oedema peripheral,OT
181741319,Infliximab Pfizer (Unknown),Nausea,OT
181741319,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,OT
181741319,Infliximab Pfizer (Unknown),Mobility decreased,OT
181741319,Infliximab Pfizer (Unknown),Malaise,OT
181741319,Infliximab Pfizer (Unknown),Lupus-like syndrome,OT
181741319,Infliximab Pfizer (Unknown),Laryngitis,OT
181741319,Infliximab Pfizer (Unknown),Joint swelling,OT
181741319,Infliximab Pfizer (Unknown),Joint stiffness,OT
181741319,Infliximab Pfizer (Unknown),Joint dislocation,OT
181741319,Infliximab Pfizer (Unknown),Infusion related reaction,OT
181741319,Infliximab Pfizer (Unknown),Infection,OT
181741319,Infliximab Pfizer (Unknown),Hypoaesthesia,OT
181741319,Infliximab Pfizer (Unknown),Hypersensitivity,OT
181741319,Infliximab Pfizer (Unknown),Hepatic enzyme increased,OT
181741319,Infliximab Pfizer (Unknown),Hepatic cirrhosis,OT
181741319,Infliximab Pfizer (Unknown),Headache,OT
181741319,Infliximab Pfizer (Unknown),Hand deformity,OT
181741319,Infliximab Pfizer (Unknown),Glossodynia,OT
181741319,Infliximab Pfizer (Unknown),General physical health deterioration,OT
181741319,Infliximab Pfizer (Unknown),Foot deformity,OT
181741319,Infliximab Pfizer (Unknown),Fatigue,OT
181741319,Infliximab Pfizer (Unknown),Exposure during pregnancy,OT
181741319,Infliximab Pfizer (Unknown),Exostosis,OT
181741319,Infliximab Pfizer (Unknown),Ear infection,OT
181741319,Infliximab Pfizer (Unknown),Drug intolerance,OT
181741319,Infliximab Pfizer (Unknown),Drug ineffective,OT
181741319,Infliximab Pfizer (Unknown),Drug hypersensitivity,OT
181741319,Infliximab Pfizer (Unknown),Dizziness,OT
181741319,Infliximab Pfizer (Unknown),Discomfort,OT
181741319,Infliximab Pfizer (Unknown),Decreased appetite,OT
181741319,Infliximab Pfizer (Unknown),Crohn's disease,OT
181741319,Infliximab Pfizer (Unknown),Contraindicated product administered,OT
181741319,Infliximab Pfizer (Unknown),Condition aggravated,OT
181741319,Infliximab Pfizer (Unknown),C-reactive protein increased,OT
181741319,Infliximab Pfizer (Unknown),Bone erosion,OT
181741319,Infliximab Pfizer (Unknown),Arthritis,OT
181741319,Infliximab Pfizer (Unknown),Arthralgia,OT
181741319,Infliximab Pfizer (Unknown),Anti-cyclic citrullinated peptide antibody positive,OT
181741319,Infliximab Pfizer (Unknown),Alopecia,OT
181741319,Infliximab Pfizer (Unknown),Abdominal discomfort,OT
182976902,Infliximab,Polyp,OT
182976902,Infliximab,Off label use,OT
182976902,Infliximab,Gingival disorder,OT
184114783,Infliximab,Weight increased,OT
184114783,Infliximab,Weight fluctuation,OT
184114783,Infliximab,Product use issue,OT
184114783,Infliximab,Pain in extremity,OT
184114783,Infliximab,Off label use,OT
184114783,Infliximab,Neck pain,OT
184114783,Infliximab,Intentional product use issue,OT
184114783,Infliximab,Inappropriate schedule of product administration,OT
184114783,Infliximab,Dizziness,OT
184114783,Infliximab,Back pain,OT
184114783,Infliximab,Arthralgia,OT
184364473,Infliximab,Weight increased,OT
184364473,Infliximab,Vomiting,OT
184364473,Infliximab,Tachycardia,OT
184364473,Infliximab,Pruritus,OT
184364473,Infliximab,Product use issue,OT
184364473,Infliximab,Peripheral swelling,OT
184364473,Infliximab,Pain in extremity,OT
184364473,Infliximab,Pain,OT
184364473,Infliximab,Off label use,OT
184364473,Infliximab,Nausea,OT
184364473,Infliximab,Joint swelling,OT
184364473,Infliximab,Joint injury,OT
184364473,Infliximab,Intentional product use issue,OT
184364473,Infliximab,Injection site pain,OT
184364473,Infliximab,Infusion site haemorrhage,OT
184364473,Infliximab,Incorrect dose administered,OT
184364473,Infliximab,Heart rate decreased,OT
184364473,Infliximab,Headache,OT
184364473,Infliximab,Hair texture abnormal,OT
184364473,Infliximab,Erythema,OT
184364473,Infliximab,Dry skin,OT
184364473,Infliximab,Drug ineffective,OT
184364473,Infliximab,Blood pressure increased,OT
184364473,Infliximab,Blood pressure fluctuation,OT
184364473,Infliximab,Back pain,OT
184885034,Infliximab,Product use issue,OT
184885034,Infliximab,Pneumonia,OT
184885034,Infliximab,Peripheral swelling,OT
184885034,Infliximab,Pain in extremity,OT
184885034,Infliximab,Osteoarthritis,OT
184885034,Infliximab,Off label use,OT
184885034,Infliximab,Obesity,OT
184885034,Infliximab,Metabolic syndrome,OT
184885034,Infliximab,Intentional product use issue,OT
184885034,Infliximab,Heart rate increased,OT
184885034,Infliximab,Heart rate decreased,OT
184885034,Infliximab,Fatigue,OT
184885034,Infliximab,Dyspnoea,OT
184885034,Infliximab,Drug ineffective,OT
184885034,Infliximab,Blood pressure fluctuation,OT
184885034,Infliximab,Arthralgia,OT
184885034,Infliximab,Product use issue,OT
184885034,Infliximab,Pneumonia,OT
184885034,Infliximab,Peripheral swelling,OT
184885034,Infliximab,Pain in extremity,OT
184885034,Infliximab,Osteoarthritis,OT
184885034,Infliximab,Off label use,OT
184885034,Infliximab,Obesity,OT
184885034,Infliximab,Metabolic syndrome,OT
184885034,Infliximab,Intentional product use issue,OT
184885034,Infliximab,Heart rate increased,OT
184885034,Infliximab,Heart rate decreased,OT
184885034,Infliximab,Fatigue,OT
184885034,Infliximab,Dyspnoea,OT
184885034,Infliximab,Drug ineffective,OT
184885034,Infliximab,Blood pressure fluctuation,OT
184885034,Infliximab,Arthralgia,OT
184970602,Infliximab,Weight decreased,OT
184970602,Infliximab,Off label use,OT
184970602,Infliximab,Hypertension,OT
184970602,Infliximab,Crohn's disease,OT
184970602,Infliximab,Blood pressure increased,OT
184970602,Infliximab,Blood pressure fluctuation,OT
185464033,Infliximab,Urinary tract infection,OT
185464033,Infliximab,Rash,OT
185464033,Infliximab,Pruritus,OT
185464033,Infliximab,Oropharyngeal discomfort,OT
185464033,Infliximab,Off label use,OT
185464033,Infliximab,Malaise,OT
185464033,Infliximab,Incorrect dose administered,OT
185464033,Infliximab,Inappropriate schedule of product administration,OT
185464033,Infliximab,Hypertension,OT
185464033,Infliximab,Heart rate decreased,OT
185464033,Infliximab,Fistula,OT
185464033,Infliximab,Eye inflammation,OT
185464033,Infliximab,Dysuria,OT
185464033,Infliximab,Drug level decreased,OT
185464033,Infliximab,Dizziness,OT
185464033,Infliximab,Dermatitis,OT
185464033,Infliximab,Cystitis,OT
185464033,Infliximab,Condition aggravated,OT
185464033,Infliximab,Blood pressure increased,OT
185464033,Infliximab,Balance disorder,OT
185464033,Infliximab,Urinary tract infection,OT
185464033,Infliximab,Rash,OT
185464033,Infliximab,Pruritus,OT
185464033,Infliximab,Oropharyngeal discomfort,OT
185464033,Infliximab,Off label use,OT
185464033,Infliximab,Malaise,OT
185464033,Infliximab,Incorrect dose administered,OT
185464033,Infliximab,Inappropriate schedule of product administration,OT
185464033,Infliximab,Hypertension,OT
185464033,Infliximab,Heart rate decreased,OT
185464033,Infliximab,Fistula,OT
185464033,Infliximab,Eye inflammation,OT
185464033,Infliximab,Dysuria,OT
185464033,Infliximab,Drug level decreased,OT
185464033,Infliximab,Dizziness,OT
185464033,Infliximab,Dermatitis,OT
185464033,Infliximab,Cystitis,OT
185464033,Infliximab,Condition aggravated,OT
185464033,Infliximab,Blood pressure increased,OT
185464033,Infliximab,Balance disorder,OT
189361473,Infliximab,White blood cell disorder,HO
189361473,Infliximab,White blood cell disorder,OT
189361473,Infliximab,Weight decreased,HO
189361473,Infliximab,Weight decreased,OT
189361473,Infliximab,Vitamin D increased,HO
189361473,Infliximab,Vitamin D increased,OT
189361473,Infliximab,Vaginal infection,HO
189361473,Infliximab,Vaginal infection,OT
189361473,Infliximab,Vaginal abscess,HO
189361473,Infliximab,Vaginal abscess,OT
189361473,Infliximab,Urinary tract infection,HO
189361473,Infliximab,Urinary tract infection,OT
189361473,Infliximab,Therapeutic product effect incomplete,HO
189361473,Infliximab,Therapeutic product effect incomplete,OT
189361473,Infliximab,Stress,HO
189361473,Infliximab,Stress,OT
189361473,Infliximab,Sinusitis,HO
189361473,Infliximab,Sinusitis,OT
189361473,Infliximab,Respiratory tract congestion,HO
189361473,Infliximab,Respiratory tract congestion,OT
189361473,Infliximab,Red blood cell sedimentation rate increased,HO
189361473,Infliximab,Red blood cell sedimentation rate increased,OT
189361473,Infliximab,Productive cough,HO
189361473,Infliximab,Productive cough,OT
189361473,Infliximab,Proctalgia,HO
189361473,Infliximab,Proctalgia,OT
189361473,Infliximab,Procedural anxiety,HO
189361473,Infliximab,Procedural anxiety,OT
189361473,Infliximab,Pneumonia,HO
189361473,Infliximab,Pneumonia,OT
189361473,Infliximab,Pharyngitis,HO
189361473,Infliximab,Pharyngitis,OT
189361473,Infliximab,Paraesthesia,HO
189361473,Infliximab,Paraesthesia,OT
189361473,Infliximab,Pain,HO
189361473,Infliximab,Pain,OT
189361473,Infliximab,Oropharyngeal pain,HO
189361473,Infliximab,Oropharyngeal pain,OT
189361473,Infliximab,Nerve compression,HO
189361473,Infliximab,Nerve compression,OT
189361473,Infliximab,Nephrolithiasis,HO
189361473,Infliximab,Nephrolithiasis,OT
189361473,Infliximab,Nausea,HO
189361473,Infliximab,Nausea,OT
189361473,Infliximab,Nasopharyngitis,HO
189361473,Infliximab,Nasopharyngitis,OT
189361473,Infliximab,Migraine,HO
189361473,Infliximab,Migraine,OT
189361473,Infliximab,Malaise,HO
189361473,Infliximab,Malaise,OT
189361473,Infliximab,Lower respiratory tract infection,HO
189361473,Infliximab,Lower respiratory tract infection,OT
189361473,Infliximab,Large intestinal ulcer,HO
189361473,Infliximab,Large intestinal ulcer,OT
189361473,Infliximab,Lactose intolerance,HO
189361473,Infliximab,Lactose intolerance,OT
189361473,Infliximab,Irritable bowel syndrome,HO
189361473,Infliximab,Irritable bowel syndrome,OT
189361473,Infliximab,Intentional product use issue,HO
189361473,Infliximab,Intentional product use issue,OT
189361473,Infliximab,Injury,HO
189361473,Infliximab,Injury,OT
189361473,Infliximab,Infusion site streaking,HO
189361473,Infliximab,Infusion site streaking,OT
189361473,Infliximab,Incontinence,HO
189361473,Infliximab,Incontinence,OT
189361473,Infliximab,Inappropriate schedule of product administration,HO
189361473,Infliximab,Inappropriate schedule of product administration,OT
189361473,Infliximab,Heart rate decreased,HO
189361473,Infliximab,Heart rate decreased,OT
189361473,Infliximab,Headache,HO
189361473,Infliximab,Headache,OT
189361473,Infliximab,Haemorrhoids,HO
189361473,Infliximab,Haemorrhoids,OT
189361473,Infliximab,Haemoglobin increased,HO
189361473,Infliximab,Haemoglobin increased,OT
189361473,Infliximab,Haematocrit increased,HO
189361473,Infliximab,Haematocrit increased,OT
189361473,Infliximab,Frequent bowel movements,HO
189361473,Infliximab,Frequent bowel movements,OT
189361473,Infliximab,Food allergy,HO
189361473,Infliximab,Food allergy,OT
189361473,Infliximab,Flatulence,HO
189361473,Infliximab,Flatulence,OT
189361473,Infliximab,Fistula,HO
189361473,Infliximab,Fistula,OT
189361473,Infliximab,Fibromyalgia,HO
189361473,Infliximab,Fibromyalgia,OT
189361473,Infliximab,Female genital tract fistula,HO
189361473,Infliximab,Female genital tract fistula,OT
189361473,Infliximab,Fear of injection,HO
189361473,Infliximab,Fear of injection,OT
189361473,Infliximab,Dyspepsia,HO
189361473,Infliximab,Dyspepsia,OT
189361473,Infliximab,Diverticulum,HO
189361473,Infliximab,Diverticulum,OT
189361473,Infliximab,Discomfort,HO
189361473,Infliximab,Discomfort,OT
189361473,Infliximab,Diarrhoea,HO
189361473,Infliximab,Diarrhoea,OT
189361473,Infliximab,Cystic fibrosis,HO
189361473,Infliximab,Cystic fibrosis,OT
189361473,Infliximab,Cough,HO
189361473,Infliximab,Cough,OT
189361473,Infliximab,Clostridium difficile infection,HO
189361473,Infliximab,Clostridium difficile infection,OT
189361473,Infliximab,COVID-19,HO
189361473,Infliximab,COVID-19,OT
189361473,Infliximab,C-reactive protein abnormal,HO
189361473,Infliximab,C-reactive protein abnormal,OT
189361473,Infliximab,Burning sensation,HO
189361473,Infliximab,Burning sensation,OT
189361473,Infliximab,Blood triglycerides increased,HO
189361473,Infliximab,Blood triglycerides increased,OT
189361473,Infliximab,Blood pressure systolic increased,HO
189361473,Infliximab,Blood pressure systolic increased,OT
189361473,Infliximab,Blood cholesterol increased,HO
189361473,Infliximab,Blood cholesterol increased,OT
189361473,Infliximab,Back pain,HO
189361473,Infliximab,Back pain,OT
189361473,Infliximab,Arthritis,HO
189361473,Infliximab,Arthritis,OT
189361473,Infliximab,Anxiety,HO
189361473,Infliximab,Anxiety,OT
189361473,Infliximab,Anorectal discomfort,HO
189361473,Infliximab,Anorectal discomfort,OT
189361473,Infliximab,Anal skin tags,HO
189361473,Infliximab,Anal skin tags,OT
189361473,Infliximab,Alopecia,HO
189361473,Infliximab,Alopecia,OT
189361473,Infliximab,Alanine aminotransferase increased,HO
189361473,Infliximab,Alanine aminotransferase increased,OT
189361473,Infliximab,Abdominal discomfort,HO
189361473,Infliximab,Abdominal discomfort,OT
191108792,Infliximab,White blood cell count increased,OT
191108792,Infliximab,Seasonal allergy,OT
191108792,Infliximab,Protein total increased,OT
191108792,Infliximab,Platelet count decreased,OT
191108792,Infliximab,Off label use,OT
191108792,Infliximab,Mean cell volume increased,OT
191108792,Infliximab,Intentional product use issue,OT
191108792,Infliximab,Inappropriate schedule of product administration,OT
191108792,Infliximab,Glomerular filtration rate decreased,OT
191108792,Infliximab,Cough,OT
191108792,Infliximab,C-reactive protein increased,OT
191108792,Infliximab,Blood glucose increased,OT
191108792,Infliximab,Blood creatinine increased,OT
191810712,Infliximab,Upper respiratory fungal infection,OT
191810712,Infliximab,Platelet count decreased,OT
191810712,Infliximab,Oropharyngeal candidiasis,OT
191810712,Infliximab,Oral fungal infection,OT
191810712,Infliximab,Oral candidiasis,OT
191810712,Infliximab,Muscular weakness,OT
191810712,Infliximab,Increased tendency to bruise,OT
191810712,Infliximab,Feeling abnormal,OT
191810712,Infliximab,Fatigue,OT
191810712,Infliximab,Dizziness,OT
191810712,Infliximab,Cough,OT
191810712,Infliximab,Condition aggravated,OT
191810712,Infliximab,Balance disorder,OT
191810712,Infliximab,Upper respiratory fungal infection,OT
191810712,Infliximab,Platelet count decreased,OT
191810712,Infliximab,Oropharyngeal candidiasis,OT
191810712,Infliximab,Oral fungal infection,OT
191810712,Infliximab,Oral candidiasis,OT
191810712,Infliximab,Muscular weakness,OT
191810712,Infliximab,Increased tendency to bruise,OT
191810712,Infliximab,Feeling abnormal,OT
191810712,Infliximab,Fatigue,OT
191810712,Infliximab,Dizziness,OT
191810712,Infliximab,Cough,OT
191810712,Infliximab,Condition aggravated,OT
191810712,Infliximab,Balance disorder,OT
192440232,Infliximab,Weight increased,OT
192440232,Infliximab,Pruritus,OT
192440232,Infliximab,Post procedural infection,OT
192440232,Infliximab,Inappropriate schedule of product administration,OT
192440232,Infliximab,Constipation,OT
192440232,Infliximab,Condition aggravated,OT
192440232,Infliximab,Abdominal pain,OT
192440232,Infliximab,Abdominal distension,OT
192544092,Infliximab,Oxygen saturation abnormal,OT
192544092,Infliximab,Off label use,OT
192544092,Infliximab,Intentional product use issue,OT
192544092,Infliximab,Condition aggravated,OT
192544092,Infliximab,Body temperature decreased,OT
192544092,Infliximab,Blood pressure increased,OT
192711462,Infliximab,Off label use,HO
192711462,Infliximab,Condition aggravated,HO
192711462,Infliximab,Colitis ulcerative,HO
192711462,Infliximab,Blood pressure diastolic increased,HO
192711462,Infliximab,Off label use,HO
192711462,Infliximab,Condition aggravated,HO
192711462,Infliximab,Colitis ulcerative,HO
192711462,Infliximab,Blood pressure diastolic increased,HO
194793841,Infliximab,Weight decreased,OT
194793841,Infliximab,Vision blurred,OT
194793841,Infliximab,Tinnitus,OT
194793841,Infliximab,Therapeutic product effect incomplete,OT
194793841,Infliximab,Rash papular,OT
194793841,Infliximab,Rash,OT
194793841,Infliximab,Product use issue,OT
194793841,Infliximab,Off label use,OT
194793841,Infliximab,Nausea,OT
194793841,Infliximab,Muscle spasms,OT
194793841,Infliximab,Migraine,OT
194793841,Infliximab,Maternal exposure during pregnancy,OT
194793841,Infliximab,Malaise,OT
194793841,Infliximab,Intentional product use issue,OT
194793841,Infliximab,Incorrect dose administered,OT
194793841,Infliximab,Inappropriate schedule of product administration,OT
194793841,Infliximab,Hyperhidrosis,OT
194793841,Infliximab,Heart rate irregular,OT
194793841,Infliximab,Fatigue,OT
194793841,Infliximab,Faeces discoloured,OT
194793841,Infliximab,Drug level below therapeutic,OT
194793841,Infliximab,Drug level above therapeutic,OT
194793841,Infliximab,Decreased appetite,OT
194793841,Infliximab,Anorectal discomfort,OT
194793841,Infliximab,Abortion,OT
194793841,Infliximab,Weight decreased,OT
194793841,Infliximab,Vision blurred,OT
194793841,Infliximab,Tinnitus,OT
194793841,Infliximab,Therapeutic product effect incomplete,OT
194793841,Infliximab,Rash papular,OT
194793841,Infliximab,Rash,OT
194793841,Infliximab,Product use issue,OT
194793841,Infliximab,Off label use,OT
194793841,Infliximab,Nausea,OT
194793841,Infliximab,Muscle spasms,OT
194793841,Infliximab,Migraine,OT
194793841,Infliximab,Maternal exposure during pregnancy,OT
194793841,Infliximab,Malaise,OT
194793841,Infliximab,Intentional product use issue,OT
194793841,Infliximab,Incorrect dose administered,OT
194793841,Infliximab,Inappropriate schedule of product administration,OT
194793841,Infliximab,Hyperhidrosis,OT
194793841,Infliximab,Heart rate irregular,OT
194793841,Infliximab,Fatigue,OT
194793841,Infliximab,Faeces discoloured,OT
194793841,Infliximab,Drug level below therapeutic,OT
194793841,Infliximab,Drug level above therapeutic,OT
194793841,Infliximab,Decreased appetite,OT
194793841,Infliximab,Anorectal discomfort,OT
194793841,Infliximab,Abortion,OT
194857541,Infliximab (Unknown),Loss of therapeutic response,OT
194857541,Infliximab (Unknown),Drug specific antibody present,OT
194857541,Infliximab (Unknown),Colitis ulcerative,OT
194857541,Infliximab (Unknown),Clostridium difficile infection,OT
194857541,Infliximab (Unknown),Loss of therapeutic response,OT
194857541,Infliximab (Unknown),Drug specific antibody present,OT
194857541,Infliximab (Unknown),Colitis ulcerative,OT
194857541,Infliximab (Unknown),Clostridium difficile infection,OT
194979931,Infliximab,Weight increased,OT
194979931,Infliximab,Weight decreased,OT
194979931,Infliximab,Product dose omission issue,OT
194979931,Infliximab,Off label use,OT
194979931,Infliximab,Maternal exposure during pregnancy,OT
194979931,Infliximab,Intentional product use issue,OT
194979931,Infliximab,Inappropriate schedule of product administration,OT
194979931,Infliximab,Heart rate increased,OT
194979931,Infliximab,General physical health deterioration,OT
194979931,Infliximab,Condition aggravated,OT
197073421,Infliximab,Off label use,OT
197073421,Infliximab,Off label use,HO
197073421,Infliximab,Infusion related reaction,OT
197073421,Infliximab,Infusion related reaction,HO
197073421,Infliximab,Drug ineffective,OT
197073421,Infliximab,Drug ineffective,HO
197073421,Infliximab,Colitis ulcerative,OT
197073421,Infliximab,Colitis ulcerative,HO
197457011,Infliximab,Heart rate decreased,OT
197457011,Infliximab,Body temperature decreased,OT
197457011,Infliximab,Blood pressure fluctuation,OT
197457011,Infliximab,Abscess bacterial,OT
197702582,Infliximab,Weight increased,OT
197702582,Infliximab,Urticaria,OT
197702582,Infliximab,Palpitations,OT
197702582,Infliximab,Off label use,OT
197702582,Infliximab,Nausea,OT
197702582,Infliximab,Malaise,OT
197702582,Infliximab,Hyperhidrosis,OT
197702582,Infliximab,Flushing,OT
197702582,Infliximab,Fatigue,OT
197702582,Infliximab,Cystitis,OT
197702582,Infliximab,Condition aggravated,OT
197702582,Infliximab,Abdominal discomfort,OT
197717981,Infliximab,Weight increased,OT
197717981,Infliximab,Weight fluctuation,OT
197717981,Infliximab,Therapeutic response shortened,OT
197717981,Infliximab,Off label use,OT
197717981,Infliximab,Night sweats,OT
197717981,Infliximab,Nasopharyngitis,OT
197717981,Infliximab,Intentional product use issue,OT
197717981,Infliximab,Heart rate decreased,OT
197717981,Infliximab,Fluid retention,OT
197717981,Infliximab,Fatigue,OT
197717981,Infliximab,Cough,OT
197717981,Infliximab,Condition aggravated,OT
197717981,Infliximab,Blood pressure increased,OT
197717981,Infliximab,Blood pressure fluctuation,OT
197858211,Infliximab,Product use issue,OT
197858211,Infliximab,Nausea,OT
197858211,Infliximab,Infection,OT
197858211,Infliximab,Inappropriate schedule of product administration,OT
197858211,Infliximab,Glaucoma,OT
197858211,Infliximab,Dizziness,OT
197858211,Infliximab,Cataract,OT
197995941,Infliximab,Off label use,OT
197995941,Infliximab,Intentional product use issue,OT
197995941,Infliximab,Condition aggravated,OT
198214171,Infliximab,Syncope,OT
198214171,Infliximab,Post procedural haemorrhage,OT
198214171,Infliximab,Off label use,OT
198214171,Infliximab,Intentional product use issue,OT
198397861,Infliximab,Product use in unapproved indication,OT
198397861,Infliximab,Off label use,OT
198397861,Infliximab,Abscess,OT
198454701,Infliximab,Product use issue,OT
198454701,Infliximab,Pain,OT
198454701,Infliximab,Off label use,OT
198454701,Infliximab,Loss of personal independence in daily activities,OT
198454701,Infliximab,Intentional product use issue,OT
198454701,Infliximab,Fistula discharge,OT
198454701,Infliximab,Discomfort,OT
198454701,Infliximab,Anorectal discomfort,OT
198454701,Infliximab,Anal fistula,OT
198454701,Infliximab,Anal abscess,OT
198804691,Infliximab,Weight decreased,HO
198804691,Infliximab,Weight decreased,OT
198804691,Infliximab,Swelling face,HO
198804691,Infliximab,Swelling face,OT
198804691,Infliximab,Off label use,HO
198804691,Infliximab,Off label use,OT
198804691,Infliximab,Dyspnoea,HO
198804691,Infliximab,Dyspnoea,OT
198804691,Infliximab,Campylobacter gastroenteritis,HO
198804691,Infliximab,Campylobacter gastroenteritis,OT
198804691,Infliximab,Abdominal pain,HO
198804691,Infliximab,Abdominal pain,OT
198804691,Infliximab,Abdominal discomfort,HO
198804691,Infliximab,Abdominal discomfort,OT
198851161,Infliximab (Unknown),Off label use,NULL
198851161,Infliximab (Unknown),Drug effective for unapproved indication,NULL
160852255,Infliximab,Product use issue,OT
160852255,Infliximab,Off label use,OT
160852255,Infliximab,Intentional product use issue,OT
160852255,Infliximab,Incorrect dose administered,OT
160852255,Infliximab,Inappropriate schedule of product administration,OT
160852255,Infliximab,Hypertension,OT
160852255,Infliximab,Heart rate irregular,OT
160852255,Infliximab,Heart rate increased,OT
160852255,Infliximab,Gastrointestinal disorder,OT
160852255,Infliximab,Drug level above therapeutic,OT
160852255,Infliximab,Condition aggravated,OT
160852255,Infliximab,Blood pressure fluctuation,OT
160852255,Infliximab,Product use issue,OT
160852255,Infliximab,Off label use,OT
160852255,Infliximab,Intentional product use issue,OT
160852255,Infliximab,Incorrect dose administered,OT
160852255,Infliximab,Inappropriate schedule of product administration,OT
160852255,Infliximab,Hypertension,OT
160852255,Infliximab,Heart rate irregular,OT
160852255,Infliximab,Heart rate increased,OT
160852255,Infliximab,Gastrointestinal disorder,OT
160852255,Infliximab,Drug level above therapeutic,OT
160852255,Infliximab,Condition aggravated,OT
160852255,Infliximab,Blood pressure fluctuation,OT
166917072,Infliximab,Product use issue,HO
166917072,Infliximab,Product use issue,OT
166917072,Infliximab,Off label use,HO
166917072,Infliximab,Off label use,OT
166917072,Infliximab,Intentional product use issue,HO
166917072,Infliximab,Intentional product use issue,OT
166917072,Infliximab,Drug level decreased,HO
166917072,Infliximab,Drug level decreased,OT
166917072,Infliximab,Condition aggravated,HO
166917072,Infliximab,Condition aggravated,OT
166917072,Infliximab,Product use issue,HO
166917072,Infliximab,Product use issue,OT
166917072,Infliximab,Off label use,HO
166917072,Infliximab,Off label use,OT
166917072,Infliximab,Intentional product use issue,HO
166917072,Infliximab,Intentional product use issue,OT
166917072,Infliximab,Drug level decreased,HO
166917072,Infliximab,Drug level decreased,OT
166917072,Infliximab,Condition aggravated,HO
166917072,Infliximab,Condition aggravated,OT
167286575,Infliximab,Obstruction,HO
167286575,Infliximab,Drug intolerance,HO
167286575,Infliximab,Drug ineffective,HO
167286575,Infliximab,Obstruction,HO
167286575,Infliximab,Drug intolerance,HO
167286575,Infliximab,Drug ineffective,HO
167286575,Infliximab,Obstruction,HO
167286575,Infliximab,Drug intolerance,HO
167286575,Infliximab,Drug ineffective,HO
175261555,Infliximab,Treatment failure,OT
175261555,Infliximab,Treatment failure,HO
175261555,Infliximab,Therapeutic response decreased,OT
175261555,Infliximab,Therapeutic response decreased,HO
175261555,Infliximab,Therapeutic product effect decreased,OT
175261555,Infliximab,Therapeutic product effect decreased,HO
175261555,Infliximab,Surgery,OT
175261555,Infliximab,Surgery,HO
175261555,Infliximab,Rheumatoid arthritis,OT
175261555,Infliximab,Rheumatoid arthritis,HO
175261555,Infliximab,Renal impairment,OT
175261555,Infliximab,Renal impairment,HO
175261555,Infliximab,Osteoarthritis,OT
175261555,Infliximab,Osteoarthritis,HO
175261555,Infliximab,Off label use,OT
175261555,Infliximab,Off label use,HO
175261555,Infliximab,Influenza,OT
175261555,Infliximab,Influenza,HO
175261555,Infliximab,Impaired gastric emptying,OT
175261555,Infliximab,Impaired gastric emptying,HO
175261555,Infliximab,Ill-defined disorder,OT
175261555,Infliximab,Ill-defined disorder,HO
175261555,Infliximab,Hypersensitivity,OT
175261555,Infliximab,Hypersensitivity,HO
175261555,Infliximab,Drug intolerance,OT
175261555,Infliximab,Drug intolerance,HO
175261555,Infliximab,Drug ineffective,OT
175261555,Infliximab,Drug ineffective,HO
175261555,Infliximab,Drug hypersensitivity,OT
175261555,Infliximab,Drug hypersensitivity,HO
175261555,Infliximab,Diabetes mellitus,OT
175261555,Infliximab,Diabetes mellitus,HO
175261555,Infliximab,Demyelination,OT
175261555,Infliximab,Demyelination,HO
175261555,Infliximab,Contraindicated product administered,OT
175261555,Infliximab,Contraindicated product administered,HO
175261555,Infliximab,Condition aggravated,OT
175261555,Infliximab,Condition aggravated,HO
175261555,Infliximab,Arthropathy,OT
175261555,Infliximab,Arthropathy,HO
175261555,Infliximab,Ankylosing spondylitis,OT
175261555,Infliximab,Ankylosing spondylitis,HO
175261555,Infliximab,Adverse event,OT
175261555,Infliximab,Adverse event,HO
175261555,Infliximab,Treatment failure,OT
175261555,Infliximab,Treatment failure,HO
175261555,Infliximab,Therapeutic response decreased,OT
175261555,Infliximab,Therapeutic response decreased,HO
175261555,Infliximab,Therapeutic product effect decreased,OT
175261555,Infliximab,Therapeutic product effect decreased,HO
175261555,Infliximab,Surgery,OT
175261555,Infliximab,Surgery,HO
175261555,Infliximab,Rheumatoid arthritis,OT
175261555,Infliximab,Rheumatoid arthritis,HO
175261555,Infliximab,Renal impairment,OT
175261555,Infliximab,Renal impairment,HO
175261555,Infliximab,Osteoarthritis,OT
175261555,Infliximab,Osteoarthritis,HO
175261555,Infliximab,Off label use,OT
175261555,Infliximab,Off label use,HO
175261555,Infliximab,Influenza,OT
175261555,Infliximab,Influenza,HO
175261555,Infliximab,Impaired gastric emptying,OT
175261555,Infliximab,Impaired gastric emptying,HO
175261555,Infliximab,Ill-defined disorder,OT
175261555,Infliximab,Ill-defined disorder,HO
175261555,Infliximab,Hypersensitivity,OT
175261555,Infliximab,Hypersensitivity,HO
175261555,Infliximab,Drug intolerance,OT
175261555,Infliximab,Drug intolerance,HO
175261555,Infliximab,Drug ineffective,OT
175261555,Infliximab,Drug ineffective,HO
175261555,Infliximab,Drug hypersensitivity,OT
175261555,Infliximab,Drug hypersensitivity,HO
175261555,Infliximab,Diabetes mellitus,OT
175261555,Infliximab,Diabetes mellitus,HO
175261555,Infliximab,Demyelination,OT
175261555,Infliximab,Demyelination,HO
175261555,Infliximab,Contraindicated product administered,OT
175261555,Infliximab,Contraindicated product administered,HO
175261555,Infliximab,Condition aggravated,OT
175261555,Infliximab,Condition aggravated,HO
175261555,Infliximab,Arthropathy,OT
175261555,Infliximab,Arthropathy,HO
175261555,Infliximab,Ankylosing spondylitis,OT
175261555,Infliximab,Ankylosing spondylitis,HO
175261555,Infliximab,Adverse event,OT
175261555,Infliximab,Adverse event,HO
175261555,Infliximab,Treatment failure,OT
175261555,Infliximab,Treatment failure,HO
175261555,Infliximab,Therapeutic response decreased,OT
175261555,Infliximab,Therapeutic response decreased,HO
175261555,Infliximab,Therapeutic product effect decreased,OT
175261555,Infliximab,Therapeutic product effect decreased,HO
175261555,Infliximab,Surgery,OT
175261555,Infliximab,Surgery,HO
175261555,Infliximab,Rheumatoid arthritis,OT
175261555,Infliximab,Rheumatoid arthritis,HO
175261555,Infliximab,Renal impairment,OT
175261555,Infliximab,Renal impairment,HO
175261555,Infliximab,Osteoarthritis,OT
175261555,Infliximab,Osteoarthritis,HO
175261555,Infliximab,Off label use,OT
175261555,Infliximab,Off label use,HO
175261555,Infliximab,Influenza,OT
175261555,Infliximab,Influenza,HO
175261555,Infliximab,Impaired gastric emptying,OT
175261555,Infliximab,Impaired gastric emptying,HO
175261555,Infliximab,Ill-defined disorder,OT
175261555,Infliximab,Ill-defined disorder,HO
175261555,Infliximab,Hypersensitivity,OT
175261555,Infliximab,Hypersensitivity,HO
175261555,Infliximab,Drug intolerance,OT
175261555,Infliximab,Drug intolerance,HO
175261555,Infliximab,Drug ineffective,OT
175261555,Infliximab,Drug ineffective,HO
175261555,Infliximab,Drug hypersensitivity,OT
175261555,Infliximab,Drug hypersensitivity,HO
175261555,Infliximab,Diabetes mellitus,OT
175261555,Infliximab,Diabetes mellitus,HO
175261555,Infliximab,Demyelination,OT
175261555,Infliximab,Demyelination,HO
175261555,Infliximab,Contraindicated product administered,OT
175261555,Infliximab,Contraindicated product administered,HO
175261555,Infliximab,Condition aggravated,OT
175261555,Infliximab,Condition aggravated,HO
175261555,Infliximab,Arthropathy,OT
175261555,Infliximab,Arthropathy,HO
175261555,Infliximab,Ankylosing spondylitis,OT
175261555,Infliximab,Ankylosing spondylitis,HO
175261555,Infliximab,Adverse event,OT
175261555,Infliximab,Adverse event,HO
175261555,Infliximab,Treatment failure,OT
175261555,Infliximab,Treatment failure,HO
175261555,Infliximab,Therapeutic response decreased,OT
175261555,Infliximab,Therapeutic response decreased,HO
175261555,Infliximab,Therapeutic product effect decreased,OT
175261555,Infliximab,Therapeutic product effect decreased,HO
175261555,Infliximab,Surgery,OT
175261555,Infliximab,Surgery,HO
175261555,Infliximab,Rheumatoid arthritis,OT
175261555,Infliximab,Rheumatoid arthritis,HO
175261555,Infliximab,Renal impairment,OT
175261555,Infliximab,Renal impairment,HO
175261555,Infliximab,Osteoarthritis,OT
175261555,Infliximab,Osteoarthritis,HO
175261555,Infliximab,Off label use,OT
175261555,Infliximab,Off label use,HO
175261555,Infliximab,Influenza,OT
175261555,Infliximab,Influenza,HO
175261555,Infliximab,Impaired gastric emptying,OT
175261555,Infliximab,Impaired gastric emptying,HO
175261555,Infliximab,Ill-defined disorder,OT
175261555,Infliximab,Ill-defined disorder,HO
175261555,Infliximab,Hypersensitivity,OT
175261555,Infliximab,Hypersensitivity,HO
175261555,Infliximab,Drug intolerance,OT
175261555,Infliximab,Drug intolerance,HO
175261555,Infliximab,Drug ineffective,OT
175261555,Infliximab,Drug ineffective,HO
175261555,Infliximab,Drug hypersensitivity,OT
175261555,Infliximab,Drug hypersensitivity,HO
175261555,Infliximab,Diabetes mellitus,OT
175261555,Infliximab,Diabetes mellitus,HO
175261555,Infliximab,Demyelination,OT
175261555,Infliximab,Demyelination,HO
175261555,Infliximab,Contraindicated product administered,OT
175261555,Infliximab,Contraindicated product administered,HO
175261555,Infliximab,Condition aggravated,OT
175261555,Infliximab,Condition aggravated,HO
175261555,Infliximab,Arthropathy,OT
175261555,Infliximab,Arthropathy,HO
175261555,Infliximab,Ankylosing spondylitis,OT
175261555,Infliximab,Ankylosing spondylitis,HO
175261555,Infliximab,Adverse event,OT
175261555,Infliximab,Adverse event,HO
175590132,Infliximab,Treatment failure,OT
175590132,Infliximab,Rheumatoid arthritis,OT
175590132,Infliximab,Off label use,OT
176058013,Infliximab,Stress,OT
176058013,Infliximab,Skin cancer,OT
176058013,Infliximab,Productive cough,OT
176058013,Infliximab,Product use issue,OT
176058013,Infliximab,Oropharyngeal pain,OT
176058013,Infliximab,Off label use,OT
176058013,Infliximab,Malaise,OT
176058013,Infliximab,Intentional product use issue,OT
176058013,Infliximab,Gastric disorder,OT
176058013,Infliximab,Cough,OT
176058013,Infliximab,Condition aggravated,OT
176058013,Infliximab,Blood pressure fluctuation,OT
176182714,Infliximab,Wrong product administered,OT
176182714,Infliximab,Weight increased,OT
176182714,Infliximab,Weight decreased,OT
176182714,Infliximab,Urinary tract infection,OT
176182714,Infliximab,Therapeutic product effect delayed,OT
176182714,Infliximab,Rectal haemorrhage,OT
176182714,Infliximab,Pharyngitis,OT
176182714,Infliximab,Oral candidiasis,OT
176182714,Infliximab,Off label use,OT
176182714,Infliximab,Nausea,OT
176182714,Infliximab,Nasopharyngitis,OT
176182714,Infliximab,Nasal congestion,OT
176182714,Infliximab,Malaise,OT
176182714,Infliximab,Influenza,OT
176182714,Infliximab,Incorrect dose administered,OT
176182714,Infliximab,Inappropriate schedule of product administration,OT
176182714,Infliximab,Headache,OT
176182714,Infliximab,Fatigue,OT
176182714,Infliximab,Dyspnoea,OT
176182714,Infliximab,Dyspepsia,OT
176182714,Infliximab,Drug ineffective,OT
176182714,Infliximab,Dizziness,OT
176182714,Infliximab,Diarrhoea,OT
176182714,Infliximab,Decreased appetite,OT
176182714,Infliximab,Condition aggravated,OT
176182714,Infliximab,Blood iron decreased,OT
176182714,Infliximab,Asthenia,OT
176182714,Infliximab,Anxiety,OT
176182714,Infliximab,Alopecia,OT
176182714,Infliximab,Abdominal pain upper,OT
176182714,Infliximab,Abdominal distension,OT
176182714,Infliximab,Wrong product administered,OT
176182714,Infliximab,Weight increased,OT
176182714,Infliximab,Weight decreased,OT
176182714,Infliximab,Urinary tract infection,OT
176182714,Infliximab,Therapeutic product effect delayed,OT
176182714,Infliximab,Rectal haemorrhage,OT
176182714,Infliximab,Pharyngitis,OT
176182714,Infliximab,Oral candidiasis,OT
176182714,Infliximab,Off label use,OT
176182714,Infliximab,Nausea,OT
176182714,Infliximab,Nasopharyngitis,OT
176182714,Infliximab,Nasal congestion,OT
176182714,Infliximab,Malaise,OT
176182714,Infliximab,Influenza,OT
176182714,Infliximab,Incorrect dose administered,OT
176182714,Infliximab,Inappropriate schedule of product administration,OT
176182714,Infliximab,Headache,OT
176182714,Infliximab,Fatigue,OT
176182714,Infliximab,Dyspnoea,OT
176182714,Infliximab,Dyspepsia,OT
176182714,Infliximab,Drug ineffective,OT
176182714,Infliximab,Dizziness,OT
176182714,Infliximab,Diarrhoea,OT
176182714,Infliximab,Decreased appetite,OT
176182714,Infliximab,Condition aggravated,OT
176182714,Infliximab,Blood iron decreased,OT
176182714,Infliximab,Asthenia,OT
176182714,Infliximab,Anxiety,OT
176182714,Infliximab,Alopecia,OT
176182714,Infliximab,Abdominal pain upper,OT
176182714,Infliximab,Abdominal distension,OT
176345884,Infliximab,Weight decreased,OT
176345884,Infliximab,Vaginal infection,OT
176345884,Infliximab,Systemic lupus erythematosus,OT
176345884,Infliximab,Pyrexia,OT
176345884,Infliximab,Pruritus,OT
176345884,Infliximab,Product use issue,OT
176345884,Infliximab,Off label use,OT
176345884,Infliximab,Oesophageal pain,OT
176345884,Infliximab,Oedema peripheral,OT
176345884,Infliximab,Oedema,OT
176345884,Infliximab,Odynophagia,OT
176345884,Infliximab,Joint effusion,OT
176345884,Infliximab,Intentional product use issue,OT
176345884,Infliximab,Infusion site erythema,OT
176345884,Infliximab,Inappropriate schedule of product administration,OT
176345884,Infliximab,Gastric disorder,OT
176345884,Infliximab,Fatigue,OT
176345884,Infliximab,Erythema,OT
176345884,Infliximab,Dysphagia,OT
176345884,Infliximab,Cough,OT
176345884,Infliximab,Breast cyst,OT
176345884,Infliximab,Breast cancer,OT
176345884,Infliximab,Breast calcifications,OT
176345884,Infliximab,Body temperature fluctuation,OT
176345884,Infliximab,Blood test abnormal,OT
176345884,Infliximab,Arthralgia,OT
176345884,Infliximab,Antinuclear antibody positive,OT
176345884,Infliximab,Weight decreased,OT
176345884,Infliximab,Vaginal infection,OT
176345884,Infliximab,Systemic lupus erythematosus,OT
176345884,Infliximab,Pyrexia,OT
176345884,Infliximab,Pruritus,OT
176345884,Infliximab,Product use issue,OT
176345884,Infliximab,Off label use,OT
176345884,Infliximab,Oesophageal pain,OT
176345884,Infliximab,Oedema peripheral,OT
176345884,Infliximab,Oedema,OT
176345884,Infliximab,Odynophagia,OT
176345884,Infliximab,Joint effusion,OT
176345884,Infliximab,Intentional product use issue,OT
176345884,Infliximab,Infusion site erythema,OT
176345884,Infliximab,Inappropriate schedule of product administration,OT
176345884,Infliximab,Gastric disorder,OT
176345884,Infliximab,Fatigue,OT
176345884,Infliximab,Erythema,OT
176345884,Infliximab,Dysphagia,OT
176345884,Infliximab,Cough,OT
176345884,Infliximab,Breast cyst,OT
176345884,Infliximab,Breast cancer,OT
176345884,Infliximab,Breast calcifications,OT
176345884,Infliximab,Body temperature fluctuation,OT
176345884,Infliximab,Blood test abnormal,OT
176345884,Infliximab,Arthralgia,OT
176345884,Infliximab,Antinuclear antibody positive,OT
176353392,Infliximab,Therapeutic response shortened,HO
176353392,Infliximab,Off label use,HO
176353392,Infliximab,Intentional product use issue,HO
176353392,Infliximab,Feeling abnormal,HO
176353392,Infliximab,Condition aggravated,HO
176353392,Infliximab,Back pain,HO
176353392,Infliximab,Asthenia,HO
176353392,Infliximab,Arthralgia,HO
176579914,Infliximab,Weight increased,OT
176579914,Infliximab,Skin exfoliation,OT
176579914,Infliximab,Rhinorrhoea,OT
176579914,Infliximab,Rectal haemorrhage,OT
176579914,Infliximab,Pyrexia,OT
176579914,Infliximab,Pruritus,OT
176579914,Infliximab,Pain,OT
176579914,Infliximab,Oropharyngeal pain,OT
176579914,Infliximab,Off label use,OT
176579914,Infliximab,Oedema,OT
176579914,Infliximab,Nausea,OT
176579914,Infliximab,Mucous stools,OT
176579914,Infliximab,Mood swings,OT
176579914,Infliximab,Migraine,OT
176579914,Infliximab,Intentional product use issue,OT
176579914,Infliximab,Insomnia,OT
176579914,Infliximab,Influenza,OT
176579914,Infliximab,Inappropriate schedule of product administration,OT
176579914,Infliximab,Hypoaesthesia,OT
176579914,Infliximab,Heart rate irregular,OT
176579914,Infliximab,Heart rate decreased,OT
176579914,Infliximab,Headache,OT
176579914,Infliximab,Fatigue,OT
176579914,Infliximab,Ear pain,OT
176579914,Infliximab,Dizziness,OT
176579914,Infliximab,Disease recurrence,OT
176579914,Infliximab,Diarrhoea,OT
176579914,Infliximab,Decreased appetite,OT
176579914,Infliximab,Condition aggravated,OT
176579914,Infliximab,Blood pressure fluctuation,OT
176579914,Infliximab,Asthenia,OT
176579914,Infliximab,Arthralgia,OT
176579914,Infliximab,Abdominal pain upper,OT
176579914,Infliximab,Abdominal pain,OT
176579914,Infliximab,Abdominal distension,OT
176579914,Infliximab,Weight increased,OT
176579914,Infliximab,Skin exfoliation,OT
176579914,Infliximab,Rhinorrhoea,OT
176579914,Infliximab,Rectal haemorrhage,OT
176579914,Infliximab,Pyrexia,OT
176579914,Infliximab,Pruritus,OT
176579914,Infliximab,Pain,OT
176579914,Infliximab,Oropharyngeal pain,OT
176579914,Infliximab,Off label use,OT
176579914,Infliximab,Oedema,OT
176579914,Infliximab,Nausea,OT
176579914,Infliximab,Mucous stools,OT
176579914,Infliximab,Mood swings,OT
176579914,Infliximab,Migraine,OT
176579914,Infliximab,Intentional product use issue,OT
176579914,Infliximab,Insomnia,OT
176579914,Infliximab,Influenza,OT
176579914,Infliximab,Inappropriate schedule of product administration,OT
176579914,Infliximab,Hypoaesthesia,OT
176579914,Infliximab,Heart rate irregular,OT
176579914,Infliximab,Heart rate decreased,OT
176579914,Infliximab,Headache,OT
176579914,Infliximab,Fatigue,OT
176579914,Infliximab,Ear pain,OT
176579914,Infliximab,Dizziness,OT
176579914,Infliximab,Disease recurrence,OT
176579914,Infliximab,Diarrhoea,OT
176579914,Infliximab,Decreased appetite,OT
176579914,Infliximab,Condition aggravated,OT
176579914,Infliximab,Blood pressure fluctuation,OT
176579914,Infliximab,Asthenia,OT
176579914,Infliximab,Arthralgia,OT
176579914,Infliximab,Abdominal pain upper,OT
176579914,Infliximab,Abdominal pain,OT
176579914,Infliximab,Abdominal distension,OT
176674432,Infliximab,Product use issue,OT
176674432,Infliximab,Off label use,OT
176674432,Infliximab,Intentional product use issue,OT
176674432,Infliximab,Expired product administered,OT
176674432,Infliximab,Blood pressure increased,OT
176674432,Infliximab,Blood pressure fluctuation,OT
178122744,Infliximab,Somnolence,OT
178122744,Infliximab,Pruritus,OT
178122744,Infliximab,Off label use,OT
178122744,Infliximab,Malaise,OT
178122744,Infliximab,Lung neoplasm,OT
178122744,Infliximab,Iron deficiency anaemia,OT
178122744,Infliximab,Inflammatory bowel disease,OT
178122744,Infliximab,Inappropriate schedule of product administration,OT
178122744,Infliximab,Hypertension,OT
178122744,Infliximab,Haemorrhoidal haemorrhage,OT
178122744,Infliximab,Haematochezia,OT
178122744,Infliximab,Drug level above therapeutic,OT
178122744,Infliximab,Condition aggravated,OT
178122744,Infliximab,Blood pressure systolic increased,OT
178122744,Infliximab,Blood pressure increased,OT
178122744,Infliximab,Blood pressure fluctuation,OT
178122744,Infliximab,Anxiety,OT
182637054,Infliximab,Off label use,HO
182637054,Infliximab,Off label use,OT
182637054,Infliximab,Kidney infection,HO
182637054,Infliximab,Kidney infection,OT
182637054,Infliximab,Joint lock,HO
182637054,Infliximab,Joint lock,OT
182637054,Infliximab,Intentional product use issue,HO
182637054,Infliximab,Intentional product use issue,OT
182637054,Infliximab,Infection,HO
182637054,Infliximab,Infection,OT
182637054,Infliximab,Incorrect dose administered,HO
182637054,Infliximab,Incorrect dose administered,OT
182637054,Infliximab,Inappropriate schedule of product administration,HO
182637054,Infliximab,Inappropriate schedule of product administration,OT
182637054,Infliximab,Heart rate increased,HO
182637054,Infliximab,Heart rate increased,OT
182637054,Infliximab,Heart rate decreased,HO
182637054,Infliximab,Heart rate decreased,OT
182637054,Infliximab,Drug level below therapeutic,HO
182637054,Infliximab,Drug level below therapeutic,OT
182637054,Infliximab,Diarrhoea,HO
182637054,Infliximab,Diarrhoea,OT
182637054,Infliximab,Condition aggravated,HO
182637054,Infliximab,Condition aggravated,OT
182637054,Infliximab,Bone disorder,HO
182637054,Infliximab,Bone disorder,OT
182637054,Infliximab,Blood pressure fluctuation,HO
182637054,Infliximab,Blood pressure fluctuation,OT
182637054,Infliximab,Arthropathy,HO
182637054,Infliximab,Arthropathy,OT
182637054,Infliximab,Arthralgia,HO
182637054,Infliximab,Arthralgia,OT
183976622,Infliximab,Sinusitis,OT
183976622,Infliximab,Sinusitis,HO
183976622,Infliximab,Pruritus,OT
183976622,Infliximab,Pruritus,HO
183976622,Infliximab,Product use issue,OT
183976622,Infliximab,Product use issue,HO
183976622,Infliximab,Off label use,OT
183976622,Infliximab,Off label use,HO
183976622,Infliximab,Nasopharyngitis,OT
183976622,Infliximab,Nasopharyngitis,HO
183976622,Infliximab,Malaise,OT
183976622,Infliximab,Malaise,HO
183976622,Infliximab,Intentional product use issue,OT
183976622,Infliximab,Intentional product use issue,HO
183976622,Infliximab,Influenza,OT
183976622,Infliximab,Influenza,HO
183976622,Infliximab,Induration,OT
183976622,Infliximab,Induration,HO
183976622,Infliximab,Inappropriate schedule of product administration,OT
183976622,Infliximab,Inappropriate schedule of product administration,HO
183976622,Infliximab,Headache,OT
183976622,Infliximab,Headache,HO
183976622,Infliximab,Haematochezia,OT
183976622,Infliximab,Haematochezia,HO
183976622,Infliximab,Fatigue,OT
183976622,Infliximab,Fatigue,HO
183976622,Infliximab,Cough,OT
183976622,Infliximab,Cough,HO
183976622,Infliximab,Condition aggravated,OT
183976622,Infliximab,Condition aggravated,HO
183976622,Infliximab,Abdominal pain,OT
183976622,Infliximab,Abdominal pain,HO
183976622,Infliximab,Sinusitis,OT
183976622,Infliximab,Sinusitis,HO
183976622,Infliximab,Pruritus,OT
183976622,Infliximab,Pruritus,HO
183976622,Infliximab,Product use issue,OT
183976622,Infliximab,Product use issue,HO
183976622,Infliximab,Off label use,OT
183976622,Infliximab,Off label use,HO
183976622,Infliximab,Nasopharyngitis,OT
183976622,Infliximab,Nasopharyngitis,HO
183976622,Infliximab,Malaise,OT
183976622,Infliximab,Malaise,HO
183976622,Infliximab,Intentional product use issue,OT
183976622,Infliximab,Intentional product use issue,HO
183976622,Infliximab,Influenza,OT
183976622,Infliximab,Influenza,HO
183976622,Infliximab,Induration,OT
183976622,Infliximab,Induration,HO
183976622,Infliximab,Inappropriate schedule of product administration,OT
183976622,Infliximab,Inappropriate schedule of product administration,HO
183976622,Infliximab,Headache,OT
183976622,Infliximab,Headache,HO
183976622,Infliximab,Haematochezia,OT
183976622,Infliximab,Haematochezia,HO
183976622,Infliximab,Fatigue,OT
183976622,Infliximab,Fatigue,HO
183976622,Infliximab,Cough,OT
183976622,Infliximab,Cough,HO
183976622,Infliximab,Condition aggravated,OT
183976622,Infliximab,Condition aggravated,HO
183976622,Infliximab,Abdominal pain,OT
183976622,Infliximab,Abdominal pain,HO
184680703,Infliximab,Vomiting,HO
184680703,Infliximab,Product use issue,HO
184680703,Infliximab,Off label use,HO
184680703,Infliximab,Nausea,HO
184680703,Infliximab,Malaise,HO
184680703,Infliximab,Intentional product use issue,HO
184680703,Infliximab,Inappropriate schedule of product administration,HO
184680703,Infliximab,Heart rate increased,HO
184680703,Infliximab,Condition aggravated,HO
184680703,Infliximab,Blood pressure decreased,HO
184680703,Infliximab,Vomiting,HO
184680703,Infliximab,Product use issue,HO
184680703,Infliximab,Off label use,HO
184680703,Infliximab,Nausea,HO
184680703,Infliximab,Malaise,HO
184680703,Infliximab,Intentional product use issue,HO
184680703,Infliximab,Inappropriate schedule of product administration,HO
184680703,Infliximab,Heart rate increased,HO
184680703,Infliximab,Condition aggravated,HO
184680703,Infliximab,Blood pressure decreased,HO
184807602,Infliximab,Therapeutic product effect incomplete,OT
184807602,Infliximab,Sinus disorder,OT
184807602,Infliximab,Off label use,OT
184807602,Infliximab,Malaise,OT
184807602,Infliximab,Intentional product use issue,OT
184807602,Infliximab,Inappropriate schedule of product administration,OT
184807602,Infliximab,Heart rate increased,OT
184807602,Infliximab,Headache,OT
184807602,Infliximab,Eye infection viral,OT
184807602,Infliximab,Expired product administered,OT
184807602,Infliximab,Drug level decreased,OT
184807602,Infliximab,Diarrhoea,OT
184807602,Infliximab,Condition aggravated,OT
184807602,Infliximab,Blood pressure increased,OT
184865274,Infliximab,Pneumonia,HO
184865274,Infliximab,Pneumonia,OT
184865274,Infliximab,Off label use,HO
184865274,Infliximab,Off label use,OT
184865274,Infliximab,Myocardial infarction,HO
184865274,Infliximab,Myocardial infarction,OT
184865274,Infliximab,Lung disorder,HO
184865274,Infliximab,Lung disorder,OT
184865274,Infliximab,Infusion site swelling,HO
184865274,Infliximab,Infusion site swelling,OT
184865274,Infliximab,Infusion site pain,HO
184865274,Infliximab,Infusion site pain,OT
184865274,Infliximab,Infusion site erythema,HO
184865274,Infliximab,Infusion site erythema,OT
184865274,Infliximab,Inappropriate schedule of product administration,HO
184865274,Infliximab,Inappropriate schedule of product administration,OT
184865274,Infliximab,Dyspnoea exertional,HO
184865274,Infliximab,Dyspnoea exertional,OT
184865274,Infliximab,Dyspnoea,HO
184865274,Infliximab,Dyspnoea,OT
184865274,Infliximab,Chest pain,HO
184865274,Infliximab,Chest pain,OT
184865274,Infliximab,Cardiac failure,HO
184865274,Infliximab,Cardiac failure,OT
191544732,Infliximab,Weight increased,OT
191544732,Infliximab,Weight fluctuation,OT
191544732,Infliximab,Weight decreased,OT
191544732,Infliximab,Proctalgia,OT
191544732,Infliximab,Off label use,OT
191544732,Infliximab,Maternal exposure during pregnancy,OT
191544732,Infliximab,Intentional product use issue,OT
191544732,Infliximab,Incorrect dose administered,OT
191544732,Infliximab,Haemorrhage,OT
191544732,Infliximab,Fistula discharge,OT
191544732,Infliximab,Anal fistula,OT
191544732,Infliximab,Weight increased,OT
191544732,Infliximab,Weight fluctuation,OT
191544732,Infliximab,Weight decreased,OT
191544732,Infliximab,Proctalgia,OT
191544732,Infliximab,Off label use,OT
191544732,Infliximab,Maternal exposure during pregnancy,OT
191544732,Infliximab,Intentional product use issue,OT
191544732,Infliximab,Incorrect dose administered,OT
191544732,Infliximab,Haemorrhage,OT
191544732,Infliximab,Fistula discharge,OT
191544732,Infliximab,Anal fistula,OT
192017992,Infliximab,Weight increased,HO
192017992,Infliximab,Weight increased,OT
192017992,Infliximab,Product use issue,HO
192017992,Infliximab,Product use issue,OT
192017992,Infliximab,Off label use,HO
192017992,Infliximab,Off label use,OT
192017992,Infliximab,Intentional product use issue,HO
192017992,Infliximab,Intentional product use issue,OT
192017992,Infliximab,Incorrect dose administered,HO
192017992,Infliximab,Incorrect dose administered,OT
192017992,Infliximab,Heart rate abnormal,HO
192017992,Infliximab,Heart rate abnormal,OT
192017992,Infliximab,Clostridium difficile infection,HO
192017992,Infliximab,Clostridium difficile infection,OT
192017992,Infliximab,Blood pressure increased,HO
192017992,Infliximab,Blood pressure increased,OT
192017992,Infliximab,Weight increased,HO
192017992,Infliximab,Weight increased,OT
192017992,Infliximab,Product use issue,HO
192017992,Infliximab,Product use issue,OT
192017992,Infliximab,Off label use,HO
192017992,Infliximab,Off label use,OT
192017992,Infliximab,Intentional product use issue,HO
192017992,Infliximab,Intentional product use issue,OT
192017992,Infliximab,Incorrect dose administered,HO
192017992,Infliximab,Incorrect dose administered,OT
192017992,Infliximab,Heart rate abnormal,HO
192017992,Infliximab,Heart rate abnormal,OT
192017992,Infliximab,Clostridium difficile infection,HO
192017992,Infliximab,Clostridium difficile infection,OT
192017992,Infliximab,Blood pressure increased,HO
192017992,Infliximab,Blood pressure increased,OT
192964662,Infliximab,Weight increased,HO
192964662,Infliximab,Weight increased,OT
192964662,Infliximab,Therapeutic response shortened,HO
192964662,Infliximab,Therapeutic response shortened,OT
192964662,Infliximab,Poor venous access,HO
192964662,Infliximab,Poor venous access,OT
192964662,Infliximab,Off label use,HO
192964662,Infliximab,Off label use,OT
192964662,Infliximab,Malaise,HO
192964662,Infliximab,Malaise,OT
192964662,Infliximab,Inappropriate schedule of product administration,HO
192964662,Infliximab,Inappropriate schedule of product administration,OT
192964662,Infliximab,Fatigue,HO
192964662,Infliximab,Fatigue,OT
192964662,Infliximab,Drug ineffective,HO
192964662,Infliximab,Drug ineffective,OT
192964662,Infliximab,Condition aggravated,HO
192964662,Infliximab,Condition aggravated,OT
192964662,Infliximab,Clostridium difficile infection,HO
192964662,Infliximab,Clostridium difficile infection,OT
192964662,Infliximab,Blood pressure systolic increased,HO
192964662,Infliximab,Blood pressure systolic increased,OT
193982172,Infliximab,Weight increased,OT
193982172,Infliximab,Weight decreased,OT
193982172,Infliximab,Stress,OT
193982172,Infliximab,Off label use,OT
193982172,Infliximab,Intentional product use issue,OT
193982172,Infliximab,Condition aggravated,OT
193982172,Infliximab,Arthralgia,OT
194234763,Infliximab,Psoriasis,OT
194234763,Infliximab,Migraine,OT
194234763,Infliximab,Incorrect route of product administration,OT
194234763,Infliximab,Hypertension,OT
194234763,Infliximab,Endometriosis,OT
194234763,Infliximab,Drug specific antibody,OT
194234763,Infliximab,Drug intolerance,OT
194234763,Infliximab,Drug ineffective,OT
194234763,Infliximab,Depression,OT
194234763,Infliximab,Chronic kidney disease,OT
194234763,Infliximab,Asthma,OT
194234763,Infliximab,Arthritis,OT
195218001,Infliximab Pfizer (Unknown),Off label use,HO
195218001,Infliximab Pfizer (Unknown),Condition aggravated,HO
195218001,Infliximab Pfizer (Unknown),Off label use,HO
195218001,Infliximab Pfizer (Unknown),Condition aggravated,HO
195218001,Infliximab Pfizer (Unknown),Off label use,HO
195218001,Infliximab Pfizer (Unknown),Condition aggravated,HO
195618781,Infliximab,Off label use,OT
195618781,Infliximab,Intentional product use issue,OT
195618781,Infliximab,Drug level above therapeutic,OT
195618781,Infliximab,Condition aggravated,OT
195618781,Infliximab,Body temperature decreased,OT
195618781,Infliximab,Blood pressure fluctuation,OT
196150542,Infliximab,Product use in unapproved indication,OT
196150542,Infliximab,Pneumonia,OT
196150542,Infliximab,Oxygen saturation decreased,OT
196150542,Infliximab,Off label use,OT
196150542,Infliximab,Dyspnoea,OT
196150542,Infliximab,Cough,OT
196151451,Infliximab,Off label use,OT
196151451,Infliximab,Intentional product use issue,OT
196151451,Infliximab,Heart rate decreased,OT
196151451,Infliximab,Drug specific antibody,OT
196151451,Infliximab,Drug level decreased,OT
196151451,Infliximab,Drug ineffective,OT
196151451,Infliximab,Condition aggravated,OT
196323681,Infliximab,Product use issue,OT
196323681,Infliximab,Off label use,OT
196323681,Infliximab,Injection site phlebitis,OT
196323681,Infliximab,Infusion site erythema,OT
196323681,Infliximab,Hypertension,OT
196323681,Infliximab,Heart rate irregular,OT
196323681,Infliximab,Heart rate decreased,OT
196323681,Infliximab,Fatigue,OT
196323681,Infliximab,Colitis,OT
196323681,Infliximab,Blood pressure increased,OT
196654961,Infliximab,Myocardial infarction,LT
196654961,Infliximab,Myocardial infarction,HO
196654961,Infliximab,Fatigue,LT
196654961,Infliximab,Fatigue,HO
196654961,Infliximab,Blood pressure diastolic decreased,LT
196654961,Infliximab,Blood pressure diastolic decreased,HO
196891101,Infliximab,Therapeutic product effect incomplete,OT
196891101,Infliximab,Spinal pain,OT
196891101,Infliximab,Hypertension,OT
196891101,Infliximab,Heart rate irregular,OT
196891101,Infliximab,Blood pressure increased,OT
196891101,Infliximab,Blood pressure fluctuation,OT
196891722,Infliximab,Scleritis,OT
196891722,Infliximab,Pain in extremity,OT
196891722,Infliximab,Off label use,OT
196891722,Infliximab,Nausea,OT
196891722,Infliximab,Intentional product use issue,OT
196891722,Infliximab,Blood pressure systolic increased,OT
196891722,Infliximab,Blood pressure increased,OT
196891722,Infliximab,Arthralgia,OT
197370141,Infliximab,Product use in unapproved indication,OT
197370141,Infliximab,Off label use,OT
197370141,Infliximab,Nausea,OT
197370141,Infliximab,Infusion site extravasation,OT
197512001,Infliximab,Off label use,OT
197512001,Infliximab,Intentional product use issue,OT
197512001,Infliximab,Heart rate abnormal,OT
197512001,Infliximab,Crohn's disease,OT
197591151,Infliximab,Death,DE
197869481,Infliximab,Uveitis,OT
197869481,Infliximab,Therapeutic response shortened,OT
197869481,Infliximab,Off label use,OT
197869481,Infliximab,Intentional product use issue,OT
197869481,Infliximab,Feeling abnormal,OT
197869481,Infliximab,Eczema,OT
197869481,Infliximab,Drug ineffective,OT
197869481,Infliximab,Condition aggravated,OT
197869481,Infliximab,Arthralgia,OT
197869481,Infliximab,Anal fissure,OT
197988181,Infliximab?abda,Vomiting,HO
197988181,Infliximab?abda,Mental status changes,HO
197988181,Infliximab?abda,Hypovolaemic shock,HO
197988181,Infliximab?abda,Hyponatraemia,HO
197988181,Infliximab?abda,Diarrhoea,HO
198108681,Infliximab,Weight increased,HO
198108681,Infliximab,Vision blurred,HO
198108681,Infliximab,Off label use,HO
198108681,Infliximab,Nervous system disorder,HO
198108681,Infliximab,Inappropriate schedule of product administration,HO
198108681,Infliximab,Dizziness,HO
198193461,Infliximab,Varices oesophageal,OT
198193461,Infliximab,Urinary tract infection,OT
198193461,Infliximab,Tooth infection,OT
198193461,Infliximab,Therapeutic product effect incomplete,OT
198193461,Infliximab,Product use issue,OT
198193461,Infliximab,Pancytopenia,OT
198193461,Infliximab,Off label use,OT
198193461,Infliximab,Intentional product use issue,OT
198193461,Infliximab,Dysphagia,OT
198193461,Infliximab,Drug specific antibody,OT
198193461,Infliximab,Drug level below therapeutic,OT
198193461,Infliximab,Discomfort,OT
198193461,Infliximab,Condition aggravated,OT
198193461,Infliximab,Abdominal pain lower,OT
198350411,Infliximab,Skin atrophy,OT
198350411,Infliximab,Pyoderma gangrenosum,OT
198350411,Infliximab,Off label use,OT
198350411,Infliximab,Monoclonal gammopathy,OT
198476301,Infliximab,Weight fluctuation,OT
198476301,Infliximab,Tachycardia,OT
198476301,Infliximab,Off label use,OT
198476301,Infliximab,Intentional product use issue,OT
198476301,Infliximab,Heart rate increased,OT
198476301,Infliximab,Blood pressure diastolic increased,OT
160798784,Infliximab,Product use issue,OT
160798784,Infliximab,Product use in unapproved indication,OT
160798784,Infliximab,Off label use,OT
160798784,Infliximab,Intentional product use issue,OT
160798784,Infliximab,Inappropriate schedule of product administration,OT
160798784,Infliximab,Herpes zoster,OT
160798784,Infliximab,Heart rate decreased,OT
160798784,Infliximab,Blood pressure increased,OT
160798784,Infliximab,Blood pressure fluctuation,OT
160798784,Infliximab,Product use issue,OT
160798784,Infliximab,Product use in unapproved indication,OT
160798784,Infliximab,Off label use,OT
160798784,Infliximab,Intentional product use issue,OT
160798784,Infliximab,Inappropriate schedule of product administration,OT
160798784,Infliximab,Herpes zoster,OT
160798784,Infliximab,Heart rate decreased,OT
160798784,Infliximab,Blood pressure increased,OT
160798784,Infliximab,Blood pressure fluctuation,OT
160798784,Infliximab,Product use issue,OT
160798784,Infliximab,Product use in unapproved indication,OT
160798784,Infliximab,Off label use,OT
160798784,Infliximab,Intentional product use issue,OT
160798784,Infliximab,Inappropriate schedule of product administration,OT
160798784,Infliximab,Herpes zoster,OT
160798784,Infliximab,Heart rate decreased,OT
160798784,Infliximab,Blood pressure increased,OT
160798784,Infliximab,Blood pressure fluctuation,OT
160813525,Infliximab,Weight increased,OT
160813525,Infliximab,Weight decreased,OT
160813525,Infliximab,Seborrhoeic dermatitis,OT
160813525,Infliximab,Product use issue,OT
160813525,Infliximab,Off label use,OT
160813525,Infliximab,Loss of personal independence in daily activities,OT
160813525,Infliximab,Intentional product use issue,OT
160813525,Infliximab,Inappropriate schedule of product administration,OT
160813525,Infliximab,Faecal calprotectin increased,OT
160813525,Infliximab,Drug level below therapeutic,OT
160813525,Infliximab,Drug level above therapeutic,OT
160813525,Infliximab,Drug ineffective,OT
160813525,Infliximab,Constipation,OT
160813525,Infliximab,Condition aggravated,OT
1638803213,Infliximab,Wound,HO
1638803213,Infliximab,Wound,LT
1638803213,Infliximab,Wound,OT
1638803213,Infliximab,Wound,DS
1638803213,Infliximab,Wheezing,HO
1638803213,Infliximab,Wheezing,LT
1638803213,Infliximab,Wheezing,OT
1638803213,Infliximab,Wheezing,DS
1638803213,Infliximab,Vomiting,HO
1638803213,Infliximab,Vomiting,LT
1638803213,Infliximab,Vomiting,OT
1638803213,Infliximab,Vomiting,DS
1638803213,Infliximab,Type 2 diabetes mellitus,HO
1638803213,Infliximab,Type 2 diabetes mellitus,LT
1638803213,Infliximab,Type 2 diabetes mellitus,OT
1638803213,Infliximab,Type 2 diabetes mellitus,DS
1638803213,Infliximab,Treatment failure,HO
1638803213,Infliximab,Treatment failure,LT
1638803213,Infliximab,Treatment failure,OT
1638803213,Infliximab,Treatment failure,DS
1638803213,Infliximab,Therapeutic product effect decreased,HO
1638803213,Infliximab,Therapeutic product effect decreased,LT
1638803213,Infliximab,Therapeutic product effect decreased,OT
1638803213,Infliximab,Therapeutic product effect decreased,DS
1638803213,Infliximab,Systemic lupus erythematosus,HO
1638803213,Infliximab,Systemic lupus erythematosus,LT
1638803213,Infliximab,Systemic lupus erythematosus,OT
1638803213,Infliximab,Systemic lupus erythematosus,DS
1638803213,Infliximab,Synovitis,HO
1638803213,Infliximab,Synovitis,LT
1638803213,Infliximab,Synovitis,OT
1638803213,Infliximab,Synovitis,DS
1638803213,Infliximab,Swollen joint count increased,HO
1638803213,Infliximab,Swollen joint count increased,LT
1638803213,Infliximab,Swollen joint count increased,OT
1638803213,Infliximab,Swollen joint count increased,DS
1638803213,Infliximab,Swelling,HO
1638803213,Infliximab,Swelling,LT
1638803213,Infliximab,Swelling,OT
1638803213,Infliximab,Swelling,DS
1638803213,Infliximab,Sinusitis,HO
1638803213,Infliximab,Sinusitis,LT
1638803213,Infliximab,Sinusitis,OT
1638803213,Infliximab,Sinusitis,DS
1638803213,Infliximab,Sciatica,HO
1638803213,Infliximab,Sciatica,LT
1638803213,Infliximab,Sciatica,OT
1638803213,Infliximab,Sciatica,DS
1638803213,Infliximab,Rheumatoid factor positive,HO
1638803213,Infliximab,Rheumatoid factor positive,LT
1638803213,Infliximab,Rheumatoid factor positive,OT
1638803213,Infliximab,Rheumatoid factor positive,DS
1638803213,Infliximab,Rheumatoid arthritis,HO
1638803213,Infliximab,Rheumatoid arthritis,LT
1638803213,Infliximab,Rheumatoid arthritis,OT
1638803213,Infliximab,Rheumatoid arthritis,DS
1638803213,Infliximab,Rheumatic fever,HO
1638803213,Infliximab,Rheumatic fever,LT
1638803213,Infliximab,Rheumatic fever,OT
1638803213,Infliximab,Rheumatic fever,DS
1638803213,Infliximab,Rash,HO
1638803213,Infliximab,Rash,LT
1638803213,Infliximab,Rash,OT
1638803213,Infliximab,Rash,DS
1638803213,Infliximab,Psoriatic arthropathy,HO
1638803213,Infliximab,Psoriatic arthropathy,LT
1638803213,Infliximab,Psoriatic arthropathy,OT
1638803213,Infliximab,Psoriatic arthropathy,DS
1638803213,Infliximab,Product use issue,HO
1638803213,Infliximab,Product use issue,LT
1638803213,Infliximab,Product use issue,OT
1638803213,Infliximab,Product use issue,DS
1638803213,Infliximab,Product use in unapproved indication,HO
1638803213,Infliximab,Product use in unapproved indication,LT
1638803213,Infliximab,Product use in unapproved indication,OT
1638803213,Infliximab,Product use in unapproved indication,DS
1638803213,Infliximab,Prescribed overdose,HO
1638803213,Infliximab,Prescribed overdose,LT
1638803213,Infliximab,Prescribed overdose,OT
1638803213,Infliximab,Prescribed overdose,DS
1638803213,Infliximab,Pericarditis,HO
1638803213,Infliximab,Pericarditis,LT
1638803213,Infliximab,Pericarditis,OT
1638803213,Infliximab,Pericarditis,DS
1638803213,Infliximab,Pemphigus,HO
1638803213,Infliximab,Pemphigus,LT
1638803213,Infliximab,Pemphigus,OT
1638803213,Infliximab,Pemphigus,DS
1638803213,Infliximab,Pain,HO
1638803213,Infliximab,Pain,LT
1638803213,Infliximab,Pain,OT
1638803213,Infliximab,Pain,DS
1638803213,Infliximab,Off label use,HO
1638803213,Infliximab,Off label use,LT
1638803213,Infliximab,Off label use,OT
1638803213,Infliximab,Off label use,DS
1638803213,Infliximab,Oedema,HO
1638803213,Infliximab,Oedema,LT
1638803213,Infliximab,Oedema,OT
1638803213,Infliximab,Oedema,DS
1638803213,Infliximab,Nausea,HO
1638803213,Infliximab,Nausea,LT
1638803213,Infliximab,Nausea,OT
1638803213,Infliximab,Nausea,DS
1638803213,Infliximab,Musculoskeletal stiffness,HO
1638803213,Infliximab,Musculoskeletal stiffness,LT
1638803213,Infliximab,Musculoskeletal stiffness,OT
1638803213,Infliximab,Musculoskeletal stiffness,DS
1638803213,Infliximab,Mobility decreased,HO
1638803213,Infliximab,Mobility decreased,LT
1638803213,Infliximab,Mobility decreased,OT
1638803213,Infliximab,Mobility decreased,DS
1638803213,Infliximab,Maternal exposure during pregnancy,HO
1638803213,Infliximab,Maternal exposure during pregnancy,LT
1638803213,Infliximab,Maternal exposure during pregnancy,OT
1638803213,Infliximab,Maternal exposure during pregnancy,DS
1638803213,Infliximab,Malaise,HO
1638803213,Infliximab,Malaise,LT
1638803213,Infliximab,Malaise,OT
1638803213,Infliximab,Malaise,DS
1638803213,Infliximab,Liver injury,HO
1638803213,Infliximab,Liver injury,LT
1638803213,Infliximab,Liver injury,OT
1638803213,Infliximab,Liver injury,DS
1638803213,Infliximab,Knee arthroplasty,HO
1638803213,Infliximab,Knee arthroplasty,LT
1638803213,Infliximab,Knee arthroplasty,OT
1638803213,Infliximab,Knee arthroplasty,DS
1638803213,Infliximab,Joint swelling,HO
1638803213,Infliximab,Joint swelling,LT
1638803213,Infliximab,Joint swelling,OT
1638803213,Infliximab,Joint swelling,DS
1638803213,Infliximab,Intentional product use issue,HO
1638803213,Infliximab,Intentional product use issue,LT
1638803213,Infliximab,Intentional product use issue,OT
1638803213,Infliximab,Intentional product use issue,DS
1638803213,Infliximab,Injury,HO
1638803213,Infliximab,Injury,LT
1638803213,Infliximab,Injury,OT
1638803213,Infliximab,Injury,DS
1638803213,Infliximab,Infusion related reaction,HO
1638803213,Infliximab,Infusion related reaction,LT
1638803213,Infliximab,Infusion related reaction,OT
1638803213,Infliximab,Infusion related reaction,DS
1638803213,Infliximab,Hypoaesthesia,HO
1638803213,Infliximab,Hypoaesthesia,LT
1638803213,Infliximab,Hypoaesthesia,OT
1638803213,Infliximab,Hypoaesthesia,DS
1638803213,Infliximab,Hypertension,HO
1638803213,Infliximab,Hypertension,LT
1638803213,Infliximab,Hypertension,OT
1638803213,Infliximab,Hypertension,DS
1638803213,Infliximab,Hypersensitivity,HO
1638803213,Infliximab,Hypersensitivity,LT
1638803213,Infliximab,Hypersensitivity,OT
1638803213,Infliximab,Hypersensitivity,DS
1638803213,Infliximab,Hip arthroplasty,HO
1638803213,Infliximab,Hip arthroplasty,LT
1638803213,Infliximab,Hip arthroplasty,OT
1638803213,Infliximab,Hip arthroplasty,DS
1638803213,Infliximab,Hepatic enzyme increased,HO
1638803213,Infliximab,Hepatic enzyme increased,LT
1638803213,Infliximab,Hepatic enzyme increased,OT
1638803213,Infliximab,Hepatic enzyme increased,DS
1638803213,Infliximab,Helicobacter infection,HO
1638803213,Infliximab,Helicobacter infection,LT
1638803213,Infliximab,Helicobacter infection,OT
1638803213,Infliximab,Helicobacter infection,DS
1638803213,Infliximab,Headache,HO
1638803213,Infliximab,Headache,LT
1638803213,Infliximab,Headache,OT
1638803213,Infliximab,Headache,DS
1638803213,Infliximab,Hand deformity,HO
1638803213,Infliximab,Hand deformity,LT
1638803213,Infliximab,Hand deformity,OT
1638803213,Infliximab,Hand deformity,DS
1638803213,Infliximab,Glossodynia,HO
1638803213,Infliximab,Glossodynia,LT
1638803213,Infliximab,Glossodynia,OT
1638803213,Infliximab,Glossodynia,DS
1638803213,Infliximab,General physical health deterioration,HO
1638803213,Infliximab,General physical health deterioration,LT
1638803213,Infliximab,General physical health deterioration,OT
1638803213,Infliximab,General physical health deterioration,DS
1638803213,Infliximab,Fibromyalgia,HO
1638803213,Infliximab,Fibromyalgia,LT
1638803213,Infliximab,Fibromyalgia,OT
1638803213,Infliximab,Fibromyalgia,DS
1638803213,Infliximab,Fatigue,HO
1638803213,Infliximab,Fatigue,LT
1638803213,Infliximab,Fatigue,OT
1638803213,Infliximab,Fatigue,DS
1638803213,Infliximab,Exposure during pregnancy,HO
1638803213,Infliximab,Exposure during pregnancy,LT
1638803213,Infliximab,Exposure during pregnancy,OT
1638803213,Infliximab,Exposure during pregnancy,DS
1638803213,Infliximab,Duodenal ulcer perforation,HO
1638803213,Infliximab,Duodenal ulcer perforation,LT
1638803213,Infliximab,Duodenal ulcer perforation,OT
1638803213,Infliximab,Duodenal ulcer perforation,DS
1638803213,Infliximab,Drug intolerance,HO
1638803213,Infliximab,Drug intolerance,LT
1638803213,Infliximab,Drug intolerance,OT
1638803213,Infliximab,Drug intolerance,DS
1638803213,Infliximab,Drug ineffective,HO
1638803213,Infliximab,Drug ineffective,LT
1638803213,Infliximab,Drug ineffective,OT
1638803213,Infliximab,Drug ineffective,DS
1638803213,Infliximab,Drug hypersensitivity,HO
1638803213,Infliximab,Drug hypersensitivity,LT
1638803213,Infliximab,Drug hypersensitivity,OT
1638803213,Infliximab,Drug hypersensitivity,DS
1638803213,Infliximab,Dizziness,HO
1638803213,Infliximab,Dizziness,LT
1638803213,Infliximab,Dizziness,OT
1638803213,Infliximab,Dizziness,DS
1638803213,Infliximab,Discomfort,HO
1638803213,Infliximab,Discomfort,LT
1638803213,Infliximab,Discomfort,OT
1638803213,Infliximab,Discomfort,DS
1638803213,Infliximab,Diarrhoea,HO
1638803213,Infliximab,Diarrhoea,LT
1638803213,Infliximab,Diarrhoea,OT
1638803213,Infliximab,Diarrhoea,DS
1638803213,Infliximab,Decreased appetite,HO
1638803213,Infliximab,Decreased appetite,LT
1638803213,Infliximab,Decreased appetite,OT
1638803213,Infliximab,Decreased appetite,DS
1638803213,Infliximab,Contraindicated product administered,HO
1638803213,Infliximab,Contraindicated product administered,LT
1638803213,Infliximab,Contraindicated product administered,OT
1638803213,Infliximab,Contraindicated product administered,DS
1638803213,Infliximab,Condition aggravated,HO
1638803213,Infliximab,Condition aggravated,LT
1638803213,Infliximab,Condition aggravated,OT
1638803213,Infliximab,Condition aggravated,DS
1638803213,Infliximab,Blood cholesterol increased,HO
1638803213,Infliximab,Blood cholesterol increased,LT
1638803213,Infliximab,Blood cholesterol increased,OT
1638803213,Infliximab,Blood cholesterol increased,DS
1638803213,Infliximab,Blister,HO
1638803213,Infliximab,Blister,LT
1638803213,Infliximab,Blister,OT
1638803213,Infliximab,Blister,DS
1638803213,Infliximab,Arthropathy,HO
1638803213,Infliximab,Arthropathy,LT
1638803213,Infliximab,Arthropathy,OT
1638803213,Infliximab,Arthropathy,DS
1638803213,Infliximab,Arthralgia,HO
1638803213,Infliximab,Arthralgia,LT
1638803213,Infliximab,Arthralgia,OT
1638803213,Infliximab,Arthralgia,DS
1638803213,Infliximab,Anti-cyclic citrullinated peptide antibody positive,HO
1638803213,Infliximab,Anti-cyclic citrullinated peptide antibody positive,LT
1638803213,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
1638803213,Infliximab,Anti-cyclic citrullinated peptide antibody positive,DS
1638803213,Infliximab,Alopecia,HO
1638803213,Infliximab,Alopecia,LT
1638803213,Infliximab,Alopecia,OT
1638803213,Infliximab,Alopecia,DS
1638803213,Infliximab,Adverse event,HO
1638803213,Infliximab,Adverse event,LT
1638803213,Infliximab,Adverse event,OT
1638803213,Infliximab,Adverse event,DS
1638803213,Infliximab,Adverse drug reaction,HO
1638803213,Infliximab,Adverse drug reaction,LT
1638803213,Infliximab,Adverse drug reaction,OT
1638803213,Infliximab,Adverse drug reaction,DS
1638803213,Infliximab,Abdominal pain upper,HO
1638803213,Infliximab,Abdominal pain upper,LT
1638803213,Infliximab,Abdominal pain upper,OT
1638803213,Infliximab,Abdominal pain upper,DS
1638803213,Infliximab,Abdominal pain,HO
1638803213,Infliximab,Abdominal pain,LT
1638803213,Infliximab,Abdominal pain,OT
1638803213,Infliximab,Abdominal pain,DS
1638803213,Infliximab,Abdominal discomfort,HO
1638803213,Infliximab,Abdominal discomfort,LT
1638803213,Infliximab,Abdominal discomfort,OT
1638803213,Infliximab,Abdominal discomfort,DS
165761576,Infliximab,Weight increased,HO
165761576,Infliximab,Weight decreased,HO
165761576,Infliximab,Product use issue,HO
165761576,Infliximab,Off label use,HO
165761576,Infliximab,Maternal exposure during pregnancy,HO
165761576,Infliximab,Mastitis,HO
165761576,Infliximab,Malaise,HO
165761576,Infliximab,Influenza,HO
165761576,Infliximab,Inappropriate schedule of product administration,HO
165761576,Infliximab,Headache,HO
165761576,Infliximab,Feeling abnormal,HO
165761576,Infliximab,Fatigue,HO
165761576,Infliximab,Dizziness,HO
165761576,Infliximab,Blood pressure systolic increased,HO
165761576,Infliximab,Blood pressure increased,HO
165761576,Infliximab,Blood pressure fluctuation,HO
165761576,Infliximab,Weight increased,HO
165761576,Infliximab,Weight decreased,HO
165761576,Infliximab,Product use issue,HO
165761576,Infliximab,Off label use,HO
165761576,Infliximab,Maternal exposure during pregnancy,HO
165761576,Infliximab,Mastitis,HO
165761576,Infliximab,Malaise,HO
165761576,Infliximab,Influenza,HO
165761576,Infliximab,Inappropriate schedule of product administration,HO
165761576,Infliximab,Headache,HO
165761576,Infliximab,Feeling abnormal,HO
165761576,Infliximab,Fatigue,HO
165761576,Infliximab,Dizziness,HO
165761576,Infliximab,Blood pressure systolic increased,HO
165761576,Infliximab,Blood pressure increased,HO
165761576,Infliximab,Blood pressure fluctuation,HO
166843694,Infliximab,Weight increased,OT
166843694,Infliximab,Vomiting,OT
166843694,Infliximab,Therapeutic product effect incomplete,OT
166843694,Infliximab,Sacroiliitis,OT
166843694,Infliximab,Pruritus,OT
166843694,Infliximab,Product use issue,OT
166843694,Infliximab,Off label use,OT
166843694,Infliximab,Nausea,OT
166843694,Infliximab,Nasopharyngitis,OT
166843694,Infliximab,Migraine,OT
166843694,Infliximab,Lower respiratory tract infection,OT
166843694,Infliximab,Intentional product use issue,OT
166843694,Infliximab,Heart rate abnormal,OT
166843694,Infliximab,Headache,OT
166843694,Infliximab,Gastrointestinal disorder,OT
166843694,Infliximab,Condition aggravated,OT
166843694,Infliximab,Chills,OT
166843694,Infliximab,Body temperature fluctuation,OT
166843694,Infliximab,Blood pressure fluctuation,OT
166843694,Infliximab,Back pain,OT
166843694,Infliximab,Arthralgia,OT
168792877,Infliximab,Weight increased,HO
168792877,Infliximab,Weight increased,OT
168792877,Infliximab,Sputum discoloured,HO
168792877,Infliximab,Sputum discoloured,OT
168792877,Infliximab,Secretion discharge,HO
168792877,Infliximab,Secretion discharge,OT
168792877,Infliximab,Rectal abscess,HO
168792877,Infliximab,Rectal abscess,OT
168792877,Infliximab,Pyrexia,HO
168792877,Infliximab,Pyrexia,OT
168792877,Infliximab,Product use issue,HO
168792877,Infliximab,Product use issue,OT
168792877,Infliximab,Pharyngeal erythema,HO
168792877,Infliximab,Pharyngeal erythema,OT
168792877,Infliximab,Pain,HO
168792877,Infliximab,Pain,OT
168792877,Infliximab,Oropharyngeal pain,HO
168792877,Infliximab,Oropharyngeal pain,OT
168792877,Infliximab,Oral mucosal erythema,HO
168792877,Infliximab,Oral mucosal erythema,OT
168792877,Infliximab,Oral infection,HO
168792877,Infliximab,Oral infection,OT
168792877,Infliximab,Off label use,HO
168792877,Infliximab,Off label use,OT
168792877,Infliximab,Nasal congestion,HO
168792877,Infliximab,Nasal congestion,OT
168792877,Infliximab,Mouth swelling,HO
168792877,Infliximab,Mouth swelling,OT
168792877,Infliximab,Malaise,HO
168792877,Infliximab,Malaise,OT
168792877,Infliximab,Intentional product use issue,HO
168792877,Infliximab,Intentional product use issue,OT
168792877,Infliximab,Influenza,HO
168792877,Infliximab,Influenza,OT
168792877,Infliximab,Illness,HO
168792877,Infliximab,Illness,OT
168792877,Infliximab,Heart rate irregular,HO
168792877,Infliximab,Heart rate irregular,OT
168792877,Infliximab,Heart rate abnormal,HO
168792877,Infliximab,Heart rate abnormal,OT
168792877,Infliximab,Headache,HO
168792877,Infliximab,Headache,OT
168792877,Infliximab,Feeling abnormal,HO
168792877,Infliximab,Feeling abnormal,OT
168792877,Infliximab,Fatigue,HO
168792877,Infliximab,Fatigue,OT
168792877,Infliximab,Decreased appetite,HO
168792877,Infliximab,Decreased appetite,OT
168792877,Infliximab,Cough,HO
168792877,Infliximab,Cough,OT
168792877,Infliximab,Condition aggravated,HO
168792877,Infliximab,Condition aggravated,OT
168792877,Infliximab,Bronchitis,HO
168792877,Infliximab,Bronchitis,OT
168792877,Infliximab,Aphthous ulcer,HO
168792877,Infliximab,Aphthous ulcer,OT
168792877,Infliximab,Aphasia,HO
168792877,Infliximab,Aphasia,OT
168792877,Infliximab,Anal fistula,HO
168792877,Infliximab,Anal fistula,OT
168792877,Infliximab,Anal fissure,HO
168792877,Infliximab,Anal fissure,OT
168792877,Infliximab,Abdominal pain,HO
168792877,Infliximab,Abdominal pain,OT
168792877,Infliximab,Weight increased,HO
168792877,Infliximab,Weight increased,OT
168792877,Infliximab,Sputum discoloured,HO
168792877,Infliximab,Sputum discoloured,OT
168792877,Infliximab,Secretion discharge,HO
168792877,Infliximab,Secretion discharge,OT
168792877,Infliximab,Rectal abscess,HO
168792877,Infliximab,Rectal abscess,OT
168792877,Infliximab,Pyrexia,HO
168792877,Infliximab,Pyrexia,OT
168792877,Infliximab,Product use issue,HO
168792877,Infliximab,Product use issue,OT
168792877,Infliximab,Pharyngeal erythema,HO
168792877,Infliximab,Pharyngeal erythema,OT
168792877,Infliximab,Pain,HO
168792877,Infliximab,Pain,OT
168792877,Infliximab,Oropharyngeal pain,HO
168792877,Infliximab,Oropharyngeal pain,OT
168792877,Infliximab,Oral mucosal erythema,HO
168792877,Infliximab,Oral mucosal erythema,OT
168792877,Infliximab,Oral infection,HO
168792877,Infliximab,Oral infection,OT
168792877,Infliximab,Off label use,HO
168792877,Infliximab,Off label use,OT
168792877,Infliximab,Nasal congestion,HO
168792877,Infliximab,Nasal congestion,OT
168792877,Infliximab,Mouth swelling,HO
168792877,Infliximab,Mouth swelling,OT
168792877,Infliximab,Malaise,HO
168792877,Infliximab,Malaise,OT
168792877,Infliximab,Intentional product use issue,HO
168792877,Infliximab,Intentional product use issue,OT
168792877,Infliximab,Influenza,HO
168792877,Infliximab,Influenza,OT
168792877,Infliximab,Illness,HO
168792877,Infliximab,Illness,OT
168792877,Infliximab,Heart rate irregular,HO
168792877,Infliximab,Heart rate irregular,OT
168792877,Infliximab,Heart rate abnormal,HO
168792877,Infliximab,Heart rate abnormal,OT
168792877,Infliximab,Headache,HO
168792877,Infliximab,Headache,OT
168792877,Infliximab,Feeling abnormal,HO
168792877,Infliximab,Feeling abnormal,OT
168792877,Infliximab,Fatigue,HO
168792877,Infliximab,Fatigue,OT
168792877,Infliximab,Decreased appetite,HO
168792877,Infliximab,Decreased appetite,OT
168792877,Infliximab,Cough,HO
168792877,Infliximab,Cough,OT
168792877,Infliximab,Condition aggravated,HO
168792877,Infliximab,Condition aggravated,OT
168792877,Infliximab,Bronchitis,HO
168792877,Infliximab,Bronchitis,OT
168792877,Infliximab,Aphthous ulcer,HO
168792877,Infliximab,Aphthous ulcer,OT
168792877,Infliximab,Aphasia,HO
168792877,Infliximab,Aphasia,OT
168792877,Infliximab,Anal fistula,HO
168792877,Infliximab,Anal fistula,OT
168792877,Infliximab,Anal fissure,HO
168792877,Infliximab,Anal fissure,OT
168792877,Infliximab,Abdominal pain,HO
168792877,Infliximab,Abdominal pain,OT
168792877,Infliximab,Weight increased,HO
168792877,Infliximab,Weight increased,OT
168792877,Infliximab,Sputum discoloured,HO
168792877,Infliximab,Sputum discoloured,OT
168792877,Infliximab,Secretion discharge,HO
168792877,Infliximab,Secretion discharge,OT
168792877,Infliximab,Rectal abscess,HO
168792877,Infliximab,Rectal abscess,OT
168792877,Infliximab,Pyrexia,HO
168792877,Infliximab,Pyrexia,OT
168792877,Infliximab,Product use issue,HO
168792877,Infliximab,Product use issue,OT
168792877,Infliximab,Pharyngeal erythema,HO
168792877,Infliximab,Pharyngeal erythema,OT
168792877,Infliximab,Pain,HO
168792877,Infliximab,Pain,OT
168792877,Infliximab,Oropharyngeal pain,HO
168792877,Infliximab,Oropharyngeal pain,OT
168792877,Infliximab,Oral mucosal erythema,HO
168792877,Infliximab,Oral mucosal erythema,OT
168792877,Infliximab,Oral infection,HO
168792877,Infliximab,Oral infection,OT
168792877,Infliximab,Off label use,HO
168792877,Infliximab,Off label use,OT
168792877,Infliximab,Nasal congestion,HO
168792877,Infliximab,Nasal congestion,OT
168792877,Infliximab,Mouth swelling,HO
168792877,Infliximab,Mouth swelling,OT
168792877,Infliximab,Malaise,HO
168792877,Infliximab,Malaise,OT
168792877,Infliximab,Intentional product use issue,HO
168792877,Infliximab,Intentional product use issue,OT
168792877,Infliximab,Influenza,HO
168792877,Infliximab,Influenza,OT
168792877,Infliximab,Illness,HO
168792877,Infliximab,Illness,OT
168792877,Infliximab,Heart rate irregular,HO
168792877,Infliximab,Heart rate irregular,OT
168792877,Infliximab,Heart rate abnormal,HO
168792877,Infliximab,Heart rate abnormal,OT
168792877,Infliximab,Headache,HO
168792877,Infliximab,Headache,OT
168792877,Infliximab,Feeling abnormal,HO
168792877,Infliximab,Feeling abnormal,OT
168792877,Infliximab,Fatigue,HO
168792877,Infliximab,Fatigue,OT
168792877,Infliximab,Decreased appetite,HO
168792877,Infliximab,Decreased appetite,OT
168792877,Infliximab,Cough,HO
168792877,Infliximab,Cough,OT
168792877,Infliximab,Condition aggravated,HO
168792877,Infliximab,Condition aggravated,OT
168792877,Infliximab,Bronchitis,HO
168792877,Infliximab,Bronchitis,OT
168792877,Infliximab,Aphthous ulcer,HO
168792877,Infliximab,Aphthous ulcer,OT
168792877,Infliximab,Aphasia,HO
168792877,Infliximab,Aphasia,OT
168792877,Infliximab,Anal fistula,HO
168792877,Infliximab,Anal fistula,OT
168792877,Infliximab,Anal fissure,HO
168792877,Infliximab,Anal fissure,OT
168792877,Infliximab,Abdominal pain,HO
168792877,Infliximab,Abdominal pain,OT
173484753,Infliximab,White blood cell count increased,OT
173484753,Infliximab,Weight increased,OT
173484753,Infliximab,Weight decreased,OT
173484753,Infliximab,Urticaria,OT
173484753,Infliximab,Toothache,OT
173484753,Infliximab,Swelling face,OT
173484753,Infliximab,Serum ferritin decreased,OT
173484753,Infliximab,Rash pustular,OT
173484753,Infliximab,Rash,OT
173484753,Infliximab,Product use issue,OT
173484753,Infliximab,Platelet count increased,OT
173484753,Infliximab,Periodontitis,OT
173484753,Infliximab,Pallor,OT
173484753,Infliximab,Off label use,OT
173484753,Infliximab,Heart rate irregular,OT
173484753,Infliximab,Gastrointestinal disorder,OT
173484753,Infliximab,Faeces discoloured,OT
173484753,Infliximab,Erythema,OT
173484753,Infliximab,Condition aggravated,OT
173484753,Infliximab,Blood pressure increased,OT
173484753,Infliximab,Blood albumin decreased,OT
173484753,Infliximab,White blood cell count increased,OT
173484753,Infliximab,Weight increased,OT
173484753,Infliximab,Weight decreased,OT
173484753,Infliximab,Urticaria,OT
173484753,Infliximab,Toothache,OT
173484753,Infliximab,Swelling face,OT
173484753,Infliximab,Serum ferritin decreased,OT
173484753,Infliximab,Rash pustular,OT
173484753,Infliximab,Rash,OT
173484753,Infliximab,Product use issue,OT
173484753,Infliximab,Platelet count increased,OT
173484753,Infliximab,Periodontitis,OT
173484753,Infliximab,Pallor,OT
173484753,Infliximab,Off label use,OT
173484753,Infliximab,Heart rate irregular,OT
173484753,Infliximab,Gastrointestinal disorder,OT
173484753,Infliximab,Faeces discoloured,OT
173484753,Infliximab,Erythema,OT
173484753,Infliximab,Condition aggravated,OT
173484753,Infliximab,Blood pressure increased,OT
173484753,Infliximab,Blood albumin decreased,OT
174110932,Infliximab,Weight decreased,OT
174110932,Infliximab,Weight decreased,HO
174110932,Infliximab,Tooth disorder,OT
174110932,Infliximab,Tooth disorder,HO
174110932,Infliximab,Systemic lupus erythematosus,OT
174110932,Infliximab,Systemic lupus erythematosus,HO
174110932,Infliximab,Syncope,OT
174110932,Infliximab,Syncope,HO
174110932,Infliximab,Rib fracture,OT
174110932,Infliximab,Rib fracture,HO
174110932,Infliximab,Renal failure,OT
174110932,Infliximab,Renal failure,HO
174110932,Infliximab,Product use issue,OT
174110932,Infliximab,Product use issue,HO
174110932,Infliximab,Pneumothorax,OT
174110932,Infliximab,Pneumothorax,HO
174110932,Infliximab,Pain,OT
174110932,Infliximab,Pain,HO
174110932,Infliximab,Osteoporosis,OT
174110932,Infliximab,Osteoporosis,HO
174110932,Infliximab,Oropharyngeal pain,OT
174110932,Infliximab,Oropharyngeal pain,HO
174110932,Infliximab,Off label use,OT
174110932,Infliximab,Off label use,HO
174110932,Infliximab,Intentional product use issue,OT
174110932,Infliximab,Intentional product use issue,HO
174110932,Infliximab,Headache,OT
174110932,Infliximab,Headache,HO
174110932,Infliximab,Haemorrhoids,OT
174110932,Infliximab,Haemorrhoids,HO
174110932,Infliximab,Haemorrhoidal haemorrhage,OT
174110932,Infliximab,Haemorrhoidal haemorrhage,HO
174110932,Infliximab,Haematochezia,OT
174110932,Infliximab,Haematochezia,HO
174110932,Infliximab,Gout,OT
174110932,Infliximab,Gout,HO
174110932,Infliximab,Frequent bowel movements,OT
174110932,Infliximab,Frequent bowel movements,HO
174110932,Infliximab,Fall,OT
174110932,Infliximab,Fall,HO
174110932,Infliximab,Diverticulum,OT
174110932,Infliximab,Diverticulum,HO
174110932,Infliximab,Diarrhoea,OT
174110932,Infliximab,Diarrhoea,HO
174110932,Infliximab,Cystitis,OT
174110932,Infliximab,Cystitis,HO
174110932,Infliximab,Condition aggravated,OT
174110932,Infliximab,Condition aggravated,HO
174110932,Infliximab,Cardiac disorder,OT
174110932,Infliximab,Cardiac disorder,HO
174110932,Infliximab,Blood pressure fluctuation,OT
174110932,Infliximab,Blood pressure fluctuation,HO
174110932,Infliximab,Arthralgia,OT
174110932,Infliximab,Arthralgia,HO
174110932,Infliximab,Abdominal pain,OT
174110932,Infliximab,Abdominal pain,HO
174222124,Infliximab,Weight increased,OT
174222124,Infliximab,Weight decreased,OT
174222124,Infliximab,Tremor,OT
174222124,Infliximab,Stress,OT
174222124,Infliximab,Product use issue,OT
174222124,Infliximab,Off label use,OT
174222124,Infliximab,Intentional product use issue,OT
174222124,Infliximab,Inappropriate schedule of product administration,OT
174222124,Infliximab,Hyperhidrosis,OT
174222124,Infliximab,Heart rate decreased,OT
174222124,Infliximab,Feeling abnormal,OT
174222124,Infliximab,Dyspepsia,OT
174222124,Infliximab,Drug level increased,OT
174222124,Infliximab,Condition aggravated,OT
174222124,Infliximab,Clostridium difficile infection,OT
174222124,Infliximab,C-reactive protein increased,OT
174538753,Infliximab,Off label use,OT
174538753,Infliximab,Intentional product use issue,OT
174538753,Infliximab,Incorrect dose administered,OT
174538753,Infliximab,Inappropriate schedule of product administration,OT
174538753,Infliximab,Heart rate irregular,OT
174538753,Infliximab,Heart rate decreased,OT
174538753,Infliximab,Faecal calprotectin abnormal,OT
174538753,Infliximab,Drug ineffective,OT
174538753,Infliximab,Coronary artery disease,OT
174538753,Infliximab,Cardiac disorder,OT
174538753,Infliximab,Blood pressure fluctuation,OT
174538753,Infliximab,Aortic valve disease,OT
175606913,Infliximab,Weight decreased,OT
175606913,Infliximab,Weight decreased,HO
175606913,Infliximab,Haematochezia,OT
175606913,Infliximab,Haematochezia,HO
175606913,Infliximab,Drug level decreased,OT
175606913,Infliximab,Drug level decreased,HO
175606913,Infliximab,Dehydration,OT
175606913,Infliximab,Dehydration,HO
175606913,Infliximab,Blood pressure decreased,OT
175606913,Infliximab,Blood pressure decreased,HO
175606913,Infliximab,Bacterial infection,OT
175606913,Infliximab,Bacterial infection,HO
176209033,Infliximab,Weight decreased,OT
176209033,Infliximab,Therapeutic response shortened,OT
176209033,Infliximab,Rectal haemorrhage,OT
176209033,Infliximab,Peripheral swelling,OT
176209033,Infliximab,Pain in extremity,OT
176209033,Infliximab,Oral candidiasis,OT
176209033,Infliximab,Nasopharyngitis,OT
176209033,Infliximab,Nasal congestion,OT
176209033,Infliximab,Localised infection,OT
176209033,Infliximab,Infusion site pain,OT
176209033,Infliximab,Hypothyroidism,OT
176209033,Infliximab,Headache,OT
176209033,Infliximab,Feeling cold,OT
176209033,Infliximab,Erythema,OT
176209033,Infliximab,Dyspepsia,OT
176209033,Infliximab,Drug ineffective,OT
176209033,Infliximab,Cough,OT
176209033,Infliximab,Condition aggravated,OT
176209033,Infliximab,Blood pressure fluctuation,OT
176209033,Infliximab,Anal fissure,OT
176209033,Infliximab,Weight decreased,OT
176209033,Infliximab,Therapeutic response shortened,OT
176209033,Infliximab,Rectal haemorrhage,OT
176209033,Infliximab,Peripheral swelling,OT
176209033,Infliximab,Pain in extremity,OT
176209033,Infliximab,Oral candidiasis,OT
176209033,Infliximab,Nasopharyngitis,OT
176209033,Infliximab,Nasal congestion,OT
176209033,Infliximab,Localised infection,OT
176209033,Infliximab,Infusion site pain,OT
176209033,Infliximab,Hypothyroidism,OT
176209033,Infliximab,Headache,OT
176209033,Infliximab,Feeling cold,OT
176209033,Infliximab,Erythema,OT
176209033,Infliximab,Dyspepsia,OT
176209033,Infliximab,Drug ineffective,OT
176209033,Infliximab,Cough,OT
176209033,Infliximab,Condition aggravated,OT
176209033,Infliximab,Blood pressure fluctuation,OT
176209033,Infliximab,Anal fissure,OT
176209033,Infliximab,Weight decreased,OT
176209033,Infliximab,Therapeutic response shortened,OT
176209033,Infliximab,Rectal haemorrhage,OT
176209033,Infliximab,Peripheral swelling,OT
176209033,Infliximab,Pain in extremity,OT
176209033,Infliximab,Oral candidiasis,OT
176209033,Infliximab,Nasopharyngitis,OT
176209033,Infliximab,Nasal congestion,OT
176209033,Infliximab,Localised infection,OT
176209033,Infliximab,Infusion site pain,OT
176209033,Infliximab,Hypothyroidism,OT
176209033,Infliximab,Headache,OT
176209033,Infliximab,Feeling cold,OT
176209033,Infliximab,Erythema,OT
176209033,Infliximab,Dyspepsia,OT
176209033,Infliximab,Drug ineffective,OT
176209033,Infliximab,Cough,OT
176209033,Infliximab,Condition aggravated,OT
176209033,Infliximab,Blood pressure fluctuation,OT
176209033,Infliximab,Anal fissure,OT
176266656,Infliximab,Wheezing,OT
176266656,Infliximab,Weight increased,OT
176266656,Infliximab,Weight fluctuation,OT
176266656,Infliximab,Weight decreased,OT
176266656,Infliximab,Vulvovaginal mycotic infection,OT
176266656,Infliximab,Vomiting,OT
176266656,Infliximab,Vaginal infection,OT
176266656,Infliximab,Therapeutic response shortened,OT
176266656,Infliximab,Syncope,OT
176266656,Infliximab,Rib fracture,OT
176266656,Infliximab,Productive cough,OT
176266656,Infliximab,Product use issue,OT
176266656,Infliximab,Pain,OT
176266656,Infliximab,Off label use,OT
176266656,Infliximab,Nausea,OT
176266656,Infliximab,Nasopharyngitis,OT
176266656,Infliximab,Malaise,OT
176266656,Infliximab,Intentional product use issue,OT
176266656,Infliximab,Heart rate irregular,OT
176266656,Infliximab,Fungal skin infection,OT
176266656,Infliximab,Fatigue,OT
176266656,Infliximab,Cough,OT
176266656,Infliximab,Condition aggravated,OT
176266656,Infliximab,Blood pressure fluctuation,OT
176266656,Infliximab,Blood pressure decreased,OT
176266656,Infliximab,Wheezing,OT
176266656,Infliximab,Weight increased,OT
176266656,Infliximab,Weight fluctuation,OT
176266656,Infliximab,Weight decreased,OT
176266656,Infliximab,Vulvovaginal mycotic infection,OT
176266656,Infliximab,Vomiting,OT
176266656,Infliximab,Vaginal infection,OT
176266656,Infliximab,Therapeutic response shortened,OT
176266656,Infliximab,Syncope,OT
176266656,Infliximab,Rib fracture,OT
176266656,Infliximab,Productive cough,OT
176266656,Infliximab,Product use issue,OT
176266656,Infliximab,Pain,OT
176266656,Infliximab,Off label use,OT
176266656,Infliximab,Nausea,OT
176266656,Infliximab,Nasopharyngitis,OT
176266656,Infliximab,Malaise,OT
176266656,Infliximab,Intentional product use issue,OT
176266656,Infliximab,Heart rate irregular,OT
176266656,Infliximab,Fungal skin infection,OT
176266656,Infliximab,Fatigue,OT
176266656,Infliximab,Cough,OT
176266656,Infliximab,Condition aggravated,OT
176266656,Infliximab,Blood pressure fluctuation,OT
176266656,Infliximab,Blood pressure decreased,OT
176345792,Infliximab,White blood cell count increased,OT
176345792,Infliximab,White blood cell count increased,DS
176345792,Infliximab,Weight increased,OT
176345792,Infliximab,Weight increased,DS
176345792,Infliximab,Therapeutic product effect incomplete,OT
176345792,Infliximab,Therapeutic product effect incomplete,DS
176345792,Infliximab,Product dose omission issue,OT
176345792,Infliximab,Product dose omission issue,DS
176345792,Infliximab,Pain,OT
176345792,Infliximab,Pain,DS
176345792,Infliximab,Off label use,OT
176345792,Infliximab,Off label use,DS
176345792,Infliximab,Malaise,OT
176345792,Infliximab,Malaise,DS
176345792,Infliximab,Intentional product use issue,OT
176345792,Infliximab,Intentional product use issue,DS
176345792,Infliximab,Inappropriate schedule of product administration,OT
176345792,Infliximab,Inappropriate schedule of product administration,DS
176345792,Infliximab,Fatigue,OT
176345792,Infliximab,Fatigue,DS
176345792,Infliximab,Drug level decreased,OT
176345792,Infliximab,Drug level decreased,DS
176345792,Infliximab,Condition aggravated,OT
176345792,Infliximab,Condition aggravated,DS
176345792,Infliximab,Abdominal pain,OT
176345792,Infliximab,Abdominal pain,DS
176441014,Infliximab,Weight increased,OT
176441014,Infliximab,Product use issue,OT
176441014,Infliximab,Off label use,OT
176441014,Infliximab,Intentional product use issue,OT
176441014,Infliximab,Incorrect dose administered,OT
176441014,Infliximab,Inappropriate schedule of product administration,OT
176441014,Infliximab,Hypertension,OT
176441014,Infliximab,Heart rate irregular,OT
176441014,Infliximab,Heart rate increased,OT
176441014,Infliximab,Fatigue,OT
176441014,Infliximab,Expired product administered,OT
176441014,Infliximab,Condition aggravated,OT
176441014,Infliximab,Chest discomfort,OT
176441014,Infliximab,Body temperature decreased,OT
176441014,Infliximab,Blood pressure fluctuation,OT
176441014,Infliximab,Weight increased,OT
176441014,Infliximab,Product use issue,OT
176441014,Infliximab,Off label use,OT
176441014,Infliximab,Intentional product use issue,OT
176441014,Infliximab,Incorrect dose administered,OT
176441014,Infliximab,Inappropriate schedule of product administration,OT
176441014,Infliximab,Hypertension,OT
176441014,Infliximab,Heart rate irregular,OT
176441014,Infliximab,Heart rate increased,OT
176441014,Infliximab,Fatigue,OT
176441014,Infliximab,Expired product administered,OT
176441014,Infliximab,Condition aggravated,OT
176441014,Infliximab,Chest discomfort,OT
176441014,Infliximab,Body temperature decreased,OT
176441014,Infliximab,Blood pressure fluctuation,OT
176474664,Infliximab,Product use issue,OT
176474664,Infliximab,Off label use,OT
176474664,Infliximab,Myalgia,OT
176474664,Infliximab,Intentional product use issue,OT
176474664,Infliximab,Incorrect dose administered,OT
176474664,Infliximab,Inappropriate schedule of product administration,OT
176474664,Infliximab,Cough,OT
176474664,Infliximab,Constipation,OT
176474664,Infliximab,Condition aggravated,OT
176474664,Infliximab,Blood pressure increased,OT
176474664,Infliximab,Acne,OT
176474664,Infliximab,Abdominal pain,OT
176545142,Infliximab,Weight increased,OT
176545142,Infliximab,Weight increased,HO
176545142,Infliximab,Upper respiratory tract infection,OT
176545142,Infliximab,Upper respiratory tract infection,HO
176545142,Infliximab,Stress,OT
176545142,Infliximab,Stress,HO
176545142,Infliximab,Sleep disorder,OT
176545142,Infliximab,Sleep disorder,HO
176545142,Infliximab,Rhinorrhoea,OT
176545142,Infliximab,Rhinorrhoea,HO
176545142,Infliximab,Pyelonephritis,OT
176545142,Infliximab,Pyelonephritis,HO
176545142,Infliximab,Pulmonary mass,OT
176545142,Infliximab,Pulmonary mass,HO
176545142,Infliximab,Productive cough,OT
176545142,Infliximab,Productive cough,HO
176545142,Infliximab,Pneumonia,OT
176545142,Infliximab,Pneumonia,HO
176545142,Infliximab,Pancreatitis,OT
176545142,Infliximab,Pancreatitis,HO
176545142,Infliximab,Pain in extremity,OT
176545142,Infliximab,Pain in extremity,HO
176545142,Infliximab,Oropharyngeal pain,OT
176545142,Infliximab,Oropharyngeal pain,HO
176545142,Infliximab,Oral fungal infection,OT
176545142,Infliximab,Oral fungal infection,HO
176545142,Infliximab,Off label use,OT
176545142,Infliximab,Off label use,HO
176545142,Infliximab,Nausea,OT
176545142,Infliximab,Nausea,HO
176545142,Infliximab,Nasopharyngitis,OT
176545142,Infliximab,Nasopharyngitis,HO
176545142,Infliximab,Nasal congestion,OT
176545142,Infliximab,Nasal congestion,HO
176545142,Infliximab,Malaise,OT
176545142,Infliximab,Malaise,HO
176545142,Infliximab,Influenza,OT
176545142,Infliximab,Influenza,HO
176545142,Infliximab,Inappropriate schedule of product administration,OT
176545142,Infliximab,Inappropriate schedule of product administration,HO
176545142,Infliximab,Hepatic enzyme increased,OT
176545142,Infliximab,Hepatic enzyme increased,HO
176545142,Infliximab,Heart rate irregular,OT
176545142,Infliximab,Heart rate irregular,HO
176545142,Infliximab,Gout,OT
176545142,Infliximab,Gout,HO
176545142,Infliximab,Gallbladder enlargement,OT
176545142,Infliximab,Gallbladder enlargement,HO
176545142,Infliximab,Gallbladder disorder,OT
176545142,Infliximab,Gallbladder disorder,HO
176545142,Infliximab,Gait disturbance,OT
176545142,Infliximab,Gait disturbance,HO
176545142,Infliximab,Feeling abnormal,OT
176545142,Infliximab,Feeling abnormal,HO
176545142,Infliximab,Fatigue,OT
176545142,Infliximab,Fatigue,HO
176545142,Infliximab,Dysphonia,OT
176545142,Infliximab,Dysphonia,HO
176545142,Infliximab,Dysphagia,OT
176545142,Infliximab,Dysphagia,HO
176545142,Infliximab,Dysgeusia,OT
176545142,Infliximab,Dysgeusia,HO
176545142,Infliximab,Dizziness,OT
176545142,Infliximab,Dizziness,HO
176545142,Infliximab,Decreased appetite,OT
176545142,Infliximab,Decreased appetite,HO
176545142,Infliximab,Cough,OT
176545142,Infliximab,Cough,HO
176545142,Infliximab,Condition aggravated,OT
176545142,Infliximab,Condition aggravated,HO
176545142,Infliximab,Cholelithiasis,OT
176545142,Infliximab,Cholelithiasis,HO
176545142,Infliximab,Cellulitis,OT
176545142,Infliximab,Cellulitis,HO
176545142,Infliximab,Blood pressure fluctuation,OT
176545142,Infliximab,Blood pressure fluctuation,HO
176545142,Infliximab,Amnesia,OT
176545142,Infliximab,Amnesia,HO
176941374,Infliximab,Vomiting,HO
176941374,Infliximab,Tonsillitis,HO
176941374,Infliximab,Off label use,HO
176941374,Infliximab,Migraine,HO
176941374,Infliximab,Maternal exposure during pregnancy,HO
176941374,Infliximab,Malaise,HO
176941374,Infliximab,Intentional product use issue,HO
176941374,Infliximab,Influenza like illness,HO
176941374,Infliximab,Inappropriate schedule of product administration,HO
176941374,Infliximab,Headache,HO
176941374,Infliximab,Fatigue,HO
176941374,Infliximab,Drug ineffective,HO
176941374,Infliximab,Condition aggravated,HO
176941374,Infliximab,Bronchitis,HO
176941374,Infliximab,Body temperature decreased,HO
176941374,Infliximab,Blood pressure fluctuation,HO
176941374,Infliximab,Asthenia,HO
176941374,Infliximab,Abdominal pain,HO
176941374,Infliximab,Vomiting,HO
176941374,Infliximab,Tonsillitis,HO
176941374,Infliximab,Off label use,HO
176941374,Infliximab,Migraine,HO
176941374,Infliximab,Maternal exposure during pregnancy,HO
176941374,Infliximab,Malaise,HO
176941374,Infliximab,Intentional product use issue,HO
176941374,Infliximab,Influenza like illness,HO
176941374,Infliximab,Inappropriate schedule of product administration,HO
176941374,Infliximab,Headache,HO
176941374,Infliximab,Fatigue,HO
176941374,Infliximab,Drug ineffective,HO
176941374,Infliximab,Condition aggravated,HO
176941374,Infliximab,Bronchitis,HO
176941374,Infliximab,Body temperature decreased,HO
176941374,Infliximab,Blood pressure fluctuation,HO
176941374,Infliximab,Asthenia,HO
176941374,Infliximab,Abdominal pain,HO
176944133,Infliximab,Weight decreased,OT
176944133,Infliximab,Staphylococcal infection,OT
176944133,Infliximab,Sinusitis,OT
176944133,Infliximab,Red blood cell count increased,OT
176944133,Infliximab,Productive cough,OT
176944133,Infliximab,Pneumonia,OT
176944133,Infliximab,Pain,OT
176944133,Infliximab,Oxygen saturation decreased,OT
176944133,Infliximab,Off label use,OT
176944133,Infliximab,Malaise,OT
176944133,Infliximab,Intervertebral disc degeneration,OT
176944133,Infliximab,Intentional product use issue,OT
176944133,Infliximab,Insomnia,OT
176944133,Infliximab,Influenza like illness,OT
176944133,Infliximab,Inappropriate schedule of product administration,OT
176944133,Infliximab,Hypertension,OT
176944133,Infliximab,Hyperhidrosis,OT
176944133,Infliximab,Haemoptysis,OT
176944133,Infliximab,Furuncle,OT
176944133,Infliximab,Flushing,OT
176944133,Infliximab,Depressed mood,OT
176944133,Infliximab,Cough,OT
176944133,Infliximab,Condition aggravated,OT
176944133,Infliximab,Blood pressure fluctuation,OT
176944133,Infliximab,Back pain,OT
176944133,Infliximab,Asthenia,OT
180156362,Infliximab,Synovitis,OT
180156362,Infliximab,Rheumatoid arthritis,OT
180156362,Infliximab,Red blood cell sedimentation rate abnormal,OT
180156362,Infliximab,Drug ineffective,OT
180156362,Infliximab,Drug hypersensitivity,OT
180156362,Infliximab,C-reactive protein increased,OT
180814563,Infliximab,Weight increased,OT
180814563,Infliximab,Rectal haemorrhage,OT
180814563,Infliximab,Product use issue,OT
180814563,Infliximab,Paraesthesia,OT
180814563,Infliximab,Oxygen saturation abnormal,OT
180814563,Infliximab,Off label use,OT
180814563,Infliximab,Intentional product use issue,OT
180814563,Infliximab,Influenza,OT
180814563,Infliximab,Incorrect dose administered,OT
180814563,Infliximab,Inappropriate schedule of product administration,OT
180814563,Infliximab,Hypoaesthesia,OT
180814563,Infliximab,Condition aggravated,OT
182634202,Infliximab,Treatment failure,OT
182634202,Infliximab,Off label use,OT
182634202,Infliximab,Lower limb fracture,OT
182634202,Infliximab,Liver injury,OT
182634202,Infliximab,Ligament sprain,OT
182634202,Infliximab,Ligament rupture,OT
182634202,Infliximab,Joint swelling,OT
182634202,Infliximab,Joint injury,OT
182634202,Infliximab,Intentional product use issue,OT
182634202,Infliximab,Erythema,OT
182634202,Infliximab,Arthralgia,OT
183579752,Infliximab,Wound drainage,OT
183579752,Infliximab,Wound drainage,HO
183579752,Infliximab,Weight decreased,OT
183579752,Infliximab,Weight decreased,HO
183579752,Infliximab,Product use issue,OT
183579752,Infliximab,Product use issue,HO
183579752,Infliximab,Post procedural infection,OT
183579752,Infliximab,Post procedural infection,HO
183579752,Infliximab,Post procedural complication,OT
183579752,Infliximab,Post procedural complication,HO
183579752,Infliximab,Off label use,OT
183579752,Infliximab,Off label use,HO
183579752,Infliximab,Intestinal perforation,OT
183579752,Infliximab,Intestinal perforation,HO
183579752,Infliximab,Intentional product use issue,OT
183579752,Infliximab,Intentional product use issue,HO
183579752,Infliximab,Inappropriate schedule of product administration,OT
183579752,Infliximab,Inappropriate schedule of product administration,HO
183579752,Infliximab,Hernia,OT
183579752,Infliximab,Hernia,HO
183579752,Infliximab,Condition aggravated,OT
183579752,Infliximab,Condition aggravated,HO
183579752,Infliximab,Abdominal abscess,OT
183579752,Infliximab,Abdominal abscess,HO
183579752,Infliximab,Wound drainage,OT
183579752,Infliximab,Wound drainage,HO
183579752,Infliximab,Weight decreased,OT
183579752,Infliximab,Weight decreased,HO
183579752,Infliximab,Product use issue,OT
183579752,Infliximab,Product use issue,HO
183579752,Infliximab,Post procedural infection,OT
183579752,Infliximab,Post procedural infection,HO
183579752,Infliximab,Post procedural complication,OT
183579752,Infliximab,Post procedural complication,HO
183579752,Infliximab,Off label use,OT
183579752,Infliximab,Off label use,HO
183579752,Infliximab,Intestinal perforation,OT
183579752,Infliximab,Intestinal perforation,HO
183579752,Infliximab,Intentional product use issue,OT
183579752,Infliximab,Intentional product use issue,HO
183579752,Infliximab,Inappropriate schedule of product administration,OT
183579752,Infliximab,Inappropriate schedule of product administration,HO
183579752,Infliximab,Hernia,OT
183579752,Infliximab,Hernia,HO
183579752,Infliximab,Condition aggravated,OT
183579752,Infliximab,Condition aggravated,HO
183579752,Infliximab,Abdominal abscess,OT
183579752,Infliximab,Abdominal abscess,HO
184809383,Infliximab,Skin irritation,OT
184809383,Infliximab,Oxygen saturation decreased,OT
184809383,Infliximab,Oxygen saturation abnormal,OT
184809383,Infliximab,Off label use,OT
184809383,Infliximab,Intentional product use issue,OT
184809383,Infliximab,Condition aggravated,OT
184809383,Infliximab,Blood pressure diastolic increased,OT
184858323,Infliximab,Vomiting,OT
184858323,Infliximab,Spondyloarthropathy,OT
184858323,Infliximab,Pyrexia,OT
184858323,Infliximab,Product use issue,OT
184858323,Infliximab,Off label use,OT
184858323,Infliximab,Nausea,OT
184858323,Infliximab,Muscle hypertrophy,OT
184858323,Infliximab,Intentional product use issue,OT
184858323,Infliximab,Influenza,OT
184858323,Infliximab,Inappropriate schedule of product administration,OT
184858323,Infliximab,Headache,OT
184858323,Infliximab,Haematochezia,OT
184858323,Infliximab,Diverticulum,OT
184858323,Infliximab,Defaecation urgency,OT
184858323,Infliximab,Condition aggravated,OT
184858323,Infliximab,Chills,OT
184858323,Infliximab,Body temperature fluctuation,OT
184858323,Infliximab,Back pain,OT
184858323,Infliximab,Anorectal swelling,OT
184858323,Infliximab,Anorectal disorder,OT
184858323,Infliximab,Anal fissure,OT
184858323,Infliximab,Abscess,OT
184858323,Infliximab,Vomiting,OT
184858323,Infliximab,Spondyloarthropathy,OT
184858323,Infliximab,Pyrexia,OT
184858323,Infliximab,Product use issue,OT
184858323,Infliximab,Off label use,OT
184858323,Infliximab,Nausea,OT
184858323,Infliximab,Muscle hypertrophy,OT
184858323,Infliximab,Intentional product use issue,OT
184858323,Infliximab,Influenza,OT
184858323,Infliximab,Inappropriate schedule of product administration,OT
184858323,Infliximab,Headache,OT
184858323,Infliximab,Haematochezia,OT
184858323,Infliximab,Diverticulum,OT
184858323,Infliximab,Defaecation urgency,OT
184858323,Infliximab,Condition aggravated,OT
184858323,Infliximab,Chills,OT
184858323,Infliximab,Body temperature fluctuation,OT
184858323,Infliximab,Back pain,OT
184858323,Infliximab,Anorectal swelling,OT
184858323,Infliximab,Anorectal disorder,OT
184858323,Infliximab,Anal fissure,OT
184858323,Infliximab,Abscess,OT
185023262,Infliximab,Weight increased,OT
185023262,Infliximab,Pain,OT
185023262,Infliximab,Off label use,OT
185023262,Infliximab,Malaise,OT
185023262,Infliximab,Lethargy,OT
185023262,Infliximab,Intentional product use issue,OT
185023262,Infliximab,Inappropriate schedule of product administration,OT
185023262,Infliximab,Hypersomnia,OT
185023262,Infliximab,Heart rate increased,OT
185023262,Infliximab,Heart rate decreased,OT
185023262,Infliximab,Heart rate abnormal,OT
185023262,Infliximab,Haematochezia,OT
185023262,Infliximab,Fatigue,OT
185023262,Infliximab,Faecal calprotectin increased,OT
185023262,Infliximab,Constipation,OT
185023262,Infliximab,Condition aggravated,OT
185023262,Infliximab,C-reactive protein increased,OT
185023262,Infliximab,Bone pain,OT
185023262,Infliximab,Arthralgia,OT
185023262,Infliximab,Anorectal disorder,OT
185023262,Infliximab,Weight increased,OT
185023262,Infliximab,Pain,OT
185023262,Infliximab,Off label use,OT
185023262,Infliximab,Malaise,OT
185023262,Infliximab,Lethargy,OT
185023262,Infliximab,Intentional product use issue,OT
185023262,Infliximab,Inappropriate schedule of product administration,OT
185023262,Infliximab,Hypersomnia,OT
185023262,Infliximab,Heart rate increased,OT
185023262,Infliximab,Heart rate decreased,OT
185023262,Infliximab,Heart rate abnormal,OT
185023262,Infliximab,Haematochezia,OT
185023262,Infliximab,Fatigue,OT
185023262,Infliximab,Faecal calprotectin increased,OT
185023262,Infliximab,Constipation,OT
185023262,Infliximab,Condition aggravated,OT
185023262,Infliximab,C-reactive protein increased,OT
185023262,Infliximab,Bone pain,OT
185023262,Infliximab,Arthralgia,OT
185023262,Infliximab,Anorectal disorder,OT
185127622,Infliximab,Weight decreased,OT
185127622,Infliximab,Weight decreased,HO
185127622,Infliximab,Vomiting,OT
185127622,Infliximab,Vomiting,HO
185127622,Infliximab,Vein disorder,OT
185127622,Infliximab,Vein disorder,HO
185127622,Infliximab,Therapeutic response shortened,OT
185127622,Infliximab,Therapeutic response shortened,HO
185127622,Infliximab,Product use issue,OT
185127622,Infliximab,Product use issue,HO
185127622,Infliximab,Poor venous access,OT
185127622,Infliximab,Poor venous access,HO
185127622,Infliximab,Oropharyngitis fungal,OT
185127622,Infliximab,Oropharyngitis fungal,HO
185127622,Infliximab,Off label use,OT
185127622,Infliximab,Off label use,HO
185127622,Infliximab,Nausea,OT
185127622,Infliximab,Nausea,HO
185127622,Infliximab,Infusion site pain,OT
185127622,Infliximab,Infusion site pain,HO
185127622,Infliximab,Infusion site extravasation,OT
185127622,Infliximab,Infusion site extravasation,HO
185127622,Infliximab,Hypotension,OT
185127622,Infliximab,Hypotension,HO
185127622,Infliximab,Hepatic cirrhosis,OT
185127622,Infliximab,Hepatic cirrhosis,HO
185127622,Infliximab,Haemoglobin decreased,OT
185127622,Infliximab,Haemoglobin decreased,HO
185127622,Infliximab,Gallbladder disorder,OT
185127622,Infliximab,Gallbladder disorder,HO
185127622,Infliximab,Feeding disorder,OT
185127622,Infliximab,Feeding disorder,HO
185127622,Infliximab,Fall,OT
185127622,Infliximab,Fall,HO
185127622,Infliximab,Drug level above therapeutic,OT
185127622,Infliximab,Drug level above therapeutic,HO
185127622,Infliximab,Diarrhoea,OT
185127622,Infliximab,Diarrhoea,HO
185127622,Infliximab,Dehydration,OT
185127622,Infliximab,Dehydration,HO
185127622,Infliximab,Deep vein thrombosis,OT
185127622,Infliximab,Deep vein thrombosis,HO
185127622,Infliximab,Contusion,OT
185127622,Infliximab,Contusion,HO
185127622,Infliximab,Condition aggravated,OT
185127622,Infliximab,Condition aggravated,HO
185127622,Infliximab,Clostridium difficile colitis,OT
185127622,Infliximab,Clostridium difficile colitis,HO
185127622,Infliximab,Cellulitis,OT
185127622,Infliximab,Cellulitis,HO
185127622,Infliximab,Ascites,OT
185127622,Infliximab,Ascites,HO
185127622,Infliximab,Arthralgia,OT
185127622,Infliximab,Arthralgia,HO
186350583,Infliximab,Vomiting,DS
186350583,Infliximab,Vomiting,OT
186350583,Infliximab,Venous occlusion,DS
186350583,Infliximab,Venous occlusion,OT
186350583,Infliximab,Type 2 diabetes mellitus,DS
186350583,Infliximab,Type 2 diabetes mellitus,OT
186350583,Infliximab,Tremor,DS
186350583,Infliximab,Tremor,OT
186350583,Infliximab,Tooth disorder,DS
186350583,Infliximab,Tooth disorder,OT
186350583,Infliximab,Swelling,DS
186350583,Infliximab,Swelling,OT
186350583,Infliximab,Skin disorder,DS
186350583,Infliximab,Skin disorder,OT
186350583,Infliximab,Pain of skin,DS
186350583,Infliximab,Pain of skin,OT
186350583,Infliximab,Pain,DS
186350583,Infliximab,Pain,OT
186350583,Infliximab,Oxygen saturation decreased,DS
186350583,Infliximab,Oxygen saturation decreased,OT
186350583,Infliximab,Oxygen saturation abnormal,DS
186350583,Infliximab,Oxygen saturation abnormal,OT
186350583,Infliximab,Nausea,DS
186350583,Infliximab,Nausea,OT
186350583,Infliximab,Malaise,DS
186350583,Infliximab,Malaise,OT
186350583,Infliximab,Loss of consciousness,DS
186350583,Infliximab,Loss of consciousness,OT
186350583,Infliximab,Inflammation,DS
186350583,Infliximab,Inflammation,OT
186350583,Infliximab,Inappropriate schedule of product administration,DS
186350583,Infliximab,Inappropriate schedule of product administration,OT
186350583,Infliximab,Hyperhidrosis,DS
186350583,Infliximab,Hyperhidrosis,OT
186350583,Infliximab,Heart rate irregular,DS
186350583,Infliximab,Heart rate irregular,OT
186350583,Infliximab,Heart rate increased,DS
186350583,Infliximab,Heart rate increased,OT
186350583,Infliximab,Gastrointestinal disorder,DS
186350583,Infliximab,Gastrointestinal disorder,OT
186350583,Infliximab,Gait disturbance,DS
186350583,Infliximab,Gait disturbance,OT
186350583,Infliximab,Frequent bowel movements,DS
186350583,Infliximab,Frequent bowel movements,OT
186350583,Infliximab,Feeding disorder,DS
186350583,Infliximab,Feeding disorder,OT
186350583,Infliximab,Fall,DS
186350583,Infliximab,Fall,OT
186350583,Infliximab,Drug ineffective,DS
186350583,Infliximab,Drug ineffective,OT
186350583,Infliximab,Diarrhoea,DS
186350583,Infliximab,Diarrhoea,OT
186350583,Infliximab,Defaecation urgency,DS
186350583,Infliximab,Defaecation urgency,OT
186350583,Infliximab,Decreased appetite,DS
186350583,Infliximab,Decreased appetite,OT
186350583,Infliximab,Chills,DS
186350583,Infliximab,Chills,OT
186350583,Infliximab,Blood test abnormal,DS
186350583,Infliximab,Blood test abnormal,OT
186350583,Infliximab,Blood pressure fluctuation,DS
186350583,Infliximab,Blood pressure fluctuation,OT
186350583,Infliximab,Bedridden,DS
186350583,Infliximab,Bedridden,OT
186350583,Infliximab,Asthenia,DS
186350583,Infliximab,Asthenia,OT
186350583,Infliximab,Vomiting,DS
186350583,Infliximab,Vomiting,OT
186350583,Infliximab,Venous occlusion,DS
186350583,Infliximab,Venous occlusion,OT
186350583,Infliximab,Type 2 diabetes mellitus,DS
186350583,Infliximab,Type 2 diabetes mellitus,OT
186350583,Infliximab,Tremor,DS
186350583,Infliximab,Tremor,OT
186350583,Infliximab,Tooth disorder,DS
186350583,Infliximab,Tooth disorder,OT
186350583,Infliximab,Swelling,DS
186350583,Infliximab,Swelling,OT
186350583,Infliximab,Skin disorder,DS
186350583,Infliximab,Skin disorder,OT
186350583,Infliximab,Pain of skin,DS
186350583,Infliximab,Pain of skin,OT
186350583,Infliximab,Pain,DS
186350583,Infliximab,Pain,OT
186350583,Infliximab,Oxygen saturation decreased,DS
186350583,Infliximab,Oxygen saturation decreased,OT
186350583,Infliximab,Oxygen saturation abnormal,DS
186350583,Infliximab,Oxygen saturation abnormal,OT
186350583,Infliximab,Nausea,DS
186350583,Infliximab,Nausea,OT
186350583,Infliximab,Malaise,DS
186350583,Infliximab,Malaise,OT
186350583,Infliximab,Loss of consciousness,DS
186350583,Infliximab,Loss of consciousness,OT
186350583,Infliximab,Inflammation,DS
186350583,Infliximab,Inflammation,OT
186350583,Infliximab,Inappropriate schedule of product administration,DS
186350583,Infliximab,Inappropriate schedule of product administration,OT
186350583,Infliximab,Hyperhidrosis,DS
186350583,Infliximab,Hyperhidrosis,OT
186350583,Infliximab,Heart rate irregular,DS
186350583,Infliximab,Heart rate irregular,OT
186350583,Infliximab,Heart rate increased,DS
186350583,Infliximab,Heart rate increased,OT
186350583,Infliximab,Gastrointestinal disorder,DS
186350583,Infliximab,Gastrointestinal disorder,OT
186350583,Infliximab,Gait disturbance,DS
186350583,Infliximab,Gait disturbance,OT
186350583,Infliximab,Frequent bowel movements,DS
186350583,Infliximab,Frequent bowel movements,OT
186350583,Infliximab,Feeding disorder,DS
186350583,Infliximab,Feeding disorder,OT
186350583,Infliximab,Fall,DS
186350583,Infliximab,Fall,OT
186350583,Infliximab,Drug ineffective,DS
186350583,Infliximab,Drug ineffective,OT
186350583,Infliximab,Diarrhoea,DS
186350583,Infliximab,Diarrhoea,OT
186350583,Infliximab,Defaecation urgency,DS
186350583,Infliximab,Defaecation urgency,OT
186350583,Infliximab,Decreased appetite,DS
186350583,Infliximab,Decreased appetite,OT
186350583,Infliximab,Chills,DS
186350583,Infliximab,Chills,OT
186350583,Infliximab,Blood test abnormal,DS
186350583,Infliximab,Blood test abnormal,OT
186350583,Infliximab,Blood pressure fluctuation,DS
186350583,Infliximab,Blood pressure fluctuation,OT
186350583,Infliximab,Bedridden,DS
186350583,Infliximab,Bedridden,OT
186350583,Infliximab,Asthenia,DS
186350583,Infliximab,Asthenia,OT
186350583,Infliximab,Vomiting,DS
186350583,Infliximab,Vomiting,OT
186350583,Infliximab,Venous occlusion,DS
186350583,Infliximab,Venous occlusion,OT
186350583,Infliximab,Type 2 diabetes mellitus,DS
186350583,Infliximab,Type 2 diabetes mellitus,OT
186350583,Infliximab,Tremor,DS
186350583,Infliximab,Tremor,OT
186350583,Infliximab,Tooth disorder,DS
186350583,Infliximab,Tooth disorder,OT
186350583,Infliximab,Swelling,DS
186350583,Infliximab,Swelling,OT
186350583,Infliximab,Skin disorder,DS
186350583,Infliximab,Skin disorder,OT
186350583,Infliximab,Pain of skin,DS
186350583,Infliximab,Pain of skin,OT
186350583,Infliximab,Pain,DS
186350583,Infliximab,Pain,OT
186350583,Infliximab,Oxygen saturation decreased,DS
186350583,Infliximab,Oxygen saturation decreased,OT
186350583,Infliximab,Oxygen saturation abnormal,DS
186350583,Infliximab,Oxygen saturation abnormal,OT
186350583,Infliximab,Nausea,DS
186350583,Infliximab,Nausea,OT
186350583,Infliximab,Malaise,DS
186350583,Infliximab,Malaise,OT
186350583,Infliximab,Loss of consciousness,DS
186350583,Infliximab,Loss of consciousness,OT
186350583,Infliximab,Inflammation,DS
186350583,Infliximab,Inflammation,OT
186350583,Infliximab,Inappropriate schedule of product administration,DS
186350583,Infliximab,Inappropriate schedule of product administration,OT
186350583,Infliximab,Hyperhidrosis,DS
186350583,Infliximab,Hyperhidrosis,OT
186350583,Infliximab,Heart rate irregular,DS
186350583,Infliximab,Heart rate irregular,OT
186350583,Infliximab,Heart rate increased,DS
186350583,Infliximab,Heart rate increased,OT
186350583,Infliximab,Gastrointestinal disorder,DS
186350583,Infliximab,Gastrointestinal disorder,OT
186350583,Infliximab,Gait disturbance,DS
186350583,Infliximab,Gait disturbance,OT
186350583,Infliximab,Frequent bowel movements,DS
186350583,Infliximab,Frequent bowel movements,OT
186350583,Infliximab,Feeding disorder,DS
186350583,Infliximab,Feeding disorder,OT
186350583,Infliximab,Fall,DS
186350583,Infliximab,Fall,OT
186350583,Infliximab,Drug ineffective,DS
186350583,Infliximab,Drug ineffective,OT
186350583,Infliximab,Diarrhoea,DS
186350583,Infliximab,Diarrhoea,OT
186350583,Infliximab,Defaecation urgency,DS
186350583,Infliximab,Defaecation urgency,OT
186350583,Infliximab,Decreased appetite,DS
186350583,Infliximab,Decreased appetite,OT
186350583,Infliximab,Chills,DS
186350583,Infliximab,Chills,OT
186350583,Infliximab,Blood test abnormal,DS
186350583,Infliximab,Blood test abnormal,OT
186350583,Infliximab,Blood pressure fluctuation,DS
186350583,Infliximab,Blood pressure fluctuation,OT
186350583,Infliximab,Bedridden,DS
186350583,Infliximab,Bedridden,OT
186350583,Infliximab,Asthenia,DS
186350583,Infliximab,Asthenia,OT
186350583,Infliximab,Vomiting,DS
186350583,Infliximab,Vomiting,OT
186350583,Infliximab,Venous occlusion,DS
186350583,Infliximab,Venous occlusion,OT
186350583,Infliximab,Type 2 diabetes mellitus,DS
186350583,Infliximab,Type 2 diabetes mellitus,OT
186350583,Infliximab,Tremor,DS
186350583,Infliximab,Tremor,OT
186350583,Infliximab,Tooth disorder,DS
186350583,Infliximab,Tooth disorder,OT
186350583,Infliximab,Swelling,DS
186350583,Infliximab,Swelling,OT
186350583,Infliximab,Skin disorder,DS
186350583,Infliximab,Skin disorder,OT
186350583,Infliximab,Pain of skin,DS
186350583,Infliximab,Pain of skin,OT
186350583,Infliximab,Pain,DS
186350583,Infliximab,Pain,OT
186350583,Infliximab,Oxygen saturation decreased,DS
186350583,Infliximab,Oxygen saturation decreased,OT
186350583,Infliximab,Oxygen saturation abnormal,DS
186350583,Infliximab,Oxygen saturation abnormal,OT
186350583,Infliximab,Nausea,DS
186350583,Infliximab,Nausea,OT
186350583,Infliximab,Malaise,DS
186350583,Infliximab,Malaise,OT
186350583,Infliximab,Loss of consciousness,DS
186350583,Infliximab,Loss of consciousness,OT
186350583,Infliximab,Inflammation,DS
186350583,Infliximab,Inflammation,OT
186350583,Infliximab,Inappropriate schedule of product administration,DS
186350583,Infliximab,Inappropriate schedule of product administration,OT
186350583,Infliximab,Hyperhidrosis,DS
186350583,Infliximab,Hyperhidrosis,OT
186350583,Infliximab,Heart rate irregular,DS
186350583,Infliximab,Heart rate irregular,OT
186350583,Infliximab,Heart rate increased,DS
186350583,Infliximab,Heart rate increased,OT
186350583,Infliximab,Gastrointestinal disorder,DS
186350583,Infliximab,Gastrointestinal disorder,OT
186350583,Infliximab,Gait disturbance,DS
186350583,Infliximab,Gait disturbance,OT
186350583,Infliximab,Frequent bowel movements,DS
186350583,Infliximab,Frequent bowel movements,OT
186350583,Infliximab,Feeding disorder,DS
186350583,Infliximab,Feeding disorder,OT
186350583,Infliximab,Fall,DS
186350583,Infliximab,Fall,OT
186350583,Infliximab,Drug ineffective,DS
186350583,Infliximab,Drug ineffective,OT
186350583,Infliximab,Diarrhoea,DS
186350583,Infliximab,Diarrhoea,OT
186350583,Infliximab,Defaecation urgency,DS
186350583,Infliximab,Defaecation urgency,OT
186350583,Infliximab,Decreased appetite,DS
186350583,Infliximab,Decreased appetite,OT
186350583,Infliximab,Chills,DS
186350583,Infliximab,Chills,OT
186350583,Infliximab,Blood test abnormal,DS
186350583,Infliximab,Blood test abnormal,OT
186350583,Infliximab,Blood pressure fluctuation,DS
186350583,Infliximab,Blood pressure fluctuation,OT
186350583,Infliximab,Bedridden,DS
186350583,Infliximab,Bedridden,OT
186350583,Infliximab,Asthenia,DS
186350583,Infliximab,Asthenia,OT
189241102,Infliximab,Osteopenia,OT
189241102,Infliximab,Osteonecrosis,OT
189241102,Infliximab,Off label use,OT
189241102,Infliximab,Leukopenia,OT
189241102,Infliximab,Hypertension,OT
189241102,Infliximab,Drug ineffective for unapproved indication,OT
189241102,Infliximab,Drug ineffective,OT
189241102,Infliximab,Diabetes mellitus,OT
189692222,Infliximab,Upper limb fracture,OT
189692222,Infliximab,Off label use,OT
189692222,Infliximab,Lower limb fracture,OT
189692222,Infliximab,Accident at work,OT
189692222,Infliximab,Upper limb fracture,OT
189692222,Infliximab,Off label use,OT
189692222,Infliximab,Lower limb fracture,OT
189692222,Infliximab,Accident at work,OT
191107693,Infliximab,Therapy non-responder,OT
191107693,Infliximab,Product use issue,OT
191107693,Infliximab,Off label use,OT
191107693,Infliximab,Intestinal obstruction,OT
191107693,Infliximab,Inappropriate schedule of product administration,OT
191107693,Infliximab,Heart rate irregular,OT
191107693,Infliximab,Drug ineffective,OT
191107693,Infliximab,Therapy non-responder,OT
191107693,Infliximab,Product use issue,OT
191107693,Infliximab,Off label use,OT
191107693,Infliximab,Intestinal obstruction,OT
191107693,Infliximab,Inappropriate schedule of product administration,OT
191107693,Infliximab,Heart rate irregular,OT
191107693,Infliximab,Drug ineffective,OT
191107693,Infliximab,Therapy non-responder,OT
191107693,Infliximab,Product use issue,OT
191107693,Infliximab,Off label use,OT
191107693,Infliximab,Intestinal obstruction,OT
191107693,Infliximab,Inappropriate schedule of product administration,OT
191107693,Infliximab,Heart rate irregular,OT
191107693,Infliximab,Drug ineffective,OT
192590492,Infliximab,Weight increased,OT
192590492,Infliximab,Proctitis,OT
192590492,Infliximab,Off label use,OT
192590492,Infliximab,Necrosis,OT
192590492,Infliximab,Intentional product use issue,OT
192590492,Infliximab,Condition aggravated,OT
192590492,Infliximab,Blood pressure decreased,OT
192590492,Infliximab,Anal fissure,OT
192590492,Infliximab,Abnormal faeces,OT
193139722,Infliximab,Skin lesion,OT
193139722,Infliximab,Product use issue,OT
193139722,Infliximab,Off label use,OT
193139722,Infliximab,Intentional product use issue,OT
193139722,Infliximab,Heart rate increased,OT
193139722,Infliximab,Condition aggravated,OT
193139722,Infliximab,Skin lesion,OT
193139722,Infliximab,Product use issue,OT
193139722,Infliximab,Off label use,OT
193139722,Infliximab,Intentional product use issue,OT
193139722,Infliximab,Heart rate increased,OT
193139722,Infliximab,Condition aggravated,OT
194935661,Infliximab,Off label use,OT
194935661,Infliximab,Neutropenia,OT
194935661,Infliximab,Blood test abnormal,OT
194986373,Infliximab,Colitis ulcerative,OT
194986373,Infliximab,Colitis ulcerative,HO
195465221,Infliximab (Unknown),Therapy partial responder,OT
195465221,Infliximab (Unknown),Headache,OT
195884961,Infliximab,Weight decreased,HO
195884961,Infliximab,Somnolence,HO
195884961,Infliximab,Poor venous access,HO
195884961,Infliximab,Off label use,HO
195884961,Infliximab,Nausea,HO
195884961,Infliximab,Heart rate decreased,HO
195884961,Infliximab,Headache,HO
195884961,Infliximab,Drug level above therapeutic,HO
195884961,Infliximab,Defaecation urgency,HO
195884961,Infliximab,Condition aggravated,HO
195884961,Infliximab,Anxiety,HO
195884961,Infliximab,Abdominal pain,HO
195896951,Infliximab,Weight increased,OT
195896951,Infliximab,Weight decreased,OT
195896951,Infliximab,Oropharyngeal pain,OT
195896951,Infliximab,Malaise,OT
195896951,Infliximab,Inappropriate schedule of product administration,OT
195896951,Infliximab,Condition aggravated,OT
195896951,Infliximab,Abdominal discomfort,OT
196263991,Infliximab,Immune reconstitution inflammatory syndrome,OT
196263991,Infliximab,Hepatitis B reactivation,OT
196649701,Infliximab (Unknown),Pyrexia,OT
196649701,Infliximab (Unknown),Hidradenitis,OT
196651441,Infliximab (Unknown),Peritoneal tuberculosis,OT
196651441,Infliximab (Unknown),Peritoneal tuberculosis,HO
196651441,Infliximab (Unknown),Overdose,OT
196651441,Infliximab (Unknown),Overdose,HO
196923491,Infliximab,Oral disorder,OT
196923491,Infliximab,Haematochezia,OT
196923491,Infliximab,Faeces soft,OT
196923491,Infliximab,Oral disorder,OT
196923491,Infliximab,Haematochezia,OT
196923491,Infliximab,Faeces soft,OT
196936481,Infliximab,Weight increased,OT
196936481,Infliximab,Weight decreased,OT
196936481,Infliximab,Vitamin D deficiency,OT
196936481,Infliximab,Off label use,OT
196936481,Infliximab,Maternal exposure during pregnancy,OT
196936481,Infliximab,Intentional product use issue,OT
196936481,Infliximab,Faecal calprotectin increased,OT
196936481,Infliximab,Drug specific antibody present,OT
196936481,Infliximab,Drug level above therapeutic,OT
196936481,Infliximab,Condition aggravated,OT
196936481,Infliximab,Blood pressure increased,OT
196936481,Infliximab,Anal fissure,OT
197030051,Infliximab,Cutaneous leishmaniasis,HO
197301261,Infliximab Pfizer (Unknown),Ulcer,HO
197301261,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,HO
197301261,Infliximab Pfizer (Unknown),Local reaction,HO
197301261,Infliximab Pfizer (Unknown),Intestinal ulcer,HO
197301261,Infliximab Pfizer (Unknown),Frequent bowel movements,HO
197301261,Infliximab Pfizer (Unknown),Drug level decreased,HO
197301261,Infliximab Pfizer (Unknown),Drug intolerance,HO
197301261,Infliximab Pfizer (Unknown),Drug ineffective,HO
197301261,Infliximab Pfizer (Unknown),Depression,HO
197301261,Infliximab Pfizer (Unknown),Colitis ulcerative,HO
197301261,Infliximab Pfizer (Unknown),Colitis,HO
197301261,Infliximab Pfizer (Unknown),Arthritis,HO
197736121,Infliximab,Weight increased,HO
197736121,Infliximab,Weight increased,OT
197736121,Infliximab,Umbilical hernia,HO
197736121,Infliximab,Umbilical hernia,OT
197736121,Infliximab,Tremor,HO
197736121,Infliximab,Tremor,OT
197736121,Infliximab,Sneezing,HO
197736121,Infliximab,Sneezing,OT
197736121,Infliximab,Off label use,HO
197736121,Infliximab,Off label use,OT
197736121,Infliximab,Intestinal obstruction,HO
197736121,Infliximab,Intestinal obstruction,OT
197736121,Infliximab,Intentional product use issue,HO
197736121,Infliximab,Intentional product use issue,OT
197736121,Infliximab,Dizziness,HO
197736121,Infliximab,Dizziness,OT
197736121,Infliximab,Blood pressure increased,HO
197736121,Infliximab,Blood pressure increased,OT
197736121,Infliximab,Abdominal pain,HO
197736121,Infliximab,Abdominal pain,OT
197915651,Infliximab,Off label use,OT
197915651,Infliximab,Intentional product use issue,OT
197915651,Infliximab,Drug ineffective,OT
197915651,Infliximab,Crohn's disease,OT
198005991,Infliximab,Tubulointerstitial nephritis,HO
198005991,Infliximab,Tubulointerstitial nephritis,OT
198005991,Infliximab,Glomerulonephritis,HO
198005991,Infliximab,Glomerulonephritis,OT
198078651,Infliximab,Off label use,HO
198078651,Infliximab,Inappropriate schedule of product administration,HO
198078651,Infliximab,Drug level below therapeutic,HO
198078651,Infliximab,Drug level above therapeutic,HO
198078651,Infliximab,Condition aggravated,HO
198078651,Infliximab,Blood pressure diastolic decreased,HO
198078651,Infliximab,Bacterial infection,HO
198201661,Infliximab,Neoplasm malignant,OT
198201661,Infliximab,Malaise,OT
198201661,Infliximab,Influenza like illness,OT
198201661,Infliximab,Drug specific antibody present,OT
198201661,Infliximab,Dermatitis contact,OT
198201661,Infliximab,Chest pain,OT
198201661,Infliximab,Chest discomfort,OT
198434611,Infliximab,Spinal pain,OT
198434611,Infliximab,Off label use,OT
198434611,Infliximab,Neuropathy peripheral,OT
198434611,Infliximab,Intentional product use issue,OT
198434611,Infliximab,Inflammatory bowel disease,OT
198434611,Infliximab,Condition aggravated,OT
198729241,Infliximab,Respiratory rate increased,OT
198729241,Infliximab,Pyrexia,OT
198729241,Infliximab,Product use issue,OT
198729241,Infliximab,Oxygen saturation abnormal,OT
198729241,Infliximab,Off label use,OT
198729241,Infliximab,Heart rate irregular,OT
198729241,Infliximab,Headache,OT
198729241,Infliximab,Flushing,OT
198729241,Infliximab,Erythema,OT
198729241,Infliximab,Dyspnoea,OT
198729241,Infliximab,Cough,OT
198729241,Infliximab,Condition aggravated,OT
198729241,Infliximab,Chills,OT
198729241,Infliximab,COVID-19,OT
198729241,Infliximab,Blood pressure fluctuation,OT
198729241,Infliximab,Anaphylactoid reaction,OT
198872461,Infliximab (Unknown),Off label use,NULL
198872461,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198912741,Infliximab,Pneumonia,HO
198912741,Infliximab,Pneumonia,DE
198912741,Infliximab,Death,HO
198912741,Infliximab,Death,DE
164921503,Infliximab,Treatment failure,OT
164921503,Infliximab,Rheumatoid arthritis,OT
164921503,Infliximab,Hypercholesterolaemia,OT
164921503,Infliximab,Drug ineffective,OT
164921935,Infliximab,Weight increased,HO
164921935,Infliximab,Weight increased,OT
164921935,Infliximab,Therapeutic product effect decreased,HO
164921935,Infliximab,Therapeutic product effect decreased,OT
164921935,Infliximab,Pyrexia,HO
164921935,Infliximab,Pyrexia,OT
164921935,Infliximab,Poor venous access,HO
164921935,Infliximab,Poor venous access,OT
164921935,Infliximab,Off label use,HO
164921935,Infliximab,Off label use,OT
164921935,Infliximab,Nausea,HO
164921935,Infliximab,Nausea,OT
164921935,Infliximab,Joint stiffness,HO
164921935,Infliximab,Joint stiffness,OT
164921935,Infliximab,Intentional product use issue,HO
164921935,Infliximab,Intentional product use issue,OT
164921935,Infliximab,Heart rate irregular,HO
164921935,Infliximab,Heart rate irregular,OT
164921935,Infliximab,Drug specific antibody present,HO
164921935,Infliximab,Drug specific antibody present,OT
164921935,Infliximab,Drug level below therapeutic,HO
164921935,Infliximab,Drug level below therapeutic,OT
164921935,Infliximab,Dizziness,HO
164921935,Infliximab,Dizziness,OT
164921935,Infliximab,Dehydration,HO
164921935,Infliximab,Dehydration,OT
164921935,Infliximab,Condition aggravated,HO
164921935,Infliximab,Condition aggravated,OT
164921935,Infliximab,Anal abscess,HO
164921935,Infliximab,Anal abscess,OT
164921935,Infliximab,Weight increased,HO
164921935,Infliximab,Weight increased,OT
164921935,Infliximab,Therapeutic product effect decreased,HO
164921935,Infliximab,Therapeutic product effect decreased,OT
164921935,Infliximab,Pyrexia,HO
164921935,Infliximab,Pyrexia,OT
164921935,Infliximab,Poor venous access,HO
164921935,Infliximab,Poor venous access,OT
164921935,Infliximab,Off label use,HO
164921935,Infliximab,Off label use,OT
164921935,Infliximab,Nausea,HO
164921935,Infliximab,Nausea,OT
164921935,Infliximab,Joint stiffness,HO
164921935,Infliximab,Joint stiffness,OT
164921935,Infliximab,Intentional product use issue,HO
164921935,Infliximab,Intentional product use issue,OT
164921935,Infliximab,Heart rate irregular,HO
164921935,Infliximab,Heart rate irregular,OT
164921935,Infliximab,Drug specific antibody present,HO
164921935,Infliximab,Drug specific antibody present,OT
164921935,Infliximab,Drug level below therapeutic,HO
164921935,Infliximab,Drug level below therapeutic,OT
164921935,Infliximab,Dizziness,HO
164921935,Infliximab,Dizziness,OT
164921935,Infliximab,Dehydration,HO
164921935,Infliximab,Dehydration,OT
164921935,Infliximab,Condition aggravated,HO
164921935,Infliximab,Condition aggravated,OT
164921935,Infliximab,Anal abscess,HO
164921935,Infliximab,Anal abscess,OT
164921935,Infliximab,Weight increased,HO
164921935,Infliximab,Weight increased,OT
164921935,Infliximab,Therapeutic product effect decreased,HO
164921935,Infliximab,Therapeutic product effect decreased,OT
164921935,Infliximab,Pyrexia,HO
164921935,Infliximab,Pyrexia,OT
164921935,Infliximab,Poor venous access,HO
164921935,Infliximab,Poor venous access,OT
164921935,Infliximab,Off label use,HO
164921935,Infliximab,Off label use,OT
164921935,Infliximab,Nausea,HO
164921935,Infliximab,Nausea,OT
164921935,Infliximab,Joint stiffness,HO
164921935,Infliximab,Joint stiffness,OT
164921935,Infliximab,Intentional product use issue,HO
164921935,Infliximab,Intentional product use issue,OT
164921935,Infliximab,Heart rate irregular,HO
164921935,Infliximab,Heart rate irregular,OT
164921935,Infliximab,Drug specific antibody present,HO
164921935,Infliximab,Drug specific antibody present,OT
164921935,Infliximab,Drug level below therapeutic,HO
164921935,Infliximab,Drug level below therapeutic,OT
164921935,Infliximab,Dizziness,HO
164921935,Infliximab,Dizziness,OT
164921935,Infliximab,Dehydration,HO
164921935,Infliximab,Dehydration,OT
164921935,Infliximab,Condition aggravated,HO
164921935,Infliximab,Condition aggravated,OT
164921935,Infliximab,Anal abscess,HO
164921935,Infliximab,Anal abscess,OT
168814264,Infliximab,Weight increased,OT
168814264,Infliximab,Product use issue,OT
168814264,Infliximab,Off label use,OT
168814264,Infliximab,Maternal exposure during pregnancy,OT
168814264,Infliximab,Intentional product use issue,OT
168814264,Infliximab,Inappropriate schedule of product administration,OT
168814264,Infliximab,Heart rate irregular,OT
168814264,Infliximab,Heart rate increased,OT
168814264,Infliximab,Heart rate decreased,OT
168814264,Infliximab,Condition aggravated,OT
168814264,Infliximab,Blood albumin decreased,OT
168814264,Infliximab,Weight increased,OT
168814264,Infliximab,Product use issue,OT
168814264,Infliximab,Off label use,OT
168814264,Infliximab,Maternal exposure during pregnancy,OT
168814264,Infliximab,Intentional product use issue,OT
168814264,Infliximab,Inappropriate schedule of product administration,OT
168814264,Infliximab,Heart rate irregular,OT
168814264,Infliximab,Heart rate increased,OT
168814264,Infliximab,Heart rate decreased,OT
168814264,Infliximab,Condition aggravated,OT
168814264,Infliximab,Blood albumin decreased,OT
168814274,Infliximab,Weight increased,OT
168814274,Infliximab,Weight increased,HO
168814274,Infliximab,Tooth abscess,OT
168814274,Infliximab,Tooth abscess,HO
168814274,Infliximab,Root canal infection,OT
168814274,Infliximab,Root canal infection,HO
168814274,Infliximab,Product use issue,OT
168814274,Infliximab,Product use issue,HO
168814274,Infliximab,Off label use,OT
168814274,Infliximab,Off label use,HO
168814274,Infliximab,Nasopharyngitis,OT
168814274,Infliximab,Nasopharyngitis,HO
168814274,Infliximab,Intentional product use issue,OT
168814274,Infliximab,Intentional product use issue,HO
168814274,Infliximab,Influenza,OT
168814274,Infliximab,Influenza,HO
168814274,Infliximab,Incorrect dose administered,OT
168814274,Infliximab,Incorrect dose administered,HO
168814274,Infliximab,Inappropriate schedule of product administration,OT
168814274,Infliximab,Inappropriate schedule of product administration,HO
168814274,Infliximab,Body temperature increased,OT
168814274,Infliximab,Body temperature increased,HO
168814274,Infliximab,Blood pressure increased,OT
168814274,Infliximab,Blood pressure increased,HO
168814274,Infliximab,Blood pressure fluctuation,OT
168814274,Infliximab,Blood pressure fluctuation,HO
168814274,Infliximab,Blood pressure decreased,OT
168814274,Infliximab,Blood pressure decreased,HO
168917674,Infliximab,Sputum discoloured,OT
168917674,Infliximab,Rhinorrhoea,OT
168917674,Infliximab,Rectal tenesmus,OT
168917674,Infliximab,Rectal discharge,OT
168917674,Infliximab,Productive cough,OT
168917674,Infliximab,Product use issue,OT
168917674,Infliximab,Off label use,OT
168917674,Infliximab,Nasopharyngitis,OT
168917674,Infliximab,Mucous stools,OT
168917674,Infliximab,Intentional product use issue,OT
168917674,Infliximab,Infusion site pain,OT
168917674,Infliximab,Infusion site oedema,OT
168917674,Infliximab,Inappropriate schedule of product administration,OT
168917674,Infliximab,Haematochezia,OT
168917674,Infliximab,Drug level below therapeutic,OT
168917674,Infliximab,Drug ineffective,OT
168917674,Infliximab,Condition aggravated,OT
168917674,Infliximab,Blood pressure fluctuation,OT
168917674,Infliximab,Arthralgia,OT
168917674,Infliximab,Sputum discoloured,OT
168917674,Infliximab,Rhinorrhoea,OT
168917674,Infliximab,Rectal tenesmus,OT
168917674,Infliximab,Rectal discharge,OT
168917674,Infliximab,Productive cough,OT
168917674,Infliximab,Product use issue,OT
168917674,Infliximab,Off label use,OT
168917674,Infliximab,Nasopharyngitis,OT
168917674,Infliximab,Mucous stools,OT
168917674,Infliximab,Intentional product use issue,OT
168917674,Infliximab,Infusion site pain,OT
168917674,Infliximab,Infusion site oedema,OT
168917674,Infliximab,Inappropriate schedule of product administration,OT
168917674,Infliximab,Haematochezia,OT
168917674,Infliximab,Drug level below therapeutic,OT
168917674,Infliximab,Drug ineffective,OT
168917674,Infliximab,Condition aggravated,OT
168917674,Infliximab,Blood pressure fluctuation,OT
168917674,Infliximab,Arthralgia,OT
168917674,Infliximab,Sputum discoloured,OT
168917674,Infliximab,Rhinorrhoea,OT
168917674,Infliximab,Rectal tenesmus,OT
168917674,Infliximab,Rectal discharge,OT
168917674,Infliximab,Productive cough,OT
168917674,Infliximab,Product use issue,OT
168917674,Infliximab,Off label use,OT
168917674,Infliximab,Nasopharyngitis,OT
168917674,Infliximab,Mucous stools,OT
168917674,Infliximab,Intentional product use issue,OT
168917674,Infliximab,Infusion site pain,OT
168917674,Infliximab,Infusion site oedema,OT
168917674,Infliximab,Inappropriate schedule of product administration,OT
168917674,Infliximab,Haematochezia,OT
168917674,Infliximab,Drug level below therapeutic,OT
168917674,Infliximab,Drug ineffective,OT
168917674,Infliximab,Condition aggravated,OT
168917674,Infliximab,Blood pressure fluctuation,OT
168917674,Infliximab,Arthralgia,OT
168917674,Infliximab,Sputum discoloured,OT
168917674,Infliximab,Rhinorrhoea,OT
168917674,Infliximab,Rectal tenesmus,OT
168917674,Infliximab,Rectal discharge,OT
168917674,Infliximab,Productive cough,OT
168917674,Infliximab,Product use issue,OT
168917674,Infliximab,Off label use,OT
168917674,Infliximab,Nasopharyngitis,OT
168917674,Infliximab,Mucous stools,OT
168917674,Infliximab,Intentional product use issue,OT
168917674,Infliximab,Infusion site pain,OT
168917674,Infliximab,Infusion site oedema,OT
168917674,Infliximab,Inappropriate schedule of product administration,OT
168917674,Infliximab,Haematochezia,OT
168917674,Infliximab,Drug level below therapeutic,OT
168917674,Infliximab,Drug ineffective,OT
168917674,Infliximab,Condition aggravated,OT
168917674,Infliximab,Blood pressure fluctuation,OT
168917674,Infliximab,Arthralgia,OT
168917674,Infliximab,Sputum discoloured,OT
168917674,Infliximab,Rhinorrhoea,OT
168917674,Infliximab,Rectal tenesmus,OT
168917674,Infliximab,Rectal discharge,OT
168917674,Infliximab,Productive cough,OT
168917674,Infliximab,Product use issue,OT
168917674,Infliximab,Off label use,OT
168917674,Infliximab,Nasopharyngitis,OT
168917674,Infliximab,Mucous stools,OT
168917674,Infliximab,Intentional product use issue,OT
168917674,Infliximab,Infusion site pain,OT
168917674,Infliximab,Infusion site oedema,OT
168917674,Infliximab,Inappropriate schedule of product administration,OT
168917674,Infliximab,Haematochezia,OT
168917674,Infliximab,Drug level below therapeutic,OT
168917674,Infliximab,Drug ineffective,OT
168917674,Infliximab,Condition aggravated,OT
168917674,Infliximab,Blood pressure fluctuation,OT
168917674,Infliximab,Arthralgia,OT
168917674,Infliximab,Sputum discoloured,OT
168917674,Infliximab,Rhinorrhoea,OT
168917674,Infliximab,Rectal tenesmus,OT
168917674,Infliximab,Rectal discharge,OT
168917674,Infliximab,Productive cough,OT
168917674,Infliximab,Product use issue,OT
168917674,Infliximab,Off label use,OT
168917674,Infliximab,Nasopharyngitis,OT
168917674,Infliximab,Mucous stools,OT
168917674,Infliximab,Intentional product use issue,OT
168917674,Infliximab,Infusion site pain,OT
168917674,Infliximab,Infusion site oedema,OT
168917674,Infliximab,Inappropriate schedule of product administration,OT
168917674,Infliximab,Haematochezia,OT
168917674,Infliximab,Drug level below therapeutic,OT
168917674,Infliximab,Drug ineffective,OT
168917674,Infliximab,Condition aggravated,OT
168917674,Infliximab,Blood pressure fluctuation,OT
168917674,Infliximab,Arthralgia,OT
168917674,Infliximab,Sputum discoloured,OT
168917674,Infliximab,Rhinorrhoea,OT
168917674,Infliximab,Rectal tenesmus,OT
168917674,Infliximab,Rectal discharge,OT
168917674,Infliximab,Productive cough,OT
168917674,Infliximab,Product use issue,OT
168917674,Infliximab,Off label use,OT
168917674,Infliximab,Nasopharyngitis,OT
168917674,Infliximab,Mucous stools,OT
168917674,Infliximab,Intentional product use issue,OT
168917674,Infliximab,Infusion site pain,OT
168917674,Infliximab,Infusion site oedema,OT
168917674,Infliximab,Inappropriate schedule of product administration,OT
168917674,Infliximab,Haematochezia,OT
168917674,Infliximab,Drug level below therapeutic,OT
168917674,Infliximab,Drug ineffective,OT
168917674,Infliximab,Condition aggravated,OT
168917674,Infliximab,Blood pressure fluctuation,OT
168917674,Infliximab,Arthralgia,OT
168917674,Infliximab,Sputum discoloured,OT
168917674,Infliximab,Rhinorrhoea,OT
168917674,Infliximab,Rectal tenesmus,OT
168917674,Infliximab,Rectal discharge,OT
168917674,Infliximab,Productive cough,OT
168917674,Infliximab,Product use issue,OT
168917674,Infliximab,Off label use,OT
168917674,Infliximab,Nasopharyngitis,OT
168917674,Infliximab,Mucous stools,OT
168917674,Infliximab,Intentional product use issue,OT
168917674,Infliximab,Infusion site pain,OT
168917674,Infliximab,Infusion site oedema,OT
168917674,Infliximab,Inappropriate schedule of product administration,OT
168917674,Infliximab,Haematochezia,OT
168917674,Infliximab,Drug level below therapeutic,OT
168917674,Infliximab,Drug ineffective,OT
168917674,Infliximab,Condition aggravated,OT
168917674,Infliximab,Blood pressure fluctuation,OT
168917674,Infliximab,Arthralgia,OT
171031602,Infliximab,Weight increased,OT
171031602,Infliximab,Weight increased,HO
171031602,Infliximab,Therapy non-responder,OT
171031602,Infliximab,Therapy non-responder,HO
171031602,Infliximab,Swelling,OT
171031602,Infliximab,Swelling,HO
171031602,Infliximab,Proctalgia,OT
171031602,Infliximab,Proctalgia,HO
171031602,Infliximab,Drug ineffective,OT
171031602,Infliximab,Drug ineffective,HO
171031602,Infliximab,Diarrhoea,OT
171031602,Infliximab,Diarrhoea,HO
171031602,Infliximab,Condition aggravated,OT
171031602,Infliximab,Condition aggravated,HO
171031602,Infliximab,Clostridium difficile infection,OT
171031602,Infliximab,Clostridium difficile infection,HO
171031602,Infliximab,Abdominal pain,OT
171031602,Infliximab,Abdominal pain,HO
172745453,Infliximab,Weight increased,OT
172745453,Infliximab,Therapeutic product effect decreased,OT
172745453,Infliximab,Pyrexia,OT
172745453,Infliximab,Psoriasis,OT
172745453,Infliximab,Product use issue,OT
172745453,Infliximab,Off label use,OT
172745453,Infliximab,Neoplasm progression,OT
172745453,Infliximab,Malaise,OT
172745453,Infliximab,Lymph node calcification,OT
172745453,Infliximab,Inappropriate schedule of product administration,OT
172745453,Infliximab,Impaired quality of life,OT
172745453,Infliximab,Hiatus hernia,OT
172745453,Infliximab,Glaucoma,OT
172745453,Infliximab,Fatigue,OT
172745453,Infliximab,Drug level increased,OT
172745453,Infliximab,Drug ineffective,OT
172745453,Infliximab,Drug clearance increased,OT
172745453,Infliximab,Condition aggravated,OT
172745453,Infliximab,Cholelithiasis,OT
172745453,Infliximab,COVID-19,OT
172745453,Infliximab,Blood pressure systolic increased,OT
172745453,Infliximab,Blood pressure fluctuation,OT
172745453,Infliximab,Arthritis,OT
172745453,Infliximab,Arthralgia,OT
174110754,Infliximab,Vasculitis,HO
174110754,Infliximab,Vasculitis,OT
174110754,Infliximab,Treatment failure,HO
174110754,Infliximab,Treatment failure,OT
174110754,Infliximab,Rheumatoid arthritis,HO
174110754,Infliximab,Rheumatoid arthritis,OT
174110754,Infliximab,Proteinuria,HO
174110754,Infliximab,Proteinuria,OT
174110754,Infliximab,Pain,HO
174110754,Infliximab,Pain,OT
174110754,Infliximab,Off label use,HO
174110754,Infliximab,Off label use,OT
174110754,Infliximab,Nausea,HO
174110754,Infliximab,Nausea,OT
174110754,Infliximab,Musculoskeletal stiffness,HO
174110754,Infliximab,Musculoskeletal stiffness,OT
174110754,Infliximab,Joint swelling,HO
174110754,Infliximab,Joint swelling,OT
174110754,Infliximab,Inflammation,HO
174110754,Infliximab,Inflammation,OT
174110754,Infliximab,Hypersensitivity,HO
174110754,Infliximab,Hypersensitivity,OT
174110754,Infliximab,Headache,HO
174110754,Infliximab,Headache,OT
174110754,Infliximab,Drug intolerance,HO
174110754,Infliximab,Drug intolerance,OT
174110754,Infliximab,Drug ineffective,HO
174110754,Infliximab,Drug ineffective,OT
174110754,Infliximab,Drug hypersensitivity,HO
174110754,Infliximab,Drug hypersensitivity,OT
174110754,Infliximab,Diarrhoea,HO
174110754,Infliximab,Diarrhoea,OT
174110754,Infliximab,Contraindicated product administered,HO
174110754,Infliximab,Contraindicated product administered,OT
174110754,Infliximab,Chest pain,HO
174110754,Infliximab,Chest pain,OT
174110754,Infliximab,Arthralgia,HO
174110754,Infliximab,Arthralgia,OT
174110754,Infliximab,Anti-neutrophil cytoplasmic antibody positive vasculitis,HO
174110754,Infliximab,Anti-neutrophil cytoplasmic antibody positive vasculitis,OT
174110754,Infliximab,Acute kidney injury,HO
174110754,Infliximab,Acute kidney injury,OT
174477404,Infliximab,Urinary tract infection,OT
174477404,Infliximab,Urinary tract infection,HO
174477404,Infliximab,Thermal burn,OT
174477404,Infliximab,Thermal burn,HO
174477404,Infliximab,Rhinorrhoea,OT
174477404,Infliximab,Rhinorrhoea,HO
174477404,Infliximab,Pruritus,OT
174477404,Infliximab,Pruritus,HO
174477404,Infliximab,Productive cough,OT
174477404,Infliximab,Productive cough,HO
174477404,Infliximab,Proctalgia,OT
174477404,Infliximab,Proctalgia,HO
174477404,Infliximab,Peripheral swelling,OT
174477404,Infliximab,Peripheral swelling,HO
174477404,Infliximab,Pelvic pain,OT
174477404,Infliximab,Pelvic pain,HO
174477404,Infliximab,Pelvic inflammatory disease,OT
174477404,Infliximab,Pelvic inflammatory disease,HO
174477404,Infliximab,Pelvic abscess,OT
174477404,Infliximab,Pelvic abscess,HO
174477404,Infliximab,Pain,OT
174477404,Infliximab,Pain,HO
174477404,Infliximab,Oral pain,OT
174477404,Infliximab,Oral pain,HO
174477404,Infliximab,Off label use,OT
174477404,Infliximab,Off label use,HO
174477404,Infliximab,Nasopharyngitis,OT
174477404,Infliximab,Nasopharyngitis,HO
174477404,Infliximab,Nasal congestion,OT
174477404,Infliximab,Nasal congestion,HO
174477404,Infliximab,Inappropriate schedule of product administration,OT
174477404,Infliximab,Inappropriate schedule of product administration,HO
174477404,Infliximab,Haematochezia,OT
174477404,Infliximab,Haematochezia,HO
174477404,Infliximab,Gingival pain,OT
174477404,Infliximab,Gingival pain,HO
174477404,Infliximab,Fistula discharge,OT
174477404,Infliximab,Fistula discharge,HO
174477404,Infliximab,Female genital tract fistula,OT
174477404,Infliximab,Female genital tract fistula,HO
174477404,Infliximab,Faecal calprotectin decreased,OT
174477404,Infliximab,Faecal calprotectin decreased,HO
174477404,Infliximab,Erythema,OT
174477404,Infliximab,Erythema,HO
174477404,Infliximab,Drug level below therapeutic,OT
174477404,Infliximab,Drug level below therapeutic,HO
174477404,Infliximab,Drug level above therapeutic,OT
174477404,Infliximab,Drug level above therapeutic,HO
174477404,Infliximab,Disease recurrence,OT
174477404,Infliximab,Disease recurrence,HO
174477404,Infliximab,Condition aggravated,OT
174477404,Infliximab,Condition aggravated,HO
174477404,Infliximab,Chapped lips,OT
174477404,Infliximab,Chapped lips,HO
174477404,Infliximab,Blood pressure increased,OT
174477404,Infliximab,Blood pressure increased,HO
174477404,Infliximab,Blister infected,OT
174477404,Infliximab,Blister infected,HO
174477404,Infliximab,Anal abscess,OT
174477404,Infliximab,Anal abscess,HO
174477404,Infliximab,Urinary tract infection,OT
174477404,Infliximab,Urinary tract infection,HO
174477404,Infliximab,Thermal burn,OT
174477404,Infliximab,Thermal burn,HO
174477404,Infliximab,Rhinorrhoea,OT
174477404,Infliximab,Rhinorrhoea,HO
174477404,Infliximab,Pruritus,OT
174477404,Infliximab,Pruritus,HO
174477404,Infliximab,Productive cough,OT
174477404,Infliximab,Productive cough,HO
174477404,Infliximab,Proctalgia,OT
174477404,Infliximab,Proctalgia,HO
174477404,Infliximab,Peripheral swelling,OT
174477404,Infliximab,Peripheral swelling,HO
174477404,Infliximab,Pelvic pain,OT
174477404,Infliximab,Pelvic pain,HO
174477404,Infliximab,Pelvic inflammatory disease,OT
174477404,Infliximab,Pelvic inflammatory disease,HO
174477404,Infliximab,Pelvic abscess,OT
174477404,Infliximab,Pelvic abscess,HO
174477404,Infliximab,Pain,OT
174477404,Infliximab,Pain,HO
174477404,Infliximab,Oral pain,OT
174477404,Infliximab,Oral pain,HO
174477404,Infliximab,Off label use,OT
174477404,Infliximab,Off label use,HO
174477404,Infliximab,Nasopharyngitis,OT
174477404,Infliximab,Nasopharyngitis,HO
174477404,Infliximab,Nasal congestion,OT
174477404,Infliximab,Nasal congestion,HO
174477404,Infliximab,Inappropriate schedule of product administration,OT
174477404,Infliximab,Inappropriate schedule of product administration,HO
174477404,Infliximab,Haematochezia,OT
174477404,Infliximab,Haematochezia,HO
174477404,Infliximab,Gingival pain,OT
174477404,Infliximab,Gingival pain,HO
174477404,Infliximab,Fistula discharge,OT
174477404,Infliximab,Fistula discharge,HO
174477404,Infliximab,Female genital tract fistula,OT
174477404,Infliximab,Female genital tract fistula,HO
174477404,Infliximab,Faecal calprotectin decreased,OT
174477404,Infliximab,Faecal calprotectin decreased,HO
174477404,Infliximab,Erythema,OT
174477404,Infliximab,Erythema,HO
174477404,Infliximab,Drug level below therapeutic,OT
174477404,Infliximab,Drug level below therapeutic,HO
174477404,Infliximab,Drug level above therapeutic,OT
174477404,Infliximab,Drug level above therapeutic,HO
174477404,Infliximab,Disease recurrence,OT
174477404,Infliximab,Disease recurrence,HO
174477404,Infliximab,Condition aggravated,OT
174477404,Infliximab,Condition aggravated,HO
174477404,Infliximab,Chapped lips,OT
174477404,Infliximab,Chapped lips,HO
174477404,Infliximab,Blood pressure increased,OT
174477404,Infliximab,Blood pressure increased,HO
174477404,Infliximab,Blister infected,OT
174477404,Infliximab,Blister infected,HO
174477404,Infliximab,Anal abscess,OT
174477404,Infliximab,Anal abscess,HO
176178844,Infliximab,Weight increased,OT
176178844,Infliximab,Therapeutic response shortened,OT
176178844,Infliximab,Therapeutic product effect incomplete,OT
176178844,Infliximab,Sleep disorder,OT
176178844,Infliximab,Pain,OT
176178844,Infliximab,Off label use,OT
176178844,Infliximab,Myalgia,OT
176178844,Infliximab,Musculoskeletal pain,OT
176178844,Infliximab,Mass,OT
176178844,Infliximab,Intentional product use issue,OT
176178844,Infliximab,Infusion site haemorrhage,OT
176178844,Infliximab,Infusion site haematoma,OT
176178844,Infliximab,Inappropriate schedule of product administration,OT
176178844,Infliximab,Heart rate decreased,OT
176178844,Infliximab,Groin pain,OT
176178844,Infliximab,Fatigue,OT
176178844,Infliximab,Dyspnoea,OT
176178844,Infliximab,Condition aggravated,OT
176178844,Infliximab,Chest pain,OT
176178844,Infliximab,Blood pressure increased,OT
176178844,Infliximab,Blood pressure fluctuation,OT
176178844,Infliximab,Back pain,OT
176178844,Infliximab,Arthralgia,OT
176178844,Infliximab,Aortic disorder,OT
176178844,Infliximab,Aortic aneurysm,OT
176178844,Infliximab,Weight increased,OT
176178844,Infliximab,Therapeutic response shortened,OT
176178844,Infliximab,Therapeutic product effect incomplete,OT
176178844,Infliximab,Sleep disorder,OT
176178844,Infliximab,Pain,OT
176178844,Infliximab,Off label use,OT
176178844,Infliximab,Myalgia,OT
176178844,Infliximab,Musculoskeletal pain,OT
176178844,Infliximab,Mass,OT
176178844,Infliximab,Intentional product use issue,OT
176178844,Infliximab,Infusion site haemorrhage,OT
176178844,Infliximab,Infusion site haematoma,OT
176178844,Infliximab,Inappropriate schedule of product administration,OT
176178844,Infliximab,Heart rate decreased,OT
176178844,Infliximab,Groin pain,OT
176178844,Infliximab,Fatigue,OT
176178844,Infliximab,Dyspnoea,OT
176178844,Infliximab,Condition aggravated,OT
176178844,Infliximab,Chest pain,OT
176178844,Infliximab,Blood pressure increased,OT
176178844,Infliximab,Blood pressure fluctuation,OT
176178844,Infliximab,Back pain,OT
176178844,Infliximab,Arthralgia,OT
176178844,Infliximab,Aortic disorder,OT
176178844,Infliximab,Aortic aneurysm,OT
176178844,Infliximab,Weight increased,OT
176178844,Infliximab,Therapeutic response shortened,OT
176178844,Infliximab,Therapeutic product effect incomplete,OT
176178844,Infliximab,Sleep disorder,OT
176178844,Infliximab,Pain,OT
176178844,Infliximab,Off label use,OT
176178844,Infliximab,Myalgia,OT
176178844,Infliximab,Musculoskeletal pain,OT
176178844,Infliximab,Mass,OT
176178844,Infliximab,Intentional product use issue,OT
176178844,Infliximab,Infusion site haemorrhage,OT
176178844,Infliximab,Infusion site haematoma,OT
176178844,Infliximab,Inappropriate schedule of product administration,OT
176178844,Infliximab,Heart rate decreased,OT
176178844,Infliximab,Groin pain,OT
176178844,Infliximab,Fatigue,OT
176178844,Infliximab,Dyspnoea,OT
176178844,Infliximab,Condition aggravated,OT
176178844,Infliximab,Chest pain,OT
176178844,Infliximab,Blood pressure increased,OT
176178844,Infliximab,Blood pressure fluctuation,OT
176178844,Infliximab,Back pain,OT
176178844,Infliximab,Arthralgia,OT
176178844,Infliximab,Aortic disorder,OT
176178844,Infliximab,Aortic aneurysm,OT
176178844,Infliximab,Weight increased,OT
176178844,Infliximab,Therapeutic response shortened,OT
176178844,Infliximab,Therapeutic product effect incomplete,OT
176178844,Infliximab,Sleep disorder,OT
176178844,Infliximab,Pain,OT
176178844,Infliximab,Off label use,OT
176178844,Infliximab,Myalgia,OT
176178844,Infliximab,Musculoskeletal pain,OT
176178844,Infliximab,Mass,OT
176178844,Infliximab,Intentional product use issue,OT
176178844,Infliximab,Infusion site haemorrhage,OT
176178844,Infliximab,Infusion site haematoma,OT
176178844,Infliximab,Inappropriate schedule of product administration,OT
176178844,Infliximab,Heart rate decreased,OT
176178844,Infliximab,Groin pain,OT
176178844,Infliximab,Fatigue,OT
176178844,Infliximab,Dyspnoea,OT
176178844,Infliximab,Condition aggravated,OT
176178844,Infliximab,Chest pain,OT
176178844,Infliximab,Blood pressure increased,OT
176178844,Infliximab,Blood pressure fluctuation,OT
176178844,Infliximab,Back pain,OT
176178844,Infliximab,Arthralgia,OT
176178844,Infliximab,Aortic disorder,OT
176178844,Infliximab,Aortic aneurysm,OT
176763524,Infliximab,Respiratory rate increased,OT
176763524,Infliximab,Poor venous access,OT
176763524,Infliximab,Off label use,OT
176763524,Infliximab,Intentional product use issue,OT
176763524,Infliximab,Incorrect dosage administered,OT
176763524,Infliximab,Hypertension,OT
176763524,Infliximab,Heart rate irregular,OT
176763524,Infliximab,Blood pressure increased,OT
176763524,Infliximab,Blood pressure fluctuation,OT
176763524,Infliximab,Respiratory rate increased,OT
176763524,Infliximab,Poor venous access,OT
176763524,Infliximab,Off label use,OT
176763524,Infliximab,Intentional product use issue,OT
176763524,Infliximab,Incorrect dosage administered,OT
176763524,Infliximab,Hypertension,OT
176763524,Infliximab,Heart rate irregular,OT
176763524,Infliximab,Blood pressure increased,OT
176763524,Infliximab,Blood pressure fluctuation,OT
177669774,Infliximab,Wound,HO
177669774,Infliximab,Wound,OT
177669774,Infliximab,Weight increased,HO
177669774,Infliximab,Weight increased,OT
177669774,Infliximab,Weight decreased,HO
177669774,Infliximab,Weight decreased,OT
177669774,Infliximab,Upper limb fracture,HO
177669774,Infliximab,Upper limb fracture,OT
177669774,Infliximab,Product use issue,HO
177669774,Infliximab,Product use issue,OT
177669774,Infliximab,Phlebitis,HO
177669774,Infliximab,Phlebitis,OT
177669774,Infliximab,Paralysis,HO
177669774,Infliximab,Paralysis,OT
177669774,Infliximab,Off label use,HO
177669774,Infliximab,Off label use,OT
177669774,Infliximab,Intentional product use issue,HO
177669774,Infliximab,Intentional product use issue,OT
177669774,Infliximab,Incorrect dose administered,HO
177669774,Infliximab,Incorrect dose administered,OT
177669774,Infliximab,Inappropriate schedule of product administration,HO
177669774,Infliximab,Inappropriate schedule of product administration,OT
177669774,Infliximab,Haemoglobin decreased,HO
177669774,Infliximab,Haemoglobin decreased,OT
177669774,Infliximab,Gastrointestinal infection,HO
177669774,Infliximab,Gastrointestinal infection,OT
177669774,Infliximab,Fracture,HO
177669774,Infliximab,Fracture,OT
177669774,Infliximab,Fatigue,HO
177669774,Infliximab,Fatigue,OT
177669774,Infliximab,Dysphagia,HO
177669774,Infliximab,Dysphagia,OT
177669774,Infliximab,Drug level below therapeutic,HO
177669774,Infliximab,Drug level below therapeutic,OT
177669774,Infliximab,Condition aggravated,HO
177669774,Infliximab,Condition aggravated,OT
177669774,Infliximab,Cerebrovascular accident,HO
177669774,Infliximab,Cerebrovascular accident,OT
177669774,Infliximab,Bone fissure,HO
177669774,Infliximab,Bone fissure,OT
177669774,Infliximab,Blood pressure fluctuation,HO
177669774,Infliximab,Blood pressure fluctuation,OT
177669774,Infliximab,Blood pressure diastolic decreased,HO
177669774,Infliximab,Blood pressure diastolic decreased,OT
177669774,Infliximab,Asthenia,HO
177669774,Infliximab,Asthenia,OT
177669774,Infliximab,Arthralgia,HO
177669774,Infliximab,Arthralgia,OT
177669774,Infliximab,Wound,HO
177669774,Infliximab,Wound,OT
177669774,Infliximab,Weight increased,HO
177669774,Infliximab,Weight increased,OT
177669774,Infliximab,Weight decreased,HO
177669774,Infliximab,Weight decreased,OT
177669774,Infliximab,Upper limb fracture,HO
177669774,Infliximab,Upper limb fracture,OT
177669774,Infliximab,Product use issue,HO
177669774,Infliximab,Product use issue,OT
177669774,Infliximab,Phlebitis,HO
177669774,Infliximab,Phlebitis,OT
177669774,Infliximab,Paralysis,HO
177669774,Infliximab,Paralysis,OT
177669774,Infliximab,Off label use,HO
177669774,Infliximab,Off label use,OT
177669774,Infliximab,Intentional product use issue,HO
177669774,Infliximab,Intentional product use issue,OT
177669774,Infliximab,Incorrect dose administered,HO
177669774,Infliximab,Incorrect dose administered,OT
177669774,Infliximab,Inappropriate schedule of product administration,HO
177669774,Infliximab,Inappropriate schedule of product administration,OT
177669774,Infliximab,Haemoglobin decreased,HO
177669774,Infliximab,Haemoglobin decreased,OT
177669774,Infliximab,Gastrointestinal infection,HO
177669774,Infliximab,Gastrointestinal infection,OT
177669774,Infliximab,Fracture,HO
177669774,Infliximab,Fracture,OT
177669774,Infliximab,Fatigue,HO
177669774,Infliximab,Fatigue,OT
177669774,Infliximab,Dysphagia,HO
177669774,Infliximab,Dysphagia,OT
177669774,Infliximab,Drug level below therapeutic,HO
177669774,Infliximab,Drug level below therapeutic,OT
177669774,Infliximab,Condition aggravated,HO
177669774,Infliximab,Condition aggravated,OT
177669774,Infliximab,Cerebrovascular accident,HO
177669774,Infliximab,Cerebrovascular accident,OT
177669774,Infliximab,Bone fissure,HO
177669774,Infliximab,Bone fissure,OT
177669774,Infliximab,Blood pressure fluctuation,HO
177669774,Infliximab,Blood pressure fluctuation,OT
177669774,Infliximab,Blood pressure diastolic decreased,HO
177669774,Infliximab,Blood pressure diastolic decreased,OT
177669774,Infliximab,Asthenia,HO
177669774,Infliximab,Asthenia,OT
177669774,Infliximab,Arthralgia,HO
177669774,Infliximab,Arthralgia,OT
178632414,Infliximab,Weight increased,OT
178632414,Infliximab,Uveitis,OT
178632414,Infliximab,Seasonal allergy,OT
178632414,Infliximab,Peripheral swelling,OT
178632414,Infliximab,Pain,OT
178632414,Infliximab,Off label use,OT
178632414,Infliximab,Intentional product use issue,OT
178632414,Infliximab,Hypersensitivity,OT
178632414,Infliximab,Erythema nodosum,OT
178632414,Infliximab,Drug level above therapeutic,OT
178632414,Infliximab,Condition aggravated,OT
178632414,Infliximab,Blood pressure increased,OT
178632414,Infliximab,Blood pressure fluctuation,OT
178632414,Infliximab,Arthralgia,OT
178632414,Infliximab,Aphthous ulcer,OT
178632414,Infliximab,Weight increased,OT
178632414,Infliximab,Uveitis,OT
178632414,Infliximab,Seasonal allergy,OT
178632414,Infliximab,Peripheral swelling,OT
178632414,Infliximab,Pain,OT
178632414,Infliximab,Off label use,OT
178632414,Infliximab,Intentional product use issue,OT
178632414,Infliximab,Hypersensitivity,OT
178632414,Infliximab,Erythema nodosum,OT
178632414,Infliximab,Drug level above therapeutic,OT
178632414,Infliximab,Condition aggravated,OT
178632414,Infliximab,Blood pressure increased,OT
178632414,Infliximab,Blood pressure fluctuation,OT
178632414,Infliximab,Arthralgia,OT
178632414,Infliximab,Aphthous ulcer,OT
179794214,Infliximab,Weight decreased,HO
179794214,Infliximab,Off label use,HO
179794214,Infliximab,Intentional product use issue,HO
179794214,Infliximab,Incorrect dose administered,HO
179794214,Infliximab,Hordeolum,HO
179794214,Infliximab,Fatigue,HO
179794214,Infliximab,Discomfort,HO
179794214,Infliximab,Conjunctivitis,HO
179794214,Infliximab,Condition aggravated,HO
179794214,Infliximab,Blood pressure increased,HO
179794214,Infliximab,Blood pressure fluctuation,HO
179794214,Infliximab,Blood disorder,HO
179794214,Infliximab,Abscess,HO
179794214,Infliximab,Weight decreased,HO
179794214,Infliximab,Off label use,HO
179794214,Infliximab,Intentional product use issue,HO
179794214,Infliximab,Incorrect dose administered,HO
179794214,Infliximab,Hordeolum,HO
179794214,Infliximab,Fatigue,HO
179794214,Infliximab,Discomfort,HO
179794214,Infliximab,Conjunctivitis,HO
179794214,Infliximab,Condition aggravated,HO
179794214,Infliximab,Blood pressure increased,HO
179794214,Infliximab,Blood pressure fluctuation,HO
179794214,Infliximab,Blood disorder,HO
179794214,Infliximab,Abscess,HO
180295523,Infliximab,Somnolence,OT
180295523,Infliximab,Somnolence,HO
180295523,Infliximab,Scar,OT
180295523,Infliximab,Scar,HO
180295523,Infliximab,Rash maculo-papular,OT
180295523,Infliximab,Rash maculo-papular,HO
180295523,Infliximab,Psychotic disorder,OT
180295523,Infliximab,Psychotic disorder,HO
180295523,Infliximab,Pruritus,OT
180295523,Infliximab,Pruritus,HO
180295523,Infliximab,Product use in unapproved indication,OT
180295523,Infliximab,Product use in unapproved indication,HO
180295523,Infliximab,Poor venous access,OT
180295523,Infliximab,Poor venous access,HO
180295523,Infliximab,Pain in extremity,OT
180295523,Infliximab,Pain in extremity,HO
180295523,Infliximab,Oropharyngeal pain,OT
180295523,Infliximab,Oropharyngeal pain,HO
180295523,Infliximab,Off label use,OT
180295523,Infliximab,Off label use,HO
180295523,Infliximab,Limb injury,OT
180295523,Infliximab,Limb injury,HO
180295523,Infliximab,Kidney infection,OT
180295523,Infliximab,Kidney infection,HO
180295523,Infliximab,Incorrect dose administered,OT
180295523,Infliximab,Incorrect dose administered,HO
180295523,Infliximab,Inappropriate schedule of product administration,OT
180295523,Infliximab,Inappropriate schedule of product administration,HO
180295523,Infliximab,Headache,OT
180295523,Infliximab,Headache,HO
180295523,Infliximab,Ear pain,OT
180295523,Infliximab,Ear pain,HO
180295523,Infliximab,Dyspnoea,OT
180295523,Infliximab,Dyspnoea,HO
180295523,Infliximab,Drug effective for unapproved indication,OT
180295523,Infliximab,Drug effective for unapproved indication,HO
180295523,Infliximab,Drug dependence,OT
180295523,Infliximab,Drug dependence,HO
183668883,Infliximab,Weight increased,OT
183668883,Infliximab,Therapeutic response shortened,OT
183668883,Infliximab,Product use in unapproved indication,OT
183668883,Infliximab,Off label use,OT
183668883,Infliximab,Oesophageal candidiasis,OT
183668883,Infliximab,Odynophagia,OT
183668883,Infliximab,Dysphagia,OT
183668883,Infliximab,Condition aggravated,OT
183668883,Infliximab,Blood pressure diastolic decreased,OT
183668883,Infliximab,Antibody test negative,OT
183668883,Infliximab,Weight increased,OT
183668883,Infliximab,Therapeutic response shortened,OT
183668883,Infliximab,Product use in unapproved indication,OT
183668883,Infliximab,Off label use,OT
183668883,Infliximab,Oesophageal candidiasis,OT
183668883,Infliximab,Odynophagia,OT
183668883,Infliximab,Dysphagia,OT
183668883,Infliximab,Condition aggravated,OT
183668883,Infliximab,Blood pressure diastolic decreased,OT
183668883,Infliximab,Antibody test negative,OT
183668883,Infliximab,Weight increased,OT
183668883,Infliximab,Therapeutic response shortened,OT
183668883,Infliximab,Product use in unapproved indication,OT
183668883,Infliximab,Off label use,OT
183668883,Infliximab,Oesophageal candidiasis,OT
183668883,Infliximab,Odynophagia,OT
183668883,Infliximab,Dysphagia,OT
183668883,Infliximab,Condition aggravated,OT
183668883,Infliximab,Blood pressure diastolic decreased,OT
183668883,Infliximab,Antibody test negative,OT
183668883,Infliximab,Weight increased,OT
183668883,Infliximab,Therapeutic response shortened,OT
183668883,Infliximab,Product use in unapproved indication,OT
183668883,Infliximab,Off label use,OT
183668883,Infliximab,Oesophageal candidiasis,OT
183668883,Infliximab,Odynophagia,OT
183668883,Infliximab,Dysphagia,OT
183668883,Infliximab,Condition aggravated,OT
183668883,Infliximab,Blood pressure diastolic decreased,OT
183668883,Infliximab,Antibody test negative,OT
184202852,Infliximab,Weight increased,OT
184202852,Infliximab,Weight decreased,OT
184202852,Infliximab,Therapeutic response shortened,OT
184202852,Infliximab,Off label use,OT
184202852,Infliximab,Intentional product use issue,OT
184202852,Infliximab,Incorrect dose administered,OT
184202852,Infliximab,Inappropriate schedule of product administration,OT
184202852,Infliximab,Hypotension,OT
184202852,Infliximab,Heart rate irregular,OT
184202852,Infliximab,Headache,OT
184202852,Infliximab,Gastrointestinal sounds abnormal,OT
184202852,Infliximab,Feeling abnormal,OT
184202852,Infliximab,Condition aggravated,OT
184202852,Infliximab,Blood pressure fluctuation,OT
184202852,Infliximab,Blood pressure decreased,OT
184202852,Infliximab,Weight increased,OT
184202852,Infliximab,Weight decreased,OT
184202852,Infliximab,Therapeutic response shortened,OT
184202852,Infliximab,Off label use,OT
184202852,Infliximab,Intentional product use issue,OT
184202852,Infliximab,Incorrect dose administered,OT
184202852,Infliximab,Inappropriate schedule of product administration,OT
184202852,Infliximab,Hypotension,OT
184202852,Infliximab,Heart rate irregular,OT
184202852,Infliximab,Headache,OT
184202852,Infliximab,Gastrointestinal sounds abnormal,OT
184202852,Infliximab,Feeling abnormal,OT
184202852,Infliximab,Condition aggravated,OT
184202852,Infliximab,Blood pressure fluctuation,OT
184202852,Infliximab,Blood pressure decreased,OT
184212783,Infliximab,Weight increased,OT
184212783,Infliximab,Off label use,OT
184212783,Infliximab,Intentional product use issue,OT
184212783,Infliximab,Inappropriate schedule of product administration,OT
184212783,Infliximab,Fistula,OT
184212783,Infliximab,Cortical dysplasia,OT
184212783,Infliximab,Condition aggravated,OT
184259682,Infliximab,Weight decreased,OT
184259682,Infliximab,Sleep disorder,OT
184259682,Infliximab,Pulmonary embolism,OT
184259682,Infliximab,Osteoarthritis,OT
184259682,Infliximab,Off label use,OT
184259682,Infliximab,Intentional product use issue,OT
184259682,Infliximab,Blood pressure increased,OT
184259682,Infliximab,Blood pressure fluctuation,OT
184259682,Infliximab,Blood pressure abnormal,OT
184259682,Infliximab,Back disorder,OT
184529584,Infliximab,Weight decreased,HO
184529584,Infliximab,Weight decreased,OT
184529584,Infliximab,Road traffic accident,HO
184529584,Infliximab,Road traffic accident,OT
184529584,Infliximab,Product use issue,HO
184529584,Infliximab,Product use issue,OT
184529584,Infliximab,Off label use,HO
184529584,Infliximab,Off label use,OT
184529584,Infliximab,Intentional product use issue,HO
184529584,Infliximab,Intentional product use issue,OT
184529584,Infliximab,Insomnia,HO
184529584,Infliximab,Insomnia,OT
184529584,Infliximab,Inappropriate schedule of product administration,HO
184529584,Infliximab,Inappropriate schedule of product administration,OT
184630552,Infliximab,Product use issue,OT
184630552,Infliximab,Oxygen saturation decreased,OT
184630552,Infliximab,Oxygen saturation abnormal,OT
184630552,Infliximab,Off label use,OT
184630552,Infliximab,Intentional product use issue,OT
184630552,Infliximab,Heart rate decreased,OT
184630552,Infliximab,Heart rate abnormal,OT
184630552,Infliximab,Body temperature decreased,OT
184630552,Infliximab,Blood pressure systolic increased,OT
184630552,Infliximab,Blood pressure fluctuation,OT
185357832,Infliximab,Therapeutic response shortened,HO
185357832,Infliximab,Therapeutic response shortened,OT
185357832,Infliximab,Pneumonia,HO
185357832,Infliximab,Pneumonia,OT
185357832,Infliximab,Off label use,HO
185357832,Infliximab,Off label use,OT
185357832,Infliximab,Mouth ulceration,HO
185357832,Infliximab,Mouth ulceration,OT
185357832,Infliximab,Intentional product use issue,HO
185357832,Infliximab,Intentional product use issue,OT
185357832,Infliximab,Hypertension,HO
185357832,Infliximab,Hypertension,OT
185357832,Infliximab,Heart rate increased,HO
185357832,Infliximab,Heart rate increased,OT
185357832,Infliximab,Gastroenteritis,HO
185357832,Infliximab,Gastroenteritis,OT
185357832,Infliximab,Condition aggravated,HO
185357832,Infliximab,Condition aggravated,OT
185357832,Infliximab,Arthritis,HO
185357832,Infliximab,Arthritis,OT
185357832,Infliximab,Abdominal pain,HO
185357832,Infliximab,Abdominal pain,OT
187816052,Infliximab,Product use issue,OT
187816052,Infliximab,Off label use,OT
187816052,Infliximab,Nasopharyngitis,OT
187816052,Infliximab,Malaise,OT
187816052,Infliximab,Ingrown hair,OT
187816052,Infliximab,Inappropriate schedule of product administration,OT
187816052,Infliximab,Condition aggravated,OT
187816052,Infliximab,Abscess,OT
189662402,Infliximab,Overdose,OT
189662402,Infliximab,Overdose,DE
195138571,Infliximab,Drug ineffective,HO
195138571,Infliximab,Drug ineffective,HO
195254341,Infliximab BS for I.V. Infusion100 mg [NK],Underdose,HO
195254341,Infliximab BS for I.V. Infusion100 mg [NK],Off label use,HO
195254341,Infliximab BS for I.V. Infusion100 mg [NK],Cytomegalovirus hepatitis,HO
195821831,Infliximab,Staphylococcal infection,HO
195821831,Infliximab,Staphylococcal infection,OT
195821831,Infliximab,Product use issue,HO
195821831,Infliximab,Product use issue,OT
195821831,Infliximab,Peripheral swelling,HO
195821831,Infliximab,Peripheral swelling,OT
195821831,Infliximab,Pain in extremity,HO
195821831,Infliximab,Pain in extremity,OT
195821831,Infliximab,Pain,HO
195821831,Infliximab,Pain,OT
195821831,Infliximab,Off label use,HO
195821831,Infliximab,Off label use,OT
195821831,Infliximab,Muscular weakness,HO
195821831,Infliximab,Muscular weakness,OT
195821831,Infliximab,Intentional product use issue,HO
195821831,Infliximab,Intentional product use issue,OT
195821831,Infliximab,Inappropriate schedule of product administration,HO
195821831,Infliximab,Inappropriate schedule of product administration,OT
195821831,Infliximab,Hypoaesthesia,HO
195821831,Infliximab,Hypoaesthesia,OT
195821831,Infliximab,Fistula,HO
195821831,Infliximab,Fistula,OT
195821831,Infliximab,Dysstasia,HO
195821831,Infliximab,Dysstasia,OT
195821831,Infliximab,Condition aggravated,HO
195821831,Infliximab,Condition aggravated,OT
195821831,Infliximab,Asthenia,HO
195821831,Infliximab,Asthenia,OT
195821831,Infliximab,Arthralgia,HO
195821831,Infliximab,Arthralgia,OT
195821831,Infliximab,Abdominal abscess,HO
195821831,Infliximab,Abdominal abscess,OT
195821831,Infliximab,Staphylococcal infection,HO
195821831,Infliximab,Staphylococcal infection,OT
195821831,Infliximab,Product use issue,HO
195821831,Infliximab,Product use issue,OT
195821831,Infliximab,Peripheral swelling,HO
195821831,Infliximab,Peripheral swelling,OT
195821831,Infliximab,Pain in extremity,HO
195821831,Infliximab,Pain in extremity,OT
195821831,Infliximab,Pain,HO
195821831,Infliximab,Pain,OT
195821831,Infliximab,Off label use,HO
195821831,Infliximab,Off label use,OT
195821831,Infliximab,Muscular weakness,HO
195821831,Infliximab,Muscular weakness,OT
195821831,Infliximab,Intentional product use issue,HO
195821831,Infliximab,Intentional product use issue,OT
195821831,Infliximab,Inappropriate schedule of product administration,HO
195821831,Infliximab,Inappropriate schedule of product administration,OT
195821831,Infliximab,Hypoaesthesia,HO
195821831,Infliximab,Hypoaesthesia,OT
195821831,Infliximab,Fistula,HO
195821831,Infliximab,Fistula,OT
195821831,Infliximab,Dysstasia,HO
195821831,Infliximab,Dysstasia,OT
195821831,Infliximab,Condition aggravated,HO
195821831,Infliximab,Condition aggravated,OT
195821831,Infliximab,Asthenia,HO
195821831,Infliximab,Asthenia,OT
195821831,Infliximab,Arthralgia,HO
195821831,Infliximab,Arthralgia,OT
195821831,Infliximab,Abdominal abscess,HO
195821831,Infliximab,Abdominal abscess,OT
196127421,Infliximab (Unknown),Weight decreased,OT
196127421,Infliximab (Unknown),Tuberculosis gastrointestinal,OT
196127421,Infliximab (Unknown),Pyrexia,OT
196127421,Infliximab (Unknown),Pulmonary tuberculosis,OT
196127421,Infliximab (Unknown),Immunosuppression,OT
196127421,Infliximab (Unknown),Diarrhoea,OT
196127421,Infliximab (Unknown),Cutaneous tuberculosis,OT
196127421,Infliximab (Unknown),Condition aggravated,OT
196127421,Infliximab (Unknown),Abdominal pain,OT
196518261,Infliximab,Therapeutic response shortened,OT
196518261,Infliximab,Therapeutic response shortened,HO
196518261,Infliximab,Rhinorrhoea,OT
196518261,Infliximab,Rhinorrhoea,HO
196518261,Infliximab,Off label use,OT
196518261,Infliximab,Off label use,HO
196518261,Infliximab,Muscle spasms,OT
196518261,Infliximab,Muscle spasms,HO
196518261,Infliximab,Malaise,OT
196518261,Infliximab,Malaise,HO
196518261,Infliximab,Hypertension,OT
196518261,Infliximab,Hypertension,HO
196518261,Infliximab,Fatigue,OT
196518261,Infliximab,Fatigue,HO
196518261,Infliximab,Ear disorder,OT
196518261,Infliximab,Ear disorder,HO
196518261,Infliximab,Drug level decreased,OT
196518261,Infliximab,Drug level decreased,HO
196518261,Infliximab,Dizziness,OT
196518261,Infliximab,Dizziness,HO
196518261,Infliximab,Diarrhoea,OT
196518261,Infliximab,Diarrhoea,HO
196518261,Infliximab,Cough,OT
196518261,Infliximab,Cough,HO
196518261,Infliximab,Blood pressure increased,OT
196518261,Infliximab,Blood pressure increased,HO
196518261,Infliximab,Therapeutic response shortened,OT
196518261,Infliximab,Therapeutic response shortened,HO
196518261,Infliximab,Rhinorrhoea,OT
196518261,Infliximab,Rhinorrhoea,HO
196518261,Infliximab,Off label use,OT
196518261,Infliximab,Off label use,HO
196518261,Infliximab,Muscle spasms,OT
196518261,Infliximab,Muscle spasms,HO
196518261,Infliximab,Malaise,OT
196518261,Infliximab,Malaise,HO
196518261,Infliximab,Hypertension,OT
196518261,Infliximab,Hypertension,HO
196518261,Infliximab,Fatigue,OT
196518261,Infliximab,Fatigue,HO
196518261,Infliximab,Ear disorder,OT
196518261,Infliximab,Ear disorder,HO
196518261,Infliximab,Drug level decreased,OT
196518261,Infliximab,Drug level decreased,HO
196518261,Infliximab,Dizziness,OT
196518261,Infliximab,Dizziness,HO
196518261,Infliximab,Diarrhoea,OT
196518261,Infliximab,Diarrhoea,HO
196518261,Infliximab,Cough,OT
196518261,Infliximab,Cough,HO
196518261,Infliximab,Blood pressure increased,OT
196518261,Infliximab,Blood pressure increased,HO
196518321,Infliximab,Herpes zoster,HO
196518321,Infliximab,Condition aggravated,HO
196518321,Infliximab,Abdominal pain,HO
196654761,Infliximab,Skin disorder,OT
196654761,Infliximab,Off label use,OT
196654761,Infliximab,Intentional product use issue,OT
196654761,Infliximab,Inappropriate schedule of product administration,OT
196670051,Infliximab (Unknown),Tongue oedema,HO
196670051,Infliximab (Unknown),Pruritus,HO
196670051,Infliximab (Unknown),Hypotension,HO
196670051,Infliximab (Unknown),Dyspnoea,HO
196670051,Infliximab (Unknown),Bronchospasm,HO
196670051,Infliximab (Unknown),Angioedema,HO
197031901,Infliximab (Unknown),Castleman's disease,HO
197241682,Infliximab,Treatment failure,OT
197241682,Infliximab,Treatment failure,HO
197241682,Infliximab,Cellulitis,OT
197241682,Infliximab,Cellulitis,HO
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Off label use,OT
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Off label use,HO
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Lymphocyte stimulation test positive,OT
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Lymphocyte stimulation test positive,HO
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Interstitial lung disease,OT
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Interstitial lung disease,HO
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Off label use,OT
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Off label use,HO
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Lymphocyte stimulation test positive,OT
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Lymphocyte stimulation test positive,HO
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Interstitial lung disease,OT
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Interstitial lung disease,HO
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Off label use,OT
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Off label use,HO
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Lymphocyte stimulation test positive,OT
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Lymphocyte stimulation test positive,HO
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Interstitial lung disease,OT
197331432,Infliximab BS for I.V. Infusion100 mg (CTH),Interstitial lung disease,HO
197333431,Infliximab,Therapy non-responder,HO
197410421,Infliximab,Product use issue,OT
197410421,Infliximab,Loss of therapeutic response,OT
197410421,Infliximab,Colitis ulcerative,OT
197458981,Infliximab,Urticaria,OT
197458981,Infliximab,Throat tightness,OT
197458981,Infliximab,Tenderness,OT
197458981,Infliximab,Livedo reticularis,OT
197458981,Infliximab,Infusion related reaction,OT
197458981,Infliximab,Inappropriate schedule of product administration,OT
197458981,Infliximab,Flushing,OT
197458981,Infliximab,Erythema,OT
197458981,Infliximab,Dyspnoea,OT
197458981,Infliximab,Drug specific antibody present,OT
197458981,Infliximab,Condition aggravated,OT
197458981,Infliximab,Chills,OT
197458981,Infliximab,Blood pressure increased,OT
197458981,Infliximab,Blood pressure diastolic increased,OT
197458981,Infliximab,Anal fissure,OT
197486431,Infliximab,Paraplegia,OT
197486431,Infliximab,Myelitis transverse,OT
197486431,Infliximab,Myelitis,OT
197486431,Infliximab,Infestation,OT
197486431,Infliximab,Paraplegia,OT
197486431,Infliximab,Myelitis transverse,OT
197486431,Infliximab,Myelitis,OT
197486431,Infliximab,Infestation,OT
197486431,Infliximab,Paraplegia,OT
197486431,Infliximab,Myelitis transverse,OT
197486431,Infliximab,Myelitis,OT
197486431,Infliximab,Infestation,OT
197486431,Infliximab,Paraplegia,OT
197486431,Infliximab,Myelitis transverse,OT
197486431,Infliximab,Myelitis,OT
197486431,Infliximab,Infestation,OT
197995921,Infliximab,Weight decreased,OT
197995921,Infliximab,Weight decreased,HO
197995921,Infliximab,Vomiting,OT
197995921,Infliximab,Vomiting,HO
197995921,Infliximab,Urosepsis,OT
197995921,Infliximab,Urosepsis,HO
197995921,Infliximab,Tremor,OT
197995921,Infliximab,Tremor,HO
197995921,Infliximab,Suspected COVID-19,OT
197995921,Infliximab,Suspected COVID-19,HO
197995921,Infliximab,Pyrexia,OT
197995921,Infliximab,Pyrexia,HO
197995921,Infliximab,Off label use,OT
197995921,Infliximab,Off label use,HO
197995921,Infliximab,Intentional product use issue,OT
197995921,Infliximab,Intentional product use issue,HO
197995921,Infliximab,Incorrect dose administered,OT
197995921,Infliximab,Incorrect dose administered,HO
197995921,Infliximab,Inappropriate schedule of product administration,OT
197995921,Infliximab,Inappropriate schedule of product administration,HO
197995921,Infliximab,Haematochezia,OT
197995921,Infliximab,Haematochezia,HO
197995921,Infliximab,Drug ineffective,OT
197995921,Infliximab,Drug ineffective,HO
197995921,Infliximab,Diarrhoea,OT
197995921,Infliximab,Diarrhoea,HO
197995921,Infliximab,Dehydration,OT
197995921,Infliximab,Dehydration,HO
197995921,Infliximab,Condition aggravated,OT
197995921,Infliximab,Condition aggravated,HO
197995921,Infliximab,Blood pressure fluctuation,OT
197995921,Infliximab,Blood pressure fluctuation,HO
197995921,Infliximab,Atrial fibrillation,OT
197995921,Infliximab,Atrial fibrillation,HO
197995921,Infliximab,Asthenia,OT
197995921,Infliximab,Asthenia,HO
197995921,Infliximab,Abdominal pain,OT
197995921,Infliximab,Abdominal pain,HO
198015921,Infliximab Pfizer (Unknown),Urticaria,OT
198015921,Infliximab Pfizer (Unknown),Urticaria,HO
198015921,Infliximab Pfizer (Unknown),Urticaria,DS
198015921,Infliximab Pfizer (Unknown),Ulcer,OT
198015921,Infliximab Pfizer (Unknown),Ulcer,HO
198015921,Infliximab Pfizer (Unknown),Ulcer,DS
198015921,Infliximab Pfizer (Unknown),Treatment failure,OT
198015921,Infliximab Pfizer (Unknown),Treatment failure,HO
198015921,Infliximab Pfizer (Unknown),Treatment failure,DS
198015921,Infliximab Pfizer (Unknown),Tongue disorder,OT
198015921,Infliximab Pfizer (Unknown),Tongue disorder,HO
198015921,Infliximab Pfizer (Unknown),Tongue disorder,DS
198015921,Infliximab Pfizer (Unknown),Therapy non-responder,OT
198015921,Infliximab Pfizer (Unknown),Therapy non-responder,HO
198015921,Infliximab Pfizer (Unknown),Therapy non-responder,DS
198015921,Infliximab Pfizer (Unknown),Tenosynovitis,OT
198015921,Infliximab Pfizer (Unknown),Tenosynovitis,HO
198015921,Infliximab Pfizer (Unknown),Tenosynovitis,DS
198015921,Infliximab Pfizer (Unknown),Tendonitis,OT
198015921,Infliximab Pfizer (Unknown),Tendonitis,HO
198015921,Infliximab Pfizer (Unknown),Tendonitis,DS
198015921,Infliximab Pfizer (Unknown),Synovitis,OT
198015921,Infliximab Pfizer (Unknown),Synovitis,HO
198015921,Infliximab Pfizer (Unknown),Synovitis,DS
198015921,Infliximab Pfizer (Unknown),Skin ulcer,OT
198015921,Infliximab Pfizer (Unknown),Skin ulcer,HO
198015921,Infliximab Pfizer (Unknown),Skin ulcer,DS
198015921,Infliximab Pfizer (Unknown),Skin necrosis,OT
198015921,Infliximab Pfizer (Unknown),Skin necrosis,HO
198015921,Infliximab Pfizer (Unknown),Skin necrosis,DS
198015921,Infliximab Pfizer (Unknown),Rheumatoid nodule,OT
198015921,Infliximab Pfizer (Unknown),Rheumatoid nodule,HO
198015921,Infliximab Pfizer (Unknown),Rheumatoid nodule,DS
198015921,Infliximab Pfizer (Unknown),Rheumatoid arthritis,OT
198015921,Infliximab Pfizer (Unknown),Rheumatoid arthritis,HO
198015921,Infliximab Pfizer (Unknown),Rheumatoid arthritis,DS
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,OT
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,HO
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,DS
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,OT
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,HO
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,DS
198015921,Infliximab Pfizer (Unknown),Rash pruritic,OT
198015921,Infliximab Pfizer (Unknown),Rash pruritic,HO
198015921,Infliximab Pfizer (Unknown),Rash pruritic,DS
198015921,Infliximab Pfizer (Unknown),Rash,OT
198015921,Infliximab Pfizer (Unknown),Rash,HO
198015921,Infliximab Pfizer (Unknown),Rash,DS
198015921,Infliximab Pfizer (Unknown),Psoriatic arthropathy,OT
198015921,Infliximab Pfizer (Unknown),Psoriatic arthropathy,HO
198015921,Infliximab Pfizer (Unknown),Psoriatic arthropathy,DS
198015921,Infliximab Pfizer (Unknown),Product use issue,OT
198015921,Infliximab Pfizer (Unknown),Product use issue,HO
198015921,Infliximab Pfizer (Unknown),Product use issue,DS
198015921,Infliximab Pfizer (Unknown),Peripheral swelling,OT
198015921,Infliximab Pfizer (Unknown),Peripheral swelling,HO
198015921,Infliximab Pfizer (Unknown),Peripheral swelling,DS
198015921,Infliximab Pfizer (Unknown),Panniculitis,OT
198015921,Infliximab Pfizer (Unknown),Panniculitis,HO
198015921,Infliximab Pfizer (Unknown),Panniculitis,DS
198015921,Infliximab Pfizer (Unknown),Pain,OT
198015921,Infliximab Pfizer (Unknown),Pain,HO
198015921,Infliximab Pfizer (Unknown),Pain,DS
198015921,Infliximab Pfizer (Unknown),Off label use,OT
198015921,Infliximab Pfizer (Unknown),Off label use,HO
198015921,Infliximab Pfizer (Unknown),Off label use,DS
198015921,Infliximab Pfizer (Unknown),Nausea,OT
198015921,Infliximab Pfizer (Unknown),Nausea,HO
198015921,Infliximab Pfizer (Unknown),Nausea,DS
198015921,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,OT
198015921,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,HO
198015921,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,DS
198015921,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,OT
198015921,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,HO
198015921,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,DS
198015921,Infliximab Pfizer (Unknown),Joint swelling,OT
198015921,Infliximab Pfizer (Unknown),Joint swelling,HO
198015921,Infliximab Pfizer (Unknown),Joint swelling,DS
198015921,Infliximab Pfizer (Unknown),Joint injury,OT
198015921,Infliximab Pfizer (Unknown),Joint injury,HO
198015921,Infliximab Pfizer (Unknown),Joint injury,DS
198015921,Infliximab Pfizer (Unknown),Insomnia,OT
198015921,Infliximab Pfizer (Unknown),Insomnia,HO
198015921,Infliximab Pfizer (Unknown),Insomnia,DS
198015921,Infliximab Pfizer (Unknown),Infusion related reaction,OT
198015921,Infliximab Pfizer (Unknown),Infusion related reaction,HO
198015921,Infliximab Pfizer (Unknown),Infusion related reaction,DS
198015921,Infliximab Pfizer (Unknown),Inflammation,OT
198015921,Infliximab Pfizer (Unknown),Inflammation,HO
198015921,Infliximab Pfizer (Unknown),Inflammation,DS
198015921,Infliximab Pfizer (Unknown),Hypercalcaemia,OT
198015921,Infliximab Pfizer (Unknown),Hypercalcaemia,HO
198015921,Infliximab Pfizer (Unknown),Hypercalcaemia,DS
198015921,Infliximab Pfizer (Unknown),Headache,OT
198015921,Infliximab Pfizer (Unknown),Headache,HO
198015921,Infliximab Pfizer (Unknown),Headache,DS
198015921,Infliximab Pfizer (Unknown),Granuloma skin,OT
198015921,Infliximab Pfizer (Unknown),Granuloma skin,HO
198015921,Infliximab Pfizer (Unknown),Granuloma skin,DS
198015921,Infliximab Pfizer (Unknown),General physical health deterioration,OT
198015921,Infliximab Pfizer (Unknown),General physical health deterioration,HO
198015921,Infliximab Pfizer (Unknown),General physical health deterioration,DS
198015921,Infliximab Pfizer (Unknown),Fear of injection,OT
198015921,Infliximab Pfizer (Unknown),Fear of injection,HO
198015921,Infliximab Pfizer (Unknown),Fear of injection,DS
198015921,Infliximab Pfizer (Unknown),Fatigue,OT
198015921,Infliximab Pfizer (Unknown),Fatigue,HO
198015921,Infliximab Pfizer (Unknown),Fatigue,DS
198015921,Infliximab Pfizer (Unknown),Erythema,OT
198015921,Infliximab Pfizer (Unknown),Erythema,HO
198015921,Infliximab Pfizer (Unknown),Erythema,DS
198015921,Infliximab Pfizer (Unknown),Enthesopathy,OT
198015921,Infliximab Pfizer (Unknown),Enthesopathy,HO
198015921,Infliximab Pfizer (Unknown),Enthesopathy,DS
198015921,Infliximab Pfizer (Unknown),Drug intolerance,OT
198015921,Infliximab Pfizer (Unknown),Drug intolerance,HO
198015921,Infliximab Pfizer (Unknown),Drug intolerance,DS
198015921,Infliximab Pfizer (Unknown),Drug hypersensitivity,OT
198015921,Infliximab Pfizer (Unknown),Drug hypersensitivity,HO
198015921,Infliximab Pfizer (Unknown),Drug hypersensitivity,DS
198015921,Infliximab Pfizer (Unknown),Drug eruption,OT
198015921,Infliximab Pfizer (Unknown),Drug eruption,HO
198015921,Infliximab Pfizer (Unknown),Drug eruption,DS
198015921,Infliximab Pfizer (Unknown),Diarrhoea,OT
198015921,Infliximab Pfizer (Unknown),Diarrhoea,HO
198015921,Infliximab Pfizer (Unknown),Diarrhoea,DS
198015921,Infliximab Pfizer (Unknown),Decreased appetite,OT
198015921,Infliximab Pfizer (Unknown),Decreased appetite,HO
198015921,Infliximab Pfizer (Unknown),Decreased appetite,DS
198015921,Infliximab Pfizer (Unknown),Contraindicated product administered,OT
198015921,Infliximab Pfizer (Unknown),Contraindicated product administered,HO
198015921,Infliximab Pfizer (Unknown),Contraindicated product administered,DS
198015921,Infliximab Pfizer (Unknown),C-reactive protein abnormal,OT
198015921,Infliximab Pfizer (Unknown),C-reactive protein abnormal,HO
198015921,Infliximab Pfizer (Unknown),C-reactive protein abnormal,DS
198015921,Infliximab Pfizer (Unknown),Blood pressure systolic increased,OT
198015921,Infliximab Pfizer (Unknown),Blood pressure systolic increased,HO
198015921,Infliximab Pfizer (Unknown),Blood pressure systolic increased,DS
198015921,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,OT
198015921,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,HO
198015921,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,DS
198015921,Infliximab Pfizer (Unknown),Blood creatinine increased,OT
198015921,Infliximab Pfizer (Unknown),Blood creatinine increased,HO
198015921,Infliximab Pfizer (Unknown),Blood creatinine increased,DS
198015921,Infliximab Pfizer (Unknown),Basal cell carcinoma,OT
198015921,Infliximab Pfizer (Unknown),Basal cell carcinoma,HO
198015921,Infliximab Pfizer (Unknown),Basal cell carcinoma,DS
198015921,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,OT
198015921,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,HO
198015921,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,DS
198015921,Infliximab Pfizer (Unknown),Arthropathy,OT
198015921,Infliximab Pfizer (Unknown),Arthropathy,HO
198015921,Infliximab Pfizer (Unknown),Arthropathy,DS
198015921,Infliximab Pfizer (Unknown),Arthritis,OT
198015921,Infliximab Pfizer (Unknown),Arthritis,HO
198015921,Infliximab Pfizer (Unknown),Arthritis,DS
198015921,Infliximab Pfizer (Unknown),Arthralgia,OT
198015921,Infliximab Pfizer (Unknown),Arthralgia,HO
198015921,Infliximab Pfizer (Unknown),Arthralgia,DS
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,OT
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,HO
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,DS
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,OT
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,HO
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,DS
198015921,Infliximab Pfizer (Unknown),Abdominal discomfort,OT
198015921,Infliximab Pfizer (Unknown),Abdominal discomfort,HO
198015921,Infliximab Pfizer (Unknown),Abdominal discomfort,DS
198015921,Infliximab Pfizer (Unknown),Urticaria,OT
198015921,Infliximab Pfizer (Unknown),Urticaria,HO
198015921,Infliximab Pfizer (Unknown),Urticaria,DS
198015921,Infliximab Pfizer (Unknown),Ulcer,OT
198015921,Infliximab Pfizer (Unknown),Ulcer,HO
198015921,Infliximab Pfizer (Unknown),Ulcer,DS
198015921,Infliximab Pfizer (Unknown),Treatment failure,OT
198015921,Infliximab Pfizer (Unknown),Treatment failure,HO
198015921,Infliximab Pfizer (Unknown),Treatment failure,DS
198015921,Infliximab Pfizer (Unknown),Tongue disorder,OT
198015921,Infliximab Pfizer (Unknown),Tongue disorder,HO
198015921,Infliximab Pfizer (Unknown),Tongue disorder,DS
198015921,Infliximab Pfizer (Unknown),Therapy non-responder,OT
198015921,Infliximab Pfizer (Unknown),Therapy non-responder,HO
198015921,Infliximab Pfizer (Unknown),Therapy non-responder,DS
198015921,Infliximab Pfizer (Unknown),Tenosynovitis,OT
198015921,Infliximab Pfizer (Unknown),Tenosynovitis,HO
198015921,Infliximab Pfizer (Unknown),Tenosynovitis,DS
198015921,Infliximab Pfizer (Unknown),Tendonitis,OT
198015921,Infliximab Pfizer (Unknown),Tendonitis,HO
198015921,Infliximab Pfizer (Unknown),Tendonitis,DS
198015921,Infliximab Pfizer (Unknown),Synovitis,OT
198015921,Infliximab Pfizer (Unknown),Synovitis,HO
198015921,Infliximab Pfizer (Unknown),Synovitis,DS
198015921,Infliximab Pfizer (Unknown),Skin ulcer,OT
198015921,Infliximab Pfizer (Unknown),Skin ulcer,HO
198015921,Infliximab Pfizer (Unknown),Skin ulcer,DS
198015921,Infliximab Pfizer (Unknown),Skin necrosis,OT
198015921,Infliximab Pfizer (Unknown),Skin necrosis,HO
198015921,Infliximab Pfizer (Unknown),Skin necrosis,DS
198015921,Infliximab Pfizer (Unknown),Rheumatoid nodule,OT
198015921,Infliximab Pfizer (Unknown),Rheumatoid nodule,HO
198015921,Infliximab Pfizer (Unknown),Rheumatoid nodule,DS
198015921,Infliximab Pfizer (Unknown),Rheumatoid arthritis,OT
198015921,Infliximab Pfizer (Unknown),Rheumatoid arthritis,HO
198015921,Infliximab Pfizer (Unknown),Rheumatoid arthritis,DS
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,OT
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,HO
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,DS
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,OT
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,HO
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,DS
198015921,Infliximab Pfizer (Unknown),Rash pruritic,OT
198015921,Infliximab Pfizer (Unknown),Rash pruritic,HO
198015921,Infliximab Pfizer (Unknown),Rash pruritic,DS
198015921,Infliximab Pfizer (Unknown),Rash,OT
198015921,Infliximab Pfizer (Unknown),Rash,HO
198015921,Infliximab Pfizer (Unknown),Rash,DS
198015921,Infliximab Pfizer (Unknown),Psoriatic arthropathy,OT
198015921,Infliximab Pfizer (Unknown),Psoriatic arthropathy,HO
198015921,Infliximab Pfizer (Unknown),Psoriatic arthropathy,DS
198015921,Infliximab Pfizer (Unknown),Product use issue,OT
198015921,Infliximab Pfizer (Unknown),Product use issue,HO
198015921,Infliximab Pfizer (Unknown),Product use issue,DS
198015921,Infliximab Pfizer (Unknown),Peripheral swelling,OT
198015921,Infliximab Pfizer (Unknown),Peripheral swelling,HO
198015921,Infliximab Pfizer (Unknown),Peripheral swelling,DS
198015921,Infliximab Pfizer (Unknown),Panniculitis,OT
198015921,Infliximab Pfizer (Unknown),Panniculitis,HO
198015921,Infliximab Pfizer (Unknown),Panniculitis,DS
198015921,Infliximab Pfizer (Unknown),Pain,OT
198015921,Infliximab Pfizer (Unknown),Pain,HO
198015921,Infliximab Pfizer (Unknown),Pain,DS
198015921,Infliximab Pfizer (Unknown),Off label use,OT
198015921,Infliximab Pfizer (Unknown),Off label use,HO
198015921,Infliximab Pfizer (Unknown),Off label use,DS
198015921,Infliximab Pfizer (Unknown),Nausea,OT
198015921,Infliximab Pfizer (Unknown),Nausea,HO
198015921,Infliximab Pfizer (Unknown),Nausea,DS
198015921,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,OT
198015921,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,HO
198015921,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,DS
198015921,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,OT
198015921,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,HO
198015921,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,DS
198015921,Infliximab Pfizer (Unknown),Joint swelling,OT
198015921,Infliximab Pfizer (Unknown),Joint swelling,HO
198015921,Infliximab Pfizer (Unknown),Joint swelling,DS
198015921,Infliximab Pfizer (Unknown),Joint injury,OT
198015921,Infliximab Pfizer (Unknown),Joint injury,HO
198015921,Infliximab Pfizer (Unknown),Joint injury,DS
198015921,Infliximab Pfizer (Unknown),Insomnia,OT
198015921,Infliximab Pfizer (Unknown),Insomnia,HO
198015921,Infliximab Pfizer (Unknown),Insomnia,DS
198015921,Infliximab Pfizer (Unknown),Infusion related reaction,OT
198015921,Infliximab Pfizer (Unknown),Infusion related reaction,HO
198015921,Infliximab Pfizer (Unknown),Infusion related reaction,DS
198015921,Infliximab Pfizer (Unknown),Inflammation,OT
198015921,Infliximab Pfizer (Unknown),Inflammation,HO
198015921,Infliximab Pfizer (Unknown),Inflammation,DS
198015921,Infliximab Pfizer (Unknown),Hypercalcaemia,OT
198015921,Infliximab Pfizer (Unknown),Hypercalcaemia,HO
198015921,Infliximab Pfizer (Unknown),Hypercalcaemia,DS
198015921,Infliximab Pfizer (Unknown),Headache,OT
198015921,Infliximab Pfizer (Unknown),Headache,HO
198015921,Infliximab Pfizer (Unknown),Headache,DS
198015921,Infliximab Pfizer (Unknown),Granuloma skin,OT
198015921,Infliximab Pfizer (Unknown),Granuloma skin,HO
198015921,Infliximab Pfizer (Unknown),Granuloma skin,DS
198015921,Infliximab Pfizer (Unknown),General physical health deterioration,OT
198015921,Infliximab Pfizer (Unknown),General physical health deterioration,HO
198015921,Infliximab Pfizer (Unknown),General physical health deterioration,DS
198015921,Infliximab Pfizer (Unknown),Fear of injection,OT
198015921,Infliximab Pfizer (Unknown),Fear of injection,HO
198015921,Infliximab Pfizer (Unknown),Fear of injection,DS
198015921,Infliximab Pfizer (Unknown),Fatigue,OT
198015921,Infliximab Pfizer (Unknown),Fatigue,HO
198015921,Infliximab Pfizer (Unknown),Fatigue,DS
198015921,Infliximab Pfizer (Unknown),Erythema,OT
198015921,Infliximab Pfizer (Unknown),Erythema,HO
198015921,Infliximab Pfizer (Unknown),Erythema,DS
198015921,Infliximab Pfizer (Unknown),Enthesopathy,OT
198015921,Infliximab Pfizer (Unknown),Enthesopathy,HO
198015921,Infliximab Pfizer (Unknown),Enthesopathy,DS
198015921,Infliximab Pfizer (Unknown),Drug intolerance,OT
198015921,Infliximab Pfizer (Unknown),Drug intolerance,HO
198015921,Infliximab Pfizer (Unknown),Drug intolerance,DS
198015921,Infliximab Pfizer (Unknown),Drug hypersensitivity,OT
198015921,Infliximab Pfizer (Unknown),Drug hypersensitivity,HO
198015921,Infliximab Pfizer (Unknown),Drug hypersensitivity,DS
198015921,Infliximab Pfizer (Unknown),Drug eruption,OT
198015921,Infliximab Pfizer (Unknown),Drug eruption,HO
198015921,Infliximab Pfizer (Unknown),Drug eruption,DS
198015921,Infliximab Pfizer (Unknown),Diarrhoea,OT
198015921,Infliximab Pfizer (Unknown),Diarrhoea,HO
198015921,Infliximab Pfizer (Unknown),Diarrhoea,DS
198015921,Infliximab Pfizer (Unknown),Decreased appetite,OT
198015921,Infliximab Pfizer (Unknown),Decreased appetite,HO
198015921,Infliximab Pfizer (Unknown),Decreased appetite,DS
198015921,Infliximab Pfizer (Unknown),Contraindicated product administered,OT
198015921,Infliximab Pfizer (Unknown),Contraindicated product administered,HO
198015921,Infliximab Pfizer (Unknown),Contraindicated product administered,DS
198015921,Infliximab Pfizer (Unknown),C-reactive protein abnormal,OT
198015921,Infliximab Pfizer (Unknown),C-reactive protein abnormal,HO
198015921,Infliximab Pfizer (Unknown),C-reactive protein abnormal,DS
198015921,Infliximab Pfizer (Unknown),Blood pressure systolic increased,OT
198015921,Infliximab Pfizer (Unknown),Blood pressure systolic increased,HO
198015921,Infliximab Pfizer (Unknown),Blood pressure systolic increased,DS
198015921,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,OT
198015921,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,HO
198015921,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,DS
198015921,Infliximab Pfizer (Unknown),Blood creatinine increased,OT
198015921,Infliximab Pfizer (Unknown),Blood creatinine increased,HO
198015921,Infliximab Pfizer (Unknown),Blood creatinine increased,DS
198015921,Infliximab Pfizer (Unknown),Basal cell carcinoma,OT
198015921,Infliximab Pfizer (Unknown),Basal cell carcinoma,HO
198015921,Infliximab Pfizer (Unknown),Basal cell carcinoma,DS
198015921,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,OT
198015921,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,HO
198015921,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,DS
198015921,Infliximab Pfizer (Unknown),Arthropathy,OT
198015921,Infliximab Pfizer (Unknown),Arthropathy,HO
198015921,Infliximab Pfizer (Unknown),Arthropathy,DS
198015921,Infliximab Pfizer (Unknown),Arthritis,OT
198015921,Infliximab Pfizer (Unknown),Arthritis,HO
198015921,Infliximab Pfizer (Unknown),Arthritis,DS
198015921,Infliximab Pfizer (Unknown),Arthralgia,OT
198015921,Infliximab Pfizer (Unknown),Arthralgia,HO
198015921,Infliximab Pfizer (Unknown),Arthralgia,DS
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,OT
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,HO
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,DS
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,OT
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,HO
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,DS
198015921,Infliximab Pfizer (Unknown),Abdominal discomfort,OT
198015921,Infliximab Pfizer (Unknown),Abdominal discomfort,HO
198015921,Infliximab Pfizer (Unknown),Abdominal discomfort,DS
198015921,Infliximab Pfizer (Unknown),Urticaria,OT
198015921,Infliximab Pfizer (Unknown),Urticaria,HO
198015921,Infliximab Pfizer (Unknown),Urticaria,DS
198015921,Infliximab Pfizer (Unknown),Ulcer,OT
198015921,Infliximab Pfizer (Unknown),Ulcer,HO
198015921,Infliximab Pfizer (Unknown),Ulcer,DS
198015921,Infliximab Pfizer (Unknown),Treatment failure,OT
198015921,Infliximab Pfizer (Unknown),Treatment failure,HO
198015921,Infliximab Pfizer (Unknown),Treatment failure,DS
198015921,Infliximab Pfizer (Unknown),Tongue disorder,OT
198015921,Infliximab Pfizer (Unknown),Tongue disorder,HO
198015921,Infliximab Pfizer (Unknown),Tongue disorder,DS
198015921,Infliximab Pfizer (Unknown),Therapy non-responder,OT
198015921,Infliximab Pfizer (Unknown),Therapy non-responder,HO
198015921,Infliximab Pfizer (Unknown),Therapy non-responder,DS
198015921,Infliximab Pfizer (Unknown),Tenosynovitis,OT
198015921,Infliximab Pfizer (Unknown),Tenosynovitis,HO
198015921,Infliximab Pfizer (Unknown),Tenosynovitis,DS
198015921,Infliximab Pfizer (Unknown),Tendonitis,OT
198015921,Infliximab Pfizer (Unknown),Tendonitis,HO
198015921,Infliximab Pfizer (Unknown),Tendonitis,DS
198015921,Infliximab Pfizer (Unknown),Synovitis,OT
198015921,Infliximab Pfizer (Unknown),Synovitis,HO
198015921,Infliximab Pfizer (Unknown),Synovitis,DS
198015921,Infliximab Pfizer (Unknown),Skin ulcer,OT
198015921,Infliximab Pfizer (Unknown),Skin ulcer,HO
198015921,Infliximab Pfizer (Unknown),Skin ulcer,DS
198015921,Infliximab Pfizer (Unknown),Skin necrosis,OT
198015921,Infliximab Pfizer (Unknown),Skin necrosis,HO
198015921,Infliximab Pfizer (Unknown),Skin necrosis,DS
198015921,Infliximab Pfizer (Unknown),Rheumatoid nodule,OT
198015921,Infliximab Pfizer (Unknown),Rheumatoid nodule,HO
198015921,Infliximab Pfizer (Unknown),Rheumatoid nodule,DS
198015921,Infliximab Pfizer (Unknown),Rheumatoid arthritis,OT
198015921,Infliximab Pfizer (Unknown),Rheumatoid arthritis,HO
198015921,Infliximab Pfizer (Unknown),Rheumatoid arthritis,DS
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,OT
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,HO
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,DS
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,OT
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,HO
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,DS
198015921,Infliximab Pfizer (Unknown),Rash pruritic,OT
198015921,Infliximab Pfizer (Unknown),Rash pruritic,HO
198015921,Infliximab Pfizer (Unknown),Rash pruritic,DS
198015921,Infliximab Pfizer (Unknown),Rash,OT
198015921,Infliximab Pfizer (Unknown),Rash,HO
198015921,Infliximab Pfizer (Unknown),Rash,DS
198015921,Infliximab Pfizer (Unknown),Psoriatic arthropathy,OT
198015921,Infliximab Pfizer (Unknown),Psoriatic arthropathy,HO
198015921,Infliximab Pfizer (Unknown),Psoriatic arthropathy,DS
198015921,Infliximab Pfizer (Unknown),Product use issue,OT
198015921,Infliximab Pfizer (Unknown),Product use issue,HO
198015921,Infliximab Pfizer (Unknown),Product use issue,DS
198015921,Infliximab Pfizer (Unknown),Peripheral swelling,OT
198015921,Infliximab Pfizer (Unknown),Peripheral swelling,HO
198015921,Infliximab Pfizer (Unknown),Peripheral swelling,DS
198015921,Infliximab Pfizer (Unknown),Panniculitis,OT
198015921,Infliximab Pfizer (Unknown),Panniculitis,HO
198015921,Infliximab Pfizer (Unknown),Panniculitis,DS
198015921,Infliximab Pfizer (Unknown),Pain,OT
198015921,Infliximab Pfizer (Unknown),Pain,HO
198015921,Infliximab Pfizer (Unknown),Pain,DS
198015921,Infliximab Pfizer (Unknown),Off label use,OT
198015921,Infliximab Pfizer (Unknown),Off label use,HO
198015921,Infliximab Pfizer (Unknown),Off label use,DS
198015921,Infliximab Pfizer (Unknown),Nausea,OT
198015921,Infliximab Pfizer (Unknown),Nausea,HO
198015921,Infliximab Pfizer (Unknown),Nausea,DS
198015921,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,OT
198015921,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,HO
198015921,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,DS
198015921,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,OT
198015921,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,HO
198015921,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,DS
198015921,Infliximab Pfizer (Unknown),Joint swelling,OT
198015921,Infliximab Pfizer (Unknown),Joint swelling,HO
198015921,Infliximab Pfizer (Unknown),Joint swelling,DS
198015921,Infliximab Pfizer (Unknown),Joint injury,OT
198015921,Infliximab Pfizer (Unknown),Joint injury,HO
198015921,Infliximab Pfizer (Unknown),Joint injury,DS
198015921,Infliximab Pfizer (Unknown),Insomnia,OT
198015921,Infliximab Pfizer (Unknown),Insomnia,HO
198015921,Infliximab Pfizer (Unknown),Insomnia,DS
198015921,Infliximab Pfizer (Unknown),Infusion related reaction,OT
198015921,Infliximab Pfizer (Unknown),Infusion related reaction,HO
198015921,Infliximab Pfizer (Unknown),Infusion related reaction,DS
198015921,Infliximab Pfizer (Unknown),Inflammation,OT
198015921,Infliximab Pfizer (Unknown),Inflammation,HO
198015921,Infliximab Pfizer (Unknown),Inflammation,DS
198015921,Infliximab Pfizer (Unknown),Hypercalcaemia,OT
198015921,Infliximab Pfizer (Unknown),Hypercalcaemia,HO
198015921,Infliximab Pfizer (Unknown),Hypercalcaemia,DS
198015921,Infliximab Pfizer (Unknown),Headache,OT
198015921,Infliximab Pfizer (Unknown),Headache,HO
198015921,Infliximab Pfizer (Unknown),Headache,DS
198015921,Infliximab Pfizer (Unknown),Granuloma skin,OT
198015921,Infliximab Pfizer (Unknown),Granuloma skin,HO
198015921,Infliximab Pfizer (Unknown),Granuloma skin,DS
198015921,Infliximab Pfizer (Unknown),General physical health deterioration,OT
198015921,Infliximab Pfizer (Unknown),General physical health deterioration,HO
198015921,Infliximab Pfizer (Unknown),General physical health deterioration,DS
198015921,Infliximab Pfizer (Unknown),Fear of injection,OT
198015921,Infliximab Pfizer (Unknown),Fear of injection,HO
198015921,Infliximab Pfizer (Unknown),Fear of injection,DS
198015921,Infliximab Pfizer (Unknown),Fatigue,OT
198015921,Infliximab Pfizer (Unknown),Fatigue,HO
198015921,Infliximab Pfizer (Unknown),Fatigue,DS
198015921,Infliximab Pfizer (Unknown),Erythema,OT
198015921,Infliximab Pfizer (Unknown),Erythema,HO
198015921,Infliximab Pfizer (Unknown),Erythema,DS
198015921,Infliximab Pfizer (Unknown),Enthesopathy,OT
198015921,Infliximab Pfizer (Unknown),Enthesopathy,HO
198015921,Infliximab Pfizer (Unknown),Enthesopathy,DS
198015921,Infliximab Pfizer (Unknown),Drug intolerance,OT
198015921,Infliximab Pfizer (Unknown),Drug intolerance,HO
198015921,Infliximab Pfizer (Unknown),Drug intolerance,DS
198015921,Infliximab Pfizer (Unknown),Drug hypersensitivity,OT
198015921,Infliximab Pfizer (Unknown),Drug hypersensitivity,HO
198015921,Infliximab Pfizer (Unknown),Drug hypersensitivity,DS
198015921,Infliximab Pfizer (Unknown),Drug eruption,OT
198015921,Infliximab Pfizer (Unknown),Drug eruption,HO
198015921,Infliximab Pfizer (Unknown),Drug eruption,DS
198015921,Infliximab Pfizer (Unknown),Diarrhoea,OT
198015921,Infliximab Pfizer (Unknown),Diarrhoea,HO
198015921,Infliximab Pfizer (Unknown),Diarrhoea,DS
198015921,Infliximab Pfizer (Unknown),Decreased appetite,OT
198015921,Infliximab Pfizer (Unknown),Decreased appetite,HO
198015921,Infliximab Pfizer (Unknown),Decreased appetite,DS
198015921,Infliximab Pfizer (Unknown),Contraindicated product administered,OT
198015921,Infliximab Pfizer (Unknown),Contraindicated product administered,HO
198015921,Infliximab Pfizer (Unknown),Contraindicated product administered,DS
198015921,Infliximab Pfizer (Unknown),C-reactive protein abnormal,OT
198015921,Infliximab Pfizer (Unknown),C-reactive protein abnormal,HO
198015921,Infliximab Pfizer (Unknown),C-reactive protein abnormal,DS
198015921,Infliximab Pfizer (Unknown),Blood pressure systolic increased,OT
198015921,Infliximab Pfizer (Unknown),Blood pressure systolic increased,HO
198015921,Infliximab Pfizer (Unknown),Blood pressure systolic increased,DS
198015921,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,OT
198015921,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,HO
198015921,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,DS
198015921,Infliximab Pfizer (Unknown),Blood creatinine increased,OT
198015921,Infliximab Pfizer (Unknown),Blood creatinine increased,HO
198015921,Infliximab Pfizer (Unknown),Blood creatinine increased,DS
198015921,Infliximab Pfizer (Unknown),Basal cell carcinoma,OT
198015921,Infliximab Pfizer (Unknown),Basal cell carcinoma,HO
198015921,Infliximab Pfizer (Unknown),Basal cell carcinoma,DS
198015921,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,OT
198015921,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,HO
198015921,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,DS
198015921,Infliximab Pfizer (Unknown),Arthropathy,OT
198015921,Infliximab Pfizer (Unknown),Arthropathy,HO
198015921,Infliximab Pfizer (Unknown),Arthropathy,DS
198015921,Infliximab Pfizer (Unknown),Arthritis,OT
198015921,Infliximab Pfizer (Unknown),Arthritis,HO
198015921,Infliximab Pfizer (Unknown),Arthritis,DS
198015921,Infliximab Pfizer (Unknown),Arthralgia,OT
198015921,Infliximab Pfizer (Unknown),Arthralgia,HO
198015921,Infliximab Pfizer (Unknown),Arthralgia,DS
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,OT
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,HO
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,DS
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,OT
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,HO
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,DS
198015921,Infliximab Pfizer (Unknown),Abdominal discomfort,OT
198015921,Infliximab Pfizer (Unknown),Abdominal discomfort,HO
198015921,Infliximab Pfizer (Unknown),Abdominal discomfort,DS
198015921,Infliximab Pfizer (Unknown),Urticaria,OT
198015921,Infliximab Pfizer (Unknown),Urticaria,HO
198015921,Infliximab Pfizer (Unknown),Urticaria,DS
198015921,Infliximab Pfizer (Unknown),Ulcer,OT
198015921,Infliximab Pfizer (Unknown),Ulcer,HO
198015921,Infliximab Pfizer (Unknown),Ulcer,DS
198015921,Infliximab Pfizer (Unknown),Treatment failure,OT
198015921,Infliximab Pfizer (Unknown),Treatment failure,HO
198015921,Infliximab Pfizer (Unknown),Treatment failure,DS
198015921,Infliximab Pfizer (Unknown),Tongue disorder,OT
198015921,Infliximab Pfizer (Unknown),Tongue disorder,HO
198015921,Infliximab Pfizer (Unknown),Tongue disorder,DS
198015921,Infliximab Pfizer (Unknown),Therapy non-responder,OT
198015921,Infliximab Pfizer (Unknown),Therapy non-responder,HO
198015921,Infliximab Pfizer (Unknown),Therapy non-responder,DS
198015921,Infliximab Pfizer (Unknown),Tenosynovitis,OT
198015921,Infliximab Pfizer (Unknown),Tenosynovitis,HO
198015921,Infliximab Pfizer (Unknown),Tenosynovitis,DS
198015921,Infliximab Pfizer (Unknown),Tendonitis,OT
198015921,Infliximab Pfizer (Unknown),Tendonitis,HO
198015921,Infliximab Pfizer (Unknown),Tendonitis,DS
198015921,Infliximab Pfizer (Unknown),Synovitis,OT
198015921,Infliximab Pfizer (Unknown),Synovitis,HO
198015921,Infliximab Pfizer (Unknown),Synovitis,DS
198015921,Infliximab Pfizer (Unknown),Skin ulcer,OT
198015921,Infliximab Pfizer (Unknown),Skin ulcer,HO
198015921,Infliximab Pfizer (Unknown),Skin ulcer,DS
198015921,Infliximab Pfizer (Unknown),Skin necrosis,OT
198015921,Infliximab Pfizer (Unknown),Skin necrosis,HO
198015921,Infliximab Pfizer (Unknown),Skin necrosis,DS
198015921,Infliximab Pfizer (Unknown),Rheumatoid nodule,OT
198015921,Infliximab Pfizer (Unknown),Rheumatoid nodule,HO
198015921,Infliximab Pfizer (Unknown),Rheumatoid nodule,DS
198015921,Infliximab Pfizer (Unknown),Rheumatoid arthritis,OT
198015921,Infliximab Pfizer (Unknown),Rheumatoid arthritis,HO
198015921,Infliximab Pfizer (Unknown),Rheumatoid arthritis,DS
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,OT
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,HO
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate increased,DS
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,OT
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,HO
198015921,Infliximab Pfizer (Unknown),Red blood cell sedimentation rate,DS
198015921,Infliximab Pfizer (Unknown),Rash pruritic,OT
198015921,Infliximab Pfizer (Unknown),Rash pruritic,HO
198015921,Infliximab Pfizer (Unknown),Rash pruritic,DS
198015921,Infliximab Pfizer (Unknown),Rash,OT
198015921,Infliximab Pfizer (Unknown),Rash,HO
198015921,Infliximab Pfizer (Unknown),Rash,DS
198015921,Infliximab Pfizer (Unknown),Psoriatic arthropathy,OT
198015921,Infliximab Pfizer (Unknown),Psoriatic arthropathy,HO
198015921,Infliximab Pfizer (Unknown),Psoriatic arthropathy,DS
198015921,Infliximab Pfizer (Unknown),Product use issue,OT
198015921,Infliximab Pfizer (Unknown),Product use issue,HO
198015921,Infliximab Pfizer (Unknown),Product use issue,DS
198015921,Infliximab Pfizer (Unknown),Peripheral swelling,OT
198015921,Infliximab Pfizer (Unknown),Peripheral swelling,HO
198015921,Infliximab Pfizer (Unknown),Peripheral swelling,DS
198015921,Infliximab Pfizer (Unknown),Panniculitis,OT
198015921,Infliximab Pfizer (Unknown),Panniculitis,HO
198015921,Infliximab Pfizer (Unknown),Panniculitis,DS
198015921,Infliximab Pfizer (Unknown),Pain,OT
198015921,Infliximab Pfizer (Unknown),Pain,HO
198015921,Infliximab Pfizer (Unknown),Pain,DS
198015921,Infliximab Pfizer (Unknown),Off label use,OT
198015921,Infliximab Pfizer (Unknown),Off label use,HO
198015921,Infliximab Pfizer (Unknown),Off label use,DS
198015921,Infliximab Pfizer (Unknown),Nausea,OT
198015921,Infliximab Pfizer (Unknown),Nausea,HO
198015921,Infliximab Pfizer (Unknown),Nausea,DS
198015921,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,OT
198015921,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,HO
198015921,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,DS
198015921,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,OT
198015921,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,HO
198015921,Infliximab Pfizer (Unknown),Loss of personal independence in daily activities,DS
198015921,Infliximab Pfizer (Unknown),Joint swelling,OT
198015921,Infliximab Pfizer (Unknown),Joint swelling,HO
198015921,Infliximab Pfizer (Unknown),Joint swelling,DS
198015921,Infliximab Pfizer (Unknown),Joint injury,OT
198015921,Infliximab Pfizer (Unknown),Joint injury,HO
198015921,Infliximab Pfizer (Unknown),Joint injury,DS
198015921,Infliximab Pfizer (Unknown),Insomnia,OT
198015921,Infliximab Pfizer (Unknown),Insomnia,HO
198015921,Infliximab Pfizer (Unknown),Insomnia,DS
198015921,Infliximab Pfizer (Unknown),Infusion related reaction,OT
198015921,Infliximab Pfizer (Unknown),Infusion related reaction,HO
198015921,Infliximab Pfizer (Unknown),Infusion related reaction,DS
198015921,Infliximab Pfizer (Unknown),Inflammation,OT
198015921,Infliximab Pfizer (Unknown),Inflammation,HO
198015921,Infliximab Pfizer (Unknown),Inflammation,DS
198015921,Infliximab Pfizer (Unknown),Hypercalcaemia,OT
198015921,Infliximab Pfizer (Unknown),Hypercalcaemia,HO
198015921,Infliximab Pfizer (Unknown),Hypercalcaemia,DS
198015921,Infliximab Pfizer (Unknown),Headache,OT
198015921,Infliximab Pfizer (Unknown),Headache,HO
198015921,Infliximab Pfizer (Unknown),Headache,DS
198015921,Infliximab Pfizer (Unknown),Granuloma skin,OT
198015921,Infliximab Pfizer (Unknown),Granuloma skin,HO
198015921,Infliximab Pfizer (Unknown),Granuloma skin,DS
198015921,Infliximab Pfizer (Unknown),General physical health deterioration,OT
198015921,Infliximab Pfizer (Unknown),General physical health deterioration,HO
198015921,Infliximab Pfizer (Unknown),General physical health deterioration,DS
198015921,Infliximab Pfizer (Unknown),Fear of injection,OT
198015921,Infliximab Pfizer (Unknown),Fear of injection,HO
198015921,Infliximab Pfizer (Unknown),Fear of injection,DS
198015921,Infliximab Pfizer (Unknown),Fatigue,OT
198015921,Infliximab Pfizer (Unknown),Fatigue,HO
198015921,Infliximab Pfizer (Unknown),Fatigue,DS
198015921,Infliximab Pfizer (Unknown),Erythema,OT
198015921,Infliximab Pfizer (Unknown),Erythema,HO
198015921,Infliximab Pfizer (Unknown),Erythema,DS
198015921,Infliximab Pfizer (Unknown),Enthesopathy,OT
198015921,Infliximab Pfizer (Unknown),Enthesopathy,HO
198015921,Infliximab Pfizer (Unknown),Enthesopathy,DS
198015921,Infliximab Pfizer (Unknown),Drug intolerance,OT
198015921,Infliximab Pfizer (Unknown),Drug intolerance,HO
198015921,Infliximab Pfizer (Unknown),Drug intolerance,DS
198015921,Infliximab Pfizer (Unknown),Drug hypersensitivity,OT
198015921,Infliximab Pfizer (Unknown),Drug hypersensitivity,HO
198015921,Infliximab Pfizer (Unknown),Drug hypersensitivity,DS
198015921,Infliximab Pfizer (Unknown),Drug eruption,OT
198015921,Infliximab Pfizer (Unknown),Drug eruption,HO
198015921,Infliximab Pfizer (Unknown),Drug eruption,DS
198015921,Infliximab Pfizer (Unknown),Diarrhoea,OT
198015921,Infliximab Pfizer (Unknown),Diarrhoea,HO
198015921,Infliximab Pfizer (Unknown),Diarrhoea,DS
198015921,Infliximab Pfizer (Unknown),Decreased appetite,OT
198015921,Infliximab Pfizer (Unknown),Decreased appetite,HO
198015921,Infliximab Pfizer (Unknown),Decreased appetite,DS
198015921,Infliximab Pfizer (Unknown),Contraindicated product administered,OT
198015921,Infliximab Pfizer (Unknown),Contraindicated product administered,HO
198015921,Infliximab Pfizer (Unknown),Contraindicated product administered,DS
198015921,Infliximab Pfizer (Unknown),C-reactive protein abnormal,OT
198015921,Infliximab Pfizer (Unknown),C-reactive protein abnormal,HO
198015921,Infliximab Pfizer (Unknown),C-reactive protein abnormal,DS
198015921,Infliximab Pfizer (Unknown),Blood pressure systolic increased,OT
198015921,Infliximab Pfizer (Unknown),Blood pressure systolic increased,HO
198015921,Infliximab Pfizer (Unknown),Blood pressure systolic increased,DS
198015921,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,OT
198015921,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,HO
198015921,Infliximab Pfizer (Unknown),Blood parathyroid hormone decreased,DS
198015921,Infliximab Pfizer (Unknown),Blood creatinine increased,OT
198015921,Infliximab Pfizer (Unknown),Blood creatinine increased,HO
198015921,Infliximab Pfizer (Unknown),Blood creatinine increased,DS
198015921,Infliximab Pfizer (Unknown),Basal cell carcinoma,OT
198015921,Infliximab Pfizer (Unknown),Basal cell carcinoma,HO
198015921,Infliximab Pfizer (Unknown),Basal cell carcinoma,DS
198015921,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,OT
198015921,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,HO
198015921,Infliximab Pfizer (Unknown),Aspartate aminotransferase increased,DS
198015921,Infliximab Pfizer (Unknown),Arthropathy,OT
198015921,Infliximab Pfizer (Unknown),Arthropathy,HO
198015921,Infliximab Pfizer (Unknown),Arthropathy,DS
198015921,Infliximab Pfizer (Unknown),Arthritis,OT
198015921,Infliximab Pfizer (Unknown),Arthritis,HO
198015921,Infliximab Pfizer (Unknown),Arthritis,DS
198015921,Infliximab Pfizer (Unknown),Arthralgia,OT
198015921,Infliximab Pfizer (Unknown),Arthralgia,HO
198015921,Infliximab Pfizer (Unknown),Arthralgia,DS
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,OT
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,HO
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase increased,DS
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,OT
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,HO
198015921,Infliximab Pfizer (Unknown),Alanine aminotransferase abnormal,DS
198015921,Infliximab Pfizer (Unknown),Abdominal discomfort,OT
198015921,Infliximab Pfizer (Unknown),Abdominal discomfort,HO
198015921,Infliximab Pfizer (Unknown),Abdominal discomfort,DS
198201651,Infliximab,Weight fluctuation,HO
198201651,Infliximab,Weight fluctuation,OT
198201651,Infliximab,Rhinitis,HO
198201651,Infliximab,Rhinitis,OT
198201651,Infliximab,Pharyngitis,HO
198201651,Infliximab,Pharyngitis,OT
198201651,Infliximab,Off label use,HO
198201651,Infliximab,Off label use,OT
198201651,Infliximab,Malaise,HO
198201651,Infliximab,Malaise,OT
198201651,Infliximab,Infection,HO
198201651,Infliximab,Infection,OT
198201651,Infliximab,Impaired quality of life,HO
198201651,Infliximab,Impaired quality of life,OT
198201651,Infliximab,Haematochezia,HO
198201651,Infliximab,Haematochezia,OT
198201651,Infliximab,Drug specific antibody present,HO
198201651,Infliximab,Drug specific antibody present,OT
198201651,Infliximab,Drug level below therapeutic,HO
198201651,Infliximab,Drug level below therapeutic,OT
198201651,Infliximab,Condition aggravated,HO
198201651,Infliximab,Condition aggravated,OT
198201651,Infliximab,Blood pressure increased,HO
198201651,Infliximab,Blood pressure increased,OT
198201651,Infliximab,Arthralgia,HO
198201651,Infliximab,Arthralgia,OT
198201651,Infliximab,Anal haemorrhage,HO
198201651,Infliximab,Anal haemorrhage,OT
198201651,Infliximab,Anal fistula,HO
198201651,Infliximab,Anal fistula,OT
198767561,Infliximab,Drug ineffective,HO
198767561,Infliximab,Colitis ulcerative,HO
165609106,Infliximab,Vein rupture,HO
165609106,Infliximab,Vein rupture,OT
165609106,Infliximab,Toothache,HO
165609106,Infliximab,Toothache,OT
165609106,Infliximab,Staphylococcal skin infection,HO
165609106,Infliximab,Staphylococcal skin infection,OT
165609106,Infliximab,Staphylococcal infection,HO
165609106,Infliximab,Staphylococcal infection,OT
165609106,Infliximab,Product use issue,HO
165609106,Infliximab,Product use issue,OT
165609106,Infliximab,Post procedural infection,HO
165609106,Infliximab,Post procedural infection,OT
165609106,Infliximab,Poor venous access,HO
165609106,Infliximab,Poor venous access,OT
165609106,Infliximab,Pain,HO
165609106,Infliximab,Pain,OT
165609106,Infliximab,Off label use,HO
165609106,Infliximab,Off label use,OT
165609106,Infliximab,Migraine,HO
165609106,Infliximab,Migraine,OT
165609106,Infliximab,Intentional product use issue,HO
165609106,Infliximab,Intentional product use issue,OT
165609106,Infliximab,Infusion site swelling,HO
165609106,Infliximab,Infusion site swelling,OT
165609106,Infliximab,Infusion site bruising,HO
165609106,Infliximab,Infusion site bruising,OT
165609106,Infliximab,Inappropriate schedule of product administration,HO
165609106,Infliximab,Inappropriate schedule of product administration,OT
165609106,Infliximab,Hypertension,HO
165609106,Infliximab,Hypertension,OT
165609106,Infliximab,Herpes zoster,HO
165609106,Infliximab,Herpes zoster,OT
165609106,Infliximab,Condition aggravated,HO
165609106,Infliximab,Condition aggravated,OT
165609106,Infliximab,Blood pressure fluctuation,HO
165609106,Infliximab,Blood pressure fluctuation,OT
165609106,Infliximab,Anal fistula,HO
165609106,Infliximab,Anal fistula,OT
165609106,Infliximab,Alopecia,HO
165609106,Infliximab,Alopecia,OT
165679793,Infliximab,Sinus congestion,OT
165679793,Infliximab,Product use in unapproved indication,OT
165679793,Infliximab,Off label use,OT
165679793,Infliximab,Nasopharyngitis,OT
165679793,Infliximab,Headache,OT
165679793,Infliximab,Head discomfort,OT
165679793,Infliximab,Fatigue,OT
165679793,Infliximab,Eye swelling,OT
165679793,Infliximab,Erythema,OT
165679793,Infliximab,Ear swelling,OT
165679793,Infliximab,Body temperature increased,OT
165679793,Infliximab,Body temperature decreased,OT
165679793,Infliximab,Blood pressure systolic increased,OT
165679793,Infliximab,Blood pressure fluctuation,OT
165679793,Infliximab,Blood pressure decreased,OT
165679793,Infliximab,Asthenopia,OT
165679793,Infliximab,Sinus congestion,OT
165679793,Infliximab,Product use in unapproved indication,OT
165679793,Infliximab,Off label use,OT
165679793,Infliximab,Nasopharyngitis,OT
165679793,Infliximab,Headache,OT
165679793,Infliximab,Head discomfort,OT
165679793,Infliximab,Fatigue,OT
165679793,Infliximab,Eye swelling,OT
165679793,Infliximab,Erythema,OT
165679793,Infliximab,Ear swelling,OT
165679793,Infliximab,Body temperature increased,OT
165679793,Infliximab,Body temperature decreased,OT
165679793,Infliximab,Blood pressure systolic increased,OT
165679793,Infliximab,Blood pressure fluctuation,OT
165679793,Infliximab,Blood pressure decreased,OT
165679793,Infliximab,Asthenopia,OT
168879595,Infliximab,Weight decreased,OT
168879595,Infliximab,Swelling face,OT
168879595,Infliximab,Skin disorder,OT
168879595,Infliximab,Sinusitis,OT
168879595,Infliximab,Rosacea,OT
168879595,Infliximab,Rheumatoid arthritis,OT
168879595,Infliximab,Rash erythematous,OT
168879595,Infliximab,Product use issue,OT
168879595,Infliximab,Peripheral swelling,OT
168879595,Infliximab,Paranasal sinus discomfort,OT
168879595,Infliximab,Palpitations,OT
168879595,Infliximab,Pain in extremity,OT
168879595,Infliximab,Pain,OT
168879595,Infliximab,Osteoarthritis,OT
168879595,Infliximab,Oropharyngeal pain,OT
168879595,Infliximab,Off label use,OT
168879595,Infliximab,Nasopharyngitis,OT
168879595,Infliximab,Nasal congestion,OT
168879595,Infliximab,Malaise,OT
168879595,Infliximab,Joint swelling,OT
168879595,Infliximab,Joint effusion,OT
168879595,Infliximab,Intentional product use issue,OT
168879595,Infliximab,Hypoaesthesia,OT
168879595,Infliximab,Heart rate decreased,OT
168879595,Infliximab,Heart rate abnormal,OT
168879595,Infliximab,Headache,OT
168879595,Infliximab,Haematochezia,OT
168879595,Infliximab,Gait disturbance,OT
168879595,Infliximab,Fatigue,OT
168879595,Infliximab,Erythema,OT
168879595,Infliximab,Drug hypersensitivity,OT
168879595,Infliximab,Dizziness,OT
168879595,Infliximab,Diarrhoea haemorrhagic,OT
168879595,Infliximab,Condition aggravated,OT
168879595,Infliximab,Blood pressure increased,OT
168879595,Infliximab,Blood pressure fluctuation,OT
168879595,Infliximab,Arthritis,OT
168879595,Infliximab,Arthralgia,OT
168879595,Infliximab,Weight decreased,OT
168879595,Infliximab,Swelling face,OT
168879595,Infliximab,Skin disorder,OT
168879595,Infliximab,Sinusitis,OT
168879595,Infliximab,Rosacea,OT
168879595,Infliximab,Rheumatoid arthritis,OT
168879595,Infliximab,Rash erythematous,OT
168879595,Infliximab,Product use issue,OT
168879595,Infliximab,Peripheral swelling,OT
168879595,Infliximab,Paranasal sinus discomfort,OT
168879595,Infliximab,Palpitations,OT
168879595,Infliximab,Pain in extremity,OT
168879595,Infliximab,Pain,OT
168879595,Infliximab,Osteoarthritis,OT
168879595,Infliximab,Oropharyngeal pain,OT
168879595,Infliximab,Off label use,OT
168879595,Infliximab,Nasopharyngitis,OT
168879595,Infliximab,Nasal congestion,OT
168879595,Infliximab,Malaise,OT
168879595,Infliximab,Joint swelling,OT
168879595,Infliximab,Joint effusion,OT
168879595,Infliximab,Intentional product use issue,OT
168879595,Infliximab,Hypoaesthesia,OT
168879595,Infliximab,Heart rate decreased,OT
168879595,Infliximab,Heart rate abnormal,OT
168879595,Infliximab,Headache,OT
168879595,Infliximab,Haematochezia,OT
168879595,Infliximab,Gait disturbance,OT
168879595,Infliximab,Fatigue,OT
168879595,Infliximab,Erythema,OT
168879595,Infliximab,Drug hypersensitivity,OT
168879595,Infliximab,Dizziness,OT
168879595,Infliximab,Diarrhoea haemorrhagic,OT
168879595,Infliximab,Condition aggravated,OT
168879595,Infliximab,Blood pressure increased,OT
168879595,Infliximab,Blood pressure fluctuation,OT
168879595,Infliximab,Arthritis,OT
168879595,Infliximab,Arthralgia,OT
175584712,Infliximab,Supraventricular tachycardia,OT
175584712,Infliximab,Product use issue,OT
175584712,Infliximab,Off label use,OT
175584712,Infliximab,Intentional product use issue,OT
175584712,Infliximab,Supraventricular tachycardia,OT
175584712,Infliximab,Product use issue,OT
175584712,Infliximab,Off label use,OT
175584712,Infliximab,Intentional product use issue,OT
176024566,Infliximab,Weight increased,HO
176024566,Infliximab,Weight increased,OT
176024566,Infliximab,Vertigo,HO
176024566,Infliximab,Vertigo,OT
176024566,Infliximab,Therapeutic product effect incomplete,HO
176024566,Infliximab,Therapeutic product effect incomplete,OT
176024566,Infliximab,Rhinorrhoea,HO
176024566,Infliximab,Rhinorrhoea,OT
176024566,Infliximab,Retinal tear,HO
176024566,Infliximab,Retinal tear,OT
176024566,Infliximab,Retinal haemorrhage,HO
176024566,Infliximab,Retinal haemorrhage,OT
176024566,Infliximab,Pyrexia,HO
176024566,Infliximab,Pyrexia,OT
176024566,Infliximab,Product use issue,HO
176024566,Infliximab,Product use issue,OT
176024566,Infliximab,Pain in extremity,HO
176024566,Infliximab,Pain in extremity,OT
176024566,Infliximab,Oropharyngeal pain,HO
176024566,Infliximab,Oropharyngeal pain,OT
176024566,Infliximab,Off label use,HO
176024566,Infliximab,Off label use,OT
176024566,Infliximab,Nasopharyngitis,HO
176024566,Infliximab,Nasopharyngitis,OT
176024566,Infliximab,Musculoskeletal stiffness,HO
176024566,Infliximab,Musculoskeletal stiffness,OT
176024566,Infliximab,Muscle spasms,HO
176024566,Infliximab,Muscle spasms,OT
176024566,Infliximab,Malaise,HO
176024566,Infliximab,Malaise,OT
176024566,Infliximab,Intentional product use issue,HO
176024566,Infliximab,Intentional product use issue,OT
176024566,Infliximab,Inflammation,HO
176024566,Infliximab,Inflammation,OT
176024566,Infliximab,Incorrect dosage administered,HO
176024566,Infliximab,Incorrect dosage administered,OT
176024566,Infliximab,Inappropriate schedule of product administration,HO
176024566,Infliximab,Inappropriate schedule of product administration,OT
176024566,Infliximab,Food poisoning,HO
176024566,Infliximab,Food poisoning,OT
176024566,Infliximab,Dyspepsia,HO
176024566,Infliximab,Dyspepsia,OT
176024566,Infliximab,Diarrhoea,HO
176024566,Infliximab,Diarrhoea,OT
176024566,Infliximab,Condition aggravated,HO
176024566,Infliximab,Condition aggravated,OT
176024566,Infliximab,Blood pressure increased,HO
176024566,Infliximab,Blood pressure increased,OT
176024566,Infliximab,Blood pressure fluctuation,HO
176024566,Infliximab,Blood pressure fluctuation,OT
176024566,Infliximab,Asthenia,HO
176024566,Infliximab,Asthenia,OT
176024663,Infliximab,Weight increased,OT
176024663,Infliximab,Tooth infection,OT
176024663,Infliximab,Sinusitis,OT
176024663,Infliximab,Pyrexia,OT
176024663,Infliximab,Product use issue,OT
176024663,Infliximab,Product prescribing error,OT
176024663,Infliximab,Peripheral swelling,OT
176024663,Infliximab,Paraesthesia,OT
176024663,Infliximab,Off label use,OT
176024663,Infliximab,Nasopharyngitis,OT
176024663,Infliximab,Lower respiratory tract infection,OT
176024663,Infliximab,Lacrimation increased,OT
176024663,Infliximab,Joint swelling,OT
176024663,Infliximab,Intentional product use issue,OT
176024663,Infliximab,Inflammation,OT
176024663,Infliximab,Incorrect dose administered,OT
176024663,Infliximab,Inappropriate schedule of product administration,OT
176024663,Infliximab,Heart rate irregular,OT
176024663,Infliximab,Heart rate increased,OT
176024663,Infliximab,Eye swelling,OT
176024663,Infliximab,Drug level below therapeutic,OT
176024663,Infliximab,Diarrhoea,OT
176024663,Infliximab,Condition aggravated,OT
176024663,Infliximab,Blood pressure increased,OT
176024663,Infliximab,Blood pressure fluctuation,OT
176024663,Infliximab,Aphthous ulcer,OT
176024663,Infliximab,Weight increased,OT
176024663,Infliximab,Tooth infection,OT
176024663,Infliximab,Sinusitis,OT
176024663,Infliximab,Pyrexia,OT
176024663,Infliximab,Product use issue,OT
176024663,Infliximab,Product prescribing error,OT
176024663,Infliximab,Peripheral swelling,OT
176024663,Infliximab,Paraesthesia,OT
176024663,Infliximab,Off label use,OT
176024663,Infliximab,Nasopharyngitis,OT
176024663,Infliximab,Lower respiratory tract infection,OT
176024663,Infliximab,Lacrimation increased,OT
176024663,Infliximab,Joint swelling,OT
176024663,Infliximab,Intentional product use issue,OT
176024663,Infliximab,Inflammation,OT
176024663,Infliximab,Incorrect dose administered,OT
176024663,Infliximab,Inappropriate schedule of product administration,OT
176024663,Infliximab,Heart rate irregular,OT
176024663,Infliximab,Heart rate increased,OT
176024663,Infliximab,Eye swelling,OT
176024663,Infliximab,Drug level below therapeutic,OT
176024663,Infliximab,Diarrhoea,OT
176024663,Infliximab,Condition aggravated,OT
176024663,Infliximab,Blood pressure increased,OT
176024663,Infliximab,Blood pressure fluctuation,OT
176024663,Infliximab,Aphthous ulcer,OT
176058034,Infliximab,Weight increased,OT
176058034,Infliximab,Therapeutic response decreased,OT
176058034,Infliximab,Product use issue,OT
176058034,Infliximab,Off label use,OT
176058034,Infliximab,Immunosuppression,OT
176058034,Infliximab,Heart rate irregular,OT
176058034,Infliximab,Heart rate decreased,OT
176058034,Infliximab,Faecal calprotectin increased,OT
176058034,Infliximab,Drug level decreased,OT
176058034,Infliximab,Condition aggravated,OT
176110794,Infliximab,Therapeutic response shortened,OT
176110794,Infliximab,Rectal haemorrhage,OT
176110794,Infliximab,Off label use,OT
176110794,Infliximab,Intentional product use issue,OT
176110794,Infliximab,Faecal calprotectin increased,OT
176110794,Infliximab,Drug specific antibody present,OT
176110794,Infliximab,Drug specific antibody,OT
176110794,Infliximab,Constipation,OT
176110794,Infliximab,Condition aggravated,OT
176335002,Infliximab,Weight increased,OT
176335002,Infliximab,Product use issue,OT
176335002,Infliximab,Off label use,OT
176335002,Infliximab,Intentional product use issue,OT
176335002,Infliximab,Incorrect dose administered,OT
176335002,Infliximab,Heart rate decreased,OT
176335002,Infliximab,Haematochezia,OT
176335002,Infliximab,Fatigue,OT
176335002,Infliximab,Condition aggravated,OT
176335002,Infliximab,Blood pressure diastolic increased,OT
176396003,Infliximab,COVID-19,OT
177178845,Infliximab,Throat irritation,OT
177178845,Infliximab,Therapeutic response shortened,OT
177178845,Infliximab,Stress at work,OT
177178845,Infliximab,Stress,OT
177178845,Infliximab,Shock,OT
177178845,Infliximab,Respiratory disorder,OT
177178845,Infliximab,Pyrexia,OT
177178845,Infliximab,Psoriasis,OT
177178845,Infliximab,Product use issue,OT
177178845,Infliximab,Pelvic pain,OT
177178845,Infliximab,Pain in extremity,OT
177178845,Infliximab,Pain,OT
177178845,Infliximab,Off label use,OT
177178845,Infliximab,Nausea,OT
177178845,Infliximab,Mobility decreased,OT
177178845,Infliximab,Malaise,OT
177178845,Infliximab,Lip swelling,OT
177178845,Infliximab,Lip erythema,OT
177178845,Infliximab,Lip blister,OT
177178845,Infliximab,Joint swelling,OT
177178845,Infliximab,Intentional product use issue,OT
177178845,Infliximab,Inappropriate schedule of product administration,OT
177178845,Infliximab,Immune system disorder,OT
177178845,Infliximab,Hyperventilation,OT
177178845,Infliximab,Groin pain,OT
177178845,Infliximab,General physical health deterioration,OT
177178845,Infliximab,Gait disturbance,OT
177178845,Infliximab,Fatigue,OT
177178845,Infliximab,Ear infection,OT
177178845,Infliximab,Drug ineffective,OT
177178845,Infliximab,Dizziness,OT
177178845,Infliximab,Decreased immune responsiveness,OT
177178845,Infliximab,Condition aggravated,OT
177178845,Infliximab,Bacterial infection,OT
177178845,Infliximab,Asthenia,OT
177178845,Infliximab,Arthralgia,OT
177178845,Infliximab,Anxiety,OT
177178845,Infliximab,Throat irritation,OT
177178845,Infliximab,Therapeutic response shortened,OT
177178845,Infliximab,Stress at work,OT
177178845,Infliximab,Stress,OT
177178845,Infliximab,Shock,OT
177178845,Infliximab,Respiratory disorder,OT
177178845,Infliximab,Pyrexia,OT
177178845,Infliximab,Psoriasis,OT
177178845,Infliximab,Product use issue,OT
177178845,Infliximab,Pelvic pain,OT
177178845,Infliximab,Pain in extremity,OT
177178845,Infliximab,Pain,OT
177178845,Infliximab,Off label use,OT
177178845,Infliximab,Nausea,OT
177178845,Infliximab,Mobility decreased,OT
177178845,Infliximab,Malaise,OT
177178845,Infliximab,Lip swelling,OT
177178845,Infliximab,Lip erythema,OT
177178845,Infliximab,Lip blister,OT
177178845,Infliximab,Joint swelling,OT
177178845,Infliximab,Intentional product use issue,OT
177178845,Infliximab,Inappropriate schedule of product administration,OT
177178845,Infliximab,Immune system disorder,OT
177178845,Infliximab,Hyperventilation,OT
177178845,Infliximab,Groin pain,OT
177178845,Infliximab,General physical health deterioration,OT
177178845,Infliximab,Gait disturbance,OT
177178845,Infliximab,Fatigue,OT
177178845,Infliximab,Ear infection,OT
177178845,Infliximab,Drug ineffective,OT
177178845,Infliximab,Dizziness,OT
177178845,Infliximab,Decreased immune responsiveness,OT
177178845,Infliximab,Condition aggravated,OT
177178845,Infliximab,Bacterial infection,OT
177178845,Infliximab,Asthenia,OT
177178845,Infliximab,Arthralgia,OT
177178845,Infliximab,Anxiety,OT
177297244,Infliximab,Sneezing,HO
177297244,Infliximab,Sneezing,OT
177297244,Infliximab,Pneumonia,HO
177297244,Infliximab,Pneumonia,OT
177297244,Infliximab,Oropharyngeal pain,HO
177297244,Infliximab,Oropharyngeal pain,OT
177297244,Infliximab,Off label use,HO
177297244,Infliximab,Off label use,OT
177297244,Infliximab,Nasopharyngitis,HO
177297244,Infliximab,Nasopharyngitis,OT
177297244,Infliximab,Nasal congestion,HO
177297244,Infliximab,Nasal congestion,OT
177297244,Infliximab,Memory impairment,HO
177297244,Infliximab,Memory impairment,OT
177297244,Infliximab,Malaise,HO
177297244,Infliximab,Malaise,OT
177297244,Infliximab,Lower respiratory tract infection,HO
177297244,Infliximab,Lower respiratory tract infection,OT
177297244,Infliximab,Inappropriate schedule of product administration,HO
177297244,Infliximab,Inappropriate schedule of product administration,OT
177297244,Infliximab,Heart rate irregular,HO
177297244,Infliximab,Heart rate irregular,OT
177297244,Infliximab,Heart rate increased,HO
177297244,Infliximab,Heart rate increased,OT
177297244,Infliximab,Blood pressure increased,HO
177297244,Infliximab,Blood pressure increased,OT
177297244,Infliximab,Blood pressure fluctuation,HO
177297244,Infliximab,Blood pressure fluctuation,OT
177646763,Infliximab,Weight increased,OT
177646763,Infliximab,Weight decreased,OT
177646763,Infliximab,Urticaria,OT
177646763,Infliximab,Pruritus,OT
177646763,Infliximab,Parasitic gastroenteritis,OT
177646763,Infliximab,Off label use,OT
177646763,Infliximab,Incorrect dose administered,OT
177646763,Infliximab,Condition aggravated,OT
177646763,Infliximab,Blood pressure increased,OT
181268186,Infliximab,Product use in unapproved indication,HO
181268186,Infliximab,Product use in unapproved indication,OT
181268186,Infliximab,Off label use,HO
181268186,Infliximab,Off label use,OT
181268186,Infliximab,Castleman's disease,HO
181268186,Infliximab,Castleman's disease,OT
181268186,Infliximab,Product use in unapproved indication,HO
181268186,Infliximab,Product use in unapproved indication,OT
181268186,Infliximab,Off label use,HO
181268186,Infliximab,Off label use,OT
181268186,Infliximab,Castleman's disease,HO
181268186,Infliximab,Castleman's disease,OT
184040973,Infliximab,Weight decreased,OT
184040973,Infliximab,Throat tightness,OT
184040973,Infliximab,Sensation of foreign body,OT
184040973,Infliximab,Oropharyngeal pain,OT
184040973,Infliximab,Off label use,OT
184040973,Infliximab,Intentional product use issue,OT
184040973,Infliximab,Incorrect dose administered,OT
184040973,Infliximab,Illness,OT
184040973,Infliximab,Gastrooesophageal reflux disease,OT
184040973,Infliximab,Foot fracture,OT
184040973,Infliximab,Food poisoning,OT
184040973,Infliximab,Dysphagia,OT
184040973,Infliximab,Drug level below therapeutic,OT
184040973,Infliximab,Chest pain,OT
184040973,Infliximab,Chest discomfort,OT
184040973,Infliximab,Weight decreased,OT
184040973,Infliximab,Throat tightness,OT
184040973,Infliximab,Sensation of foreign body,OT
184040973,Infliximab,Oropharyngeal pain,OT
184040973,Infliximab,Off label use,OT
184040973,Infliximab,Intentional product use issue,OT
184040973,Infliximab,Incorrect dose administered,OT
184040973,Infliximab,Illness,OT
184040973,Infliximab,Gastrooesophageal reflux disease,OT
184040973,Infliximab,Foot fracture,OT
184040973,Infliximab,Food poisoning,OT
184040973,Infliximab,Dysphagia,OT
184040973,Infliximab,Drug level below therapeutic,OT
184040973,Infliximab,Chest pain,OT
184040973,Infliximab,Chest discomfort,OT
184747512,Infliximab,Weight increased,OT
184747512,Infliximab,Weight increased,HO
184747512,Infliximab,Weight decreased,OT
184747512,Infliximab,Weight decreased,HO
184747512,Infliximab,Vessel puncture site haemorrhage,OT
184747512,Infliximab,Vessel puncture site haemorrhage,HO
184747512,Infliximab,Ureterolithiasis,OT
184747512,Infliximab,Ureterolithiasis,HO
184747512,Infliximab,Thyroid disorder,OT
184747512,Infliximab,Thyroid disorder,HO
184747512,Infliximab,Therapeutic response shortened,OT
184747512,Infliximab,Therapeutic response shortened,HO
184747512,Infliximab,Poor venous access,OT
184747512,Infliximab,Poor venous access,HO
184747512,Infliximab,Off label use,OT
184747512,Infliximab,Off label use,HO
184747512,Infliximab,Nephrolithiasis,OT
184747512,Infliximab,Nephrolithiasis,HO
184747512,Infliximab,Maternal exposure during pregnancy,OT
184747512,Infliximab,Maternal exposure during pregnancy,HO
184747512,Infliximab,Inappropriate schedule of product administration,OT
184747512,Infliximab,Inappropriate schedule of product administration,HO
184747512,Infliximab,Frequent bowel movements,OT
184747512,Infliximab,Frequent bowel movements,HO
184747512,Infliximab,Emotional disorder,OT
184747512,Infliximab,Emotional disorder,HO
184747512,Infliximab,Disease recurrence,OT
184747512,Infliximab,Disease recurrence,HO
184747512,Infliximab,Decreased appetite,OT
184747512,Infliximab,Decreased appetite,HO
184747512,Infliximab,Constipation,OT
184747512,Infliximab,Constipation,HO
184747512,Infliximab,Blood pressure fluctuation,OT
184747512,Infliximab,Blood pressure fluctuation,HO
184747512,Infliximab,Anal abscess,OT
184747512,Infliximab,Anal abscess,HO
184747512,Infliximab,Abdominal discomfort,OT
184747512,Infliximab,Abdominal discomfort,HO
184853162,Infliximab,Weight fluctuation,OT
184853162,Infliximab,Weight fluctuation,HO
184853162,Infliximab,Therapeutic product effect incomplete,OT
184853162,Infliximab,Therapeutic product effect incomplete,HO
184853162,Infliximab,Product use issue,OT
184853162,Infliximab,Product use issue,HO
184853162,Infliximab,Patella fracture,OT
184853162,Infliximab,Patella fracture,HO
184853162,Infliximab,Off label use,OT
184853162,Infliximab,Off label use,HO
184853162,Infliximab,Lower limb fracture,OT
184853162,Infliximab,Lower limb fracture,HO
184853162,Infliximab,Hypertension,OT
184853162,Infliximab,Hypertension,HO
184853162,Infliximab,Fall,OT
184853162,Infliximab,Fall,HO
184853162,Infliximab,Faecal calprotectin increased,OT
184853162,Infliximab,Faecal calprotectin increased,HO
184853162,Infliximab,Condition aggravated,OT
184853162,Infliximab,Condition aggravated,HO
184853162,Infliximab,Blood iron decreased,OT
184853162,Infliximab,Blood iron decreased,HO
184853162,Infliximab,Blindness unilateral,OT
184853162,Infliximab,Blindness unilateral,HO
184853162,Infliximab,Balance disorder,OT
184853162,Infliximab,Balance disorder,HO
185046313,Infliximab,Weight increased,HO
185046313,Infliximab,Skin laceration,HO
185046313,Infliximab,Product use issue,HO
185046313,Infliximab,Peripheral swelling,HO
185046313,Infliximab,Off label use,HO
185046313,Infliximab,Nerve compression,HO
185046313,Infliximab,Nausea,HO
185046313,Infliximab,Limb injury,HO
185046313,Infliximab,Inappropriate schedule of product administration,HO
185046313,Infliximab,Herpes zoster,HO
185046313,Infliximab,Fatigue,HO
185046313,Infliximab,Fall,HO
192521762,Infliximab,COVID-19,OT
192604343,Infliximab,Ureterolithiasis,HO
192604343,Infliximab,Ureterolithiasis,OT
192604343,Infliximab,Hypersensitivity,HO
192604343,Infliximab,Hypersensitivity,OT
192604343,Infliximab,Crohn's disease,HO
192604343,Infliximab,Crohn's disease,OT
192604343,Infliximab,Ureterolithiasis,HO
192604343,Infliximab,Ureterolithiasis,OT
192604343,Infliximab,Hypersensitivity,HO
192604343,Infliximab,Hypersensitivity,OT
192604343,Infliximab,Crohn's disease,HO
192604343,Infliximab,Crohn's disease,OT
192780812,Infliximab,Weight fluctuation,OT
192780812,Infliximab,Weight fluctuation,HO
192780812,Infliximab,Tooth infection,OT
192780812,Infliximab,Tooth infection,HO
192780812,Infliximab,Off label use,OT
192780812,Infliximab,Off label use,HO
192780812,Infliximab,Migraine,OT
192780812,Infliximab,Migraine,HO
192780812,Infliximab,Intentional product use issue,OT
192780812,Infliximab,Intentional product use issue,HO
192780812,Infliximab,Condition aggravated,OT
192780812,Infliximab,Condition aggravated,HO
193601372,Infliximab,Poor venous access,OT
193601372,Infliximab,Off label use,OT
193601372,Infliximab,Infusion site extravasation,OT
193601372,Infliximab,Inappropriate schedule of product administration,OT
193601372,Infliximab,Headache,OT
193601372,Infliximab,Gastric disorder,OT
193601372,Infliximab,Drug ineffective,OT
193601372,Infliximab,Cellulitis,OT
193601372,Infliximab,Blood pressure fluctuation,OT
193601372,Infliximab,Arthralgia,OT
194834831,Infliximab,Dyspnoea,OT
194834831,Infliximab,Chest pain,OT
195950352,Infliximab,Proctectomy,HO
196781671,Infliximab (Unknown),Polyarthritis,HO
196805711,Infliximab,Product use issue,OT
196805711,Infliximab,Poor venous access,OT
196805711,Infliximab,Off label use,OT
196805711,Infliximab,Hypothyroidism,OT
196805711,Infliximab,Asthma,OT
196805901,Infliximab,Sputum discoloured,OT
196805901,Infliximab,Rhinorrhoea,OT
196805901,Infliximab,Productive cough,OT
196805901,Infliximab,Postoperative wound complication,OT
196805901,Infliximab,Oropharyngeal pain,OT
196805901,Infliximab,Off label use,OT
196805901,Infliximab,Nasopharyngitis,OT
196805901,Infliximab,Intentional product use issue,OT
196805901,Infliximab,Headache,OT
196805901,Infliximab,Fatigue,OT
196805901,Infliximab,Breast cancer,OT
196805901,Infliximab,Blood pressure fluctuation,OT
196805901,Infliximab,Asthma,OT
196805901,Infliximab,Abscess,OT
196998601,Infliximab (Unknown),Overdose,LT
196998601,Infliximab (Unknown),Chest pain,LT
196998601,Infliximab (Unknown),Overdose,LT
196998601,Infliximab (Unknown),Chest pain,LT
197389151,Infliximab,Vein rupture,OT
197389151,Infliximab,Off label use,OT
197389151,Infliximab,Intentional product use issue,OT
197389151,Infliximab,Hypertension,OT
197389151,Infliximab,Body temperature fluctuation,OT
197389151,Infliximab,Blood pressure increased,OT
197389151,Infliximab,Blood pressure fluctuation,OT
197648851,Infliximab,Type 2 diabetes mellitus,OT
197648851,Infliximab,Pruritus,OT
197648851,Infliximab,Malaise,OT
197648851,Infliximab,Inappropriate schedule of product administration,OT
197648851,Infliximab,Heart rate increased,OT
197648851,Infliximab,Fibromyalgia,OT
197648851,Infliximab,Blood pressure increased,OT
197648851,Infliximab,Arthralgia,OT
197648851,Infliximab,Type 2 diabetes mellitus,OT
197648851,Infliximab,Pruritus,OT
197648851,Infliximab,Malaise,OT
197648851,Infliximab,Inappropriate schedule of product administration,OT
197648851,Infliximab,Heart rate increased,OT
197648851,Infliximab,Fibromyalgia,OT
197648851,Infliximab,Blood pressure increased,OT
197648851,Infliximab,Arthralgia,OT
197792171,Infliximab,Small intestinal obstruction,OT
197792171,Infliximab,Small intestinal obstruction,HO
197792171,Infliximab,Procedural complication,OT
197792171,Infliximab,Procedural complication,HO
197792171,Infliximab,Off label use,OT
197792171,Infliximab,Off label use,HO
197792171,Infliximab,Hypotension,OT
197792171,Infliximab,Hypotension,HO
197792171,Infliximab,Drug ineffective,OT
197792171,Infliximab,Drug ineffective,HO
197792171,Infliximab,Dehydration,OT
197792171,Infliximab,Dehydration,HO
197792171,Infliximab,Condition aggravated,OT
197792171,Infliximab,Condition aggravated,HO
197792171,Infliximab,Arrhythmia,OT
197792171,Infliximab,Arrhythmia,HO
197792171,Infliximab,Acute kidney injury,OT
197792171,Infliximab,Acute kidney injury,HO
198189451,Infliximab Pfizer (Unknown),Drug ineffective,DE
198204761,Infliximab,Oesophageal fibrosis,HO
198204761,Infliximab,Oesophageal fibrosis,OT
198204761,Infliximab,Dysphagia,HO
198204761,Infliximab,Dysphagia,OT
198476321,Infliximab,Dementia,OT
198606531,Infliximab (Unknown),Treatment failure,NULL
198606531,Infliximab (Unknown),Condition aggravated,NULL
198863791,Infliximab (Unknown),Pneumonitis,NULL
198863791,Infliximab (Unknown),Off label use,NULL
198863791,Infliximab (Unknown),Disease recurrence,NULL
198871291,Infliximab (Unknown),Off label use,NULL
198871291,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198912711,Infliximab,Off label use,DE
198912711,Infliximab,Inappropriate schedule of product administration,DE
198912711,Infliximab,Death,DE
198912751,Infliximab,Therapeutic product effect incomplete,DE
198912751,Infliximab,Malaise,DE
198912751,Infliximab,Localised infection,DE
198912751,Infliximab,Intercepted product dispensing error,DE
198912751,Infliximab,Inappropriate schedule of product administration,DE
198912751,Infliximab,Hypertension,DE
198912751,Infliximab,Heart rate decreased,DE
198912751,Infliximab,Death,DE
198912751,Infliximab,Blood pressure increased,DE
198912751,Infliximab,Blood pressure decreased,DE
198912751,Infliximab,Therapeutic product effect incomplete,DE
198912751,Infliximab,Malaise,DE
198912751,Infliximab,Localised infection,DE
198912751,Infliximab,Intercepted product dispensing error,DE
198912751,Infliximab,Inappropriate schedule of product administration,DE
198912751,Infliximab,Hypertension,DE
198912751,Infliximab,Heart rate decreased,DE
198912751,Infliximab,Death,DE
198912751,Infliximab,Blood pressure increased,DE
198912751,Infliximab,Blood pressure decreased,DE
199021541,Infliximab,Pruritus,HO
199021541,Infliximab,Paraesthesia oral,HO
199021541,Infliximab,Inappropriate schedule of product administration,HO
199021541,Infliximab,Heart rate increased,HO
199021541,Infliximab,Headache,HO
199021541,Infliximab,COVID-19,HO
160798724,Infliximab,Weight increased,OT
160798724,Infliximab,Underdose,OT
160798724,Infliximab,Therapeutic response shortened,OT
160798724,Infliximab,Pyrexia,OT
160798724,Infliximab,Product use issue,OT
160798724,Infliximab,Polyarthritis,OT
160798724,Infliximab,Pain,OT
160798724,Infliximab,Off label use,OT
160798724,Infliximab,Nasopharyngitis,OT
160798724,Infliximab,Nasal congestion,OT
160798724,Infliximab,Malaise,OT
160798724,Infliximab,Inappropriate schedule of product administration,OT
160798724,Infliximab,Illness,OT
160798724,Infliximab,Hypertension,OT
160798724,Infliximab,Heart rate increased,OT
160798724,Infliximab,Headache,OT
160798724,Infliximab,Drug ineffective,OT
160798724,Infliximab,Condition aggravated,OT
160798724,Infliximab,Blood pressure fluctuation,OT
160798724,Infliximab,Blood pressure abnormal,OT
160798724,Infliximab,Weight increased,OT
160798724,Infliximab,Underdose,OT
160798724,Infliximab,Therapeutic response shortened,OT
160798724,Infliximab,Pyrexia,OT
160798724,Infliximab,Product use issue,OT
160798724,Infliximab,Polyarthritis,OT
160798724,Infliximab,Pain,OT
160798724,Infliximab,Off label use,OT
160798724,Infliximab,Nasopharyngitis,OT
160798724,Infliximab,Nasal congestion,OT
160798724,Infliximab,Malaise,OT
160798724,Infliximab,Inappropriate schedule of product administration,OT
160798724,Infliximab,Illness,OT
160798724,Infliximab,Hypertension,OT
160798724,Infliximab,Heart rate increased,OT
160798724,Infliximab,Headache,OT
160798724,Infliximab,Drug ineffective,OT
160798724,Infliximab,Condition aggravated,OT
160798724,Infliximab,Blood pressure fluctuation,OT
160798724,Infliximab,Blood pressure abnormal,OT
160813505,Infliximab,Weight decreased,OT
160813505,Infliximab,Underdose,OT
160813505,Infliximab,Rash pruritic,OT
160813505,Infliximab,Rash,OT
160813505,Infliximab,Pruritus,OT
160813505,Infliximab,Product use issue,OT
160813505,Infliximab,Prescribed overdose,OT
160813505,Infliximab,Oropharyngeal pain,OT
160813505,Infliximab,Off label use,OT
160813505,Infliximab,Intentional product use issue,OT
160813505,Infliximab,Intentional overdose,OT
160813505,Infliximab,Incorrect dose administered,OT
160813505,Infliximab,Inappropriate schedule of product administration,OT
160813505,Infliximab,Heart rate irregular,OT
160813505,Infliximab,Heart rate decreased,OT
160813505,Infliximab,Headache,OT
160813505,Infliximab,Fungal infection,OT
160813505,Infliximab,Drug ineffective,OT
160813505,Infliximab,Condition aggravated,OT
160813505,Infliximab,Body temperature decreased,OT
160813505,Infliximab,Blood pressure diastolic decreased,OT
160813505,Infliximab,Weight decreased,OT
160813505,Infliximab,Underdose,OT
160813505,Infliximab,Rash pruritic,OT
160813505,Infliximab,Rash,OT
160813505,Infliximab,Pruritus,OT
160813505,Infliximab,Product use issue,OT
160813505,Infliximab,Prescribed overdose,OT
160813505,Infliximab,Oropharyngeal pain,OT
160813505,Infliximab,Off label use,OT
160813505,Infliximab,Intentional product use issue,OT
160813505,Infliximab,Intentional overdose,OT
160813505,Infliximab,Incorrect dose administered,OT
160813505,Infliximab,Inappropriate schedule of product administration,OT
160813505,Infliximab,Heart rate irregular,OT
160813505,Infliximab,Heart rate decreased,OT
160813505,Infliximab,Headache,OT
160813505,Infliximab,Fungal infection,OT
160813505,Infliximab,Drug ineffective,OT
160813505,Infliximab,Condition aggravated,OT
160813505,Infliximab,Body temperature decreased,OT
160813505,Infliximab,Blood pressure diastolic decreased,OT
160813505,Infliximab,Weight decreased,OT
160813505,Infliximab,Underdose,OT
160813505,Infliximab,Rash pruritic,OT
160813505,Infliximab,Rash,OT
160813505,Infliximab,Pruritus,OT
160813505,Infliximab,Product use issue,OT
160813505,Infliximab,Prescribed overdose,OT
160813505,Infliximab,Oropharyngeal pain,OT
160813505,Infliximab,Off label use,OT
160813505,Infliximab,Intentional product use issue,OT
160813505,Infliximab,Intentional overdose,OT
160813505,Infliximab,Incorrect dose administered,OT
160813505,Infliximab,Inappropriate schedule of product administration,OT
160813505,Infliximab,Heart rate irregular,OT
160813505,Infliximab,Heart rate decreased,OT
160813505,Infliximab,Headache,OT
160813505,Infliximab,Fungal infection,OT
160813505,Infliximab,Drug ineffective,OT
160813505,Infliximab,Condition aggravated,OT
160813505,Infliximab,Body temperature decreased,OT
160813505,Infliximab,Blood pressure diastolic decreased,OT
165679784,Infliximab,Weight decreased,OT
165679784,Infliximab,Toothache,OT
165679784,Infliximab,Systemic lupus erythematosus,OT
165679784,Infliximab,Sinusitis,OT
165679784,Infliximab,Rhinorrhoea,OT
165679784,Infliximab,Rash,OT
165679784,Infliximab,Product use issue,OT
165679784,Infliximab,Paronychia,OT
165679784,Infliximab,Onychalgia,OT
165679784,Infliximab,Off label use,OT
165679784,Infliximab,Nail infection,OT
165679784,Infliximab,Intentional product use issue,OT
165679784,Infliximab,Heart rate increased,OT
165679784,Infliximab,Heart rate decreased,OT
165679784,Infliximab,Hangnail,OT
165679784,Infliximab,Ear pain,OT
165679784,Infliximab,Disease recurrence,OT
165679784,Infliximab,Condition aggravated,OT
165679784,Infliximab,Arthralgia,OT
165679784,Infliximab,Abdominal discomfort,OT
165679784,Infliximab,Weight decreased,OT
165679784,Infliximab,Toothache,OT
165679784,Infliximab,Systemic lupus erythematosus,OT
165679784,Infliximab,Sinusitis,OT
165679784,Infliximab,Rhinorrhoea,OT
165679784,Infliximab,Rash,OT
165679784,Infliximab,Product use issue,OT
165679784,Infliximab,Paronychia,OT
165679784,Infliximab,Onychalgia,OT
165679784,Infliximab,Off label use,OT
165679784,Infliximab,Nail infection,OT
165679784,Infliximab,Intentional product use issue,OT
165679784,Infliximab,Heart rate increased,OT
165679784,Infliximab,Heart rate decreased,OT
165679784,Infliximab,Hangnail,OT
165679784,Infliximab,Ear pain,OT
165679784,Infliximab,Disease recurrence,OT
165679784,Infliximab,Condition aggravated,OT
165679784,Infliximab,Arthralgia,OT
165679784,Infliximab,Abdominal discomfort,OT
173070058,Infliximab,Wound,HO
173070058,Infliximab,Wound,OT
173070058,Infliximab,Wound,DS
173070058,Infliximab,Weight increased,HO
173070058,Infliximab,Weight increased,OT
173070058,Infliximab,Weight increased,DS
173070058,Infliximab,Urticaria,HO
173070058,Infliximab,Urticaria,OT
173070058,Infliximab,Urticaria,DS
173070058,Infliximab,Treatment failure,HO
173070058,Infliximab,Treatment failure,OT
173070058,Infliximab,Treatment failure,DS
173070058,Infliximab,Therapy non-responder,HO
173070058,Infliximab,Therapy non-responder,OT
173070058,Infliximab,Therapy non-responder,DS
173070058,Infliximab,Therapeutic product effect decreased,HO
173070058,Infliximab,Therapeutic product effect decreased,OT
173070058,Infliximab,Therapeutic product effect decreased,DS
173070058,Infliximab,Systemic lupus erythematosus,HO
173070058,Infliximab,Systemic lupus erythematosus,OT
173070058,Infliximab,Systemic lupus erythematosus,DS
173070058,Infliximab,Synovitis,HO
173070058,Infliximab,Synovitis,OT
173070058,Infliximab,Synovitis,DS
173070058,Infliximab,Swelling,HO
173070058,Infliximab,Swelling,OT
173070058,Infliximab,Swelling,DS
173070058,Infliximab,Stomatitis,HO
173070058,Infliximab,Stomatitis,OT
173070058,Infliximab,Stomatitis,DS
173070058,Infliximab,"Sleep disorder due to general medical condition, insomnia type",HO
173070058,Infliximab,"Sleep disorder due to general medical condition, insomnia type",OT
173070058,Infliximab,"Sleep disorder due to general medical condition, insomnia type",DS
173070058,Infliximab,Sinusitis,HO
173070058,Infliximab,Sinusitis,OT
173070058,Infliximab,Sinusitis,DS
173070058,Infliximab,Rheumatoid arthritis,HO
173070058,Infliximab,Rheumatoid arthritis,OT
173070058,Infliximab,Rheumatoid arthritis,DS
173070058,Infliximab,Rash,HO
173070058,Infliximab,Rash,OT
173070058,Infliximab,Rash,DS
173070058,Infliximab,Pyrexia,HO
173070058,Infliximab,Pyrexia,OT
173070058,Infliximab,Pyrexia,DS
173070058,Infliximab,Pruritus,HO
173070058,Infliximab,Pruritus,OT
173070058,Infliximab,Pruritus,DS
173070058,Infliximab,Product use issue,HO
173070058,Infliximab,Product use issue,OT
173070058,Infliximab,Product use issue,DS
173070058,Infliximab,Product use in unapproved indication,HO
173070058,Infliximab,Product use in unapproved indication,OT
173070058,Infliximab,Product use in unapproved indication,DS
173070058,Infliximab,Pregnancy,HO
173070058,Infliximab,Pregnancy,OT
173070058,Infliximab,Pregnancy,DS
173070058,Infliximab,Peripheral swelling,HO
173070058,Infliximab,Peripheral swelling,OT
173070058,Infliximab,Peripheral swelling,DS
173070058,Infliximab,Pericarditis,HO
173070058,Infliximab,Pericarditis,OT
173070058,Infliximab,Pericarditis,DS
173070058,Infliximab,Pemphigus,HO
173070058,Infliximab,Pemphigus,OT
173070058,Infliximab,Pemphigus,DS
173070058,Infliximab,Pain,HO
173070058,Infliximab,Pain,OT
173070058,Infliximab,Pain,DS
173070058,Infliximab,Off label use,HO
173070058,Infliximab,Off label use,OT
173070058,Infliximab,Off label use,DS
173070058,Infliximab,Nasopharyngitis,HO
173070058,Infliximab,Nasopharyngitis,OT
173070058,Infliximab,Nasopharyngitis,DS
173070058,Infliximab,Muscle injury,HO
173070058,Infliximab,Muscle injury,OT
173070058,Infliximab,Muscle injury,DS
173070058,Infliximab,Maternal exposure during pregnancy,HO
173070058,Infliximab,Maternal exposure during pregnancy,OT
173070058,Infliximab,Maternal exposure during pregnancy,DS
173070058,Infliximab,Lower respiratory tract infection,HO
173070058,Infliximab,Lower respiratory tract infection,OT
173070058,Infliximab,Lower respiratory tract infection,DS
173070058,Infliximab,Joint swelling,HO
173070058,Infliximab,Joint swelling,OT
173070058,Infliximab,Joint swelling,DS
173070058,Infliximab,Irritable bowel syndrome,HO
173070058,Infliximab,Irritable bowel syndrome,OT
173070058,Infliximab,Irritable bowel syndrome,DS
173070058,Infliximab,Intentional product use issue,HO
173070058,Infliximab,Intentional product use issue,OT
173070058,Infliximab,Intentional product use issue,DS
173070058,Infliximab,Injury,HO
173070058,Infliximab,Injury,OT
173070058,Infliximab,Injury,DS
173070058,Infliximab,Infusion related reaction,HO
173070058,Infliximab,Infusion related reaction,OT
173070058,Infliximab,Infusion related reaction,DS
173070058,Infliximab,Infection,HO
173070058,Infliximab,Infection,OT
173070058,Infliximab,Infection,DS
173070058,Infliximab,Impaired healing,HO
173070058,Infliximab,Impaired healing,OT
173070058,Infliximab,Impaired healing,DS
173070058,Infliximab,Ill-defined disorder,HO
173070058,Infliximab,Ill-defined disorder,OT
173070058,Infliximab,Ill-defined disorder,DS
173070058,Infliximab,Hypersensitivity,HO
173070058,Infliximab,Hypersensitivity,OT
173070058,Infliximab,Hypersensitivity,DS
173070058,Infliximab,Hepatic enzyme increased,HO
173070058,Infliximab,Hepatic enzyme increased,OT
173070058,Infliximab,Hepatic enzyme increased,DS
173070058,Infliximab,Helicobacter infection,HO
173070058,Infliximab,Helicobacter infection,OT
173070058,Infliximab,Helicobacter infection,DS
173070058,Infliximab,Hand deformity,HO
173070058,Infliximab,Hand deformity,OT
173070058,Infliximab,Hand deformity,DS
173070058,Infliximab,Glossodynia,HO
173070058,Infliximab,Glossodynia,OT
173070058,Infliximab,Glossodynia,DS
173070058,Infliximab,General physical health deterioration,HO
173070058,Infliximab,General physical health deterioration,OT
173070058,Infliximab,General physical health deterioration,DS
173070058,Infliximab,Gastrointestinal disorder,HO
173070058,Infliximab,Gastrointestinal disorder,OT
173070058,Infliximab,Gastrointestinal disorder,DS
173070058,Infliximab,Folliculitis,HO
173070058,Infliximab,Folliculitis,OT
173070058,Infliximab,Folliculitis,DS
173070058,Infliximab,Fatigue,HO
173070058,Infliximab,Fatigue,OT
173070058,Infliximab,Fatigue,DS
173070058,Infliximab,Exposure during pregnancy,HO
173070058,Infliximab,Exposure during pregnancy,OT
173070058,Infliximab,Exposure during pregnancy,DS
173070058,Infliximab,Dyspnoea,HO
173070058,Infliximab,Dyspnoea,OT
173070058,Infliximab,Dyspnoea,DS
173070058,Infliximab,Duodenal ulcer perforation,HO
173070058,Infliximab,Duodenal ulcer perforation,OT
173070058,Infliximab,Duodenal ulcer perforation,DS
173070058,Infliximab,Drug intolerance,HO
173070058,Infliximab,Drug intolerance,OT
173070058,Infliximab,Drug intolerance,DS
173070058,Infliximab,Drug ineffective,HO
173070058,Infliximab,Drug ineffective,OT
173070058,Infliximab,Drug ineffective,DS
173070058,Infliximab,Drug hypersensitivity,HO
173070058,Infliximab,Drug hypersensitivity,OT
173070058,Infliximab,Drug hypersensitivity,DS
173070058,Infliximab,Discomfort,HO
173070058,Infliximab,Discomfort,OT
173070058,Infliximab,Discomfort,DS
173070058,Infliximab,Contusion,HO
173070058,Infliximab,Contusion,OT
173070058,Infliximab,Contusion,DS
173070058,Infliximab,Contraindicated product administered,HO
173070058,Infliximab,Contraindicated product administered,OT
173070058,Infliximab,Contraindicated product administered,DS
173070058,Infliximab,Confusional state,HO
173070058,Infliximab,Confusional state,OT
173070058,Infliximab,Confusional state,DS
173070058,Infliximab,Condition aggravated,HO
173070058,Infliximab,Condition aggravated,OT
173070058,Infliximab,Condition aggravated,DS
173070058,Infliximab,Chest pain,HO
173070058,Infliximab,Chest pain,OT
173070058,Infliximab,Chest pain,DS
173070058,Infliximab,Blister,HO
173070058,Infliximab,Blister,OT
173070058,Infliximab,Blister,DS
173070058,Infliximab,Arthropathy,HO
173070058,Infliximab,Arthropathy,OT
173070058,Infliximab,Arthropathy,DS
173070058,Infliximab,Arthralgia,HO
173070058,Infliximab,Arthralgia,OT
173070058,Infliximab,Arthralgia,DS
173070058,Infliximab,Anti-cyclic citrullinated peptide antibody positive,HO
173070058,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
173070058,Infliximab,Anti-cyclic citrullinated peptide antibody positive,DS
173070058,Infliximab,Alopecia,HO
173070058,Infliximab,Alopecia,OT
173070058,Infliximab,Alopecia,DS
173070058,Infliximab,Abdominal discomfort,HO
173070058,Infliximab,Abdominal discomfort,OT
173070058,Infliximab,Abdominal discomfort,DS
175199165,Infliximab,Weight increased,OT
175199165,Infliximab,Weight decreased,OT
175199165,Infliximab,Twin pregnancy,OT
175199165,Infliximab,Somnolence,OT
175199165,Infliximab,Skin lesion,OT
175199165,Infliximab,Scratch,OT
175199165,Infliximab,Rhinorrhoea,OT
175199165,Infliximab,Rectal haemorrhage,OT
175199165,Infliximab,Rash pruritic,OT
175199165,Infliximab,Pyrexia,OT
175199165,Infliximab,Pain in extremity,OT
175199165,Infliximab,Oxygen saturation abnormal,OT
175199165,Infliximab,Oropharyngeal pain,OT
175199165,Infliximab,Off label use,OT
175199165,Infliximab,Nausea,OT
175199165,Infliximab,Nasal congestion,OT
175199165,Infliximab,Maternal exposure during pregnancy,OT
175199165,Infliximab,Malaise,OT
175199165,Infliximab,Incorrect dose administered,OT
175199165,Infliximab,Heart rate irregular,OT
175199165,Infliximab,Heart rate increased,OT
175199165,Infliximab,Headache,OT
175199165,Infliximab,Haematochezia,OT
175199165,Infliximab,Fatigue,OT
175199165,Infliximab,Eczema,OT
175199165,Infliximab,Ear pain,OT
175199165,Infliximab,Dyspepsia,OT
175199165,Infliximab,Drug ineffective,OT
175199165,Infliximab,Decreased appetite,OT
175199165,Infliximab,Condition aggravated,OT
175199165,Infliximab,Colitis ulcerative,OT
175199165,Infliximab,Chest discomfort,OT
175199165,Infliximab,Body temperature fluctuation,OT
175199165,Infliximab,Body temperature decreased,OT
175590154,Infliximab,Wound,HO
175590154,Infliximab,Wound,OT
175590154,Infliximab,Uterine leiomyoma,HO
175590154,Infliximab,Uterine leiomyoma,OT
175590154,Infliximab,Therapeutic response shortened,HO
175590154,Infliximab,Therapeutic response shortened,OT
175590154,Infliximab,Swelling face,HO
175590154,Infliximab,Swelling face,OT
175590154,Infliximab,Secretion discharge,HO
175590154,Infliximab,Secretion discharge,OT
175590154,Infliximab,Rheumatoid arthritis,HO
175590154,Infliximab,Rheumatoid arthritis,OT
175590154,Infliximab,Respiratory syncytial virus infection,HO
175590154,Infliximab,Respiratory syncytial virus infection,OT
175590154,Infliximab,Pyrexia,HO
175590154,Infliximab,Pyrexia,OT
175590154,Infliximab,Pruritus,HO
175590154,Infliximab,Pruritus,OT
175590154,Infliximab,Productive cough,HO
175590154,Infliximab,Productive cough,OT
175590154,Infliximab,Pneumonia,HO
175590154,Infliximab,Pneumonia,OT
175590154,Infliximab,Palpitations,HO
175590154,Infliximab,Palpitations,OT
175590154,Infliximab,Off label use,HO
175590154,Infliximab,Off label use,OT
175590154,Infliximab,Nausea,HO
175590154,Infliximab,Nausea,OT
175590154,Infliximab,Nasal discomfort,HO
175590154,Infliximab,Nasal discomfort,OT
175590154,Infliximab,Malaise,HO
175590154,Infliximab,Malaise,OT
175590154,Infliximab,Lower respiratory tract infection,HO
175590154,Infliximab,Lower respiratory tract infection,OT
175590154,Infliximab,Joint swelling,HO
175590154,Infliximab,Joint swelling,OT
175590154,Infliximab,Inappropriate schedule of product administration,HO
175590154,Infliximab,Inappropriate schedule of product administration,OT
175590154,Infliximab,Heart rate increased,HO
175590154,Infliximab,Heart rate increased,OT
175590154,Infliximab,Headache,HO
175590154,Infliximab,Headache,OT
175590154,Infliximab,Gastrointestinal disorder,HO
175590154,Infliximab,Gastrointestinal disorder,OT
175590154,Infliximab,Gait inability,HO
175590154,Infliximab,Gait inability,OT
175590154,Infliximab,Fatigue,HO
175590154,Infliximab,Fatigue,OT
175590154,Infliximab,Ear infection,HO
175590154,Infliximab,Ear infection,OT
175590154,Infliximab,Dyspnoea,HO
175590154,Infliximab,Dyspnoea,OT
175590154,Infliximab,Cyst,HO
175590154,Infliximab,Cyst,OT
175590154,Infliximab,Condition aggravated,HO
175590154,Infliximab,Condition aggravated,OT
175590154,Infliximab,Chills,HO
175590154,Infliximab,Chills,OT
175590154,Infliximab,Chest pain,HO
175590154,Infliximab,Chest pain,OT
175590154,Infliximab,Blood pressure fluctuation,HO
175590154,Infliximab,Blood pressure fluctuation,OT
175590154,Infliximab,Arthralgia,HO
175590154,Infliximab,Arthralgia,OT
175590154,Infliximab,Acrochordon,HO
175590154,Infliximab,Acrochordon,OT
176232845,Infliximab,Perineal fistula,OT
176232845,Infliximab,Off label use,OT
176232845,Infliximab,Intentional product use issue,OT
176232845,Infliximab,Incorrect dose administered,OT
176232845,Infliximab,Inappropriate schedule of product administration,OT
176232845,Infliximab,Heart rate decreased,OT
176232845,Infliximab,Fatigue,OT
176232845,Infliximab,Drug level below therapeutic,OT
176232845,Infliximab,Drug ineffective,OT
176232845,Infliximab,Condition aggravated,OT
176232845,Infliximab,Blood pressure increased,OT
176232845,Infliximab,Blood pressure fluctuation,OT
176232845,Infliximab,Arthralgia,OT
176232845,Infliximab,Perineal fistula,OT
176232845,Infliximab,Off label use,OT
176232845,Infliximab,Intentional product use issue,OT
176232845,Infliximab,Incorrect dose administered,OT
176232845,Infliximab,Inappropriate schedule of product administration,OT
176232845,Infliximab,Heart rate decreased,OT
176232845,Infliximab,Fatigue,OT
176232845,Infliximab,Drug level below therapeutic,OT
176232845,Infliximab,Drug ineffective,OT
176232845,Infliximab,Condition aggravated,OT
176232845,Infliximab,Blood pressure increased,OT
176232845,Infliximab,Blood pressure fluctuation,OT
176232845,Infliximab,Arthralgia,OT
176232845,Infliximab,Perineal fistula,OT
176232845,Infliximab,Off label use,OT
176232845,Infliximab,Intentional product use issue,OT
176232845,Infliximab,Incorrect dose administered,OT
176232845,Infliximab,Inappropriate schedule of product administration,OT
176232845,Infliximab,Heart rate decreased,OT
176232845,Infliximab,Fatigue,OT
176232845,Infliximab,Drug level below therapeutic,OT
176232845,Infliximab,Drug ineffective,OT
176232845,Infliximab,Condition aggravated,OT
176232845,Infliximab,Blood pressure increased,OT
176232845,Infliximab,Blood pressure fluctuation,OT
176232845,Infliximab,Arthralgia,OT
176390006,Infliximab,Therapeutic product effect incomplete,OT
176390006,Infliximab,Product use issue,OT
176390006,Infliximab,Off label use,OT
176390006,Infliximab,Nasal congestion,OT
176390006,Infliximab,Intentional product use issue,OT
176390006,Infliximab,Inappropriate schedule of product administration,OT
176390006,Infliximab,Heart rate abnormal,OT
176390006,Infliximab,Gastritis,OT
176390006,Infliximab,Condition aggravated,OT
176390006,Infliximab,Body temperature decreased,OT
176390006,Infliximab,Blood pressure increased,OT
176390006,Infliximab,Blood pressure fluctuation,OT
176390006,Infliximab,Therapeutic product effect incomplete,OT
176390006,Infliximab,Product use issue,OT
176390006,Infliximab,Off label use,OT
176390006,Infliximab,Nasal congestion,OT
176390006,Infliximab,Intentional product use issue,OT
176390006,Infliximab,Inappropriate schedule of product administration,OT
176390006,Infliximab,Heart rate abnormal,OT
176390006,Infliximab,Gastritis,OT
176390006,Infliximab,Condition aggravated,OT
176390006,Infliximab,Body temperature decreased,OT
176390006,Infliximab,Blood pressure increased,OT
176390006,Infliximab,Blood pressure fluctuation,OT
176545264,Infliximab,Pain,OT
176545264,Infliximab,Off label use,OT
176545264,Infliximab,Nasopharyngitis,OT
176545264,Infliximab,Muscle spasms,OT
176545264,Infliximab,Malaise,OT
176545264,Infliximab,Intentional product use issue,OT
176545264,Infliximab,Inflammation,OT
176545264,Infliximab,Incorrect dose administered,OT
176545264,Infliximab,Inappropriate schedule of product administration,OT
176545264,Infliximab,Hypersensitivity,OT
176545264,Infliximab,Dyspnoea exertional,OT
176545264,Infliximab,Dysgeusia,OT
176545264,Infliximab,Condition aggravated,OT
176545264,Infliximab,C-reactive protein increased,OT
176545264,Infliximab,Body temperature decreased,OT
176545264,Infliximab,Blood pressure increased,OT
176545264,Infliximab,Blood pressure fluctuation,OT
176545264,Infliximab,Alanine aminotransferase increased,OT
176545264,Infliximab,Abdominal pain lower,OT
176545264,Infliximab,Abdominal distension,OT
176545264,Infliximab,Pain,OT
176545264,Infliximab,Off label use,OT
176545264,Infliximab,Nasopharyngitis,OT
176545264,Infliximab,Muscle spasms,OT
176545264,Infliximab,Malaise,OT
176545264,Infliximab,Intentional product use issue,OT
176545264,Infliximab,Inflammation,OT
176545264,Infliximab,Incorrect dose administered,OT
176545264,Infliximab,Inappropriate schedule of product administration,OT
176545264,Infliximab,Hypersensitivity,OT
176545264,Infliximab,Dyspnoea exertional,OT
176545264,Infliximab,Dysgeusia,OT
176545264,Infliximab,Condition aggravated,OT
176545264,Infliximab,C-reactive protein increased,OT
176545264,Infliximab,Body temperature decreased,OT
176545264,Infliximab,Blood pressure increased,OT
176545264,Infliximab,Blood pressure fluctuation,OT
176545264,Infliximab,Alanine aminotransferase increased,OT
176545264,Infliximab,Abdominal pain lower,OT
176545264,Infliximab,Abdominal distension,OT
176580274,Infliximab,Wound,OT
176580274,Infliximab,Wound,HO
176580274,Infliximab,Weight increased,OT
176580274,Infliximab,Weight increased,HO
176580274,Infliximab,Weight decreased,OT
176580274,Infliximab,Weight decreased,HO
176580274,Infliximab,Visual impairment,OT
176580274,Infliximab,Visual impairment,HO
176580274,Infliximab,Vision blurred,OT
176580274,Infliximab,Vision blurred,HO
176580274,Infliximab,Tremor,OT
176580274,Infliximab,Tremor,HO
176580274,Infliximab,Systolic hypertension,OT
176580274,Infliximab,Systolic hypertension,HO
176580274,Infliximab,Stomatitis,OT
176580274,Infliximab,Stomatitis,HO
176580274,Infliximab,Pruritus,OT
176580274,Infliximab,Pruritus,HO
176580274,Infliximab,Off label use,OT
176580274,Infliximab,Off label use,HO
176580274,Infliximab,Nausea,OT
176580274,Infliximab,Nausea,HO
176580274,Infliximab,Muscle tightness,OT
176580274,Infliximab,Muscle tightness,HO
176580274,Infliximab,Infection,OT
176580274,Infliximab,Infection,HO
176580274,Infliximab,Incorrect dose administered,OT
176580274,Infliximab,Incorrect dose administered,HO
176580274,Infliximab,Hyperhidrosis,OT
176580274,Infliximab,Hyperhidrosis,HO
176580274,Infliximab,Headache,OT
176580274,Infliximab,Headache,HO
176580274,Infliximab,Dry eye,OT
176580274,Infliximab,Dry eye,HO
176580274,Infliximab,Drug level increased,OT
176580274,Infliximab,Drug level increased,HO
176580274,Infliximab,Drug ineffective,OT
176580274,Infliximab,Drug ineffective,HO
176580274,Infliximab,Diarrhoea,OT
176580274,Infliximab,Diarrhoea,HO
176580274,Infliximab,Condition aggravated,OT
176580274,Infliximab,Condition aggravated,HO
176580274,Infliximab,Blood pressure fluctuation,OT
176580274,Infliximab,Blood pressure fluctuation,HO
176580274,Infliximab,Blood glucose increased,OT
176580274,Infliximab,Blood glucose increased,HO
176580274,Infliximab,Wound,OT
176580274,Infliximab,Wound,HO
176580274,Infliximab,Weight increased,OT
176580274,Infliximab,Weight increased,HO
176580274,Infliximab,Weight decreased,OT
176580274,Infliximab,Weight decreased,HO
176580274,Infliximab,Visual impairment,OT
176580274,Infliximab,Visual impairment,HO
176580274,Infliximab,Vision blurred,OT
176580274,Infliximab,Vision blurred,HO
176580274,Infliximab,Tremor,OT
176580274,Infliximab,Tremor,HO
176580274,Infliximab,Systolic hypertension,OT
176580274,Infliximab,Systolic hypertension,HO
176580274,Infliximab,Stomatitis,OT
176580274,Infliximab,Stomatitis,HO
176580274,Infliximab,Pruritus,OT
176580274,Infliximab,Pruritus,HO
176580274,Infliximab,Off label use,OT
176580274,Infliximab,Off label use,HO
176580274,Infliximab,Nausea,OT
176580274,Infliximab,Nausea,HO
176580274,Infliximab,Muscle tightness,OT
176580274,Infliximab,Muscle tightness,HO
176580274,Infliximab,Infection,OT
176580274,Infliximab,Infection,HO
176580274,Infliximab,Incorrect dose administered,OT
176580274,Infliximab,Incorrect dose administered,HO
176580274,Infliximab,Hyperhidrosis,OT
176580274,Infliximab,Hyperhidrosis,HO
176580274,Infliximab,Headache,OT
176580274,Infliximab,Headache,HO
176580274,Infliximab,Dry eye,OT
176580274,Infliximab,Dry eye,HO
176580274,Infliximab,Drug level increased,OT
176580274,Infliximab,Drug level increased,HO
176580274,Infliximab,Drug ineffective,OT
176580274,Infliximab,Drug ineffective,HO
176580274,Infliximab,Diarrhoea,OT
176580274,Infliximab,Diarrhoea,HO
176580274,Infliximab,Condition aggravated,OT
176580274,Infliximab,Condition aggravated,HO
176580274,Infliximab,Blood pressure fluctuation,OT
176580274,Infliximab,Blood pressure fluctuation,HO
176580274,Infliximab,Blood glucose increased,OT
176580274,Infliximab,Blood glucose increased,HO
176938635,Infliximab,Vomiting,OT
176938635,Infliximab,Rhinorrhoea,OT
176938635,Infliximab,Pruritus,OT
176938635,Infliximab,Pneumonia,OT
176938635,Infliximab,Off label use,OT
176938635,Infliximab,Nausea,OT
176938635,Infliximab,Nasopharyngitis,OT
176938635,Infliximab,Nasal congestion,OT
176938635,Infliximab,Migraine,OT
176938635,Infliximab,Inappropriate schedule of product administration,OT
176938635,Infliximab,Hot flush,OT
176938635,Infliximab,Headache,OT
176938635,Infliximab,Fatigue,OT
176938635,Infliximab,Dizziness,OT
176938635,Infliximab,Condition aggravated,OT
176938635,Infliximab,Body temperature fluctuation,OT
176938635,Infliximab,Blood pressure increased,OT
176938635,Infliximab,Blood pressure fluctuation,OT
176938635,Infliximab,Acne,OT
176938635,Infliximab,Vomiting,OT
176938635,Infliximab,Rhinorrhoea,OT
176938635,Infliximab,Pruritus,OT
176938635,Infliximab,Pneumonia,OT
176938635,Infliximab,Off label use,OT
176938635,Infliximab,Nausea,OT
176938635,Infliximab,Nasopharyngitis,OT
176938635,Infliximab,Nasal congestion,OT
176938635,Infliximab,Migraine,OT
176938635,Infliximab,Inappropriate schedule of product administration,OT
176938635,Infliximab,Hot flush,OT
176938635,Infliximab,Headache,OT
176938635,Infliximab,Fatigue,OT
176938635,Infliximab,Dizziness,OT
176938635,Infliximab,Condition aggravated,OT
176938635,Infliximab,Body temperature fluctuation,OT
176938635,Infliximab,Blood pressure increased,OT
176938635,Infliximab,Blood pressure fluctuation,OT
176938635,Infliximab,Acne,OT
182608522,Infliximab,Weight decreased,OT
182608522,Infliximab,Weight decreased,HO
182608522,Infliximab,Urinary tract infection,OT
182608522,Infliximab,Urinary tract infection,HO
182608522,Infliximab,Pyrexia,OT
182608522,Infliximab,Pyrexia,HO
182608522,Infliximab,Nephrolithiasis,OT
182608522,Infliximab,Nephrolithiasis,HO
182608522,Infliximab,Condition aggravated,OT
182608522,Infliximab,Condition aggravated,HO
182608522,Infliximab,Chills,OT
182608522,Infliximab,Chills,HO
182608522,Infliximab,Angina pectoris,OT
182608522,Infliximab,Angina pectoris,HO
182608522,Infliximab,Weight decreased,OT
182608522,Infliximab,Weight decreased,HO
182608522,Infliximab,Urinary tract infection,OT
182608522,Infliximab,Urinary tract infection,HO
182608522,Infliximab,Pyrexia,OT
182608522,Infliximab,Pyrexia,HO
182608522,Infliximab,Nephrolithiasis,OT
182608522,Infliximab,Nephrolithiasis,HO
182608522,Infliximab,Condition aggravated,OT
182608522,Infliximab,Condition aggravated,HO
182608522,Infliximab,Chills,OT
182608522,Infliximab,Chills,HO
182608522,Infliximab,Angina pectoris,OT
182608522,Infliximab,Angina pectoris,HO
183617112,Infliximab,Product use issue,OT
183617112,Infliximab,Off label use,OT
183617112,Infliximab,Intentional product use issue,OT
183617112,Infliximab,Condition aggravated,OT
183617112,Infliximab,Arthralgia,OT
183617112,Infliximab,Ankylosing spondylitis,OT
183617112,Infliximab,Product use issue,OT
183617112,Infliximab,Off label use,OT
183617112,Infliximab,Intentional product use issue,OT
183617112,Infliximab,Condition aggravated,OT
183617112,Infliximab,Arthralgia,OT
183617112,Infliximab,Ankylosing spondylitis,OT
184059572,Infliximab,Weight decreased,HO
184059572,Infliximab,Weight decreased,OT
184059572,Infliximab,Tachycardia,HO
184059572,Infliximab,Tachycardia,OT
184059572,Infliximab,Skin reaction,HO
184059572,Infliximab,Skin reaction,OT
184059572,Infliximab,Pyrexia,HO
184059572,Infliximab,Pyrexia,OT
184059572,Infliximab,Pulmonary pain,HO
184059572,Infliximab,Pulmonary pain,OT
184059572,Infliximab,Pruritus,HO
184059572,Infliximab,Pruritus,OT
184059572,Infliximab,Product use issue,HO
184059572,Infliximab,Product use issue,OT
184059572,Infliximab,Pneumonia,HO
184059572,Infliximab,Pneumonia,OT
184059572,Infliximab,Pharyngitis streptococcal,HO
184059572,Infliximab,Pharyngitis streptococcal,OT
184059572,Infliximab,Pain in extremity,HO
184059572,Infliximab,Pain in extremity,OT
184059572,Infliximab,Oral pruritus,HO
184059572,Infliximab,Oral pruritus,OT
184059572,Infliximab,Off label use,HO
184059572,Infliximab,Off label use,OT
184059572,Infliximab,Malaise,HO
184059572,Infliximab,Malaise,OT
184059572,Infliximab,Lower respiratory tract infection,HO
184059572,Infliximab,Lower respiratory tract infection,OT
184059572,Infliximab,Intentional product use issue,HO
184059572,Infliximab,Intentional product use issue,OT
184059572,Infliximab,Influenza,HO
184059572,Infliximab,Influenza,OT
184059572,Infliximab,Inappropriate schedule of product administration,HO
184059572,Infliximab,Inappropriate schedule of product administration,OT
184059572,Infliximab,Hypertension,HO
184059572,Infliximab,Hypertension,OT
184059572,Infliximab,Hernia,HO
184059572,Infliximab,Hernia,OT
184059572,Infliximab,Haematochezia,HO
184059572,Infliximab,Haematochezia,OT
184059572,Infliximab,Dehydration,HO
184059572,Infliximab,Dehydration,OT
184059572,Infliximab,Colitis ulcerative,HO
184059572,Infliximab,Colitis ulcerative,OT
184059572,Infliximab,Blood pressure increased,HO
184059572,Infliximab,Blood pressure increased,OT
184059572,Infliximab,Blood pressure fluctuation,HO
184059572,Infliximab,Blood pressure fluctuation,OT
184059572,Infliximab,Weight decreased,HO
184059572,Infliximab,Weight decreased,OT
184059572,Infliximab,Tachycardia,HO
184059572,Infliximab,Tachycardia,OT
184059572,Infliximab,Skin reaction,HO
184059572,Infliximab,Skin reaction,OT
184059572,Infliximab,Pyrexia,HO
184059572,Infliximab,Pyrexia,OT
184059572,Infliximab,Pulmonary pain,HO
184059572,Infliximab,Pulmonary pain,OT
184059572,Infliximab,Pruritus,HO
184059572,Infliximab,Pruritus,OT
184059572,Infliximab,Product use issue,HO
184059572,Infliximab,Product use issue,OT
184059572,Infliximab,Pneumonia,HO
184059572,Infliximab,Pneumonia,OT
184059572,Infliximab,Pharyngitis streptococcal,HO
184059572,Infliximab,Pharyngitis streptococcal,OT
184059572,Infliximab,Pain in extremity,HO
184059572,Infliximab,Pain in extremity,OT
184059572,Infliximab,Oral pruritus,HO
184059572,Infliximab,Oral pruritus,OT
184059572,Infliximab,Off label use,HO
184059572,Infliximab,Off label use,OT
184059572,Infliximab,Malaise,HO
184059572,Infliximab,Malaise,OT
184059572,Infliximab,Lower respiratory tract infection,HO
184059572,Infliximab,Lower respiratory tract infection,OT
184059572,Infliximab,Intentional product use issue,HO
184059572,Infliximab,Intentional product use issue,OT
184059572,Infliximab,Influenza,HO
184059572,Infliximab,Influenza,OT
184059572,Infliximab,Inappropriate schedule of product administration,HO
184059572,Infliximab,Inappropriate schedule of product administration,OT
184059572,Infliximab,Hypertension,HO
184059572,Infliximab,Hypertension,OT
184059572,Infliximab,Hernia,HO
184059572,Infliximab,Hernia,OT
184059572,Infliximab,Haematochezia,HO
184059572,Infliximab,Haematochezia,OT
184059572,Infliximab,Dehydration,HO
184059572,Infliximab,Dehydration,OT
184059572,Infliximab,Colitis ulcerative,HO
184059572,Infliximab,Colitis ulcerative,OT
184059572,Infliximab,Blood pressure increased,HO
184059572,Infliximab,Blood pressure increased,OT
184059572,Infliximab,Blood pressure fluctuation,HO
184059572,Infliximab,Blood pressure fluctuation,OT
184059572,Infliximab,Weight decreased,HO
184059572,Infliximab,Weight decreased,OT
184059572,Infliximab,Tachycardia,HO
184059572,Infliximab,Tachycardia,OT
184059572,Infliximab,Skin reaction,HO
184059572,Infliximab,Skin reaction,OT
184059572,Infliximab,Pyrexia,HO
184059572,Infliximab,Pyrexia,OT
184059572,Infliximab,Pulmonary pain,HO
184059572,Infliximab,Pulmonary pain,OT
184059572,Infliximab,Pruritus,HO
184059572,Infliximab,Pruritus,OT
184059572,Infliximab,Product use issue,HO
184059572,Infliximab,Product use issue,OT
184059572,Infliximab,Pneumonia,HO
184059572,Infliximab,Pneumonia,OT
184059572,Infliximab,Pharyngitis streptococcal,HO
184059572,Infliximab,Pharyngitis streptococcal,OT
184059572,Infliximab,Pain in extremity,HO
184059572,Infliximab,Pain in extremity,OT
184059572,Infliximab,Oral pruritus,HO
184059572,Infliximab,Oral pruritus,OT
184059572,Infliximab,Off label use,HO
184059572,Infliximab,Off label use,OT
184059572,Infliximab,Malaise,HO
184059572,Infliximab,Malaise,OT
184059572,Infliximab,Lower respiratory tract infection,HO
184059572,Infliximab,Lower respiratory tract infection,OT
184059572,Infliximab,Intentional product use issue,HO
184059572,Infliximab,Intentional product use issue,OT
184059572,Infliximab,Influenza,HO
184059572,Infliximab,Influenza,OT
184059572,Infliximab,Inappropriate schedule of product administration,HO
184059572,Infliximab,Inappropriate schedule of product administration,OT
184059572,Infliximab,Hypertension,HO
184059572,Infliximab,Hypertension,OT
184059572,Infliximab,Hernia,HO
184059572,Infliximab,Hernia,OT
184059572,Infliximab,Haematochezia,HO
184059572,Infliximab,Haematochezia,OT
184059572,Infliximab,Dehydration,HO
184059572,Infliximab,Dehydration,OT
184059572,Infliximab,Colitis ulcerative,HO
184059572,Infliximab,Colitis ulcerative,OT
184059572,Infliximab,Blood pressure increased,HO
184059572,Infliximab,Blood pressure increased,OT
184059572,Infliximab,Blood pressure fluctuation,HO
184059572,Infliximab,Blood pressure fluctuation,OT
184059572,Infliximab,Weight decreased,HO
184059572,Infliximab,Weight decreased,OT
184059572,Infliximab,Tachycardia,HO
184059572,Infliximab,Tachycardia,OT
184059572,Infliximab,Skin reaction,HO
184059572,Infliximab,Skin reaction,OT
184059572,Infliximab,Pyrexia,HO
184059572,Infliximab,Pyrexia,OT
184059572,Infliximab,Pulmonary pain,HO
184059572,Infliximab,Pulmonary pain,OT
184059572,Infliximab,Pruritus,HO
184059572,Infliximab,Pruritus,OT
184059572,Infliximab,Product use issue,HO
184059572,Infliximab,Product use issue,OT
184059572,Infliximab,Pneumonia,HO
184059572,Infliximab,Pneumonia,OT
184059572,Infliximab,Pharyngitis streptococcal,HO
184059572,Infliximab,Pharyngitis streptococcal,OT
184059572,Infliximab,Pain in extremity,HO
184059572,Infliximab,Pain in extremity,OT
184059572,Infliximab,Oral pruritus,HO
184059572,Infliximab,Oral pruritus,OT
184059572,Infliximab,Off label use,HO
184059572,Infliximab,Off label use,OT
184059572,Infliximab,Malaise,HO
184059572,Infliximab,Malaise,OT
184059572,Infliximab,Lower respiratory tract infection,HO
184059572,Infliximab,Lower respiratory tract infection,OT
184059572,Infliximab,Intentional product use issue,HO
184059572,Infliximab,Intentional product use issue,OT
184059572,Infliximab,Influenza,HO
184059572,Infliximab,Influenza,OT
184059572,Infliximab,Inappropriate schedule of product administration,HO
184059572,Infliximab,Inappropriate schedule of product administration,OT
184059572,Infliximab,Hypertension,HO
184059572,Infliximab,Hypertension,OT
184059572,Infliximab,Hernia,HO
184059572,Infliximab,Hernia,OT
184059572,Infliximab,Haematochezia,HO
184059572,Infliximab,Haematochezia,OT
184059572,Infliximab,Dehydration,HO
184059572,Infliximab,Dehydration,OT
184059572,Infliximab,Colitis ulcerative,HO
184059572,Infliximab,Colitis ulcerative,OT
184059572,Infliximab,Blood pressure increased,HO
184059572,Infliximab,Blood pressure increased,OT
184059572,Infliximab,Blood pressure fluctuation,HO
184059572,Infliximab,Blood pressure fluctuation,OT
184379204,Infliximab,Wound secretion,OT
184379204,Infliximab,Wound,OT
184379204,Infliximab,Weight increased,OT
184379204,Infliximab,Weight decreased,OT
184379204,Infliximab,Vision blurred,OT
184379204,Infliximab,Toothache,OT
184379204,Infliximab,Tooth abscess,OT
184379204,Infliximab,Somnolence,OT
184379204,Infliximab,Skin plaque,OT
184379204,Infliximab,Sinusitis,OT
184379204,Infliximab,Rhinorrhoea,OT
184379204,Infliximab,Pyrexia,OT
184379204,Infliximab,Pruritus,OT
184379204,Infliximab,Periorbital oedema,OT
184379204,Infliximab,Oropharyngeal pain,OT
184379204,Infliximab,Off label use,OT
184379204,Infliximab,Muscular weakness,OT
184379204,Infliximab,Intentional product use issue,OT
184379204,Infliximab,Influenza,OT
184379204,Infliximab,Incorrect dose administered,OT
184379204,Infliximab,Inappropriate schedule of product administration,OT
184379204,Infliximab,Hypoaesthesia,OT
184379204,Infliximab,Hyperthermia,OT
184379204,Infliximab,Hot flush,OT
184379204,Infliximab,Heart rate increased,OT
184379204,Infliximab,Heart rate abnormal,OT
184379204,Infliximab,Frequent bowel movements,OT
184379204,Infliximab,Fatigue,OT
184379204,Infliximab,Fall,OT
184379204,Infliximab,Diarrhoea,OT
184379204,Infliximab,Decreased appetite,OT
184379204,Infliximab,Cough,OT
184379204,Infliximab,Cold sweat,OT
184379204,Infliximab,Body temperature increased,OT
184379204,Infliximab,Blood pressure fluctuation,OT
184379204,Infliximab,Asthenia,OT
184379204,Infliximab,Abdominal pain upper,OT
184688032,Infliximab,Weight decreased,OT
184688032,Infliximab,Weight decreased,HO
184688032,Infliximab,Vomiting,OT
184688032,Infliximab,Vomiting,HO
184688032,Infliximab,Viral infection,OT
184688032,Infliximab,Viral infection,HO
184688032,Infliximab,Uveitis,OT
184688032,Infliximab,Uveitis,HO
184688032,Infliximab,Urinary tract infection,OT
184688032,Infliximab,Urinary tract infection,HO
184688032,Infliximab,Upper-airway cough syndrome,OT
184688032,Infliximab,Upper-airway cough syndrome,HO
184688032,Infliximab,Stress,OT
184688032,Infliximab,Stress,HO
184688032,Infliximab,Sneezing,OT
184688032,Infliximab,Sneezing,HO
184688032,Infliximab,Skin laceration,OT
184688032,Infliximab,Skin laceration,HO
184688032,Infliximab,Sinusitis,OT
184688032,Infliximab,Sinusitis,HO
184688032,Infliximab,Secretion discharge,OT
184688032,Infliximab,Secretion discharge,HO
184688032,Infliximab,Rhinorrhoea,OT
184688032,Infliximab,Rhinorrhoea,HO
184688032,Infliximab,Rash,OT
184688032,Infliximab,Rash,HO
184688032,Infliximab,Oropharyngeal pain,OT
184688032,Infliximab,Oropharyngeal pain,HO
184688032,Infliximab,Off label use,OT
184688032,Infliximab,Off label use,HO
184688032,Infliximab,Nausea,OT
184688032,Infliximab,Nausea,HO
184688032,Infliximab,Nasopharyngitis,OT
184688032,Infliximab,Nasopharyngitis,HO
184688032,Infliximab,Myalgia,OT
184688032,Infliximab,Myalgia,HO
184688032,Infliximab,Muscle spasms,OT
184688032,Infliximab,Muscle spasms,HO
184688032,Infliximab,Mouth ulceration,OT
184688032,Infliximab,Mouth ulceration,HO
184688032,Infliximab,Menstrual disorder,OT
184688032,Infliximab,Menstrual disorder,HO
184688032,Infliximab,Malaise,OT
184688032,Infliximab,Malaise,HO
184688032,Infliximab,Infusion site pruritus,OT
184688032,Infliximab,Infusion site pruritus,HO
184688032,Infliximab,Influenza,OT
184688032,Infliximab,Influenza,HO
184688032,Infliximab,Hypersensitivity,OT
184688032,Infliximab,Hypersensitivity,HO
184688032,Infliximab,Heart rate irregular,OT
184688032,Infliximab,Heart rate irregular,HO
184688032,Infliximab,Haemorrhage,OT
184688032,Infliximab,Haemorrhage,HO
184688032,Infliximab,Food poisoning,OT
184688032,Infliximab,Food poisoning,HO
184688032,Infliximab,Fistula,OT
184688032,Infliximab,Fistula,HO
184688032,Infliximab,Feeling hot,OT
184688032,Infliximab,Feeling hot,HO
184688032,Infliximab,Fatigue,OT
184688032,Infliximab,Fatigue,HO
184688032,Infliximab,Drug level below therapeutic,OT
184688032,Infliximab,Drug level below therapeutic,HO
184688032,Infliximab,Dizziness,OT
184688032,Infliximab,Dizziness,HO
184688032,Infliximab,Diarrhoea,OT
184688032,Infliximab,Diarrhoea,HO
184688032,Infliximab,Cough,OT
184688032,Infliximab,Cough,HO
184688032,Infliximab,Condition aggravated,OT
184688032,Infliximab,Condition aggravated,HO
184688032,Infliximab,Body temperature increased,OT
184688032,Infliximab,Body temperature increased,HO
184688032,Infliximab,Arthralgia,OT
184688032,Infliximab,Arthralgia,HO
184688032,Infliximab,Antibody test positive,OT
184688032,Infliximab,Antibody test positive,HO
184688032,Infliximab,Anal fissure,OT
184688032,Infliximab,Anal fissure,HO
184688032,Infliximab,Abscess,OT
184688032,Infliximab,Abscess,HO
184688032,Infliximab,Abdominal pain,OT
184688032,Infliximab,Abdominal pain,HO
185046333,Infliximab,Thrombosis,OT
185046333,Infliximab,Off label use,OT
185046333,Infliximab,Intentional product use issue,OT
185046333,Infliximab,Inappropriate schedule of product administration,OT
185046333,Infliximab,Heart rate irregular,OT
185046333,Infliximab,Heart rate decreased,OT
185046333,Infliximab,Blood pressure increased,OT
185046333,Infliximab,Blood pressure fluctuation,OT
185046333,Infliximab,Thrombosis,OT
185046333,Infliximab,Off label use,OT
185046333,Infliximab,Intentional product use issue,OT
185046333,Infliximab,Inappropriate schedule of product administration,OT
185046333,Infliximab,Heart rate irregular,OT
185046333,Infliximab,Heart rate decreased,OT
185046333,Infliximab,Blood pressure increased,OT
185046333,Infliximab,Blood pressure fluctuation,OT
191952032,Infliximab,Weight increased,OT
191952032,Infliximab,Weight decreased,OT
191952032,Infliximab,Product use issue,OT
191952032,Infliximab,Poor venous access,OT
191952032,Infliximab,Pain in extremity,OT
191952032,Infliximab,Off label use,OT
191952032,Infliximab,Obesity,OT
191952032,Infliximab,Menstrual discomfort,OT
191952032,Infliximab,Malaise,OT
191952032,Infliximab,Intentional product use issue,OT
191952032,Infliximab,Incorrect dose administered,OT
191952032,Infliximab,Inappropriate schedule of product administration,OT
191952032,Infliximab,Hypoaesthesia,OT
191952032,Infliximab,Condition aggravated,OT
191952032,Infliximab,Blood pressure increased,OT
192573472,Infliximab,Loss of personal independence in daily activities,HO
192573472,Infliximab,Hypertension,HO
192573472,Infliximab,Drug level below therapeutic,HO
192573472,Infliximab,Condition aggravated,HO
192629852,Infliximab,Peripheral swelling,OT
192629852,Infliximab,Off label use,OT
192629852,Infliximab,Joint swelling,OT
192629852,Infliximab,Intentional product use issue,OT
192629852,Infliximab,Incorrect dose administered,OT
192629852,Infliximab,Blood pressure diastolic decreased,OT
194980121,Infliximab,Weight increased,HO
194980121,Infliximab,Weight decreased,HO
194980121,Infliximab,Food poisoning,HO
194980121,Infliximab,Blood pressure diastolic decreased,HO
195720451,Infliximab,Weight increased,OT
195720451,Infliximab,Respiratory rate increased,OT
195720451,Infliximab,Pyrexia,OT
195720451,Infliximab,Pruritus,OT
195720451,Infliximab,Pallor,OT
195720451,Infliximab,Oxygen saturation decreased,OT
195720451,Infliximab,Nervousness,OT
195720451,Infliximab,Nausea,OT
195720451,Infliximab,Malaise,OT
195720451,Infliximab,Insomnia,OT
195720451,Infliximab,Infusion related reaction,OT
195720451,Infliximab,Incorrect dose administered,OT
195720451,Infliximab,Inappropriate schedule of product administration,OT
195720451,Infliximab,Feeling hot,OT
195720451,Infliximab,Fatigue,OT
195720451,Infliximab,Dizziness,OT
195720451,Infliximab,Cold sweat,OT
195720451,Infliximab,Chills,OT
195720451,Infliximab,Blood pressure increased,OT
195720451,Infliximab,Blood pressure fluctuation,OT
195720451,Infliximab,Abdominal pain upper,OT
195720451,Infliximab,Weight increased,OT
195720451,Infliximab,Respiratory rate increased,OT
195720451,Infliximab,Pyrexia,OT
195720451,Infliximab,Pruritus,OT
195720451,Infliximab,Pallor,OT
195720451,Infliximab,Oxygen saturation decreased,OT
195720451,Infliximab,Nervousness,OT
195720451,Infliximab,Nausea,OT
195720451,Infliximab,Malaise,OT
195720451,Infliximab,Insomnia,OT
195720451,Infliximab,Infusion related reaction,OT
195720451,Infliximab,Incorrect dose administered,OT
195720451,Infliximab,Inappropriate schedule of product administration,OT
195720451,Infliximab,Feeling hot,OT
195720451,Infliximab,Fatigue,OT
195720451,Infliximab,Dizziness,OT
195720451,Infliximab,Cold sweat,OT
195720451,Infliximab,Chills,OT
195720451,Infliximab,Blood pressure increased,OT
195720451,Infliximab,Blood pressure fluctuation,OT
195720451,Infliximab,Abdominal pain upper,OT
196105641,Infliximab,Meningitis listeria,HO
196105641,Infliximab,Meningitis listeria,OT
196105641,Infliximab,Crohn's disease,HO
196105641,Infliximab,Crohn's disease,OT
196150471,Infliximab,Rash papular,OT
196150471,Infliximab,Pyrexia,OT
196150471,Infliximab,Myalgia,OT
196150471,Infliximab,Dyspnoea,OT
196150471,Infliximab,Drug specific antibody present,OT
196150471,Infliximab,Drug level below therapeutic,OT
196150471,Infliximab,Chest pain,OT
196150471,Infliximab,Arthralgia,OT
196150471,Infliximab,Rash papular,OT
196150471,Infliximab,Pyrexia,OT
196150471,Infliximab,Myalgia,OT
196150471,Infliximab,Dyspnoea,OT
196150471,Infliximab,Drug specific antibody present,OT
196150471,Infliximab,Drug level below therapeutic,OT
196150471,Infliximab,Chest pain,OT
196150471,Infliximab,Arthralgia,OT
196204891,Infliximab,Drug ineffective,HO
196391311,Infliximab,Weight increased,OT
196391311,Infliximab,Weight decreased,OT
196391311,Infliximab,Product use issue,OT
196391311,Infliximab,Off label use,OT
196391311,Infliximab,Intentional product use issue,OT
196391311,Infliximab,Incorrect dose administered,OT
196391311,Infliximab,Inappropriate schedule of product administration,OT
196391311,Infliximab,Heart rate decreased,OT
196391311,Infliximab,Blood pressure increased,OT
196518181,Infliximab,Off label use,OT
196518181,Infliximab,Intentional product use issue,OT
196518181,Infliximab,Glomerulonephritis,OT
196518181,Infliximab,Blood pressure increased,OT
196518181,Infliximab,Ankylosing spondylitis,OT
197105101,Infliximab,Wound,OT
197105101,Infliximab,Weight increased,OT
197105101,Infliximab,Rash,OT
197105101,Infliximab,Off label use,OT
197105101,Infliximab,Metastases to bone,OT
197105101,Infliximab,Lymphoma,OT
197105101,Infliximab,Intentional product use issue,OT
197105101,Infliximab,Condition aggravated,OT
197105101,Infliximab,Bone cancer,OT
197105101,Infliximab,Body temperature abnormal,OT
197146861,Infliximab,Premature delivery,DE
197146861,Infliximab,Premature delivery,OT
197146861,Infliximab,Exposure during pregnancy,DE
197146861,Infliximab,Exposure during pregnancy,OT
197146861,Infliximab,Death,DE
197146861,Infliximab,Death,OT
197247291,Infliximab (Unknown),Angioedema,OT
197521272,Infliximab,Skin reaction,HO
197521272,Infliximab,Drug ineffective,HO
197697901,Infliximab,Rash,HO
197697901,Infliximab,Product use issue,HO
197697901,Infliximab,Off label use,HO
197697901,Infliximab,Mental disorder,HO
197697901,Infliximab,Inappropriate schedule of product administration,HO
197697901,Infliximab,Fistula,HO
197697901,Infliximab,Fatigue,HO
197697901,Infliximab,Condition aggravated,HO
197697901,Infliximab,Anal fissure,HO
197829322,Infliximab,Maternal exposure during pregnancy,OT
197829322,Infliximab,Hypersensitivity,OT
197829322,Infliximab,Gastrointestinal disorder,OT
197829322,Infliximab,Drug ineffective,OT
198056581,Infliximab,Weight increased,OT
198056581,Infliximab,Therapeutic response shortened,OT
198056581,Infliximab,Off label use,OT
198056581,Infliximab,Intentional product use issue,OT
198056581,Infliximab,Inappropriate schedule of product administration,OT
198056581,Infliximab,Condition aggravated,OT
198213231,Infliximab,Immune reconstitution inflammatory syndrome,OT
198213231,Infliximab,Hepatitis B reactivation,OT
198298441,Infliximab,Weight increased,HO
198298441,Infliximab,Weight increased,OT
198298441,Infliximab,Weight decreased,HO
198298441,Infliximab,Weight decreased,OT
198298441,Infliximab,Pulmonary oedema,HO
198298441,Infliximab,Pulmonary oedema,OT
198298441,Infliximab,Pancreatitis,HO
198298441,Infliximab,Pancreatitis,OT
198298441,Infliximab,Oligoarthritis,HO
198298441,Infliximab,Oligoarthritis,OT
198298441,Infliximab,Off label use,HO
198298441,Infliximab,Off label use,OT
198298441,Infliximab,Intentional product use issue,HO
198298441,Infliximab,Intentional product use issue,OT
198298441,Infliximab,Condition aggravated,HO
198298441,Infliximab,Condition aggravated,OT
198298441,Infliximab,Cholelithiasis,HO
198298441,Infliximab,Cholelithiasis,OT
198333131,Infliximab Hospira,Oesophageal fibrosis,OT
198333131,Infliximab Hospira,Oesophageal fibrosis,HO
198333131,Infliximab Hospira,Dysphagia,OT
198333131,Infliximab Hospira,Dysphagia,HO
198351111,Infliximab,Salmonella bacteraemia,HO
198351111,Infliximab,Pyrexia,HO
198351111,Infliximab,Pulmonary embolism,HO
198351111,Infliximab,Infusion site swelling,HO
198351111,Infliximab,Infusion site pain,HO
198351111,Infliximab,Infusion site extravasation,HO
198351111,Infliximab,Inappropriate schedule of product administration,HO
198351111,Infliximab,Gastrointestinal viral infection,HO
198351111,Infliximab,Anal fissure,HO
198391591,Infliximab,Pyrexia,OT
198391591,Infliximab,Off label use,OT
198391591,Infliximab,Dyspnoea,OT
198391591,Infliximab,Dysgeusia,OT
198391591,Infliximab,Diarrhoea,OT
198391591,Infliximab,Cough,OT
198391591,Infliximab,COVID-19,OT
198391591,Infliximab,Anosmia,OT
198569621,Infliximab,Haematochezia,OT
198642661,Infliximab,Wound,OT
198642661,Infliximab,Pain,OT
198642661,Infliximab,Off label use,OT
198642661,Infliximab,Obstruction,OT
198642661,Infliximab,Malaise,OT
198642661,Infliximab,Lung disorder,OT
198642661,Infliximab,Intentional product use issue,OT
198642661,Infliximab,Impaired healing,OT
198642661,Infliximab,Hypertension,OT
198642661,Infliximab,Heart rate decreased,OT
198642661,Infliximab,Drug level above therapeutic,OT
198642661,Infliximab,Condition aggravated,OT
198642661,Infliximab,Abdominal pain,OT
198729261,Infliximab,Off label use,OT
198729261,Infliximab,Mouth ulceration,OT
198729261,Infliximab,Intentional product use issue,OT
198729261,Infliximab,Hernia,OT
198729261,Infliximab,Erythema nodosum,OT
198729261,Infliximab,Condition aggravated,OT
198729261,Infliximab,Blood pressure increased,OT
198729261,Infliximab,Aphthous ulcer,OT
198729261,Infliximab,Anal fissure,OT
198771902,Infliximab,Multiple organ dysfunction syndrome,HO
198771902,Infliximab,Multiple organ dysfunction syndrome,DE
198771902,Infliximab,COVID-19,HO
198771902,Infliximab,COVID-19,DE
198771902,Infliximab,Acute respiratory distress syndrome,HO
198771902,Infliximab,Acute respiratory distress syndrome,DE
198781251,Infliximab (Unknown),Off label use,NULL
198781251,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198874791,Infliximab,Small for dates baby,OT
198874791,Infliximab,Small for dates baby,CA
198874791,Infliximab,Marcus Gunn syndrome,OT
198874791,Infliximab,Marcus Gunn syndrome,CA
198874791,Infliximab,Foetal exposure during pregnancy,OT
198874791,Infliximab,Foetal exposure during pregnancy,CA
198874791,Infliximab,Eyelid ptosis congenital,OT
198874791,Infliximab,Eyelid ptosis congenital,CA
198959631,Infliximab,Treatment failure,HO
198959631,Infliximab,Haematochezia,HO
198959631,Infliximab,Epstein-Barr virus infection,HO
160798585,Infliximab,Sinusitis,HO
160798585,Infliximab,Sinusitis,OT
160798585,Infliximab,Psoriasis,HO
160798585,Infliximab,Psoriasis,OT
160798585,Infliximab,Product use issue,HO
160798585,Infliximab,Product use issue,OT
160798585,Infliximab,Pneumonia,HO
160798585,Infliximab,Pneumonia,OT
160798585,Infliximab,Off label use,HO
160798585,Infliximab,Off label use,OT
160798585,Infliximab,Intentional product use issue,HO
160798585,Infliximab,Intentional product use issue,OT
160798585,Infliximab,Herpes zoster,HO
160798585,Infliximab,Herpes zoster,OT
160798585,Infliximab,Heart rate irregular,HO
160798585,Infliximab,Heart rate irregular,OT
160798585,Infliximab,Family stress,HO
160798585,Infliximab,Family stress,OT
160798585,Infliximab,Faeces hard,HO
160798585,Infliximab,Faeces hard,OT
160798585,Infliximab,Faecal volume increased,HO
160798585,Infliximab,Faecal volume increased,OT
160798585,Infliximab,Eczema,HO
160798585,Infliximab,Eczema,OT
160798585,Infliximab,Drug level above therapeutic,HO
160798585,Infliximab,Drug level above therapeutic,OT
160798585,Infliximab,Drug ineffective,HO
160798585,Infliximab,Drug ineffective,OT
160798585,Infliximab,Constipation,HO
160798585,Infliximab,Constipation,OT
160798585,Infliximab,Condition aggravated,HO
160798585,Infliximab,Condition aggravated,OT
160798585,Infliximab,Blood pressure fluctuation,HO
160798585,Infliximab,Blood pressure fluctuation,OT
160798585,Infliximab,Arthralgia,HO
160798585,Infliximab,Arthralgia,OT
160798585,Infliximab,Abdominal pain upper,HO
160798585,Infliximab,Abdominal pain upper,OT
160798585,Infliximab,Sinusitis,HO
160798585,Infliximab,Sinusitis,OT
160798585,Infliximab,Psoriasis,HO
160798585,Infliximab,Psoriasis,OT
160798585,Infliximab,Product use issue,HO
160798585,Infliximab,Product use issue,OT
160798585,Infliximab,Pneumonia,HO
160798585,Infliximab,Pneumonia,OT
160798585,Infliximab,Off label use,HO
160798585,Infliximab,Off label use,OT
160798585,Infliximab,Intentional product use issue,HO
160798585,Infliximab,Intentional product use issue,OT
160798585,Infliximab,Herpes zoster,HO
160798585,Infliximab,Herpes zoster,OT
160798585,Infliximab,Heart rate irregular,HO
160798585,Infliximab,Heart rate irregular,OT
160798585,Infliximab,Family stress,HO
160798585,Infliximab,Family stress,OT
160798585,Infliximab,Faeces hard,HO
160798585,Infliximab,Faeces hard,OT
160798585,Infliximab,Faecal volume increased,HO
160798585,Infliximab,Faecal volume increased,OT
160798585,Infliximab,Eczema,HO
160798585,Infliximab,Eczema,OT
160798585,Infliximab,Drug level above therapeutic,HO
160798585,Infliximab,Drug level above therapeutic,OT
160798585,Infliximab,Drug ineffective,HO
160798585,Infliximab,Drug ineffective,OT
160798585,Infliximab,Constipation,HO
160798585,Infliximab,Constipation,OT
160798585,Infliximab,Condition aggravated,HO
160798585,Infliximab,Condition aggravated,OT
160798585,Infliximab,Blood pressure fluctuation,HO
160798585,Infliximab,Blood pressure fluctuation,OT
160798585,Infliximab,Arthralgia,HO
160798585,Infliximab,Arthralgia,OT
160798585,Infliximab,Abdominal pain upper,HO
160798585,Infliximab,Abdominal pain upper,OT
160798585,Infliximab,Sinusitis,HO
160798585,Infliximab,Sinusitis,OT
160798585,Infliximab,Psoriasis,HO
160798585,Infliximab,Psoriasis,OT
160798585,Infliximab,Product use issue,HO
160798585,Infliximab,Product use issue,OT
160798585,Infliximab,Pneumonia,HO
160798585,Infliximab,Pneumonia,OT
160798585,Infliximab,Off label use,HO
160798585,Infliximab,Off label use,OT
160798585,Infliximab,Intentional product use issue,HO
160798585,Infliximab,Intentional product use issue,OT
160798585,Infliximab,Herpes zoster,HO
160798585,Infliximab,Herpes zoster,OT
160798585,Infliximab,Heart rate irregular,HO
160798585,Infliximab,Heart rate irregular,OT
160798585,Infliximab,Family stress,HO
160798585,Infliximab,Family stress,OT
160798585,Infliximab,Faeces hard,HO
160798585,Infliximab,Faeces hard,OT
160798585,Infliximab,Faecal volume increased,HO
160798585,Infliximab,Faecal volume increased,OT
160798585,Infliximab,Eczema,HO
160798585,Infliximab,Eczema,OT
160798585,Infliximab,Drug level above therapeutic,HO
160798585,Infliximab,Drug level above therapeutic,OT
160798585,Infliximab,Drug ineffective,HO
160798585,Infliximab,Drug ineffective,OT
160798585,Infliximab,Constipation,HO
160798585,Infliximab,Constipation,OT
160798585,Infliximab,Condition aggravated,HO
160798585,Infliximab,Condition aggravated,OT
160798585,Infliximab,Blood pressure fluctuation,HO
160798585,Infliximab,Blood pressure fluctuation,OT
160798585,Infliximab,Arthralgia,HO
160798585,Infliximab,Arthralgia,OT
160798585,Infliximab,Abdominal pain upper,HO
160798585,Infliximab,Abdominal pain upper,OT
160821705,Infliximab,Rectal haemorrhage,OT
160821705,Infliximab,Rash pruritic,OT
160821705,Infliximab,Oxygen saturation decreased,OT
160821705,Infliximab,Off label use,OT
160821705,Infliximab,Intentional product use issue,OT
160821705,Infliximab,Condition aggravated,OT
160821705,Infliximab,Rectal haemorrhage,OT
160821705,Infliximab,Rash pruritic,OT
160821705,Infliximab,Oxygen saturation decreased,OT
160821705,Infliximab,Off label use,OT
160821705,Infliximab,Intentional product use issue,OT
160821705,Infliximab,Condition aggravated,OT
160821705,Infliximab,Rectal haemorrhage,OT
160821705,Infliximab,Rash pruritic,OT
160821705,Infliximab,Oxygen saturation decreased,OT
160821705,Infliximab,Off label use,OT
160821705,Infliximab,Intentional product use issue,OT
160821705,Infliximab,Condition aggravated,OT
165679614,Infliximab,Viral infection,OT
165679614,Infliximab,Viral infection,HO
165679614,Infliximab,Rhinorrhoea,OT
165679614,Infliximab,Rhinorrhoea,HO
165679614,Infliximab,Rash pustular,OT
165679614,Infliximab,Rash pustular,HO
165679614,Infliximab,Pyrexia,OT
165679614,Infliximab,Pyrexia,HO
165679614,Infliximab,Product use issue,OT
165679614,Infliximab,Product use issue,HO
165679614,Infliximab,Post procedural discharge,OT
165679614,Infliximab,Post procedural discharge,HO
165679614,Infliximab,Pain,OT
165679614,Infliximab,Pain,HO
165679614,Infliximab,Oropharyngeal pain,OT
165679614,Infliximab,Oropharyngeal pain,HO
165679614,Infliximab,Off label use,OT
165679614,Infliximab,Off label use,HO
165679614,Infliximab,Nasopharyngitis,OT
165679614,Infliximab,Nasopharyngitis,HO
165679614,Infliximab,Malaise,OT
165679614,Infliximab,Malaise,HO
165679614,Infliximab,Ingrowing nail,OT
165679614,Infliximab,Ingrowing nail,HO
165679614,Infliximab,Infection,OT
165679614,Infliximab,Infection,HO
165679614,Infliximab,Inappropriate schedule of product administration,OT
165679614,Infliximab,Inappropriate schedule of product administration,HO
165679614,Infliximab,Hypersensitivity,OT
165679614,Infliximab,Hypersensitivity,HO
165679614,Infliximab,Hyperhidrosis,OT
165679614,Infliximab,Hyperhidrosis,HO
165679614,Infliximab,Herpes zoster,OT
165679614,Infliximab,Herpes zoster,HO
165679614,Infliximab,Headache,OT
165679614,Infliximab,Headache,HO
165679614,Infliximab,Furuncle,OT
165679614,Infliximab,Furuncle,HO
165679614,Infliximab,Fatigue,OT
165679614,Infliximab,Fatigue,HO
165679614,Infliximab,Drug level decreased,OT
165679614,Infliximab,Drug level decreased,HO
165679614,Infliximab,Drug ineffective,OT
165679614,Infliximab,Drug ineffective,HO
165679614,Infliximab,Condition aggravated,OT
165679614,Infliximab,Condition aggravated,HO
165679614,Infliximab,Breast abscess,OT
165679614,Infliximab,Breast abscess,HO
165679614,Infliximab,Blood pressure increased,OT
165679614,Infliximab,Blood pressure increased,HO
165679614,Infliximab,Blood pressure fluctuation,OT
165679614,Infliximab,Blood pressure fluctuation,HO
165679614,Infliximab,Arthralgia,OT
165679614,Infliximab,Arthralgia,HO
165679614,Infliximab,Abscess,OT
165679614,Infliximab,Abscess,HO
165679614,Infliximab,Viral infection,OT
165679614,Infliximab,Viral infection,HO
165679614,Infliximab,Rhinorrhoea,OT
165679614,Infliximab,Rhinorrhoea,HO
165679614,Infliximab,Rash pustular,OT
165679614,Infliximab,Rash pustular,HO
165679614,Infliximab,Pyrexia,OT
165679614,Infliximab,Pyrexia,HO
165679614,Infliximab,Product use issue,OT
165679614,Infliximab,Product use issue,HO
165679614,Infliximab,Post procedural discharge,OT
165679614,Infliximab,Post procedural discharge,HO
165679614,Infliximab,Pain,OT
165679614,Infliximab,Pain,HO
165679614,Infliximab,Oropharyngeal pain,OT
165679614,Infliximab,Oropharyngeal pain,HO
165679614,Infliximab,Off label use,OT
165679614,Infliximab,Off label use,HO
165679614,Infliximab,Nasopharyngitis,OT
165679614,Infliximab,Nasopharyngitis,HO
165679614,Infliximab,Malaise,OT
165679614,Infliximab,Malaise,HO
165679614,Infliximab,Ingrowing nail,OT
165679614,Infliximab,Ingrowing nail,HO
165679614,Infliximab,Infection,OT
165679614,Infliximab,Infection,HO
165679614,Infliximab,Inappropriate schedule of product administration,OT
165679614,Infliximab,Inappropriate schedule of product administration,HO
165679614,Infliximab,Hypersensitivity,OT
165679614,Infliximab,Hypersensitivity,HO
165679614,Infliximab,Hyperhidrosis,OT
165679614,Infliximab,Hyperhidrosis,HO
165679614,Infliximab,Herpes zoster,OT
165679614,Infliximab,Herpes zoster,HO
165679614,Infliximab,Headache,OT
165679614,Infliximab,Headache,HO
165679614,Infliximab,Furuncle,OT
165679614,Infliximab,Furuncle,HO
165679614,Infliximab,Fatigue,OT
165679614,Infliximab,Fatigue,HO
165679614,Infliximab,Drug level decreased,OT
165679614,Infliximab,Drug level decreased,HO
165679614,Infliximab,Drug ineffective,OT
165679614,Infliximab,Drug ineffective,HO
165679614,Infliximab,Condition aggravated,OT
165679614,Infliximab,Condition aggravated,HO
165679614,Infliximab,Breast abscess,OT
165679614,Infliximab,Breast abscess,HO
165679614,Infliximab,Blood pressure increased,OT
165679614,Infliximab,Blood pressure increased,HO
165679614,Infliximab,Blood pressure fluctuation,OT
165679614,Infliximab,Blood pressure fluctuation,HO
165679614,Infliximab,Arthralgia,OT
165679614,Infliximab,Arthralgia,HO
165679614,Infliximab,Abscess,OT
165679614,Infliximab,Abscess,HO
168860253,Infliximab,Product use issue,OT
168860253,Infliximab,Hypertension,OT
168860253,Infliximab,Blood pressure increased,OT
168860253,Infliximab,Blood pressure fluctuation,OT
168860253,Infliximab,Product use issue,OT
168860253,Infliximab,Hypertension,OT
168860253,Infliximab,Blood pressure increased,OT
168860253,Infliximab,Blood pressure fluctuation,OT
172265474,Infliximab,Off label use,OT
172265474,Infliximab,Inappropriate schedule of product administration,OT
172265474,Infliximab,Haemorrhoids,OT
172265474,Infliximab,Drug ineffective,OT
172265474,Infliximab,Condition aggravated,OT
172265474,Infliximab,Blood pressure fluctuation,OT
175099134,Infliximab,Wound infection,OT
175099134,Infliximab,Weight increased,OT
175099134,Infliximab,Tooth abscess,OT
175099134,Infliximab,Inflammation,OT
175099134,Infliximab,Incorrect dose administered,OT
175099134,Infliximab,Inappropriate schedule of product administration,OT
175099134,Infliximab,Heart rate decreased,OT
175099134,Infliximab,Feeling hot,OT
175099134,Infliximab,Erythema,OT
175099134,Infliximab,Drug level below therapeutic,OT
175099134,Infliximab,Condition aggravated,OT
175099134,Infliximab,Blood pressure increased,OT
175099134,Infliximab,Blood pressure fluctuation,OT
175099134,Infliximab,Wound infection,OT
175099134,Infliximab,Weight increased,OT
175099134,Infliximab,Tooth abscess,OT
175099134,Infliximab,Inflammation,OT
175099134,Infliximab,Incorrect dose administered,OT
175099134,Infliximab,Inappropriate schedule of product administration,OT
175099134,Infliximab,Heart rate decreased,OT
175099134,Infliximab,Feeling hot,OT
175099134,Infliximab,Erythema,OT
175099134,Infliximab,Drug level below therapeutic,OT
175099134,Infliximab,Condition aggravated,OT
175099134,Infliximab,Blood pressure increased,OT
175099134,Infliximab,Blood pressure fluctuation,OT
175099134,Infliximab,Wound infection,OT
175099134,Infliximab,Weight increased,OT
175099134,Infliximab,Tooth abscess,OT
175099134,Infliximab,Inflammation,OT
175099134,Infliximab,Incorrect dose administered,OT
175099134,Infliximab,Inappropriate schedule of product administration,OT
175099134,Infliximab,Heart rate decreased,OT
175099134,Infliximab,Feeling hot,OT
175099134,Infliximab,Erythema,OT
175099134,Infliximab,Drug level below therapeutic,OT
175099134,Infliximab,Condition aggravated,OT
175099134,Infliximab,Blood pressure increased,OT
175099134,Infliximab,Blood pressure fluctuation,OT
175099134,Infliximab,Wound infection,OT
175099134,Infliximab,Weight increased,OT
175099134,Infliximab,Tooth abscess,OT
175099134,Infliximab,Inflammation,OT
175099134,Infliximab,Incorrect dose administered,OT
175099134,Infliximab,Inappropriate schedule of product administration,OT
175099134,Infliximab,Heart rate decreased,OT
175099134,Infliximab,Feeling hot,OT
175099134,Infliximab,Erythema,OT
175099134,Infliximab,Drug level below therapeutic,OT
175099134,Infliximab,Condition aggravated,OT
175099134,Infliximab,Blood pressure increased,OT
175099134,Infliximab,Blood pressure fluctuation,OT
175190642,Infliximab,Vomiting,HO
175190642,Infliximab,Pharyngitis streptococcal,HO
175190642,Infliximab,Off label use,HO
175190642,Infliximab,Nausea,HO
175190642,Infliximab,Malaise,HO
175190642,Infliximab,Hypovolaemia,HO
175190642,Infliximab,Headache,HO
175190642,Infliximab,Crohn's disease,HO
175190642,Infliximab,Blood electrolytes abnormal,HO
175190642,Infliximab,Vomiting,HO
175190642,Infliximab,Pharyngitis streptococcal,HO
175190642,Infliximab,Off label use,HO
175190642,Infliximab,Nausea,HO
175190642,Infliximab,Malaise,HO
175190642,Infliximab,Hypovolaemia,HO
175190642,Infliximab,Headache,HO
175190642,Infliximab,Crohn's disease,HO
175190642,Infliximab,Blood electrolytes abnormal,HO
176178634,Infliximab,Weight decreased,OT
176178634,Infliximab,Weight decreased,HO
176178634,Infliximab,Vomiting,OT
176178634,Infliximab,Vomiting,HO
176178634,Infliximab,Visual impairment,OT
176178634,Infliximab,Visual impairment,HO
176178634,Infliximab,Spinal cord oedema,OT
176178634,Infliximab,Spinal cord oedema,HO
176178634,Infliximab,Product use issue,OT
176178634,Infliximab,Product use issue,HO
176178634,Infliximab,Pharyngitis bacterial,OT
176178634,Infliximab,Pharyngitis bacterial,HO
176178634,Infliximab,Periarthritis,OT
176178634,Infliximab,Periarthritis,HO
176178634,Infliximab,Otorrhoea,OT
176178634,Infliximab,Otorrhoea,HO
176178634,Infliximab,Off label use,OT
176178634,Infliximab,Off label use,HO
176178634,Infliximab,Oedema peripheral,OT
176178634,Infliximab,Oedema peripheral,HO
176178634,Infliximab,Nausea,OT
176178634,Infliximab,Nausea,HO
176178634,Infliximab,Malaise,OT
176178634,Infliximab,Malaise,HO
176178634,Infliximab,Ligament sprain,OT
176178634,Infliximab,Ligament sprain,HO
176178634,Infliximab,Injury,OT
176178634,Infliximab,Injury,HO
176178634,Infliximab,Influenza,OT
176178634,Infliximab,Influenza,HO
176178634,Infliximab,Inappropriate schedule of product administration,OT
176178634,Infliximab,Inappropriate schedule of product administration,HO
176178634,Infliximab,Illness,OT
176178634,Infliximab,Illness,HO
176178634,Infliximab,Helicobacter infection,OT
176178634,Infliximab,Helicobacter infection,HO
176178634,Infliximab,Helicobacter gastritis,OT
176178634,Infliximab,Helicobacter gastritis,HO
176178634,Infliximab,Haemophilus infection,OT
176178634,Infliximab,Haemophilus infection,HO
176178634,Infliximab,Gastrooesophageal reflux disease,OT
176178634,Infliximab,Gastrooesophageal reflux disease,HO
176178634,Infliximab,Fatigue,OT
176178634,Infliximab,Fatigue,HO
176178634,Infliximab,Fall,OT
176178634,Infliximab,Fall,HO
176178634,Infliximab,Erythema nodosum,OT
176178634,Infliximab,Erythema nodosum,HO
176178634,Infliximab,Dyspepsia,OT
176178634,Infliximab,Dyspepsia,HO
176178634,Infliximab,Drug level below therapeutic,OT
176178634,Infliximab,Drug level below therapeutic,HO
176178634,Infliximab,Drug ineffective,OT
176178634,Infliximab,Drug ineffective,HO
176178634,Infliximab,Dizziness,OT
176178634,Infliximab,Dizziness,HO
176178634,Infliximab,Diarrhoea,OT
176178634,Infliximab,Diarrhoea,HO
176178634,Infliximab,Condition aggravated,OT
176178634,Infliximab,Condition aggravated,HO
176178634,Infliximab,Bacterial infection,OT
176178634,Infliximab,Bacterial infection,HO
176178634,Infliximab,Antibody test abnormal,OT
176178634,Infliximab,Antibody test abnormal,HO
176178634,Infliximab,Abdominal pain upper,OT
176178634,Infliximab,Abdominal pain upper,HO
176178634,Infliximab,Weight decreased,OT
176178634,Infliximab,Weight decreased,HO
176178634,Infliximab,Vomiting,OT
176178634,Infliximab,Vomiting,HO
176178634,Infliximab,Visual impairment,OT
176178634,Infliximab,Visual impairment,HO
176178634,Infliximab,Spinal cord oedema,OT
176178634,Infliximab,Spinal cord oedema,HO
176178634,Infliximab,Product use issue,OT
176178634,Infliximab,Product use issue,HO
176178634,Infliximab,Pharyngitis bacterial,OT
176178634,Infliximab,Pharyngitis bacterial,HO
176178634,Infliximab,Periarthritis,OT
176178634,Infliximab,Periarthritis,HO
176178634,Infliximab,Otorrhoea,OT
176178634,Infliximab,Otorrhoea,HO
176178634,Infliximab,Off label use,OT
176178634,Infliximab,Off label use,HO
176178634,Infliximab,Oedema peripheral,OT
176178634,Infliximab,Oedema peripheral,HO
176178634,Infliximab,Nausea,OT
176178634,Infliximab,Nausea,HO
176178634,Infliximab,Malaise,OT
176178634,Infliximab,Malaise,HO
176178634,Infliximab,Ligament sprain,OT
176178634,Infliximab,Ligament sprain,HO
176178634,Infliximab,Injury,OT
176178634,Infliximab,Injury,HO
176178634,Infliximab,Influenza,OT
176178634,Infliximab,Influenza,HO
176178634,Infliximab,Inappropriate schedule of product administration,OT
176178634,Infliximab,Inappropriate schedule of product administration,HO
176178634,Infliximab,Illness,OT
176178634,Infliximab,Illness,HO
176178634,Infliximab,Helicobacter infection,OT
176178634,Infliximab,Helicobacter infection,HO
176178634,Infliximab,Helicobacter gastritis,OT
176178634,Infliximab,Helicobacter gastritis,HO
176178634,Infliximab,Haemophilus infection,OT
176178634,Infliximab,Haemophilus infection,HO
176178634,Infliximab,Gastrooesophageal reflux disease,OT
176178634,Infliximab,Gastrooesophageal reflux disease,HO
176178634,Infliximab,Fatigue,OT
176178634,Infliximab,Fatigue,HO
176178634,Infliximab,Fall,OT
176178634,Infliximab,Fall,HO
176178634,Infliximab,Erythema nodosum,OT
176178634,Infliximab,Erythema nodosum,HO
176178634,Infliximab,Dyspepsia,OT
176178634,Infliximab,Dyspepsia,HO
176178634,Infliximab,Drug level below therapeutic,OT
176178634,Infliximab,Drug level below therapeutic,HO
176178634,Infliximab,Drug ineffective,OT
176178634,Infliximab,Drug ineffective,HO
176178634,Infliximab,Dizziness,OT
176178634,Infliximab,Dizziness,HO
176178634,Infliximab,Diarrhoea,OT
176178634,Infliximab,Diarrhoea,HO
176178634,Infliximab,Condition aggravated,OT
176178634,Infliximab,Condition aggravated,HO
176178634,Infliximab,Bacterial infection,OT
176178634,Infliximab,Bacterial infection,HO
176178634,Infliximab,Antibody test abnormal,OT
176178634,Infliximab,Antibody test abnormal,HO
176178634,Infliximab,Abdominal pain upper,OT
176178634,Infliximab,Abdominal pain upper,HO
176178634,Infliximab,Weight decreased,OT
176178634,Infliximab,Weight decreased,HO
176178634,Infliximab,Vomiting,OT
176178634,Infliximab,Vomiting,HO
176178634,Infliximab,Visual impairment,OT
176178634,Infliximab,Visual impairment,HO
176178634,Infliximab,Spinal cord oedema,OT
176178634,Infliximab,Spinal cord oedema,HO
176178634,Infliximab,Product use issue,OT
176178634,Infliximab,Product use issue,HO
176178634,Infliximab,Pharyngitis bacterial,OT
176178634,Infliximab,Pharyngitis bacterial,HO
176178634,Infliximab,Periarthritis,OT
176178634,Infliximab,Periarthritis,HO
176178634,Infliximab,Otorrhoea,OT
176178634,Infliximab,Otorrhoea,HO
176178634,Infliximab,Off label use,OT
176178634,Infliximab,Off label use,HO
176178634,Infliximab,Oedema peripheral,OT
176178634,Infliximab,Oedema peripheral,HO
176178634,Infliximab,Nausea,OT
176178634,Infliximab,Nausea,HO
176178634,Infliximab,Malaise,OT
176178634,Infliximab,Malaise,HO
176178634,Infliximab,Ligament sprain,OT
176178634,Infliximab,Ligament sprain,HO
176178634,Infliximab,Injury,OT
176178634,Infliximab,Injury,HO
176178634,Infliximab,Influenza,OT
176178634,Infliximab,Influenza,HO
176178634,Infliximab,Inappropriate schedule of product administration,OT
176178634,Infliximab,Inappropriate schedule of product administration,HO
176178634,Infliximab,Illness,OT
176178634,Infliximab,Illness,HO
176178634,Infliximab,Helicobacter infection,OT
176178634,Infliximab,Helicobacter infection,HO
176178634,Infliximab,Helicobacter gastritis,OT
176178634,Infliximab,Helicobacter gastritis,HO
176178634,Infliximab,Haemophilus infection,OT
176178634,Infliximab,Haemophilus infection,HO
176178634,Infliximab,Gastrooesophageal reflux disease,OT
176178634,Infliximab,Gastrooesophageal reflux disease,HO
176178634,Infliximab,Fatigue,OT
176178634,Infliximab,Fatigue,HO
176178634,Infliximab,Fall,OT
176178634,Infliximab,Fall,HO
176178634,Infliximab,Erythema nodosum,OT
176178634,Infliximab,Erythema nodosum,HO
176178634,Infliximab,Dyspepsia,OT
176178634,Infliximab,Dyspepsia,HO
176178634,Infliximab,Drug level below therapeutic,OT
176178634,Infliximab,Drug level below therapeutic,HO
176178634,Infliximab,Drug ineffective,OT
176178634,Infliximab,Drug ineffective,HO
176178634,Infliximab,Dizziness,OT
176178634,Infliximab,Dizziness,HO
176178634,Infliximab,Diarrhoea,OT
176178634,Infliximab,Diarrhoea,HO
176178634,Infliximab,Condition aggravated,OT
176178634,Infliximab,Condition aggravated,HO
176178634,Infliximab,Bacterial infection,OT
176178634,Infliximab,Bacterial infection,HO
176178634,Infliximab,Antibody test abnormal,OT
176178634,Infliximab,Antibody test abnormal,HO
176178634,Infliximab,Abdominal pain upper,OT
176178634,Infliximab,Abdominal pain upper,HO
176478483,Infliximab,Vomiting,HO
176478483,Infliximab,Vomiting,OT
176478483,Infliximab,Off label use,HO
176478483,Infliximab,Off label use,OT
176478483,Infliximab,Nausea,HO
176478483,Infliximab,Nausea,OT
176478483,Infliximab,Intentional product use issue,HO
176478483,Infliximab,Intentional product use issue,OT
176478483,Infliximab,Blood pressure increased,HO
176478483,Infliximab,Blood pressure increased,OT
176478483,Infliximab,Blood pressure fluctuation,HO
176478483,Infliximab,Blood pressure fluctuation,OT
176478483,Infliximab,Abdominal pain,HO
176478483,Infliximab,Abdominal pain,OT
177515993,Infliximab,Weight increased,OT
177515993,Infliximab,Weight decreased,OT
177515993,Infliximab,Urticaria,OT
177515993,Infliximab,Therapeutic response shortened,OT
177515993,Infliximab,Therapeutic product effect incomplete,OT
177515993,Infliximab,Rash pruritic,OT
177515993,Infliximab,Pustular psoriasis,OT
177515993,Infliximab,Product use issue,OT
177515993,Infliximab,Pneumonia,OT
177515993,Infliximab,Pain,OT
177515993,Infliximab,Off label use,OT
177515993,Infliximab,Ocular hyperaemia,OT
177515993,Infliximab,Nausea,OT
177515993,Infliximab,Malaise,OT
177515993,Infliximab,Infusion related reaction,OT
177515993,Infliximab,Inappropriate schedule of product administration,OT
177515993,Infliximab,Heart rate irregular,OT
177515993,Infliximab,Eye oedema,OT
177515993,Infliximab,Eye injury,OT
177515993,Infliximab,Eye infection,OT
177515993,Infliximab,Dry skin,OT
177515993,Infliximab,Drug level changed,OT
177515993,Infliximab,Discoloured vomit,OT
177515993,Infliximab,Condition aggravated,OT
177515993,Infliximab,Blister,OT
177515993,Infliximab,Alopecia,OT
177515993,Infliximab,Abdominal pain upper,OT
177515993,Infliximab,Weight increased,OT
177515993,Infliximab,Weight decreased,OT
177515993,Infliximab,Urticaria,OT
177515993,Infliximab,Therapeutic response shortened,OT
177515993,Infliximab,Therapeutic product effect incomplete,OT
177515993,Infliximab,Rash pruritic,OT
177515993,Infliximab,Pustular psoriasis,OT
177515993,Infliximab,Product use issue,OT
177515993,Infliximab,Pneumonia,OT
177515993,Infliximab,Pain,OT
177515993,Infliximab,Off label use,OT
177515993,Infliximab,Ocular hyperaemia,OT
177515993,Infliximab,Nausea,OT
177515993,Infliximab,Malaise,OT
177515993,Infliximab,Infusion related reaction,OT
177515993,Infliximab,Inappropriate schedule of product administration,OT
177515993,Infliximab,Heart rate irregular,OT
177515993,Infliximab,Eye oedema,OT
177515993,Infliximab,Eye injury,OT
177515993,Infliximab,Eye infection,OT
177515993,Infliximab,Dry skin,OT
177515993,Infliximab,Drug level changed,OT
177515993,Infliximab,Discoloured vomit,OT
177515993,Infliximab,Condition aggravated,OT
177515993,Infliximab,Blister,OT
177515993,Infliximab,Alopecia,OT
177515993,Infliximab,Abdominal pain upper,OT
177515993,Infliximab,Weight increased,OT
177515993,Infliximab,Weight decreased,OT
177515993,Infliximab,Urticaria,OT
177515993,Infliximab,Therapeutic response shortened,OT
177515993,Infliximab,Therapeutic product effect incomplete,OT
177515993,Infliximab,Rash pruritic,OT
177515993,Infliximab,Pustular psoriasis,OT
177515993,Infliximab,Product use issue,OT
177515993,Infliximab,Pneumonia,OT
177515993,Infliximab,Pain,OT
177515993,Infliximab,Off label use,OT
177515993,Infliximab,Ocular hyperaemia,OT
177515993,Infliximab,Nausea,OT
177515993,Infliximab,Malaise,OT
177515993,Infliximab,Infusion related reaction,OT
177515993,Infliximab,Inappropriate schedule of product administration,OT
177515993,Infliximab,Heart rate irregular,OT
177515993,Infliximab,Eye oedema,OT
177515993,Infliximab,Eye injury,OT
177515993,Infliximab,Eye infection,OT
177515993,Infliximab,Dry skin,OT
177515993,Infliximab,Drug level changed,OT
177515993,Infliximab,Discoloured vomit,OT
177515993,Infliximab,Condition aggravated,OT
177515993,Infliximab,Blister,OT
177515993,Infliximab,Alopecia,OT
177515993,Infliximab,Abdominal pain upper,OT
178663574,Infliximab,Weight decreased,OT
178663574,Infliximab,Toothache,OT
178663574,Infliximab,Tooth loss,OT
178663574,Infliximab,Skin infection,OT
178663574,Infliximab,Sinusitis,OT
178663574,Infliximab,Seasonal allergy,OT
178663574,Infliximab,Scab,OT
178663574,Infliximab,Rhinitis,OT
178663574,Infliximab,Pulmonary congestion,OT
178663574,Infliximab,Product dose omission issue,OT
178663574,Infliximab,Off label use,OT
178663574,Infliximab,Nasal dryness,OT
178663574,Infliximab,Nasal discharge discolouration,OT
178663574,Infliximab,Nasal congestion,OT
178663574,Infliximab,Intentional product use issue,OT
178663574,Infliximab,Infection susceptibility increased,OT
178663574,Infliximab,Increased bronchial secretion,OT
178663574,Infliximab,Inappropriate schedule of product administration,OT
178663574,Infliximab,Impaired healing,OT
178663574,Infliximab,Hypoaesthesia,OT
178663574,Infliximab,Human bite,OT
178663574,Infliximab,Fatigue,OT
178663574,Infliximab,Eye pruritus,OT
178663574,Infliximab,Drug level below therapeutic,OT
178663574,Infliximab,Dehydration,OT
178663574,Infliximab,Cough,OT
178663574,Infliximab,Condition aggravated,OT
178663574,Infliximab,Bloody discharge,OT
178663574,Infliximab,Blood pressure decreased,OT
178663574,Infliximab,Asthenia,OT
178663574,Infliximab,Abscess oral,OT
178663574,Infliximab,Abdominal pain,OT
183731692,Infliximab,Product use issue,OT
183731692,Infliximab,Off label use,OT
183731692,Infliximab,Intentional product use issue,OT
183731692,Infliximab,Inappropriate schedule of product administration,OT
183731692,Infliximab,Cellulitis,OT
183731692,Infliximab,Blood pressure increased,OT
183731692,Infliximab,Blood pressure fluctuation,OT
183731692,Infliximab,Appendicitis,OT
184160243,Infliximab,Therapeutic product effect incomplete,OT
184160243,Infliximab,Root canal infection,OT
184160243,Infliximab,Rectal haemorrhage,OT
184160243,Infliximab,Product use issue,OT
184160243,Infliximab,Off label use,OT
184160243,Infliximab,Intentional product use issue,OT
184160243,Infliximab,Heart rate decreased,OT
184160243,Infliximab,Condition aggravated,OT
184160243,Infliximab,Blood pressure fluctuation,OT
184292994,Infliximab,Skin irritation,OT
184292994,Infliximab,SARS-CoV-2 test positive,OT
184292994,Infliximab,Rash,OT
184292994,Infliximab,Pruritus,OT
184292994,Infliximab,Pericarditis infective,OT
184292994,Infliximab,Pallor,OT
184292994,Infliximab,Oropharyngeal pain,OT
184292994,Infliximab,Off label use,OT
184292994,Infliximab,Nausea,OT
184292994,Infliximab,Inappropriate schedule of product administration,OT
184292994,Infliximab,Hypotension,OT
184292994,Infliximab,Headache,OT
184292994,Infliximab,Fatigue,OT
184292994,Infliximab,Drug level decreased,OT
184292994,Infliximab,Drug intolerance,OT
184292994,Infliximab,Condition aggravated,OT
184292994,Infliximab,Chest pain,OT
184292994,Infliximab,Blood pressure fluctuation,OT
184292994,Infliximab,Blood pressure decreased,OT
184292994,Infliximab,Asthenia,OT
184292994,Infliximab,Skin irritation,OT
184292994,Infliximab,SARS-CoV-2 test positive,OT
184292994,Infliximab,Rash,OT
184292994,Infliximab,Pruritus,OT
184292994,Infliximab,Pericarditis infective,OT
184292994,Infliximab,Pallor,OT
184292994,Infliximab,Oropharyngeal pain,OT
184292994,Infliximab,Off label use,OT
184292994,Infliximab,Nausea,OT
184292994,Infliximab,Inappropriate schedule of product administration,OT
184292994,Infliximab,Hypotension,OT
184292994,Infliximab,Headache,OT
184292994,Infliximab,Fatigue,OT
184292994,Infliximab,Drug level decreased,OT
184292994,Infliximab,Drug intolerance,OT
184292994,Infliximab,Condition aggravated,OT
184292994,Infliximab,Chest pain,OT
184292994,Infliximab,Blood pressure fluctuation,OT
184292994,Infliximab,Blood pressure decreased,OT
184292994,Infliximab,Asthenia,OT
184303893,Infliximab,Therapeutic product effect incomplete,OT
184303893,Infliximab,Psoriasis,OT
184303893,Infliximab,Product use issue,OT
184303893,Infliximab,Off label use,OT
184303893,Infliximab,Intentional product use issue,OT
184303893,Infliximab,Incorrect dose administered,OT
184303893,Infliximab,Inappropriate schedule of product administration,OT
184303893,Infliximab,Erythema nodosum,OT
184303893,Infliximab,Drug level increased,OT
184303893,Infliximab,Condition aggravated,OT
184303893,Infliximab,Bronchitis,OT
184303893,Infliximab,Blood pressure fluctuation,OT
184303893,Infliximab,Arthralgia,OT
184440903,Infliximab,Sinusitis,OT
184440903,Infliximab,Product use issue,OT
184440903,Infliximab,Pneumonia,OT
184440903,Infliximab,Off label use,OT
184440903,Infliximab,Nausea,OT
184440903,Infliximab,Myalgia,OT
184440903,Infliximab,Malaise,OT
184440903,Infliximab,Intentional product use issue,OT
184440903,Infliximab,Injection site pain,OT
184440903,Infliximab,Influenza,OT
184440903,Infliximab,Inflammation,OT
184440903,Infliximab,Inappropriate schedule of product administration,OT
184440903,Infliximab,Illness,OT
184440903,Infliximab,Hypoaesthesia,OT
184440903,Infliximab,Feeling hot,OT
184440903,Infliximab,Fatigue,OT
184440903,Infliximab,Condition aggravated,OT
184440903,Infliximab,Chills,OT
184440903,Infliximab,Bronchitis,OT
184440903,Infliximab,Arthralgia,OT
184440903,Infliximab,Sinusitis,OT
184440903,Infliximab,Product use issue,OT
184440903,Infliximab,Pneumonia,OT
184440903,Infliximab,Off label use,OT
184440903,Infliximab,Nausea,OT
184440903,Infliximab,Myalgia,OT
184440903,Infliximab,Malaise,OT
184440903,Infliximab,Intentional product use issue,OT
184440903,Infliximab,Injection site pain,OT
184440903,Infliximab,Influenza,OT
184440903,Infliximab,Inflammation,OT
184440903,Infliximab,Inappropriate schedule of product administration,OT
184440903,Infliximab,Illness,OT
184440903,Infliximab,Hypoaesthesia,OT
184440903,Infliximab,Feeling hot,OT
184440903,Infliximab,Fatigue,OT
184440903,Infliximab,Condition aggravated,OT
184440903,Infliximab,Chills,OT
184440903,Infliximab,Bronchitis,OT
184440903,Infliximab,Arthralgia,OT
185020842,Infliximab,Prescribed overdose,OT
185020842,Infliximab,Off label use,OT
185020842,Infliximab,Nausea,OT
185020842,Infliximab,Intentional product use issue,OT
185020842,Infliximab,Hypertension,OT
185020842,Infliximab,Heart rate increased,OT
185020842,Infliximab,Haemorrhage,OT
185020842,Infliximab,Feeling abnormal,OT
185020842,Infliximab,Condition aggravated,OT
185020842,Infliximab,Blood pressure increased,OT
185020842,Infliximab,Prescribed overdose,OT
185020842,Infliximab,Off label use,OT
185020842,Infliximab,Nausea,OT
185020842,Infliximab,Intentional product use issue,OT
185020842,Infliximab,Hypertension,OT
185020842,Infliximab,Heart rate increased,OT
185020842,Infliximab,Haemorrhage,OT
185020842,Infliximab,Feeling abnormal,OT
185020842,Infliximab,Condition aggravated,OT
185020842,Infliximab,Blood pressure increased,OT
185022682,Infliximab,Product use issue,OT
185022682,Infliximab,Off label use,OT
185022682,Infliximab,Hypertension,OT
185022682,Infliximab,Heart rate decreased,OT
185022682,Infliximab,Drug level below therapeutic,OT
185022682,Infliximab,Blood pressure increased,OT
185022682,Infliximab,Blood pressure fluctuation,OT
185022682,Infliximab,Abdominal discomfort,OT
185022682,Infliximab,Product use issue,OT
185022682,Infliximab,Off label use,OT
185022682,Infliximab,Hypertension,OT
185022682,Infliximab,Heart rate decreased,OT
185022682,Infliximab,Drug level below therapeutic,OT
185022682,Infliximab,Blood pressure increased,OT
185022682,Infliximab,Blood pressure fluctuation,OT
185022682,Infliximab,Abdominal discomfort,OT
185353462,Infliximab,Synovitis,OT
185353462,Infliximab,Rheumatoid arthritis,OT
185353462,Infliximab,Pain in extremity,OT
185353462,Infliximab,Off label use,OT
185353462,Infliximab,Neck pain,OT
185353462,Infliximab,Musculoskeletal stiffness,OT
185353462,Infliximab,Joint swelling,OT
185353462,Infliximab,Hypersensitivity,OT
185353462,Infliximab,Gait inability,OT
185353462,Infliximab,Drug ineffective,OT
185353462,Infliximab,Arthralgia,OT
185353462,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
185353462,Infliximab,Synovitis,OT
185353462,Infliximab,Rheumatoid arthritis,OT
185353462,Infliximab,Pain in extremity,OT
185353462,Infliximab,Off label use,OT
185353462,Infliximab,Neck pain,OT
185353462,Infliximab,Musculoskeletal stiffness,OT
185353462,Infliximab,Joint swelling,OT
185353462,Infliximab,Hypersensitivity,OT
185353462,Infliximab,Gait inability,OT
185353462,Infliximab,Drug ineffective,OT
185353462,Infliximab,Arthralgia,OT
185353462,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
185438132,Infliximab,Weight increased,HO
185438132,Infliximab,Presyncope,HO
185438132,Infliximab,Off label use,HO
185438132,Infliximab,Inappropriate schedule of product administration,HO
185438132,Infliximab,Heart rate decreased,HO
185438132,Infliximab,Haematochezia,HO
185438132,Infliximab,Fatigue,HO
185438132,Infliximab,Diarrhoea,HO
185438132,Infliximab,Blood pressure fluctuation,HO
185438132,Infliximab,Abdominal pain,HO
185438132,Infliximab,Weight increased,HO
185438132,Infliximab,Presyncope,HO
185438132,Infliximab,Off label use,HO
185438132,Infliximab,Inappropriate schedule of product administration,HO
185438132,Infliximab,Heart rate decreased,HO
185438132,Infliximab,Haematochezia,HO
185438132,Infliximab,Fatigue,HO
185438132,Infliximab,Diarrhoea,HO
185438132,Infliximab,Blood pressure fluctuation,HO
185438132,Infliximab,Abdominal pain,HO
185505154,Infliximab,Weight increased,OT
185505154,Infliximab,Urticaria,OT
185505154,Infliximab,Rash pruritic,OT
185505154,Infliximab,Rash macular,OT
185505154,Infliximab,Rash,OT
185505154,Infliximab,Psoriasis,OT
185505154,Infliximab,Off label use,OT
185505154,Infliximab,Mouth ulceration,OT
185505154,Infliximab,Lupus-like syndrome,OT
185505154,Infliximab,Intentional product use issue,OT
185505154,Infliximab,Infusion site pain,OT
185505154,Infliximab,Gingival swelling,OT
185505154,Infliximab,Frustration tolerance decreased,OT
185505154,Infliximab,Fatigue,OT
185505154,Infliximab,Emotional disorder,OT
185505154,Infliximab,Drug level above therapeutic,OT
185505154,Infliximab,Dermatitis allergic,OT
185505154,Infliximab,Constipation,OT
185505154,Infliximab,Condition aggravated,OT
185505154,Infliximab,Arthralgia,OT
185505154,Infliximab,Weight increased,OT
185505154,Infliximab,Urticaria,OT
185505154,Infliximab,Rash pruritic,OT
185505154,Infliximab,Rash macular,OT
185505154,Infliximab,Rash,OT
185505154,Infliximab,Psoriasis,OT
185505154,Infliximab,Off label use,OT
185505154,Infliximab,Mouth ulceration,OT
185505154,Infliximab,Lupus-like syndrome,OT
185505154,Infliximab,Intentional product use issue,OT
185505154,Infliximab,Infusion site pain,OT
185505154,Infliximab,Gingival swelling,OT
185505154,Infliximab,Frustration tolerance decreased,OT
185505154,Infliximab,Fatigue,OT
185505154,Infliximab,Emotional disorder,OT
185505154,Infliximab,Drug level above therapeutic,OT
185505154,Infliximab,Dermatitis allergic,OT
185505154,Infliximab,Constipation,OT
185505154,Infliximab,Condition aggravated,OT
185505154,Infliximab,Arthralgia,OT
185957603,Infliximab,Weight increased,OT
185957603,Infliximab,Throat irritation,OT
185957603,Infliximab,Pyrexia,OT
185957603,Infliximab,Oropharyngeal discomfort,OT
185957603,Infliximab,Off label use,OT
185957603,Infliximab,Myocardial infarction,OT
185957603,Infliximab,Liver disorder,OT
185957603,Infliximab,Intentional product use issue,OT
185957603,Infliximab,Influenza,OT
185957603,Infliximab,Inappropriate schedule of product administration,OT
185957603,Infliximab,Hypertension,OT
185957603,Infliximab,Hyperlipidaemia,OT
185957603,Infliximab,Hepatic mass,OT
185957603,Infliximab,Gastroenteritis,OT
185957603,Infliximab,Erythema,OT
185957603,Infliximab,Dyspnoea exertional,OT
185957603,Infliximab,Drug level increased,OT
185957603,Infliximab,Drug level below therapeutic,OT
185957603,Infliximab,Condition aggravated,OT
185957603,Infliximab,Cardiac disorder,OT
185957603,Infliximab,Blood pressure increased,OT
185957603,Infliximab,Blood parathyroid hormone abnormal,OT
189524152,Infliximab,Hodgkin's disease,OT
191832392,Infliximab,Weight decreased,OT
191832392,Infliximab,Weight decreased,HO
191832392,Infliximab,Vomiting,OT
191832392,Infliximab,Vomiting,HO
191832392,Infliximab,Off label use,OT
191832392,Infliximab,Off label use,HO
191832392,Infliximab,Nausea,OT
191832392,Infliximab,Nausea,HO
191832392,Infliximab,Maternal exposure during pregnancy,OT
191832392,Infliximab,Maternal exposure during pregnancy,HO
191832392,Infliximab,Inappropriate schedule of product administration,OT
191832392,Infliximab,Inappropriate schedule of product administration,HO
191832392,Infliximab,Heavy menstrual bleeding,OT
191832392,Infliximab,Heavy menstrual bleeding,HO
191832392,Infliximab,Foot fracture,OT
191832392,Infliximab,Foot fracture,HO
191832392,Infliximab,Constipation,OT
191832392,Infliximab,Constipation,HO
191832392,Infliximab,Condition aggravated,OT
191832392,Infliximab,Condition aggravated,HO
191832392,Infliximab,Colitis ulcerative,OT
191832392,Infliximab,Colitis ulcerative,HO
191832392,Infliximab,Abortion spontaneous,OT
191832392,Infliximab,Abortion spontaneous,HO
191832392,Infliximab,Abdominal pain,OT
191832392,Infliximab,Abdominal pain,HO
191832392,Infliximab,Weight decreased,OT
191832392,Infliximab,Weight decreased,HO
191832392,Infliximab,Vomiting,OT
191832392,Infliximab,Vomiting,HO
191832392,Infliximab,Off label use,OT
191832392,Infliximab,Off label use,HO
191832392,Infliximab,Nausea,OT
191832392,Infliximab,Nausea,HO
191832392,Infliximab,Maternal exposure during pregnancy,OT
191832392,Infliximab,Maternal exposure during pregnancy,HO
191832392,Infliximab,Inappropriate schedule of product administration,OT
191832392,Infliximab,Inappropriate schedule of product administration,HO
191832392,Infliximab,Heavy menstrual bleeding,OT
191832392,Infliximab,Heavy menstrual bleeding,HO
191832392,Infliximab,Foot fracture,OT
191832392,Infliximab,Foot fracture,HO
191832392,Infliximab,Constipation,OT
191832392,Infliximab,Constipation,HO
191832392,Infliximab,Condition aggravated,OT
191832392,Infliximab,Condition aggravated,HO
191832392,Infliximab,Colitis ulcerative,OT
191832392,Infliximab,Colitis ulcerative,HO
191832392,Infliximab,Abortion spontaneous,OT
191832392,Infliximab,Abortion spontaneous,HO
191832392,Infliximab,Abdominal pain,OT
191832392,Infliximab,Abdominal pain,HO
193120504,Infliximab,Haematochezia,OT
193120504,Infliximab,Drug ineffective,OT
193120504,Infliximab,Diarrhoea,OT
193120504,Infliximab,Colitis ulcerative,OT
194590052,Infliximab,Weight decreased,OT
194590052,Infliximab,Hypertension,OT
194590052,Infliximab,Condition aggravated,OT
194590052,Infliximab,Colitis ulcerative,OT
194590052,Infliximab,Blood pressure increased,OT
195144801,Infliximab,Dyspnoea,OT
195144801,Infliximab,Dyspnoea,HO
195144801,Infliximab,Bundle branch block,OT
195144801,Infliximab,Bundle branch block,HO
195144801,Infliximab,Arrhythmia,OT
195144801,Infliximab,Arrhythmia,HO
195570951,Infliximab,Treatment failure,HO
195570951,Infliximab,Off label use,HO
195570951,Infliximab,Erythrasma,HO
195894641,Infliximab,Pain,OT
195894641,Infliximab,Pain,HO
195894641,Infliximab,Off label use,OT
195894641,Infliximab,Off label use,HO
195894641,Infliximab,Inappropriate schedule of product administration,OT
195894641,Infliximab,Inappropriate schedule of product administration,HO
195894641,Infliximab,Herpes zoster,OT
195894641,Infliximab,Herpes zoster,HO
195894641,Infliximab,Headache,OT
195894641,Infliximab,Headache,HO
195894641,Infliximab,Head discomfort,OT
195894641,Infliximab,Head discomfort,HO
195894641,Infliximab,Gastrooesophageal reflux disease,OT
195894641,Infliximab,Gastrooesophageal reflux disease,HO
195894641,Infliximab,Crohn's disease,OT
195894641,Infliximab,Crohn's disease,HO
195894641,Infliximab,Condition aggravated,OT
195894641,Infliximab,Condition aggravated,HO
196127911,Infliximab (Unknown),Therapy change,OT
196127911,Infliximab (Unknown),Meningitis listeria,OT
196127911,Infliximab (Unknown),Therapy change,OT
196127911,Infliximab (Unknown),Meningitis listeria,OT
196248481,Infliximab,Uveitis,OT
196248481,Infliximab,Spinal pain,OT
196248481,Infliximab,Product use issue,OT
196248481,Infliximab,Off label use,OT
196248481,Infliximab,Intentional product use issue,OT
196248481,Infliximab,Inappropriate schedule of product administration,OT
196248481,Infliximab,Hypertension,OT
196282241,Infliximab,Off label use,DE
196282241,Infliximab,Intentional product use issue,DE
196282241,Infliximab,Heart rate decreased,DE
196282241,Infliximab,Death,DE
196543191,Infliximab (Unknown),Pyrexia,HO
196543191,Infliximab (Unknown),Purulent discharge,HO
196543191,Infliximab (Unknown),Pseudopolyp,HO
196543191,Infliximab (Unknown),Proctalgia,HO
196543191,Infliximab (Unknown),Overdose,HO
196543191,Infliximab (Unknown),Oedema,HO
196543191,Infliximab (Unknown),Mucosal ulceration,HO
196543191,Infliximab (Unknown),Malnutrition,HO
196543191,Infliximab (Unknown),Anal abscess,HO
196543191,Infliximab (Unknown),Pyrexia,HO
196543191,Infliximab (Unknown),Purulent discharge,HO
196543191,Infliximab (Unknown),Pseudopolyp,HO
196543191,Infliximab (Unknown),Proctalgia,HO
196543191,Infliximab (Unknown),Overdose,HO
196543191,Infliximab (Unknown),Oedema,HO
196543191,Infliximab (Unknown),Mucosal ulceration,HO
196543191,Infliximab (Unknown),Malnutrition,HO
196543191,Infliximab (Unknown),Anal abscess,HO
196543191,Infliximab (Unknown),Pyrexia,HO
196543191,Infliximab (Unknown),Purulent discharge,HO
196543191,Infliximab (Unknown),Pseudopolyp,HO
196543191,Infliximab (Unknown),Proctalgia,HO
196543191,Infliximab (Unknown),Overdose,HO
196543191,Infliximab (Unknown),Oedema,HO
196543191,Infliximab (Unknown),Mucosal ulceration,HO
196543191,Infliximab (Unknown),Malnutrition,HO
196543191,Infliximab (Unknown),Anal abscess,HO
196670441,Infliximab (Unknown),Urticaria,OT
196670441,Infliximab (Unknown),Pruritus,OT
196670441,Infliximab (Unknown),Headache,OT
196670441,Infliximab (Unknown),Dyspnoea,OT
196670441,Infliximab (Unknown),Ankylosing spondylitis,OT
196811671,Infliximab,Product use issue,OT
196811671,Infliximab,Off label use,OT
196811671,Infliximab,Melanocytic naevus,OT
196811671,Infliximab,Intentional product use issue,OT
196811671,Infliximab,Inappropriate schedule of product administration,OT
196811671,Infliximab,Dyspnoea,OT
196811671,Infliximab,Cough,OT
196811671,Infliximab,Cataract,OT
196811671,Infliximab,Blood pressure systolic increased,OT
196811671,Infliximab,Blood pressure fluctuation,OT
196811671,Infliximab,Blood pressure diastolic decreased,OT
196811671,Infliximab,Product use issue,OT
196811671,Infliximab,Off label use,OT
196811671,Infliximab,Melanocytic naevus,OT
196811671,Infliximab,Intentional product use issue,OT
196811671,Infliximab,Inappropriate schedule of product administration,OT
196811671,Infliximab,Dyspnoea,OT
196811671,Infliximab,Cough,OT
196811671,Infliximab,Cataract,OT
196811671,Infliximab,Blood pressure systolic increased,OT
196811671,Infliximab,Blood pressure fluctuation,OT
196811671,Infliximab,Blood pressure diastolic decreased,OT
197064391,Infliximab,Premature delivery,OT
197064391,Infliximab,Off label use,OT
197064391,Infliximab,Maternal exposure during pregnancy,OT
197576201,Infliximab,Skin laceration,HO
197576201,Infliximab,Skin laceration,OT
197576201,Infliximab,Off label use,HO
197576201,Infliximab,Off label use,OT
197576201,Infliximab,Intentional product use issue,HO
197576201,Infliximab,Intentional product use issue,OT
197576201,Infliximab,Inappropriate schedule of product administration,HO
197576201,Infliximab,Inappropriate schedule of product administration,OT
197576201,Infliximab,Heart rate decreased,HO
197576201,Infliximab,Heart rate decreased,OT
197576201,Infliximab,Head injury,HO
197576201,Infliximab,Head injury,OT
197576201,Infliximab,Cellulitis,HO
197576201,Infliximab,Cellulitis,OT
197591291,Infliximab,Death,DE
198050081,Infliximab,Off label use,OT
198050081,Infliximab,Faecal calprotectin increased,OT
198050081,Infliximab,Constipation,OT
198050081,Infliximab,Condition aggravated,OT
198050081,Infliximab,Cellulitis,OT
198050081,Infliximab,Off label use,OT
198050081,Infliximab,Faecal calprotectin increased,OT
198050081,Infliximab,Constipation,OT
198050081,Infliximab,Condition aggravated,OT
198050081,Infliximab,Cellulitis,OT
198241552,Infliximab,Off label use,OT
198241552,Infliximab,Off label use,HO
198241552,Infliximab,Drug ineffective,OT
198241552,Infliximab,Drug ineffective,HO
198241552,Infliximab,Cytomegalovirus infection,OT
198241552,Infliximab,Cytomegalovirus infection,HO
198241552,Infliximab,Off label use,OT
198241552,Infliximab,Off label use,HO
198241552,Infliximab,Drug ineffective,OT
198241552,Infliximab,Drug ineffective,HO
198241552,Infliximab,Cytomegalovirus infection,OT
198241552,Infliximab,Cytomegalovirus infection,HO
198241552,Infliximab,Off label use,OT
198241552,Infliximab,Off label use,HO
198241552,Infliximab,Drug ineffective,OT
198241552,Infliximab,Drug ineffective,HO
198241552,Infliximab,Cytomegalovirus infection,OT
198241552,Infliximab,Cytomegalovirus infection,HO
198241552,Infliximab,Off label use,OT
198241552,Infliximab,Off label use,HO
198241552,Infliximab,Drug ineffective,OT
198241552,Infliximab,Drug ineffective,HO
198241552,Infliximab,Cytomegalovirus infection,OT
198241552,Infliximab,Cytomegalovirus infection,HO
198241552,Infliximab,Off label use,OT
198241552,Infliximab,Off label use,HO
198241552,Infliximab,Drug ineffective,OT
198241552,Infliximab,Drug ineffective,HO
198241552,Infliximab,Cytomegalovirus infection,OT
198241552,Infliximab,Cytomegalovirus infection,HO
198241552,Infliximab,Off label use,OT
198241552,Infliximab,Off label use,HO
198241552,Infliximab,Drug ineffective,OT
198241552,Infliximab,Drug ineffective,HO
198241552,Infliximab,Cytomegalovirus infection,OT
198241552,Infliximab,Cytomegalovirus infection,HO
198241552,Infliximab,Off label use,OT
198241552,Infliximab,Off label use,HO
198241552,Infliximab,Drug ineffective,OT
198241552,Infliximab,Drug ineffective,HO
198241552,Infliximab,Cytomegalovirus infection,OT
198241552,Infliximab,Cytomegalovirus infection,HO
198241552,Infliximab,Off label use,OT
198241552,Infliximab,Off label use,HO
198241552,Infliximab,Drug ineffective,OT
198241552,Infliximab,Drug ineffective,HO
198241552,Infliximab,Cytomegalovirus infection,OT
198241552,Infliximab,Cytomegalovirus infection,HO
198241552,Infliximab,Off label use,OT
198241552,Infliximab,Off label use,HO
198241552,Infliximab,Drug ineffective,OT
198241552,Infliximab,Drug ineffective,HO
198241552,Infliximab,Cytomegalovirus infection,OT
198241552,Infliximab,Cytomegalovirus infection,HO
198241552,Infliximab,Off label use,OT
198241552,Infliximab,Off label use,HO
198241552,Infliximab,Drug ineffective,OT
198241552,Infliximab,Drug ineffective,HO
198241552,Infliximab,Cytomegalovirus infection,OT
198241552,Infliximab,Cytomegalovirus infection,HO
152566893,Infliximab,Off label use,OT
152566893,Infliximab,Off label use,HO
152566893,Infliximab,Intestinal stenosis,OT
152566893,Infliximab,Intestinal stenosis,HO
160703985,Infliximab,Weight increased,OT
160703985,Infliximab,Weight decreased,OT
160703985,Infliximab,Product use issue,OT
160703985,Infliximab,Poor venous access,OT
160703985,Infliximab,Pneumonia,OT
160703985,Infliximab,Off label use,OT
160703985,Infliximab,Nasopharyngitis,OT
160703985,Infliximab,Ear pain,OT
160703985,Infliximab,Drug ineffective,OT
160703985,Infliximab,Blood pressure diastolic increased,OT
176065964,Infliximab,Vulvovaginal pain,HO
176065964,Infliximab,Vulvovaginal pain,OT
176065964,Infliximab,Vaginal ulceration,HO
176065964,Infliximab,Vaginal ulceration,OT
176065964,Infliximab,Vaginal lesion,HO
176065964,Infliximab,Vaginal lesion,OT
176065964,Infliximab,Vaginal infection,HO
176065964,Infliximab,Vaginal infection,OT
176065964,Infliximab,Nasopharyngitis,HO
176065964,Infliximab,Nasopharyngitis,OT
176065964,Infliximab,Nasal congestion,HO
176065964,Infliximab,Nasal congestion,OT
176065964,Infliximab,Inflammatory bowel disease,HO
176065964,Infliximab,Inflammatory bowel disease,OT
176065964,Infliximab,Inappropriate schedule of product administration,HO
176065964,Infliximab,Inappropriate schedule of product administration,OT
176065964,Infliximab,Impaired healing,HO
176065964,Infliximab,Impaired healing,OT
176065964,Infliximab,Haemorrhoidal haemorrhage,HO
176065964,Infliximab,Haemorrhoidal haemorrhage,OT
176065964,Infliximab,Fatigue,HO
176065964,Infliximab,Fatigue,OT
176065964,Infliximab,Endometriosis,HO
176065964,Infliximab,Endometriosis,OT
176065964,Infliximab,Disease recurrence,HO
176065964,Infliximab,Disease recurrence,OT
176065964,Infliximab,Condition aggravated,HO
176065964,Infliximab,Condition aggravated,OT
176065964,Infliximab,Bacterial vaginosis,HO
176065964,Infliximab,Bacterial vaginosis,OT
176065964,Infliximab,Alopecia,HO
176065964,Infliximab,Alopecia,OT
176065964,Infliximab,Abscess,HO
176065964,Infliximab,Abscess,OT
176065964,Infliximab,Abdominal pain,HO
176065964,Infliximab,Abdominal pain,OT
176478514,Infliximab,Weight increased,OT
176478514,Infliximab,Weight decreased,OT
176478514,Infliximab,Sinusitis,OT
176478514,Infliximab,Poor venous access,OT
176478514,Infliximab,Peripheral swelling,OT
176478514,Infliximab,Off label use,OT
176478514,Infliximab,Oedema,OT
176478514,Infliximab,Nasopharyngitis,OT
176478514,Infliximab,Malaise,OT
176478514,Infliximab,Infusion site extravasation,OT
176478514,Infliximab,Influenza,OT
176478514,Infliximab,Inappropriate schedule of product administration,OT
176478514,Infliximab,Heart rate irregular,OT
176478514,Infliximab,Heart rate increased,OT
176478514,Infliximab,Erythema,OT
176478514,Infliximab,Drug ineffective,OT
176478514,Infliximab,Condition aggravated,OT
176478514,Infliximab,Body temperature fluctuation,OT
176478514,Infliximab,Body temperature decreased,OT
176478514,Infliximab,Blood pressure increased,OT
176478514,Infliximab,Blood pressure fluctuation,OT
176478514,Infliximab,Blood pressure diastolic increased,OT
176478514,Infliximab,Anxiety,OT
176478514,Infliximab,Weight increased,OT
176478514,Infliximab,Weight decreased,OT
176478514,Infliximab,Sinusitis,OT
176478514,Infliximab,Poor venous access,OT
176478514,Infliximab,Peripheral swelling,OT
176478514,Infliximab,Off label use,OT
176478514,Infliximab,Oedema,OT
176478514,Infliximab,Nasopharyngitis,OT
176478514,Infliximab,Malaise,OT
176478514,Infliximab,Infusion site extravasation,OT
176478514,Infliximab,Influenza,OT
176478514,Infliximab,Inappropriate schedule of product administration,OT
176478514,Infliximab,Heart rate irregular,OT
176478514,Infliximab,Heart rate increased,OT
176478514,Infliximab,Erythema,OT
176478514,Infliximab,Drug ineffective,OT
176478514,Infliximab,Condition aggravated,OT
176478514,Infliximab,Body temperature fluctuation,OT
176478514,Infliximab,Body temperature decreased,OT
176478514,Infliximab,Blood pressure increased,OT
176478514,Infliximab,Blood pressure fluctuation,OT
176478514,Infliximab,Blood pressure diastolic increased,OT
176478514,Infliximab,Anxiety,OT
176824133,Infliximab,Skin cancer,OT
176824133,Infliximab,Pyrexia,OT
176824133,Infliximab,Productive cough,OT
176824133,Infliximab,Product use issue,OT
176824133,Infliximab,Oropharyngeal pain,OT
176824133,Infliximab,Off label use,OT
176824133,Infliximab,Malaise,OT
176824133,Infliximab,Intentional product use issue,OT
176824133,Infliximab,Influenza,OT
176824133,Infliximab,Inappropriate schedule of product administration,OT
176824133,Infliximab,Illness,OT
176824133,Infliximab,Gastrooesophageal reflux disease,OT
176824133,Infliximab,Fatigue,OT
176824133,Infliximab,Dyspnoea,OT
176824133,Infliximab,Drug ineffective,OT
176824133,Infliximab,Cough,OT
176824133,Infliximab,Condition aggravated,OT
176824133,Infliximab,Blood pressure increased,OT
176824133,Infliximab,Blood pressure fluctuation,OT
176824133,Infliximab,Skin cancer,OT
176824133,Infliximab,Pyrexia,OT
176824133,Infliximab,Productive cough,OT
176824133,Infliximab,Product use issue,OT
176824133,Infliximab,Oropharyngeal pain,OT
176824133,Infliximab,Off label use,OT
176824133,Infliximab,Malaise,OT
176824133,Infliximab,Intentional product use issue,OT
176824133,Infliximab,Influenza,OT
176824133,Infliximab,Inappropriate schedule of product administration,OT
176824133,Infliximab,Illness,OT
176824133,Infliximab,Gastrooesophageal reflux disease,OT
176824133,Infliximab,Fatigue,OT
176824133,Infliximab,Dyspnoea,OT
176824133,Infliximab,Drug ineffective,OT
176824133,Infliximab,Cough,OT
176824133,Infliximab,Condition aggravated,OT
176824133,Infliximab,Blood pressure increased,OT
176824133,Infliximab,Blood pressure fluctuation,OT
177877495,Infliximab,Ulcer,HO
177877495,Infliximab,Ulcer,DS
177877495,Infliximab,Ulcer,OT
177877495,Infliximab,Tongue disorder,HO
177877495,Infliximab,Tongue disorder,DS
177877495,Infliximab,Tongue disorder,OT
177877495,Infliximab,Therapeutic response decreased,HO
177877495,Infliximab,Therapeutic response decreased,DS
177877495,Infliximab,Therapeutic response decreased,OT
177877495,Infliximab,Therapeutic product effect incomplete,HO
177877495,Infliximab,Therapeutic product effect incomplete,DS
177877495,Infliximab,Therapeutic product effect incomplete,OT
177877495,Infliximab,Therapeutic product effect decreased,HO
177877495,Infliximab,Therapeutic product effect decreased,DS
177877495,Infliximab,Therapeutic product effect decreased,OT
177877495,Infliximab,Tenosynovitis,HO
177877495,Infliximab,Tenosynovitis,DS
177877495,Infliximab,Tenosynovitis,OT
177877495,Infliximab,Tendonitis,HO
177877495,Infliximab,Tendonitis,DS
177877495,Infliximab,Tendonitis,OT
177877495,Infliximab,Synovitis,HO
177877495,Infliximab,Synovitis,DS
177877495,Infliximab,Synovitis,OT
177877495,Infliximab,Skin ulcer,HO
177877495,Infliximab,Skin ulcer,DS
177877495,Infliximab,Skin ulcer,OT
177877495,Infliximab,Skin necrosis,HO
177877495,Infliximab,Skin necrosis,DS
177877495,Infliximab,Skin necrosis,OT
177877495,Infliximab,Rheumatoid nodule,HO
177877495,Infliximab,Rheumatoid nodule,DS
177877495,Infliximab,Rheumatoid nodule,OT
177877495,Infliximab,Rheumatoid arthritis,HO
177877495,Infliximab,Rheumatoid arthritis,DS
177877495,Infliximab,Rheumatoid arthritis,OT
177877495,Infliximab,Red blood cell sedimentation rate increased,HO
177877495,Infliximab,Red blood cell sedimentation rate increased,DS
177877495,Infliximab,Red blood cell sedimentation rate increased,OT
177877495,Infliximab,Rash pruritic,HO
177877495,Infliximab,Rash pruritic,DS
177877495,Infliximab,Rash pruritic,OT
177877495,Infliximab,Rash,HO
177877495,Infliximab,Rash,DS
177877495,Infliximab,Rash,OT
177877495,Infliximab,Psoriatic arthropathy,HO
177877495,Infliximab,Psoriatic arthropathy,DS
177877495,Infliximab,Psoriatic arthropathy,OT
177877495,Infliximab,Product use issue,HO
177877495,Infliximab,Product use issue,DS
177877495,Infliximab,Product use issue,OT
177877495,Infliximab,Peripheral swelling,HO
177877495,Infliximab,Peripheral swelling,DS
177877495,Infliximab,Peripheral swelling,OT
177877495,Infliximab,Panniculitis,HO
177877495,Infliximab,Panniculitis,DS
177877495,Infliximab,Panniculitis,OT
177877495,Infliximab,Pain,HO
177877495,Infliximab,Pain,DS
177877495,Infliximab,Pain,OT
177877495,Infliximab,Off label use,HO
177877495,Infliximab,Off label use,DS
177877495,Infliximab,Off label use,OT
177877495,Infliximab,Nausea,HO
177877495,Infliximab,Nausea,DS
177877495,Infliximab,Nausea,OT
177877495,Infliximab,Musculoskeletal stiffness,HO
177877495,Infliximab,Musculoskeletal stiffness,DS
177877495,Infliximab,Musculoskeletal stiffness,OT
177877495,Infliximab,Musculoskeletal disorder,HO
177877495,Infliximab,Musculoskeletal disorder,DS
177877495,Infliximab,Musculoskeletal disorder,OT
177877495,Infliximab,Loss of personal independence in daily activities,HO
177877495,Infliximab,Loss of personal independence in daily activities,DS
177877495,Infliximab,Loss of personal independence in daily activities,OT
177877495,Infliximab,Infusion related reaction,HO
177877495,Infliximab,Infusion related reaction,DS
177877495,Infliximab,Infusion related reaction,OT
177877495,Infliximab,Inflammation,HO
177877495,Infliximab,Inflammation,DS
177877495,Infliximab,Inflammation,OT
177877495,Infliximab,Hypersensitivity,HO
177877495,Infliximab,Hypersensitivity,DS
177877495,Infliximab,Hypersensitivity,OT
177877495,Infliximab,Hypercalcaemia,HO
177877495,Infliximab,Hypercalcaemia,DS
177877495,Infliximab,Hypercalcaemia,OT
177877495,Infliximab,Headache,HO
177877495,Infliximab,Headache,DS
177877495,Infliximab,Headache,OT
177877495,Infliximab,Granuloma skin,HO
177877495,Infliximab,Granuloma skin,DS
177877495,Infliximab,Granuloma skin,OT
177877495,Infliximab,Gastric disorder,HO
177877495,Infliximab,Gastric disorder,DS
177877495,Infliximab,Gastric disorder,OT
177877495,Infliximab,Erythema,HO
177877495,Infliximab,Erythema,DS
177877495,Infliximab,Erythema,OT
177877495,Infliximab,Enthesopathy,HO
177877495,Infliximab,Enthesopathy,DS
177877495,Infliximab,Enthesopathy,OT
177877495,Infliximab,Drug tolerance decreased,HO
177877495,Infliximab,Drug tolerance decreased,DS
177877495,Infliximab,Drug tolerance decreased,OT
177877495,Infliximab,Drug tolerance,HO
177877495,Infliximab,Drug tolerance,DS
177877495,Infliximab,Drug tolerance,OT
177877495,Infliximab,Drug intolerance,HO
177877495,Infliximab,Drug intolerance,DS
177877495,Infliximab,Drug intolerance,OT
177877495,Infliximab,Drug ineffective,HO
177877495,Infliximab,Drug ineffective,DS
177877495,Infliximab,Drug ineffective,OT
177877495,Infliximab,Drug hypersensitivity,HO
177877495,Infliximab,Drug hypersensitivity,DS
177877495,Infliximab,Drug hypersensitivity,OT
177877495,Infliximab,Drug eruption,HO
177877495,Infliximab,Drug eruption,DS
177877495,Infliximab,Drug eruption,OT
177877495,Infliximab,Condition aggravated,HO
177877495,Infliximab,Condition aggravated,DS
177877495,Infliximab,Condition aggravated,OT
177877495,Infliximab,C-reactive protein increased,HO
177877495,Infliximab,C-reactive protein increased,DS
177877495,Infliximab,C-reactive protein increased,OT
177877495,Infliximab,C-reactive protein abnormal,HO
177877495,Infliximab,C-reactive protein abnormal,DS
177877495,Infliximab,C-reactive protein abnormal,OT
177877495,Infliximab,Blood parathyroid hormone decreased,HO
177877495,Infliximab,Blood parathyroid hormone decreased,DS
177877495,Infliximab,Blood parathyroid hormone decreased,OT
177877495,Infliximab,Basal cell carcinoma,HO
177877495,Infliximab,Basal cell carcinoma,DS
177877495,Infliximab,Basal cell carcinoma,OT
177877495,Infliximab,Aspartate aminotransferase increased,HO
177877495,Infliximab,Aspartate aminotransferase increased,DS
177877495,Infliximab,Aspartate aminotransferase increased,OT
177877495,Infliximab,Arthralgia,HO
177877495,Infliximab,Arthralgia,DS
177877495,Infliximab,Arthralgia,OT
177877495,Infliximab,Alopecia,HO
177877495,Infliximab,Alopecia,DS
177877495,Infliximab,Alopecia,OT
177877495,Infliximab,Alanine aminotransferase increased,HO
177877495,Infliximab,Alanine aminotransferase increased,DS
177877495,Infliximab,Alanine aminotransferase increased,OT
177877495,Infliximab,Adverse event,HO
177877495,Infliximab,Adverse event,DS
177877495,Infliximab,Adverse event,OT
179053683,Infliximab,Wheezing,HO
179053683,Infliximab,Wheezing,OT
179053683,Infliximab,Weight decreased,HO
179053683,Infliximab,Weight decreased,OT
179053683,Infliximab,Urinary tract infection,HO
179053683,Infliximab,Urinary tract infection,OT
179053683,Infliximab,Pyrexia,HO
179053683,Infliximab,Pyrexia,OT
179053683,Infliximab,Pyelonephritis,HO
179053683,Infliximab,Pyelonephritis,OT
179053683,Infliximab,Productive cough,HO
179053683,Infliximab,Productive cough,OT
179053683,Infliximab,Pneumonia,HO
179053683,Infliximab,Pneumonia,OT
179053683,Infliximab,Pain in extremity,HO
179053683,Infliximab,Pain in extremity,OT
179053683,Infliximab,Pain,HO
179053683,Infliximab,Pain,OT
179053683,Infliximab,Off label use,HO
179053683,Infliximab,Off label use,OT
179053683,Infliximab,Oedema peripheral,HO
179053683,Infliximab,Oedema peripheral,OT
179053683,Infliximab,Nasopharyngitis,HO
179053683,Infliximab,Nasopharyngitis,OT
179053683,Infliximab,Myalgia,HO
179053683,Infliximab,Myalgia,OT
179053683,Infliximab,Malaise,HO
179053683,Infliximab,Malaise,OT
179053683,Infliximab,Kidney infection,HO
179053683,Infliximab,Kidney infection,OT
179053683,Infliximab,Influenza,HO
179053683,Infliximab,Influenza,OT
179053683,Infliximab,Inappropriate schedule of product administration,HO
179053683,Infliximab,Inappropriate schedule of product administration,OT
179053683,Infliximab,Gastrointestinal pain,HO
179053683,Infliximab,Gastrointestinal pain,OT
179053683,Infliximab,Fatigue,HO
179053683,Infliximab,Fatigue,OT
179053683,Infliximab,Dyspnoea,HO
179053683,Infliximab,Dyspnoea,OT
179053683,Infliximab,Drug ineffective,HO
179053683,Infliximab,Drug ineffective,OT
179053683,Infliximab,Diarrhoea,HO
179053683,Infliximab,Diarrhoea,OT
179053683,Infliximab,Cystitis,HO
179053683,Infliximab,Cystitis,OT
179053683,Infliximab,Cough,HO
179053683,Infliximab,Cough,OT
179053683,Infliximab,Condition aggravated,HO
179053683,Infliximab,Condition aggravated,OT
179053683,Infliximab,Chest pain,HO
179053683,Infliximab,Chest pain,OT
179053683,Infliximab,Blood pressure fluctuation,HO
179053683,Infliximab,Blood pressure fluctuation,OT
179053683,Infliximab,Asthenia,HO
179053683,Infliximab,Asthenia,OT
179053683,Infliximab,Arthralgia,HO
179053683,Infliximab,Arthralgia,OT
179053683,Infliximab,Aphonia,HO
179053683,Infliximab,Aphonia,OT
179053683,Infliximab,Abdominal pain,HO
179053683,Infliximab,Abdominal pain,OT
179053683,Infliximab,Abdominal distension,HO
179053683,Infliximab,Abdominal distension,OT
179053683,Infliximab,Wheezing,HO
179053683,Infliximab,Wheezing,OT
179053683,Infliximab,Weight decreased,HO
179053683,Infliximab,Weight decreased,OT
179053683,Infliximab,Urinary tract infection,HO
179053683,Infliximab,Urinary tract infection,OT
179053683,Infliximab,Pyrexia,HO
179053683,Infliximab,Pyrexia,OT
179053683,Infliximab,Pyelonephritis,HO
179053683,Infliximab,Pyelonephritis,OT
179053683,Infliximab,Productive cough,HO
179053683,Infliximab,Productive cough,OT
179053683,Infliximab,Pneumonia,HO
179053683,Infliximab,Pneumonia,OT
179053683,Infliximab,Pain in extremity,HO
179053683,Infliximab,Pain in extremity,OT
179053683,Infliximab,Pain,HO
179053683,Infliximab,Pain,OT
179053683,Infliximab,Off label use,HO
179053683,Infliximab,Off label use,OT
179053683,Infliximab,Oedema peripheral,HO
179053683,Infliximab,Oedema peripheral,OT
179053683,Infliximab,Nasopharyngitis,HO
179053683,Infliximab,Nasopharyngitis,OT
179053683,Infliximab,Myalgia,HO
179053683,Infliximab,Myalgia,OT
179053683,Infliximab,Malaise,HO
179053683,Infliximab,Malaise,OT
179053683,Infliximab,Kidney infection,HO
179053683,Infliximab,Kidney infection,OT
179053683,Infliximab,Influenza,HO
179053683,Infliximab,Influenza,OT
179053683,Infliximab,Inappropriate schedule of product administration,HO
179053683,Infliximab,Inappropriate schedule of product administration,OT
179053683,Infliximab,Gastrointestinal pain,HO
179053683,Infliximab,Gastrointestinal pain,OT
179053683,Infliximab,Fatigue,HO
179053683,Infliximab,Fatigue,OT
179053683,Infliximab,Dyspnoea,HO
179053683,Infliximab,Dyspnoea,OT
179053683,Infliximab,Drug ineffective,HO
179053683,Infliximab,Drug ineffective,OT
179053683,Infliximab,Diarrhoea,HO
179053683,Infliximab,Diarrhoea,OT
179053683,Infliximab,Cystitis,HO
179053683,Infliximab,Cystitis,OT
179053683,Infliximab,Cough,HO
179053683,Infliximab,Cough,OT
179053683,Infliximab,Condition aggravated,HO
179053683,Infliximab,Condition aggravated,OT
179053683,Infliximab,Chest pain,HO
179053683,Infliximab,Chest pain,OT
179053683,Infliximab,Blood pressure fluctuation,HO
179053683,Infliximab,Blood pressure fluctuation,OT
179053683,Infliximab,Asthenia,HO
179053683,Infliximab,Asthenia,OT
179053683,Infliximab,Arthralgia,HO
179053683,Infliximab,Arthralgia,OT
179053683,Infliximab,Aphonia,HO
179053683,Infliximab,Aphonia,OT
179053683,Infliximab,Abdominal pain,HO
179053683,Infliximab,Abdominal pain,OT
179053683,Infliximab,Abdominal distension,HO
179053683,Infliximab,Abdominal distension,OT
179053683,Infliximab,Wheezing,HO
179053683,Infliximab,Wheezing,OT
179053683,Infliximab,Weight decreased,HO
179053683,Infliximab,Weight decreased,OT
179053683,Infliximab,Urinary tract infection,HO
179053683,Infliximab,Urinary tract infection,OT
179053683,Infliximab,Pyrexia,HO
179053683,Infliximab,Pyrexia,OT
179053683,Infliximab,Pyelonephritis,HO
179053683,Infliximab,Pyelonephritis,OT
179053683,Infliximab,Productive cough,HO
179053683,Infliximab,Productive cough,OT
179053683,Infliximab,Pneumonia,HO
179053683,Infliximab,Pneumonia,OT
179053683,Infliximab,Pain in extremity,HO
179053683,Infliximab,Pain in extremity,OT
179053683,Infliximab,Pain,HO
179053683,Infliximab,Pain,OT
179053683,Infliximab,Off label use,HO
179053683,Infliximab,Off label use,OT
179053683,Infliximab,Oedema peripheral,HO
179053683,Infliximab,Oedema peripheral,OT
179053683,Infliximab,Nasopharyngitis,HO
179053683,Infliximab,Nasopharyngitis,OT
179053683,Infliximab,Myalgia,HO
179053683,Infliximab,Myalgia,OT
179053683,Infliximab,Malaise,HO
179053683,Infliximab,Malaise,OT
179053683,Infliximab,Kidney infection,HO
179053683,Infliximab,Kidney infection,OT
179053683,Infliximab,Influenza,HO
179053683,Infliximab,Influenza,OT
179053683,Infliximab,Inappropriate schedule of product administration,HO
179053683,Infliximab,Inappropriate schedule of product administration,OT
179053683,Infliximab,Gastrointestinal pain,HO
179053683,Infliximab,Gastrointestinal pain,OT
179053683,Infliximab,Fatigue,HO
179053683,Infliximab,Fatigue,OT
179053683,Infliximab,Dyspnoea,HO
179053683,Infliximab,Dyspnoea,OT
179053683,Infliximab,Drug ineffective,HO
179053683,Infliximab,Drug ineffective,OT
179053683,Infliximab,Diarrhoea,HO
179053683,Infliximab,Diarrhoea,OT
179053683,Infliximab,Cystitis,HO
179053683,Infliximab,Cystitis,OT
179053683,Infliximab,Cough,HO
179053683,Infliximab,Cough,OT
179053683,Infliximab,Condition aggravated,HO
179053683,Infliximab,Condition aggravated,OT
179053683,Infliximab,Chest pain,HO
179053683,Infliximab,Chest pain,OT
179053683,Infliximab,Blood pressure fluctuation,HO
179053683,Infliximab,Blood pressure fluctuation,OT
179053683,Infliximab,Asthenia,HO
179053683,Infliximab,Asthenia,OT
179053683,Infliximab,Arthralgia,HO
179053683,Infliximab,Arthralgia,OT
179053683,Infliximab,Aphonia,HO
179053683,Infliximab,Aphonia,OT
179053683,Infliximab,Abdominal pain,HO
179053683,Infliximab,Abdominal pain,OT
179053683,Infliximab,Abdominal distension,HO
179053683,Infliximab,Abdominal distension,OT
182450004,Infliximab,Weight decreased,DE
182450004,Infliximab,Weight decreased,HO
182450004,Infliximab,Weight decreased,OT
182450004,Infliximab,Rectal haemorrhage,DE
182450004,Infliximab,Rectal haemorrhage,HO
182450004,Infliximab,Rectal haemorrhage,OT
182450004,Infliximab,Product use issue,DE
182450004,Infliximab,Product use issue,HO
182450004,Infliximab,Product use issue,OT
182450004,Infliximab,Off label use,DE
182450004,Infliximab,Off label use,HO
182450004,Infliximab,Off label use,OT
182450004,Infliximab,Oedema peripheral,DE
182450004,Infliximab,Oedema peripheral,HO
182450004,Infliximab,Oedema peripheral,OT
182450004,Infliximab,Myocardial infarction,DE
182450004,Infliximab,Myocardial infarction,HO
182450004,Infliximab,Myocardial infarction,OT
182450004,Infliximab,Loss of consciousness,DE
182450004,Infliximab,Loss of consciousness,HO
182450004,Infliximab,Loss of consciousness,OT
182450004,Infliximab,Intentional product use issue,DE
182450004,Infliximab,Intentional product use issue,HO
182450004,Infliximab,Intentional product use issue,OT
182450004,Infliximab,Incorrect dose administered,DE
182450004,Infliximab,Incorrect dose administered,HO
182450004,Infliximab,Incorrect dose administered,OT
182450004,Infliximab,Inappropriate schedule of product administration,DE
182450004,Infliximab,Inappropriate schedule of product administration,HO
182450004,Infliximab,Inappropriate schedule of product administration,OT
182450004,Infliximab,Heart rate decreased,DE
182450004,Infliximab,Heart rate decreased,HO
182450004,Infliximab,Heart rate decreased,OT
182450004,Infliximab,General physical health deterioration,DE
182450004,Infliximab,General physical health deterioration,HO
182450004,Infliximab,General physical health deterioration,OT
182450004,Infliximab,Gastrointestinal haemorrhage,DE
182450004,Infliximab,Gastrointestinal haemorrhage,HO
182450004,Infliximab,Gastrointestinal haemorrhage,OT
182450004,Infliximab,Faecal calprotectin increased,DE
182450004,Infliximab,Faecal calprotectin increased,HO
182450004,Infliximab,Faecal calprotectin increased,OT
182450004,Infliximab,Drug level decreased,DE
182450004,Infliximab,Drug level decreased,HO
182450004,Infliximab,Drug level decreased,OT
182450004,Infliximab,Drug level below therapeutic,DE
182450004,Infliximab,Drug level below therapeutic,HO
182450004,Infliximab,Drug level below therapeutic,OT
182450004,Infliximab,Drug level above therapeutic,DE
182450004,Infliximab,Drug level above therapeutic,HO
182450004,Infliximab,Drug level above therapeutic,OT
182450004,Infliximab,Condition aggravated,DE
182450004,Infliximab,Condition aggravated,HO
182450004,Infliximab,Condition aggravated,OT
182450004,Infliximab,Cerebral artery occlusion,DE
182450004,Infliximab,Cerebral artery occlusion,HO
182450004,Infliximab,Cerebral artery occlusion,OT
182450004,Infliximab,Blood pressure diastolic decreased,DE
182450004,Infliximab,Blood pressure diastolic decreased,HO
182450004,Infliximab,Blood pressure diastolic decreased,OT
182450004,Infliximab,Blood pressure decreased,DE
182450004,Infliximab,Blood pressure decreased,HO
182450004,Infliximab,Blood pressure decreased,OT
182450004,Infliximab,Blood iron decreased,DE
182450004,Infliximab,Blood iron decreased,HO
182450004,Infliximab,Blood iron decreased,OT
182450004,Infliximab,Anaemia,DE
182450004,Infliximab,Anaemia,HO
182450004,Infliximab,Anaemia,OT
184125033,Infliximab,Vertigo,OT
184125033,Infliximab,Renal failure,OT
184125033,Infliximab,Product use issue,OT
184125033,Infliximab,Off label use,OT
184125033,Infliximab,Intentional product use issue,OT
184125033,Infliximab,Head discomfort,OT
184125033,Infliximab,Fatigue,OT
184125033,Infliximab,Drug level above therapeutic,OT
184125033,Infliximab,Condition aggravated,OT
184125033,Infliximab,Blood pressure fluctuation,OT
184125033,Infliximab,Alopecia,OT
184125033,Infliximab,Vertigo,OT
184125033,Infliximab,Renal failure,OT
184125033,Infliximab,Product use issue,OT
184125033,Infliximab,Off label use,OT
184125033,Infliximab,Intentional product use issue,OT
184125033,Infliximab,Head discomfort,OT
184125033,Infliximab,Fatigue,OT
184125033,Infliximab,Drug level above therapeutic,OT
184125033,Infliximab,Condition aggravated,OT
184125033,Infliximab,Blood pressure fluctuation,OT
184125033,Infliximab,Alopecia,OT
184516295,Infliximab,Vaginal fistula,HO
184516295,Infliximab,Vaginal fistula,OT
184516295,Infliximab,Small intestinal perforation,HO
184516295,Infliximab,Small intestinal perforation,OT
184516295,Infliximab,Inflammation,HO
184516295,Infliximab,Inflammation,OT
184606843,Infliximab,Wheelchair user,HO
184606843,Infliximab,Wheelchair user,OT
184606843,Infliximab,Vomiting,HO
184606843,Infliximab,Vomiting,OT
184606843,Infliximab,Therapy non-responder,HO
184606843,Infliximab,Therapy non-responder,OT
184606843,Infliximab,Therapeutic product effect decreased,HO
184606843,Infliximab,Therapeutic product effect decreased,OT
184606843,Infliximab,Synovitis,HO
184606843,Infliximab,Synovitis,OT
184606843,Infliximab,Septic shock,HO
184606843,Infliximab,Septic shock,OT
184606843,Infliximab,Rheumatoid factor positive,HO
184606843,Infliximab,Rheumatoid factor positive,OT
184606843,Infliximab,Rheumatoid arthritis,HO
184606843,Infliximab,Rheumatoid arthritis,OT
184606843,Infliximab,Red blood cell sedimentation rate abnormal,HO
184606843,Infliximab,Red blood cell sedimentation rate abnormal,OT
184606843,Infliximab,Pyrexia,HO
184606843,Infliximab,Pyrexia,OT
184606843,Infliximab,Pulmonary fibrosis,HO
184606843,Infliximab,Pulmonary fibrosis,OT
184606843,Infliximab,Psoriasis,HO
184606843,Infliximab,Psoriasis,OT
184606843,Infliximab,Product use in unapproved indication,HO
184606843,Infliximab,Product use in unapproved indication,OT
184606843,Infliximab,Polyarthritis,HO
184606843,Infliximab,Polyarthritis,OT
184606843,Infliximab,Pleural effusion,HO
184606843,Infliximab,Pleural effusion,OT
184606843,Infliximab,Off label use,HO
184606843,Infliximab,Off label use,OT
184606843,Infliximab,Obesity,HO
184606843,Infliximab,Obesity,OT
184606843,Infliximab,Nodule,HO
184606843,Infliximab,Nodule,OT
184606843,Infliximab,Nausea,HO
184606843,Infliximab,Nausea,OT
184606843,Infliximab,Mobility decreased,HO
184606843,Infliximab,Mobility decreased,OT
184606843,Infliximab,Malaise,HO
184606843,Infliximab,Malaise,OT
184606843,Infliximab,Loss of personal independence in daily activities,HO
184606843,Infliximab,Loss of personal independence in daily activities,OT
184606843,Infliximab,Loss of consciousness,HO
184606843,Infliximab,Loss of consciousness,OT
184606843,Infliximab,Limb discomfort,HO
184606843,Infliximab,Limb discomfort,OT
184606843,Infliximab,Joint destruction,HO
184606843,Infliximab,Joint destruction,OT
184606843,Infliximab,Intentional product use issue,HO
184606843,Infliximab,Intentional product use issue,OT
184606843,Infliximab,Infection,HO
184606843,Infliximab,Infection,OT
184606843,Infliximab,Immunodeficiency,HO
184606843,Infliximab,Immunodeficiency,OT
184606843,Infliximab,Ill-defined disorder,HO
184606843,Infliximab,Ill-defined disorder,OT
184606843,Infliximab,Hypotension,HO
184606843,Infliximab,Hypotension,OT
184606843,Infliximab,Hypokalaemia,HO
184606843,Infliximab,Hypokalaemia,OT
184606843,Infliximab,Hypocalcaemia,HO
184606843,Infliximab,Hypocalcaemia,OT
184606843,Infliximab,Hypertension,HO
184606843,Infliximab,Hypertension,OT
184606843,Infliximab,Hand deformity,HO
184606843,Infliximab,Hand deformity,OT
184606843,Infliximab,Gastroenteritis viral,HO
184606843,Infliximab,Gastroenteritis viral,OT
184606843,Infliximab,Foot operation,HO
184606843,Infliximab,Foot operation,OT
184606843,Infliximab,Foot deformity,HO
184606843,Infliximab,Foot deformity,OT
184606843,Infliximab,Drug intolerance,HO
184606843,Infliximab,Drug intolerance,OT
184606843,Infliximab,Drug ineffective,HO
184606843,Infliximab,Drug ineffective,OT
184606843,Infliximab,Drug hypersensitivity,HO
184606843,Infliximab,Drug hypersensitivity,OT
184606843,Infliximab,Dizziness,HO
184606843,Infliximab,Dizziness,OT
184606843,Infliximab,Diarrhoea,HO
184606843,Infliximab,Diarrhoea,OT
184606843,Infliximab,Contraindicated product administered,HO
184606843,Infliximab,Contraindicated product administered,OT
184606843,Infliximab,Condition aggravated,HO
184606843,Infliximab,Condition aggravated,OT
184606843,Infliximab,Arthropathy,HO
184606843,Infliximab,Arthropathy,OT
184606843,Infliximab,Arthritis,HO
184606843,Infliximab,Arthritis,OT
184606843,Infliximab,Anti-cyclic citrullinated peptide antibody positive,HO
184606843,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
184606843,Infliximab,Ankle arthroplasty,HO
184606843,Infliximab,Ankle arthroplasty,OT
184606843,Infliximab,Adrenal insufficiency,HO
184606843,Infliximab,Adrenal insufficiency,OT
184606843,Infliximab,Wheelchair user,HO
184606843,Infliximab,Wheelchair user,OT
184606843,Infliximab,Vomiting,HO
184606843,Infliximab,Vomiting,OT
184606843,Infliximab,Therapy non-responder,HO
184606843,Infliximab,Therapy non-responder,OT
184606843,Infliximab,Therapeutic product effect decreased,HO
184606843,Infliximab,Therapeutic product effect decreased,OT
184606843,Infliximab,Synovitis,HO
184606843,Infliximab,Synovitis,OT
184606843,Infliximab,Septic shock,HO
184606843,Infliximab,Septic shock,OT
184606843,Infliximab,Rheumatoid factor positive,HO
184606843,Infliximab,Rheumatoid factor positive,OT
184606843,Infliximab,Rheumatoid arthritis,HO
184606843,Infliximab,Rheumatoid arthritis,OT
184606843,Infliximab,Red blood cell sedimentation rate abnormal,HO
184606843,Infliximab,Red blood cell sedimentation rate abnormal,OT
184606843,Infliximab,Pyrexia,HO
184606843,Infliximab,Pyrexia,OT
184606843,Infliximab,Pulmonary fibrosis,HO
184606843,Infliximab,Pulmonary fibrosis,OT
184606843,Infliximab,Psoriasis,HO
184606843,Infliximab,Psoriasis,OT
184606843,Infliximab,Product use in unapproved indication,HO
184606843,Infliximab,Product use in unapproved indication,OT
184606843,Infliximab,Polyarthritis,HO
184606843,Infliximab,Polyarthritis,OT
184606843,Infliximab,Pleural effusion,HO
184606843,Infliximab,Pleural effusion,OT
184606843,Infliximab,Off label use,HO
184606843,Infliximab,Off label use,OT
184606843,Infliximab,Obesity,HO
184606843,Infliximab,Obesity,OT
184606843,Infliximab,Nodule,HO
184606843,Infliximab,Nodule,OT
184606843,Infliximab,Nausea,HO
184606843,Infliximab,Nausea,OT
184606843,Infliximab,Mobility decreased,HO
184606843,Infliximab,Mobility decreased,OT
184606843,Infliximab,Malaise,HO
184606843,Infliximab,Malaise,OT
184606843,Infliximab,Loss of personal independence in daily activities,HO
184606843,Infliximab,Loss of personal independence in daily activities,OT
184606843,Infliximab,Loss of consciousness,HO
184606843,Infliximab,Loss of consciousness,OT
184606843,Infliximab,Limb discomfort,HO
184606843,Infliximab,Limb discomfort,OT
184606843,Infliximab,Joint destruction,HO
184606843,Infliximab,Joint destruction,OT
184606843,Infliximab,Intentional product use issue,HO
184606843,Infliximab,Intentional product use issue,OT
184606843,Infliximab,Infection,HO
184606843,Infliximab,Infection,OT
184606843,Infliximab,Immunodeficiency,HO
184606843,Infliximab,Immunodeficiency,OT
184606843,Infliximab,Ill-defined disorder,HO
184606843,Infliximab,Ill-defined disorder,OT
184606843,Infliximab,Hypotension,HO
184606843,Infliximab,Hypotension,OT
184606843,Infliximab,Hypokalaemia,HO
184606843,Infliximab,Hypokalaemia,OT
184606843,Infliximab,Hypocalcaemia,HO
184606843,Infliximab,Hypocalcaemia,OT
184606843,Infliximab,Hypertension,HO
184606843,Infliximab,Hypertension,OT
184606843,Infliximab,Hand deformity,HO
184606843,Infliximab,Hand deformity,OT
184606843,Infliximab,Gastroenteritis viral,HO
184606843,Infliximab,Gastroenteritis viral,OT
184606843,Infliximab,Foot operation,HO
184606843,Infliximab,Foot operation,OT
184606843,Infliximab,Foot deformity,HO
184606843,Infliximab,Foot deformity,OT
184606843,Infliximab,Drug intolerance,HO
184606843,Infliximab,Drug intolerance,OT
184606843,Infliximab,Drug ineffective,HO
184606843,Infliximab,Drug ineffective,OT
184606843,Infliximab,Drug hypersensitivity,HO
184606843,Infliximab,Drug hypersensitivity,OT
184606843,Infliximab,Dizziness,HO
184606843,Infliximab,Dizziness,OT
184606843,Infliximab,Diarrhoea,HO
184606843,Infliximab,Diarrhoea,OT
184606843,Infliximab,Contraindicated product administered,HO
184606843,Infliximab,Contraindicated product administered,OT
184606843,Infliximab,Condition aggravated,HO
184606843,Infliximab,Condition aggravated,OT
184606843,Infliximab,Arthropathy,HO
184606843,Infliximab,Arthropathy,OT
184606843,Infliximab,Arthritis,HO
184606843,Infliximab,Arthritis,OT
184606843,Infliximab,Anti-cyclic citrullinated peptide antibody positive,HO
184606843,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
184606843,Infliximab,Ankle arthroplasty,HO
184606843,Infliximab,Ankle arthroplasty,OT
184606843,Infliximab,Adrenal insufficiency,HO
184606843,Infliximab,Adrenal insufficiency,OT
184606843,Infliximab,Wheelchair user,HO
184606843,Infliximab,Wheelchair user,OT
184606843,Infliximab,Vomiting,HO
184606843,Infliximab,Vomiting,OT
184606843,Infliximab,Therapy non-responder,HO
184606843,Infliximab,Therapy non-responder,OT
184606843,Infliximab,Therapeutic product effect decreased,HO
184606843,Infliximab,Therapeutic product effect decreased,OT
184606843,Infliximab,Synovitis,HO
184606843,Infliximab,Synovitis,OT
184606843,Infliximab,Septic shock,HO
184606843,Infliximab,Septic shock,OT
184606843,Infliximab,Rheumatoid factor positive,HO
184606843,Infliximab,Rheumatoid factor positive,OT
184606843,Infliximab,Rheumatoid arthritis,HO
184606843,Infliximab,Rheumatoid arthritis,OT
184606843,Infliximab,Red blood cell sedimentation rate abnormal,HO
184606843,Infliximab,Red blood cell sedimentation rate abnormal,OT
184606843,Infliximab,Pyrexia,HO
184606843,Infliximab,Pyrexia,OT
184606843,Infliximab,Pulmonary fibrosis,HO
184606843,Infliximab,Pulmonary fibrosis,OT
184606843,Infliximab,Psoriasis,HO
184606843,Infliximab,Psoriasis,OT
184606843,Infliximab,Product use in unapproved indication,HO
184606843,Infliximab,Product use in unapproved indication,OT
184606843,Infliximab,Polyarthritis,HO
184606843,Infliximab,Polyarthritis,OT
184606843,Infliximab,Pleural effusion,HO
184606843,Infliximab,Pleural effusion,OT
184606843,Infliximab,Off label use,HO
184606843,Infliximab,Off label use,OT
184606843,Infliximab,Obesity,HO
184606843,Infliximab,Obesity,OT
184606843,Infliximab,Nodule,HO
184606843,Infliximab,Nodule,OT
184606843,Infliximab,Nausea,HO
184606843,Infliximab,Nausea,OT
184606843,Infliximab,Mobility decreased,HO
184606843,Infliximab,Mobility decreased,OT
184606843,Infliximab,Malaise,HO
184606843,Infliximab,Malaise,OT
184606843,Infliximab,Loss of personal independence in daily activities,HO
184606843,Infliximab,Loss of personal independence in daily activities,OT
184606843,Infliximab,Loss of consciousness,HO
184606843,Infliximab,Loss of consciousness,OT
184606843,Infliximab,Limb discomfort,HO
184606843,Infliximab,Limb discomfort,OT
184606843,Infliximab,Joint destruction,HO
184606843,Infliximab,Joint destruction,OT
184606843,Infliximab,Intentional product use issue,HO
184606843,Infliximab,Intentional product use issue,OT
184606843,Infliximab,Infection,HO
184606843,Infliximab,Infection,OT
184606843,Infliximab,Immunodeficiency,HO
184606843,Infliximab,Immunodeficiency,OT
184606843,Infliximab,Ill-defined disorder,HO
184606843,Infliximab,Ill-defined disorder,OT
184606843,Infliximab,Hypotension,HO
184606843,Infliximab,Hypotension,OT
184606843,Infliximab,Hypokalaemia,HO
184606843,Infliximab,Hypokalaemia,OT
184606843,Infliximab,Hypocalcaemia,HO
184606843,Infliximab,Hypocalcaemia,OT
184606843,Infliximab,Hypertension,HO
184606843,Infliximab,Hypertension,OT
184606843,Infliximab,Hand deformity,HO
184606843,Infliximab,Hand deformity,OT
184606843,Infliximab,Gastroenteritis viral,HO
184606843,Infliximab,Gastroenteritis viral,OT
184606843,Infliximab,Foot operation,HO
184606843,Infliximab,Foot operation,OT
184606843,Infliximab,Foot deformity,HO
184606843,Infliximab,Foot deformity,OT
184606843,Infliximab,Drug intolerance,HO
184606843,Infliximab,Drug intolerance,OT
184606843,Infliximab,Drug ineffective,HO
184606843,Infliximab,Drug ineffective,OT
184606843,Infliximab,Drug hypersensitivity,HO
184606843,Infliximab,Drug hypersensitivity,OT
184606843,Infliximab,Dizziness,HO
184606843,Infliximab,Dizziness,OT
184606843,Infliximab,Diarrhoea,HO
184606843,Infliximab,Diarrhoea,OT
184606843,Infliximab,Contraindicated product administered,HO
184606843,Infliximab,Contraindicated product administered,OT
184606843,Infliximab,Condition aggravated,HO
184606843,Infliximab,Condition aggravated,OT
184606843,Infliximab,Arthropathy,HO
184606843,Infliximab,Arthropathy,OT
184606843,Infliximab,Arthritis,HO
184606843,Infliximab,Arthritis,OT
184606843,Infliximab,Anti-cyclic citrullinated peptide antibody positive,HO
184606843,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
184606843,Infliximab,Ankle arthroplasty,HO
184606843,Infliximab,Ankle arthroplasty,OT
184606843,Infliximab,Adrenal insufficiency,HO
184606843,Infliximab,Adrenal insufficiency,OT
185069813,Infliximab,Pyrexia,OT
185069813,Infliximab,Off label use,OT
185069813,Infliximab,Loss of consciousness,OT
185069813,Infliximab,Illness,OT
185069813,Infliximab,Fatigue,OT
185069813,Infliximab,Drug ineffective,OT
185069813,Infliximab,Condition aggravated,OT
185069813,Infliximab,Blood pressure diastolic increased,OT
185069813,Infliximab,Abdominal tenderness,OT
185069813,Infliximab,Abdominal distension,OT
185069813,Infliximab,Pyrexia,OT
185069813,Infliximab,Off label use,OT
185069813,Infliximab,Loss of consciousness,OT
185069813,Infliximab,Illness,OT
185069813,Infliximab,Fatigue,OT
185069813,Infliximab,Drug ineffective,OT
185069813,Infliximab,Condition aggravated,OT
185069813,Infliximab,Blood pressure diastolic increased,OT
185069813,Infliximab,Abdominal tenderness,OT
185069813,Infliximab,Abdominal distension,OT
185279712,Infliximab,Pancreatitis,HO
185279712,Infliximab,Pancreatitis,OT
185279712,Infliximab,Pancreatic disorder,HO
185279712,Infliximab,Pancreatic disorder,OT
185279712,Infliximab,Off label use,HO
185279712,Infliximab,Off label use,OT
185279712,Infliximab,Intentional product use issue,HO
185279712,Infliximab,Intentional product use issue,OT
185279712,Infliximab,Inappropriate schedule of product administration,HO
185279712,Infliximab,Inappropriate schedule of product administration,OT
185279712,Infliximab,Body temperature decreased,HO
185279712,Infliximab,Body temperature decreased,OT
185279712,Infliximab,Blood pressure fluctuation,HO
185279712,Infliximab,Blood pressure fluctuation,OT
185279712,Infliximab,Blood pressure diastolic decreased,HO
185279712,Infliximab,Blood pressure diastolic decreased,OT
185279712,Infliximab,Pancreatitis,HO
185279712,Infliximab,Pancreatitis,OT
185279712,Infliximab,Pancreatic disorder,HO
185279712,Infliximab,Pancreatic disorder,OT
185279712,Infliximab,Off label use,HO
185279712,Infliximab,Off label use,OT
185279712,Infliximab,Intentional product use issue,HO
185279712,Infliximab,Intentional product use issue,OT
185279712,Infliximab,Inappropriate schedule of product administration,HO
185279712,Infliximab,Inappropriate schedule of product administration,OT
185279712,Infliximab,Body temperature decreased,HO
185279712,Infliximab,Body temperature decreased,OT
185279712,Infliximab,Blood pressure fluctuation,HO
185279712,Infliximab,Blood pressure fluctuation,OT
185279712,Infliximab,Blood pressure diastolic decreased,HO
185279712,Infliximab,Blood pressure diastolic decreased,OT
185416502,Infliximab,Vision blurred,OT
185416502,Infliximab,Vision blurred,HO
185416502,Infliximab,Product use issue,OT
185416502,Infliximab,Product use issue,HO
185416502,Infliximab,Off label use,OT
185416502,Infliximab,Off label use,HO
185416502,Infliximab,Inappropriate schedule of product administration,OT
185416502,Infliximab,Inappropriate schedule of product administration,HO
185416502,Infliximab,Haemorrhoids,OT
185416502,Infliximab,Haemorrhoids,HO
185416502,Infliximab,Drug level below therapeutic,OT
185416502,Infliximab,Drug level below therapeutic,HO
185416502,Infliximab,Diarrhoea,OT
185416502,Infliximab,Diarrhoea,HO
185416502,Infliximab,Cough,OT
185416502,Infliximab,Cough,HO
185416502,Infliximab,Condition aggravated,OT
185416502,Infliximab,Condition aggravated,HO
185416502,Infliximab,Colitis ulcerative,OT
185416502,Infliximab,Colitis ulcerative,HO
185416502,Infliximab,Colitis,OT
185416502,Infliximab,Colitis,HO
185416502,Infliximab,Chest discomfort,OT
185416502,Infliximab,Chest discomfort,HO
185416502,Infliximab,Blood pressure increased,OT
185416502,Infliximab,Blood pressure increased,HO
185416502,Infliximab,Vision blurred,OT
185416502,Infliximab,Vision blurred,HO
185416502,Infliximab,Product use issue,OT
185416502,Infliximab,Product use issue,HO
185416502,Infliximab,Off label use,OT
185416502,Infliximab,Off label use,HO
185416502,Infliximab,Inappropriate schedule of product administration,OT
185416502,Infliximab,Inappropriate schedule of product administration,HO
185416502,Infliximab,Haemorrhoids,OT
185416502,Infliximab,Haemorrhoids,HO
185416502,Infliximab,Drug level below therapeutic,OT
185416502,Infliximab,Drug level below therapeutic,HO
185416502,Infliximab,Diarrhoea,OT
185416502,Infliximab,Diarrhoea,HO
185416502,Infliximab,Cough,OT
185416502,Infliximab,Cough,HO
185416502,Infliximab,Condition aggravated,OT
185416502,Infliximab,Condition aggravated,HO
185416502,Infliximab,Colitis ulcerative,OT
185416502,Infliximab,Colitis ulcerative,HO
185416502,Infliximab,Colitis,OT
185416502,Infliximab,Colitis,HO
185416502,Infliximab,Chest discomfort,OT
185416502,Infliximab,Chest discomfort,HO
185416502,Infliximab,Blood pressure increased,OT
185416502,Infliximab,Blood pressure increased,HO
190951723,Infliximab (Unknown),Tumour ulceration,OT
190951723,Infliximab (Unknown),Scab,OT
190951723,Infliximab (Unknown),Pseudolymphoma,OT
190951723,Infliximab (Unknown),Off label use,OT
190951723,Infliximab (Unknown),Lymphoid tissue hyperplasia,OT
190951723,Infliximab (Unknown),Ear swelling,OT
190951723,Infliximab (Unknown),Chronic papillomatous dermatitis,OT
190951723,Infliximab (Unknown),Tumour ulceration,OT
190951723,Infliximab (Unknown),Scab,OT
190951723,Infliximab (Unknown),Pseudolymphoma,OT
190951723,Infliximab (Unknown),Off label use,OT
190951723,Infliximab (Unknown),Lymphoid tissue hyperplasia,OT
190951723,Infliximab (Unknown),Ear swelling,OT
190951723,Infliximab (Unknown),Chronic papillomatous dermatitis,OT
190951723,Infliximab (Unknown),Tumour ulceration,OT
190951723,Infliximab (Unknown),Scab,OT
190951723,Infliximab (Unknown),Pseudolymphoma,OT
190951723,Infliximab (Unknown),Off label use,OT
190951723,Infliximab (Unknown),Lymphoid tissue hyperplasia,OT
190951723,Infliximab (Unknown),Ear swelling,OT
190951723,Infliximab (Unknown),Chronic papillomatous dermatitis,OT
192827252,Infliximab,Off label use,OT
192827252,Infliximab,Crohn's disease,OT
192827252,Infliximab,Off label use,OT
192827252,Infliximab,Crohn's disease,OT
192860762,Infliximab,Seasonal allergy,OT
192860762,Infliximab,Rhinitis,OT
192860762,Infliximab,Off label use,OT
192860762,Infliximab,Lower respiratory tract infection,OT
192860762,Infliximab,Intentional product use issue,OT
192860762,Infliximab,Inappropriate schedule of product administration,OT
192860762,Infliximab,Diarrhoea,OT
192860762,Infliximab,Blood pressure fluctuation,OT
192860762,Infliximab,Arthralgia,OT
194058792,Infliximab,Off label use,HO
194058792,Infliximab,Intentional product use issue,HO
194058792,Infliximab,Heart rate increased,HO
194058792,Infliximab,Dizziness,HO
194058792,Infliximab,Condition aggravated,HO
194058792,Infliximab,Asthenia,HO
194972181,Infliximab,Weight increased,OT
194972181,Infliximab,Weight decreased,OT
194972181,Infliximab,Therapeutic response shortened,OT
194972181,Infliximab,Therapeutic product effect decreased,OT
194972181,Infliximab,Product use issue,OT
194972181,Infliximab,Off label use,OT
194972181,Infliximab,Intentional product use issue,OT
194972181,Infliximab,Incorrect product administration duration,OT
194972181,Infliximab,Incorrect dose administered,OT
194972181,Infliximab,Drug specific antibody present,OT
194972181,Infliximab,Drug level below therapeutic,OT
194972181,Infliximab,Condition aggravated,OT
194972181,Infliximab,Arthralgia,OT
194972181,Infliximab,Arterial injury,OT
194972181,Infliximab,Anaemia,OT
194972181,Infliximab,Malaise,OT
194972181,Infliximab,Weight increased,OT
194972181,Infliximab,Weight decreased,OT
194972181,Infliximab,Therapeutic response shortened,OT
194972181,Infliximab,Therapeutic product effect decreased,OT
194972181,Infliximab,Product use issue,OT
194972181,Infliximab,Off label use,OT
194972181,Infliximab,Intentional product use issue,OT
194972181,Infliximab,Incorrect product administration duration,OT
194972181,Infliximab,Incorrect dose administered,OT
194972181,Infliximab,Drug specific antibody present,OT
194972181,Infliximab,Drug level below therapeutic,OT
194972181,Infliximab,Condition aggravated,OT
194972181,Infliximab,Arthralgia,OT
194972181,Infliximab,Arterial injury,OT
194972181,Infliximab,Anaemia,OT
194972181,Infliximab,Malaise,OT
196026211,Infliximab,Therapeutic response shortened,OT
196026211,Infliximab,Therapeutic response shortened,HO
196026211,Infliximab,Somnolence,OT
196026211,Infliximab,Somnolence,HO
196026211,Infliximab,Skin lesion,OT
196026211,Infliximab,Skin lesion,HO
196026211,Infliximab,Road traffic accident,OT
196026211,Infliximab,Road traffic accident,HO
196026211,Infliximab,Rectal tenesmus,OT
196026211,Infliximab,Rectal tenesmus,HO
196026211,Infliximab,Pruritus,OT
196026211,Infliximab,Pruritus,HO
196026211,Infliximab,Off label use,OT
196026211,Infliximab,Off label use,HO
196026211,Infliximab,Nasopharyngitis,OT
196026211,Infliximab,Nasopharyngitis,HO
196026211,Infliximab,Mucous stools,OT
196026211,Infliximab,Mucous stools,HO
196026211,Infliximab,Intentional product use issue,OT
196026211,Infliximab,Intentional product use issue,HO
196026211,Infliximab,Inappropriate schedule of product administration,OT
196026211,Infliximab,Inappropriate schedule of product administration,HO
196026211,Infliximab,Headache,OT
196026211,Infliximab,Headache,HO
196026211,Infliximab,Gastrointestinal disorder,OT
196026211,Infliximab,Gastrointestinal disorder,HO
196026211,Infliximab,Food intolerance,OT
196026211,Infliximab,Food intolerance,HO
196026211,Infliximab,Fatigue,OT
196026211,Infliximab,Fatigue,HO
196026211,Infliximab,Faecal calprotectin increased,OT
196026211,Infliximab,Faecal calprotectin increased,HO
196026211,Infliximab,Drug ineffective,OT
196026211,Infliximab,Drug ineffective,HO
196026211,Infliximab,Dizziness,OT
196026211,Infliximab,Dizziness,HO
196026211,Infliximab,Condition aggravated,OT
196026211,Infliximab,Condition aggravated,HO
196026211,Infliximab,Asthenia,OT
196026211,Infliximab,Asthenia,HO
196038431,Infliximab,Off label use,OT
196038431,Infliximab,Intentional product use issue,OT
196038431,Infliximab,Infusion related reaction,OT
196038431,Infliximab,Flatulence,OT
196038431,Infliximab,Drug level decreased,OT
196038431,Infliximab,Condition aggravated,OT
196038431,Infliximab,Colitis ulcerative,OT
196038431,Infliximab,Abdominal distension,OT
196072681,Infliximab,Weight increased,OT
196072681,Infliximab,Off label use,OT
196072681,Infliximab,Incorrect dose administered,OT
196072681,Infliximab,Inappropriate schedule of product administration,OT
196072681,Infliximab,Heart rate irregular,OT
196072681,Infliximab,Blood pressure fluctuation,OT
196072681,Infliximab,Blood loss anaemia,OT
196103162,Infliximab Hospira,Liver function test decreased,OT
196103162,Infliximab Hospira,Liver function test decreased,HO
196103162,Infliximab Hospira,Interstitial lung disease,OT
196103162,Infliximab Hospira,Interstitial lung disease,HO
196103162,Infliximab Hospira,Dyspnoea,OT
196103162,Infliximab Hospira,Dyspnoea,HO
196103162,Infliximab Hospira,Drug ineffective,OT
196103162,Infliximab Hospira,Drug ineffective,HO
196103162,Infliximab Hospira,Disease recurrence,OT
196103162,Infliximab Hospira,Disease recurrence,HO
196103162,Infliximab Hospira,Cough,OT
196103162,Infliximab Hospira,Cough,HO
196103162,Infliximab Hospira,Liver function test decreased,OT
196103162,Infliximab Hospira,Liver function test decreased,HO
196103162,Infliximab Hospira,Interstitial lung disease,OT
196103162,Infliximab Hospira,Interstitial lung disease,HO
196103162,Infliximab Hospira,Dyspnoea,OT
196103162,Infliximab Hospira,Dyspnoea,HO
196103162,Infliximab Hospira,Drug ineffective,OT
196103162,Infliximab Hospira,Drug ineffective,HO
196103162,Infliximab Hospira,Disease recurrence,OT
196103162,Infliximab Hospira,Disease recurrence,HO
196103162,Infliximab Hospira,Cough,OT
196103162,Infliximab Hospira,Cough,HO
196495921,Infliximab (Unknown),Pneumocystis jirovecii pneumonia,HO
196495921,Infliximab (Unknown),Overdose,HO
196574051,Infliximab,Segmented hyalinising vasculitis,OT
196574051,Infliximab,Polychondritis,OT
196574051,Infliximab,Polyarthritis,OT
196574051,Infliximab,Off label use,OT
196574051,Infliximab,Drug ineffective for unapproved indication,OT
197487331,Infliximab,Pruritus,OT
197487331,Infliximab,Off label use,OT
197487331,Infliximab,Nephrolithiasis,OT
197487331,Infliximab,Macular fibrosis,OT
197702692,Infliximab,Rash,OT
197702692,Infliximab,Post procedural infection,OT
197702692,Infliximab,Off label use,OT
197702692,Infliximab,Intentional product use issue,OT
197702692,Infliximab,Incorrect dose administered,OT
197702692,Infliximab,Heart rate decreased,OT
197702692,Infliximab,Fistula,OT
197702692,Infliximab,Condition aggravated,OT
197702692,Infliximab,Blood pressure diastolic decreased,OT
197795651,Infliximab,Deafness unilateral,OT
197795651,Infliximab,Deafness neurosensory,OT
198283291,Infliximab,Off label use,HO
198283291,Infliximab,Off label use,OT
198283291,Infliximab,Large intestinal stenosis,HO
198283291,Infliximab,Large intestinal stenosis,OT
198283291,Infliximab,Intestinal obstruction,HO
198283291,Infliximab,Intestinal obstruction,OT
198283291,Infliximab,Intentional product use issue,HO
198283291,Infliximab,Intentional product use issue,OT
198283291,Infliximab,Infusion related reaction,HO
198283291,Infliximab,Infusion related reaction,OT
198283291,Infliximab,Inappropriate schedule of product administration,HO
198283291,Infliximab,Inappropriate schedule of product administration,OT
198283291,Infliximab,Condition aggravated,HO
198283291,Infliximab,Condition aggravated,OT
198283291,Infliximab,Blood pressure fluctuation,HO
198283291,Infliximab,Blood pressure fluctuation,OT
198342271,Infliximab,Therapy non-responder,OT
198912671,Infliximab,Product use issue,DE
198912671,Infliximab,Death,DE
198968021,Infliximab,Quality of life decreased,OT
198968021,Infliximab,Pain,OT
198968021,Infliximab,Off label use,OT
198968021,Infliximab,Intentional dose omission,OT
198968021,Infliximab,Hypotension,OT
198968021,Infliximab,Fatigue,OT
198968021,Infliximab,Dyspnoea,OT
198968021,Infliximab,Dizziness,OT
198968021,Infliximab,Decreased appetite,OT
198968021,Infliximab,Condition aggravated,OT
198968021,Infliximab,Clostridium difficile infection,OT
198968021,Infliximab,Arthralgia,OT
198968021,Infliximab,Abdominal pain upper,OT
1214122814,Infliximab Hospira,Swelling,OT
1214122814,Infliximab Hospira,Subcutaneous abscess,OT
1214122814,Infliximab Hospira,Skin warm,OT
1214122814,Infliximab Hospira,Rash,OT
1214122814,Infliximab Hospira,Purulent discharge,OT
1214122814,Infliximab Hospira,Pain,OT
1214122814,Infliximab Hospira,Joint swelling,OT
1214122814,Infliximab Hospira,Exposure during pregnancy,OT
1214122814,Infliximab Hospira,Arthropod bite,OT
1214122814,Infliximab Hospira,Abdominal pain upper,OT
158264983,Infliximab,Therapeutic response decreased,OT
158264983,Infliximab,Therapeutic response decreased,HO
158264983,Infliximab,Product use in unapproved indication,OT
158264983,Infliximab,Product use in unapproved indication,HO
158264983,Infliximab,Functional gastrointestinal disorder,OT
158264983,Infliximab,Functional gastrointestinal disorder,HO
158264983,Infliximab,Drug ineffective for unapproved indication,OT
158264983,Infliximab,Drug ineffective for unapproved indication,HO
158264983,Infliximab,Drug ineffective,OT
158264983,Infliximab,Drug ineffective,HO
158264983,Infliximab,Clostridium difficile colitis,OT
158264983,Infliximab,Clostridium difficile colitis,HO
158264983,Infliximab,Bile acid malabsorption,OT
158264983,Infliximab,Bile acid malabsorption,HO
158264983,Infliximab,Abdominal pain,OT
158264983,Infliximab,Abdominal pain,HO
160737275,Infliximab,Weight increased,OT
160737275,Infliximab,Urticaria,OT
160737275,Infliximab,Therapeutic product effect incomplete,OT
160737275,Infliximab,Rheumatoid arthritis,OT
160737275,Infliximab,Product use issue,OT
160737275,Infliximab,Off label use,OT
160737275,Infliximab,Nausea,OT
160737275,Infliximab,Malaise,OT
160737275,Infliximab,Intentional product use issue,OT
160737275,Infliximab,Influenza,OT
160737275,Infliximab,Incorrect product administration duration,OT
160737275,Infliximab,Incorrect dose administered,OT
160737275,Infliximab,Illness,OT
160737275,Infliximab,Heart rate decreased,OT
160737275,Infliximab,Faecal calprotectin increased,OT
160737275,Infliximab,Condition aggravated,OT
160737275,Infliximab,Body temperature decreased,OT
160737275,Infliximab,Blood pressure decreased,OT
160737275,Infliximab,Blister,OT
160737275,Infliximab,Abdominal discomfort,OT
160737275,Infliximab,Weight increased,OT
160737275,Infliximab,Urticaria,OT
160737275,Infliximab,Therapeutic product effect incomplete,OT
160737275,Infliximab,Rheumatoid arthritis,OT
160737275,Infliximab,Product use issue,OT
160737275,Infliximab,Off label use,OT
160737275,Infliximab,Nausea,OT
160737275,Infliximab,Malaise,OT
160737275,Infliximab,Intentional product use issue,OT
160737275,Infliximab,Influenza,OT
160737275,Infliximab,Incorrect product administration duration,OT
160737275,Infliximab,Incorrect dose administered,OT
160737275,Infliximab,Illness,OT
160737275,Infliximab,Heart rate decreased,OT
160737275,Infliximab,Faecal calprotectin increased,OT
160737275,Infliximab,Condition aggravated,OT
160737275,Infliximab,Body temperature decreased,OT
160737275,Infliximab,Blood pressure decreased,OT
160737275,Infliximab,Blister,OT
160737275,Infliximab,Abdominal discomfort,OT
160798555,Infliximab,Weight fluctuation,HO
160798555,Infliximab,Product use issue,HO
160798555,Infliximab,Off label use,HO
160798555,Infliximab,Intentional product use issue,HO
160798555,Infliximab,Influenza like illness,HO
160798555,Infliximab,Heart rate decreased,HO
160798555,Infliximab,Fungal infection,HO
160798555,Infliximab,Fatigue,HO
160798555,Infliximab,Cough,HO
160798555,Infliximab,Condition aggravated,HO
160798555,Infliximab,Capillary nail refill test abnormal,HO
160798555,Infliximab,Blood test abnormal,HO
160798555,Infliximab,Blood pressure fluctuation,HO
160798555,Infliximab,Weight fluctuation,HO
160798555,Infliximab,Product use issue,HO
160798555,Infliximab,Off label use,HO
160798555,Infliximab,Intentional product use issue,HO
160798555,Infliximab,Influenza like illness,HO
160798555,Infliximab,Heart rate decreased,HO
160798555,Infliximab,Fungal infection,HO
160798555,Infliximab,Fatigue,HO
160798555,Infliximab,Cough,HO
160798555,Infliximab,Condition aggravated,HO
160798555,Infliximab,Capillary nail refill test abnormal,HO
160798555,Infliximab,Blood test abnormal,HO
160798555,Infliximab,Blood pressure fluctuation,HO
160798555,Infliximab,Weight fluctuation,HO
160798555,Infliximab,Product use issue,HO
160798555,Infliximab,Off label use,HO
160798555,Infliximab,Intentional product use issue,HO
160798555,Infliximab,Influenza like illness,HO
160798555,Infliximab,Heart rate decreased,HO
160798555,Infliximab,Fungal infection,HO
160798555,Infliximab,Fatigue,HO
160798555,Infliximab,Cough,HO
160798555,Infliximab,Condition aggravated,HO
160798555,Infliximab,Capillary nail refill test abnormal,HO
160798555,Infliximab,Blood test abnormal,HO
160798555,Infliximab,Blood pressure fluctuation,HO
176489283,Infliximab,Stress at work,OT
176489283,Infliximab,Somnolence,OT
176489283,Infliximab,Product use issue,OT
176489283,Infliximab,Pain,OT
176489283,Infliximab,Off label use,OT
176489283,Infliximab,Non-cardiac chest pain,OT
176489283,Infliximab,Myalgia,OT
176489283,Infliximab,Musculoskeletal pain,OT
176489283,Infliximab,Incorrect dose administered,OT
176489283,Infliximab,Hypertension,OT
176489283,Infliximab,Heart rate decreased,OT
176489283,Infliximab,Headache,OT
176489283,Infliximab,Drug ineffective,OT
176489283,Infliximab,Crohn's disease,OT
176489283,Infliximab,Condition aggravated,OT
176489283,Infliximab,Blood pressure fluctuation,OT
176489283,Infliximab,Arthralgia,OT
176527323,Infliximab,Weight decreased,OT
176527323,Infliximab,Weight decreased,HO
176527323,Infliximab,Vomiting,OT
176527323,Infliximab,Vomiting,HO
176527323,Infliximab,Tenderness,OT
176527323,Infliximab,Tenderness,HO
176527323,Infliximab,Suicidal ideation,OT
176527323,Infliximab,Suicidal ideation,HO
176527323,Infliximab,Pyrexia,OT
176527323,Infliximab,Pyrexia,HO
176527323,Infliximab,Product use issue,OT
176527323,Infliximab,Product use issue,HO
176527323,Infliximab,Pain,OT
176527323,Infliximab,Pain,HO
176527323,Infliximab,Off label use,OT
176527323,Infliximab,Off label use,HO
176527323,Infliximab,Nausea,OT
176527323,Infliximab,Nausea,HO
176527323,Infliximab,Malaise,OT
176527323,Infliximab,Malaise,HO
176527323,Infliximab,Intentional product use issue,OT
176527323,Infliximab,Intentional product use issue,HO
176527323,Infliximab,Insomnia,OT
176527323,Infliximab,Insomnia,HO
176527323,Infliximab,Inappropriate schedule of product administration,OT
176527323,Infliximab,Inappropriate schedule of product administration,HO
176527323,Infliximab,Fear of injection,OT
176527323,Infliximab,Fear of injection,HO
176527323,Infliximab,Eating disorder,OT
176527323,Infliximab,Eating disorder,HO
176527323,Infliximab,Diarrhoea,OT
176527323,Infliximab,Diarrhoea,HO
176527323,Infliximab,Depression,OT
176527323,Infliximab,Depression,HO
176527323,Infliximab,Decreased appetite,OT
176527323,Infliximab,Decreased appetite,HO
176527323,Infliximab,Condition aggravated,OT
176527323,Infliximab,Condition aggravated,HO
176527323,Infliximab,Bowel movement irregularity,OT
176527323,Infliximab,Bowel movement irregularity,HO
176527323,Infliximab,Arthralgia,OT
176527323,Infliximab,Arthralgia,HO
176527323,Infliximab,Anxiety disorder,OT
176527323,Infliximab,Anxiety disorder,HO
176527323,Infliximab,Agitation,OT
176527323,Infliximab,Agitation,HO
176527323,Infliximab,Abdominal pain,OT
176527323,Infliximab,Abdominal pain,HO
176527323,Infliximab,Abdominal distension,OT
176527323,Infliximab,Abdominal distension,HO
176860204,Infliximab,Vertigo,OT
176860204,Infliximab,Vertigo,HO
176860204,Infliximab,Therapeutic response shortened,OT
176860204,Infliximab,Therapeutic response shortened,HO
176860204,Infliximab,Stomatitis,OT
176860204,Infliximab,Stomatitis,HO
176860204,Infliximab,Rash erythematous,OT
176860204,Infliximab,Rash erythematous,HO
176860204,Infliximab,Product use issue,OT
176860204,Infliximab,Product use issue,HO
176860204,Infliximab,Panic attack,OT
176860204,Infliximab,Panic attack,HO
176860204,Infliximab,Off label use,OT
176860204,Infliximab,Off label use,HO
176860204,Infliximab,Nephrolithiasis,OT
176860204,Infliximab,Nephrolithiasis,HO
176860204,Infliximab,Intentional product use issue,OT
176860204,Infliximab,Intentional product use issue,HO
176860204,Infliximab,Hypoglycaemia,OT
176860204,Infliximab,Hypoglycaemia,HO
176860204,Infliximab,Flushing,OT
176860204,Infliximab,Flushing,HO
176860204,Infliximab,Condition aggravated,OT
176860204,Infliximab,Condition aggravated,HO
176860204,Infliximab,Body temperature decreased,OT
176860204,Infliximab,Body temperature decreased,HO
176860204,Infliximab,Blood pressure fluctuation,OT
176860204,Infliximab,Blood pressure fluctuation,HO
176860204,Infliximab,Arthralgia,OT
176860204,Infliximab,Arthralgia,HO
176860204,Infliximab,Aphthous ulcer,OT
176860204,Infliximab,Aphthous ulcer,HO
176860204,Infliximab,Abdominal pain,OT
176860204,Infliximab,Abdominal pain,HO
176860204,Infliximab,Vertigo,OT
176860204,Infliximab,Vertigo,HO
176860204,Infliximab,Therapeutic response shortened,OT
176860204,Infliximab,Therapeutic response shortened,HO
176860204,Infliximab,Stomatitis,OT
176860204,Infliximab,Stomatitis,HO
176860204,Infliximab,Rash erythematous,OT
176860204,Infliximab,Rash erythematous,HO
176860204,Infliximab,Product use issue,OT
176860204,Infliximab,Product use issue,HO
176860204,Infliximab,Panic attack,OT
176860204,Infliximab,Panic attack,HO
176860204,Infliximab,Off label use,OT
176860204,Infliximab,Off label use,HO
176860204,Infliximab,Nephrolithiasis,OT
176860204,Infliximab,Nephrolithiasis,HO
176860204,Infliximab,Intentional product use issue,OT
176860204,Infliximab,Intentional product use issue,HO
176860204,Infliximab,Hypoglycaemia,OT
176860204,Infliximab,Hypoglycaemia,HO
176860204,Infliximab,Flushing,OT
176860204,Infliximab,Flushing,HO
176860204,Infliximab,Condition aggravated,OT
176860204,Infliximab,Condition aggravated,HO
176860204,Infliximab,Body temperature decreased,OT
176860204,Infliximab,Body temperature decreased,HO
176860204,Infliximab,Blood pressure fluctuation,OT
176860204,Infliximab,Blood pressure fluctuation,HO
176860204,Infliximab,Arthralgia,OT
176860204,Infliximab,Arthralgia,HO
176860204,Infliximab,Aphthous ulcer,OT
176860204,Infliximab,Aphthous ulcer,HO
176860204,Infliximab,Abdominal pain,OT
176860204,Infliximab,Abdominal pain,HO
177586464,Infliximab,Therapeutic response decreased,OT
177586464,Infliximab,Therapeutic response decreased,HO
177586464,Infliximab,Kaposi's sarcoma,OT
177586464,Infliximab,Kaposi's sarcoma,HO
177586464,Infliximab,Infection reactivation,OT
177586464,Infliximab,Infection reactivation,HO
177586464,Infliximab,Human herpesvirus 8 infection,OT
177586464,Infliximab,Human herpesvirus 8 infection,HO
177646734,Infliximab,Weight increased,OT
177646734,Infliximab,Vomiting,OT
177646734,Infliximab,Viral infection,OT
177646734,Infliximab,Upper respiratory tract infection,OT
177646734,Infliximab,Therapeutic response shortened,OT
177646734,Infliximab,Stress,OT
177646734,Infliximab,Skin irritation,OT
177646734,Infliximab,Skin fissures,OT
177646734,Infliximab,Sinus disorder,OT
177646734,Infliximab,Sensitivity to weather change,OT
177646734,Infliximab,Rash,OT
177646734,Infliximab,Pyrexia,OT
177646734,Infliximab,Productive cough,OT
177646734,Infliximab,Product use issue,OT
177646734,Infliximab,Pain in extremity,OT
177646734,Infliximab,Off label use,OT
177646734,Infliximab,Nausea,OT
177646734,Infliximab,Nasopharyngitis,OT
177646734,Infliximab,Musculoskeletal stiffness,OT
177646734,Infliximab,Migraine,OT
177646734,Infliximab,Malaise,OT
177646734,Infliximab,Intentional product use issue,OT
177646734,Infliximab,Insomnia,OT
177646734,Infliximab,Influenza,OT
177646734,Infliximab,Inappropriate schedule of product administration,OT
177646734,Infliximab,Impaired healing,OT
177646734,Infliximab,Headache,OT
177646734,Infliximab,Formication,OT
177646734,Infliximab,Feeling abnormal,OT
177646734,Infliximab,Fatigue,OT
177646734,Infliximab,Emotional disorder,OT
177646734,Infliximab,Drug ineffective,OT
177646734,Infliximab,Diarrhoea,OT
177646734,Infliximab,Cough,OT
177646734,Infliximab,Costochondritis,OT
177646734,Infliximab,Condition aggravated,OT
177646734,Infliximab,Chest pain,OT
177646734,Infliximab,Weight increased,OT
177646734,Infliximab,Vomiting,OT
177646734,Infliximab,Viral infection,OT
177646734,Infliximab,Upper respiratory tract infection,OT
177646734,Infliximab,Therapeutic response shortened,OT
177646734,Infliximab,Stress,OT
177646734,Infliximab,Skin irritation,OT
177646734,Infliximab,Skin fissures,OT
177646734,Infliximab,Sinus disorder,OT
177646734,Infliximab,Sensitivity to weather change,OT
177646734,Infliximab,Rash,OT
177646734,Infliximab,Pyrexia,OT
177646734,Infliximab,Productive cough,OT
177646734,Infliximab,Product use issue,OT
177646734,Infliximab,Pain in extremity,OT
177646734,Infliximab,Off label use,OT
177646734,Infliximab,Nausea,OT
177646734,Infliximab,Nasopharyngitis,OT
177646734,Infliximab,Musculoskeletal stiffness,OT
177646734,Infliximab,Migraine,OT
177646734,Infliximab,Malaise,OT
177646734,Infliximab,Intentional product use issue,OT
177646734,Infliximab,Insomnia,OT
177646734,Infliximab,Influenza,OT
177646734,Infliximab,Inappropriate schedule of product administration,OT
177646734,Infliximab,Impaired healing,OT
177646734,Infliximab,Headache,OT
177646734,Infliximab,Formication,OT
177646734,Infliximab,Feeling abnormal,OT
177646734,Infliximab,Fatigue,OT
177646734,Infliximab,Emotional disorder,OT
177646734,Infliximab,Drug ineffective,OT
177646734,Infliximab,Diarrhoea,OT
177646734,Infliximab,Cough,OT
177646734,Infliximab,Costochondritis,OT
177646734,Infliximab,Condition aggravated,OT
177646734,Infliximab,Chest pain,OT
177646734,Infliximab,Weight increased,OT
177646734,Infliximab,Vomiting,OT
177646734,Infliximab,Viral infection,OT
177646734,Infliximab,Upper respiratory tract infection,OT
177646734,Infliximab,Therapeutic response shortened,OT
177646734,Infliximab,Stress,OT
177646734,Infliximab,Skin irritation,OT
177646734,Infliximab,Skin fissures,OT
177646734,Infliximab,Sinus disorder,OT
177646734,Infliximab,Sensitivity to weather change,OT
177646734,Infliximab,Rash,OT
177646734,Infliximab,Pyrexia,OT
177646734,Infliximab,Productive cough,OT
177646734,Infliximab,Product use issue,OT
177646734,Infliximab,Pain in extremity,OT
177646734,Infliximab,Off label use,OT
177646734,Infliximab,Nausea,OT
177646734,Infliximab,Nasopharyngitis,OT
177646734,Infliximab,Musculoskeletal stiffness,OT
177646734,Infliximab,Migraine,OT
177646734,Infliximab,Malaise,OT
177646734,Infliximab,Intentional product use issue,OT
177646734,Infliximab,Insomnia,OT
177646734,Infliximab,Influenza,OT
177646734,Infliximab,Inappropriate schedule of product administration,OT
177646734,Infliximab,Impaired healing,OT
177646734,Infliximab,Headache,OT
177646734,Infliximab,Formication,OT
177646734,Infliximab,Feeling abnormal,OT
177646734,Infliximab,Fatigue,OT
177646734,Infliximab,Emotional disorder,OT
177646734,Infliximab,Drug ineffective,OT
177646734,Infliximab,Diarrhoea,OT
177646734,Infliximab,Cough,OT
177646734,Infliximab,Costochondritis,OT
177646734,Infliximab,Condition aggravated,OT
177646734,Infliximab,Chest pain,OT
177878863,Infliximab,Off label use,OT
177878863,Infliximab,Lung disorder,OT
177878863,Infliximab,Lower respiratory tract infection,OT
177878863,Infliximab,Drug level below therapeutic,OT
177878863,Infliximab,Drug ineffective,OT
177878863,Infliximab,Dehydration,OT
177878863,Infliximab,Blood pressure fluctuation,OT
177878863,Infliximab,Asthma,OT
177878863,Infliximab,Arthralgia,OT
177878863,Infliximab,Off label use,OT
177878863,Infliximab,Lung disorder,OT
177878863,Infliximab,Lower respiratory tract infection,OT
177878863,Infliximab,Drug level below therapeutic,OT
177878863,Infliximab,Drug ineffective,OT
177878863,Infliximab,Dehydration,OT
177878863,Infliximab,Blood pressure fluctuation,OT
177878863,Infliximab,Asthma,OT
177878863,Infliximab,Arthralgia,OT
184366153,Infliximab,Viral infection,OT
184366153,Infliximab,Transient ischaemic attack,OT
184366153,Infliximab,Therapeutic response shortened,OT
184366153,Infliximab,Sinusitis,OT
184366153,Infliximab,Seizure,OT
184366153,Infliximab,Respiratory tract infection,OT
184366153,Infliximab,Pyrexia,OT
184366153,Infliximab,Product use issue,OT
184366153,Infliximab,Pain,OT
184366153,Infliximab,Off label use,OT
184366153,Infliximab,Nasopharyngitis,OT
184366153,Infliximab,Memory impairment,OT
184366153,Infliximab,Lower respiratory tract infection,OT
184366153,Infliximab,Intentional product use issue,OT
184366153,Infliximab,Inappropriate schedule of product administration,OT
184366153,Infliximab,Impaired quality of life,OT
184366153,Infliximab,Heart rate decreased,OT
184366153,Infliximab,Fatigue,OT
184366153,Infliximab,Dyspnoea,OT
184366153,Infliximab,Drug ineffective,OT
184366153,Infliximab,Diarrhoea,OT
184366153,Infliximab,Defaecation urgency,OT
184366153,Infliximab,Cough,OT
184366153,Infliximab,Constipation,OT
184366153,Infliximab,Condition aggravated,OT
184366153,Infliximab,Chest discomfort,OT
184366153,Infliximab,Blood pressure systolic increased,OT
184366153,Infliximab,Blood pressure increased,OT
184366153,Infliximab,Blood pressure fluctuation,OT
184366153,Infliximab,Blood pressure decreased,OT
184366153,Infliximab,Blood pressure abnormal,OT
184366153,Infliximab,Arthralgia,OT
184366153,Infliximab,Aphasia,OT
184366153,Infliximab,Abdominal discomfort,OT
184366153,Infliximab,Viral infection,OT
184366153,Infliximab,Transient ischaemic attack,OT
184366153,Infliximab,Therapeutic response shortened,OT
184366153,Infliximab,Sinusitis,OT
184366153,Infliximab,Seizure,OT
184366153,Infliximab,Respiratory tract infection,OT
184366153,Infliximab,Pyrexia,OT
184366153,Infliximab,Product use issue,OT
184366153,Infliximab,Pain,OT
184366153,Infliximab,Off label use,OT
184366153,Infliximab,Nasopharyngitis,OT
184366153,Infliximab,Memory impairment,OT
184366153,Infliximab,Lower respiratory tract infection,OT
184366153,Infliximab,Intentional product use issue,OT
184366153,Infliximab,Inappropriate schedule of product administration,OT
184366153,Infliximab,Impaired quality of life,OT
184366153,Infliximab,Heart rate decreased,OT
184366153,Infliximab,Fatigue,OT
184366153,Infliximab,Dyspnoea,OT
184366153,Infliximab,Drug ineffective,OT
184366153,Infliximab,Diarrhoea,OT
184366153,Infliximab,Defaecation urgency,OT
184366153,Infliximab,Cough,OT
184366153,Infliximab,Constipation,OT
184366153,Infliximab,Condition aggravated,OT
184366153,Infliximab,Chest discomfort,OT
184366153,Infliximab,Blood pressure systolic increased,OT
184366153,Infliximab,Blood pressure increased,OT
184366153,Infliximab,Blood pressure fluctuation,OT
184366153,Infliximab,Blood pressure decreased,OT
184366153,Infliximab,Blood pressure abnormal,OT
184366153,Infliximab,Arthralgia,OT
184366153,Infliximab,Aphasia,OT
184366153,Infliximab,Abdominal discomfort,OT
184366153,Infliximab,Viral infection,OT
184366153,Infliximab,Transient ischaemic attack,OT
184366153,Infliximab,Therapeutic response shortened,OT
184366153,Infliximab,Sinusitis,OT
184366153,Infliximab,Seizure,OT
184366153,Infliximab,Respiratory tract infection,OT
184366153,Infliximab,Pyrexia,OT
184366153,Infliximab,Product use issue,OT
184366153,Infliximab,Pain,OT
184366153,Infliximab,Off label use,OT
184366153,Infliximab,Nasopharyngitis,OT
184366153,Infliximab,Memory impairment,OT
184366153,Infliximab,Lower respiratory tract infection,OT
184366153,Infliximab,Intentional product use issue,OT
184366153,Infliximab,Inappropriate schedule of product administration,OT
184366153,Infliximab,Impaired quality of life,OT
184366153,Infliximab,Heart rate decreased,OT
184366153,Infliximab,Fatigue,OT
184366153,Infliximab,Dyspnoea,OT
184366153,Infliximab,Drug ineffective,OT
184366153,Infliximab,Diarrhoea,OT
184366153,Infliximab,Defaecation urgency,OT
184366153,Infliximab,Cough,OT
184366153,Infliximab,Constipation,OT
184366153,Infliximab,Condition aggravated,OT
184366153,Infliximab,Chest discomfort,OT
184366153,Infliximab,Blood pressure systolic increased,OT
184366153,Infliximab,Blood pressure increased,OT
184366153,Infliximab,Blood pressure fluctuation,OT
184366153,Infliximab,Blood pressure decreased,OT
184366153,Infliximab,Blood pressure abnormal,OT
184366153,Infliximab,Arthralgia,OT
184366153,Infliximab,Aphasia,OT
184366153,Infliximab,Abdominal discomfort,OT
184537132,Infliximab,Vitamin D decreased,OT
184537132,Infliximab,Red blood cell count decreased,OT
184537132,Infliximab,Product use issue,OT
184537132,Infliximab,Proctitis,OT
184537132,Infliximab,Oxygen saturation decreased,OT
184537132,Infliximab,Oxygen saturation abnormal,OT
184537132,Infliximab,Off label use,OT
184537132,Infliximab,Neutrophil count increased,OT
184537132,Infliximab,Lymphocyte count decreased,OT
184537132,Infliximab,Intestinal obstruction,OT
184537132,Infliximab,Intentional product use issue,OT
184537132,Infliximab,Inflammation,OT
184537132,Infliximab,Inappropriate schedule of product administration,OT
184537132,Infliximab,Hepatitis B surface antibody negative,OT
184537132,Infliximab,Faecal calprotectin increased,OT
184537132,Infliximab,Condition aggravated,OT
184537132,Infliximab,C-reactive protein increased,OT
184537132,Infliximab,Blood pressure fluctuation,OT
184537132,Infliximab,Blood albumin decreased,OT
184537132,Infliximab,Alanine aminotransferase increased,OT
184942612,Infliximab,White coat hypertension,OT
184942612,Infliximab,Oxygen saturation abnormal,OT
184942612,Infliximab,Off label use,OT
184942612,Infliximab,Intentional product use issue,OT
184942612,Infliximab,Condition aggravated,OT
184942612,Infliximab,Blood pressure increased,OT
184942612,Infliximab,Blood pressure fluctuation,OT
184942612,Infliximab,Anxiety,OT
185446812,Infliximab,Off label use,OT
185446812,Infliximab,Intentional product use issue,OT
185446812,Infliximab,Inappropriate schedule of product administration,OT
185446812,Infliximab,Crohn's disease,OT
185446812,Infliximab,Condition aggravated,OT
185581132,Infliximab,Weight decreased,OT
185581132,Infliximab,Weight decreased,HO
185581132,Infliximab,Throat irritation,OT
185581132,Infliximab,Throat irritation,HO
185581132,Infliximab,Therapeutic response shortened,OT
185581132,Infliximab,Therapeutic response shortened,HO
185581132,Infliximab,Therapeutic product effect incomplete,OT
185581132,Infliximab,Therapeutic product effect incomplete,HO
185581132,Infliximab,Productive cough,OT
185581132,Infliximab,Productive cough,HO
185581132,Infliximab,Poor venous access,OT
185581132,Infliximab,Poor venous access,HO
185581132,Infliximab,Off label use,OT
185581132,Infliximab,Off label use,HO
185581132,Infliximab,Nasopharyngitis,OT
185581132,Infliximab,Nasopharyngitis,HO
185581132,Infliximab,Malaise,OT
185581132,Infliximab,Malaise,HO
185581132,Infliximab,Inappropriate schedule of product administration,OT
185581132,Infliximab,Inappropriate schedule of product administration,HO
185581132,Infliximab,Hypertension,OT
185581132,Infliximab,Hypertension,HO
185581132,Infliximab,Heart rate increased,OT
185581132,Infliximab,Heart rate increased,HO
185581132,Infliximab,Crohn's disease,OT
185581132,Infliximab,Crohn's disease,HO
185581132,Infliximab,Blood pressure fluctuation,OT
185581132,Infliximab,Blood pressure fluctuation,HO
185581132,Infliximab,Weight decreased,OT
185581132,Infliximab,Weight decreased,HO
185581132,Infliximab,Throat irritation,OT
185581132,Infliximab,Throat irritation,HO
185581132,Infliximab,Therapeutic response shortened,OT
185581132,Infliximab,Therapeutic response shortened,HO
185581132,Infliximab,Therapeutic product effect incomplete,OT
185581132,Infliximab,Therapeutic product effect incomplete,HO
185581132,Infliximab,Productive cough,OT
185581132,Infliximab,Productive cough,HO
185581132,Infliximab,Poor venous access,OT
185581132,Infliximab,Poor venous access,HO
185581132,Infliximab,Off label use,OT
185581132,Infliximab,Off label use,HO
185581132,Infliximab,Nasopharyngitis,OT
185581132,Infliximab,Nasopharyngitis,HO
185581132,Infliximab,Malaise,OT
185581132,Infliximab,Malaise,HO
185581132,Infliximab,Inappropriate schedule of product administration,OT
185581132,Infliximab,Inappropriate schedule of product administration,HO
185581132,Infliximab,Hypertension,OT
185581132,Infliximab,Hypertension,HO
185581132,Infliximab,Heart rate increased,OT
185581132,Infliximab,Heart rate increased,HO
185581132,Infliximab,Crohn's disease,OT
185581132,Infliximab,Crohn's disease,HO
185581132,Infliximab,Blood pressure fluctuation,OT
185581132,Infliximab,Blood pressure fluctuation,HO
185581132,Infliximab,Weight decreased,OT
185581132,Infliximab,Weight decreased,HO
185581132,Infliximab,Throat irritation,OT
185581132,Infliximab,Throat irritation,HO
185581132,Infliximab,Therapeutic response shortened,OT
185581132,Infliximab,Therapeutic response shortened,HO
185581132,Infliximab,Therapeutic product effect incomplete,OT
185581132,Infliximab,Therapeutic product effect incomplete,HO
185581132,Infliximab,Productive cough,OT
185581132,Infliximab,Productive cough,HO
185581132,Infliximab,Poor venous access,OT
185581132,Infliximab,Poor venous access,HO
185581132,Infliximab,Off label use,OT
185581132,Infliximab,Off label use,HO
185581132,Infliximab,Nasopharyngitis,OT
185581132,Infliximab,Nasopharyngitis,HO
185581132,Infliximab,Malaise,OT
185581132,Infliximab,Malaise,HO
185581132,Infliximab,Inappropriate schedule of product administration,OT
185581132,Infliximab,Inappropriate schedule of product administration,HO
185581132,Infliximab,Hypertension,OT
185581132,Infliximab,Hypertension,HO
185581132,Infliximab,Heart rate increased,OT
185581132,Infliximab,Heart rate increased,HO
185581132,Infliximab,Crohn's disease,OT
185581132,Infliximab,Crohn's disease,HO
185581132,Infliximab,Blood pressure fluctuation,OT
185581132,Infliximab,Blood pressure fluctuation,HO
185912323,Infliximab,Weight decreased,OT
185912323,Infliximab,Tooth infection,OT
185912323,Infliximab,Therapeutic product effect incomplete,OT
185912323,Infliximab,SARS-CoV-2 test positive,OT
185912323,Infliximab,Prescribed underdose,OT
185912323,Infliximab,Off label use,OT
185912323,Infliximab,Malaise,OT
185912323,Infliximab,Intentional product use issue,OT
185912323,Infliximab,Heart rate irregular,OT
185912323,Infliximab,Eye infection,OT
185912323,Infliximab,Coronavirus test positive,OT
185912323,Infliximab,Condition aggravated,OT
185912323,Infliximab,Blood pressure increased,OT
185912323,Infliximab,Blood pressure fluctuation,OT
185912323,Infliximab,Blood pressure diastolic abnormal,OT
185912323,Infliximab,Weight decreased,OT
185912323,Infliximab,Tooth infection,OT
185912323,Infliximab,Therapeutic product effect incomplete,OT
185912323,Infliximab,SARS-CoV-2 test positive,OT
185912323,Infliximab,Prescribed underdose,OT
185912323,Infliximab,Off label use,OT
185912323,Infliximab,Malaise,OT
185912323,Infliximab,Intentional product use issue,OT
185912323,Infliximab,Heart rate irregular,OT
185912323,Infliximab,Eye infection,OT
185912323,Infliximab,Coronavirus test positive,OT
185912323,Infliximab,Condition aggravated,OT
185912323,Infliximab,Blood pressure increased,OT
185912323,Infliximab,Blood pressure fluctuation,OT
185912323,Infliximab,Blood pressure diastolic abnormal,OT
185912323,Infliximab,Weight decreased,OT
185912323,Infliximab,Tooth infection,OT
185912323,Infliximab,Therapeutic product effect incomplete,OT
185912323,Infliximab,SARS-CoV-2 test positive,OT
185912323,Infliximab,Prescribed underdose,OT
185912323,Infliximab,Off label use,OT
185912323,Infliximab,Malaise,OT
185912323,Infliximab,Intentional product use issue,OT
185912323,Infliximab,Heart rate irregular,OT
185912323,Infliximab,Eye infection,OT
185912323,Infliximab,Coronavirus test positive,OT
185912323,Infliximab,Condition aggravated,OT
185912323,Infliximab,Blood pressure increased,OT
185912323,Infliximab,Blood pressure fluctuation,OT
185912323,Infliximab,Blood pressure diastolic abnormal,OT
186410012,Infliximab,Wound secretion,OT
186410012,Infliximab,Wound secretion,HO
186410012,Infliximab,Wound,OT
186410012,Infliximab,Wound,HO
186410012,Infliximab,Weight increased,OT
186410012,Infliximab,Weight increased,HO
186410012,Infliximab,Therapeutic product effect incomplete,OT
186410012,Infliximab,Therapeutic product effect incomplete,HO
186410012,Infliximab,Gastrointestinal disorder,OT
186410012,Infliximab,Gastrointestinal disorder,HO
186410012,Infliximab,Blood pressure increased,OT
186410012,Infliximab,Blood pressure increased,HO
186410012,Infliximab,Blood pressure fluctuation,OT
186410012,Infliximab,Blood pressure fluctuation,HO
186410012,Infliximab,Adhesion,OT
186410012,Infliximab,Adhesion,HO
186410012,Infliximab,Wound secretion,OT
186410012,Infliximab,Wound secretion,HO
186410012,Infliximab,Wound,OT
186410012,Infliximab,Wound,HO
186410012,Infliximab,Weight increased,OT
186410012,Infliximab,Weight increased,HO
186410012,Infliximab,Therapeutic product effect incomplete,OT
186410012,Infliximab,Therapeutic product effect incomplete,HO
186410012,Infliximab,Gastrointestinal disorder,OT
186410012,Infliximab,Gastrointestinal disorder,HO
186410012,Infliximab,Blood pressure increased,OT
186410012,Infliximab,Blood pressure increased,HO
186410012,Infliximab,Blood pressure fluctuation,OT
186410012,Infliximab,Blood pressure fluctuation,HO
186410012,Infliximab,Adhesion,OT
186410012,Infliximab,Adhesion,HO
187323753,Infliximab,Weight increased,OT
187323753,Infliximab,Tuberculosis,OT
187323753,Infliximab,Product use in unapproved indication,OT
187323753,Infliximab,Pain in extremity,OT
187323753,Infliximab,Off label use,OT
187323753,Infliximab,Limb discomfort,OT
187323753,Infliximab,Latent tuberculosis,OT
187323753,Infliximab,Intentional product use issue,OT
187323753,Infliximab,Inappropriate schedule of product administration,OT
187323753,Infliximab,Chest pain,OT
187323753,Infliximab,Body temperature decreased,OT
187323753,Infliximab,Blood pressure increased,OT
187323753,Infliximab,Back pain,OT
187323753,Infliximab,Weight increased,OT
187323753,Infliximab,Tuberculosis,OT
187323753,Infliximab,Product use in unapproved indication,OT
187323753,Infliximab,Pain in extremity,OT
187323753,Infliximab,Off label use,OT
187323753,Infliximab,Limb discomfort,OT
187323753,Infliximab,Latent tuberculosis,OT
187323753,Infliximab,Intentional product use issue,OT
187323753,Infliximab,Inappropriate schedule of product administration,OT
187323753,Infliximab,Chest pain,OT
187323753,Infliximab,Body temperature decreased,OT
187323753,Infliximab,Blood pressure increased,OT
187323753,Infliximab,Back pain,OT
187472972,Infliximab,Weight fluctuation,OT
187472972,Infliximab,Tinnitus,OT
187472972,Infliximab,Sleep disorder,OT
187472972,Infliximab,Product use issue,OT
187472972,Infliximab,Paraesthesia,OT
187472972,Infliximab,Off label use,OT
187472972,Infliximab,Mouth ulceration,OT
187472972,Infliximab,Intentional product use issue,OT
187472972,Infliximab,Heart rate decreased,OT
187472972,Infliximab,Headache,OT
187472972,Infliximab,Fatigue,OT
187472972,Infliximab,Faecal calprotectin decreased,OT
187472972,Infliximab,Condition aggravated,OT
187472972,Infliximab,Blood pressure increased,OT
187472972,Infliximab,Blood iron decreased,OT
187472972,Infliximab,Arthralgia,OT
187472972,Infliximab,Anaemia,OT
187472972,Infliximab,Abdominal distension,OT
188352874,Infliximab,Visual impairment,OT
188352874,Infliximab,Rash,OT
188352874,Infliximab,Pruritus,OT
188352874,Infliximab,Impaired driving ability,OT
188352874,Infliximab,Headache,OT
188352874,Infliximab,Fistula,OT
188352874,Infliximab,Feeling abnormal,OT
188352874,Infliximab,Erythema,OT
188352874,Infliximab,Dizziness,OT
188352874,Infliximab,Diplopia,OT
188352874,Infliximab,Cataract,OT
188352874,Infliximab,Blood pressure systolic decreased,OT
188352874,Infliximab,Blood pressure increased,OT
188352874,Infliximab,Blood glucose increased,OT
188352874,Infliximab,Arthralgia,OT
189816522,Infliximab,Treatment failure,OT
189816522,Infliximab,Therapeutic response decreased,OT
189816522,Infliximab,Therapeutic product effect decreased,OT
189816522,Infliximab,Rheumatoid arthritis,OT
189816522,Infliximab,Renal impairment,OT
189816522,Infliximab,Influenza,OT
189816522,Infliximab,Impaired gastric emptying,OT
189816522,Infliximab,Drug ineffective,OT
189816522,Infliximab,Drug hypersensitivity,OT
189816522,Infliximab,Diabetes mellitus,OT
189816522,Infliximab,Demyelination,OT
189816522,Infliximab,Contraindicated product administered,OT
189816522,Infliximab,Condition aggravated,OT
189816522,Infliximab,Arthropathy,OT
189816522,Infliximab,Ankylosing spondylitis,OT
189816522,Infliximab,Treatment failure,OT
189816522,Infliximab,Therapeutic response decreased,OT
189816522,Infliximab,Therapeutic product effect decreased,OT
189816522,Infliximab,Rheumatoid arthritis,OT
189816522,Infliximab,Renal impairment,OT
189816522,Infliximab,Influenza,OT
189816522,Infliximab,Impaired gastric emptying,OT
189816522,Infliximab,Drug ineffective,OT
189816522,Infliximab,Drug hypersensitivity,OT
189816522,Infliximab,Diabetes mellitus,OT
189816522,Infliximab,Demyelination,OT
189816522,Infliximab,Contraindicated product administered,OT
189816522,Infliximab,Condition aggravated,OT
189816522,Infliximab,Arthropathy,OT
189816522,Infliximab,Ankylosing spondylitis,OT
191950582,Infliximab,Umbilical hernia,OT
191950582,Infliximab,Off label use,OT
191950582,Infliximab,Intentional product use issue,OT
191950582,Infliximab,Inappropriate schedule of product administration,OT
191950582,Infliximab,Heart rate decreased,OT
191950582,Infliximab,Condition aggravated,OT
191950582,Infliximab,Body temperature decreased,OT
191950582,Infliximab,Blood pressure increased,OT
191950582,Infliximab,Blood pressure fluctuation,OT
191950582,Infliximab,Umbilical hernia,OT
191950582,Infliximab,Off label use,OT
191950582,Infliximab,Intentional product use issue,OT
191950582,Infliximab,Inappropriate schedule of product administration,OT
191950582,Infliximab,Heart rate decreased,OT
191950582,Infliximab,Condition aggravated,OT
191950582,Infliximab,Body temperature decreased,OT
191950582,Infliximab,Blood pressure increased,OT
191950582,Infliximab,Blood pressure fluctuation,OT
192238942,Infliximab,Off label use,OT
192238942,Infliximab,Nasopharyngitis,OT
192238942,Infliximab,Nasal congestion,OT
192238942,Infliximab,Gout,OT
192238942,Infliximab,Drug level decreased,OT
192238942,Infliximab,Cough,OT
192238942,Infliximab,Conjunctivitis,OT
192238942,Infliximab,Condition aggravated,OT
192238942,Infliximab,Off label use,OT
192238942,Infliximab,Nasopharyngitis,OT
192238942,Infliximab,Nasal congestion,OT
192238942,Infliximab,Gout,OT
192238942,Infliximab,Drug level decreased,OT
192238942,Infliximab,Cough,OT
192238942,Infliximab,Conjunctivitis,OT
192238942,Infliximab,Condition aggravated,OT
192394372,Infliximab,Off label use,OT
192394372,Infliximab,Mouth ulceration,OT
192394372,Infliximab,Condition aggravated,OT
192394372,Infliximab,Arthralgia,OT
194874811,Infliximab,Off label use,HO
194874811,Infliximab,Off label use,DE
194874811,Infliximab,Multiple organ dysfunction syndrome,HO
194874811,Infliximab,Multiple organ dysfunction syndrome,DE
194874811,Infliximab,Immune-mediated lung disease,HO
194874811,Infliximab,Immune-mediated lung disease,DE
194874811,Infliximab,Aspergillus infection,HO
194874811,Infliximab,Aspergillus infection,DE
194874811,Infliximab,Acute respiratory failure,HO
194874811,Infliximab,Acute respiratory failure,DE
195080631,Infliximab,Weight increased,OT
195080631,Infliximab,Therapeutic product effect incomplete,OT
195080631,Infliximab,Product use issue,OT
195080631,Infliximab,Off label use,OT
195080631,Infliximab,Intentional product use issue,OT
195080631,Infliximab,Heart rate increased,OT
195080631,Infliximab,Fatigue,OT
195080631,Infliximab,Drug level increased,OT
195080631,Infliximab,Condition aggravated,OT
195080631,Infliximab,Blood pressure diastolic increased,OT
195894681,Infliximab,Tonsillitis bacterial,OT
195894681,Infliximab,Therapeutic response shortened,OT
195894681,Infliximab,Product use issue,OT
195894681,Infliximab,Off label use,OT
195894681,Infliximab,Nasopharyngitis,OT
195894681,Infliximab,Intentional product use issue,OT
195894681,Infliximab,Injection site coldness,OT
195894681,Infliximab,Infusion site coldness,OT
195894681,Infliximab,Inappropriate schedule of product administration,OT
195894681,Infliximab,Fatigue,OT
195894681,Infliximab,Diarrhoea,OT
195894681,Infliximab,Condition aggravated,OT
195894681,Infliximab,Colitis,OT
195894681,Infliximab,Blood pressure increased,OT
195894681,Infliximab,Arthralgia,OT
195896681,Infliximab,Therapeutic response decreased,OT
195896681,Infliximab,Therapeutic response decreased,HO
195896681,Infliximab,Kaposi's sarcoma,OT
195896681,Infliximab,Kaposi's sarcoma,HO
195896681,Infliximab,Infection reactivation,OT
195896681,Infliximab,Infection reactivation,HO
195896681,Infliximab,Human herpesvirus 8 infection,OT
195896681,Infliximab,Human herpesvirus 8 infection,HO
196018031,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,HO
196018031,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,OT
196018031,Infliximab Pfizer (Unknown),Eosinophilic pneumonia,HO
196018031,Infliximab Pfizer (Unknown),Eosinophilic pneumonia,OT
196018031,Infliximab Pfizer (Unknown),Colitis ulcerative,HO
196018031,Infliximab Pfizer (Unknown),Colitis ulcerative,OT
196022442,Infliximab BS for I.V. Infusion100 mg [NK],Listeria encephalitis,HO
196022442,Infliximab BS for I.V. Infusion100 mg [NK],Hydrocephalus,HO
196654781,Infliximab,Loss of therapeutic response,OT
196654781,Infliximab,Intestinal obstruction,OT
196654781,Infliximab,Hypoalbuminaemia,OT
196654781,Infliximab,Drug specific antibody absent,OT
196654781,Infliximab,Drug level below therapeutic,OT
196654781,Infliximab,Drug clearance increased,OT
196654781,Infliximab,Crohn's disease,OT
196654781,Infliximab,Blood creatinine increased,OT
196654781,Infliximab,Anaemia,OT
196654781,Infliximab,Loss of therapeutic response,OT
196654781,Infliximab,Intestinal obstruction,OT
196654781,Infliximab,Hypoalbuminaemia,OT
196654781,Infliximab,Drug specific antibody absent,OT
196654781,Infliximab,Drug level below therapeutic,OT
196654781,Infliximab,Drug clearance increased,OT
196654781,Infliximab,Crohn's disease,OT
196654781,Infliximab,Blood creatinine increased,OT
196654781,Infliximab,Anaemia,OT
196654781,Infliximab,Loss of therapeutic response,OT
196654781,Infliximab,Intestinal obstruction,OT
196654781,Infliximab,Hypoalbuminaemia,OT
196654781,Infliximab,Drug specific antibody absent,OT
196654781,Infliximab,Drug level below therapeutic,OT
196654781,Infliximab,Drug clearance increased,OT
196654781,Infliximab,Crohn's disease,OT
196654781,Infliximab,Blood creatinine increased,OT
196654781,Infliximab,Anaemia,OT
196891531,Infliximab,Weight decreased,HO
196891531,Infliximab,Off label use,HO
196891531,Infliximab,Inappropriate schedule of product administration,HO
196891531,Infliximab,Illness,HO
196891531,Infliximab,Headache,HO
196891531,Infliximab,Fatigue,HO
196891531,Infliximab,Drug ineffective,HO
196891531,Infliximab,Condition aggravated,HO
196891531,Infliximab,Chest pain,HO
196891531,Infliximab,Blood pressure fluctuation,HO
196891531,Infliximab,Back pain,HO
196891531,Infliximab,Abdominal pain upper,HO
197002271,Infliximab,Off label use,OT
197002271,Infliximab,Haematochezia,OT
197002271,Infliximab,Blood pressure increased,OT
197102461,Infliximab,White blood cell count decreased,OT
197102461,Infliximab,Urticarial vasculitis,OT
197102461,Infliximab,Urticaria,OT
197102461,Infliximab,Therapeutic response shortened,OT
197102461,Infliximab,Synovitis,OT
197102461,Infliximab,Sjogren's syndrome,OT
197102461,Infliximab,Rash,OT
197102461,Infliximab,Pruritus,OT
197102461,Infliximab,Off label use,OT
197102461,Infliximab,Multiple-drug resistance,OT
197102461,Infliximab,Haemoglobin decreased,OT
197102461,Infliximab,Fatigue,OT
197102461,Infliximab,Blood pressure systolic increased,OT
197102461,Infliximab,Blood creatinine decreased,OT
197753461,Infliximab,Off label use,OT
197753461,Infliximab,Drug ineffective,OT
197753461,Infliximab,Condition aggravated,OT
198060921,Infliximab,Drug ineffective,OT
198060921,Infliximab,Condition aggravated,OT
198128811,Infliximab,Weight decreased,HO
198128811,Infliximab,Nephrolithiasis,HO
198128811,Infliximab,Nasal congestion,HO
198128811,Infliximab,Influenza,HO
198128811,Infliximab,Inappropriate schedule of product administration,HO
198128811,Infliximab,Condition aggravated,HO
198128811,Infliximab,Blood pressure fluctuation,HO
198269242,Infliximab,Psoriasis,HO
198269242,Infliximab,Psoriasis,OT
198269242,Infliximab,Lymphadenopathy,HO
198269242,Infliximab,Lymphadenopathy,OT
198269242,Infliximab,Ear swelling,HO
198269242,Infliximab,Ear swelling,OT
198269242,Infliximab,Psoriasis,HO
198269242,Infliximab,Psoriasis,OT
198269242,Infliximab,Lymphadenopathy,HO
198269242,Infliximab,Lymphadenopathy,OT
198269242,Infliximab,Ear swelling,HO
198269242,Infliximab,Ear swelling,OT
198269952,Infliximab,Off label use,OT
198269952,Infliximab,Off label use,HO
198269952,Infliximab,Drug ineffective,OT
198269952,Infliximab,Drug ineffective,HO
198269952,Infliximab,Cytomegalovirus infection,OT
198269952,Infliximab,Cytomegalovirus infection,HO
198269952,Infliximab,Off label use,OT
198269952,Infliximab,Off label use,HO
198269952,Infliximab,Drug ineffective,OT
198269952,Infliximab,Drug ineffective,HO
198269952,Infliximab,Cytomegalovirus infection,OT
198269952,Infliximab,Cytomegalovirus infection,HO
198477311,Infliximab,Drug ineffective,OT
198732061,Infliximab,Weight decreased,OT
198732061,Infliximab,Product use issue,OT
198732061,Infliximab,Off label use,OT
198732061,Infliximab,Intentional product use issue,OT
198732061,Infliximab,Heart rate decreased,OT
198732061,Infliximab,Condition aggravated,OT
198832761,Infliximab,Therapeutic response shortened,OT
198832761,Infliximab,Therapeutic response shortened,HO
198832761,Infliximab,Therapeutic product effect incomplete,OT
198832761,Infliximab,Therapeutic product effect incomplete,HO
198832761,Infliximab,Product use issue,OT
198832761,Infliximab,Product use issue,HO
198832761,Infliximab,Off label use,OT
198832761,Infliximab,Off label use,HO
198832761,Infliximab,Muscle spasms,OT
198832761,Infliximab,Muscle spasms,HO
198832761,Infliximab,Intentional product use issue,OT
198832761,Infliximab,Intentional product use issue,HO
198832761,Infliximab,Infusion related reaction,OT
198832761,Infliximab,Infusion related reaction,HO
198832761,Infliximab,Fatigue,OT
198832761,Infliximab,Fatigue,HO
198832761,Infliximab,Ear infection,OT
198832761,Infliximab,Ear infection,HO
198832761,Infliximab,Discomfort,OT
198832761,Infliximab,Discomfort,HO
198832761,Infliximab,Condition aggravated,OT
198832761,Infliximab,Condition aggravated,HO
198832761,Infliximab,Chest discomfort,OT
198832761,Infliximab,Chest discomfort,HO
198832761,Infliximab,Blood pressure diastolic decreased,OT
198832761,Infliximab,Blood pressure diastolic decreased,HO
198832761,Infliximab,Back pain,OT
198832761,Infliximab,Back pain,HO
198832761,Infliximab,Angina pectoris,OT
198832761,Infliximab,Angina pectoris,HO
198832761,Infliximab,Abscess intestinal,OT
198832761,Infliximab,Abscess intestinal,HO
198832761,Infliximab,Therapeutic response shortened,OT
198832761,Infliximab,Therapeutic response shortened,HO
198832761,Infliximab,Therapeutic product effect incomplete,OT
198832761,Infliximab,Therapeutic product effect incomplete,HO
198832761,Infliximab,Product use issue,OT
198832761,Infliximab,Product use issue,HO
198832761,Infliximab,Off label use,OT
198832761,Infliximab,Off label use,HO
198832761,Infliximab,Muscle spasms,OT
198832761,Infliximab,Muscle spasms,HO
198832761,Infliximab,Intentional product use issue,OT
198832761,Infliximab,Intentional product use issue,HO
198832761,Infliximab,Infusion related reaction,OT
198832761,Infliximab,Infusion related reaction,HO
198832761,Infliximab,Fatigue,OT
198832761,Infliximab,Fatigue,HO
198832761,Infliximab,Ear infection,OT
198832761,Infliximab,Ear infection,HO
198832761,Infliximab,Discomfort,OT
198832761,Infliximab,Discomfort,HO
198832761,Infliximab,Condition aggravated,OT
198832761,Infliximab,Condition aggravated,HO
198832761,Infliximab,Chest discomfort,OT
198832761,Infliximab,Chest discomfort,HO
198832761,Infliximab,Blood pressure diastolic decreased,OT
198832761,Infliximab,Blood pressure diastolic decreased,HO
198832761,Infliximab,Back pain,OT
198832761,Infliximab,Back pain,HO
198832761,Infliximab,Angina pectoris,OT
198832761,Infliximab,Angina pectoris,HO
198832761,Infliximab,Abscess intestinal,OT
198832761,Infliximab,Abscess intestinal,HO
198917541,Infliximab,Throat irritation,OT
198917541,Infliximab,Product administration error,OT
198917541,Infliximab,Off label use,OT
198917541,Infliximab,Nausea,OT
198917541,Infliximab,Inappropriate schedule of product administration,OT
198917541,Infliximab,Hyperhidrosis,OT
198917541,Infliximab,Heart rate increased,OT
198917541,Infliximab,Haemorrhage,OT
198917541,Infliximab,Fatigue,OT
198917541,Infliximab,Drug interaction,OT
198917541,Infliximab,Dizziness,OT
198917541,Infliximab,Condition aggravated,OT
198917541,Infliximab,Clostridium difficile colitis,OT
198917541,Infliximab,Blood pressure increased,OT
198917541,Infliximab,Arthropathy,OT
198917541,Infliximab,Arthralgia,OT
198917541,Infliximab,Abdominal pain,OT
172096612,Infliximab,Tooth disorder,OT
172096612,Infliximab,Tooth abscess,OT
172096612,Infliximab,Product use issue,OT
172096612,Infliximab,Oedema peripheral,OT
172096612,Infliximab,Inappropriate schedule of product administration,OT
172096612,Infliximab,Heart rate irregular,OT
172096612,Infliximab,Heart rate decreased,OT
172096612,Infliximab,Blood pressure fluctuation,OT
172096612,Infliximab,Arthritis,OT
172096612,Infliximab,Arthralgia,OT
173865553,Infliximab,Sleep disorder,OT
173865553,Infliximab,Off label use,OT
173865553,Infliximab,Lower respiratory tract infection,OT
173865553,Infliximab,Inappropriate schedule of product administration,OT
173865553,Infliximab,Fatigue,OT
173865553,Infliximab,Faecal calprotectin increased,OT
173865553,Infliximab,Drug specific antibody present,OT
173865553,Infliximab,Drug level above therapeutic,OT
173865553,Infliximab,Condition aggravated,OT
173865553,Infliximab,Clostridium difficile infection,OT
173865553,Infliximab,COVID-19,OT
173865553,Infliximab,Blood pressure increased,OT
173865553,Infliximab,Blood pressure fluctuation,OT
173865553,Infliximab,Abdominal pain lower,OT
174110614,Infliximab,Weight decreased,OT
174110614,Infliximab,Tooth abscess,OT
174110614,Infliximab,Throat irritation,OT
174110614,Infliximab,Therapeutic response shortened,OT
174110614,Infliximab,Therapeutic product effect decreased,OT
174110614,Infliximab,Syncope,OT
174110614,Infliximab,Sunburn,OT
174110614,Infliximab,Sinusitis,OT
174110614,Infliximab,Sinus pain,OT
174110614,Infliximab,Rhinorrhoea,OT
174110614,Infliximab,Rash,OT
174110614,Infliximab,Pyrexia,OT
174110614,Infliximab,Pruritus,OT
174110614,Infliximab,Productive cough,OT
174110614,Infliximab,Product use issue,OT
174110614,Infliximab,Product use in unapproved indication,OT
174110614,Infliximab,Photosensitivity reaction,OT
174110614,Infliximab,Pain in jaw,OT
174110614,Infliximab,Pain in extremity,OT
174110614,Infliximab,Oropharyngeal pain,OT
174110614,Infliximab,Off label use,OT
174110614,Infliximab,Oedema peripheral,OT
174110614,Infliximab,Nasopharyngitis,OT
174110614,Infliximab,Nasal congestion,OT
174110614,Infliximab,Musculoskeletal stiffness,OT
174110614,Infliximab,Intentional product use issue,OT
174110614,Infliximab,Injection site pain,OT
174110614,Infliximab,Infusion site pain,OT
174110614,Infliximab,Inappropriate schedule of product administration,OT
174110614,Infliximab,Hot flush,OT
174110614,Infliximab,Fatigue,OT
174110614,Infliximab,Expired product administered,OT
174110614,Infliximab,Erythema,OT
174110614,Infliximab,Drug ineffective,OT
174110614,Infliximab,Dizziness,OT
174110614,Infliximab,Cough,OT
174110614,Infliximab,Condition aggravated,OT
174110614,Infliximab,Bronchitis,OT
174110614,Infliximab,Body temperature fluctuation,OT
174110614,Infliximab,Body temperature decreased,OT
174110614,Infliximab,Blood pressure increased,OT
174110614,Infliximab,Blood pressure fluctuation,OT
174110614,Infliximab,Arthralgia,OT
174110614,Infliximab,Acne,OT
174110614,Infliximab,Weight decreased,OT
174110614,Infliximab,Tooth abscess,OT
174110614,Infliximab,Throat irritation,OT
174110614,Infliximab,Therapeutic response shortened,OT
174110614,Infliximab,Therapeutic product effect decreased,OT
174110614,Infliximab,Syncope,OT
174110614,Infliximab,Sunburn,OT
174110614,Infliximab,Sinusitis,OT
174110614,Infliximab,Sinus pain,OT
174110614,Infliximab,Rhinorrhoea,OT
174110614,Infliximab,Rash,OT
174110614,Infliximab,Pyrexia,OT
174110614,Infliximab,Pruritus,OT
174110614,Infliximab,Productive cough,OT
174110614,Infliximab,Product use issue,OT
174110614,Infliximab,Product use in unapproved indication,OT
174110614,Infliximab,Photosensitivity reaction,OT
174110614,Infliximab,Pain in jaw,OT
174110614,Infliximab,Pain in extremity,OT
174110614,Infliximab,Oropharyngeal pain,OT
174110614,Infliximab,Off label use,OT
174110614,Infliximab,Oedema peripheral,OT
174110614,Infliximab,Nasopharyngitis,OT
174110614,Infliximab,Nasal congestion,OT
174110614,Infliximab,Musculoskeletal stiffness,OT
174110614,Infliximab,Intentional product use issue,OT
174110614,Infliximab,Injection site pain,OT
174110614,Infliximab,Infusion site pain,OT
174110614,Infliximab,Inappropriate schedule of product administration,OT
174110614,Infliximab,Hot flush,OT
174110614,Infliximab,Fatigue,OT
174110614,Infliximab,Expired product administered,OT
174110614,Infliximab,Erythema,OT
174110614,Infliximab,Drug ineffective,OT
174110614,Infliximab,Dizziness,OT
174110614,Infliximab,Cough,OT
174110614,Infliximab,Condition aggravated,OT
174110614,Infliximab,Bronchitis,OT
174110614,Infliximab,Body temperature fluctuation,OT
174110614,Infliximab,Body temperature decreased,OT
174110614,Infliximab,Blood pressure increased,OT
174110614,Infliximab,Blood pressure fluctuation,OT
174110614,Infliximab,Arthralgia,OT
174110614,Infliximab,Acne,OT
174110614,Infliximab,Weight decreased,OT
174110614,Infliximab,Tooth abscess,OT
174110614,Infliximab,Throat irritation,OT
174110614,Infliximab,Therapeutic response shortened,OT
174110614,Infliximab,Therapeutic product effect decreased,OT
174110614,Infliximab,Syncope,OT
174110614,Infliximab,Sunburn,OT
174110614,Infliximab,Sinusitis,OT
174110614,Infliximab,Sinus pain,OT
174110614,Infliximab,Rhinorrhoea,OT
174110614,Infliximab,Rash,OT
174110614,Infliximab,Pyrexia,OT
174110614,Infliximab,Pruritus,OT
174110614,Infliximab,Productive cough,OT
174110614,Infliximab,Product use issue,OT
174110614,Infliximab,Product use in unapproved indication,OT
174110614,Infliximab,Photosensitivity reaction,OT
174110614,Infliximab,Pain in jaw,OT
174110614,Infliximab,Pain in extremity,OT
174110614,Infliximab,Oropharyngeal pain,OT
174110614,Infliximab,Off label use,OT
174110614,Infliximab,Oedema peripheral,OT
174110614,Infliximab,Nasopharyngitis,OT
174110614,Infliximab,Nasal congestion,OT
174110614,Infliximab,Musculoskeletal stiffness,OT
174110614,Infliximab,Intentional product use issue,OT
174110614,Infliximab,Injection site pain,OT
174110614,Infliximab,Infusion site pain,OT
174110614,Infliximab,Inappropriate schedule of product administration,OT
174110614,Infliximab,Hot flush,OT
174110614,Infliximab,Fatigue,OT
174110614,Infliximab,Expired product administered,OT
174110614,Infliximab,Erythema,OT
174110614,Infliximab,Drug ineffective,OT
174110614,Infliximab,Dizziness,OT
174110614,Infliximab,Cough,OT
174110614,Infliximab,Condition aggravated,OT
174110614,Infliximab,Bronchitis,OT
174110614,Infliximab,Body temperature fluctuation,OT
174110614,Infliximab,Body temperature decreased,OT
174110614,Infliximab,Blood pressure increased,OT
174110614,Infliximab,Blood pressure fluctuation,OT
174110614,Infliximab,Arthralgia,OT
174110614,Infliximab,Acne,OT
174804433,Infliximab,Weight increased,HO
174804433,Infliximab,Weight increased,OT
174804433,Infliximab,Therapeutic product effect incomplete,HO
174804433,Infliximab,Therapeutic product effect incomplete,OT
174804433,Infliximab,Product use issue,HO
174804433,Infliximab,Product use issue,OT
174804433,Infliximab,Off label use,HO
174804433,Infliximab,Off label use,OT
174804433,Infliximab,Nausea,HO
174804433,Infliximab,Nausea,OT
174804433,Infliximab,Hypertension,HO
174804433,Infliximab,Hypertension,OT
174804433,Infliximab,Heart rate decreased,HO
174804433,Infliximab,Heart rate decreased,OT
174804433,Infliximab,Fatigue,HO
174804433,Infliximab,Fatigue,OT
174804433,Infliximab,Drug level below therapeutic,HO
174804433,Infliximab,Drug level below therapeutic,OT
174804433,Infliximab,Cough,HO
174804433,Infliximab,Cough,OT
174804433,Infliximab,Condition aggravated,HO
174804433,Infliximab,Condition aggravated,OT
174804433,Infliximab,Blood pressure increased,HO
174804433,Infliximab,Blood pressure increased,OT
174804433,Infliximab,Blood pressure fluctuation,HO
174804433,Infliximab,Blood pressure fluctuation,OT
174804433,Infliximab,Arthralgia,HO
174804433,Infliximab,Arthralgia,OT
174804433,Infliximab,Abdominal pain,HO
174804433,Infliximab,Abdominal pain,OT
176335663,Infliximab,Weight increased,OT
176335663,Infliximab,Weight increased,HO
176335663,Infliximab,Vein collapse,OT
176335663,Infliximab,Vein collapse,HO
176335663,Infliximab,Sinus disorder,OT
176335663,Infliximab,Sinus disorder,HO
176335663,Infliximab,Rales,OT
176335663,Infliximab,Rales,HO
176335663,Infliximab,Product use issue,OT
176335663,Infliximab,Product use issue,HO
176335663,Infliximab,Pneumonia,OT
176335663,Infliximab,Pneumonia,HO
176335663,Infliximab,Off label use,OT
176335663,Infliximab,Off label use,HO
176335663,Infliximab,Oedema peripheral,OT
176335663,Infliximab,Oedema peripheral,HO
176335663,Infliximab,Lung disorder,OT
176335663,Infliximab,Lung disorder,HO
176335663,Infliximab,Intentional product use issue,OT
176335663,Infliximab,Intentional product use issue,HO
176335663,Infliximab,Infection,OT
176335663,Infliximab,Infection,HO
176335663,Infliximab,Incorrect dose administered,OT
176335663,Infliximab,Incorrect dose administered,HO
176335663,Infliximab,Fistula,OT
176335663,Infliximab,Fistula,HO
176335663,Infliximab,Fatigue,OT
176335663,Infliximab,Fatigue,HO
176335663,Infliximab,Dyspnoea,OT
176335663,Infliximab,Dyspnoea,HO
176335663,Infliximab,Dysphagia,OT
176335663,Infliximab,Dysphagia,HO
176335663,Infliximab,Drug level below therapeutic,OT
176335663,Infliximab,Drug level below therapeutic,HO
176335663,Infliximab,Cough,OT
176335663,Infliximab,Cough,HO
176335663,Infliximab,Condition aggravated,OT
176335663,Infliximab,Condition aggravated,HO
176335663,Infliximab,Chronic obstructive pulmonary disease,OT
176335663,Infliximab,Chronic obstructive pulmonary disease,HO
176335663,Infliximab,C-reactive protein increased,OT
176335663,Infliximab,C-reactive protein increased,HO
176335663,Infliximab,Body temperature increased,OT
176335663,Infliximab,Body temperature increased,HO
176335663,Infliximab,Body temperature fluctuation,OT
176335663,Infliximab,Body temperature fluctuation,HO
176335663,Infliximab,Blood sodium decreased,OT
176335663,Infliximab,Blood sodium decreased,HO
176335663,Infliximab,Blood pressure fluctuation,OT
176335663,Infliximab,Blood pressure fluctuation,HO
176335663,Infliximab,Arthritis,OT
176335663,Infliximab,Arthritis,HO
176355903,Infliximab,Weight increased,OT
176355903,Infliximab,Weight increased,HO
176355903,Infliximab,Weight decreased,OT
176355903,Infliximab,Weight decreased,HO
176355903,Infliximab,Off label use,OT
176355903,Infliximab,Off label use,HO
176355903,Infliximab,Nausea,OT
176355903,Infliximab,Nausea,HO
176355903,Infliximab,Nasopharyngitis,OT
176355903,Infliximab,Nasopharyngitis,HO
176355903,Infliximab,Movement disorder,OT
176355903,Infliximab,Movement disorder,HO
176355903,Infliximab,Incorrect dose administered,OT
176355903,Infliximab,Incorrect dose administered,HO
176355903,Infliximab,Inappropriate schedule of product administration,OT
176355903,Infliximab,Inappropriate schedule of product administration,HO
176355903,Infliximab,Heart rate increased,OT
176355903,Infliximab,Heart rate increased,HO
176355903,Infliximab,Heart rate decreased,OT
176355903,Infliximab,Heart rate decreased,HO
176355903,Infliximab,Drug level increased,OT
176355903,Infliximab,Drug level increased,HO
176355903,Infliximab,Dehydration,OT
176355903,Infliximab,Dehydration,HO
176355903,Infliximab,Condition aggravated,OT
176355903,Infliximab,Condition aggravated,HO
176355903,Infliximab,Body temperature fluctuation,OT
176355903,Infliximab,Body temperature fluctuation,HO
176355903,Infliximab,Blood pressure increased,OT
176355903,Infliximab,Blood pressure increased,HO
176355903,Infliximab,Blood pressure fluctuation,OT
176355903,Infliximab,Blood pressure fluctuation,HO
176355903,Infliximab,Back pain,OT
176355903,Infliximab,Back pain,HO
176641995,Infliximab,Tooth infection,OT
176641995,Infliximab,Tooth abscess,OT
176641995,Infliximab,Somnolence,OT
176641995,Infliximab,Skin disorder,OT
176641995,Infliximab,Rash pruritic,OT
176641995,Infliximab,Rash erythematous,OT
176641995,Infliximab,Pruritus,OT
176641995,Infliximab,Pain,OT
176641995,Infliximab,Off label use,OT
176641995,Infliximab,Infusion site pain,OT
176641995,Infliximab,Infusion site oedema,OT
176641995,Infliximab,Infusion site extravasation,OT
176641995,Infliximab,Inappropriate schedule of product administration,OT
176641995,Infliximab,Headache,OT
176641995,Infliximab,Fatigue,OT
176641995,Infliximab,Eyelid ptosis,OT
176641995,Infliximab,Euphoric mood,OT
176641995,Infliximab,Disturbance in attention,OT
176641995,Infliximab,Disorganised speech,OT
176641995,Infliximab,Confusional state,OT
176641995,Infliximab,Condition aggravated,OT
176641995,Infliximab,Blood pressure fluctuation,OT
176641995,Infliximab,Blood pressure decreased,OT
176641995,Infliximab,Tooth infection,OT
176641995,Infliximab,Tooth abscess,OT
176641995,Infliximab,Somnolence,OT
176641995,Infliximab,Skin disorder,OT
176641995,Infliximab,Rash pruritic,OT
176641995,Infliximab,Rash erythematous,OT
176641995,Infliximab,Pruritus,OT
176641995,Infliximab,Pain,OT
176641995,Infliximab,Off label use,OT
176641995,Infliximab,Infusion site pain,OT
176641995,Infliximab,Infusion site oedema,OT
176641995,Infliximab,Infusion site extravasation,OT
176641995,Infliximab,Inappropriate schedule of product administration,OT
176641995,Infliximab,Headache,OT
176641995,Infliximab,Fatigue,OT
176641995,Infliximab,Eyelid ptosis,OT
176641995,Infliximab,Euphoric mood,OT
176641995,Infliximab,Disturbance in attention,OT
176641995,Infliximab,Disorganised speech,OT
176641995,Infliximab,Confusional state,OT
176641995,Infliximab,Condition aggravated,OT
176641995,Infliximab,Blood pressure fluctuation,OT
176641995,Infliximab,Blood pressure decreased,OT
176941404,Infliximab,Vomiting,HO
176941404,Infliximab,Vomiting,OT
176941404,Infliximab,Tooth abscess,HO
176941404,Infliximab,Tooth abscess,OT
176941404,Infliximab,Stress,HO
176941404,Infliximab,Stress,OT
176941404,Infliximab,Rhinorrhoea,HO
176941404,Infliximab,Rhinorrhoea,OT
176941404,Infliximab,Productive cough,HO
176941404,Infliximab,Productive cough,OT
176941404,Infliximab,Oropharyngeal pain,HO
176941404,Infliximab,Oropharyngeal pain,OT
176941404,Infliximab,Oral herpes,HO
176941404,Infliximab,Oral herpes,OT
176941404,Infliximab,Off label use,HO
176941404,Infliximab,Off label use,OT
176941404,Infliximab,Nausea,HO
176941404,Infliximab,Nausea,OT
176941404,Infliximab,Nasopharyngitis,HO
176941404,Infliximab,Nasopharyngitis,OT
176941404,Infliximab,Nasal discharge discolouration,HO
176941404,Infliximab,Nasal discharge discolouration,OT
176941404,Infliximab,Nasal congestion,HO
176941404,Infliximab,Nasal congestion,OT
176941404,Infliximab,Myalgia,HO
176941404,Infliximab,Myalgia,OT
176941404,Infliximab,Maternal exposure during pregnancy,HO
176941404,Infliximab,Maternal exposure during pregnancy,OT
176941404,Infliximab,Intentional product use issue,HO
176941404,Infliximab,Intentional product use issue,OT
176941404,Infliximab,Incorrect dose administered,HO
176941404,Infliximab,Incorrect dose administered,OT
176941404,Infliximab,Headache,HO
176941404,Infliximab,Headache,OT
176941404,Infliximab,Dysphonia,HO
176941404,Infliximab,Dysphonia,OT
176941404,Infliximab,Cough,HO
176941404,Infliximab,Cough,OT
176941404,Infliximab,Caesarean section,HO
176941404,Infliximab,Caesarean section,OT
176941404,Infliximab,Blood pressure fluctuation,HO
176941404,Infliximab,Blood pressure fluctuation,OT
176941404,Infliximab,Back pain,HO
176941404,Infliximab,Back pain,OT
176941404,Infliximab,Vomiting,HO
176941404,Infliximab,Vomiting,OT
176941404,Infliximab,Tooth abscess,HO
176941404,Infliximab,Tooth abscess,OT
176941404,Infliximab,Stress,HO
176941404,Infliximab,Stress,OT
176941404,Infliximab,Rhinorrhoea,HO
176941404,Infliximab,Rhinorrhoea,OT
176941404,Infliximab,Productive cough,HO
176941404,Infliximab,Productive cough,OT
176941404,Infliximab,Oropharyngeal pain,HO
176941404,Infliximab,Oropharyngeal pain,OT
176941404,Infliximab,Oral herpes,HO
176941404,Infliximab,Oral herpes,OT
176941404,Infliximab,Off label use,HO
176941404,Infliximab,Off label use,OT
176941404,Infliximab,Nausea,HO
176941404,Infliximab,Nausea,OT
176941404,Infliximab,Nasopharyngitis,HO
176941404,Infliximab,Nasopharyngitis,OT
176941404,Infliximab,Nasal discharge discolouration,HO
176941404,Infliximab,Nasal discharge discolouration,OT
176941404,Infliximab,Nasal congestion,HO
176941404,Infliximab,Nasal congestion,OT
176941404,Infliximab,Myalgia,HO
176941404,Infliximab,Myalgia,OT
176941404,Infliximab,Maternal exposure during pregnancy,HO
176941404,Infliximab,Maternal exposure during pregnancy,OT
176941404,Infliximab,Intentional product use issue,HO
176941404,Infliximab,Intentional product use issue,OT
176941404,Infliximab,Incorrect dose administered,HO
176941404,Infliximab,Incorrect dose administered,OT
176941404,Infliximab,Headache,HO
176941404,Infliximab,Headache,OT
176941404,Infliximab,Dysphonia,HO
176941404,Infliximab,Dysphonia,OT
176941404,Infliximab,Cough,HO
176941404,Infliximab,Cough,OT
176941404,Infliximab,Caesarean section,HO
176941404,Infliximab,Caesarean section,OT
176941404,Infliximab,Blood pressure fluctuation,HO
176941404,Infliximab,Blood pressure fluctuation,OT
176941404,Infliximab,Back pain,HO
176941404,Infliximab,Back pain,OT
176941404,Infliximab,Vomiting,HO
176941404,Infliximab,Vomiting,OT
176941404,Infliximab,Tooth abscess,HO
176941404,Infliximab,Tooth abscess,OT
176941404,Infliximab,Stress,HO
176941404,Infliximab,Stress,OT
176941404,Infliximab,Rhinorrhoea,HO
176941404,Infliximab,Rhinorrhoea,OT
176941404,Infliximab,Productive cough,HO
176941404,Infliximab,Productive cough,OT
176941404,Infliximab,Oropharyngeal pain,HO
176941404,Infliximab,Oropharyngeal pain,OT
176941404,Infliximab,Oral herpes,HO
176941404,Infliximab,Oral herpes,OT
176941404,Infliximab,Off label use,HO
176941404,Infliximab,Off label use,OT
176941404,Infliximab,Nausea,HO
176941404,Infliximab,Nausea,OT
176941404,Infliximab,Nasopharyngitis,HO
176941404,Infliximab,Nasopharyngitis,OT
176941404,Infliximab,Nasal discharge discolouration,HO
176941404,Infliximab,Nasal discharge discolouration,OT
176941404,Infliximab,Nasal congestion,HO
176941404,Infliximab,Nasal congestion,OT
176941404,Infliximab,Myalgia,HO
176941404,Infliximab,Myalgia,OT
176941404,Infliximab,Maternal exposure during pregnancy,HO
176941404,Infliximab,Maternal exposure during pregnancy,OT
176941404,Infliximab,Intentional product use issue,HO
176941404,Infliximab,Intentional product use issue,OT
176941404,Infliximab,Incorrect dose administered,HO
176941404,Infliximab,Incorrect dose administered,OT
176941404,Infliximab,Headache,HO
176941404,Infliximab,Headache,OT
176941404,Infliximab,Dysphonia,HO
176941404,Infliximab,Dysphonia,OT
176941404,Infliximab,Cough,HO
176941404,Infliximab,Cough,OT
176941404,Infliximab,Caesarean section,HO
176941404,Infliximab,Caesarean section,OT
176941404,Infliximab,Blood pressure fluctuation,HO
176941404,Infliximab,Blood pressure fluctuation,OT
176941404,Infliximab,Back pain,HO
176941404,Infliximab,Back pain,OT
176941404,Infliximab,Vomiting,HO
176941404,Infliximab,Vomiting,OT
176941404,Infliximab,Tooth abscess,HO
176941404,Infliximab,Tooth abscess,OT
176941404,Infliximab,Stress,HO
176941404,Infliximab,Stress,OT
176941404,Infliximab,Rhinorrhoea,HO
176941404,Infliximab,Rhinorrhoea,OT
176941404,Infliximab,Productive cough,HO
176941404,Infliximab,Productive cough,OT
176941404,Infliximab,Oropharyngeal pain,HO
176941404,Infliximab,Oropharyngeal pain,OT
176941404,Infliximab,Oral herpes,HO
176941404,Infliximab,Oral herpes,OT
176941404,Infliximab,Off label use,HO
176941404,Infliximab,Off label use,OT
176941404,Infliximab,Nausea,HO
176941404,Infliximab,Nausea,OT
176941404,Infliximab,Nasopharyngitis,HO
176941404,Infliximab,Nasopharyngitis,OT
176941404,Infliximab,Nasal discharge discolouration,HO
176941404,Infliximab,Nasal discharge discolouration,OT
176941404,Infliximab,Nasal congestion,HO
176941404,Infliximab,Nasal congestion,OT
176941404,Infliximab,Myalgia,HO
176941404,Infliximab,Myalgia,OT
176941404,Infliximab,Maternal exposure during pregnancy,HO
176941404,Infliximab,Maternal exposure during pregnancy,OT
176941404,Infliximab,Intentional product use issue,HO
176941404,Infliximab,Intentional product use issue,OT
176941404,Infliximab,Incorrect dose administered,HO
176941404,Infliximab,Incorrect dose administered,OT
176941404,Infliximab,Headache,HO
176941404,Infliximab,Headache,OT
176941404,Infliximab,Dysphonia,HO
176941404,Infliximab,Dysphonia,OT
176941404,Infliximab,Cough,HO
176941404,Infliximab,Cough,OT
176941404,Infliximab,Caesarean section,HO
176941404,Infliximab,Caesarean section,OT
176941404,Infliximab,Blood pressure fluctuation,HO
176941404,Infliximab,Blood pressure fluctuation,OT
176941404,Infliximab,Back pain,HO
176941404,Infliximab,Back pain,OT
177056563,Infliximab,Somnolence,OT
177056563,Infliximab,Rectal haemorrhage,OT
177056563,Infliximab,Pyrexia,OT
177056563,Infliximab,Product use issue,OT
177056563,Infliximab,Premature rupture of membranes,OT
177056563,Infliximab,Premature delivery,OT
177056563,Infliximab,Oxygen saturation decreased,OT
177056563,Infliximab,Off label use,OT
177056563,Infliximab,Ocular hyperaemia,OT
177056563,Infliximab,Maternal exposure during pregnancy,OT
177056563,Infliximab,Infusion site pain,OT
177056563,Infliximab,Fatigue,OT
177056563,Infliximab,Faeces soft,OT
177056563,Infliximab,Eyelid margin crusting,OT
177056563,Infliximab,Eye pain,OT
177056563,Infliximab,Drug level above therapeutic,OT
177056563,Infliximab,Condition aggravated,OT
177056563,Infliximab,Breech delivery,OT
177056563,Infliximab,Arthralgia,OT
177056563,Infliximab,Amniotic cavity infection,OT
177056563,Infliximab,Somnolence,OT
177056563,Infliximab,Rectal haemorrhage,OT
177056563,Infliximab,Pyrexia,OT
177056563,Infliximab,Product use issue,OT
177056563,Infliximab,Premature rupture of membranes,OT
177056563,Infliximab,Premature delivery,OT
177056563,Infliximab,Oxygen saturation decreased,OT
177056563,Infliximab,Off label use,OT
177056563,Infliximab,Ocular hyperaemia,OT
177056563,Infliximab,Maternal exposure during pregnancy,OT
177056563,Infliximab,Infusion site pain,OT
177056563,Infliximab,Fatigue,OT
177056563,Infliximab,Faeces soft,OT
177056563,Infliximab,Eyelid margin crusting,OT
177056563,Infliximab,Eye pain,OT
177056563,Infliximab,Drug level above therapeutic,OT
177056563,Infliximab,Condition aggravated,OT
177056563,Infliximab,Breech delivery,OT
177056563,Infliximab,Arthralgia,OT
177056563,Infliximab,Amniotic cavity infection,OT
177567024,Infliximab,Serum ferritin decreased,OT
177567024,Infliximab,Rectal haemorrhage,OT
177567024,Infliximab,Pruritus,OT
177567024,Infliximab,Proctitis ulcerative,OT
177567024,Infliximab,Pain,OT
177567024,Infliximab,Off label use,OT
177567024,Infliximab,Nausea,OT
177567024,Infliximab,Nasopharyngitis,OT
177567024,Infliximab,Mean cell haemoglobin concentration decreased,OT
177567024,Infliximab,Malaise,OT
177567024,Infliximab,Incorrect dose administered,OT
177567024,Infliximab,Inappropriate schedule of product administration,OT
177567024,Infliximab,Fatigue,OT
177567024,Infliximab,Drug level below therapeutic,OT
177567024,Infliximab,Drug ineffective,OT
177567024,Infliximab,Constipation,OT
177567024,Infliximab,Condition aggravated,OT
177567024,Infliximab,Bone pain,OT
177567024,Infliximab,Blood sodium decreased,OT
177567024,Infliximab,Arthritis,OT
177567024,Infliximab,Serum ferritin decreased,OT
177567024,Infliximab,Rectal haemorrhage,OT
177567024,Infliximab,Pruritus,OT
177567024,Infliximab,Proctitis ulcerative,OT
177567024,Infliximab,Pain,OT
177567024,Infliximab,Off label use,OT
177567024,Infliximab,Nausea,OT
177567024,Infliximab,Nasopharyngitis,OT
177567024,Infliximab,Mean cell haemoglobin concentration decreased,OT
177567024,Infliximab,Malaise,OT
177567024,Infliximab,Incorrect dose administered,OT
177567024,Infliximab,Inappropriate schedule of product administration,OT
177567024,Infliximab,Fatigue,OT
177567024,Infliximab,Drug level below therapeutic,OT
177567024,Infliximab,Drug ineffective,OT
177567024,Infliximab,Constipation,OT
177567024,Infliximab,Condition aggravated,OT
177567024,Infliximab,Bone pain,OT
177567024,Infliximab,Blood sodium decreased,OT
177567024,Infliximab,Arthritis,OT
178167663,Infliximab,Wound,OT
178167663,Infliximab,Urinary tract infection,OT
178167663,Infliximab,Skin plaque,OT
178167663,Infliximab,Product use issue,OT
178167663,Infliximab,Off label use,OT
178167663,Infliximab,Nasopharyngitis,OT
178167663,Infliximab,Intentional product use issue,OT
178167663,Infliximab,Inappropriate schedule of product administration,OT
178167663,Infliximab,Impaired healing,OT
178167663,Infliximab,Heart rate decreased,OT
178167663,Infliximab,Eczema,OT
178167663,Infliximab,Drug ineffective,OT
178167663,Infliximab,Disease recurrence,OT
178167663,Infliximab,Cough,OT
178167663,Infliximab,Condition aggravated,OT
178167663,Infliximab,Blood pressure fluctuation,OT
178167663,Infliximab,Arthralgia,OT
178167663,Infliximab,Abdominal pain,OT
178167663,Infliximab,Wound,OT
178167663,Infliximab,Urinary tract infection,OT
178167663,Infliximab,Skin plaque,OT
178167663,Infliximab,Product use issue,OT
178167663,Infliximab,Off label use,OT
178167663,Infliximab,Nasopharyngitis,OT
178167663,Infliximab,Intentional product use issue,OT
178167663,Infliximab,Inappropriate schedule of product administration,OT
178167663,Infliximab,Impaired healing,OT
178167663,Infliximab,Heart rate decreased,OT
178167663,Infliximab,Eczema,OT
178167663,Infliximab,Drug ineffective,OT
178167663,Infliximab,Disease recurrence,OT
178167663,Infliximab,Cough,OT
178167663,Infliximab,Condition aggravated,OT
178167663,Infliximab,Blood pressure fluctuation,OT
178167663,Infliximab,Arthralgia,OT
178167663,Infliximab,Abdominal pain,OT
178167663,Infliximab,Wound,OT
178167663,Infliximab,Urinary tract infection,OT
178167663,Infliximab,Skin plaque,OT
178167663,Infliximab,Product use issue,OT
178167663,Infliximab,Off label use,OT
178167663,Infliximab,Nasopharyngitis,OT
178167663,Infliximab,Intentional product use issue,OT
178167663,Infliximab,Inappropriate schedule of product administration,OT
178167663,Infliximab,Impaired healing,OT
178167663,Infliximab,Heart rate decreased,OT
178167663,Infliximab,Eczema,OT
178167663,Infliximab,Drug ineffective,OT
178167663,Infliximab,Disease recurrence,OT
178167663,Infliximab,Cough,OT
178167663,Infliximab,Condition aggravated,OT
178167663,Infliximab,Blood pressure fluctuation,OT
178167663,Infliximab,Arthralgia,OT
178167663,Infliximab,Abdominal pain,OT
184913923,Infliximab,Rectal haemorrhage,OT
184913923,Infliximab,Polyp,OT
184913923,Infliximab,Off label use,OT
184913923,Infliximab,Intentional product use issue,OT
184913923,Infliximab,Drug level above therapeutic,OT
184913923,Infliximab,Drug level abnormal,OT
184913923,Infliximab,Condition aggravated,OT
184913923,Infliximab,Blood pressure diastolic decreased,OT
184965892,Infliximab,Off label use,OT
184965892,Infliximab,Intentional product use issue,OT
184965892,Infliximab,Heart rate decreased,OT
184965892,Infliximab,Drug level above therapeutic,OT
184965892,Infliximab,Condition aggravated,OT
184965892,Infliximab,Body temperature decreased,OT
184965892,Infliximab,Blood pressure increased,OT
185021282,Infliximab,Pyrexia,OT
185021282,Infliximab,Product use in unapproved indication,OT
185021282,Infliximab,Off label use,OT
185021282,Infliximab,Body temperature fluctuation,OT
185021282,Infliximab,Arrhythmia,OT
185357923,Infliximab,Therapeutic response shortened,OT
185357923,Infliximab,Stomal hernia,OT
185357923,Infliximab,Seasonal allergy,OT
185357923,Infliximab,Product use issue,OT
185357923,Infliximab,Off label use,OT
185357923,Infliximab,Nephrolithiasis,OT
185357923,Infliximab,Intentional product use issue,OT
185357923,Infliximab,Inappropriate schedule of product administration,OT
185357923,Infliximab,Heart rate decreased,OT
185357923,Infliximab,Condition aggravated,OT
185464292,Infliximab,Rhinorrhoea,OT
185464292,Infliximab,Rhinorrhoea,HO
185464292,Infliximab,Respiratory rate decreased,OT
185464292,Infliximab,Respiratory rate decreased,HO
185464292,Infliximab,Rectal fissure,OT
185464292,Infliximab,Rectal fissure,HO
185464292,Infliximab,Pulmonary fibrosis,OT
185464292,Infliximab,Pulmonary fibrosis,HO
185464292,Infliximab,Productive cough,OT
185464292,Infliximab,Productive cough,HO
185464292,Infliximab,Otorrhoea,OT
185464292,Infliximab,Otorrhoea,HO
185464292,Infliximab,Off label use,OT
185464292,Infliximab,Off label use,HO
185464292,Infliximab,Nasopharyngitis,OT
185464292,Infliximab,Nasopharyngitis,HO
185464292,Infliximab,Nasal congestion,OT
185464292,Infliximab,Nasal congestion,HO
185464292,Infliximab,Malaise,OT
185464292,Infliximab,Malaise,HO
185464292,Infliximab,Lung disorder,OT
185464292,Infliximab,Lung disorder,HO
185464292,Infliximab,Intentional product use issue,OT
185464292,Infliximab,Intentional product use issue,HO
185464292,Infliximab,Influenza like illness,OT
185464292,Infliximab,Influenza like illness,HO
185464292,Infliximab,Fatigue,OT
185464292,Infliximab,Fatigue,HO
185464292,Infliximab,Ear infection,OT
185464292,Infliximab,Ear infection,HO
185464292,Infliximab,Ear discomfort,OT
185464292,Infliximab,Ear discomfort,HO
185464292,Infliximab,Dyspnoea,OT
185464292,Infliximab,Dyspnoea,HO
185464292,Infliximab,Drug ineffective,OT
185464292,Infliximab,Drug ineffective,HO
185464292,Infliximab,Cough,OT
185464292,Infliximab,Cough,HO
185464292,Infliximab,Condition aggravated,OT
185464292,Infliximab,Condition aggravated,HO
185464292,Infliximab,Cellulitis,OT
185464292,Infliximab,Cellulitis,HO
185464292,Infliximab,Body temperature fluctuation,OT
185464292,Infliximab,Body temperature fluctuation,HO
185464292,Infliximab,Blood pressure fluctuation,OT
185464292,Infliximab,Blood pressure fluctuation,HO
185464292,Infliximab,Asthma,OT
185464292,Infliximab,Asthma,HO
185464292,Infliximab,Anal fistula,OT
185464292,Infliximab,Anal fistula,HO
185464292,Infliximab,Acne,OT
185464292,Infliximab,Acne,HO
185464292,Infliximab,Abdominal pain upper,OT
185464292,Infliximab,Abdominal pain upper,HO
186350593,Infliximab,Therapeutic response shortened,OT
186350593,Infliximab,Rectal haemorrhage,OT
186350593,Infliximab,Off label use,OT
186350593,Infliximab,Nasopharyngitis,OT
186350593,Infliximab,Myalgia,OT
186350593,Infliximab,Musculoskeletal stiffness,OT
186350593,Infliximab,Inappropriate schedule of product administration,OT
186350593,Infliximab,Drug ineffective,OT
186350593,Infliximab,Diarrhoea,OT
186350593,Infliximab,Condition aggravated,OT
186350593,Infliximab,Bronchitis,OT
186350593,Infliximab,Back pain,OT
186350593,Infliximab,Therapeutic response shortened,OT
186350593,Infliximab,Rectal haemorrhage,OT
186350593,Infliximab,Off label use,OT
186350593,Infliximab,Nasopharyngitis,OT
186350593,Infliximab,Myalgia,OT
186350593,Infliximab,Musculoskeletal stiffness,OT
186350593,Infliximab,Inappropriate schedule of product administration,OT
186350593,Infliximab,Drug ineffective,OT
186350593,Infliximab,Diarrhoea,OT
186350593,Infliximab,Condition aggravated,OT
186350593,Infliximab,Bronchitis,OT
186350593,Infliximab,Back pain,OT
191704952,Infliximab,Rectal haemorrhage,OT
191704952,Infliximab,Off label use,OT
191704952,Infliximab,Malaise,OT
191704952,Infliximab,Intentional product use issue,OT
191704952,Infliximab,Haemorrhoids,OT
191704952,Infliximab,Blood iron decreased,OT
191704952,Infliximab,Asthenia,OT
192494632,Infliximab,Rectal haemorrhage,OT
192494632,Infliximab,Pain,OT
192494632,Infliximab,Condition aggravated,OT
192494632,Infliximab,Rectal haemorrhage,OT
192494632,Infliximab,Pain,OT
192494632,Infliximab,Condition aggravated,OT
192755012,Infliximab,Wound infection,OT
192755012,Infliximab,Withdrawal syndrome,OT
192755012,Infliximab,Swelling,OT
192755012,Infliximab,Pyrexia,OT
192755012,Infliximab,Product use issue,OT
192755012,Infliximab,Off label use,OT
192755012,Infliximab,Intentional product use issue,OT
192755012,Infliximab,Condition aggravated,OT
192755012,Infliximab,Body temperature fluctuation,OT
192755012,Infliximab,Blood pressure increased,OT
192755012,Infliximab,Blood pressure fluctuation,OT
192755012,Infliximab,Arthralgia,OT
192755012,Infliximab,Wound infection,OT
192755012,Infliximab,Withdrawal syndrome,OT
192755012,Infliximab,Swelling,OT
192755012,Infliximab,Pyrexia,OT
192755012,Infliximab,Product use issue,OT
192755012,Infliximab,Off label use,OT
192755012,Infliximab,Intentional product use issue,OT
192755012,Infliximab,Condition aggravated,OT
192755012,Infliximab,Body temperature fluctuation,OT
192755012,Infliximab,Blood pressure increased,OT
192755012,Infliximab,Blood pressure fluctuation,OT
192755012,Infliximab,Arthralgia,OT
194235722,Infliximab,Dyspnoea exertional,HO
194235722,Infliximab,Abdominal pain,HO
194743422,Infliximab (Unknown),Small intestinal perforation,LT
194743422,Infliximab (Unknown),Small intestinal perforation,HO
194743422,Infliximab (Unknown),Small intestinal perforation,OT
194743422,Infliximab (Unknown),Septic shock,LT
194743422,Infliximab (Unknown),Septic shock,HO
194743422,Infliximab (Unknown),Septic shock,OT
194743422,Infliximab (Unknown),Liver abscess,LT
194743422,Infliximab (Unknown),Liver abscess,HO
194743422,Infliximab (Unknown),Liver abscess,OT
194743422,Infliximab (Unknown),Crohn's disease,LT
194743422,Infliximab (Unknown),Crohn's disease,HO
194743422,Infliximab (Unknown),Crohn's disease,OT
194902845,Infliximab,Type I hypersensitivity,OT
194902845,Infliximab,Hypersensitivity,OT
194902845,Infliximab,Drug level decreased,OT
194902845,Infliximab,Antibody test abnormal,OT
194902845,Infliximab,Type I hypersensitivity,OT
194902845,Infliximab,Hypersensitivity,OT
194902845,Infliximab,Drug level decreased,OT
194902845,Infliximab,Antibody test abnormal,OT
195142741,Infliximab,Osteomyelitis,HO
195142741,Infliximab,Infectious pleural effusion,HO
195142741,Infliximab,Disseminated mycobacterium avium complex infection,HO
195142741,Infliximab,Bone erosion,HO
195252982,Infliximab (Unknown),Skin disorder,OT
195252982,Infliximab (Unknown),Maternal exposure during pregnancy,OT
195252982,Infliximab (Unknown),Arthritis,OT
196470431,Infliximab,Sarcoidosis,HO
196470431,Infliximab,Sarcoidosis,OT
196470431,Infliximab,Pyrexia,HO
196470431,Infliximab,Pyrexia,OT
196470431,Infliximab,Pulmonary congestion,HO
196470431,Infliximab,Pulmonary congestion,OT
196470431,Infliximab,Off label use,HO
196470431,Infliximab,Off label use,OT
196470431,Infliximab,Nasopharyngitis,HO
196470431,Infliximab,Nasopharyngitis,OT
196470431,Infliximab,Myalgia,HO
196470431,Infliximab,Myalgia,OT
196470431,Infliximab,Limb injury,HO
196470431,Infliximab,Limb injury,OT
196470431,Infliximab,Intentional product use issue,HO
196470431,Infliximab,Intentional product use issue,OT
196470431,Infliximab,Dyspnoea,HO
196470431,Infliximab,Dyspnoea,OT
196470431,Infliximab,Drug level below therapeutic,HO
196470431,Infliximab,Drug level below therapeutic,OT
196470431,Infliximab,Condition aggravated,HO
196470431,Infliximab,Condition aggravated,OT
196470431,Infliximab,C-reactive protein increased,HO
196470431,Infliximab,C-reactive protein increased,OT
196470431,Infliximab,Blood pressure increased,HO
196470431,Infliximab,Blood pressure increased,OT
196690781,Infliximab,Weight increased,OT
196690781,Infliximab,Therapeutic response shortened,OT
196690781,Infliximab,Product use issue,OT
196690781,Infliximab,Off label use,OT
196690781,Infliximab,Malaise,OT
196690781,Infliximab,Intentional product use issue,OT
196690781,Infliximab,Inappropriate schedule of product administration,OT
196690781,Infliximab,Drug level below therapeutic,OT
196690781,Infliximab,Condition aggravated,OT
196690781,Infliximab,Colitis ulcerative,OT
196690781,Infliximab,Blood potassium decreased,OT
196746311,Infliximab,Weight increased,OT
196746311,Infliximab,Off label use,OT
196746311,Infliximab,Haemorrhoids,OT
196746311,Infliximab,Condition aggravated,OT
196746311,Infliximab,Clostridium difficile infection,OT
196746311,Infliximab,Blood pressure increased,OT
197354031,Infliximab,Throat irritation,OT
197354031,Infliximab,Rash,OT
197354031,Infliximab,Pruritus,OT
197354031,Infliximab,Product use issue,OT
197354031,Infliximab,Off label use,OT
197354031,Infliximab,Lip swelling,OT
197602741,Infliximab,Weight increased,OT
197602741,Infliximab,Tremor,OT
197602741,Infliximab,Swollen tongue,OT
197602741,Infliximab,Swelling face,OT
197602741,Infliximab,Somnolence,OT
197602741,Infliximab,Respiratory rate increased,OT
197602741,Infliximab,Pruritus,OT
197602741,Infliximab,Pharyngeal swelling,OT
197602741,Infliximab,Paraesthesia,OT
197602741,Infliximab,Panic disorder,OT
197602741,Infliximab,Palpitations,OT
197602741,Infliximab,Pallor,OT
197602741,Infliximab,Off label use,OT
197602741,Infliximab,Ocular discomfort,OT
197602741,Infliximab,Muscle spasms,OT
197602741,Infliximab,Lip swelling,OT
197602741,Infliximab,Inappropriate schedule of product administration,OT
197602741,Infliximab,Heart rate increased,OT
197602741,Infliximab,Furuncle,OT
197602741,Infliximab,Feeling abnormal,OT
197602741,Infliximab,Fatigue,OT
197602741,Infliximab,Ear infection,OT
197602741,Infliximab,Dyspnoea,OT
197602741,Infliximab,Dizziness,OT
197602741,Infliximab,Diarrhoea,OT
197602741,Infliximab,Chills,OT
197602741,Infliximab,Chest pain,OT
197602741,Infliximab,Chest discomfort,OT
197602741,Infliximab,Blood pressure fluctuation,OT
197602741,Infliximab,Arthralgia,OT
197602741,Infliximab,Abdominal pain upper,OT
197996681,Infliximab,Vomiting,OT
197996681,Infliximab,Visual impairment,OT
197996681,Infliximab,Rectal haemorrhage,OT
197996681,Infliximab,Pyrexia,OT
197996681,Infliximab,Product use issue,OT
197996681,Infliximab,Nausea,OT
197996681,Infliximab,Mucous stools,OT
197996681,Infliximab,Haematochezia,OT
197996681,Infliximab,Faecal volume decreased,OT
197996681,Infliximab,Constipation,OT
197996681,Infliximab,Blindness,OT
197996681,Infliximab,Abdominal pain,OT
197996681,Infliximab,Abdominal distension,OT
197996681,Infliximab,Vomiting,OT
197996681,Infliximab,Visual impairment,OT
197996681,Infliximab,Rectal haemorrhage,OT
197996681,Infliximab,Pyrexia,OT
197996681,Infliximab,Product use issue,OT
197996681,Infliximab,Nausea,OT
197996681,Infliximab,Mucous stools,OT
197996681,Infliximab,Haematochezia,OT
197996681,Infliximab,Faecal volume decreased,OT
197996681,Infliximab,Constipation,OT
197996681,Infliximab,Blindness,OT
197996681,Infliximab,Abdominal pain,OT
197996681,Infliximab,Abdominal distension,OT
197996681,Infliximab,Vomiting,OT
197996681,Infliximab,Visual impairment,OT
197996681,Infliximab,Rectal haemorrhage,OT
197996681,Infliximab,Pyrexia,OT
197996681,Infliximab,Product use issue,OT
197996681,Infliximab,Nausea,OT
197996681,Infliximab,Mucous stools,OT
197996681,Infliximab,Haematochezia,OT
197996681,Infliximab,Faecal volume decreased,OT
197996681,Infliximab,Constipation,OT
197996681,Infliximab,Blindness,OT
197996681,Infliximab,Abdominal pain,OT
197996681,Infliximab,Abdominal distension,OT
198050391,Infliximab,Off label use,HO
198050391,Infliximab,Drug level decreased,HO
198050391,Infliximab,Drug ineffective,HO
198050391,Infliximab,Condition aggravated,HO
198682571,Infliximab,Weight decreased,OT
198682571,Infliximab,Type 2 diabetes mellitus,OT
198682571,Infliximab,Product dose omission issue,OT
198682571,Infliximab,Nasopharyngitis,OT
198682571,Infliximab,Malaise,OT
198682571,Infliximab,Inappropriate schedule of product administration,OT
198682571,Infliximab,Food poisoning,OT
198682571,Infliximab,Diarrhoea,OT
198682571,Infliximab,Chest discomfort,OT
198682571,Infliximab,Abdominal distension,OT
198845461,Infliximab (Unknown),Off label use,NULL
198845461,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198851431,Infliximab (Unknown),Palpitations,NULL
198851431,Infliximab (Unknown),Off label use,NULL
198851431,Infliximab (Unknown),Dyspnoea,NULL
198851431,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198851431,Infliximab (Unknown),Palpitations,NULL
198851431,Infliximab (Unknown),Off label use,NULL
198851431,Infliximab (Unknown),Dyspnoea,NULL
198851431,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198851431,Infliximab (Unknown),Palpitations,NULL
198851431,Infliximab (Unknown),Off label use,NULL
198851431,Infliximab (Unknown),Dyspnoea,NULL
198851431,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198851431,Infliximab (Unknown),Palpitations,NULL
198851431,Infliximab (Unknown),Off label use,NULL
198851431,Infliximab (Unknown),Dyspnoea,NULL
198851431,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198851701,Infliximab (Unknown),Off label use,NULL
198851701,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198870691,Infliximab (Unknown),Off label use,NULL
198870691,Infliximab (Unknown),Drug effective for unapproved indication,NULL
199002041,Infliximab,Underdose,NULL
199002041,Infliximab,SARS-CoV-2 antibody test positive,NULL
199002041,Infliximab,Overdose,NULL
199002041,Infliximab,Off label use,NULL
199002041,Infliximab,Antibody test abnormal,NULL
199002041,Infliximab,Underdose,NULL
199002041,Infliximab,SARS-CoV-2 antibody test positive,NULL
199002041,Infliximab,Overdose,NULL
199002041,Infliximab,Off label use,NULL
199002041,Infliximab,Antibody test abnormal,NULL
176111443,Infliximab,Weight increased,OT
176111443,Infliximab,Rectal haemorrhage,OT
176111443,Infliximab,Product use issue,OT
176111443,Infliximab,Off label use,OT
176111443,Infliximab,Malaise,OT
176111443,Infliximab,Intentional product use issue,OT
176111443,Infliximab,Heart rate decreased,OT
176111443,Infliximab,Frequent bowel movements,OT
176111443,Infliximab,Condition aggravated,OT
176111443,Infliximab,Body temperature decreased,OT
176111443,Infliximab,Blood pressure fluctuation,OT
176179184,Infliximab,Wound infection,OT
176179184,Infliximab,Venous injury,OT
176179184,Infliximab,Vascular access site occlusion,OT
176179184,Infliximab,Urinary tract infection bacterial,OT
176179184,Infliximab,Sinusitis,OT
176179184,Infliximab,Pyrexia,OT
176179184,Infliximab,Psoriasis,OT
176179184,Infliximab,Product use issue,OT
176179184,Infliximab,Product use in unapproved indication,OT
176179184,Infliximab,Poor venous access,OT
176179184,Infliximab,Off label use,OT
176179184,Infliximab,Irritable bowel syndrome,OT
176179184,Infliximab,Intentional product use issue,OT
176179184,Infliximab,Injection site extravasation,OT
176179184,Infliximab,Infusion site oedema,OT
176179184,Infliximab,Infusion site coldness,OT
176179184,Infliximab,Incorrect dose administered,OT
176179184,Infliximab,Gastrointestinal inflammation,OT
176179184,Infliximab,Fatigue,OT
176179184,Infliximab,Drug level below therapeutic,OT
176179184,Infliximab,Drug ineffective,OT
176179184,Infliximab,Condition aggravated,OT
176179184,Infliximab,Blood pressure increased,OT
176179184,Infliximab,Anal skin tags,OT
176179184,Infliximab,Anal incontinence,OT
176179184,Infliximab,Abscess intestinal,OT
176179184,Infliximab,Wound infection,OT
176179184,Infliximab,Venous injury,OT
176179184,Infliximab,Vascular access site occlusion,OT
176179184,Infliximab,Urinary tract infection bacterial,OT
176179184,Infliximab,Sinusitis,OT
176179184,Infliximab,Pyrexia,OT
176179184,Infliximab,Psoriasis,OT
176179184,Infliximab,Product use issue,OT
176179184,Infliximab,Product use in unapproved indication,OT
176179184,Infliximab,Poor venous access,OT
176179184,Infliximab,Off label use,OT
176179184,Infliximab,Irritable bowel syndrome,OT
176179184,Infliximab,Intentional product use issue,OT
176179184,Infliximab,Injection site extravasation,OT
176179184,Infliximab,Infusion site oedema,OT
176179184,Infliximab,Infusion site coldness,OT
176179184,Infliximab,Incorrect dose administered,OT
176179184,Infliximab,Gastrointestinal inflammation,OT
176179184,Infliximab,Fatigue,OT
176179184,Infliximab,Drug level below therapeutic,OT
176179184,Infliximab,Drug ineffective,OT
176179184,Infliximab,Condition aggravated,OT
176179184,Infliximab,Blood pressure increased,OT
176179184,Infliximab,Anal skin tags,OT
176179184,Infliximab,Anal incontinence,OT
176179184,Infliximab,Abscess intestinal,OT
176179184,Infliximab,Wound infection,OT
176179184,Infliximab,Venous injury,OT
176179184,Infliximab,Vascular access site occlusion,OT
176179184,Infliximab,Urinary tract infection bacterial,OT
176179184,Infliximab,Sinusitis,OT
176179184,Infliximab,Pyrexia,OT
176179184,Infliximab,Psoriasis,OT
176179184,Infliximab,Product use issue,OT
176179184,Infliximab,Product use in unapproved indication,OT
176179184,Infliximab,Poor venous access,OT
176179184,Infliximab,Off label use,OT
176179184,Infliximab,Irritable bowel syndrome,OT
176179184,Infliximab,Intentional product use issue,OT
176179184,Infliximab,Injection site extravasation,OT
176179184,Infliximab,Infusion site oedema,OT
176179184,Infliximab,Infusion site coldness,OT
176179184,Infliximab,Incorrect dose administered,OT
176179184,Infliximab,Gastrointestinal inflammation,OT
176179184,Infliximab,Fatigue,OT
176179184,Infliximab,Drug level below therapeutic,OT
176179184,Infliximab,Drug ineffective,OT
176179184,Infliximab,Condition aggravated,OT
176179184,Infliximab,Blood pressure increased,OT
176179184,Infliximab,Anal skin tags,OT
176179184,Infliximab,Anal incontinence,OT
176179184,Infliximab,Abscess intestinal,OT
176179184,Infliximab,Wound infection,OT
176179184,Infliximab,Venous injury,OT
176179184,Infliximab,Vascular access site occlusion,OT
176179184,Infliximab,Urinary tract infection bacterial,OT
176179184,Infliximab,Sinusitis,OT
176179184,Infliximab,Pyrexia,OT
176179184,Infliximab,Psoriasis,OT
176179184,Infliximab,Product use issue,OT
176179184,Infliximab,Product use in unapproved indication,OT
176179184,Infliximab,Poor venous access,OT
176179184,Infliximab,Off label use,OT
176179184,Infliximab,Irritable bowel syndrome,OT
176179184,Infliximab,Intentional product use issue,OT
176179184,Infliximab,Injection site extravasation,OT
176179184,Infliximab,Infusion site oedema,OT
176179184,Infliximab,Infusion site coldness,OT
176179184,Infliximab,Incorrect dose administered,OT
176179184,Infliximab,Gastrointestinal inflammation,OT
176179184,Infliximab,Fatigue,OT
176179184,Infliximab,Drug level below therapeutic,OT
176179184,Infliximab,Drug ineffective,OT
176179184,Infliximab,Condition aggravated,OT
176179184,Infliximab,Blood pressure increased,OT
176179184,Infliximab,Anal skin tags,OT
176179184,Infliximab,Anal incontinence,OT
176179184,Infliximab,Abscess intestinal,OT
176179184,Infliximab,Wound infection,OT
176179184,Infliximab,Venous injury,OT
176179184,Infliximab,Vascular access site occlusion,OT
176179184,Infliximab,Urinary tract infection bacterial,OT
176179184,Infliximab,Sinusitis,OT
176179184,Infliximab,Pyrexia,OT
176179184,Infliximab,Psoriasis,OT
176179184,Infliximab,Product use issue,OT
176179184,Infliximab,Product use in unapproved indication,OT
176179184,Infliximab,Poor venous access,OT
176179184,Infliximab,Off label use,OT
176179184,Infliximab,Irritable bowel syndrome,OT
176179184,Infliximab,Intentional product use issue,OT
176179184,Infliximab,Injection site extravasation,OT
176179184,Infliximab,Infusion site oedema,OT
176179184,Infliximab,Infusion site coldness,OT
176179184,Infliximab,Incorrect dose administered,OT
176179184,Infliximab,Gastrointestinal inflammation,OT
176179184,Infliximab,Fatigue,OT
176179184,Infliximab,Drug level below therapeutic,OT
176179184,Infliximab,Drug ineffective,OT
176179184,Infliximab,Condition aggravated,OT
176179184,Infliximab,Blood pressure increased,OT
176179184,Infliximab,Anal skin tags,OT
176179184,Infliximab,Anal incontinence,OT
176179184,Infliximab,Abscess intestinal,OT
176266453,Infliximab,Weight decreased,OT
176266453,Infliximab,Vaginal infection,OT
176266453,Infliximab,Skin lesion,OT
176266453,Infliximab,Seasonal allergy,OT
176266453,Infliximab,Rhinorrhoea,OT
176266453,Infliximab,Productive cough,OT
176266453,Infliximab,Product use issue,OT
176266453,Infliximab,Pharyngitis,OT
176266453,Infliximab,Pain,OT
176266453,Infliximab,Oropharyngeal pain,OT
176266453,Infliximab,Off label use,OT
176266453,Infliximab,Nausea,OT
176266453,Infliximab,Nasopharyngitis,OT
176266453,Infliximab,Malaise,OT
176266453,Infliximab,Limb injury,OT
176266453,Infliximab,Laryngopharyngitis,OT
176266453,Infliximab,Laryngitis,OT
176266453,Infliximab,Intentional product use issue,OT
176266453,Infliximab,Injection site bruising,OT
176266453,Infliximab,Ingrowing nail,OT
176266453,Infliximab,Infusion site erythema,OT
176266453,Infliximab,Inappropriate schedule of product administration,OT
176266453,Infliximab,Impaired healing,OT
176266453,Infliximab,Hypokinesia,OT
176266453,Infliximab,Heavy menstrual bleeding,OT
176266453,Infliximab,Gingival disorder,OT
176266453,Infliximab,Gastric disorder,OT
176266453,Infliximab,Flatulence,OT
176266453,Infliximab,Fatigue,OT
176266453,Infliximab,Drug ineffective,OT
176266453,Infliximab,Dizziness,OT
176266453,Infliximab,Cough,OT
176266453,Infliximab,Condition aggravated,OT
176266453,Infliximab,Chills,OT
176266453,Infliximab,Bursitis,OT
176266453,Infliximab,Bronchitis,OT
176266453,Infliximab,Blood pressure fluctuation,OT
176266453,Infliximab,Arthralgia,OT
176266453,Infliximab,Aphthous ulcer,OT
176266453,Infliximab,Abdominal distension,OT
176519224,Infliximab,Therapeutic response shortened,OT
176519224,Infliximab,Product use in unapproved indication,OT
176519224,Infliximab,Peripheral swelling,OT
176519224,Infliximab,Off label use,OT
176519224,Infliximab,Intentional product use issue,OT
176519224,Infliximab,Inappropriate schedule of product administration,OT
176519224,Infliximab,Hypotension,OT
176519224,Infliximab,Heart rate decreased,OT
176519224,Infliximab,Flushing,OT
176519224,Infliximab,Fatigue,OT
176519224,Infliximab,Dyspnoea exertional,OT
176519224,Infliximab,Drug effective for unapproved indication,OT
176519224,Infliximab,Blood pressure fluctuation,OT
176519224,Infliximab,Therapeutic response shortened,OT
176519224,Infliximab,Product use in unapproved indication,OT
176519224,Infliximab,Peripheral swelling,OT
176519224,Infliximab,Off label use,OT
176519224,Infliximab,Intentional product use issue,OT
176519224,Infliximab,Inappropriate schedule of product administration,OT
176519224,Infliximab,Hypotension,OT
176519224,Infliximab,Heart rate decreased,OT
176519224,Infliximab,Flushing,OT
176519224,Infliximab,Fatigue,OT
176519224,Infliximab,Dyspnoea exertional,OT
176519224,Infliximab,Drug effective for unapproved indication,OT
176519224,Infliximab,Blood pressure fluctuation,OT
176583053,Infliximab,Urticaria,OT
176583053,Infliximab,Product use issue,OT
176583053,Infliximab,Pain in extremity,OT
176583053,Infliximab,Off label use,OT
176583053,Infliximab,Intentional product use issue,OT
176583053,Infliximab,Heart rate irregular,OT
176583053,Infliximab,Drug ineffective,OT
176583053,Infliximab,Condition aggravated,OT
176583053,Infliximab,Body temperature fluctuation,OT
176583053,Infliximab,Arthralgia,OT
176583053,Infliximab,Urticaria,OT
176583053,Infliximab,Product use issue,OT
176583053,Infliximab,Pain in extremity,OT
176583053,Infliximab,Off label use,OT
176583053,Infliximab,Intentional product use issue,OT
176583053,Infliximab,Heart rate irregular,OT
176583053,Infliximab,Drug ineffective,OT
176583053,Infliximab,Condition aggravated,OT
176583053,Infliximab,Body temperature fluctuation,OT
176583053,Infliximab,Arthralgia,OT
176990243,Infliximab,Weight increased,OT
176990243,Infliximab,Weight increased,HO
176990243,Infliximab,Therapeutic response shortened,OT
176990243,Infliximab,Therapeutic response shortened,HO
176990243,Infliximab,Pain,OT
176990243,Infliximab,Pain,HO
176990243,Infliximab,Off label use,OT
176990243,Infliximab,Off label use,HO
176990243,Infliximab,Muscle spasms,OT
176990243,Infliximab,Muscle spasms,HO
176990243,Infliximab,Intentional product use issue,OT
176990243,Infliximab,Intentional product use issue,HO
176990243,Infliximab,Insomnia,OT
176990243,Infliximab,Insomnia,HO
176990243,Infliximab,Incorrect dose administered,OT
176990243,Infliximab,Incorrect dose administered,HO
176990243,Infliximab,Inappropriate schedule of product administration,OT
176990243,Infliximab,Inappropriate schedule of product administration,HO
176990243,Infliximab,Heart rate abnormal,OT
176990243,Infliximab,Heart rate abnormal,HO
176990243,Infliximab,Fatigue,OT
176990243,Infliximab,Fatigue,HO
176990243,Infliximab,Condition aggravated,OT
176990243,Infliximab,Condition aggravated,HO
176990243,Infliximab,Body temperature fluctuation,OT
176990243,Infliximab,Body temperature fluctuation,HO
176990243,Infliximab,Blood pressure increased,OT
176990243,Infliximab,Blood pressure increased,HO
176990243,Infliximab,Blood pressure fluctuation,OT
176990243,Infliximab,Blood pressure fluctuation,HO
176990243,Infliximab,Anal fistula,OT
176990243,Infliximab,Anal fistula,HO
176990243,Infliximab,Abscess,OT
176990243,Infliximab,Abscess,HO
176990243,Infliximab,Abdominal pain,OT
176990243,Infliximab,Abdominal pain,HO
176990243,Infliximab,Weight increased,OT
176990243,Infliximab,Weight increased,HO
176990243,Infliximab,Therapeutic response shortened,OT
176990243,Infliximab,Therapeutic response shortened,HO
176990243,Infliximab,Pain,OT
176990243,Infliximab,Pain,HO
176990243,Infliximab,Off label use,OT
176990243,Infliximab,Off label use,HO
176990243,Infliximab,Muscle spasms,OT
176990243,Infliximab,Muscle spasms,HO
176990243,Infliximab,Intentional product use issue,OT
176990243,Infliximab,Intentional product use issue,HO
176990243,Infliximab,Insomnia,OT
176990243,Infliximab,Insomnia,HO
176990243,Infliximab,Incorrect dose administered,OT
176990243,Infliximab,Incorrect dose administered,HO
176990243,Infliximab,Inappropriate schedule of product administration,OT
176990243,Infliximab,Inappropriate schedule of product administration,HO
176990243,Infliximab,Heart rate abnormal,OT
176990243,Infliximab,Heart rate abnormal,HO
176990243,Infliximab,Fatigue,OT
176990243,Infliximab,Fatigue,HO
176990243,Infliximab,Condition aggravated,OT
176990243,Infliximab,Condition aggravated,HO
176990243,Infliximab,Body temperature fluctuation,OT
176990243,Infliximab,Body temperature fluctuation,HO
176990243,Infliximab,Blood pressure increased,OT
176990243,Infliximab,Blood pressure increased,HO
176990243,Infliximab,Blood pressure fluctuation,OT
176990243,Infliximab,Blood pressure fluctuation,HO
176990243,Infliximab,Anal fistula,OT
176990243,Infliximab,Anal fistula,HO
176990243,Infliximab,Abscess,OT
176990243,Infliximab,Abscess,HO
176990243,Infliximab,Abdominal pain,OT
176990243,Infliximab,Abdominal pain,HO
177004393,Infliximab,Weight increased,OT
177004393,Infliximab,Weight decreased,OT
177004393,Infliximab,Off label use,OT
177004393,Infliximab,Inappropriate schedule of product administration,OT
177004393,Infliximab,Haematochezia,OT
177004393,Infliximab,Fungal infection,OT
177004393,Infliximab,Drug level increased,OT
177004393,Infliximab,Drug level decreased,OT
177004393,Infliximab,Defaecation urgency,OT
177004393,Infliximab,Cystitis,OT
177004393,Infliximab,Cough,OT
177004393,Infliximab,Condition aggravated,OT
177004393,Infliximab,Blood pressure increased,OT
178308483,Infliximab,Weight decreased,HO
178308483,Infliximab,Weight decreased,LT
178308483,Infliximab,Weight decreased,OT
178308483,Infliximab,Toothache,HO
178308483,Infliximab,Toothache,LT
178308483,Infliximab,Toothache,OT
178308483,Infliximab,Radius fracture,HO
178308483,Infliximab,Radius fracture,LT
178308483,Infliximab,Radius fracture,OT
178308483,Infliximab,Product use issue,HO
178308483,Infliximab,Product use issue,LT
178308483,Infliximab,Product use issue,OT
178308483,Infliximab,Product use in unapproved indication,HO
178308483,Infliximab,Product use in unapproved indication,LT
178308483,Infliximab,Product use in unapproved indication,OT
178308483,Infliximab,Off label use,HO
178308483,Infliximab,Off label use,LT
178308483,Infliximab,Off label use,OT
178308483,Infliximab,Nervousness,HO
178308483,Infliximab,Nervousness,LT
178308483,Infliximab,Nervousness,OT
178308483,Infliximab,Intentional product use issue,HO
178308483,Infliximab,Intentional product use issue,LT
178308483,Infliximab,Intentional product use issue,OT
178308483,Infliximab,Heart rate decreased,HO
178308483,Infliximab,Heart rate decreased,LT
178308483,Infliximab,Heart rate decreased,OT
178308483,Infliximab,Dyspnoea,HO
178308483,Infliximab,Dyspnoea,LT
178308483,Infliximab,Dyspnoea,OT
178308483,Infliximab,Drug effective for unapproved indication,HO
178308483,Infliximab,Drug effective for unapproved indication,LT
178308483,Infliximab,Drug effective for unapproved indication,OT
178308483,Infliximab,Dizziness,HO
178308483,Infliximab,Dizziness,LT
178308483,Infliximab,Dizziness,OT
178308483,Infliximab,Abdominal hernia,HO
178308483,Infliximab,Abdominal hernia,LT
178308483,Infliximab,Abdominal hernia,OT
178308483,Infliximab,Weight decreased,HO
178308483,Infliximab,Weight decreased,LT
178308483,Infliximab,Weight decreased,OT
178308483,Infliximab,Toothache,HO
178308483,Infliximab,Toothache,LT
178308483,Infliximab,Toothache,OT
178308483,Infliximab,Radius fracture,HO
178308483,Infliximab,Radius fracture,LT
178308483,Infliximab,Radius fracture,OT
178308483,Infliximab,Product use issue,HO
178308483,Infliximab,Product use issue,LT
178308483,Infliximab,Product use issue,OT
178308483,Infliximab,Product use in unapproved indication,HO
178308483,Infliximab,Product use in unapproved indication,LT
178308483,Infliximab,Product use in unapproved indication,OT
178308483,Infliximab,Off label use,HO
178308483,Infliximab,Off label use,LT
178308483,Infliximab,Off label use,OT
178308483,Infliximab,Nervousness,HO
178308483,Infliximab,Nervousness,LT
178308483,Infliximab,Nervousness,OT
178308483,Infliximab,Intentional product use issue,HO
178308483,Infliximab,Intentional product use issue,LT
178308483,Infliximab,Intentional product use issue,OT
178308483,Infliximab,Heart rate decreased,HO
178308483,Infliximab,Heart rate decreased,LT
178308483,Infliximab,Heart rate decreased,OT
178308483,Infliximab,Dyspnoea,HO
178308483,Infliximab,Dyspnoea,LT
178308483,Infliximab,Dyspnoea,OT
178308483,Infliximab,Drug effective for unapproved indication,HO
178308483,Infliximab,Drug effective for unapproved indication,LT
178308483,Infliximab,Drug effective for unapproved indication,OT
178308483,Infliximab,Dizziness,HO
178308483,Infliximab,Dizziness,LT
178308483,Infliximab,Dizziness,OT
178308483,Infliximab,Abdominal hernia,HO
178308483,Infliximab,Abdominal hernia,LT
178308483,Infliximab,Abdominal hernia,OT
183749072,Infliximab (Unknown),Cellulitis,HO
183779172,Infliximab,Weight increased,OT
183779172,Infliximab,Weight fluctuation,OT
183779172,Infliximab,Vomiting,OT
183779172,Infliximab,Uveitis,OT
183779172,Infliximab,Renal pain,OT
183779172,Infliximab,Product use issue,OT
183779172,Infliximab,Poor venous access,OT
183779172,Infliximab,Off label use,OT
183779172,Infliximab,Malaise,OT
183779172,Infliximab,Lacrimation increased,OT
183779172,Infliximab,Intentional product use issue,OT
183779172,Infliximab,Incorrect dose administered,OT
183779172,Infliximab,Inappropriate schedule of product administration,OT
183779172,Infliximab,Heart rate irregular,OT
183779172,Infliximab,Fatigue,OT
183779172,Infliximab,Faecal calprotectin increased,OT
183779172,Infliximab,Eye pain,OT
183779172,Infliximab,Eye disorder,OT
183779172,Infliximab,Drug level below therapeutic,OT
183779172,Infliximab,Drug level above therapeutic,OT
183779172,Infliximab,Drug ineffective,OT
183779172,Infliximab,Condition aggravated,OT
183779172,Infliximab,Arthralgia,OT
183779172,Infliximab,Aphthous ulcer,OT
183779172,Infliximab,Anal fissure,OT
183779172,Infliximab,Weight increased,OT
183779172,Infliximab,Weight fluctuation,OT
183779172,Infliximab,Vomiting,OT
183779172,Infliximab,Uveitis,OT
183779172,Infliximab,Renal pain,OT
183779172,Infliximab,Product use issue,OT
183779172,Infliximab,Poor venous access,OT
183779172,Infliximab,Off label use,OT
183779172,Infliximab,Malaise,OT
183779172,Infliximab,Lacrimation increased,OT
183779172,Infliximab,Intentional product use issue,OT
183779172,Infliximab,Incorrect dose administered,OT
183779172,Infliximab,Inappropriate schedule of product administration,OT
183779172,Infliximab,Heart rate irregular,OT
183779172,Infliximab,Fatigue,OT
183779172,Infliximab,Faecal calprotectin increased,OT
183779172,Infliximab,Eye pain,OT
183779172,Infliximab,Eye disorder,OT
183779172,Infliximab,Drug level below therapeutic,OT
183779172,Infliximab,Drug level above therapeutic,OT
183779172,Infliximab,Drug ineffective,OT
183779172,Infliximab,Condition aggravated,OT
183779172,Infliximab,Arthralgia,OT
183779172,Infliximab,Aphthous ulcer,OT
183779172,Infliximab,Anal fissure,OT
183964262,Infliximab,Weight increased,OT
183964262,Infliximab,Off label use,OT
183964262,Infliximab,Intentional product use issue,OT
183964262,Infliximab,Heart rate increased,OT
183964262,Infliximab,Heart rate decreased,OT
183964262,Infliximab,Condition aggravated,OT
183964262,Infliximab,Blood pressure increased,OT
183964262,Infliximab,Blood pressure fluctuation,OT
184391344,Infliximab,Psoriasis,OT
184391344,Infliximab,Psoriasis,DS
184391344,Infliximab,Off label use,OT
184391344,Infliximab,Off label use,DS
184391344,Infliximab,Intentional product use issue,OT
184391344,Infliximab,Intentional product use issue,DS
184391344,Infliximab,Heart rate decreased,OT
184391344,Infliximab,Heart rate decreased,DS
184391344,Infliximab,Headache,OT
184391344,Infliximab,Headache,DS
184391344,Infliximab,Fatigue,OT
184391344,Infliximab,Fatigue,DS
184391344,Infliximab,Eczema,OT
184391344,Infliximab,Eczema,DS
184391344,Infliximab,Cough,OT
184391344,Infliximab,Cough,DS
184391344,Infliximab,Blood pressure increased,OT
184391344,Infliximab,Blood pressure increased,DS
184391344,Infliximab,Blood pressure fluctuation,OT
184391344,Infliximab,Blood pressure fluctuation,DS
184391344,Infliximab,Back pain,OT
184391344,Infliximab,Back pain,DS
184391344,Infliximab,Psoriasis,OT
184391344,Infliximab,Psoriasis,DS
184391344,Infliximab,Off label use,OT
184391344,Infliximab,Off label use,DS
184391344,Infliximab,Intentional product use issue,OT
184391344,Infliximab,Intentional product use issue,DS
184391344,Infliximab,Heart rate decreased,OT
184391344,Infliximab,Heart rate decreased,DS
184391344,Infliximab,Headache,OT
184391344,Infliximab,Headache,DS
184391344,Infliximab,Fatigue,OT
184391344,Infliximab,Fatigue,DS
184391344,Infliximab,Eczema,OT
184391344,Infliximab,Eczema,DS
184391344,Infliximab,Cough,OT
184391344,Infliximab,Cough,DS
184391344,Infliximab,Blood pressure increased,OT
184391344,Infliximab,Blood pressure increased,DS
184391344,Infliximab,Blood pressure fluctuation,OT
184391344,Infliximab,Blood pressure fluctuation,DS
184391344,Infliximab,Back pain,OT
184391344,Infliximab,Back pain,DS
184391344,Infliximab,Psoriasis,OT
184391344,Infliximab,Psoriasis,DS
184391344,Infliximab,Off label use,OT
184391344,Infliximab,Off label use,DS
184391344,Infliximab,Intentional product use issue,OT
184391344,Infliximab,Intentional product use issue,DS
184391344,Infliximab,Heart rate decreased,OT
184391344,Infliximab,Heart rate decreased,DS
184391344,Infliximab,Headache,OT
184391344,Infliximab,Headache,DS
184391344,Infliximab,Fatigue,OT
184391344,Infliximab,Fatigue,DS
184391344,Infliximab,Eczema,OT
184391344,Infliximab,Eczema,DS
184391344,Infliximab,Cough,OT
184391344,Infliximab,Cough,DS
184391344,Infliximab,Blood pressure increased,OT
184391344,Infliximab,Blood pressure increased,DS
184391344,Infliximab,Blood pressure fluctuation,OT
184391344,Infliximab,Blood pressure fluctuation,DS
184391344,Infliximab,Back pain,OT
184391344,Infliximab,Back pain,DS
184582152,Infliximab,Interstitial lung disease,OT
184628264,Infliximab,White blood cell count decreased,OT
184628264,Infliximab,Weight fluctuation,OT
184628264,Infliximab,Off label use,OT
184628264,Infliximab,Neutrophil count decreased,OT
184628264,Infliximab,Intentional product use issue,OT
184628264,Infliximab,Incorrect dose administered,OT
184628264,Infliximab,Impetigo,OT
184628264,Infliximab,Hypertension,OT
184628264,Infliximab,Condition aggravated,OT
184628264,Infliximab,Antinuclear antibody positive,OT
184628264,Infliximab,Alanine aminotransferase increased,OT
184628264,Infliximab,White blood cell count decreased,OT
184628264,Infliximab,Weight fluctuation,OT
184628264,Infliximab,Off label use,OT
184628264,Infliximab,Neutrophil count decreased,OT
184628264,Infliximab,Intentional product use issue,OT
184628264,Infliximab,Incorrect dose administered,OT
184628264,Infliximab,Impetigo,OT
184628264,Infliximab,Hypertension,OT
184628264,Infliximab,Condition aggravated,OT
184628264,Infliximab,Antinuclear antibody positive,OT
184628264,Infliximab,Alanine aminotransferase increased,OT
184916143,Infliximab,Wound,OT
184916143,Infliximab,Weight decreased,OT
184916143,Infliximab,Vomiting,OT
184916143,Infliximab,Urinary tract infection,OT
184916143,Infliximab,Sputum discoloured,OT
184916143,Infliximab,Productive cough,OT
184916143,Infliximab,Pneumonia,OT
184916143,Infliximab,Pharyngitis,OT
184916143,Infliximab,Pharyngeal mass,OT
184916143,Infliximab,Pain,OT
184916143,Infliximab,Off label use,OT
184916143,Infliximab,Nausea,OT
184916143,Infliximab,Nasopharyngitis,OT
184916143,Infliximab,Laryngitis,OT
184916143,Infliximab,Intentional product use issue,OT
184916143,Infliximab,Influenza,OT
184916143,Infliximab,Infection,OT
184916143,Infliximab,Inappropriate schedule of product administration,OT
184916143,Infliximab,Heart rate irregular,OT
184916143,Infliximab,Heart rate decreased,OT
184916143,Infliximab,Ear infection,OT
184916143,Infliximab,Drug level below therapeutic,OT
184916143,Infliximab,Body temperature decreased,OT
184916143,Infliximab,Blood pressure increased,OT
184916143,Infliximab,Blood pressure fluctuation,OT
184916143,Infliximab,Arthralgia,OT
184916143,Infliximab,Anaemia,OT
184916143,Infliximab,Abdominal pain upper,OT
184916143,Infliximab,Abdominal pain,OT
184916143,Infliximab,Sinusitis,OT
184916143,Infliximab,Wound,OT
184916143,Infliximab,Weight decreased,OT
184916143,Infliximab,Vomiting,OT
184916143,Infliximab,Urinary tract infection,OT
184916143,Infliximab,Sputum discoloured,OT
184916143,Infliximab,Productive cough,OT
184916143,Infliximab,Pneumonia,OT
184916143,Infliximab,Pharyngitis,OT
184916143,Infliximab,Pharyngeal mass,OT
184916143,Infliximab,Pain,OT
184916143,Infliximab,Off label use,OT
184916143,Infliximab,Nausea,OT
184916143,Infliximab,Nasopharyngitis,OT
184916143,Infliximab,Laryngitis,OT
184916143,Infliximab,Intentional product use issue,OT
184916143,Infliximab,Influenza,OT
184916143,Infliximab,Infection,OT
184916143,Infliximab,Inappropriate schedule of product administration,OT
184916143,Infliximab,Heart rate irregular,OT
184916143,Infliximab,Heart rate decreased,OT
184916143,Infliximab,Ear infection,OT
184916143,Infliximab,Drug level below therapeutic,OT
184916143,Infliximab,Body temperature decreased,OT
184916143,Infliximab,Blood pressure increased,OT
184916143,Infliximab,Blood pressure fluctuation,OT
184916143,Infliximab,Arthralgia,OT
184916143,Infliximab,Anaemia,OT
184916143,Infliximab,Abdominal pain upper,OT
184916143,Infliximab,Abdominal pain,OT
184916143,Infliximab,Sinusitis,OT
185025232,Infliximab,Weight increased,OT
185025232,Infliximab,Weight increased,HO
185025232,Infliximab,Therapeutic response shortened,OT
185025232,Infliximab,Therapeutic response shortened,HO
185025232,Infliximab,Therapeutic product effect incomplete,OT
185025232,Infliximab,Therapeutic product effect incomplete,HO
185025232,Infliximab,Suspected COVID-19,OT
185025232,Infliximab,Suspected COVID-19,HO
185025232,Infliximab,Road traffic accident,OT
185025232,Infliximab,Road traffic accident,HO
185025232,Infliximab,Poor quality sleep,OT
185025232,Infliximab,Poor quality sleep,HO
185025232,Infliximab,Pain in jaw,OT
185025232,Infliximab,Pain in jaw,HO
185025232,Infliximab,Osteopenia,OT
185025232,Infliximab,Osteopenia,HO
185025232,Infliximab,Off label use,OT
185025232,Infliximab,Off label use,HO
185025232,Infliximab,Musculoskeletal pain,OT
185025232,Infliximab,Musculoskeletal pain,HO
185025232,Infliximab,Joint injury,OT
185025232,Infliximab,Joint injury,HO
185025232,Infliximab,Insomnia,OT
185025232,Infliximab,Insomnia,HO
185025232,Infliximab,Heart rate decreased,OT
185025232,Infliximab,Heart rate decreased,HO
185025232,Infliximab,Glaucoma,OT
185025232,Infliximab,Glaucoma,HO
185025232,Infliximab,Fall,OT
185025232,Infliximab,Fall,HO
185025232,Infliximab,Diarrhoea,OT
185025232,Infliximab,Diarrhoea,HO
185025232,Infliximab,Colitis,OT
185025232,Infliximab,Colitis,HO
185025232,Infliximab,Blood cholesterol abnormal,OT
185025232,Infliximab,Blood cholesterol abnormal,HO
185025232,Infliximab,Arthritis,OT
185025232,Infliximab,Arthritis,HO
185025232,Infliximab,Arthralgia,OT
185025232,Infliximab,Arthralgia,HO
185025232,Infliximab,Abdominal pain,OT
185025232,Infliximab,Abdominal pain,HO
185025232,Infliximab,Weight increased,OT
185025232,Infliximab,Weight increased,HO
185025232,Infliximab,Therapeutic response shortened,OT
185025232,Infliximab,Therapeutic response shortened,HO
185025232,Infliximab,Therapeutic product effect incomplete,OT
185025232,Infliximab,Therapeutic product effect incomplete,HO
185025232,Infliximab,Suspected COVID-19,OT
185025232,Infliximab,Suspected COVID-19,HO
185025232,Infliximab,Road traffic accident,OT
185025232,Infliximab,Road traffic accident,HO
185025232,Infliximab,Poor quality sleep,OT
185025232,Infliximab,Poor quality sleep,HO
185025232,Infliximab,Pain in jaw,OT
185025232,Infliximab,Pain in jaw,HO
185025232,Infliximab,Osteopenia,OT
185025232,Infliximab,Osteopenia,HO
185025232,Infliximab,Off label use,OT
185025232,Infliximab,Off label use,HO
185025232,Infliximab,Musculoskeletal pain,OT
185025232,Infliximab,Musculoskeletal pain,HO
185025232,Infliximab,Joint injury,OT
185025232,Infliximab,Joint injury,HO
185025232,Infliximab,Insomnia,OT
185025232,Infliximab,Insomnia,HO
185025232,Infliximab,Heart rate decreased,OT
185025232,Infliximab,Heart rate decreased,HO
185025232,Infliximab,Glaucoma,OT
185025232,Infliximab,Glaucoma,HO
185025232,Infliximab,Fall,OT
185025232,Infliximab,Fall,HO
185025232,Infliximab,Diarrhoea,OT
185025232,Infliximab,Diarrhoea,HO
185025232,Infliximab,Colitis,OT
185025232,Infliximab,Colitis,HO
185025232,Infliximab,Blood cholesterol abnormal,OT
185025232,Infliximab,Blood cholesterol abnormal,HO
185025232,Infliximab,Arthritis,OT
185025232,Infliximab,Arthritis,HO
185025232,Infliximab,Arthralgia,OT
185025232,Infliximab,Arthralgia,HO
185025232,Infliximab,Abdominal pain,OT
185025232,Infliximab,Abdominal pain,HO
185031974,Infliximab,Weight increased,OT
185031974,Infliximab,Weight decreased,OT
185031974,Infliximab,Off label use,OT
185031974,Infliximab,Malaise,OT
185031974,Infliximab,Listless,OT
185031974,Infliximab,Intestinal polyp,OT
185031974,Infliximab,Intentional product use issue,OT
185031974,Infliximab,Incorrect dose administered,OT
185031974,Infliximab,Heart rate decreased,OT
185031974,Infliximab,Fatigue,OT
185031974,Infliximab,Erythema nodosum,OT
185031974,Infliximab,Drug level below therapeutic,OT
185031974,Infliximab,Blood pressure systolic increased,OT
185031974,Infliximab,Blood pressure increased,OT
185031974,Infliximab,Blood pressure decreased,OT
185031974,Infliximab,Abdominal pain,OT
185237413,Infliximab,Weight increased,HO
185237413,Infliximab,Weight increased,OT
185237413,Infliximab,Vein disorder,HO
185237413,Infliximab,Vein disorder,OT
185237413,Infliximab,Skin laceration,HO
185237413,Infliximab,Skin laceration,OT
185237413,Infliximab,Sinusitis,HO
185237413,Infliximab,Sinusitis,OT
185237413,Infliximab,Pyoderma gangrenosum,HO
185237413,Infliximab,Pyoderma gangrenosum,OT
185237413,Infliximab,Product dose omission issue,HO
185237413,Infliximab,Product dose omission issue,OT
185237413,Infliximab,Poor venous access,HO
185237413,Infliximab,Poor venous access,OT
185237413,Infliximab,Pneumonia,HO
185237413,Infliximab,Pneumonia,OT
185237413,Infliximab,Off label use,HO
185237413,Infliximab,Off label use,OT
185237413,Infliximab,Nasopharyngitis,HO
185237413,Infliximab,Nasopharyngitis,OT
185237413,Infliximab,Intentional product use issue,HO
185237413,Infliximab,Intentional product use issue,OT
185237413,Infliximab,Incorrect dose administered,HO
185237413,Infliximab,Incorrect dose administered,OT
185237413,Infliximab,Inappropriate schedule of product administration,HO
185237413,Infliximab,Inappropriate schedule of product administration,OT
185237413,Infliximab,Drug specific antibody present,HO
185237413,Infliximab,Drug specific antibody present,OT
185237413,Infliximab,Drug level below therapeutic,HO
185237413,Infliximab,Drug level below therapeutic,OT
185237413,Infliximab,Disease recurrence,HO
185237413,Infliximab,Disease recurrence,OT
185237413,Infliximab,Dermal cyst,HO
185237413,Infliximab,Dermal cyst,OT
185237413,Infliximab,Dehydration,HO
185237413,Infliximab,Dehydration,OT
185237413,Infliximab,Condition aggravated,HO
185237413,Infliximab,Condition aggravated,OT
185237413,Infliximab,Blood pressure increased,HO
185237413,Infliximab,Blood pressure increased,OT
185237413,Infliximab,Acne cystic,HO
185237413,Infliximab,Acne cystic,OT
185237413,Infliximab,Acne,HO
185237413,Infliximab,Acne,OT
185381472,Infliximab,Pyrexia,HO
185381472,Infliximab,Pyrexia,OT
185381472,Infliximab,Off label use,HO
185381472,Infliximab,Off label use,OT
185381472,Infliximab,Muscle spasms,HO
185381472,Infliximab,Muscle spasms,OT
185381472,Infliximab,Memory impairment,HO
185381472,Infliximab,Memory impairment,OT
185381472,Infliximab,Intentional product use issue,HO
185381472,Infliximab,Intentional product use issue,OT
185381472,Infliximab,Infection,HO
185381472,Infliximab,Infection,OT
185381472,Infliximab,Inappropriate schedule of product administration,HO
185381472,Infliximab,Inappropriate schedule of product administration,OT
185381472,Infliximab,Heart rate irregular,HO
185381472,Infliximab,Heart rate irregular,OT
185381472,Infliximab,Heart rate increased,HO
185381472,Infliximab,Heart rate increased,OT
185381472,Infliximab,Drug level decreased,HO
185381472,Infliximab,Drug level decreased,OT
185381472,Infliximab,Dementia,HO
185381472,Infliximab,Dementia,OT
185381472,Infliximab,Blood pressure increased,HO
185381472,Infliximab,Blood pressure increased,OT
185381472,Infliximab,Blood pressure fluctuation,HO
185381472,Infliximab,Blood pressure fluctuation,OT
186250823,Infliximab,Therapeutic product effect incomplete,OT
186250823,Infliximab,Spinal fracture,OT
186250823,Infliximab,Rib fracture,OT
186250823,Infliximab,Product use issue,OT
186250823,Infliximab,Off label use,OT
186250823,Infliximab,Nasopharyngitis,OT
186250823,Infliximab,Intentional product use issue,OT
186250823,Infliximab,Incorrect product administration duration,OT
186250823,Infliximab,Inappropriate schedule of product administration,OT
186250823,Infliximab,Fall,OT
186250823,Infliximab,Blood pressure increased,OT
186250823,Infliximab,Blood pressure fluctuation,OT
190860602,Infliximab,Tonsillitis,OT
190860602,Infliximab,Off label use,OT
190860602,Infliximab,Intentional product use issue,OT
190860602,Infliximab,Inappropriate schedule of product administration,OT
190860602,Infliximab,Illness,OT
190860602,Infliximab,Hand fracture,OT
190860602,Infliximab,Fall,OT
190860602,Infliximab,Ear pain,OT
190860602,Infliximab,COVID-19,OT
190860602,Infliximab,C-reactive protein increased,OT
191958122,Infliximab,Weight decreased,OT
191958122,Infliximab,Weight decreased,HO
191958122,Infliximab,Intestinal obstruction,OT
191958122,Infliximab,Intestinal obstruction,HO
191958122,Infliximab,Crohn's disease,OT
191958122,Infliximab,Crohn's disease,HO
191958122,Infliximab,Condition aggravated,OT
191958122,Infliximab,Condition aggravated,HO
191958122,Infliximab,Weight decreased,OT
191958122,Infliximab,Weight decreased,HO
191958122,Infliximab,Intestinal obstruction,OT
191958122,Infliximab,Intestinal obstruction,HO
191958122,Infliximab,Crohn's disease,OT
191958122,Infliximab,Crohn's disease,HO
191958122,Infliximab,Condition aggravated,OT
191958122,Infliximab,Condition aggravated,HO
192245052,Infliximab,Weight increased,OT
192245052,Infliximab,Product use in unapproved indication,OT
192245052,Infliximab,Poor venous access,OT
192245052,Infliximab,Off label use,OT
192245052,Infliximab,Nodule,OT
192245052,Infliximab,Malaise,OT
192245052,Infliximab,Intentional product use issue,OT
192245052,Infliximab,Inappropriate schedule of product administration,OT
192245052,Infliximab,Fistula discharge,OT
192245052,Infliximab,Drug ineffective,OT
192245052,Infliximab,Condition aggravated,OT
192245052,Infliximab,Abscess,OT
195033182,Infliximab,Somnolence,OT
195033182,Infliximab,Oxygen saturation decreased,OT
195033182,Infliximab,Off label use,OT
195033182,Infliximab,Intentional product use issue,OT
195033182,Infliximab,Heart rate decreased,OT
195033182,Infliximab,Fatigue,OT
195033182,Infliximab,Blood pressure increased,OT
195033182,Infliximab,Blood pressure fluctuation,OT
195595971,Infliximab,Stress,OT
195595971,Infliximab,Off label use,OT
195595971,Infliximab,Malaise,OT
195595971,Infliximab,Hypertrophic cardiomyopathy,OT
195595971,Infliximab,Fistula,OT
195595971,Infliximab,Dyspnoea,OT
195595971,Infliximab,Diarrhoea,OT
195595971,Infliximab,Condition aggravated,OT
195595971,Infliximab,Blood thyroid stimulating hormone decreased,OT
195595971,Infliximab,Anxiety,OT
195595971,Infliximab,Abdominal pain lower,OT
195779381,Infliximab,Pain in extremity,OT
195779381,Infliximab,Off label use,OT
195779381,Infliximab,Inappropriate schedule of product administration,OT
195779381,Infliximab,Headache,OT
195779381,Infliximab,Discomfort,OT
195779381,Infliximab,Condition aggravated,OT
195779381,Infliximab,Arthralgia,OT
195958871,Infliximab,Wound complication,OT
195958871,Infliximab,Wound complication,HO
195958871,Infliximab,Wound,OT
195958871,Infliximab,Wound,HO
195958871,Infliximab,Urticaria,OT
195958871,Infliximab,Urticaria,HO
195958871,Infliximab,Therapeutic response shortened,OT
195958871,Infliximab,Therapeutic response shortened,HO
195958871,Infliximab,Tendonitis,OT
195958871,Infliximab,Tendonitis,HO
195958871,Infliximab,Sleep disorder,OT
195958871,Infliximab,Sleep disorder,HO
195958871,Infliximab,Skin wound,OT
195958871,Infliximab,Skin wound,HO
195958871,Infliximab,Red blood cell sedimentation rate increased,OT
195958871,Infliximab,Red blood cell sedimentation rate increased,HO
195958871,Infliximab,Pain in jaw,OT
195958871,Infliximab,Pain in jaw,HO
195958871,Infliximab,Pain in extremity,OT
195958871,Infliximab,Pain in extremity,HO
195958871,Infliximab,Pain,OT
195958871,Infliximab,Pain,HO
195958871,Infliximab,Off label use,OT
195958871,Infliximab,Off label use,HO
195958871,Infliximab,Oesophagitis,OT
195958871,Infliximab,Oesophagitis,HO
195958871,Infliximab,Nasopharyngitis,OT
195958871,Infliximab,Nasopharyngitis,HO
195958871,Infliximab,Nasal congestion,OT
195958871,Infliximab,Nasal congestion,HO
195958871,Infliximab,Myalgia,OT
195958871,Infliximab,Myalgia,HO
195958871,Infliximab,Musculoskeletal stiffness,OT
195958871,Infliximab,Musculoskeletal stiffness,HO
195958871,Infliximab,Loss of personal independence in daily activities,OT
195958871,Infliximab,Loss of personal independence in daily activities,HO
195958871,Infliximab,Joint swelling,OT
195958871,Infliximab,Joint swelling,HO
195958871,Infliximab,Joint injury,OT
195958871,Infliximab,Joint injury,HO
195958871,Infliximab,Insomnia,OT
195958871,Infliximab,Insomnia,HO
195958871,Infliximab,Infection,OT
195958871,Infliximab,Infection,HO
195958871,Infliximab,Impetigo,OT
195958871,Infliximab,Impetigo,HO
195958871,Infliximab,Impaired quality of life,OT
195958871,Infliximab,Impaired quality of life,HO
195958871,Infliximab,Heart rate irregular,OT
195958871,Infliximab,Heart rate irregular,HO
195958871,Infliximab,Fibromyalgia,OT
195958871,Infliximab,Fibromyalgia,HO
195958871,Infliximab,Fat tissue increased,OT
195958871,Infliximab,Fat tissue increased,HO
195958871,Infliximab,Drug ineffective,OT
195958871,Infliximab,Drug ineffective,HO
195958871,Infliximab,Cough,OT
195958871,Infliximab,Cough,HO
195958871,Infliximab,Coccydynia,OT
195958871,Infliximab,Coccydynia,HO
195958871,Infliximab,C-reactive protein increased,OT
195958871,Infliximab,C-reactive protein increased,HO
195958871,Infliximab,Blood pressure fluctuation,OT
195958871,Infliximab,Blood pressure fluctuation,HO
195958871,Infliximab,Arthralgia,OT
195958871,Infliximab,Arthralgia,HO
195958871,Infliximab,Wound complication,OT
195958871,Infliximab,Wound complication,HO
195958871,Infliximab,Wound,OT
195958871,Infliximab,Wound,HO
195958871,Infliximab,Urticaria,OT
195958871,Infliximab,Urticaria,HO
195958871,Infliximab,Therapeutic response shortened,OT
195958871,Infliximab,Therapeutic response shortened,HO
195958871,Infliximab,Tendonitis,OT
195958871,Infliximab,Tendonitis,HO
195958871,Infliximab,Sleep disorder,OT
195958871,Infliximab,Sleep disorder,HO
195958871,Infliximab,Skin wound,OT
195958871,Infliximab,Skin wound,HO
195958871,Infliximab,Red blood cell sedimentation rate increased,OT
195958871,Infliximab,Red blood cell sedimentation rate increased,HO
195958871,Infliximab,Pain in jaw,OT
195958871,Infliximab,Pain in jaw,HO
195958871,Infliximab,Pain in extremity,OT
195958871,Infliximab,Pain in extremity,HO
195958871,Infliximab,Pain,OT
195958871,Infliximab,Pain,HO
195958871,Infliximab,Off label use,OT
195958871,Infliximab,Off label use,HO
195958871,Infliximab,Oesophagitis,OT
195958871,Infliximab,Oesophagitis,HO
195958871,Infliximab,Nasopharyngitis,OT
195958871,Infliximab,Nasopharyngitis,HO
195958871,Infliximab,Nasal congestion,OT
195958871,Infliximab,Nasal congestion,HO
195958871,Infliximab,Myalgia,OT
195958871,Infliximab,Myalgia,HO
195958871,Infliximab,Musculoskeletal stiffness,OT
195958871,Infliximab,Musculoskeletal stiffness,HO
195958871,Infliximab,Loss of personal independence in daily activities,OT
195958871,Infliximab,Loss of personal independence in daily activities,HO
195958871,Infliximab,Joint swelling,OT
195958871,Infliximab,Joint swelling,HO
195958871,Infliximab,Joint injury,OT
195958871,Infliximab,Joint injury,HO
195958871,Infliximab,Insomnia,OT
195958871,Infliximab,Insomnia,HO
195958871,Infliximab,Infection,OT
195958871,Infliximab,Infection,HO
195958871,Infliximab,Impetigo,OT
195958871,Infliximab,Impetigo,HO
195958871,Infliximab,Impaired quality of life,OT
195958871,Infliximab,Impaired quality of life,HO
195958871,Infliximab,Heart rate irregular,OT
195958871,Infliximab,Heart rate irregular,HO
195958871,Infliximab,Fibromyalgia,OT
195958871,Infliximab,Fibromyalgia,HO
195958871,Infliximab,Fat tissue increased,OT
195958871,Infliximab,Fat tissue increased,HO
195958871,Infliximab,Drug ineffective,OT
195958871,Infliximab,Drug ineffective,HO
195958871,Infliximab,Cough,OT
195958871,Infliximab,Cough,HO
195958871,Infliximab,Coccydynia,OT
195958871,Infliximab,Coccydynia,HO
195958871,Infliximab,C-reactive protein increased,OT
195958871,Infliximab,C-reactive protein increased,HO
195958871,Infliximab,Blood pressure fluctuation,OT
195958871,Infliximab,Blood pressure fluctuation,HO
195958871,Infliximab,Arthralgia,OT
195958871,Infliximab,Arthralgia,HO
195958871,Infliximab,Wound complication,OT
195958871,Infliximab,Wound complication,HO
195958871,Infliximab,Wound,OT
195958871,Infliximab,Wound,HO
195958871,Infliximab,Urticaria,OT
195958871,Infliximab,Urticaria,HO
195958871,Infliximab,Therapeutic response shortened,OT
195958871,Infliximab,Therapeutic response shortened,HO
195958871,Infliximab,Tendonitis,OT
195958871,Infliximab,Tendonitis,HO
195958871,Infliximab,Sleep disorder,OT
195958871,Infliximab,Sleep disorder,HO
195958871,Infliximab,Skin wound,OT
195958871,Infliximab,Skin wound,HO
195958871,Infliximab,Red blood cell sedimentation rate increased,OT
195958871,Infliximab,Red blood cell sedimentation rate increased,HO
195958871,Infliximab,Pain in jaw,OT
195958871,Infliximab,Pain in jaw,HO
195958871,Infliximab,Pain in extremity,OT
195958871,Infliximab,Pain in extremity,HO
195958871,Infliximab,Pain,OT
195958871,Infliximab,Pain,HO
195958871,Infliximab,Off label use,OT
195958871,Infliximab,Off label use,HO
195958871,Infliximab,Oesophagitis,OT
195958871,Infliximab,Oesophagitis,HO
195958871,Infliximab,Nasopharyngitis,OT
195958871,Infliximab,Nasopharyngitis,HO
195958871,Infliximab,Nasal congestion,OT
195958871,Infliximab,Nasal congestion,HO
195958871,Infliximab,Myalgia,OT
195958871,Infliximab,Myalgia,HO
195958871,Infliximab,Musculoskeletal stiffness,OT
195958871,Infliximab,Musculoskeletal stiffness,HO
195958871,Infliximab,Loss of personal independence in daily activities,OT
195958871,Infliximab,Loss of personal independence in daily activities,HO
195958871,Infliximab,Joint swelling,OT
195958871,Infliximab,Joint swelling,HO
195958871,Infliximab,Joint injury,OT
195958871,Infliximab,Joint injury,HO
195958871,Infliximab,Insomnia,OT
195958871,Infliximab,Insomnia,HO
195958871,Infliximab,Infection,OT
195958871,Infliximab,Infection,HO
195958871,Infliximab,Impetigo,OT
195958871,Infliximab,Impetigo,HO
195958871,Infliximab,Impaired quality of life,OT
195958871,Infliximab,Impaired quality of life,HO
195958871,Infliximab,Heart rate irregular,OT
195958871,Infliximab,Heart rate irregular,HO
195958871,Infliximab,Fibromyalgia,OT
195958871,Infliximab,Fibromyalgia,HO
195958871,Infliximab,Fat tissue increased,OT
195958871,Infliximab,Fat tissue increased,HO
195958871,Infliximab,Drug ineffective,OT
195958871,Infliximab,Drug ineffective,HO
195958871,Infliximab,Cough,OT
195958871,Infliximab,Cough,HO
195958871,Infliximab,Coccydynia,OT
195958871,Infliximab,Coccydynia,HO
195958871,Infliximab,C-reactive protein increased,OT
195958871,Infliximab,C-reactive protein increased,HO
195958871,Infliximab,Blood pressure fluctuation,OT
195958871,Infliximab,Blood pressure fluctuation,HO
195958871,Infliximab,Arthralgia,OT
195958871,Infliximab,Arthralgia,HO
195958871,Infliximab,Wound complication,OT
195958871,Infliximab,Wound complication,HO
195958871,Infliximab,Wound,OT
195958871,Infliximab,Wound,HO
195958871,Infliximab,Urticaria,OT
195958871,Infliximab,Urticaria,HO
195958871,Infliximab,Therapeutic response shortened,OT
195958871,Infliximab,Therapeutic response shortened,HO
195958871,Infliximab,Tendonitis,OT
195958871,Infliximab,Tendonitis,HO
195958871,Infliximab,Sleep disorder,OT
195958871,Infliximab,Sleep disorder,HO
195958871,Infliximab,Skin wound,OT
195958871,Infliximab,Skin wound,HO
195958871,Infliximab,Red blood cell sedimentation rate increased,OT
195958871,Infliximab,Red blood cell sedimentation rate increased,HO
195958871,Infliximab,Pain in jaw,OT
195958871,Infliximab,Pain in jaw,HO
195958871,Infliximab,Pain in extremity,OT
195958871,Infliximab,Pain in extremity,HO
195958871,Infliximab,Pain,OT
195958871,Infliximab,Pain,HO
195958871,Infliximab,Off label use,OT
195958871,Infliximab,Off label use,HO
195958871,Infliximab,Oesophagitis,OT
195958871,Infliximab,Oesophagitis,HO
195958871,Infliximab,Nasopharyngitis,OT
195958871,Infliximab,Nasopharyngitis,HO
195958871,Infliximab,Nasal congestion,OT
195958871,Infliximab,Nasal congestion,HO
195958871,Infliximab,Myalgia,OT
195958871,Infliximab,Myalgia,HO
195958871,Infliximab,Musculoskeletal stiffness,OT
195958871,Infliximab,Musculoskeletal stiffness,HO
195958871,Infliximab,Loss of personal independence in daily activities,OT
195958871,Infliximab,Loss of personal independence in daily activities,HO
195958871,Infliximab,Joint swelling,OT
195958871,Infliximab,Joint swelling,HO
195958871,Infliximab,Joint injury,OT
195958871,Infliximab,Joint injury,HO
195958871,Infliximab,Insomnia,OT
195958871,Infliximab,Insomnia,HO
195958871,Infliximab,Infection,OT
195958871,Infliximab,Infection,HO
195958871,Infliximab,Impetigo,OT
195958871,Infliximab,Impetigo,HO
195958871,Infliximab,Impaired quality of life,OT
195958871,Infliximab,Impaired quality of life,HO
195958871,Infliximab,Heart rate irregular,OT
195958871,Infliximab,Heart rate irregular,HO
195958871,Infliximab,Fibromyalgia,OT
195958871,Infliximab,Fibromyalgia,HO
195958871,Infliximab,Fat tissue increased,OT
195958871,Infliximab,Fat tissue increased,HO
195958871,Infliximab,Drug ineffective,OT
195958871,Infliximab,Drug ineffective,HO
195958871,Infliximab,Cough,OT
195958871,Infliximab,Cough,HO
195958871,Infliximab,Coccydynia,OT
195958871,Infliximab,Coccydynia,HO
195958871,Infliximab,C-reactive protein increased,OT
195958871,Infliximab,C-reactive protein increased,HO
195958871,Infliximab,Blood pressure fluctuation,OT
195958871,Infliximab,Blood pressure fluctuation,HO
195958871,Infliximab,Arthralgia,OT
195958871,Infliximab,Arthralgia,HO
195958871,Infliximab,Wound complication,OT
195958871,Infliximab,Wound complication,HO
195958871,Infliximab,Wound,OT
195958871,Infliximab,Wound,HO
195958871,Infliximab,Urticaria,OT
195958871,Infliximab,Urticaria,HO
195958871,Infliximab,Therapeutic response shortened,OT
195958871,Infliximab,Therapeutic response shortened,HO
195958871,Infliximab,Tendonitis,OT
195958871,Infliximab,Tendonitis,HO
195958871,Infliximab,Sleep disorder,OT
195958871,Infliximab,Sleep disorder,HO
195958871,Infliximab,Skin wound,OT
195958871,Infliximab,Skin wound,HO
195958871,Infliximab,Red blood cell sedimentation rate increased,OT
195958871,Infliximab,Red blood cell sedimentation rate increased,HO
195958871,Infliximab,Pain in jaw,OT
195958871,Infliximab,Pain in jaw,HO
195958871,Infliximab,Pain in extremity,OT
195958871,Infliximab,Pain in extremity,HO
195958871,Infliximab,Pain,OT
195958871,Infliximab,Pain,HO
195958871,Infliximab,Off label use,OT
195958871,Infliximab,Off label use,HO
195958871,Infliximab,Oesophagitis,OT
195958871,Infliximab,Oesophagitis,HO
195958871,Infliximab,Nasopharyngitis,OT
195958871,Infliximab,Nasopharyngitis,HO
195958871,Infliximab,Nasal congestion,OT
195958871,Infliximab,Nasal congestion,HO
195958871,Infliximab,Myalgia,OT
195958871,Infliximab,Myalgia,HO
195958871,Infliximab,Musculoskeletal stiffness,OT
195958871,Infliximab,Musculoskeletal stiffness,HO
195958871,Infliximab,Loss of personal independence in daily activities,OT
195958871,Infliximab,Loss of personal independence in daily activities,HO
195958871,Infliximab,Joint swelling,OT
195958871,Infliximab,Joint swelling,HO
195958871,Infliximab,Joint injury,OT
195958871,Infliximab,Joint injury,HO
195958871,Infliximab,Insomnia,OT
195958871,Infliximab,Insomnia,HO
195958871,Infliximab,Infection,OT
195958871,Infliximab,Infection,HO
195958871,Infliximab,Impetigo,OT
195958871,Infliximab,Impetigo,HO
195958871,Infliximab,Impaired quality of life,OT
195958871,Infliximab,Impaired quality of life,HO
195958871,Infliximab,Heart rate irregular,OT
195958871,Infliximab,Heart rate irregular,HO
195958871,Infliximab,Fibromyalgia,OT
195958871,Infliximab,Fibromyalgia,HO
195958871,Infliximab,Fat tissue increased,OT
195958871,Infliximab,Fat tissue increased,HO
195958871,Infliximab,Drug ineffective,OT
195958871,Infliximab,Drug ineffective,HO
195958871,Infliximab,Cough,OT
195958871,Infliximab,Cough,HO
195958871,Infliximab,Coccydynia,OT
195958871,Infliximab,Coccydynia,HO
195958871,Infliximab,C-reactive protein increased,OT
195958871,Infliximab,C-reactive protein increased,HO
195958871,Infliximab,Blood pressure fluctuation,OT
195958871,Infliximab,Blood pressure fluctuation,HO
195958871,Infliximab,Arthralgia,OT
195958871,Infliximab,Arthralgia,HO
195958871,Infliximab,Wound complication,OT
195958871,Infliximab,Wound complication,HO
195958871,Infliximab,Wound,OT
195958871,Infliximab,Wound,HO
195958871,Infliximab,Urticaria,OT
195958871,Infliximab,Urticaria,HO
195958871,Infliximab,Therapeutic response shortened,OT
195958871,Infliximab,Therapeutic response shortened,HO
195958871,Infliximab,Tendonitis,OT
195958871,Infliximab,Tendonitis,HO
195958871,Infliximab,Sleep disorder,OT
195958871,Infliximab,Sleep disorder,HO
195958871,Infliximab,Skin wound,OT
195958871,Infliximab,Skin wound,HO
195958871,Infliximab,Red blood cell sedimentation rate increased,OT
195958871,Infliximab,Red blood cell sedimentation rate increased,HO
195958871,Infliximab,Pain in jaw,OT
195958871,Infliximab,Pain in jaw,HO
195958871,Infliximab,Pain in extremity,OT
195958871,Infliximab,Pain in extremity,HO
195958871,Infliximab,Pain,OT
195958871,Infliximab,Pain,HO
195958871,Infliximab,Off label use,OT
195958871,Infliximab,Off label use,HO
195958871,Infliximab,Oesophagitis,OT
195958871,Infliximab,Oesophagitis,HO
195958871,Infliximab,Nasopharyngitis,OT
195958871,Infliximab,Nasopharyngitis,HO
195958871,Infliximab,Nasal congestion,OT
195958871,Infliximab,Nasal congestion,HO
195958871,Infliximab,Myalgia,OT
195958871,Infliximab,Myalgia,HO
195958871,Infliximab,Musculoskeletal stiffness,OT
195958871,Infliximab,Musculoskeletal stiffness,HO
195958871,Infliximab,Loss of personal independence in daily activities,OT
195958871,Infliximab,Loss of personal independence in daily activities,HO
195958871,Infliximab,Joint swelling,OT
195958871,Infliximab,Joint swelling,HO
195958871,Infliximab,Joint injury,OT
195958871,Infliximab,Joint injury,HO
195958871,Infliximab,Insomnia,OT
195958871,Infliximab,Insomnia,HO
195958871,Infliximab,Infection,OT
195958871,Infliximab,Infection,HO
195958871,Infliximab,Impetigo,OT
195958871,Infliximab,Impetigo,HO
195958871,Infliximab,Impaired quality of life,OT
195958871,Infliximab,Impaired quality of life,HO
195958871,Infliximab,Heart rate irregular,OT
195958871,Infliximab,Heart rate irregular,HO
195958871,Infliximab,Fibromyalgia,OT
195958871,Infliximab,Fibromyalgia,HO
195958871,Infliximab,Fat tissue increased,OT
195958871,Infliximab,Fat tissue increased,HO
195958871,Infliximab,Drug ineffective,OT
195958871,Infliximab,Drug ineffective,HO
195958871,Infliximab,Cough,OT
195958871,Infliximab,Cough,HO
195958871,Infliximab,Coccydynia,OT
195958871,Infliximab,Coccydynia,HO
195958871,Infliximab,C-reactive protein increased,OT
195958871,Infliximab,C-reactive protein increased,HO
195958871,Infliximab,Blood pressure fluctuation,OT
195958871,Infliximab,Blood pressure fluctuation,HO
195958871,Infliximab,Arthralgia,OT
195958871,Infliximab,Arthralgia,HO
195958871,Infliximab,Wound complication,OT
195958871,Infliximab,Wound complication,HO
195958871,Infliximab,Wound,OT
195958871,Infliximab,Wound,HO
195958871,Infliximab,Urticaria,OT
195958871,Infliximab,Urticaria,HO
195958871,Infliximab,Therapeutic response shortened,OT
195958871,Infliximab,Therapeutic response shortened,HO
195958871,Infliximab,Tendonitis,OT
195958871,Infliximab,Tendonitis,HO
195958871,Infliximab,Sleep disorder,OT
195958871,Infliximab,Sleep disorder,HO
195958871,Infliximab,Skin wound,OT
195958871,Infliximab,Skin wound,HO
195958871,Infliximab,Red blood cell sedimentation rate increased,OT
195958871,Infliximab,Red blood cell sedimentation rate increased,HO
195958871,Infliximab,Pain in jaw,OT
195958871,Infliximab,Pain in jaw,HO
195958871,Infliximab,Pain in extremity,OT
195958871,Infliximab,Pain in extremity,HO
195958871,Infliximab,Pain,OT
195958871,Infliximab,Pain,HO
195958871,Infliximab,Off label use,OT
195958871,Infliximab,Off label use,HO
195958871,Infliximab,Oesophagitis,OT
195958871,Infliximab,Oesophagitis,HO
195958871,Infliximab,Nasopharyngitis,OT
195958871,Infliximab,Nasopharyngitis,HO
195958871,Infliximab,Nasal congestion,OT
195958871,Infliximab,Nasal congestion,HO
195958871,Infliximab,Myalgia,OT
195958871,Infliximab,Myalgia,HO
195958871,Infliximab,Musculoskeletal stiffness,OT
195958871,Infliximab,Musculoskeletal stiffness,HO
195958871,Infliximab,Loss of personal independence in daily activities,OT
195958871,Infliximab,Loss of personal independence in daily activities,HO
195958871,Infliximab,Joint swelling,OT
195958871,Infliximab,Joint swelling,HO
195958871,Infliximab,Joint injury,OT
195958871,Infliximab,Joint injury,HO
195958871,Infliximab,Insomnia,OT
195958871,Infliximab,Insomnia,HO
195958871,Infliximab,Infection,OT
195958871,Infliximab,Infection,HO
195958871,Infliximab,Impetigo,OT
195958871,Infliximab,Impetigo,HO
195958871,Infliximab,Impaired quality of life,OT
195958871,Infliximab,Impaired quality of life,HO
195958871,Infliximab,Heart rate irregular,OT
195958871,Infliximab,Heart rate irregular,HO
195958871,Infliximab,Fibromyalgia,OT
195958871,Infliximab,Fibromyalgia,HO
195958871,Infliximab,Fat tissue increased,OT
195958871,Infliximab,Fat tissue increased,HO
195958871,Infliximab,Drug ineffective,OT
195958871,Infliximab,Drug ineffective,HO
195958871,Infliximab,Cough,OT
195958871,Infliximab,Cough,HO
195958871,Infliximab,Coccydynia,OT
195958871,Infliximab,Coccydynia,HO
195958871,Infliximab,C-reactive protein increased,OT
195958871,Infliximab,C-reactive protein increased,HO
195958871,Infliximab,Blood pressure fluctuation,OT
195958871,Infliximab,Blood pressure fluctuation,HO
195958871,Infliximab,Arthralgia,OT
195958871,Infliximab,Arthralgia,HO
195958871,Infliximab,Wound complication,OT
195958871,Infliximab,Wound complication,HO
195958871,Infliximab,Wound,OT
195958871,Infliximab,Wound,HO
195958871,Infliximab,Urticaria,OT
195958871,Infliximab,Urticaria,HO
195958871,Infliximab,Therapeutic response shortened,OT
195958871,Infliximab,Therapeutic response shortened,HO
195958871,Infliximab,Tendonitis,OT
195958871,Infliximab,Tendonitis,HO
195958871,Infliximab,Sleep disorder,OT
195958871,Infliximab,Sleep disorder,HO
195958871,Infliximab,Skin wound,OT
195958871,Infliximab,Skin wound,HO
195958871,Infliximab,Red blood cell sedimentation rate increased,OT
195958871,Infliximab,Red blood cell sedimentation rate increased,HO
195958871,Infliximab,Pain in jaw,OT
195958871,Infliximab,Pain in jaw,HO
195958871,Infliximab,Pain in extremity,OT
195958871,Infliximab,Pain in extremity,HO
195958871,Infliximab,Pain,OT
195958871,Infliximab,Pain,HO
195958871,Infliximab,Off label use,OT
195958871,Infliximab,Off label use,HO
195958871,Infliximab,Oesophagitis,OT
195958871,Infliximab,Oesophagitis,HO
195958871,Infliximab,Nasopharyngitis,OT
195958871,Infliximab,Nasopharyngitis,HO
195958871,Infliximab,Nasal congestion,OT
195958871,Infliximab,Nasal congestion,HO
195958871,Infliximab,Myalgia,OT
195958871,Infliximab,Myalgia,HO
195958871,Infliximab,Musculoskeletal stiffness,OT
195958871,Infliximab,Musculoskeletal stiffness,HO
195958871,Infliximab,Loss of personal independence in daily activities,OT
195958871,Infliximab,Loss of personal independence in daily activities,HO
195958871,Infliximab,Joint swelling,OT
195958871,Infliximab,Joint swelling,HO
195958871,Infliximab,Joint injury,OT
195958871,Infliximab,Joint injury,HO
195958871,Infliximab,Insomnia,OT
195958871,Infliximab,Insomnia,HO
195958871,Infliximab,Infection,OT
195958871,Infliximab,Infection,HO
195958871,Infliximab,Impetigo,OT
195958871,Infliximab,Impetigo,HO
195958871,Infliximab,Impaired quality of life,OT
195958871,Infliximab,Impaired quality of life,HO
195958871,Infliximab,Heart rate irregular,OT
195958871,Infliximab,Heart rate irregular,HO
195958871,Infliximab,Fibromyalgia,OT
195958871,Infliximab,Fibromyalgia,HO
195958871,Infliximab,Fat tissue increased,OT
195958871,Infliximab,Fat tissue increased,HO
195958871,Infliximab,Drug ineffective,OT
195958871,Infliximab,Drug ineffective,HO
195958871,Infliximab,Cough,OT
195958871,Infliximab,Cough,HO
195958871,Infliximab,Coccydynia,OT
195958871,Infliximab,Coccydynia,HO
195958871,Infliximab,C-reactive protein increased,OT
195958871,Infliximab,C-reactive protein increased,HO
195958871,Infliximab,Blood pressure fluctuation,OT
195958871,Infliximab,Blood pressure fluctuation,HO
195958871,Infliximab,Arthralgia,OT
195958871,Infliximab,Arthralgia,HO
196364861,Infliximab,Urticaria,OT
196364861,Infliximab,Pruritus,OT
196364861,Infliximab,Off label use,OT
196364861,Infliximab,Heart rate irregular,OT
196364861,Infliximab,Erythema,OT
196364861,Infliximab,Blood pressure increased,OT
196364861,Infliximab,Blood pressure fluctuation,OT
196648631,Infliximab (Unknown),Iron deficiency anaemia,OT
196648631,Infliximab (Unknown),Iron deficiency anaemia,HO
196648631,Infliximab (Unknown),Ileus,OT
196648631,Infliximab (Unknown),Ileus,HO
196842812,Infliximab,Therapeutic product effect decreased,OT
196842812,Infliximab,Dental caries,OT
196867671,Infliximab,Weight increased,OT
196867671,Infliximab,Pulmonary congestion,OT
196867671,Infliximab,Pneumonia,OT
196867671,Infliximab,Peripheral swelling,OT
196867671,Infliximab,Off label use,OT
196867671,Infliximab,Intentional product use issue,OT
196867671,Infliximab,Inappropriate schedule of product administration,OT
196867671,Infliximab,Headache,OT
196867671,Infliximab,Condition aggravated,OT
196867671,Infliximab,Blood pressure systolic increased,OT
196867671,Infliximab,Blood pressure increased,OT
197178111,Infliximab,Therapeutic product effect incomplete,OT
197178111,Infliximab,Off label use,OT
197178111,Infliximab,Inappropriate schedule of product administration,OT
197178111,Infliximab,Hypertension,OT
197178111,Infliximab,Fistula,OT
197178111,Infliximab,Clostridium difficile infection,OT
197178111,Infliximab,Blood pressure decreased,OT
197908521,Infliximab Pfizer (Unknown),Treatment failure,HO
197908521,Infliximab Pfizer (Unknown),Condition aggravated,HO
197915601,Infliximab,Renal disorder,HO
197915601,Infliximab,Renal disorder,OT
197915601,Infliximab,Product use issue,HO
197915601,Infliximab,Product use issue,OT
197915601,Infliximab,Off label use,HO
197915601,Infliximab,Off label use,OT
197915601,Infliximab,Malaise,HO
197915601,Infliximab,Malaise,OT
197915601,Infliximab,Intentional product use issue,HO
197915601,Infliximab,Intentional product use issue,OT
197915601,Infliximab,Inappropriate schedule of product administration,HO
197915601,Infliximab,Inappropriate schedule of product administration,OT
197915601,Infliximab,Diarrhoea,HO
197915601,Infliximab,Diarrhoea,OT
197915601,Infliximab,Clostridium difficile infection,HO
197915601,Infliximab,Clostridium difficile infection,OT
197915601,Infliximab,Blood potassium abnormal,HO
197915601,Infliximab,Blood potassium abnormal,OT
197915601,Infliximab,Renal disorder,HO
197915601,Infliximab,Renal disorder,OT
197915601,Infliximab,Product use issue,HO
197915601,Infliximab,Product use issue,OT
197915601,Infliximab,Off label use,HO
197915601,Infliximab,Off label use,OT
197915601,Infliximab,Malaise,HO
197915601,Infliximab,Malaise,OT
197915601,Infliximab,Intentional product use issue,HO
197915601,Infliximab,Intentional product use issue,OT
197915601,Infliximab,Inappropriate schedule of product administration,HO
197915601,Infliximab,Inappropriate schedule of product administration,OT
197915601,Infliximab,Diarrhoea,HO
197915601,Infliximab,Diarrhoea,OT
197915601,Infliximab,Clostridium difficile infection,HO
197915601,Infliximab,Clostridium difficile infection,OT
197915601,Infliximab,Blood potassium abnormal,HO
197915601,Infliximab,Blood potassium abnormal,OT
198054191,Infliximab,Renal function test abnormal,DE
198054191,Infliximab,Renal function test abnormal,OT
198054191,Infliximab,Renal function test abnormal,LT
198054191,Infliximab,Renal function test abnormal,HO
198054191,Infliximab,Peripheral swelling,DE
198054191,Infliximab,Peripheral swelling,OT
198054191,Infliximab,Peripheral swelling,LT
198054191,Infliximab,Peripheral swelling,HO
198054191,Infliximab,Oliguria,DE
198054191,Infliximab,Oliguria,OT
198054191,Infliximab,Oliguria,LT
198054191,Infliximab,Oliguria,HO
198054191,Infliximab,Multiple organ dysfunction syndrome,DE
198054191,Infliximab,Multiple organ dysfunction syndrome,OT
198054191,Infliximab,Multiple organ dysfunction syndrome,LT
198054191,Infliximab,Multiple organ dysfunction syndrome,HO
198054191,Infliximab,Hydronephrosis,DE
198054191,Infliximab,Hydronephrosis,OT
198054191,Infliximab,Hydronephrosis,LT
198054191,Infliximab,Hydronephrosis,HO
198054191,Infliximab,Hodgkin's disease stage I,DE
198054191,Infliximab,Hodgkin's disease stage I,OT
198054191,Infliximab,Hodgkin's disease stage I,LT
198054191,Infliximab,Hodgkin's disease stage I,HO
198054191,Infliximab,General physical health deterioration,DE
198054191,Infliximab,General physical health deterioration,OT
198054191,Infliximab,General physical health deterioration,LT
198054191,Infliximab,General physical health deterioration,HO
198054191,Infliximab,Drug ineffective,DE
198054191,Infliximab,Drug ineffective,OT
198054191,Infliximab,Drug ineffective,LT
198054191,Infliximab,Drug ineffective,HO
198054191,Infliximab,Disease progression,DE
198054191,Infliximab,Disease progression,OT
198054191,Infliximab,Disease progression,LT
198054191,Infliximab,Disease progression,HO
198054191,Infliximab,Cardiopulmonary failure,DE
198054191,Infliximab,Cardiopulmonary failure,OT
198054191,Infliximab,Cardiopulmonary failure,LT
198054191,Infliximab,Cardiopulmonary failure,HO
198054191,Infliximab,C-reactive protein increased,DE
198054191,Infliximab,C-reactive protein increased,OT
198054191,Infliximab,C-reactive protein increased,LT
198054191,Infliximab,C-reactive protein increased,HO
198054191,Infliximab,Blood creatinine increased,DE
198054191,Infliximab,Blood creatinine increased,OT
198054191,Infliximab,Blood creatinine increased,LT
198054191,Infliximab,Blood creatinine increased,HO
198054191,Infliximab,Abdominal lymphadenopathy,DE
198054191,Infliximab,Abdominal lymphadenopathy,OT
198054191,Infliximab,Abdominal lymphadenopathy,LT
198054191,Infliximab,Abdominal lymphadenopathy,HO
198060931,Infliximab,Product use issue,OT
198060931,Infliximab,Off label use,OT
198060931,Infliximab,Nephrolithiasis,OT
198060931,Infliximab,Intentional product use issue,OT
198395731,Infliximab,Off label use,OT
198395731,Infliximab,Drug ineffective,OT
198395731,Infliximab,Off label use,OT
198395731,Infliximab,Drug ineffective,OT
198580102,Infliximab,Therapy non-responder,OT
198580102,Infliximab,Off label use,OT
198580102,Infliximab,No adverse event,OT
198623101,Infliximab,Kaposi's sarcoma,OT
198623101,Infliximab,Crohn's disease,OT
198740251,Infliximab,Pruritus,OT
198846011,Infliximab (Unknown),Upper respiratory tract infection,NULL
198846011,Infliximab (Unknown),Off label use,NULL
198846011,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198863071,Infliximab (Unknown),Off label use,NULL
198863071,Infliximab (Unknown),Drug effective for unapproved indication,NULL
160798325,Infliximab,Therapeutic response shortened,OT
160798325,Infliximab,Pharyngitis streptococcal,OT
160798325,Infliximab,Off label use,OT
160798325,Infliximab,Melaena,OT
160798325,Infliximab,Intentional product use issue,OT
160798325,Infliximab,Inappropriate schedule of product administration,OT
160798325,Infliximab,Heart rate irregular,OT
160798325,Infliximab,Condition aggravated,OT
160798325,Infliximab,Acne,OT
160798325,Infliximab,Abdominal pain,OT
160798325,Infliximab,Abdominal discomfort,OT
164921545,Infliximab,Weight increased,OT
164921545,Infliximab,Weight increased,HO
164921545,Infliximab,Weight increased,LT
164921545,Infliximab,Product use issue,OT
164921545,Infliximab,Product use issue,HO
164921545,Infliximab,Product use issue,LT
164921545,Infliximab,Off label use,OT
164921545,Infliximab,Off label use,HO
164921545,Infliximab,Off label use,LT
164921545,Infliximab,Nasopharyngitis,OT
164921545,Infliximab,Nasopharyngitis,HO
164921545,Infliximab,Nasopharyngitis,LT
164921545,Infliximab,Intentional product use issue,OT
164921545,Infliximab,Intentional product use issue,HO
164921545,Infliximab,Intentional product use issue,LT
164921545,Infliximab,Inappropriate schedule of product administration,OT
164921545,Infliximab,Inappropriate schedule of product administration,HO
164921545,Infliximab,Inappropriate schedule of product administration,LT
164921545,Infliximab,Hypertension,OT
164921545,Infliximab,Hypertension,HO
164921545,Infliximab,Hypertension,LT
164921545,Infliximab,Hypersensitivity,OT
164921545,Infliximab,Hypersensitivity,HO
164921545,Infliximab,Hypersensitivity,LT
164921545,Infliximab,Cough,OT
164921545,Infliximab,Cough,HO
164921545,Infliximab,Cough,LT
164921545,Infliximab,C-reactive protein increased,OT
164921545,Infliximab,C-reactive protein increased,HO
164921545,Infliximab,C-reactive protein increased,LT
164921545,Infliximab,Blood pressure fluctuation,OT
164921545,Infliximab,Blood pressure fluctuation,HO
164921545,Infliximab,Blood pressure fluctuation,LT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
172871997,Infliximab,Wheelchair user,LT
172871997,Infliximab,Wheelchair user,HO
172871997,Infliximab,Wheelchair user,DS
172871997,Infliximab,Wheelchair user,OT
172871997,Infliximab,Vomiting,LT
172871997,Infliximab,Vomiting,HO
172871997,Infliximab,Vomiting,DS
172871997,Infliximab,Vomiting,OT
172871997,Infliximab,Underdose,LT
172871997,Infliximab,Underdose,HO
172871997,Infliximab,Underdose,DS
172871997,Infliximab,Underdose,OT
172871997,Infliximab,Therapy non-responder,LT
172871997,Infliximab,Therapy non-responder,HO
172871997,Infliximab,Therapy non-responder,DS
172871997,Infliximab,Therapy non-responder,OT
172871997,Infliximab,Therapeutic product effect decreased,LT
172871997,Infliximab,Therapeutic product effect decreased,HO
172871997,Infliximab,Therapeutic product effect decreased,DS
172871997,Infliximab,Therapeutic product effect decreased,OT
172871997,Infliximab,Synovitis,LT
172871997,Infliximab,Synovitis,HO
172871997,Infliximab,Synovitis,DS
172871997,Infliximab,Synovitis,OT
172871997,Infliximab,Short stature,LT
172871997,Infliximab,Short stature,HO
172871997,Infliximab,Short stature,DS
172871997,Infliximab,Short stature,OT
172871997,Infliximab,Septic shock,LT
172871997,Infliximab,Septic shock,HO
172871997,Infliximab,Septic shock,DS
172871997,Infliximab,Septic shock,OT
172871997,Infliximab,Rheumatoid arthritis,LT
172871997,Infliximab,Rheumatoid arthritis,HO
172871997,Infliximab,Rheumatoid arthritis,DS
172871997,Infliximab,Rheumatoid arthritis,OT
172871997,Infliximab,Red blood cell sedimentation rate increased,LT
172871997,Infliximab,Red blood cell sedimentation rate increased,HO
172871997,Infliximab,Red blood cell sedimentation rate increased,DS
172871997,Infliximab,Red blood cell sedimentation rate increased,OT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,LT
172871997,Infliximab,Red blood cell sedimentation rate abnormal,HO
172871997,Infliximab,Red blood cell sedimentation rate abnormal,DS
172871997,Infliximab,Red blood cell sedimentation rate abnormal,OT
172871997,Infliximab,Quality of life decreased,LT
172871997,Infliximab,Quality of life decreased,HO
172871997,Infliximab,Quality of life decreased,DS
172871997,Infliximab,Quality of life decreased,OT
172871997,Infliximab,Pyrexia,LT
172871997,Infliximab,Pyrexia,HO
172871997,Infliximab,Pyrexia,DS
172871997,Infliximab,Pyrexia,OT
172871997,Infliximab,Psoriasis,LT
172871997,Infliximab,Psoriasis,HO
172871997,Infliximab,Psoriasis,DS
172871997,Infliximab,Psoriasis,OT
172871997,Infliximab,Product use issue,LT
172871997,Infliximab,Product use issue,HO
172871997,Infliximab,Product use issue,DS
172871997,Infliximab,Product use issue,OT
172871997,Infliximab,Product use in unapproved indication,LT
172871997,Infliximab,Product use in unapproved indication,HO
172871997,Infliximab,Product use in unapproved indication,DS
172871997,Infliximab,Product use in unapproved indication,OT
172871997,Infliximab,Prescribed underdose,LT
172871997,Infliximab,Prescribed underdose,HO
172871997,Infliximab,Prescribed underdose,DS
172871997,Infliximab,Prescribed underdose,OT
172871997,Infliximab,Polyarthritis,LT
172871997,Infliximab,Polyarthritis,HO
172871997,Infliximab,Polyarthritis,DS
172871997,Infliximab,Polyarthritis,OT
172871997,Infliximab,Pleural effusion,LT
172871997,Infliximab,Pleural effusion,HO
172871997,Infliximab,Pleural effusion,DS
172871997,Infliximab,Pleural effusion,OT
172871997,Infliximab,Off label use,LT
172871997,Infliximab,Off label use,HO
172871997,Infliximab,Off label use,DS
172871997,Infliximab,Off label use,OT
172871997,Infliximab,Obesity,LT
172871997,Infliximab,Obesity,HO
172871997,Infliximab,Obesity,DS
172871997,Infliximab,Obesity,OT
172871997,Infliximab,Nausea,LT
172871997,Infliximab,Nausea,HO
172871997,Infliximab,Nausea,DS
172871997,Infliximab,Nausea,OT
172871997,Infliximab,Mobility decreased,LT
172871997,Infliximab,Mobility decreased,HO
172871997,Infliximab,Mobility decreased,DS
172871997,Infliximab,Mobility decreased,OT
172871997,Infliximab,Loss of personal independence in daily activities,LT
172871997,Infliximab,Loss of personal independence in daily activities,HO
172871997,Infliximab,Loss of personal independence in daily activities,DS
172871997,Infliximab,Loss of personal independence in daily activities,OT
172871997,Infliximab,Loss of consciousness,LT
172871997,Infliximab,Loss of consciousness,HO
172871997,Infliximab,Loss of consciousness,DS
172871997,Infliximab,Loss of consciousness,OT
172871997,Infliximab,Liver function test abnormal,LT
172871997,Infliximab,Liver function test abnormal,HO
172871997,Infliximab,Liver function test abnormal,DS
172871997,Infliximab,Liver function test abnormal,OT
172871997,Infliximab,Juvenile idiopathic arthritis,LT
172871997,Infliximab,Juvenile idiopathic arthritis,HO
172871997,Infliximab,Juvenile idiopathic arthritis,DS
172871997,Infliximab,Juvenile idiopathic arthritis,OT
172871997,Infliximab,Joint injury,LT
172871997,Infliximab,Joint injury,HO
172871997,Infliximab,Joint injury,DS
172871997,Infliximab,Joint injury,OT
172871997,Infliximab,Joint effusion,LT
172871997,Infliximab,Joint effusion,HO
172871997,Infliximab,Joint effusion,DS
172871997,Infliximab,Joint effusion,OT
172871997,Infliximab,Joint destruction,LT
172871997,Infliximab,Joint destruction,HO
172871997,Infliximab,Joint destruction,DS
172871997,Infliximab,Joint destruction,OT
172871997,Infliximab,Intentional product use issue,LT
172871997,Infliximab,Intentional product use issue,HO
172871997,Infliximab,Intentional product use issue,DS
172871997,Infliximab,Intentional product use issue,OT
172871997,Infliximab,Immunodeficiency,LT
172871997,Infliximab,Immunodeficiency,HO
172871997,Infliximab,Immunodeficiency,DS
172871997,Infliximab,Immunodeficiency,OT
172871997,Infliximab,Hypotension,LT
172871997,Infliximab,Hypotension,HO
172871997,Infliximab,Hypotension,DS
172871997,Infliximab,Hypotension,OT
172871997,Infliximab,Hypokalaemia,LT
172871997,Infliximab,Hypokalaemia,HO
172871997,Infliximab,Hypokalaemia,DS
172871997,Infliximab,Hypokalaemia,OT
172871997,Infliximab,Hypocalcaemia,LT
172871997,Infliximab,Hypocalcaemia,HO
172871997,Infliximab,Hypocalcaemia,DS
172871997,Infliximab,Hypocalcaemia,OT
172871997,Infliximab,Human antichimeric antibody positive,LT
172871997,Infliximab,Human antichimeric antibody positive,HO
172871997,Infliximab,Human antichimeric antibody positive,DS
172871997,Infliximab,Human antichimeric antibody positive,OT
172871997,Infliximab,Gastroenteritis viral,LT
172871997,Infliximab,Gastroenteritis viral,HO
172871997,Infliximab,Gastroenteritis viral,DS
172871997,Infliximab,Gastroenteritis viral,OT
172871997,Infliximab,Drug specific antibody,LT
172871997,Infliximab,Drug specific antibody,HO
172871997,Infliximab,Drug specific antibody,DS
172871997,Infliximab,Drug specific antibody,OT
172871997,Infliximab,Drug intolerance,LT
172871997,Infliximab,Drug intolerance,HO
172871997,Infliximab,Drug intolerance,DS
172871997,Infliximab,Drug intolerance,OT
172871997,Infliximab,Drug ineffective,LT
172871997,Infliximab,Drug ineffective,HO
172871997,Infliximab,Drug ineffective,DS
172871997,Infliximab,Drug ineffective,OT
172871997,Infliximab,Dizziness,LT
172871997,Infliximab,Dizziness,HO
172871997,Infliximab,Dizziness,DS
172871997,Infliximab,Dizziness,OT
172871997,Infliximab,Diarrhoea,LT
172871997,Infliximab,Diarrhoea,HO
172871997,Infliximab,Diarrhoea,DS
172871997,Infliximab,Diarrhoea,OT
172871997,Infliximab,Contraindicated product administered,LT
172871997,Infliximab,Contraindicated product administered,HO
172871997,Infliximab,Contraindicated product administered,DS
172871997,Infliximab,Contraindicated product administered,OT
172871997,Infliximab,Condition aggravated,LT
172871997,Infliximab,Condition aggravated,HO
172871997,Infliximab,Condition aggravated,DS
172871997,Infliximab,Condition aggravated,OT
172871997,Infliximab,C-reactive protein increased,LT
172871997,Infliximab,C-reactive protein increased,HO
172871997,Infliximab,C-reactive protein increased,DS
172871997,Infliximab,C-reactive protein increased,OT
172871997,Infliximab,C-reactive protein abnormal,LT
172871997,Infliximab,C-reactive protein abnormal,HO
172871997,Infliximab,C-reactive protein abnormal,DS
172871997,Infliximab,C-reactive protein abnormal,OT
172871997,Infliximab,Bone density increased,LT
172871997,Infliximab,Bone density increased,HO
172871997,Infliximab,Bone density increased,DS
172871997,Infliximab,Bone density increased,OT
172871997,Infliximab,Bone density decreased,LT
172871997,Infliximab,Bone density decreased,HO
172871997,Infliximab,Bone density decreased,DS
172871997,Infliximab,Bone density decreased,OT
172871997,Infliximab,Body height below normal,LT
172871997,Infliximab,Body height below normal,HO
172871997,Infliximab,Body height below normal,DS
172871997,Infliximab,Body height below normal,OT
172871997,Infliximab,Arthropathy,LT
172871997,Infliximab,Arthropathy,HO
172871997,Infliximab,Arthropathy,DS
172871997,Infliximab,Arthropathy,OT
172871997,Infliximab,Arthritis,LT
172871997,Infliximab,Arthritis,HO
172871997,Infliximab,Arthritis,DS
172871997,Infliximab,Arthritis,OT
172871997,Infliximab,Arthralgia,LT
172871997,Infliximab,Arthralgia,HO
172871997,Infliximab,Arthralgia,DS
172871997,Infliximab,Arthralgia,OT
172871997,Infliximab,Antibody test positive,LT
172871997,Infliximab,Antibody test positive,HO
172871997,Infliximab,Antibody test positive,DS
172871997,Infliximab,Antibody test positive,OT
172871997,Infliximab,Adrenal insufficiency,LT
172871997,Infliximab,Adrenal insufficiency,HO
172871997,Infliximab,Adrenal insufficiency,DS
172871997,Infliximab,Adrenal insufficiency,OT
176052024,Infliximab,Syncope,OT
176052024,Infliximab,Sinusitis,OT
176052024,Infliximab,Photophobia,OT
176052024,Infliximab,Pain in extremity,OT
176052024,Infliximab,Inappropriate schedule of product administration,OT
176052024,Infliximab,Hordeolum,OT
176052024,Infliximab,Fatigue,OT
176052024,Infliximab,Dehydration,OT
176052024,Infliximab,Body temperature fluctuation,OT
176052024,Infliximab,Arthralgia,OT
176169974,Infliximab,Varicella,HO
176169974,Infliximab,Varicella,OT
176169974,Infliximab,Pyrexia,HO
176169974,Infliximab,Pyrexia,OT
176169974,Infliximab,Nasopharyngitis,HO
176169974,Infliximab,Nasopharyngitis,OT
176169974,Infliximab,Inappropriate schedule of product administration,HO
176169974,Infliximab,Inappropriate schedule of product administration,OT
176169974,Infliximab,Headache,HO
176169974,Infliximab,Headache,OT
176169974,Infliximab,Drug level below therapeutic,HO
176169974,Infliximab,Drug level below therapeutic,OT
176169974,Infliximab,Condition aggravated,HO
176169974,Infliximab,Condition aggravated,OT
176169974,Infliximab,Body temperature fluctuation,HO
176169974,Infliximab,Body temperature fluctuation,OT
176169974,Infliximab,Blood pressure fluctuation,HO
176169974,Infliximab,Blood pressure fluctuation,OT
176169974,Infliximab,Antibody test abnormal,HO
176169974,Infliximab,Antibody test abnormal,OT
176169974,Infliximab,Varicella,HO
176169974,Infliximab,Varicella,OT
176169974,Infliximab,Pyrexia,HO
176169974,Infliximab,Pyrexia,OT
176169974,Infliximab,Nasopharyngitis,HO
176169974,Infliximab,Nasopharyngitis,OT
176169974,Infliximab,Inappropriate schedule of product administration,HO
176169974,Infliximab,Inappropriate schedule of product administration,OT
176169974,Infliximab,Headache,HO
176169974,Infliximab,Headache,OT
176169974,Infliximab,Drug level below therapeutic,HO
176169974,Infliximab,Drug level below therapeutic,OT
176169974,Infliximab,Condition aggravated,HO
176169974,Infliximab,Condition aggravated,OT
176169974,Infliximab,Body temperature fluctuation,HO
176169974,Infliximab,Body temperature fluctuation,OT
176169974,Infliximab,Blood pressure fluctuation,HO
176169974,Infliximab,Blood pressure fluctuation,OT
176169974,Infliximab,Antibody test abnormal,HO
176169974,Infliximab,Antibody test abnormal,OT
181251813,Infliximab,White blood cell count increased,OT
181251813,Infliximab,White blood cell count decreased,OT
181251813,Infliximab,Weight increased,OT
181251813,Infliximab,Weight decreased,OT
181251813,Infliximab,Therapeutic response shortened,OT
181251813,Infliximab,Serum ferritin decreased,OT
181251813,Infliximab,Psoriasis,OT
181251813,Infliximab,Prescribed overdose,OT
181251813,Infliximab,Platelet count increased,OT
181251813,Infliximab,Platelet count decreased,OT
181251813,Infliximab,Pain,OT
181251813,Infliximab,Off label use,OT
181251813,Infliximab,Neutrophil count increased,OT
181251813,Infliximab,Mean cell volume decreased,OT
181251813,Infliximab,Mean cell haemoglobin decreased,OT
181251813,Infliximab,Leukocytosis,OT
181251813,Infliximab,Intentional product use issue,OT
181251813,Infliximab,Inappropriate schedule of product administration,OT
181251813,Infliximab,Haemoglobin increased,OT
181251813,Infliximab,Haemoglobin decreased,OT
181251813,Infliximab,Drug level above therapeutic,OT
181251813,Infliximab,Constipation,OT
181251813,Infliximab,Condition aggravated,OT
181251813,Infliximab,Clostridium difficile infection,OT
181251813,Infliximab,C-reactive protein decreased,OT
181251813,Infliximab,C-reactive protein abnormal,OT
181251813,Infliximab,Anaemia,OT
181251813,Infliximab,Alanine aminotransferase increased,OT
181251813,Infliximab,White blood cell count increased,OT
181251813,Infliximab,White blood cell count decreased,OT
181251813,Infliximab,Weight increased,OT
181251813,Infliximab,Weight decreased,OT
181251813,Infliximab,Therapeutic response shortened,OT
181251813,Infliximab,Serum ferritin decreased,OT
181251813,Infliximab,Psoriasis,OT
181251813,Infliximab,Prescribed overdose,OT
181251813,Infliximab,Platelet count increased,OT
181251813,Infliximab,Platelet count decreased,OT
181251813,Infliximab,Pain,OT
181251813,Infliximab,Off label use,OT
181251813,Infliximab,Neutrophil count increased,OT
181251813,Infliximab,Mean cell volume decreased,OT
181251813,Infliximab,Mean cell haemoglobin decreased,OT
181251813,Infliximab,Leukocytosis,OT
181251813,Infliximab,Intentional product use issue,OT
181251813,Infliximab,Inappropriate schedule of product administration,OT
181251813,Infliximab,Haemoglobin increased,OT
181251813,Infliximab,Haemoglobin decreased,OT
181251813,Infliximab,Drug level above therapeutic,OT
181251813,Infliximab,Constipation,OT
181251813,Infliximab,Condition aggravated,OT
181251813,Infliximab,Clostridium difficile infection,OT
181251813,Infliximab,C-reactive protein decreased,OT
181251813,Infliximab,C-reactive protein abnormal,OT
181251813,Infliximab,Anaemia,OT
181251813,Infliximab,Alanine aminotransferase increased,OT
183879812,Infliximab,Rectal haemorrhage,OT
183879812,Infliximab,Pyoderma,OT
183879812,Infliximab,Nausea,OT
183879812,Infliximab,Mucous stools,OT
183879812,Infliximab,Infusion related reaction,OT
183879812,Infliximab,Drug ineffective,OT
183879812,Infliximab,Colitis ulcerative,OT
183879812,Infliximab,Anal incontinence,OT
183879812,Infliximab,Rectal haemorrhage,OT
183879812,Infliximab,Pyoderma,OT
183879812,Infliximab,Nausea,OT
183879812,Infliximab,Mucous stools,OT
183879812,Infliximab,Infusion related reaction,OT
183879812,Infliximab,Drug ineffective,OT
183879812,Infliximab,Colitis ulcerative,OT
183879812,Infliximab,Anal incontinence,OT
184915772,Infliximab,Peripheral swelling,HO
184915772,Infliximab,Peripheral swelling,OT
184915772,Infliximab,Periarthritis,HO
184915772,Infliximab,Periarthritis,OT
184915772,Infliximab,Nerve injury,HO
184915772,Infliximab,Nerve injury,OT
184915772,Infliximab,Nausea,HO
184915772,Infliximab,Nausea,OT
184915772,Infliximab,Myalgia,HO
184915772,Infliximab,Myalgia,OT
184915772,Infliximab,Muscular weakness,HO
184915772,Infliximab,Muscular weakness,OT
184915772,Infliximab,Multifocal motor neuropathy,HO
184915772,Infliximab,Multifocal motor neuropathy,OT
184915772,Infliximab,Motor dysfunction,HO
184915772,Infliximab,Motor dysfunction,OT
184915772,Infliximab,Loss of personal independence in daily activities,HO
184915772,Infliximab,Loss of personal independence in daily activities,OT
184915772,Infliximab,Limb injury,HO
184915772,Infliximab,Limb injury,OT
184915772,Infliximab,Joint stiffness,HO
184915772,Infliximab,Joint stiffness,OT
184915772,Infliximab,Inappropriate schedule of product administration,HO
184915772,Infliximab,Inappropriate schedule of product administration,OT
184915772,Infliximab,Hypoaesthesia,HO
184915772,Infliximab,Hypoaesthesia,OT
184915772,Infliximab,Hemiparesis,HO
184915772,Infliximab,Hemiparesis,OT
184915772,Infliximab,Heart rate decreased,HO
184915772,Infliximab,Heart rate decreased,OT
184915772,Infliximab,Headache,HO
184915772,Infliximab,Headache,OT
184915772,Infliximab,Gait disturbance,HO
184915772,Infliximab,Gait disturbance,OT
184915772,Infliximab,Fatigue,HO
184915772,Infliximab,Fatigue,OT
184915772,Infliximab,Fall,HO
184915772,Infliximab,Fall,OT
184915772,Infliximab,Disease progression,HO
184915772,Infliximab,Disease progression,OT
184915772,Infliximab,Decreased appetite,HO
184915772,Infliximab,Decreased appetite,OT
184915772,Infliximab,Crying,HO
184915772,Infliximab,Crying,OT
184915772,Infliximab,Condition aggravated,HO
184915772,Infliximab,Condition aggravated,OT
184915772,Infliximab,Arthralgia,HO
184915772,Infliximab,Arthralgia,OT
184915772,Infliximab,Peripheral swelling,HO
184915772,Infliximab,Peripheral swelling,OT
184915772,Infliximab,Periarthritis,HO
184915772,Infliximab,Periarthritis,OT
184915772,Infliximab,Nerve injury,HO
184915772,Infliximab,Nerve injury,OT
184915772,Infliximab,Nausea,HO
184915772,Infliximab,Nausea,OT
184915772,Infliximab,Myalgia,HO
184915772,Infliximab,Myalgia,OT
184915772,Infliximab,Muscular weakness,HO
184915772,Infliximab,Muscular weakness,OT
184915772,Infliximab,Multifocal motor neuropathy,HO
184915772,Infliximab,Multifocal motor neuropathy,OT
184915772,Infliximab,Motor dysfunction,HO
184915772,Infliximab,Motor dysfunction,OT
184915772,Infliximab,Loss of personal independence in daily activities,HO
184915772,Infliximab,Loss of personal independence in daily activities,OT
184915772,Infliximab,Limb injury,HO
184915772,Infliximab,Limb injury,OT
184915772,Infliximab,Joint stiffness,HO
184915772,Infliximab,Joint stiffness,OT
184915772,Infliximab,Inappropriate schedule of product administration,HO
184915772,Infliximab,Inappropriate schedule of product administration,OT
184915772,Infliximab,Hypoaesthesia,HO
184915772,Infliximab,Hypoaesthesia,OT
184915772,Infliximab,Hemiparesis,HO
184915772,Infliximab,Hemiparesis,OT
184915772,Infliximab,Heart rate decreased,HO
184915772,Infliximab,Heart rate decreased,OT
184915772,Infliximab,Headache,HO
184915772,Infliximab,Headache,OT
184915772,Infliximab,Gait disturbance,HO
184915772,Infliximab,Gait disturbance,OT
184915772,Infliximab,Fatigue,HO
184915772,Infliximab,Fatigue,OT
184915772,Infliximab,Fall,HO
184915772,Infliximab,Fall,OT
184915772,Infliximab,Disease progression,HO
184915772,Infliximab,Disease progression,OT
184915772,Infliximab,Decreased appetite,HO
184915772,Infliximab,Decreased appetite,OT
184915772,Infliximab,Crying,HO
184915772,Infliximab,Crying,OT
184915772,Infliximab,Condition aggravated,HO
184915772,Infliximab,Condition aggravated,OT
184915772,Infliximab,Arthralgia,HO
184915772,Infliximab,Arthralgia,OT
185496483,Infliximab,Tremor,HO
185496483,Infliximab,Tremor,OT
185496483,Infliximab,Sensation of foreign body,HO
185496483,Infliximab,Sensation of foreign body,OT
185496483,Infliximab,Respiratory rate increased,HO
185496483,Infliximab,Respiratory rate increased,OT
185496483,Infliximab,Pruritus,HO
185496483,Infliximab,Pruritus,OT
185496483,Infliximab,Paraesthesia,HO
185496483,Infliximab,Paraesthesia,OT
185496483,Infliximab,Oropharyngeal discomfort,HO
185496483,Infliximab,Oropharyngeal discomfort,OT
185496483,Infliximab,Off label use,HO
185496483,Infliximab,Off label use,OT
185496483,Infliximab,Hypersensitivity,HO
185496483,Infliximab,Hypersensitivity,OT
185496483,Infliximab,Heart rate increased,HO
185496483,Infliximab,Heart rate increased,OT
185496483,Infliximab,Erythema,HO
185496483,Infliximab,Erythema,OT
185496483,Infliximab,Ear discomfort,HO
185496483,Infliximab,Ear discomfort,OT
185496483,Infliximab,Dyspnoea,HO
185496483,Infliximab,Dyspnoea,OT
185496483,Infliximab,Dry mouth,HO
185496483,Infliximab,Dry mouth,OT
185496483,Infliximab,Cystitis,HO
185496483,Infliximab,Cystitis,OT
185496483,Infliximab,Blood pressure increased,HO
185496483,Infliximab,Blood pressure increased,OT
185496483,Infliximab,Arthritis,HO
185496483,Infliximab,Arthritis,OT
185496483,Infliximab,Aphonia,HO
185496483,Infliximab,Aphonia,OT
185496483,Infliximab,Anaphylactic reaction,HO
185496483,Infliximab,Anaphylactic reaction,OT
185536933,Infliximab,Weight increased,OT
185536933,Infliximab,Weight decreased,OT
185536933,Infliximab,Off label use,OT
185536933,Infliximab,Intentional product use issue,OT
185536933,Infliximab,Inappropriate schedule of product administration,OT
185536933,Infliximab,Heart rate irregular,OT
185536933,Infliximab,Body temperature decreased,OT
185536933,Infliximab,Body temperature abnormal,OT
185536933,Infliximab,Blood pressure increased,OT
185536933,Infliximab,Blood pressure fluctuation,OT
185536933,Infliximab,Weight increased,OT
185536933,Infliximab,Weight decreased,OT
185536933,Infliximab,Off label use,OT
185536933,Infliximab,Intentional product use issue,OT
185536933,Infliximab,Inappropriate schedule of product administration,OT
185536933,Infliximab,Heart rate irregular,OT
185536933,Infliximab,Body temperature decreased,OT
185536933,Infliximab,Body temperature abnormal,OT
185536933,Infliximab,Blood pressure increased,OT
185536933,Infliximab,Blood pressure fluctuation,OT
190147132,Infliximab,Rhinorrhoea,OT
190147132,Infliximab,Oropharyngeal pain,OT
190147132,Infliximab,Fatigue,OT
190147132,Infliximab,Exposure during pregnancy,OT
190147132,Infliximab,Drug ineffective,OT
190147132,Infliximab,Condition aggravated,OT
190147132,Infliximab,Colitis microscopic,OT
190147132,Infliximab,Abortion spontaneous,OT
190147132,Infliximab,Rhinorrhoea,OT
190147132,Infliximab,Oropharyngeal pain,OT
190147132,Infliximab,Fatigue,OT
190147132,Infliximab,Exposure during pregnancy,OT
190147132,Infliximab,Drug ineffective,OT
190147132,Infliximab,Condition aggravated,OT
190147132,Infliximab,Colitis microscopic,OT
190147132,Infliximab,Abortion spontaneous,OT
190906033,Infliximab,Product use in unapproved indication,HO
190906033,Infliximab,Product use in unapproved indication,OT
190906033,Infliximab,Off label use,HO
190906033,Infliximab,Off label use,OT
190906033,Infliximab,Maternal exposure during pregnancy,HO
190906033,Infliximab,Maternal exposure during pregnancy,OT
190906033,Infliximab,Intentional product use issue,HO
190906033,Infliximab,Intentional product use issue,OT
190906033,Infliximab,Influenza like illness,HO
190906033,Infliximab,Influenza like illness,OT
190906033,Infliximab,Exposure during pregnancy,HO
190906033,Infliximab,Exposure during pregnancy,OT
190943292,Infliximab (Unknown),VACTERL syndrome,OT
190943292,Infliximab (Unknown),Off label use,OT
190943292,Infliximab (Unknown),Maternal exposure during pregnancy,OT
190943292,Infliximab (Unknown),Abortion induced,OT
190943292,Infliximab (Unknown),Abortion,OT
194507464,Infliximab BS for I.V. Infusion100 mg [NK],Brain neoplasm,HO
194507464,Infliximab BS for I.V. Infusion100 mg [NK],Brain neoplasm,HO
194507464,Infliximab BS for I.V. Infusion100 mg [NK],Brain neoplasm,HO
194507464,Infliximab BS for I.V. Infusion100 mg [NK],Brain neoplasm,HO
194507464,Infliximab BS for I.V. Infusion100 mg [NK],Brain neoplasm,HO
194507464,Infliximab BS for I.V. Infusion100 mg [NK],Brain neoplasm,HO
194507464,Infliximab BS for I.V. Infusion100 mg [NK],Brain neoplasm,HO
194507464,Infliximab BS for I.V. Infusion100 mg [NK],Brain neoplasm,HO
194507464,Infliximab BS for I.V. Infusion100 mg [NK],Brain neoplasm,HO
194507464,Infliximab BS for I.V. Infusion100 mg [NK],Brain neoplasm,HO
195094492,Infliximab (Unknown),Sleep disorder,OT
195094492,Infliximab (Unknown),Pollakiuria,OT
195094492,Infliximab (Unknown),Pain,OT
195094492,Infliximab (Unknown),Mood swings,OT
195094492,Infliximab (Unknown),Mobility decreased,OT
195094492,Infliximab (Unknown),Liver function test increased,OT
195094492,Infliximab (Unknown),Intestinal perforation,OT
195094492,Infliximab (Unknown),Increased appetite,OT
195094492,Infliximab (Unknown),Facial pain,OT
195094492,Infliximab (Unknown),Dyslexia,OT
195094492,Infliximab (Unknown),Dizziness,OT
195094492,Infliximab (Unknown),Crohn's disease,OT
195094492,Infliximab (Unknown),Anaphylactic reaction,OT
195211071,Infliximab,Maternal exposure during pregnancy,LT
195211071,Infliximab,Drug specific antibody present,LT
196831071,Infliximab Pfizer (Unknown),Lower limb fracture,OT
197058481,Infliximab,Therapeutic response shortened,OT
197058481,Infliximab,Off label use,OT
197058481,Infliximab,Heart rate abnormal,OT
197058481,Infliximab,Fatigue,OT
197058481,Infliximab,Drug level above therapeutic,OT
197058481,Infliximab,Blood pressure fluctuation,OT
197355131,Infliximab (Unknown),Off label use,DE
197355131,Infliximab (Unknown),Interstitial lung disease,DE
197355131,Infliximab (Unknown),Disease progression,DE
197640281,Infliximab,Sepsis,HO
197640281,Infliximab,Sepsis,LT
197640281,Infliximab,Pyrexia,HO
197640281,Infliximab,Pyrexia,LT
197640281,Infliximab,Hypotension,HO
197640281,Infliximab,Hypotension,LT
197640281,Infliximab,Hypersensitivity,HO
197640281,Infliximab,Hypersensitivity,LT
197640281,Infliximab,Feeling abnormal,HO
197640281,Infliximab,Feeling abnormal,LT
197640281,Infliximab,Cold sweat,HO
197640281,Infliximab,Cold sweat,LT
197640281,Infliximab,Sepsis,HO
197640281,Infliximab,Sepsis,LT
197640281,Infliximab,Pyrexia,HO
197640281,Infliximab,Pyrexia,LT
197640281,Infliximab,Hypotension,HO
197640281,Infliximab,Hypotension,LT
197640281,Infliximab,Hypersensitivity,HO
197640281,Infliximab,Hypersensitivity,LT
197640281,Infliximab,Feeling abnormal,HO
197640281,Infliximab,Feeling abnormal,LT
197640281,Infliximab,Cold sweat,HO
197640281,Infliximab,Cold sweat,LT
197645771,Infliximab Pfizer (Unknown),Off label use,OT
197645771,Infliximab Pfizer (Unknown),Hepatotoxicity,OT
197645771,Infliximab Pfizer (Unknown),Drug intolerance,OT
197645771,Infliximab Pfizer (Unknown),Drug ineffective for unapproved indication,OT
198056611,Infliximab,Off label use,DE
198056611,Infliximab,Death,DE
198213401,Infliximab,Weight increased,OT
198213401,Infliximab,Off label use,OT
198213401,Infliximab,Intentional product use issue,OT
198213401,Infliximab,Incorrect dose administered,OT
198213401,Infliximab,Inappropriate schedule of product administration,OT
198213401,Infliximab,Hypotension,OT
198213401,Infliximab,Condition aggravated,OT
198213401,Infliximab,Weight increased,OT
198213401,Infliximab,Off label use,OT
198213401,Infliximab,Intentional product use issue,OT
198213401,Infliximab,Incorrect dose administered,OT
198213401,Infliximab,Inappropriate schedule of product administration,OT
198213401,Infliximab,Hypotension,OT
198213401,Infliximab,Condition aggravated,OT
198294161,Infliximab,White blood cell count increased,OT
198294161,Infliximab,Vitamin D decreased,OT
198294161,Infliximab,Therapeutic response shortened,OT
198294161,Infliximab,Skin lesion inflammation,OT
198294161,Infliximab,Skin lesion,OT
198294161,Infliximab,Red cell distribution width increased,OT
198294161,Infliximab,Red blood cell count increased,OT
198294161,Infliximab,Product use issue,OT
198294161,Infliximab,Product use in unapproved indication,OT
198294161,Infliximab,Off label use,OT
198294161,Infliximab,Mean cell volume decreased,OT
198294161,Infliximab,Mean cell haemoglobin decreased,OT
198294161,Infliximab,Inappropriate schedule of product administration,OT
198294161,Infliximab,Haemoglobin decreased,OT
198294161,Infliximab,Erythema multiforme,OT
198294161,Infliximab,Condition aggravated,OT
198294161,Infliximab,C-reactive protein increased,OT
198294161,Infliximab,Burning sensation,OT
198294161,Infliximab,Blood test abnormal,OT
198294161,Infliximab,Blood pressure increased,OT
198294161,Infliximab,Blood potassium increased,OT
198294161,Infliximab,Acute febrile neutrophilic dermatosis,OT
198430071,Infliximab,Immune reconstitution inflammatory syndrome,OT
198430071,Infliximab,Hepatitis B reactivation,OT
198618091,Infliximab,Off label use,OT
198618091,Infliximab,Inappropriate schedule of product administration,OT
198618091,Infliximab,Condition aggravated,OT
198851971,Infliximab,Drug ineffective,OT
198851971,Infliximab,Ankylosing spondylitis,OT
198913381,Infliximab,Weight decreased,OT
198913381,Infliximab,Weight decreased,HO
198913381,Infliximab,Pulmonary embolism,OT
198913381,Infliximab,Pulmonary embolism,HO
198913381,Infliximab,Pneumocystis jirovecii pneumonia,OT
198913381,Infliximab,Pneumocystis jirovecii pneumonia,HO
198913381,Infliximab,Pallor,OT
198913381,Infliximab,Pallor,HO
198913381,Infliximab,Malnutrition,OT
198913381,Infliximab,Malnutrition,HO
198913381,Infliximab,Intestinal ulcer,OT
198913381,Infliximab,Intestinal ulcer,HO
198913381,Infliximab,Insomnia,OT
198913381,Infliximab,Insomnia,HO
198913381,Infliximab,Incorrect dose administered,OT
198913381,Infliximab,Incorrect dose administered,HO
198913381,Infliximab,Inappropriate schedule of product administration,OT
198913381,Infliximab,Inappropriate schedule of product administration,HO
198913381,Infliximab,Head discomfort,OT
198913381,Infliximab,Head discomfort,HO
198913381,Infliximab,Haematochezia,OT
198913381,Infliximab,Haematochezia,HO
198913381,Infliximab,Gait inability,OT
198913381,Infliximab,Gait inability,HO
198913381,Infliximab,Eczema,OT
198913381,Infliximab,Eczema,HO
198913381,Infliximab,Eating disorder,OT
198913381,Infliximab,Eating disorder,HO
198913381,Infliximab,Drug intolerance,OT
198913381,Infliximab,Drug intolerance,HO
198913381,Infliximab,Dehydration,OT
198913381,Infliximab,Dehydration,HO
198913381,Infliximab,Cerebrovascular accident,OT
198913381,Infliximab,Cerebrovascular accident,HO
198913381,Infliximab,Cardiac failure congestive,OT
198913381,Infliximab,Cardiac failure congestive,HO
198913381,Infliximab,Asthenia,OT
198913381,Infliximab,Asthenia,HO
198913381,Infliximab,Aphthous ulcer,OT
198913381,Infliximab,Aphthous ulcer,HO
198913381,Infliximab,Abdominal pain upper,OT
198913381,Infliximab,Abdominal pain upper,HO
160799715,Infliximab,Weight increased,OT
160799715,Infliximab,Weight increased,DS
160799715,Infliximab,Treatment noncompliance,OT
160799715,Infliximab,Treatment noncompliance,DS
160799715,Infliximab,Product use issue,OT
160799715,Infliximab,Product use issue,DS
160799715,Infliximab,Off label use,OT
160799715,Infliximab,Off label use,DS
160799715,Infliximab,Intentional product use issue,OT
160799715,Infliximab,Intentional product use issue,DS
160799715,Infliximab,Incorrect dose administered,OT
160799715,Infliximab,Incorrect dose administered,DS
160799715,Infliximab,Impetigo,OT
160799715,Infliximab,Impetigo,DS
160799715,Infliximab,Heart rate decreased,OT
160799715,Infliximab,Heart rate decreased,DS
160799715,Infliximab,Headache,OT
160799715,Infliximab,Headache,DS
160799715,Infliximab,Head injury,OT
160799715,Infliximab,Head injury,DS
160799715,Infliximab,Drug ineffective,OT
160799715,Infliximab,Drug ineffective,DS
160799715,Infliximab,Conjunctivitis,OT
160799715,Infliximab,Conjunctivitis,DS
160799715,Infliximab,Condition aggravated,OT
160799715,Infliximab,Condition aggravated,DS
160799715,Infliximab,Blood pressure increased,OT
160799715,Infliximab,Blood pressure increased,DS
160799715,Infliximab,Blood pressure fluctuation,OT
160799715,Infliximab,Blood pressure fluctuation,DS
160799715,Infliximab,Weight increased,OT
160799715,Infliximab,Weight increased,DS
160799715,Infliximab,Treatment noncompliance,OT
160799715,Infliximab,Treatment noncompliance,DS
160799715,Infliximab,Product use issue,OT
160799715,Infliximab,Product use issue,DS
160799715,Infliximab,Off label use,OT
160799715,Infliximab,Off label use,DS
160799715,Infliximab,Intentional product use issue,OT
160799715,Infliximab,Intentional product use issue,DS
160799715,Infliximab,Incorrect dose administered,OT
160799715,Infliximab,Incorrect dose administered,DS
160799715,Infliximab,Impetigo,OT
160799715,Infliximab,Impetigo,DS
160799715,Infliximab,Heart rate decreased,OT
160799715,Infliximab,Heart rate decreased,DS
160799715,Infliximab,Headache,OT
160799715,Infliximab,Headache,DS
160799715,Infliximab,Head injury,OT
160799715,Infliximab,Head injury,DS
160799715,Infliximab,Drug ineffective,OT
160799715,Infliximab,Drug ineffective,DS
160799715,Infliximab,Conjunctivitis,OT
160799715,Infliximab,Conjunctivitis,DS
160799715,Infliximab,Condition aggravated,OT
160799715,Infliximab,Condition aggravated,DS
160799715,Infliximab,Blood pressure increased,OT
160799715,Infliximab,Blood pressure increased,DS
160799715,Infliximab,Blood pressure fluctuation,OT
160799715,Infliximab,Blood pressure fluctuation,DS
164921405,Infliximab,Weight increased,OT
164921405,Infliximab,Tooth abscess,OT
164921405,Infliximab,Skin plaque,OT
164921405,Infliximab,Skin lesion,OT
164921405,Infliximab,Pruritus,OT
164921405,Infliximab,Pharyngeal paraesthesia,OT
164921405,Infliximab,Pain,OT
164921405,Infliximab,Off label use,OT
164921405,Infliximab,Intentional product use issue,OT
164921405,Infliximab,Infusion related reaction,OT
164921405,Infliximab,Incorrect dose administered,OT
164921405,Infliximab,Hypoacusis,OT
164921405,Infliximab,Hypertension,OT
164921405,Infliximab,Erythema,OT
164921405,Infliximab,Dry throat,OT
164921405,Infliximab,Bronchitis,OT
164921405,Infliximab,Blood pressure increased,OT
164921405,Infliximab,Blood pressure fluctuation,OT
164921405,Infliximab,Arthralgia,OT
164921405,Infliximab,Aphthous ulcer,OT
164921405,Infliximab,Alopecia,OT
164921405,Infliximab,Acne,OT
164921405,Infliximab,Weight increased,OT
164921405,Infliximab,Tooth abscess,OT
164921405,Infliximab,Skin plaque,OT
164921405,Infliximab,Skin lesion,OT
164921405,Infliximab,Pruritus,OT
164921405,Infliximab,Pharyngeal paraesthesia,OT
164921405,Infliximab,Pain,OT
164921405,Infliximab,Off label use,OT
164921405,Infliximab,Intentional product use issue,OT
164921405,Infliximab,Infusion related reaction,OT
164921405,Infliximab,Incorrect dose administered,OT
164921405,Infliximab,Hypoacusis,OT
164921405,Infliximab,Hypertension,OT
164921405,Infliximab,Erythema,OT
164921405,Infliximab,Dry throat,OT
164921405,Infliximab,Bronchitis,OT
164921405,Infliximab,Blood pressure increased,OT
164921405,Infliximab,Blood pressure fluctuation,OT
164921405,Infliximab,Arthralgia,OT
164921405,Infliximab,Aphthous ulcer,OT
164921405,Infliximab,Alopecia,OT
164921405,Infliximab,Acne,OT
166834225,Infliximab,Wound secretion,OT
166834225,Infliximab,Rectal polyp,OT
166834225,Infliximab,Product use issue,OT
166834225,Infliximab,Off label use,OT
166834225,Infliximab,Intentional product use issue,OT
166834225,Infliximab,Incorrect product administration duration,OT
166834225,Infliximab,Inappropriate schedule of product administration,OT
166834225,Infliximab,Heart rate decreased,OT
166834225,Infliximab,Haemorrhoids,OT
166834225,Infliximab,Faecal calprotectin increased,OT
166834225,Infliximab,Faecal calprotectin abnormal,OT
166834225,Infliximab,Drug level above therapeutic,OT
166834225,Infliximab,Drug ineffective,OT
166834225,Infliximab,Condition aggravated,OT
166834225,Infliximab,Wound secretion,OT
166834225,Infliximab,Rectal polyp,OT
166834225,Infliximab,Product use issue,OT
166834225,Infliximab,Off label use,OT
166834225,Infliximab,Intentional product use issue,OT
166834225,Infliximab,Incorrect product administration duration,OT
166834225,Infliximab,Inappropriate schedule of product administration,OT
166834225,Infliximab,Heart rate decreased,OT
166834225,Infliximab,Haemorrhoids,OT
166834225,Infliximab,Faecal calprotectin increased,OT
166834225,Infliximab,Faecal calprotectin abnormal,OT
166834225,Infliximab,Drug level above therapeutic,OT
166834225,Infliximab,Drug ineffective,OT
166834225,Infliximab,Condition aggravated,OT
166834225,Infliximab,Wound secretion,OT
166834225,Infliximab,Rectal polyp,OT
166834225,Infliximab,Product use issue,OT
166834225,Infliximab,Off label use,OT
166834225,Infliximab,Intentional product use issue,OT
166834225,Infliximab,Incorrect product administration duration,OT
166834225,Infliximab,Inappropriate schedule of product administration,OT
166834225,Infliximab,Heart rate decreased,OT
166834225,Infliximab,Haemorrhoids,OT
166834225,Infliximab,Faecal calprotectin increased,OT
166834225,Infliximab,Faecal calprotectin abnormal,OT
166834225,Infliximab,Drug level above therapeutic,OT
166834225,Infliximab,Drug ineffective,OT
166834225,Infliximab,Condition aggravated,OT
168316674,Infliximab,Weight decreased,OT
168316674,Infliximab,Upper respiratory tract infection,OT
168316674,Infliximab,Seasonal allergy,OT
168316674,Infliximab,Pharyngitis streptococcal,OT
168316674,Infliximab,Heart rate irregular,OT
168316674,Infliximab,Fatigue,OT
168316674,Infliximab,Cough,OT
168316674,Infliximab,Condition aggravated,OT
168316674,Infliximab,Blood pressure decreased,OT
174124094,Infliximab,White blood cell count decreased,OT
174124094,Infliximab,Quality of life decreased,OT
174124094,Infliximab,Neutrophil count decreased,OT
174124094,Infliximab,Heart rate decreased,OT
174124094,Infliximab,Fatigue,OT
174124094,Infliximab,Condition aggravated,OT
174477424,Infliximab,Viral infection,OT
174477424,Infliximab,Urine abnormality,OT
174477424,Infliximab,Therapeutic response shortened,OT
174477424,Infliximab,Therapeutic product effect decreased,OT
174477424,Infliximab,Stress,OT
174477424,Infliximab,Sleep disorder,OT
174477424,Infliximab,Seasonal allergy,OT
174477424,Infliximab,Pyrexia,OT
174477424,Infliximab,Productive cough,OT
174477424,Infliximab,Pain,OT
174477424,Infliximab,Oropharyngeal pain,OT
174477424,Infliximab,Off label use,OT
174477424,Infliximab,Nasopharyngitis,OT
174477424,Infliximab,Myalgia,OT
174477424,Infliximab,Mobility decreased,OT
174477424,Infliximab,Malaise,OT
174477424,Infliximab,Insomnia,OT
174477424,Infliximab,Increased upper airway secretion,OT
174477424,Infliximab,Incorrect dose administered,OT
174477424,Infliximab,Hypersomnia,OT
174477424,Infliximab,Heart rate decreased,OT
174477424,Infliximab,Gastrointestinal disorder,OT
174477424,Infliximab,Fatigue,OT
174477424,Infliximab,Epistaxis,OT
174477424,Infliximab,Dizziness,OT
174477424,Infliximab,Diarrhoea,OT
174477424,Infliximab,Cough,OT
174477424,Infliximab,Contusion,OT
174477424,Infliximab,Condition aggravated,OT
174477424,Infliximab,Blood pressure fluctuation,OT
174477424,Infliximab,Blood pressure diastolic increased,OT
174477424,Infliximab,Bladder disorder,OT
174477424,Infliximab,Back pain,OT
174477424,Infliximab,Arthralgia,OT
174477424,Infliximab,Adjustment disorder with depressed mood,OT
174477424,Infliximab,Viral infection,OT
174477424,Infliximab,Urine abnormality,OT
174477424,Infliximab,Therapeutic response shortened,OT
174477424,Infliximab,Therapeutic product effect decreased,OT
174477424,Infliximab,Stress,OT
174477424,Infliximab,Sleep disorder,OT
174477424,Infliximab,Seasonal allergy,OT
174477424,Infliximab,Pyrexia,OT
174477424,Infliximab,Productive cough,OT
174477424,Infliximab,Pain,OT
174477424,Infliximab,Oropharyngeal pain,OT
174477424,Infliximab,Off label use,OT
174477424,Infliximab,Nasopharyngitis,OT
174477424,Infliximab,Myalgia,OT
174477424,Infliximab,Mobility decreased,OT
174477424,Infliximab,Malaise,OT
174477424,Infliximab,Insomnia,OT
174477424,Infliximab,Increased upper airway secretion,OT
174477424,Infliximab,Incorrect dose administered,OT
174477424,Infliximab,Hypersomnia,OT
174477424,Infliximab,Heart rate decreased,OT
174477424,Infliximab,Gastrointestinal disorder,OT
174477424,Infliximab,Fatigue,OT
174477424,Infliximab,Epistaxis,OT
174477424,Infliximab,Dizziness,OT
174477424,Infliximab,Diarrhoea,OT
174477424,Infliximab,Cough,OT
174477424,Infliximab,Contusion,OT
174477424,Infliximab,Condition aggravated,OT
174477424,Infliximab,Blood pressure fluctuation,OT
174477424,Infliximab,Blood pressure diastolic increased,OT
174477424,Infliximab,Bladder disorder,OT
174477424,Infliximab,Back pain,OT
174477424,Infliximab,Arthralgia,OT
174477424,Infliximab,Adjustment disorder with depressed mood,OT
176053634,Infliximab,Treatment failure,OT
176053634,Infliximab,Synovitis,OT
176053634,Infliximab,Rheumatoid arthritis,OT
176053634,Infliximab,Red blood cell sedimentation rate increased,OT
176053634,Infliximab,Pain,OT
176053634,Infliximab,Off label use,OT
176053634,Infliximab,Nausea,OT
176053634,Infliximab,Malaise,OT
176053634,Infliximab,Liver disorder,OT
176053634,Infliximab,Joint injury,OT
176053634,Infliximab,Inflammation,OT
176053634,Infliximab,Headache,OT
176053634,Infliximab,Fatigue,OT
176053634,Infliximab,Fall,OT
176053634,Infliximab,Drug use disorder,OT
176053634,Infliximab,Drug intolerance,OT
176053634,Infliximab,Drug ineffective,OT
176053634,Infliximab,Drug dependence,OT
176053634,Infliximab,Diarrhoea,OT
176053634,Infliximab,Depression,OT
176053634,Infliximab,Contraindicated product administered,OT
176053634,Infliximab,Asthenia,OT
176053634,Infliximab,Aspartate aminotransferase increased,OT
176053634,Infliximab,Arthralgia,OT
176053634,Infliximab,Anxiety,OT
176053634,Infliximab,Alopecia,OT
176053634,Infliximab,Alanine aminotransferase increased,OT
176053634,Infliximab,Adverse drug reaction,OT
176053634,Infliximab,Abdominal pain upper,OT
176053634,Infliximab,Treatment failure,OT
176053634,Infliximab,Synovitis,OT
176053634,Infliximab,Rheumatoid arthritis,OT
176053634,Infliximab,Red blood cell sedimentation rate increased,OT
176053634,Infliximab,Pain,OT
176053634,Infliximab,Off label use,OT
176053634,Infliximab,Nausea,OT
176053634,Infliximab,Malaise,OT
176053634,Infliximab,Liver disorder,OT
176053634,Infliximab,Joint injury,OT
176053634,Infliximab,Inflammation,OT
176053634,Infliximab,Headache,OT
176053634,Infliximab,Fatigue,OT
176053634,Infliximab,Fall,OT
176053634,Infliximab,Drug use disorder,OT
176053634,Infliximab,Drug intolerance,OT
176053634,Infliximab,Drug ineffective,OT
176053634,Infliximab,Drug dependence,OT
176053634,Infliximab,Diarrhoea,OT
176053634,Infliximab,Depression,OT
176053634,Infliximab,Contraindicated product administered,OT
176053634,Infliximab,Asthenia,OT
176053634,Infliximab,Aspartate aminotransferase increased,OT
176053634,Infliximab,Arthralgia,OT
176053634,Infliximab,Anxiety,OT
176053634,Infliximab,Alopecia,OT
176053634,Infliximab,Alanine aminotransferase increased,OT
176053634,Infliximab,Adverse drug reaction,OT
176053634,Infliximab,Abdominal pain upper,OT
176256913,Infliximab,Weight increased,OT
176256913,Infliximab,Weight increased,HO
176256913,Infliximab,Weight decreased,OT
176256913,Infliximab,Weight decreased,HO
176256913,Infliximab,Product use issue,OT
176256913,Infliximab,Product use issue,HO
176256913,Infliximab,Off label use,OT
176256913,Infliximab,Off label use,HO
176256913,Infliximab,Intentional product use issue,OT
176256913,Infliximab,Intentional product use issue,HO
176256913,Infliximab,Inappropriate schedule of product administration,OT
176256913,Infliximab,Inappropriate schedule of product administration,HO
176256913,Infliximab,Heart rate irregular,OT
176256913,Infliximab,Heart rate irregular,HO
176256913,Infliximab,Cerebral venous sinus thrombosis,OT
176256913,Infliximab,Cerebral venous sinus thrombosis,HO
176256913,Infliximab,Blood pressure increased,OT
176256913,Infliximab,Blood pressure increased,HO
176256913,Infliximab,Blood pressure fluctuation,OT
176256913,Infliximab,Blood pressure fluctuation,HO
176256913,Infliximab,Anal squamous cell carcinoma,OT
176256913,Infliximab,Anal squamous cell carcinoma,HO
176256913,Infliximab,Weight increased,OT
176256913,Infliximab,Weight increased,HO
176256913,Infliximab,Weight decreased,OT
176256913,Infliximab,Weight decreased,HO
176256913,Infliximab,Product use issue,OT
176256913,Infliximab,Product use issue,HO
176256913,Infliximab,Off label use,OT
176256913,Infliximab,Off label use,HO
176256913,Infliximab,Intentional product use issue,OT
176256913,Infliximab,Intentional product use issue,HO
176256913,Infliximab,Inappropriate schedule of product administration,OT
176256913,Infliximab,Inappropriate schedule of product administration,HO
176256913,Infliximab,Heart rate irregular,OT
176256913,Infliximab,Heart rate irregular,HO
176256913,Infliximab,Cerebral venous sinus thrombosis,OT
176256913,Infliximab,Cerebral venous sinus thrombosis,HO
176256913,Infliximab,Blood pressure increased,OT
176256913,Infliximab,Blood pressure increased,HO
176256913,Infliximab,Blood pressure fluctuation,OT
176256913,Infliximab,Blood pressure fluctuation,HO
176256913,Infliximab,Anal squamous cell carcinoma,OT
176256913,Infliximab,Anal squamous cell carcinoma,HO
176475123,Infliximab,Poor venous access,HO
176475123,Infliximab,Pain,HO
176475123,Infliximab,Off label use,HO
176475123,Infliximab,Nasopharyngitis,HO
176475123,Infliximab,Musculoskeletal stiffness,HO
176475123,Infliximab,Muscle spasms,HO
176475123,Infliximab,Intentional product use issue,HO
176475123,Infliximab,Incorrect dose administered,HO
176475123,Infliximab,Inappropriate schedule of product administration,HO
176475123,Infliximab,Heart rate decreased,HO
176475123,Infliximab,Feeling abnormal,HO
176475123,Infliximab,Condition aggravated,HO
176475123,Infliximab,Back pain,HO
176475123,Infliximab,Asthenia,HO
176475123,Infliximab,Arthralgia,HO
176475123,Infliximab,Poor venous access,HO
176475123,Infliximab,Pain,HO
176475123,Infliximab,Off label use,HO
176475123,Infliximab,Nasopharyngitis,HO
176475123,Infliximab,Musculoskeletal stiffness,HO
176475123,Infliximab,Muscle spasms,HO
176475123,Infliximab,Intentional product use issue,HO
176475123,Infliximab,Incorrect dose administered,HO
176475123,Infliximab,Inappropriate schedule of product administration,HO
176475123,Infliximab,Heart rate decreased,HO
176475123,Infliximab,Feeling abnormal,HO
176475123,Infliximab,Condition aggravated,HO
176475123,Infliximab,Back pain,HO
176475123,Infliximab,Asthenia,HO
176475123,Infliximab,Arthralgia,HO
176531093,Infliximab,Weight increased,OT
176531093,Infliximab,Productive cough,OT
176531093,Infliximab,Product use issue,OT
176531093,Infliximab,Off label use,OT
176531093,Infliximab,Nasopharyngitis,OT
176531093,Infliximab,Joint stiffness,OT
176531093,Infliximab,Intentional product use issue,OT
176531093,Infliximab,Inappropriate schedule of product administration,OT
176531093,Infliximab,Cough,OT
176531093,Infliximab,Condition aggravated,OT
176531093,Infliximab,Blood pressure increased,OT
176531093,Infliximab,Blood pressure fluctuation,OT
176531093,Infliximab,Arthralgia,OT
176583013,Infliximab,Weight increased,OT
176583013,Infliximab,Weight decreased,OT
176583013,Infliximab,Therapeutic product effect incomplete,OT
176583013,Infliximab,Rectal haemorrhage,OT
176583013,Infliximab,Product use issue,OT
176583013,Infliximab,Product administration error,OT
176583013,Infliximab,Off label use,OT
176583013,Infliximab,Intentional product use issue,OT
176583013,Infliximab,Inappropriate schedule of product administration,OT
176583013,Infliximab,Heart rate irregular,OT
176583013,Infliximab,Gastrointestinal inflammation,OT
176583013,Infliximab,Faecal calprotectin increased,OT
176583013,Infliximab,Drug level above therapeutic,OT
176583013,Infliximab,Condition aggravated,OT
176583013,Infliximab,Body temperature decreased,OT
176583013,Infliximab,Weight increased,OT
176583013,Infliximab,Weight decreased,OT
176583013,Infliximab,Therapeutic product effect incomplete,OT
176583013,Infliximab,Rectal haemorrhage,OT
176583013,Infliximab,Product use issue,OT
176583013,Infliximab,Product administration error,OT
176583013,Infliximab,Off label use,OT
176583013,Infliximab,Intentional product use issue,OT
176583013,Infliximab,Inappropriate schedule of product administration,OT
176583013,Infliximab,Heart rate irregular,OT
176583013,Infliximab,Gastrointestinal inflammation,OT
176583013,Infliximab,Faecal calprotectin increased,OT
176583013,Infliximab,Drug level above therapeutic,OT
176583013,Infliximab,Condition aggravated,OT
176583013,Infliximab,Body temperature decreased,OT
177781753,Infliximab,Off label use,OT
177781753,Infliximab,Intentional product use issue,OT
177781753,Infliximab,Inappropriate schedule of product administration,OT
177781753,Infliximab,Heart rate increased,OT
177781753,Infliximab,Blood pressure fluctuation,OT
177781753,Infliximab,Off label use,OT
177781753,Infliximab,Intentional product use issue,OT
177781753,Infliximab,Inappropriate schedule of product administration,OT
177781753,Infliximab,Heart rate increased,OT
177781753,Infliximab,Blood pressure fluctuation,OT
182021016,Infliximab,Vitamin D deficiency,HO
182021016,Infliximab,Vitamin D deficiency,OT
182021016,Infliximab,Pulpitis dental,HO
182021016,Infliximab,Pulpitis dental,OT
182021016,Infliximab,Hordeolum,HO
182021016,Infliximab,Hordeolum,OT
182021016,Infliximab,Colitis,HO
182021016,Infliximab,Colitis,OT
182021016,Infliximab,Adverse drug reaction,HO
182021016,Infliximab,Adverse drug reaction,OT
183813672,Infliximab,Weight increased,OT
183813672,Infliximab,Weight decreased,OT
183813672,Infliximab,Urticaria,OT
183813672,Infliximab,Therapy non-responder,OT
183813672,Infliximab,Scar,OT
183813672,Infliximab,Pruritus,OT
183813672,Infliximab,Postoperative wound infection,OT
183813672,Infliximab,Pain,OT
183813672,Infliximab,Off label use,OT
183813672,Infliximab,Myalgia,OT
183813672,Infliximab,Maternal exposure during pregnancy,OT
183813672,Infliximab,Intentional product use issue,OT
183813672,Infliximab,Ingrown hair,OT
183813672,Infliximab,Inappropriate schedule of product administration,OT
183813672,Infliximab,Hot flush,OT
183813672,Infliximab,Heart rate irregular,OT
183813672,Infliximab,Flushing,OT
183813672,Infliximab,Erythema,OT
183813672,Infliximab,Drug level decreased,OT
183813672,Infliximab,Cough,OT
183813672,Infliximab,Condition aggravated,OT
183813672,Infliximab,Blood pressure increased,OT
183813672,Infliximab,Asthma,OT
183813672,Infliximab,Arthralgia,OT
183813672,Infliximab,Anal fissure,OT
184364443,Infliximab,Weight increased,OT
184364443,Infliximab,Premature delivery,OT
184364443,Infliximab,Perineal injury,OT
184364443,Infliximab,Off label use,OT
184364443,Infliximab,Maternal exposure during pregnancy,OT
184364443,Infliximab,Intentional product use issue,OT
184364443,Infliximab,Impaired healing,OT
184364443,Infliximab,Foetal growth restriction,OT
184364443,Infliximab,Fatigue,OT
184364443,Infliximab,Condition aggravated,OT
184364443,Infliximab,Anxiety,OT
184364443,Infliximab,Weight increased,OT
184364443,Infliximab,Premature delivery,OT
184364443,Infliximab,Perineal injury,OT
184364443,Infliximab,Off label use,OT
184364443,Infliximab,Maternal exposure during pregnancy,OT
184364443,Infliximab,Intentional product use issue,OT
184364443,Infliximab,Impaired healing,OT
184364443,Infliximab,Foetal growth restriction,OT
184364443,Infliximab,Fatigue,OT
184364443,Infliximab,Condition aggravated,OT
184364443,Infliximab,Anxiety,OT
184364443,Infliximab,Weight increased,OT
184364443,Infliximab,Premature delivery,OT
184364443,Infliximab,Perineal injury,OT
184364443,Infliximab,Off label use,OT
184364443,Infliximab,Maternal exposure during pregnancy,OT
184364443,Infliximab,Intentional product use issue,OT
184364443,Infliximab,Impaired healing,OT
184364443,Infliximab,Foetal growth restriction,OT
184364443,Infliximab,Fatigue,OT
184364443,Infliximab,Condition aggravated,OT
184364443,Infliximab,Anxiety,OT
184364443,Infliximab,Weight increased,OT
184364443,Infliximab,Premature delivery,OT
184364443,Infliximab,Perineal injury,OT
184364443,Infliximab,Off label use,OT
184364443,Infliximab,Maternal exposure during pregnancy,OT
184364443,Infliximab,Intentional product use issue,OT
184364443,Infliximab,Impaired healing,OT
184364443,Infliximab,Foetal growth restriction,OT
184364443,Infliximab,Fatigue,OT
184364443,Infliximab,Condition aggravated,OT
184364443,Infliximab,Anxiety,OT
184365772,Infliximab,Uveitis,OT
184365772,Infliximab,Therapeutic product effect incomplete,OT
184365772,Infliximab,Scrotal infection,OT
184365772,Infliximab,Product use issue,OT
184365772,Infliximab,Pneumonia,OT
184365772,Infliximab,Off label use,OT
184365772,Infliximab,Intentional product use issue,OT
184365772,Infliximab,Incorrect dose administered,OT
184365772,Infliximab,Eye inflammation,OT
184365772,Infliximab,Condition aggravated,OT
184365772,Infliximab,Blood pressure increased,OT
184365772,Infliximab,Arthralgia,OT
184365772,Infliximab,Uveitis,OT
184365772,Infliximab,Therapeutic product effect incomplete,OT
184365772,Infliximab,Scrotal infection,OT
184365772,Infliximab,Product use issue,OT
184365772,Infliximab,Pneumonia,OT
184365772,Infliximab,Off label use,OT
184365772,Infliximab,Intentional product use issue,OT
184365772,Infliximab,Incorrect dose administered,OT
184365772,Infliximab,Eye inflammation,OT
184365772,Infliximab,Condition aggravated,OT
184365772,Infliximab,Blood pressure increased,OT
184365772,Infliximab,Arthralgia,OT
184365772,Infliximab,Uveitis,OT
184365772,Infliximab,Therapeutic product effect incomplete,OT
184365772,Infliximab,Scrotal infection,OT
184365772,Infliximab,Product use issue,OT
184365772,Infliximab,Pneumonia,OT
184365772,Infliximab,Off label use,OT
184365772,Infliximab,Intentional product use issue,OT
184365772,Infliximab,Incorrect dose administered,OT
184365772,Infliximab,Eye inflammation,OT
184365772,Infliximab,Condition aggravated,OT
184365772,Infliximab,Blood pressure increased,OT
184365772,Infliximab,Arthralgia,OT
184365772,Infliximab,Uveitis,OT
184365772,Infliximab,Therapeutic product effect incomplete,OT
184365772,Infliximab,Scrotal infection,OT
184365772,Infliximab,Product use issue,OT
184365772,Infliximab,Pneumonia,OT
184365772,Infliximab,Off label use,OT
184365772,Infliximab,Intentional product use issue,OT
184365772,Infliximab,Incorrect dose administered,OT
184365772,Infliximab,Eye inflammation,OT
184365772,Infliximab,Condition aggravated,OT
184365772,Infliximab,Blood pressure increased,OT
184365772,Infliximab,Arthralgia,OT
184462573,Infliximab,Vomiting,OT
184462573,Infliximab,Rhinorrhoea,OT
184462573,Infliximab,Off label use,OT
184462573,Infliximab,Nausea,OT
184462573,Infliximab,Nasopharyngitis,OT
184462573,Infliximab,Nasal congestion,OT
184462573,Infliximab,Malaise,OT
184462573,Infliximab,Intestinal haemorrhage,OT
184462573,Infliximab,Insomnia,OT
184462573,Infliximab,Inappropriate schedule of product administration,OT
184462573,Infliximab,Heart rate irregular,OT
184462573,Infliximab,Heart rate increased,OT
184462573,Infliximab,Haemorrhage,OT
184462573,Infliximab,Drug level below therapeutic,OT
184462573,Infliximab,Cough,OT
184462573,Infliximab,Condition aggravated,OT
184462573,Infliximab,Bronchitis,OT
184462573,Infliximab,Asthenia,OT
184462573,Infliximab,Abdominal pain,OT
184462573,Infliximab,Vomiting,OT
184462573,Infliximab,Rhinorrhoea,OT
184462573,Infliximab,Off label use,OT
184462573,Infliximab,Nausea,OT
184462573,Infliximab,Nasopharyngitis,OT
184462573,Infliximab,Nasal congestion,OT
184462573,Infliximab,Malaise,OT
184462573,Infliximab,Intestinal haemorrhage,OT
184462573,Infliximab,Insomnia,OT
184462573,Infliximab,Inappropriate schedule of product administration,OT
184462573,Infliximab,Heart rate irregular,OT
184462573,Infliximab,Heart rate increased,OT
184462573,Infliximab,Haemorrhage,OT
184462573,Infliximab,Drug level below therapeutic,OT
184462573,Infliximab,Cough,OT
184462573,Infliximab,Condition aggravated,OT
184462573,Infliximab,Bronchitis,OT
184462573,Infliximab,Asthenia,OT
184462573,Infliximab,Abdominal pain,OT
184693274,Infliximab,Off label use,OT
184693274,Infliximab,Intentional product use issue,OT
184693274,Infliximab,Incorrect dosage administered,OT
184693274,Infliximab,Condition aggravated,OT
184699623,Infliximab,Weight increased,OT
184699623,Infliximab,Vomiting,OT
184699623,Infliximab,Urinary incontinence,OT
184699623,Infliximab,Upper limb fracture,OT
184699623,Infliximab,Poor venous access,OT
184699623,Infliximab,Off label use,OT
184699623,Infliximab,Influenza like illness,OT
184699623,Infliximab,Incorrect dose administered,OT
184699623,Infliximab,Inappropriate schedule of product administration,OT
184699623,Infliximab,Drug ineffective,OT
184699623,Infliximab,Diarrhoea,OT
184699623,Infliximab,Cardiomegaly,OT
184699623,Infliximab,Body temperature increased,OT
184699623,Infliximab,Weight increased,OT
184699623,Infliximab,Vomiting,OT
184699623,Infliximab,Urinary incontinence,OT
184699623,Infliximab,Upper limb fracture,OT
184699623,Infliximab,Poor venous access,OT
184699623,Infliximab,Off label use,OT
184699623,Infliximab,Influenza like illness,OT
184699623,Infliximab,Incorrect dose administered,OT
184699623,Infliximab,Inappropriate schedule of product administration,OT
184699623,Infliximab,Drug ineffective,OT
184699623,Infliximab,Diarrhoea,OT
184699623,Infliximab,Cardiomegaly,OT
184699623,Infliximab,Body temperature increased,OT
184699623,Infliximab,Weight increased,OT
184699623,Infliximab,Vomiting,OT
184699623,Infliximab,Urinary incontinence,OT
184699623,Infliximab,Upper limb fracture,OT
184699623,Infliximab,Poor venous access,OT
184699623,Infliximab,Off label use,OT
184699623,Infliximab,Influenza like illness,OT
184699623,Infliximab,Incorrect dose administered,OT
184699623,Infliximab,Inappropriate schedule of product administration,OT
184699623,Infliximab,Drug ineffective,OT
184699623,Infliximab,Diarrhoea,OT
184699623,Infliximab,Cardiomegaly,OT
184699623,Infliximab,Body temperature increased,OT
184699623,Infliximab,Weight increased,OT
184699623,Infliximab,Vomiting,OT
184699623,Infliximab,Urinary incontinence,OT
184699623,Infliximab,Upper limb fracture,OT
184699623,Infliximab,Poor venous access,OT
184699623,Infliximab,Off label use,OT
184699623,Infliximab,Influenza like illness,OT
184699623,Infliximab,Incorrect dose administered,OT
184699623,Infliximab,Inappropriate schedule of product administration,OT
184699623,Infliximab,Drug ineffective,OT
184699623,Infliximab,Diarrhoea,OT
184699623,Infliximab,Cardiomegaly,OT
184699623,Infliximab,Body temperature increased,OT
185112392,Infliximab,Weight increased,OT
185112392,Infliximab,Off label use,OT
185112392,Infliximab,Lower respiratory tract infection,OT
185112392,Infliximab,Iritis,OT
185112392,Infliximab,Intentional product use issue,OT
185112392,Infliximab,Inappropriate schedule of product administration,OT
185112392,Infliximab,Body temperature increased,OT
185112392,Infliximab,Body temperature fluctuation,OT
185112392,Infliximab,Blood pressure increased,OT
185112392,Infliximab,Blood pressure fluctuation,OT
185112392,Infliximab,Arthritis infective,OT
185403324,Infliximab,Rash,OT
185403324,Infliximab,Rash,HO
185403324,Infliximab,Off label use,OT
185403324,Infliximab,Off label use,HO
185403324,Infliximab,Heart rate irregular,OT
185403324,Infliximab,Heart rate irregular,HO
185403324,Infliximab,Drug level above therapeutic,OT
185403324,Infliximab,Drug level above therapeutic,HO
185403324,Infliximab,Condition aggravated,OT
185403324,Infliximab,Condition aggravated,HO
185403324,Infliximab,Blood pressure decreased,OT
185403324,Infliximab,Blood pressure decreased,HO
185403324,Infliximab,Acne,OT
185403324,Infliximab,Acne,HO
185403324,Infliximab,Rash,OT
185403324,Infliximab,Rash,HO
185403324,Infliximab,Off label use,OT
185403324,Infliximab,Off label use,HO
185403324,Infliximab,Heart rate irregular,OT
185403324,Infliximab,Heart rate irregular,HO
185403324,Infliximab,Drug level above therapeutic,OT
185403324,Infliximab,Drug level above therapeutic,HO
185403324,Infliximab,Condition aggravated,OT
185403324,Infliximab,Condition aggravated,HO
185403324,Infliximab,Blood pressure decreased,OT
185403324,Infliximab,Blood pressure decreased,HO
185403324,Infliximab,Acne,OT
185403324,Infliximab,Acne,HO
191801992,Infliximab,Weight increased,OT
191801992,Infliximab,Spondylitis,OT
191801992,Infliximab,Off label use,OT
191801992,Infliximab,Intentional product use issue,OT
191801992,Infliximab,Condition aggravated,OT
191801992,Infliximab,Colitis ulcerative,OT
191801992,Infliximab,Blood pressure increased,OT
191801992,Infliximab,Arthralgia,OT
192946942,Infliximab,Weight decreased,OT
192946942,Infliximab,Off label use,OT
192946942,Infliximab,Intentional product use issue,OT
192946942,Infliximab,Gastrointestinal pain,OT
192946942,Infliximab,Condition aggravated,OT
192946942,Infliximab,Colitis ulcerative,OT
192946942,Infliximab,Blood pressure increased,OT
193766582,Infliximab,Therapeutic response shortened,OT
193766582,Infliximab,Swelling face,OT
193766582,Infliximab,Root canal infection,OT
193766582,Infliximab,Psoriasis,OT
193766582,Infliximab,Oral pain,OT
193766582,Infliximab,Off label use,OT
193766582,Infliximab,Nasopharyngitis,OT
193766582,Infliximab,Intentional product use issue,OT
193766582,Infliximab,Infection,OT
193766582,Infliximab,Hot flush,OT
193766582,Infliximab,Feeling hot,OT
193766582,Infliximab,Drug effect less than expected,OT
193766582,Infliximab,Blood pressure systolic increased,OT
194434332,Infliximab,Pain,OT
194434332,Infliximab,Off label use,OT
194434332,Infliximab,Muscle spasms,OT
194434332,Infliximab,Drug level decreased,OT
194434332,Infliximab,Drug level below therapeutic,OT
194434332,Infliximab,Dizziness,OT
194434332,Infliximab,Condition aggravated,OT
194434332,Infliximab,Asthenia,OT
195142442,Infliximab,No adverse event,NULL
195185511,Infliximab Pfizer (Unknown),Vascular pseudoaneurysm,HO
195894691,Infliximab,Weight increased,OT
195894691,Infliximab,Weight decreased,OT
195894691,Infliximab,Somnolence,OT
195894691,Infliximab,Respiratory rate increased,OT
195894691,Infliximab,Product use issue,OT
195894691,Infliximab,Overdose,OT
195894691,Infliximab,Off label use,OT
195894691,Infliximab,Dyspnoea,OT
195894691,Infliximab,Chest discomfort,OT
195894691,Infliximab,Body temperature increased,OT
196240181,Infliximab,Weight decreased,OT
196240181,Infliximab,Rash,OT
196240181,Infliximab,Pruritus,OT
196240181,Infliximab,Osteomyelitis,OT
196240181,Infliximab,Oral infection,OT
196240181,Infliximab,Infusion related reaction,OT
196240181,Infliximab,Hypertension,OT
196240181,Infliximab,Fatigue,OT
196240181,Infliximab,Dyspnoea,OT
196240181,Infliximab,Dry skin,OT
196307841,Infliximab,Urticaria,OT
196307841,Infliximab,Red blood cell sedimentation rate increased,OT
196307841,Infliximab,Joint swelling,OT
196307841,Infliximab,Inflammation,OT
196307841,Infliximab,Drug ineffective,OT
196307841,Infliximab,Cardiovascular disorder,OT
196307841,Infliximab,Arthralgia,OT
196307841,Infliximab,Anaphylactic reaction,OT
196866261,Infliximab,Weight increased,OT
196866261,Infliximab,Off label use,OT
196866261,Infliximab,Intentional product use issue,OT
196866261,Infliximab,Hepatic enzyme increased,OT
196866261,Infliximab,Condition aggravated,OT
196866261,Infliximab,Blood pressure increased,OT
196866261,Infliximab,Anxiety,OT
196866261,Infliximab,Weight increased,OT
196866261,Infliximab,Off label use,OT
196866261,Infliximab,Intentional product use issue,OT
196866261,Infliximab,Hepatic enzyme increased,OT
196866261,Infliximab,Condition aggravated,OT
196866261,Infliximab,Blood pressure increased,OT
196866261,Infliximab,Anxiety,OT
197102241,Infliximab,White blood cell count increased,OT
197102241,Infliximab,Streptococcal infection,OT
197102241,Infliximab,Pharyngitis,OT
197102241,Infliximab,Hernia,OT
197407311,Infliximab,Thermal burn,HO
197407311,Infliximab,Off label use,HO
197407311,Infliximab,Intentional product use issue,HO
197407311,Infliximab,Inappropriate schedule of product administration,HO
197407311,Infliximab,Heart rate decreased,HO
197487361,Infliximab,Product use in unapproved indication,OT
197487361,Infliximab,Product use in unapproved indication,LT
197487361,Infliximab,Off label use,OT
197487361,Infliximab,Off label use,LT
197487361,Infliximab,Adverse event,OT
197487361,Infliximab,Adverse event,LT
197858101,Infliximab,Urticaria,OT
197858101,Infliximab,Stoma site rash,OT
197858101,Infliximab,Stoma site pain,OT
197858101,Infliximab,Stoma site infection,OT
197858101,Infliximab,Stoma site erythema,OT
197858101,Infliximab,Stoma site discomfort,OT
197858101,Infliximab,Rash pruritic,OT
197858101,Infliximab,Rash,OT
197858101,Infliximab,Inappropriate schedule of product administration,OT
197858101,Infliximab,Diarrhoea,OT
197858101,Infliximab,Bacterial infection,OT
197869631,Infliximab,Weight fluctuation,DE
197869631,Infliximab,Death,DE
198023601,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,OT
198023601,Infliximab BS for I.V. Infusion100 mg [NK],Cerebral venous sinus thrombosis,OT
198023601,Infliximab BS for I.V. Infusion100 mg [NK],Overdose,OT
198023601,Infliximab BS for I.V. Infusion100 mg [NK],Cerebral venous sinus thrombosis,OT
198294201,Infliximab,Weight increased,OT
198294201,Infliximab,Therapeutic product effect delayed,OT
198294201,Infliximab,Pneumonia,OT
198294201,Infliximab,Inappropriate schedule of product administration,OT
198294201,Infliximab,Blood pressure diastolic decreased,OT
198445262,Infliximab,Infusion related reaction,OT
198445262,Infliximab,Immune-mediated enterocolitis,OT
198445262,Infliximab,Drug ineffective,OT
198598181,Infliximab,Proctitis,OT
198598181,Infliximab,Proctitis,HO
198598181,Infliximab,Post procedural discharge,OT
198598181,Infliximab,Post procedural discharge,HO
198598181,Infliximab,Pancreatitis,OT
198598181,Infliximab,Pancreatitis,HO
198598181,Infliximab,Off label use,OT
198598181,Infliximab,Off label use,HO
198611931,Infliximab Pfizer,Maternal exposure during pregnancy,HO
198611931,Infliximab Pfizer,Maternal exposure during pregnancy,OT
198611931,Infliximab Pfizer,Listeriosis,HO
198611931,Infliximab Pfizer,Listeriosis,OT
198611931,Infliximab Pfizer,Abortion,HO
198611931,Infliximab Pfizer,Abortion,OT
198731521,Infliximab,Weight decreased,OT
198731521,Infliximab,Therapeutic response shortened,OT
198731521,Infliximab,Rash,OT
198731521,Infliximab,Product use issue,OT
198731521,Infliximab,Poor venous access,OT
198731521,Infliximab,Off label use,OT
198731521,Infliximab,Gait disturbance,OT
198731521,Infliximab,Drug level decreased,OT
198731521,Infliximab,Condition aggravated,OT
198731521,Infliximab,Chills,OT
198731521,Infliximab,Cellulitis,OT
198731521,Infliximab,Blood pressure increased,OT
198731521,Infliximab,Back pain,OT
198731521,Infliximab,Arthralgia,OT
198731521,Infliximab,Weight decreased,OT
198731521,Infliximab,Therapeutic response shortened,OT
198731521,Infliximab,Rash,OT
198731521,Infliximab,Product use issue,OT
198731521,Infliximab,Poor venous access,OT
198731521,Infliximab,Off label use,OT
198731521,Infliximab,Gait disturbance,OT
198731521,Infliximab,Drug level decreased,OT
198731521,Infliximab,Condition aggravated,OT
198731521,Infliximab,Chills,OT
198731521,Infliximab,Cellulitis,OT
198731521,Infliximab,Blood pressure increased,OT
198731521,Infliximab,Back pain,OT
198731521,Infliximab,Arthralgia,OT
198834211,Infliximab,Pseudopolyposis,OT
198834211,Infliximab,Protein-losing gastroenteropathy,OT
198834211,Infliximab,Blood albumin decreased,OT
198939461,Infliximab,Off label use,HO
198939461,Infliximab,Condition aggravated,HO
164803334,Infliximab,Weight decreased,OT
164803334,Infliximab,Product use issue,OT
164803334,Infliximab,Off label use,OT
164803334,Infliximab,Loss of consciousness,OT
164803334,Infliximab,Intentional product use issue,OT
164803334,Infliximab,Hernia,OT
164803334,Infliximab,Heart rate irregular,OT
164803334,Infliximab,Heart rate decreased,OT
164803334,Infliximab,Condition aggravated,OT
164803334,Infliximab,Weight decreased,OT
164803334,Infliximab,Product use issue,OT
164803334,Infliximab,Off label use,OT
164803334,Infliximab,Loss of consciousness,OT
164803334,Infliximab,Intentional product use issue,OT
164803334,Infliximab,Hernia,OT
164803334,Infliximab,Heart rate irregular,OT
164803334,Infliximab,Heart rate decreased,OT
164803334,Infliximab,Condition aggravated,OT
168305783,Infliximab,Seizure,OT
168305783,Infliximab,Seizure,HO
168305783,Infliximab,Rash,OT
168305783,Infliximab,Rash,HO
168305783,Infliximab,Purpura,OT
168305783,Infliximab,Purpura,HO
168305783,Infliximab,Pruritus,OT
168305783,Infliximab,Pruritus,HO
168305783,Infliximab,Product use issue,OT
168305783,Infliximab,Product use issue,HO
168305783,Infliximab,Proctitis,OT
168305783,Infliximab,Proctitis,HO
168305783,Infliximab,Poor quality sleep,OT
168305783,Infliximab,Poor quality sleep,HO
168305783,Infliximab,Pneumonia,OT
168305783,Infliximab,Pneumonia,HO
168305783,Infliximab,Off label use,OT
168305783,Infliximab,Off label use,HO
168305783,Infliximab,Nasopharyngitis,OT
168305783,Infliximab,Nasopharyngitis,HO
168305783,Infliximab,Malaise,OT
168305783,Infliximab,Malaise,HO
168305783,Infliximab,Inappropriate schedule of product administration,OT
168305783,Infliximab,Inappropriate schedule of product administration,HO
168305783,Infliximab,Heart rate increased,OT
168305783,Infliximab,Heart rate increased,HO
168305783,Infliximab,Glaucoma,OT
168305783,Infliximab,Glaucoma,HO
168305783,Infliximab,Fatigue,OT
168305783,Infliximab,Fatigue,HO
168305783,Infliximab,Dermatitis acneiform,OT
168305783,Infliximab,Dermatitis acneiform,HO
168305783,Infliximab,Constipation,OT
168305783,Infliximab,Constipation,HO
168305783,Infliximab,Condition aggravated,OT
168305783,Infliximab,Condition aggravated,HO
168305783,Infliximab,Seizure,OT
168305783,Infliximab,Seizure,HO
168305783,Infliximab,Rash,OT
168305783,Infliximab,Rash,HO
168305783,Infliximab,Purpura,OT
168305783,Infliximab,Purpura,HO
168305783,Infliximab,Pruritus,OT
168305783,Infliximab,Pruritus,HO
168305783,Infliximab,Product use issue,OT
168305783,Infliximab,Product use issue,HO
168305783,Infliximab,Proctitis,OT
168305783,Infliximab,Proctitis,HO
168305783,Infliximab,Poor quality sleep,OT
168305783,Infliximab,Poor quality sleep,HO
168305783,Infliximab,Pneumonia,OT
168305783,Infliximab,Pneumonia,HO
168305783,Infliximab,Off label use,OT
168305783,Infliximab,Off label use,HO
168305783,Infliximab,Nasopharyngitis,OT
168305783,Infliximab,Nasopharyngitis,HO
168305783,Infliximab,Malaise,OT
168305783,Infliximab,Malaise,HO
168305783,Infliximab,Inappropriate schedule of product administration,OT
168305783,Infliximab,Inappropriate schedule of product administration,HO
168305783,Infliximab,Heart rate increased,OT
168305783,Infliximab,Heart rate increased,HO
168305783,Infliximab,Glaucoma,OT
168305783,Infliximab,Glaucoma,HO
168305783,Infliximab,Fatigue,OT
168305783,Infliximab,Fatigue,HO
168305783,Infliximab,Dermatitis acneiform,OT
168305783,Infliximab,Dermatitis acneiform,HO
168305783,Infliximab,Constipation,OT
168305783,Infliximab,Constipation,HO
168305783,Infliximab,Condition aggravated,OT
168305783,Infliximab,Condition aggravated,HO
168879575,Infliximab,Weight increased,OT
168879575,Infliximab,Weight decreased,OT
168879575,Infliximab,Off label use,OT
168879575,Infliximab,Intentional product use issue,OT
168879575,Infliximab,Incorrect dose administered,OT
168879575,Infliximab,Inappropriate schedule of product administration,OT
168879575,Infliximab,Heart rate irregular,OT
168879575,Infliximab,Heart rate decreased,OT
168879575,Infliximab,Blood pressure decreased,OT
174110583,Infliximab,Weight decreased,OT
174110583,Infliximab,Therapeutic response decreased,OT
174110583,Infliximab,Off label use,OT
174110583,Infliximab,Malaise,OT
174110583,Infliximab,Inappropriate schedule of product administration,OT
174110583,Infliximab,Hypertension,OT
174110583,Infliximab,Flatulence,OT
174110583,Infliximab,Faecal calprotectin increased,OT
174110583,Infliximab,Condition aggravated,OT
174110583,Infliximab,Colitis ulcerative,OT
174110583,Infliximab,Blood pressure fluctuation,OT
174110583,Infliximab,Weight decreased,OT
174110583,Infliximab,Therapeutic response decreased,OT
174110583,Infliximab,Off label use,OT
174110583,Infliximab,Malaise,OT
174110583,Infliximab,Inappropriate schedule of product administration,OT
174110583,Infliximab,Hypertension,OT
174110583,Infliximab,Flatulence,OT
174110583,Infliximab,Faecal calprotectin increased,OT
174110583,Infliximab,Condition aggravated,OT
174110583,Infliximab,Colitis ulcerative,OT
174110583,Infliximab,Blood pressure fluctuation,OT
174957173,Infliximab,Product use issue,OT
174957173,Infliximab,Off label use,OT
174957173,Infliximab,Intentional product use issue,OT
174957173,Infliximab,Infusion site extravasation,OT
174957173,Infliximab,Inappropriate schedule of product administration,OT
174957173,Infliximab,Condition aggravated,OT
175526153,Infliximab,Weight increased,OT
175526153,Infliximab,Weight decreased,OT
175526153,Infliximab,Vomiting,OT
175526153,Infliximab,Tooth infection,OT
175526153,Infliximab,Sensitivity to weather change,OT
175526153,Infliximab,Oropharyngeal pain,OT
175526153,Infliximab,Off label use,OT
175526153,Infliximab,Nasopharyngitis,OT
175526153,Infliximab,Malaise,OT
175526153,Infliximab,Loss of personal independence in daily activities,OT
175526153,Infliximab,Intentional product use issue,OT
175526153,Infliximab,Inappropriate schedule of product administration,OT
175526153,Infliximab,Illness,OT
175526153,Infliximab,Headache,OT
175526153,Infliximab,Gastrointestinal inflammation,OT
175526153,Infliximab,Fatigue,OT
175526153,Infliximab,Drug level above therapeutic,OT
175526153,Infliximab,Condition aggravated,OT
175526153,Infliximab,Blood pressure fluctuation,OT
175526153,Infliximab,Anxiety,OT
175526153,Infliximab,Weight increased,OT
175526153,Infliximab,Weight decreased,OT
175526153,Infliximab,Vomiting,OT
175526153,Infliximab,Tooth infection,OT
175526153,Infliximab,Sensitivity to weather change,OT
175526153,Infliximab,Oropharyngeal pain,OT
175526153,Infliximab,Off label use,OT
175526153,Infliximab,Nasopharyngitis,OT
175526153,Infliximab,Malaise,OT
175526153,Infliximab,Loss of personal independence in daily activities,OT
175526153,Infliximab,Intentional product use issue,OT
175526153,Infliximab,Inappropriate schedule of product administration,OT
175526153,Infliximab,Illness,OT
175526153,Infliximab,Headache,OT
175526153,Infliximab,Gastrointestinal inflammation,OT
175526153,Infliximab,Fatigue,OT
175526153,Infliximab,Drug level above therapeutic,OT
175526153,Infliximab,Condition aggravated,OT
175526153,Infliximab,Blood pressure fluctuation,OT
175526153,Infliximab,Anxiety,OT
176066155,Infliximab,Off label use,OT
176066155,Infliximab,Intentional product use issue,OT
176066155,Infliximab,Inappropriate schedule of product administration,OT
176066155,Infliximab,Hypotension,OT
176066155,Infliximab,Drug level below therapeutic,OT
176066155,Infliximab,Dehydration,OT
176066155,Infliximab,Condition aggravated,OT
176066155,Infliximab,Blood pressure fluctuation,OT
176066155,Infliximab,Arthralgia,OT
176066155,Infliximab,Off label use,OT
176066155,Infliximab,Intentional product use issue,OT
176066155,Infliximab,Inappropriate schedule of product administration,OT
176066155,Infliximab,Hypotension,OT
176066155,Infliximab,Drug level below therapeutic,OT
176066155,Infliximab,Dehydration,OT
176066155,Infliximab,Condition aggravated,OT
176066155,Infliximab,Blood pressure fluctuation,OT
176066155,Infliximab,Arthralgia,OT
176066155,Infliximab,Off label use,OT
176066155,Infliximab,Intentional product use issue,OT
176066155,Infliximab,Inappropriate schedule of product administration,OT
176066155,Infliximab,Hypotension,OT
176066155,Infliximab,Drug level below therapeutic,OT
176066155,Infliximab,Dehydration,OT
176066155,Infliximab,Condition aggravated,OT
176066155,Infliximab,Blood pressure fluctuation,OT
176066155,Infliximab,Arthralgia,OT
176470154,Infliximab,Weight decreased,OT
176470154,Infliximab,Vomiting,OT
176470154,Infliximab,Product use issue,OT
176470154,Infliximab,Peripheral swelling,OT
176470154,Infliximab,Off label use,OT
176470154,Infliximab,Malaise,OT
176470154,Infliximab,Intentional product use issue,OT
176470154,Infliximab,Incorrect product administration duration,OT
176470154,Infliximab,Incorrect dosage administered,OT
176470154,Infliximab,Hypertension,OT
176470154,Infliximab,Heart rate increased,OT
176470154,Infliximab,Gastrointestinal infection,OT
176470154,Infliximab,Gait disturbance,OT
176470154,Infliximab,Diarrhoea,OT
176470154,Infliximab,Blood pressure fluctuation,OT
176796414,Infliximab,Therapeutic product effect incomplete,OT
176796414,Infliximab,Tachycardia,OT
176796414,Infliximab,Pneumonia,OT
176796414,Infliximab,Off label use,OT
176796414,Infliximab,Nausea,OT
176796414,Infliximab,Nasopharyngitis,OT
176796414,Infliximab,Malaise,OT
176796414,Infliximab,Intentional product use issue,OT
176796414,Infliximab,Inappropriate schedule of product administration,OT
176796414,Infliximab,Heart rate irregular,OT
176796414,Infliximab,Heart rate increased,OT
176796414,Infliximab,Heart rate decreased,OT
176796414,Infliximab,Feeling cold,OT
176796414,Infliximab,Fatigue,OT
176796414,Infliximab,Condition aggravated,OT
176796414,Infliximab,Blood pressure systolic increased,OT
176796414,Infliximab,Blood pressure fluctuation,OT
176796414,Infliximab,Acne pustular,OT
176796414,Infliximab,Acne,OT
176796414,Infliximab,Therapeutic product effect incomplete,OT
176796414,Infliximab,Tachycardia,OT
176796414,Infliximab,Pneumonia,OT
176796414,Infliximab,Off label use,OT
176796414,Infliximab,Nausea,OT
176796414,Infliximab,Nasopharyngitis,OT
176796414,Infliximab,Malaise,OT
176796414,Infliximab,Intentional product use issue,OT
176796414,Infliximab,Inappropriate schedule of product administration,OT
176796414,Infliximab,Heart rate irregular,OT
176796414,Infliximab,Heart rate increased,OT
176796414,Infliximab,Heart rate decreased,OT
176796414,Infliximab,Feeling cold,OT
176796414,Infliximab,Fatigue,OT
176796414,Infliximab,Condition aggravated,OT
176796414,Infliximab,Blood pressure systolic increased,OT
176796414,Infliximab,Blood pressure fluctuation,OT
176796414,Infliximab,Acne pustular,OT
176796414,Infliximab,Acne,OT
177179993,Infliximab,Weight decreased,OT
177179993,Infliximab,Weight decreased,HO
177179993,Infliximab,Road traffic accident,OT
177179993,Infliximab,Road traffic accident,HO
177179993,Infliximab,Product use issue,OT
177179993,Infliximab,Product use issue,HO
177179993,Infliximab,Post-traumatic pain,OT
177179993,Infliximab,Post-traumatic pain,HO
177179993,Infliximab,Off label use,OT
177179993,Infliximab,Off label use,HO
177179993,Infliximab,Large intestine polyp,OT
177179993,Infliximab,Large intestine polyp,HO
177179993,Infliximab,Large intestinal stenosis,OT
177179993,Infliximab,Large intestinal stenosis,HO
177179993,Infliximab,Infusion site pain,OT
177179993,Infliximab,Infusion site pain,HO
177179993,Infliximab,Infusion site extravasation,OT
177179993,Infliximab,Infusion site extravasation,HO
177179993,Infliximab,Infusion site erythema,OT
177179993,Infliximab,Infusion site erythema,HO
177179993,Infliximab,Incorrect dose administered,OT
177179993,Infliximab,Incorrect dose administered,HO
177179993,Infliximab,Inappropriate schedule of product administration,OT
177179993,Infliximab,Inappropriate schedule of product administration,HO
177179993,Infliximab,Hip fracture,OT
177179993,Infliximab,Hip fracture,HO
177179993,Infliximab,Drug ineffective,OT
177179993,Infliximab,Drug ineffective,HO
177179993,Infliximab,Condition aggravated,OT
177179993,Infliximab,Condition aggravated,HO
177179993,Infliximab,Blood pressure fluctuation,OT
177179993,Infliximab,Blood pressure fluctuation,HO
177302764,Infliximab,Weight increased,OT
177302764,Infliximab,Therapeutic product effect incomplete,OT
177302764,Infliximab,Respiratory rate increased,OT
177302764,Infliximab,Productive cough,OT
177302764,Infliximab,Product prescribing error,OT
177302764,Infliximab,Pain,OT
177302764,Infliximab,Oxygen saturation decreased,OT
177302764,Infliximab,Oxygen saturation abnormal,OT
177302764,Infliximab,Off label use,OT
177302764,Infliximab,Nasopharyngitis,OT
177302764,Infliximab,Malaise,OT
177302764,Infliximab,Lower respiratory tract infection,OT
177302764,Infliximab,Insomnia,OT
177302764,Infliximab,Incorrect dose administered,OT
177302764,Infliximab,Flatulence,OT
177302764,Infliximab,Feeling abnormal,OT
177302764,Infliximab,Drug level below therapeutic,OT
177302764,Infliximab,Cough,OT
177302764,Infliximab,Condition aggravated,OT
177302764,Infliximab,Body temperature fluctuation,OT
177302764,Infliximab,Body temperature decreased,OT
177302764,Infliximab,Anal fissure,OT
177302764,Infliximab,Abscess,OT
177302764,Infliximab,Weight increased,OT
177302764,Infliximab,Therapeutic product effect incomplete,OT
177302764,Infliximab,Respiratory rate increased,OT
177302764,Infliximab,Productive cough,OT
177302764,Infliximab,Product prescribing error,OT
177302764,Infliximab,Pain,OT
177302764,Infliximab,Oxygen saturation decreased,OT
177302764,Infliximab,Oxygen saturation abnormal,OT
177302764,Infliximab,Off label use,OT
177302764,Infliximab,Nasopharyngitis,OT
177302764,Infliximab,Malaise,OT
177302764,Infliximab,Lower respiratory tract infection,OT
177302764,Infliximab,Insomnia,OT
177302764,Infliximab,Incorrect dose administered,OT
177302764,Infliximab,Flatulence,OT
177302764,Infliximab,Feeling abnormal,OT
177302764,Infliximab,Drug level below therapeutic,OT
177302764,Infliximab,Cough,OT
177302764,Infliximab,Condition aggravated,OT
177302764,Infliximab,Body temperature fluctuation,OT
177302764,Infliximab,Body temperature decreased,OT
177302764,Infliximab,Anal fissure,OT
177302764,Infliximab,Abscess,OT
177626903,Infliximab,White coat hypertension,OT
177626903,Infliximab,Urinary tract pain,OT
177626903,Infliximab,Tongue ulceration,OT
177626903,Infliximab,Tongue neoplasm,OT
177626903,Infliximab,Skin haemorrhage,OT
177626903,Infliximab,Rash pruritic,OT
177626903,Infliximab,Rash erythematous,OT
177626903,Infliximab,Rash,OT
177626903,Infliximab,Pruritus,OT
177626903,Infliximab,Product use issue,OT
177626903,Infliximab,Off label use,OT
177626903,Infliximab,Nephrolithiasis,OT
177626903,Infliximab,Malaise,OT
177626903,Infliximab,Intentional product use issue,OT
177626903,Infliximab,Fatigue,OT
177626903,Infliximab,Erythema nodosum,OT
177626903,Infliximab,Drug ineffective,OT
177626903,Infliximab,Condition aggravated,OT
177626903,Infliximab,Blood urine present,OT
177626903,Infliximab,Blood pressure systolic increased,OT
177626903,Infliximab,Blood pressure increased,OT
177626903,Infliximab,Blood pressure fluctuation,OT
177626903,Infliximab,White coat hypertension,OT
177626903,Infliximab,Urinary tract pain,OT
177626903,Infliximab,Tongue ulceration,OT
177626903,Infliximab,Tongue neoplasm,OT
177626903,Infliximab,Skin haemorrhage,OT
177626903,Infliximab,Rash pruritic,OT
177626903,Infliximab,Rash erythematous,OT
177626903,Infliximab,Rash,OT
177626903,Infliximab,Pruritus,OT
177626903,Infliximab,Product use issue,OT
177626903,Infliximab,Off label use,OT
177626903,Infliximab,Nephrolithiasis,OT
177626903,Infliximab,Malaise,OT
177626903,Infliximab,Intentional product use issue,OT
177626903,Infliximab,Fatigue,OT
177626903,Infliximab,Erythema nodosum,OT
177626903,Infliximab,Drug ineffective,OT
177626903,Infliximab,Condition aggravated,OT
177626903,Infliximab,Blood urine present,OT
177626903,Infliximab,Blood pressure systolic increased,OT
177626903,Infliximab,Blood pressure increased,OT
177626903,Infliximab,Blood pressure fluctuation,OT
177917424,Infliximab,Weight increased,HO
177917424,Infliximab,Weight increased,OT
177917424,Infliximab,Weight fluctuation,HO
177917424,Infliximab,Weight fluctuation,OT
177917424,Infliximab,Weight decreased,HO
177917424,Infliximab,Weight decreased,OT
177917424,Infliximab,Product use issue,HO
177917424,Infliximab,Product use issue,OT
177917424,Infliximab,Off label use,HO
177917424,Infliximab,Off label use,OT
177917424,Infliximab,Intestinal obstruction,HO
177917424,Infliximab,Intestinal obstruction,OT
177917424,Infliximab,Intentional product use issue,HO
177917424,Infliximab,Intentional product use issue,OT
177917424,Infliximab,Influenza like illness,HO
177917424,Infliximab,Influenza like illness,OT
177917424,Infliximab,Infection,HO
177917424,Infliximab,Infection,OT
177917424,Infliximab,Inappropriate schedule of product administration,HO
177917424,Infliximab,Inappropriate schedule of product administration,OT
177917424,Infliximab,Gastroenteritis viral,HO
177917424,Infliximab,Gastroenteritis viral,OT
177917424,Infliximab,Condition aggravated,HO
177917424,Infliximab,Condition aggravated,OT
177917424,Infliximab,Body temperature fluctuation,HO
177917424,Infliximab,Body temperature fluctuation,OT
177917424,Infliximab,Blood pressure fluctuation,HO
177917424,Infliximab,Blood pressure fluctuation,OT
177917424,Infliximab,Weight increased,HO
177917424,Infliximab,Weight increased,OT
177917424,Infliximab,Weight fluctuation,HO
177917424,Infliximab,Weight fluctuation,OT
177917424,Infliximab,Weight decreased,HO
177917424,Infliximab,Weight decreased,OT
177917424,Infliximab,Product use issue,HO
177917424,Infliximab,Product use issue,OT
177917424,Infliximab,Off label use,HO
177917424,Infliximab,Off label use,OT
177917424,Infliximab,Intestinal obstruction,HO
177917424,Infliximab,Intestinal obstruction,OT
177917424,Infliximab,Intentional product use issue,HO
177917424,Infliximab,Intentional product use issue,OT
177917424,Infliximab,Influenza like illness,HO
177917424,Infliximab,Influenza like illness,OT
177917424,Infliximab,Infection,HO
177917424,Infliximab,Infection,OT
177917424,Infliximab,Inappropriate schedule of product administration,HO
177917424,Infliximab,Inappropriate schedule of product administration,OT
177917424,Infliximab,Gastroenteritis viral,HO
177917424,Infliximab,Gastroenteritis viral,OT
177917424,Infliximab,Condition aggravated,HO
177917424,Infliximab,Condition aggravated,OT
177917424,Infliximab,Body temperature fluctuation,HO
177917424,Infliximab,Body temperature fluctuation,OT
177917424,Infliximab,Blood pressure fluctuation,HO
177917424,Infliximab,Blood pressure fluctuation,OT
178180535,Infliximab,Weight increased,OT
178180535,Infliximab,Skin burning sensation,OT
178180535,Infliximab,Rash pruritic,OT
178180535,Infliximab,Rash,OT
178180535,Infliximab,Product use issue,OT
178180535,Infliximab,Paraesthesia,OT
178180535,Infliximab,Off label use,OT
178180535,Infliximab,Intentional product use issue,OT
178180535,Infliximab,Incorrect dose administered,OT
178180535,Infliximab,Inappropriate schedule of product administration,OT
178180535,Infliximab,Hypotension,OT
178180535,Infliximab,Hypoaesthesia,OT
178180535,Infliximab,Herpes zoster,OT
178180535,Infliximab,Haematochezia,OT
178180535,Infliximab,Fatigue,OT
178180535,Infliximab,Dyspnoea,OT
178180535,Infliximab,Dermatitis infected,OT
178180535,Infliximab,Dermatitis contact,OT
178180535,Infliximab,Condition aggravated,OT
178180535,Infliximab,Chest discomfort,OT
178180535,Infliximab,Body temperature fluctuation,OT
178180535,Infliximab,Blood pressure fluctuation,OT
178180535,Infliximab,Abdominal pain,OT
178180535,Infliximab,Weight increased,OT
178180535,Infliximab,Skin burning sensation,OT
178180535,Infliximab,Rash pruritic,OT
178180535,Infliximab,Rash,OT
178180535,Infliximab,Product use issue,OT
178180535,Infliximab,Paraesthesia,OT
178180535,Infliximab,Off label use,OT
178180535,Infliximab,Intentional product use issue,OT
178180535,Infliximab,Incorrect dose administered,OT
178180535,Infliximab,Inappropriate schedule of product administration,OT
178180535,Infliximab,Hypotension,OT
178180535,Infliximab,Hypoaesthesia,OT
178180535,Infliximab,Herpes zoster,OT
178180535,Infliximab,Haematochezia,OT
178180535,Infliximab,Fatigue,OT
178180535,Infliximab,Dyspnoea,OT
178180535,Infliximab,Dermatitis infected,OT
178180535,Infliximab,Dermatitis contact,OT
178180535,Infliximab,Condition aggravated,OT
178180535,Infliximab,Chest discomfort,OT
178180535,Infliximab,Body temperature fluctuation,OT
178180535,Infliximab,Blood pressure fluctuation,OT
178180535,Infliximab,Abdominal pain,OT
178572514,Infliximab,Weight increased,OT
178572514,Infliximab,Vomiting,OT
178572514,Infliximab,Therapeutic response shortened,OT
178572514,Infliximab,Rash macular,OT
178572514,Infliximab,Rash,OT
178572514,Infliximab,Pruritus,OT
178572514,Infliximab,Off label use,OT
178572514,Infliximab,Nausea,OT
178572514,Infliximab,Muscle spasms,OT
178572514,Infliximab,Lacrimation increased,OT
178572514,Infliximab,Hyperhidrosis,OT
178572514,Infliximab,Frequent bowel movements,OT
178572514,Infliximab,Eyelid skin dryness,OT
178572514,Infliximab,Drug level below therapeutic,OT
178572514,Infliximab,Defaecation urgency,OT
178572514,Infliximab,Condition aggravated,OT
178572514,Infliximab,Colitis ulcerative,OT
178572514,Infliximab,Blood pressure fluctuation,OT
178572514,Infliximab,Acne,OT
178572514,Infliximab,Abdominal pain,OT
178572514,Infliximab,Weight increased,OT
178572514,Infliximab,Vomiting,OT
178572514,Infliximab,Therapeutic response shortened,OT
178572514,Infliximab,Rash macular,OT
178572514,Infliximab,Rash,OT
178572514,Infliximab,Pruritus,OT
178572514,Infliximab,Off label use,OT
178572514,Infliximab,Nausea,OT
178572514,Infliximab,Muscle spasms,OT
178572514,Infliximab,Lacrimation increased,OT
178572514,Infliximab,Hyperhidrosis,OT
178572514,Infliximab,Frequent bowel movements,OT
178572514,Infliximab,Eyelid skin dryness,OT
178572514,Infliximab,Drug level below therapeutic,OT
178572514,Infliximab,Defaecation urgency,OT
178572514,Infliximab,Condition aggravated,OT
178572514,Infliximab,Colitis ulcerative,OT
178572514,Infliximab,Blood pressure fluctuation,OT
178572514,Infliximab,Acne,OT
178572514,Infliximab,Abdominal pain,OT
182461562,Infliximab,Sensitivity to weather change,HO
182461562,Infliximab,Pelvic pain,HO
182461562,Infliximab,Pain in extremity,HO
182461562,Infliximab,Pain,HO
182461562,Infliximab,Nervousness,HO
182461562,Infliximab,Musculoskeletal chest pain,HO
182461562,Infliximab,Lethargy,HO
182461562,Infliximab,Lacrimation increased,HO
182461562,Infliximab,Headache,HO
182461562,Infliximab,Chest discomfort,HO
182461562,Infliximab,Blood pressure fluctuation,HO
182461562,Infliximab,Arthralgia,HO
182461562,Infliximab,Sensitivity to weather change,HO
182461562,Infliximab,Pelvic pain,HO
182461562,Infliximab,Pain in extremity,HO
182461562,Infliximab,Pain,HO
182461562,Infliximab,Nervousness,HO
182461562,Infliximab,Musculoskeletal chest pain,HO
182461562,Infliximab,Lethargy,HO
182461562,Infliximab,Lacrimation increased,HO
182461562,Infliximab,Headache,HO
182461562,Infliximab,Chest discomfort,HO
182461562,Infliximab,Blood pressure fluctuation,HO
182461562,Infliximab,Arthralgia,HO
183656212,Infliximab,Pyrexia,OT
183656212,Infliximab,Product use issue,OT
183656212,Infliximab,Off label use,OT
183656212,Infliximab,Nausea,OT
183656212,Infliximab,Intentional product use issue,OT
183656212,Infliximab,Inappropriate schedule of product administration,OT
183656212,Infliximab,Heart rate irregular,OT
183656212,Infliximab,Heart rate increased,OT
183656212,Infliximab,Diarrhoea,OT
183656212,Infliximab,Condition aggravated,OT
183656212,Infliximab,Blood pressure diastolic decreased,OT
183656212,Infliximab,Pyrexia,OT
183656212,Infliximab,Product use issue,OT
183656212,Infliximab,Off label use,OT
183656212,Infliximab,Nausea,OT
183656212,Infliximab,Intentional product use issue,OT
183656212,Infliximab,Inappropriate schedule of product administration,OT
183656212,Infliximab,Heart rate irregular,OT
183656212,Infliximab,Heart rate increased,OT
183656212,Infliximab,Diarrhoea,OT
183656212,Infliximab,Condition aggravated,OT
183656212,Infliximab,Blood pressure diastolic decreased,OT
183820344,Infliximab,Urinary tract pain,OT
183820344,Infliximab,Urinary tract pain,HO
183820344,Infliximab,Urinary tract infection,OT
183820344,Infliximab,Urinary tract infection,HO
183820344,Infliximab,Urinary incontinence,OT
183820344,Infliximab,Urinary incontinence,HO
183820344,Infliximab,Polyuria,OT
183820344,Infliximab,Polyuria,HO
183820344,Infliximab,Off label use,OT
183820344,Infliximab,Off label use,HO
183820344,Infliximab,Inappropriate schedule of product administration,OT
183820344,Infliximab,Inappropriate schedule of product administration,HO
183820344,Infliximab,Drug specific antibody present,OT
183820344,Infliximab,Drug specific antibody present,HO
183820344,Infliximab,Drug level below therapeutic,OT
183820344,Infliximab,Drug level below therapeutic,HO
183820344,Infliximab,Diarrhoea,OT
183820344,Infliximab,Diarrhoea,HO
183820344,Infliximab,Cough,OT
183820344,Infliximab,Cough,HO
183820344,Infliximab,Condition aggravated,OT
183820344,Infliximab,Condition aggravated,HO
183820344,Infliximab,Cardiac valve disease,OT
183820344,Infliximab,Cardiac valve disease,HO
183820344,Infliximab,Cardiac disorder,OT
183820344,Infliximab,Cardiac disorder,HO
183820344,Infliximab,Blood pressure increased,OT
183820344,Infliximab,Blood pressure increased,HO
183820344,Infliximab,Blood pressure fluctuation,OT
183820344,Infliximab,Blood pressure fluctuation,HO
183820344,Infliximab,Anal abscess,OT
183820344,Infliximab,Anal abscess,HO
183820344,Infliximab,Urinary tract pain,OT
183820344,Infliximab,Urinary tract pain,HO
183820344,Infliximab,Urinary tract infection,OT
183820344,Infliximab,Urinary tract infection,HO
183820344,Infliximab,Urinary incontinence,OT
183820344,Infliximab,Urinary incontinence,HO
183820344,Infliximab,Polyuria,OT
183820344,Infliximab,Polyuria,HO
183820344,Infliximab,Off label use,OT
183820344,Infliximab,Off label use,HO
183820344,Infliximab,Inappropriate schedule of product administration,OT
183820344,Infliximab,Inappropriate schedule of product administration,HO
183820344,Infliximab,Drug specific antibody present,OT
183820344,Infliximab,Drug specific antibody present,HO
183820344,Infliximab,Drug level below therapeutic,OT
183820344,Infliximab,Drug level below therapeutic,HO
183820344,Infliximab,Diarrhoea,OT
183820344,Infliximab,Diarrhoea,HO
183820344,Infliximab,Cough,OT
183820344,Infliximab,Cough,HO
183820344,Infliximab,Condition aggravated,OT
183820344,Infliximab,Condition aggravated,HO
183820344,Infliximab,Cardiac valve disease,OT
183820344,Infliximab,Cardiac valve disease,HO
183820344,Infliximab,Cardiac disorder,OT
183820344,Infliximab,Cardiac disorder,HO
183820344,Infliximab,Blood pressure increased,OT
183820344,Infliximab,Blood pressure increased,HO
183820344,Infliximab,Blood pressure fluctuation,OT
183820344,Infliximab,Blood pressure fluctuation,HO
183820344,Infliximab,Anal abscess,OT
183820344,Infliximab,Anal abscess,HO
184164233,Infliximab,Weight increased,OT
184164233,Infliximab,Weight decreased,OT
184164233,Infliximab,Vitamin D decreased,OT
184164233,Infliximab,Systemic lupus erythematosus,OT
184164233,Infliximab,Stomatitis,OT
184164233,Infliximab,Pain in extremity,OT
184164233,Infliximab,Pain,OT
184164233,Infliximab,Oral herpes,OT
184164233,Infliximab,Off label use,OT
184164233,Infliximab,Oedema peripheral,OT
184164233,Infliximab,Nausea,OT
184164233,Infliximab,Nasopharyngitis,OT
184164233,Infliximab,Incorrect dose administered,OT
184164233,Infliximab,Inappropriate schedule of product administration,OT
184164233,Infliximab,Hyperaesthesia,OT
184164233,Infliximab,Headache,OT
184164233,Infliximab,Fatigue,OT
184164233,Infliximab,Erythema,OT
184164233,Infliximab,Dyspnoea,OT
184164233,Infliximab,Condition aggravated,OT
184164233,Infliximab,Cholelithiasis,OT
184164233,Infliximab,Back pain,OT
184164233,Infliximab,Arthralgia,OT
184164233,Infliximab,Weight increased,OT
184164233,Infliximab,Weight decreased,OT
184164233,Infliximab,Vitamin D decreased,OT
184164233,Infliximab,Systemic lupus erythematosus,OT
184164233,Infliximab,Stomatitis,OT
184164233,Infliximab,Pain in extremity,OT
184164233,Infliximab,Pain,OT
184164233,Infliximab,Oral herpes,OT
184164233,Infliximab,Off label use,OT
184164233,Infliximab,Oedema peripheral,OT
184164233,Infliximab,Nausea,OT
184164233,Infliximab,Nasopharyngitis,OT
184164233,Infliximab,Incorrect dose administered,OT
184164233,Infliximab,Inappropriate schedule of product administration,OT
184164233,Infliximab,Hyperaesthesia,OT
184164233,Infliximab,Headache,OT
184164233,Infliximab,Fatigue,OT
184164233,Infliximab,Erythema,OT
184164233,Infliximab,Dyspnoea,OT
184164233,Infliximab,Condition aggravated,OT
184164233,Infliximab,Cholelithiasis,OT
184164233,Infliximab,Back pain,OT
184164233,Infliximab,Arthralgia,OT
184418773,Infliximab,Therapeutic response shortened,OT
184418773,Infliximab,Therapeutic product effect incomplete,OT
184418773,Infliximab,Sitting disability,OT
184418773,Infliximab,Pain,OT
184418773,Infliximab,Oxygen saturation abnormal,OT
184418773,Infliximab,Off label use,OT
184418773,Infliximab,Intentional product use issue,OT
184418773,Infliximab,Incorrect dose administered,OT
184418773,Infliximab,Heart rate decreased,OT
184418773,Infliximab,Fibromyalgia,OT
184418773,Infliximab,Drug level decreased,OT
184418773,Infliximab,Condition aggravated,OT
184418773,Infliximab,Coccydynia,OT
184418773,Infliximab,Cataract,OT
184418773,Infliximab,Therapeutic response shortened,OT
184418773,Infliximab,Therapeutic product effect incomplete,OT
184418773,Infliximab,Sitting disability,OT
184418773,Infliximab,Pain,OT
184418773,Infliximab,Oxygen saturation abnormal,OT
184418773,Infliximab,Off label use,OT
184418773,Infliximab,Intentional product use issue,OT
184418773,Infliximab,Incorrect dose administered,OT
184418773,Infliximab,Heart rate decreased,OT
184418773,Infliximab,Fibromyalgia,OT
184418773,Infliximab,Drug level decreased,OT
184418773,Infliximab,Condition aggravated,OT
184418773,Infliximab,Coccydynia,OT
184418773,Infliximab,Cataract,OT
185069932,Infliximab,Vein disorder,OT
185069932,Infliximab,Peripheral venous disease,OT
185069932,Infliximab,Pain,OT
185069932,Infliximab,Off label use,OT
185069932,Infliximab,Limb discomfort,OT
185069932,Infliximab,Joint stiffness,OT
185069932,Infliximab,Intentional product use issue,OT
185069932,Infliximab,Heart rate decreased,OT
185069932,Infliximab,Headache,OT
185069932,Infliximab,Fatigue,OT
185069932,Infliximab,Eczema,OT
185069932,Infliximab,Crohn's disease,OT
185069932,Infliximab,Asthenia,OT
185069932,Infliximab,Arthralgia,OT
185305605,Infliximab,Crohn's disease,OT
185305605,Infliximab,Crohn's disease,HO
185305605,Infliximab,Colonic abscess,OT
185305605,Infliximab,Colonic abscess,HO
185305605,Infliximab,Abdominal abscess,OT
185305605,Infliximab,Abdominal abscess,HO
185305605,Infliximab,Crohn's disease,OT
185305605,Infliximab,Crohn's disease,HO
185305605,Infliximab,Colonic abscess,OT
185305605,Infliximab,Colonic abscess,HO
185305605,Infliximab,Abdominal abscess,OT
185305605,Infliximab,Abdominal abscess,HO
189004702,Infliximab,Multiple sclerosis,OT
189004702,Infliximab,Drug ineffective,OT
190505167,Infliximab (Unknown),Vitiligo,OT
190505167,Infliximab (Unknown),Varicella zoster virus infection,OT
190505167,Infliximab (Unknown),Toxicity to various agents,OT
190505167,Infliximab (Unknown),Thrombocytopenia,OT
190505167,Infliximab (Unknown),Superinfection bacterial,OT
190505167,Infliximab (Unknown),Still's disease,OT
190505167,Infliximab (Unknown),Secondary adrenocortical insufficiency,OT
190505167,Infliximab (Unknown),Red blood cell sedimentation rate increased,OT
190505167,Infliximab (Unknown),Pulmonary function test abnormal,OT
190505167,Infliximab (Unknown),Osteopenia,OT
190505167,Infliximab (Unknown),Off label use,OT
190505167,Infliximab (Unknown),Obliterative bronchiolitis,OT
190505167,Infliximab (Unknown),Juvenile idiopathic arthritis,OT
190505167,Infliximab (Unknown),Joint effusion,OT
190505167,Infliximab (Unknown),Inflammation,OT
190505167,Infliximab (Unknown),Infection reactivation,OT
190505167,Infliximab (Unknown),Infection,OT
190505167,Infliximab (Unknown),Impaired quality of life,OT
190505167,Infliximab (Unknown),Immune thrombocytopenia,OT
190505167,Infliximab (Unknown),Ill-defined disorder,OT
190505167,Infliximab (Unknown),Hypothyroidism,OT
190505167,Infliximab (Unknown),Hypertension,OT
190505167,Infliximab (Unknown),Hyperplasia,OT
190505167,Infliximab (Unknown),Herpes zoster infection neurological,OT
190505167,Infliximab (Unknown),Herpes zoster,OT
190505167,Infliximab (Unknown),Hepatic cytolysis,OT
190505167,Infliximab (Unknown),Growth retardation,OT
190505167,Infliximab (Unknown),Graft versus host disease in skin,OT
190505167,Infliximab (Unknown),Graft versus host disease in gastrointestinal tract,OT
190505167,Infliximab (Unknown),Focal nodular hyperplasia,OT
190505167,Infliximab (Unknown),Drug resistance,OT
190505167,Infliximab (Unknown),Cushingoid,OT
190505167,Infliximab (Unknown),Condition aggravated,OT
190505167,Infliximab (Unknown),Clostridium difficile colitis,OT
190505167,Infliximab (Unknown),Cellulitis staphylococcal,OT
190505167,Infliximab (Unknown),C-reactive protein increased,OT
190505167,Infliximab (Unknown),Bacterial sepsis,OT
190505167,Infliximab (Unknown),Autoimmune thyroiditis,OT
190505167,Infliximab (Unknown),Arthralgia,OT
190505167,Infliximab (Unknown),Aplasia,OT
190505167,Infliximab (Unknown),Actinomycotic sepsis,OT
190505167,Infliximab (Unknown),Vitiligo,OT
190505167,Infliximab (Unknown),Varicella zoster virus infection,OT
190505167,Infliximab (Unknown),Toxicity to various agents,OT
190505167,Infliximab (Unknown),Thrombocytopenia,OT
190505167,Infliximab (Unknown),Superinfection bacterial,OT
190505167,Infliximab (Unknown),Still's disease,OT
190505167,Infliximab (Unknown),Secondary adrenocortical insufficiency,OT
190505167,Infliximab (Unknown),Red blood cell sedimentation rate increased,OT
190505167,Infliximab (Unknown),Pulmonary function test abnormal,OT
190505167,Infliximab (Unknown),Osteopenia,OT
190505167,Infliximab (Unknown),Off label use,OT
190505167,Infliximab (Unknown),Obliterative bronchiolitis,OT
190505167,Infliximab (Unknown),Juvenile idiopathic arthritis,OT
190505167,Infliximab (Unknown),Joint effusion,OT
190505167,Infliximab (Unknown),Inflammation,OT
190505167,Infliximab (Unknown),Infection reactivation,OT
190505167,Infliximab (Unknown),Infection,OT
190505167,Infliximab (Unknown),Impaired quality of life,OT
190505167,Infliximab (Unknown),Immune thrombocytopenia,OT
190505167,Infliximab (Unknown),Ill-defined disorder,OT
190505167,Infliximab (Unknown),Hypothyroidism,OT
190505167,Infliximab (Unknown),Hypertension,OT
190505167,Infliximab (Unknown),Hyperplasia,OT
190505167,Infliximab (Unknown),Herpes zoster infection neurological,OT
190505167,Infliximab (Unknown),Herpes zoster,OT
190505167,Infliximab (Unknown),Hepatic cytolysis,OT
190505167,Infliximab (Unknown),Growth retardation,OT
190505167,Infliximab (Unknown),Graft versus host disease in skin,OT
190505167,Infliximab (Unknown),Graft versus host disease in gastrointestinal tract,OT
190505167,Infliximab (Unknown),Focal nodular hyperplasia,OT
190505167,Infliximab (Unknown),Drug resistance,OT
190505167,Infliximab (Unknown),Cushingoid,OT
190505167,Infliximab (Unknown),Condition aggravated,OT
190505167,Infliximab (Unknown),Clostridium difficile colitis,OT
190505167,Infliximab (Unknown),Cellulitis staphylococcal,OT
190505167,Infliximab (Unknown),C-reactive protein increased,OT
190505167,Infliximab (Unknown),Bacterial sepsis,OT
190505167,Infliximab (Unknown),Autoimmune thyroiditis,OT
190505167,Infliximab (Unknown),Arthralgia,OT
190505167,Infliximab (Unknown),Aplasia,OT
190505167,Infliximab (Unknown),Actinomycotic sepsis,OT
190505167,Infliximab (Unknown),Vitiligo,OT
190505167,Infliximab (Unknown),Varicella zoster virus infection,OT
190505167,Infliximab (Unknown),Toxicity to various agents,OT
190505167,Infliximab (Unknown),Thrombocytopenia,OT
190505167,Infliximab (Unknown),Superinfection bacterial,OT
190505167,Infliximab (Unknown),Still's disease,OT
190505167,Infliximab (Unknown),Secondary adrenocortical insufficiency,OT
190505167,Infliximab (Unknown),Red blood cell sedimentation rate increased,OT
190505167,Infliximab (Unknown),Pulmonary function test abnormal,OT
190505167,Infliximab (Unknown),Osteopenia,OT
190505167,Infliximab (Unknown),Off label use,OT
190505167,Infliximab (Unknown),Obliterative bronchiolitis,OT
190505167,Infliximab (Unknown),Juvenile idiopathic arthritis,OT
190505167,Infliximab (Unknown),Joint effusion,OT
190505167,Infliximab (Unknown),Inflammation,OT
190505167,Infliximab (Unknown),Infection reactivation,OT
190505167,Infliximab (Unknown),Infection,OT
190505167,Infliximab (Unknown),Impaired quality of life,OT
190505167,Infliximab (Unknown),Immune thrombocytopenia,OT
190505167,Infliximab (Unknown),Ill-defined disorder,OT
190505167,Infliximab (Unknown),Hypothyroidism,OT
190505167,Infliximab (Unknown),Hypertension,OT
190505167,Infliximab (Unknown),Hyperplasia,OT
190505167,Infliximab (Unknown),Herpes zoster infection neurological,OT
190505167,Infliximab (Unknown),Herpes zoster,OT
190505167,Infliximab (Unknown),Hepatic cytolysis,OT
190505167,Infliximab (Unknown),Growth retardation,OT
190505167,Infliximab (Unknown),Graft versus host disease in skin,OT
190505167,Infliximab (Unknown),Graft versus host disease in gastrointestinal tract,OT
190505167,Infliximab (Unknown),Focal nodular hyperplasia,OT
190505167,Infliximab (Unknown),Drug resistance,OT
190505167,Infliximab (Unknown),Cushingoid,OT
190505167,Infliximab (Unknown),Condition aggravated,OT
190505167,Infliximab (Unknown),Clostridium difficile colitis,OT
190505167,Infliximab (Unknown),Cellulitis staphylococcal,OT
190505167,Infliximab (Unknown),C-reactive protein increased,OT
190505167,Infliximab (Unknown),Bacterial sepsis,OT
190505167,Infliximab (Unknown),Autoimmune thyroiditis,OT
190505167,Infliximab (Unknown),Arthralgia,OT
190505167,Infliximab (Unknown),Aplasia,OT
190505167,Infliximab (Unknown),Actinomycotic sepsis,OT
191408642,Infliximab,Weight increased,OT
191408642,Infliximab,Weight decreased,OT
191408642,Infliximab,Proctalgia,OT
191408642,Infliximab,Pain,OT
191408642,Infliximab,Off label use,OT
191408642,Infliximab,Muscle spasms,OT
191408642,Infliximab,Mucous stools,OT
191408642,Infliximab,Heart rate decreased,OT
191408642,Infliximab,Haematochezia,OT
191408642,Infliximab,General physical health deterioration,OT
191408642,Infliximab,Fatigue,OT
191408642,Infliximab,Drug ineffective,OT
191408642,Infliximab,Diarrhoea,OT
191408642,Infliximab,Decreased appetite,OT
191408642,Infliximab,Condition aggravated,OT
191408642,Infliximab,Back pain,OT
191408642,Infliximab,Arthralgia,OT
191408642,Infliximab,Aphthous ulcer,OT
191408642,Infliximab,Anxiety,OT
191408642,Infliximab,Anal ulcer,OT
191408642,Infliximab,Anal fissure,OT
191408642,Infliximab,Abdominal pain,OT
191621182,Infliximab,Psoriasis,OT
191621182,Infliximab,Migraine,OT
191621182,Infliximab,Hypertension,OT
191621182,Infliximab,Endometriosis,OT
191621182,Infliximab,Drug specific antibody,OT
191621182,Infliximab,Drug intolerance,OT
191621182,Infliximab,Drug ineffective,OT
191621182,Infliximab,Depression,OT
191621182,Infliximab,Chronic kidney disease,OT
191621182,Infliximab,Asthma,OT
191621182,Infliximab,Arthritis,OT
192016942,Infliximab,Weight increased,OT
192016942,Infliximab,Weight decreased,OT
192016942,Infliximab,Off label use,OT
192016942,Infliximab,Nasopharyngitis,OT
192016942,Infliximab,Inappropriate schedule of product administration,OT
192084122,Infliximab,Urinary tract infection,OT
192084122,Infliximab,Tinnitus,OT
192084122,Infliximab,Therapeutic response shortened,OT
192084122,Infliximab,Tension headache,OT
192084122,Infliximab,Skin cancer,OT
192084122,Infliximab,Rhinorrhoea,OT
192084122,Infliximab,Product use issue,OT
192084122,Infliximab,Pain of skin,OT
192084122,Infliximab,Oropharyngeal pain,OT
192084122,Infliximab,Off label use,OT
192084122,Infliximab,Nasopharyngitis,OT
192084122,Infliximab,Nasal discharge discolouration,OT
192084122,Infliximab,Intentional product use issue,OT
192084122,Infliximab,Heart rate irregular,OT
192084122,Infliximab,Heart rate decreased,OT
192084122,Infliximab,Headache,OT
192084122,Infliximab,Dysuria,OT
192084122,Infliximab,Drug level below therapeutic,OT
192084122,Infliximab,Cystitis,OT
192084122,Infliximab,Condition aggravated,OT
192084122,Infliximab,Blood pressure systolic increased,OT
192084122,Infliximab,Blood pressure increased,OT
192084122,Infliximab,Back pain,OT
192084122,Infliximab,Arthralgia,OT
192084122,Infliximab,Urinary tract infection,OT
192084122,Infliximab,Tinnitus,OT
192084122,Infliximab,Therapeutic response shortened,OT
192084122,Infliximab,Tension headache,OT
192084122,Infliximab,Skin cancer,OT
192084122,Infliximab,Rhinorrhoea,OT
192084122,Infliximab,Product use issue,OT
192084122,Infliximab,Pain of skin,OT
192084122,Infliximab,Oropharyngeal pain,OT
192084122,Infliximab,Off label use,OT
192084122,Infliximab,Nasopharyngitis,OT
192084122,Infliximab,Nasal discharge discolouration,OT
192084122,Infliximab,Intentional product use issue,OT
192084122,Infliximab,Heart rate irregular,OT
192084122,Infliximab,Heart rate decreased,OT
192084122,Infliximab,Headache,OT
192084122,Infliximab,Dysuria,OT
192084122,Infliximab,Drug level below therapeutic,OT
192084122,Infliximab,Cystitis,OT
192084122,Infliximab,Condition aggravated,OT
192084122,Infliximab,Blood pressure systolic increased,OT
192084122,Infliximab,Blood pressure increased,OT
192084122,Infliximab,Back pain,OT
192084122,Infliximab,Arthralgia,OT
192084122,Infliximab,Urinary tract infection,OT
192084122,Infliximab,Tinnitus,OT
192084122,Infliximab,Therapeutic response shortened,OT
192084122,Infliximab,Tension headache,OT
192084122,Infliximab,Skin cancer,OT
192084122,Infliximab,Rhinorrhoea,OT
192084122,Infliximab,Product use issue,OT
192084122,Infliximab,Pain of skin,OT
192084122,Infliximab,Oropharyngeal pain,OT
192084122,Infliximab,Off label use,OT
192084122,Infliximab,Nasopharyngitis,OT
192084122,Infliximab,Nasal discharge discolouration,OT
192084122,Infliximab,Intentional product use issue,OT
192084122,Infliximab,Heart rate irregular,OT
192084122,Infliximab,Heart rate decreased,OT
192084122,Infliximab,Headache,OT
192084122,Infliximab,Dysuria,OT
192084122,Infliximab,Drug level below therapeutic,OT
192084122,Infliximab,Cystitis,OT
192084122,Infliximab,Condition aggravated,OT
192084122,Infliximab,Blood pressure systolic increased,OT
192084122,Infliximab,Blood pressure increased,OT
192084122,Infliximab,Back pain,OT
192084122,Infliximab,Arthralgia,OT
192084122,Infliximab,Urinary tract infection,OT
192084122,Infliximab,Tinnitus,OT
192084122,Infliximab,Therapeutic response shortened,OT
192084122,Infliximab,Tension headache,OT
192084122,Infliximab,Skin cancer,OT
192084122,Infliximab,Rhinorrhoea,OT
192084122,Infliximab,Product use issue,OT
192084122,Infliximab,Pain of skin,OT
192084122,Infliximab,Oropharyngeal pain,OT
192084122,Infliximab,Off label use,OT
192084122,Infliximab,Nasopharyngitis,OT
192084122,Infliximab,Nasal discharge discolouration,OT
192084122,Infliximab,Intentional product use issue,OT
192084122,Infliximab,Heart rate irregular,OT
192084122,Infliximab,Heart rate decreased,OT
192084122,Infliximab,Headache,OT
192084122,Infliximab,Dysuria,OT
192084122,Infliximab,Drug level below therapeutic,OT
192084122,Infliximab,Cystitis,OT
192084122,Infliximab,Condition aggravated,OT
192084122,Infliximab,Blood pressure systolic increased,OT
192084122,Infliximab,Blood pressure increased,OT
192084122,Infliximab,Back pain,OT
192084122,Infliximab,Arthralgia,OT
192084122,Infliximab,Urinary tract infection,OT
192084122,Infliximab,Tinnitus,OT
192084122,Infliximab,Therapeutic response shortened,OT
192084122,Infliximab,Tension headache,OT
192084122,Infliximab,Skin cancer,OT
192084122,Infliximab,Rhinorrhoea,OT
192084122,Infliximab,Product use issue,OT
192084122,Infliximab,Pain of skin,OT
192084122,Infliximab,Oropharyngeal pain,OT
192084122,Infliximab,Off label use,OT
192084122,Infliximab,Nasopharyngitis,OT
192084122,Infliximab,Nasal discharge discolouration,OT
192084122,Infliximab,Intentional product use issue,OT
192084122,Infliximab,Heart rate irregular,OT
192084122,Infliximab,Heart rate decreased,OT
192084122,Infliximab,Headache,OT
192084122,Infliximab,Dysuria,OT
192084122,Infliximab,Drug level below therapeutic,OT
192084122,Infliximab,Cystitis,OT
192084122,Infliximab,Condition aggravated,OT
192084122,Infliximab,Blood pressure systolic increased,OT
192084122,Infliximab,Blood pressure increased,OT
192084122,Infliximab,Back pain,OT
192084122,Infliximab,Arthralgia,OT
192423902,Infliximab,Weight decreased,HO
192423902,Infliximab,Product use issue,HO
192423902,Infliximab,Off label use,HO
192423902,Infliximab,Intentional product use issue,HO
192423902,Infliximab,Inappropriate schedule of product administration,HO
192423902,Infliximab,Diabetic ketoacidosis,HO
192423902,Infliximab,Condition aggravated,HO
192423902,Infliximab,Arthralgia,HO
192423902,Infliximab,Acute myocardial infarction,HO
192788606,Infliximab,Psoriasis,HO
192788606,Infliximab,Lymphadenopathy,HO
192788606,Infliximab,Ear swelling,HO
192920632,Infliximab,Pain in extremity,OT
192920632,Infliximab,Pain,OT
192920632,Infliximab,Infusion site swelling,OT
192920632,Infliximab,Infusion site pain,OT
192920632,Infliximab,Infusion site discolouration,OT
192920632,Infliximab,Infusion related reaction,OT
192920632,Infliximab,Condition aggravated,OT
192920632,Infliximab,Body temperature decreased,OT
192920632,Infliximab,Arthralgia,OT
194732802,Infliximab,Off label use,OT
194732802,Infliximab,Intentional product use issue,OT
194732802,Infliximab,Insomnia,OT
194732802,Infliximab,Herpes zoster,OT
194732802,Infliximab,Blood pressure increased,OT
194732802,Infliximab,Blood pressure fluctuation,OT
194732802,Infliximab,Back pain,OT
194732802,Infliximab,Arthralgia,OT
194732802,Infliximab,Anxiety,OT
194732802,Infliximab,Abdominal pain upper,OT
194732802,Infliximab,Off label use,OT
194732802,Infliximab,Intentional product use issue,OT
194732802,Infliximab,Insomnia,OT
194732802,Infliximab,Herpes zoster,OT
194732802,Infliximab,Blood pressure increased,OT
194732802,Infliximab,Blood pressure fluctuation,OT
194732802,Infliximab,Back pain,OT
194732802,Infliximab,Arthralgia,OT
194732802,Infliximab,Anxiety,OT
194732802,Infliximab,Abdominal pain upper,OT
194850471,Infliximab (Unknown),Therapy change,OT
194850471,Infliximab (Unknown),Therapy change,HO
194850471,Infliximab (Unknown),Takayasu's arteritis,OT
194850471,Infliximab (Unknown),Takayasu's arteritis,HO
194850471,Infliximab (Unknown),Pyrexia,OT
194850471,Infliximab (Unknown),Pyrexia,HO
194850471,Infliximab (Unknown),Pleural effusion,OT
194850471,Infliximab (Unknown),Pleural effusion,HO
194850471,Infliximab (Unknown),Malaise,OT
194850471,Infliximab (Unknown),Malaise,HO
194850471,Infliximab (Unknown),Dermatitis psoriasiform,OT
194850471,Infliximab (Unknown),Dermatitis psoriasiform,HO
194850471,Infliximab (Unknown),Abdominal pain,OT
194850471,Infliximab (Unknown),Abdominal pain,HO
195572001,Infliximab,Maternal exposure during pregnancy,OT
195572001,Infliximab,Infusion related reaction,OT
196017363,Infliximab,Gastrointestinal infection,HO
196526491,Infliximab,Weight increased,OT
196526491,Infliximab,Product use issue,OT
196526491,Infliximab,Headache,OT
196526491,Infliximab,Dizziness,OT
196690791,Infliximab,Weight increased,OT
196690791,Infliximab,Product use issue,OT
196690791,Infliximab,Off label use,OT
196690791,Infliximab,Intentional product use issue,OT
196690791,Infliximab,Heart rate irregular,OT
196690791,Infliximab,Blood pressure fluctuation,OT
196811151,Infliximab,Off label use,OT
196811151,Infliximab,Intentional product use issue,OT
196811151,Infliximab,Cataract,OT
196811151,Infliximab,Blood pressure increased,OT
197166311,Infliximab,Off label use,OT
197166311,Infliximab,Intentional product use issue,OT
197166311,Infliximab,Cataract,OT
197417961,Infliximab,Off label use,OT
197417961,Infliximab,Arthropathy,OT
197749781,Infliximab,Therapy partial responder,OT
197749781,Infliximab,Gastrointestinal disorder,OT
197749781,Infliximab,Drug ineffective,OT
197869421,Infliximab,Product use issue,OT
197869421,Infliximab,Pain in extremity,OT
197869421,Infliximab,Off label use,OT
197869421,Infliximab,Muscle contractions involuntary,OT
197869421,Infliximab,Movement disorder,OT
197869421,Infliximab,Influenza,OT
197869421,Infliximab,Heart rate irregular,OT
197869421,Infliximab,Headache,OT
197869421,Infliximab,Gait inability,OT
197869421,Infliximab,Feeling cold,OT
197869421,Infliximab,Condition aggravated,OT
197869421,Infliximab,Chills,OT
197869421,Infliximab,Arthralgia,OT
197869421,Infliximab,Abdominal pain,OT
197936981,Infliximab,Tubulointerstitial nephritis,HO
197936981,Infliximab,Product use in unapproved indication,HO
198196411,Infliximab,Therapy non-responder,OT
198196411,Infliximab,Steroid diabetes,OT
198213311,Infliximab,Dyspnoea,DE
198213311,Infliximab,Dyspnoea,OT
198213311,Infliximab,Dyspnoea,HO
198213311,Infliximab,Death,DE
198213311,Infliximab,Death,OT
198213311,Infliximab,Death,HO
198213311,Infliximab,Abdominal pain,DE
198213311,Infliximab,Abdominal pain,OT
198213311,Infliximab,Abdominal pain,HO
198298091,Infliximab,Uveitis,OT
198298091,Infliximab,Off label use,OT
198298091,Infliximab,Intentional product use issue,OT
198298091,Infliximab,Incorrect dose administered,OT
198371441,Infliximab,Vasculitis,HO
198371441,Infliximab,Tubulointerstitial nephritis,HO
198371441,Infliximab,Paradoxical psoriasis,HO
198371441,Infliximab,Glomerulonephritis,HO
198469821,Infliximab,Therapy non-responder,OT
198469821,Infliximab,Off label use,OT
198476191,Infliximab,Weight increased,OT
198476191,Infliximab,Skin laceration,OT
198476191,Infliximab,Pain in extremity,OT
198476191,Infliximab,Oral herpes,OT
198476191,Infliximab,Nausea,OT
198476191,Infliximab,Muscle spasms,OT
198476191,Infliximab,Mouth ulceration,OT
198476191,Infliximab,Malaise,OT
198476191,Infliximab,Infusion related reaction,OT
198476191,Infliximab,Hot flush,OT
198476191,Infliximab,Heart rate abnormal,OT
198476191,Infliximab,Gait disturbance,OT
198476191,Infliximab,Erythema,OT
198476191,Infliximab,Dyspnoea,OT
198476191,Infliximab,Discomfort,OT
198476191,Infliximab,Condition aggravated,OT
198476191,Infliximab,Chest pain,OT
198476191,Infliximab,Chest discomfort,OT
198476191,Infliximab,Blood pressure fluctuation,OT
198476191,Infliximab,Back pain,OT
198476191,Infliximab,Arthralgia,OT
198643651,Infliximab,Off label use,OT
198643651,Infliximab,Off label use,DE
198643651,Infliximab,Fall,OT
198643651,Infliximab,Fall,DE
198643651,Infliximab,Death,OT
198643651,Infliximab,Death,DE
198785351,Infliximab (Unknown),Off label use,NULL
198785351,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198802121,Infliximab,Sepsis,DE
198802121,Infliximab,Off label use,DE
198996421,Infliximab,Weight increased,OT
198996421,Infliximab,Weight decreased,OT
198996421,Infliximab,Off label use,OT
198996421,Infliximab,Fatigue,OT
198996421,Infliximab,Diarrhoea,OT
198996421,Infliximab,Condition aggravated,OT
198996421,Infliximab,Blood pressure increased,OT
198996421,Infliximab,Arthralgia,OT
160704054,Infliximab,Weight increased,OT
160704054,Infliximab,Weight decreased,OT
160704054,Infliximab,Product use issue,OT
160704054,Infliximab,Pollakiuria,OT
160704054,Infliximab,Off label use,OT
160704054,Infliximab,Measles,OT
160704054,Infliximab,Influenza,OT
160704054,Infliximab,Inappropriate schedule of product administration,OT
160704054,Infliximab,Dysuria,OT
160704054,Infliximab,Disease recurrence,OT
160704054,Infliximab,Weight increased,OT
160704054,Infliximab,Weight decreased,OT
160704054,Infliximab,Product use issue,OT
160704054,Infliximab,Pollakiuria,OT
160704054,Infliximab,Off label use,OT
160704054,Infliximab,Measles,OT
160704054,Infliximab,Influenza,OT
160704054,Infliximab,Inappropriate schedule of product administration,OT
160704054,Infliximab,Dysuria,OT
160704054,Infliximab,Disease recurrence,OT
160798662,Infliximab,Weight decreased,OT
160798662,Infliximab,Weight decreased,HO
160798662,Infliximab,Pyrexia,OT
160798662,Infliximab,Pyrexia,HO
160798662,Infliximab,Infusion related reaction,OT
160798662,Infliximab,Infusion related reaction,HO
160798662,Infliximab,Heart rate irregular,OT
160798662,Infliximab,Heart rate irregular,HO
160798662,Infliximab,Erythema,OT
160798662,Infliximab,Erythema,HO
160798662,Infliximab,Dizziness,OT
160798662,Infliximab,Dizziness,HO
160798662,Infliximab,Blood pressure fluctuation,OT
160798662,Infliximab,Blood pressure fluctuation,HO
164449343,Infliximab,Pancreatitis,OT
164449343,Infliximab,Drug intolerance,OT
164449343,Infliximab,Pancreatitis,OT
164449343,Infliximab,Drug intolerance,OT
166917744,Infliximab,Weight increased,OT
166917744,Infliximab,Weight increased,HO
166917744,Infliximab,Weight decreased,OT
166917744,Infliximab,Weight decreased,HO
166917744,Infliximab,Transient ischaemic attack,OT
166917744,Infliximab,Transient ischaemic attack,HO
166917744,Infliximab,Tendonitis,OT
166917744,Infliximab,Tendonitis,HO
166917744,Infliximab,Spinal stenosis,OT
166917744,Infliximab,Spinal stenosis,HO
166917744,Infliximab,Poor quality sleep,OT
166917744,Infliximab,Poor quality sleep,HO
166917744,Infliximab,Periarthritis,OT
166917744,Infliximab,Periarthritis,HO
166917744,Infliximab,Pain in extremity,OT
166917744,Infliximab,Pain in extremity,HO
166917744,Infliximab,Off label use,OT
166917744,Infliximab,Off label use,HO
166917744,Infliximab,Myocardial infarction,OT
166917744,Infliximab,Myocardial infarction,HO
166917744,Infliximab,Mobility decreased,OT
166917744,Infliximab,Mobility decreased,HO
166917744,Infliximab,Lung disorder,OT
166917744,Infliximab,Lung disorder,HO
166917744,Infliximab,Insomnia,OT
166917744,Infliximab,Insomnia,HO
166917744,Infliximab,Incorrect dose administered,OT
166917744,Infliximab,Incorrect dose administered,HO
166917744,Infliximab,Hypotension,OT
166917744,Infliximab,Hypotension,HO
166917744,Infliximab,Hemiplegia,OT
166917744,Infliximab,Hemiplegia,HO
166917744,Infliximab,Heart rate irregular,OT
166917744,Infliximab,Heart rate irregular,HO
166917744,Infliximab,Haematochezia,OT
166917744,Infliximab,Haematochezia,HO
166917744,Infliximab,Gastroenteritis,OT
166917744,Infliximab,Gastroenteritis,HO
166917744,Infliximab,Fatigue,OT
166917744,Infliximab,Fatigue,HO
166917744,Infliximab,Faecal calprotectin increased,OT
166917744,Infliximab,Faecal calprotectin increased,HO
166917744,Infliximab,Drug level decreased,OT
166917744,Infliximab,Drug level decreased,HO
166917744,Infliximab,Dizziness,OT
166917744,Infliximab,Dizziness,HO
166917744,Infliximab,Diabetes mellitus,OT
166917744,Infliximab,Diabetes mellitus,HO
166917744,Infliximab,Condition aggravated,OT
166917744,Infliximab,Condition aggravated,HO
166917744,Infliximab,Cerebrovascular accident,OT
166917744,Infliximab,Cerebrovascular accident,HO
166917744,Infliximab,Bursitis,OT
166917744,Infliximab,Bursitis,HO
166917744,Infliximab,Blood pressure fluctuation,OT
166917744,Infliximab,Blood pressure fluctuation,HO
166917744,Infliximab,Asthma,OT
166917744,Infliximab,Asthma,HO
166917744,Infliximab,Arthralgia,OT
166917744,Infliximab,Arthralgia,HO
166917744,Infliximab,Aphasia,OT
166917744,Infliximab,Aphasia,HO
166917744,Infliximab,Angina pectoris,OT
166917744,Infliximab,Angina pectoris,HO
166917744,Infliximab,Abdominal pain,OT
166917744,Infliximab,Abdominal pain,HO
166917744,Infliximab,Sensory loss,OT
166917744,Infliximab,Sensory loss,HO
166917744,Infliximab,Weight increased,OT
166917744,Infliximab,Weight increased,HO
166917744,Infliximab,Weight decreased,OT
166917744,Infliximab,Weight decreased,HO
166917744,Infliximab,Transient ischaemic attack,OT
166917744,Infliximab,Transient ischaemic attack,HO
166917744,Infliximab,Tendonitis,OT
166917744,Infliximab,Tendonitis,HO
166917744,Infliximab,Spinal stenosis,OT
166917744,Infliximab,Spinal stenosis,HO
166917744,Infliximab,Poor quality sleep,OT
166917744,Infliximab,Poor quality sleep,HO
166917744,Infliximab,Periarthritis,OT
166917744,Infliximab,Periarthritis,HO
166917744,Infliximab,Pain in extremity,OT
166917744,Infliximab,Pain in extremity,HO
166917744,Infliximab,Off label use,OT
166917744,Infliximab,Off label use,HO
166917744,Infliximab,Myocardial infarction,OT
166917744,Infliximab,Myocardial infarction,HO
166917744,Infliximab,Mobility decreased,OT
166917744,Infliximab,Mobility decreased,HO
166917744,Infliximab,Lung disorder,OT
166917744,Infliximab,Lung disorder,HO
166917744,Infliximab,Insomnia,OT
166917744,Infliximab,Insomnia,HO
166917744,Infliximab,Incorrect dose administered,OT
166917744,Infliximab,Incorrect dose administered,HO
166917744,Infliximab,Hypotension,OT
166917744,Infliximab,Hypotension,HO
166917744,Infliximab,Hemiplegia,OT
166917744,Infliximab,Hemiplegia,HO
166917744,Infliximab,Heart rate irregular,OT
166917744,Infliximab,Heart rate irregular,HO
166917744,Infliximab,Haematochezia,OT
166917744,Infliximab,Haematochezia,HO
166917744,Infliximab,Gastroenteritis,OT
166917744,Infliximab,Gastroenteritis,HO
166917744,Infliximab,Fatigue,OT
166917744,Infliximab,Fatigue,HO
166917744,Infliximab,Faecal calprotectin increased,OT
166917744,Infliximab,Faecal calprotectin increased,HO
166917744,Infliximab,Drug level decreased,OT
166917744,Infliximab,Drug level decreased,HO
166917744,Infliximab,Dizziness,OT
166917744,Infliximab,Dizziness,HO
166917744,Infliximab,Diabetes mellitus,OT
166917744,Infliximab,Diabetes mellitus,HO
166917744,Infliximab,Condition aggravated,OT
166917744,Infliximab,Condition aggravated,HO
166917744,Infliximab,Cerebrovascular accident,OT
166917744,Infliximab,Cerebrovascular accident,HO
166917744,Infliximab,Bursitis,OT
166917744,Infliximab,Bursitis,HO
166917744,Infliximab,Blood pressure fluctuation,OT
166917744,Infliximab,Blood pressure fluctuation,HO
166917744,Infliximab,Asthma,OT
166917744,Infliximab,Asthma,HO
166917744,Infliximab,Arthralgia,OT
166917744,Infliximab,Arthralgia,HO
166917744,Infliximab,Aphasia,OT
166917744,Infliximab,Aphasia,HO
166917744,Infliximab,Angina pectoris,OT
166917744,Infliximab,Angina pectoris,HO
166917744,Infliximab,Abdominal pain,OT
166917744,Infliximab,Abdominal pain,HO
166917744,Infliximab,Sensory loss,OT
166917744,Infliximab,Sensory loss,HO
166917744,Infliximab,Weight increased,OT
166917744,Infliximab,Weight increased,HO
166917744,Infliximab,Weight decreased,OT
166917744,Infliximab,Weight decreased,HO
166917744,Infliximab,Transient ischaemic attack,OT
166917744,Infliximab,Transient ischaemic attack,HO
166917744,Infliximab,Tendonitis,OT
166917744,Infliximab,Tendonitis,HO
166917744,Infliximab,Spinal stenosis,OT
166917744,Infliximab,Spinal stenosis,HO
166917744,Infliximab,Poor quality sleep,OT
166917744,Infliximab,Poor quality sleep,HO
166917744,Infliximab,Periarthritis,OT
166917744,Infliximab,Periarthritis,HO
166917744,Infliximab,Pain in extremity,OT
166917744,Infliximab,Pain in extremity,HO
166917744,Infliximab,Off label use,OT
166917744,Infliximab,Off label use,HO
166917744,Infliximab,Myocardial infarction,OT
166917744,Infliximab,Myocardial infarction,HO
166917744,Infliximab,Mobility decreased,OT
166917744,Infliximab,Mobility decreased,HO
166917744,Infliximab,Lung disorder,OT
166917744,Infliximab,Lung disorder,HO
166917744,Infliximab,Insomnia,OT
166917744,Infliximab,Insomnia,HO
166917744,Infliximab,Incorrect dose administered,OT
166917744,Infliximab,Incorrect dose administered,HO
166917744,Infliximab,Hypotension,OT
166917744,Infliximab,Hypotension,HO
166917744,Infliximab,Hemiplegia,OT
166917744,Infliximab,Hemiplegia,HO
166917744,Infliximab,Heart rate irregular,OT
166917744,Infliximab,Heart rate irregular,HO
166917744,Infliximab,Haematochezia,OT
166917744,Infliximab,Haematochezia,HO
166917744,Infliximab,Gastroenteritis,OT
166917744,Infliximab,Gastroenteritis,HO
166917744,Infliximab,Fatigue,OT
166917744,Infliximab,Fatigue,HO
166917744,Infliximab,Faecal calprotectin increased,OT
166917744,Infliximab,Faecal calprotectin increased,HO
166917744,Infliximab,Drug level decreased,OT
166917744,Infliximab,Drug level decreased,HO
166917744,Infliximab,Dizziness,OT
166917744,Infliximab,Dizziness,HO
166917744,Infliximab,Diabetes mellitus,OT
166917744,Infliximab,Diabetes mellitus,HO
166917744,Infliximab,Condition aggravated,OT
166917744,Infliximab,Condition aggravated,HO
166917744,Infliximab,Cerebrovascular accident,OT
166917744,Infliximab,Cerebrovascular accident,HO
166917744,Infliximab,Bursitis,OT
166917744,Infliximab,Bursitis,HO
166917744,Infliximab,Blood pressure fluctuation,OT
166917744,Infliximab,Blood pressure fluctuation,HO
166917744,Infliximab,Asthma,OT
166917744,Infliximab,Asthma,HO
166917744,Infliximab,Arthralgia,OT
166917744,Infliximab,Arthralgia,HO
166917744,Infliximab,Aphasia,OT
166917744,Infliximab,Aphasia,HO
166917744,Infliximab,Angina pectoris,OT
166917744,Infliximab,Angina pectoris,HO
166917744,Infliximab,Abdominal pain,OT
166917744,Infliximab,Abdominal pain,HO
166917744,Infliximab,Sensory loss,OT
166917744,Infliximab,Sensory loss,HO
171022253,Infliximab,Wheezing,OT
171022253,Infliximab,Weight increased,OT
171022253,Infliximab,Weight decreased,OT
171022253,Infliximab,Sputum purulent,OT
171022253,Infliximab,Respiratory tract infection,OT
171022253,Infliximab,Product use issue,OT
171022253,Infliximab,Otorrhoea,OT
171022253,Infliximab,Off label use,OT
171022253,Infliximab,Nasopharyngitis,OT
171022253,Infliximab,Nasal congestion,OT
171022253,Infliximab,Intentional product use issue,OT
171022253,Infliximab,Inappropriate schedule of product administration,OT
171022253,Infliximab,Ear infection,OT
171022253,Infliximab,Condition aggravated,OT
171022253,Infliximab,Asthenia,OT
173198366,Infliximab,Yellow skin,OT
173198366,Infliximab,Uveitis,OT
173198366,Infliximab,Skin plaque,OT
173198366,Infliximab,Rash pruritic,OT
173198366,Infliximab,Pharyngeal erythema,OT
173198366,Infliximab,Oropharyngeal pain,OT
173198366,Infliximab,Off label use,OT
173198366,Infliximab,Nasopharyngitis,OT
173198366,Infliximab,Musculoskeletal stiffness,OT
173198366,Infliximab,Malaise,OT
173198366,Infliximab,Joint stiffness,OT
173198366,Infliximab,Intentional product use issue,OT
173198366,Infliximab,Inappropriate schedule of product administration,OT
173198366,Infliximab,Illness,OT
173198366,Infliximab,Hot flush,OT
173198366,Infliximab,Heart rate irregular,OT
173198366,Infliximab,Heart rate increased,OT
173198366,Infliximab,Erythema nodosum,OT
173198366,Infliximab,Cough,OT
173198366,Infliximab,Conjunctivitis,OT
173198366,Infliximab,Condition aggravated,OT
173198366,Infliximab,Blood pressure increased,OT
173198366,Infliximab,Blood pressure fluctuation,OT
173198366,Infliximab,Arthritis,OT
173198366,Infliximab,Arthralgia,OT
173198366,Infliximab,Application site erythema,OT
173198366,Infliximab,Aphthous ulcer,OT
173198366,Infliximab,Administration site discolouration,OT
173198366,Infliximab,Acne,OT
173937125,Infliximab,Product use issue,OT
173937125,Infliximab,Poor venous access,OT
173937125,Infliximab,Off label use,OT
173937125,Infliximab,Intentional product use issue,OT
173937125,Infliximab,Incorrect dose administered,OT
173937125,Infliximab,Inappropriate schedule of product administration,OT
173937125,Infliximab,Hypersensitivity,OT
173937125,Infliximab,Herpes zoster,OT
173937125,Infliximab,Haemorrhage,OT
173937125,Infliximab,Feeling hot,OT
173937125,Infliximab,Erythema,OT
173937125,Infliximab,Drug level below therapeutic,OT
173937125,Infliximab,Diarrhoea,OT
173937125,Infliximab,Dehydration,OT
173937125,Infliximab,Product use issue,OT
173937125,Infliximab,Poor venous access,OT
173937125,Infliximab,Off label use,OT
173937125,Infliximab,Intentional product use issue,OT
173937125,Infliximab,Incorrect dose administered,OT
173937125,Infliximab,Inappropriate schedule of product administration,OT
173937125,Infliximab,Hypersensitivity,OT
173937125,Infliximab,Herpes zoster,OT
173937125,Infliximab,Haemorrhage,OT
173937125,Infliximab,Feeling hot,OT
173937125,Infliximab,Erythema,OT
173937125,Infliximab,Drug level below therapeutic,OT
173937125,Infliximab,Diarrhoea,OT
173937125,Infliximab,Dehydration,OT
174804352,Infliximab,Pyrexia,OT
174804352,Infliximab,Oropharyngeal pain,OT
174804352,Infliximab,Off label use,OT
174804352,Infliximab,Nephrolithiasis,OT
174804352,Infliximab,Nausea,OT
174804352,Infliximab,Malaise,OT
174804352,Infliximab,Heart rate irregular,OT
174804352,Infliximab,Drug level decreased,OT
174804352,Infliximab,Cough,OT
174804352,Infliximab,Chills,OT
174804352,Infliximab,Pyrexia,OT
174804352,Infliximab,Oropharyngeal pain,OT
174804352,Infliximab,Off label use,OT
174804352,Infliximab,Nephrolithiasis,OT
174804352,Infliximab,Nausea,OT
174804352,Infliximab,Malaise,OT
174804352,Infliximab,Heart rate irregular,OT
174804352,Infliximab,Drug level decreased,OT
174804352,Infliximab,Cough,OT
174804352,Infliximab,Chills,OT
175974486,Infliximab,Product administered at inappropriate site,OT
175974486,Infliximab,Pain,OT
175974486,Infliximab,Off label use,OT
175974486,Infliximab,Malaise,OT
175974486,Infliximab,Lower respiratory tract infection,OT
175974486,Infliximab,Loss of consciousness,OT
175974486,Infliximab,Lethargy,OT
175974486,Infliximab,Lacrimation increased,OT
175974486,Infliximab,Intentional product use issue,OT
175974486,Infliximab,Hyperhidrosis,OT
175974486,Infliximab,Heart rate irregular,OT
175974486,Infliximab,Fatigue,OT
175974486,Infliximab,Faecal calprotectin increased,OT
175974486,Infliximab,Contusion,OT
175974486,Infliximab,Body temperature fluctuation,OT
175974486,Infliximab,Blood pressure fluctuation,OT
176003074,Infliximab,Spinal osteoarthritis,OT
176003074,Infliximab,Pyrexia,OT
176003074,Infliximab,Pelvic discomfort,OT
176003074,Infliximab,Neoplasm malignant,OT
176003074,Infliximab,Heart rate decreased,OT
176003074,Infliximab,Enteritis,OT
176003074,Infliximab,Condition aggravated,OT
176003074,Infliximab,Chest discomfort,OT
176003074,Infliximab,Blood pressure increased,OT
176003074,Infliximab,Blood pressure fluctuation,OT
176003074,Infliximab,Arthralgia,OT
176003074,Infliximab,Anxiety disorder,OT
176003074,Infliximab,Abdominal pain upper,OT
176006475,Infliximab,Skin infection,OT
176006475,Infliximab,Sinus pain,OT
176006475,Infliximab,Rhinorrhoea,OT
176006475,Infliximab,Oropharyngeal pain,OT
176006475,Infliximab,Off label use,OT
176006475,Infliximab,Nasopharyngitis,OT
176006475,Infliximab,Nasal congestion,OT
176006475,Infliximab,Inflammatory marker increased,OT
176006475,Infliximab,Heart rate irregular,OT
176006475,Infliximab,Headache,OT
176006475,Infliximab,Fatigue,OT
176006475,Infliximab,Erythema,OT
176006475,Infliximab,Dermatitis,OT
176006475,Infliximab,Condition aggravated,OT
176006475,Infliximab,Cellulitis,OT
176006475,Infliximab,Body temperature fluctuation,OT
176006475,Infliximab,Body temperature decreased,OT
176006475,Infliximab,Blood pressure increased,OT
176006475,Infliximab,Blood pressure fluctuation,OT
176006475,Infliximab,Skin infection,OT
176006475,Infliximab,Sinus pain,OT
176006475,Infliximab,Rhinorrhoea,OT
176006475,Infliximab,Oropharyngeal pain,OT
176006475,Infliximab,Off label use,OT
176006475,Infliximab,Nasopharyngitis,OT
176006475,Infliximab,Nasal congestion,OT
176006475,Infliximab,Inflammatory marker increased,OT
176006475,Infliximab,Heart rate irregular,OT
176006475,Infliximab,Headache,OT
176006475,Infliximab,Fatigue,OT
176006475,Infliximab,Erythema,OT
176006475,Infliximab,Dermatitis,OT
176006475,Infliximab,Condition aggravated,OT
176006475,Infliximab,Cellulitis,OT
176006475,Infliximab,Body temperature fluctuation,OT
176006475,Infliximab,Body temperature decreased,OT
176006475,Infliximab,Blood pressure increased,OT
176006475,Infliximab,Blood pressure fluctuation,OT
176530003,Infliximab,Weight increased,OT
176530003,Infliximab,Weight decreased,OT
176530003,Infliximab,Therapeutic response shortened,OT
176530003,Infliximab,Pruritus,OT
176530003,Infliximab,Poor venous access,OT
176530003,Infliximab,Pain,OT
176530003,Infliximab,Oxygen saturation abnormal,OT
176530003,Infliximab,Off label use,OT
176530003,Infliximab,Malaise,OT
176530003,Infliximab,Fatigue,OT
176530003,Infliximab,Condition aggravated,OT
176530003,Infliximab,Asthenia,OT
176530003,Infliximab,Arthralgia,OT
176530003,Infliximab,Weight increased,OT
176530003,Infliximab,Weight decreased,OT
176530003,Infliximab,Therapeutic response shortened,OT
176530003,Infliximab,Pruritus,OT
176530003,Infliximab,Poor venous access,OT
176530003,Infliximab,Pain,OT
176530003,Infliximab,Oxygen saturation abnormal,OT
176530003,Infliximab,Off label use,OT
176530003,Infliximab,Malaise,OT
176530003,Infliximab,Fatigue,OT
176530003,Infliximab,Condition aggravated,OT
176530003,Infliximab,Asthenia,OT
176530003,Infliximab,Arthralgia,OT
176847932,Infliximab,Urinary tract infection,HO
176847932,Infliximab,Urinary tract infection,OT
176847932,Infliximab,Traumatic lung injury,HO
176847932,Infliximab,Traumatic lung injury,OT
176847932,Infliximab,Rib fracture,HO
176847932,Infliximab,Rib fracture,OT
176847932,Infliximab,Proteinuria,HO
176847932,Infliximab,Proteinuria,OT
176847932,Infliximab,Protein urine present,HO
176847932,Infliximab,Protein urine present,OT
176847932,Infliximab,Penile pain,HO
176847932,Infliximab,Penile pain,OT
176847932,Infliximab,Nausea,HO
176847932,Infliximab,Nausea,OT
176847932,Infliximab,Hypersomnia,HO
176847932,Infliximab,Hypersomnia,OT
176847932,Infliximab,Headache,HO
176847932,Infliximab,Headache,OT
176847932,Infliximab,Fall,HO
176847932,Infliximab,Fall,OT
176847932,Infliximab,Defaecation urgency,HO
176847932,Infliximab,Defaecation urgency,OT
176847932,Infliximab,Constipation,HO
176847932,Infliximab,Constipation,OT
176847932,Infliximab,Condition aggravated,HO
176847932,Infliximab,Condition aggravated,OT
176847932,Infliximab,Catheter site pain,HO
176847932,Infliximab,Catheter site pain,OT
176847932,Infliximab,Ankylosing spondylitis,HO
176847932,Infliximab,Ankylosing spondylitis,OT
177004403,Infliximab,Weight increased,OT
177004403,Infliximab,Weight decreased,OT
177004403,Infliximab,Pyrexia,OT
177004403,Infliximab,Pharyngitis streptococcal,OT
177004403,Infliximab,Off label use,OT
177004403,Infliximab,Nervousness,OT
177004403,Infliximab,Nasopharyngitis,OT
177004403,Infliximab,Muscle rupture,OT
177004403,Infliximab,Malaise,OT
177004403,Infliximab,Lip blister,OT
177004403,Infliximab,Intentional product use issue,OT
177004403,Infliximab,Infection,OT
177004403,Infliximab,Incorrect dose administered,OT
177004403,Infliximab,Inappropriate schedule of product administration,OT
177004403,Infliximab,Haematochezia,OT
177004403,Infliximab,Feeling hot,OT
177004403,Infliximab,Dyspnoea,OT
177004403,Infliximab,Decreased immune responsiveness,OT
177004403,Infliximab,Condition aggravated,OT
177004403,Infliximab,Blood pressure fluctuation,OT
177004403,Infliximab,Arthralgia,OT
177004403,Infliximab,Abdominal pain lower,OT
177303184,Infliximab,Weight decreased,HO
177303184,Infliximab,Weight decreased,OT
177303184,Infliximab,Staphylococcal infection,HO
177303184,Infliximab,Staphylococcal infection,OT
177303184,Infliximab,Pyrexia,HO
177303184,Infliximab,Pyrexia,OT
177303184,Infliximab,Poor venous access,HO
177303184,Infliximab,Poor venous access,OT
177303184,Infliximab,Off label use,HO
177303184,Infliximab,Off label use,OT
177303184,Infliximab,Malaise,HO
177303184,Infliximab,Malaise,OT
177303184,Infliximab,Iron deficiency anaemia,HO
177303184,Infliximab,Iron deficiency anaemia,OT
177303184,Infliximab,Inappropriate schedule of product administration,HO
177303184,Infliximab,Inappropriate schedule of product administration,OT
177303184,Infliximab,Immune system disorder,HO
177303184,Infliximab,Immune system disorder,OT
177303184,Infliximab,Drug level below therapeutic,HO
177303184,Infliximab,Drug level below therapeutic,OT
177303184,Infliximab,Drug ineffective,HO
177303184,Infliximab,Drug ineffective,OT
177303184,Infliximab,Diarrhoea,HO
177303184,Infliximab,Diarrhoea,OT
177303184,Infliximab,Decreased immune responsiveness,HO
177303184,Infliximab,Decreased immune responsiveness,OT
177303184,Infliximab,Condition aggravated,HO
177303184,Infliximab,Condition aggravated,OT
177303184,Infliximab,Blood pressure fluctuation,HO
177303184,Infliximab,Blood pressure fluctuation,OT
177303184,Infliximab,Anal fissure,HO
177303184,Infliximab,Anal fissure,OT
177303184,Infliximab,Anal abscess,HO
177303184,Infliximab,Anal abscess,OT
177303184,Infliximab,Abscess,HO
177303184,Infliximab,Abscess,OT
177303184,Infliximab,Abdominal pain,HO
177303184,Infliximab,Abdominal pain,OT
177303184,Infliximab,Weight decreased,HO
177303184,Infliximab,Weight decreased,OT
177303184,Infliximab,Staphylococcal infection,HO
177303184,Infliximab,Staphylococcal infection,OT
177303184,Infliximab,Pyrexia,HO
177303184,Infliximab,Pyrexia,OT
177303184,Infliximab,Poor venous access,HO
177303184,Infliximab,Poor venous access,OT
177303184,Infliximab,Off label use,HO
177303184,Infliximab,Off label use,OT
177303184,Infliximab,Malaise,HO
177303184,Infliximab,Malaise,OT
177303184,Infliximab,Iron deficiency anaemia,HO
177303184,Infliximab,Iron deficiency anaemia,OT
177303184,Infliximab,Inappropriate schedule of product administration,HO
177303184,Infliximab,Inappropriate schedule of product administration,OT
177303184,Infliximab,Immune system disorder,HO
177303184,Infliximab,Immune system disorder,OT
177303184,Infliximab,Drug level below therapeutic,HO
177303184,Infliximab,Drug level below therapeutic,OT
177303184,Infliximab,Drug ineffective,HO
177303184,Infliximab,Drug ineffective,OT
177303184,Infliximab,Diarrhoea,HO
177303184,Infliximab,Diarrhoea,OT
177303184,Infliximab,Decreased immune responsiveness,HO
177303184,Infliximab,Decreased immune responsiveness,OT
177303184,Infliximab,Condition aggravated,HO
177303184,Infliximab,Condition aggravated,OT
177303184,Infliximab,Blood pressure fluctuation,HO
177303184,Infliximab,Blood pressure fluctuation,OT
177303184,Infliximab,Anal fissure,HO
177303184,Infliximab,Anal fissure,OT
177303184,Infliximab,Anal abscess,HO
177303184,Infliximab,Anal abscess,OT
177303184,Infliximab,Abscess,HO
177303184,Infliximab,Abscess,OT
177303184,Infliximab,Abdominal pain,HO
177303184,Infliximab,Abdominal pain,OT
183459583,Infliximab,Weight increased,OT
183459583,Infliximab,Rash,OT
183459583,Infliximab,Dermatitis,OT
183459583,Infliximab,Condition aggravated,OT
183459583,Infliximab,Blood pressure fluctuation,OT
183459583,Infliximab,Blood pressure decreased,OT
183459583,Infliximab,Weight increased,OT
183459583,Infliximab,Rash,OT
183459583,Infliximab,Dermatitis,OT
183459583,Infliximab,Condition aggravated,OT
183459583,Infliximab,Blood pressure fluctuation,OT
183459583,Infliximab,Blood pressure decreased,OT
183816662,Infliximab,Weight increased,OT
183816662,Infliximab,Weight decreased,OT
183816662,Infliximab,Inappropriate schedule of product administration,OT
183816662,Infliximab,Dry skin,OT
183816662,Infliximab,Condition aggravated,OT
183816662,Infliximab,Colitis ulcerative,OT
183816662,Infliximab,Blood pressure increased,OT
183816662,Infliximab,Blood pressure fluctuation,OT
183816662,Infliximab,Arthralgia,OT
184058692,Infliximab,Visual impairment,OT
184058692,Infliximab,Visual impairment,HO
184058692,Infliximab,Urticaria,OT
184058692,Infliximab,Urticaria,HO
184058692,Infliximab,Pruritus,OT
184058692,Infliximab,Pruritus,HO
184058692,Infliximab,Off label use,OT
184058692,Infliximab,Off label use,HO
184058692,Infliximab,Oedema peripheral,OT
184058692,Infliximab,Oedema peripheral,HO
184058692,Infliximab,Infusion related reaction,OT
184058692,Infliximab,Infusion related reaction,HO
184058692,Infliximab,Inappropriate schedule of product administration,OT
184058692,Infliximab,Inappropriate schedule of product administration,HO
184058692,Infliximab,Erythema,OT
184058692,Infliximab,Erythema,HO
184058692,Infliximab,Coronary artery disease,OT
184058692,Infliximab,Coronary artery disease,HO
184058692,Infliximab,Chest discomfort,OT
184058692,Infliximab,Chest discomfort,HO
184058692,Infliximab,Blood pressure fluctuation,OT
184058692,Infliximab,Blood pressure fluctuation,HO
184058692,Infliximab,Blood pressure decreased,OT
184058692,Infliximab,Blood pressure decreased,HO
184058692,Infliximab,Abdominal pain upper,OT
184058692,Infliximab,Abdominal pain upper,HO
184323443,Infliximab,Toothache,OT
184323443,Infliximab,Sleep disorder,OT
184323443,Infliximab,Off label use,OT
184323443,Infliximab,Miliaria,OT
184323443,Infliximab,Loss of personal independence in daily activities,OT
184323443,Infliximab,Intentional product use issue,OT
184323443,Infliximab,Incorrect dose administered,OT
184323443,Infliximab,Heart rate decreased,OT
184323443,Infliximab,Condition aggravated,OT
184323443,Infliximab,Blood pressure systolic increased,OT
184323443,Infliximab,Blood pressure increased,OT
184323443,Infliximab,Blood pressure fluctuation,OT
184323443,Infliximab,Asthenia,OT
184323443,Infliximab,Acne,OT
184323443,Infliximab,Abdominal distension,OT
184330554,Infliximab,Product use in unapproved indication,OT
184330554,Infliximab,Product use in unapproved indication,HO
184330554,Infliximab,Poor venous access,OT
184330554,Infliximab,Poor venous access,HO
184330554,Infliximab,Off label use,OT
184330554,Infliximab,Off label use,HO
184330554,Infliximab,Intentional product use issue,OT
184330554,Infliximab,Intentional product use issue,HO
184330554,Infliximab,Inappropriate schedule of product administration,OT
184330554,Infliximab,Inappropriate schedule of product administration,HO
184330554,Infliximab,Heart rate irregular,OT
184330554,Infliximab,Heart rate irregular,HO
184330554,Infliximab,Heart rate decreased,OT
184330554,Infliximab,Heart rate decreased,HO
184330554,Infliximab,Dyspnoea,OT
184330554,Infliximab,Dyspnoea,HO
184330554,Infliximab,Drug effective for unapproved indication,OT
184330554,Infliximab,Drug effective for unapproved indication,HO
184330554,Infliximab,Dizziness,OT
184330554,Infliximab,Dizziness,HO
184330554,Infliximab,Cough,OT
184330554,Infliximab,Cough,HO
184330554,Infliximab,Condition aggravated,OT
184330554,Infliximab,Condition aggravated,HO
184330554,Infliximab,Cardiac arrest,OT
184330554,Infliximab,Cardiac arrest,HO
184330554,Infliximab,Blood pressure diastolic increased,OT
184330554,Infliximab,Blood pressure diastolic increased,HO
184330554,Infliximab,Blood pressure decreased,OT
184330554,Infliximab,Blood pressure decreased,HO
184330554,Infliximab,Product use in unapproved indication,OT
184330554,Infliximab,Product use in unapproved indication,HO
184330554,Infliximab,Poor venous access,OT
184330554,Infliximab,Poor venous access,HO
184330554,Infliximab,Off label use,OT
184330554,Infliximab,Off label use,HO
184330554,Infliximab,Intentional product use issue,OT
184330554,Infliximab,Intentional product use issue,HO
184330554,Infliximab,Inappropriate schedule of product administration,OT
184330554,Infliximab,Inappropriate schedule of product administration,HO
184330554,Infliximab,Heart rate irregular,OT
184330554,Infliximab,Heart rate irregular,HO
184330554,Infliximab,Heart rate decreased,OT
184330554,Infliximab,Heart rate decreased,HO
184330554,Infliximab,Dyspnoea,OT
184330554,Infliximab,Dyspnoea,HO
184330554,Infliximab,Drug effective for unapproved indication,OT
184330554,Infliximab,Drug effective for unapproved indication,HO
184330554,Infliximab,Dizziness,OT
184330554,Infliximab,Dizziness,HO
184330554,Infliximab,Cough,OT
184330554,Infliximab,Cough,HO
184330554,Infliximab,Condition aggravated,OT
184330554,Infliximab,Condition aggravated,HO
184330554,Infliximab,Cardiac arrest,OT
184330554,Infliximab,Cardiac arrest,HO
184330554,Infliximab,Blood pressure diastolic increased,OT
184330554,Infliximab,Blood pressure diastolic increased,HO
184330554,Infliximab,Blood pressure decreased,OT
184330554,Infliximab,Blood pressure decreased,HO
184365673,Infliximab,Off label use,OT
184365673,Infliximab,Heart rate decreased,OT
184365673,Infliximab,Fatigue,OT
184365673,Infliximab,Drug ineffective,OT
184365673,Infliximab,Depression,OT
184365673,Infliximab,Condition aggravated,OT
184365673,Infliximab,Blood pressure increased,OT
184365673,Infliximab,Blood pressure fluctuation,OT
184365673,Infliximab,Anxiety,OT
184365673,Infliximab,Off label use,OT
184365673,Infliximab,Heart rate decreased,OT
184365673,Infliximab,Fatigue,OT
184365673,Infliximab,Drug ineffective,OT
184365673,Infliximab,Depression,OT
184365673,Infliximab,Condition aggravated,OT
184365673,Infliximab,Blood pressure increased,OT
184365673,Infliximab,Blood pressure fluctuation,OT
184365673,Infliximab,Anxiety,OT
184970594,Infliximab,Weight increased,OT
184970594,Infliximab,Weight increased,HO
184970594,Infliximab,Umbilical hernia,OT
184970594,Infliximab,Umbilical hernia,HO
184970594,Infliximab,Respiratory rate increased,OT
184970594,Infliximab,Respiratory rate increased,HO
184970594,Infliximab,Pulmonary embolism,OT
184970594,Infliximab,Pulmonary embolism,HO
184970594,Infliximab,Pulmonary congestion,OT
184970594,Infliximab,Pulmonary congestion,HO
184970594,Infliximab,Postoperative wound infection,OT
184970594,Infliximab,Postoperative wound infection,HO
184970594,Infliximab,Off label use,OT
184970594,Infliximab,Off label use,HO
184970594,Infliximab,Myocardial infarction,OT
184970594,Infliximab,Myocardial infarction,HO
184970594,Infliximab,Musculoskeletal stiffness,OT
184970594,Infliximab,Musculoskeletal stiffness,HO
184970594,Infliximab,Musculoskeletal pain,OT
184970594,Infliximab,Musculoskeletal pain,HO
184970594,Infliximab,Malaise,OT
184970594,Infliximab,Malaise,HO
184970594,Infliximab,Irritable bowel syndrome,OT
184970594,Infliximab,Irritable bowel syndrome,HO
184970594,Infliximab,Intentional product use issue,OT
184970594,Infliximab,Intentional product use issue,HO
184970594,Infliximab,Inappropriate schedule of product administration,OT
184970594,Infliximab,Inappropriate schedule of product administration,HO
184970594,Infliximab,Heart rate irregular,OT
184970594,Infliximab,Heart rate irregular,HO
184970594,Infliximab,Frequent bowel movements,OT
184970594,Infliximab,Frequent bowel movements,HO
184970594,Infliximab,Fatigue,OT
184970594,Infliximab,Fatigue,HO
184970594,Infliximab,Erythema,OT
184970594,Infliximab,Erythema,HO
184970594,Infliximab,Energy increased,OT
184970594,Infliximab,Energy increased,HO
184970594,Infliximab,Dyspnoea,OT
184970594,Infliximab,Dyspnoea,HO
184970594,Infliximab,Drug level below therapeutic,OT
184970594,Infliximab,Drug level below therapeutic,HO
184970594,Infliximab,Discharge,OT
184970594,Infliximab,Discharge,HO
184970594,Infliximab,Diabetes mellitus,OT
184970594,Infliximab,Diabetes mellitus,HO
184970594,Infliximab,Cough,OT
184970594,Infliximab,Cough,HO
184970594,Infliximab,Condition aggravated,OT
184970594,Infliximab,Condition aggravated,HO
184970594,Infliximab,Choking,OT
184970594,Infliximab,Choking,HO
184970594,Infliximab,Bronchospasm,OT
184970594,Infliximab,Bronchospasm,HO
184970594,Infliximab,Blood pressure fluctuation,OT
184970594,Infliximab,Blood pressure fluctuation,HO
184970594,Infliximab,Arthralgia,OT
184970594,Infliximab,Arthralgia,HO
184970594,Infliximab,Abdominal pain,OT
184970594,Infliximab,Abdominal pain,HO
184970594,Infliximab,Weight increased,OT
184970594,Infliximab,Weight increased,HO
184970594,Infliximab,Umbilical hernia,OT
184970594,Infliximab,Umbilical hernia,HO
184970594,Infliximab,Respiratory rate increased,OT
184970594,Infliximab,Respiratory rate increased,HO
184970594,Infliximab,Pulmonary embolism,OT
184970594,Infliximab,Pulmonary embolism,HO
184970594,Infliximab,Pulmonary congestion,OT
184970594,Infliximab,Pulmonary congestion,HO
184970594,Infliximab,Postoperative wound infection,OT
184970594,Infliximab,Postoperative wound infection,HO
184970594,Infliximab,Off label use,OT
184970594,Infliximab,Off label use,HO
184970594,Infliximab,Myocardial infarction,OT
184970594,Infliximab,Myocardial infarction,HO
184970594,Infliximab,Musculoskeletal stiffness,OT
184970594,Infliximab,Musculoskeletal stiffness,HO
184970594,Infliximab,Musculoskeletal pain,OT
184970594,Infliximab,Musculoskeletal pain,HO
184970594,Infliximab,Malaise,OT
184970594,Infliximab,Malaise,HO
184970594,Infliximab,Irritable bowel syndrome,OT
184970594,Infliximab,Irritable bowel syndrome,HO
184970594,Infliximab,Intentional product use issue,OT
184970594,Infliximab,Intentional product use issue,HO
184970594,Infliximab,Inappropriate schedule of product administration,OT
184970594,Infliximab,Inappropriate schedule of product administration,HO
184970594,Infliximab,Heart rate irregular,OT
184970594,Infliximab,Heart rate irregular,HO
184970594,Infliximab,Frequent bowel movements,OT
184970594,Infliximab,Frequent bowel movements,HO
184970594,Infliximab,Fatigue,OT
184970594,Infliximab,Fatigue,HO
184970594,Infliximab,Erythema,OT
184970594,Infliximab,Erythema,HO
184970594,Infliximab,Energy increased,OT
184970594,Infliximab,Energy increased,HO
184970594,Infliximab,Dyspnoea,OT
184970594,Infliximab,Dyspnoea,HO
184970594,Infliximab,Drug level below therapeutic,OT
184970594,Infliximab,Drug level below therapeutic,HO
184970594,Infliximab,Discharge,OT
184970594,Infliximab,Discharge,HO
184970594,Infliximab,Diabetes mellitus,OT
184970594,Infliximab,Diabetes mellitus,HO
184970594,Infliximab,Cough,OT
184970594,Infliximab,Cough,HO
184970594,Infliximab,Condition aggravated,OT
184970594,Infliximab,Condition aggravated,HO
184970594,Infliximab,Choking,OT
184970594,Infliximab,Choking,HO
184970594,Infliximab,Bronchospasm,OT
184970594,Infliximab,Bronchospasm,HO
184970594,Infliximab,Blood pressure fluctuation,OT
184970594,Infliximab,Blood pressure fluctuation,HO
184970594,Infliximab,Arthralgia,OT
184970594,Infliximab,Arthralgia,HO
184970594,Infliximab,Abdominal pain,OT
184970594,Infliximab,Abdominal pain,HO
185021273,Infliximab,Weight increased,OT
185021273,Infliximab,Product use issue,OT
185021273,Infliximab,Off label use,OT
185021273,Infliximab,Intentional product use issue,OT
185021273,Infliximab,Inappropriate schedule of product administration,OT
185021273,Infliximab,Ileal ulcer,OT
185021273,Infliximab,Heart rate increased,OT
185021273,Infliximab,Fatigue,OT
185021273,Infliximab,Drug ineffective,OT
185021273,Infliximab,Diarrhoea,OT
185021273,Infliximab,Condition aggravated,OT
185021273,Infliximab,Blood pressure increased,OT
185021273,Infliximab,Blood pressure fluctuation,OT
185021273,Infliximab,Weight increased,OT
185021273,Infliximab,Product use issue,OT
185021273,Infliximab,Off label use,OT
185021273,Infliximab,Intentional product use issue,OT
185021273,Infliximab,Inappropriate schedule of product administration,OT
185021273,Infliximab,Ileal ulcer,OT
185021273,Infliximab,Heart rate increased,OT
185021273,Infliximab,Fatigue,OT
185021273,Infliximab,Drug ineffective,OT
185021273,Infliximab,Diarrhoea,OT
185021273,Infliximab,Condition aggravated,OT
185021273,Infliximab,Blood pressure increased,OT
185021273,Infliximab,Blood pressure fluctuation,OT
185912433,Infliximab,Tachycardia,OT
185912433,Infliximab,Product use issue,OT
185912433,Infliximab,Off label use,OT
185912433,Infliximab,Inappropriate schedule of product administration,OT
185912433,Infliximab,Heart rate irregular,OT
185912433,Infliximab,Heart rate decreased,OT
185912433,Infliximab,Tachycardia,OT
185912433,Infliximab,Product use issue,OT
185912433,Infliximab,Off label use,OT
185912433,Infliximab,Inappropriate schedule of product administration,OT
185912433,Infliximab,Heart rate irregular,OT
185912433,Infliximab,Heart rate decreased,OT
185912433,Infliximab,Tachycardia,OT
185912433,Infliximab,Product use issue,OT
185912433,Infliximab,Off label use,OT
185912433,Infliximab,Inappropriate schedule of product administration,OT
185912433,Infliximab,Heart rate irregular,OT
185912433,Infliximab,Heart rate decreased,OT
187257453,Infliximab,Weight decreased,OT
187257453,Infliximab,Tooth disorder,OT
187257453,Infliximab,Therapeutic product effect incomplete,OT
187257453,Infliximab,Peripheral vein occlusion,OT
187257453,Infliximab,Off label use,OT
187257453,Infliximab,Inappropriate schedule of product administration,OT
187257453,Infliximab,Heart rate irregular,OT
187257453,Infliximab,Heart rate decreased,OT
187257453,Infliximab,Frequent bowel movements,OT
187257453,Infliximab,Eating disorder,OT
187257453,Infliximab,Diet failure,OT
187257453,Infliximab,Condition aggravated,OT
187257453,Infliximab,Blood pressure increased,OT
191220972,Infliximab,Treatment failure,OT
191220972,Infliximab,Herpes zoster,OT
191220972,Infliximab,Colitis ulcerative,OT
191220972,Infliximab,Colitis,OT
192076982,Infliximab,Skin plaque,OT
192076982,Infliximab,Skin plaque,HO
192076982,Infliximab,Skin burning sensation,OT
192076982,Infliximab,Skin burning sensation,HO
192076982,Infliximab,Rash,OT
192076982,Infliximab,Rash,HO
192076982,Infliximab,Product use issue,OT
192076982,Infliximab,Product use issue,HO
192076982,Infliximab,Oral candidiasis,OT
192076982,Infliximab,Oral candidiasis,HO
192076982,Infliximab,Off label use,OT
192076982,Infliximab,Off label use,HO
192076982,Infliximab,Myocardial infarction,OT
192076982,Infliximab,Myocardial infarction,HO
192076982,Infliximab,Headache,OT
192076982,Infliximab,Headache,HO
192076982,Infliximab,Condition aggravated,OT
192076982,Infliximab,Condition aggravated,HO
192076982,Infliximab,Bronchitis,OT
192076982,Infliximab,Bronchitis,HO
192076982,Infliximab,Body temperature decreased,OT
192076982,Infliximab,Body temperature decreased,HO
192076982,Infliximab,Blood pressure increased,OT
192076982,Infliximab,Blood pressure increased,HO
192076982,Infliximab,Blood pressure fluctuation,OT
192076982,Infliximab,Blood pressure fluctuation,HO
192388352,Infliximab,Myocardial infarction,HO
192388352,Infliximab,Myocardial infarction,OT
192388352,Infliximab,Inappropriate schedule of product administration,HO
192388352,Infliximab,Inappropriate schedule of product administration,OT
192388352,Infliximab,Hypertension,HO
192388352,Infliximab,Hypertension,OT
192388352,Infliximab,Condition aggravated,HO
192388352,Infliximab,Condition aggravated,OT
194811392,Infliximab,Vomiting,OT
194811392,Infliximab,Pyrexia,OT
194811392,Infliximab,Nausea,OT
194811392,Infliximab,Meningitis aseptic,OT
194811392,Infliximab,Headache,OT
194811392,Infliximab,Confusional state,OT
194811392,Infliximab,Asthenia,OT
194811392,Infliximab,Vomiting,OT
194811392,Infliximab,Pyrexia,OT
194811392,Infliximab,Nausea,OT
194811392,Infliximab,Meningitis aseptic,OT
194811392,Infliximab,Headache,OT
194811392,Infliximab,Confusional state,OT
194811392,Infliximab,Asthenia,OT
194859311,Infliximab,Off label use,OT
194859311,Infliximab,Ankle fracture,OT
194874861,Infliximab,Skin laceration,DE
194874861,Infliximab,Skin laceration,OT
194874861,Infliximab,Skin laceration,HO
194874861,Infliximab,Skin infection,DE
194874861,Infliximab,Skin infection,OT
194874861,Infliximab,Skin infection,HO
194874861,Infliximab,Skin atrophy,DE
194874861,Infliximab,Skin atrophy,OT
194874861,Infliximab,Skin atrophy,HO
194874861,Infliximab,Purulent discharge,DE
194874861,Infliximab,Purulent discharge,OT
194874861,Infliximab,Purulent discharge,HO
194874861,Infliximab,Procedural pain,DE
194874861,Infliximab,Procedural pain,OT
194874861,Infliximab,Procedural pain,HO
194874861,Infliximab,Peripheral swelling,DE
194874861,Infliximab,Peripheral swelling,OT
194874861,Infliximab,Peripheral swelling,HO
194874861,Infliximab,Joint swelling,DE
194874861,Infliximab,Joint swelling,OT
194874861,Infliximab,Joint swelling,HO
194874861,Infliximab,Infection,DE
194874861,Infliximab,Infection,OT
194874861,Infliximab,Infection,HO
194874861,Infliximab,Fistula,DE
194874861,Infliximab,Fistula,OT
194874861,Infliximab,Fistula,HO
194874861,Infliximab,Death,DE
194874861,Infliximab,Death,OT
194874861,Infliximab,Death,HO
194874861,Infliximab,Contusion,DE
194874861,Infliximab,Contusion,OT
194874861,Infliximab,Contusion,HO
195142731,Infliximab,Off label use,HO
195142731,Infliximab,Inappropriate schedule of product administration,HO
195142731,Infliximab,Feeling abnormal,HO
195142731,Infliximab,Drug ineffective,HO
195142731,Infliximab,Crohn's disease,HO
195142731,Infliximab,Blood pressure systolic increased,HO
195142731,Infliximab,Off label use,HO
195142731,Infliximab,Inappropriate schedule of product administration,HO
195142731,Infliximab,Feeling abnormal,HO
195142731,Infliximab,Drug ineffective,HO
195142731,Infliximab,Crohn's disease,HO
195142731,Infliximab,Blood pressure systolic increased,HO
195618771,Infliximab,Treatment failure,OT
195618771,Infliximab,Off label use,OT
195618771,Infliximab,Erythrasma,OT
195802351,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,HO
195802351,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,OT
195802351,Infliximab Pfizer (Unknown),Small intestinal obstruction,HO
195802351,Infliximab Pfizer (Unknown),Small intestinal obstruction,OT
195802351,Infliximab Pfizer (Unknown),Scar,HO
195802351,Infliximab Pfizer (Unknown),Scar,OT
195802351,Infliximab Pfizer (Unknown),Nausea,HO
195802351,Infliximab Pfizer (Unknown),Nausea,OT
195802351,Infliximab Pfizer (Unknown),Arthropathy,HO
195802351,Infliximab Pfizer (Unknown),Arthropathy,OT
195802351,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,HO
195802351,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,OT
195802351,Infliximab Pfizer (Unknown),Small intestinal obstruction,HO
195802351,Infliximab Pfizer (Unknown),Small intestinal obstruction,OT
195802351,Infliximab Pfizer (Unknown),Scar,HO
195802351,Infliximab Pfizer (Unknown),Scar,OT
195802351,Infliximab Pfizer (Unknown),Nausea,HO
195802351,Infliximab Pfizer (Unknown),Nausea,OT
195802351,Infliximab Pfizer (Unknown),Arthropathy,HO
195802351,Infliximab Pfizer (Unknown),Arthropathy,OT
195802351,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,HO
195802351,Infliximab Pfizer (Unknown),Therapeutic product effect decreased,OT
195802351,Infliximab Pfizer (Unknown),Small intestinal obstruction,HO
195802351,Infliximab Pfizer (Unknown),Small intestinal obstruction,OT
195802351,Infliximab Pfizer (Unknown),Scar,HO
195802351,Infliximab Pfizer (Unknown),Scar,OT
195802351,Infliximab Pfizer (Unknown),Nausea,HO
195802351,Infliximab Pfizer (Unknown),Nausea,OT
195802351,Infliximab Pfizer (Unknown),Arthropathy,HO
195802351,Infliximab Pfizer (Unknown),Arthropathy,OT
196148301,Infliximab,Sinusitis bacterial,OT
196148301,Infliximab,Off label use,OT
196148301,Infliximab,Intentional product use issue,OT
196148301,Infliximab,Hypoaesthesia,OT
196148301,Infliximab,Fatigue,OT
196148301,Infliximab,Dyspnoea exertional,OT
196148301,Infliximab,Asthenia,OT
196307971,Infliximab,Pain,OT
196307971,Infliximab,Oropharyngeal pain,OT
196307971,Infliximab,Influenza like illness,OT
196307971,Infliximab,Headache,OT
196307971,Infliximab,Fatigue,OT
196307971,Infliximab,Condition aggravated,OT
196806141,Infliximab,Tooth disorder,OT
196806141,Infliximab,Therapeutic response shortened,OT
196806141,Infliximab,Off label use,OT
196806141,Infliximab,Nausea,OT
196806141,Infliximab,Intentional product use issue,OT
196806141,Infliximab,Infection,OT
196806141,Infliximab,Fistula,OT
196806141,Infliximab,Condition aggravated,OT
196806141,Infliximab,Chlamydial infection,OT
196806141,Infliximab,Chest discomfort,OT
196806141,Infliximab,Blood pressure systolic increased,OT
196806141,Infliximab,Tooth disorder,OT
196806141,Infliximab,Therapeutic response shortened,OT
196806141,Infliximab,Off label use,OT
196806141,Infliximab,Nausea,OT
196806141,Infliximab,Intentional product use issue,OT
196806141,Infliximab,Infection,OT
196806141,Infliximab,Fistula,OT
196806141,Infliximab,Condition aggravated,OT
196806141,Infliximab,Chlamydial infection,OT
196806141,Infliximab,Chest discomfort,OT
196806141,Infliximab,Blood pressure systolic increased,OT
196811791,Infliximab,Vaginal cyst,OT
196811791,Infliximab,Vaginal cyst,HO
196811791,Infliximab,Product use issue,OT
196811791,Infliximab,Product use issue,HO
196811791,Infliximab,Off label use,OT
196811791,Infliximab,Off label use,HO
196811791,Infliximab,Infection,OT
196811791,Infliximab,Infection,HO
196877721,Infliximab (Unknown),Off label use,OT
196877721,Infliximab (Unknown),Drug ineffective for unapproved indication,OT
196877721,Infliximab (Unknown),Diabetes mellitus,OT
196891501,Infliximab,Throat tightness,OT
196891501,Infliximab,Somnolence,OT
196891501,Infliximab,Shock,OT
196891501,Infliximab,Respiratory rate increased,OT
196891501,Infliximab,Rash,OT
196891501,Infliximab,Post procedural haemorrhage,OT
196891501,Infliximab,Pallor,OT
196891501,Infliximab,Off label use,OT
196891501,Infliximab,Hypotension,OT
196891501,Infliximab,Hyperhidrosis,OT
196891501,Infliximab,Hot flush,OT
196891501,Infliximab,Haematochezia,OT
196891501,Infliximab,Feeling cold,OT
196891501,Infliximab,Dyspnoea,OT
196891501,Infliximab,Condition aggravated,OT
196891501,Infliximab,Chills,OT
196891501,Infliximab,Chest discomfort,OT
196891501,Infliximab,Anaphylactic reaction,OT
196891501,Infliximab,Abdominal discomfort,OT
197385191,Infliximab,Tubulointerstitial nephritis,OT
197385191,Infliximab,Acute kidney injury,OT
197393631,Infliximab Pfizer (Unknown),Treatment failure,OT
197393631,Infliximab Pfizer (Unknown),Neuropathy peripheral,OT
197393631,Infliximab Pfizer (Unknown),Nausea,OT
197393631,Infliximab Pfizer (Unknown),Lethargy,OT
197393631,Infliximab Pfizer (Unknown),Headache,OT
197393631,Infliximab Pfizer (Unknown),Drug ineffective,OT
197393631,Infliximab Pfizer (Unknown),Disease recurrence,OT
197393631,Infliximab Pfizer (Unknown),Treatment failure,OT
197393631,Infliximab Pfizer (Unknown),Neuropathy peripheral,OT
197393631,Infliximab Pfizer (Unknown),Nausea,OT
197393631,Infliximab Pfizer (Unknown),Lethargy,OT
197393631,Infliximab Pfizer (Unknown),Headache,OT
197393631,Infliximab Pfizer (Unknown),Drug ineffective,OT
197393631,Infliximab Pfizer (Unknown),Disease recurrence,OT
197393631,Infliximab Pfizer (Unknown),Treatment failure,OT
197393631,Infliximab Pfizer (Unknown),Neuropathy peripheral,OT
197393631,Infliximab Pfizer (Unknown),Nausea,OT
197393631,Infliximab Pfizer (Unknown),Lethargy,OT
197393631,Infliximab Pfizer (Unknown),Headache,OT
197393631,Infliximab Pfizer (Unknown),Drug ineffective,OT
197393631,Infliximab Pfizer (Unknown),Disease recurrence,OT
197875281,Infliximab,Weight decreased,OT
197875281,Infliximab,Procedural pain,OT
197875281,Infliximab,Heart rate decreased,OT
197875281,Infliximab,Defaecation urgency,OT
197875281,Infliximab,Breast cancer,OT
197875281,Infliximab,Anal incontinence,OT
197996411,Infliximab,Treatment failure,HO
197996411,Infliximab,Pyrexia,HO
197996411,Infliximab,Heart rate decreased,HO
197996411,Infliximab,Haemorrhage,HO
197996411,Infliximab,Abdominal pain upper,HO
198051501,Infliximab,Off label use,HO
198051501,Infliximab,Intestinal obstruction,HO
198051501,Infliximab,Intentional product use issue,HO
198051501,Infliximab,Heart rate decreased,HO
198051501,Infliximab,Drug level above therapeutic,HO
198051501,Infliximab,Blood pressure increased,HO
198051501,Infliximab,Blood pressure fluctuation,HO
198110981,Infliximab Pfizer (Unknown),Urinary tract infection,OT
198110981,Infliximab Pfizer (Unknown),Treatment failure,OT
198110981,Infliximab Pfizer (Unknown),Psoriatic arthropathy,OT
198110981,Infliximab Pfizer (Unknown),Psoriasis,OT
198110981,Infliximab Pfizer (Unknown),Paraesthesia,OT
198110981,Infliximab Pfizer (Unknown),Pain in extremity,OT
198110981,Infliximab Pfizer (Unknown),Nausea,OT
198110981,Infliximab Pfizer (Unknown),Musculoskeletal stiffness,OT
198110981,Infliximab Pfizer (Unknown),Joint swelling,OT
198110981,Infliximab Pfizer (Unknown),Hypokalaemia,OT
198110981,Infliximab Pfizer (Unknown),Hyperhidrosis,OT
198110981,Infliximab Pfizer (Unknown),Gastrointestinal disorder,OT
198110981,Infliximab Pfizer (Unknown),Foot deformity,OT
198110981,Infliximab Pfizer (Unknown),Drug intolerance,OT
198110981,Infliximab Pfizer (Unknown),Breast abscess,OT
198110981,Infliximab Pfizer (Unknown),Blood pressure systolic decreased,OT
198110981,Infliximab Pfizer (Unknown),Blood pressure decreased,OT
198110981,Infliximab Pfizer (Unknown),Arthritis,OT
198110981,Infliximab Pfizer (Unknown),Arthralgia,OT
198214181,Infliximab,Pain,OT
198214181,Infliximab,Off label use,OT
198214181,Infliximab,Mood altered,OT
198214181,Infliximab,Inappropriate schedule of product administration,OT
198214181,Infliximab,Haemorrhage,OT
198214181,Infliximab,Flatulence,OT
198214181,Infliximab,Drug specific antibody present,OT
198214181,Infliximab,Drug level below therapeutic,OT
198214181,Infliximab,Condition aggravated,OT
198214181,Infliximab,Cellulitis,OT
198214181,Infliximab,Arthralgia,OT
198214181,Infliximab,Anal fistula,OT
198214181,Infliximab,Abdominal pain,OT
198370031,Infliximab,Drug ineffective,HO
198370031,Infliximab,Diarrhoea,HO
198370031,Infliximab,Colitis,HO
198370031,Infliximab,Clostridium difficile infection,HO
198370031,Infliximab,Drug ineffective,HO
198370031,Infliximab,Diarrhoea,HO
198370031,Infliximab,Colitis,HO
198370031,Infliximab,Clostridium difficile infection,HO
198569091,Infliximab,Weight increased,OT
198569091,Infliximab,Weight decreased,OT
198569091,Infliximab,Thiopurine methyltransferase decreased,OT
198569091,Infliximab,Therapeutic response shortened,OT
198569091,Infliximab,Swelling,OT
198569091,Infliximab,Stoma site pain,OT
198569091,Infliximab,Pain in extremity,OT
198569091,Infliximab,Off label use,OT
198569091,Infliximab,Mobility decreased,OT
198569091,Infliximab,Intestinal ulcer,OT
198569091,Infliximab,Intentional product use issue,OT
198569091,Infliximab,Granuloma,OT
198569091,Infliximab,Gait disturbance,OT
198569091,Infliximab,Fatigue,OT
198569091,Infliximab,Faecal calprotectin abnormal,OT
198569091,Infliximab,Drug level below therapeutic,OT
198569091,Infliximab,Condition aggravated,OT
198569091,Infliximab,Blood pressure increased,OT
198569091,Infliximab,Blood pressure fluctuation,OT
198569091,Infliximab,Arthralgia,OT
198569091,Infliximab,Weight increased,OT
198569091,Infliximab,Weight decreased,OT
198569091,Infliximab,Thiopurine methyltransferase decreased,OT
198569091,Infliximab,Therapeutic response shortened,OT
198569091,Infliximab,Swelling,OT
198569091,Infliximab,Stoma site pain,OT
198569091,Infliximab,Pain in extremity,OT
198569091,Infliximab,Off label use,OT
198569091,Infliximab,Mobility decreased,OT
198569091,Infliximab,Intestinal ulcer,OT
198569091,Infliximab,Intentional product use issue,OT
198569091,Infliximab,Granuloma,OT
198569091,Infliximab,Gait disturbance,OT
198569091,Infliximab,Fatigue,OT
198569091,Infliximab,Faecal calprotectin abnormal,OT
198569091,Infliximab,Drug level below therapeutic,OT
198569091,Infliximab,Condition aggravated,OT
198569091,Infliximab,Blood pressure increased,OT
198569091,Infliximab,Blood pressure fluctuation,OT
198569091,Infliximab,Arthralgia,OT
198732081,Infliximab,Serum sickness,HO
198732081,Infliximab,Pyrexia,HO
198732081,Infliximab,Pain in extremity,HO
198732081,Infliximab,Joint stiffness,HO
198867881,Infliximab (Unknown),Off label use,NULL
198867881,Infliximab (Unknown),Herpes zoster,NULL
198867881,Infliximab (Unknown),Drug effective for unapproved indication,NULL
160963755,Infliximab,Weight decreased,HO
160963755,Infliximab,Weight decreased,OT
160963755,Infliximab,Streptococcal infection,HO
160963755,Infliximab,Streptococcal infection,OT
160963755,Infliximab,Staphylococcal infection,HO
160963755,Infliximab,Staphylococcal infection,OT
160963755,Infliximab,Sinusitis,HO
160963755,Infliximab,Sinusitis,OT
160963755,Infliximab,Seasonal allergy,HO
160963755,Infliximab,Seasonal allergy,OT
160963755,Infliximab,Purulent discharge,HO
160963755,Infliximab,Purulent discharge,OT
160963755,Infliximab,Product use issue,HO
160963755,Infliximab,Product use issue,OT
160963755,Infliximab,Peripheral swelling,HO
160963755,Infliximab,Peripheral swelling,OT
160963755,Infliximab,Pain in extremity,HO
160963755,Infliximab,Pain in extremity,OT
160963755,Infliximab,Pain,HO
160963755,Infliximab,Pain,OT
160963755,Infliximab,Off label use,HO
160963755,Infliximab,Off label use,OT
160963755,Infliximab,Limb injury,HO
160963755,Infliximab,Limb injury,OT
160963755,Infliximab,Intentional product use issue,HO
160963755,Infliximab,Intentional product use issue,OT
160963755,Infliximab,Incorrect product administration duration,HO
160963755,Infliximab,Incorrect product administration duration,OT
160963755,Infliximab,Inappropriate schedule of product administration,HO
160963755,Infliximab,Inappropriate schedule of product administration,OT
160963755,Infliximab,Hypertension,HO
160963755,Infliximab,Hypertension,OT
160963755,Infliximab,Feeling hot,HO
160963755,Infliximab,Feeling hot,OT
160963755,Infliximab,Fatigue,HO
160963755,Infliximab,Fatigue,OT
160963755,Infliximab,Condition aggravated,HO
160963755,Infliximab,Condition aggravated,OT
160963755,Infliximab,Chest discomfort,HO
160963755,Infliximab,Chest discomfort,OT
160963755,Infliximab,Cardiac disorder,HO
160963755,Infliximab,Cardiac disorder,OT
160963755,Infliximab,Body temperature decreased,HO
160963755,Infliximab,Body temperature decreased,OT
160963755,Infliximab,Blood pressure increased,HO
160963755,Infliximab,Blood pressure increased,OT
160963755,Infliximab,Blood pressure fluctuation,HO
160963755,Infliximab,Blood pressure fluctuation,OT
160963755,Infliximab,Weight decreased,HO
160963755,Infliximab,Weight decreased,OT
160963755,Infliximab,Streptococcal infection,HO
160963755,Infliximab,Streptococcal infection,OT
160963755,Infliximab,Staphylococcal infection,HO
160963755,Infliximab,Staphylococcal infection,OT
160963755,Infliximab,Sinusitis,HO
160963755,Infliximab,Sinusitis,OT
160963755,Infliximab,Seasonal allergy,HO
160963755,Infliximab,Seasonal allergy,OT
160963755,Infliximab,Purulent discharge,HO
160963755,Infliximab,Purulent discharge,OT
160963755,Infliximab,Product use issue,HO
160963755,Infliximab,Product use issue,OT
160963755,Infliximab,Peripheral swelling,HO
160963755,Infliximab,Peripheral swelling,OT
160963755,Infliximab,Pain in extremity,HO
160963755,Infliximab,Pain in extremity,OT
160963755,Infliximab,Pain,HO
160963755,Infliximab,Pain,OT
160963755,Infliximab,Off label use,HO
160963755,Infliximab,Off label use,OT
160963755,Infliximab,Limb injury,HO
160963755,Infliximab,Limb injury,OT
160963755,Infliximab,Intentional product use issue,HO
160963755,Infliximab,Intentional product use issue,OT
160963755,Infliximab,Incorrect product administration duration,HO
160963755,Infliximab,Incorrect product administration duration,OT
160963755,Infliximab,Inappropriate schedule of product administration,HO
160963755,Infliximab,Inappropriate schedule of product administration,OT
160963755,Infliximab,Hypertension,HO
160963755,Infliximab,Hypertension,OT
160963755,Infliximab,Feeling hot,HO
160963755,Infliximab,Feeling hot,OT
160963755,Infliximab,Fatigue,HO
160963755,Infliximab,Fatigue,OT
160963755,Infliximab,Condition aggravated,HO
160963755,Infliximab,Condition aggravated,OT
160963755,Infliximab,Chest discomfort,HO
160963755,Infliximab,Chest discomfort,OT
160963755,Infliximab,Cardiac disorder,HO
160963755,Infliximab,Cardiac disorder,OT
160963755,Infliximab,Body temperature decreased,HO
160963755,Infliximab,Body temperature decreased,OT
160963755,Infliximab,Blood pressure increased,HO
160963755,Infliximab,Blood pressure increased,OT
160963755,Infliximab,Blood pressure fluctuation,HO
160963755,Infliximab,Blood pressure fluctuation,OT
165095213,Infliximab,Weight increased,OT
165095213,Infliximab,Weight increased,HO
165095213,Infliximab,Weight decreased,OT
165095213,Infliximab,Weight decreased,HO
165095213,Infliximab,Stress,OT
165095213,Infliximab,Stress,HO
165095213,Infliximab,Product use issue,OT
165095213,Infliximab,Product use issue,HO
165095213,Infliximab,Plantar fasciitis,OT
165095213,Infliximab,Plantar fasciitis,HO
165095213,Infliximab,Pain in extremity,OT
165095213,Infliximab,Pain in extremity,HO
165095213,Infliximab,Off label use,OT
165095213,Infliximab,Off label use,HO
165095213,Infliximab,Malaise,OT
165095213,Infliximab,Malaise,HO
165095213,Infliximab,Intentional product use issue,OT
165095213,Infliximab,Intentional product use issue,HO
165095213,Infliximab,Insomnia,OT
165095213,Infliximab,Insomnia,HO
165095213,Infliximab,Impaired work ability,OT
165095213,Infliximab,Impaired work ability,HO
165095213,Infliximab,Illness,OT
165095213,Infliximab,Illness,HO
165095213,Infliximab,Hypertension,OT
165095213,Infliximab,Hypertension,HO
165095213,Infliximab,Heart rate irregular,OT
165095213,Infliximab,Heart rate irregular,HO
165095213,Infliximab,Fluid retention,OT
165095213,Infliximab,Fluid retention,HO
165095213,Infliximab,Dyspnoea exertional,OT
165095213,Infliximab,Dyspnoea exertional,HO
165095213,Infliximab,Condition aggravated,OT
165095213,Infliximab,Condition aggravated,HO
165095213,Infliximab,Colon cancer,OT
165095213,Infliximab,Colon cancer,HO
165095213,Infliximab,Chest pain,OT
165095213,Infliximab,Chest pain,HO
165095213,Infliximab,Blood pressure fluctuation,OT
165095213,Infliximab,Blood pressure fluctuation,HO
165095213,Infliximab,Blood pressure decreased,OT
165095213,Infliximab,Blood pressure decreased,HO
165654875,Infliximab,Vomiting,OT
165654875,Infliximab,Vomiting,HO
165654875,Infliximab,Sinusitis,OT
165654875,Infliximab,Sinusitis,HO
165654875,Infliximab,Pneumonia,OT
165654875,Infliximab,Pneumonia,HO
165654875,Infliximab,Pain in extremity,OT
165654875,Infliximab,Pain in extremity,HO
165654875,Infliximab,Off label use,OT
165654875,Infliximab,Off label use,HO
165654875,Infliximab,Musculoskeletal chest pain,OT
165654875,Infliximab,Musculoskeletal chest pain,HO
165654875,Infliximab,Muscle spasms,OT
165654875,Infliximab,Muscle spasms,HO
165654875,Infliximab,Intentional product use issue,OT
165654875,Infliximab,Intentional product use issue,HO
165654875,Infliximab,Gallbladder disorder,OT
165654875,Infliximab,Gallbladder disorder,HO
165654875,Infliximab,Feeling abnormal,OT
165654875,Infliximab,Feeling abnormal,HO
165654875,Infliximab,Ear discomfort,OT
165654875,Infliximab,Ear discomfort,HO
165654875,Infliximab,Dizziness,OT
165654875,Infliximab,Dizziness,HO
165654875,Infliximab,Cough,OT
165654875,Infliximab,Cough,HO
165654875,Infliximab,Contusion,OT
165654875,Infliximab,Contusion,HO
165654875,Infliximab,Condition aggravated,OT
165654875,Infliximab,Condition aggravated,HO
165654875,Infliximab,Blood pressure decreased,OT
165654875,Infliximab,Blood pressure decreased,HO
165654875,Infliximab,Bile duct stone,OT
165654875,Infliximab,Bile duct stone,HO
165654875,Infliximab,Aphonia,OT
165654875,Infliximab,Aphonia,HO
165654875,Infliximab,Alopecia,OT
165654875,Infliximab,Alopecia,HO
165654875,Infliximab,Ageusia,OT
165654875,Infliximab,Ageusia,HO
165654875,Infliximab,Vomiting,OT
165654875,Infliximab,Vomiting,HO
165654875,Infliximab,Sinusitis,OT
165654875,Infliximab,Sinusitis,HO
165654875,Infliximab,Pneumonia,OT
165654875,Infliximab,Pneumonia,HO
165654875,Infliximab,Pain in extremity,OT
165654875,Infliximab,Pain in extremity,HO
165654875,Infliximab,Off label use,OT
165654875,Infliximab,Off label use,HO
165654875,Infliximab,Musculoskeletal chest pain,OT
165654875,Infliximab,Musculoskeletal chest pain,HO
165654875,Infliximab,Muscle spasms,OT
165654875,Infliximab,Muscle spasms,HO
165654875,Infliximab,Intentional product use issue,OT
165654875,Infliximab,Intentional product use issue,HO
165654875,Infliximab,Gallbladder disorder,OT
165654875,Infliximab,Gallbladder disorder,HO
165654875,Infliximab,Feeling abnormal,OT
165654875,Infliximab,Feeling abnormal,HO
165654875,Infliximab,Ear discomfort,OT
165654875,Infliximab,Ear discomfort,HO
165654875,Infliximab,Dizziness,OT
165654875,Infliximab,Dizziness,HO
165654875,Infliximab,Cough,OT
165654875,Infliximab,Cough,HO
165654875,Infliximab,Contusion,OT
165654875,Infliximab,Contusion,HO
165654875,Infliximab,Condition aggravated,OT
165654875,Infliximab,Condition aggravated,HO
165654875,Infliximab,Blood pressure decreased,OT
165654875,Infliximab,Blood pressure decreased,HO
165654875,Infliximab,Bile duct stone,OT
165654875,Infliximab,Bile duct stone,HO
165654875,Infliximab,Aphonia,OT
165654875,Infliximab,Aphonia,HO
165654875,Infliximab,Alopecia,OT
165654875,Infliximab,Alopecia,HO
165654875,Infliximab,Ageusia,OT
165654875,Infliximab,Ageusia,HO
173069782,Infliximab,Syncope,OT
173069782,Infliximab,Rash,OT
173069782,Infliximab,Product use issue,OT
173069782,Infliximab,Presyncope,OT
173069782,Infliximab,Photophobia,OT
173069782,Infliximab,Off label use,OT
173069782,Infliximab,Neurogenic shock,OT
173069782,Infliximab,Migraine,OT
173069782,Infliximab,Loss of consciousness,OT
173069782,Infliximab,Insomnia,OT
173069782,Infliximab,Inflammation,OT
173069782,Infliximab,Hot flush,OT
173069782,Infliximab,Gait disturbance,OT
173069782,Infliximab,Dyspnoea,OT
173069782,Infliximab,Dyspepsia,OT
173069782,Infliximab,Dizziness,OT
173069782,Infliximab,Anxiety,OT
173069782,Infliximab,Abdominal pain upper,OT
173069782,Infliximab,Abdominal pain,OT
173069782,Infliximab,Syncope,OT
173069782,Infliximab,Rash,OT
173069782,Infliximab,Product use issue,OT
173069782,Infliximab,Presyncope,OT
173069782,Infliximab,Photophobia,OT
173069782,Infliximab,Off label use,OT
173069782,Infliximab,Neurogenic shock,OT
173069782,Infliximab,Migraine,OT
173069782,Infliximab,Loss of consciousness,OT
173069782,Infliximab,Insomnia,OT
173069782,Infliximab,Inflammation,OT
173069782,Infliximab,Hot flush,OT
173069782,Infliximab,Gait disturbance,OT
173069782,Infliximab,Dyspnoea,OT
173069782,Infliximab,Dyspepsia,OT
173069782,Infliximab,Dizziness,OT
173069782,Infliximab,Anxiety,OT
173069782,Infliximab,Abdominal pain upper,OT
173069782,Infliximab,Abdominal pain,OT
175099164,Infliximab,Vomiting,HO
175099164,Infliximab,Product use issue,HO
175099164,Infliximab,Pain,HO
175099164,Infliximab,Off label use,HO
175099164,Infliximab,Intestinal obstruction,HO
175099164,Infliximab,Intentional product use issue,HO
175099164,Infliximab,Hypertension,HO
175099164,Infliximab,Heart rate irregular,HO
175099164,Infliximab,Blood pressure fluctuation,HO
175099164,Infliximab,Vomiting,HO
175099164,Infliximab,Product use issue,HO
175099164,Infliximab,Pain,HO
175099164,Infliximab,Off label use,HO
175099164,Infliximab,Intestinal obstruction,HO
175099164,Infliximab,Intentional product use issue,HO
175099164,Infliximab,Hypertension,HO
175099164,Infliximab,Heart rate irregular,HO
175099164,Infliximab,Blood pressure fluctuation,HO
176475154,Infliximab,Therapeutic product effect incomplete,OT
176475154,Infliximab,Product use issue,OT
176475154,Infliximab,Poor venous access,OT
176475154,Infliximab,Off label use,OT
176475154,Infliximab,Intentional product use issue,OT
176475154,Infliximab,Heart rate decreased,OT
176475154,Infliximab,Gastrointestinal inflammation,OT
176475154,Infliximab,Faecal calprotectin increased,OT
176475154,Infliximab,Drug level below therapeutic,OT
176475154,Infliximab,Drug level above therapeutic,OT
176475154,Infliximab,Condition aggravated,OT
176475154,Infliximab,Blood pressure systolic increased,OT
176475154,Infliximab,Blood pressure fluctuation,OT
176475154,Infliximab,Blood pressure diastolic decreased,OT
176475154,Infliximab,Arthralgia,OT
176475154,Infliximab,Therapeutic product effect incomplete,OT
176475154,Infliximab,Product use issue,OT
176475154,Infliximab,Poor venous access,OT
176475154,Infliximab,Off label use,OT
176475154,Infliximab,Intentional product use issue,OT
176475154,Infliximab,Heart rate decreased,OT
176475154,Infliximab,Gastrointestinal inflammation,OT
176475154,Infliximab,Faecal calprotectin increased,OT
176475154,Infliximab,Drug level below therapeutic,OT
176475154,Infliximab,Drug level above therapeutic,OT
176475154,Infliximab,Condition aggravated,OT
176475154,Infliximab,Blood pressure systolic increased,OT
176475154,Infliximab,Blood pressure fluctuation,OT
176475154,Infliximab,Blood pressure diastolic decreased,OT
176475154,Infliximab,Arthralgia,OT
176478283,Infliximab,Therapeutic product effect incomplete,OT
176478283,Infliximab,Pyrexia,OT
176478283,Infliximab,Oropharyngeal pain,OT
176478283,Infliximab,Off label use,OT
176478283,Infliximab,Nasal congestion,OT
176478283,Infliximab,Lower respiratory tract infection,OT
176478283,Infliximab,Intentional product use issue,OT
176478283,Infliximab,Inappropriate schedule of product administration,OT
176478283,Infliximab,Hypersensitivity,OT
176478283,Infliximab,Faeces discoloured,OT
176478283,Infliximab,Drug ineffective,OT
176478283,Infliximab,Diarrhoea,OT
176478283,Infliximab,Body temperature fluctuation,OT
176478283,Infliximab,Blood pressure fluctuation,OT
176478283,Infliximab,Abdominal pain,OT
176478283,Infliximab,Abdominal distension,OT
176478283,Infliximab,Therapeutic product effect incomplete,OT
176478283,Infliximab,Pyrexia,OT
176478283,Infliximab,Oropharyngeal pain,OT
176478283,Infliximab,Off label use,OT
176478283,Infliximab,Nasal congestion,OT
176478283,Infliximab,Lower respiratory tract infection,OT
176478283,Infliximab,Intentional product use issue,OT
176478283,Infliximab,Inappropriate schedule of product administration,OT
176478283,Infliximab,Hypersensitivity,OT
176478283,Infliximab,Faeces discoloured,OT
176478283,Infliximab,Drug ineffective,OT
176478283,Infliximab,Diarrhoea,OT
176478283,Infliximab,Body temperature fluctuation,OT
176478283,Infliximab,Blood pressure fluctuation,OT
176478283,Infliximab,Abdominal pain,OT
176478283,Infliximab,Abdominal distension,OT
176521554,Infliximab,Weight increased,OT
176521554,Infliximab,Vertigo,OT
176521554,Infliximab,Productive cough,OT
176521554,Infliximab,Postoperative wound infection,OT
176521554,Infliximab,Pain,OT
176521554,Infliximab,Off label use,OT
176521554,Infliximab,Nasopharyngitis,OT
176521554,Infliximab,Incorrect dose administered,OT
176521554,Infliximab,Incision site pain,OT
176521554,Infliximab,Incision site erythema,OT
176521554,Infliximab,Headache,OT
176521554,Infliximab,Fibromyalgia,OT
176521554,Infliximab,Fatigue,OT
176521554,Infliximab,Dizziness,OT
176521554,Infliximab,Condition aggravated,OT
176521554,Infliximab,Cholelithiasis,OT
176521554,Infliximab,Chills,OT
176521554,Infliximab,Burning sensation,OT
176521554,Infliximab,Blood pressure increased,OT
176521554,Infliximab,Blood pressure fluctuation,OT
176521554,Infliximab,Blood pressure diastolic increased,OT
176521554,Infliximab,Weight increased,OT
176521554,Infliximab,Vertigo,OT
176521554,Infliximab,Productive cough,OT
176521554,Infliximab,Postoperative wound infection,OT
176521554,Infliximab,Pain,OT
176521554,Infliximab,Off label use,OT
176521554,Infliximab,Nasopharyngitis,OT
176521554,Infliximab,Incorrect dose administered,OT
176521554,Infliximab,Incision site pain,OT
176521554,Infliximab,Incision site erythema,OT
176521554,Infliximab,Headache,OT
176521554,Infliximab,Fibromyalgia,OT
176521554,Infliximab,Fatigue,OT
176521554,Infliximab,Dizziness,OT
176521554,Infliximab,Condition aggravated,OT
176521554,Infliximab,Cholelithiasis,OT
176521554,Infliximab,Chills,OT
176521554,Infliximab,Burning sensation,OT
176521554,Infliximab,Blood pressure increased,OT
176521554,Infliximab,Blood pressure fluctuation,OT
176521554,Infliximab,Blood pressure diastolic increased,OT
176529214,Infliximab,Uveitis,OT
176529214,Infliximab,Off label use,OT
176529214,Infliximab,Nasopharyngitis,OT
176529214,Infliximab,Nasal septum deviation,OT
176529214,Infliximab,Malaise,OT
176529214,Infliximab,Intentional product use issue,OT
176529214,Infliximab,Feeling abnormal,OT
176529214,Infliximab,Fatigue,OT
176529214,Infliximab,Eye swelling,OT
176529214,Infliximab,Eye pain,OT
176529214,Infliximab,Eye irritation,OT
176529214,Infliximab,Ear discomfort,OT
176529214,Infliximab,Dry eye,OT
176529214,Infliximab,Disease recurrence,OT
176529214,Infliximab,Condition aggravated,OT
176529214,Infliximab,Chronic sinusitis,OT
176529214,Infliximab,Blood pressure increased,OT
176529214,Infliximab,Blood pressure fluctuation,OT
176529214,Infliximab,Arthralgia,OT
176529214,Infliximab,Anal skin tags,OT
176529214,Infliximab,Anal fissure,OT
176551784,Infliximab,Weight increased,OT
176551784,Infliximab,Weight decreased,OT
176551784,Infliximab,Vomiting,OT
176551784,Infliximab,Vitamin D decreased,OT
176551784,Infliximab,Swelling face,OT
176551784,Infliximab,Swelling,OT
176551784,Infliximab,Somnolence,OT
176551784,Infliximab,Seasonal allergy,OT
176551784,Infliximab,Poor venous access,OT
176551784,Infliximab,Off label use,OT
176551784,Infliximab,Nausea,OT
176551784,Infliximab,Intentional product use issue,OT
176551784,Infliximab,Inappropriate schedule of product administration,OT
176551784,Infliximab,Headache,OT
176551784,Infliximab,Frequent bowel movements,OT
176551784,Infliximab,Fatigue,OT
176551784,Infliximab,Faecal calprotectin increased,OT
176551784,Infliximab,Dyspnoea,OT
176551784,Infliximab,Drug level above therapeutic,OT
176551784,Infliximab,Condition aggravated,OT
176551784,Infliximab,C-reactive protein increased,OT
176551784,Infliximab,Bowel movement irregularity,OT
176551784,Infliximab,Blood bilirubin increased,OT
176551784,Infliximab,Blood albumin increased,OT
176551784,Infliximab,Blood 25-hydroxycholecalciferol decreased,OT
176551784,Infliximab,Asthenia,OT
176551784,Infliximab,Abdominal pain,OT
176551784,Infliximab,Abdominal distension,OT
176552814,Infliximab,Umbilical hernia,OT
176552814,Infliximab,Umbilical hernia,HO
176552814,Infliximab,Tongue ulceration,OT
176552814,Infliximab,Tongue ulceration,HO
176552814,Infliximab,Tissue infiltration,OT
176552814,Infliximab,Tissue infiltration,HO
176552814,Infliximab,Stomatitis,OT
176552814,Infliximab,Stomatitis,HO
176552814,Infliximab,Sinusitis,OT
176552814,Infliximab,Sinusitis,HO
176552814,Infliximab,Oral candidiasis,OT
176552814,Infliximab,Oral candidiasis,HO
176552814,Infliximab,Off label use,OT
176552814,Infliximab,Off label use,HO
176552814,Infliximab,Neck pain,OT
176552814,Infliximab,Neck pain,HO
176552814,Infliximab,Musculoskeletal stiffness,OT
176552814,Infliximab,Musculoskeletal stiffness,HO
176552814,Infliximab,Mouth ulceration,OT
176552814,Infliximab,Mouth ulceration,HO
176552814,Infliximab,Macular degeneration,OT
176552814,Infliximab,Macular degeneration,HO
176552814,Infliximab,Intentional product use issue,OT
176552814,Infliximab,Intentional product use issue,HO
176552814,Infliximab,Inappropriate schedule of product administration,OT
176552814,Infliximab,Inappropriate schedule of product administration,HO
176552814,Infliximab,Hot flush,OT
176552814,Infliximab,Hot flush,HO
176552814,Infliximab,Headache,OT
176552814,Infliximab,Headache,HO
176552814,Infliximab,Glossodynia,OT
176552814,Infliximab,Glossodynia,HO
176552814,Infliximab,Gastrointestinal bacterial infection,OT
176552814,Infliximab,Gastrointestinal bacterial infection,HO
176552814,Infliximab,Condition aggravated,OT
176552814,Infliximab,Condition aggravated,HO
176552814,Infliximab,Cheilitis,OT
176552814,Infliximab,Cheilitis,HO
176552814,Infliximab,Body temperature fluctuation,OT
176552814,Infliximab,Body temperature fluctuation,HO
176552814,Infliximab,Blood pressure increased,OT
176552814,Infliximab,Blood pressure increased,HO
176552814,Infliximab,Blood pressure fluctuation,OT
176552814,Infliximab,Blood pressure fluctuation,HO
176552814,Infliximab,Arthralgia,OT
176552814,Infliximab,Arthralgia,HO
176552814,Infliximab,Appendix disorder,OT
176552814,Infliximab,Appendix disorder,HO
176552814,Infliximab,Abdominal pain upper,OT
176552814,Infliximab,Abdominal pain upper,HO
176552814,Infliximab,Abdominal pain,OT
176552814,Infliximab,Abdominal pain,HO
176552814,Infliximab,Abdominal distension,OT
176552814,Infliximab,Abdominal distension,HO
176860195,Infliximab,Uveitis,OT
176860195,Infliximab,Stress,OT
176860195,Infliximab,Road traffic accident,OT
176860195,Infliximab,Product use issue,OT
176860195,Infliximab,Onychoclasis,OT
176860195,Infliximab,Off label use,OT
176860195,Infliximab,Nail disorder,OT
176860195,Infliximab,Intentional product use issue,OT
176860195,Infliximab,Inappropriate schedule of product administration,OT
176860195,Infliximab,Fatigue,OT
176860195,Infliximab,Erythema nodosum,OT
176860195,Infliximab,Blood pressure increased,OT
176860195,Infliximab,Blood pressure fluctuation,OT
176860195,Infliximab,Bacterial vulvovaginitis,OT
176860195,Infliximab,Arthralgia,OT
176860195,Infliximab,Aphthous ulcer,OT
176860195,Infliximab,Alopecia,OT
177298665,Infliximab,Weight increased,OT
177298665,Infliximab,Weight increased,HO
177298665,Infliximab,Vomiting,OT
177298665,Infliximab,Vomiting,HO
177298665,Infliximab,Pyrexia,OT
177298665,Infliximab,Pyrexia,HO
177298665,Infliximab,Poor venous access,OT
177298665,Infliximab,Poor venous access,HO
177298665,Infliximab,Pneumonia,OT
177298665,Infliximab,Pneumonia,HO
177298665,Infliximab,Paraesthesia oral,OT
177298665,Infliximab,Paraesthesia oral,HO
177298665,Infliximab,Oropharyngeal pain,OT
177298665,Infliximab,Oropharyngeal pain,HO
177298665,Infliximab,Off label use,OT
177298665,Infliximab,Off label use,HO
177298665,Infliximab,Nausea,OT
177298665,Infliximab,Nausea,HO
177298665,Infliximab,Incorrect dose administered,OT
177298665,Infliximab,Incorrect dose administered,HO
177298665,Infliximab,Inappropriate schedule of product administration,OT
177298665,Infliximab,Inappropriate schedule of product administration,HO
177298665,Infliximab,Drug level below therapeutic,OT
177298665,Infliximab,Drug level below therapeutic,HO
177298665,Infliximab,Diarrhoea,OT
177298665,Infliximab,Diarrhoea,HO
177298665,Infliximab,Condition aggravated,OT
177298665,Infliximab,Condition aggravated,HO
177298665,Infliximab,Colitis,OT
177298665,Infliximab,Colitis,HO
177298665,Infliximab,Blood pressure systolic increased,OT
177298665,Infliximab,Blood pressure systolic increased,HO
177298665,Infliximab,Blood pressure increased,OT
177298665,Infliximab,Blood pressure increased,HO
177298665,Infliximab,Blood pressure fluctuation,OT
177298665,Infliximab,Blood pressure fluctuation,HO
177298665,Infliximab,Arthralgia,OT
177298665,Infliximab,Arthralgia,HO
185792082,Infliximab,Wheezing,OT
185792082,Infliximab,Throat irritation,OT
185792082,Infliximab,Sneezing,OT
185792082,Infliximab,Productive cough,OT
185792082,Infliximab,Pharyngeal paraesthesia,OT
185792082,Infliximab,Paraesthesia,OT
185792082,Infliximab,Oxygen saturation decreased,OT
185792082,Infliximab,Off label use,OT
185792082,Infliximab,Nasopharyngitis,OT
185792082,Infliximab,Nasal congestion,OT
185792082,Infliximab,Intentional product use issue,OT
185792082,Infliximab,Inappropriate schedule of product administration,OT
185792082,Infliximab,Heart rate decreased,OT
185792082,Infliximab,Feeling hot,OT
185792082,Infliximab,Erythema,OT
185792082,Infliximab,Cough,OT
185792082,Infliximab,Chest pain,OT
185792082,Infliximab,Blood pressure diastolic decreased,OT
185792082,Infliximab,Arthralgia,OT
185792082,Infliximab,Wheezing,OT
185792082,Infliximab,Throat irritation,OT
185792082,Infliximab,Sneezing,OT
185792082,Infliximab,Productive cough,OT
185792082,Infliximab,Pharyngeal paraesthesia,OT
185792082,Infliximab,Paraesthesia,OT
185792082,Infliximab,Oxygen saturation decreased,OT
185792082,Infliximab,Off label use,OT
185792082,Infliximab,Nasopharyngitis,OT
185792082,Infliximab,Nasal congestion,OT
185792082,Infliximab,Intentional product use issue,OT
185792082,Infliximab,Inappropriate schedule of product administration,OT
185792082,Infliximab,Heart rate decreased,OT
185792082,Infliximab,Feeling hot,OT
185792082,Infliximab,Erythema,OT
185792082,Infliximab,Cough,OT
185792082,Infliximab,Chest pain,OT
185792082,Infliximab,Blood pressure diastolic decreased,OT
185792082,Infliximab,Arthralgia,OT
186601352,Infliximab,Tuberculosis,OT
187184852,Infliximab,Drug intolerance,OT
187184852,Infliximab,Drug ineffective,OT
187184852,Infliximab,Abdominal discomfort,OT
188941643,Infliximab,Therapeutic response shortened,OT
188941643,Infliximab,Product use issue,OT
188941643,Infliximab,Off label use,OT
188941643,Infliximab,Inappropriate schedule of product administration,OT
188941643,Infliximab,Heart rate decreased,OT
188941643,Infliximab,Feeling abnormal,OT
188941643,Infliximab,Drug specific antibody present,OT
188941643,Infliximab,Drug level below therapeutic,OT
188941643,Infliximab,Drug ineffective,OT
188941643,Infliximab,Cortical dysplasia,OT
188941643,Infliximab,Condition aggravated,OT
188941643,Infliximab,Blood pressure increased,OT
191540622,Infliximab,Urinary tract infection,OT
191540622,Infliximab,Urinary tract infection,HO
191540622,Infliximab,Sleep disorder,OT
191540622,Infliximab,Sleep disorder,HO
191540622,Infliximab,Off label use,OT
191540622,Infliximab,Off label use,HO
191540622,Infliximab,Malaise,OT
191540622,Infliximab,Malaise,HO
191540622,Infliximab,Hypotension,OT
191540622,Infliximab,Hypotension,HO
191540622,Infliximab,Hypertension,OT
191540622,Infliximab,Hypertension,HO
191540622,Infliximab,Depression,OT
191540622,Infliximab,Depression,HO
191540622,Infliximab,Constipation,OT
191540622,Infliximab,Constipation,HO
191540622,Infliximab,Chronic kidney disease,OT
191540622,Infliximab,Chronic kidney disease,HO
191540622,Infliximab,Blood magnesium decreased,OT
191540622,Infliximab,Blood magnesium decreased,HO
191540622,Infliximab,Acute kidney injury,OT
191540622,Infliximab,Acute kidney injury,HO
193961562,Infliximab,Sinus tachycardia,OT
193961562,Infliximab,Off label use,OT
193961562,Infliximab,Hypertension,OT
193961562,Infliximab,Drug interaction,OT
194793761,Infliximab,Tooth infection,OT
194793761,Infliximab,Productive cough,OT
194793761,Infliximab,Product use issue,OT
194793761,Infliximab,Off label use,OT
194793761,Infliximab,Loss of consciousness,OT
194793761,Infliximab,Intentional product use issue,OT
194793761,Infliximab,Illness,OT
194793761,Infliximab,Gingivitis,OT
194793761,Infliximab,Fear of injection,OT
194793761,Infliximab,Ear pain,OT
194793761,Infliximab,Diarrhoea,OT
194793761,Infliximab,Cough,OT
194793761,Infliximab,Condition aggravated,OT
194793761,Infliximab,Chest discomfort,OT
194793761,Infliximab,Arthralgia,OT
194793761,Infliximab,Abdominal discomfort,OT
194793821,Infliximab,Sleep disorder,OT
194793821,Infliximab,Pain,OT
194793821,Infliximab,Off label use,OT
194793821,Infliximab,Loss of personal independence in daily activities,OT
194793821,Infliximab,Intentional product use issue,OT
194793821,Infliximab,Hypertension,OT
194793821,Infliximab,Fatigue,OT
194793821,Infliximab,Cellulitis,OT
194793821,Infliximab,Arthritis,OT
194793821,Infliximab,Anxiety,OT
195947161,Infliximab,Weight decreased,OT
195947161,Infliximab,Temporomandibular joint syndrome,OT
195947161,Infliximab,Product use issue,OT
195947161,Infliximab,Palpitations,OT
195947161,Infliximab,Osteomyelitis,OT
195947161,Infliximab,Off label use,OT
195947161,Infliximab,Nasopharyngitis,OT
195947161,Infliximab,Intentional product use issue,OT
195947161,Infliximab,Heart rate increased,OT
195947161,Infliximab,Condition aggravated,OT
195947161,Infliximab,Blood pressure increased,OT
196123661,Infliximab,Maternal exposure during pregnancy,OT
196123661,Infliximab,Live birth,OT
196123661,Infliximab,Cholestasis of pregnancy,OT
196123661,Infliximab,Cholestasis,OT
196451951,Infliximab,Weight increased,OT
196451951,Infliximab,Weight increased,HO
196451951,Infliximab,Weight decreased,OT
196451951,Infliximab,Weight decreased,HO
196451951,Infliximab,Vomiting,OT
196451951,Infliximab,Vomiting,HO
196451951,Infliximab,Urinary tract infection,OT
196451951,Infliximab,Urinary tract infection,HO
196451951,Infliximab,Thinking abnormal,OT
196451951,Infliximab,Thinking abnormal,HO
196451951,Infliximab,Off label use,OT
196451951,Infliximab,Off label use,HO
196451951,Infliximab,Mouth ulceration,OT
196451951,Infliximab,Mouth ulceration,HO
196451951,Infliximab,Maternal exposure during pregnancy,OT
196451951,Infliximab,Maternal exposure during pregnancy,HO
196451951,Infliximab,Kidney infection,OT
196451951,Infliximab,Kidney infection,HO
196451951,Infliximab,Intentional product use issue,OT
196451951,Infliximab,Intentional product use issue,HO
196451951,Infliximab,Infusion site swelling,OT
196451951,Infliximab,Infusion site swelling,HO
196451951,Infliximab,Infusion site pain,OT
196451951,Infliximab,Infusion site pain,HO
196451951,Infliximab,Increased appetite,OT
196451951,Infliximab,Increased appetite,HO
196451951,Infliximab,Inappropriate schedule of product administration,OT
196451951,Infliximab,Inappropriate schedule of product administration,HO
196451951,Infliximab,Haemolysis,OT
196451951,Infliximab,Haemolysis,HO
196451951,Infliximab,Faeces hard,OT
196451951,Infliximab,Faeces hard,HO
196451951,Infliximab,Diarrhoea,OT
196451951,Infliximab,Diarrhoea,HO
196451951,Infliximab,Dermal cyst,OT
196451951,Infliximab,Dermal cyst,HO
196451951,Infliximab,Constipation,OT
196451951,Infliximab,Constipation,HO
196451951,Infliximab,Condition aggravated,OT
196451951,Infliximab,Condition aggravated,HO
196451951,Infliximab,Blood pressure fluctuation,OT
196451951,Infliximab,Blood pressure fluctuation,HO
196451951,Infliximab,Blood pressure decreased,OT
196451951,Infliximab,Blood pressure decreased,HO
196451951,Infliximab,Bartholin's cyst,OT
196451951,Infliximab,Bartholin's cyst,HO
196451951,Infliximab,Arthralgia,OT
196451951,Infliximab,Arthralgia,HO
196451951,Infliximab,Abortion spontaneous,OT
196451951,Infliximab,Abortion spontaneous,HO
196451951,Infliximab,Abdominal distension,OT
196451951,Infliximab,Abdominal distension,HO
196551491,Infliximab (Unknown),Off label use,OT
196551491,Infliximab (Unknown),Diffuse large B-cell lymphoma,OT
196811141,Infliximab,Off label use,OT
196811141,Infliximab,Intentional product use issue,OT
196811141,Infliximab,Inappropriate schedule of product administration,OT
196811141,Infliximab,Fall,OT
196811141,Infliximab,Eye discharge,OT
196811141,Infliximab,Enterocutaneous fistula,OT
196811141,Infliximab,Condition aggravated,OT
196811141,Infliximab,Blood pressure fluctuation,OT
197070731,Infliximab,Drug ineffective,OT
197070731,Infliximab,Drug ineffective,HO
197102421,Infliximab,Uveitis,OT
197102421,Infliximab,Therapeutic product effect delayed,OT
197102421,Infliximab,Tearfulness,OT
197102421,Infliximab,Off label use,OT
197102421,Infliximab,Nausea,OT
197102421,Infliximab,Incorrect dose administered,OT
197102421,Infliximab,Emotional distress,OT
197102421,Infliximab,Condition aggravated,OT
197102421,Infliximab,Blood pressure increased,OT
197102421,Infliximab,Arthralgia,OT
197102421,Infliximab,Administration site extravasation,OT
197102421,Infliximab,Abdominal pain,OT
197137202,Infliximab,Off label use,OT
197137202,Infliximab,Myalgia,OT
197137202,Infliximab,Headache,OT
197137202,Infliximab,Arthralgia,OT
197137202,Infliximab,Off label use,OT
197137202,Infliximab,Myalgia,OT
197137202,Infliximab,Headache,OT
197137202,Infliximab,Arthralgia,OT
197137202,Infliximab,Off label use,OT
197137202,Infliximab,Myalgia,OT
197137202,Infliximab,Headache,OT
197137202,Infliximab,Arthralgia,OT
197439741,Infliximab,Upper respiratory tract infection,OT
197439741,Infliximab,Nasopharyngitis,OT
197439741,Infliximab,Infusion related reaction,OT
197439741,Infliximab,Drug ineffective,OT
197439741,Infliximab,Bronchitis,OT
197439741,Infliximab,Adverse event,OT
197439741,Infliximab,Upper respiratory tract infection,OT
197439741,Infliximab,Nasopharyngitis,OT
197439741,Infliximab,Infusion related reaction,OT
197439741,Infliximab,Drug ineffective,OT
197439741,Infliximab,Bronchitis,OT
197439741,Infliximab,Adverse event,OT
197439741,Infliximab,Upper respiratory tract infection,OT
197439741,Infliximab,Nasopharyngitis,OT
197439741,Infliximab,Infusion related reaction,OT
197439741,Infliximab,Drug ineffective,OT
197439741,Infliximab,Bronchitis,OT
197439741,Infliximab,Adverse event,OT
198060941,Infliximab,Sleep disorder due to a general medical condition,HO
198060941,Infliximab,Off label use,HO
198060941,Infliximab,Condition aggravated,HO
198190651,Infliximab,Strongyloidiasis,OT
198190651,Infliximab,Strongyloidiasis,HO
198190651,Infliximab,Septic shock,OT
198190651,Infliximab,Septic shock,HO
198190651,Infliximab,Pneumonia,OT
198190651,Infliximab,Pneumonia,HO
198190651,Infliximab,Immunodeficiency,OT
198190651,Infliximab,Immunodeficiency,HO
198190651,Infliximab,Enterococcal bacteraemia,OT
198190651,Infliximab,Enterococcal bacteraemia,HO
198190651,Infliximab,Disseminated strongyloidiasis,OT
198190651,Infliximab,Disseminated strongyloidiasis,HO
198298061,Infliximab,Weight decreased,OT
198298061,Infliximab,Off label use,OT
198298061,Infliximab,Intentional product use issue,OT
198298061,Infliximab,Feeling abnormal,OT
198298061,Infliximab,Drug ineffective,OT
198298061,Infliximab,Abscess,OT
198845081,Infliximab (Unknown),Off label use,NULL
198845081,Infliximab (Unknown),Liver function test increased,NULL
198845081,Infliximab (Unknown),Off label use,NULL
198845081,Infliximab (Unknown),Liver function test increased,NULL
198845081,Infliximab (Unknown),Off label use,NULL
198845081,Infliximab (Unknown),Liver function test increased,NULL
198871901,Infliximab (Unknown),Off label use,NULL
198871901,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198912681,Infliximab,Off label use,DE
198912681,Infliximab,Death,DE
198912701,Infliximab,Off label use,DE
198912701,Infliximab,Death,DE
153326142,Infliximab,Product use issue,OT
153326142,Infliximab,Product use in unapproved indication,OT
153326142,Infliximab,Off label use,OT
153326142,Infliximab,Adenovirus infection,OT
153326142,Infliximab,Product use issue,OT
153326142,Infliximab,Product use in unapproved indication,OT
153326142,Infliximab,Off label use,OT
153326142,Infliximab,Adenovirus infection,OT
160799235,Infliximab,Wheelchair user,OT
160799235,Infliximab,Wheelchair user,HO
160799235,Infliximab,Vomiting,OT
160799235,Infliximab,Vomiting,HO
160799235,Infliximab,Synovitis,OT
160799235,Infliximab,Synovitis,HO
160799235,Infliximab,Septic shock,OT
160799235,Infliximab,Septic shock,HO
160799235,Infliximab,Red blood cell sedimentation rate increased,OT
160799235,Infliximab,Red blood cell sedimentation rate increased,HO
160799235,Infliximab,Psoriasis,OT
160799235,Infliximab,Psoriasis,HO
160799235,Infliximab,Polyarthritis,OT
160799235,Infliximab,Polyarthritis,HO
160799235,Infliximab,Off label use,OT
160799235,Infliximab,Off label use,HO
160799235,Infliximab,Obesity,OT
160799235,Infliximab,Obesity,HO
160799235,Infliximab,Nausea,OT
160799235,Infliximab,Nausea,HO
160799235,Infliximab,Mobility decreased,OT
160799235,Infliximab,Mobility decreased,HO
160799235,Infliximab,Loss of personal independence in daily activities,OT
160799235,Infliximab,Loss of personal independence in daily activities,HO
160799235,Infliximab,Juvenile idiopathic arthritis,OT
160799235,Infliximab,Juvenile idiopathic arthritis,HO
160799235,Infliximab,Human antichimeric antibody positive,OT
160799235,Infliximab,Human antichimeric antibody positive,HO
160799235,Infliximab,Drug specific antibody,OT
160799235,Infliximab,Drug specific antibody,HO
160799235,Infliximab,Drug intolerance,OT
160799235,Infliximab,Drug intolerance,HO
160799235,Infliximab,Drug ineffective,OT
160799235,Infliximab,Drug ineffective,HO
160799235,Infliximab,Dizziness,OT
160799235,Infliximab,Dizziness,HO
160799235,Infliximab,Diarrhoea,OT
160799235,Infliximab,Diarrhoea,HO
160799235,Infliximab,Contraindicated product administered,OT
160799235,Infliximab,Contraindicated product administered,HO
160799235,Infliximab,Condition aggravated,OT
160799235,Infliximab,Condition aggravated,HO
160799235,Infliximab,C-reactive protein increased,OT
160799235,Infliximab,C-reactive protein increased,HO
160799235,Infliximab,Bone density increased,OT
160799235,Infliximab,Bone density increased,HO
160799235,Infliximab,Bone density decreased,OT
160799235,Infliximab,Bone density decreased,HO
160799235,Infliximab,Body height below normal,OT
160799235,Infliximab,Body height below normal,HO
160799235,Infliximab,Arthropathy,OT
160799235,Infliximab,Arthropathy,HO
160799235,Infliximab,Arthritis,OT
160799235,Infliximab,Arthritis,HO
160799235,Infliximab,Antibody test positive,OT
160799235,Infliximab,Antibody test positive,HO
160799235,Infliximab,Adrenal insufficiency,OT
160799235,Infliximab,Adrenal insufficiency,HO
160799235,Infliximab,Wheelchair user,OT
160799235,Infliximab,Wheelchair user,HO
160799235,Infliximab,Vomiting,OT
160799235,Infliximab,Vomiting,HO
160799235,Infliximab,Synovitis,OT
160799235,Infliximab,Synovitis,HO
160799235,Infliximab,Septic shock,OT
160799235,Infliximab,Septic shock,HO
160799235,Infliximab,Red blood cell sedimentation rate increased,OT
160799235,Infliximab,Red blood cell sedimentation rate increased,HO
160799235,Infliximab,Psoriasis,OT
160799235,Infliximab,Psoriasis,HO
160799235,Infliximab,Polyarthritis,OT
160799235,Infliximab,Polyarthritis,HO
160799235,Infliximab,Off label use,OT
160799235,Infliximab,Off label use,HO
160799235,Infliximab,Obesity,OT
160799235,Infliximab,Obesity,HO
160799235,Infliximab,Nausea,OT
160799235,Infliximab,Nausea,HO
160799235,Infliximab,Mobility decreased,OT
160799235,Infliximab,Mobility decreased,HO
160799235,Infliximab,Loss of personal independence in daily activities,OT
160799235,Infliximab,Loss of personal independence in daily activities,HO
160799235,Infliximab,Juvenile idiopathic arthritis,OT
160799235,Infliximab,Juvenile idiopathic arthritis,HO
160799235,Infliximab,Human antichimeric antibody positive,OT
160799235,Infliximab,Human antichimeric antibody positive,HO
160799235,Infliximab,Drug specific antibody,OT
160799235,Infliximab,Drug specific antibody,HO
160799235,Infliximab,Drug intolerance,OT
160799235,Infliximab,Drug intolerance,HO
160799235,Infliximab,Drug ineffective,OT
160799235,Infliximab,Drug ineffective,HO
160799235,Infliximab,Dizziness,OT
160799235,Infliximab,Dizziness,HO
160799235,Infliximab,Diarrhoea,OT
160799235,Infliximab,Diarrhoea,HO
160799235,Infliximab,Contraindicated product administered,OT
160799235,Infliximab,Contraindicated product administered,HO
160799235,Infliximab,Condition aggravated,OT
160799235,Infliximab,Condition aggravated,HO
160799235,Infliximab,C-reactive protein increased,OT
160799235,Infliximab,C-reactive protein increased,HO
160799235,Infliximab,Bone density increased,OT
160799235,Infliximab,Bone density increased,HO
160799235,Infliximab,Bone density decreased,OT
160799235,Infliximab,Bone density decreased,HO
160799235,Infliximab,Body height below normal,OT
160799235,Infliximab,Body height below normal,HO
160799235,Infliximab,Arthropathy,OT
160799235,Infliximab,Arthropathy,HO
160799235,Infliximab,Arthritis,OT
160799235,Infliximab,Arthritis,HO
160799235,Infliximab,Antibody test positive,OT
160799235,Infliximab,Antibody test positive,HO
160799235,Infliximab,Adrenal insufficiency,OT
160799235,Infliximab,Adrenal insufficiency,HO
160813576,Infliximab,Wound infection,OT
160813576,Infliximab,Wound infection,HO
160813576,Infliximab,Weight increased,OT
160813576,Infliximab,Weight increased,HO
160813576,Infliximab,Weight decreased,OT
160813576,Infliximab,Weight decreased,HO
160813576,Infliximab,Urinary tract infection,OT
160813576,Infliximab,Urinary tract infection,HO
160813576,Infliximab,Spinal osteoarthritis,OT
160813576,Infliximab,Spinal osteoarthritis,HO
160813576,Infliximab,SARS-CoV-2 test positive,OT
160813576,Infliximab,SARS-CoV-2 test positive,HO
160813576,Infliximab,Product use issue,OT
160813576,Infliximab,Product use issue,HO
160813576,Infliximab,Pain,OT
160813576,Infliximab,Pain,HO
160813576,Infliximab,Off label use,OT
160813576,Infliximab,Off label use,HO
160813576,Infliximab,Neck pain,OT
160813576,Infliximab,Neck pain,HO
160813576,Infliximab,Ligament injury,OT
160813576,Infliximab,Ligament injury,HO
160813576,Infliximab,Intentional product use issue,OT
160813576,Infliximab,Intentional product use issue,HO
160813576,Infliximab,Inappropriate schedule of product administration,OT
160813576,Infliximab,Inappropriate schedule of product administration,HO
160813576,Infliximab,Frequent bowel movements,OT
160813576,Infliximab,Frequent bowel movements,HO
160813576,Infliximab,Foot fracture,OT
160813576,Infliximab,Foot fracture,HO
160813576,Infliximab,Fatigue,OT
160813576,Infliximab,Fatigue,HO
160813576,Infliximab,Eye inflammation,OT
160813576,Infliximab,Eye inflammation,HO
160813576,Infliximab,Condition aggravated,OT
160813576,Infliximab,Condition aggravated,HO
160813576,Infliximab,Appendix cancer,OT
160813576,Infliximab,Appendix cancer,HO
160813576,Infliximab,Appendicitis,OT
160813576,Infliximab,Appendicitis,HO
160813576,Infliximab,Abdominal pain upper,OT
160813576,Infliximab,Abdominal pain upper,HO
160821794,Infliximab,Weight increased,HO
160821794,Infliximab,Weight increased,OT
160821794,Infliximab,Therapeutic response shortened,HO
160821794,Infliximab,Therapeutic response shortened,OT
160821794,Infliximab,Therapeutic product effect incomplete,HO
160821794,Infliximab,Therapeutic product effect incomplete,OT
160821794,Infliximab,Stress,HO
160821794,Infliximab,Stress,OT
160821794,Infliximab,Sinusitis,HO
160821794,Infliximab,Sinusitis,OT
160821794,Infliximab,Rectal haemorrhage,HO
160821794,Infliximab,Rectal haemorrhage,OT
160821794,Infliximab,Psoriasis,HO
160821794,Infliximab,Psoriasis,OT
160821794,Infliximab,Migraine,HO
160821794,Infliximab,Migraine,OT
160821794,Infliximab,Incorrect dose administered,HO
160821794,Infliximab,Incorrect dose administered,OT
160821794,Infliximab,Inappropriate schedule of product administration,HO
160821794,Infliximab,Inappropriate schedule of product administration,OT
160821794,Infliximab,Heart rate irregular,HO
160821794,Infliximab,Heart rate irregular,OT
160821794,Infliximab,Haematochezia,HO
160821794,Infliximab,Haematochezia,OT
160821794,Infliximab,Diet noncompliance,HO
160821794,Infliximab,Diet noncompliance,OT
160821794,Infliximab,Diarrhoea,HO
160821794,Infliximab,Diarrhoea,OT
160821794,Infliximab,Diabetes mellitus,HO
160821794,Infliximab,Diabetes mellitus,OT
160821794,Infliximab,Condition aggravated,HO
160821794,Infliximab,Condition aggravated,OT
160821794,Infliximab,Blood pressure increased,HO
160821794,Infliximab,Blood pressure increased,OT
160821794,Infliximab,Blood pressure fluctuation,HO
160821794,Infliximab,Blood pressure fluctuation,OT
160821794,Infliximab,Weight increased,HO
160821794,Infliximab,Weight increased,OT
160821794,Infliximab,Therapeutic response shortened,HO
160821794,Infliximab,Therapeutic response shortened,OT
160821794,Infliximab,Therapeutic product effect incomplete,HO
160821794,Infliximab,Therapeutic product effect incomplete,OT
160821794,Infliximab,Stress,HO
160821794,Infliximab,Stress,OT
160821794,Infliximab,Sinusitis,HO
160821794,Infliximab,Sinusitis,OT
160821794,Infliximab,Rectal haemorrhage,HO
160821794,Infliximab,Rectal haemorrhage,OT
160821794,Infliximab,Psoriasis,HO
160821794,Infliximab,Psoriasis,OT
160821794,Infliximab,Migraine,HO
160821794,Infliximab,Migraine,OT
160821794,Infliximab,Incorrect dose administered,HO
160821794,Infliximab,Incorrect dose administered,OT
160821794,Infliximab,Inappropriate schedule of product administration,HO
160821794,Infliximab,Inappropriate schedule of product administration,OT
160821794,Infliximab,Heart rate irregular,HO
160821794,Infliximab,Heart rate irregular,OT
160821794,Infliximab,Haematochezia,HO
160821794,Infliximab,Haematochezia,OT
160821794,Infliximab,Diet noncompliance,HO
160821794,Infliximab,Diet noncompliance,OT
160821794,Infliximab,Diarrhoea,HO
160821794,Infliximab,Diarrhoea,OT
160821794,Infliximab,Diabetes mellitus,HO
160821794,Infliximab,Diabetes mellitus,OT
160821794,Infliximab,Condition aggravated,HO
160821794,Infliximab,Condition aggravated,OT
160821794,Infliximab,Blood pressure increased,HO
160821794,Infliximab,Blood pressure increased,OT
160821794,Infliximab,Blood pressure fluctuation,HO
160821794,Infliximab,Blood pressure fluctuation,OT
173511524,Infliximab,Product use issue,HO
173511524,Infliximab,Pneumonia,HO
173511524,Infliximab,Off label use,HO
173511524,Infliximab,Infusion site extravasation,HO
173511524,Infliximab,Hypertension,HO
173511524,Infliximab,Headache,HO
173511524,Infliximab,Blood pressure fluctuation,HO
173557443,Infliximab,Weight increased,OT
173557443,Infliximab,Therapeutic response shortened,OT
173557443,Infliximab,Product use in unapproved indication,OT
173557443,Infliximab,Off label use,OT
173557443,Infliximab,Intentional product use issue,OT
173557443,Infliximab,Inappropriate schedule of product administration,OT
173557443,Infliximab,Haemorrhage urinary tract,OT
173557443,Infliximab,Dysuria,OT
173557443,Infliximab,Condition aggravated,OT
173557443,Infliximab,Blood pressure increased,OT
173557443,Infliximab,Blood pressure decreased,OT
173557443,Infliximab,Weight increased,OT
173557443,Infliximab,Therapeutic response shortened,OT
173557443,Infliximab,Product use in unapproved indication,OT
173557443,Infliximab,Off label use,OT
173557443,Infliximab,Intentional product use issue,OT
173557443,Infliximab,Inappropriate schedule of product administration,OT
173557443,Infliximab,Haemorrhage urinary tract,OT
173557443,Infliximab,Dysuria,OT
173557443,Infliximab,Condition aggravated,OT
173557443,Infliximab,Blood pressure increased,OT
173557443,Infliximab,Blood pressure decreased,OT
173557443,Infliximab,Weight increased,OT
173557443,Infliximab,Therapeutic response shortened,OT
173557443,Infliximab,Product use in unapproved indication,OT
173557443,Infliximab,Off label use,OT
173557443,Infliximab,Intentional product use issue,OT
173557443,Infliximab,Inappropriate schedule of product administration,OT
173557443,Infliximab,Haemorrhage urinary tract,OT
173557443,Infliximab,Dysuria,OT
173557443,Infliximab,Condition aggravated,OT
173557443,Infliximab,Blood pressure increased,OT
173557443,Infliximab,Blood pressure decreased,OT
175842783,Infliximab,Weight decreased,OT
175842783,Infliximab,Nasopharyngitis,OT
175842783,Infliximab,Heart rate irregular,OT
175842783,Infliximab,Heart rate decreased,OT
175842783,Infliximab,Condition aggravated,OT
175842783,Infliximab,COVID-19,OT
175842783,Infliximab,Blood pressure fluctuation,OT
175842783,Infliximab,Blood pressure diastolic decreased,OT
175842783,Infliximab,Blood pressure decreased,OT
175842783,Infliximab,Weight decreased,OT
175842783,Infliximab,Nasopharyngitis,OT
175842783,Infliximab,Heart rate irregular,OT
175842783,Infliximab,Heart rate decreased,OT
175842783,Infliximab,Condition aggravated,OT
175842783,Infliximab,COVID-19,OT
175842783,Infliximab,Blood pressure fluctuation,OT
175842783,Infliximab,Blood pressure diastolic decreased,OT
175842783,Infliximab,Blood pressure decreased,OT
176024604,Infliximab,Therapeutic product effect incomplete,OT
176024604,Infliximab,Spinal deformity,OT
176024604,Infliximab,Skin ulcer,OT
176024604,Infliximab,Rib fracture,OT
176024604,Infliximab,Purulent discharge,OT
176024604,Infliximab,Product use issue,OT
176024604,Infliximab,Pain,OT
176024604,Infliximab,Off label use,OT
176024604,Infliximab,Musculoskeletal pain,OT
176024604,Infliximab,Malaise,OT
176024604,Infliximab,Intentional product use issue,OT
176024604,Infliximab,Injection site swelling,OT
176024604,Infliximab,Infusion site swelling,OT
176024604,Infliximab,Inappropriate schedule of product administration,OT
176024604,Infliximab,Hypertension,OT
176024604,Infliximab,Fatigue,OT
176024604,Infliximab,Drug ineffective,OT
176024604,Infliximab,Dizziness,OT
176024604,Infliximab,Condition aggravated,OT
176024604,Infliximab,Chest discomfort,OT
176024604,Infliximab,Blood pressure fluctuation,OT
176024604,Infliximab,Blood pressure decreased,OT
176024604,Infliximab,Back pain,OT
176024604,Infliximab,Arthralgia,OT
176024604,Infliximab,Therapeutic product effect incomplete,OT
176024604,Infliximab,Spinal deformity,OT
176024604,Infliximab,Skin ulcer,OT
176024604,Infliximab,Rib fracture,OT
176024604,Infliximab,Purulent discharge,OT
176024604,Infliximab,Product use issue,OT
176024604,Infliximab,Pain,OT
176024604,Infliximab,Off label use,OT
176024604,Infliximab,Musculoskeletal pain,OT
176024604,Infliximab,Malaise,OT
176024604,Infliximab,Intentional product use issue,OT
176024604,Infliximab,Injection site swelling,OT
176024604,Infliximab,Infusion site swelling,OT
176024604,Infliximab,Inappropriate schedule of product administration,OT
176024604,Infliximab,Hypertension,OT
176024604,Infliximab,Fatigue,OT
176024604,Infliximab,Drug ineffective,OT
176024604,Infliximab,Dizziness,OT
176024604,Infliximab,Condition aggravated,OT
176024604,Infliximab,Chest discomfort,OT
176024604,Infliximab,Blood pressure fluctuation,OT
176024604,Infliximab,Blood pressure decreased,OT
176024604,Infliximab,Back pain,OT
176024604,Infliximab,Arthralgia,OT
176024604,Infliximab,Therapeutic product effect incomplete,OT
176024604,Infliximab,Spinal deformity,OT
176024604,Infliximab,Skin ulcer,OT
176024604,Infliximab,Rib fracture,OT
176024604,Infliximab,Purulent discharge,OT
176024604,Infliximab,Product use issue,OT
176024604,Infliximab,Pain,OT
176024604,Infliximab,Off label use,OT
176024604,Infliximab,Musculoskeletal pain,OT
176024604,Infliximab,Malaise,OT
176024604,Infliximab,Intentional product use issue,OT
176024604,Infliximab,Injection site swelling,OT
176024604,Infliximab,Infusion site swelling,OT
176024604,Infliximab,Inappropriate schedule of product administration,OT
176024604,Infliximab,Hypertension,OT
176024604,Infliximab,Fatigue,OT
176024604,Infliximab,Drug ineffective,OT
176024604,Infliximab,Dizziness,OT
176024604,Infliximab,Condition aggravated,OT
176024604,Infliximab,Chest discomfort,OT
176024604,Infliximab,Blood pressure fluctuation,OT
176024604,Infliximab,Blood pressure decreased,OT
176024604,Infliximab,Back pain,OT
176024604,Infliximab,Arthralgia,OT
176024604,Infliximab,Therapeutic product effect incomplete,OT
176024604,Infliximab,Spinal deformity,OT
176024604,Infliximab,Skin ulcer,OT
176024604,Infliximab,Rib fracture,OT
176024604,Infliximab,Purulent discharge,OT
176024604,Infliximab,Product use issue,OT
176024604,Infliximab,Pain,OT
176024604,Infliximab,Off label use,OT
176024604,Infliximab,Musculoskeletal pain,OT
176024604,Infliximab,Malaise,OT
176024604,Infliximab,Intentional product use issue,OT
176024604,Infliximab,Injection site swelling,OT
176024604,Infliximab,Infusion site swelling,OT
176024604,Infliximab,Inappropriate schedule of product administration,OT
176024604,Infliximab,Hypertension,OT
176024604,Infliximab,Fatigue,OT
176024604,Infliximab,Drug ineffective,OT
176024604,Infliximab,Dizziness,OT
176024604,Infliximab,Condition aggravated,OT
176024604,Infliximab,Chest discomfort,OT
176024604,Infliximab,Blood pressure fluctuation,OT
176024604,Infliximab,Blood pressure decreased,OT
176024604,Infliximab,Back pain,OT
176024604,Infliximab,Arthralgia,OT
176024604,Infliximab,Therapeutic product effect incomplete,OT
176024604,Infliximab,Spinal deformity,OT
176024604,Infliximab,Skin ulcer,OT
176024604,Infliximab,Rib fracture,OT
176024604,Infliximab,Purulent discharge,OT
176024604,Infliximab,Product use issue,OT
176024604,Infliximab,Pain,OT
176024604,Infliximab,Off label use,OT
176024604,Infliximab,Musculoskeletal pain,OT
176024604,Infliximab,Malaise,OT
176024604,Infliximab,Intentional product use issue,OT
176024604,Infliximab,Injection site swelling,OT
176024604,Infliximab,Infusion site swelling,OT
176024604,Infliximab,Inappropriate schedule of product administration,OT
176024604,Infliximab,Hypertension,OT
176024604,Infliximab,Fatigue,OT
176024604,Infliximab,Drug ineffective,OT
176024604,Infliximab,Dizziness,OT
176024604,Infliximab,Condition aggravated,OT
176024604,Infliximab,Chest discomfort,OT
176024604,Infliximab,Blood pressure fluctuation,OT
176024604,Infliximab,Blood pressure decreased,OT
176024604,Infliximab,Back pain,OT
176024604,Infliximab,Arthralgia,OT
176024604,Infliximab,Therapeutic product effect incomplete,OT
176024604,Infliximab,Spinal deformity,OT
176024604,Infliximab,Skin ulcer,OT
176024604,Infliximab,Rib fracture,OT
176024604,Infliximab,Purulent discharge,OT
176024604,Infliximab,Product use issue,OT
176024604,Infliximab,Pain,OT
176024604,Infliximab,Off label use,OT
176024604,Infliximab,Musculoskeletal pain,OT
176024604,Infliximab,Malaise,OT
176024604,Infliximab,Intentional product use issue,OT
176024604,Infliximab,Injection site swelling,OT
176024604,Infliximab,Infusion site swelling,OT
176024604,Infliximab,Inappropriate schedule of product administration,OT
176024604,Infliximab,Hypertension,OT
176024604,Infliximab,Fatigue,OT
176024604,Infliximab,Drug ineffective,OT
176024604,Infliximab,Dizziness,OT
176024604,Infliximab,Condition aggravated,OT
176024604,Infliximab,Chest discomfort,OT
176024604,Infliximab,Blood pressure fluctuation,OT
176024604,Infliximab,Blood pressure decreased,OT
176024604,Infliximab,Back pain,OT
176024604,Infliximab,Arthralgia,OT
176057973,Infliximab,Weight increased,OT
176057973,Infliximab,Weight increased,HO
176057973,Infliximab,Rectal haemorrhage,OT
176057973,Infliximab,Rectal haemorrhage,HO
176057973,Infliximab,Pyrexia,OT
176057973,Infliximab,Pyrexia,HO
176057973,Infliximab,Product use issue,OT
176057973,Infliximab,Product use issue,HO
176057973,Infliximab,Pain,OT
176057973,Infliximab,Pain,HO
176057973,Infliximab,Off label use,OT
176057973,Infliximab,Off label use,HO
176057973,Infliximab,Nasopharyngitis,OT
176057973,Infliximab,Nasopharyngitis,HO
176057973,Infliximab,Malaise,OT
176057973,Infliximab,Malaise,HO
176057973,Infliximab,Influenza like illness,OT
176057973,Infliximab,Influenza like illness,HO
176057973,Infliximab,Inappropriate schedule of product administration,OT
176057973,Infliximab,Inappropriate schedule of product administration,HO
176057973,Infliximab,Heart rate irregular,OT
176057973,Infliximab,Heart rate irregular,HO
176057973,Infliximab,Heart rate decreased,OT
176057973,Infliximab,Heart rate decreased,HO
176057973,Infliximab,Drug level below therapeutic,OT
176057973,Infliximab,Drug level below therapeutic,HO
176057973,Infliximab,Drug level above therapeutic,OT
176057973,Infliximab,Drug level above therapeutic,HO
176057973,Infliximab,Condition aggravated,OT
176057973,Infliximab,Condition aggravated,HO
176057973,Infliximab,Anal fistula,OT
176057973,Infliximab,Anal fistula,HO
176057973,Infliximab,Weight increased,OT
176057973,Infliximab,Weight increased,HO
176057973,Infliximab,Rectal haemorrhage,OT
176057973,Infliximab,Rectal haemorrhage,HO
176057973,Infliximab,Pyrexia,OT
176057973,Infliximab,Pyrexia,HO
176057973,Infliximab,Product use issue,OT
176057973,Infliximab,Product use issue,HO
176057973,Infliximab,Pain,OT
176057973,Infliximab,Pain,HO
176057973,Infliximab,Off label use,OT
176057973,Infliximab,Off label use,HO
176057973,Infliximab,Nasopharyngitis,OT
176057973,Infliximab,Nasopharyngitis,HO
176057973,Infliximab,Malaise,OT
176057973,Infliximab,Malaise,HO
176057973,Infliximab,Influenza like illness,OT
176057973,Infliximab,Influenza like illness,HO
176057973,Infliximab,Inappropriate schedule of product administration,OT
176057973,Infliximab,Inappropriate schedule of product administration,HO
176057973,Infliximab,Heart rate irregular,OT
176057973,Infliximab,Heart rate irregular,HO
176057973,Infliximab,Heart rate decreased,OT
176057973,Infliximab,Heart rate decreased,HO
176057973,Infliximab,Drug level below therapeutic,OT
176057973,Infliximab,Drug level below therapeutic,HO
176057973,Infliximab,Drug level above therapeutic,OT
176057973,Infliximab,Drug level above therapeutic,HO
176057973,Infliximab,Condition aggravated,OT
176057973,Infliximab,Condition aggravated,HO
176057973,Infliximab,Anal fistula,OT
176057973,Infliximab,Anal fistula,HO
176057973,Infliximab,Weight increased,OT
176057973,Infliximab,Weight increased,HO
176057973,Infliximab,Rectal haemorrhage,OT
176057973,Infliximab,Rectal haemorrhage,HO
176057973,Infliximab,Pyrexia,OT
176057973,Infliximab,Pyrexia,HO
176057973,Infliximab,Product use issue,OT
176057973,Infliximab,Product use issue,HO
176057973,Infliximab,Pain,OT
176057973,Infliximab,Pain,HO
176057973,Infliximab,Off label use,OT
176057973,Infliximab,Off label use,HO
176057973,Infliximab,Nasopharyngitis,OT
176057973,Infliximab,Nasopharyngitis,HO
176057973,Infliximab,Malaise,OT
176057973,Infliximab,Malaise,HO
176057973,Infliximab,Influenza like illness,OT
176057973,Infliximab,Influenza like illness,HO
176057973,Infliximab,Inappropriate schedule of product administration,OT
176057973,Infliximab,Inappropriate schedule of product administration,HO
176057973,Infliximab,Heart rate irregular,OT
176057973,Infliximab,Heart rate irregular,HO
176057973,Infliximab,Heart rate decreased,OT
176057973,Infliximab,Heart rate decreased,HO
176057973,Infliximab,Drug level below therapeutic,OT
176057973,Infliximab,Drug level below therapeutic,HO
176057973,Infliximab,Drug level above therapeutic,OT
176057973,Infliximab,Drug level above therapeutic,HO
176057973,Infliximab,Condition aggravated,OT
176057973,Infliximab,Condition aggravated,HO
176057973,Infliximab,Anal fistula,OT
176057973,Infliximab,Anal fistula,HO
176469554,Infliximab,Tonsillitis,HO
176469554,Infliximab,Tonsillitis,OT
176469554,Infliximab,Tachycardia,HO
176469554,Infliximab,Tachycardia,OT
176469554,Infliximab,Sinus congestion,HO
176469554,Infliximab,Sinus congestion,OT
176469554,Infliximab,Pyrexia,HO
176469554,Infliximab,Pyrexia,OT
176469554,Infliximab,Product use issue,HO
176469554,Infliximab,Product use issue,OT
176469554,Infliximab,Pneumonia,HO
176469554,Infliximab,Pneumonia,OT
176469554,Infliximab,Pain,HO
176469554,Infliximab,Pain,OT
176469554,Infliximab,Off label use,HO
176469554,Infliximab,Off label use,OT
176469554,Infliximab,Intentional product use issue,HO
176469554,Infliximab,Intentional product use issue,OT
176469554,Infliximab,Inflammation,HO
176469554,Infliximab,Inflammation,OT
176469554,Infliximab,Inappropriate schedule of product administration,HO
176469554,Infliximab,Inappropriate schedule of product administration,OT
176469554,Infliximab,Headache,HO
176469554,Infliximab,Headache,OT
176469554,Infliximab,Gastrooesophageal reflux disease,HO
176469554,Infliximab,Gastrooesophageal reflux disease,OT
176469554,Infliximab,Dyspepsia,HO
176469554,Infliximab,Dyspepsia,OT
176469554,Infliximab,Diarrhoea,HO
176469554,Infliximab,Diarrhoea,OT
176469554,Infliximab,Decreased appetite,HO
176469554,Infliximab,Decreased appetite,OT
176469554,Infliximab,Condition aggravated,HO
176469554,Infliximab,Condition aggravated,OT
176469554,Infliximab,Chills,HO
176469554,Infliximab,Chills,OT
176469554,Infliximab,Body temperature fluctuation,HO
176469554,Infliximab,Body temperature fluctuation,OT
176469554,Infliximab,Body temperature decreased,HO
176469554,Infliximab,Body temperature decreased,OT
176469554,Infliximab,Blood pressure increased,HO
176469554,Infliximab,Blood pressure increased,OT
176469554,Infliximab,Blood pressure fluctuation,HO
176469554,Infliximab,Blood pressure fluctuation,OT
176469554,Infliximab,Arrhythmia,HO
176469554,Infliximab,Arrhythmia,OT
176469554,Infliximab,Abdominal pain,HO
176469554,Infliximab,Abdominal pain,OT
176469554,Infliximab,Tonsillitis,HO
176469554,Infliximab,Tonsillitis,OT
176469554,Infliximab,Tachycardia,HO
176469554,Infliximab,Tachycardia,OT
176469554,Infliximab,Sinus congestion,HO
176469554,Infliximab,Sinus congestion,OT
176469554,Infliximab,Pyrexia,HO
176469554,Infliximab,Pyrexia,OT
176469554,Infliximab,Product use issue,HO
176469554,Infliximab,Product use issue,OT
176469554,Infliximab,Pneumonia,HO
176469554,Infliximab,Pneumonia,OT
176469554,Infliximab,Pain,HO
176469554,Infliximab,Pain,OT
176469554,Infliximab,Off label use,HO
176469554,Infliximab,Off label use,OT
176469554,Infliximab,Intentional product use issue,HO
176469554,Infliximab,Intentional product use issue,OT
176469554,Infliximab,Inflammation,HO
176469554,Infliximab,Inflammation,OT
176469554,Infliximab,Inappropriate schedule of product administration,HO
176469554,Infliximab,Inappropriate schedule of product administration,OT
176469554,Infliximab,Headache,HO
176469554,Infliximab,Headache,OT
176469554,Infliximab,Gastrooesophageal reflux disease,HO
176469554,Infliximab,Gastrooesophageal reflux disease,OT
176469554,Infliximab,Dyspepsia,HO
176469554,Infliximab,Dyspepsia,OT
176469554,Infliximab,Diarrhoea,HO
176469554,Infliximab,Diarrhoea,OT
176469554,Infliximab,Decreased appetite,HO
176469554,Infliximab,Decreased appetite,OT
176469554,Infliximab,Condition aggravated,HO
176469554,Infliximab,Condition aggravated,OT
176469554,Infliximab,Chills,HO
176469554,Infliximab,Chills,OT
176469554,Infliximab,Body temperature fluctuation,HO
176469554,Infliximab,Body temperature fluctuation,OT
176469554,Infliximab,Body temperature decreased,HO
176469554,Infliximab,Body temperature decreased,OT
176469554,Infliximab,Blood pressure increased,HO
176469554,Infliximab,Blood pressure increased,OT
176469554,Infliximab,Blood pressure fluctuation,HO
176469554,Infliximab,Blood pressure fluctuation,OT
176469554,Infliximab,Arrhythmia,HO
176469554,Infliximab,Arrhythmia,OT
176469554,Infliximab,Abdominal pain,HO
176469554,Infliximab,Abdominal pain,OT
176529303,Infliximab,Weight increased,OT
176529303,Infliximab,Rhinorrhoea,OT
176529303,Infliximab,Productive cough,OT
176529303,Infliximab,Off label use,OT
176529303,Infliximab,Nasopharyngitis,OT
176529303,Infliximab,Nasal congestion,OT
176529303,Infliximab,Malaise,OT
176529303,Infliximab,Inappropriate schedule of product administration,OT
176529303,Infliximab,Heart rate irregular,OT
176529303,Infliximab,Headache,OT
176529303,Infliximab,Furuncle,OT
176529303,Infliximab,Eye disorder,OT
176529303,Infliximab,Drug level below therapeutic,OT
176529303,Infliximab,Drug level above therapeutic,OT
176529303,Infliximab,Diarrhoea,OT
176529303,Infliximab,Crohn's disease,OT
176529303,Infliximab,Blood pressure fluctuation,OT
176529303,Infliximab,Back pain,OT
176529303,Infliximab,Anal abscess,OT
176529303,Infliximab,Abscess oral,OT
176529303,Infliximab,Abscess limb,OT
176529303,Infliximab,Abdominal pain upper,OT
176529303,Infliximab,Abdominal pain,OT
176582985,Infliximab,Weight decreased,OT
176582985,Infliximab,Uveitis,OT
176582985,Infliximab,Therapeutic response shortened,OT
176582985,Infliximab,Stress,OT
176582985,Infliximab,Steatorrhoea,OT
176582985,Infliximab,Oropharyngeal discomfort,OT
176582985,Infliximab,Off label use,OT
176582985,Infliximab,Musculoskeletal discomfort,OT
176582985,Infliximab,Inflammatory bowel disease,OT
176582985,Infliximab,Inflammation,OT
176582985,Infliximab,Inappropriate schedule of product administration,OT
176582985,Infliximab,Heart rate irregular,OT
176582985,Infliximab,Feeling abnormal,OT
176582985,Infliximab,Faeces discoloured,OT
176582985,Infliximab,Dyspnoea,OT
176582985,Infliximab,Drug level above therapeutic,OT
176582985,Infliximab,Diverticulitis,OT
176582985,Infliximab,Constipation,OT
176582985,Infliximab,Condition aggravated,OT
176582985,Infliximab,Chest pain,OT
176582985,Infliximab,Chest discomfort,OT
176582985,Infliximab,Blood pressure diastolic decreased,OT
176582985,Infliximab,Arthralgia,OT
176582985,Infliximab,Anal fissure,OT
176582985,Infliximab,Abnormal faeces,OT
176582985,Infliximab,Abdominal pain,OT
176582985,Infliximab,Abdominal distension,OT
176895935,Infliximab,Therapeutic response shortened,OT
176895935,Infliximab,Therapeutic response shortened,HO
176895935,Infliximab,Peripheral swelling,OT
176895935,Infliximab,Peripheral swelling,HO
176895935,Infliximab,Off label use,OT
176895935,Infliximab,Off label use,HO
176895935,Infliximab,Musculoskeletal stiffness,OT
176895935,Infliximab,Musculoskeletal stiffness,HO
176895935,Infliximab,Melaena,OT
176895935,Infliximab,Melaena,HO
176895935,Infliximab,Malaise,OT
176895935,Infliximab,Malaise,HO
176895935,Infliximab,Intestinal obstruction,OT
176895935,Infliximab,Intestinal obstruction,HO
176895935,Infliximab,Infusion site swelling,OT
176895935,Infliximab,Infusion site swelling,HO
176895935,Infliximab,Hypoaesthesia,OT
176895935,Infliximab,Hypoaesthesia,HO
176895935,Infliximab,Hypertension,OT
176895935,Infliximab,Hypertension,HO
176895935,Infliximab,Heart rate decreased,OT
176895935,Infliximab,Heart rate decreased,HO
176895935,Infliximab,Drug level below therapeutic,OT
176895935,Infliximab,Drug level below therapeutic,HO
176895935,Infliximab,Drug ineffective,OT
176895935,Infliximab,Drug ineffective,HO
176895935,Infliximab,Condition aggravated,OT
176895935,Infliximab,Condition aggravated,HO
176895935,Infliximab,Blood pressure fluctuation,OT
176895935,Infliximab,Blood pressure fluctuation,HO
176895935,Infliximab,Therapeutic response shortened,OT
176895935,Infliximab,Therapeutic response shortened,HO
176895935,Infliximab,Peripheral swelling,OT
176895935,Infliximab,Peripheral swelling,HO
176895935,Infliximab,Off label use,OT
176895935,Infliximab,Off label use,HO
176895935,Infliximab,Musculoskeletal stiffness,OT
176895935,Infliximab,Musculoskeletal stiffness,HO
176895935,Infliximab,Melaena,OT
176895935,Infliximab,Melaena,HO
176895935,Infliximab,Malaise,OT
176895935,Infliximab,Malaise,HO
176895935,Infliximab,Intestinal obstruction,OT
176895935,Infliximab,Intestinal obstruction,HO
176895935,Infliximab,Infusion site swelling,OT
176895935,Infliximab,Infusion site swelling,HO
176895935,Infliximab,Hypoaesthesia,OT
176895935,Infliximab,Hypoaesthesia,HO
176895935,Infliximab,Hypertension,OT
176895935,Infliximab,Hypertension,HO
176895935,Infliximab,Heart rate decreased,OT
176895935,Infliximab,Heart rate decreased,HO
176895935,Infliximab,Drug level below therapeutic,OT
176895935,Infliximab,Drug level below therapeutic,HO
176895935,Infliximab,Drug ineffective,OT
176895935,Infliximab,Drug ineffective,HO
176895935,Infliximab,Condition aggravated,OT
176895935,Infliximab,Condition aggravated,HO
176895935,Infliximab,Blood pressure fluctuation,OT
176895935,Infliximab,Blood pressure fluctuation,HO
176945373,Infliximab,Weight increased,OT
176945373,Infliximab,Weight decreased,OT
176945373,Infliximab,Vomiting,OT
176945373,Infliximab,Urinary tract infection,OT
176945373,Infliximab,Tonsillar inflammation,OT
176945373,Infliximab,Suspected COVID-19,OT
176945373,Infliximab,Stress,OT
176945373,Infliximab,Sensation of foreign body,OT
176945373,Infliximab,Oropharyngeal pain,OT
176945373,Infliximab,Off label use,OT
176945373,Infliximab,Nausea,OT
176945373,Infliximab,Myalgia,OT
176945373,Infliximab,Malaise,OT
176945373,Infliximab,Intentional product use issue,OT
176945373,Infliximab,Influenza,OT
176945373,Infliximab,Headache,OT
176945373,Infliximab,Fatigue,OT
176945373,Infliximab,Endometrial disorder,OT
176945373,Infliximab,Cough,OT
176945373,Infliximab,Chest pain,OT
176945373,Infliximab,Blood pressure increased,OT
176945373,Infliximab,Weight increased,OT
176945373,Infliximab,Weight decreased,OT
176945373,Infliximab,Vomiting,OT
176945373,Infliximab,Urinary tract infection,OT
176945373,Infliximab,Tonsillar inflammation,OT
176945373,Infliximab,Suspected COVID-19,OT
176945373,Infliximab,Stress,OT
176945373,Infliximab,Sensation of foreign body,OT
176945373,Infliximab,Oropharyngeal pain,OT
176945373,Infliximab,Off label use,OT
176945373,Infliximab,Nausea,OT
176945373,Infliximab,Myalgia,OT
176945373,Infliximab,Malaise,OT
176945373,Infliximab,Intentional product use issue,OT
176945373,Infliximab,Influenza,OT
176945373,Infliximab,Headache,OT
176945373,Infliximab,Fatigue,OT
176945373,Infliximab,Endometrial disorder,OT
176945373,Infliximab,Cough,OT
176945373,Infliximab,Chest pain,OT
176945373,Infliximab,Blood pressure increased,OT
177005654,Infliximab,Product use issue,HO
177005654,Infliximab,Obstruction,HO
177005654,Infliximab,Drug intolerance,HO
177005654,Infliximab,Drug ineffective,HO
177005654,Infliximab,Product use issue,HO
177005654,Infliximab,Obstruction,HO
177005654,Infliximab,Drug intolerance,HO
177005654,Infliximab,Drug ineffective,HO
177005654,Infliximab,Product use issue,HO
177005654,Infliximab,Obstruction,HO
177005654,Infliximab,Drug intolerance,HO
177005654,Infliximab,Drug ineffective,HO
177005654,Infliximab,Product use issue,HO
177005654,Infliximab,Obstruction,HO
177005654,Infliximab,Drug intolerance,HO
177005654,Infliximab,Drug ineffective,HO
184164252,Infliximab,Skin ulcer,OT
184164252,Infliximab,Skin discharge,OT
184164252,Infliximab,Sensitivity to weather change,OT
184164252,Infliximab,Rhinorrhoea,OT
184164252,Infliximab,Pulmonary embolism,OT
184164252,Infliximab,Nausea,OT
184164252,Infliximab,Nasopharyngitis,OT
184164252,Infliximab,Malaise,OT
184164252,Infliximab,Influenza,OT
184164252,Infliximab,Incorrect dose administered,OT
184164252,Infliximab,Illness,OT
184164252,Infliximab,Headache,OT
184164252,Infliximab,Fatigue,OT
184164252,Infliximab,Dysphonia,OT
184164252,Infliximab,Dyspepsia,OT
184164252,Infliximab,Cough,OT
184164252,Infliximab,Condition aggravated,OT
184164252,Infliximab,Body temperature increased,OT
184164252,Infliximab,Blood pressure increased,OT
184164252,Infliximab,Blood pressure fluctuation,OT
184164252,Infliximab,Arthralgia,OT
185068533,Infliximab,Weight decreased,OT
185068533,Infliximab,Therapeutic response shortened,OT
185068533,Infliximab,Synovial cyst,OT
185068533,Infliximab,Swelling,OT
185068533,Infliximab,Rheumatoid arthritis,OT
185068533,Infliximab,Product use issue,OT
185068533,Infliximab,Pneumonia,OT
185068533,Infliximab,Painful respiration,OT
185068533,Infliximab,Pain in extremity,OT
185068533,Infliximab,Pain,OT
185068533,Infliximab,Off label use,OT
185068533,Infliximab,Musculoskeletal pain,OT
185068533,Infliximab,Middle insomnia,OT
185068533,Infliximab,Lethargy,OT
185068533,Infliximab,Joint stiffness,OT
185068533,Infliximab,Inappropriate schedule of product administration,OT
185068533,Infliximab,Heart rate decreased,OT
185068533,Infliximab,Fatigue,OT
185068533,Infliximab,Blood pressure increased,OT
185068533,Infliximab,Blood pressure fluctuation,OT
185068533,Infliximab,Back pain,OT
185068533,Infliximab,Arthralgia,OT
185068533,Infliximab,Weight decreased,OT
185068533,Infliximab,Therapeutic response shortened,OT
185068533,Infliximab,Synovial cyst,OT
185068533,Infliximab,Swelling,OT
185068533,Infliximab,Rheumatoid arthritis,OT
185068533,Infliximab,Product use issue,OT
185068533,Infliximab,Pneumonia,OT
185068533,Infliximab,Painful respiration,OT
185068533,Infliximab,Pain in extremity,OT
185068533,Infliximab,Pain,OT
185068533,Infliximab,Off label use,OT
185068533,Infliximab,Musculoskeletal pain,OT
185068533,Infliximab,Middle insomnia,OT
185068533,Infliximab,Lethargy,OT
185068533,Infliximab,Joint stiffness,OT
185068533,Infliximab,Inappropriate schedule of product administration,OT
185068533,Infliximab,Heart rate decreased,OT
185068533,Infliximab,Fatigue,OT
185068533,Infliximab,Blood pressure increased,OT
185068533,Infliximab,Blood pressure fluctuation,OT
185068533,Infliximab,Back pain,OT
185068533,Infliximab,Arthralgia,OT
185068533,Infliximab,Weight decreased,OT
185068533,Infliximab,Therapeutic response shortened,OT
185068533,Infliximab,Synovial cyst,OT
185068533,Infliximab,Swelling,OT
185068533,Infliximab,Rheumatoid arthritis,OT
185068533,Infliximab,Product use issue,OT
185068533,Infliximab,Pneumonia,OT
185068533,Infliximab,Painful respiration,OT
185068533,Infliximab,Pain in extremity,OT
185068533,Infliximab,Pain,OT
185068533,Infliximab,Off label use,OT
185068533,Infliximab,Musculoskeletal pain,OT
185068533,Infliximab,Middle insomnia,OT
185068533,Infliximab,Lethargy,OT
185068533,Infliximab,Joint stiffness,OT
185068533,Infliximab,Inappropriate schedule of product administration,OT
185068533,Infliximab,Heart rate decreased,OT
185068533,Infliximab,Fatigue,OT
185068533,Infliximab,Blood pressure increased,OT
185068533,Infliximab,Blood pressure fluctuation,OT
185068533,Infliximab,Back pain,OT
185068533,Infliximab,Arthralgia,OT
188909974,Infliximab (Unknown),Vitamin D deficiency,HO
188909974,Infliximab (Unknown),Pulpitis dental,HO
188909974,Infliximab (Unknown),Hordeolum,HO
188909974,Infliximab (Unknown),Colitis,HO
188909974,Infliximab (Unknown),Adverse drug reaction,HO
194793751,Infliximab,Weight decreased,OT
194793751,Infliximab,Therapeutic product effect incomplete,OT
194793751,Infliximab,Product use issue,OT
194793751,Infliximab,Off label use,OT
194793751,Infliximab,Illness,OT
194849791,Infliximab (Unknown),Weight decreased,OT
194849791,Infliximab (Unknown),Therapy partial responder,OT
194849791,Infliximab (Unknown),Pyrexia,OT
194849791,Infliximab (Unknown),Off label use,OT
194849791,Infliximab (Unknown),Neoplasm malignant,OT
194849791,Infliximab (Unknown),Diarrhoea haemorrhagic,OT
194849791,Infliximab (Unknown),Condition aggravated,OT
194849791,Infliximab (Unknown),Colon dysplasia,OT
194849791,Infliximab (Unknown),Arthritis enteropathic,OT
195012481,Infliximab Pfizer (Unknown),Takayasu's arteritis,OT
195140142,Infliximab (Unknown),Anaphylactic reaction,HO
195140142,Infliximab (Unknown),Anaphylactic reaction,OT
195140142,Infliximab (Unknown),Anaphylactic reaction,HO
195140142,Infliximab (Unknown),Anaphylactic reaction,OT
195446311,Infliximab,Oropharyngeal pain,OT
195446311,Infliximab,Nasopharyngitis,OT
195446311,Infliximab,Nasal congestion,OT
195446311,Infliximab,Mucous stools,OT
195446311,Infliximab,Haematochezia,OT
195446311,Infliximab,Condition aggravated,OT
195446311,Infliximab,Anal fissure,OT
195628421,Infliximab,Off label use,OT
195628421,Infliximab,Heart rate irregular,OT
195628421,Infliximab,Gastrointestinal disorder,OT
195628421,Infliximab,Body temperature decreased,OT
195628421,Infliximab,Blood pressure fluctuation,OT
196654671,Infliximab (Unknown),Off label use,OT
196654671,Infliximab (Unknown),Drug specific antibody present,OT
196654671,Infliximab (Unknown),Drug ineffective,OT
196654671,Infliximab (Unknown),Anaphylactic reaction,OT
197101021,Infliximab,Psoriasis,OT
197101021,Infliximab,Migraine,OT
197101021,Infliximab,Incorrect route of product administration,OT
197101021,Infliximab,Hypertension,OT
197101021,Infliximab,Endometriosis,OT
197101021,Infliximab,Drug specific antibody,OT
197101021,Infliximab,Drug intolerance,OT
197101021,Infliximab,Drug ineffective,OT
197101021,Infliximab,Depression,OT
197101021,Infliximab,Chronic kidney disease,OT
197101021,Infliximab,Asthma,OT
197101021,Infliximab,Arthritis,OT
197105091,Infliximab,Pain,OT
197105091,Infliximab,Off label use,OT
197105091,Infliximab,Muscle spasms,OT
197386012,Infliximab,Takayasu's arteritis,LT
197386012,Infliximab,Takayasu's arteritis,OT
197386012,Infliximab,Skin infection,LT
197386012,Infliximab,Skin infection,OT
197386012,Infliximab,Off label use,LT
197386012,Infliximab,Off label use,OT
197386012,Infliximab,Klebsiella bacteraemia,LT
197386012,Infliximab,Klebsiella bacteraemia,OT
197386012,Infliximab,Cytomegalovirus test positive,LT
197386012,Infliximab,Cytomegalovirus test positive,OT
197386012,Infliximab,Bacteraemia,LT
197386012,Infliximab,Bacteraemia,OT
197467831,Infliximab,Sinusitis,OT
197467831,Infliximab,Poor venous access,OT
197467831,Infliximab,Off label use,OT
197467831,Infliximab,Inappropriate schedule of product administration,OT
197535201,Infliximab,Off label use,OT
197535201,Infliximab,Loss of consciousness,OT
197535201,Infliximab,Inappropriate schedule of product administration,OT
197535201,Infliximab,Diarrhoea,OT
197535201,Infliximab,Chest pain,OT
198051591,Infliximab,Off label use,HO
198051591,Infliximab,Drug ineffective for unapproved indication,HO
198241541,Infliximab,Drug ineffective,OT
198241541,Infliximab,Drug ineffective,HO
198241541,Infliximab,Cytomegalovirus infection,OT
198241541,Infliximab,Cytomegalovirus infection,HO
198241541,Infliximab,Drug ineffective,OT
198241541,Infliximab,Drug ineffective,HO
198241541,Infliximab,Cytomegalovirus infection,OT
198241541,Infliximab,Cytomegalovirus infection,HO
198241541,Infliximab,Drug ineffective,OT
198241541,Infliximab,Drug ineffective,HO
198241541,Infliximab,Cytomegalovirus infection,OT
198241541,Infliximab,Cytomegalovirus infection,HO
198241541,Infliximab,Drug ineffective,OT
198241541,Infliximab,Drug ineffective,HO
198241541,Infliximab,Cytomegalovirus infection,OT
198241541,Infliximab,Cytomegalovirus infection,HO
198241541,Infliximab,Drug ineffective,OT
198241541,Infliximab,Drug ineffective,HO
198241541,Infliximab,Cytomegalovirus infection,OT
198241541,Infliximab,Cytomegalovirus infection,HO
198241541,Infliximab,Drug ineffective,OT
198241541,Infliximab,Drug ineffective,HO
198241541,Infliximab,Cytomegalovirus infection,OT
198241541,Infliximab,Cytomegalovirus infection,HO
198283201,Infliximab,Weight increased,HO
198283201,Infliximab,Weight increased,OT
198283201,Infliximab,Vomiting,HO
198283201,Infliximab,Vomiting,OT
198283201,Infliximab,Vaginal disorder,HO
198283201,Infliximab,Vaginal disorder,OT
198283201,Infliximab,Vaginal discharge,HO
198283201,Infliximab,Vaginal discharge,OT
198283201,Infliximab,Upper respiratory tract infection,HO
198283201,Infliximab,Upper respiratory tract infection,OT
198283201,Infliximab,Suicidal ideation,HO
198283201,Infliximab,Suicidal ideation,OT
198283201,Infliximab,Pyrexia,HO
198283201,Infliximab,Pyrexia,OT
198283201,Infliximab,Product use issue,HO
198283201,Infliximab,Product use issue,OT
198283201,Infliximab,Pancreatitis,HO
198283201,Infliximab,Pancreatitis,OT
198283201,Infliximab,Oxygen saturation decreased,HO
198283201,Infliximab,Oxygen saturation decreased,OT
198283201,Infliximab,Off label use,HO
198283201,Infliximab,Off label use,OT
198283201,Infliximab,Nausea,HO
198283201,Infliximab,Nausea,OT
198283201,Infliximab,Intentional product use issue,HO
198283201,Infliximab,Intentional product use issue,OT
198283201,Infliximab,Influenza,HO
198283201,Infliximab,Influenza,OT
198283201,Infliximab,Inappropriate schedule of product administration,HO
198283201,Infliximab,Inappropriate schedule of product administration,OT
198283201,Infliximab,Haemoptysis,HO
198283201,Infliximab,Haemoptysis,OT
198283201,Infliximab,Haematochezia,HO
198283201,Infliximab,Haematochezia,OT
198283201,Infliximab,Diarrhoea,HO
198283201,Infliximab,Diarrhoea,OT
198283201,Infliximab,Cough,HO
198283201,Infliximab,Cough,OT
198283201,Infliximab,Condition aggravated,HO
198283201,Infliximab,Condition aggravated,OT
198283201,Infliximab,COVID-19,HO
198283201,Infliximab,COVID-19,OT
198283201,Infliximab,C-reactive protein increased,HO
198283201,Infliximab,C-reactive protein increased,OT
198283201,Infliximab,Bacterial vaginosis,HO
198283201,Infliximab,Bacterial vaginosis,OT
198283201,Infliximab,Anxiety,HO
198283201,Infliximab,Anxiety,OT
198283201,Infliximab,Abdominal pain,HO
198283201,Infliximab,Abdominal pain,OT
198293851,Infliximab,Psoriatic arthropathy,OT
198293851,Infliximab,Psoriasis,OT
198293851,Infliximab,Off label use,OT
198293851,Infliximab,Heart rate decreased,OT
198293851,Infliximab,Drug level increased,OT
198293851,Infliximab,Body temperature fluctuation,OT
198293851,Infliximab,Blood pressure fluctuation,OT
198293851,Infliximab,Blood pressure diastolic decreased,OT
198359291,Infliximab,Off label use,OT
198359291,Infliximab,Intentional product use issue,OT
198359291,Infliximab,Insomnia,OT
198359291,Infliximab,Hyperhidrosis,OT
198359291,Infliximab,Heart rate decreased,OT
198359291,Infliximab,Dyspnoea exertional,OT
198359291,Infliximab,Dizziness,OT
198359291,Infliximab,Condition aggravated,OT
198359291,Infliximab,Blood pressure increased,OT
198359291,Infliximab,Arthralgia,OT
198395651,Infliximab,Wound,DS
198395651,Infliximab,Wound,OT
198395651,Infliximab,Treatment failure,DS
198395651,Infliximab,Treatment failure,OT
198395651,Infliximab,Systemic lupus erythematosus,DS
198395651,Infliximab,Systemic lupus erythematosus,OT
198395651,Infliximab,Synovitis,DS
198395651,Infliximab,Synovitis,OT
198395651,Infliximab,Swelling,DS
198395651,Infliximab,Swelling,OT
198395651,Infliximab,Rheumatoid arthritis,DS
198395651,Infliximab,Rheumatoid arthritis,OT
198395651,Infliximab,Rash,DS
198395651,Infliximab,Rash,OT
198395651,Infliximab,Product use issue,DS
198395651,Infliximab,Product use issue,OT
198395651,Infliximab,Pericarditis,DS
198395651,Infliximab,Pericarditis,OT
198395651,Infliximab,Pemphigus,DS
198395651,Infliximab,Pemphigus,OT
198395651,Infliximab,Pain,DS
198395651,Infliximab,Pain,OT
198395651,Infliximab,Maternal exposure during pregnancy,DS
198395651,Infliximab,Maternal exposure during pregnancy,OT
198395651,Infliximab,Joint swelling,DS
198395651,Infliximab,Joint swelling,OT
198395651,Infliximab,Intentional product use issue,DS
198395651,Infliximab,Intentional product use issue,OT
198395651,Infliximab,Injury,DS
198395651,Infliximab,Injury,OT
198395651,Infliximab,Infusion related reaction,DS
198395651,Infliximab,Infusion related reaction,OT
198395651,Infliximab,Hypersensitivity,DS
198395651,Infliximab,Hypersensitivity,OT
198395651,Infliximab,Hepatic enzyme increased,DS
198395651,Infliximab,Hepatic enzyme increased,OT
198395651,Infliximab,Helicobacter infection,DS
198395651,Infliximab,Helicobacter infection,OT
198395651,Infliximab,Hand deformity,DS
198395651,Infliximab,Hand deformity,OT
198395651,Infliximab,Glossodynia,DS
198395651,Infliximab,Glossodynia,OT
198395651,Infliximab,General physical health deterioration,DS
198395651,Infliximab,General physical health deterioration,OT
198395651,Infliximab,Fatigue,DS
198395651,Infliximab,Fatigue,OT
198395651,Infliximab,Duodenal ulcer perforation,DS
198395651,Infliximab,Duodenal ulcer perforation,OT
198395651,Infliximab,Drug intolerance,DS
198395651,Infliximab,Drug intolerance,OT
198395651,Infliximab,Drug ineffective,DS
198395651,Infliximab,Drug ineffective,OT
198395651,Infliximab,Discomfort,DS
198395651,Infliximab,Discomfort,OT
198395651,Infliximab,Contraindicated product administered,DS
198395651,Infliximab,Contraindicated product administered,OT
198395651,Infliximab,Condition aggravated,DS
198395651,Infliximab,Condition aggravated,OT
198395651,Infliximab,Blister,DS
198395651,Infliximab,Blister,OT
198395651,Infliximab,Arthropathy,DS
198395651,Infliximab,Arthropathy,OT
198395651,Infliximab,Anti-cyclic citrullinated peptide antibody positive,DS
198395651,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
198395651,Infliximab,Alopecia,DS
198395651,Infliximab,Alopecia,OT
198395651,Infliximab,Abdominal discomfort,DS
198395651,Infliximab,Abdominal discomfort,OT
198752551,Infliximab,Immunosuppression,OT
198752551,Infliximab,Drug ineffective,OT
198752551,Infliximab,Cutaneous leishmaniasis,OT
198851251,Infliximab (Unknown),Off label use,NULL
198851251,Infliximab (Unknown),Herpes zoster,NULL
198851251,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198957831,Infliximab (Unknown),Overdose,NULL
198957831,Infliximab (Unknown),Off label use,NULL
198957831,Infliximab (Unknown),Drug ineffective,NULL
198957831,Infliximab (Unknown),Overdose,NULL
198957831,Infliximab (Unknown),Off label use,NULL
198957831,Infliximab (Unknown),Drug ineffective,NULL
160798835,Infliximab,Thrombophlebitis superficial,OT
160798835,Infliximab,Thrombophlebitis superficial,HO
160798835,Infliximab,Thermal burn,OT
160798835,Infliximab,Thermal burn,HO
160798835,Infliximab,Therapeutic response shortened,OT
160798835,Infliximab,Therapeutic response shortened,HO
160798835,Infliximab,Product use issue,OT
160798835,Infliximab,Product use issue,HO
160798835,Infliximab,Phlebitis,OT
160798835,Infliximab,Phlebitis,HO
160798835,Infliximab,Off label use,OT
160798835,Infliximab,Off label use,HO
160798835,Infliximab,Incorrect dose administered,OT
160798835,Infliximab,Incorrect dose administered,HO
160798835,Infliximab,Faeces soft,OT
160798835,Infliximab,Faeces soft,HO
160798835,Infliximab,Dizziness,OT
160798835,Infliximab,Dizziness,HO
160798835,Infliximab,Burns second degree,OT
160798835,Infliximab,Burns second degree,HO
160821533,Infliximab,Urinary tract infection,OT
160821533,Infliximab,Pyrexia,OT
160821533,Infliximab,Oropharyngeal pain,OT
160821533,Infliximab,Off label use,OT
160821533,Infliximab,Localised infection,OT
160821533,Infliximab,Intentional product use issue,OT
160821533,Infliximab,Inappropriate schedule of product administration,OT
160821533,Infliximab,Heart rate irregular,OT
160821533,Infliximab,Headache,OT
160821533,Infliximab,Fall,OT
160821533,Infliximab,Eye swelling,OT
160821533,Infliximab,Drug level increased,OT
160821533,Infliximab,Drug level decreased,OT
160821533,Infliximab,Crohn's disease,OT
160821533,Infliximab,Condition aggravated,OT
160821533,Infliximab,Blood pressure fluctuation,OT
160821533,Infliximab,Back pain,OT
160821533,Infliximab,Anal haemorrhage,OT
160821533,Infliximab,Urinary tract infection,OT
160821533,Infliximab,Pyrexia,OT
160821533,Infliximab,Oropharyngeal pain,OT
160821533,Infliximab,Off label use,OT
160821533,Infliximab,Localised infection,OT
160821533,Infliximab,Intentional product use issue,OT
160821533,Infliximab,Inappropriate schedule of product administration,OT
160821533,Infliximab,Heart rate irregular,OT
160821533,Infliximab,Headache,OT
160821533,Infliximab,Fall,OT
160821533,Infliximab,Eye swelling,OT
160821533,Infliximab,Drug level increased,OT
160821533,Infliximab,Drug level decreased,OT
160821533,Infliximab,Crohn's disease,OT
160821533,Infliximab,Condition aggravated,OT
160821533,Infliximab,Blood pressure fluctuation,OT
160821533,Infliximab,Back pain,OT
160821533,Infliximab,Anal haemorrhage,OT
160821533,Infliximab,Urinary tract infection,OT
160821533,Infliximab,Pyrexia,OT
160821533,Infliximab,Oropharyngeal pain,OT
160821533,Infliximab,Off label use,OT
160821533,Infliximab,Localised infection,OT
160821533,Infliximab,Intentional product use issue,OT
160821533,Infliximab,Inappropriate schedule of product administration,OT
160821533,Infliximab,Heart rate irregular,OT
160821533,Infliximab,Headache,OT
160821533,Infliximab,Fall,OT
160821533,Infliximab,Eye swelling,OT
160821533,Infliximab,Drug level increased,OT
160821533,Infliximab,Drug level decreased,OT
160821533,Infliximab,Crohn's disease,OT
160821533,Infliximab,Condition aggravated,OT
160821533,Infliximab,Blood pressure fluctuation,OT
160821533,Infliximab,Back pain,OT
160821533,Infliximab,Anal haemorrhage,OT
165668035,Infliximab,Weight decreased,OT
165668035,Infliximab,Therapeutic response shortened,OT
165668035,Infliximab,Therapeutic product effect incomplete,OT
165668035,Infliximab,Skin laceration,OT
165668035,Infliximab,Skin exfoliation,OT
165668035,Infliximab,Pyrexia,OT
165668035,Infliximab,Pruritus,OT
165668035,Infliximab,Photosensitivity reaction,OT
165668035,Infliximab,Oropharyngeal pain,OT
165668035,Infliximab,Nasopharyngitis,OT
165668035,Infliximab,Nasal congestion,OT
165668035,Infliximab,Influenza,OT
165668035,Infliximab,Inappropriate schedule of product administration,OT
165668035,Infliximab,Hypertension,OT
165668035,Infliximab,Hyperhidrosis,OT
165668035,Infliximab,Heart rate increased,OT
165668035,Infliximab,Headache,OT
165668035,Infliximab,Frequent bowel movements,OT
165668035,Infliximab,Feeling of body temperature change,OT
165668035,Infliximab,Erythema nodosum,OT
165668035,Infliximab,Erythema,OT
165668035,Infliximab,Drug ineffective,OT
165668035,Infliximab,Diarrhoea,OT
165668035,Infliximab,Decreased appetite,OT
165668035,Infliximab,Condition aggravated,OT
165668035,Infliximab,Blood pressure increased,OT
165668035,Infliximab,Blood pressure fluctuation,OT
165668035,Infliximab,Arthralgia,OT
165668035,Infliximab,Abdominal pain,OT
165668035,Infliximab,Weight decreased,OT
165668035,Infliximab,Therapeutic response shortened,OT
165668035,Infliximab,Therapeutic product effect incomplete,OT
165668035,Infliximab,Skin laceration,OT
165668035,Infliximab,Skin exfoliation,OT
165668035,Infliximab,Pyrexia,OT
165668035,Infliximab,Pruritus,OT
165668035,Infliximab,Photosensitivity reaction,OT
165668035,Infliximab,Oropharyngeal pain,OT
165668035,Infliximab,Nasopharyngitis,OT
165668035,Infliximab,Nasal congestion,OT
165668035,Infliximab,Influenza,OT
165668035,Infliximab,Inappropriate schedule of product administration,OT
165668035,Infliximab,Hypertension,OT
165668035,Infliximab,Hyperhidrosis,OT
165668035,Infliximab,Heart rate increased,OT
165668035,Infliximab,Headache,OT
165668035,Infliximab,Frequent bowel movements,OT
165668035,Infliximab,Feeling of body temperature change,OT
165668035,Infliximab,Erythema nodosum,OT
165668035,Infliximab,Erythema,OT
165668035,Infliximab,Drug ineffective,OT
165668035,Infliximab,Diarrhoea,OT
165668035,Infliximab,Decreased appetite,OT
165668035,Infliximab,Condition aggravated,OT
165668035,Infliximab,Blood pressure increased,OT
165668035,Infliximab,Blood pressure fluctuation,OT
165668035,Infliximab,Arthralgia,OT
165668035,Infliximab,Abdominal pain,OT
166905925,Infliximab,Weight increased,OT
166905925,Infliximab,Weight decreased,OT
166905925,Infliximab,Product use issue,OT
166905925,Infliximab,Off label use,OT
166905925,Infliximab,Intentional product use issue,OT
166905925,Infliximab,Inappropriate schedule of product administration,OT
166905925,Infliximab,Herpes zoster,OT
166905925,Infliximab,Heart rate decreased,OT
166905925,Infliximab,Haematochezia,OT
166905925,Infliximab,Frequent bowel movements,OT
166905925,Infliximab,Drug level below therapeutic,OT
166905925,Infliximab,Drug level above therapeutic,OT
166905925,Infliximab,Drug ineffective,OT
166905925,Infliximab,Blood pressure increased,OT
166905925,Infliximab,Blood pressure fluctuation,OT
166905925,Infliximab,Weight increased,OT
166905925,Infliximab,Weight decreased,OT
166905925,Infliximab,Product use issue,OT
166905925,Infliximab,Off label use,OT
166905925,Infliximab,Intentional product use issue,OT
166905925,Infliximab,Inappropriate schedule of product administration,OT
166905925,Infliximab,Herpes zoster,OT
166905925,Infliximab,Heart rate decreased,OT
166905925,Infliximab,Haematochezia,OT
166905925,Infliximab,Frequent bowel movements,OT
166905925,Infliximab,Drug level below therapeutic,OT
166905925,Infliximab,Drug level above therapeutic,OT
166905925,Infliximab,Drug ineffective,OT
166905925,Infliximab,Blood pressure increased,OT
166905925,Infliximab,Blood pressure fluctuation,OT
166905925,Infliximab,Weight increased,OT
166905925,Infliximab,Weight decreased,OT
166905925,Infliximab,Product use issue,OT
166905925,Infliximab,Off label use,OT
166905925,Infliximab,Intentional product use issue,OT
166905925,Infliximab,Inappropriate schedule of product administration,OT
166905925,Infliximab,Herpes zoster,OT
166905925,Infliximab,Heart rate decreased,OT
166905925,Infliximab,Haematochezia,OT
166905925,Infliximab,Frequent bowel movements,OT
166905925,Infliximab,Drug level below therapeutic,OT
166905925,Infliximab,Drug level above therapeutic,OT
166905925,Infliximab,Drug ineffective,OT
166905925,Infliximab,Blood pressure increased,OT
166905925,Infliximab,Blood pressure fluctuation,OT
168284163,Infliximab,Urticaria,HO
168284163,Infliximab,Urticaria,OT
168284163,Infliximab,Tenosynovitis,HO
168284163,Infliximab,Tenosynovitis,OT
168284163,Infliximab,Tendonitis,HO
168284163,Infliximab,Tendonitis,OT
168284163,Infliximab,Pruritus,HO
168284163,Infliximab,Pruritus,OT
168284163,Infliximab,Product use issue,HO
168284163,Infliximab,Product use issue,OT
168284163,Infliximab,Postoperative wound infection,HO
168284163,Infliximab,Postoperative wound infection,OT
168284163,Infliximab,Off label use,HO
168284163,Infliximab,Off label use,OT
168284163,Infliximab,Migraine,HO
168284163,Infliximab,Migraine,OT
168284163,Infliximab,Maternal exposure during pregnancy,HO
168284163,Infliximab,Maternal exposure during pregnancy,OT
168284163,Infliximab,Infusion related reaction,HO
168284163,Infliximab,Infusion related reaction,OT
168284163,Infliximab,Hypersensitivity,HO
168284163,Infliximab,Hypersensitivity,OT
168284163,Infliximab,Heart rate irregular,HO
168284163,Infliximab,Heart rate irregular,OT
168284163,Infliximab,Food poisoning,HO
168284163,Infliximab,Food poisoning,OT
168284163,Infliximab,Flushing,HO
168284163,Infliximab,Flushing,OT
168284163,Infliximab,Enthesopathy,HO
168284163,Infliximab,Enthesopathy,OT
168284163,Infliximab,Dry skin,HO
168284163,Infliximab,Dry skin,OT
168284163,Infliximab,Drug specific antibody present,HO
168284163,Infliximab,Drug specific antibody present,OT
168284163,Infliximab,Drug level below therapeutic,HO
168284163,Infliximab,Drug level below therapeutic,OT
168284163,Infliximab,Drug ineffective,HO
168284163,Infliximab,Drug ineffective,OT
168284163,Infliximab,Condition aggravated,HO
168284163,Infliximab,Condition aggravated,OT
168284163,Infliximab,Chest discomfort,HO
168284163,Infliximab,Chest discomfort,OT
168284163,Infliximab,Arthropathy,HO
168284163,Infliximab,Arthropathy,OT
168284163,Infliximab,Arthritis,HO
168284163,Infliximab,Arthritis,OT
168284163,Infliximab,Arthralgia,HO
168284163,Infliximab,Arthralgia,OT
168284163,Infliximab,Alopecia,HO
168284163,Infliximab,Alopecia,OT
168284163,Infliximab,Urticaria,HO
168284163,Infliximab,Urticaria,OT
168284163,Infliximab,Tenosynovitis,HO
168284163,Infliximab,Tenosynovitis,OT
168284163,Infliximab,Tendonitis,HO
168284163,Infliximab,Tendonitis,OT
168284163,Infliximab,Pruritus,HO
168284163,Infliximab,Pruritus,OT
168284163,Infliximab,Product use issue,HO
168284163,Infliximab,Product use issue,OT
168284163,Infliximab,Postoperative wound infection,HO
168284163,Infliximab,Postoperative wound infection,OT
168284163,Infliximab,Off label use,HO
168284163,Infliximab,Off label use,OT
168284163,Infliximab,Migraine,HO
168284163,Infliximab,Migraine,OT
168284163,Infliximab,Maternal exposure during pregnancy,HO
168284163,Infliximab,Maternal exposure during pregnancy,OT
168284163,Infliximab,Infusion related reaction,HO
168284163,Infliximab,Infusion related reaction,OT
168284163,Infliximab,Hypersensitivity,HO
168284163,Infliximab,Hypersensitivity,OT
168284163,Infliximab,Heart rate irregular,HO
168284163,Infliximab,Heart rate irregular,OT
168284163,Infliximab,Food poisoning,HO
168284163,Infliximab,Food poisoning,OT
168284163,Infliximab,Flushing,HO
168284163,Infliximab,Flushing,OT
168284163,Infliximab,Enthesopathy,HO
168284163,Infliximab,Enthesopathy,OT
168284163,Infliximab,Dry skin,HO
168284163,Infliximab,Dry skin,OT
168284163,Infliximab,Drug specific antibody present,HO
168284163,Infliximab,Drug specific antibody present,OT
168284163,Infliximab,Drug level below therapeutic,HO
168284163,Infliximab,Drug level below therapeutic,OT
168284163,Infliximab,Drug ineffective,HO
168284163,Infliximab,Drug ineffective,OT
168284163,Infliximab,Condition aggravated,HO
168284163,Infliximab,Condition aggravated,OT
168284163,Infliximab,Chest discomfort,HO
168284163,Infliximab,Chest discomfort,OT
168284163,Infliximab,Arthropathy,HO
168284163,Infliximab,Arthropathy,OT
168284163,Infliximab,Arthritis,HO
168284163,Infliximab,Arthritis,OT
168284163,Infliximab,Arthralgia,HO
168284163,Infliximab,Arthralgia,OT
168284163,Infliximab,Alopecia,HO
168284163,Infliximab,Alopecia,OT
168284163,Infliximab,Urticaria,HO
168284163,Infliximab,Urticaria,OT
168284163,Infliximab,Tenosynovitis,HO
168284163,Infliximab,Tenosynovitis,OT
168284163,Infliximab,Tendonitis,HO
168284163,Infliximab,Tendonitis,OT
168284163,Infliximab,Pruritus,HO
168284163,Infliximab,Pruritus,OT
168284163,Infliximab,Product use issue,HO
168284163,Infliximab,Product use issue,OT
168284163,Infliximab,Postoperative wound infection,HO
168284163,Infliximab,Postoperative wound infection,OT
168284163,Infliximab,Off label use,HO
168284163,Infliximab,Off label use,OT
168284163,Infliximab,Migraine,HO
168284163,Infliximab,Migraine,OT
168284163,Infliximab,Maternal exposure during pregnancy,HO
168284163,Infliximab,Maternal exposure during pregnancy,OT
168284163,Infliximab,Infusion related reaction,HO
168284163,Infliximab,Infusion related reaction,OT
168284163,Infliximab,Hypersensitivity,HO
168284163,Infliximab,Hypersensitivity,OT
168284163,Infliximab,Heart rate irregular,HO
168284163,Infliximab,Heart rate irregular,OT
168284163,Infliximab,Food poisoning,HO
168284163,Infliximab,Food poisoning,OT
168284163,Infliximab,Flushing,HO
168284163,Infliximab,Flushing,OT
168284163,Infliximab,Enthesopathy,HO
168284163,Infliximab,Enthesopathy,OT
168284163,Infliximab,Dry skin,HO
168284163,Infliximab,Dry skin,OT
168284163,Infliximab,Drug specific antibody present,HO
168284163,Infliximab,Drug specific antibody present,OT
168284163,Infliximab,Drug level below therapeutic,HO
168284163,Infliximab,Drug level below therapeutic,OT
168284163,Infliximab,Drug ineffective,HO
168284163,Infliximab,Drug ineffective,OT
168284163,Infliximab,Condition aggravated,HO
168284163,Infliximab,Condition aggravated,OT
168284163,Infliximab,Chest discomfort,HO
168284163,Infliximab,Chest discomfort,OT
168284163,Infliximab,Arthropathy,HO
168284163,Infliximab,Arthropathy,OT
168284163,Infliximab,Arthritis,HO
168284163,Infliximab,Arthritis,OT
168284163,Infliximab,Arthralgia,HO
168284163,Infliximab,Arthralgia,OT
168284163,Infliximab,Alopecia,HO
168284163,Infliximab,Alopecia,OT
173910493,Infliximab,Weight increased,OT
173910493,Infliximab,Weight fluctuation,OT
173910493,Infliximab,Uveitis,OT
173910493,Infliximab,Therapeutic response shortened,OT
173910493,Infliximab,Pyoderma gangrenosum,OT
173910493,Infliximab,Product use issue,OT
173910493,Infliximab,Product prescribing error,OT
173910493,Infliximab,Pain,OT
173910493,Infliximab,Off label use,OT
173910493,Infliximab,Intentional product use issue,OT
173910493,Infliximab,Fistula,OT
173910493,Infliximab,Fatigue,OT
173910493,Infliximab,Erythema nodosum,OT
173910493,Infliximab,Drug level above therapeutic,OT
173910493,Infliximab,Drug ineffective,OT
173910493,Infliximab,Condition aggravated,OT
173910493,Infliximab,Blood pressure fluctuation,OT
173910493,Infliximab,Back pain,OT
173910493,Infliximab,Arthralgia,OT
173910493,Infliximab,Aphthous ulcer,OT
173910493,Infliximab,Anal fissure,OT
173910493,Infliximab,Abscess,OT
175913452,Infliximab,Weight increased,HO
175913452,Infliximab,Poor quality sleep,HO
175913452,Infliximab,Off label use,HO
175913452,Infliximab,Loss of personal independence in daily activities,HO
175913452,Infliximab,Heart rate irregular,HO
175913452,Infliximab,Heart rate increased,HO
175913452,Infliximab,Drug level below therapeutic,HO
175913452,Infliximab,Condition aggravated,HO
175913452,Infliximab,Weight increased,HO
175913452,Infliximab,Poor quality sleep,HO
175913452,Infliximab,Off label use,HO
175913452,Infliximab,Loss of personal independence in daily activities,HO
175913452,Infliximab,Heart rate irregular,HO
175913452,Infliximab,Heart rate increased,HO
175913452,Infliximab,Drug level below therapeutic,HO
175913452,Infliximab,Condition aggravated,HO
176353524,Infliximab,Wheezing,OT
176353524,Infliximab,Pyrexia,OT
176353524,Infliximab,Product use issue,OT
176353524,Infliximab,Pneumonia,OT
176353524,Infliximab,Pain,OT
176353524,Infliximab,Off label use,OT
176353524,Infliximab,Inappropriate schedule of product administration,OT
176353524,Infliximab,Heart rate decreased,OT
176353524,Infliximab,Gait disturbance,OT
176353524,Infliximab,Faecal calprotectin increased,OT
176353524,Infliximab,Dyspnoea,OT
176353524,Infliximab,Cough,OT
176353524,Infliximab,Condition aggravated,OT
176353524,Infliximab,Blood pressure increased,OT
176353524,Infliximab,Blood pressure fluctuation,OT
176353524,Infliximab,Arthralgia,OT
176353524,Infliximab,Wheezing,OT
176353524,Infliximab,Pyrexia,OT
176353524,Infliximab,Product use issue,OT
176353524,Infliximab,Pneumonia,OT
176353524,Infliximab,Pain,OT
176353524,Infliximab,Off label use,OT
176353524,Infliximab,Inappropriate schedule of product administration,OT
176353524,Infliximab,Heart rate decreased,OT
176353524,Infliximab,Gait disturbance,OT
176353524,Infliximab,Faecal calprotectin increased,OT
176353524,Infliximab,Dyspnoea,OT
176353524,Infliximab,Cough,OT
176353524,Infliximab,Condition aggravated,OT
176353524,Infliximab,Blood pressure increased,OT
176353524,Infliximab,Blood pressure fluctuation,OT
176353524,Infliximab,Arthralgia,OT
176594632,Infliximab,Product use issue,OT
176594632,Infliximab,Off label use,OT
176594632,Infliximab,Malaise,OT
176594632,Infliximab,Lower respiratory tract infection,OT
176594632,Infliximab,Food poisoning,OT
176594632,Infliximab,Dyspnoea,OT
176594632,Infliximab,Drug level decreased,OT
176594632,Infliximab,C-reactive protein increased,OT
176594632,Infliximab,Abdominal pain lower,OT
177522443,Infliximab,Underdose,OT
177522443,Infliximab,Tension headache,OT
177522443,Infliximab,Swelling face,OT
177522443,Infliximab,Sputum discoloured,OT
177522443,Infliximab,Sneezing,OT
177522443,Infliximab,Sinus pain,OT
177522443,Infliximab,Rhinorrhoea,OT
177522443,Infliximab,Product use issue,OT
177522443,Infliximab,Oropharyngeal pain,OT
177522443,Infliximab,Off label use,OT
177522443,Infliximab,Nasopharyngitis,OT
177522443,Infliximab,Malaise,OT
177522443,Infliximab,Loss of personal independence in daily activities,OT
177522443,Infliximab,Localised infection,OT
177522443,Infliximab,Intentional product use issue,OT
177522443,Infliximab,Insomnia,OT
177522443,Infliximab,Incorrect dose administered,OT
177522443,Infliximab,Inappropriate schedule of product administration,OT
177522443,Infliximab,Heart rate irregular,OT
177522443,Infliximab,Headache,OT
177522443,Infliximab,Haemoglobin decreased,OT
177522443,Infliximab,Furuncle,OT
177522443,Infliximab,Feeling hot,OT
177522443,Infliximab,Feeling abnormal,OT
177522443,Infliximab,Fatigue,OT
177522443,Infliximab,Erythema,OT
177522443,Infliximab,Ear discomfort,OT
177522443,Infliximab,Drug hypersensitivity,OT
177522443,Infliximab,Cough,OT
177522443,Infliximab,Condition aggravated,OT
177522443,Infliximab,Blood iron decreased,OT
177522443,Infliximab,Acne,OT
179036054,Infliximab,Weight decreased,OT
179036054,Infliximab,Urethral stenosis,OT
179036054,Infliximab,Off label use,OT
179036054,Infliximab,Inappropriate schedule of product administration,OT
179036054,Infliximab,Fungal infection,OT
179036054,Infliximab,Cystitis,OT
179036054,Infliximab,Conjunctivitis,OT
179036054,Infliximab,Weight decreased,OT
179036054,Infliximab,Urethral stenosis,OT
179036054,Infliximab,Off label use,OT
179036054,Infliximab,Inappropriate schedule of product administration,OT
179036054,Infliximab,Fungal infection,OT
179036054,Infliximab,Cystitis,OT
179036054,Infliximab,Conjunctivitis,OT
182097535,Infliximab,Therapeutic response unexpected,OT
182097535,Infliximab,Off label use,OT
182097535,Infliximab,Intentional product misuse,OT
182097535,Infliximab,Drug ineffective,OT
182097535,Infliximab,Crohn's disease,OT
182608512,Infliximab,Ulcer,OT
182608512,Infliximab,Somnolence,OT
182608512,Infliximab,Rheumatoid arthritis,OT
182608512,Infliximab,Pyrexia,OT
182608512,Infliximab,Off label use,OT
182608512,Infliximab,Myalgia,OT
182608512,Infliximab,Muscular weakness,OT
182608512,Infliximab,Malaise,OT
182608512,Infliximab,Influenza like illness,OT
182608512,Infliximab,Inflammation,OT
182608512,Infliximab,Hyperhidrosis,OT
182608512,Infliximab,Hyperaemia,OT
182608512,Infliximab,Granuloma,OT
182608512,Infliximab,Gait inability,OT
182608512,Infliximab,Gait disturbance,OT
182608512,Infliximab,Fatigue,OT
182608512,Infliximab,Dysgeusia,OT
182608512,Infliximab,Dizziness,OT
182608512,Infliximab,Condition aggravated,OT
182608512,Infliximab,Chills,OT
182608512,Infliximab,Chest discomfort,OT
182608512,Infliximab,C-reactive protein increased,OT
182608512,Infliximab,Balance disorder,OT
182608512,Infliximab,Anaemia,OT
182608512,Infliximab,Ulcer,OT
182608512,Infliximab,Somnolence,OT
182608512,Infliximab,Rheumatoid arthritis,OT
182608512,Infliximab,Pyrexia,OT
182608512,Infliximab,Off label use,OT
182608512,Infliximab,Myalgia,OT
182608512,Infliximab,Muscular weakness,OT
182608512,Infliximab,Malaise,OT
182608512,Infliximab,Influenza like illness,OT
182608512,Infliximab,Inflammation,OT
182608512,Infliximab,Hyperhidrosis,OT
182608512,Infliximab,Hyperaemia,OT
182608512,Infliximab,Granuloma,OT
182608512,Infliximab,Gait inability,OT
182608512,Infliximab,Gait disturbance,OT
182608512,Infliximab,Fatigue,OT
182608512,Infliximab,Dysgeusia,OT
182608512,Infliximab,Dizziness,OT
182608512,Infliximab,Condition aggravated,OT
182608512,Infliximab,Chills,OT
182608512,Infliximab,Chest discomfort,OT
182608512,Infliximab,C-reactive protein increased,OT
182608512,Infliximab,Balance disorder,OT
182608512,Infliximab,Anaemia,OT
183497433,Infliximab,Skin lesion,OT
183497433,Infliximab,Oxygen saturation decreased,OT
183497433,Infliximab,Off label use,OT
183497433,Infliximab,Lower respiratory tract infection,OT
183497433,Infliximab,Incorrect dose administered,OT
183497433,Infliximab,Drug level decreased,OT
183497433,Infliximab,Blood pressure fluctuation,OT
183497433,Infliximab,Skin lesion,OT
183497433,Infliximab,Oxygen saturation decreased,OT
183497433,Infliximab,Off label use,OT
183497433,Infliximab,Lower respiratory tract infection,OT
183497433,Infliximab,Incorrect dose administered,OT
183497433,Infliximab,Drug level decreased,OT
183497433,Infliximab,Blood pressure fluctuation,OT
183983292,Infliximab,Wheezing,OT
183983292,Infliximab,Off label use,OT
183983292,Infliximab,Intentional product use issue,OT
183983292,Infliximab,Cough,OT
183983292,Infliximab,Blood pressure increased,OT
183983292,Infliximab,Blood pressure fluctuation,OT
183983292,Infliximab,Asthma,OT
183983292,Infliximab,Anxiety,OT
184885014,Infliximab,Therapeutic response shortened,OT
184885014,Infliximab,Off label use,OT
184885014,Infliximab,Intentional product use issue,OT
184885014,Infliximab,Heart rate increased,OT
184885014,Infliximab,Heart rate decreased,OT
184885014,Infliximab,Condition aggravated,OT
184885014,Infliximab,Anal fissure,OT
184885014,Infliximab,Abscess intestinal,OT
185073103,Infliximab,Wound,OT
185073103,Infliximab,Post procedural infection,OT
185073103,Infliximab,Off label use,OT
185073103,Infliximab,Joint injury,OT
185073103,Infliximab,Intentional product use issue,OT
185073103,Infliximab,Inappropriate schedule of product administration,OT
185073103,Infliximab,Condition aggravated,OT
185073103,Infliximab,Blood pressure increased,OT
185073103,Infliximab,Blood pressure fluctuation,OT
185073103,Infliximab,Wound,OT
185073103,Infliximab,Post procedural infection,OT
185073103,Infliximab,Off label use,OT
185073103,Infliximab,Joint injury,OT
185073103,Infliximab,Intentional product use issue,OT
185073103,Infliximab,Inappropriate schedule of product administration,OT
185073103,Infliximab,Condition aggravated,OT
185073103,Infliximab,Blood pressure increased,OT
185073103,Infliximab,Blood pressure fluctuation,OT
186427063,Infliximab,Vomiting,OT
186427063,Infliximab,Uveitis,OT
186427063,Infliximab,Oropharyngeal pain,OT
186427063,Infliximab,Off label use,OT
186427063,Infliximab,Migraine,OT
186427063,Infliximab,Malaise,OT
186427063,Infliximab,Intentional product use issue,OT
186427063,Infliximab,Inappropriate schedule of product administration,OT
186427063,Infliximab,Heart rate irregular,OT
186427063,Infliximab,Headache,OT
186427063,Infliximab,Flushing,OT
186427063,Infliximab,Feeling abnormal,OT
186427063,Infliximab,Dyspnoea,OT
186427063,Infliximab,Drug hypersensitivity,OT
186427063,Infliximab,Dizziness,OT
186427063,Infliximab,Diarrhoea,OT
186427063,Infliximab,Condition aggravated,OT
186427063,Infliximab,Chest discomfort,OT
186427063,Infliximab,Body temperature decreased,OT
186427063,Infliximab,Blood pressure fluctuation,OT
186427063,Infliximab,Arthralgia,OT
186427063,Infliximab,Abdominal pain upper,OT
186427063,Infliximab,Abdominal pain,OT
190663632,Infliximab,Pleural effusion,HO
190663632,Infliximab,Histoplasmosis disseminated,HO
190663632,Infliximab,Granulomatous liver disease,HO
190663632,Infliximab,Cholestasis,HO
190663632,Infliximab,Cardiac tamponade,HO
191235982,Infliximab,Uterine infection,OT
191235982,Infliximab,Off label use,OT
191235982,Infliximab,Nerve compression,OT
191235982,Infliximab,Migraine,OT
191235982,Infliximab,Cystitis,OT
191858902,Infliximab,Weight increased,OT
191858902,Infliximab,Off label use,OT
191858902,Infliximab,Malaise,OT
191858902,Infliximab,Drug level above therapeutic,OT
191858902,Infliximab,Decreased appetite,OT
191858902,Infliximab,Condition aggravated,OT
192920172,Infliximab,Weight decreased,OT
192920172,Infliximab,Off label use,OT
192920172,Infliximab,Incorrect dose administered,OT
192920172,Infliximab,Fatigue,OT
192920172,Infliximab,Condition aggravated,OT
192920172,Infliximab,Blood pressure increased,OT
192920172,Infliximab,Weight decreased,OT
192920172,Infliximab,Off label use,OT
192920172,Infliximab,Incorrect dose administered,OT
192920172,Infliximab,Fatigue,OT
192920172,Infliximab,Condition aggravated,OT
192920172,Infliximab,Blood pressure increased,OT
194979921,Infliximab,Weight decreased,HO
194979921,Infliximab,Weight decreased,OT
194979921,Infliximab,Sleep disorder,HO
194979921,Infliximab,Sleep disorder,OT
194979921,Infliximab,Off label use,HO
194979921,Infliximab,Off label use,OT
194979921,Infliximab,Intentional product use issue,HO
194979921,Infliximab,Intentional product use issue,OT
194979921,Infliximab,Gait disturbance,HO
194979921,Infliximab,Gait disturbance,OT
194979921,Infliximab,Feeling abnormal,HO
194979921,Infliximab,Feeling abnormal,OT
194979921,Infliximab,Fall,HO
194979921,Infliximab,Fall,OT
194979921,Infliximab,Eye pruritus,HO
194979921,Infliximab,Eye pruritus,OT
194979921,Infliximab,Eye inflammation,HO
194979921,Infliximab,Eye inflammation,OT
194979921,Infliximab,Eye infection,HO
194979921,Infliximab,Eye infection,OT
194979921,Infliximab,Diarrhoea,HO
194979921,Infliximab,Diarrhoea,OT
194979921,Infliximab,Crohn's disease,HO
194979921,Infliximab,Crohn's disease,OT
194979921,Infliximab,Condition aggravated,HO
194979921,Infliximab,Condition aggravated,OT
194979921,Infliximab,Burning sensation,HO
194979921,Infliximab,Burning sensation,OT
194979921,Infliximab,Blood pressure increased,HO
194979921,Infliximab,Blood pressure increased,OT
194979921,Infliximab,Blood pressure fluctuation,HO
194979921,Infliximab,Blood pressure fluctuation,OT
194979921,Infliximab,Balance disorder,HO
194979921,Infliximab,Balance disorder,OT
194979921,Infliximab,Asthenia,HO
194979921,Infliximab,Asthenia,OT
194979921,Infliximab,Abdominal pain,HO
194979921,Infliximab,Abdominal pain,OT
195031351,Infliximab,Therapeutic product effect incomplete,OT
195031351,Infliximab,Stress,OT
195031351,Infliximab,Heart rate increased,OT
195031351,Infliximab,Flushing,OT
195031351,Infliximab,Condition aggravated,OT
195031351,Infliximab,Blood pressure increased,OT
195031351,Infliximab,Ankylosing spondylitis,OT
195396821,Infliximab,Weight increased,OT
195396821,Infliximab,Urticaria,OT
195396821,Infliximab,Rash pustular,OT
195396821,Infliximab,Pruritus,OT
195396821,Infliximab,Paraesthesia,OT
195396821,Infliximab,Pallor,OT
195396821,Infliximab,Off label use,OT
195396821,Infliximab,Nausea,OT
195396821,Infliximab,Intentional product use issue,OT
195396821,Infliximab,Infusion related reaction,OT
195396821,Infliximab,Heart rate decreased,OT
195396821,Infliximab,Flushing,OT
195396821,Infliximab,Exfoliative rash,OT
195396821,Infliximab,Eczema,OT
195396821,Infliximab,Dyspnoea,OT
195396821,Infliximab,Dizziness,OT
195396821,Infliximab,Chest discomfort,OT
195396821,Infliximab,Anal fistula,OT
195396821,Infliximab,Anal abscess,OT
195396821,Infliximab,Abdominal pain,OT
196104041,Infliximab,Uveitis,OT
196104041,Infliximab,Swelling face,OT
196104041,Infliximab,Swelling,OT
196104041,Infliximab,Skin lesion,OT
196104041,Infliximab,Rash,OT
196104041,Infliximab,Papule,OT
196104041,Infliximab,Off label use,OT
196104041,Infliximab,Myalgia,OT
196104041,Infliximab,Intentional product use issue,OT
196104041,Infliximab,Incorrect dose administered,OT
196104041,Infliximab,Eye irritation,OT
196104041,Infliximab,Drug specific antibody present,OT
196104041,Infliximab,Blood pressure increased,OT
196248431,Infliximab,Ventricular extrasystoles,OT
196248431,Infliximab,Off label use,OT
196248431,Infliximab,Maternal exposure during pregnancy,OT
196248431,Infliximab,Kidney infection,OT
196248431,Infliximab,Intentional product use issue,OT
196343342,Infliximab Pfizer (Unknown),Uveitis,OT
196343342,Infliximab Pfizer (Unknown),Psoriatic arthropathy,OT
196343342,Infliximab Pfizer (Unknown),Iridocyclitis,OT
196343342,Infliximab Pfizer (Unknown),Drug ineffective,OT
196343342,Infliximab Pfizer (Unknown),Disease recurrence,OT
196343342,Infliximab Pfizer (Unknown),Uveitis,OT
196343342,Infliximab Pfizer (Unknown),Psoriatic arthropathy,OT
196343342,Infliximab Pfizer (Unknown),Iridocyclitis,OT
196343342,Infliximab Pfizer (Unknown),Drug ineffective,OT
196343342,Infliximab Pfizer (Unknown),Disease recurrence,OT
196805511,Infliximab,Rotator cuff syndrome,OT
196805511,Infliximab,Blood pressure increased,OT
196867421,Infliximab,Weight increased,OT
196867421,Infliximab,Sinusitis,OT
196867421,Infliximab,Pyrexia,OT
196867421,Infliximab,Off label use,OT
196867421,Infliximab,Malaise,OT
196867421,Infliximab,Intentional product use issue,OT
196867421,Infliximab,Inappropriate schedule of product administration,OT
196867421,Infliximab,Heart rate decreased,OT
196867421,Infliximab,Fatigue,OT
196867421,Infliximab,Condition aggravated,OT
196867421,Infliximab,COVID-19,OT
196867421,Infliximab,Blood iron decreased,OT
196867421,Infliximab,Arthritis,OT
196867421,Infliximab,Arthralgia,OT
196924521,Infliximab,White blood cell count increased,HO
196924521,Infliximab,White blood cell count increased,OT
196924521,Infliximab,Weight decreased,HO
196924521,Infliximab,Weight decreased,OT
196924521,Infliximab,Stress,HO
196924521,Infliximab,Stress,OT
196924521,Infliximab,Red blood cell count decreased,HO
196924521,Infliximab,Red blood cell count decreased,OT
196924521,Infliximab,Pain,HO
196924521,Infliximab,Pain,OT
196924521,Infliximab,Off label use,HO
196924521,Infliximab,Off label use,OT
196924521,Infliximab,Neutrophil count increased,HO
196924521,Infliximab,Neutrophil count increased,OT
196924521,Infliximab,Monocyte count increased,HO
196924521,Infliximab,Monocyte count increased,OT
196924521,Infliximab,Mean cell haemoglobin concentration decreased,HO
196924521,Infliximab,Mean cell haemoglobin concentration decreased,OT
196924521,Infliximab,Lymphocyte count decreased,HO
196924521,Infliximab,Lymphocyte count decreased,OT
196924521,Infliximab,Insomnia,HO
196924521,Infliximab,Insomnia,OT
196924521,Infliximab,Inappropriate schedule of product administration,HO
196924521,Infliximab,Inappropriate schedule of product administration,OT
196924521,Infliximab,Haemoglobin decreased,HO
196924521,Infliximab,Haemoglobin decreased,OT
196924521,Infliximab,Haematocrit decreased,HO
196924521,Infliximab,Haematocrit decreased,OT
196924521,Infliximab,Emphysema,HO
196924521,Infliximab,Emphysema,OT
196924521,Infliximab,Dyspnoea,HO
196924521,Infliximab,Dyspnoea,OT
196924521,Infliximab,Drug ineffective,HO
196924521,Infliximab,Drug ineffective,OT
196924521,Infliximab,Disease progression,HO
196924521,Infliximab,Disease progression,OT
196924521,Infliximab,Crohn's disease,HO
196924521,Infliximab,Crohn's disease,OT
196924521,Infliximab,Condition aggravated,HO
196924521,Infliximab,Condition aggravated,OT
196924521,Infliximab,Chills,HO
196924521,Infliximab,Chills,OT
196924521,Infliximab,Chest discomfort,HO
196924521,Infliximab,Chest discomfort,OT
196924521,Infliximab,C-reactive protein increased,HO
196924521,Infliximab,C-reactive protein increased,OT
196924521,Infliximab,Arthralgia,HO
196924521,Infliximab,Arthralgia,OT
196924521,Infliximab,Alanine aminotransferase increased,HO
196924521,Infliximab,Alanine aminotransferase increased,OT
196938372,Infliximab (Unknown),Tinea capitis,OT
196938372,Infliximab (Unknown),Psoriasis,OT
196938372,Infliximab (Unknown),Dermatophytosis,OT
196938372,Infliximab (Unknown),Body tinea,OT
196938372,Infliximab (Unknown),Tinea capitis,OT
196938372,Infliximab (Unknown),Psoriasis,OT
196938372,Infliximab (Unknown),Dermatophytosis,OT
196938372,Infliximab (Unknown),Body tinea,OT
197101881,Infliximab,Weight fluctuation,OT
197101881,Infliximab,Therapeutic response shortened,OT
197101881,Infliximab,Pruritus,OT
197101881,Infliximab,Off label use,OT
197101881,Infliximab,Intentional product use issue,OT
197101881,Infliximab,Inappropriate schedule of product administration,OT
197101881,Infliximab,Heart rate irregular,OT
197101881,Infliximab,Heart rate decreased,OT
197101881,Infliximab,Haemorrhage,OT
197101881,Infliximab,Drug level below therapeutic,OT
197101881,Infliximab,Condition aggravated,OT
197101881,Infliximab,Body temperature increased,OT
197101881,Infliximab,Blood pressure fluctuation,OT
197101881,Infliximab,Blood pressure decreased,OT
197534871,Infliximab,Vomiting,HO
197534871,Infliximab,Sedation,HO
197534871,Infliximab,Panic attack,HO
197534871,Infliximab,Off label use,HO
197534871,Infliximab,Migraine,HO
197534871,Infliximab,Intentional product use issue,HO
197534871,Infliximab,Inappropriate schedule of product administration,HO
197534871,Infliximab,Headache,HO
197534871,Infliximab,Drug specific antibody absent,HO
197534871,Infliximab,Drug level decreased,HO
197534871,Infliximab,Condition aggravated,HO
197534871,Infliximab,Arthralgia,HO
197795531,Infliximab,Seizure,OT
197795531,Infliximab,Seizure,HO
197795531,Infliximab,Glioma,OT
197795531,Infliximab,Glioma,HO
197795531,Infliximab,Drug ineffective,OT
197795531,Infliximab,Drug ineffective,HO
198059941,Infliximab,Photophobia,OT
198059941,Infliximab,Off label use,OT
198059941,Infliximab,Nausea,OT
198059941,Infliximab,Mydriasis,OT
198059941,Infliximab,Intentional product use issue,OT
198059941,Infliximab,Hot flush,OT
198059941,Infliximab,Eye inflammation,OT
198059941,Infliximab,Condition aggravated,OT
198059941,Infliximab,Catheter site infection,OT
198059941,Infliximab,Cataract,OT
198437371,Infliximab,Paraesthesia oral,OT
198437371,Infliximab,Oxygen saturation decreased,OT
198437371,Infliximab,Off label use,OT
198437371,Infliximab,Malaise,OT
198437371,Infliximab,Intentional product use issue,OT
198437371,Infliximab,Hypoaesthesia oral,OT
198437371,Infliximab,Flushing,OT
198437371,Infliximab,Fatigue,OT
198437371,Infliximab,Blood pressure fluctuation,OT
198657581,Infliximab,Drug ineffective,OT
198829921,Infliximab,Product use in unapproved indication,HO
198829921,Infliximab,Henoch-Schonlein purpura,HO
198912901,Infliximab,Product use issue,DE
198912901,Infliximab,Off label use,DE
198912901,Infliximab,Death,DE
199021031,Infliximab,White blood cell count decreased,OT
199021031,Infliximab,Weight increased,OT
199021031,Infliximab,Weight fluctuation,OT
199021031,Infliximab,Therapeutic product effect incomplete,OT
199021031,Infliximab,Pyrexia,OT
199021031,Infliximab,Polyp,OT
199021031,Infliximab,Pallor,OT
199021031,Infliximab,Off label use,OT
199021031,Infliximab,Neutrophil count decreased,OT
199021031,Infliximab,Mean cell haemoglobin concentration increased,OT
199021031,Infliximab,Intentional product use issue,OT
199021031,Infliximab,Insomnia,OT
199021031,Infliximab,Incorrect dose administered,OT
199021031,Infliximab,Heart rate increased,OT
199021031,Infliximab,Fatigue,OT
199021031,Infliximab,Drug level below therapeutic,OT
199021031,Infliximab,Dizziness,OT
199021031,Infliximab,Condition aggravated,OT
199021031,Infliximab,C-reactive protein increased,OT
199021031,Infliximab,Blood pressure diastolic decreased,OT
199021031,Infliximab,Arthralgia,OT
199021031,Infliximab,Anaemia,OT
199021031,Infliximab,Abnormal behaviour,OT
1235507243,Infliximab Hospira,Urticaria,HO
1235507243,Infliximab Hospira,Urticaria,DS
1235507243,Infliximab Hospira,Urticaria,OT
1235507243,Infliximab Hospira,Ulcer,HO
1235507243,Infliximab Hospira,Ulcer,DS
1235507243,Infliximab Hospira,Ulcer,OT
1235507243,Infliximab Hospira,Treatment failure,HO
1235507243,Infliximab Hospira,Treatment failure,DS
1235507243,Infliximab Hospira,Treatment failure,OT
1235507243,Infliximab Hospira,Tongue disorder,HO
1235507243,Infliximab Hospira,Tongue disorder,DS
1235507243,Infliximab Hospira,Tongue disorder,OT
1235507243,Infliximab Hospira,Therapy non-responder,HO
1235507243,Infliximab Hospira,Therapy non-responder,DS
1235507243,Infliximab Hospira,Therapy non-responder,OT
1235507243,Infliximab Hospira,Therapeutic response decreased,HO
1235507243,Infliximab Hospira,Therapeutic response decreased,DS
1235507243,Infliximab Hospira,Therapeutic response decreased,OT
1235507243,Infliximab Hospira,Therapeutic product effect incomplete,HO
1235507243,Infliximab Hospira,Therapeutic product effect incomplete,DS
1235507243,Infliximab Hospira,Therapeutic product effect incomplete,OT
1235507243,Infliximab Hospira,Therapeutic product effect decreased,HO
1235507243,Infliximab Hospira,Therapeutic product effect decreased,DS
1235507243,Infliximab Hospira,Therapeutic product effect decreased,OT
1235507243,Infliximab Hospira,Tenosynovitis,HO
1235507243,Infliximab Hospira,Tenosynovitis,DS
1235507243,Infliximab Hospira,Tenosynovitis,OT
1235507243,Infliximab Hospira,Tendonitis,HO
1235507243,Infliximab Hospira,Tendonitis,DS
1235507243,Infliximab Hospira,Tendonitis,OT
1235507243,Infliximab Hospira,Synovitis,HO
1235507243,Infliximab Hospira,Synovitis,DS
1235507243,Infliximab Hospira,Synovitis,OT
1235507243,Infliximab Hospira,Skin ulcer,HO
1235507243,Infliximab Hospira,Skin ulcer,DS
1235507243,Infliximab Hospira,Skin ulcer,OT
1235507243,Infliximab Hospira,Skin necrosis,HO
1235507243,Infliximab Hospira,Skin necrosis,DS
1235507243,Infliximab Hospira,Skin necrosis,OT
1235507243,Infliximab Hospira,Rheumatoid nodule,HO
1235507243,Infliximab Hospira,Rheumatoid nodule,DS
1235507243,Infliximab Hospira,Rheumatoid nodule,OT
1235507243,Infliximab Hospira,Rheumatoid lung,HO
1235507243,Infliximab Hospira,Rheumatoid lung,DS
1235507243,Infliximab Hospira,Rheumatoid lung,OT
1235507243,Infliximab Hospira,Rheumatoid arthritis,HO
1235507243,Infliximab Hospira,Rheumatoid arthritis,DS
1235507243,Infliximab Hospira,Rheumatoid arthritis,OT
1235507243,Infliximab Hospira,Red blood cell sedimentation rate increased,HO
1235507243,Infliximab Hospira,Red blood cell sedimentation rate increased,DS
1235507243,Infliximab Hospira,Red blood cell sedimentation rate increased,OT
1235507243,Infliximab Hospira,Red blood cell sedimentation rate,HO
1235507243,Infliximab Hospira,Red blood cell sedimentation rate,DS
1235507243,Infliximab Hospira,Red blood cell sedimentation rate,OT
1235507243,Infliximab Hospira,Rash pruritic,HO
1235507243,Infliximab Hospira,Rash pruritic,DS
1235507243,Infliximab Hospira,Rash pruritic,OT
1235507243,Infliximab Hospira,Rash,HO
1235507243,Infliximab Hospira,Rash,DS
1235507243,Infliximab Hospira,Rash,OT
1235507243,Infliximab Hospira,Pulmonary fibrosis,HO
1235507243,Infliximab Hospira,Pulmonary fibrosis,DS
1235507243,Infliximab Hospira,Pulmonary fibrosis,OT
1235507243,Infliximab Hospira,Psoriatic arthropathy,HO
1235507243,Infliximab Hospira,Psoriatic arthropathy,DS
1235507243,Infliximab Hospira,Psoriatic arthropathy,OT
1235507243,Infliximab Hospira,Product use issue,HO
1235507243,Infliximab Hospira,Product use issue,DS
1235507243,Infliximab Hospira,Product use issue,OT
1235507243,Infliximab Hospira,Peripheral swelling,HO
1235507243,Infliximab Hospira,Peripheral swelling,DS
1235507243,Infliximab Hospira,Peripheral swelling,OT
1235507243,Infliximab Hospira,Panniculitis,HO
1235507243,Infliximab Hospira,Panniculitis,DS
1235507243,Infliximab Hospira,Panniculitis,OT
1235507243,Infliximab Hospira,Pain,HO
1235507243,Infliximab Hospira,Pain,DS
1235507243,Infliximab Hospira,Pain,OT
1235507243,Infliximab Hospira,Overdose,HO
1235507243,Infliximab Hospira,Overdose,DS
1235507243,Infliximab Hospira,Overdose,OT
1235507243,Infliximab Hospira,Osteomyelitis,HO
1235507243,Infliximab Hospira,Osteomyelitis,DS
1235507243,Infliximab Hospira,Osteomyelitis,OT
1235507243,Infliximab Hospira,Off label use,HO
1235507243,Infliximab Hospira,Off label use,DS
1235507243,Infliximab Hospira,Off label use,OT
1235507243,Infliximab Hospira,Nausea,HO
1235507243,Infliximab Hospira,Nausea,DS
1235507243,Infliximab Hospira,Nausea,OT
1235507243,Infliximab Hospira,Musculoskeletal stiffness,HO
1235507243,Infliximab Hospira,Musculoskeletal stiffness,DS
1235507243,Infliximab Hospira,Musculoskeletal stiffness,OT
1235507243,Infliximab Hospira,Musculoskeletal disorder,HO
1235507243,Infliximab Hospira,Musculoskeletal disorder,DS
1235507243,Infliximab Hospira,Musculoskeletal disorder,OT
1235507243,Infliximab Hospira,Mobility decreased,HO
1235507243,Infliximab Hospira,Mobility decreased,DS
1235507243,Infliximab Hospira,Mobility decreased,OT
1235507243,Infliximab Hospira,Malaise,HO
1235507243,Infliximab Hospira,Malaise,DS
1235507243,Infliximab Hospira,Malaise,OT
1235507243,Infliximab Hospira,Loss of personal independence in daily activities,HO
1235507243,Infliximab Hospira,Loss of personal independence in daily activities,DS
1235507243,Infliximab Hospira,Loss of personal independence in daily activities,OT
1235507243,Infliximab Hospira,Joint swelling,HO
1235507243,Infliximab Hospira,Joint swelling,DS
1235507243,Infliximab Hospira,Joint swelling,OT
1235507243,Infliximab Hospira,Joint injury,HO
1235507243,Infliximab Hospira,Joint injury,DS
1235507243,Infliximab Hospira,Joint injury,OT
1235507243,Infliximab Hospira,Insomnia,HO
1235507243,Infliximab Hospira,Insomnia,DS
1235507243,Infliximab Hospira,Insomnia,OT
1235507243,Infliximab Hospira,Infusion related reaction,HO
1235507243,Infliximab Hospira,Infusion related reaction,DS
1235507243,Infliximab Hospira,Infusion related reaction,OT
1235507243,Infliximab Hospira,Inflammation,HO
1235507243,Infliximab Hospira,Inflammation,DS
1235507243,Infliximab Hospira,Inflammation,OT
1235507243,Infliximab Hospira,Hypertension,HO
1235507243,Infliximab Hospira,Hypertension,DS
1235507243,Infliximab Hospira,Hypertension,OT
1235507243,Infliximab Hospira,Hypercalcaemia,HO
1235507243,Infliximab Hospira,Hypercalcaemia,DS
1235507243,Infliximab Hospira,Hypercalcaemia,OT
1235507243,Infliximab Hospira,Headache,HO
1235507243,Infliximab Hospira,Headache,DS
1235507243,Infliximab Hospira,Headache,OT
1235507243,Infliximab Hospira,Granuloma skin,HO
1235507243,Infliximab Hospira,Granuloma skin,DS
1235507243,Infliximab Hospira,Granuloma skin,OT
1235507243,Infliximab Hospira,Granuloma,HO
1235507243,Infliximab Hospira,Granuloma,DS
1235507243,Infliximab Hospira,Granuloma,OT
1235507243,Infliximab Hospira,General physical health deterioration,HO
1235507243,Infliximab Hospira,General physical health deterioration,DS
1235507243,Infliximab Hospira,General physical health deterioration,OT
1235507243,Infliximab Hospira,Gastric disorder,HO
1235507243,Infliximab Hospira,Gastric disorder,DS
1235507243,Infliximab Hospira,Gastric disorder,OT
1235507243,Infliximab Hospira,Fear of injection,HO
1235507243,Infliximab Hospira,Fear of injection,DS
1235507243,Infliximab Hospira,Fear of injection,OT
1235507243,Infliximab Hospira,Fatigue,HO
1235507243,Infliximab Hospira,Fatigue,DS
1235507243,Infliximab Hospira,Fatigue,OT
1235507243,Infliximab Hospira,Erythema,HO
1235507243,Infliximab Hospira,Erythema,DS
1235507243,Infliximab Hospira,Erythema,OT
1235507243,Infliximab Hospira,Enthesopathy,HO
1235507243,Infliximab Hospira,Enthesopathy,DS
1235507243,Infliximab Hospira,Enthesopathy,OT
1235507243,Infliximab Hospira,Drug tolerance decreased,HO
1235507243,Infliximab Hospira,Drug tolerance decreased,DS
1235507243,Infliximab Hospira,Drug tolerance decreased,OT
1235507243,Infliximab Hospira,Drug tolerance,HO
1235507243,Infliximab Hospira,Drug tolerance,DS
1235507243,Infliximab Hospira,Drug tolerance,OT
1235507243,Infliximab Hospira,Drug intolerance,HO
1235507243,Infliximab Hospira,Drug intolerance,DS
1235507243,Infliximab Hospira,Drug intolerance,OT
1235507243,Infliximab Hospira,Drug ineffective,HO
1235507243,Infliximab Hospira,Drug ineffective,DS
1235507243,Infliximab Hospira,Drug ineffective,OT
1235507243,Infliximab Hospira,Drug hypersensitivity,HO
1235507243,Infliximab Hospira,Drug hypersensitivity,DS
1235507243,Infliximab Hospira,Drug hypersensitivity,OT
1235507243,Infliximab Hospira,Drug eruption,HO
1235507243,Infliximab Hospira,Drug eruption,DS
1235507243,Infliximab Hospira,Drug eruption,OT
1235507243,Infliximab Hospira,Diarrhoea,HO
1235507243,Infliximab Hospira,Diarrhoea,DS
1235507243,Infliximab Hospira,Diarrhoea,OT
1235507243,Infliximab Hospira,Decreased appetite,HO
1235507243,Infliximab Hospira,Decreased appetite,DS
1235507243,Infliximab Hospira,Decreased appetite,OT
1235507243,Infliximab Hospira,Contraindicated product administered,HO
1235507243,Infliximab Hospira,Contraindicated product administered,DS
1235507243,Infliximab Hospira,Contraindicated product administered,OT
1235507243,Infliximab Hospira,Condition aggravated,HO
1235507243,Infliximab Hospira,Condition aggravated,DS
1235507243,Infliximab Hospira,Condition aggravated,OT
1235507243,Infliximab Hospira,C-reactive protein increased,HO
1235507243,Infliximab Hospira,C-reactive protein increased,DS
1235507243,Infliximab Hospira,C-reactive protein increased,OT
1235507243,Infliximab Hospira,C-reactive protein abnormal,HO
1235507243,Infliximab Hospira,C-reactive protein abnormal,DS
1235507243,Infliximab Hospira,C-reactive protein abnormal,OT
1235507243,Infliximab Hospira,Blood pressure systolic increased,HO
1235507243,Infliximab Hospira,Blood pressure systolic increased,DS
1235507243,Infliximab Hospira,Blood pressure systolic increased,OT
1235507243,Infliximab Hospira,Blood parathyroid hormone decreased,HO
1235507243,Infliximab Hospira,Blood parathyroid hormone decreased,DS
1235507243,Infliximab Hospira,Blood parathyroid hormone decreased,OT
1235507243,Infliximab Hospira,Blood creatinine increased,HO
1235507243,Infliximab Hospira,Blood creatinine increased,DS
1235507243,Infliximab Hospira,Blood creatinine increased,OT
1235507243,Infliximab Hospira,Basal cell carcinoma,HO
1235507243,Infliximab Hospira,Basal cell carcinoma,DS
1235507243,Infliximab Hospira,Basal cell carcinoma,OT
1235507243,Infliximab Hospira,Aspartate aminotransferase increased,HO
1235507243,Infliximab Hospira,Aspartate aminotransferase increased,DS
1235507243,Infliximab Hospira,Aspartate aminotransferase increased,OT
1235507243,Infliximab Hospira,Arthropathy,HO
1235507243,Infliximab Hospira,Arthropathy,DS
1235507243,Infliximab Hospira,Arthropathy,OT
1235507243,Infliximab Hospira,Arthritis,HO
1235507243,Infliximab Hospira,Arthritis,DS
1235507243,Infliximab Hospira,Arthritis,OT
1235507243,Infliximab Hospira,Arthralgia,HO
1235507243,Infliximab Hospira,Arthralgia,DS
1235507243,Infliximab Hospira,Arthralgia,OT
1235507243,Infliximab Hospira,Alopecia,HO
1235507243,Infliximab Hospira,Alopecia,DS
1235507243,Infliximab Hospira,Alopecia,OT
1235507243,Infliximab Hospira,Alanine aminotransferase increased,HO
1235507243,Infliximab Hospira,Alanine aminotransferase increased,DS
1235507243,Infliximab Hospira,Alanine aminotransferase increased,OT
1235507243,Infliximab Hospira,Alanine aminotransferase abnormal,HO
1235507243,Infliximab Hospira,Alanine aminotransferase abnormal,DS
1235507243,Infliximab Hospira,Alanine aminotransferase abnormal,OT
1235507243,Infliximab Hospira,Abdominal discomfort,HO
1235507243,Infliximab Hospira,Abdominal discomfort,DS
1235507243,Infliximab Hospira,Abdominal discomfort,OT
1235507243,Infliximab Hospira,Urticaria,HO
1235507243,Infliximab Hospira,Urticaria,DS
1235507243,Infliximab Hospira,Urticaria,OT
1235507243,Infliximab Hospira,Ulcer,HO
1235507243,Infliximab Hospira,Ulcer,DS
1235507243,Infliximab Hospira,Ulcer,OT
1235507243,Infliximab Hospira,Treatment failure,HO
1235507243,Infliximab Hospira,Treatment failure,DS
1235507243,Infliximab Hospira,Treatment failure,OT
1235507243,Infliximab Hospira,Tongue disorder,HO
1235507243,Infliximab Hospira,Tongue disorder,DS
1235507243,Infliximab Hospira,Tongue disorder,OT
1235507243,Infliximab Hospira,Therapy non-responder,HO
1235507243,Infliximab Hospira,Therapy non-responder,DS
1235507243,Infliximab Hospira,Therapy non-responder,OT
1235507243,Infliximab Hospira,Therapeutic response decreased,HO
1235507243,Infliximab Hospira,Therapeutic response decreased,DS
1235507243,Infliximab Hospira,Therapeutic response decreased,OT
1235507243,Infliximab Hospira,Therapeutic product effect incomplete,HO
1235507243,Infliximab Hospira,Therapeutic product effect incomplete,DS
1235507243,Infliximab Hospira,Therapeutic product effect incomplete,OT
1235507243,Infliximab Hospira,Therapeutic product effect decreased,HO
1235507243,Infliximab Hospira,Therapeutic product effect decreased,DS
1235507243,Infliximab Hospira,Therapeutic product effect decreased,OT
1235507243,Infliximab Hospira,Tenosynovitis,HO
1235507243,Infliximab Hospira,Tenosynovitis,DS
1235507243,Infliximab Hospira,Tenosynovitis,OT
1235507243,Infliximab Hospira,Tendonitis,HO
1235507243,Infliximab Hospira,Tendonitis,DS
1235507243,Infliximab Hospira,Tendonitis,OT
1235507243,Infliximab Hospira,Synovitis,HO
1235507243,Infliximab Hospira,Synovitis,DS
1235507243,Infliximab Hospira,Synovitis,OT
1235507243,Infliximab Hospira,Skin ulcer,HO
1235507243,Infliximab Hospira,Skin ulcer,DS
1235507243,Infliximab Hospira,Skin ulcer,OT
1235507243,Infliximab Hospira,Skin necrosis,HO
1235507243,Infliximab Hospira,Skin necrosis,DS
1235507243,Infliximab Hospira,Skin necrosis,OT
1235507243,Infliximab Hospira,Rheumatoid nodule,HO
1235507243,Infliximab Hospira,Rheumatoid nodule,DS
1235507243,Infliximab Hospira,Rheumatoid nodule,OT
1235507243,Infliximab Hospira,Rheumatoid lung,HO
1235507243,Infliximab Hospira,Rheumatoid lung,DS
1235507243,Infliximab Hospira,Rheumatoid lung,OT
1235507243,Infliximab Hospira,Rheumatoid arthritis,HO
1235507243,Infliximab Hospira,Rheumatoid arthritis,DS
1235507243,Infliximab Hospira,Rheumatoid arthritis,OT
1235507243,Infliximab Hospira,Red blood cell sedimentation rate increased,HO
1235507243,Infliximab Hospira,Red blood cell sedimentation rate increased,DS
1235507243,Infliximab Hospira,Red blood cell sedimentation rate increased,OT
1235507243,Infliximab Hospira,Red blood cell sedimentation rate,HO
1235507243,Infliximab Hospira,Red blood cell sedimentation rate,DS
1235507243,Infliximab Hospira,Red blood cell sedimentation rate,OT
1235507243,Infliximab Hospira,Rash pruritic,HO
1235507243,Infliximab Hospira,Rash pruritic,DS
1235507243,Infliximab Hospira,Rash pruritic,OT
1235507243,Infliximab Hospira,Rash,HO
1235507243,Infliximab Hospira,Rash,DS
1235507243,Infliximab Hospira,Rash,OT
1235507243,Infliximab Hospira,Pulmonary fibrosis,HO
1235507243,Infliximab Hospira,Pulmonary fibrosis,DS
1235507243,Infliximab Hospira,Pulmonary fibrosis,OT
1235507243,Infliximab Hospira,Psoriatic arthropathy,HO
1235507243,Infliximab Hospira,Psoriatic arthropathy,DS
1235507243,Infliximab Hospira,Psoriatic arthropathy,OT
1235507243,Infliximab Hospira,Product use issue,HO
1235507243,Infliximab Hospira,Product use issue,DS
1235507243,Infliximab Hospira,Product use issue,OT
1235507243,Infliximab Hospira,Peripheral swelling,HO
1235507243,Infliximab Hospira,Peripheral swelling,DS
1235507243,Infliximab Hospira,Peripheral swelling,OT
1235507243,Infliximab Hospira,Panniculitis,HO
1235507243,Infliximab Hospira,Panniculitis,DS
1235507243,Infliximab Hospira,Panniculitis,OT
1235507243,Infliximab Hospira,Pain,HO
1235507243,Infliximab Hospira,Pain,DS
1235507243,Infliximab Hospira,Pain,OT
1235507243,Infliximab Hospira,Overdose,HO
1235507243,Infliximab Hospira,Overdose,DS
1235507243,Infliximab Hospira,Overdose,OT
1235507243,Infliximab Hospira,Osteomyelitis,HO
1235507243,Infliximab Hospira,Osteomyelitis,DS
1235507243,Infliximab Hospira,Osteomyelitis,OT
1235507243,Infliximab Hospira,Off label use,HO
1235507243,Infliximab Hospira,Off label use,DS
1235507243,Infliximab Hospira,Off label use,OT
1235507243,Infliximab Hospira,Nausea,HO
1235507243,Infliximab Hospira,Nausea,DS
1235507243,Infliximab Hospira,Nausea,OT
1235507243,Infliximab Hospira,Musculoskeletal stiffness,HO
1235507243,Infliximab Hospira,Musculoskeletal stiffness,DS
1235507243,Infliximab Hospira,Musculoskeletal stiffness,OT
1235507243,Infliximab Hospira,Musculoskeletal disorder,HO
1235507243,Infliximab Hospira,Musculoskeletal disorder,DS
1235507243,Infliximab Hospira,Musculoskeletal disorder,OT
1235507243,Infliximab Hospira,Mobility decreased,HO
1235507243,Infliximab Hospira,Mobility decreased,DS
1235507243,Infliximab Hospira,Mobility decreased,OT
1235507243,Infliximab Hospira,Malaise,HO
1235507243,Infliximab Hospira,Malaise,DS
1235507243,Infliximab Hospira,Malaise,OT
1235507243,Infliximab Hospira,Loss of personal independence in daily activities,HO
1235507243,Infliximab Hospira,Loss of personal independence in daily activities,DS
1235507243,Infliximab Hospira,Loss of personal independence in daily activities,OT
1235507243,Infliximab Hospira,Joint swelling,HO
1235507243,Infliximab Hospira,Joint swelling,DS
1235507243,Infliximab Hospira,Joint swelling,OT
1235507243,Infliximab Hospira,Joint injury,HO
1235507243,Infliximab Hospira,Joint injury,DS
1235507243,Infliximab Hospira,Joint injury,OT
1235507243,Infliximab Hospira,Insomnia,HO
1235507243,Infliximab Hospira,Insomnia,DS
1235507243,Infliximab Hospira,Insomnia,OT
1235507243,Infliximab Hospira,Infusion related reaction,HO
1235507243,Infliximab Hospira,Infusion related reaction,DS
1235507243,Infliximab Hospira,Infusion related reaction,OT
1235507243,Infliximab Hospira,Inflammation,HO
1235507243,Infliximab Hospira,Inflammation,DS
1235507243,Infliximab Hospira,Inflammation,OT
1235507243,Infliximab Hospira,Hypertension,HO
1235507243,Infliximab Hospira,Hypertension,DS
1235507243,Infliximab Hospira,Hypertension,OT
1235507243,Infliximab Hospira,Hypercalcaemia,HO
1235507243,Infliximab Hospira,Hypercalcaemia,DS
1235507243,Infliximab Hospira,Hypercalcaemia,OT
1235507243,Infliximab Hospira,Headache,HO
1235507243,Infliximab Hospira,Headache,DS
1235507243,Infliximab Hospira,Headache,OT
1235507243,Infliximab Hospira,Granuloma skin,HO
1235507243,Infliximab Hospira,Granuloma skin,DS
1235507243,Infliximab Hospira,Granuloma skin,OT
1235507243,Infliximab Hospira,Granuloma,HO
1235507243,Infliximab Hospira,Granuloma,DS
1235507243,Infliximab Hospira,Granuloma,OT
1235507243,Infliximab Hospira,General physical health deterioration,HO
1235507243,Infliximab Hospira,General physical health deterioration,DS
1235507243,Infliximab Hospira,General physical health deterioration,OT
1235507243,Infliximab Hospira,Gastric disorder,HO
1235507243,Infliximab Hospira,Gastric disorder,DS
1235507243,Infliximab Hospira,Gastric disorder,OT
1235507243,Infliximab Hospira,Fear of injection,HO
1235507243,Infliximab Hospira,Fear of injection,DS
1235507243,Infliximab Hospira,Fear of injection,OT
1235507243,Infliximab Hospira,Fatigue,HO
1235507243,Infliximab Hospira,Fatigue,DS
1235507243,Infliximab Hospira,Fatigue,OT
1235507243,Infliximab Hospira,Erythema,HO
1235507243,Infliximab Hospira,Erythema,DS
1235507243,Infliximab Hospira,Erythema,OT
1235507243,Infliximab Hospira,Enthesopathy,HO
1235507243,Infliximab Hospira,Enthesopathy,DS
1235507243,Infliximab Hospira,Enthesopathy,OT
1235507243,Infliximab Hospira,Drug tolerance decreased,HO
1235507243,Infliximab Hospira,Drug tolerance decreased,DS
1235507243,Infliximab Hospira,Drug tolerance decreased,OT
1235507243,Infliximab Hospira,Drug tolerance,HO
1235507243,Infliximab Hospira,Drug tolerance,DS
1235507243,Infliximab Hospira,Drug tolerance,OT
1235507243,Infliximab Hospira,Drug intolerance,HO
1235507243,Infliximab Hospira,Drug intolerance,DS
1235507243,Infliximab Hospira,Drug intolerance,OT
1235507243,Infliximab Hospira,Drug ineffective,HO
1235507243,Infliximab Hospira,Drug ineffective,DS
1235507243,Infliximab Hospira,Drug ineffective,OT
1235507243,Infliximab Hospira,Drug hypersensitivity,HO
1235507243,Infliximab Hospira,Drug hypersensitivity,DS
1235507243,Infliximab Hospira,Drug hypersensitivity,OT
1235507243,Infliximab Hospira,Drug eruption,HO
1235507243,Infliximab Hospira,Drug eruption,DS
1235507243,Infliximab Hospira,Drug eruption,OT
1235507243,Infliximab Hospira,Diarrhoea,HO
1235507243,Infliximab Hospira,Diarrhoea,DS
1235507243,Infliximab Hospira,Diarrhoea,OT
1235507243,Infliximab Hospira,Decreased appetite,HO
1235507243,Infliximab Hospira,Decreased appetite,DS
1235507243,Infliximab Hospira,Decreased appetite,OT
1235507243,Infliximab Hospira,Contraindicated product administered,HO
1235507243,Infliximab Hospira,Contraindicated product administered,DS
1235507243,Infliximab Hospira,Contraindicated product administered,OT
1235507243,Infliximab Hospira,Condition aggravated,HO
1235507243,Infliximab Hospira,Condition aggravated,DS
1235507243,Infliximab Hospira,Condition aggravated,OT
1235507243,Infliximab Hospira,C-reactive protein increased,HO
1235507243,Infliximab Hospira,C-reactive protein increased,DS
1235507243,Infliximab Hospira,C-reactive protein increased,OT
1235507243,Infliximab Hospira,C-reactive protein abnormal,HO
1235507243,Infliximab Hospira,C-reactive protein abnormal,DS
1235507243,Infliximab Hospira,C-reactive protein abnormal,OT
1235507243,Infliximab Hospira,Blood pressure systolic increased,HO
1235507243,Infliximab Hospira,Blood pressure systolic increased,DS
1235507243,Infliximab Hospira,Blood pressure systolic increased,OT
1235507243,Infliximab Hospira,Blood parathyroid hormone decreased,HO
1235507243,Infliximab Hospira,Blood parathyroid hormone decreased,DS
1235507243,Infliximab Hospira,Blood parathyroid hormone decreased,OT
1235507243,Infliximab Hospira,Blood creatinine increased,HO
1235507243,Infliximab Hospira,Blood creatinine increased,DS
1235507243,Infliximab Hospira,Blood creatinine increased,OT
1235507243,Infliximab Hospira,Basal cell carcinoma,HO
1235507243,Infliximab Hospira,Basal cell carcinoma,DS
1235507243,Infliximab Hospira,Basal cell carcinoma,OT
1235507243,Infliximab Hospira,Aspartate aminotransferase increased,HO
1235507243,Infliximab Hospira,Aspartate aminotransferase increased,DS
1235507243,Infliximab Hospira,Aspartate aminotransferase increased,OT
1235507243,Infliximab Hospira,Arthropathy,HO
1235507243,Infliximab Hospira,Arthropathy,DS
1235507243,Infliximab Hospira,Arthropathy,OT
1235507243,Infliximab Hospira,Arthritis,HO
1235507243,Infliximab Hospira,Arthritis,DS
1235507243,Infliximab Hospira,Arthritis,OT
1235507243,Infliximab Hospira,Arthralgia,HO
1235507243,Infliximab Hospira,Arthralgia,DS
1235507243,Infliximab Hospira,Arthralgia,OT
1235507243,Infliximab Hospira,Alopecia,HO
1235507243,Infliximab Hospira,Alopecia,DS
1235507243,Infliximab Hospira,Alopecia,OT
1235507243,Infliximab Hospira,Alanine aminotransferase increased,HO
1235507243,Infliximab Hospira,Alanine aminotransferase increased,DS
1235507243,Infliximab Hospira,Alanine aminotransferase increased,OT
1235507243,Infliximab Hospira,Alanine aminotransferase abnormal,HO
1235507243,Infliximab Hospira,Alanine aminotransferase abnormal,DS
1235507243,Infliximab Hospira,Alanine aminotransferase abnormal,OT
1235507243,Infliximab Hospira,Abdominal discomfort,HO
1235507243,Infliximab Hospira,Abdominal discomfort,DS
1235507243,Infliximab Hospira,Abdominal discomfort,OT
1235507243,Infliximab Hospira,Urticaria,HO
1235507243,Infliximab Hospira,Urticaria,DS
1235507243,Infliximab Hospira,Urticaria,OT
1235507243,Infliximab Hospira,Ulcer,HO
1235507243,Infliximab Hospira,Ulcer,DS
1235507243,Infliximab Hospira,Ulcer,OT
1235507243,Infliximab Hospira,Treatment failure,HO
1235507243,Infliximab Hospira,Treatment failure,DS
1235507243,Infliximab Hospira,Treatment failure,OT
1235507243,Infliximab Hospira,Tongue disorder,HO
1235507243,Infliximab Hospira,Tongue disorder,DS
1235507243,Infliximab Hospira,Tongue disorder,OT
1235507243,Infliximab Hospira,Therapy non-responder,HO
1235507243,Infliximab Hospira,Therapy non-responder,DS
1235507243,Infliximab Hospira,Therapy non-responder,OT
1235507243,Infliximab Hospira,Therapeutic response decreased,HO
1235507243,Infliximab Hospira,Therapeutic response decreased,DS
1235507243,Infliximab Hospira,Therapeutic response decreased,OT
1235507243,Infliximab Hospira,Therapeutic product effect incomplete,HO
1235507243,Infliximab Hospira,Therapeutic product effect incomplete,DS
1235507243,Infliximab Hospira,Therapeutic product effect incomplete,OT
1235507243,Infliximab Hospira,Therapeutic product effect decreased,HO
1235507243,Infliximab Hospira,Therapeutic product effect decreased,DS
1235507243,Infliximab Hospira,Therapeutic product effect decreased,OT
1235507243,Infliximab Hospira,Tenosynovitis,HO
1235507243,Infliximab Hospira,Tenosynovitis,DS
1235507243,Infliximab Hospira,Tenosynovitis,OT
1235507243,Infliximab Hospira,Tendonitis,HO
1235507243,Infliximab Hospira,Tendonitis,DS
1235507243,Infliximab Hospira,Tendonitis,OT
1235507243,Infliximab Hospira,Synovitis,HO
1235507243,Infliximab Hospira,Synovitis,DS
1235507243,Infliximab Hospira,Synovitis,OT
1235507243,Infliximab Hospira,Skin ulcer,HO
1235507243,Infliximab Hospira,Skin ulcer,DS
1235507243,Infliximab Hospira,Skin ulcer,OT
1235507243,Infliximab Hospira,Skin necrosis,HO
1235507243,Infliximab Hospira,Skin necrosis,DS
1235507243,Infliximab Hospira,Skin necrosis,OT
1235507243,Infliximab Hospira,Rheumatoid nodule,HO
1235507243,Infliximab Hospira,Rheumatoid nodule,DS
1235507243,Infliximab Hospira,Rheumatoid nodule,OT
1235507243,Infliximab Hospira,Rheumatoid lung,HO
1235507243,Infliximab Hospira,Rheumatoid lung,DS
1235507243,Infliximab Hospira,Rheumatoid lung,OT
1235507243,Infliximab Hospira,Rheumatoid arthritis,HO
1235507243,Infliximab Hospira,Rheumatoid arthritis,DS
1235507243,Infliximab Hospira,Rheumatoid arthritis,OT
1235507243,Infliximab Hospira,Red blood cell sedimentation rate increased,HO
1235507243,Infliximab Hospira,Red blood cell sedimentation rate increased,DS
1235507243,Infliximab Hospira,Red blood cell sedimentation rate increased,OT
1235507243,Infliximab Hospira,Red blood cell sedimentation rate,HO
1235507243,Infliximab Hospira,Red blood cell sedimentation rate,DS
1235507243,Infliximab Hospira,Red blood cell sedimentation rate,OT
1235507243,Infliximab Hospira,Rash pruritic,HO
1235507243,Infliximab Hospira,Rash pruritic,DS
1235507243,Infliximab Hospira,Rash pruritic,OT
1235507243,Infliximab Hospira,Rash,HO
1235507243,Infliximab Hospira,Rash,DS
1235507243,Infliximab Hospira,Rash,OT
1235507243,Infliximab Hospira,Pulmonary fibrosis,HO
1235507243,Infliximab Hospira,Pulmonary fibrosis,DS
1235507243,Infliximab Hospira,Pulmonary fibrosis,OT
1235507243,Infliximab Hospira,Psoriatic arthropathy,HO
1235507243,Infliximab Hospira,Psoriatic arthropathy,DS
1235507243,Infliximab Hospira,Psoriatic arthropathy,OT
1235507243,Infliximab Hospira,Product use issue,HO
1235507243,Infliximab Hospira,Product use issue,DS
1235507243,Infliximab Hospira,Product use issue,OT
1235507243,Infliximab Hospira,Peripheral swelling,HO
1235507243,Infliximab Hospira,Peripheral swelling,DS
1235507243,Infliximab Hospira,Peripheral swelling,OT
1235507243,Infliximab Hospira,Panniculitis,HO
1235507243,Infliximab Hospira,Panniculitis,DS
1235507243,Infliximab Hospira,Panniculitis,OT
1235507243,Infliximab Hospira,Pain,HO
1235507243,Infliximab Hospira,Pain,DS
1235507243,Infliximab Hospira,Pain,OT
1235507243,Infliximab Hospira,Overdose,HO
1235507243,Infliximab Hospira,Overdose,DS
1235507243,Infliximab Hospira,Overdose,OT
1235507243,Infliximab Hospira,Osteomyelitis,HO
1235507243,Infliximab Hospira,Osteomyelitis,DS
1235507243,Infliximab Hospira,Osteomyelitis,OT
1235507243,Infliximab Hospira,Off label use,HO
1235507243,Infliximab Hospira,Off label use,DS
1235507243,Infliximab Hospira,Off label use,OT
1235507243,Infliximab Hospira,Nausea,HO
1235507243,Infliximab Hospira,Nausea,DS
1235507243,Infliximab Hospira,Nausea,OT
1235507243,Infliximab Hospira,Musculoskeletal stiffness,HO
1235507243,Infliximab Hospira,Musculoskeletal stiffness,DS
1235507243,Infliximab Hospira,Musculoskeletal stiffness,OT
1235507243,Infliximab Hospira,Musculoskeletal disorder,HO
1235507243,Infliximab Hospira,Musculoskeletal disorder,DS
1235507243,Infliximab Hospira,Musculoskeletal disorder,OT
1235507243,Infliximab Hospira,Mobility decreased,HO
1235507243,Infliximab Hospira,Mobility decreased,DS
1235507243,Infliximab Hospira,Mobility decreased,OT
1235507243,Infliximab Hospira,Malaise,HO
1235507243,Infliximab Hospira,Malaise,DS
1235507243,Infliximab Hospira,Malaise,OT
1235507243,Infliximab Hospira,Loss of personal independence in daily activities,HO
1235507243,Infliximab Hospira,Loss of personal independence in daily activities,DS
1235507243,Infliximab Hospira,Loss of personal independence in daily activities,OT
1235507243,Infliximab Hospira,Joint swelling,HO
1235507243,Infliximab Hospira,Joint swelling,DS
1235507243,Infliximab Hospira,Joint swelling,OT
1235507243,Infliximab Hospira,Joint injury,HO
1235507243,Infliximab Hospira,Joint injury,DS
1235507243,Infliximab Hospira,Joint injury,OT
1235507243,Infliximab Hospira,Insomnia,HO
1235507243,Infliximab Hospira,Insomnia,DS
1235507243,Infliximab Hospira,Insomnia,OT
1235507243,Infliximab Hospira,Infusion related reaction,HO
1235507243,Infliximab Hospira,Infusion related reaction,DS
1235507243,Infliximab Hospira,Infusion related reaction,OT
1235507243,Infliximab Hospira,Inflammation,HO
1235507243,Infliximab Hospira,Inflammation,DS
1235507243,Infliximab Hospira,Inflammation,OT
1235507243,Infliximab Hospira,Hypertension,HO
1235507243,Infliximab Hospira,Hypertension,DS
1235507243,Infliximab Hospira,Hypertension,OT
1235507243,Infliximab Hospira,Hypercalcaemia,HO
1235507243,Infliximab Hospira,Hypercalcaemia,DS
1235507243,Infliximab Hospira,Hypercalcaemia,OT
1235507243,Infliximab Hospira,Headache,HO
1235507243,Infliximab Hospira,Headache,DS
1235507243,Infliximab Hospira,Headache,OT
1235507243,Infliximab Hospira,Granuloma skin,HO
1235507243,Infliximab Hospira,Granuloma skin,DS
1235507243,Infliximab Hospira,Granuloma skin,OT
1235507243,Infliximab Hospira,Granuloma,HO
1235507243,Infliximab Hospira,Granuloma,DS
1235507243,Infliximab Hospira,Granuloma,OT
1235507243,Infliximab Hospira,General physical health deterioration,HO
1235507243,Infliximab Hospira,General physical health deterioration,DS
1235507243,Infliximab Hospira,General physical health deterioration,OT
1235507243,Infliximab Hospira,Gastric disorder,HO
1235507243,Infliximab Hospira,Gastric disorder,DS
1235507243,Infliximab Hospira,Gastric disorder,OT
1235507243,Infliximab Hospira,Fear of injection,HO
1235507243,Infliximab Hospira,Fear of injection,DS
1235507243,Infliximab Hospira,Fear of injection,OT
1235507243,Infliximab Hospira,Fatigue,HO
1235507243,Infliximab Hospira,Fatigue,DS
1235507243,Infliximab Hospira,Fatigue,OT
1235507243,Infliximab Hospira,Erythema,HO
1235507243,Infliximab Hospira,Erythema,DS
1235507243,Infliximab Hospira,Erythema,OT
1235507243,Infliximab Hospira,Enthesopathy,HO
1235507243,Infliximab Hospira,Enthesopathy,DS
1235507243,Infliximab Hospira,Enthesopathy,OT
1235507243,Infliximab Hospira,Drug tolerance decreased,HO
1235507243,Infliximab Hospira,Drug tolerance decreased,DS
1235507243,Infliximab Hospira,Drug tolerance decreased,OT
1235507243,Infliximab Hospira,Drug tolerance,HO
1235507243,Infliximab Hospira,Drug tolerance,DS
1235507243,Infliximab Hospira,Drug tolerance,OT
1235507243,Infliximab Hospira,Drug intolerance,HO
1235507243,Infliximab Hospira,Drug intolerance,DS
1235507243,Infliximab Hospira,Drug intolerance,OT
1235507243,Infliximab Hospira,Drug ineffective,HO
1235507243,Infliximab Hospira,Drug ineffective,DS
1235507243,Infliximab Hospira,Drug ineffective,OT
1235507243,Infliximab Hospira,Drug hypersensitivity,HO
1235507243,Infliximab Hospira,Drug hypersensitivity,DS
1235507243,Infliximab Hospira,Drug hypersensitivity,OT
1235507243,Infliximab Hospira,Drug eruption,HO
1235507243,Infliximab Hospira,Drug eruption,DS
1235507243,Infliximab Hospira,Drug eruption,OT
1235507243,Infliximab Hospira,Diarrhoea,HO
1235507243,Infliximab Hospira,Diarrhoea,DS
1235507243,Infliximab Hospira,Diarrhoea,OT
1235507243,Infliximab Hospira,Decreased appetite,HO
1235507243,Infliximab Hospira,Decreased appetite,DS
1235507243,Infliximab Hospira,Decreased appetite,OT
1235507243,Infliximab Hospira,Contraindicated product administered,HO
1235507243,Infliximab Hospira,Contraindicated product administered,DS
1235507243,Infliximab Hospira,Contraindicated product administered,OT
1235507243,Infliximab Hospira,Condition aggravated,HO
1235507243,Infliximab Hospira,Condition aggravated,DS
1235507243,Infliximab Hospira,Condition aggravated,OT
1235507243,Infliximab Hospira,C-reactive protein increased,HO
1235507243,Infliximab Hospira,C-reactive protein increased,DS
1235507243,Infliximab Hospira,C-reactive protein increased,OT
1235507243,Infliximab Hospira,C-reactive protein abnormal,HO
1235507243,Infliximab Hospira,C-reactive protein abnormal,DS
1235507243,Infliximab Hospira,C-reactive protein abnormal,OT
1235507243,Infliximab Hospira,Blood pressure systolic increased,HO
1235507243,Infliximab Hospira,Blood pressure systolic increased,DS
1235507243,Infliximab Hospira,Blood pressure systolic increased,OT
1235507243,Infliximab Hospira,Blood parathyroid hormone decreased,HO
1235507243,Infliximab Hospira,Blood parathyroid hormone decreased,DS
1235507243,Infliximab Hospira,Blood parathyroid hormone decreased,OT
1235507243,Infliximab Hospira,Blood creatinine increased,HO
1235507243,Infliximab Hospira,Blood creatinine increased,DS
1235507243,Infliximab Hospira,Blood creatinine increased,OT
1235507243,Infliximab Hospira,Basal cell carcinoma,HO
1235507243,Infliximab Hospira,Basal cell carcinoma,DS
1235507243,Infliximab Hospira,Basal cell carcinoma,OT
1235507243,Infliximab Hospira,Aspartate aminotransferase increased,HO
1235507243,Infliximab Hospira,Aspartate aminotransferase increased,DS
1235507243,Infliximab Hospira,Aspartate aminotransferase increased,OT
1235507243,Infliximab Hospira,Arthropathy,HO
1235507243,Infliximab Hospira,Arthropathy,DS
1235507243,Infliximab Hospira,Arthropathy,OT
1235507243,Infliximab Hospira,Arthritis,HO
1235507243,Infliximab Hospira,Arthritis,DS
1235507243,Infliximab Hospira,Arthritis,OT
1235507243,Infliximab Hospira,Arthralgia,HO
1235507243,Infliximab Hospira,Arthralgia,DS
1235507243,Infliximab Hospira,Arthralgia,OT
1235507243,Infliximab Hospira,Alopecia,HO
1235507243,Infliximab Hospira,Alopecia,DS
1235507243,Infliximab Hospira,Alopecia,OT
1235507243,Infliximab Hospira,Alanine aminotransferase increased,HO
1235507243,Infliximab Hospira,Alanine aminotransferase increased,DS
1235507243,Infliximab Hospira,Alanine aminotransferase increased,OT
1235507243,Infliximab Hospira,Alanine aminotransferase abnormal,HO
1235507243,Infliximab Hospira,Alanine aminotransferase abnormal,DS
1235507243,Infliximab Hospira,Alanine aminotransferase abnormal,OT
1235507243,Infliximab Hospira,Abdominal discomfort,HO
1235507243,Infliximab Hospira,Abdominal discomfort,DS
1235507243,Infliximab Hospira,Abdominal discomfort,OT
160798705,Infliximab,Tremor,HO
160798705,Infliximab,Tremor,OT
160798705,Infliximab,Tenderness,HO
160798705,Infliximab,Tenderness,OT
160798705,Infliximab,Product use issue,HO
160798705,Infliximab,Product use issue,OT
160798705,Infliximab,Oxygen saturation abnormal,HO
160798705,Infliximab,Oxygen saturation abnormal,OT
160798705,Infliximab,Off label use,HO
160798705,Infliximab,Off label use,OT
160798705,Infliximab,Nervousness,HO
160798705,Infliximab,Nervousness,OT
160798705,Infliximab,Malaise,HO
160798705,Infliximab,Malaise,OT
160798705,Infliximab,Joint swelling,HO
160798705,Infliximab,Joint swelling,OT
160798705,Infliximab,Infusion site pruritus,HO
160798705,Infliximab,Infusion site pruritus,OT
160798705,Infliximab,Influenza,HO
160798705,Infliximab,Influenza,OT
160798705,Infliximab,Inappropriate schedule of product administration,HO
160798705,Infliximab,Inappropriate schedule of product administration,OT
160798705,Infliximab,Illness,HO
160798705,Infliximab,Illness,OT
160798705,Infliximab,Hypertension,HO
160798705,Infliximab,Hypertension,OT
160798705,Infliximab,Hyperhidrosis,HO
160798705,Infliximab,Hyperhidrosis,OT
160798705,Infliximab,Heart rate irregular,HO
160798705,Infliximab,Heart rate irregular,OT
160798705,Infliximab,Heart rate increased,HO
160798705,Infliximab,Heart rate increased,OT
160798705,Infliximab,Eye swelling,HO
160798705,Infliximab,Eye swelling,OT
160798705,Infliximab,Blood pressure fluctuation,HO
160798705,Infliximab,Blood pressure fluctuation,OT
160798705,Infliximab,Arthralgia,HO
160798705,Infliximab,Arthralgia,OT
160798705,Infliximab,Abdominal discomfort,HO
160798705,Infliximab,Abdominal discomfort,OT
160798705,Infliximab,Tremor,HO
160798705,Infliximab,Tremor,OT
160798705,Infliximab,Tenderness,HO
160798705,Infliximab,Tenderness,OT
160798705,Infliximab,Product use issue,HO
160798705,Infliximab,Product use issue,OT
160798705,Infliximab,Oxygen saturation abnormal,HO
160798705,Infliximab,Oxygen saturation abnormal,OT
160798705,Infliximab,Off label use,HO
160798705,Infliximab,Off label use,OT
160798705,Infliximab,Nervousness,HO
160798705,Infliximab,Nervousness,OT
160798705,Infliximab,Malaise,HO
160798705,Infliximab,Malaise,OT
160798705,Infliximab,Joint swelling,HO
160798705,Infliximab,Joint swelling,OT
160798705,Infliximab,Infusion site pruritus,HO
160798705,Infliximab,Infusion site pruritus,OT
160798705,Infliximab,Influenza,HO
160798705,Infliximab,Influenza,OT
160798705,Infliximab,Inappropriate schedule of product administration,HO
160798705,Infliximab,Inappropriate schedule of product administration,OT
160798705,Infliximab,Illness,HO
160798705,Infliximab,Illness,OT
160798705,Infliximab,Hypertension,HO
160798705,Infliximab,Hypertension,OT
160798705,Infliximab,Hyperhidrosis,HO
160798705,Infliximab,Hyperhidrosis,OT
160798705,Infliximab,Heart rate irregular,HO
160798705,Infliximab,Heart rate irregular,OT
160798705,Infliximab,Heart rate increased,HO
160798705,Infliximab,Heart rate increased,OT
160798705,Infliximab,Eye swelling,HO
160798705,Infliximab,Eye swelling,OT
160798705,Infliximab,Blood pressure fluctuation,HO
160798705,Infliximab,Blood pressure fluctuation,OT
160798705,Infliximab,Arthralgia,HO
160798705,Infliximab,Arthralgia,OT
160798705,Infliximab,Abdominal discomfort,HO
160798705,Infliximab,Abdominal discomfort,OT
175099295,Infliximab,Weight increased,OT
175099295,Infliximab,Viral infection,OT
175099295,Infliximab,Tonsillitis,OT
175099295,Infliximab,Swollen tongue,OT
175099295,Infliximab,Sinusitis,OT
175099295,Infliximab,Rhinorrhoea,OT
175099295,Infliximab,Pyrexia,OT
175099295,Infliximab,Pneumonia,OT
175099295,Infliximab,Pharyngitis,OT
175099295,Infliximab,Palpitations,OT
175099295,Infliximab,Off label use,OT
175099295,Infliximab,Nasal congestion,OT
175099295,Infliximab,Malaise,OT
175099295,Infliximab,Laryngitis,OT
175099295,Infliximab,Intentional product use issue,OT
175099295,Infliximab,Insomnia,OT
175099295,Infliximab,Influenza like illness,OT
175099295,Infliximab,Inappropriate schedule of product administration,OT
175099295,Infliximab,Illness,OT
175099295,Infliximab,Heart rate irregular,OT
175099295,Infliximab,Heart rate increased,OT
175099295,Infliximab,Headache,OT
175099295,Infliximab,General physical health deterioration,OT
175099295,Infliximab,Fatigue,OT
175099295,Infliximab,Erythema,OT
175099295,Infliximab,Eating disorder,OT
175099295,Infliximab,Drug hypersensitivity,OT
175099295,Infliximab,Cough,OT
175099295,Infliximab,Condition aggravated,OT
175099295,Infliximab,Asthmatic crisis,OT
175099295,Infliximab,Arthralgia,OT
176065953,Infliximab,Psoriasis,OT
176065953,Infliximab,Prescribed overdose,OT
176065953,Infliximab,Off label use,OT
176065953,Infliximab,Nasopharyngitis,OT
176065953,Infliximab,Intentional product use issue,OT
176065953,Infliximab,Influenza,OT
176065953,Infliximab,Incorrect dose administered,OT
176065953,Infliximab,Feeling abnormal,OT
176065953,Infliximab,Condition aggravated,OT
176065953,Infliximab,Blood pressure increased,OT
176065953,Infliximab,Blood pressure fluctuation,OT
176111253,Infliximab,Product use issue,OT
176111253,Infliximab,Off label use,OT
176111253,Infliximab,Intentional product use issue,OT
176111253,Infliximab,Heart rate irregular,OT
176111253,Infliximab,Heart rate decreased,OT
176111253,Infliximab,Blood pressure systolic increased,OT
176111253,Infliximab,Blood pressure fluctuation,OT
176111253,Infliximab,Product use issue,OT
176111253,Infliximab,Off label use,OT
176111253,Infliximab,Intentional product use issue,OT
176111253,Infliximab,Heart rate irregular,OT
176111253,Infliximab,Heart rate decreased,OT
176111253,Infliximab,Blood pressure systolic increased,OT
176111253,Infliximab,Blood pressure fluctuation,OT
176345904,Infliximab,Venous occlusion,OT
176345904,Infliximab,Off label use,OT
176345904,Infliximab,Incorrect dose administered,OT
176345904,Infliximab,Fall,OT
176345904,Infliximab,Cataract,OT
176345904,Infliximab,Blood pressure increased,OT
176345904,Infliximab,Blood pressure fluctuation,OT
176345904,Infliximab,Back injury,OT
176345904,Infliximab,Venous occlusion,OT
176345904,Infliximab,Off label use,OT
176345904,Infliximab,Incorrect dose administered,OT
176345904,Infliximab,Fall,OT
176345904,Infliximab,Cataract,OT
176345904,Infliximab,Blood pressure increased,OT
176345904,Infliximab,Blood pressure fluctuation,OT
176345904,Infliximab,Back injury,OT
176395924,Infliximab,Urticaria,OT
176395924,Infliximab,Urticaria,HO
176395924,Infliximab,Tooth infection,OT
176395924,Infliximab,Tooth infection,HO
176395924,Infliximab,Tooth abscess,OT
176395924,Infliximab,Tooth abscess,HO
176395924,Infliximab,Pyrexia,OT
176395924,Infliximab,Pyrexia,HO
176395924,Infliximab,Product use issue,OT
176395924,Infliximab,Product use issue,HO
176395924,Infliximab,Product dose omission issue,OT
176395924,Infliximab,Product dose omission issue,HO
176395924,Infliximab,Poor venous access,OT
176395924,Infliximab,Poor venous access,HO
176395924,Infliximab,Pallor,OT
176395924,Infliximab,Pallor,HO
176395924,Infliximab,Oropharyngeal pain,OT
176395924,Infliximab,Oropharyngeal pain,HO
176395924,Infliximab,Off label use,OT
176395924,Infliximab,Off label use,HO
176395924,Infliximab,Injection site extravasation,OT
176395924,Infliximab,Injection site extravasation,HO
176395924,Infliximab,Incorrect route of product administration,OT
176395924,Infliximab,Incorrect route of product administration,HO
176395924,Infliximab,Inappropriate schedule of product administration,OT
176395924,Infliximab,Inappropriate schedule of product administration,HO
176395924,Infliximab,Hypersensitivity,OT
176395924,Infliximab,Hypersensitivity,HO
176395924,Infliximab,Haemoglobin decreased,OT
176395924,Infliximab,Haemoglobin decreased,HO
176395924,Infliximab,Feeling of body temperature change,OT
176395924,Infliximab,Feeling of body temperature change,HO
176395924,Infliximab,Expired product administered,OT
176395924,Infliximab,Expired product administered,HO
176395924,Infliximab,Dysphonia,OT
176395924,Infliximab,Dysphonia,HO
176395924,Infliximab,Body temperature decreased,OT
176395924,Infliximab,Body temperature decreased,HO
176395924,Infliximab,Blood iron decreased,OT
176395924,Infliximab,Blood iron decreased,HO
176395924,Infliximab,Urticaria,OT
176395924,Infliximab,Urticaria,HO
176395924,Infliximab,Tooth infection,OT
176395924,Infliximab,Tooth infection,HO
176395924,Infliximab,Tooth abscess,OT
176395924,Infliximab,Tooth abscess,HO
176395924,Infliximab,Pyrexia,OT
176395924,Infliximab,Pyrexia,HO
176395924,Infliximab,Product use issue,OT
176395924,Infliximab,Product use issue,HO
176395924,Infliximab,Product dose omission issue,OT
176395924,Infliximab,Product dose omission issue,HO
176395924,Infliximab,Poor venous access,OT
176395924,Infliximab,Poor venous access,HO
176395924,Infliximab,Pallor,OT
176395924,Infliximab,Pallor,HO
176395924,Infliximab,Oropharyngeal pain,OT
176395924,Infliximab,Oropharyngeal pain,HO
176395924,Infliximab,Off label use,OT
176395924,Infliximab,Off label use,HO
176395924,Infliximab,Injection site extravasation,OT
176395924,Infliximab,Injection site extravasation,HO
176395924,Infliximab,Incorrect route of product administration,OT
176395924,Infliximab,Incorrect route of product administration,HO
176395924,Infliximab,Inappropriate schedule of product administration,OT
176395924,Infliximab,Inappropriate schedule of product administration,HO
176395924,Infliximab,Hypersensitivity,OT
176395924,Infliximab,Hypersensitivity,HO
176395924,Infliximab,Haemoglobin decreased,OT
176395924,Infliximab,Haemoglobin decreased,HO
176395924,Infliximab,Feeling of body temperature change,OT
176395924,Infliximab,Feeling of body temperature change,HO
176395924,Infliximab,Expired product administered,OT
176395924,Infliximab,Expired product administered,HO
176395924,Infliximab,Dysphonia,OT
176395924,Infliximab,Dysphonia,HO
176395924,Infliximab,Body temperature decreased,OT
176395924,Infliximab,Body temperature decreased,HO
176395924,Infliximab,Blood iron decreased,OT
176395924,Infliximab,Blood iron decreased,HO
177227923,Infliximab,Ovarian cyst ruptured,HO
177227923,Infliximab,Ovarian cyst ruptured,OT
177227923,Infliximab,Hypersensitivity,HO
177227923,Infliximab,Hypersensitivity,OT
177227923,Infliximab,Dehydration,HO
177227923,Infliximab,Dehydration,OT
177227923,Infliximab,Ovarian cyst ruptured,HO
177227923,Infliximab,Ovarian cyst ruptured,OT
177227923,Infliximab,Hypersensitivity,HO
177227923,Infliximab,Hypersensitivity,OT
177227923,Infliximab,Dehydration,HO
177227923,Infliximab,Dehydration,OT
177299874,Infliximab,Weight decreased,OT
177299874,Infliximab,Weight decreased,HO
177299874,Infliximab,Sleep apnoea syndrome,OT
177299874,Infliximab,Sleep apnoea syndrome,HO
177299874,Infliximab,Sinusitis,OT
177299874,Infliximab,Sinusitis,HO
177299874,Infliximab,Rhinorrhoea,OT
177299874,Infliximab,Rhinorrhoea,HO
177299874,Infliximab,Rectal abscess,OT
177299874,Infliximab,Rectal abscess,HO
177299874,Infliximab,Pericarditis,OT
177299874,Infliximab,Pericarditis,HO
177299874,Infliximab,Oxygen saturation abnormal,OT
177299874,Infliximab,Oxygen saturation abnormal,HO
177299874,Infliximab,Off label use,OT
177299874,Infliximab,Off label use,HO
177299874,Infliximab,Nasal congestion,OT
177299874,Infliximab,Nasal congestion,HO
177299874,Infliximab,Myocardial infarction,OT
177299874,Infliximab,Myocardial infarction,HO
177299874,Infliximab,Malaise,OT
177299874,Infliximab,Malaise,HO
177299874,Infliximab,Intentional product use issue,OT
177299874,Infliximab,Intentional product use issue,HO
177299874,Infliximab,Infected fistula,OT
177299874,Infliximab,Infected fistula,HO
177299874,Infliximab,Incorrect dose administered,OT
177299874,Infliximab,Incorrect dose administered,HO
177299874,Infliximab,Inappropriate schedule of product administration,OT
177299874,Infliximab,Inappropriate schedule of product administration,HO
177299874,Infliximab,Illness,OT
177299874,Infliximab,Illness,HO
177299874,Infliximab,Heart rate irregular,OT
177299874,Infliximab,Heart rate irregular,HO
177299874,Infliximab,Heart rate decreased,OT
177299874,Infliximab,Heart rate decreased,HO
177299874,Infliximab,Headache,OT
177299874,Infliximab,Headache,HO
177299874,Infliximab,Gastric disorder,OT
177299874,Infliximab,Gastric disorder,HO
177299874,Infliximab,Fistula,OT
177299874,Infliximab,Fistula,HO
177299874,Infliximab,Fatigue,OT
177299874,Infliximab,Fatigue,HO
177299874,Infliximab,Drug ineffective,OT
177299874,Infliximab,Drug ineffective,HO
177299874,Infliximab,Dizziness,OT
177299874,Infliximab,Dizziness,HO
177299874,Infliximab,Cough,OT
177299874,Infliximab,Cough,HO
177299874,Infliximab,Condition aggravated,OT
177299874,Infliximab,Condition aggravated,HO
177299874,Infliximab,Body temperature fluctuation,OT
177299874,Infliximab,Body temperature fluctuation,HO
177299874,Infliximab,Body temperature decreased,OT
177299874,Infliximab,Body temperature decreased,HO
177299874,Infliximab,Blood pressure increased,OT
177299874,Infliximab,Blood pressure increased,HO
177299874,Infliximab,Back pain,OT
177299874,Infliximab,Back pain,HO
177299874,Infliximab,Asthenia,OT
177299874,Infliximab,Asthenia,HO
177299874,Infliximab,Anorectal discomfort,OT
177299874,Infliximab,Anorectal discomfort,HO
177299874,Infliximab,Anal fissure,OT
177299874,Infliximab,Anal fissure,HO
177299874,Infliximab,Anal abscess,OT
177299874,Infliximab,Anal abscess,HO
177299874,Infliximab,Abscess intestinal,OT
177299874,Infliximab,Abscess intestinal,HO
177299874,Infliximab,Abscess,OT
177299874,Infliximab,Abscess,HO
177299874,Infliximab,Weight decreased,OT
177299874,Infliximab,Weight decreased,HO
177299874,Infliximab,Sleep apnoea syndrome,OT
177299874,Infliximab,Sleep apnoea syndrome,HO
177299874,Infliximab,Sinusitis,OT
177299874,Infliximab,Sinusitis,HO
177299874,Infliximab,Rhinorrhoea,OT
177299874,Infliximab,Rhinorrhoea,HO
177299874,Infliximab,Rectal abscess,OT
177299874,Infliximab,Rectal abscess,HO
177299874,Infliximab,Pericarditis,OT
177299874,Infliximab,Pericarditis,HO
177299874,Infliximab,Oxygen saturation abnormal,OT
177299874,Infliximab,Oxygen saturation abnormal,HO
177299874,Infliximab,Off label use,OT
177299874,Infliximab,Off label use,HO
177299874,Infliximab,Nasal congestion,OT
177299874,Infliximab,Nasal congestion,HO
177299874,Infliximab,Myocardial infarction,OT
177299874,Infliximab,Myocardial infarction,HO
177299874,Infliximab,Malaise,OT
177299874,Infliximab,Malaise,HO
177299874,Infliximab,Intentional product use issue,OT
177299874,Infliximab,Intentional product use issue,HO
177299874,Infliximab,Infected fistula,OT
177299874,Infliximab,Infected fistula,HO
177299874,Infliximab,Incorrect dose administered,OT
177299874,Infliximab,Incorrect dose administered,HO
177299874,Infliximab,Inappropriate schedule of product administration,OT
177299874,Infliximab,Inappropriate schedule of product administration,HO
177299874,Infliximab,Illness,OT
177299874,Infliximab,Illness,HO
177299874,Infliximab,Heart rate irregular,OT
177299874,Infliximab,Heart rate irregular,HO
177299874,Infliximab,Heart rate decreased,OT
177299874,Infliximab,Heart rate decreased,HO
177299874,Infliximab,Headache,OT
177299874,Infliximab,Headache,HO
177299874,Infliximab,Gastric disorder,OT
177299874,Infliximab,Gastric disorder,HO
177299874,Infliximab,Fistula,OT
177299874,Infliximab,Fistula,HO
177299874,Infliximab,Fatigue,OT
177299874,Infliximab,Fatigue,HO
177299874,Infliximab,Drug ineffective,OT
177299874,Infliximab,Drug ineffective,HO
177299874,Infliximab,Dizziness,OT
177299874,Infliximab,Dizziness,HO
177299874,Infliximab,Cough,OT
177299874,Infliximab,Cough,HO
177299874,Infliximab,Condition aggravated,OT
177299874,Infliximab,Condition aggravated,HO
177299874,Infliximab,Body temperature fluctuation,OT
177299874,Infliximab,Body temperature fluctuation,HO
177299874,Infliximab,Body temperature decreased,OT
177299874,Infliximab,Body temperature decreased,HO
177299874,Infliximab,Blood pressure increased,OT
177299874,Infliximab,Blood pressure increased,HO
177299874,Infliximab,Back pain,OT
177299874,Infliximab,Back pain,HO
177299874,Infliximab,Asthenia,OT
177299874,Infliximab,Asthenia,HO
177299874,Infliximab,Anorectal discomfort,OT
177299874,Infliximab,Anorectal discomfort,HO
177299874,Infliximab,Anal fissure,OT
177299874,Infliximab,Anal fissure,HO
177299874,Infliximab,Anal abscess,OT
177299874,Infliximab,Anal abscess,HO
177299874,Infliximab,Abscess intestinal,OT
177299874,Infliximab,Abscess intestinal,HO
177299874,Infliximab,Abscess,OT
177299874,Infliximab,Abscess,HO
177299874,Infliximab,Weight decreased,OT
177299874,Infliximab,Weight decreased,HO
177299874,Infliximab,Sleep apnoea syndrome,OT
177299874,Infliximab,Sleep apnoea syndrome,HO
177299874,Infliximab,Sinusitis,OT
177299874,Infliximab,Sinusitis,HO
177299874,Infliximab,Rhinorrhoea,OT
177299874,Infliximab,Rhinorrhoea,HO
177299874,Infliximab,Rectal abscess,OT
177299874,Infliximab,Rectal abscess,HO
177299874,Infliximab,Pericarditis,OT
177299874,Infliximab,Pericarditis,HO
177299874,Infliximab,Oxygen saturation abnormal,OT
177299874,Infliximab,Oxygen saturation abnormal,HO
177299874,Infliximab,Off label use,OT
177299874,Infliximab,Off label use,HO
177299874,Infliximab,Nasal congestion,OT
177299874,Infliximab,Nasal congestion,HO
177299874,Infliximab,Myocardial infarction,OT
177299874,Infliximab,Myocardial infarction,HO
177299874,Infliximab,Malaise,OT
177299874,Infliximab,Malaise,HO
177299874,Infliximab,Intentional product use issue,OT
177299874,Infliximab,Intentional product use issue,HO
177299874,Infliximab,Infected fistula,OT
177299874,Infliximab,Infected fistula,HO
177299874,Infliximab,Incorrect dose administered,OT
177299874,Infliximab,Incorrect dose administered,HO
177299874,Infliximab,Inappropriate schedule of product administration,OT
177299874,Infliximab,Inappropriate schedule of product administration,HO
177299874,Infliximab,Illness,OT
177299874,Infliximab,Illness,HO
177299874,Infliximab,Heart rate irregular,OT
177299874,Infliximab,Heart rate irregular,HO
177299874,Infliximab,Heart rate decreased,OT
177299874,Infliximab,Heart rate decreased,HO
177299874,Infliximab,Headache,OT
177299874,Infliximab,Headache,HO
177299874,Infliximab,Gastric disorder,OT
177299874,Infliximab,Gastric disorder,HO
177299874,Infliximab,Fistula,OT
177299874,Infliximab,Fistula,HO
177299874,Infliximab,Fatigue,OT
177299874,Infliximab,Fatigue,HO
177299874,Infliximab,Drug ineffective,OT
177299874,Infliximab,Drug ineffective,HO
177299874,Infliximab,Dizziness,OT
177299874,Infliximab,Dizziness,HO
177299874,Infliximab,Cough,OT
177299874,Infliximab,Cough,HO
177299874,Infliximab,Condition aggravated,OT
177299874,Infliximab,Condition aggravated,HO
177299874,Infliximab,Body temperature fluctuation,OT
177299874,Infliximab,Body temperature fluctuation,HO
177299874,Infliximab,Body temperature decreased,OT
177299874,Infliximab,Body temperature decreased,HO
177299874,Infliximab,Blood pressure increased,OT
177299874,Infliximab,Blood pressure increased,HO
177299874,Infliximab,Back pain,OT
177299874,Infliximab,Back pain,HO
177299874,Infliximab,Asthenia,OT
177299874,Infliximab,Asthenia,HO
177299874,Infliximab,Anorectal discomfort,OT
177299874,Infliximab,Anorectal discomfort,HO
177299874,Infliximab,Anal fissure,OT
177299874,Infliximab,Anal fissure,HO
177299874,Infliximab,Anal abscess,OT
177299874,Infliximab,Anal abscess,HO
177299874,Infliximab,Abscess intestinal,OT
177299874,Infliximab,Abscess intestinal,HO
177299874,Infliximab,Abscess,OT
177299874,Infliximab,Abscess,HO
177464378,Infliximab,Stoma site inflammation,OT
177464378,Infliximab,Stoma site inflammation,HO
177464378,Infliximab,Splenomegaly,OT
177464378,Infliximab,Splenomegaly,HO
177464378,Infliximab,Muscle spasms,OT
177464378,Infliximab,Muscle spasms,HO
177464378,Infliximab,Mood altered,OT
177464378,Infliximab,Mood altered,HO
177464378,Infliximab,Liver disorder,OT
177464378,Infliximab,Liver disorder,HO
177464378,Infliximab,Iron deficiency,OT
177464378,Infliximab,Iron deficiency,HO
177464378,Infliximab,Impaired healing,OT
177464378,Infliximab,Impaired healing,HO
177464378,Infliximab,Hepatosplenomegaly,OT
177464378,Infliximab,Hepatosplenomegaly,HO
177464378,Infliximab,Headache,OT
177464378,Infliximab,Headache,HO
177464378,Infliximab,Granuloma,OT
177464378,Infliximab,Granuloma,HO
177464378,Infliximab,Gastric polyps,OT
177464378,Infliximab,Gastric polyps,HO
177464378,Infliximab,Flank pain,OT
177464378,Infliximab,Flank pain,HO
177464378,Infliximab,Fatigue,OT
177464378,Infliximab,Fatigue,HO
177464378,Infliximab,Disturbance in attention,OT
177464378,Infliximab,Disturbance in attention,HO
177464378,Infliximab,Device related infection,OT
177464378,Infliximab,Device related infection,HO
177464378,Infliximab,Decreased appetite,OT
177464378,Infliximab,Decreased appetite,HO
177464378,Infliximab,Cholecystitis,OT
177464378,Infliximab,Cholecystitis,HO
177464378,Infliximab,Chest pain,OT
177464378,Infliximab,Chest pain,HO
177464378,Infliximab,Catheter site pain,OT
177464378,Infliximab,Catheter site pain,HO
177464378,Infliximab,Breast pain,OT
177464378,Infliximab,Breast pain,HO
177464378,Infliximab,Arthralgia,OT
177464378,Infliximab,Arthralgia,HO
177464378,Infliximab,Abdominal pain,OT
177464378,Infliximab,Abdominal pain,HO
177958743,Infliximab,Weight decreased,HO
177958743,Infliximab,Weight decreased,OT
177958743,Infliximab,Off label use,HO
177958743,Infliximab,Off label use,OT
177958743,Infliximab,Intestinal perforation,HO
177958743,Infliximab,Intestinal perforation,OT
177958743,Infliximab,Intestinal obstruction,HO
177958743,Infliximab,Intestinal obstruction,OT
177958743,Infliximab,Inappropriate schedule of product administration,HO
177958743,Infliximab,Inappropriate schedule of product administration,OT
177958743,Infliximab,Condition aggravated,HO
177958743,Infliximab,Condition aggravated,OT
179986456,Infliximab,Kaposi's sarcoma,OT
179986456,Infliximab,Crohn's disease,OT
179986456,Infliximab,Kaposi's sarcoma,OT
179986456,Infliximab,Crohn's disease,OT
179986456,Infliximab,Kaposi's sarcoma,OT
179986456,Infliximab,Crohn's disease,OT
179986456,Infliximab,Kaposi's sarcoma,OT
179986456,Infliximab,Crohn's disease,OT
179986456,Infliximab,Kaposi's sarcoma,OT
179986456,Infliximab,Crohn's disease,OT
184124772,Infliximab,Therapeutic product effect incomplete,OT
184124772,Infliximab,Soft tissue infection,OT
184124772,Infliximab,Poor venous access,OT
184124772,Infliximab,Migraine,OT
184124772,Infliximab,Maternal exposure during pregnancy,OT
184124772,Infliximab,Incorrect dose administered,OT
184124772,Infliximab,Inappropriate schedule of product administration,OT
184124772,Infliximab,Condition aggravated,OT
184124772,Infliximab,Asthma,OT
184124772,Infliximab,Anal fissure,OT
184124772,Infliximab,Alopecia,OT
184124772,Infliximab,Therapeutic product effect incomplete,OT
184124772,Infliximab,Soft tissue infection,OT
184124772,Infliximab,Poor venous access,OT
184124772,Infliximab,Migraine,OT
184124772,Infliximab,Maternal exposure during pregnancy,OT
184124772,Infliximab,Incorrect dose administered,OT
184124772,Infliximab,Inappropriate schedule of product administration,OT
184124772,Infliximab,Condition aggravated,OT
184124772,Infliximab,Asthma,OT
184124772,Infliximab,Anal fissure,OT
184124772,Infliximab,Alopecia,OT
184292982,Infliximab,Weight decreased,OT
184292982,Infliximab,Weight decreased,HO
184292982,Infliximab,Rhinorrhoea,OT
184292982,Infliximab,Rhinorrhoea,HO
184292982,Infliximab,Respiratory disorder,OT
184292982,Infliximab,Respiratory disorder,HO
184292982,Infliximab,Pharyngitis bacterial,OT
184292982,Infliximab,Pharyngitis bacterial,HO
184292982,Infliximab,Off label use,OT
184292982,Infliximab,Off label use,HO
184292982,Infliximab,Nasopharyngitis,OT
184292982,Infliximab,Nasopharyngitis,HO
184292982,Infliximab,Localised infection,OT
184292982,Infliximab,Localised infection,HO
184292982,Infliximab,Intentional product use issue,OT
184292982,Infliximab,Intentional product use issue,HO
184292982,Infliximab,Infection,OT
184292982,Infliximab,Infection,HO
184292982,Infliximab,Inappropriate schedule of product administration,OT
184292982,Infliximab,Inappropriate schedule of product administration,HO
184292982,Infliximab,Illness,OT
184292982,Infliximab,Illness,HO
184292982,Infliximab,Heart rate decreased,OT
184292982,Infliximab,Heart rate decreased,HO
184292982,Infliximab,Erythema,OT
184292982,Infliximab,Erythema,HO
184292982,Infliximab,Dyspnoea,OT
184292982,Infliximab,Dyspnoea,HO
184292982,Infliximab,Drug specific antibody,OT
184292982,Infliximab,Drug specific antibody,HO
184292982,Infliximab,Drug level below therapeutic,OT
184292982,Infliximab,Drug level below therapeutic,HO
184292982,Infliximab,Cough,OT
184292982,Infliximab,Cough,HO
184292982,Infliximab,Condition aggravated,OT
184292982,Infliximab,Condition aggravated,HO
184292982,Infliximab,Chest discomfort,OT
184292982,Infliximab,Chest discomfort,HO
184292982,Infliximab,Blood pressure fluctuation,OT
184292982,Infliximab,Blood pressure fluctuation,HO
184292982,Infliximab,Anal abscess,OT
184292982,Infliximab,Anal abscess,HO
184292982,Infliximab,Weight decreased,OT
184292982,Infliximab,Weight decreased,HO
184292982,Infliximab,Rhinorrhoea,OT
184292982,Infliximab,Rhinorrhoea,HO
184292982,Infliximab,Respiratory disorder,OT
184292982,Infliximab,Respiratory disorder,HO
184292982,Infliximab,Pharyngitis bacterial,OT
184292982,Infliximab,Pharyngitis bacterial,HO
184292982,Infliximab,Off label use,OT
184292982,Infliximab,Off label use,HO
184292982,Infliximab,Nasopharyngitis,OT
184292982,Infliximab,Nasopharyngitis,HO
184292982,Infliximab,Localised infection,OT
184292982,Infliximab,Localised infection,HO
184292982,Infliximab,Intentional product use issue,OT
184292982,Infliximab,Intentional product use issue,HO
184292982,Infliximab,Infection,OT
184292982,Infliximab,Infection,HO
184292982,Infliximab,Inappropriate schedule of product administration,OT
184292982,Infliximab,Inappropriate schedule of product administration,HO
184292982,Infliximab,Illness,OT
184292982,Infliximab,Illness,HO
184292982,Infliximab,Heart rate decreased,OT
184292982,Infliximab,Heart rate decreased,HO
184292982,Infliximab,Erythema,OT
184292982,Infliximab,Erythema,HO
184292982,Infliximab,Dyspnoea,OT
184292982,Infliximab,Dyspnoea,HO
184292982,Infliximab,Drug specific antibody,OT
184292982,Infliximab,Drug specific antibody,HO
184292982,Infliximab,Drug level below therapeutic,OT
184292982,Infliximab,Drug level below therapeutic,HO
184292982,Infliximab,Cough,OT
184292982,Infliximab,Cough,HO
184292982,Infliximab,Condition aggravated,OT
184292982,Infliximab,Condition aggravated,HO
184292982,Infliximab,Chest discomfort,OT
184292982,Infliximab,Chest discomfort,HO
184292982,Infliximab,Blood pressure fluctuation,OT
184292982,Infliximab,Blood pressure fluctuation,HO
184292982,Infliximab,Anal abscess,OT
184292982,Infliximab,Anal abscess,HO
184364043,Infliximab,Weight increased,OT
184364043,Infliximab,Rectal haemorrhage,OT
184364043,Infliximab,Off label use,OT
184364043,Infliximab,Intentional product use issue,OT
184364043,Infliximab,Inappropriate schedule of product administration,OT
184364043,Infliximab,Hypotension,OT
184364043,Infliximab,Fistula,OT
184364043,Infliximab,Condition aggravated,OT
184364043,Infliximab,Anal fissure,OT
184866813,Infliximab,Weight decreased,OT
184866813,Infliximab,Weight decreased,HO
184866813,Infliximab,Vomiting,OT
184866813,Infliximab,Vomiting,HO
184866813,Infliximab,Rhinorrhoea,OT
184866813,Infliximab,Rhinorrhoea,HO
184866813,Infliximab,Rectal abscess,OT
184866813,Infliximab,Rectal abscess,HO
184866813,Infliximab,Oropharyngeal pain,OT
184866813,Infliximab,Oropharyngeal pain,HO
184866813,Infliximab,Off label use,OT
184866813,Infliximab,Off label use,HO
184866813,Infliximab,Nausea,OT
184866813,Infliximab,Nausea,HO
184866813,Infliximab,Musculoskeletal pain,OT
184866813,Infliximab,Musculoskeletal pain,HO
184866813,Infliximab,Malaise,OT
184866813,Infliximab,Malaise,HO
184866813,Infliximab,Intentional product use issue,OT
184866813,Infliximab,Intentional product use issue,HO
184866813,Infliximab,Inappropriate schedule of product administration,OT
184866813,Infliximab,Inappropriate schedule of product administration,HO
184866813,Infliximab,Heart rate irregular,OT
184866813,Infliximab,Heart rate irregular,HO
184866813,Infliximab,Heart rate increased,OT
184866813,Infliximab,Heart rate increased,HO
184866813,Infliximab,Erythema nodosum,OT
184866813,Infliximab,Erythema nodosum,HO
184866813,Infliximab,Cough,OT
184866813,Infliximab,Cough,HO
184866813,Infliximab,Condition aggravated,OT
184866813,Infliximab,Condition aggravated,HO
184866813,Infliximab,Body temperature increased,OT
184866813,Infliximab,Body temperature increased,HO
184866813,Infliximab,Body temperature fluctuation,OT
184866813,Infliximab,Body temperature fluctuation,HO
184866813,Infliximab,Asthma,OT
184866813,Infliximab,Asthma,HO
184866813,Infliximab,Anal abscess,OT
184866813,Infliximab,Anal abscess,HO
184866813,Infliximab,Abscess,OT
184866813,Infliximab,Abscess,HO
184866813,Infliximab,Weight decreased,OT
184866813,Infliximab,Weight decreased,HO
184866813,Infliximab,Vomiting,OT
184866813,Infliximab,Vomiting,HO
184866813,Infliximab,Rhinorrhoea,OT
184866813,Infliximab,Rhinorrhoea,HO
184866813,Infliximab,Rectal abscess,OT
184866813,Infliximab,Rectal abscess,HO
184866813,Infliximab,Oropharyngeal pain,OT
184866813,Infliximab,Oropharyngeal pain,HO
184866813,Infliximab,Off label use,OT
184866813,Infliximab,Off label use,HO
184866813,Infliximab,Nausea,OT
184866813,Infliximab,Nausea,HO
184866813,Infliximab,Musculoskeletal pain,OT
184866813,Infliximab,Musculoskeletal pain,HO
184866813,Infliximab,Malaise,OT
184866813,Infliximab,Malaise,HO
184866813,Infliximab,Intentional product use issue,OT
184866813,Infliximab,Intentional product use issue,HO
184866813,Infliximab,Inappropriate schedule of product administration,OT
184866813,Infliximab,Inappropriate schedule of product administration,HO
184866813,Infliximab,Heart rate irregular,OT
184866813,Infliximab,Heart rate irregular,HO
184866813,Infliximab,Heart rate increased,OT
184866813,Infliximab,Heart rate increased,HO
184866813,Infliximab,Erythema nodosum,OT
184866813,Infliximab,Erythema nodosum,HO
184866813,Infliximab,Cough,OT
184866813,Infliximab,Cough,HO
184866813,Infliximab,Condition aggravated,OT
184866813,Infliximab,Condition aggravated,HO
184866813,Infliximab,Body temperature increased,OT
184866813,Infliximab,Body temperature increased,HO
184866813,Infliximab,Body temperature fluctuation,OT
184866813,Infliximab,Body temperature fluctuation,HO
184866813,Infliximab,Asthma,OT
184866813,Infliximab,Asthma,HO
184866813,Infliximab,Anal abscess,OT
184866813,Infliximab,Anal abscess,HO
184866813,Infliximab,Abscess,OT
184866813,Infliximab,Abscess,HO
185257142,Infliximab,Weight increased,OT
185257142,Infliximab,Weight decreased,OT
185257142,Infliximab,Paraesthesia,OT
185257142,Infliximab,Off label use,OT
185257142,Infliximab,Nodule,OT
185257142,Infliximab,Intentional product use issue,OT
185257142,Infliximab,Injection site streaking,OT
185257142,Infliximab,Drug level decreased,OT
185257142,Infliximab,Condition aggravated,OT
185257142,Infliximab,Weight increased,OT
185257142,Infliximab,Weight decreased,OT
185257142,Infliximab,Paraesthesia,OT
185257142,Infliximab,Off label use,OT
185257142,Infliximab,Nodule,OT
185257142,Infliximab,Intentional product use issue,OT
185257142,Infliximab,Injection site streaking,OT
185257142,Infliximab,Drug level decreased,OT
185257142,Infliximab,Condition aggravated,OT
190362377,Infliximab,Therapeutic response unexpected,OT
190362377,Infliximab,Off label use,OT
190362377,Infliximab,Intentional product misuse,OT
190362377,Infliximab,Drug ineffective,OT
190362377,Infliximab,Crohn's disease,OT
190630322,Infliximab,Type 2 diabetes mellitus,OT
190630322,Infliximab,Throat irritation,OT
190630322,Infliximab,Stress at work,OT
190630322,Infliximab,Skin lesion,OT
190630322,Infliximab,Rhinitis,OT
190630322,Infliximab,Pruritus,OT
190630322,Infliximab,Paraesthesia,OT
190630322,Infliximab,Papule,OT
190630322,Infliximab,Pain of skin,OT
190630322,Infliximab,Oxygen saturation decreased,OT
190630322,Infliximab,Off label use,OT
190630322,Infliximab,Nasopharyngitis,OT
190630322,Infliximab,Myalgia,OT
190630322,Infliximab,Musculoskeletal stiffness,OT
190630322,Infliximab,Musculoskeletal pain,OT
190630322,Infliximab,Muscular weakness,OT
190630322,Infliximab,Intentional product use issue,OT
190630322,Infliximab,Influenza,OT
190630322,Infliximab,Feeling hot,OT
190630322,Infliximab,Fatigue,OT
190630322,Infliximab,Exercise tolerance decreased,OT
190630322,Infliximab,Drug specific antibody,OT
190630322,Infliximab,Cough,OT
190630322,Infliximab,Condition aggravated,OT
190630322,Infliximab,Blood pressure increased,OT
190630322,Infliximab,Arthralgia,OT
190630322,Infliximab,Acne,OT
190855813,Infliximab (Unknown),Ventricular septal defect,CA
190855813,Infliximab (Unknown),VACTERL syndrome,CA
190855813,Infliximab (Unknown),Uterine hypoplasia,CA
190855813,Infliximab (Unknown),Thrombocytopenia-absent radius syndrome,CA
190855813,Infliximab (Unknown),Single umbilical artery,CA
190855813,Infliximab (Unknown),Roberts syndrome,CA
190855813,Infliximab (Unknown),Renal hypoplasia,CA
190855813,Infliximab (Unknown),Pulmonary malformation,CA
190855813,Infliximab (Unknown),Foetal exposure during pregnancy,CA
190855813,Infliximab (Unknown),Ear malformation,CA
190855813,Infliximab (Unknown),Congenital ureteric anomaly,CA
190855813,Infliximab (Unknown),Congenital musculoskeletal anomaly,CA
190855813,Infliximab (Unknown),Congenital jaw malformation,CA
190855813,Infliximab (Unknown),Congenital intestinal malformation,CA
190855813,Infliximab (Unknown),Congenital cardiovascular anomaly,CA
190855813,Infliximab (Unknown),CHARGE syndrome,CA
190855813,Infliximab (Unknown),Anal atresia,CA
190855813,Infliximab (Unknown),Ventricular septal defect,CA
190855813,Infliximab (Unknown),VACTERL syndrome,CA
190855813,Infliximab (Unknown),Uterine hypoplasia,CA
190855813,Infliximab (Unknown),Thrombocytopenia-absent radius syndrome,CA
190855813,Infliximab (Unknown),Single umbilical artery,CA
190855813,Infliximab (Unknown),Roberts syndrome,CA
190855813,Infliximab (Unknown),Renal hypoplasia,CA
190855813,Infliximab (Unknown),Pulmonary malformation,CA
190855813,Infliximab (Unknown),Foetal exposure during pregnancy,CA
190855813,Infliximab (Unknown),Ear malformation,CA
190855813,Infliximab (Unknown),Congenital ureteric anomaly,CA
190855813,Infliximab (Unknown),Congenital musculoskeletal anomaly,CA
190855813,Infliximab (Unknown),Congenital jaw malformation,CA
190855813,Infliximab (Unknown),Congenital intestinal malformation,CA
190855813,Infliximab (Unknown),Congenital cardiovascular anomaly,CA
190855813,Infliximab (Unknown),CHARGE syndrome,CA
190855813,Infliximab (Unknown),Anal atresia,CA
192289322,Infliximab,Off label use,HO
192289322,Infliximab,Enteritis,HO
192289322,Infliximab,Drug resistance,HO
192289322,Infliximab,Drug ineffective,HO
192289322,Infliximab,Cytomegalovirus test positive,HO
192289322,Infliximab,Cytomegalovirus enterocolitis,HO
192289322,Infliximab,Off label use,HO
192289322,Infliximab,Enteritis,HO
192289322,Infliximab,Drug resistance,HO
192289322,Infliximab,Drug ineffective,HO
192289322,Infliximab,Cytomegalovirus test positive,HO
192289322,Infliximab,Cytomegalovirus enterocolitis,HO
192624335,Infliximab (Unknown),Synovitis,OT
192624335,Infliximab (Unknown),Mycobacterial infection,OT
192703762,Infliximab,Weight increased,OT
192703762,Infliximab,Weight decreased,OT
192703762,Infliximab,Pain,OT
192703762,Infliximab,Off label use,OT
192703762,Infliximab,Fatigue,OT
192703762,Infliximab,Condition aggravated,OT
192703762,Infliximab,Blood pressure diastolic increased,OT
192703762,Infliximab,Abdominal pain,OT
192703762,Infliximab,Abdominal distension,OT
192709862,Infliximab,Off label use,OT
192709862,Infliximab,Malaise,OT
192709862,Infliximab,Intentional product use issue,OT
192709862,Infliximab,Drug ineffective,OT
192709862,Infliximab,Condition aggravated,OT
192709862,Infliximab,Blood pressure increased,OT
192709862,Infliximab,Off label use,OT
192709862,Infliximab,Malaise,OT
192709862,Infliximab,Intentional product use issue,OT
192709862,Infliximab,Drug ineffective,OT
192709862,Infliximab,Condition aggravated,OT
192709862,Infliximab,Blood pressure increased,OT
194664793,Infliximab (Unknown),Obsessive-compulsive disorder,HO
194664793,Infliximab (Unknown),Drug level above therapeutic,HO
194664793,Infliximab (Unknown),Obsessive-compulsive disorder,HO
194664793,Infliximab (Unknown),Drug level above therapeutic,HO
194664793,Infliximab (Unknown),Obsessive-compulsive disorder,HO
194664793,Infliximab (Unknown),Drug level above therapeutic,HO
194664793,Infliximab (Unknown),Obsessive-compulsive disorder,HO
194664793,Infliximab (Unknown),Drug level above therapeutic,HO
196526511,Infliximab,Tremor,OT
196526511,Infliximab,SARS-CoV-2 test positive,OT
196526511,Infliximab,Peripheral swelling,OT
196526511,Infliximab,Off label use,OT
196526511,Infliximab,Nasopharyngitis,OT
196526511,Infliximab,Intentional product use issue,OT
196526511,Infliximab,Hypertension,OT
196526511,Infliximab,Haematoma,OT
196526511,Infliximab,Fall,OT
196526511,Infliximab,Cough,OT
196526511,Infliximab,Contusion,OT
196526511,Infliximab,Body temperature decreased,OT
196526511,Infliximab,Blood pressure increased,OT
196526511,Infliximab,Blood pressure fluctuation,OT
196687411,Infliximab,Immunosuppression,OT
196687411,Infliximab,Drug ineffective,OT
196687411,Infliximab,Cutaneous leishmaniasis,OT
196687491,Infliximab,Therapeutic product effect delayed,OT
196687491,Infliximab,Product use issue,OT
196687491,Infliximab,Off label use,OT
196687491,Infliximab,Heart rate increased,OT
196687491,Infliximab,Heart rate decreased,OT
196687491,Infliximab,Haemoglobin decreased,OT
196687491,Infliximab,Haematochezia,OT
196687491,Infliximab,Body temperature fluctuation,OT
196687491,Infliximab,Blood pressure fluctuation,OT
196809721,Infliximab,Drug ineffective,HO
196809721,Infliximab,Colitis ulcerative,HO
196811781,Infliximab,Off label use,OT
196811781,Infliximab,Loss of personal independence in daily activities,OT
196811781,Infliximab,Intestinal obstruction,OT
196811781,Infliximab,Intentional product use issue,OT
196811781,Infliximab,Drug level below therapeutic,OT
196811781,Infliximab,Dermatitis psoriasiform,OT
196811781,Infliximab,Condition aggravated,OT
196811781,Infliximab,Arthralgia,OT
196811781,Infliximab,Aphthous ulcer,OT
196923831,Infliximab,Root canal infection,OT
196923831,Infliximab,Off label use,OT
196923831,Infliximab,Intentional product use issue,OT
196923831,Infliximab,Heart rate irregular,OT
196923831,Infliximab,Condition aggravated,OT
196923831,Infliximab,Cataract,OT
197389141,Infliximab,Vulval disorder,HO
197389141,Infliximab,Vein collapse,HO
197389141,Infliximab,Oedema genital,HO
197389141,Infliximab,Mobility decreased,HO
197389141,Infliximab,Memory impairment,HO
197389141,Infliximab,Malaise,HO
197389141,Infliximab,Incontinence,HO
197389141,Infliximab,Gait disturbance,HO
197389141,Infliximab,Drug ineffective,HO
197389141,Infliximab,Condition aggravated,HO
197389141,Infliximab,Cerebrovascular accident,HO
197389141,Infliximab,Blood pressure systolic increased,HO
197389141,Infliximab,Balance disorder,HO
197389141,Infliximab,Asthenia,HO
197602791,Infliximab,Weight increased,OT
197602791,Infliximab,Toothache,OT
197602791,Infliximab,Tooth disorder,OT
197602791,Infliximab,Therapy non-responder,OT
197602791,Infliximab,Therapeutic response decreased,OT
197602791,Infliximab,Therapeutic product effect decreased,OT
197602791,Infliximab,Suicidal ideation,OT
197602791,Infliximab,Smear cervix abnormal,OT
197602791,Infliximab,Skin fissures,OT
197602791,Infliximab,Rheumatoid arthritis,OT
197602791,Infliximab,Rash,OT
197602791,Infliximab,Peripheral swelling,OT
197602791,Infliximab,Pain,OT
197602791,Infliximab,Nasopharyngitis,OT
197602791,Infliximab,Medication error,OT
197602791,Infliximab,Malaise,OT
197602791,Infliximab,Localised infection,OT
197602791,Infliximab,Joint swelling,OT
197602791,Infliximab,Infusion related reaction,OT
197602791,Infliximab,Impaired healing,OT
197602791,Infliximab,Ill-defined disorder,OT
197602791,Infliximab,Herpes zoster,OT
197602791,Infliximab,Heart rate decreased,OT
197602791,Infliximab,Flushing,OT
197602791,Infliximab,Endodontic procedure,OT
197602791,Infliximab,Drug intolerance,OT
197602791,Infliximab,Drug ineffective,OT
197602791,Infliximab,Depression,OT
197602791,Infliximab,Blood pressure increased,OT
197602791,Infliximab,Blood pressure fluctuation,OT
197602791,Infliximab,Abdominal pain,OT
197942701,Infliximab,Tuberculin test positive,OT
197942701,Infliximab,Treatment failure,OT
197942701,Infliximab,Therapeutic response decreased,OT
197942701,Infliximab,Therapeutic product effect decreased,OT
197942701,Infliximab,Rheumatoid arthritis,OT
197942701,Infliximab,Renal impairment,OT
197942701,Infliximab,Pain,OT
197942701,Infliximab,Off label use,OT
197942701,Infliximab,Musculoskeletal stiffness,OT
197942701,Infliximab,Lupus-like syndrome,OT
197942701,Infliximab,Influenza,OT
197942701,Infliximab,Impaired gastric emptying,OT
197942701,Infliximab,Gait disturbance,OT
197942701,Infliximab,Dyspnoea,OT
197942701,Infliximab,Drug ineffective,OT
197942701,Infliximab,Drug hypersensitivity,OT
197942701,Infliximab,Diabetes mellitus,OT
197942701,Infliximab,Demyelination,OT
197942701,Infliximab,Contraindicated product administered,OT
197942701,Infliximab,Arthropathy,OT
197942701,Infliximab,Ankylosing spondylitis,OT
197942701,Infliximab,Anaphylactic reaction,OT
197942701,Infliximab,Tuberculin test positive,OT
197942701,Infliximab,Treatment failure,OT
197942701,Infliximab,Therapeutic response decreased,OT
197942701,Infliximab,Therapeutic product effect decreased,OT
197942701,Infliximab,Rheumatoid arthritis,OT
197942701,Infliximab,Renal impairment,OT
197942701,Infliximab,Pain,OT
197942701,Infliximab,Off label use,OT
197942701,Infliximab,Musculoskeletal stiffness,OT
197942701,Infliximab,Lupus-like syndrome,OT
197942701,Infliximab,Influenza,OT
197942701,Infliximab,Impaired gastric emptying,OT
197942701,Infliximab,Gait disturbance,OT
197942701,Infliximab,Dyspnoea,OT
197942701,Infliximab,Drug ineffective,OT
197942701,Infliximab,Drug hypersensitivity,OT
197942701,Infliximab,Diabetes mellitus,OT
197942701,Infliximab,Demyelination,OT
197942701,Infliximab,Contraindicated product administered,OT
197942701,Infliximab,Arthropathy,OT
197942701,Infliximab,Ankylosing spondylitis,OT
197942701,Infliximab,Anaphylactic reaction,OT
198172041,Infliximab,Therapeutic product effect incomplete,HO
198172041,Infliximab,Therapeutic product effect incomplete,DE
198172041,Infliximab,Therapeutic product effect incomplete,OT
198172041,Infliximab,Oedema peripheral,HO
198172041,Infliximab,Oedema peripheral,DE
198172041,Infliximab,Oedema peripheral,OT
198172041,Infliximab,Leukopenia,HO
198172041,Infliximab,Leukopenia,DE
198172041,Infliximab,Leukopenia,OT
198172041,Infliximab,Haemophagocytic lymphohistiocytosis,HO
198172041,Infliximab,Haemophagocytic lymphohistiocytosis,DE
198172041,Infliximab,Haemophagocytic lymphohistiocytosis,OT
198172041,Infliximab,Condition aggravated,HO
198172041,Infliximab,Condition aggravated,DE
198172041,Infliximab,Condition aggravated,OT
198172041,Infliximab,Colitis ulcerative,HO
198172041,Infliximab,Colitis ulcerative,DE
198172041,Infliximab,Colitis ulcerative,OT
198172041,Infliximab,Blood albumin decreased,HO
198172041,Infliximab,Blood albumin decreased,DE
198172041,Infliximab,Blood albumin decreased,OT
198172041,Infliximab,Ascites,HO
198172041,Infliximab,Ascites,DE
198172041,Infliximab,Ascites,OT
198172041,Infliximab,Anaemia,HO
198172041,Infliximab,Anaemia,DE
198172041,Infliximab,Anaemia,OT
198294241,Infliximab,Wound secretion,OT
198294241,Infliximab,Wound,OT
198294241,Infliximab,Weight decreased,OT
198294241,Infliximab,Scab,OT
198294241,Infliximab,Product use issue,OT
198294241,Infliximab,Off label use,OT
198294241,Infliximab,Necrosis,OT
198294241,Infliximab,Eschar,OT
198294241,Infliximab,Drug level below therapeutic,OT
198294241,Infliximab,Decubitus ulcer,OT
198294241,Infliximab,Arthralgia,OT
198294241,Infliximab,Abscess,OT
198569021,Infliximab,Off label use,OT
198569021,Infliximab,Memory impairment,OT
198569021,Infliximab,Hypertension,OT
198569021,Infliximab,Condition aggravated,OT
198569021,Infliximab,Blood pressure fluctuation,OT
198781661,Infliximab (Unknown),Off label use,NULL
198781661,Infliximab (Unknown),Herpes zoster,NULL
198781661,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198785721,Infliximab (Unknown),Off label use,NULL
198785721,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198842651,Infliximab,Sepsis,DE
198842651,Infliximab,Off label use,DE
198871611,Infliximab (Unknown),Off label use,NULL
198912691,Infliximab,Respiratory tract infection,DE
198912691,Infliximab,Respiratory tract infection,OT
198912691,Infliximab,Product use issue,DE
198912691,Infliximab,Product use issue,OT
198912691,Infliximab,Off label use,DE
198912691,Infliximab,Off label use,OT
198912691,Infliximab,Death,DE
198912691,Infliximab,Death,OT
198912721,Infliximab,Product use in unapproved indication,HO
198912721,Infliximab,Product use in unapproved indication,DE
198912721,Infliximab,Off label use,HO
198912721,Infliximab,Off label use,DE
198912721,Infliximab,Death,HO
198912721,Infliximab,Death,DE
198912721,Infliximab,Product use in unapproved indication,HO
198912721,Infliximab,Product use in unapproved indication,DE
198912721,Infliximab,Off label use,HO
198912721,Infliximab,Off label use,DE
198912721,Infliximab,Death,HO
198912721,Infliximab,Death,DE
199051961,Infliximab,Pulmonary embolism,OT
199051961,Infliximab,Pulmonary embolism,DE
199051961,Infliximab,Off label use,OT
199051961,Infliximab,Off label use,DE
199051961,Infliximab,Meningitis tuberculous,OT
199051961,Infliximab,Meningitis tuberculous,DE
1557482724,Infliximab Hospira,Wound,OT
1557482724,Infliximab Hospira,Visual impairment,OT
1557482724,Infliximab Hospira,Treatment failure,OT
1557482724,Infliximab Hospira,Therapeutic product effect incomplete,OT
1557482724,Infliximab Hospira,Therapeutic product effect decreased,OT
1557482724,Infliximab Hospira,Systemic lupus erythematosus,OT
1557482724,Infliximab Hospira,Synovitis,OT
1557482724,Infliximab Hospira,Rheumatoid factor positive,OT
1557482724,Infliximab Hospira,Rheumatoid arthritis,OT
1557482724,Infliximab Hospira,Retinitis,OT
1557482724,Infliximab Hospira,Red blood cell sedimentation rate increased,OT
1557482724,Infliximab Hospira,Rash,OT
1557482724,Infliximab Hospira,Product use issue,OT
1557482724,Infliximab Hospira,Product use in unapproved indication,OT
1557482724,Infliximab Hospira,Pneumonia,OT
1557482724,Infliximab Hospira,Pericarditis,OT
1557482724,Infliximab Hospira,Pemphigus,OT
1557482724,Infliximab Hospira,Pain in extremity,OT
1557482724,Infliximab Hospira,Pain,OT
1557482724,Infliximab Hospira,Osteoporosis,OT
1557482724,Infliximab Hospira,Osteoarthritis,OT
1557482724,Infliximab Hospira,Off label use,OT
1557482724,Infliximab Hospira,Oedema peripheral,OT
1557482724,Infliximab Hospira,Nausea,OT
1557482724,Infliximab Hospira,Musculoskeletal stiffness,OT
1557482724,Infliximab Hospira,Mobility decreased,OT
1557482724,Infliximab Hospira,Malaise,OT
1557482724,Infliximab Hospira,Lupus-like syndrome,OT
1557482724,Infliximab Hospira,Laryngitis,OT
1557482724,Infliximab Hospira,Joint swelling,OT
1557482724,Infliximab Hospira,Joint stiffness,OT
1557482724,Infliximab Hospira,Joint dislocation,OT
1557482724,Infliximab Hospira,Infusion related reaction,OT
1557482724,Infliximab Hospira,Infection,OT
1557482724,Infliximab Hospira,Hypoaesthesia,OT
1557482724,Infliximab Hospira,Hypersensitivity,OT
1557482724,Infliximab Hospira,Hepatic enzyme increased,OT
1557482724,Infliximab Hospira,Hepatic cirrhosis,OT
1557482724,Infliximab Hospira,Headache,OT
1557482724,Infliximab Hospira,Hand deformity,OT
1557482724,Infliximab Hospira,Glossodynia,OT
1557482724,Infliximab Hospira,General physical health deterioration,OT
1557482724,Infliximab Hospira,Foot deformity,OT
1557482724,Infliximab Hospira,Fatigue,OT
1557482724,Infliximab Hospira,Exposure during pregnancy,OT
1557482724,Infliximab Hospira,Exostosis,OT
1557482724,Infliximab Hospira,Ear infection,OT
1557482724,Infliximab Hospira,Drug intolerance,OT
1557482724,Infliximab Hospira,Drug ineffective,OT
1557482724,Infliximab Hospira,Drug hypersensitivity,OT
1557482724,Infliximab Hospira,Dizziness,OT
1557482724,Infliximab Hospira,Discomfort,OT
1557482724,Infliximab Hospira,Decreased appetite,OT
1557482724,Infliximab Hospira,Crohn's disease,OT
1557482724,Infliximab Hospira,Contraindicated product administered,OT
1557482724,Infliximab Hospira,Condition aggravated,OT
1557482724,Infliximab Hospira,C-reactive protein increased,OT
1557482724,Infliximab Hospira,Bone erosion,OT
1557482724,Infliximab Hospira,Arthritis,OT
1557482724,Infliximab Hospira,Arthralgia,OT
1557482724,Infliximab Hospira,Anti-cyclic citrullinated peptide antibody positive,OT
1557482724,Infliximab Hospira,Alopecia,OT
1557482724,Infliximab Hospira,Abdominal discomfort,OT
1557482724,Infliximab Hospira,Wound,OT
1557482724,Infliximab Hospira,Visual impairment,OT
1557482724,Infliximab Hospira,Treatment failure,OT
1557482724,Infliximab Hospira,Therapeutic product effect incomplete,OT
1557482724,Infliximab Hospira,Therapeutic product effect decreased,OT
1557482724,Infliximab Hospira,Systemic lupus erythematosus,OT
1557482724,Infliximab Hospira,Synovitis,OT
1557482724,Infliximab Hospira,Rheumatoid factor positive,OT
1557482724,Infliximab Hospira,Rheumatoid arthritis,OT
1557482724,Infliximab Hospira,Retinitis,OT
1557482724,Infliximab Hospira,Red blood cell sedimentation rate increased,OT
1557482724,Infliximab Hospira,Rash,OT
1557482724,Infliximab Hospira,Product use issue,OT
1557482724,Infliximab Hospira,Product use in unapproved indication,OT
1557482724,Infliximab Hospira,Pneumonia,OT
1557482724,Infliximab Hospira,Pericarditis,OT
1557482724,Infliximab Hospira,Pemphigus,OT
1557482724,Infliximab Hospira,Pain in extremity,OT
1557482724,Infliximab Hospira,Pain,OT
1557482724,Infliximab Hospira,Osteoporosis,OT
1557482724,Infliximab Hospira,Osteoarthritis,OT
1557482724,Infliximab Hospira,Off label use,OT
1557482724,Infliximab Hospira,Oedema peripheral,OT
1557482724,Infliximab Hospira,Nausea,OT
1557482724,Infliximab Hospira,Musculoskeletal stiffness,OT
1557482724,Infliximab Hospira,Mobility decreased,OT
1557482724,Infliximab Hospira,Malaise,OT
1557482724,Infliximab Hospira,Lupus-like syndrome,OT
1557482724,Infliximab Hospira,Laryngitis,OT
1557482724,Infliximab Hospira,Joint swelling,OT
1557482724,Infliximab Hospira,Joint stiffness,OT
1557482724,Infliximab Hospira,Joint dislocation,OT
1557482724,Infliximab Hospira,Infusion related reaction,OT
1557482724,Infliximab Hospira,Infection,OT
1557482724,Infliximab Hospira,Hypoaesthesia,OT
1557482724,Infliximab Hospira,Hypersensitivity,OT
1557482724,Infliximab Hospira,Hepatic enzyme increased,OT
1557482724,Infliximab Hospira,Hepatic cirrhosis,OT
1557482724,Infliximab Hospira,Headache,OT
1557482724,Infliximab Hospira,Hand deformity,OT
1557482724,Infliximab Hospira,Glossodynia,OT
1557482724,Infliximab Hospira,General physical health deterioration,OT
1557482724,Infliximab Hospira,Foot deformity,OT
1557482724,Infliximab Hospira,Fatigue,OT
1557482724,Infliximab Hospira,Exposure during pregnancy,OT
1557482724,Infliximab Hospira,Exostosis,OT
1557482724,Infliximab Hospira,Ear infection,OT
1557482724,Infliximab Hospira,Drug intolerance,OT
1557482724,Infliximab Hospira,Drug ineffective,OT
1557482724,Infliximab Hospira,Drug hypersensitivity,OT
1557482724,Infliximab Hospira,Dizziness,OT
1557482724,Infliximab Hospira,Discomfort,OT
1557482724,Infliximab Hospira,Decreased appetite,OT
1557482724,Infliximab Hospira,Crohn's disease,OT
1557482724,Infliximab Hospira,Contraindicated product administered,OT
1557482724,Infliximab Hospira,Condition aggravated,OT
1557482724,Infliximab Hospira,C-reactive protein increased,OT
1557482724,Infliximab Hospira,Bone erosion,OT
1557482724,Infliximab Hospira,Arthritis,OT
1557482724,Infliximab Hospira,Arthralgia,OT
1557482724,Infliximab Hospira,Anti-cyclic citrullinated peptide antibody positive,OT
1557482724,Infliximab Hospira,Alopecia,OT
1557482724,Infliximab Hospira,Abdominal discomfort,OT
1557482724,Infliximab Hospira,Wound,OT
1557482724,Infliximab Hospira,Visual impairment,OT
1557482724,Infliximab Hospira,Treatment failure,OT
1557482724,Infliximab Hospira,Therapeutic product effect incomplete,OT
1557482724,Infliximab Hospira,Therapeutic product effect decreased,OT
1557482724,Infliximab Hospira,Systemic lupus erythematosus,OT
1557482724,Infliximab Hospira,Synovitis,OT
1557482724,Infliximab Hospira,Rheumatoid factor positive,OT
1557482724,Infliximab Hospira,Rheumatoid arthritis,OT
1557482724,Infliximab Hospira,Retinitis,OT
1557482724,Infliximab Hospira,Red blood cell sedimentation rate increased,OT
1557482724,Infliximab Hospira,Rash,OT
1557482724,Infliximab Hospira,Product use issue,OT
1557482724,Infliximab Hospira,Product use in unapproved indication,OT
1557482724,Infliximab Hospira,Pneumonia,OT
1557482724,Infliximab Hospira,Pericarditis,OT
1557482724,Infliximab Hospira,Pemphigus,OT
1557482724,Infliximab Hospira,Pain in extremity,OT
1557482724,Infliximab Hospira,Pain,OT
1557482724,Infliximab Hospira,Osteoporosis,OT
1557482724,Infliximab Hospira,Osteoarthritis,OT
1557482724,Infliximab Hospira,Off label use,OT
1557482724,Infliximab Hospira,Oedema peripheral,OT
1557482724,Infliximab Hospira,Nausea,OT
1557482724,Infliximab Hospira,Musculoskeletal stiffness,OT
1557482724,Infliximab Hospira,Mobility decreased,OT
1557482724,Infliximab Hospira,Malaise,OT
1557482724,Infliximab Hospira,Lupus-like syndrome,OT
1557482724,Infliximab Hospira,Laryngitis,OT
1557482724,Infliximab Hospira,Joint swelling,OT
1557482724,Infliximab Hospira,Joint stiffness,OT
1557482724,Infliximab Hospira,Joint dislocation,OT
1557482724,Infliximab Hospira,Infusion related reaction,OT
1557482724,Infliximab Hospira,Infection,OT
1557482724,Infliximab Hospira,Hypoaesthesia,OT
1557482724,Infliximab Hospira,Hypersensitivity,OT
1557482724,Infliximab Hospira,Hepatic enzyme increased,OT
1557482724,Infliximab Hospira,Hepatic cirrhosis,OT
1557482724,Infliximab Hospira,Headache,OT
1557482724,Infliximab Hospira,Hand deformity,OT
1557482724,Infliximab Hospira,Glossodynia,OT
1557482724,Infliximab Hospira,General physical health deterioration,OT
1557482724,Infliximab Hospira,Foot deformity,OT
1557482724,Infliximab Hospira,Fatigue,OT
1557482724,Infliximab Hospira,Exposure during pregnancy,OT
1557482724,Infliximab Hospira,Exostosis,OT
1557482724,Infliximab Hospira,Ear infection,OT
1557482724,Infliximab Hospira,Drug intolerance,OT
1557482724,Infliximab Hospira,Drug ineffective,OT
1557482724,Infliximab Hospira,Drug hypersensitivity,OT
1557482724,Infliximab Hospira,Dizziness,OT
1557482724,Infliximab Hospira,Discomfort,OT
1557482724,Infliximab Hospira,Decreased appetite,OT
1557482724,Infliximab Hospira,Crohn's disease,OT
1557482724,Infliximab Hospira,Contraindicated product administered,OT
1557482724,Infliximab Hospira,Condition aggravated,OT
1557482724,Infliximab Hospira,C-reactive protein increased,OT
1557482724,Infliximab Hospira,Bone erosion,OT
1557482724,Infliximab Hospira,Arthritis,OT
1557482724,Infliximab Hospira,Arthralgia,OT
1557482724,Infliximab Hospira,Anti-cyclic citrullinated peptide antibody positive,OT
1557482724,Infliximab Hospira,Alopecia,OT
1557482724,Infliximab Hospira,Abdominal discomfort,OT
1557482724,Infliximab Hospira,Wound,OT
1557482724,Infliximab Hospira,Visual impairment,OT
1557482724,Infliximab Hospira,Treatment failure,OT
1557482724,Infliximab Hospira,Therapeutic product effect incomplete,OT
1557482724,Infliximab Hospira,Therapeutic product effect decreased,OT
1557482724,Infliximab Hospira,Systemic lupus erythematosus,OT
1557482724,Infliximab Hospira,Synovitis,OT
1557482724,Infliximab Hospira,Rheumatoid factor positive,OT
1557482724,Infliximab Hospira,Rheumatoid arthritis,OT
1557482724,Infliximab Hospira,Retinitis,OT
1557482724,Infliximab Hospira,Red blood cell sedimentation rate increased,OT
1557482724,Infliximab Hospira,Rash,OT
1557482724,Infliximab Hospira,Product use issue,OT
1557482724,Infliximab Hospira,Product use in unapproved indication,OT
1557482724,Infliximab Hospira,Pneumonia,OT
1557482724,Infliximab Hospira,Pericarditis,OT
1557482724,Infliximab Hospira,Pemphigus,OT
1557482724,Infliximab Hospira,Pain in extremity,OT
1557482724,Infliximab Hospira,Pain,OT
1557482724,Infliximab Hospira,Osteoporosis,OT
1557482724,Infliximab Hospira,Osteoarthritis,OT
1557482724,Infliximab Hospira,Off label use,OT
1557482724,Infliximab Hospira,Oedema peripheral,OT
1557482724,Infliximab Hospira,Nausea,OT
1557482724,Infliximab Hospira,Musculoskeletal stiffness,OT
1557482724,Infliximab Hospira,Mobility decreased,OT
1557482724,Infliximab Hospira,Malaise,OT
1557482724,Infliximab Hospira,Lupus-like syndrome,OT
1557482724,Infliximab Hospira,Laryngitis,OT
1557482724,Infliximab Hospira,Joint swelling,OT
1557482724,Infliximab Hospira,Joint stiffness,OT
1557482724,Infliximab Hospira,Joint dislocation,OT
1557482724,Infliximab Hospira,Infusion related reaction,OT
1557482724,Infliximab Hospira,Infection,OT
1557482724,Infliximab Hospira,Hypoaesthesia,OT
1557482724,Infliximab Hospira,Hypersensitivity,OT
1557482724,Infliximab Hospira,Hepatic enzyme increased,OT
1557482724,Infliximab Hospira,Hepatic cirrhosis,OT
1557482724,Infliximab Hospira,Headache,OT
1557482724,Infliximab Hospira,Hand deformity,OT
1557482724,Infliximab Hospira,Glossodynia,OT
1557482724,Infliximab Hospira,General physical health deterioration,OT
1557482724,Infliximab Hospira,Foot deformity,OT
1557482724,Infliximab Hospira,Fatigue,OT
1557482724,Infliximab Hospira,Exposure during pregnancy,OT
1557482724,Infliximab Hospira,Exostosis,OT
1557482724,Infliximab Hospira,Ear infection,OT
1557482724,Infliximab Hospira,Drug intolerance,OT
1557482724,Infliximab Hospira,Drug ineffective,OT
1557482724,Infliximab Hospira,Drug hypersensitivity,OT
1557482724,Infliximab Hospira,Dizziness,OT
1557482724,Infliximab Hospira,Discomfort,OT
1557482724,Infliximab Hospira,Decreased appetite,OT
1557482724,Infliximab Hospira,Crohn's disease,OT
1557482724,Infliximab Hospira,Contraindicated product administered,OT
1557482724,Infliximab Hospira,Condition aggravated,OT
1557482724,Infliximab Hospira,C-reactive protein increased,OT
1557482724,Infliximab Hospira,Bone erosion,OT
1557482724,Infliximab Hospira,Arthritis,OT
1557482724,Infliximab Hospira,Arthralgia,OT
1557482724,Infliximab Hospira,Anti-cyclic citrullinated peptide antibody positive,OT
1557482724,Infliximab Hospira,Alopecia,OT
1557482724,Infliximab Hospira,Abdominal discomfort,OT
160798614,Infliximab,Ulcer,DS
160798614,Infliximab,Ulcer,OT
160798614,Infliximab,Ulcer,HO
160798614,Infliximab,Treatment failure,DS
160798614,Infliximab,Treatment failure,OT
160798614,Infliximab,Treatment failure,HO
160798614,Infliximab,Tongue disorder,DS
160798614,Infliximab,Tongue disorder,OT
160798614,Infliximab,Tongue disorder,HO
160798614,Infliximab,Therapy non-responder,DS
160798614,Infliximab,Therapy non-responder,OT
160798614,Infliximab,Therapy non-responder,HO
160798614,Infliximab,Tenosynovitis,DS
160798614,Infliximab,Tenosynovitis,OT
160798614,Infliximab,Tenosynovitis,HO
160798614,Infliximab,Tendonitis,DS
160798614,Infliximab,Tendonitis,OT
160798614,Infliximab,Tendonitis,HO
160798614,Infliximab,Synovitis,DS
160798614,Infliximab,Synovitis,OT
160798614,Infliximab,Synovitis,HO
160798614,Infliximab,Skin ulcer,DS
160798614,Infliximab,Skin ulcer,OT
160798614,Infliximab,Skin ulcer,HO
160798614,Infliximab,Skin necrosis,DS
160798614,Infliximab,Skin necrosis,OT
160798614,Infliximab,Skin necrosis,HO
160798614,Infliximab,Rheumatoid nodule,DS
160798614,Infliximab,Rheumatoid nodule,OT
160798614,Infliximab,Rheumatoid nodule,HO
160798614,Infliximab,Rheumatoid arthritis,DS
160798614,Infliximab,Rheumatoid arthritis,OT
160798614,Infliximab,Rheumatoid arthritis,HO
160798614,Infliximab,Red blood cell sedimentation rate,DS
160798614,Infliximab,Red blood cell sedimentation rate,OT
160798614,Infliximab,Red blood cell sedimentation rate,HO
160798614,Infliximab,Rash pruritic,DS
160798614,Infliximab,Rash pruritic,OT
160798614,Infliximab,Rash pruritic,HO
160798614,Infliximab,Rash,DS
160798614,Infliximab,Rash,OT
160798614,Infliximab,Rash,HO
160798614,Infliximab,Psoriatic arthropathy,DS
160798614,Infliximab,Psoriatic arthropathy,OT
160798614,Infliximab,Psoriatic arthropathy,HO
160798614,Infliximab,Peripheral swelling,DS
160798614,Infliximab,Peripheral swelling,OT
160798614,Infliximab,Peripheral swelling,HO
160798614,Infliximab,Panniculitis,DS
160798614,Infliximab,Panniculitis,OT
160798614,Infliximab,Panniculitis,HO
160798614,Infliximab,Pain,DS
160798614,Infliximab,Pain,OT
160798614,Infliximab,Pain,HO
160798614,Infliximab,Off label use,DS
160798614,Infliximab,Off label use,OT
160798614,Infliximab,Off label use,HO
160798614,Infliximab,Nausea,DS
160798614,Infliximab,Nausea,OT
160798614,Infliximab,Nausea,HO
160798614,Infliximab,Mucosal inflammation,DS
160798614,Infliximab,Mucosal inflammation,OT
160798614,Infliximab,Mucosal inflammation,HO
160798614,Infliximab,Mobility decreased,DS
160798614,Infliximab,Mobility decreased,OT
160798614,Infliximab,Mobility decreased,HO
160798614,Infliximab,Loss of personal independence in daily activities,DS
160798614,Infliximab,Loss of personal independence in daily activities,OT
160798614,Infliximab,Loss of personal independence in daily activities,HO
160798614,Infliximab,Infusion related reaction,DS
160798614,Infliximab,Infusion related reaction,OT
160798614,Infliximab,Infusion related reaction,HO
160798614,Infliximab,Inflammation,DS
160798614,Infliximab,Inflammation,OT
160798614,Infliximab,Inflammation,HO
160798614,Infliximab,Infection,DS
160798614,Infliximab,Infection,OT
160798614,Infliximab,Infection,HO
160798614,Infliximab,Hypersensitivity,DS
160798614,Infliximab,Hypersensitivity,OT
160798614,Infliximab,Hypersensitivity,HO
160798614,Infliximab,Hypercalcaemia,DS
160798614,Infliximab,Hypercalcaemia,OT
160798614,Infliximab,Hypercalcaemia,HO
160798614,Infliximab,Hepatic enzyme increased,DS
160798614,Infliximab,Hepatic enzyme increased,OT
160798614,Infliximab,Hepatic enzyme increased,HO
160798614,Infliximab,Headache,DS
160798614,Infliximab,Headache,OT
160798614,Infliximab,Headache,HO
160798614,Infliximab,Granuloma skin,DS
160798614,Infliximab,Granuloma skin,OT
160798614,Infliximab,Granuloma skin,HO
160798614,Infliximab,General physical health deterioration,DS
160798614,Infliximab,General physical health deterioration,OT
160798614,Infliximab,General physical health deterioration,HO
160798614,Infliximab,Fatigue,DS
160798614,Infliximab,Fatigue,OT
160798614,Infliximab,Fatigue,HO
160798614,Infliximab,Erythema,DS
160798614,Infliximab,Erythema,OT
160798614,Infliximab,Erythema,HO
160798614,Infliximab,Enthesopathy,DS
160798614,Infliximab,Enthesopathy,OT
160798614,Infliximab,Enthesopathy,HO
160798614,Infliximab,Drug intolerance,DS
160798614,Infliximab,Drug intolerance,OT
160798614,Infliximab,Drug intolerance,HO
160798614,Infliximab,Drug ineffective,DS
160798614,Infliximab,Drug ineffective,OT
160798614,Infliximab,Drug ineffective,HO
160798614,Infliximab,Drug hypersensitivity,DS
160798614,Infliximab,Drug hypersensitivity,OT
160798614,Infliximab,Drug hypersensitivity,HO
160798614,Infliximab,Drug eruption,DS
160798614,Infliximab,Drug eruption,OT
160798614,Infliximab,Drug eruption,HO
160798614,Infliximab,Contraindicated product administered,DS
160798614,Infliximab,Contraindicated product administered,OT
160798614,Infliximab,Contraindicated product administered,HO
160798614,Infliximab,C-reactive protein increased,DS
160798614,Infliximab,C-reactive protein increased,OT
160798614,Infliximab,C-reactive protein increased,HO
160798614,Infliximab,C-reactive protein abnormal,DS
160798614,Infliximab,C-reactive protein abnormal,OT
160798614,Infliximab,C-reactive protein abnormal,HO
160798614,Infliximab,Blood parathyroid hormone decreased,DS
160798614,Infliximab,Blood parathyroid hormone decreased,OT
160798614,Infliximab,Blood parathyroid hormone decreased,HO
160798614,Infliximab,Basal cell carcinoma,DS
160798614,Infliximab,Basal cell carcinoma,OT
160798614,Infliximab,Basal cell carcinoma,HO
160798614,Infliximab,Aspartate aminotransferase increased,DS
160798614,Infliximab,Aspartate aminotransferase increased,OT
160798614,Infliximab,Aspartate aminotransferase increased,HO
160798614,Infliximab,Alanine aminotransferase increased,DS
160798614,Infliximab,Alanine aminotransferase increased,OT
160798614,Infliximab,Alanine aminotransferase increased,HO
160798614,Infliximab,Alanine aminotransferase abnormal,DS
160798614,Infliximab,Alanine aminotransferase abnormal,OT
160798614,Infliximab,Alanine aminotransferase abnormal,HO
160798844,Infliximab,Urinary tract infection,OT
160798844,Infliximab,Throat irritation,OT
160798844,Infliximab,Rhinorrhoea,OT
160798844,Infliximab,Product use issue,OT
160798844,Infliximab,Pollakiuria,OT
160798844,Infliximab,Pelvic pain,OT
160798844,Infliximab,Oropharyngeal pain,OT
160798844,Infliximab,Off label use,OT
160798844,Infliximab,Ocular hyperaemia,OT
160798844,Infliximab,Nasopharyngitis,OT
160798844,Infliximab,Nasal congestion,OT
160798844,Infliximab,Muscle spasms,OT
160798844,Infliximab,Lacrimation increased,OT
160798844,Infliximab,Intentional product use issue,OT
160798844,Infliximab,Incorrect dose administered,OT
160798844,Infliximab,Inappropriate schedule of product administration,OT
160798844,Infliximab,Fatigue,OT
160798844,Infliximab,Faecal calprotectin increased,OT
160798844,Infliximab,Eye pruritus,OT
160798844,Infliximab,Urinary tract infection,OT
160798844,Infliximab,Throat irritation,OT
160798844,Infliximab,Rhinorrhoea,OT
160798844,Infliximab,Product use issue,OT
160798844,Infliximab,Pollakiuria,OT
160798844,Infliximab,Pelvic pain,OT
160798844,Infliximab,Oropharyngeal pain,OT
160798844,Infliximab,Off label use,OT
160798844,Infliximab,Ocular hyperaemia,OT
160798844,Infliximab,Nasopharyngitis,OT
160798844,Infliximab,Nasal congestion,OT
160798844,Infliximab,Muscle spasms,OT
160798844,Infliximab,Lacrimation increased,OT
160798844,Infliximab,Intentional product use issue,OT
160798844,Infliximab,Incorrect dose administered,OT
160798844,Infliximab,Inappropriate schedule of product administration,OT
160798844,Infliximab,Fatigue,OT
160798844,Infliximab,Faecal calprotectin increased,OT
160798844,Infliximab,Eye pruritus,OT
165568255,Infliximab,Weight increased,OT
165568255,Infliximab,Rash,OT
165568255,Infliximab,Product use issue,OT
165568255,Infliximab,Off label use,OT
165568255,Infliximab,Intentional product use issue,OT
165568255,Infliximab,Infection,OT
165568255,Infliximab,Incorrect dose administered,OT
165568255,Infliximab,Inappropriate schedule of product administration,OT
165568255,Infliximab,Hypertension,OT
165568255,Infliximab,Heart rate irregular,OT
165568255,Infliximab,Fatigue,OT
165568255,Infliximab,Erythema,OT
165568255,Infliximab,Condition aggravated,OT
165568255,Infliximab,Blood pressure increased,OT
165568255,Infliximab,Blood pressure fluctuation,OT
165568255,Infliximab,Arthritis,OT
165568255,Infliximab,Arthralgia,OT
165632335,Infliximab,Weight increased,OT
165632335,Infliximab,Weight decreased,OT
165632335,Infliximab,Vomiting,OT
165632335,Infliximab,Therapeutic product effect incomplete,OT
165632335,Infliximab,Sleep disorder,OT
165632335,Infliximab,Sinusitis,OT
165632335,Infliximab,Red blood cell sedimentation rate increased,OT
165632335,Infliximab,Pyrexia,OT
165632335,Infliximab,Pulmonary mass,OT
165632335,Infliximab,Psoriasis,OT
165632335,Infliximab,Posture abnormal,OT
165632335,Infliximab,Pharyngitis,OT
165632335,Infliximab,Oropharyngeal pain,OT
165632335,Infliximab,Off label use,OT
165632335,Infliximab,Nausea,OT
165632335,Infliximab,Nasal congestion,OT
165632335,Infliximab,Myalgia,OT
165632335,Infliximab,Musculoskeletal chest pain,OT
165632335,Infliximab,Intentional product use issue,OT
165632335,Infliximab,Insomnia,OT
165632335,Infliximab,Influenza,OT
165632335,Infliximab,Incorrect dose administered,OT
165632335,Infliximab,Hypertension,OT
165632335,Infliximab,Hot flush,OT
165632335,Infliximab,Fatigue,OT
165632335,Infliximab,Eye oedema,OT
165632335,Infliximab,Ear congestion,OT
165632335,Infliximab,Diarrhoea,OT
165632335,Infliximab,Cataract,OT
165632335,Infliximab,C-reactive protein decreased,OT
165632335,Infliximab,Body temperature fluctuation,OT
165632335,Infliximab,Blood pressure increased,OT
165632335,Infliximab,Blood pressure fluctuation,OT
165632335,Infliximab,Asthenia,OT
165632335,Infliximab,Abdominal pain,OT
165632335,Infliximab,Abdominal discomfort,OT
165632335,Infliximab,Weight increased,OT
165632335,Infliximab,Weight decreased,OT
165632335,Infliximab,Vomiting,OT
165632335,Infliximab,Therapeutic product effect incomplete,OT
165632335,Infliximab,Sleep disorder,OT
165632335,Infliximab,Sinusitis,OT
165632335,Infliximab,Red blood cell sedimentation rate increased,OT
165632335,Infliximab,Pyrexia,OT
165632335,Infliximab,Pulmonary mass,OT
165632335,Infliximab,Psoriasis,OT
165632335,Infliximab,Posture abnormal,OT
165632335,Infliximab,Pharyngitis,OT
165632335,Infliximab,Oropharyngeal pain,OT
165632335,Infliximab,Off label use,OT
165632335,Infliximab,Nausea,OT
165632335,Infliximab,Nasal congestion,OT
165632335,Infliximab,Myalgia,OT
165632335,Infliximab,Musculoskeletal chest pain,OT
165632335,Infliximab,Intentional product use issue,OT
165632335,Infliximab,Insomnia,OT
165632335,Infliximab,Influenza,OT
165632335,Infliximab,Incorrect dose administered,OT
165632335,Infliximab,Hypertension,OT
165632335,Infliximab,Hot flush,OT
165632335,Infliximab,Fatigue,OT
165632335,Infliximab,Eye oedema,OT
165632335,Infliximab,Ear congestion,OT
165632335,Infliximab,Diarrhoea,OT
165632335,Infliximab,Cataract,OT
165632335,Infliximab,C-reactive protein decreased,OT
165632335,Infliximab,Body temperature fluctuation,OT
165632335,Infliximab,Blood pressure increased,OT
165632335,Infliximab,Blood pressure fluctuation,OT
165632335,Infliximab,Asthenia,OT
165632335,Infliximab,Abdominal pain,OT
165632335,Infliximab,Abdominal discomfort,OT
166867115,Infliximab,Skin disorder,OT
166867115,Infliximab,Pruritus,OT
166867115,Infliximab,Product use issue,OT
166867115,Infliximab,Off label use,OT
166867115,Infliximab,Intentional product use issue,OT
166867115,Infliximab,Faecal calprotectin increased,OT
166867115,Infliximab,Drug level decreased,OT
166867115,Infliximab,Condition aggravated,OT
166867115,Infliximab,Blood pressure systolic increased,OT
166867115,Infliximab,Anastomotic ulcer,OT
166867115,Infliximab,Skin disorder,OT
166867115,Infliximab,Pruritus,OT
166867115,Infliximab,Product use issue,OT
166867115,Infliximab,Off label use,OT
166867115,Infliximab,Intentional product use issue,OT
166867115,Infliximab,Faecal calprotectin increased,OT
166867115,Infliximab,Drug level decreased,OT
166867115,Infliximab,Condition aggravated,OT
166867115,Infliximab,Blood pressure systolic increased,OT
166867115,Infliximab,Anastomotic ulcer,OT
167363804,Infliximab,Tuberculosis,OT
167363804,Infliximab,Product use issue,OT
167363804,Infliximab,Off label use,OT
167363804,Infliximab,Maternal exposure during pregnancy,OT
167363804,Infliximab,Inappropriate schedule of product administration,OT
167363804,Infliximab,Hypoalbuminaemia,OT
167363804,Infliximab,Condition aggravated,OT
170935424,Infliximab,Weight fluctuation,OT
170935424,Infliximab,Weight decreased,OT
170935424,Infliximab,Uveitis,OT
170935424,Infliximab,Therapeutic response shortened,OT
170935424,Infliximab,Spinal pain,OT
170935424,Infliximab,Psoriatic arthropathy,OT
170935424,Infliximab,Psoriasis,OT
170935424,Infliximab,Product use in unapproved indication,OT
170935424,Infliximab,Off label use,OT
170935424,Infliximab,Nervousness,OT
170935424,Infliximab,Nausea,OT
170935424,Infliximab,Iritis,OT
170935424,Infliximab,Intentional product use issue,OT
170935424,Infliximab,Inappropriate schedule of product administration,OT
170935424,Infliximab,Flushing,OT
170935424,Infliximab,Fatigue,OT
170935424,Infliximab,Fall,OT
170935424,Infliximab,Drug ineffective,OT
170935424,Infliximab,Blood pressure fluctuation,OT
170935424,Infliximab,Blood iron decreased,OT
170935424,Infliximab,Back pain,OT
170935424,Infliximab,Asthenia,OT
170935424,Infliximab,Ankle fracture,OT
170935424,Infliximab,Weight fluctuation,OT
170935424,Infliximab,Weight decreased,OT
170935424,Infliximab,Uveitis,OT
170935424,Infliximab,Therapeutic response shortened,OT
170935424,Infliximab,Spinal pain,OT
170935424,Infliximab,Psoriatic arthropathy,OT
170935424,Infliximab,Psoriasis,OT
170935424,Infliximab,Product use in unapproved indication,OT
170935424,Infliximab,Off label use,OT
170935424,Infliximab,Nervousness,OT
170935424,Infliximab,Nausea,OT
170935424,Infliximab,Iritis,OT
170935424,Infliximab,Intentional product use issue,OT
170935424,Infliximab,Inappropriate schedule of product administration,OT
170935424,Infliximab,Flushing,OT
170935424,Infliximab,Fatigue,OT
170935424,Infliximab,Fall,OT
170935424,Infliximab,Drug ineffective,OT
170935424,Infliximab,Blood pressure fluctuation,OT
170935424,Infliximab,Blood iron decreased,OT
170935424,Infliximab,Back pain,OT
170935424,Infliximab,Asthenia,OT
170935424,Infliximab,Ankle fracture,OT
170935424,Infliximab,Weight fluctuation,OT
170935424,Infliximab,Weight decreased,OT
170935424,Infliximab,Uveitis,OT
170935424,Infliximab,Therapeutic response shortened,OT
170935424,Infliximab,Spinal pain,OT
170935424,Infliximab,Psoriatic arthropathy,OT
170935424,Infliximab,Psoriasis,OT
170935424,Infliximab,Product use in unapproved indication,OT
170935424,Infliximab,Off label use,OT
170935424,Infliximab,Nervousness,OT
170935424,Infliximab,Nausea,OT
170935424,Infliximab,Iritis,OT
170935424,Infliximab,Intentional product use issue,OT
170935424,Infliximab,Inappropriate schedule of product administration,OT
170935424,Infliximab,Flushing,OT
170935424,Infliximab,Fatigue,OT
170935424,Infliximab,Fall,OT
170935424,Infliximab,Drug ineffective,OT
170935424,Infliximab,Blood pressure fluctuation,OT
170935424,Infliximab,Blood iron decreased,OT
170935424,Infliximab,Back pain,OT
170935424,Infliximab,Asthenia,OT
170935424,Infliximab,Ankle fracture,OT
173937102,Infliximab,Transaminases increased,OT
173937102,Infliximab,Off label use,OT
173937102,Infliximab,Myocardial infarction,OT
173937102,Infliximab,Intentional product use issue,OT
173937102,Infliximab,Hepatic steatosis,OT
173937102,Infliximab,Condition aggravated,OT
175199694,Infliximab,Therapeutic response shortened,OT
175199694,Infliximab,Sleep disorder,OT
175199694,Infliximab,Sinusitis,OT
175199694,Infliximab,Psoriasis,OT
175199694,Infliximab,Pneumonia,OT
175199694,Infliximab,Pain in extremity,OT
175199694,Infliximab,Pain,OT
175199694,Infliximab,Off label use,OT
175199694,Infliximab,Nasopharyngitis,OT
175199694,Infliximab,Nasal congestion,OT
175199694,Infliximab,Myalgia,OT
175199694,Infliximab,Malaise,OT
175199694,Infliximab,Inappropriate schedule of product administration,OT
175199694,Infliximab,Illness,OT
175199694,Infliximab,Hypertension,OT
175199694,Infliximab,Hot flush,OT
175199694,Infliximab,Gastrooesophageal reflux disease,OT
175199694,Infliximab,Fatigue,OT
175199694,Infliximab,Drug level above therapeutic,OT
175199694,Infliximab,Constipation,OT
175199694,Infliximab,Condition aggravated,OT
175199694,Infliximab,Blood pressure fluctuation,OT
175199694,Infliximab,Arthritis,OT
175199694,Infliximab,Arthralgia,OT
175199694,Infliximab,Therapeutic response shortened,OT
175199694,Infliximab,Sleep disorder,OT
175199694,Infliximab,Sinusitis,OT
175199694,Infliximab,Psoriasis,OT
175199694,Infliximab,Pneumonia,OT
175199694,Infliximab,Pain in extremity,OT
175199694,Infliximab,Pain,OT
175199694,Infliximab,Off label use,OT
175199694,Infliximab,Nasopharyngitis,OT
175199694,Infliximab,Nasal congestion,OT
175199694,Infliximab,Myalgia,OT
175199694,Infliximab,Malaise,OT
175199694,Infliximab,Inappropriate schedule of product administration,OT
175199694,Infliximab,Illness,OT
175199694,Infliximab,Hypertension,OT
175199694,Infliximab,Hot flush,OT
175199694,Infliximab,Gastrooesophageal reflux disease,OT
175199694,Infliximab,Fatigue,OT
175199694,Infliximab,Drug level above therapeutic,OT
175199694,Infliximab,Constipation,OT
175199694,Infliximab,Condition aggravated,OT
175199694,Infliximab,Blood pressure fluctuation,OT
175199694,Infliximab,Arthritis,OT
175199694,Infliximab,Arthralgia,OT
176242143,Infliximab,Poor venous access,OT
176242143,Infliximab,Poor venous access,HO
176242143,Infliximab,Off label use,OT
176242143,Infliximab,Off label use,HO
176242143,Infliximab,Intentional product use issue,OT
176242143,Infliximab,Intentional product use issue,HO
176242143,Infliximab,Heart rate increased,OT
176242143,Infliximab,Heart rate increased,HO
176242143,Infliximab,Faecal calprotectin increased,OT
176242143,Infliximab,Faecal calprotectin increased,HO
176242143,Infliximab,Drug level below therapeutic,OT
176242143,Infliximab,Drug level below therapeutic,HO
176242143,Infliximab,Drug level above therapeutic,OT
176242143,Infliximab,Drug level above therapeutic,HO
176242143,Infliximab,Condition aggravated,OT
176242143,Infliximab,Condition aggravated,HO
176242143,Infliximab,Body temperature increased,OT
176242143,Infliximab,Body temperature increased,HO
176242143,Infliximab,Blood pressure diastolic decreased,OT
176242143,Infliximab,Blood pressure diastolic decreased,HO
176962434,Infliximab,Weight increased,OT
176962434,Infliximab,Weight decreased,OT
176962434,Infliximab,Vein disorder,OT
176962434,Infliximab,Therapeutic response shortened,OT
176962434,Infliximab,Sinusitis,OT
176962434,Infliximab,Sinus disorder,OT
176962434,Infliximab,Rhinorrhoea,OT
176962434,Infliximab,Pyrexia,OT
176962434,Infliximab,Productive cough,OT
176962434,Infliximab,Product use issue,OT
176962434,Infliximab,Poor venous access,OT
176962434,Infliximab,Oropharyngeal pain,OT
176962434,Infliximab,Off label use,OT
176962434,Infliximab,Nasopharyngitis,OT
176962434,Infliximab,Nasal congestion,OT
176962434,Infliximab,Kidney infection,OT
176962434,Infliximab,Intentional product use issue,OT
176962434,Infliximab,Inappropriate schedule of product administration,OT
176962434,Infliximab,Headache,OT
176962434,Infliximab,Feeling hot,OT
176962434,Infliximab,Ear pain,OT
176962434,Infliximab,Condition aggravated,OT
176962434,Infliximab,Body temperature fluctuation,OT
176962434,Infliximab,Abdominal pain,OT
179492114,Infliximab,Weight increased,OT
179492114,Infliximab,Weight decreased,OT
179492114,Infliximab,Stress fracture,OT
179492114,Infliximab,Product use issue,OT
179492114,Infliximab,Off label use,OT
179492114,Infliximab,Nasopharyngitis,OT
179492114,Infliximab,Inappropriate schedule of product administration,OT
179492114,Infliximab,Heart rate irregular,OT
179492114,Infliximab,Heart rate decreased,OT
179492114,Infliximab,Crying,OT
179492114,Infliximab,Condition aggravated,OT
179492114,Infliximab,Blood pressure increased,OT
179492114,Infliximab,Blood pressure fluctuation,OT
179492114,Infliximab,Weight increased,OT
179492114,Infliximab,Weight decreased,OT
179492114,Infliximab,Stress fracture,OT
179492114,Infliximab,Product use issue,OT
179492114,Infliximab,Off label use,OT
179492114,Infliximab,Nasopharyngitis,OT
179492114,Infliximab,Inappropriate schedule of product administration,OT
179492114,Infliximab,Heart rate irregular,OT
179492114,Infliximab,Heart rate decreased,OT
179492114,Infliximab,Crying,OT
179492114,Infliximab,Condition aggravated,OT
179492114,Infliximab,Blood pressure increased,OT
179492114,Infliximab,Blood pressure fluctuation,OT
182871235,Infliximab (Unknown),Granulomatous liver disease,HO
182871235,Infliximab (Unknown),Granulomatous liver disease,OT
182871235,Infliximab (Unknown),Cutaneous vasculitis,HO
182871235,Infliximab (Unknown),Cutaneous vasculitis,OT
182871235,Infliximab (Unknown),Bile duct stenosis,HO
182871235,Infliximab (Unknown),Bile duct stenosis,OT
183964354,Infliximab,Weight increased,OT
183964354,Infliximab,Therapeutic response shortened,OT
183964354,Infliximab,Product use issue,OT
183964354,Infliximab,Off label use,OT
183964354,Infliximab,Intentional product use issue,OT
183964354,Infliximab,Inappropriate schedule of product administration,OT
183964354,Infliximab,Heart rate decreased,OT
183964354,Infliximab,Gastrooesophageal reflux disease,OT
183964354,Infliximab,Cough,OT
183964354,Infliximab,Condition aggravated,OT
183964354,Infliximab,Burning sensation,OT
183964354,Infliximab,Blood pressure increased,OT
183964354,Infliximab,Blood pressure fluctuation,OT
184680723,Infliximab,Weight increased,HO
184680723,Infliximab,Therapeutic response shortened,HO
184680723,Infliximab,Therapeutic product effect incomplete,HO
184680723,Infliximab,Poor venous access,HO
184680723,Infliximab,Off label use,HO
184680723,Infliximab,Nephrolithiasis,HO
184680723,Infliximab,Gastrooesophageal reflux disease,HO
184680723,Infliximab,Cough,HO
184680723,Infliximab,Condition aggravated,HO
184680723,Infliximab,Bone density decreased,HO
184680723,Infliximab,Blood pressure fluctuation,HO
184680723,Infliximab,Anal fistula,HO
184996674,Infliximab,Product use issue,HO
184996674,Infliximab,Product use issue,OT
184996674,Infliximab,Oxygen saturation increased,HO
184996674,Infliximab,Oxygen saturation increased,OT
184996674,Infliximab,Off label use,HO
184996674,Infliximab,Off label use,OT
184996674,Infliximab,Intentional product use issue,HO
184996674,Infliximab,Intentional product use issue,OT
184996674,Infliximab,Heart rate irregular,HO
184996674,Infliximab,Heart rate irregular,OT
184996674,Infliximab,Heart rate increased,HO
184996674,Infliximab,Heart rate increased,OT
184996674,Infliximab,Foreign body in eye,HO
184996674,Infliximab,Foreign body in eye,OT
184996674,Infliximab,Condition aggravated,HO
184996674,Infliximab,Condition aggravated,OT
184996674,Infliximab,Body temperature increased,HO
184996674,Infliximab,Body temperature increased,OT
184996674,Infliximab,Body temperature fluctuation,HO
184996674,Infliximab,Body temperature fluctuation,OT
184996674,Infliximab,Blood pressure increased,HO
184996674,Infliximab,Blood pressure increased,OT
184996674,Infliximab,Blood pressure fluctuation,HO
184996674,Infliximab,Blood pressure fluctuation,OT
184996674,Infliximab,Back pain,HO
184996674,Infliximab,Back pain,OT
184996674,Infliximab,Arthralgia,HO
184996674,Infliximab,Arthralgia,OT
187183832,Infliximab,Secretion discharge,OT
187183832,Infliximab,Pseudopolyp,OT
187183832,Infliximab,Oropharyngeal pain,OT
187183832,Infliximab,Off label use,OT
187183832,Infliximab,Nasal congestion,OT
187183832,Infliximab,Malaise,OT
187183832,Infliximab,Intentional product use issue,OT
187183832,Infliximab,Increased upper airway secretion,OT
187183832,Infliximab,Heart rate decreased,OT
187183832,Infliximab,Haemorrhage,OT
187183832,Infliximab,Faecal calprotectin increased,OT
187183832,Infliximab,Dysphonia,OT
187183832,Infliximab,Drug level below therapeutic,OT
187183832,Infliximab,Diarrhoea,OT
187183832,Infliximab,Cough,OT
187183832,Infliximab,Condition aggravated,OT
187183832,Infliximab,Chest pain,OT
187183832,Infliximab,Body temperature decreased,OT
187183832,Infliximab,Blood pressure increased,OT
187183832,Infliximab,Blood pressure fluctuation,OT
187183832,Infliximab,Blood pressure diastolic abnormal,OT
187183832,Infliximab,Arthralgia,OT
187183832,Infliximab,Abdominal pain,OT
187183832,Infliximab,Secretion discharge,OT
187183832,Infliximab,Pseudopolyp,OT
187183832,Infliximab,Oropharyngeal pain,OT
187183832,Infliximab,Off label use,OT
187183832,Infliximab,Nasal congestion,OT
187183832,Infliximab,Malaise,OT
187183832,Infliximab,Intentional product use issue,OT
187183832,Infliximab,Increased upper airway secretion,OT
187183832,Infliximab,Heart rate decreased,OT
187183832,Infliximab,Haemorrhage,OT
187183832,Infliximab,Faecal calprotectin increased,OT
187183832,Infliximab,Dysphonia,OT
187183832,Infliximab,Drug level below therapeutic,OT
187183832,Infliximab,Diarrhoea,OT
187183832,Infliximab,Cough,OT
187183832,Infliximab,Condition aggravated,OT
187183832,Infliximab,Chest pain,OT
187183832,Infliximab,Body temperature decreased,OT
187183832,Infliximab,Blood pressure increased,OT
187183832,Infliximab,Blood pressure fluctuation,OT
187183832,Infliximab,Blood pressure diastolic abnormal,OT
187183832,Infliximab,Arthralgia,OT
187183832,Infliximab,Abdominal pain,OT
189789822,Infliximab Pfizer (Unknown),Hepatic cytolysis,NULL
192750352,Infliximab,Wound,OT
192750352,Infliximab,Therapeutic response shortened,OT
192750352,Infliximab,Therapeutic product effect decreased,OT
192750352,Infliximab,Rash,OT
192750352,Infliximab,Pruritus,OT
192750352,Infliximab,Off label use,OT
192750352,Infliximab,Nail injury,OT
192750352,Infliximab,Malaise,OT
192750352,Infliximab,Limb injury,OT
192750352,Infliximab,Intentional product use issue,OT
192750352,Infliximab,Influenza like illness,OT
192750352,Infliximab,Incorrect dose administered,OT
192750352,Infliximab,Inappropriate schedule of product administration,OT
192750352,Infliximab,Herpes virus infection,OT
192750352,Infliximab,Headache,OT
192750352,Infliximab,Hand fracture,OT
192750352,Infliximab,Drug level below therapeutic,OT
192750352,Infliximab,Drug level above therapeutic,OT
192750352,Infliximab,Condition aggravated,OT
192750352,Infliximab,Chills,OT
192750352,Infliximab,Chest pain,OT
192750352,Infliximab,Blood pressure fluctuation,OT
192750352,Infliximab,Antibody test positive,OT
192750352,Infliximab,Wound,OT
192750352,Infliximab,Therapeutic response shortened,OT
192750352,Infliximab,Therapeutic product effect decreased,OT
192750352,Infliximab,Rash,OT
192750352,Infliximab,Pruritus,OT
192750352,Infliximab,Off label use,OT
192750352,Infliximab,Nail injury,OT
192750352,Infliximab,Malaise,OT
192750352,Infliximab,Limb injury,OT
192750352,Infliximab,Intentional product use issue,OT
192750352,Infliximab,Influenza like illness,OT
192750352,Infliximab,Incorrect dose administered,OT
192750352,Infliximab,Inappropriate schedule of product administration,OT
192750352,Infliximab,Herpes virus infection,OT
192750352,Infliximab,Headache,OT
192750352,Infliximab,Hand fracture,OT
192750352,Infliximab,Drug level below therapeutic,OT
192750352,Infliximab,Drug level above therapeutic,OT
192750352,Infliximab,Condition aggravated,OT
192750352,Infliximab,Chills,OT
192750352,Infliximab,Chest pain,OT
192750352,Infliximab,Blood pressure fluctuation,OT
192750352,Infliximab,Antibody test positive,OT
194511402,Infliximab,Wound,OT
194511402,Infliximab,Wheezing,OT
194511402,Infliximab,Vomiting,OT
194511402,Infliximab,Type 2 diabetes mellitus,OT
194511402,Infliximab,Treatment failure,OT
194511402,Infliximab,Therapeutic product effect decreased,OT
194511402,Infliximab,Systemic lupus erythematosus,OT
194511402,Infliximab,Synovitis,OT
194511402,Infliximab,Swollen joint count increased,OT
194511402,Infliximab,Swelling,OT
194511402,Infliximab,Sinusitis,OT
194511402,Infliximab,Sciatica,OT
194511402,Infliximab,Rheumatoid factor positive,OT
194511402,Infliximab,Rheumatoid arthritis,OT
194511402,Infliximab,Rheumatic fever,OT
194511402,Infliximab,Rash,OT
194511402,Infliximab,Psoriatic arthropathy,OT
194511402,Infliximab,Product use issue,OT
194511402,Infliximab,Prescribed overdose,OT
194511402,Infliximab,Pericarditis,OT
194511402,Infliximab,Pemphigus,OT
194511402,Infliximab,Pain,OT
194511402,Infliximab,Off label use,OT
194511402,Infliximab,Oedema,OT
194511402,Infliximab,Musculoskeletal stiffness,OT
194511402,Infliximab,Mobility decreased,OT
194511402,Infliximab,Maternal exposure during pregnancy,OT
194511402,Infliximab,Malaise,OT
194511402,Infliximab,Liver injury,OT
194511402,Infliximab,Joint swelling,OT
194511402,Infliximab,Intentional product use issue,OT
194511402,Infliximab,Injury,OT
194511402,Infliximab,Infusion related reaction,OT
194511402,Infliximab,Hypoaesthesia,OT
194511402,Infliximab,Hypertension,OT
194511402,Infliximab,Hypersensitivity,OT
194511402,Infliximab,Hepatic enzyme increased,OT
194511402,Infliximab,Helicobacter infection,OT
194511402,Infliximab,Headache,OT
194511402,Infliximab,Hand deformity,OT
194511402,Infliximab,Glossodynia,OT
194511402,Infliximab,General physical health deterioration,OT
194511402,Infliximab,Fibromyalgia,OT
194511402,Infliximab,Fatigue,OT
194511402,Infliximab,Duodenal ulcer perforation,OT
194511402,Infliximab,Drug intolerance,OT
194511402,Infliximab,Drug ineffective,OT
194511402,Infliximab,Drug hypersensitivity,OT
194511402,Infliximab,Discomfort,OT
194511402,Infliximab,Diarrhoea,OT
194511402,Infliximab,Decreased appetite,OT
194511402,Infliximab,Contraindicated product administered,OT
194511402,Infliximab,Condition aggravated,OT
194511402,Infliximab,Blood cholesterol increased,OT
194511402,Infliximab,Blister,OT
194511402,Infliximab,Arthropathy,OT
194511402,Infliximab,Arthralgia,OT
194511402,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
194511402,Infliximab,Alopecia,OT
194511402,Infliximab,Adverse drug reaction,OT
194511402,Infliximab,Abdominal pain upper,OT
194511402,Infliximab,Abdominal discomfort,OT
194511402,Infliximab,Wound,OT
194511402,Infliximab,Wheezing,OT
194511402,Infliximab,Vomiting,OT
194511402,Infliximab,Type 2 diabetes mellitus,OT
194511402,Infliximab,Treatment failure,OT
194511402,Infliximab,Therapeutic product effect decreased,OT
194511402,Infliximab,Systemic lupus erythematosus,OT
194511402,Infliximab,Synovitis,OT
194511402,Infliximab,Swollen joint count increased,OT
194511402,Infliximab,Swelling,OT
194511402,Infliximab,Sinusitis,OT
194511402,Infliximab,Sciatica,OT
194511402,Infliximab,Rheumatoid factor positive,OT
194511402,Infliximab,Rheumatoid arthritis,OT
194511402,Infliximab,Rheumatic fever,OT
194511402,Infliximab,Rash,OT
194511402,Infliximab,Psoriatic arthropathy,OT
194511402,Infliximab,Product use issue,OT
194511402,Infliximab,Prescribed overdose,OT
194511402,Infliximab,Pericarditis,OT
194511402,Infliximab,Pemphigus,OT
194511402,Infliximab,Pain,OT
194511402,Infliximab,Off label use,OT
194511402,Infliximab,Oedema,OT
194511402,Infliximab,Musculoskeletal stiffness,OT
194511402,Infliximab,Mobility decreased,OT
194511402,Infliximab,Maternal exposure during pregnancy,OT
194511402,Infliximab,Malaise,OT
194511402,Infliximab,Liver injury,OT
194511402,Infliximab,Joint swelling,OT
194511402,Infliximab,Intentional product use issue,OT
194511402,Infliximab,Injury,OT
194511402,Infliximab,Infusion related reaction,OT
194511402,Infliximab,Hypoaesthesia,OT
194511402,Infliximab,Hypertension,OT
194511402,Infliximab,Hypersensitivity,OT
194511402,Infliximab,Hepatic enzyme increased,OT
194511402,Infliximab,Helicobacter infection,OT
194511402,Infliximab,Headache,OT
194511402,Infliximab,Hand deformity,OT
194511402,Infliximab,Glossodynia,OT
194511402,Infliximab,General physical health deterioration,OT
194511402,Infliximab,Fibromyalgia,OT
194511402,Infliximab,Fatigue,OT
194511402,Infliximab,Duodenal ulcer perforation,OT
194511402,Infliximab,Drug intolerance,OT
194511402,Infliximab,Drug ineffective,OT
194511402,Infliximab,Drug hypersensitivity,OT
194511402,Infliximab,Discomfort,OT
194511402,Infliximab,Diarrhoea,OT
194511402,Infliximab,Decreased appetite,OT
194511402,Infliximab,Contraindicated product administered,OT
194511402,Infliximab,Condition aggravated,OT
194511402,Infliximab,Blood cholesterol increased,OT
194511402,Infliximab,Blister,OT
194511402,Infliximab,Arthropathy,OT
194511402,Infliximab,Arthralgia,OT
194511402,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
194511402,Infliximab,Alopecia,OT
194511402,Infliximab,Adverse drug reaction,OT
194511402,Infliximab,Abdominal pain upper,OT
194511402,Infliximab,Abdominal discomfort,OT
194511402,Infliximab,Wound,OT
194511402,Infliximab,Wheezing,OT
194511402,Infliximab,Vomiting,OT
194511402,Infliximab,Type 2 diabetes mellitus,OT
194511402,Infliximab,Treatment failure,OT
194511402,Infliximab,Therapeutic product effect decreased,OT
194511402,Infliximab,Systemic lupus erythematosus,OT
194511402,Infliximab,Synovitis,OT
194511402,Infliximab,Swollen joint count increased,OT
194511402,Infliximab,Swelling,OT
194511402,Infliximab,Sinusitis,OT
194511402,Infliximab,Sciatica,OT
194511402,Infliximab,Rheumatoid factor positive,OT
194511402,Infliximab,Rheumatoid arthritis,OT
194511402,Infliximab,Rheumatic fever,OT
194511402,Infliximab,Rash,OT
194511402,Infliximab,Psoriatic arthropathy,OT
194511402,Infliximab,Product use issue,OT
194511402,Infliximab,Prescribed overdose,OT
194511402,Infliximab,Pericarditis,OT
194511402,Infliximab,Pemphigus,OT
194511402,Infliximab,Pain,OT
194511402,Infliximab,Off label use,OT
194511402,Infliximab,Oedema,OT
194511402,Infliximab,Musculoskeletal stiffness,OT
194511402,Infliximab,Mobility decreased,OT
194511402,Infliximab,Maternal exposure during pregnancy,OT
194511402,Infliximab,Malaise,OT
194511402,Infliximab,Liver injury,OT
194511402,Infliximab,Joint swelling,OT
194511402,Infliximab,Intentional product use issue,OT
194511402,Infliximab,Injury,OT
194511402,Infliximab,Infusion related reaction,OT
194511402,Infliximab,Hypoaesthesia,OT
194511402,Infliximab,Hypertension,OT
194511402,Infliximab,Hypersensitivity,OT
194511402,Infliximab,Hepatic enzyme increased,OT
194511402,Infliximab,Helicobacter infection,OT
194511402,Infliximab,Headache,OT
194511402,Infliximab,Hand deformity,OT
194511402,Infliximab,Glossodynia,OT
194511402,Infliximab,General physical health deterioration,OT
194511402,Infliximab,Fibromyalgia,OT
194511402,Infliximab,Fatigue,OT
194511402,Infliximab,Duodenal ulcer perforation,OT
194511402,Infliximab,Drug intolerance,OT
194511402,Infliximab,Drug ineffective,OT
194511402,Infliximab,Drug hypersensitivity,OT
194511402,Infliximab,Discomfort,OT
194511402,Infliximab,Diarrhoea,OT
194511402,Infliximab,Decreased appetite,OT
194511402,Infliximab,Contraindicated product administered,OT
194511402,Infliximab,Condition aggravated,OT
194511402,Infliximab,Blood cholesterol increased,OT
194511402,Infliximab,Blister,OT
194511402,Infliximab,Arthropathy,OT
194511402,Infliximab,Arthralgia,OT
194511402,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
194511402,Infliximab,Alopecia,OT
194511402,Infliximab,Adverse drug reaction,OT
194511402,Infliximab,Abdominal pain upper,OT
194511402,Infliximab,Abdominal discomfort,OT
194511402,Infliximab,Wound,OT
194511402,Infliximab,Wheezing,OT
194511402,Infliximab,Vomiting,OT
194511402,Infliximab,Type 2 diabetes mellitus,OT
194511402,Infliximab,Treatment failure,OT
194511402,Infliximab,Therapeutic product effect decreased,OT
194511402,Infliximab,Systemic lupus erythematosus,OT
194511402,Infliximab,Synovitis,OT
194511402,Infliximab,Swollen joint count increased,OT
194511402,Infliximab,Swelling,OT
194511402,Infliximab,Sinusitis,OT
194511402,Infliximab,Sciatica,OT
194511402,Infliximab,Rheumatoid factor positive,OT
194511402,Infliximab,Rheumatoid arthritis,OT
194511402,Infliximab,Rheumatic fever,OT
194511402,Infliximab,Rash,OT
194511402,Infliximab,Psoriatic arthropathy,OT
194511402,Infliximab,Product use issue,OT
194511402,Infliximab,Prescribed overdose,OT
194511402,Infliximab,Pericarditis,OT
194511402,Infliximab,Pemphigus,OT
194511402,Infliximab,Pain,OT
194511402,Infliximab,Off label use,OT
194511402,Infliximab,Oedema,OT
194511402,Infliximab,Musculoskeletal stiffness,OT
194511402,Infliximab,Mobility decreased,OT
194511402,Infliximab,Maternal exposure during pregnancy,OT
194511402,Infliximab,Malaise,OT
194511402,Infliximab,Liver injury,OT
194511402,Infliximab,Joint swelling,OT
194511402,Infliximab,Intentional product use issue,OT
194511402,Infliximab,Injury,OT
194511402,Infliximab,Infusion related reaction,OT
194511402,Infliximab,Hypoaesthesia,OT
194511402,Infliximab,Hypertension,OT
194511402,Infliximab,Hypersensitivity,OT
194511402,Infliximab,Hepatic enzyme increased,OT
194511402,Infliximab,Helicobacter infection,OT
194511402,Infliximab,Headache,OT
194511402,Infliximab,Hand deformity,OT
194511402,Infliximab,Glossodynia,OT
194511402,Infliximab,General physical health deterioration,OT
194511402,Infliximab,Fibromyalgia,OT
194511402,Infliximab,Fatigue,OT
194511402,Infliximab,Duodenal ulcer perforation,OT
194511402,Infliximab,Drug intolerance,OT
194511402,Infliximab,Drug ineffective,OT
194511402,Infliximab,Drug hypersensitivity,OT
194511402,Infliximab,Discomfort,OT
194511402,Infliximab,Diarrhoea,OT
194511402,Infliximab,Decreased appetite,OT
194511402,Infliximab,Contraindicated product administered,OT
194511402,Infliximab,Condition aggravated,OT
194511402,Infliximab,Blood cholesterol increased,OT
194511402,Infliximab,Blister,OT
194511402,Infliximab,Arthropathy,OT
194511402,Infliximab,Arthralgia,OT
194511402,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
194511402,Infliximab,Alopecia,OT
194511402,Infliximab,Adverse drug reaction,OT
194511402,Infliximab,Abdominal pain upper,OT
194511402,Infliximab,Abdominal discomfort,OT
194950271,Infliximab Pfizer (Unknown),Pyrexia,OT
194950271,Infliximab Pfizer (Unknown),Off label use,OT
194950271,Infliximab Pfizer (Unknown),Dysplasia,OT
194950271,Infliximab Pfizer (Unknown),Drug ineffective for unapproved indication,OT
194950271,Infliximab Pfizer (Unknown),Colon cancer,OT
194950271,Infliximab Pfizer (Unknown),Colitis,OT
194950271,Infliximab Pfizer (Unknown),Arthritis enteropathic,OT
195578221,Infliximab,Uveitis,OT
195578221,Infliximab,Pterygium,OT
195578221,Infliximab,Off label use,OT
195578221,Infliximab,Hypersensitivity,OT
195578221,Infliximab,Body temperature decreased,OT
195578221,Infliximab,Arthralgia,OT
195581011,Infliximab,Weight increased,OT
195581011,Infliximab,Weight decreased,OT
195581011,Infliximab,Vitamin B12 increased,OT
195581011,Infliximab,Red cell distribution width increased,OT
195581011,Infliximab,Pharyngitis bacterial,OT
195581011,Infliximab,Lymphocyte count decreased,OT
195581011,Infliximab,Incorrect dose administered,OT
195581011,Infliximab,Glomerular filtration rate decreased,OT
195581011,Infliximab,Condition aggravated,OT
195581011,Infliximab,Blood thyroid stimulating hormone increased,OT
195581011,Infliximab,Blood creatinine increased,OT
195778951,Infliximab,Rash,OT
195778951,Infliximab,Psoriasis,OT
195778951,Infliximab,Paralysis,OT
195778951,Infliximab,Pain,OT
195778951,Infliximab,Musculoskeletal stiffness,OT
195778951,Infliximab,Influenza like illness,OT
195778951,Infliximab,Hot flush,OT
195778951,Infliximab,Erythema,OT
195778951,Infliximab,Dyspnoea,OT
195778951,Infliximab,Drug hypersensitivity,OT
195778951,Infliximab,Cough,OT
195778951,Infliximab,Bone pain,OT
195800051,Infliximab,Drug ineffective,OT
195894621,Infliximab,Weight increased,OT
195894621,Infliximab,Weight decreased,OT
195894621,Infliximab,Product use issue,OT
195894621,Infliximab,Off label use,OT
195894621,Infliximab,Incorrect drug administration rate,OT
195894621,Infliximab,Heart rate irregular,OT
195894621,Infliximab,Blood pressure increased,OT
196573951,Infliximab,Weight increased,OT
196573951,Infliximab,Weight decreased,OT
196573951,Infliximab,Product use issue,OT
196573951,Infliximab,Off label use,OT
196573951,Infliximab,Maternal exposure during pregnancy,OT
196573951,Infliximab,Intentional product use issue,OT
196573951,Infliximab,Injection site swelling,OT
196573951,Infliximab,Injection site erythema,OT
196573951,Infliximab,Infusion site extravasation,OT
196573951,Infliximab,Incorrect dose administered,OT
196573951,Infliximab,Inappropriate schedule of product administration,OT
196573951,Infliximab,Gestational diabetes,OT
196573951,Infliximab,Faecal calprotectin increased,OT
196573951,Infliximab,Drug ineffective,OT
196573951,Infliximab,Condition aggravated,OT
196573951,Infliximab,C-reactive protein increased,OT
196653251,Infliximab (Unknown),Maternal exposure before pregnancy,OT
196653251,Infliximab (Unknown),Abortion induced,OT
196695371,Infliximab,Urinary tract adhesions,HO
196695371,Infliximab,Urinary tract adhesions,OT
196695371,Infliximab,Product use issue,HO
196695371,Infliximab,Product use issue,OT
196695371,Infliximab,Off label use,HO
196695371,Infliximab,Off label use,OT
196695371,Infliximab,Intentional product use issue,HO
196695371,Infliximab,Intentional product use issue,OT
196695371,Infliximab,Dysuria,HO
196695371,Infliximab,Dysuria,OT
196842731,Infliximab,Off label use,HO
196842731,Infliximab,Intentional product use issue,HO
196842731,Infliximab,Condition aggravated,HO
196842731,Infliximab,Blood pressure increased,HO
196842731,Infliximab,Blood pressure fluctuation,HO
197302201,Infliximab,Osteoporosis,NULL
197457001,Infliximab,Small intestine carcinoma,OT
197457001,Infliximab,Poor venous access,OT
197457001,Infliximab,Oropharyngeal pain,OT
197457001,Infliximab,Off label use,OT
197457001,Infliximab,Intentional product use issue,OT
197457001,Infliximab,Condition aggravated,OT
197457001,Infliximab,Small intestine carcinoma,OT
197457001,Infliximab,Poor venous access,OT
197457001,Infliximab,Oropharyngeal pain,OT
197457001,Infliximab,Off label use,OT
197457001,Infliximab,Intentional product use issue,OT
197457001,Infliximab,Condition aggravated,OT
197513551,Infliximab,Ulcer,OT
197513551,Infliximab,Ulcer,HO
197513551,Infliximab,Therapeutic product effect decreased,OT
197513551,Infliximab,Therapeutic product effect decreased,HO
197513551,Infliximab,Local reaction,OT
197513551,Infliximab,Local reaction,HO
197513551,Infliximab,Intestinal ulcer,OT
197513551,Infliximab,Intestinal ulcer,HO
197513551,Infliximab,Hospitalisation,OT
197513551,Infliximab,Hospitalisation,HO
197513551,Infliximab,Frequent bowel movements,OT
197513551,Infliximab,Frequent bowel movements,HO
197513551,Infliximab,Drug level decreased,OT
197513551,Infliximab,Drug level decreased,HO
197513551,Infliximab,Drug intolerance,OT
197513551,Infliximab,Drug intolerance,HO
197513551,Infliximab,Drug ineffective,OT
197513551,Infliximab,Drug ineffective,HO
197513551,Infliximab,Depression,OT
197513551,Infliximab,Depression,HO
197513551,Infliximab,Colitis ulcerative,OT
197513551,Infliximab,Colitis ulcerative,HO
197513551,Infliximab,Colitis,OT
197513551,Infliximab,Colitis,HO
197513551,Infliximab,Arthritis,OT
197513551,Infliximab,Arthritis,HO
197640231,Infliximab,Therapeutic product effect decreased,OT
197640231,Infliximab,Off label use,OT
197640231,Infliximab,Maternal exposure during pregnancy,OT
197640231,Infliximab,Drug hypersensitivity,OT
197640231,Infliximab,Arthritis,OT
197654831,Infliximab,Off label use,DE
197654831,Infliximab,Death,DE
197654831,Infliximab,Anal fissure,DE
198132621,Infliximab (Unknown),Suspected COVID-19,OT
198132621,Infliximab (Unknown),Drug hypersensitivity,OT
198194471,Infliximab,Autoimmune haemolytic anaemia,OT
198282543,Infliximab,Oesophageal fibrosis,OT
198282543,Infliximab,Oesophageal fibrosis,HO
198282543,Infliximab,Dysphagia,OT
198282543,Infliximab,Dysphagia,HO
198461361,Infliximab,Segmented hyalinising vasculitis,OT
198461361,Infliximab,Polychondritis,OT
198461361,Infliximab,Polyarthritis,OT
198461361,Infliximab,Off label use,OT
198461361,Infliximab,Drug ineffective for unapproved indication,OT
198580241,Infliximab,Histoplasmosis disseminated,HO
198580241,Infliximab,Granulomatous liver disease,HO
198751181,Infliximab,Off label use,OT
198751181,Infliximab,Off label use,LT
198751181,Infliximab,Extranodal marginal zone B-cell lymphoma (MALT type),OT
198751181,Infliximab,Extranodal marginal zone B-cell lymphoma (MALT type),LT
198751181,Infliximab,Arthralgia,OT
198751181,Infliximab,Arthralgia,LT
198781701,Infliximab (Unknown),Off label use,NULL
198781701,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198781701,Infliximab (Unknown),Off label use,NULL
198781701,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198857351,Infliximab,Therapeutic product effect incomplete,OT
198857351,Infliximab,Therapeutic product effect incomplete,HO
198857351,Infliximab,Haemorrhoidal haemorrhage,OT
198857351,Infliximab,Haemorrhoidal haemorrhage,HO
198857351,Infliximab,Haemorrhage,OT
198857351,Infliximab,Haemorrhage,HO
198857351,Infliximab,Faecal calprotectin increased,OT
198857351,Infliximab,Faecal calprotectin increased,HO
198915221,Infliximab,Weight increased,OT
198915221,Infliximab,Inappropriate schedule of product administration,OT
198915221,Infliximab,Condition aggravated,OT
198915221,Infliximab,Anal abscess,OT
198949981,Infliximab (Unknown),Therapy non-responder,NULL
198949981,Infliximab (Unknown),Drug intolerance,NULL
198949981,Infliximab (Unknown),Therapy non-responder,NULL
198949981,Infliximab (Unknown),Drug intolerance,NULL
165640774,Infliximab,Weight increased,OT
165640774,Infliximab,Upper respiratory tract infection,OT
165640774,Infliximab,Rhinorrhoea,OT
165640774,Infliximab,Off label use,OT
165640774,Infliximab,Intentional product use issue,OT
165640774,Infliximab,Incorrect drug administration rate,OT
165640774,Infliximab,Inappropriate schedule of product administration,OT
165640774,Infliximab,Hypertension,OT
165640774,Infliximab,Extra dose administered,OT
165640774,Infliximab,Cough,OT
165640774,Infliximab,Condition aggravated,OT
165640774,Infliximab,Blood pressure increased,OT
165640774,Infliximab,Blood pressure fluctuation,OT
165640774,Infliximab,Blood pressure decreased,OT
165640774,Infliximab,Arthralgia,OT
165640774,Infliximab,Abdominal pain,OT
166888585,Infliximab,Wound,OT
166888585,Infliximab,Wound,HO
166888585,Infliximab,Weight increased,OT
166888585,Infliximab,Weight increased,HO
166888585,Infliximab,Weight decreased,OT
166888585,Infliximab,Weight decreased,HO
166888585,Infliximab,Vein rupture,OT
166888585,Infliximab,Vein rupture,HO
166888585,Infliximab,Urinary tract infection,OT
166888585,Infliximab,Urinary tract infection,HO
166888585,Infliximab,Thyroglobulin increased,OT
166888585,Infliximab,Thyroglobulin increased,HO
166888585,Infliximab,Skin lesion,OT
166888585,Infliximab,Skin lesion,HO
166888585,Infliximab,Product use issue,OT
166888585,Infliximab,Product use issue,HO
166888585,Infliximab,Poor venous access,OT
166888585,Infliximab,Poor venous access,HO
166888585,Infliximab,Pharyngitis,OT
166888585,Infliximab,Pharyngitis,HO
166888585,Infliximab,Pancreatic cyst,OT
166888585,Infliximab,Pancreatic cyst,HO
166888585,Infliximab,Pain,OT
166888585,Infliximab,Pain,HO
166888585,Infliximab,Overweight,OT
166888585,Infliximab,Overweight,HO
166888585,Infliximab,Off label use,OT
166888585,Infliximab,Off label use,HO
166888585,Infliximab,Nausea,OT
166888585,Infliximab,Nausea,HO
166888585,Infliximab,Intentional product use issue,OT
166888585,Infliximab,Intentional product use issue,HO
166888585,Infliximab,Hyperkeratosis,OT
166888585,Infliximab,Hyperkeratosis,HO
166888585,Infliximab,Haemolysis,OT
166888585,Infliximab,Haemolysis,HO
166888585,Infliximab,Haematochezia,OT
166888585,Infliximab,Haematochezia,HO
166888585,Infliximab,Gastroenteritis,OT
166888585,Infliximab,Gastroenteritis,HO
166888585,Infliximab,Fungal skin infection,OT
166888585,Infliximab,Fungal skin infection,HO
166888585,Infliximab,Diarrhoea,OT
166888585,Infliximab,Diarrhoea,HO
166888585,Infliximab,Condition aggravated,OT
166888585,Infliximab,Condition aggravated,HO
166888585,Infliximab,Cataract,OT
166888585,Infliximab,Cataract,HO
166888585,Infliximab,Blood pressure fluctuation,OT
166888585,Infliximab,Blood pressure fluctuation,HO
166888585,Infliximab,Wound,OT
166888585,Infliximab,Wound,HO
166888585,Infliximab,Weight increased,OT
166888585,Infliximab,Weight increased,HO
166888585,Infliximab,Weight decreased,OT
166888585,Infliximab,Weight decreased,HO
166888585,Infliximab,Vein rupture,OT
166888585,Infliximab,Vein rupture,HO
166888585,Infliximab,Urinary tract infection,OT
166888585,Infliximab,Urinary tract infection,HO
166888585,Infliximab,Thyroglobulin increased,OT
166888585,Infliximab,Thyroglobulin increased,HO
166888585,Infliximab,Skin lesion,OT
166888585,Infliximab,Skin lesion,HO
166888585,Infliximab,Product use issue,OT
166888585,Infliximab,Product use issue,HO
166888585,Infliximab,Poor venous access,OT
166888585,Infliximab,Poor venous access,HO
166888585,Infliximab,Pharyngitis,OT
166888585,Infliximab,Pharyngitis,HO
166888585,Infliximab,Pancreatic cyst,OT
166888585,Infliximab,Pancreatic cyst,HO
166888585,Infliximab,Pain,OT
166888585,Infliximab,Pain,HO
166888585,Infliximab,Overweight,OT
166888585,Infliximab,Overweight,HO
166888585,Infliximab,Off label use,OT
166888585,Infliximab,Off label use,HO
166888585,Infliximab,Nausea,OT
166888585,Infliximab,Nausea,HO
166888585,Infliximab,Intentional product use issue,OT
166888585,Infliximab,Intentional product use issue,HO
166888585,Infliximab,Hyperkeratosis,OT
166888585,Infliximab,Hyperkeratosis,HO
166888585,Infliximab,Haemolysis,OT
166888585,Infliximab,Haemolysis,HO
166888585,Infliximab,Haematochezia,OT
166888585,Infliximab,Haematochezia,HO
166888585,Infliximab,Gastroenteritis,OT
166888585,Infliximab,Gastroenteritis,HO
166888585,Infliximab,Fungal skin infection,OT
166888585,Infliximab,Fungal skin infection,HO
166888585,Infliximab,Diarrhoea,OT
166888585,Infliximab,Diarrhoea,HO
166888585,Infliximab,Condition aggravated,OT
166888585,Infliximab,Condition aggravated,HO
166888585,Infliximab,Cataract,OT
166888585,Infliximab,Cataract,HO
166888585,Infliximab,Blood pressure fluctuation,OT
166888585,Infliximab,Blood pressure fluctuation,HO
172745484,Infliximab,Pyrexia,OT
172745484,Infliximab,Pneumonia,OT
172745484,Infliximab,Off label use,OT
172745484,Infliximab,Malaise,OT
172745484,Infliximab,Incorrect dosage administered,OT
172745484,Infliximab,Illness,OT
172745484,Infliximab,Heart rate irregular,OT
172745484,Infliximab,Pyrexia,OT
172745484,Infliximab,Pneumonia,OT
172745484,Infliximab,Off label use,OT
172745484,Infliximab,Malaise,OT
172745484,Infliximab,Incorrect dosage administered,OT
172745484,Infliximab,Illness,OT
172745484,Infliximab,Heart rate irregular,OT
175483323,Infliximab,Weight decreased,OT
175483323,Infliximab,Pyelonephritis,OT
175483323,Infliximab,Prostatitis,OT
175483323,Infliximab,Poor venous access,OT
175483323,Infliximab,Pain,OT
175483323,Infliximab,Off label use,OT
175483323,Infliximab,Nasopharyngitis,OT
175483323,Infliximab,Nasal congestion,OT
175483323,Infliximab,Intentional product use issue,OT
175483323,Infliximab,Headache,OT
175483323,Infliximab,Drug level above therapeutic,OT
175483323,Infliximab,Cough,OT
175483323,Infliximab,Condition aggravated,OT
175483323,Infliximab,C-reactive protein increased,OT
175483323,Infliximab,Blood pressure systolic increased,OT
175483323,Infliximab,Blood pressure fluctuation,OT
175483323,Infliximab,Abdominal distension,OT
176208923,Infliximab,Wound infection,OT
176208923,Infliximab,Product use issue,OT
176208923,Infliximab,Off label use,OT
176208923,Infliximab,Nausea,OT
176208923,Infliximab,Localised infection,OT
176208923,Infliximab,Incorrect dose administered,OT
176208923,Infliximab,Headache,OT
176208923,Infliximab,Faecal calprotectin increased,OT
176208923,Infliximab,Drug level above therapeutic,OT
176208923,Infliximab,Condition aggravated,OT
176208923,Infliximab,Wound infection,OT
176208923,Infliximab,Product use issue,OT
176208923,Infliximab,Off label use,OT
176208923,Infliximab,Nausea,OT
176208923,Infliximab,Localised infection,OT
176208923,Infliximab,Incorrect dose administered,OT
176208923,Infliximab,Headache,OT
176208923,Infliximab,Faecal calprotectin increased,OT
176208923,Infliximab,Drug level above therapeutic,OT
176208923,Infliximab,Condition aggravated,OT
176267405,Infliximab,Tooth infection,HO
176267405,Infliximab,Product use issue,HO
176267405,Infliximab,Oxygen saturation abnormal,HO
176267405,Infliximab,Oral infection,HO
176267405,Infliximab,Off label use,HO
176267405,Infliximab,Intentional product use issue,HO
176267405,Infliximab,Inappropriate schedule of product administration,HO
176267405,Infliximab,Bone pain,HO
176267405,Infliximab,Arthralgia,HO
176267405,Infliximab,Tooth infection,HO
176267405,Infliximab,Product use issue,HO
176267405,Infliximab,Oxygen saturation abnormal,HO
176267405,Infliximab,Oral infection,HO
176267405,Infliximab,Off label use,HO
176267405,Infliximab,Intentional product use issue,HO
176267405,Infliximab,Inappropriate schedule of product administration,HO
176267405,Infliximab,Bone pain,HO
176267405,Infliximab,Arthralgia,HO
176530363,Infliximab,Pain,OT
176530363,Infliximab,Off label use,OT
176530363,Infliximab,Inappropriate schedule of product administration,OT
176530363,Infliximab,Fistula,OT
176530363,Infliximab,Eczema,OT
176530363,Infliximab,Drug level below therapeutic,OT
176530363,Infliximab,Drug ineffective,OT
176530363,Infliximab,Condition aggravated,OT
176530363,Infliximab,Blood pressure increased,OT
176530363,Infliximab,Blood pressure fluctuation,OT
176530363,Infliximab,Arthralgia,OT
176530363,Infliximab,Pain,OT
176530363,Infliximab,Off label use,OT
176530363,Infliximab,Inappropriate schedule of product administration,OT
176530363,Infliximab,Fistula,OT
176530363,Infliximab,Eczema,OT
176530363,Infliximab,Drug level below therapeutic,OT
176530363,Infliximab,Drug ineffective,OT
176530363,Infliximab,Condition aggravated,OT
176530363,Infliximab,Blood pressure increased,OT
176530363,Infliximab,Blood pressure fluctuation,OT
176530363,Infliximab,Arthralgia,OT
176584644,Infliximab,Sputum discoloured,OT
176584644,Infliximab,Sputum discoloured,HO
176584644,Infliximab,Sepsis,OT
176584644,Infliximab,Sepsis,HO
176584644,Infliximab,Productive cough,OT
176584644,Infliximab,Productive cough,HO
176584644,Infliximab,Nasopharyngitis,OT
176584644,Infliximab,Nasopharyngitis,HO
176584644,Infliximab,Mental disorder,OT
176584644,Infliximab,Mental disorder,HO
176584644,Infliximab,Malaise,OT
176584644,Infliximab,Malaise,HO
176584644,Infliximab,Inappropriate schedule of product administration,OT
176584644,Infliximab,Inappropriate schedule of product administration,HO
176584644,Infliximab,Immune system disorder,OT
176584644,Infliximab,Immune system disorder,HO
176584644,Infliximab,Hernia,OT
176584644,Infliximab,Hernia,HO
176584644,Infliximab,Diabetes mellitus,OT
176584644,Infliximab,Diabetes mellitus,HO
176584644,Infliximab,Decreased immune responsiveness,OT
176584644,Infliximab,Decreased immune responsiveness,HO
176584644,Infliximab,Condition aggravated,OT
176584644,Infliximab,Condition aggravated,HO
176584644,Infliximab,Arthralgia,OT
176584644,Infliximab,Arthralgia,HO
176797873,Infliximab,Weight increased,OT
176797873,Infliximab,Weight increased,HO
176797873,Infliximab,Ulcer,OT
176797873,Infliximab,Ulcer,HO
176797873,Infliximab,Therapeutic product effect incomplete,OT
176797873,Infliximab,Therapeutic product effect incomplete,HO
176797873,Infliximab,Therapeutic product effect delayed,OT
176797873,Infliximab,Therapeutic product effect delayed,HO
176797873,Infliximab,Rectal haemorrhage,OT
176797873,Infliximab,Rectal haemorrhage,HO
176797873,Infliximab,Product use issue,OT
176797873,Infliximab,Product use issue,HO
176797873,Infliximab,Pharyngitis,OT
176797873,Infliximab,Pharyngitis,HO
176797873,Infliximab,Off label use,OT
176797873,Infliximab,Off label use,HO
176797873,Infliximab,Nasopharyngitis,OT
176797873,Infliximab,Nasopharyngitis,HO
176797873,Infliximab,Malaise,OT
176797873,Infliximab,Malaise,HO
176797873,Infliximab,Intentional product use issue,OT
176797873,Infliximab,Intentional product use issue,HO
176797873,Infliximab,Inappropriate schedule of product administration,OT
176797873,Infliximab,Inappropriate schedule of product administration,HO
176797873,Infliximab,Heart rate decreased,OT
176797873,Infliximab,Heart rate decreased,HO
176797873,Infliximab,Headache,OT
176797873,Infliximab,Headache,HO
176797873,Infliximab,Gallbladder disorder,OT
176797873,Infliximab,Gallbladder disorder,HO
176797873,Infliximab,Furuncle,OT
176797873,Infliximab,Furuncle,HO
176797873,Infliximab,Fatigue,OT
176797873,Infliximab,Fatigue,HO
176797873,Infliximab,Drug level increased,OT
176797873,Infliximab,Drug level increased,HO
176797873,Infliximab,Dermatitis,OT
176797873,Infliximab,Dermatitis,HO
176797873,Infliximab,COVID-19,OT
176797873,Infliximab,COVID-19,HO
176797873,Infliximab,C-reactive protein increased,OT
176797873,Infliximab,C-reactive protein increased,HO
176797873,Infliximab,Balance disorder,OT
176797873,Infliximab,Balance disorder,HO
176797873,Infliximab,Asthenia,OT
176797873,Infliximab,Asthenia,HO
176797873,Infliximab,Abscess,OT
176797873,Infliximab,Abscess,HO
176943134,Infliximab,Skin lesion,HO
176943134,Infliximab,Skin lesion,OT
176943134,Infliximab,Poor venous access,HO
176943134,Infliximab,Poor venous access,OT
176943134,Infliximab,Intestinal obstruction,HO
176943134,Infliximab,Intestinal obstruction,OT
176943134,Infliximab,Insomnia,HO
176943134,Infliximab,Insomnia,OT
176943134,Infliximab,Inappropriate schedule of product administration,HO
176943134,Infliximab,Inappropriate schedule of product administration,OT
176943134,Infliximab,Herpes zoster,HO
176943134,Infliximab,Herpes zoster,OT
176943134,Infliximab,Heart rate irregular,HO
176943134,Infliximab,Heart rate irregular,OT
176943134,Infliximab,Fatigue,HO
176943134,Infliximab,Fatigue,OT
176943134,Infliximab,Condition aggravated,HO
176943134,Infliximab,Condition aggravated,OT
176943134,Infliximab,Blood pressure increased,HO
176943134,Infliximab,Blood pressure increased,OT
176943134,Infliximab,Blood pressure fluctuation,HO
176943134,Infliximab,Blood pressure fluctuation,OT
176943134,Infliximab,Skin lesion,HO
176943134,Infliximab,Skin lesion,OT
176943134,Infliximab,Poor venous access,HO
176943134,Infliximab,Poor venous access,OT
176943134,Infliximab,Intestinal obstruction,HO
176943134,Infliximab,Intestinal obstruction,OT
176943134,Infliximab,Insomnia,HO
176943134,Infliximab,Insomnia,OT
176943134,Infliximab,Inappropriate schedule of product administration,HO
176943134,Infliximab,Inappropriate schedule of product administration,OT
176943134,Infliximab,Herpes zoster,HO
176943134,Infliximab,Herpes zoster,OT
176943134,Infliximab,Heart rate irregular,HO
176943134,Infliximab,Heart rate irregular,OT
176943134,Infliximab,Fatigue,HO
176943134,Infliximab,Fatigue,OT
176943134,Infliximab,Condition aggravated,HO
176943134,Infliximab,Condition aggravated,OT
176943134,Infliximab,Blood pressure increased,HO
176943134,Infliximab,Blood pressure increased,OT
176943134,Infliximab,Blood pressure fluctuation,HO
176943134,Infliximab,Blood pressure fluctuation,OT
177093133,Infliximab,Weight decreased,OT
177093133,Infliximab,Viral infection,OT
177093133,Infliximab,Tremor,OT
177093133,Infliximab,Pain,OT
177093133,Infliximab,Oropharyngeal pain,OT
177093133,Infliximab,Off label use,OT
177093133,Infliximab,Muscle tightness,OT
177093133,Infliximab,Intentional product use issue,OT
177093133,Infliximab,Inappropriate schedule of product administration,OT
177093133,Infliximab,Headache,OT
177093133,Infliximab,Fatigue,OT
177093133,Infliximab,Drug ineffective,OT
177093133,Infliximab,Condition aggravated,OT
177093133,Infliximab,COVID-19,OT
177093133,Infliximab,Blood pressure fluctuation,OT
177093133,Infliximab,Back pain,OT
177093133,Infliximab,Asthenia,OT
177093133,Infliximab,Arthralgia,OT
177093133,Infliximab,Weight decreased,OT
177093133,Infliximab,Viral infection,OT
177093133,Infliximab,Tremor,OT
177093133,Infliximab,Pain,OT
177093133,Infliximab,Oropharyngeal pain,OT
177093133,Infliximab,Off label use,OT
177093133,Infliximab,Muscle tightness,OT
177093133,Infliximab,Intentional product use issue,OT
177093133,Infliximab,Inappropriate schedule of product administration,OT
177093133,Infliximab,Headache,OT
177093133,Infliximab,Fatigue,OT
177093133,Infliximab,Drug ineffective,OT
177093133,Infliximab,Condition aggravated,OT
177093133,Infliximab,COVID-19,OT
177093133,Infliximab,Blood pressure fluctuation,OT
177093133,Infliximab,Back pain,OT
177093133,Infliximab,Asthenia,OT
177093133,Infliximab,Arthralgia,OT
177334144,Infliximab,Weight increased,OT
177334144,Infliximab,Therapeutic product effect incomplete,OT
177334144,Infliximab,Stress,OT
177334144,Infliximab,Rectal haemorrhage,OT
177334144,Infliximab,Product use issue,OT
177334144,Infliximab,Off label use,OT
177334144,Infliximab,Heart rate decreased,OT
177334144,Infliximab,Haemorrhoids,OT
177334144,Infliximab,Gallbladder disorder,OT
177334144,Infliximab,Faecal calprotectin increased,OT
177334144,Infliximab,Drug level below therapeutic,OT
177334144,Infliximab,Condition aggravated,OT
177334144,Infliximab,Blood pressure fluctuation,OT
178480714,Infliximab,Underdose,OT
178480714,Infliximab,Therapeutic product effect incomplete,OT
178480714,Infliximab,Product use issue,OT
178480714,Infliximab,Pain,OT
178480714,Infliximab,Off label use,OT
178480714,Infliximab,Nausea,OT
178480714,Infliximab,Mood altered,OT
178480714,Infliximab,Malaise,OT
178480714,Infliximab,Lower respiratory tract infection,OT
178480714,Infliximab,Liver function test increased,OT
178480714,Infliximab,Incorrect dose administered,OT
178480714,Infliximab,Inappropriate schedule of product administration,OT
178480714,Infliximab,Hepatic pain,OT
178480714,Infliximab,Hepatic enzyme increased,OT
178480714,Infliximab,Gait disturbance,OT
178480714,Infliximab,Fibromyalgia,OT
178480714,Infliximab,Fear of injection,OT
178480714,Infliximab,Fatigue,OT
178480714,Infliximab,Faecal calprotectin increased,OT
178480714,Infliximab,Eating disorder,OT
178480714,Infliximab,Dysmenorrhoea,OT
178480714,Infliximab,Drug level below therapeutic,OT
178480714,Infliximab,Drug level above therapeutic,OT
178480714,Infliximab,Disturbance in attention,OT
178480714,Infliximab,Condition aggravated,OT
178480714,Infliximab,Bronchitis,OT
178480714,Infliximab,Blood pressure decreased,OT
178480714,Infliximab,Anxiety,OT
178480714,Infliximab,Abdominal pain upper,OT
178480714,Infliximab,Underdose,OT
178480714,Infliximab,Therapeutic product effect incomplete,OT
178480714,Infliximab,Product use issue,OT
178480714,Infliximab,Pain,OT
178480714,Infliximab,Off label use,OT
178480714,Infliximab,Nausea,OT
178480714,Infliximab,Mood altered,OT
178480714,Infliximab,Malaise,OT
178480714,Infliximab,Lower respiratory tract infection,OT
178480714,Infliximab,Liver function test increased,OT
178480714,Infliximab,Incorrect dose administered,OT
178480714,Infliximab,Inappropriate schedule of product administration,OT
178480714,Infliximab,Hepatic pain,OT
178480714,Infliximab,Hepatic enzyme increased,OT
178480714,Infliximab,Gait disturbance,OT
178480714,Infliximab,Fibromyalgia,OT
178480714,Infliximab,Fear of injection,OT
178480714,Infliximab,Fatigue,OT
178480714,Infliximab,Faecal calprotectin increased,OT
178480714,Infliximab,Eating disorder,OT
178480714,Infliximab,Dysmenorrhoea,OT
178480714,Infliximab,Drug level below therapeutic,OT
178480714,Infliximab,Drug level above therapeutic,OT
178480714,Infliximab,Disturbance in attention,OT
178480714,Infliximab,Condition aggravated,OT
178480714,Infliximab,Bronchitis,OT
178480714,Infliximab,Blood pressure decreased,OT
178480714,Infliximab,Anxiety,OT
178480714,Infliximab,Abdominal pain upper,OT
178572533,Infliximab,Weight decreased,OT
178572533,Infliximab,Systolic hypertension,OT
178572533,Infliximab,Stress,OT
178572533,Infliximab,Product use issue,OT
178572533,Infliximab,Off label use,OT
178572533,Infliximab,Nausea,OT
178572533,Infliximab,Lethargy,OT
178572533,Infliximab,Intentional product use issue,OT
178572533,Infliximab,Inappropriate schedule of product administration,OT
178572533,Infliximab,Hypertension,OT
178572533,Infliximab,Heart rate irregular,OT
178572533,Infliximab,Fatigue,OT
178572533,Infliximab,Fall,OT
178572533,Infliximab,Decreased appetite,OT
178572533,Infliximab,Condition aggravated,OT
178572533,Infliximab,Concussion,OT
178572533,Infliximab,Body temperature fluctuation,OT
178572533,Infliximab,Blood pressure fluctuation,OT
178572533,Infliximab,Arthralgia,OT
178572533,Infliximab,Anxiety,OT
178572533,Infliximab,Anal incontinence,OT
183459593,Infliximab,Off label use,HO
183459593,Infliximab,Migraine,HO
183459593,Infliximab,Intentional product use issue,HO
183459593,Infliximab,Heart rate irregular,HO
183459593,Infliximab,Headache,HO
183459593,Infliximab,Condition aggravated,HO
183459593,Infliximab,Blood pressure fluctuation,HO
183459593,Infliximab,Off label use,HO
183459593,Infliximab,Migraine,HO
183459593,Infliximab,Intentional product use issue,HO
183459593,Infliximab,Heart rate irregular,HO
183459593,Infliximab,Headache,HO
183459593,Infliximab,Condition aggravated,HO
183459593,Infliximab,Blood pressure fluctuation,HO
183883283,Infliximab,Urinary tract infection,OT
183883283,Infliximab,Pyrexia,OT
183883283,Infliximab,Product use issue,OT
183883283,Infliximab,Off label use,OT
183883283,Infliximab,Intentional product use issue,OT
183883283,Infliximab,Inappropriate schedule of product administration,OT
183883283,Infliximab,Heart rate irregular,OT
183883283,Infliximab,Heart rate increased,OT
183883283,Infliximab,Cystitis,OT
183883283,Infliximab,Condition aggravated,OT
183883283,Infliximab,Blood pressure increased,OT
183883283,Infliximab,Blood pressure fluctuation,OT
183883283,Infliximab,Asthma,OT
183883283,Infliximab,Arthropathy,OT
183883283,Infliximab,Arthralgia,OT
183883283,Infliximab,Anxiety disorder,OT
183883283,Infliximab,Urinary tract infection,OT
183883283,Infliximab,Pyrexia,OT
183883283,Infliximab,Product use issue,OT
183883283,Infliximab,Off label use,OT
183883283,Infliximab,Intentional product use issue,OT
183883283,Infliximab,Inappropriate schedule of product administration,OT
183883283,Infliximab,Heart rate irregular,OT
183883283,Infliximab,Heart rate increased,OT
183883283,Infliximab,Cystitis,OT
183883283,Infliximab,Condition aggravated,OT
183883283,Infliximab,Blood pressure increased,OT
183883283,Infliximab,Blood pressure fluctuation,OT
183883283,Infliximab,Asthma,OT
183883283,Infliximab,Arthropathy,OT
183883283,Infliximab,Arthralgia,OT
183883283,Infliximab,Anxiety disorder,OT
183983243,Infliximab,Weight increased,HO
183983243,Infliximab,Weight increased,OT
183983243,Infliximab,Weight decreased,HO
183983243,Infliximab,Weight decreased,OT
183983243,Infliximab,Taste disorder,HO
183983243,Infliximab,Taste disorder,OT
183983243,Infliximab,Skin disorder,HO
183983243,Infliximab,Skin disorder,OT
183983243,Infliximab,Red blood cell count decreased,HO
183983243,Infliximab,Red blood cell count decreased,OT
183983243,Infliximab,Pericarditis,HO
183983243,Infliximab,Pericarditis,OT
183983243,Infliximab,Oxygen saturation decreased,HO
183983243,Infliximab,Oxygen saturation decreased,OT
183983243,Infliximab,Oxygen saturation abnormal,HO
183983243,Infliximab,Oxygen saturation abnormal,OT
183983243,Infliximab,Off label use,HO
183983243,Infliximab,Off label use,OT
183983243,Infliximab,Oesophageal haemorrhage,HO
183983243,Infliximab,Oesophageal haemorrhage,OT
183983243,Infliximab,Nausea,HO
183983243,Infliximab,Nausea,OT
183983243,Infliximab,Muscular weakness,HO
183983243,Infliximab,Muscular weakness,OT
183983243,Infliximab,Intentional product use issue,HO
183983243,Infliximab,Intentional product use issue,OT
183983243,Infliximab,Hyperthermia,HO
183983243,Infliximab,Hyperthermia,OT
183983243,Infliximab,Hypersomnia,HO
183983243,Infliximab,Hypersomnia,OT
183983243,Infliximab,Heart rate irregular,HO
183983243,Infliximab,Heart rate irregular,OT
183983243,Infliximab,Heart rate increased,HO
183983243,Infliximab,Heart rate increased,OT
183983243,Infliximab,Heart rate abnormal,HO
183983243,Infliximab,Heart rate abnormal,OT
183983243,Infliximab,Haemorrhage,HO
183983243,Infliximab,Haemorrhage,OT
183983243,Infliximab,Haemoglobin decreased,HO
183983243,Infliximab,Haemoglobin decreased,OT
183983243,Infliximab,Gallbladder disorder,HO
183983243,Infliximab,Gallbladder disorder,OT
183983243,Infliximab,Fatigue,HO
183983243,Infliximab,Fatigue,OT
183983243,Infliximab,Erythema nodosum,HO
183983243,Infliximab,Erythema nodosum,OT
183983243,Infliximab,Dyspnoea,HO
183983243,Infliximab,Dyspnoea,OT
183983243,Infliximab,Dysphagia,HO
183983243,Infliximab,Dysphagia,OT
183983243,Infliximab,Dyspepsia,HO
183983243,Infliximab,Dyspepsia,OT
183983243,Infliximab,Dehydration,HO
183983243,Infliximab,Dehydration,OT
183983243,Infliximab,Decreased appetite,HO
183983243,Infliximab,Decreased appetite,OT
183983243,Infliximab,Cystic fibrosis,HO
183983243,Infliximab,Cystic fibrosis,OT
183983243,Infliximab,Cough,HO
183983243,Infliximab,Cough,OT
183983243,Infliximab,Constipation,HO
183983243,Infliximab,Constipation,OT
183983243,Infliximab,Condition aggravated,HO
183983243,Infliximab,Condition aggravated,OT
183983243,Infliximab,Chronic obstructive pulmonary disease,HO
183983243,Infliximab,Chronic obstructive pulmonary disease,OT
183983243,Infliximab,Bronchitis,HO
183983243,Infliximab,Bronchitis,OT
183983243,Infliximab,Body temperature increased,HO
183983243,Infliximab,Body temperature increased,OT
183983243,Infliximab,Blood pressure increased,HO
183983243,Infliximab,Blood pressure increased,OT
183983243,Infliximab,Blood pressure fluctuation,HO
183983243,Infliximab,Blood pressure fluctuation,OT
183983243,Infliximab,Asthenia,HO
183983243,Infliximab,Asthenia,OT
183983243,Infliximab,Arthralgia,HO
183983243,Infliximab,Arthralgia,OT
183983243,Infliximab,Anaemia,HO
183983243,Infliximab,Anaemia,OT
183983243,Infliximab,Abdominal pain,HO
183983243,Infliximab,Abdominal pain,OT
183983243,Infliximab,Weight increased,HO
183983243,Infliximab,Weight increased,OT
183983243,Infliximab,Weight decreased,HO
183983243,Infliximab,Weight decreased,OT
183983243,Infliximab,Taste disorder,HO
183983243,Infliximab,Taste disorder,OT
183983243,Infliximab,Skin disorder,HO
183983243,Infliximab,Skin disorder,OT
183983243,Infliximab,Red blood cell count decreased,HO
183983243,Infliximab,Red blood cell count decreased,OT
183983243,Infliximab,Pericarditis,HO
183983243,Infliximab,Pericarditis,OT
183983243,Infliximab,Oxygen saturation decreased,HO
183983243,Infliximab,Oxygen saturation decreased,OT
183983243,Infliximab,Oxygen saturation abnormal,HO
183983243,Infliximab,Oxygen saturation abnormal,OT
183983243,Infliximab,Off label use,HO
183983243,Infliximab,Off label use,OT
183983243,Infliximab,Oesophageal haemorrhage,HO
183983243,Infliximab,Oesophageal haemorrhage,OT
183983243,Infliximab,Nausea,HO
183983243,Infliximab,Nausea,OT
183983243,Infliximab,Muscular weakness,HO
183983243,Infliximab,Muscular weakness,OT
183983243,Infliximab,Intentional product use issue,HO
183983243,Infliximab,Intentional product use issue,OT
183983243,Infliximab,Hyperthermia,HO
183983243,Infliximab,Hyperthermia,OT
183983243,Infliximab,Hypersomnia,HO
183983243,Infliximab,Hypersomnia,OT
183983243,Infliximab,Heart rate irregular,HO
183983243,Infliximab,Heart rate irregular,OT
183983243,Infliximab,Heart rate increased,HO
183983243,Infliximab,Heart rate increased,OT
183983243,Infliximab,Heart rate abnormal,HO
183983243,Infliximab,Heart rate abnormal,OT
183983243,Infliximab,Haemorrhage,HO
183983243,Infliximab,Haemorrhage,OT
183983243,Infliximab,Haemoglobin decreased,HO
183983243,Infliximab,Haemoglobin decreased,OT
183983243,Infliximab,Gallbladder disorder,HO
183983243,Infliximab,Gallbladder disorder,OT
183983243,Infliximab,Fatigue,HO
183983243,Infliximab,Fatigue,OT
183983243,Infliximab,Erythema nodosum,HO
183983243,Infliximab,Erythema nodosum,OT
183983243,Infliximab,Dyspnoea,HO
183983243,Infliximab,Dyspnoea,OT
183983243,Infliximab,Dysphagia,HO
183983243,Infliximab,Dysphagia,OT
183983243,Infliximab,Dyspepsia,HO
183983243,Infliximab,Dyspepsia,OT
183983243,Infliximab,Dehydration,HO
183983243,Infliximab,Dehydration,OT
183983243,Infliximab,Decreased appetite,HO
183983243,Infliximab,Decreased appetite,OT
183983243,Infliximab,Cystic fibrosis,HO
183983243,Infliximab,Cystic fibrosis,OT
183983243,Infliximab,Cough,HO
183983243,Infliximab,Cough,OT
183983243,Infliximab,Constipation,HO
183983243,Infliximab,Constipation,OT
183983243,Infliximab,Condition aggravated,HO
183983243,Infliximab,Condition aggravated,OT
183983243,Infliximab,Chronic obstructive pulmonary disease,HO
183983243,Infliximab,Chronic obstructive pulmonary disease,OT
183983243,Infliximab,Bronchitis,HO
183983243,Infliximab,Bronchitis,OT
183983243,Infliximab,Body temperature increased,HO
183983243,Infliximab,Body temperature increased,OT
183983243,Infliximab,Blood pressure increased,HO
183983243,Infliximab,Blood pressure increased,OT
183983243,Infliximab,Blood pressure fluctuation,HO
183983243,Infliximab,Blood pressure fluctuation,OT
183983243,Infliximab,Asthenia,HO
183983243,Infliximab,Asthenia,OT
183983243,Infliximab,Arthralgia,HO
183983243,Infliximab,Arthralgia,OT
183983243,Infliximab,Anaemia,HO
183983243,Infliximab,Anaemia,OT
183983243,Infliximab,Abdominal pain,HO
183983243,Infliximab,Abdominal pain,OT
184202473,Infliximab,Weight increased,OT
184202473,Infliximab,Weight fluctuation,OT
184202473,Infliximab,Somnolence,OT
184202473,Infliximab,Rash pruritic,OT
184202473,Infliximab,Rash,OT
184202473,Infliximab,Pruritus,OT
184202473,Infliximab,Product use issue,OT
184202473,Infliximab,Pain in extremity,OT
184202473,Infliximab,Pain,OT
184202473,Infliximab,Off label use,OT
184202473,Infliximab,Nasopharyngitis,OT
184202473,Infliximab,Nasal dryness,OT
184202473,Infliximab,Myalgia,OT
184202473,Infliximab,Muscular weakness,OT
184202473,Infliximab,Malaise,OT
184202473,Infliximab,Kidney infection,OT
184202473,Infliximab,Joint swelling,OT
184202473,Infliximab,Incorrect dose administered,OT
184202473,Infliximab,Inappropriate schedule of product administration,OT
184202473,Infliximab,Hypertension,OT
184202473,Infliximab,Headache,OT
184202473,Infliximab,Gingival bleeding,OT
184202473,Infliximab,Gait disturbance,OT
184202473,Infliximab,Feeling cold,OT
184202473,Infliximab,Fatigue,OT
184202473,Infliximab,Eye swelling,OT
184202473,Infliximab,Epistaxis,OT
184202473,Infliximab,Cystitis,OT
184202473,Infliximab,Body temperature increased,OT
184202473,Infliximab,Blood pressure fluctuation,OT
184202473,Infliximab,Asthenia,OT
184202473,Infliximab,Arthralgia,OT
184202473,Infliximab,Weight increased,OT
184202473,Infliximab,Weight fluctuation,OT
184202473,Infliximab,Somnolence,OT
184202473,Infliximab,Rash pruritic,OT
184202473,Infliximab,Rash,OT
184202473,Infliximab,Pruritus,OT
184202473,Infliximab,Product use issue,OT
184202473,Infliximab,Pain in extremity,OT
184202473,Infliximab,Pain,OT
184202473,Infliximab,Off label use,OT
184202473,Infliximab,Nasopharyngitis,OT
184202473,Infliximab,Nasal dryness,OT
184202473,Infliximab,Myalgia,OT
184202473,Infliximab,Muscular weakness,OT
184202473,Infliximab,Malaise,OT
184202473,Infliximab,Kidney infection,OT
184202473,Infliximab,Joint swelling,OT
184202473,Infliximab,Incorrect dose administered,OT
184202473,Infliximab,Inappropriate schedule of product administration,OT
184202473,Infliximab,Hypertension,OT
184202473,Infliximab,Headache,OT
184202473,Infliximab,Gingival bleeding,OT
184202473,Infliximab,Gait disturbance,OT
184202473,Infliximab,Feeling cold,OT
184202473,Infliximab,Fatigue,OT
184202473,Infliximab,Eye swelling,OT
184202473,Infliximab,Epistaxis,OT
184202473,Infliximab,Cystitis,OT
184202473,Infliximab,Body temperature increased,OT
184202473,Infliximab,Blood pressure fluctuation,OT
184202473,Infliximab,Asthenia,OT
184202473,Infliximab,Arthralgia,OT
184202473,Infliximab,Weight increased,OT
184202473,Infliximab,Weight fluctuation,OT
184202473,Infliximab,Somnolence,OT
184202473,Infliximab,Rash pruritic,OT
184202473,Infliximab,Rash,OT
184202473,Infliximab,Pruritus,OT
184202473,Infliximab,Product use issue,OT
184202473,Infliximab,Pain in extremity,OT
184202473,Infliximab,Pain,OT
184202473,Infliximab,Off label use,OT
184202473,Infliximab,Nasopharyngitis,OT
184202473,Infliximab,Nasal dryness,OT
184202473,Infliximab,Myalgia,OT
184202473,Infliximab,Muscular weakness,OT
184202473,Infliximab,Malaise,OT
184202473,Infliximab,Kidney infection,OT
184202473,Infliximab,Joint swelling,OT
184202473,Infliximab,Incorrect dose administered,OT
184202473,Infliximab,Inappropriate schedule of product administration,OT
184202473,Infliximab,Hypertension,OT
184202473,Infliximab,Headache,OT
184202473,Infliximab,Gingival bleeding,OT
184202473,Infliximab,Gait disturbance,OT
184202473,Infliximab,Feeling cold,OT
184202473,Infliximab,Fatigue,OT
184202473,Infliximab,Eye swelling,OT
184202473,Infliximab,Epistaxis,OT
184202473,Infliximab,Cystitis,OT
184202473,Infliximab,Body temperature increased,OT
184202473,Infliximab,Blood pressure fluctuation,OT
184202473,Infliximab,Asthenia,OT
184202473,Infliximab,Arthralgia,OT
185181283,Infliximab,Weight decreased,HO
185181283,Infliximab,Weight decreased,OT
185181283,Infliximab,Vitreous disorder,HO
185181283,Infliximab,Vitreous disorder,OT
185181283,Infliximab,Steroid dependence,HO
185181283,Infliximab,Steroid dependence,OT
185181283,Infliximab,Skin disorder,HO
185181283,Infliximab,Skin disorder,OT
185181283,Infliximab,Scleral discolouration,HO
185181283,Infliximab,Scleral discolouration,OT
185181283,Infliximab,Peripheral swelling,HO
185181283,Infliximab,Peripheral swelling,OT
185181283,Infliximab,Off label use,HO
185181283,Infliximab,Off label use,OT
185181283,Infliximab,Limb mass,HO
185181283,Infliximab,Limb mass,OT
185181283,Infliximab,Inflammation,HO
185181283,Infliximab,Inflammation,OT
185181283,Infliximab,Heart rate decreased,HO
185181283,Infliximab,Heart rate decreased,OT
185181283,Infliximab,Haemorrhage,HO
185181283,Infliximab,Haemorrhage,OT
185181283,Infliximab,Gait inability,HO
185181283,Infliximab,Gait inability,OT
185181283,Infliximab,Furuncle,HO
185181283,Infliximab,Furuncle,OT
185181283,Infliximab,Flushing,HO
185181283,Infliximab,Flushing,OT
185181283,Infliximab,Fatigue,HO
185181283,Infliximab,Fatigue,OT
185181283,Infliximab,Drug specific antibody present,HO
185181283,Infliximab,Drug specific antibody present,OT
185181283,Infliximab,Drug level decreased,HO
185181283,Infliximab,Drug level decreased,OT
185181283,Infliximab,Drug level below therapeutic,HO
185181283,Infliximab,Drug level below therapeutic,OT
185181283,Infliximab,Diarrhoea,HO
185181283,Infliximab,Diarrhoea,OT
185181283,Infliximab,Condition aggravated,HO
185181283,Infliximab,Condition aggravated,OT
185181283,Infliximab,Clostridium difficile infection,HO
185181283,Infliximab,Clostridium difficile infection,OT
185181283,Infliximab,Chest discomfort,HO
185181283,Infliximab,Chest discomfort,OT
185181283,Infliximab,C-reactive protein decreased,HO
185181283,Infliximab,C-reactive protein decreased,OT
185181283,Infliximab,Blood pressure increased,HO
185181283,Infliximab,Blood pressure increased,OT
185181283,Infliximab,Blood pressure fluctuation,HO
185181283,Infliximab,Blood pressure fluctuation,OT
185181283,Infliximab,Blindness unilateral,HO
185181283,Infliximab,Blindness unilateral,OT
185181283,Infliximab,Back pain,HO
185181283,Infliximab,Back pain,OT
185181283,Infliximab,Arthropathy,HO
185181283,Infliximab,Arthropathy,OT
185181283,Infliximab,Arthralgia,HO
185181283,Infliximab,Arthralgia,OT
185181283,Infliximab,Acne,HO
185181283,Infliximab,Acne,OT
185181283,Infliximab,Weight decreased,HO
185181283,Infliximab,Weight decreased,OT
185181283,Infliximab,Vitreous disorder,HO
185181283,Infliximab,Vitreous disorder,OT
185181283,Infliximab,Steroid dependence,HO
185181283,Infliximab,Steroid dependence,OT
185181283,Infliximab,Skin disorder,HO
185181283,Infliximab,Skin disorder,OT
185181283,Infliximab,Scleral discolouration,HO
185181283,Infliximab,Scleral discolouration,OT
185181283,Infliximab,Peripheral swelling,HO
185181283,Infliximab,Peripheral swelling,OT
185181283,Infliximab,Off label use,HO
185181283,Infliximab,Off label use,OT
185181283,Infliximab,Limb mass,HO
185181283,Infliximab,Limb mass,OT
185181283,Infliximab,Inflammation,HO
185181283,Infliximab,Inflammation,OT
185181283,Infliximab,Heart rate decreased,HO
185181283,Infliximab,Heart rate decreased,OT
185181283,Infliximab,Haemorrhage,HO
185181283,Infliximab,Haemorrhage,OT
185181283,Infliximab,Gait inability,HO
185181283,Infliximab,Gait inability,OT
185181283,Infliximab,Furuncle,HO
185181283,Infliximab,Furuncle,OT
185181283,Infliximab,Flushing,HO
185181283,Infliximab,Flushing,OT
185181283,Infliximab,Fatigue,HO
185181283,Infliximab,Fatigue,OT
185181283,Infliximab,Drug specific antibody present,HO
185181283,Infliximab,Drug specific antibody present,OT
185181283,Infliximab,Drug level decreased,HO
185181283,Infliximab,Drug level decreased,OT
185181283,Infliximab,Drug level below therapeutic,HO
185181283,Infliximab,Drug level below therapeutic,OT
185181283,Infliximab,Diarrhoea,HO
185181283,Infliximab,Diarrhoea,OT
185181283,Infliximab,Condition aggravated,HO
185181283,Infliximab,Condition aggravated,OT
185181283,Infliximab,Clostridium difficile infection,HO
185181283,Infliximab,Clostridium difficile infection,OT
185181283,Infliximab,Chest discomfort,HO
185181283,Infliximab,Chest discomfort,OT
185181283,Infliximab,C-reactive protein decreased,HO
185181283,Infliximab,C-reactive protein decreased,OT
185181283,Infliximab,Blood pressure increased,HO
185181283,Infliximab,Blood pressure increased,OT
185181283,Infliximab,Blood pressure fluctuation,HO
185181283,Infliximab,Blood pressure fluctuation,OT
185181283,Infliximab,Blindness unilateral,HO
185181283,Infliximab,Blindness unilateral,OT
185181283,Infliximab,Back pain,HO
185181283,Infliximab,Back pain,OT
185181283,Infliximab,Arthropathy,HO
185181283,Infliximab,Arthropathy,OT
185181283,Infliximab,Arthralgia,HO
185181283,Infliximab,Arthralgia,OT
185181283,Infliximab,Acne,HO
185181283,Infliximab,Acne,OT
185237913,Infliximab,Vulvovaginal mycotic infection,OT
185237913,Infliximab,Vomiting,OT
185237913,Infliximab,Urinary tract infection,OT
185237913,Infliximab,Suspected COVID-19,OT
185237913,Infliximab,Rhinorrhoea,OT
185237913,Infliximab,Renal pain,OT
185237913,Infliximab,Renal cyst infection,OT
185237913,Infliximab,Renal colic,OT
185237913,Infliximab,Rash pruritic,OT
185237913,Infliximab,Pyrexia,OT
185237913,Infliximab,Pyelonephritis,OT
185237913,Infliximab,Phobia,OT
185237913,Infliximab,Oropharyngeal pain,OT
185237913,Infliximab,Off label use,OT
185237913,Infliximab,Nephritis,OT
185237913,Infliximab,Nausea,OT
185237913,Infliximab,Malaise,OT
185237913,Infliximab,Intentional product use issue,OT
185237913,Infliximab,Inappropriate schedule of product administration,OT
185237913,Infliximab,Illness,OT
185237913,Infliximab,Headache,OT
185237913,Infliximab,Fatigue,OT
185237913,Infliximab,Cough,OT
185237913,Infliximab,Chills,OT
185237913,Infliximab,Bladder disorder,OT
185244203,Infliximab,Weight increased,HO
185244203,Infliximab,Weight decreased,HO
185244203,Infliximab,Vomiting,HO
185244203,Infliximab,Pyrexia,HO
185244203,Infliximab,Product use issue,HO
185244203,Infliximab,Off label use,HO
185244203,Infliximab,Intentional product use issue,HO
185244203,Infliximab,Incorrect dose administered,HO
185244203,Infliximab,Heart rate increased,HO
185244203,Infliximab,Drug level below therapeutic,HO
185244203,Infliximab,Condition aggravated,HO
185244203,Infliximab,Chills,HO
185244203,Infliximab,Blood pressure systolic increased,HO
185581123,Infliximab,Product use issue,OT
185581123,Infliximab,Off label use,OT
185581123,Infliximab,Malaise,OT
185581123,Infliximab,Intentional product use issue,OT
185581123,Infliximab,Incorrect dose administered,OT
185581123,Infliximab,Inappropriate schedule of product administration,OT
185581123,Infliximab,Illness,OT
185581123,Infliximab,Drug specific antibody present,OT
185581123,Infliximab,Drug specific antibody,OT
185581123,Infliximab,Drug level increased,OT
185581123,Infliximab,Drug level below therapeutic,OT
185581123,Infliximab,Cough,OT
185581123,Infliximab,Condition aggravated,OT
185581123,Infliximab,Blood pressure increased,OT
185581123,Infliximab,Blood pressure fluctuation,OT
187577513,Infliximab,Off label use,OT
187577513,Infliximab,Intentional product use issue,OT
187577513,Infliximab,Inappropriate schedule of product administration,OT
187577513,Infliximab,Impaired work ability,OT
187577513,Infliximab,Impaired quality of life,OT
187577513,Infliximab,Heart rate decreased,OT
187577513,Infliximab,Feeling abnormal,OT
187577513,Infliximab,Drug ineffective,OT
187577513,Infliximab,Condition aggravated,OT
187577513,Infliximab,COVID-19,OT
187577513,Infliximab,Blood pressure fluctuation,OT
192070942,Infliximab,Weight decreased,HO
192070942,Infliximab,Off label use,HO
192070942,Infliximab,Memory impairment,HO
192070942,Infliximab,Intentional product use issue,HO
192070942,Infliximab,Infusion site pain,HO
192070942,Infliximab,Infusion site oedema,HO
192070942,Infliximab,Infusion site extravasation,HO
192070942,Infliximab,Inappropriate schedule of product administration,HO
192070942,Infliximab,Condition aggravated,HO
195041461,Infliximab,Swelling face,OT
195041461,Infliximab,Skin disorder,OT
195041461,Infliximab,Rosacea,OT
195041461,Infliximab,Product use issue,OT
195041461,Infliximab,Off label use,OT
195041461,Infliximab,Lymphadenopathy,OT
195041461,Infliximab,Lymph node pain,OT
195041461,Infliximab,Inflammation,OT
195041461,Infliximab,Inappropriate schedule of product administration,OT
195041461,Infliximab,Gastrointestinal hypomotility,OT
195041461,Infliximab,Faecal calprotectin increased,OT
195041461,Infliximab,Facial pain,OT
195041461,Infliximab,Eye irritation,OT
195041461,Infliximab,Erythema,OT
195041461,Infliximab,Dry eye,OT
195041461,Infliximab,Constipation,OT
195041461,Infliximab,Blood pressure diastolic decreased,OT
195041461,Infliximab,Abnormal faeces,OT
196025551,Infliximab,Weight decreased,OT
196025551,Infliximab,Weight decreased,HO
196025551,Infliximab,Weight decreased,DE
196025551,Infliximab,Sepsis,OT
196025551,Infliximab,Sepsis,HO
196025551,Infliximab,Sepsis,DE
196025551,Infliximab,Pruritus,OT
196025551,Infliximab,Pruritus,HO
196025551,Infliximab,Pruritus,DE
196025551,Infliximab,Pain,OT
196025551,Infliximab,Pain,HO
196025551,Infliximab,Pain,DE
196025551,Infliximab,Off label use,OT
196025551,Infliximab,Off label use,HO
196025551,Infliximab,Off label use,DE
196025551,Infliximab,Nasopharyngitis,OT
196025551,Infliximab,Nasopharyngitis,HO
196025551,Infliximab,Nasopharyngitis,DE
196025551,Infliximab,Muscle atrophy,OT
196025551,Infliximab,Muscle atrophy,HO
196025551,Infliximab,Muscle atrophy,DE
196025551,Infliximab,Malaise,OT
196025551,Infliximab,Malaise,HO
196025551,Infliximab,Malaise,DE
196025551,Infliximab,Limb injury,OT
196025551,Infliximab,Limb injury,HO
196025551,Infliximab,Limb injury,DE
196025551,Infliximab,Intentional product use issue,OT
196025551,Infliximab,Intentional product use issue,HO
196025551,Infliximab,Intentional product use issue,DE
196025551,Infliximab,Heart rate irregular,OT
196025551,Infliximab,Heart rate irregular,HO
196025551,Infliximab,Heart rate irregular,DE
196025551,Infliximab,Heart rate decreased,OT
196025551,Infliximab,Heart rate decreased,HO
196025551,Infliximab,Heart rate decreased,DE
196025551,Infliximab,Fall,OT
196025551,Infliximab,Fall,HO
196025551,Infliximab,Fall,DE
196025551,Infliximab,Faecal calprotectin increased,OT
196025551,Infliximab,Faecal calprotectin increased,HO
196025551,Infliximab,Faecal calprotectin increased,DE
196025551,Infliximab,Drug specific antibody,OT
196025551,Infliximab,Drug specific antibody,HO
196025551,Infliximab,Drug specific antibody,DE
196025551,Infliximab,Drug level below therapeutic,OT
196025551,Infliximab,Drug level below therapeutic,HO
196025551,Infliximab,Drug level below therapeutic,DE
196025551,Infliximab,Diabetes mellitus,OT
196025551,Infliximab,Diabetes mellitus,HO
196025551,Infliximab,Diabetes mellitus,DE
196025551,Infliximab,Death,OT
196025551,Infliximab,Death,HO
196025551,Infliximab,Death,DE
196025551,Infliximab,Condition aggravated,OT
196025551,Infliximab,Condition aggravated,HO
196025551,Infliximab,Condition aggravated,DE
196025551,Infliximab,Carbohydrate antigen 19-9 increased,OT
196025551,Infliximab,Carbohydrate antigen 19-9 increased,HO
196025551,Infliximab,Carbohydrate antigen 19-9 increased,DE
196025551,Infliximab,Blood pressure increased,OT
196025551,Infliximab,Blood pressure increased,HO
196025551,Infliximab,Blood pressure increased,DE
196025551,Infliximab,Blood pressure fluctuation,OT
196025551,Infliximab,Blood pressure fluctuation,HO
196025551,Infliximab,Blood pressure fluctuation,DE
196025551,Infliximab,Autoimmune myositis,OT
196025551,Infliximab,Autoimmune myositis,HO
196025551,Infliximab,Autoimmune myositis,DE
196025551,Infliximab,Asthenia,OT
196025551,Infliximab,Asthenia,HO
196025551,Infliximab,Asthenia,DE
196025551,Infliximab,Arthralgia,OT
196025551,Infliximab,Arthralgia,HO
196025551,Infliximab,Arthralgia,DE
196078341,Infliximab,Ulcer,OT
196078341,Infliximab,Ulcer,HO
196078341,Infliximab,Therapeutic response decreased,OT
196078341,Infliximab,Therapeutic response decreased,HO
196078341,Infliximab,Therapeutic product effect incomplete,OT
196078341,Infliximab,Therapeutic product effect incomplete,HO
196078341,Infliximab,Therapeutic product effect decreased,OT
196078341,Infliximab,Therapeutic product effect decreased,HO
196078341,Infliximab,Skin ulcer,OT
196078341,Infliximab,Skin ulcer,HO
196078341,Infliximab,Skin necrosis,OT
196078341,Infliximab,Skin necrosis,HO
196078341,Infliximab,Rheumatoid nodule,OT
196078341,Infliximab,Rheumatoid nodule,HO
196078341,Infliximab,Rheumatoid arthritis,OT
196078341,Infliximab,Rheumatoid arthritis,HO
196078341,Infliximab,Red blood cell sedimentation rate increased,OT
196078341,Infliximab,Red blood cell sedimentation rate increased,HO
196078341,Infliximab,Rash pruritic,OT
196078341,Infliximab,Rash pruritic,HO
196078341,Infliximab,Rash,OT
196078341,Infliximab,Rash,HO
196078341,Infliximab,Product use issue,OT
196078341,Infliximab,Product use issue,HO
196078341,Infliximab,Peripheral swelling,OT
196078341,Infliximab,Peripheral swelling,HO
196078341,Infliximab,Panniculitis,OT
196078341,Infliximab,Panniculitis,HO
196078341,Infliximab,Pain,OT
196078341,Infliximab,Pain,HO
196078341,Infliximab,Off label use,OT
196078341,Infliximab,Off label use,HO
196078341,Infliximab,Musculoskeletal stiffness,OT
196078341,Infliximab,Musculoskeletal stiffness,HO
196078341,Infliximab,Loss of personal independence in daily activities,OT
196078341,Infliximab,Loss of personal independence in daily activities,HO
196078341,Infliximab,Infusion related reaction,OT
196078341,Infliximab,Infusion related reaction,HO
196078341,Infliximab,Inflammation,OT
196078341,Infliximab,Inflammation,HO
196078341,Infliximab,Hypersensitivity,OT
196078341,Infliximab,Hypersensitivity,HO
196078341,Infliximab,Hypercalcaemia,OT
196078341,Infliximab,Hypercalcaemia,HO
196078341,Infliximab,Granuloma skin,OT
196078341,Infliximab,Granuloma skin,HO
196078341,Infliximab,Gastric disorder,OT
196078341,Infliximab,Gastric disorder,HO
196078341,Infliximab,Erythema,OT
196078341,Infliximab,Erythema,HO
196078341,Infliximab,Drug tolerance decreased,OT
196078341,Infliximab,Drug tolerance decreased,HO
196078341,Infliximab,Drug tolerance,OT
196078341,Infliximab,Drug tolerance,HO
196078341,Infliximab,Drug intolerance,OT
196078341,Infliximab,Drug intolerance,HO
196078341,Infliximab,Drug ineffective,OT
196078341,Infliximab,Drug ineffective,HO
196078341,Infliximab,Drug hypersensitivity,OT
196078341,Infliximab,Drug hypersensitivity,HO
196078341,Infliximab,Drug eruption,OT
196078341,Infliximab,Drug eruption,HO
196078341,Infliximab,Contraindicated product administered,OT
196078341,Infliximab,Contraindicated product administered,HO
196078341,Infliximab,Condition aggravated,OT
196078341,Infliximab,Condition aggravated,HO
196078341,Infliximab,C-reactive protein increased,OT
196078341,Infliximab,C-reactive protein increased,HO
196078341,Infliximab,Blood parathyroid hormone decreased,OT
196078341,Infliximab,Blood parathyroid hormone decreased,HO
196078341,Infliximab,Basal cell carcinoma,OT
196078341,Infliximab,Basal cell carcinoma,HO
196078341,Infliximab,Aspartate aminotransferase increased,OT
196078341,Infliximab,Aspartate aminotransferase increased,HO
196078341,Infliximab,Arthralgia,OT
196078341,Infliximab,Arthralgia,HO
196078341,Infliximab,Alopecia,OT
196078341,Infliximab,Alopecia,HO
196078341,Infliximab,Alanine aminotransferase increased,OT
196078341,Infliximab,Alanine aminotransferase increased,HO
196078341,Infliximab,Adverse event,OT
196078341,Infliximab,Adverse event,HO
196150001,Infliximab,Off label use,OT
196150001,Infliximab,Impaired quality of life,OT
196150001,Infliximab,Condition aggravated,OT
196651211,Infliximab (Unknown),VACTERL syndrome,CA
196651211,Infliximab (Unknown),Talipes,CA
196651211,Infliximab (Unknown),Renal aplasia,CA
196651211,Infliximab (Unknown),Oesophageal atresia,CA
196651211,Infliximab (Unknown),Maternal exposure before pregnancy,CA
196651211,Infliximab (Unknown),Foetal exposure during pregnancy,CA
196651211,Infliximab (Unknown),Congenital ureteric anomaly,CA
196651211,Infliximab (Unknown),Abortion induced,CA
196854061,Infliximab,Thrombosis,OT
196854061,Infliximab,Exposure during pregnancy,OT
196854061,Infliximab,Anaemia,OT
197027021,Infliximab (Unknown),Takayasu's arteritis,OT
197027021,Infliximab (Unknown),Off label use,OT
197027021,Infliximab (Unknown),Neuropathy peripheral,OT
197027021,Infliximab (Unknown),Condition aggravated,OT
197070921,Infliximab,Weight increased,OT
197070921,Infliximab,Product use issue,OT
197070921,Infliximab,Periorbital cellulitis,OT
197070921,Infliximab,Off label use,OT
197070921,Infliximab,Intentional product use issue,OT
197070921,Infliximab,Inappropriate schedule of product administration,OT
197070921,Infliximab,Condition aggravated,OT
197070921,Infliximab,Cardiovascular disorder,OT
197070921,Infliximab,Alopecia,OT
197425501,Infliximab,Wound,OT
197425501,Infliximab,Visual impairment,OT
197425501,Infliximab,Treatment failure,OT
197425501,Infliximab,Therapeutic product effect incomplete,OT
197425501,Infliximab,Therapeutic product effect decreased,OT
197425501,Infliximab,Systemic lupus erythematosus,OT
197425501,Infliximab,Synovitis,OT
197425501,Infliximab,Rheumatoid factor positive,OT
197425501,Infliximab,Rheumatoid arthritis,OT
197425501,Infliximab,Retinitis,OT
197425501,Infliximab,Red blood cell sedimentation rate increased,OT
197425501,Infliximab,Rash,OT
197425501,Infliximab,Product use issue,OT
197425501,Infliximab,Product use in unapproved indication,OT
197425501,Infliximab,Pneumonia,OT
197425501,Infliximab,Pericarditis,OT
197425501,Infliximab,Pemphigus,OT
197425501,Infliximab,Pain in extremity,OT
197425501,Infliximab,Pain,OT
197425501,Infliximab,Osteoporosis,OT
197425501,Infliximab,Osteoarthritis,OT
197425501,Infliximab,Off label use,OT
197425501,Infliximab,Oedema peripheral,OT
197425501,Infliximab,Nausea,OT
197425501,Infliximab,Musculoskeletal stiffness,OT
197425501,Infliximab,Mobility decreased,OT
197425501,Infliximab,Malaise,OT
197425501,Infliximab,Lupus-like syndrome,OT
197425501,Infliximab,Laryngitis,OT
197425501,Infliximab,Joint swelling,OT
197425501,Infliximab,Joint stiffness,OT
197425501,Infliximab,Joint dislocation,OT
197425501,Infliximab,Infusion related reaction,OT
197425501,Infliximab,Infection,OT
197425501,Infliximab,Hypoaesthesia,OT
197425501,Infliximab,Hypersensitivity,OT
197425501,Infliximab,Hepatic enzyme increased,OT
197425501,Infliximab,Hepatic cirrhosis,OT
197425501,Infliximab,Headache,OT
197425501,Infliximab,Hand deformity,OT
197425501,Infliximab,Glossodynia,OT
197425501,Infliximab,General physical health deterioration,OT
197425501,Infliximab,Foot deformity,OT
197425501,Infliximab,Fatigue,OT
197425501,Infliximab,Exposure during pregnancy,OT
197425501,Infliximab,Exostosis,OT
197425501,Infliximab,Ear infection,OT
197425501,Infliximab,Drug intolerance,OT
197425501,Infliximab,Drug ineffective,OT
197425501,Infliximab,Drug hypersensitivity,OT
197425501,Infliximab,Dizziness,OT
197425501,Infliximab,Discomfort,OT
197425501,Infliximab,Decreased appetite,OT
197425501,Infliximab,Crohn's disease,OT
197425501,Infliximab,Contraindicated product administered,OT
197425501,Infliximab,Condition aggravated,OT
197425501,Infliximab,C-reactive protein increased,OT
197425501,Infliximab,Bone erosion,OT
197425501,Infliximab,Arthritis,OT
197425501,Infliximab,Arthralgia,OT
197425501,Infliximab,Anti-cyclic citrullinated peptide antibody positive,OT
197425501,Infliximab,Alopecia,OT
197425501,Infliximab,Adverse drug reaction,OT
197425501,Infliximab,Abdominal discomfort,OT
197575321,Infliximab,Weight increased,OT
197575321,Infliximab,Weight decreased,OT
197575321,Infliximab,Therapeutic response shortened,OT
197575321,Infliximab,Syncope,OT
197575321,Infliximab,Rash,OT
197575321,Infliximab,Peripheral coldness,OT
197575321,Infliximab,Off label use,OT
197575321,Infliximab,Hypotension,OT
197575321,Infliximab,Heart rate decreased,OT
197575321,Infliximab,Dizziness,OT
197575321,Infliximab,Condition aggravated,OT
197575321,Infliximab,Body temperature fluctuation,OT
197575321,Infliximab,Blood pressure diastolic decreased,OT
197576171,Infliximab,Toothache,OT
197576171,Infliximab,Therapeutic product effect incomplete,OT
197576171,Infliximab,Peripheral coldness,OT
197576171,Infliximab,Off label use,OT
197576171,Infliximab,Inappropriate schedule of product administration,OT
197576171,Infliximab,Hypertension,OT
197576171,Infliximab,Hyperaesthesia teeth,OT
197576171,Infliximab,Heart rate decreased,OT
197576171,Infliximab,Glaucoma,OT
197576171,Infliximab,Eye irritation,OT
197576171,Infliximab,Diarrhoea,OT
197576171,Infliximab,Diabetes mellitus,OT
197576171,Infliximab,Blood pressure fluctuation,OT
197576171,Infliximab,Anal fissure,OT
197995911,Infliximab,Weight decreased,OT
197995911,Infliximab,Therapeutic response shortened,OT
197995911,Infliximab,Off label use,OT
197995911,Infliximab,Heart rate decreased,OT
197995911,Infliximab,Eating disorder,OT
197995911,Infliximab,Drug level below therapeutic,OT
197995911,Infliximab,Drug ineffective,OT
197995911,Infliximab,Condition aggravated,OT
197995911,Infliximab,Arthralgia,OT
197995911,Infliximab,Anaemia,OT
197995911,Infliximab,Abdominal pain upper,OT
198293901,Infliximab,Off label use,HO
198293901,Infliximab,Melkersson-Rosenthal syndrome,HO
198293901,Infliximab,Drug ineffective for unapproved indication,HO
198293901,Infliximab,Off label use,HO
198293901,Infliximab,Melkersson-Rosenthal syndrome,HO
198293901,Infliximab,Drug ineffective for unapproved indication,HO
198912761,Infliximab,Inappropriate schedule of product administration,DE
198912761,Infliximab,Drug ineffective,DE
198912761,Infliximab,Death,DE
165083514,Infliximab,Product use issue,OT
165083514,Infliximab,Off label use,OT
165083514,Infliximab,Intentional product use issue,OT
165083514,Infliximab,Incorrect dose administered,OT
165083514,Infliximab,Inappropriate schedule of product administration,OT
165083514,Infliximab,Hypertension,OT
165083514,Infliximab,Hip fracture,OT
165083514,Infliximab,Drug level below therapeutic,OT
165083514,Infliximab,Condition aggravated,OT
165083514,Infliximab,Blood pressure increased,OT
165083514,Infliximab,Blood pressure fluctuation,OT
165083514,Infliximab,Arthralgia,OT
165083514,Infliximab,Product use issue,OT
165083514,Infliximab,Off label use,OT
165083514,Infliximab,Intentional product use issue,OT
165083514,Infliximab,Incorrect dose administered,OT
165083514,Infliximab,Inappropriate schedule of product administration,OT
165083514,Infliximab,Hypertension,OT
165083514,Infliximab,Hip fracture,OT
165083514,Infliximab,Drug level below therapeutic,OT
165083514,Infliximab,Condition aggravated,OT
165083514,Infliximab,Blood pressure increased,OT
165083514,Infliximab,Blood pressure fluctuation,OT
165083514,Infliximab,Arthralgia,OT
166843535,Infliximab,Pancreatitis,OT
166843535,Infliximab,Drug intolerance,OT
166843535,Infliximab,Pancreatitis,OT
166843535,Infliximab,Drug intolerance,OT
166843535,Infliximab,Pancreatitis,OT
166843535,Infliximab,Drug intolerance,OT
166846073,Infliximab,Weight decreased,HO
166846073,Infliximab,Weight decreased,OT
166846073,Infliximab,Insomnia,HO
166846073,Infliximab,Insomnia,OT
166846073,Infliximab,Incorrect dose administered,HO
166846073,Infliximab,Incorrect dose administered,OT
166846073,Infliximab,Fatigue,HO
166846073,Infliximab,Fatigue,OT
166846073,Infliximab,Fall,HO
166846073,Infliximab,Fall,OT
166846073,Infliximab,Ear pain,HO
166846073,Infliximab,Ear pain,OT
166846073,Infliximab,Condition aggravated,HO
166846073,Infliximab,Condition aggravated,OT
166846073,Infliximab,Body temperature decreased,HO
166846073,Infliximab,Body temperature decreased,OT
166846073,Infliximab,Blood pressure increased,HO
166846073,Infliximab,Blood pressure increased,OT
166846073,Infliximab,Blood pressure fluctuation,HO
166846073,Infliximab,Blood pressure fluctuation,OT
166846073,Infliximab,Back pain,HO
166846073,Infliximab,Back pain,OT
166846073,Infliximab,Anal fistula,HO
166846073,Infliximab,Anal fistula,OT
166846073,Infliximab,Anal fissure,HO
166846073,Infliximab,Anal fissure,OT
166846073,Infliximab,Anal abscess,HO
166846073,Infliximab,Anal abscess,OT
166846073,Infliximab,Weight decreased,HO
166846073,Infliximab,Weight decreased,OT
166846073,Infliximab,Insomnia,HO
166846073,Infliximab,Insomnia,OT
166846073,Infliximab,Incorrect dose administered,HO
166846073,Infliximab,Incorrect dose administered,OT
166846073,Infliximab,Fatigue,HO
166846073,Infliximab,Fatigue,OT
166846073,Infliximab,Fall,HO
166846073,Infliximab,Fall,OT
166846073,Infliximab,Ear pain,HO
166846073,Infliximab,Ear pain,OT
166846073,Infliximab,Condition aggravated,HO
166846073,Infliximab,Condition aggravated,OT
166846073,Infliximab,Body temperature decreased,HO
166846073,Infliximab,Body temperature decreased,OT
166846073,Infliximab,Blood pressure increased,HO
166846073,Infliximab,Blood pressure increased,OT
166846073,Infliximab,Blood pressure fluctuation,HO
166846073,Infliximab,Blood pressure fluctuation,OT
166846073,Infliximab,Back pain,HO
166846073,Infliximab,Back pain,OT
166846073,Infliximab,Anal fistula,HO
166846073,Infliximab,Anal fistula,OT
166846073,Infliximab,Anal fissure,HO
166846073,Infliximab,Anal fissure,OT
166846073,Infliximab,Anal abscess,HO
166846073,Infliximab,Anal abscess,OT
168216955,Infliximab,Vision blurred,OT
168216955,Infliximab,Tinnitus,OT
168216955,Infliximab,Pruritus,OT
168216955,Infliximab,Off label use,OT
168216955,Infliximab,Lung disorder,OT
168216955,Infliximab,Liver disorder,OT
168216955,Infliximab,Intentional product use issue,OT
168216955,Infliximab,Inappropriate schedule of product administration,OT
168216955,Infliximab,Hyperthermia,OT
168216955,Infliximab,Dyspnoea,OT
168216955,Infliximab,Drug level decreased,OT
168216955,Infliximab,Dizziness,OT
168216955,Infliximab,Diarrhoea,OT
168216955,Infliximab,Cough,OT
168216955,Infliximab,Condition aggravated,OT
168216955,Infliximab,Bronchospasm,OT
168216955,Infliximab,Blood pressure fluctuation,OT
168216955,Infliximab,Anxiety,OT
168216955,Infliximab,Vision blurred,OT
168216955,Infliximab,Tinnitus,OT
168216955,Infliximab,Pruritus,OT
168216955,Infliximab,Off label use,OT
168216955,Infliximab,Lung disorder,OT
168216955,Infliximab,Liver disorder,OT
168216955,Infliximab,Intentional product use issue,OT
168216955,Infliximab,Inappropriate schedule of product administration,OT
168216955,Infliximab,Hyperthermia,OT
168216955,Infliximab,Dyspnoea,OT
168216955,Infliximab,Drug level decreased,OT
168216955,Infliximab,Dizziness,OT
168216955,Infliximab,Diarrhoea,OT
168216955,Infliximab,Cough,OT
168216955,Infliximab,Condition aggravated,OT
168216955,Infliximab,Bronchospasm,OT
168216955,Infliximab,Blood pressure fluctuation,OT
168216955,Infliximab,Anxiety,OT
176242283,Infliximab,Vitamin D decreased,HO
176242283,Infliximab,Vitamin D decreased,OT
176242283,Infliximab,Ulcerative gastritis,HO
176242283,Infliximab,Ulcerative gastritis,OT
176242283,Infliximab,Product use issue,HO
176242283,Infliximab,Product use issue,OT
176242283,Infliximab,Off label use,HO
176242283,Infliximab,Off label use,OT
176242283,Infliximab,Neutrophil count decreased,HO
176242283,Infliximab,Neutrophil count decreased,OT
176242283,Infliximab,Intentional product use issue,HO
176242283,Infliximab,Intentional product use issue,OT
176242283,Infliximab,Inappropriate schedule of product administration,HO
176242283,Infliximab,Inappropriate schedule of product administration,OT
176242283,Infliximab,Condition aggravated,HO
176242283,Infliximab,Condition aggravated,OT
176242283,Infliximab,Bronchitis,HO
176242283,Infliximab,Bronchitis,OT
176490333,Infliximab,Uveitis,OT
176490333,Infliximab,Off label use,OT
176490333,Infliximab,Nasopharyngitis,OT
176490333,Infliximab,Intentional product use issue,OT
176490333,Infliximab,Infusion site oedema,OT
176490333,Infliximab,Hypotension,OT
176490333,Infliximab,Heart rate irregular,OT
176490333,Infliximab,Fatigue,OT
176490333,Infliximab,Dyspnoea,OT
176490333,Infliximab,Dizziness,OT
176490333,Infliximab,Condition aggravated,OT
176490333,Infliximab,Blood pressure fluctuation,OT
176490333,Infliximab,Arthralgia,OT
176490333,Infliximab,Aphthous ulcer,OT
176580074,Infliximab,Weight increased,OT
176580074,Infliximab,Weight increased,HO
176580074,Infliximab,Weight decreased,OT
176580074,Infliximab,Weight decreased,HO
176580074,Infliximab,Therapeutic product effect incomplete,OT
176580074,Infliximab,Therapeutic product effect incomplete,HO
176580074,Infliximab,Off label use,OT
176580074,Infliximab,Off label use,HO
176580074,Infliximab,Intentional product use issue,OT
176580074,Infliximab,Intentional product use issue,HO
176580074,Infliximab,Hypothermia,OT
176580074,Infliximab,Hypothermia,HO
176580074,Infliximab,Heart rate decreased,OT
176580074,Infliximab,Heart rate decreased,HO
176580074,Infliximab,Gastrointestinal infection,OT
176580074,Infliximab,Gastrointestinal infection,HO
176580074,Infliximab,Expired product administered,OT
176580074,Infliximab,Expired product administered,HO
176580074,Infliximab,Crohn's disease,OT
176580074,Infliximab,Crohn's disease,HO
176580074,Infliximab,Condition aggravated,OT
176580074,Infliximab,Condition aggravated,HO
176580074,Infliximab,Body temperature fluctuation,OT
176580074,Infliximab,Body temperature fluctuation,HO
176580074,Infliximab,Body temperature decreased,OT
176580074,Infliximab,Body temperature decreased,HO
176580074,Infliximab,Blood pressure fluctuation,OT
176580074,Infliximab,Blood pressure fluctuation,HO
176798764,Infliximab,Weight increased,OT
176798764,Infliximab,Product use issue,OT
176798764,Infliximab,Off label use,OT
176798764,Infliximab,Intentional product use issue,OT
176798764,Infliximab,Infection,OT
176798764,Infliximab,Incorrect dose administered,OT
176798764,Infliximab,Inappropriate schedule of product administration,OT
176798764,Infliximab,Herpes zoster,OT
176798764,Infliximab,Heart rate irregular,OT
176798764,Infliximab,Heart rate increased,OT
176798764,Infliximab,Heart rate decreased,OT
176798764,Infliximab,Fatigue,OT
176798764,Infliximab,Condition aggravated,OT
176798764,Infliximab,Blood pressure diastolic decreased,OT
176798764,Infliximab,Arthralgia,OT
176798764,Infliximab,Abdominal pain,OT
176858324,Infliximab,Weight increased,OT
176858324,Infliximab,Therapeutic response shortened,OT
176858324,Infliximab,Somnolence,OT
176858324,Infliximab,Pseudopolyposis,OT
176858324,Infliximab,Product use issue,OT
176858324,Infliximab,Presyncope,OT
176858324,Infliximab,Pallor,OT
176858324,Infliximab,Off label use,OT
176858324,Infliximab,Nausea,OT
176858324,Infliximab,Intentional product use issue,OT
176858324,Infliximab,Infusion site extravasation,OT
176858324,Infliximab,Incorrect dose administered,OT
176858324,Infliximab,Hyperhidrosis,OT
176858324,Infliximab,Heart rate irregular,OT
176858324,Infliximab,Heart rate decreased,OT
176858324,Infliximab,Faecal calprotectin increased,OT
176858324,Infliximab,Expired product administered,OT
176858324,Infliximab,Drug level increased,OT
176858324,Infliximab,Condition aggravated,OT
176858324,Infliximab,Body temperature increased,OT
176858324,Infliximab,Blood pressure decreased,OT
176858324,Infliximab,Asthenia,OT
176858324,Infliximab,Weight increased,OT
176858324,Infliximab,Therapeutic response shortened,OT
176858324,Infliximab,Somnolence,OT
176858324,Infliximab,Pseudopolyposis,OT
176858324,Infliximab,Product use issue,OT
176858324,Infliximab,Presyncope,OT
176858324,Infliximab,Pallor,OT
176858324,Infliximab,Off label use,OT
176858324,Infliximab,Nausea,OT
176858324,Infliximab,Intentional product use issue,OT
176858324,Infliximab,Infusion site extravasation,OT
176858324,Infliximab,Incorrect dose administered,OT
176858324,Infliximab,Hyperhidrosis,OT
176858324,Infliximab,Heart rate irregular,OT
176858324,Infliximab,Heart rate decreased,OT
176858324,Infliximab,Faecal calprotectin increased,OT
176858324,Infliximab,Expired product administered,OT
176858324,Infliximab,Drug level increased,OT
176858324,Infliximab,Condition aggravated,OT
176858324,Infliximab,Body temperature increased,OT
176858324,Infliximab,Blood pressure decreased,OT
176858324,Infliximab,Asthenia,OT
176941414,Infliximab,Weight increased,OT
176941414,Infliximab,Off label use,OT
176941414,Infliximab,Intentional product use issue,OT
176941414,Infliximab,Incorrect dose administered,OT
176941414,Infliximab,Condition aggravated,OT
176941414,Infliximab,Blood pressure systolic increased,OT
176941414,Infliximab,Blood pressure increased,OT
176941414,Infliximab,Blood pressure fluctuation,OT
176941414,Infliximab,Anal fistula,OT
177336384,Infliximab,Vision blurred,OT
177336384,Infliximab,Therapeutic product effect incomplete,OT
177336384,Infliximab,Sneezing,OT
177336384,Infliximab,Poor venous access,OT
177336384,Infliximab,Peripheral swelling,OT
177336384,Infliximab,Pain in extremity,OT
177336384,Infliximab,Pain,OT
177336384,Infliximab,Oropharyngeal pain,OT
177336384,Infliximab,Off label use,OT
177336384,Infliximab,Nausea,OT
177336384,Infliximab,Nasopharyngitis,OT
177336384,Infliximab,Muscle spasms,OT
177336384,Infliximab,Mouth ulceration,OT
177336384,Infliximab,Lichen sclerosus,OT
177336384,Infliximab,Inappropriate schedule of product administration,OT
177336384,Infliximab,Headache,OT
177336384,Infliximab,Haematochezia,OT
177336384,Infliximab,Gait disturbance,OT
177336384,Infliximab,Feeling hot,OT
177336384,Infliximab,Fatigue,OT
177336384,Infliximab,Dry eye,OT
177336384,Infliximab,Disease recurrence,OT
177336384,Infliximab,Cough,OT
177336384,Infliximab,Blood pressure fluctuation,OT
177336384,Infliximab,Blood creatinine increased,OT
177336384,Infliximab,Back pain,OT
177336384,Infliximab,Anal fissure,OT
177336384,Infliximab,Abdominal pain upper,OT
177336384,Infliximab,Abdominal pain,OT
179122043,Infliximab,Wheezing,OT
179122043,Infliximab,Viral upper respiratory tract infection,OT
179122043,Infliximab,Viral infection,OT
179122043,Infliximab,Suspected COVID-19,OT
179122043,Infliximab,Sinusitis,OT
179122043,Infliximab,Rhinorrhoea,OT
179122043,Infliximab,Rash,OT
179122043,Infliximab,Pyrexia,OT
179122043,Infliximab,Productive cough,OT
179122043,Infliximab,Product use issue,OT
179122043,Infliximab,Paranasal sinus discomfort,OT
179122043,Infliximab,Oropharyngeal pain,OT
179122043,Infliximab,Off label use,OT
179122043,Infliximab,Nasopharyngitis,OT
179122043,Infliximab,Nasal congestion,OT
179122043,Infliximab,Malaise,OT
179122043,Infliximab,Influenza like illness,OT
179122043,Infliximab,Influenza,OT
179122043,Infliximab,Infection,OT
179122043,Infliximab,Illness,OT
179122043,Infliximab,Hypertension,OT
179122043,Infliximab,Heart rate decreased,OT
179122043,Infliximab,Headache,OT
179122043,Infliximab,Gastroenteritis viral,OT
179122043,Infliximab,Epistaxis,OT
179122043,Infliximab,Ear discomfort,OT
179122043,Infliximab,Ear congestion,OT
179122043,Infliximab,Dysphonia,OT
179122043,Infliximab,Dizziness,OT
179122043,Infliximab,Diarrhoea,OT
179122043,Infliximab,Cough,OT
179122043,Infliximab,Condition aggravated,OT
179122043,Infliximab,Chills,OT
179122043,Infliximab,Body temperature decreased,OT
179122043,Infliximab,Blood pressure fluctuation,OT
179122043,Infliximab,Balance disorder,OT
179122043,Infliximab,Wheezing,OT
179122043,Infliximab,Viral upper respiratory tract infection,OT
179122043,Infliximab,Viral infection,OT
179122043,Infliximab,Suspected COVID-19,OT
179122043,Infliximab,Sinusitis,OT
179122043,Infliximab,Rhinorrhoea,OT
179122043,Infliximab,Rash,OT
179122043,Infliximab,Pyrexia,OT
179122043,Infliximab,Productive cough,OT
179122043,Infliximab,Product use issue,OT
179122043,Infliximab,Paranasal sinus discomfort,OT
179122043,Infliximab,Oropharyngeal pain,OT
179122043,Infliximab,Off label use,OT
179122043,Infliximab,Nasopharyngitis,OT
179122043,Infliximab,Nasal congestion,OT
179122043,Infliximab,Malaise,OT
179122043,Infliximab,Influenza like illness,OT
179122043,Infliximab,Influenza,OT
179122043,Infliximab,Infection,OT
179122043,Infliximab,Illness,OT
179122043,Infliximab,Hypertension,OT
179122043,Infliximab,Heart rate decreased,OT
179122043,Infliximab,Headache,OT
179122043,Infliximab,Gastroenteritis viral,OT
179122043,Infliximab,Epistaxis,OT
179122043,Infliximab,Ear discomfort,OT
179122043,Infliximab,Ear congestion,OT
179122043,Infliximab,Dysphonia,OT
179122043,Infliximab,Dizziness,OT
179122043,Infliximab,Diarrhoea,OT
179122043,Infliximab,Cough,OT
179122043,Infliximab,Condition aggravated,OT
179122043,Infliximab,Chills,OT
179122043,Infliximab,Body temperature decreased,OT
179122043,Infliximab,Blood pressure fluctuation,OT
179122043,Infliximab,Balance disorder,OT
181201782,Infliximab,Therapeutic product effect incomplete,OT
181201782,Infliximab,Off label use,OT
181201782,Infliximab,Musculoskeletal discomfort,OT
181201782,Infliximab,Lower limb fracture,OT
181201782,Infliximab,Intentional product use issue,OT
181201782,Infliximab,Influenza,OT
181201782,Infliximab,Incorrect dose administered,OT
181201782,Infliximab,Chest discomfort,OT
181201782,Infliximab,Blood pressure systolic increased,OT
182642863,Infliximab,Vaginal infection,OT
182642863,Infliximab,Vaginal infection,HO
182642863,Infliximab,Vaginal fistula,OT
182642863,Infliximab,Vaginal fistula,HO
182642863,Infliximab,Vaginal cyst,OT
182642863,Infliximab,Vaginal cyst,HO
182642863,Infliximab,Skin exfoliation,OT
182642863,Infliximab,Skin exfoliation,HO
182642863,Infliximab,Sensitive skin,OT
182642863,Infliximab,Sensitive skin,HO
182642863,Infliximab,Product use issue,OT
182642863,Infliximab,Product use issue,HO
182642863,Infliximab,Off label use,OT
182642863,Infliximab,Off label use,HO
182642863,Infliximab,Intentional product use issue,OT
182642863,Infliximab,Intentional product use issue,HO
182642863,Infliximab,Infection,OT
182642863,Infliximab,Infection,HO
182642863,Infliximab,Hyperaesthesia,OT
182642863,Infliximab,Hyperaesthesia,HO
182642863,Infliximab,Eczema,OT
182642863,Infliximab,Eczema,HO
182642863,Infliximab,Vaginal infection,OT
182642863,Infliximab,Vaginal infection,HO
182642863,Infliximab,Vaginal fistula,OT
182642863,Infliximab,Vaginal fistula,HO
182642863,Infliximab,Vaginal cyst,OT
182642863,Infliximab,Vaginal cyst,HO
182642863,Infliximab,Skin exfoliation,OT
182642863,Infliximab,Skin exfoliation,HO
182642863,Infliximab,Sensitive skin,OT
182642863,Infliximab,Sensitive skin,HO
182642863,Infliximab,Product use issue,OT
182642863,Infliximab,Product use issue,HO
182642863,Infliximab,Off label use,OT
182642863,Infliximab,Off label use,HO
182642863,Infliximab,Intentional product use issue,OT
182642863,Infliximab,Intentional product use issue,HO
182642863,Infliximab,Infection,OT
182642863,Infliximab,Infection,HO
182642863,Infliximab,Hyperaesthesia,OT
182642863,Infliximab,Hyperaesthesia,HO
182642863,Infliximab,Eczema,OT
182642863,Infliximab,Eczema,HO
183281352,Infliximab,Vomiting,OT
183281352,Infliximab,Rectal haemorrhage,OT
183281352,Infliximab,Product use issue,OT
183281352,Infliximab,Pain in extremity,OT
183281352,Infliximab,Oropharyngeal pain,OT
183281352,Infliximab,Off label use,OT
183281352,Infliximab,Oesophagitis,OT
183281352,Infliximab,Nasopharyngitis,OT
183281352,Infliximab,Intentional product use issue,OT
183281352,Infliximab,Headache,OT
183281352,Infliximab,Haematemesis,OT
183281352,Infliximab,Gastrointestinal disorder,OT
183281352,Infliximab,Eating disorder,OT
183281352,Infliximab,Dysphagia,OT
183281352,Infliximab,Dyspepsia,OT
183281352,Infliximab,Diarrhoea,OT
183281352,Infliximab,Constipation,OT
183281352,Infliximab,Condition aggravated,OT
183281352,Infliximab,Chills,OT
183281352,Infliximab,Blood pressure fluctuation,OT
183281352,Infliximab,Arthralgia,OT
183281352,Infliximab,Abdominal discomfort,OT
183978293,Infliximab,Weight decreased,OT
183978293,Infliximab,Product use issue,OT
183978293,Infliximab,Off label use,OT
183978293,Infliximab,Intentional product use issue,OT
183978293,Infliximab,Weight decreased,OT
183978293,Infliximab,Product use issue,OT
183978293,Infliximab,Off label use,OT
183978293,Infliximab,Intentional product use issue,OT
184021604,Infliximab,Weight increased,OT
184021604,Infliximab,Weight decreased,OT
184021604,Infliximab,Product use issue,OT
184021604,Infliximab,Off label use,OT
184021604,Infliximab,Localised infection,OT
184021604,Infliximab,Intentional product use issue,OT
184021604,Infliximab,Heart rate irregular,OT
184021604,Infliximab,C-reactive protein increased,OT
184021604,Infliximab,Body temperature decreased,OT
184021604,Infliximab,Blood pressure increased,OT
184021604,Infliximab,Blood pressure fluctuation,OT
184858472,Infliximab,Weight increased,OT
184858472,Infliximab,Stress,OT
184858472,Infliximab,Product use issue,OT
184858472,Infliximab,Off label use,OT
184858472,Infliximab,Intentional product use issue,OT
184858472,Infliximab,Inappropriate schedule of product administration,OT
184858472,Infliximab,Hypertension,OT
184858472,Infliximab,Heart rate decreased,OT
184858472,Infliximab,Drug ineffective,OT
184858472,Infliximab,Condition aggravated,OT
184858472,Infliximab,Body temperature decreased,OT
184858472,Infliximab,Weight increased,OT
184858472,Infliximab,Stress,OT
184858472,Infliximab,Product use issue,OT
184858472,Infliximab,Off label use,OT
184858472,Infliximab,Intentional product use issue,OT
184858472,Infliximab,Inappropriate schedule of product administration,OT
184858472,Infliximab,Hypertension,OT
184858472,Infliximab,Heart rate decreased,OT
184858472,Infliximab,Drug ineffective,OT
184858472,Infliximab,Condition aggravated,OT
184858472,Infliximab,Body temperature decreased,OT
185046363,Infliximab,Off label use,OT
185046363,Infliximab,Lower limb fracture,OT
185046363,Infliximab,Inappropriate schedule of product administration,OT
185550102,Infliximab,Urinary tract disorder,HO
185550102,Infliximab,Urinary tract disorder,OT
185550102,Infliximab,Thrombosis,HO
185550102,Infliximab,Thrombosis,OT
185550102,Infliximab,Pyrexia,HO
185550102,Infliximab,Pyrexia,OT
185550102,Infliximab,Oropharyngeal pain,HO
185550102,Infliximab,Oropharyngeal pain,OT
185550102,Infliximab,Off label use,HO
185550102,Infliximab,Off label use,OT
185550102,Infliximab,Nasopharyngitis,HO
185550102,Infliximab,Nasopharyngitis,OT
185550102,Infliximab,Intentional product use issue,HO
185550102,Infliximab,Intentional product use issue,OT
185550102,Infliximab,Inappropriate schedule of product administration,HO
185550102,Infliximab,Inappropriate schedule of product administration,OT
185550102,Infliximab,Heart rate irregular,HO
185550102,Infliximab,Heart rate irregular,OT
185550102,Infliximab,Head injury,HO
185550102,Infliximab,Head injury,OT
185550102,Infliximab,Hallucination,HO
185550102,Infliximab,Hallucination,OT
185550102,Infliximab,Fall,HO
185550102,Infliximab,Fall,OT
185550102,Infliximab,Disorientation,HO
185550102,Infliximab,Disorientation,OT
185550102,Infliximab,Blood pressure fluctuation,HO
185550102,Infliximab,Blood pressure fluctuation,OT
185550102,Infliximab,Balance disorder,HO
185550102,Infliximab,Balance disorder,OT
187387962,Infliximab,Urticaria,OT
187387962,Infliximab,Syncope,OT
187387962,Infliximab,Off label use,OT
187387962,Infliximab,Intentional product use issue,OT
187387962,Infliximab,Hypertension,OT
187387962,Infliximab,Heart rate decreased,OT
187387962,Infliximab,Anxiety,OT
191111582,Infliximab,Influenza,NULL
191407842,Infliximab,Pyoderma gangrenosum,OT
191407842,Infliximab,Post procedural complication,OT
191407842,Infliximab,Off label use,OT
191407842,Infliximab,Ischaemic skin ulcer,OT
191407842,Infliximab,Intentional product use issue,OT
191407842,Infliximab,Inappropriate schedule of product administration,OT
191810702,Infliximab,Weight increased,OT
191810702,Infliximab,Product use issue,OT
191810702,Infliximab,Off label use,OT
191810702,Infliximab,Intentional product use issue,OT
191810702,Infliximab,Infection,OT
191810702,Infliximab,Faecal calprotectin abnormal,OT
191810702,Infliximab,Condition aggravated,OT
192238362,Infliximab,Off label use,OT
192238362,Infliximab,Condition aggravated,OT
193996482,Infliximab,Weight increased,OT
193996482,Infliximab,Pain,OT
193996482,Infliximab,Off label use,OT
193996482,Infliximab,Malaise,OT
193996482,Infliximab,Inappropriate schedule of product administration,OT
193996482,Infliximab,Heart rate decreased,OT
193996482,Infliximab,Haematochezia,OT
193996482,Infliximab,Drug specific antibody,OT
193996482,Infliximab,Drug ineffective,OT
193996482,Infliximab,Diarrhoea,OT
193996482,Infliximab,Appetite disorder,OT
193996482,Infliximab,Abdominal pain,OT
193996482,Infliximab,Weight increased,OT
193996482,Infliximab,Pain,OT
193996482,Infliximab,Off label use,OT
193996482,Infliximab,Malaise,OT
193996482,Infliximab,Inappropriate schedule of product administration,OT
193996482,Infliximab,Heart rate decreased,OT
193996482,Infliximab,Haematochezia,OT
193996482,Infliximab,Drug specific antibody,OT
193996482,Infliximab,Drug ineffective,OT
193996482,Infliximab,Diarrhoea,OT
193996482,Infliximab,Appetite disorder,OT
193996482,Infliximab,Abdominal pain,OT
194595042,Infliximab,Weight increased,OT
194595042,Infliximab,Weight increased,HO
194595042,Infliximab,Restlessness,OT
194595042,Infliximab,Restlessness,HO
194595042,Infliximab,Pancreatitis,OT
194595042,Infliximab,Pancreatitis,HO
194595042,Infliximab,Mood swings,OT
194595042,Infliximab,Mood swings,HO
194595042,Infliximab,Irritability,OT
194595042,Infliximab,Irritability,HO
194595042,Infliximab,Insomnia,OT
194595042,Infliximab,Insomnia,HO
194595042,Infliximab,Drug ineffective,OT
194595042,Infliximab,Drug ineffective,HO
194595042,Infliximab,Autoimmune hepatitis,OT
194595042,Infliximab,Autoimmune hepatitis,HO
196035041,Infliximab,Varicella zoster virus infection,HO
196035041,Infliximab,Poor feeding infant,HO
196035041,Infliximab,Meningitis viral,HO
196035041,Infliximab,Foetal exposure during pregnancy,HO
196035041,Infliximab,Exposure to communicable disease,HO
196078301,Infliximab (Unknown),Therapy change,OT
196078301,Infliximab (Unknown),Therapy change,HO
196078301,Infliximab (Unknown),Streptococcal bacteraemia,OT
196078301,Infliximab (Unknown),Streptococcal bacteraemia,HO
196078301,Infliximab (Unknown),Staphylococcal infection,OT
196078301,Infliximab (Unknown),Staphylococcal infection,HO
196078301,Infliximab (Unknown),Paraspinal abscess,OT
196078301,Infliximab (Unknown),Paraspinal abscess,HO
196078301,Infliximab (Unknown),Immunosuppression,OT
196078301,Infliximab (Unknown),Immunosuppression,HO
196078301,Infliximab (Unknown),Escherichia infection,OT
196078301,Infliximab (Unknown),Escherichia infection,HO
196078301,Infliximab (Unknown),Brain abscess,OT
196078301,Infliximab (Unknown),Brain abscess,HO
196240211,Infliximab,Uveitis,OT
196240211,Infliximab,Rash pruritic,OT
196240211,Infliximab,Oxygen saturation abnormal,OT
196240211,Infliximab,Off label use,OT
196240211,Infliximab,Intentional product use issue,OT
196240211,Infliximab,Cough,OT
196240211,Infliximab,Condition aggravated,OT
196240211,Infliximab,Arthralgia,OT
196240211,Infliximab,Alopecia,OT
196240211,Infliximab,Abdominal pain lower,OT
196762441,Infliximab,Condition aggravated,OT
196762441,Infliximab,Arthralgia,OT
196930791,Infliximab (Unknown),Pyrexia,OT
196930791,Infliximab (Unknown),Polyarthritis,OT
196930791,Infliximab (Unknown),Off label use,OT
196930791,Infliximab (Unknown),Muscle rigidity,OT
196930791,Infliximab (Unknown),Inflammation,OT
197026741,Infliximab (Unknown),Castleman's disease,HO
197159793,Infliximab,Off label use,OT
197159793,Infliximab,Neurosarcoidosis,OT
197159793,Infliximab,Myopathy,OT
197159793,Infliximab,Drug ineffective for unapproved indication,OT
197297471,Infliximab Pfizer (Unknown),Therapy non-responder,HO
197885761,Infliximab,Off label use,OT
197885761,Infliximab,Lupus-like syndrome,OT
197885761,Infliximab,Off label use,OT
197885761,Infliximab,Lupus-like syndrome,OT
197885761,Infliximab,Off label use,OT
197885761,Infliximab,Lupus-like syndrome,OT
198051541,Infliximab,Product use issue,OT
198051541,Infliximab,Off label use,OT
198051541,Infliximab,Nephrolithiasis,OT
198051541,Infliximab,Intentional product use issue,OT
198051541,Infliximab,Condition aggravated,OT
198051541,Infliximab,Blood pressure fluctuation,OT
198051541,Infliximab,Arthralgia,OT
198288291,Infliximab,Weight decreased,OT
198288291,Infliximab,Off label use,OT
198288291,Infliximab,Intentional product use issue,OT
198288291,Infliximab,Hypertension,OT
198288291,Infliximab,Exposure to SARS-CoV-2,OT
198729661,Infliximab,Off label use,OT
198729661,Infliximab,Intentional product use issue,OT
198729661,Infliximab,Condition aggravated,OT
198990631,Infliximab,Off label use,OT
198990631,Infliximab,Drug level below therapeutic,OT
198990631,Infliximab,Drug ineffective,OT
198990631,Infliximab,Condition aggravated,OT
160735756,Infliximab,Treatment failure,OT
160735756,Infliximab,Red blood cell sedimentation rate abnormal,OT
160735756,Infliximab,Pain,OT
160735756,Infliximab,Off label use,OT
160735756,Infliximab,Joint swelling,OT
160735756,Infliximab,Drug ineffective,OT
160735756,Infliximab,Contraindicated product administered,OT
160735756,Infliximab,Arthralgia,OT
164921876,Infliximab,Weight decreased,OT
164921876,Infliximab,Urinary tract infection,OT
164921876,Infliximab,Throat irritation,OT
164921876,Infliximab,Therapeutic response shortened,OT
164921876,Infliximab,Therapeutic product effect decreased,OT
164921876,Infliximab,Rash macular,OT
164921876,Infliximab,Product use issue,OT
164921876,Infliximab,Pain in extremity,OT
164921876,Infliximab,Pain,OT
164921876,Infliximab,Off label use,OT
164921876,Infliximab,Migraine,OT
164921876,Infliximab,Kidney infection,OT
164921876,Infliximab,Intentional product use issue,OT
164921876,Infliximab,Incorrect dose administered,OT
164921876,Infliximab,Inappropriate schedule of product administration,OT
164921876,Infliximab,Hypersensitivity,OT
164921876,Infliximab,Heart rate irregular,OT
164921876,Infliximab,Heart rate increased,OT
164921876,Infliximab,Fibromyalgia,OT
164921876,Infliximab,Feeling hot,OT
164921876,Infliximab,Fatigue,OT
164921876,Infliximab,Chest pain,OT
164921876,Infliximab,Body temperature increased,OT
164921876,Infliximab,Blood pressure fluctuation,OT
164921876,Infliximab,Arthralgia,OT
164921876,Infliximab,Weight decreased,OT
164921876,Infliximab,Urinary tract infection,OT
164921876,Infliximab,Throat irritation,OT
164921876,Infliximab,Therapeutic response shortened,OT
164921876,Infliximab,Therapeutic product effect decreased,OT
164921876,Infliximab,Rash macular,OT
164921876,Infliximab,Product use issue,OT
164921876,Infliximab,Pain in extremity,OT
164921876,Infliximab,Pain,OT
164921876,Infliximab,Off label use,OT
164921876,Infliximab,Migraine,OT
164921876,Infliximab,Kidney infection,OT
164921876,Infliximab,Intentional product use issue,OT
164921876,Infliximab,Incorrect dose administered,OT
164921876,Infliximab,Inappropriate schedule of product administration,OT
164921876,Infliximab,Hypersensitivity,OT
164921876,Infliximab,Heart rate irregular,OT
164921876,Infliximab,Heart rate increased,OT
164921876,Infliximab,Fibromyalgia,OT
164921876,Infliximab,Feeling hot,OT
164921876,Infliximab,Fatigue,OT
164921876,Infliximab,Chest pain,OT
164921876,Infliximab,Body temperature increased,OT
164921876,Infliximab,Blood pressure fluctuation,OT
164921876,Infliximab,Arthralgia,OT
164921876,Infliximab,Weight decreased,OT
164921876,Infliximab,Urinary tract infection,OT
164921876,Infliximab,Throat irritation,OT
164921876,Infliximab,Therapeutic response shortened,OT
164921876,Infliximab,Therapeutic product effect decreased,OT
164921876,Infliximab,Rash macular,OT
164921876,Infliximab,Product use issue,OT
164921876,Infliximab,Pain in extremity,OT
164921876,Infliximab,Pain,OT
164921876,Infliximab,Off label use,OT
164921876,Infliximab,Migraine,OT
164921876,Infliximab,Kidney infection,OT
164921876,Infliximab,Intentional product use issue,OT
164921876,Infliximab,Incorrect dose administered,OT
164921876,Infliximab,Inappropriate schedule of product administration,OT
164921876,Infliximab,Hypersensitivity,OT
164921876,Infliximab,Heart rate irregular,OT
164921876,Infliximab,Heart rate increased,OT
164921876,Infliximab,Fibromyalgia,OT
164921876,Infliximab,Feeling hot,OT
164921876,Infliximab,Fatigue,OT
164921876,Infliximab,Chest pain,OT
164921876,Infliximab,Body temperature increased,OT
164921876,Infliximab,Blood pressure fluctuation,OT
164921876,Infliximab,Arthralgia,OT
164921876,Infliximab,Weight decreased,OT
164921876,Infliximab,Urinary tract infection,OT
164921876,Infliximab,Throat irritation,OT
164921876,Infliximab,Therapeutic response shortened,OT
164921876,Infliximab,Therapeutic product effect decreased,OT
164921876,Infliximab,Rash macular,OT
164921876,Infliximab,Product use issue,OT
164921876,Infliximab,Pain in extremity,OT
164921876,Infliximab,Pain,OT
164921876,Infliximab,Off label use,OT
164921876,Infliximab,Migraine,OT
164921876,Infliximab,Kidney infection,OT
164921876,Infliximab,Intentional product use issue,OT
164921876,Infliximab,Incorrect dose administered,OT
164921876,Infliximab,Inappropriate schedule of product administration,OT
164921876,Infliximab,Hypersensitivity,OT
164921876,Infliximab,Heart rate irregular,OT
164921876,Infliximab,Heart rate increased,OT
164921876,Infliximab,Fibromyalgia,OT
164921876,Infliximab,Feeling hot,OT
164921876,Infliximab,Fatigue,OT
164921876,Infliximab,Chest pain,OT
164921876,Infliximab,Body temperature increased,OT
164921876,Infliximab,Blood pressure fluctuation,OT
164921876,Infliximab,Arthralgia,OT
164921876,Infliximab,Weight decreased,OT
164921876,Infliximab,Urinary tract infection,OT
164921876,Infliximab,Throat irritation,OT
164921876,Infliximab,Therapeutic response shortened,OT
164921876,Infliximab,Therapeutic product effect decreased,OT
164921876,Infliximab,Rash macular,OT
164921876,Infliximab,Product use issue,OT
164921876,Infliximab,Pain in extremity,OT
164921876,Infliximab,Pain,OT
164921876,Infliximab,Off label use,OT
164921876,Infliximab,Migraine,OT
164921876,Infliximab,Kidney infection,OT
164921876,Infliximab,Intentional product use issue,OT
164921876,Infliximab,Incorrect dose administered,OT
164921876,Infliximab,Inappropriate schedule of product administration,OT
164921876,Infliximab,Hypersensitivity,OT
164921876,Infliximab,Heart rate irregular,OT
164921876,Infliximab,Heart rate increased,OT
164921876,Infliximab,Fibromyalgia,OT
164921876,Infliximab,Feeling hot,OT
164921876,Infliximab,Fatigue,OT
164921876,Infliximab,Chest pain,OT
164921876,Infliximab,Body temperature increased,OT
164921876,Infliximab,Blood pressure fluctuation,OT
164921876,Infliximab,Arthralgia,OT
166844505,Infliximab,Weight increased,OT
166844505,Infliximab,Weight increased,HO
166844505,Infliximab,Sensitivity to weather change,OT
166844505,Infliximab,Sensitivity to weather change,HO
166844505,Infliximab,Rhinorrhoea,OT
166844505,Infliximab,Rhinorrhoea,HO
166844505,Infliximab,Restless legs syndrome,OT
166844505,Infliximab,Restless legs syndrome,HO
166844505,Infliximab,Rash,OT
166844505,Infliximab,Rash,HO
166844505,Infliximab,Pyrexia,OT
166844505,Infliximab,Pyrexia,HO
166844505,Infliximab,Pruritus,OT
166844505,Infliximab,Pruritus,HO
166844505,Infliximab,Product use issue,OT
166844505,Infliximab,Product use issue,HO
166844505,Infliximab,Photosensitivity reaction,OT
166844505,Infliximab,Photosensitivity reaction,HO
166844505,Infliximab,Off label use,OT
166844505,Infliximab,Off label use,HO
166844505,Infliximab,Nasal dryness,OT
166844505,Infliximab,Nasal dryness,HO
166844505,Infliximab,Myalgia,OT
166844505,Infliximab,Myalgia,HO
166844505,Infliximab,Intentional product use issue,OT
166844505,Infliximab,Intentional product use issue,HO
166844505,Infliximab,Inappropriate schedule of product administration,OT
166844505,Infliximab,Inappropriate schedule of product administration,HO
166844505,Infliximab,Hypoaesthesia,OT
166844505,Infliximab,Hypoaesthesia,HO
166844505,Infliximab,Heart rate decreased,OT
166844505,Infliximab,Heart rate decreased,HO
166844505,Infliximab,Headache,OT
166844505,Infliximab,Headache,HO
166844505,Infliximab,Halo vision,OT
166844505,Infliximab,Halo vision,HO
166844505,Infliximab,Haemoglobin decreased,OT
166844505,Infliximab,Haemoglobin decreased,HO
166844505,Infliximab,Fatigue,OT
166844505,Infliximab,Fatigue,HO
166844505,Infliximab,Dyspnoea,OT
166844505,Infliximab,Dyspnoea,HO
166844505,Infliximab,Drug level decreased,OT
166844505,Infliximab,Drug level decreased,HO
166844505,Infliximab,Contusion,OT
166844505,Infliximab,Contusion,HO
166844505,Infliximab,Condition aggravated,OT
166844505,Infliximab,Condition aggravated,HO
166844505,Infliximab,Chromaturia,OT
166844505,Infliximab,Chromaturia,HO
166844505,Infliximab,Blood pressure fluctuation,OT
166844505,Infliximab,Blood pressure fluctuation,HO
166844505,Infliximab,Blood iron decreased,OT
166844505,Infliximab,Blood iron decreased,HO
166844505,Infliximab,Arthropod bite,OT
166844505,Infliximab,Arthropod bite,HO
166844505,Infliximab,Arthralgia,OT
166844505,Infliximab,Arthralgia,HO
166844505,Infliximab,Abnormal faeces,OT
166844505,Infliximab,Abnormal faeces,HO
166844505,Infliximab,Abdominal distension,OT
166844505,Infliximab,Abdominal distension,HO
166844505,Infliximab,Abdominal discomfort,OT
166844505,Infliximab,Abdominal discomfort,HO
166844505,Infliximab,Weight increased,OT
166844505,Infliximab,Weight increased,HO
166844505,Infliximab,Sensitivity to weather change,OT
166844505,Infliximab,Sensitivity to weather change,HO
166844505,Infliximab,Rhinorrhoea,OT
166844505,Infliximab,Rhinorrhoea,HO
166844505,Infliximab,Restless legs syndrome,OT
166844505,Infliximab,Restless legs syndrome,HO
166844505,Infliximab,Rash,OT
166844505,Infliximab,Rash,HO
166844505,Infliximab,Pyrexia,OT
166844505,Infliximab,Pyrexia,HO
166844505,Infliximab,Pruritus,OT
166844505,Infliximab,Pruritus,HO
166844505,Infliximab,Product use issue,OT
166844505,Infliximab,Product use issue,HO
166844505,Infliximab,Photosensitivity reaction,OT
166844505,Infliximab,Photosensitivity reaction,HO
166844505,Infliximab,Off label use,OT
166844505,Infliximab,Off label use,HO
166844505,Infliximab,Nasal dryness,OT
166844505,Infliximab,Nasal dryness,HO
166844505,Infliximab,Myalgia,OT
166844505,Infliximab,Myalgia,HO
166844505,Infliximab,Intentional product use issue,OT
166844505,Infliximab,Intentional product use issue,HO
166844505,Infliximab,Inappropriate schedule of product administration,OT
166844505,Infliximab,Inappropriate schedule of product administration,HO
166844505,Infliximab,Hypoaesthesia,OT
166844505,Infliximab,Hypoaesthesia,HO
166844505,Infliximab,Heart rate decreased,OT
166844505,Infliximab,Heart rate decreased,HO
166844505,Infliximab,Headache,OT
166844505,Infliximab,Headache,HO
166844505,Infliximab,Halo vision,OT
166844505,Infliximab,Halo vision,HO
166844505,Infliximab,Haemoglobin decreased,OT
166844505,Infliximab,Haemoglobin decreased,HO
166844505,Infliximab,Fatigue,OT
166844505,Infliximab,Fatigue,HO
166844505,Infliximab,Dyspnoea,OT
166844505,Infliximab,Dyspnoea,HO
166844505,Infliximab,Drug level decreased,OT
166844505,Infliximab,Drug level decreased,HO
166844505,Infliximab,Contusion,OT
166844505,Infliximab,Contusion,HO
166844505,Infliximab,Condition aggravated,OT
166844505,Infliximab,Condition aggravated,HO
166844505,Infliximab,Chromaturia,OT
166844505,Infliximab,Chromaturia,HO
166844505,Infliximab,Blood pressure fluctuation,OT
166844505,Infliximab,Blood pressure fluctuation,HO
166844505,Infliximab,Blood iron decreased,OT
166844505,Infliximab,Blood iron decreased,HO
166844505,Infliximab,Arthropod bite,OT
166844505,Infliximab,Arthropod bite,HO
166844505,Infliximab,Arthralgia,OT
166844505,Infliximab,Arthralgia,HO
166844505,Infliximab,Abnormal faeces,OT
166844505,Infliximab,Abnormal faeces,HO
166844505,Infliximab,Abdominal distension,OT
166844505,Infliximab,Abdominal distension,HO
166844505,Infliximab,Abdominal discomfort,OT
166844505,Infliximab,Abdominal discomfort,HO
166920246,Infliximab,Weight increased,OT
166920246,Infliximab,Weight fluctuation,OT
166920246,Infliximab,Weight decreased,OT
166920246,Infliximab,Rectal haemorrhage,OT
166920246,Infliximab,Rash,OT
166920246,Infliximab,Off label use,OT
166920246,Infliximab,Incorrect dose administered,OT
166920246,Infliximab,Inappropriate schedule of product administration,OT
166920246,Infliximab,Gastrointestinal disorder,OT
166920246,Infliximab,Drug level increased,OT
166920246,Infliximab,Drug level below therapeutic,OT
166920246,Infliximab,Condition aggravated,OT
168386564,Infliximab,Weight increased,OT
168386564,Infliximab,Vision blurred,OT
168386564,Infliximab,Product dose omission issue,OT
168386564,Infliximab,Presyncope,OT
168386564,Infliximab,Off label use,OT
168386564,Infliximab,Nervousness,OT
168386564,Infliximab,Nausea,OT
168386564,Infliximab,Intentional product use issue,OT
168386564,Infliximab,Incorrect dose administered,OT
168386564,Infliximab,Inappropriate schedule of product administration,OT
168386564,Infliximab,Hypotension,OT
168386564,Infliximab,Heart rate irregular,OT
168386564,Infliximab,Heart rate decreased,OT
168386564,Infliximab,Dizziness,OT
168386564,Infliximab,Condition aggravated,OT
168386564,Infliximab,Blood pressure increased,OT
168386564,Infliximab,Blood pressure fluctuation,OT
172396424,Infliximab,Weight increased,HO
172396424,Infliximab,Weight decreased,HO
172396424,Infliximab,Product use in unapproved indication,HO
172396424,Infliximab,Paraesthesia,HO
172396424,Infliximab,Off label use,HO
172396424,Infliximab,Neurological symptom,HO
172396424,Infliximab,Incorrect dose administered,HO
172396424,Infliximab,Hypoaesthesia,HO
172396424,Infliximab,Heart rate decreased,HO
172396424,Infliximab,Headache,HO
172396424,Infliximab,Erythema,HO
172396424,Infliximab,Cough,HO
172396424,Infliximab,C-reactive protein decreased,HO
172396424,Infliximab,Body temperature fluctuation,HO
172396424,Infliximab,Body temperature decreased,HO
172396424,Infliximab,Acne,HO
172396424,Infliximab,Weight increased,HO
172396424,Infliximab,Weight decreased,HO
172396424,Infliximab,Product use in unapproved indication,HO
172396424,Infliximab,Paraesthesia,HO
172396424,Infliximab,Off label use,HO
172396424,Infliximab,Neurological symptom,HO
172396424,Infliximab,Incorrect dose administered,HO
172396424,Infliximab,Hypoaesthesia,HO
172396424,Infliximab,Heart rate decreased,HO
172396424,Infliximab,Headache,HO
172396424,Infliximab,Erythema,HO
172396424,Infliximab,Cough,HO
172396424,Infliximab,C-reactive protein decreased,HO
172396424,Infliximab,Body temperature fluctuation,HO
172396424,Infliximab,Body temperature decreased,HO
172396424,Infliximab,Acne,HO
172396424,Infliximab,Weight increased,HO
172396424,Infliximab,Weight decreased,HO
172396424,Infliximab,Product use in unapproved indication,HO
172396424,Infliximab,Paraesthesia,HO
172396424,Infliximab,Off label use,HO
172396424,Infliximab,Neurological symptom,HO
172396424,Infliximab,Incorrect dose administered,HO
172396424,Infliximab,Hypoaesthesia,HO
172396424,Infliximab,Heart rate decreased,HO
172396424,Infliximab,Headache,HO
172396424,Infliximab,Erythema,HO
172396424,Infliximab,Cough,HO
172396424,Infliximab,C-reactive protein decreased,HO
172396424,Infliximab,Body temperature fluctuation,HO
172396424,Infliximab,Body temperature decreased,HO
172396424,Infliximab,Acne,HO
172510293,Infliximab,Product use in unapproved indication,OT
172510293,Infliximab,Off label use,OT
172510293,Infliximab,Mouth ulceration,OT
172510293,Infliximab,Product use in unapproved indication,OT
172510293,Infliximab,Off label use,OT
172510293,Infliximab,Mouth ulceration,OT
174778732,Infliximab,Wheelchair user,HO
174778732,Infliximab,Wheelchair user,OT
174778732,Infliximab,Vomiting,HO
174778732,Infliximab,Vomiting,OT
174778732,Infliximab,Underdose,HO
174778732,Infliximab,Underdose,OT
174778732,Infliximab,Synovitis,HO
174778732,Infliximab,Synovitis,OT
174778732,Infliximab,Septic shock,HO
174778732,Infliximab,Septic shock,OT
174778732,Infliximab,Red blood cell sedimentation rate increased,HO
174778732,Infliximab,Red blood cell sedimentation rate increased,OT
174778732,Infliximab,Psoriasis,HO
174778732,Infliximab,Psoriasis,OT
174778732,Infliximab,Product use in unapproved indication,HO
174778732,Infliximab,Product use in unapproved indication,OT
174778732,Infliximab,Polyarthritis,HO
174778732,Infliximab,Polyarthritis,OT
174778732,Infliximab,Off label use,HO
174778732,Infliximab,Off label use,OT
174778732,Infliximab,Obesity,HO
174778732,Infliximab,Obesity,OT
174778732,Infliximab,Nausea,HO
174778732,Infliximab,Nausea,OT
174778732,Infliximab,Mobility decreased,HO
174778732,Infliximab,Mobility decreased,OT
174778732,Infliximab,Loss of personal independence in daily activities,HO
174778732,Infliximab,Loss of personal independence in daily activities,OT
174778732,Infliximab,Juvenile idiopathic arthritis,HO
174778732,Infliximab,Juvenile idiopathic arthritis,OT
174778732,Infliximab,Human antichimeric antibody positive,HO
174778732,Infliximab,Human antichimeric antibody positive,OT
174778732,Infliximab,Drug specific antibody,HO
174778732,Infliximab,Drug specific antibody,OT
174778732,Infliximab,Drug intolerance,HO
174778732,Infliximab,Drug intolerance,OT
174778732,Infliximab,Drug ineffective,HO
174778732,Infliximab,Drug ineffective,OT
174778732,Infliximab,Dizziness,HO
174778732,Infliximab,Dizziness,OT
174778732,Infliximab,Diarrhoea,HO
174778732,Infliximab,Diarrhoea,OT
174778732,Infliximab,Condition aggravated,HO
174778732,Infliximab,Condition aggravated,OT
174778732,Infliximab,C-reactive protein increased,HO
174778732,Infliximab,C-reactive protein increased,OT
174778732,Infliximab,Bone density decreased,HO
174778732,Infliximab,Bone density decreased,OT
174778732,Infliximab,Body height below normal,HO
174778732,Infliximab,Body height below normal,OT
174778732,Infliximab,Arthropathy,HO
174778732,Infliximab,Arthropathy,OT
174778732,Infliximab,Arthritis,HO
174778732,Infliximab,Arthritis,OT
174778732,Infliximab,Antibody test positive,HO
174778732,Infliximab,Antibody test positive,OT
174778732,Infliximab,Adrenal insufficiency,HO
174778732,Infliximab,Adrenal insufficiency,OT
174778732,Infliximab,Wheelchair user,HO
174778732,Infliximab,Wheelchair user,OT
174778732,Infliximab,Vomiting,HO
174778732,Infliximab,Vomiting,OT
174778732,Infliximab,Underdose,HO
174778732,Infliximab,Underdose,OT
174778732,Infliximab,Synovitis,HO
174778732,Infliximab,Synovitis,OT
174778732,Infliximab,Septic shock,HO
174778732,Infliximab,Septic shock,OT
174778732,Infliximab,Red blood cell sedimentation rate increased,HO
174778732,Infliximab,Red blood cell sedimentation rate increased,OT
174778732,Infliximab,Psoriasis,HO
174778732,Infliximab,Psoriasis,OT
174778732,Infliximab,Product use in unapproved indication,HO
174778732,Infliximab,Product use in unapproved indication,OT
174778732,Infliximab,Polyarthritis,HO
174778732,Infliximab,Polyarthritis,OT
174778732,Infliximab,Off label use,HO
174778732,Infliximab,Off label use,OT
174778732,Infliximab,Obesity,HO
174778732,Infliximab,Obesity,OT
174778732,Infliximab,Nausea,HO
174778732,Infliximab,Nausea,OT
174778732,Infliximab,Mobility decreased,HO
174778732,Infliximab,Mobility decreased,OT
174778732,Infliximab,Loss of personal independence in daily activities,HO
174778732,Infliximab,Loss of personal independence in daily activities,OT
174778732,Infliximab,Juvenile idiopathic arthritis,HO
174778732,Infliximab,Juvenile idiopathic arthritis,OT
174778732,Infliximab,Human antichimeric antibody positive,HO
174778732,Infliximab,Human antichimeric antibody positive,OT
174778732,Infliximab,Drug specific antibody,HO
174778732,Infliximab,Drug specific antibody,OT
174778732,Infliximab,Drug intolerance,HO
174778732,Infliximab,Drug intolerance,OT
174778732,Infliximab,Drug ineffective,HO
174778732,Infliximab,Drug ineffective,OT
174778732,Infliximab,Dizziness,HO
174778732,Infliximab,Dizziness,OT
174778732,Infliximab,Diarrhoea,HO
174778732,Infliximab,Diarrhoea,OT
174778732,Infliximab,Condition aggravated,HO
174778732,Infliximab,Condition aggravated,OT
174778732,Infliximab,C-reactive protein increased,HO
174778732,Infliximab,C-reactive protein increased,OT
174778732,Infliximab,Bone density decreased,HO
174778732,Infliximab,Bone density decreased,OT
174778732,Infliximab,Body height below normal,HO
174778732,Infliximab,Body height below normal,OT
174778732,Infliximab,Arthropathy,HO
174778732,Infliximab,Arthropathy,OT
174778732,Infliximab,Arthritis,HO
174778732,Infliximab,Arthritis,OT
174778732,Infliximab,Antibody test positive,HO
174778732,Infliximab,Antibody test positive,OT
174778732,Infliximab,Adrenal insufficiency,HO
174778732,Infliximab,Adrenal insufficiency,OT
174778732,Infliximab,Wheelchair user,HO
174778732,Infliximab,Wheelchair user,OT
174778732,Infliximab,Vomiting,HO
174778732,Infliximab,Vomiting,OT
174778732,Infliximab,Underdose,HO
174778732,Infliximab,Underdose,OT
174778732,Infliximab,Synovitis,HO
174778732,Infliximab,Synovitis,OT
174778732,Infliximab,Septic shock,HO
174778732,Infliximab,Septic shock,OT
174778732,Infliximab,Red blood cell sedimentation rate increased,HO
174778732,Infliximab,Red blood cell sedimentation rate increased,OT
174778732,Infliximab,Psoriasis,HO
174778732,Infliximab,Psoriasis,OT
174778732,Infliximab,Product use in unapproved indication,HO
174778732,Infliximab,Product use in unapproved indication,OT
174778732,Infliximab,Polyarthritis,HO
174778732,Infliximab,Polyarthritis,OT
174778732,Infliximab,Off label use,HO
174778732,Infliximab,Off label use,OT
174778732,Infliximab,Obesity,HO
174778732,Infliximab,Obesity,OT
174778732,Infliximab,Nausea,HO
174778732,Infliximab,Nausea,OT
174778732,Infliximab,Mobility decreased,HO
174778732,Infliximab,Mobility decreased,OT
174778732,Infliximab,Loss of personal independence in daily activities,HO
174778732,Infliximab,Loss of personal independence in daily activities,OT
174778732,Infliximab,Juvenile idiopathic arthritis,HO
174778732,Infliximab,Juvenile idiopathic arthritis,OT
174778732,Infliximab,Human antichimeric antibody positive,HO
174778732,Infliximab,Human antichimeric antibody positive,OT
174778732,Infliximab,Drug specific antibody,HO
174778732,Infliximab,Drug specific antibody,OT
174778732,Infliximab,Drug intolerance,HO
174778732,Infliximab,Drug intolerance,OT
174778732,Infliximab,Drug ineffective,HO
174778732,Infliximab,Drug ineffective,OT
174778732,Infliximab,Dizziness,HO
174778732,Infliximab,Dizziness,OT
174778732,Infliximab,Diarrhoea,HO
174778732,Infliximab,Diarrhoea,OT
174778732,Infliximab,Condition aggravated,HO
174778732,Infliximab,Condition aggravated,OT
174778732,Infliximab,C-reactive protein increased,HO
174778732,Infliximab,C-reactive protein increased,OT
174778732,Infliximab,Bone density decreased,HO
174778732,Infliximab,Bone density decreased,OT
174778732,Infliximab,Body height below normal,HO
174778732,Infliximab,Body height below normal,OT
174778732,Infliximab,Arthropathy,HO
174778732,Infliximab,Arthropathy,OT
174778732,Infliximab,Arthritis,HO
174778732,Infliximab,Arthritis,OT
174778732,Infliximab,Antibody test positive,HO
174778732,Infliximab,Antibody test positive,OT
174778732,Infliximab,Adrenal insufficiency,HO
174778732,Infliximab,Adrenal insufficiency,OT
174801683,Infliximab,Weight increased,OT
174801683,Infliximab,Weight fluctuation,OT
174801683,Infliximab,Weight decreased,OT
174801683,Infliximab,Product use issue,OT
174801683,Infliximab,Pain in extremity,OT
174801683,Infliximab,Pain,OT
174801683,Infliximab,Oxygen saturation decreased,OT
174801683,Infliximab,Off label use,OT
174801683,Infliximab,Oedema peripheral,OT
174801683,Infliximab,Intentional product use issue,OT
174801683,Infliximab,Condition aggravated,OT
174801683,Infliximab,Blood pressure increased,OT
174801683,Infliximab,Blood pressure fluctuation,OT
174801683,Infliximab,Back pain,OT
174801683,Infliximab,Weight increased,OT
174801683,Infliximab,Weight fluctuation,OT
174801683,Infliximab,Weight decreased,OT
174801683,Infliximab,Product use issue,OT
174801683,Infliximab,Pain in extremity,OT
174801683,Infliximab,Pain,OT
174801683,Infliximab,Oxygen saturation decreased,OT
174801683,Infliximab,Off label use,OT
174801683,Infliximab,Oedema peripheral,OT
174801683,Infliximab,Intentional product use issue,OT
174801683,Infliximab,Condition aggravated,OT
174801683,Infliximab,Blood pressure increased,OT
174801683,Infliximab,Blood pressure fluctuation,OT
174801683,Infliximab,Back pain,OT
174801683,Infliximab,Weight increased,OT
174801683,Infliximab,Weight fluctuation,OT
174801683,Infliximab,Weight decreased,OT
174801683,Infliximab,Product use issue,OT
174801683,Infliximab,Pain in extremity,OT
174801683,Infliximab,Pain,OT
174801683,Infliximab,Oxygen saturation decreased,OT
174801683,Infliximab,Off label use,OT
174801683,Infliximab,Oedema peripheral,OT
174801683,Infliximab,Intentional product use issue,OT
174801683,Infliximab,Condition aggravated,OT
174801683,Infliximab,Blood pressure increased,OT
174801683,Infliximab,Blood pressure fluctuation,OT
174801683,Infliximab,Back pain,OT
176057993,Infliximab,Wrist fracture,OT
176057993,Infliximab,Wrist fracture,HO
176057993,Infliximab,Therapeutic response shortened,OT
176057993,Infliximab,Therapeutic response shortened,HO
176057993,Infliximab,Therapeutic product effect decreased,OT
176057993,Infliximab,Therapeutic product effect decreased,HO
176057993,Infliximab,Product use issue,OT
176057993,Infliximab,Product use issue,HO
176057993,Infliximab,Off label use,OT
176057993,Infliximab,Off label use,HO
176057993,Infliximab,Localised infection,OT
176057993,Infliximab,Localised infection,HO
176057993,Infliximab,Intestinal stenosis,OT
176057993,Infliximab,Intestinal stenosis,HO
176057993,Infliximab,Intentional product use issue,OT
176057993,Infliximab,Intentional product use issue,HO
176057993,Infliximab,Herpes virus infection,OT
176057993,Infliximab,Herpes virus infection,HO
176057993,Infliximab,Fall,OT
176057993,Infliximab,Fall,HO
176057993,Infliximab,Condition aggravated,OT
176057993,Infliximab,Condition aggravated,HO
176057993,Infliximab,Blood pressure increased,OT
176057993,Infliximab,Blood pressure increased,HO
176057993,Infliximab,Blood pressure fluctuation,OT
176057993,Infliximab,Blood pressure fluctuation,HO
176057993,Infliximab,Blood glucose increased,OT
176057993,Infliximab,Blood glucose increased,HO
176057993,Infliximab,Arthralgia,OT
176057993,Infliximab,Arthralgia,HO
176057993,Infliximab,Aphonia,OT
176057993,Infliximab,Aphonia,HO
176057993,Infliximab,Abscess,OT
176057993,Infliximab,Abscess,HO
176472224,Infliximab,Weight decreased,OT
176472224,Infliximab,Sinusitis,OT
176472224,Infliximab,Renal failure,OT
176472224,Infliximab,Product use issue,OT
176472224,Infliximab,Poor venous access,OT
176472224,Infliximab,Off label use,OT
176472224,Infliximab,Malaise,OT
176472224,Infliximab,Intentional product use issue,OT
176472224,Infliximab,Infusion site pain,OT
176472224,Infliximab,Infusion site bruising,OT
176472224,Infliximab,Inappropriate schedule of product administration,OT
176472224,Infliximab,Drug level below therapeutic,OT
176472224,Infliximab,Condition aggravated,OT
176472224,Infliximab,Body temperature decreased,OT
176472224,Infliximab,Arthralgia,OT
176472224,Infliximab,Anal fistula,OT
176472224,Infliximab,Anal fissure,OT
176472224,Infliximab,Abdominal pain,OT
176472224,Infliximab,Weight decreased,OT
176472224,Infliximab,Sinusitis,OT
176472224,Infliximab,Renal failure,OT
176472224,Infliximab,Product use issue,OT
176472224,Infliximab,Poor venous access,OT
176472224,Infliximab,Off label use,OT
176472224,Infliximab,Malaise,OT
176472224,Infliximab,Intentional product use issue,OT
176472224,Infliximab,Infusion site pain,OT
176472224,Infliximab,Infusion site bruising,OT
176472224,Infliximab,Inappropriate schedule of product administration,OT
176472224,Infliximab,Drug level below therapeutic,OT
176472224,Infliximab,Condition aggravated,OT
176472224,Infliximab,Body temperature decreased,OT
176472224,Infliximab,Arthralgia,OT
176472224,Infliximab,Anal fistula,OT
176472224,Infliximab,Anal fissure,OT
176472224,Infliximab,Abdominal pain,OT
176529314,Infliximab,Weight decreased,OT
176529314,Infliximab,Vomiting,OT
176529314,Infliximab,Urinary tract infection,OT
176529314,Infliximab,Pyrexia,OT
176529314,Infliximab,Off label use,OT
176529314,Infliximab,Malaise,OT
176529314,Infliximab,Kidney infection,OT
176529314,Infliximab,Intentional product use issue,OT
176529314,Infliximab,Family stress,OT
176529314,Infliximab,Fall,OT
176529314,Infliximab,Diarrhoea,OT
176529314,Infliximab,Cystitis,OT
176529314,Infliximab,Contusion,OT
176529314,Infliximab,Breast mass,OT
176529314,Infliximab,Blood pressure fluctuation,OT
176529314,Infliximab,Back pain,OT
176529314,Infliximab,Ankle fracture,OT
176825894,Infliximab,Throat tightness,OT
176825894,Infliximab,Therapeutic product effect incomplete,OT
176825894,Infliximab,Sepsis,OT
176825894,Infliximab,Rectal haemorrhage,OT
176825894,Infliximab,Pyrexia,OT
176825894,Infliximab,Pain,OT
176825894,Infliximab,Off label use,OT
176825894,Infliximab,Nausea,OT
176825894,Infliximab,Intentional product use issue,OT
176825894,Infliximab,Inappropriate schedule of product administration,OT
176825894,Infliximab,Impaired healing,OT
176825894,Infliximab,Fistula discharge,OT
176825894,Infliximab,Feeling abnormal,OT
176825894,Infliximab,Drug level increased,OT
176825894,Infliximab,Drug level below therapeutic,OT
176825894,Infliximab,Condition aggravated,OT
176825894,Infliximab,Angioedema,OT
176825894,Infliximab,Anal fistula,OT
176825894,Infliximab,Throat tightness,OT
176825894,Infliximab,Therapeutic product effect incomplete,OT
176825894,Infliximab,Sepsis,OT
176825894,Infliximab,Rectal haemorrhage,OT
176825894,Infliximab,Pyrexia,OT
176825894,Infliximab,Pain,OT
176825894,Infliximab,Off label use,OT
176825894,Infliximab,Nausea,OT
176825894,Infliximab,Intentional product use issue,OT
176825894,Infliximab,Inappropriate schedule of product administration,OT
176825894,Infliximab,Impaired healing,OT
176825894,Infliximab,Fistula discharge,OT
176825894,Infliximab,Feeling abnormal,OT
176825894,Infliximab,Drug level increased,OT
176825894,Infliximab,Drug level below therapeutic,OT
176825894,Infliximab,Condition aggravated,OT
176825894,Infliximab,Angioedema,OT
176825894,Infliximab,Anal fistula,OT
176996393,Infliximab,Weight increased,OT
176996393,Infliximab,Oropharyngeal pain,OT
176996393,Infliximab,Off label use,OT
176996393,Infliximab,Nausea,OT
176996393,Infliximab,Nasopharyngitis,OT
176996393,Infliximab,Nasal congestion,OT
176996393,Infliximab,Mouth ulceration,OT
176996393,Infliximab,Intentional product use issue,OT
176996393,Infliximab,Heart rate irregular,OT
176996393,Infliximab,Flushing,OT
176996393,Infliximab,Expired product administered,OT
176996393,Infliximab,Dysphonia,OT
176996393,Infliximab,Condition aggravated,OT
176996393,Infliximab,Weight increased,OT
176996393,Infliximab,Oropharyngeal pain,OT
176996393,Infliximab,Off label use,OT
176996393,Infliximab,Nausea,OT
176996393,Infliximab,Nasopharyngitis,OT
176996393,Infliximab,Nasal congestion,OT
176996393,Infliximab,Mouth ulceration,OT
176996393,Infliximab,Intentional product use issue,OT
176996393,Infliximab,Heart rate irregular,OT
176996393,Infliximab,Flushing,OT
176996393,Infliximab,Expired product administered,OT
176996393,Infliximab,Dysphonia,OT
176996393,Infliximab,Condition aggravated,OT
177054773,Infliximab,Squamous cell carcinoma of skin,HO
177054773,Infliximab,Squamous cell carcinoma of skin,OT
177054773,Infliximab,Small intestinal obstruction,HO
177054773,Infliximab,Small intestinal obstruction,OT
177054773,Infliximab,Oropharyngeal discomfort,HO
177054773,Infliximab,Oropharyngeal discomfort,OT
177054773,Infliximab,Nasopharyngitis,HO
177054773,Infliximab,Nasopharyngitis,OT
177054773,Infliximab,Intestinal stenosis,HO
177054773,Infliximab,Intestinal stenosis,OT
177054773,Infliximab,Intestinal obstruction,HO
177054773,Infliximab,Intestinal obstruction,OT
177054773,Infliximab,Heart rate irregular,HO
177054773,Infliximab,Heart rate irregular,OT
177054773,Infliximab,Heart rate decreased,HO
177054773,Infliximab,Heart rate decreased,OT
177054773,Infliximab,Headache,HO
177054773,Infliximab,Headache,OT
177054773,Infliximab,Expired product administered,HO
177054773,Infliximab,Expired product administered,OT
177054773,Infliximab,Drug level below therapeutic,HO
177054773,Infliximab,Drug level below therapeutic,OT
177054773,Infliximab,Condition aggravated,HO
177054773,Infliximab,Condition aggravated,OT
177054773,Infliximab,Blood pressure increased,HO
177054773,Infliximab,Blood pressure increased,OT
177054773,Infliximab,Blood pressure fluctuation,HO
177054773,Infliximab,Blood pressure fluctuation,OT
177054773,Infliximab,Abdominal pain,HO
177054773,Infliximab,Abdominal pain,OT
180569862,Infliximab,Weight increased,OT
180569862,Infliximab,Vaginal haemorrhage,OT
180569862,Infliximab,Urinary tract infection,OT
180569862,Infliximab,Sputum discoloured,OT
180569862,Infliximab,Sinusitis,OT
180569862,Infliximab,Sinus pain,OT
180569862,Infliximab,Rhinorrhoea,OT
180569862,Infliximab,Pyrexia,OT
180569862,Infliximab,Product use issue,OT
180569862,Infliximab,Oropharyngeal pain,OT
180569862,Infliximab,Off label use,OT
180569862,Infliximab,Nasopharyngitis,OT
180569862,Infliximab,Nasal discharge discolouration,OT
180569862,Infliximab,Nasal congestion,OT
180569862,Infliximab,Maternal exposure during pregnancy,OT
180569862,Infliximab,Laryngitis,OT
180569862,Infliximab,Intentional product use issue,OT
180569862,Infliximab,Inappropriate schedule of product administration,OT
180569862,Infliximab,Heart rate irregular,OT
180569862,Infliximab,Haemorrhoids,OT
180569862,Infliximab,Gastroenteritis bacterial,OT
180569862,Infliximab,Dysphonia,OT
180569862,Infliximab,Drug level decreased,OT
180569862,Infliximab,Dizziness,OT
180569862,Infliximab,Diarrhoea,OT
180569862,Infliximab,Cough,OT
180569862,Infliximab,Condition aggravated,OT
180569862,Infliximab,Clostridium difficile infection,OT
180569862,Infliximab,Blood pressure fluctuation,OT
180569862,Infliximab,Blood pressure diastolic decreased,OT
180569862,Infliximab,Asthenia,OT
180569862,Infliximab,Arthralgia,OT
180569862,Infliximab,Anal fissure,OT
180569862,Infliximab,Abscess,OT
180569862,Infliximab,Abdominal pain,OT
184364052,Infliximab,Off label use,OT
184364052,Infliximab,Nausea,OT
184364052,Infliximab,Intentional product use issue,OT
184364052,Infliximab,Heart rate decreased,OT
184364052,Infliximab,Headache,OT
184364052,Infliximab,Fatigue,OT
184364052,Infliximab,Drug ineffective,OT
184364052,Infliximab,Diarrhoea,OT
184364052,Infliximab,Condition aggravated,OT
184364052,Infliximab,Blood pressure increased,OT
184364052,Infliximab,Blood pressure fluctuation,OT
184364052,Infliximab,Arthralgia,OT
185203522,Infliximab,Pulmonary tuberculosis,HO
185203522,Infliximab,Pulmonary tuberculosis,OT
185203522,Infliximab,Pulmonary granuloma,HO
185203522,Infliximab,Pulmonary granuloma,OT
185203522,Infliximab,Infection susceptibility increased,HO
185203522,Infliximab,Infection susceptibility increased,OT
185203522,Infliximab,Hypoxia,HO
185203522,Infliximab,Hypoxia,OT
185203522,Infliximab,Hypokalaemia,HO
185203522,Infliximab,Hypokalaemia,OT
185203522,Infliximab,Atelectasis,HO
185203522,Infliximab,Atelectasis,OT
185231982,Infliximab,Product use issue,OT
185231982,Infliximab,Off label use,OT
185231982,Infliximab,Intentional product use issue,OT
185231982,Infliximab,Chest pain,OT
185231982,Infliximab,Arthropathy,OT
185792093,Infliximab,SARS-CoV-2 test positive,OT
185792093,Infliximab,Pallor,OT
185792093,Infliximab,Off label use,OT
185792093,Infliximab,Malaise,OT
185792093,Infliximab,Inappropriate schedule of product administration,OT
185792093,Infliximab,Heart rate increased,OT
185792093,Infliximab,Haematochezia,OT
185792093,Infliximab,Exposure to SARS-CoV-2,OT
185792093,Infliximab,Drug level below therapeutic,OT
185792093,Infliximab,Condition aggravated,OT
185792093,Infliximab,Anxiety,OT
185792093,Infliximab,Abdominal pain,OT
185792093,Infliximab,SARS-CoV-2 test positive,OT
185792093,Infliximab,Pallor,OT
185792093,Infliximab,Off label use,OT
185792093,Infliximab,Malaise,OT
185792093,Infliximab,Inappropriate schedule of product administration,OT
185792093,Infliximab,Heart rate increased,OT
185792093,Infliximab,Haematochezia,OT
185792093,Infliximab,Exposure to SARS-CoV-2,OT
185792093,Infliximab,Drug level below therapeutic,OT
185792093,Infliximab,Condition aggravated,OT
185792093,Infliximab,Anxiety,OT
185792093,Infliximab,Abdominal pain,OT
186426542,Infliximab,Vomiting,OT
186426542,Infliximab,Malaise,OT
186426542,Infliximab,Inappropriate schedule of product administration,OT
186426542,Infliximab,Gastrointestinal inflammation,OT
186426542,Infliximab,Faecal calprotectin increased,OT
186426542,Infliximab,Dizziness,OT
187074433,Infliximab,Pyrexia,OT
187074433,Infliximab,Polyp,OT
187074433,Infliximab,Off label use,OT
187074433,Infliximab,Intentional product use issue,OT
187074433,Infliximab,Inflammatory bowel disease,OT
187074433,Infliximab,Faecal calprotectin increased,OT
187074433,Infliximab,Drug ineffective,OT
187074433,Infliximab,Cough,OT
187074433,Infliximab,Condition aggravated,OT
187074433,Infliximab,Blood pressure increased,OT
187074433,Infliximab,Blood pressure diastolic increased,OT
187074433,Infliximab,Pyrexia,OT
187074433,Infliximab,Polyp,OT
187074433,Infliximab,Off label use,OT
187074433,Infliximab,Intentional product use issue,OT
187074433,Infliximab,Inflammatory bowel disease,OT
187074433,Infliximab,Faecal calprotectin increased,OT
187074433,Infliximab,Drug ineffective,OT
187074433,Infliximab,Cough,OT
187074433,Infliximab,Condition aggravated,OT
187074433,Infliximab,Blood pressure increased,OT
187074433,Infliximab,Blood pressure diastolic increased,OT
189000592,Infliximab,Septic shock,HO
189000592,Infliximab,Septic shock,LT
189000592,Infliximab,Septic shock,OT
189000592,Infliximab,Histoplasmosis,HO
189000592,Infliximab,Histoplasmosis,LT
189000592,Infliximab,Histoplasmosis,OT
189000592,Infliximab,Herpes simplex,HO
189000592,Infliximab,Herpes simplex,LT
189000592,Infliximab,Herpes simplex,OT
189000592,Infliximab,Cutaneous nocardiosis,HO
189000592,Infliximab,Cutaneous nocardiosis,LT
189000592,Infliximab,Cutaneous nocardiosis,OT
189000592,Infliximab,Septic shock,HO
189000592,Infliximab,Septic shock,LT
189000592,Infliximab,Septic shock,OT
189000592,Infliximab,Histoplasmosis,HO
189000592,Infliximab,Histoplasmosis,LT
189000592,Infliximab,Histoplasmosis,OT
189000592,Infliximab,Herpes simplex,HO
189000592,Infliximab,Herpes simplex,LT
189000592,Infliximab,Herpes simplex,OT
189000592,Infliximab,Cutaneous nocardiosis,HO
189000592,Infliximab,Cutaneous nocardiosis,LT
189000592,Infliximab,Cutaneous nocardiosis,OT
189543382,Infliximab,Hodgkin's disease,OT
190707233,Infliximab,Synovitis,OT
190707233,Infliximab,Product use in unapproved indication,OT
190707233,Infliximab,Pneumonia,OT
190707233,Infliximab,Osteoporosis,OT
190707233,Infliximab,Osteoarthritis,OT
190707233,Infliximab,Off label use,OT
190707233,Infliximab,Nausea,OT
190707233,Infliximab,Joint stiffness,OT
190707233,Infliximab,Joint dislocation,OT
190707233,Infliximab,Infection,OT
190707233,Infliximab,Hepatic cirrhosis,OT
190707233,Infliximab,Headache,OT
190707233,Infliximab,Foot deformity,OT
190707233,Infliximab,Exostosis,OT
190707233,Infliximab,Drug-induced liver injury,OT
190707233,Infliximab,Drug intolerance,OT
190707233,Infliximab,Drug ineffective,OT
190707233,Infliximab,Drug hypersensitivity,OT
190707233,Infliximab,Dizziness,OT
190707233,Infliximab,Contraindicated product administered,OT
190707233,Infliximab,Bone erosion,OT
190707233,Infliximab,Arthritis,OT
190707233,Infliximab,Adverse drug reaction,OT
190707233,Infliximab,Synovitis,OT
190707233,Infliximab,Product use in unapproved indication,OT
190707233,Infliximab,Pneumonia,OT
190707233,Infliximab,Osteoporosis,OT
190707233,Infliximab,Osteoarthritis,OT
190707233,Infliximab,Off label use,OT
190707233,Infliximab,Nausea,OT
190707233,Infliximab,Joint stiffness,OT
190707233,Infliximab,Joint dislocation,OT
190707233,Infliximab,Infection,OT
190707233,Infliximab,Hepatic cirrhosis,OT
190707233,Infliximab,Headache,OT
190707233,Infliximab,Foot deformity,OT
190707233,Infliximab,Exostosis,OT
190707233,Infliximab,Drug-induced liver injury,OT
190707233,Infliximab,Drug intolerance,OT
190707233,Infliximab,Drug ineffective,OT
190707233,Infliximab,Drug hypersensitivity,OT
190707233,Infliximab,Dizziness,OT
190707233,Infliximab,Contraindicated product administered,OT
190707233,Infliximab,Bone erosion,OT
190707233,Infliximab,Arthritis,OT
190707233,Infliximab,Adverse drug reaction,OT
191866222,Infliximab,Venous injury,OT
191866222,Infliximab,Small intestinal obstruction,OT
191866222,Infliximab,Off label use,OT
191866222,Infliximab,Intentional product use issue,OT
191866222,Infliximab,Blood pressure diastolic decreased,OT
192709762,Infliximab,Weight increased,OT
192709762,Infliximab,Treatment failure,OT
192709762,Infliximab,Off label use,OT
192709762,Infliximab,Neuropathy peripheral,OT
192709762,Infliximab,Nausea,OT
192709762,Infliximab,Lethargy,OT
192709762,Infliximab,Heart rate decreased,OT
192709762,Infliximab,Headache,OT
192709762,Infliximab,Fatigue,OT
192709762,Infliximab,Disease recurrence,OT
192709762,Infliximab,Condition aggravated,OT
192709762,Infliximab,Body temperature decreased,OT
192709762,Infliximab,Blood pressure increased,OT
192709762,Infliximab,Weight increased,OT
192709762,Infliximab,Treatment failure,OT
192709762,Infliximab,Off label use,OT
192709762,Infliximab,Neuropathy peripheral,OT
192709762,Infliximab,Nausea,OT
192709762,Infliximab,Lethargy,OT
192709762,Infliximab,Heart rate decreased,OT
192709762,Infliximab,Headache,OT
192709762,Infliximab,Fatigue,OT
192709762,Infliximab,Disease recurrence,OT
192709762,Infliximab,Condition aggravated,OT
192709762,Infliximab,Body temperature decreased,OT
192709762,Infliximab,Blood pressure increased,OT
193599702,Infliximab,SARS-CoV-2 test positive,OT
193599702,Infliximab,Off label use,OT
193599702,Infliximab,Intentional product use issue,OT
193599702,Infliximab,Asymptomatic COVID-19,OT
193599702,Infliximab,Abdominal hernia,OT
193599702,Infliximab,SARS-CoV-2 test positive,OT
193599702,Infliximab,Off label use,OT
193599702,Infliximab,Intentional product use issue,OT
193599702,Infliximab,Asymptomatic COVID-19,OT
193599702,Infliximab,Abdominal hernia,OT
194792992,Infliximab,SARS-CoV-2 test positive,OT
194792992,Infliximab,Product use in unapproved indication,OT
194792992,Infliximab,Poor venous access,OT
194792992,Infliximab,Off label use,OT
194792992,Infliximab,Intentional product use issue,OT
194792992,Infliximab,Incorrect dose administered,OT
194792992,Infliximab,Inappropriate schedule of product administration,OT
194792992,Infliximab,C-reactive protein increased,OT
194792992,Infliximab,Blood pressure fluctuation,OT
195189261,Infliximab,Pneumonia cryptococcal,OT
195189261,Infliximab,Pneumonia cryptococcal,HO
195189261,Infliximab,Gastrointestinal disorder,OT
195189261,Infliximab,Gastrointestinal disorder,HO
195382472,Infliximab,Colitis ulcerative,OT
195382472,Infliximab,Colitis ulcerative,HO
195382472,Infliximab,Colitis ulcerative,OT
195382472,Infliximab,Colitis ulcerative,HO
195941861,Infliximab,Synovitis,HO
195941861,Infliximab,Synovitis,OT
195941861,Infliximab,Klebsiella infection,HO
195941861,Infliximab,Klebsiella infection,OT
195941861,Infliximab,Human herpesvirus 6 infection,HO
195941861,Infliximab,Human herpesvirus 6 infection,OT
195941861,Infliximab,Emphysematous cystitis,HO
195941861,Infliximab,Emphysematous cystitis,OT
195941861,Infliximab,Drug ineffective,HO
195941861,Infliximab,Drug ineffective,OT
195941861,Infliximab,Bacterial infection,HO
195941861,Infliximab,Bacterial infection,OT
196098701,Infliximab,Weight increased,OT
196098701,Infliximab,Product use issue,OT
196098701,Infliximab,Off label use,OT
196098701,Infliximab,Inappropriate schedule of product administration,OT
196098701,Infliximab,Heart rate decreased,OT
196098701,Infliximab,Condition aggravated,OT
196147671,Infliximab,Weight fluctuation,OT
196147671,Infliximab,Rash,OT
196147671,Infliximab,Poor venous access,OT
196147671,Infliximab,Off label use,OT
196147671,Infliximab,Joint swelling,OT
196147671,Infliximab,Inappropriate schedule of product administration,OT
196147671,Infliximab,Dry skin,OT
196147671,Infliximab,Colitis ulcerative,OT
196147671,Infliximab,Blood pressure increased,OT
196150461,Infliximab,Weight increased,OT
196150461,Infliximab,Off label use,OT
196150461,Infliximab,Hypothermia,OT
196150461,Infliximab,Drug level decreased,OT
196150461,Infliximab,Condition aggravated,OT
196265771,Infliximab,Immune reconstitution inflammatory syndrome,HO
196265771,Infliximab,Hepatitis B reactivation,HO
196582422,Infliximab (Unknown),Presyncope,HO
196661361,Infliximab (Unknown),Pancreatitis,HO
196661361,Infliximab (Unknown),Overdose,HO
196866881,Infliximab,White blood cell count decreased,OT
196866881,Infliximab,Urinary tract infection,OT
196866881,Infliximab,Sinusitis,OT
196866881,Infliximab,Product use issue,OT
196866881,Infliximab,Oropharyngeal pain,OT
196866881,Infliximab,Off label use,OT
196866881,Infliximab,Nasopharyngitis,OT
196866881,Infliximab,Malaise,OT
196866881,Infliximab,Intentional product use issue,OT
196866881,Infliximab,Headache,OT
196866881,Infliximab,Drug hypersensitivity,OT
196866881,Infliximab,Conjunctivitis,OT
196866881,Infliximab,Condition aggravated,OT
196891521,Infliximab,General physical health deterioration,OT
196891521,Infliximab,Gastrointestinal bacterial infection,OT
196891521,Infliximab,Abdominal pain,OT
197535531,Infliximab,PASH syndrome,OT
197535531,Infliximab,PASH syndrome,HO
197535531,Infliximab,Off label use,OT
197535531,Infliximab,Off label use,HO
197535531,Infliximab,Drug ineffective for unapproved indication,OT
197535531,Infliximab,Drug ineffective for unapproved indication,HO
197535531,Infliximab,PASH syndrome,OT
197535531,Infliximab,PASH syndrome,HO
197535531,Infliximab,Off label use,OT
197535531,Infliximab,Off label use,HO
197535531,Infliximab,Drug ineffective for unapproved indication,OT
197535531,Infliximab,Drug ineffective for unapproved indication,HO
197602801,Infliximab,Uveitis,OT
197602801,Infliximab,Oxygen saturation decreased,OT
197602801,Infliximab,Off label use,OT
197602801,Infliximab,Drug level decreased,OT
197602801,Infliximab,Blood pressure increased,OT
197602801,Infliximab,Uveitis,OT
197602801,Infliximab,Oxygen saturation decreased,OT
197602801,Infliximab,Off label use,OT
197602801,Infliximab,Drug level decreased,OT
197602801,Infliximab,Blood pressure increased,OT
198109441,Infliximab (Unknown),Infection susceptibility increased,OT
198151951,Infliximab,Tachycardia,HO
198151951,Infliximab,Off label use,HO
198151951,Infliximab,Diverticulitis,HO
198151951,Infliximab,Clostridium test positive,HO
198151951,Infliximab,Blood pressure systolic increased,HO
198562731,Infliximab,Oesophageal fibrosis,HO
198562731,Infliximab,Oesophageal fibrosis,OT
198562731,Infliximab,Dysphagia,HO
198562731,Infliximab,Dysphagia,OT
198728021,Infliximab,Pyrexia,OT
198728021,Infliximab,Pain,OT
198728021,Infliximab,Off label use,OT
198728021,Infliximab,Lung disorder,OT
198728021,Infliximab,Inappropriate schedule of product administration,OT
198728021,Infliximab,Heart rate increased,OT
198728021,Infliximab,Haemorrhoids,OT
198728021,Infliximab,Haemoglobin decreased,OT
198728021,Infliximab,Haematochezia,OT
198728021,Infliximab,Feeling cold,OT
198728021,Infliximab,Drug specific antibody present,OT
198728021,Infliximab,Diarrhoea,OT
198728021,Infliximab,Condition aggravated,OT
198728021,Infliximab,Chills,OT
198728021,Infliximab,Chest discomfort,OT
198728021,Infliximab,Anxiety,OT
198728021,Infliximab,Anaemia,OT
198785631,Infliximab,Nephropathy toxic,OT
198785631,Infliximab,Herpes zoster,OT
198785631,Infliximab,Epistaxis,OT
198785631,Infliximab,Drug ineffective,OT
198785631,Infliximab,Dermatitis allergic,OT
198785631,Infliximab,Alopecia,OT
198804391,Infliximab,Pustular psoriasis,OT
198804391,Infliximab,Product use issue,OT
198804391,Infliximab,Product dose omission issue,OT
198804391,Infliximab,Off label use,OT
198804391,Infliximab,Inappropriate schedule of product administration,OT
198804391,Infliximab,Arthropathy,OT
198804391,Infliximab,Acarodermatitis,OT
198867251,Infliximab Pfizer (Unknown),Uveitis,OT
198867251,Infliximab Pfizer (Unknown),Thyroid disorder,OT
198867251,Infliximab Pfizer (Unknown),Rhinorrhoea,OT
198867251,Infliximab Pfizer (Unknown),Psoriatic arthropathy,OT
198867251,Infliximab Pfizer (Unknown),Productive cough,OT
198867251,Infliximab Pfizer (Unknown),Oropharyngeal pain,OT
198867251,Infliximab Pfizer (Unknown),Off label use,OT
198867251,Infliximab Pfizer (Unknown),Headache,OT
198867251,Infliximab Pfizer (Unknown),Drug ineffective,OT
198867251,Infliximab Pfizer (Unknown),Colitis microscopic,OT
198867251,Infliximab Pfizer (Unknown),Basal cell carcinoma,OT
198867251,Infliximab Pfizer (Unknown),Asthma,OT
198915771,Infliximab Hospira,Pyrexia,OT
198915771,Infliximab Hospira,Off label use,OT
198915771,Infliximab Hospira,Dyspnoea,OT
198915771,Infliximab Hospira,Dysgeusia,OT
198915771,Infliximab Hospira,Diarrhoea,OT
198915771,Infliximab Hospira,Cough,OT
198915771,Infliximab Hospira,COVID-19,OT
198915771,Infliximab Hospira,Anosmia,OT
198984821,Infliximab,Product substitution issue,NULL
198984821,Infliximab,Ill-defined disorder,NULL
198984821,Infliximab,Condition aggravated,NULL
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
148426928,Infliximab Pfizer (Unknown),Weight increased,OT
148426928,Infliximab Pfizer (Unknown),Weight decreased,OT
148426928,Infliximab Pfizer (Unknown),Stress,OT
148426928,Infliximab Pfizer (Unknown),Off label use,OT
148426928,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
148426928,Infliximab Pfizer (Unknown),Heart rate decreased,OT
148426928,Infliximab Pfizer (Unknown),Drug level below therapeutic,OT
148426928,Infliximab Pfizer (Unknown),Condition aggravated,OT
148426928,Infliximab Pfizer (Unknown),Clostridium difficile infection,OT
148426928,Infliximab Pfizer (Unknown),Blood pressure fluctuation,OT
148426928,Infliximab Pfizer (Unknown),Acne,OT
160798803,Infliximab,Weight increased,OT
160798803,Infliximab,Off label use,OT
160798803,Infliximab,Loss of personal independence in daily activities,OT
160798803,Infliximab,Inappropriate schedule of product administration,OT
160798803,Infliximab,Drug level decreased,OT
160798803,Infliximab,Drug ineffective,OT
160798803,Infliximab,Blood pressure diastolic decreased,OT
160798803,Infliximab,Weight increased,OT
160798803,Infliximab,Off label use,OT
160798803,Infliximab,Loss of personal independence in daily activities,OT
160798803,Infliximab,Inappropriate schedule of product administration,OT
160798803,Infliximab,Drug level decreased,OT
160798803,Infliximab,Drug ineffective,OT
160798803,Infliximab,Blood pressure diastolic decreased,OT
160799068,Infliximab,Wheelchair user,OT
160799068,Infliximab,Wheelchair user,DS
160799068,Infliximab,Wheelchair user,HO
160799068,Infliximab,Wheelchair user,LT
160799068,Infliximab,Vomiting,OT
160799068,Infliximab,Vomiting,DS
160799068,Infliximab,Vomiting,HO
160799068,Infliximab,Vomiting,LT
160799068,Infliximab,Underdose,OT
160799068,Infliximab,Underdose,DS
160799068,Infliximab,Underdose,HO
160799068,Infliximab,Underdose,LT
160799068,Infliximab,Therapy non-responder,OT
160799068,Infliximab,Therapy non-responder,DS
160799068,Infliximab,Therapy non-responder,HO
160799068,Infliximab,Therapy non-responder,LT
160799068,Infliximab,Therapeutic product effect decreased,OT
160799068,Infliximab,Therapeutic product effect decreased,DS
160799068,Infliximab,Therapeutic product effect decreased,HO
160799068,Infliximab,Therapeutic product effect decreased,LT
160799068,Infliximab,Synovitis,OT
160799068,Infliximab,Synovitis,DS
160799068,Infliximab,Synovitis,HO
160799068,Infliximab,Synovitis,LT
160799068,Infliximab,Short stature,OT
160799068,Infliximab,Short stature,DS
160799068,Infliximab,Short stature,HO
160799068,Infliximab,Short stature,LT
160799068,Infliximab,Septic shock,OT
160799068,Infliximab,Septic shock,DS
160799068,Infliximab,Septic shock,HO
160799068,Infliximab,Septic shock,LT
160799068,Infliximab,Rheumatoid arthritis,OT
160799068,Infliximab,Rheumatoid arthritis,DS
160799068,Infliximab,Rheumatoid arthritis,HO
160799068,Infliximab,Rheumatoid arthritis,LT
160799068,Infliximab,Red blood cell sedimentation rate increased,OT
160799068,Infliximab,Red blood cell sedimentation rate increased,DS
160799068,Infliximab,Red blood cell sedimentation rate increased,HO
160799068,Infliximab,Red blood cell sedimentation rate increased,LT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,OT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,DS
160799068,Infliximab,Red blood cell sedimentation rate abnormal,HO
160799068,Infliximab,Red blood cell sedimentation rate abnormal,LT
160799068,Infliximab,Quality of life decreased,OT
160799068,Infliximab,Quality of life decreased,DS
160799068,Infliximab,Quality of life decreased,HO
160799068,Infliximab,Quality of life decreased,LT
160799068,Infliximab,Pyrexia,OT
160799068,Infliximab,Pyrexia,DS
160799068,Infliximab,Pyrexia,HO
160799068,Infliximab,Pyrexia,LT
160799068,Infliximab,Psoriasis,OT
160799068,Infliximab,Psoriasis,DS
160799068,Infliximab,Psoriasis,HO
160799068,Infliximab,Psoriasis,LT
160799068,Infliximab,Product use issue,OT
160799068,Infliximab,Product use issue,DS
160799068,Infliximab,Product use issue,HO
160799068,Infliximab,Product use issue,LT
160799068,Infliximab,Product use in unapproved indication,OT
160799068,Infliximab,Product use in unapproved indication,DS
160799068,Infliximab,Product use in unapproved indication,HO
160799068,Infliximab,Product use in unapproved indication,LT
160799068,Infliximab,Prescribed underdose,OT
160799068,Infliximab,Prescribed underdose,DS
160799068,Infliximab,Prescribed underdose,HO
160799068,Infliximab,Prescribed underdose,LT
160799068,Infliximab,Polyarthritis,OT
160799068,Infliximab,Polyarthritis,DS
160799068,Infliximab,Polyarthritis,HO
160799068,Infliximab,Polyarthritis,LT
160799068,Infliximab,Pleural effusion,OT
160799068,Infliximab,Pleural effusion,DS
160799068,Infliximab,Pleural effusion,HO
160799068,Infliximab,Pleural effusion,LT
160799068,Infliximab,Off label use,OT
160799068,Infliximab,Off label use,DS
160799068,Infliximab,Off label use,HO
160799068,Infliximab,Off label use,LT
160799068,Infliximab,Obesity,OT
160799068,Infliximab,Obesity,DS
160799068,Infliximab,Obesity,HO
160799068,Infliximab,Obesity,LT
160799068,Infliximab,Nausea,OT
160799068,Infliximab,Nausea,DS
160799068,Infliximab,Nausea,HO
160799068,Infliximab,Nausea,LT
160799068,Infliximab,Mobility decreased,OT
160799068,Infliximab,Mobility decreased,DS
160799068,Infliximab,Mobility decreased,HO
160799068,Infliximab,Mobility decreased,LT
160799068,Infliximab,Loss of personal independence in daily activities,OT
160799068,Infliximab,Loss of personal independence in daily activities,DS
160799068,Infliximab,Loss of personal independence in daily activities,HO
160799068,Infliximab,Loss of personal independence in daily activities,LT
160799068,Infliximab,Loss of consciousness,OT
160799068,Infliximab,Loss of consciousness,DS
160799068,Infliximab,Loss of consciousness,HO
160799068,Infliximab,Loss of consciousness,LT
160799068,Infliximab,Liver function test abnormal,OT
160799068,Infliximab,Liver function test abnormal,DS
160799068,Infliximab,Liver function test abnormal,HO
160799068,Infliximab,Liver function test abnormal,LT
160799068,Infliximab,Juvenile idiopathic arthritis,OT
160799068,Infliximab,Juvenile idiopathic arthritis,DS
160799068,Infliximab,Juvenile idiopathic arthritis,HO
160799068,Infliximab,Juvenile idiopathic arthritis,LT
160799068,Infliximab,Joint injury,OT
160799068,Infliximab,Joint injury,DS
160799068,Infliximab,Joint injury,HO
160799068,Infliximab,Joint injury,LT
160799068,Infliximab,Joint effusion,OT
160799068,Infliximab,Joint effusion,DS
160799068,Infliximab,Joint effusion,HO
160799068,Infliximab,Joint effusion,LT
160799068,Infliximab,Joint destruction,OT
160799068,Infliximab,Joint destruction,DS
160799068,Infliximab,Joint destruction,HO
160799068,Infliximab,Joint destruction,LT
160799068,Infliximab,Intentional product use issue,OT
160799068,Infliximab,Intentional product use issue,DS
160799068,Infliximab,Intentional product use issue,HO
160799068,Infliximab,Intentional product use issue,LT
160799068,Infliximab,Impaired quality of life,OT
160799068,Infliximab,Impaired quality of life,DS
160799068,Infliximab,Impaired quality of life,HO
160799068,Infliximab,Impaired quality of life,LT
160799068,Infliximab,Immunodeficiency,OT
160799068,Infliximab,Immunodeficiency,DS
160799068,Infliximab,Immunodeficiency,HO
160799068,Infliximab,Immunodeficiency,LT
160799068,Infliximab,Hypotension,OT
160799068,Infliximab,Hypotension,DS
160799068,Infliximab,Hypotension,HO
160799068,Infliximab,Hypotension,LT
160799068,Infliximab,Hypokalaemia,OT
160799068,Infliximab,Hypokalaemia,DS
160799068,Infliximab,Hypokalaemia,HO
160799068,Infliximab,Hypokalaemia,LT
160799068,Infliximab,Hypocalcaemia,OT
160799068,Infliximab,Hypocalcaemia,DS
160799068,Infliximab,Hypocalcaemia,HO
160799068,Infliximab,Hypocalcaemia,LT
160799068,Infliximab,Human antichimeric antibody positive,OT
160799068,Infliximab,Human antichimeric antibody positive,DS
160799068,Infliximab,Human antichimeric antibody positive,HO
160799068,Infliximab,Human antichimeric antibody positive,LT
160799068,Infliximab,Human anti-human antibody test,OT
160799068,Infliximab,Human anti-human antibody test,DS
160799068,Infliximab,Human anti-human antibody test,HO
160799068,Infliximab,Human anti-human antibody test,LT
160799068,Infliximab,Gastroenteritis viral,OT
160799068,Infliximab,Gastroenteritis viral,DS
160799068,Infliximab,Gastroenteritis viral,HO
160799068,Infliximab,Gastroenteritis viral,LT
160799068,Infliximab,Drug specific antibody present,OT
160799068,Infliximab,Drug specific antibody present,DS
160799068,Infliximab,Drug specific antibody present,HO
160799068,Infliximab,Drug specific antibody present,LT
160799068,Infliximab,Drug specific antibody,OT
160799068,Infliximab,Drug specific antibody,DS
160799068,Infliximab,Drug specific antibody,HO
160799068,Infliximab,Drug specific antibody,LT
160799068,Infliximab,Drug intolerance,OT
160799068,Infliximab,Drug intolerance,DS
160799068,Infliximab,Drug intolerance,HO
160799068,Infliximab,Drug intolerance,LT
160799068,Infliximab,Drug ineffective,OT
160799068,Infliximab,Drug ineffective,DS
160799068,Infliximab,Drug ineffective,HO
160799068,Infliximab,Drug ineffective,LT
160799068,Infliximab,Dizziness,OT
160799068,Infliximab,Dizziness,DS
160799068,Infliximab,Dizziness,HO
160799068,Infliximab,Dizziness,LT
160799068,Infliximab,Diarrhoea,OT
160799068,Infliximab,Diarrhoea,DS
160799068,Infliximab,Diarrhoea,HO
160799068,Infliximab,Diarrhoea,LT
160799068,Infliximab,Contraindicated product administered,OT
160799068,Infliximab,Contraindicated product administered,DS
160799068,Infliximab,Contraindicated product administered,HO
160799068,Infliximab,Contraindicated product administered,LT
160799068,Infliximab,Condition aggravated,OT
160799068,Infliximab,Condition aggravated,DS
160799068,Infliximab,Condition aggravated,HO
160799068,Infliximab,Condition aggravated,LT
160799068,Infliximab,C-reactive protein increased,OT
160799068,Infliximab,C-reactive protein increased,DS
160799068,Infliximab,C-reactive protein increased,HO
160799068,Infliximab,C-reactive protein increased,LT
160799068,Infliximab,C-reactive protein abnormal,OT
160799068,Infliximab,C-reactive protein abnormal,DS
160799068,Infliximab,C-reactive protein abnormal,HO
160799068,Infliximab,C-reactive protein abnormal,LT
160799068,Infliximab,Bone density increased,OT
160799068,Infliximab,Bone density increased,DS
160799068,Infliximab,Bone density increased,HO
160799068,Infliximab,Bone density increased,LT
160799068,Infliximab,Bone density decreased,OT
160799068,Infliximab,Bone density decreased,DS
160799068,Infliximab,Bone density decreased,HO
160799068,Infliximab,Bone density decreased,LT
160799068,Infliximab,Body height below normal,OT
160799068,Infliximab,Body height below normal,DS
160799068,Infliximab,Body height below normal,HO
160799068,Infliximab,Body height below normal,LT
160799068,Infliximab,Arthropathy,OT
160799068,Infliximab,Arthropathy,DS
160799068,Infliximab,Arthropathy,HO
160799068,Infliximab,Arthropathy,LT
160799068,Infliximab,Arthritis,OT
160799068,Infliximab,Arthritis,DS
160799068,Infliximab,Arthritis,HO
160799068,Infliximab,Arthritis,LT
160799068,Infliximab,Arthralgia,OT
160799068,Infliximab,Arthralgia,DS
160799068,Infliximab,Arthralgia,HO
160799068,Infliximab,Arthralgia,LT
160799068,Infliximab,Antibody test positive,OT
160799068,Infliximab,Antibody test positive,DS
160799068,Infliximab,Antibody test positive,HO
160799068,Infliximab,Antibody test positive,LT
160799068,Infliximab,Adrenal insufficiency,OT
160799068,Infliximab,Adrenal insufficiency,DS
160799068,Infliximab,Adrenal insufficiency,HO
160799068,Infliximab,Adrenal insufficiency,LT
160799068,Infliximab,Wheelchair user,OT
160799068,Infliximab,Wheelchair user,DS
160799068,Infliximab,Wheelchair user,HO
160799068,Infliximab,Wheelchair user,LT
160799068,Infliximab,Vomiting,OT
160799068,Infliximab,Vomiting,DS
160799068,Infliximab,Vomiting,HO
160799068,Infliximab,Vomiting,LT
160799068,Infliximab,Underdose,OT
160799068,Infliximab,Underdose,DS
160799068,Infliximab,Underdose,HO
160799068,Infliximab,Underdose,LT
160799068,Infliximab,Therapy non-responder,OT
160799068,Infliximab,Therapy non-responder,DS
160799068,Infliximab,Therapy non-responder,HO
160799068,Infliximab,Therapy non-responder,LT
160799068,Infliximab,Therapeutic product effect decreased,OT
160799068,Infliximab,Therapeutic product effect decreased,DS
160799068,Infliximab,Therapeutic product effect decreased,HO
160799068,Infliximab,Therapeutic product effect decreased,LT
160799068,Infliximab,Synovitis,OT
160799068,Infliximab,Synovitis,DS
160799068,Infliximab,Synovitis,HO
160799068,Infliximab,Synovitis,LT
160799068,Infliximab,Short stature,OT
160799068,Infliximab,Short stature,DS
160799068,Infliximab,Short stature,HO
160799068,Infliximab,Short stature,LT
160799068,Infliximab,Septic shock,OT
160799068,Infliximab,Septic shock,DS
160799068,Infliximab,Septic shock,HO
160799068,Infliximab,Septic shock,LT
160799068,Infliximab,Rheumatoid arthritis,OT
160799068,Infliximab,Rheumatoid arthritis,DS
160799068,Infliximab,Rheumatoid arthritis,HO
160799068,Infliximab,Rheumatoid arthritis,LT
160799068,Infliximab,Red blood cell sedimentation rate increased,OT
160799068,Infliximab,Red blood cell sedimentation rate increased,DS
160799068,Infliximab,Red blood cell sedimentation rate increased,HO
160799068,Infliximab,Red blood cell sedimentation rate increased,LT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,OT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,DS
160799068,Infliximab,Red blood cell sedimentation rate abnormal,HO
160799068,Infliximab,Red blood cell sedimentation rate abnormal,LT
160799068,Infliximab,Quality of life decreased,OT
160799068,Infliximab,Quality of life decreased,DS
160799068,Infliximab,Quality of life decreased,HO
160799068,Infliximab,Quality of life decreased,LT
160799068,Infliximab,Pyrexia,OT
160799068,Infliximab,Pyrexia,DS
160799068,Infliximab,Pyrexia,HO
160799068,Infliximab,Pyrexia,LT
160799068,Infliximab,Psoriasis,OT
160799068,Infliximab,Psoriasis,DS
160799068,Infliximab,Psoriasis,HO
160799068,Infliximab,Psoriasis,LT
160799068,Infliximab,Product use issue,OT
160799068,Infliximab,Product use issue,DS
160799068,Infliximab,Product use issue,HO
160799068,Infliximab,Product use issue,LT
160799068,Infliximab,Product use in unapproved indication,OT
160799068,Infliximab,Product use in unapproved indication,DS
160799068,Infliximab,Product use in unapproved indication,HO
160799068,Infliximab,Product use in unapproved indication,LT
160799068,Infliximab,Prescribed underdose,OT
160799068,Infliximab,Prescribed underdose,DS
160799068,Infliximab,Prescribed underdose,HO
160799068,Infliximab,Prescribed underdose,LT
160799068,Infliximab,Polyarthritis,OT
160799068,Infliximab,Polyarthritis,DS
160799068,Infliximab,Polyarthritis,HO
160799068,Infliximab,Polyarthritis,LT
160799068,Infliximab,Pleural effusion,OT
160799068,Infliximab,Pleural effusion,DS
160799068,Infliximab,Pleural effusion,HO
160799068,Infliximab,Pleural effusion,LT
160799068,Infliximab,Off label use,OT
160799068,Infliximab,Off label use,DS
160799068,Infliximab,Off label use,HO
160799068,Infliximab,Off label use,LT
160799068,Infliximab,Obesity,OT
160799068,Infliximab,Obesity,DS
160799068,Infliximab,Obesity,HO
160799068,Infliximab,Obesity,LT
160799068,Infliximab,Nausea,OT
160799068,Infliximab,Nausea,DS
160799068,Infliximab,Nausea,HO
160799068,Infliximab,Nausea,LT
160799068,Infliximab,Mobility decreased,OT
160799068,Infliximab,Mobility decreased,DS
160799068,Infliximab,Mobility decreased,HO
160799068,Infliximab,Mobility decreased,LT
160799068,Infliximab,Loss of personal independence in daily activities,OT
160799068,Infliximab,Loss of personal independence in daily activities,DS
160799068,Infliximab,Loss of personal independence in daily activities,HO
160799068,Infliximab,Loss of personal independence in daily activities,LT
160799068,Infliximab,Loss of consciousness,OT
160799068,Infliximab,Loss of consciousness,DS
160799068,Infliximab,Loss of consciousness,HO
160799068,Infliximab,Loss of consciousness,LT
160799068,Infliximab,Liver function test abnormal,OT
160799068,Infliximab,Liver function test abnormal,DS
160799068,Infliximab,Liver function test abnormal,HO
160799068,Infliximab,Liver function test abnormal,LT
160799068,Infliximab,Juvenile idiopathic arthritis,OT
160799068,Infliximab,Juvenile idiopathic arthritis,DS
160799068,Infliximab,Juvenile idiopathic arthritis,HO
160799068,Infliximab,Juvenile idiopathic arthritis,LT
160799068,Infliximab,Joint injury,OT
160799068,Infliximab,Joint injury,DS
160799068,Infliximab,Joint injury,HO
160799068,Infliximab,Joint injury,LT
160799068,Infliximab,Joint effusion,OT
160799068,Infliximab,Joint effusion,DS
160799068,Infliximab,Joint effusion,HO
160799068,Infliximab,Joint effusion,LT
160799068,Infliximab,Joint destruction,OT
160799068,Infliximab,Joint destruction,DS
160799068,Infliximab,Joint destruction,HO
160799068,Infliximab,Joint destruction,LT
160799068,Infliximab,Intentional product use issue,OT
160799068,Infliximab,Intentional product use issue,DS
160799068,Infliximab,Intentional product use issue,HO
160799068,Infliximab,Intentional product use issue,LT
160799068,Infliximab,Impaired quality of life,OT
160799068,Infliximab,Impaired quality of life,DS
160799068,Infliximab,Impaired quality of life,HO
160799068,Infliximab,Impaired quality of life,LT
160799068,Infliximab,Immunodeficiency,OT
160799068,Infliximab,Immunodeficiency,DS
160799068,Infliximab,Immunodeficiency,HO
160799068,Infliximab,Immunodeficiency,LT
160799068,Infliximab,Hypotension,OT
160799068,Infliximab,Hypotension,DS
160799068,Infliximab,Hypotension,HO
160799068,Infliximab,Hypotension,LT
160799068,Infliximab,Hypokalaemia,OT
160799068,Infliximab,Hypokalaemia,DS
160799068,Infliximab,Hypokalaemia,HO
160799068,Infliximab,Hypokalaemia,LT
160799068,Infliximab,Hypocalcaemia,OT
160799068,Infliximab,Hypocalcaemia,DS
160799068,Infliximab,Hypocalcaemia,HO
160799068,Infliximab,Hypocalcaemia,LT
160799068,Infliximab,Human antichimeric antibody positive,OT
160799068,Infliximab,Human antichimeric antibody positive,DS
160799068,Infliximab,Human antichimeric antibody positive,HO
160799068,Infliximab,Human antichimeric antibody positive,LT
160799068,Infliximab,Human anti-human antibody test,OT
160799068,Infliximab,Human anti-human antibody test,DS
160799068,Infliximab,Human anti-human antibody test,HO
160799068,Infliximab,Human anti-human antibody test,LT
160799068,Infliximab,Gastroenteritis viral,OT
160799068,Infliximab,Gastroenteritis viral,DS
160799068,Infliximab,Gastroenteritis viral,HO
160799068,Infliximab,Gastroenteritis viral,LT
160799068,Infliximab,Drug specific antibody present,OT
160799068,Infliximab,Drug specific antibody present,DS
160799068,Infliximab,Drug specific antibody present,HO
160799068,Infliximab,Drug specific antibody present,LT
160799068,Infliximab,Drug specific antibody,OT
160799068,Infliximab,Drug specific antibody,DS
160799068,Infliximab,Drug specific antibody,HO
160799068,Infliximab,Drug specific antibody,LT
160799068,Infliximab,Drug intolerance,OT
160799068,Infliximab,Drug intolerance,DS
160799068,Infliximab,Drug intolerance,HO
160799068,Infliximab,Drug intolerance,LT
160799068,Infliximab,Drug ineffective,OT
160799068,Infliximab,Drug ineffective,DS
160799068,Infliximab,Drug ineffective,HO
160799068,Infliximab,Drug ineffective,LT
160799068,Infliximab,Dizziness,OT
160799068,Infliximab,Dizziness,DS
160799068,Infliximab,Dizziness,HO
160799068,Infliximab,Dizziness,LT
160799068,Infliximab,Diarrhoea,OT
160799068,Infliximab,Diarrhoea,DS
160799068,Infliximab,Diarrhoea,HO
160799068,Infliximab,Diarrhoea,LT
160799068,Infliximab,Contraindicated product administered,OT
160799068,Infliximab,Contraindicated product administered,DS
160799068,Infliximab,Contraindicated product administered,HO
160799068,Infliximab,Contraindicated product administered,LT
160799068,Infliximab,Condition aggravated,OT
160799068,Infliximab,Condition aggravated,DS
160799068,Infliximab,Condition aggravated,HO
160799068,Infliximab,Condition aggravated,LT
160799068,Infliximab,C-reactive protein increased,OT
160799068,Infliximab,C-reactive protein increased,DS
160799068,Infliximab,C-reactive protein increased,HO
160799068,Infliximab,C-reactive protein increased,LT
160799068,Infliximab,C-reactive protein abnormal,OT
160799068,Infliximab,C-reactive protein abnormal,DS
160799068,Infliximab,C-reactive protein abnormal,HO
160799068,Infliximab,C-reactive protein abnormal,LT
160799068,Infliximab,Bone density increased,OT
160799068,Infliximab,Bone density increased,DS
160799068,Infliximab,Bone density increased,HO
160799068,Infliximab,Bone density increased,LT
160799068,Infliximab,Bone density decreased,OT
160799068,Infliximab,Bone density decreased,DS
160799068,Infliximab,Bone density decreased,HO
160799068,Infliximab,Bone density decreased,LT
160799068,Infliximab,Body height below normal,OT
160799068,Infliximab,Body height below normal,DS
160799068,Infliximab,Body height below normal,HO
160799068,Infliximab,Body height below normal,LT
160799068,Infliximab,Arthropathy,OT
160799068,Infliximab,Arthropathy,DS
160799068,Infliximab,Arthropathy,HO
160799068,Infliximab,Arthropathy,LT
160799068,Infliximab,Arthritis,OT
160799068,Infliximab,Arthritis,DS
160799068,Infliximab,Arthritis,HO
160799068,Infliximab,Arthritis,LT
160799068,Infliximab,Arthralgia,OT
160799068,Infliximab,Arthralgia,DS
160799068,Infliximab,Arthralgia,HO
160799068,Infliximab,Arthralgia,LT
160799068,Infliximab,Antibody test positive,OT
160799068,Infliximab,Antibody test positive,DS
160799068,Infliximab,Antibody test positive,HO
160799068,Infliximab,Antibody test positive,LT
160799068,Infliximab,Adrenal insufficiency,OT
160799068,Infliximab,Adrenal insufficiency,DS
160799068,Infliximab,Adrenal insufficiency,HO
160799068,Infliximab,Adrenal insufficiency,LT
160799068,Infliximab,Wheelchair user,OT
160799068,Infliximab,Wheelchair user,DS
160799068,Infliximab,Wheelchair user,HO
160799068,Infliximab,Wheelchair user,LT
160799068,Infliximab,Vomiting,OT
160799068,Infliximab,Vomiting,DS
160799068,Infliximab,Vomiting,HO
160799068,Infliximab,Vomiting,LT
160799068,Infliximab,Underdose,OT
160799068,Infliximab,Underdose,DS
160799068,Infliximab,Underdose,HO
160799068,Infliximab,Underdose,LT
160799068,Infliximab,Therapy non-responder,OT
160799068,Infliximab,Therapy non-responder,DS
160799068,Infliximab,Therapy non-responder,HO
160799068,Infliximab,Therapy non-responder,LT
160799068,Infliximab,Therapeutic product effect decreased,OT
160799068,Infliximab,Therapeutic product effect decreased,DS
160799068,Infliximab,Therapeutic product effect decreased,HO
160799068,Infliximab,Therapeutic product effect decreased,LT
160799068,Infliximab,Synovitis,OT
160799068,Infliximab,Synovitis,DS
160799068,Infliximab,Synovitis,HO
160799068,Infliximab,Synovitis,LT
160799068,Infliximab,Short stature,OT
160799068,Infliximab,Short stature,DS
160799068,Infliximab,Short stature,HO
160799068,Infliximab,Short stature,LT
160799068,Infliximab,Septic shock,OT
160799068,Infliximab,Septic shock,DS
160799068,Infliximab,Septic shock,HO
160799068,Infliximab,Septic shock,LT
160799068,Infliximab,Rheumatoid arthritis,OT
160799068,Infliximab,Rheumatoid arthritis,DS
160799068,Infliximab,Rheumatoid arthritis,HO
160799068,Infliximab,Rheumatoid arthritis,LT
160799068,Infliximab,Red blood cell sedimentation rate increased,OT
160799068,Infliximab,Red blood cell sedimentation rate increased,DS
160799068,Infliximab,Red blood cell sedimentation rate increased,HO
160799068,Infliximab,Red blood cell sedimentation rate increased,LT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,OT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,DS
160799068,Infliximab,Red blood cell sedimentation rate abnormal,HO
160799068,Infliximab,Red blood cell sedimentation rate abnormal,LT
160799068,Infliximab,Quality of life decreased,OT
160799068,Infliximab,Quality of life decreased,DS
160799068,Infliximab,Quality of life decreased,HO
160799068,Infliximab,Quality of life decreased,LT
160799068,Infliximab,Pyrexia,OT
160799068,Infliximab,Pyrexia,DS
160799068,Infliximab,Pyrexia,HO
160799068,Infliximab,Pyrexia,LT
160799068,Infliximab,Psoriasis,OT
160799068,Infliximab,Psoriasis,DS
160799068,Infliximab,Psoriasis,HO
160799068,Infliximab,Psoriasis,LT
160799068,Infliximab,Product use issue,OT
160799068,Infliximab,Product use issue,DS
160799068,Infliximab,Product use issue,HO
160799068,Infliximab,Product use issue,LT
160799068,Infliximab,Product use in unapproved indication,OT
160799068,Infliximab,Product use in unapproved indication,DS
160799068,Infliximab,Product use in unapproved indication,HO
160799068,Infliximab,Product use in unapproved indication,LT
160799068,Infliximab,Prescribed underdose,OT
160799068,Infliximab,Prescribed underdose,DS
160799068,Infliximab,Prescribed underdose,HO
160799068,Infliximab,Prescribed underdose,LT
160799068,Infliximab,Polyarthritis,OT
160799068,Infliximab,Polyarthritis,DS
160799068,Infliximab,Polyarthritis,HO
160799068,Infliximab,Polyarthritis,LT
160799068,Infliximab,Pleural effusion,OT
160799068,Infliximab,Pleural effusion,DS
160799068,Infliximab,Pleural effusion,HO
160799068,Infliximab,Pleural effusion,LT
160799068,Infliximab,Off label use,OT
160799068,Infliximab,Off label use,DS
160799068,Infliximab,Off label use,HO
160799068,Infliximab,Off label use,LT
160799068,Infliximab,Obesity,OT
160799068,Infliximab,Obesity,DS
160799068,Infliximab,Obesity,HO
160799068,Infliximab,Obesity,LT
160799068,Infliximab,Nausea,OT
160799068,Infliximab,Nausea,DS
160799068,Infliximab,Nausea,HO
160799068,Infliximab,Nausea,LT
160799068,Infliximab,Mobility decreased,OT
160799068,Infliximab,Mobility decreased,DS
160799068,Infliximab,Mobility decreased,HO
160799068,Infliximab,Mobility decreased,LT
160799068,Infliximab,Loss of personal independence in daily activities,OT
160799068,Infliximab,Loss of personal independence in daily activities,DS
160799068,Infliximab,Loss of personal independence in daily activities,HO
160799068,Infliximab,Loss of personal independence in daily activities,LT
160799068,Infliximab,Loss of consciousness,OT
160799068,Infliximab,Loss of consciousness,DS
160799068,Infliximab,Loss of consciousness,HO
160799068,Infliximab,Loss of consciousness,LT
160799068,Infliximab,Liver function test abnormal,OT
160799068,Infliximab,Liver function test abnormal,DS
160799068,Infliximab,Liver function test abnormal,HO
160799068,Infliximab,Liver function test abnormal,LT
160799068,Infliximab,Juvenile idiopathic arthritis,OT
160799068,Infliximab,Juvenile idiopathic arthritis,DS
160799068,Infliximab,Juvenile idiopathic arthritis,HO
160799068,Infliximab,Juvenile idiopathic arthritis,LT
160799068,Infliximab,Joint injury,OT
160799068,Infliximab,Joint injury,DS
160799068,Infliximab,Joint injury,HO
160799068,Infliximab,Joint injury,LT
160799068,Infliximab,Joint effusion,OT
160799068,Infliximab,Joint effusion,DS
160799068,Infliximab,Joint effusion,HO
160799068,Infliximab,Joint effusion,LT
160799068,Infliximab,Joint destruction,OT
160799068,Infliximab,Joint destruction,DS
160799068,Infliximab,Joint destruction,HO
160799068,Infliximab,Joint destruction,LT
160799068,Infliximab,Intentional product use issue,OT
160799068,Infliximab,Intentional product use issue,DS
160799068,Infliximab,Intentional product use issue,HO
160799068,Infliximab,Intentional product use issue,LT
160799068,Infliximab,Impaired quality of life,OT
160799068,Infliximab,Impaired quality of life,DS
160799068,Infliximab,Impaired quality of life,HO
160799068,Infliximab,Impaired quality of life,LT
160799068,Infliximab,Immunodeficiency,OT
160799068,Infliximab,Immunodeficiency,DS
160799068,Infliximab,Immunodeficiency,HO
160799068,Infliximab,Immunodeficiency,LT
160799068,Infliximab,Hypotension,OT
160799068,Infliximab,Hypotension,DS
160799068,Infliximab,Hypotension,HO
160799068,Infliximab,Hypotension,LT
160799068,Infliximab,Hypokalaemia,OT
160799068,Infliximab,Hypokalaemia,DS
160799068,Infliximab,Hypokalaemia,HO
160799068,Infliximab,Hypokalaemia,LT
160799068,Infliximab,Hypocalcaemia,OT
160799068,Infliximab,Hypocalcaemia,DS
160799068,Infliximab,Hypocalcaemia,HO
160799068,Infliximab,Hypocalcaemia,LT
160799068,Infliximab,Human antichimeric antibody positive,OT
160799068,Infliximab,Human antichimeric antibody positive,DS
160799068,Infliximab,Human antichimeric antibody positive,HO
160799068,Infliximab,Human antichimeric antibody positive,LT
160799068,Infliximab,Human anti-human antibody test,OT
160799068,Infliximab,Human anti-human antibody test,DS
160799068,Infliximab,Human anti-human antibody test,HO
160799068,Infliximab,Human anti-human antibody test,LT
160799068,Infliximab,Gastroenteritis viral,OT
160799068,Infliximab,Gastroenteritis viral,DS
160799068,Infliximab,Gastroenteritis viral,HO
160799068,Infliximab,Gastroenteritis viral,LT
160799068,Infliximab,Drug specific antibody present,OT
160799068,Infliximab,Drug specific antibody present,DS
160799068,Infliximab,Drug specific antibody present,HO
160799068,Infliximab,Drug specific antibody present,LT
160799068,Infliximab,Drug specific antibody,OT
160799068,Infliximab,Drug specific antibody,DS
160799068,Infliximab,Drug specific antibody,HO
160799068,Infliximab,Drug specific antibody,LT
160799068,Infliximab,Drug intolerance,OT
160799068,Infliximab,Drug intolerance,DS
160799068,Infliximab,Drug intolerance,HO
160799068,Infliximab,Drug intolerance,LT
160799068,Infliximab,Drug ineffective,OT
160799068,Infliximab,Drug ineffective,DS
160799068,Infliximab,Drug ineffective,HO
160799068,Infliximab,Drug ineffective,LT
160799068,Infliximab,Dizziness,OT
160799068,Infliximab,Dizziness,DS
160799068,Infliximab,Dizziness,HO
160799068,Infliximab,Dizziness,LT
160799068,Infliximab,Diarrhoea,OT
160799068,Infliximab,Diarrhoea,DS
160799068,Infliximab,Diarrhoea,HO
160799068,Infliximab,Diarrhoea,LT
160799068,Infliximab,Contraindicated product administered,OT
160799068,Infliximab,Contraindicated product administered,DS
160799068,Infliximab,Contraindicated product administered,HO
160799068,Infliximab,Contraindicated product administered,LT
160799068,Infliximab,Condition aggravated,OT
160799068,Infliximab,Condition aggravated,DS
160799068,Infliximab,Condition aggravated,HO
160799068,Infliximab,Condition aggravated,LT
160799068,Infliximab,C-reactive protein increased,OT
160799068,Infliximab,C-reactive protein increased,DS
160799068,Infliximab,C-reactive protein increased,HO
160799068,Infliximab,C-reactive protein increased,LT
160799068,Infliximab,C-reactive protein abnormal,OT
160799068,Infliximab,C-reactive protein abnormal,DS
160799068,Infliximab,C-reactive protein abnormal,HO
160799068,Infliximab,C-reactive protein abnormal,LT
160799068,Infliximab,Bone density increased,OT
160799068,Infliximab,Bone density increased,DS
160799068,Infliximab,Bone density increased,HO
160799068,Infliximab,Bone density increased,LT
160799068,Infliximab,Bone density decreased,OT
160799068,Infliximab,Bone density decreased,DS
160799068,Infliximab,Bone density decreased,HO
160799068,Infliximab,Bone density decreased,LT
160799068,Infliximab,Body height below normal,OT
160799068,Infliximab,Body height below normal,DS
160799068,Infliximab,Body height below normal,HO
160799068,Infliximab,Body height below normal,LT
160799068,Infliximab,Arthropathy,OT
160799068,Infliximab,Arthropathy,DS
160799068,Infliximab,Arthropathy,HO
160799068,Infliximab,Arthropathy,LT
160799068,Infliximab,Arthritis,OT
160799068,Infliximab,Arthritis,DS
160799068,Infliximab,Arthritis,HO
160799068,Infliximab,Arthritis,LT
160799068,Infliximab,Arthralgia,OT
160799068,Infliximab,Arthralgia,DS
160799068,Infliximab,Arthralgia,HO
160799068,Infliximab,Arthralgia,LT
160799068,Infliximab,Antibody test positive,OT
160799068,Infliximab,Antibody test positive,DS
160799068,Infliximab,Antibody test positive,HO
160799068,Infliximab,Antibody test positive,LT
160799068,Infliximab,Adrenal insufficiency,OT
160799068,Infliximab,Adrenal insufficiency,DS
160799068,Infliximab,Adrenal insufficiency,HO
160799068,Infliximab,Adrenal insufficiency,LT
160799068,Infliximab,Wheelchair user,OT
160799068,Infliximab,Wheelchair user,DS
160799068,Infliximab,Wheelchair user,HO
160799068,Infliximab,Wheelchair user,LT
160799068,Infliximab,Vomiting,OT
160799068,Infliximab,Vomiting,DS
160799068,Infliximab,Vomiting,HO
160799068,Infliximab,Vomiting,LT
160799068,Infliximab,Underdose,OT
160799068,Infliximab,Underdose,DS
160799068,Infliximab,Underdose,HO
160799068,Infliximab,Underdose,LT
160799068,Infliximab,Therapy non-responder,OT
160799068,Infliximab,Therapy non-responder,DS
160799068,Infliximab,Therapy non-responder,HO
160799068,Infliximab,Therapy non-responder,LT
160799068,Infliximab,Therapeutic product effect decreased,OT
160799068,Infliximab,Therapeutic product effect decreased,DS
160799068,Infliximab,Therapeutic product effect decreased,HO
160799068,Infliximab,Therapeutic product effect decreased,LT
160799068,Infliximab,Synovitis,OT
160799068,Infliximab,Synovitis,DS
160799068,Infliximab,Synovitis,HO
160799068,Infliximab,Synovitis,LT
160799068,Infliximab,Short stature,OT
160799068,Infliximab,Short stature,DS
160799068,Infliximab,Short stature,HO
160799068,Infliximab,Short stature,LT
160799068,Infliximab,Septic shock,OT
160799068,Infliximab,Septic shock,DS
160799068,Infliximab,Septic shock,HO
160799068,Infliximab,Septic shock,LT
160799068,Infliximab,Rheumatoid arthritis,OT
160799068,Infliximab,Rheumatoid arthritis,DS
160799068,Infliximab,Rheumatoid arthritis,HO
160799068,Infliximab,Rheumatoid arthritis,LT
160799068,Infliximab,Red blood cell sedimentation rate increased,OT
160799068,Infliximab,Red blood cell sedimentation rate increased,DS
160799068,Infliximab,Red blood cell sedimentation rate increased,HO
160799068,Infliximab,Red blood cell sedimentation rate increased,LT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,OT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,DS
160799068,Infliximab,Red blood cell sedimentation rate abnormal,HO
160799068,Infliximab,Red blood cell sedimentation rate abnormal,LT
160799068,Infliximab,Quality of life decreased,OT
160799068,Infliximab,Quality of life decreased,DS
160799068,Infliximab,Quality of life decreased,HO
160799068,Infliximab,Quality of life decreased,LT
160799068,Infliximab,Pyrexia,OT
160799068,Infliximab,Pyrexia,DS
160799068,Infliximab,Pyrexia,HO
160799068,Infliximab,Pyrexia,LT
160799068,Infliximab,Psoriasis,OT
160799068,Infliximab,Psoriasis,DS
160799068,Infliximab,Psoriasis,HO
160799068,Infliximab,Psoriasis,LT
160799068,Infliximab,Product use issue,OT
160799068,Infliximab,Product use issue,DS
160799068,Infliximab,Product use issue,HO
160799068,Infliximab,Product use issue,LT
160799068,Infliximab,Product use in unapproved indication,OT
160799068,Infliximab,Product use in unapproved indication,DS
160799068,Infliximab,Product use in unapproved indication,HO
160799068,Infliximab,Product use in unapproved indication,LT
160799068,Infliximab,Prescribed underdose,OT
160799068,Infliximab,Prescribed underdose,DS
160799068,Infliximab,Prescribed underdose,HO
160799068,Infliximab,Prescribed underdose,LT
160799068,Infliximab,Polyarthritis,OT
160799068,Infliximab,Polyarthritis,DS
160799068,Infliximab,Polyarthritis,HO
160799068,Infliximab,Polyarthritis,LT
160799068,Infliximab,Pleural effusion,OT
160799068,Infliximab,Pleural effusion,DS
160799068,Infliximab,Pleural effusion,HO
160799068,Infliximab,Pleural effusion,LT
160799068,Infliximab,Off label use,OT
160799068,Infliximab,Off label use,DS
160799068,Infliximab,Off label use,HO
160799068,Infliximab,Off label use,LT
160799068,Infliximab,Obesity,OT
160799068,Infliximab,Obesity,DS
160799068,Infliximab,Obesity,HO
160799068,Infliximab,Obesity,LT
160799068,Infliximab,Nausea,OT
160799068,Infliximab,Nausea,DS
160799068,Infliximab,Nausea,HO
160799068,Infliximab,Nausea,LT
160799068,Infliximab,Mobility decreased,OT
160799068,Infliximab,Mobility decreased,DS
160799068,Infliximab,Mobility decreased,HO
160799068,Infliximab,Mobility decreased,LT
160799068,Infliximab,Loss of personal independence in daily activities,OT
160799068,Infliximab,Loss of personal independence in daily activities,DS
160799068,Infliximab,Loss of personal independence in daily activities,HO
160799068,Infliximab,Loss of personal independence in daily activities,LT
160799068,Infliximab,Loss of consciousness,OT
160799068,Infliximab,Loss of consciousness,DS
160799068,Infliximab,Loss of consciousness,HO
160799068,Infliximab,Loss of consciousness,LT
160799068,Infliximab,Liver function test abnormal,OT
160799068,Infliximab,Liver function test abnormal,DS
160799068,Infliximab,Liver function test abnormal,HO
160799068,Infliximab,Liver function test abnormal,LT
160799068,Infliximab,Juvenile idiopathic arthritis,OT
160799068,Infliximab,Juvenile idiopathic arthritis,DS
160799068,Infliximab,Juvenile idiopathic arthritis,HO
160799068,Infliximab,Juvenile idiopathic arthritis,LT
160799068,Infliximab,Joint injury,OT
160799068,Infliximab,Joint injury,DS
160799068,Infliximab,Joint injury,HO
160799068,Infliximab,Joint injury,LT
160799068,Infliximab,Joint effusion,OT
160799068,Infliximab,Joint effusion,DS
160799068,Infliximab,Joint effusion,HO
160799068,Infliximab,Joint effusion,LT
160799068,Infliximab,Joint destruction,OT
160799068,Infliximab,Joint destruction,DS
160799068,Infliximab,Joint destruction,HO
160799068,Infliximab,Joint destruction,LT
160799068,Infliximab,Intentional product use issue,OT
160799068,Infliximab,Intentional product use issue,DS
160799068,Infliximab,Intentional product use issue,HO
160799068,Infliximab,Intentional product use issue,LT
160799068,Infliximab,Impaired quality of life,OT
160799068,Infliximab,Impaired quality of life,DS
160799068,Infliximab,Impaired quality of life,HO
160799068,Infliximab,Impaired quality of life,LT
160799068,Infliximab,Immunodeficiency,OT
160799068,Infliximab,Immunodeficiency,DS
160799068,Infliximab,Immunodeficiency,HO
160799068,Infliximab,Immunodeficiency,LT
160799068,Infliximab,Hypotension,OT
160799068,Infliximab,Hypotension,DS
160799068,Infliximab,Hypotension,HO
160799068,Infliximab,Hypotension,LT
160799068,Infliximab,Hypokalaemia,OT
160799068,Infliximab,Hypokalaemia,DS
160799068,Infliximab,Hypokalaemia,HO
160799068,Infliximab,Hypokalaemia,LT
160799068,Infliximab,Hypocalcaemia,OT
160799068,Infliximab,Hypocalcaemia,DS
160799068,Infliximab,Hypocalcaemia,HO
160799068,Infliximab,Hypocalcaemia,LT
160799068,Infliximab,Human antichimeric antibody positive,OT
160799068,Infliximab,Human antichimeric antibody positive,DS
160799068,Infliximab,Human antichimeric antibody positive,HO
160799068,Infliximab,Human antichimeric antibody positive,LT
160799068,Infliximab,Human anti-human antibody test,OT
160799068,Infliximab,Human anti-human antibody test,DS
160799068,Infliximab,Human anti-human antibody test,HO
160799068,Infliximab,Human anti-human antibody test,LT
160799068,Infliximab,Gastroenteritis viral,OT
160799068,Infliximab,Gastroenteritis viral,DS
160799068,Infliximab,Gastroenteritis viral,HO
160799068,Infliximab,Gastroenteritis viral,LT
160799068,Infliximab,Drug specific antibody present,OT
160799068,Infliximab,Drug specific antibody present,DS
160799068,Infliximab,Drug specific antibody present,HO
160799068,Infliximab,Drug specific antibody present,LT
160799068,Infliximab,Drug specific antibody,OT
160799068,Infliximab,Drug specific antibody,DS
160799068,Infliximab,Drug specific antibody,HO
160799068,Infliximab,Drug specific antibody,LT
160799068,Infliximab,Drug intolerance,OT
160799068,Infliximab,Drug intolerance,DS
160799068,Infliximab,Drug intolerance,HO
160799068,Infliximab,Drug intolerance,LT
160799068,Infliximab,Drug ineffective,OT
160799068,Infliximab,Drug ineffective,DS
160799068,Infliximab,Drug ineffective,HO
160799068,Infliximab,Drug ineffective,LT
160799068,Infliximab,Dizziness,OT
160799068,Infliximab,Dizziness,DS
160799068,Infliximab,Dizziness,HO
160799068,Infliximab,Dizziness,LT
160799068,Infliximab,Diarrhoea,OT
160799068,Infliximab,Diarrhoea,DS
160799068,Infliximab,Diarrhoea,HO
160799068,Infliximab,Diarrhoea,LT
160799068,Infliximab,Contraindicated product administered,OT
160799068,Infliximab,Contraindicated product administered,DS
160799068,Infliximab,Contraindicated product administered,HO
160799068,Infliximab,Contraindicated product administered,LT
160799068,Infliximab,Condition aggravated,OT
160799068,Infliximab,Condition aggravated,DS
160799068,Infliximab,Condition aggravated,HO
160799068,Infliximab,Condition aggravated,LT
160799068,Infliximab,C-reactive protein increased,OT
160799068,Infliximab,C-reactive protein increased,DS
160799068,Infliximab,C-reactive protein increased,HO
160799068,Infliximab,C-reactive protein increased,LT
160799068,Infliximab,C-reactive protein abnormal,OT
160799068,Infliximab,C-reactive protein abnormal,DS
160799068,Infliximab,C-reactive protein abnormal,HO
160799068,Infliximab,C-reactive protein abnormal,LT
160799068,Infliximab,Bone density increased,OT
160799068,Infliximab,Bone density increased,DS
160799068,Infliximab,Bone density increased,HO
160799068,Infliximab,Bone density increased,LT
160799068,Infliximab,Bone density decreased,OT
160799068,Infliximab,Bone density decreased,DS
160799068,Infliximab,Bone density decreased,HO
160799068,Infliximab,Bone density decreased,LT
160799068,Infliximab,Body height below normal,OT
160799068,Infliximab,Body height below normal,DS
160799068,Infliximab,Body height below normal,HO
160799068,Infliximab,Body height below normal,LT
160799068,Infliximab,Arthropathy,OT
160799068,Infliximab,Arthropathy,DS
160799068,Infliximab,Arthropathy,HO
160799068,Infliximab,Arthropathy,LT
160799068,Infliximab,Arthritis,OT
160799068,Infliximab,Arthritis,DS
160799068,Infliximab,Arthritis,HO
160799068,Infliximab,Arthritis,LT
160799068,Infliximab,Arthralgia,OT
160799068,Infliximab,Arthralgia,DS
160799068,Infliximab,Arthralgia,HO
160799068,Infliximab,Arthralgia,LT
160799068,Infliximab,Antibody test positive,OT
160799068,Infliximab,Antibody test positive,DS
160799068,Infliximab,Antibody test positive,HO
160799068,Infliximab,Antibody test positive,LT
160799068,Infliximab,Adrenal insufficiency,OT
160799068,Infliximab,Adrenal insufficiency,DS
160799068,Infliximab,Adrenal insufficiency,HO
160799068,Infliximab,Adrenal insufficiency,LT
160799068,Infliximab,Wheelchair user,OT
160799068,Infliximab,Wheelchair user,DS
160799068,Infliximab,Wheelchair user,HO
160799068,Infliximab,Wheelchair user,LT
160799068,Infliximab,Vomiting,OT
160799068,Infliximab,Vomiting,DS
160799068,Infliximab,Vomiting,HO
160799068,Infliximab,Vomiting,LT
160799068,Infliximab,Underdose,OT
160799068,Infliximab,Underdose,DS
160799068,Infliximab,Underdose,HO
160799068,Infliximab,Underdose,LT
160799068,Infliximab,Therapy non-responder,OT
160799068,Infliximab,Therapy non-responder,DS
160799068,Infliximab,Therapy non-responder,HO
160799068,Infliximab,Therapy non-responder,LT
160799068,Infliximab,Therapeutic product effect decreased,OT
160799068,Infliximab,Therapeutic product effect decreased,DS
160799068,Infliximab,Therapeutic product effect decreased,HO
160799068,Infliximab,Therapeutic product effect decreased,LT
160799068,Infliximab,Synovitis,OT
160799068,Infliximab,Synovitis,DS
160799068,Infliximab,Synovitis,HO
160799068,Infliximab,Synovitis,LT
160799068,Infliximab,Short stature,OT
160799068,Infliximab,Short stature,DS
160799068,Infliximab,Short stature,HO
160799068,Infliximab,Short stature,LT
160799068,Infliximab,Septic shock,OT
160799068,Infliximab,Septic shock,DS
160799068,Infliximab,Septic shock,HO
160799068,Infliximab,Septic shock,LT
160799068,Infliximab,Rheumatoid arthritis,OT
160799068,Infliximab,Rheumatoid arthritis,DS
160799068,Infliximab,Rheumatoid arthritis,HO
160799068,Infliximab,Rheumatoid arthritis,LT
160799068,Infliximab,Red blood cell sedimentation rate increased,OT
160799068,Infliximab,Red blood cell sedimentation rate increased,DS
160799068,Infliximab,Red blood cell sedimentation rate increased,HO
160799068,Infliximab,Red blood cell sedimentation rate increased,LT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,OT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,DS
160799068,Infliximab,Red blood cell sedimentation rate abnormal,HO
160799068,Infliximab,Red blood cell sedimentation rate abnormal,LT
160799068,Infliximab,Quality of life decreased,OT
160799068,Infliximab,Quality of life decreased,DS
160799068,Infliximab,Quality of life decreased,HO
160799068,Infliximab,Quality of life decreased,LT
160799068,Infliximab,Pyrexia,OT
160799068,Infliximab,Pyrexia,DS
160799068,Infliximab,Pyrexia,HO
160799068,Infliximab,Pyrexia,LT
160799068,Infliximab,Psoriasis,OT
160799068,Infliximab,Psoriasis,DS
160799068,Infliximab,Psoriasis,HO
160799068,Infliximab,Psoriasis,LT
160799068,Infliximab,Product use issue,OT
160799068,Infliximab,Product use issue,DS
160799068,Infliximab,Product use issue,HO
160799068,Infliximab,Product use issue,LT
160799068,Infliximab,Product use in unapproved indication,OT
160799068,Infliximab,Product use in unapproved indication,DS
160799068,Infliximab,Product use in unapproved indication,HO
160799068,Infliximab,Product use in unapproved indication,LT
160799068,Infliximab,Prescribed underdose,OT
160799068,Infliximab,Prescribed underdose,DS
160799068,Infliximab,Prescribed underdose,HO
160799068,Infliximab,Prescribed underdose,LT
160799068,Infliximab,Polyarthritis,OT
160799068,Infliximab,Polyarthritis,DS
160799068,Infliximab,Polyarthritis,HO
160799068,Infliximab,Polyarthritis,LT
160799068,Infliximab,Pleural effusion,OT
160799068,Infliximab,Pleural effusion,DS
160799068,Infliximab,Pleural effusion,HO
160799068,Infliximab,Pleural effusion,LT
160799068,Infliximab,Off label use,OT
160799068,Infliximab,Off label use,DS
160799068,Infliximab,Off label use,HO
160799068,Infliximab,Off label use,LT
160799068,Infliximab,Obesity,OT
160799068,Infliximab,Obesity,DS
160799068,Infliximab,Obesity,HO
160799068,Infliximab,Obesity,LT
160799068,Infliximab,Nausea,OT
160799068,Infliximab,Nausea,DS
160799068,Infliximab,Nausea,HO
160799068,Infliximab,Nausea,LT
160799068,Infliximab,Mobility decreased,OT
160799068,Infliximab,Mobility decreased,DS
160799068,Infliximab,Mobility decreased,HO
160799068,Infliximab,Mobility decreased,LT
160799068,Infliximab,Loss of personal independence in daily activities,OT
160799068,Infliximab,Loss of personal independence in daily activities,DS
160799068,Infliximab,Loss of personal independence in daily activities,HO
160799068,Infliximab,Loss of personal independence in daily activities,LT
160799068,Infliximab,Loss of consciousness,OT
160799068,Infliximab,Loss of consciousness,DS
160799068,Infliximab,Loss of consciousness,HO
160799068,Infliximab,Loss of consciousness,LT
160799068,Infliximab,Liver function test abnormal,OT
160799068,Infliximab,Liver function test abnormal,DS
160799068,Infliximab,Liver function test abnormal,HO
160799068,Infliximab,Liver function test abnormal,LT
160799068,Infliximab,Juvenile idiopathic arthritis,OT
160799068,Infliximab,Juvenile idiopathic arthritis,DS
160799068,Infliximab,Juvenile idiopathic arthritis,HO
160799068,Infliximab,Juvenile idiopathic arthritis,LT
160799068,Infliximab,Joint injury,OT
160799068,Infliximab,Joint injury,DS
160799068,Infliximab,Joint injury,HO
160799068,Infliximab,Joint injury,LT
160799068,Infliximab,Joint effusion,OT
160799068,Infliximab,Joint effusion,DS
160799068,Infliximab,Joint effusion,HO
160799068,Infliximab,Joint effusion,LT
160799068,Infliximab,Joint destruction,OT
160799068,Infliximab,Joint destruction,DS
160799068,Infliximab,Joint destruction,HO
160799068,Infliximab,Joint destruction,LT
160799068,Infliximab,Intentional product use issue,OT
160799068,Infliximab,Intentional product use issue,DS
160799068,Infliximab,Intentional product use issue,HO
160799068,Infliximab,Intentional product use issue,LT
160799068,Infliximab,Impaired quality of life,OT
160799068,Infliximab,Impaired quality of life,DS
160799068,Infliximab,Impaired quality of life,HO
160799068,Infliximab,Impaired quality of life,LT
160799068,Infliximab,Immunodeficiency,OT
160799068,Infliximab,Immunodeficiency,DS
160799068,Infliximab,Immunodeficiency,HO
160799068,Infliximab,Immunodeficiency,LT
160799068,Infliximab,Hypotension,OT
160799068,Infliximab,Hypotension,DS
160799068,Infliximab,Hypotension,HO
160799068,Infliximab,Hypotension,LT
160799068,Infliximab,Hypokalaemia,OT
160799068,Infliximab,Hypokalaemia,DS
160799068,Infliximab,Hypokalaemia,HO
160799068,Infliximab,Hypokalaemia,LT
160799068,Infliximab,Hypocalcaemia,OT
160799068,Infliximab,Hypocalcaemia,DS
160799068,Infliximab,Hypocalcaemia,HO
160799068,Infliximab,Hypocalcaemia,LT
160799068,Infliximab,Human antichimeric antibody positive,OT
160799068,Infliximab,Human antichimeric antibody positive,DS
160799068,Infliximab,Human antichimeric antibody positive,HO
160799068,Infliximab,Human antichimeric antibody positive,LT
160799068,Infliximab,Human anti-human antibody test,OT
160799068,Infliximab,Human anti-human antibody test,DS
160799068,Infliximab,Human anti-human antibody test,HO
160799068,Infliximab,Human anti-human antibody test,LT
160799068,Infliximab,Gastroenteritis viral,OT
160799068,Infliximab,Gastroenteritis viral,DS
160799068,Infliximab,Gastroenteritis viral,HO
160799068,Infliximab,Gastroenteritis viral,LT
160799068,Infliximab,Drug specific antibody present,OT
160799068,Infliximab,Drug specific antibody present,DS
160799068,Infliximab,Drug specific antibody present,HO
160799068,Infliximab,Drug specific antibody present,LT
160799068,Infliximab,Drug specific antibody,OT
160799068,Infliximab,Drug specific antibody,DS
160799068,Infliximab,Drug specific antibody,HO
160799068,Infliximab,Drug specific antibody,LT
160799068,Infliximab,Drug intolerance,OT
160799068,Infliximab,Drug intolerance,DS
160799068,Infliximab,Drug intolerance,HO
160799068,Infliximab,Drug intolerance,LT
160799068,Infliximab,Drug ineffective,OT
160799068,Infliximab,Drug ineffective,DS
160799068,Infliximab,Drug ineffective,HO
160799068,Infliximab,Drug ineffective,LT
160799068,Infliximab,Dizziness,OT
160799068,Infliximab,Dizziness,DS
160799068,Infliximab,Dizziness,HO
160799068,Infliximab,Dizziness,LT
160799068,Infliximab,Diarrhoea,OT
160799068,Infliximab,Diarrhoea,DS
160799068,Infliximab,Diarrhoea,HO
160799068,Infliximab,Diarrhoea,LT
160799068,Infliximab,Contraindicated product administered,OT
160799068,Infliximab,Contraindicated product administered,DS
160799068,Infliximab,Contraindicated product administered,HO
160799068,Infliximab,Contraindicated product administered,LT
160799068,Infliximab,Condition aggravated,OT
160799068,Infliximab,Condition aggravated,DS
160799068,Infliximab,Condition aggravated,HO
160799068,Infliximab,Condition aggravated,LT
160799068,Infliximab,C-reactive protein increased,OT
160799068,Infliximab,C-reactive protein increased,DS
160799068,Infliximab,C-reactive protein increased,HO
160799068,Infliximab,C-reactive protein increased,LT
160799068,Infliximab,C-reactive protein abnormal,OT
160799068,Infliximab,C-reactive protein abnormal,DS
160799068,Infliximab,C-reactive protein abnormal,HO
160799068,Infliximab,C-reactive protein abnormal,LT
160799068,Infliximab,Bone density increased,OT
160799068,Infliximab,Bone density increased,DS
160799068,Infliximab,Bone density increased,HO
160799068,Infliximab,Bone density increased,LT
160799068,Infliximab,Bone density decreased,OT
160799068,Infliximab,Bone density decreased,DS
160799068,Infliximab,Bone density decreased,HO
160799068,Infliximab,Bone density decreased,LT
160799068,Infliximab,Body height below normal,OT
160799068,Infliximab,Body height below normal,DS
160799068,Infliximab,Body height below normal,HO
160799068,Infliximab,Body height below normal,LT
160799068,Infliximab,Arthropathy,OT
160799068,Infliximab,Arthropathy,DS
160799068,Infliximab,Arthropathy,HO
160799068,Infliximab,Arthropathy,LT
160799068,Infliximab,Arthritis,OT
160799068,Infliximab,Arthritis,DS
160799068,Infliximab,Arthritis,HO
160799068,Infliximab,Arthritis,LT
160799068,Infliximab,Arthralgia,OT
160799068,Infliximab,Arthralgia,DS
160799068,Infliximab,Arthralgia,HO
160799068,Infliximab,Arthralgia,LT
160799068,Infliximab,Antibody test positive,OT
160799068,Infliximab,Antibody test positive,DS
160799068,Infliximab,Antibody test positive,HO
160799068,Infliximab,Antibody test positive,LT
160799068,Infliximab,Adrenal insufficiency,OT
160799068,Infliximab,Adrenal insufficiency,DS
160799068,Infliximab,Adrenal insufficiency,HO
160799068,Infliximab,Adrenal insufficiency,LT
160799068,Infliximab,Wheelchair user,OT
160799068,Infliximab,Wheelchair user,DS
160799068,Infliximab,Wheelchair user,HO
160799068,Infliximab,Wheelchair user,LT
160799068,Infliximab,Vomiting,OT
160799068,Infliximab,Vomiting,DS
160799068,Infliximab,Vomiting,HO
160799068,Infliximab,Vomiting,LT
160799068,Infliximab,Underdose,OT
160799068,Infliximab,Underdose,DS
160799068,Infliximab,Underdose,HO
160799068,Infliximab,Underdose,LT
160799068,Infliximab,Therapy non-responder,OT
160799068,Infliximab,Therapy non-responder,DS
160799068,Infliximab,Therapy non-responder,HO
160799068,Infliximab,Therapy non-responder,LT
160799068,Infliximab,Therapeutic product effect decreased,OT
160799068,Infliximab,Therapeutic product effect decreased,DS
160799068,Infliximab,Therapeutic product effect decreased,HO
160799068,Infliximab,Therapeutic product effect decreased,LT
160799068,Infliximab,Synovitis,OT
160799068,Infliximab,Synovitis,DS
160799068,Infliximab,Synovitis,HO
160799068,Infliximab,Synovitis,LT
160799068,Infliximab,Short stature,OT
160799068,Infliximab,Short stature,DS
160799068,Infliximab,Short stature,HO
160799068,Infliximab,Short stature,LT
160799068,Infliximab,Septic shock,OT
160799068,Infliximab,Septic shock,DS
160799068,Infliximab,Septic shock,HO
160799068,Infliximab,Septic shock,LT
160799068,Infliximab,Rheumatoid arthritis,OT
160799068,Infliximab,Rheumatoid arthritis,DS
160799068,Infliximab,Rheumatoid arthritis,HO
160799068,Infliximab,Rheumatoid arthritis,LT
160799068,Infliximab,Red blood cell sedimentation rate increased,OT
160799068,Infliximab,Red blood cell sedimentation rate increased,DS
160799068,Infliximab,Red blood cell sedimentation rate increased,HO
160799068,Infliximab,Red blood cell sedimentation rate increased,LT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,OT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,DS
160799068,Infliximab,Red blood cell sedimentation rate abnormal,HO
160799068,Infliximab,Red blood cell sedimentation rate abnormal,LT
160799068,Infliximab,Quality of life decreased,OT
160799068,Infliximab,Quality of life decreased,DS
160799068,Infliximab,Quality of life decreased,HO
160799068,Infliximab,Quality of life decreased,LT
160799068,Infliximab,Pyrexia,OT
160799068,Infliximab,Pyrexia,DS
160799068,Infliximab,Pyrexia,HO
160799068,Infliximab,Pyrexia,LT
160799068,Infliximab,Psoriasis,OT
160799068,Infliximab,Psoriasis,DS
160799068,Infliximab,Psoriasis,HO
160799068,Infliximab,Psoriasis,LT
160799068,Infliximab,Product use issue,OT
160799068,Infliximab,Product use issue,DS
160799068,Infliximab,Product use issue,HO
160799068,Infliximab,Product use issue,LT
160799068,Infliximab,Product use in unapproved indication,OT
160799068,Infliximab,Product use in unapproved indication,DS
160799068,Infliximab,Product use in unapproved indication,HO
160799068,Infliximab,Product use in unapproved indication,LT
160799068,Infliximab,Prescribed underdose,OT
160799068,Infliximab,Prescribed underdose,DS
160799068,Infliximab,Prescribed underdose,HO
160799068,Infliximab,Prescribed underdose,LT
160799068,Infliximab,Polyarthritis,OT
160799068,Infliximab,Polyarthritis,DS
160799068,Infliximab,Polyarthritis,HO
160799068,Infliximab,Polyarthritis,LT
160799068,Infliximab,Pleural effusion,OT
160799068,Infliximab,Pleural effusion,DS
160799068,Infliximab,Pleural effusion,HO
160799068,Infliximab,Pleural effusion,LT
160799068,Infliximab,Off label use,OT
160799068,Infliximab,Off label use,DS
160799068,Infliximab,Off label use,HO
160799068,Infliximab,Off label use,LT
160799068,Infliximab,Obesity,OT
160799068,Infliximab,Obesity,DS
160799068,Infliximab,Obesity,HO
160799068,Infliximab,Obesity,LT
160799068,Infliximab,Nausea,OT
160799068,Infliximab,Nausea,DS
160799068,Infliximab,Nausea,HO
160799068,Infliximab,Nausea,LT
160799068,Infliximab,Mobility decreased,OT
160799068,Infliximab,Mobility decreased,DS
160799068,Infliximab,Mobility decreased,HO
160799068,Infliximab,Mobility decreased,LT
160799068,Infliximab,Loss of personal independence in daily activities,OT
160799068,Infliximab,Loss of personal independence in daily activities,DS
160799068,Infliximab,Loss of personal independence in daily activities,HO
160799068,Infliximab,Loss of personal independence in daily activities,LT
160799068,Infliximab,Loss of consciousness,OT
160799068,Infliximab,Loss of consciousness,DS
160799068,Infliximab,Loss of consciousness,HO
160799068,Infliximab,Loss of consciousness,LT
160799068,Infliximab,Liver function test abnormal,OT
160799068,Infliximab,Liver function test abnormal,DS
160799068,Infliximab,Liver function test abnormal,HO
160799068,Infliximab,Liver function test abnormal,LT
160799068,Infliximab,Juvenile idiopathic arthritis,OT
160799068,Infliximab,Juvenile idiopathic arthritis,DS
160799068,Infliximab,Juvenile idiopathic arthritis,HO
160799068,Infliximab,Juvenile idiopathic arthritis,LT
160799068,Infliximab,Joint injury,OT
160799068,Infliximab,Joint injury,DS
160799068,Infliximab,Joint injury,HO
160799068,Infliximab,Joint injury,LT
160799068,Infliximab,Joint effusion,OT
160799068,Infliximab,Joint effusion,DS
160799068,Infliximab,Joint effusion,HO
160799068,Infliximab,Joint effusion,LT
160799068,Infliximab,Joint destruction,OT
160799068,Infliximab,Joint destruction,DS
160799068,Infliximab,Joint destruction,HO
160799068,Infliximab,Joint destruction,LT
160799068,Infliximab,Intentional product use issue,OT
160799068,Infliximab,Intentional product use issue,DS
160799068,Infliximab,Intentional product use issue,HO
160799068,Infliximab,Intentional product use issue,LT
160799068,Infliximab,Impaired quality of life,OT
160799068,Infliximab,Impaired quality of life,DS
160799068,Infliximab,Impaired quality of life,HO
160799068,Infliximab,Impaired quality of life,LT
160799068,Infliximab,Immunodeficiency,OT
160799068,Infliximab,Immunodeficiency,DS
160799068,Infliximab,Immunodeficiency,HO
160799068,Infliximab,Immunodeficiency,LT
160799068,Infliximab,Hypotension,OT
160799068,Infliximab,Hypotension,DS
160799068,Infliximab,Hypotension,HO
160799068,Infliximab,Hypotension,LT
160799068,Infliximab,Hypokalaemia,OT
160799068,Infliximab,Hypokalaemia,DS
160799068,Infliximab,Hypokalaemia,HO
160799068,Infliximab,Hypokalaemia,LT
160799068,Infliximab,Hypocalcaemia,OT
160799068,Infliximab,Hypocalcaemia,DS
160799068,Infliximab,Hypocalcaemia,HO
160799068,Infliximab,Hypocalcaemia,LT
160799068,Infliximab,Human antichimeric antibody positive,OT
160799068,Infliximab,Human antichimeric antibody positive,DS
160799068,Infliximab,Human antichimeric antibody positive,HO
160799068,Infliximab,Human antichimeric antibody positive,LT
160799068,Infliximab,Human anti-human antibody test,OT
160799068,Infliximab,Human anti-human antibody test,DS
160799068,Infliximab,Human anti-human antibody test,HO
160799068,Infliximab,Human anti-human antibody test,LT
160799068,Infliximab,Gastroenteritis viral,OT
160799068,Infliximab,Gastroenteritis viral,DS
160799068,Infliximab,Gastroenteritis viral,HO
160799068,Infliximab,Gastroenteritis viral,LT
160799068,Infliximab,Drug specific antibody present,OT
160799068,Infliximab,Drug specific antibody present,DS
160799068,Infliximab,Drug specific antibody present,HO
160799068,Infliximab,Drug specific antibody present,LT
160799068,Infliximab,Drug specific antibody,OT
160799068,Infliximab,Drug specific antibody,DS
160799068,Infliximab,Drug specific antibody,HO
160799068,Infliximab,Drug specific antibody,LT
160799068,Infliximab,Drug intolerance,OT
160799068,Infliximab,Drug intolerance,DS
160799068,Infliximab,Drug intolerance,HO
160799068,Infliximab,Drug intolerance,LT
160799068,Infliximab,Drug ineffective,OT
160799068,Infliximab,Drug ineffective,DS
160799068,Infliximab,Drug ineffective,HO
160799068,Infliximab,Drug ineffective,LT
160799068,Infliximab,Dizziness,OT
160799068,Infliximab,Dizziness,DS
160799068,Infliximab,Dizziness,HO
160799068,Infliximab,Dizziness,LT
160799068,Infliximab,Diarrhoea,OT
160799068,Infliximab,Diarrhoea,DS
160799068,Infliximab,Diarrhoea,HO
160799068,Infliximab,Diarrhoea,LT
160799068,Infliximab,Contraindicated product administered,OT
160799068,Infliximab,Contraindicated product administered,DS
160799068,Infliximab,Contraindicated product administered,HO
160799068,Infliximab,Contraindicated product administered,LT
160799068,Infliximab,Condition aggravated,OT
160799068,Infliximab,Condition aggravated,DS
160799068,Infliximab,Condition aggravated,HO
160799068,Infliximab,Condition aggravated,LT
160799068,Infliximab,C-reactive protein increased,OT
160799068,Infliximab,C-reactive protein increased,DS
160799068,Infliximab,C-reactive protein increased,HO
160799068,Infliximab,C-reactive protein increased,LT
160799068,Infliximab,C-reactive protein abnormal,OT
160799068,Infliximab,C-reactive protein abnormal,DS
160799068,Infliximab,C-reactive protein abnormal,HO
160799068,Infliximab,C-reactive protein abnormal,LT
160799068,Infliximab,Bone density increased,OT
160799068,Infliximab,Bone density increased,DS
160799068,Infliximab,Bone density increased,HO
160799068,Infliximab,Bone density increased,LT
160799068,Infliximab,Bone density decreased,OT
160799068,Infliximab,Bone density decreased,DS
160799068,Infliximab,Bone density decreased,HO
160799068,Infliximab,Bone density decreased,LT
160799068,Infliximab,Body height below normal,OT
160799068,Infliximab,Body height below normal,DS
160799068,Infliximab,Body height below normal,HO
160799068,Infliximab,Body height below normal,LT
160799068,Infliximab,Arthropathy,OT
160799068,Infliximab,Arthropathy,DS
160799068,Infliximab,Arthropathy,HO
160799068,Infliximab,Arthropathy,LT
160799068,Infliximab,Arthritis,OT
160799068,Infliximab,Arthritis,DS
160799068,Infliximab,Arthritis,HO
160799068,Infliximab,Arthritis,LT
160799068,Infliximab,Arthralgia,OT
160799068,Infliximab,Arthralgia,DS
160799068,Infliximab,Arthralgia,HO
160799068,Infliximab,Arthralgia,LT
160799068,Infliximab,Antibody test positive,OT
160799068,Infliximab,Antibody test positive,DS
160799068,Infliximab,Antibody test positive,HO
160799068,Infliximab,Antibody test positive,LT
160799068,Infliximab,Adrenal insufficiency,OT
160799068,Infliximab,Adrenal insufficiency,DS
160799068,Infliximab,Adrenal insufficiency,HO
160799068,Infliximab,Adrenal insufficiency,LT
160799068,Infliximab,Wheelchair user,OT
160799068,Infliximab,Wheelchair user,DS
160799068,Infliximab,Wheelchair user,HO
160799068,Infliximab,Wheelchair user,LT
160799068,Infliximab,Vomiting,OT
160799068,Infliximab,Vomiting,DS
160799068,Infliximab,Vomiting,HO
160799068,Infliximab,Vomiting,LT
160799068,Infliximab,Underdose,OT
160799068,Infliximab,Underdose,DS
160799068,Infliximab,Underdose,HO
160799068,Infliximab,Underdose,LT
160799068,Infliximab,Therapy non-responder,OT
160799068,Infliximab,Therapy non-responder,DS
160799068,Infliximab,Therapy non-responder,HO
160799068,Infliximab,Therapy non-responder,LT
160799068,Infliximab,Therapeutic product effect decreased,OT
160799068,Infliximab,Therapeutic product effect decreased,DS
160799068,Infliximab,Therapeutic product effect decreased,HO
160799068,Infliximab,Therapeutic product effect decreased,LT
160799068,Infliximab,Synovitis,OT
160799068,Infliximab,Synovitis,DS
160799068,Infliximab,Synovitis,HO
160799068,Infliximab,Synovitis,LT
160799068,Infliximab,Short stature,OT
160799068,Infliximab,Short stature,DS
160799068,Infliximab,Short stature,HO
160799068,Infliximab,Short stature,LT
160799068,Infliximab,Septic shock,OT
160799068,Infliximab,Septic shock,DS
160799068,Infliximab,Septic shock,HO
160799068,Infliximab,Septic shock,LT
160799068,Infliximab,Rheumatoid arthritis,OT
160799068,Infliximab,Rheumatoid arthritis,DS
160799068,Infliximab,Rheumatoid arthritis,HO
160799068,Infliximab,Rheumatoid arthritis,LT
160799068,Infliximab,Red blood cell sedimentation rate increased,OT
160799068,Infliximab,Red blood cell sedimentation rate increased,DS
160799068,Infliximab,Red blood cell sedimentation rate increased,HO
160799068,Infliximab,Red blood cell sedimentation rate increased,LT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,OT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,DS
160799068,Infliximab,Red blood cell sedimentation rate abnormal,HO
160799068,Infliximab,Red blood cell sedimentation rate abnormal,LT
160799068,Infliximab,Quality of life decreased,OT
160799068,Infliximab,Quality of life decreased,DS
160799068,Infliximab,Quality of life decreased,HO
160799068,Infliximab,Quality of life decreased,LT
160799068,Infliximab,Pyrexia,OT
160799068,Infliximab,Pyrexia,DS
160799068,Infliximab,Pyrexia,HO
160799068,Infliximab,Pyrexia,LT
160799068,Infliximab,Psoriasis,OT
160799068,Infliximab,Psoriasis,DS
160799068,Infliximab,Psoriasis,HO
160799068,Infliximab,Psoriasis,LT
160799068,Infliximab,Product use issue,OT
160799068,Infliximab,Product use issue,DS
160799068,Infliximab,Product use issue,HO
160799068,Infliximab,Product use issue,LT
160799068,Infliximab,Product use in unapproved indication,OT
160799068,Infliximab,Product use in unapproved indication,DS
160799068,Infliximab,Product use in unapproved indication,HO
160799068,Infliximab,Product use in unapproved indication,LT
160799068,Infliximab,Prescribed underdose,OT
160799068,Infliximab,Prescribed underdose,DS
160799068,Infliximab,Prescribed underdose,HO
160799068,Infliximab,Prescribed underdose,LT
160799068,Infliximab,Polyarthritis,OT
160799068,Infliximab,Polyarthritis,DS
160799068,Infliximab,Polyarthritis,HO
160799068,Infliximab,Polyarthritis,LT
160799068,Infliximab,Pleural effusion,OT
160799068,Infliximab,Pleural effusion,DS
160799068,Infliximab,Pleural effusion,HO
160799068,Infliximab,Pleural effusion,LT
160799068,Infliximab,Off label use,OT
160799068,Infliximab,Off label use,DS
160799068,Infliximab,Off label use,HO
160799068,Infliximab,Off label use,LT
160799068,Infliximab,Obesity,OT
160799068,Infliximab,Obesity,DS
160799068,Infliximab,Obesity,HO
160799068,Infliximab,Obesity,LT
160799068,Infliximab,Nausea,OT
160799068,Infliximab,Nausea,DS
160799068,Infliximab,Nausea,HO
160799068,Infliximab,Nausea,LT
160799068,Infliximab,Mobility decreased,OT
160799068,Infliximab,Mobility decreased,DS
160799068,Infliximab,Mobility decreased,HO
160799068,Infliximab,Mobility decreased,LT
160799068,Infliximab,Loss of personal independence in daily activities,OT
160799068,Infliximab,Loss of personal independence in daily activities,DS
160799068,Infliximab,Loss of personal independence in daily activities,HO
160799068,Infliximab,Loss of personal independence in daily activities,LT
160799068,Infliximab,Loss of consciousness,OT
160799068,Infliximab,Loss of consciousness,DS
160799068,Infliximab,Loss of consciousness,HO
160799068,Infliximab,Loss of consciousness,LT
160799068,Infliximab,Liver function test abnormal,OT
160799068,Infliximab,Liver function test abnormal,DS
160799068,Infliximab,Liver function test abnormal,HO
160799068,Infliximab,Liver function test abnormal,LT
160799068,Infliximab,Juvenile idiopathic arthritis,OT
160799068,Infliximab,Juvenile idiopathic arthritis,DS
160799068,Infliximab,Juvenile idiopathic arthritis,HO
160799068,Infliximab,Juvenile idiopathic arthritis,LT
160799068,Infliximab,Joint injury,OT
160799068,Infliximab,Joint injury,DS
160799068,Infliximab,Joint injury,HO
160799068,Infliximab,Joint injury,LT
160799068,Infliximab,Joint effusion,OT
160799068,Infliximab,Joint effusion,DS
160799068,Infliximab,Joint effusion,HO
160799068,Infliximab,Joint effusion,LT
160799068,Infliximab,Joint destruction,OT
160799068,Infliximab,Joint destruction,DS
160799068,Infliximab,Joint destruction,HO
160799068,Infliximab,Joint destruction,LT
160799068,Infliximab,Intentional product use issue,OT
160799068,Infliximab,Intentional product use issue,DS
160799068,Infliximab,Intentional product use issue,HO
160799068,Infliximab,Intentional product use issue,LT
160799068,Infliximab,Impaired quality of life,OT
160799068,Infliximab,Impaired quality of life,DS
160799068,Infliximab,Impaired quality of life,HO
160799068,Infliximab,Impaired quality of life,LT
160799068,Infliximab,Immunodeficiency,OT
160799068,Infliximab,Immunodeficiency,DS
160799068,Infliximab,Immunodeficiency,HO
160799068,Infliximab,Immunodeficiency,LT
160799068,Infliximab,Hypotension,OT
160799068,Infliximab,Hypotension,DS
160799068,Infliximab,Hypotension,HO
160799068,Infliximab,Hypotension,LT
160799068,Infliximab,Hypokalaemia,OT
160799068,Infliximab,Hypokalaemia,DS
160799068,Infliximab,Hypokalaemia,HO
160799068,Infliximab,Hypokalaemia,LT
160799068,Infliximab,Hypocalcaemia,OT
160799068,Infliximab,Hypocalcaemia,DS
160799068,Infliximab,Hypocalcaemia,HO
160799068,Infliximab,Hypocalcaemia,LT
160799068,Infliximab,Human antichimeric antibody positive,OT
160799068,Infliximab,Human antichimeric antibody positive,DS
160799068,Infliximab,Human antichimeric antibody positive,HO
160799068,Infliximab,Human antichimeric antibody positive,LT
160799068,Infliximab,Human anti-human antibody test,OT
160799068,Infliximab,Human anti-human antibody test,DS
160799068,Infliximab,Human anti-human antibody test,HO
160799068,Infliximab,Human anti-human antibody test,LT
160799068,Infliximab,Gastroenteritis viral,OT
160799068,Infliximab,Gastroenteritis viral,DS
160799068,Infliximab,Gastroenteritis viral,HO
160799068,Infliximab,Gastroenteritis viral,LT
160799068,Infliximab,Drug specific antibody present,OT
160799068,Infliximab,Drug specific antibody present,DS
160799068,Infliximab,Drug specific antibody present,HO
160799068,Infliximab,Drug specific antibody present,LT
160799068,Infliximab,Drug specific antibody,OT
160799068,Infliximab,Drug specific antibody,DS
160799068,Infliximab,Drug specific antibody,HO
160799068,Infliximab,Drug specific antibody,LT
160799068,Infliximab,Drug intolerance,OT
160799068,Infliximab,Drug intolerance,DS
160799068,Infliximab,Drug intolerance,HO
160799068,Infliximab,Drug intolerance,LT
160799068,Infliximab,Drug ineffective,OT
160799068,Infliximab,Drug ineffective,DS
160799068,Infliximab,Drug ineffective,HO
160799068,Infliximab,Drug ineffective,LT
160799068,Infliximab,Dizziness,OT
160799068,Infliximab,Dizziness,DS
160799068,Infliximab,Dizziness,HO
160799068,Infliximab,Dizziness,LT
160799068,Infliximab,Diarrhoea,OT
160799068,Infliximab,Diarrhoea,DS
160799068,Infliximab,Diarrhoea,HO
160799068,Infliximab,Diarrhoea,LT
160799068,Infliximab,Contraindicated product administered,OT
160799068,Infliximab,Contraindicated product administered,DS
160799068,Infliximab,Contraindicated product administered,HO
160799068,Infliximab,Contraindicated product administered,LT
160799068,Infliximab,Condition aggravated,OT
160799068,Infliximab,Condition aggravated,DS
160799068,Infliximab,Condition aggravated,HO
160799068,Infliximab,Condition aggravated,LT
160799068,Infliximab,C-reactive protein increased,OT
160799068,Infliximab,C-reactive protein increased,DS
160799068,Infliximab,C-reactive protein increased,HO
160799068,Infliximab,C-reactive protein increased,LT
160799068,Infliximab,C-reactive protein abnormal,OT
160799068,Infliximab,C-reactive protein abnormal,DS
160799068,Infliximab,C-reactive protein abnormal,HO
160799068,Infliximab,C-reactive protein abnormal,LT
160799068,Infliximab,Bone density increased,OT
160799068,Infliximab,Bone density increased,DS
160799068,Infliximab,Bone density increased,HO
160799068,Infliximab,Bone density increased,LT
160799068,Infliximab,Bone density decreased,OT
160799068,Infliximab,Bone density decreased,DS
160799068,Infliximab,Bone density decreased,HO
160799068,Infliximab,Bone density decreased,LT
160799068,Infliximab,Body height below normal,OT
160799068,Infliximab,Body height below normal,DS
160799068,Infliximab,Body height below normal,HO
160799068,Infliximab,Body height below normal,LT
160799068,Infliximab,Arthropathy,OT
160799068,Infliximab,Arthropathy,DS
160799068,Infliximab,Arthropathy,HO
160799068,Infliximab,Arthropathy,LT
160799068,Infliximab,Arthritis,OT
160799068,Infliximab,Arthritis,DS
160799068,Infliximab,Arthritis,HO
160799068,Infliximab,Arthritis,LT
160799068,Infliximab,Arthralgia,OT
160799068,Infliximab,Arthralgia,DS
160799068,Infliximab,Arthralgia,HO
160799068,Infliximab,Arthralgia,LT
160799068,Infliximab,Antibody test positive,OT
160799068,Infliximab,Antibody test positive,DS
160799068,Infliximab,Antibody test positive,HO
160799068,Infliximab,Antibody test positive,LT
160799068,Infliximab,Adrenal insufficiency,OT
160799068,Infliximab,Adrenal insufficiency,DS
160799068,Infliximab,Adrenal insufficiency,HO
160799068,Infliximab,Adrenal insufficiency,LT
160799068,Infliximab,Wheelchair user,OT
160799068,Infliximab,Wheelchair user,DS
160799068,Infliximab,Wheelchair user,HO
160799068,Infliximab,Wheelchair user,LT
160799068,Infliximab,Vomiting,OT
160799068,Infliximab,Vomiting,DS
160799068,Infliximab,Vomiting,HO
160799068,Infliximab,Vomiting,LT
160799068,Infliximab,Underdose,OT
160799068,Infliximab,Underdose,DS
160799068,Infliximab,Underdose,HO
160799068,Infliximab,Underdose,LT
160799068,Infliximab,Therapy non-responder,OT
160799068,Infliximab,Therapy non-responder,DS
160799068,Infliximab,Therapy non-responder,HO
160799068,Infliximab,Therapy non-responder,LT
160799068,Infliximab,Therapeutic product effect decreased,OT
160799068,Infliximab,Therapeutic product effect decreased,DS
160799068,Infliximab,Therapeutic product effect decreased,HO
160799068,Infliximab,Therapeutic product effect decreased,LT
160799068,Infliximab,Synovitis,OT
160799068,Infliximab,Synovitis,DS
160799068,Infliximab,Synovitis,HO
160799068,Infliximab,Synovitis,LT
160799068,Infliximab,Short stature,OT
160799068,Infliximab,Short stature,DS
160799068,Infliximab,Short stature,HO
160799068,Infliximab,Short stature,LT
160799068,Infliximab,Septic shock,OT
160799068,Infliximab,Septic shock,DS
160799068,Infliximab,Septic shock,HO
160799068,Infliximab,Septic shock,LT
160799068,Infliximab,Rheumatoid arthritis,OT
160799068,Infliximab,Rheumatoid arthritis,DS
160799068,Infliximab,Rheumatoid arthritis,HO
160799068,Infliximab,Rheumatoid arthritis,LT
160799068,Infliximab,Red blood cell sedimentation rate increased,OT
160799068,Infliximab,Red blood cell sedimentation rate increased,DS
160799068,Infliximab,Red blood cell sedimentation rate increased,HO
160799068,Infliximab,Red blood cell sedimentation rate increased,LT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,OT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,DS
160799068,Infliximab,Red blood cell sedimentation rate abnormal,HO
160799068,Infliximab,Red blood cell sedimentation rate abnormal,LT
160799068,Infliximab,Quality of life decreased,OT
160799068,Infliximab,Quality of life decreased,DS
160799068,Infliximab,Quality of life decreased,HO
160799068,Infliximab,Quality of life decreased,LT
160799068,Infliximab,Pyrexia,OT
160799068,Infliximab,Pyrexia,DS
160799068,Infliximab,Pyrexia,HO
160799068,Infliximab,Pyrexia,LT
160799068,Infliximab,Psoriasis,OT
160799068,Infliximab,Psoriasis,DS
160799068,Infliximab,Psoriasis,HO
160799068,Infliximab,Psoriasis,LT
160799068,Infliximab,Product use issue,OT
160799068,Infliximab,Product use issue,DS
160799068,Infliximab,Product use issue,HO
160799068,Infliximab,Product use issue,LT
160799068,Infliximab,Product use in unapproved indication,OT
160799068,Infliximab,Product use in unapproved indication,DS
160799068,Infliximab,Product use in unapproved indication,HO
160799068,Infliximab,Product use in unapproved indication,LT
160799068,Infliximab,Prescribed underdose,OT
160799068,Infliximab,Prescribed underdose,DS
160799068,Infliximab,Prescribed underdose,HO
160799068,Infliximab,Prescribed underdose,LT
160799068,Infliximab,Polyarthritis,OT
160799068,Infliximab,Polyarthritis,DS
160799068,Infliximab,Polyarthritis,HO
160799068,Infliximab,Polyarthritis,LT
160799068,Infliximab,Pleural effusion,OT
160799068,Infliximab,Pleural effusion,DS
160799068,Infliximab,Pleural effusion,HO
160799068,Infliximab,Pleural effusion,LT
160799068,Infliximab,Off label use,OT
160799068,Infliximab,Off label use,DS
160799068,Infliximab,Off label use,HO
160799068,Infliximab,Off label use,LT
160799068,Infliximab,Obesity,OT
160799068,Infliximab,Obesity,DS
160799068,Infliximab,Obesity,HO
160799068,Infliximab,Obesity,LT
160799068,Infliximab,Nausea,OT
160799068,Infliximab,Nausea,DS
160799068,Infliximab,Nausea,HO
160799068,Infliximab,Nausea,LT
160799068,Infliximab,Mobility decreased,OT
160799068,Infliximab,Mobility decreased,DS
160799068,Infliximab,Mobility decreased,HO
160799068,Infliximab,Mobility decreased,LT
160799068,Infliximab,Loss of personal independence in daily activities,OT
160799068,Infliximab,Loss of personal independence in daily activities,DS
160799068,Infliximab,Loss of personal independence in daily activities,HO
160799068,Infliximab,Loss of personal independence in daily activities,LT
160799068,Infliximab,Loss of consciousness,OT
160799068,Infliximab,Loss of consciousness,DS
160799068,Infliximab,Loss of consciousness,HO
160799068,Infliximab,Loss of consciousness,LT
160799068,Infliximab,Liver function test abnormal,OT
160799068,Infliximab,Liver function test abnormal,DS
160799068,Infliximab,Liver function test abnormal,HO
160799068,Infliximab,Liver function test abnormal,LT
160799068,Infliximab,Juvenile idiopathic arthritis,OT
160799068,Infliximab,Juvenile idiopathic arthritis,DS
160799068,Infliximab,Juvenile idiopathic arthritis,HO
160799068,Infliximab,Juvenile idiopathic arthritis,LT
160799068,Infliximab,Joint injury,OT
160799068,Infliximab,Joint injury,DS
160799068,Infliximab,Joint injury,HO
160799068,Infliximab,Joint injury,LT
160799068,Infliximab,Joint effusion,OT
160799068,Infliximab,Joint effusion,DS
160799068,Infliximab,Joint effusion,HO
160799068,Infliximab,Joint effusion,LT
160799068,Infliximab,Joint destruction,OT
160799068,Infliximab,Joint destruction,DS
160799068,Infliximab,Joint destruction,HO
160799068,Infliximab,Joint destruction,LT
160799068,Infliximab,Intentional product use issue,OT
160799068,Infliximab,Intentional product use issue,DS
160799068,Infliximab,Intentional product use issue,HO
160799068,Infliximab,Intentional product use issue,LT
160799068,Infliximab,Impaired quality of life,OT
160799068,Infliximab,Impaired quality of life,DS
160799068,Infliximab,Impaired quality of life,HO
160799068,Infliximab,Impaired quality of life,LT
160799068,Infliximab,Immunodeficiency,OT
160799068,Infliximab,Immunodeficiency,DS
160799068,Infliximab,Immunodeficiency,HO
160799068,Infliximab,Immunodeficiency,LT
160799068,Infliximab,Hypotension,OT
160799068,Infliximab,Hypotension,DS
160799068,Infliximab,Hypotension,HO
160799068,Infliximab,Hypotension,LT
160799068,Infliximab,Hypokalaemia,OT
160799068,Infliximab,Hypokalaemia,DS
160799068,Infliximab,Hypokalaemia,HO
160799068,Infliximab,Hypokalaemia,LT
160799068,Infliximab,Hypocalcaemia,OT
160799068,Infliximab,Hypocalcaemia,DS
160799068,Infliximab,Hypocalcaemia,HO
160799068,Infliximab,Hypocalcaemia,LT
160799068,Infliximab,Human antichimeric antibody positive,OT
160799068,Infliximab,Human antichimeric antibody positive,DS
160799068,Infliximab,Human antichimeric antibody positive,HO
160799068,Infliximab,Human antichimeric antibody positive,LT
160799068,Infliximab,Human anti-human antibody test,OT
160799068,Infliximab,Human anti-human antibody test,DS
160799068,Infliximab,Human anti-human antibody test,HO
160799068,Infliximab,Human anti-human antibody test,LT
160799068,Infliximab,Gastroenteritis viral,OT
160799068,Infliximab,Gastroenteritis viral,DS
160799068,Infliximab,Gastroenteritis viral,HO
160799068,Infliximab,Gastroenteritis viral,LT
160799068,Infliximab,Drug specific antibody present,OT
160799068,Infliximab,Drug specific antibody present,DS
160799068,Infliximab,Drug specific antibody present,HO
160799068,Infliximab,Drug specific antibody present,LT
160799068,Infliximab,Drug specific antibody,OT
160799068,Infliximab,Drug specific antibody,DS
160799068,Infliximab,Drug specific antibody,HO
160799068,Infliximab,Drug specific antibody,LT
160799068,Infliximab,Drug intolerance,OT
160799068,Infliximab,Drug intolerance,DS
160799068,Infliximab,Drug intolerance,HO
160799068,Infliximab,Drug intolerance,LT
160799068,Infliximab,Drug ineffective,OT
160799068,Infliximab,Drug ineffective,DS
160799068,Infliximab,Drug ineffective,HO
160799068,Infliximab,Drug ineffective,LT
160799068,Infliximab,Dizziness,OT
160799068,Infliximab,Dizziness,DS
160799068,Infliximab,Dizziness,HO
160799068,Infliximab,Dizziness,LT
160799068,Infliximab,Diarrhoea,OT
160799068,Infliximab,Diarrhoea,DS
160799068,Infliximab,Diarrhoea,HO
160799068,Infliximab,Diarrhoea,LT
160799068,Infliximab,Contraindicated product administered,OT
160799068,Infliximab,Contraindicated product administered,DS
160799068,Infliximab,Contraindicated product administered,HO
160799068,Infliximab,Contraindicated product administered,LT
160799068,Infliximab,Condition aggravated,OT
160799068,Infliximab,Condition aggravated,DS
160799068,Infliximab,Condition aggravated,HO
160799068,Infliximab,Condition aggravated,LT
160799068,Infliximab,C-reactive protein increased,OT
160799068,Infliximab,C-reactive protein increased,DS
160799068,Infliximab,C-reactive protein increased,HO
160799068,Infliximab,C-reactive protein increased,LT
160799068,Infliximab,C-reactive protein abnormal,OT
160799068,Infliximab,C-reactive protein abnormal,DS
160799068,Infliximab,C-reactive protein abnormal,HO
160799068,Infliximab,C-reactive protein abnormal,LT
160799068,Infliximab,Bone density increased,OT
160799068,Infliximab,Bone density increased,DS
160799068,Infliximab,Bone density increased,HO
160799068,Infliximab,Bone density increased,LT
160799068,Infliximab,Bone density decreased,OT
160799068,Infliximab,Bone density decreased,DS
160799068,Infliximab,Bone density decreased,HO
160799068,Infliximab,Bone density decreased,LT
160799068,Infliximab,Body height below normal,OT
160799068,Infliximab,Body height below normal,DS
160799068,Infliximab,Body height below normal,HO
160799068,Infliximab,Body height below normal,LT
160799068,Infliximab,Arthropathy,OT
160799068,Infliximab,Arthropathy,DS
160799068,Infliximab,Arthropathy,HO
160799068,Infliximab,Arthropathy,LT
160799068,Infliximab,Arthritis,OT
160799068,Infliximab,Arthritis,DS
160799068,Infliximab,Arthritis,HO
160799068,Infliximab,Arthritis,LT
160799068,Infliximab,Arthralgia,OT
160799068,Infliximab,Arthralgia,DS
160799068,Infliximab,Arthralgia,HO
160799068,Infliximab,Arthralgia,LT
160799068,Infliximab,Antibody test positive,OT
160799068,Infliximab,Antibody test positive,DS
160799068,Infliximab,Antibody test positive,HO
160799068,Infliximab,Antibody test positive,LT
160799068,Infliximab,Adrenal insufficiency,OT
160799068,Infliximab,Adrenal insufficiency,DS
160799068,Infliximab,Adrenal insufficiency,HO
160799068,Infliximab,Adrenal insufficiency,LT
160799068,Infliximab,Wheelchair user,OT
160799068,Infliximab,Wheelchair user,DS
160799068,Infliximab,Wheelchair user,HO
160799068,Infliximab,Wheelchair user,LT
160799068,Infliximab,Vomiting,OT
160799068,Infliximab,Vomiting,DS
160799068,Infliximab,Vomiting,HO
160799068,Infliximab,Vomiting,LT
160799068,Infliximab,Underdose,OT
160799068,Infliximab,Underdose,DS
160799068,Infliximab,Underdose,HO
160799068,Infliximab,Underdose,LT
160799068,Infliximab,Therapy non-responder,OT
160799068,Infliximab,Therapy non-responder,DS
160799068,Infliximab,Therapy non-responder,HO
160799068,Infliximab,Therapy non-responder,LT
160799068,Infliximab,Therapeutic product effect decreased,OT
160799068,Infliximab,Therapeutic product effect decreased,DS
160799068,Infliximab,Therapeutic product effect decreased,HO
160799068,Infliximab,Therapeutic product effect decreased,LT
160799068,Infliximab,Synovitis,OT
160799068,Infliximab,Synovitis,DS
160799068,Infliximab,Synovitis,HO
160799068,Infliximab,Synovitis,LT
160799068,Infliximab,Short stature,OT
160799068,Infliximab,Short stature,DS
160799068,Infliximab,Short stature,HO
160799068,Infliximab,Short stature,LT
160799068,Infliximab,Septic shock,OT
160799068,Infliximab,Septic shock,DS
160799068,Infliximab,Septic shock,HO
160799068,Infliximab,Septic shock,LT
160799068,Infliximab,Rheumatoid arthritis,OT
160799068,Infliximab,Rheumatoid arthritis,DS
160799068,Infliximab,Rheumatoid arthritis,HO
160799068,Infliximab,Rheumatoid arthritis,LT
160799068,Infliximab,Red blood cell sedimentation rate increased,OT
160799068,Infliximab,Red blood cell sedimentation rate increased,DS
160799068,Infliximab,Red blood cell sedimentation rate increased,HO
160799068,Infliximab,Red blood cell sedimentation rate increased,LT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,OT
160799068,Infliximab,Red blood cell sedimentation rate abnormal,DS
160799068,Infliximab,Red blood cell sedimentation rate abnormal,HO
160799068,Infliximab,Red blood cell sedimentation rate abnormal,LT
160799068,Infliximab,Quality of life decreased,OT
160799068,Infliximab,Quality of life decreased,DS
160799068,Infliximab,Quality of life decreased,HO
160799068,Infliximab,Quality of life decreased,LT
160799068,Infliximab,Pyrexia,OT
160799068,Infliximab,Pyrexia,DS
160799068,Infliximab,Pyrexia,HO
160799068,Infliximab,Pyrexia,LT
160799068,Infliximab,Psoriasis,OT
160799068,Infliximab,Psoriasis,DS
160799068,Infliximab,Psoriasis,HO
160799068,Infliximab,Psoriasis,LT
160799068,Infliximab,Product use issue,OT
160799068,Infliximab,Product use issue,DS
160799068,Infliximab,Product use issue,HO
160799068,Infliximab,Product use issue,LT
160799068,Infliximab,Product use in unapproved indication,OT
160799068,Infliximab,Product use in unapproved indication,DS
160799068,Infliximab,Product use in unapproved indication,HO
160799068,Infliximab,Product use in unapproved indication,LT
160799068,Infliximab,Prescribed underdose,OT
160799068,Infliximab,Prescribed underdose,DS
160799068,Infliximab,Prescribed underdose,HO
160799068,Infliximab,Prescribed underdose,LT
160799068,Infliximab,Polyarthritis,OT
160799068,Infliximab,Polyarthritis,DS
160799068,Infliximab,Polyarthritis,HO
160799068,Infliximab,Polyarthritis,LT
160799068,Infliximab,Pleural effusion,OT
160799068,Infliximab,Pleural effusion,DS
160799068,Infliximab,Pleural effusion,HO
160799068,Infliximab,Pleural effusion,LT
160799068,Infliximab,Off label use,OT
160799068,Infliximab,Off label use,DS
160799068,Infliximab,Off label use,HO
160799068,Infliximab,Off label use,LT
160799068,Infliximab,Obesity,OT
160799068,Infliximab,Obesity,DS
160799068,Infliximab,Obesity,HO
160799068,Infliximab,Obesity,LT
160799068,Infliximab,Nausea,OT
160799068,Infliximab,Nausea,DS
160799068,Infliximab,Nausea,HO
160799068,Infliximab,Nausea,LT
160799068,Infliximab,Mobility decreased,OT
160799068,Infliximab,Mobility decreased,DS
160799068,Infliximab,Mobility decreased,HO
160799068,Infliximab,Mobility decreased,LT
160799068,Infliximab,Loss of personal independence in daily activities,OT
160799068,Infliximab,Loss of personal independence in daily activities,DS
160799068,Infliximab,Loss of personal independence in daily activities,HO
160799068,Infliximab,Loss of personal independence in daily activities,LT
160799068,Infliximab,Loss of consciousness,OT
160799068,Infliximab,Loss of consciousness,DS
160799068,Infliximab,Loss of consciousness,HO
160799068,Infliximab,Loss of consciousness,LT
160799068,Infliximab,Liver function test abnormal,OT
160799068,Infliximab,Liver function test abnormal,DS
160799068,Infliximab,Liver function test abnormal,HO
160799068,Infliximab,Liver function test abnormal,LT
160799068,Infliximab,Juvenile idiopathic arthritis,OT
160799068,Infliximab,Juvenile idiopathic arthritis,DS
160799068,Infliximab,Juvenile idiopathic arthritis,HO
160799068,Infliximab,Juvenile idiopathic arthritis,LT
160799068,Infliximab,Joint injury,OT
160799068,Infliximab,Joint injury,DS
160799068,Infliximab,Joint injury,HO
160799068,Infliximab,Joint injury,LT
160799068,Infliximab,Joint effusion,OT
160799068,Infliximab,Joint effusion,DS
160799068,Infliximab,Joint effusion,HO
160799068,Infliximab,Joint effusion,LT
160799068,Infliximab,Joint destruction,OT
160799068,Infliximab,Joint destruction,DS
160799068,Infliximab,Joint destruction,HO
160799068,Infliximab,Joint destruction,LT
160799068,Infliximab,Intentional product use issue,OT
160799068,Infliximab,Intentional product use issue,DS
160799068,Infliximab,Intentional product use issue,HO
160799068,Infliximab,Intentional product use issue,LT
160799068,Infliximab,Impaired quality of life,OT
160799068,Infliximab,Impaired quality of life,DS
160799068,Infliximab,Impaired quality of life,HO
160799068,Infliximab,Impaired quality of life,LT
160799068,Infliximab,Immunodeficiency,OT
160799068,Infliximab,Immunodeficiency,DS
160799068,Infliximab,Immunodeficiency,HO
160799068,Infliximab,Immunodeficiency,LT
160799068,Infliximab,Hypotension,OT
160799068,Infliximab,Hypotension,DS
160799068,Infliximab,Hypotension,HO
160799068,Infliximab,Hypotension,LT
160799068,Infliximab,Hypokalaemia,OT
160799068,Infliximab,Hypokalaemia,DS
160799068,Infliximab,Hypokalaemia,HO
160799068,Infliximab,Hypokalaemia,LT
160799068,Infliximab,Hypocalcaemia,OT
160799068,Infliximab,Hypocalcaemia,DS
160799068,Infliximab,Hypocalcaemia,HO
160799068,Infliximab,Hypocalcaemia,LT
160799068,Infliximab,Human antichimeric antibody positive,OT
160799068,Infliximab,Human antichimeric antibody positive,DS
160799068,Infliximab,Human antichimeric antibody positive,HO
160799068,Infliximab,Human antichimeric antibody positive,LT
160799068,Infliximab,Human anti-human antibody test,OT
160799068,Infliximab,Human anti-human antibody test,DS
160799068,Infliximab,Human anti-human antibody test,HO
160799068,Infliximab,Human anti-human antibody test,LT
160799068,Infliximab,Gastroenteritis viral,OT
160799068,Infliximab,Gastroenteritis viral,DS
160799068,Infliximab,Gastroenteritis viral,HO
160799068,Infliximab,Gastroenteritis viral,LT
160799068,Infliximab,Drug specific antibody present,OT
160799068,Infliximab,Drug specific antibody present,DS
160799068,Infliximab,Drug specific antibody present,HO
160799068,Infliximab,Drug specific antibody present,LT
160799068,Infliximab,Drug specific antibody,OT
160799068,Infliximab,Drug specific antibody,DS
160799068,Infliximab,Drug specific antibody,HO
160799068,Infliximab,Drug specific antibody,LT
160799068,Infliximab,Drug intolerance,OT
160799068,Infliximab,Drug intolerance,DS
160799068,Infliximab,Drug intolerance,HO
160799068,Infliximab,Drug intolerance,LT
160799068,Infliximab,Drug ineffective,OT
160799068,Infliximab,Drug ineffective,DS
160799068,Infliximab,Drug ineffective,HO
160799068,Infliximab,Drug ineffective,LT
160799068,Infliximab,Dizziness,OT
160799068,Infliximab,Dizziness,DS
160799068,Infliximab,Dizziness,HO
160799068,Infliximab,Dizziness,LT
160799068,Infliximab,Diarrhoea,OT
160799068,Infliximab,Diarrhoea,DS
160799068,Infliximab,Diarrhoea,HO
160799068,Infliximab,Diarrhoea,LT
160799068,Infliximab,Contraindicated product administered,OT
160799068,Infliximab,Contraindicated product administered,DS
160799068,Infliximab,Contraindicated product administered,HO
160799068,Infliximab,Contraindicated product administered,LT
160799068,Infliximab,Condition aggravated,OT
160799068,Infliximab,Condition aggravated,DS
160799068,Infliximab,Condition aggravated,HO
160799068,Infliximab,Condition aggravated,LT
160799068,Infliximab,C-reactive protein increased,OT
160799068,Infliximab,C-reactive protein increased,DS
160799068,Infliximab,C-reactive protein increased,HO
160799068,Infliximab,C-reactive protein increased,LT
160799068,Infliximab,C-reactive protein abnormal,OT
160799068,Infliximab,C-reactive protein abnormal,DS
160799068,Infliximab,C-reactive protein abnormal,HO
160799068,Infliximab,C-reactive protein abnormal,LT
160799068,Infliximab,Bone density increased,OT
160799068,Infliximab,Bone density increased,DS
160799068,Infliximab,Bone density increased,HO
160799068,Infliximab,Bone density increased,LT
160799068,Infliximab,Bone density decreased,OT
160799068,Infliximab,Bone density decreased,DS
160799068,Infliximab,Bone density decreased,HO
160799068,Infliximab,Bone density decreased,LT
160799068,Infliximab,Body height below normal,OT
160799068,Infliximab,Body height below normal,DS
160799068,Infliximab,Body height below normal,HO
160799068,Infliximab,Body height below normal,LT
160799068,Infliximab,Arthropathy,OT
160799068,Infliximab,Arthropathy,DS
160799068,Infliximab,Arthropathy,HO
160799068,Infliximab,Arthropathy,LT
160799068,Infliximab,Arthritis,OT
160799068,Infliximab,Arthritis,DS
160799068,Infliximab,Arthritis,HO
160799068,Infliximab,Arthritis,LT
160799068,Infliximab,Arthralgia,OT
160799068,Infliximab,Arthralgia,DS
160799068,Infliximab,Arthralgia,HO
160799068,Infliximab,Arthralgia,LT
160799068,Infliximab,Antibody test positive,OT
160799068,Infliximab,Antibody test positive,DS
160799068,Infliximab,Antibody test positive,HO
160799068,Infliximab,Antibody test positive,LT
160799068,Infliximab,Adrenal insufficiency,OT
160799068,Infliximab,Adrenal insufficiency,DS
160799068,Infliximab,Adrenal insufficiency,HO
160799068,Infliximab,Adrenal insufficiency,LT
165605555,Infliximab,Rhinorrhoea,OT
165605555,Infliximab,Renal colic,OT
165605555,Infliximab,Pyrexia,OT
165605555,Infliximab,Productive cough,OT
165605555,Infliximab,Product use issue,OT
165605555,Infliximab,Off label use,OT
165605555,Infliximab,Nasopharyngitis,OT
165605555,Infliximab,Intentional product use issue,OT
165605555,Infliximab,Influenza,OT
165605555,Infliximab,Hot flush,OT
165605555,Infliximab,Heart rate decreased,OT
165605555,Infliximab,Drug ineffective,OT
165605555,Infliximab,Calculus bladder,OT
165605555,Infliximab,Bronchitis,OT
165605555,Infliximab,Blood urine present,OT
165605555,Infliximab,Blood pressure increased,OT
165605555,Infliximab,Blood pressure fluctuation,OT
165605555,Infliximab,Bladder cancer,OT
165605555,Infliximab,Rhinorrhoea,OT
165605555,Infliximab,Renal colic,OT
165605555,Infliximab,Pyrexia,OT
165605555,Infliximab,Productive cough,OT
165605555,Infliximab,Product use issue,OT
165605555,Infliximab,Off label use,OT
165605555,Infliximab,Nasopharyngitis,OT
165605555,Infliximab,Intentional product use issue,OT
165605555,Infliximab,Influenza,OT
165605555,Infliximab,Hot flush,OT
165605555,Infliximab,Heart rate decreased,OT
165605555,Infliximab,Drug ineffective,OT
165605555,Infliximab,Calculus bladder,OT
165605555,Infliximab,Bronchitis,OT
165605555,Infliximab,Blood urine present,OT
165605555,Infliximab,Blood pressure increased,OT
165605555,Infliximab,Blood pressure fluctuation,OT
165605555,Infliximab,Bladder cancer,OT
165605555,Infliximab,Rhinorrhoea,OT
165605555,Infliximab,Renal colic,OT
165605555,Infliximab,Pyrexia,OT
165605555,Infliximab,Productive cough,OT
165605555,Infliximab,Product use issue,OT
165605555,Infliximab,Off label use,OT
165605555,Infliximab,Nasopharyngitis,OT
165605555,Infliximab,Intentional product use issue,OT
165605555,Infliximab,Influenza,OT
165605555,Infliximab,Hot flush,OT
165605555,Infliximab,Heart rate decreased,OT
165605555,Infliximab,Drug ineffective,OT
165605555,Infliximab,Calculus bladder,OT
165605555,Infliximab,Bronchitis,OT
165605555,Infliximab,Blood urine present,OT
165605555,Infliximab,Blood pressure increased,OT
165605555,Infliximab,Blood pressure fluctuation,OT
165605555,Infliximab,Bladder cancer,OT
165706965,Infliximab,Product use issue,OT
165706965,Infliximab,Off label use,OT
165706965,Infliximab,Intra-abdominal haemorrhage,OT
165706965,Infliximab,Haemorrhage,OT
165706965,Infliximab,Eczema,OT
165706965,Infliximab,Condition aggravated,OT
165706965,Infliximab,Body temperature decreased,OT
165706965,Infliximab,Abdominal pain,OT
172609643,Infliximab,Product use in unapproved indication,OT
172609643,Infliximab,Palmar-plantar erythrodysaesthesia syndrome,OT
172609643,Infliximab,Off label use,OT
172609643,Infliximab,Drug effective for unapproved indication,OT
172609643,Infliximab,Product use in unapproved indication,OT
172609643,Infliximab,Palmar-plantar erythrodysaesthesia syndrome,OT
172609643,Infliximab,Off label use,OT
172609643,Infliximab,Drug effective for unapproved indication,OT
172609643,Infliximab,Product use in unapproved indication,OT
172609643,Infliximab,Palmar-plantar erythrodysaesthesia syndrome,OT
172609643,Infliximab,Off label use,OT
172609643,Infliximab,Drug effective for unapproved indication,OT
175703573,Infliximab,Small intestine carcinoma,OT
175703573,Infliximab,Rash erythematous,OT
175703573,Infliximab,Rash,OT
175703573,Infliximab,Pruritus,OT
175703573,Infliximab,Product use issue,OT
175703573,Infliximab,Off label use,OT
175703573,Infliximab,Hypertension,OT
175703573,Infliximab,Headache,OT
175703573,Infliximab,Feeling hot,OT
175703573,Infliximab,Eyelid oedema,OT
175703573,Infliximab,Erythema,OT
175703573,Infliximab,Dyspnoea,OT
175703573,Infliximab,Chest discomfort,OT
175703573,Infliximab,Blood pressure increased,OT
175703573,Infliximab,Blood pressure fluctuation,OT
175703573,Infliximab,Small intestine carcinoma,OT
175703573,Infliximab,Rash erythematous,OT
175703573,Infliximab,Rash,OT
175703573,Infliximab,Pruritus,OT
175703573,Infliximab,Product use issue,OT
175703573,Infliximab,Off label use,OT
175703573,Infliximab,Hypertension,OT
175703573,Infliximab,Headache,OT
175703573,Infliximab,Feeling hot,OT
175703573,Infliximab,Eyelid oedema,OT
175703573,Infliximab,Erythema,OT
175703573,Infliximab,Dyspnoea,OT
175703573,Infliximab,Chest discomfort,OT
175703573,Infliximab,Blood pressure increased,OT
175703573,Infliximab,Blood pressure fluctuation,OT
176478313,Infliximab,Therapeutic product effect incomplete,OT
176478313,Infliximab,Oral herpes,OT
176478313,Infliximab,Off label use,OT
176478313,Infliximab,Nausea,OT
176478313,Infliximab,Muscle spasms,OT
176478313,Infliximab,Mucous stools,OT
176478313,Infliximab,Malaise,OT
176478313,Infliximab,Headache,OT
176478313,Infliximab,Haematochezia,OT
176478313,Infliximab,Gastrointestinal inflammation,OT
176478313,Infliximab,Flatulence,OT
176478313,Infliximab,Fatigue,OT
176478313,Infliximab,Faecal calprotectin increased,OT
176478313,Infliximab,Drug level above therapeutic,OT
176478313,Infliximab,Diarrhoea,OT
176478313,Infliximab,Condition aggravated,OT
176478313,Infliximab,Abscess,OT
176478313,Infliximab,Abdominal pain upper,OT
176478313,Infliximab,Abdominal distension,OT
176478313,Infliximab,Therapeutic product effect incomplete,OT
176478313,Infliximab,Oral herpes,OT
176478313,Infliximab,Off label use,OT
176478313,Infliximab,Nausea,OT
176478313,Infliximab,Muscle spasms,OT
176478313,Infliximab,Mucous stools,OT
176478313,Infliximab,Malaise,OT
176478313,Infliximab,Headache,OT
176478313,Infliximab,Haematochezia,OT
176478313,Infliximab,Gastrointestinal inflammation,OT
176478313,Infliximab,Flatulence,OT
176478313,Infliximab,Fatigue,OT
176478313,Infliximab,Faecal calprotectin increased,OT
176478313,Infliximab,Drug level above therapeutic,OT
176478313,Infliximab,Diarrhoea,OT
176478313,Infliximab,Condition aggravated,OT
176478313,Infliximab,Abscess,OT
176478313,Infliximab,Abdominal pain upper,OT
176478313,Infliximab,Abdominal distension,OT
176478313,Infliximab,Therapeutic product effect incomplete,OT
176478313,Infliximab,Oral herpes,OT
176478313,Infliximab,Off label use,OT
176478313,Infliximab,Nausea,OT
176478313,Infliximab,Muscle spasms,OT
176478313,Infliximab,Mucous stools,OT
176478313,Infliximab,Malaise,OT
176478313,Infliximab,Headache,OT
176478313,Infliximab,Haematochezia,OT
176478313,Infliximab,Gastrointestinal inflammation,OT
176478313,Infliximab,Flatulence,OT
176478313,Infliximab,Fatigue,OT
176478313,Infliximab,Faecal calprotectin increased,OT
176478313,Infliximab,Drug level above therapeutic,OT
176478313,Infliximab,Diarrhoea,OT
176478313,Infliximab,Condition aggravated,OT
176478313,Infliximab,Abscess,OT
176478313,Infliximab,Abdominal pain upper,OT
176478313,Infliximab,Abdominal distension,OT
176583094,Infliximab,Rash erythematous,OT
176583094,Infliximab,Pruritus,OT
176583094,Infliximab,Off label use,OT
176583094,Infliximab,Inguinal hernia,OT
176583094,Infliximab,Heart rate decreased,OT
176583094,Infliximab,Condition aggravated,OT
176583094,Infliximab,Blood pressure increased,OT
176583094,Infliximab,Blood pressure fluctuation,OT
176583094,Infliximab,Rash erythematous,OT
176583094,Infliximab,Pruritus,OT
176583094,Infliximab,Off label use,OT
176583094,Infliximab,Inguinal hernia,OT
176583094,Infliximab,Heart rate decreased,OT
176583094,Infliximab,Condition aggravated,OT
176583094,Infliximab,Blood pressure increased,OT
176583094,Infliximab,Blood pressure fluctuation,OT
176583094,Infliximab,Rash erythematous,OT
176583094,Infliximab,Pruritus,OT
176583094,Infliximab,Off label use,OT
176583094,Infliximab,Inguinal hernia,OT
176583094,Infliximab,Heart rate decreased,OT
176583094,Infliximab,Condition aggravated,OT
176583094,Infliximab,Blood pressure increased,OT
176583094,Infliximab,Blood pressure fluctuation,OT
176583094,Infliximab,Rash erythematous,OT
176583094,Infliximab,Pruritus,OT
176583094,Infliximab,Off label use,OT
176583094,Infliximab,Inguinal hernia,OT
176583094,Infliximab,Heart rate decreased,OT
176583094,Infliximab,Condition aggravated,OT
176583094,Infliximab,Blood pressure increased,OT
176583094,Infliximab,Blood pressure fluctuation,OT
176856103,Infliximab,Seborrhoea,OT
176856103,Infliximab,Pyrexia,OT
176856103,Infliximab,Productive cough,OT
176856103,Infliximab,Off label use,OT
176856103,Infliximab,Lower respiratory tract infection,OT
176856103,Infliximab,Infection,OT
176856103,Infliximab,Haematochezia,OT
176856103,Infliximab,Fatigue,OT
176856103,Infliximab,Condition aggravated,OT
176856103,Infliximab,Body temperature decreased,OT
176856103,Infliximab,Acne,OT
176856103,Infliximab,Abdominal distension,OT
177917463,Infliximab,Weight increased,OT
177917463,Infliximab,Weight increased,HO
177917463,Infliximab,Vomiting,OT
177917463,Infliximab,Vomiting,HO
177917463,Infliximab,Vasculitis,OT
177917463,Infliximab,Vasculitis,HO
177917463,Infliximab,Therapeutic response shortened,OT
177917463,Infliximab,Therapeutic response shortened,HO
177917463,Infliximab,Therapeutic response decreased,OT
177917463,Infliximab,Therapeutic response decreased,HO
177917463,Infliximab,Product use issue,OT
177917463,Infliximab,Product use issue,HO
177917463,Infliximab,Pneumonia,OT
177917463,Infliximab,Pneumonia,HO
177917463,Infliximab,Off label use,OT
177917463,Infliximab,Off label use,HO
177917463,Infliximab,Nausea,OT
177917463,Infliximab,Nausea,HO
177917463,Infliximab,Movement disorder,OT
177917463,Infliximab,Movement disorder,HO
177917463,Infliximab,Intentional product use issue,OT
177917463,Infliximab,Intentional product use issue,HO
177917463,Infliximab,Inappropriate schedule of product administration,OT
177917463,Infliximab,Inappropriate schedule of product administration,HO
177917463,Infliximab,Feeding disorder,OT
177917463,Infliximab,Feeding disorder,HO
177917463,Infliximab,Eczema,OT
177917463,Infliximab,Eczema,HO
177917463,Infliximab,Ear infection,OT
177917463,Infliximab,Ear infection,HO
177917463,Infliximab,Cough,OT
177917463,Infliximab,Cough,HO
177917463,Infliximab,Abdominal pain lower,OT
177917463,Infliximab,Abdominal pain lower,HO
183417853,Infliximab,Wrist fracture,OT
183417853,Infliximab,Wrist fracture,HO
183417853,Infliximab,Weight increased,OT
183417853,Infliximab,Weight increased,HO
183417853,Infliximab,Suicide attempt,OT
183417853,Infliximab,Suicide attempt,HO
183417853,Infliximab,Rectal haemorrhage,OT
183417853,Infliximab,Rectal haemorrhage,HO
183417853,Infliximab,Pyrexia,OT
183417853,Infliximab,Pyrexia,HO
183417853,Infliximab,Productive cough,OT
183417853,Infliximab,Productive cough,HO
183417853,Infliximab,Off label use,OT
183417853,Infliximab,Off label use,HO
183417853,Infliximab,Nasopharyngitis,OT
183417853,Infliximab,Nasopharyngitis,HO
183417853,Infliximab,Malaise,OT
183417853,Infliximab,Malaise,HO
183417853,Infliximab,Intentional product use issue,OT
183417853,Infliximab,Intentional product use issue,HO
183417853,Infliximab,Inappropriate schedule of product administration,OT
183417853,Infliximab,Inappropriate schedule of product administration,HO
183417853,Infliximab,Drug level decreased,OT
183417853,Infliximab,Drug level decreased,HO
183417853,Infliximab,Condition aggravated,OT
183417853,Infliximab,Condition aggravated,HO
183417853,Infliximab,Wrist fracture,OT
183417853,Infliximab,Wrist fracture,HO
183417853,Infliximab,Weight increased,OT
183417853,Infliximab,Weight increased,HO
183417853,Infliximab,Suicide attempt,OT
183417853,Infliximab,Suicide attempt,HO
183417853,Infliximab,Rectal haemorrhage,OT
183417853,Infliximab,Rectal haemorrhage,HO
183417853,Infliximab,Pyrexia,OT
183417853,Infliximab,Pyrexia,HO
183417853,Infliximab,Productive cough,OT
183417853,Infliximab,Productive cough,HO
183417853,Infliximab,Off label use,OT
183417853,Infliximab,Off label use,HO
183417853,Infliximab,Nasopharyngitis,OT
183417853,Infliximab,Nasopharyngitis,HO
183417853,Infliximab,Malaise,OT
183417853,Infliximab,Malaise,HO
183417853,Infliximab,Intentional product use issue,OT
183417853,Infliximab,Intentional product use issue,HO
183417853,Infliximab,Inappropriate schedule of product administration,OT
183417853,Infliximab,Inappropriate schedule of product administration,HO
183417853,Infliximab,Drug level decreased,OT
183417853,Infliximab,Drug level decreased,HO
183417853,Infliximab,Condition aggravated,OT
183417853,Infliximab,Condition aggravated,HO
184529604,Infliximab,Weight decreased,OT
184529604,Infliximab,Weight decreased,HO
184529604,Infliximab,Vomiting,OT
184529604,Infliximab,Vomiting,HO
184529604,Infliximab,Pyrexia,OT
184529604,Infliximab,Pyrexia,HO
184529604,Infliximab,Psychomotor hyperactivity,OT
184529604,Infliximab,Psychomotor hyperactivity,HO
184529604,Infliximab,Product use issue,OT
184529604,Infliximab,Product use issue,HO
184529604,Infliximab,Pneumonia,OT
184529604,Infliximab,Pneumonia,HO
184529604,Infliximab,Off label use,OT
184529604,Infliximab,Off label use,HO
184529604,Infliximab,Night sweats,OT
184529604,Infliximab,Night sweats,HO
184529604,Infliximab,Musculoskeletal injury,OT
184529604,Infliximab,Musculoskeletal injury,HO
184529604,Infliximab,Intestinal obstruction,OT
184529604,Infliximab,Intestinal obstruction,HO
184529604,Infliximab,Influenza,OT
184529604,Infliximab,Influenza,HO
184529604,Infliximab,Inflammatory marker increased,OT
184529604,Infliximab,Inflammatory marker increased,HO
184529604,Infliximab,Increased appetite,OT
184529604,Infliximab,Increased appetite,HO
184529604,Infliximab,Heart rate decreased,OT
184529604,Infliximab,Heart rate decreased,HO
184529604,Infliximab,Enterocolonic fistula,OT
184529604,Infliximab,Enterocolonic fistula,HO
184529604,Infliximab,Dyspnoea,OT
184529604,Infliximab,Dyspnoea,HO
184529604,Infliximab,Cough,OT
184529604,Infliximab,Cough,HO
184529604,Infliximab,Coronavirus test positive,OT
184529604,Infliximab,Coronavirus test positive,HO
184529604,Infliximab,Condition aggravated,OT
184529604,Infliximab,Condition aggravated,HO
184529604,Infliximab,Bowel movement irregularity,OT
184529604,Infliximab,Bowel movement irregularity,HO
184529604,Infliximab,Abnormal behaviour,OT
184529604,Infliximab,Abnormal behaviour,HO
184529604,Infliximab,Abdominal tenderness,OT
184529604,Infliximab,Abdominal tenderness,HO
184529604,Infliximab,Abdominal pain lower,OT
184529604,Infliximab,Abdominal pain lower,HO
184529604,Infliximab,Abdominal mass,OT
184529604,Infliximab,Abdominal mass,HO
184529604,Infliximab,Weight decreased,OT
184529604,Infliximab,Weight decreased,HO
184529604,Infliximab,Vomiting,OT
184529604,Infliximab,Vomiting,HO
184529604,Infliximab,Pyrexia,OT
184529604,Infliximab,Pyrexia,HO
184529604,Infliximab,Psychomotor hyperactivity,OT
184529604,Infliximab,Psychomotor hyperactivity,HO
184529604,Infliximab,Product use issue,OT
184529604,Infliximab,Product use issue,HO
184529604,Infliximab,Pneumonia,OT
184529604,Infliximab,Pneumonia,HO
184529604,Infliximab,Off label use,OT
184529604,Infliximab,Off label use,HO
184529604,Infliximab,Night sweats,OT
184529604,Infliximab,Night sweats,HO
184529604,Infliximab,Musculoskeletal injury,OT
184529604,Infliximab,Musculoskeletal injury,HO
184529604,Infliximab,Intestinal obstruction,OT
184529604,Infliximab,Intestinal obstruction,HO
184529604,Infliximab,Influenza,OT
184529604,Infliximab,Influenza,HO
184529604,Infliximab,Inflammatory marker increased,OT
184529604,Infliximab,Inflammatory marker increased,HO
184529604,Infliximab,Increased appetite,OT
184529604,Infliximab,Increased appetite,HO
184529604,Infliximab,Heart rate decreased,OT
184529604,Infliximab,Heart rate decreased,HO
184529604,Infliximab,Enterocolonic fistula,OT
184529604,Infliximab,Enterocolonic fistula,HO
184529604,Infliximab,Dyspnoea,OT
184529604,Infliximab,Dyspnoea,HO
184529604,Infliximab,Cough,OT
184529604,Infliximab,Cough,HO
184529604,Infliximab,Coronavirus test positive,OT
184529604,Infliximab,Coronavirus test positive,HO
184529604,Infliximab,Condition aggravated,OT
184529604,Infliximab,Condition aggravated,HO
184529604,Infliximab,Bowel movement irregularity,OT
184529604,Infliximab,Bowel movement irregularity,HO
184529604,Infliximab,Abnormal behaviour,OT
184529604,Infliximab,Abnormal behaviour,HO
184529604,Infliximab,Abdominal tenderness,OT
184529604,Infliximab,Abdominal tenderness,HO
184529604,Infliximab,Abdominal pain lower,OT
184529604,Infliximab,Abdominal pain lower,HO
184529604,Infliximab,Abdominal mass,OT
184529604,Infliximab,Abdominal mass,HO
184913943,Infliximab,Weight increased,OT
184913943,Infliximab,Off label use,OT
184913943,Infliximab,Intentional product use issue,OT
184913943,Infliximab,Condition aggravated,OT
184913943,Infliximab,Weight increased,OT
184913943,Infliximab,Off label use,OT
184913943,Infliximab,Intentional product use issue,OT
184913943,Infliximab,Condition aggravated,OT
185257343,Infliximab,Therapeutic response shortened,OT
185257343,Infliximab,Off label use,OT
185257343,Infliximab,Nausea,OT
185257343,Infliximab,Impaired quality of life,OT
185257343,Infliximab,Illness,OT
185257343,Infliximab,Food allergy,OT
185257343,Infliximab,Flank pain,OT
185257343,Infliximab,Dizziness,OT
185257343,Infliximab,Diarrhoea,OT
185257343,Infliximab,Condition aggravated,OT
185257343,Infliximab,Colitis ulcerative,OT
185257343,Infliximab,Blood pressure increased,OT
185257343,Infliximab,Blood pressure fluctuation,OT
185529392,Infliximab,Weight increased,OT
185529392,Infliximab,Rhinorrhoea,OT
185529392,Infliximab,Respiratory disorder,OT
185529392,Infliximab,Product prescribing error,OT
185529392,Infliximab,Off label use,OT
185529392,Infliximab,Nasopharyngitis,OT
185529392,Infliximab,Nasal congestion,OT
185529392,Infliximab,Musculoskeletal discomfort,OT
185529392,Infliximab,Malaise,OT
185529392,Infliximab,Lower respiratory tract infection,OT
185529392,Infliximab,Intentional product use issue,OT
185529392,Infliximab,Intentional dose omission,OT
185529392,Infliximab,Inappropriate schedule of product administration,OT
185529392,Infliximab,Hypertension,OT
185529392,Infliximab,Headache,OT
185529392,Infliximab,Gait disturbance,OT
185529392,Infliximab,Fatigue,OT
185529392,Infliximab,Drug level below therapeutic,OT
185529392,Infliximab,Dizziness,OT
185529392,Infliximab,Cough,OT
185529392,Infliximab,Condition aggravated,OT
185529392,Infliximab,Blood pressure fluctuation,OT
185529392,Infliximab,Back pain,OT
185792542,Infliximab,Weight increased,OT
185792542,Infliximab,Rheumatoid arthritis,OT
185792542,Infliximab,Off label use,OT
185792542,Infliximab,Musculoskeletal stiffness,OT
185792542,Infliximab,Joint stiffness,OT
185792542,Infliximab,Intentional product use issue,OT
185792542,Infliximab,Inappropriate schedule of product administration,OT
185792542,Infliximab,Heart rate increased,OT
185792542,Infliximab,Condition aggravated,OT
185792542,Infliximab,Blood pressure increased,OT
185792542,Infliximab,Blood pressure fluctuation,OT
185792542,Infliximab,Weight increased,OT
185792542,Infliximab,Rheumatoid arthritis,OT
185792542,Infliximab,Off label use,OT
185792542,Infliximab,Musculoskeletal stiffness,OT
185792542,Infliximab,Joint stiffness,OT
185792542,Infliximab,Intentional product use issue,OT
185792542,Infliximab,Inappropriate schedule of product administration,OT
185792542,Infliximab,Heart rate increased,OT
185792542,Infliximab,Condition aggravated,OT
185792542,Infliximab,Blood pressure increased,OT
185792542,Infliximab,Blood pressure fluctuation,OT
185792542,Infliximab,Weight increased,OT
185792542,Infliximab,Rheumatoid arthritis,OT
185792542,Infliximab,Off label use,OT
185792542,Infliximab,Musculoskeletal stiffness,OT
185792542,Infliximab,Joint stiffness,OT
185792542,Infliximab,Intentional product use issue,OT
185792542,Infliximab,Inappropriate schedule of product administration,OT
185792542,Infliximab,Heart rate increased,OT
185792542,Infliximab,Condition aggravated,OT
185792542,Infliximab,Blood pressure increased,OT
185792542,Infliximab,Blood pressure fluctuation,OT
185792542,Infliximab,Weight increased,OT
185792542,Infliximab,Rheumatoid arthritis,OT
185792542,Infliximab,Off label use,OT
185792542,Infliximab,Musculoskeletal stiffness,OT
185792542,Infliximab,Joint stiffness,OT
185792542,Infliximab,Intentional product use issue,OT
185792542,Infliximab,Inappropriate schedule of product administration,OT
185792542,Infliximab,Heart rate increased,OT
185792542,Infliximab,Condition aggravated,OT
185792542,Infliximab,Blood pressure increased,OT
185792542,Infliximab,Blood pressure fluctuation,OT
188873742,Infliximab,Periodontal disease,OT
188873742,Infliximab,Off label use,OT
188873742,Infliximab,Intentional product use issue,OT
188873742,Infliximab,Incorrect dose administered,OT
188873742,Infliximab,Inappropriate schedule of product administration,OT
188873742,Infliximab,Hypoventilation,OT
188873742,Infliximab,Hypertension,OT
188873742,Infliximab,Headache,OT
188873742,Infliximab,Ear pain,OT
188873742,Infliximab,Cough,OT
188873742,Infliximab,Body temperature decreased,OT
188873742,Infliximab,Blood pressure fluctuation,OT
189069732,Infliximab,Urticaria,OT
189069732,Infliximab,Urticaria,HO
189069732,Infliximab,Urticaria,DS
189069732,Infliximab,Ulcer,OT
189069732,Infliximab,Ulcer,HO
189069732,Infliximab,Ulcer,DS
189069732,Infliximab,Treatment failure,OT
189069732,Infliximab,Treatment failure,HO
189069732,Infliximab,Treatment failure,DS
189069732,Infliximab,Tongue disorder,OT
189069732,Infliximab,Tongue disorder,HO
189069732,Infliximab,Tongue disorder,DS
189069732,Infliximab,Therapy non-responder,OT
189069732,Infliximab,Therapy non-responder,HO
189069732,Infliximab,Therapy non-responder,DS
189069732,Infliximab,Therapeutic product effect incomplete,OT
189069732,Infliximab,Therapeutic product effect incomplete,HO
189069732,Infliximab,Therapeutic product effect incomplete,DS
189069732,Infliximab,Therapeutic product effect decreased,OT
189069732,Infliximab,Therapeutic product effect decreased,HO
189069732,Infliximab,Therapeutic product effect decreased,DS
189069732,Infliximab,Tenosynovitis,OT
189069732,Infliximab,Tenosynovitis,HO
189069732,Infliximab,Tenosynovitis,DS
189069732,Infliximab,Tendonitis,OT
189069732,Infliximab,Tendonitis,HO
189069732,Infliximab,Tendonitis,DS
189069732,Infliximab,Synovitis,OT
189069732,Infliximab,Synovitis,HO
189069732,Infliximab,Synovitis,DS
189069732,Infliximab,Skin ulcer,OT
189069732,Infliximab,Skin ulcer,HO
189069732,Infliximab,Skin ulcer,DS
189069732,Infliximab,Skin necrosis,OT
189069732,Infliximab,Skin necrosis,HO
189069732,Infliximab,Skin necrosis,DS
189069732,Infliximab,Rheumatoid nodule,OT
189069732,Infliximab,Rheumatoid nodule,HO
189069732,Infliximab,Rheumatoid nodule,DS
189069732,Infliximab,Rheumatoid arthritis,OT
189069732,Infliximab,Rheumatoid arthritis,HO
189069732,Infliximab,Rheumatoid arthritis,DS
189069732,Infliximab,Red blood cell sedimentation rate increased,OT
189069732,Infliximab,Red blood cell sedimentation rate increased,HO
189069732,Infliximab,Red blood cell sedimentation rate increased,DS
189069732,Infliximab,Red blood cell sedimentation rate,OT
189069732,Infliximab,Red blood cell sedimentation rate,HO
189069732,Infliximab,Red blood cell sedimentation rate,DS
189069732,Infliximab,Rash pruritic,OT
189069732,Infliximab,Rash pruritic,HO
189069732,Infliximab,Rash pruritic,DS
189069732,Infliximab,Rash,OT
189069732,Infliximab,Rash,HO
189069732,Infliximab,Rash,DS
189069732,Infliximab,Psoriatic arthropathy,OT
189069732,Infliximab,Psoriatic arthropathy,HO
189069732,Infliximab,Psoriatic arthropathy,DS
189069732,Infliximab,Product use issue,OT
189069732,Infliximab,Product use issue,HO
189069732,Infliximab,Product use issue,DS
189069732,Infliximab,Peripheral swelling,OT
189069732,Infliximab,Peripheral swelling,HO
189069732,Infliximab,Peripheral swelling,DS
189069732,Infliximab,Panniculitis,OT
189069732,Infliximab,Panniculitis,HO
189069732,Infliximab,Panniculitis,DS
189069732,Infliximab,Pain,OT
189069732,Infliximab,Pain,HO
189069732,Infliximab,Pain,DS
189069732,Infliximab,Overdose,OT
189069732,Infliximab,Overdose,HO
189069732,Infliximab,Overdose,DS
189069732,Infliximab,Osteomyelitis,OT
189069732,Infliximab,Osteomyelitis,HO
189069732,Infliximab,Osteomyelitis,DS
189069732,Infliximab,Off label use,OT
189069732,Infliximab,Off label use,HO
189069732,Infliximab,Off label use,DS
189069732,Infliximab,Nausea,OT
189069732,Infliximab,Nausea,HO
189069732,Infliximab,Nausea,DS
189069732,Infliximab,Musculoskeletal stiffness,OT
189069732,Infliximab,Musculoskeletal stiffness,HO
189069732,Infliximab,Musculoskeletal stiffness,DS
189069732,Infliximab,Musculoskeletal disorder,OT
189069732,Infliximab,Musculoskeletal disorder,HO
189069732,Infliximab,Musculoskeletal disorder,DS
189069732,Infliximab,Mobility decreased,OT
189069732,Infliximab,Mobility decreased,HO
189069732,Infliximab,Mobility decreased,DS
189069732,Infliximab,Loss of personal independence in daily activities,OT
189069732,Infliximab,Loss of personal independence in daily activities,HO
189069732,Infliximab,Loss of personal independence in daily activities,DS
189069732,Infliximab,Joint swelling,OT
189069732,Infliximab,Joint swelling,HO
189069732,Infliximab,Joint swelling,DS
189069732,Infliximab,Joint injury,OT
189069732,Infliximab,Joint injury,HO
189069732,Infliximab,Joint injury,DS
189069732,Infliximab,Insomnia,OT
189069732,Infliximab,Insomnia,HO
189069732,Infliximab,Insomnia,DS
189069732,Infliximab,Infusion related reaction,OT
189069732,Infliximab,Infusion related reaction,HO
189069732,Infliximab,Infusion related reaction,DS
189069732,Infliximab,Inflammation,OT
189069732,Infliximab,Inflammation,HO
189069732,Infliximab,Inflammation,DS
189069732,Infliximab,Hypertension,OT
189069732,Infliximab,Hypertension,HO
189069732,Infliximab,Hypertension,DS
189069732,Infliximab,Hypersensitivity,OT
189069732,Infliximab,Hypersensitivity,HO
189069732,Infliximab,Hypersensitivity,DS
189069732,Infliximab,Hypercalcaemia,OT
189069732,Infliximab,Hypercalcaemia,HO
189069732,Infliximab,Hypercalcaemia,DS
189069732,Infliximab,Headache,OT
189069732,Infliximab,Headache,HO
189069732,Infliximab,Headache,DS
189069732,Infliximab,Granuloma,OT
189069732,Infliximab,Granuloma,HO
189069732,Infliximab,Granuloma,DS
189069732,Infliximab,General physical health deterioration,OT
189069732,Infliximab,General physical health deterioration,HO
189069732,Infliximab,General physical health deterioration,DS
189069732,Infliximab,Gastric disorder,OT
189069732,Infliximab,Gastric disorder,HO
189069732,Infliximab,Gastric disorder,DS
189069732,Infliximab,Fear of injection,OT
189069732,Infliximab,Fear of injection,HO
189069732,Infliximab,Fear of injection,DS
189069732,Infliximab,Fatigue,OT
189069732,Infliximab,Fatigue,HO
189069732,Infliximab,Fatigue,DS
189069732,Infliximab,Erythema,OT
189069732,Infliximab,Erythema,HO
189069732,Infliximab,Erythema,DS
189069732,Infliximab,Enthesopathy,OT
189069732,Infliximab,Enthesopathy,HO
189069732,Infliximab,Enthesopathy,DS
189069732,Infliximab,Drug tolerance decreased,OT
189069732,Infliximab,Drug tolerance decreased,HO
189069732,Infliximab,Drug tolerance decreased,DS
189069732,Infliximab,Drug tolerance,OT
189069732,Infliximab,Drug tolerance,HO
189069732,Infliximab,Drug tolerance,DS
189069732,Infliximab,Drug intolerance,OT
189069732,Infliximab,Drug intolerance,HO
189069732,Infliximab,Drug intolerance,DS
189069732,Infliximab,Drug ineffective,OT
189069732,Infliximab,Drug ineffective,HO
189069732,Infliximab,Drug ineffective,DS
189069732,Infliximab,Drug hypersensitivity,OT
189069732,Infliximab,Drug hypersensitivity,HO
189069732,Infliximab,Drug hypersensitivity,DS
189069732,Infliximab,Drug eruption,OT
189069732,Infliximab,Drug eruption,HO
189069732,Infliximab,Drug eruption,DS
189069732,Infliximab,Diarrhoea,OT
189069732,Infliximab,Diarrhoea,HO
189069732,Infliximab,Diarrhoea,DS
189069732,Infliximab,Decreased appetite,OT
189069732,Infliximab,Decreased appetite,HO
189069732,Infliximab,Decreased appetite,DS
189069732,Infliximab,Contraindicated product administered,OT
189069732,Infliximab,Contraindicated product administered,HO
189069732,Infliximab,Contraindicated product administered,DS
189069732,Infliximab,Condition aggravated,OT
189069732,Infliximab,Condition aggravated,HO
189069732,Infliximab,Condition aggravated,DS
189069732,Infliximab,C-reactive protein increased,OT
189069732,Infliximab,C-reactive protein increased,HO
189069732,Infliximab,C-reactive protein increased,DS
189069732,Infliximab,C-reactive protein abnormal,OT
189069732,Infliximab,C-reactive protein abnormal,HO
189069732,Infliximab,C-reactive protein abnormal,DS
189069732,Infliximab,Blood pressure systolic increased,OT
189069732,Infliximab,Blood pressure systolic increased,HO
189069732,Infliximab,Blood pressure systolic increased,DS
189069732,Infliximab,Blood parathyroid hormone decreased,OT
189069732,Infliximab,Blood parathyroid hormone decreased,HO
189069732,Infliximab,Blood parathyroid hormone decreased,DS
189069732,Infliximab,Blood creatinine increased,OT
189069732,Infliximab,Blood creatinine increased,HO
189069732,Infliximab,Blood creatinine increased,DS
189069732,Infliximab,Basal cell carcinoma,OT
189069732,Infliximab,Basal cell carcinoma,HO
189069732,Infliximab,Basal cell carcinoma,DS
189069732,Infliximab,Aspartate aminotransferase increased,OT
189069732,Infliximab,Aspartate aminotransferase increased,HO
189069732,Infliximab,Aspartate aminotransferase increased,DS
189069732,Infliximab,Arthropathy,OT
189069732,Infliximab,Arthropathy,HO
189069732,Infliximab,Arthropathy,DS
189069732,Infliximab,Arthritis,OT
189069732,Infliximab,Arthritis,HO
189069732,Infliximab,Arthritis,DS
189069732,Infliximab,Arthralgia,OT
189069732,Infliximab,Arthralgia,HO
189069732,Infliximab,Arthralgia,DS
189069732,Infliximab,Alopecia,OT
189069732,Infliximab,Alopecia,HO
189069732,Infliximab,Alopecia,DS
189069732,Infliximab,Alanine aminotransferase increased,OT
189069732,Infliximab,Alanine aminotransferase increased,HO
189069732,Infliximab,Alanine aminotransferase increased,DS
189069732,Infliximab,Alanine aminotransferase abnormal,OT
189069732,Infliximab,Alanine aminotransferase abnormal,HO
189069732,Infliximab,Alanine aminotransferase abnormal,DS
189069732,Infliximab,Adverse event,OT
189069732,Infliximab,Adverse event,HO
189069732,Infliximab,Adverse event,DS
189069732,Infliximab,Abdominal discomfort,OT
189069732,Infliximab,Abdominal discomfort,HO
189069732,Infliximab,Abdominal discomfort,DS
189069732,Infliximab,Urticaria,OT
189069732,Infliximab,Urticaria,HO
189069732,Infliximab,Urticaria,DS
189069732,Infliximab,Ulcer,OT
189069732,Infliximab,Ulcer,HO
189069732,Infliximab,Ulcer,DS
189069732,Infliximab,Treatment failure,OT
189069732,Infliximab,Treatment failure,HO
189069732,Infliximab,Treatment failure,DS
189069732,Infliximab,Tongue disorder,OT
189069732,Infliximab,Tongue disorder,HO
189069732,Infliximab,Tongue disorder,DS
189069732,Infliximab,Therapy non-responder,OT
189069732,Infliximab,Therapy non-responder,HO
189069732,Infliximab,Therapy non-responder,DS
189069732,Infliximab,Therapeutic product effect incomplete,OT
189069732,Infliximab,Therapeutic product effect incomplete,HO
189069732,Infliximab,Therapeutic product effect incomplete,DS
189069732,Infliximab,Therapeutic product effect decreased,OT
189069732,Infliximab,Therapeutic product effect decreased,HO
189069732,Infliximab,Therapeutic product effect decreased,DS
189069732,Infliximab,Tenosynovitis,OT
189069732,Infliximab,Tenosynovitis,HO
189069732,Infliximab,Tenosynovitis,DS
189069732,Infliximab,Tendonitis,OT
189069732,Infliximab,Tendonitis,HO
189069732,Infliximab,Tendonitis,DS
189069732,Infliximab,Synovitis,OT
189069732,Infliximab,Synovitis,HO
189069732,Infliximab,Synovitis,DS
189069732,Infliximab,Skin ulcer,OT
189069732,Infliximab,Skin ulcer,HO
189069732,Infliximab,Skin ulcer,DS
189069732,Infliximab,Skin necrosis,OT
189069732,Infliximab,Skin necrosis,HO
189069732,Infliximab,Skin necrosis,DS
189069732,Infliximab,Rheumatoid nodule,OT
189069732,Infliximab,Rheumatoid nodule,HO
189069732,Infliximab,Rheumatoid nodule,DS
189069732,Infliximab,Rheumatoid arthritis,OT
189069732,Infliximab,Rheumatoid arthritis,HO
189069732,Infliximab,Rheumatoid arthritis,DS
189069732,Infliximab,Red blood cell sedimentation rate increased,OT
189069732,Infliximab,Red blood cell sedimentation rate increased,HO
189069732,Infliximab,Red blood cell sedimentation rate increased,DS
189069732,Infliximab,Red blood cell sedimentation rate,OT
189069732,Infliximab,Red blood cell sedimentation rate,HO
189069732,Infliximab,Red blood cell sedimentation rate,DS
189069732,Infliximab,Rash pruritic,OT
189069732,Infliximab,Rash pruritic,HO
189069732,Infliximab,Rash pruritic,DS
189069732,Infliximab,Rash,OT
189069732,Infliximab,Rash,HO
189069732,Infliximab,Rash,DS
189069732,Infliximab,Psoriatic arthropathy,OT
189069732,Infliximab,Psoriatic arthropathy,HO
189069732,Infliximab,Psoriatic arthropathy,DS
189069732,Infliximab,Product use issue,OT
189069732,Infliximab,Product use issue,HO
189069732,Infliximab,Product use issue,DS
189069732,Infliximab,Peripheral swelling,OT
189069732,Infliximab,Peripheral swelling,HO
189069732,Infliximab,Peripheral swelling,DS
189069732,Infliximab,Panniculitis,OT
189069732,Infliximab,Panniculitis,HO
189069732,Infliximab,Panniculitis,DS
189069732,Infliximab,Pain,OT
189069732,Infliximab,Pain,HO
189069732,Infliximab,Pain,DS
189069732,Infliximab,Overdose,OT
189069732,Infliximab,Overdose,HO
189069732,Infliximab,Overdose,DS
189069732,Infliximab,Osteomyelitis,OT
189069732,Infliximab,Osteomyelitis,HO
189069732,Infliximab,Osteomyelitis,DS
189069732,Infliximab,Off label use,OT
189069732,Infliximab,Off label use,HO
189069732,Infliximab,Off label use,DS
189069732,Infliximab,Nausea,OT
189069732,Infliximab,Nausea,HO
189069732,Infliximab,Nausea,DS
189069732,Infliximab,Musculoskeletal stiffness,OT
189069732,Infliximab,Musculoskeletal stiffness,HO
189069732,Infliximab,Musculoskeletal stiffness,DS
189069732,Infliximab,Musculoskeletal disorder,OT
189069732,Infliximab,Musculoskeletal disorder,HO
189069732,Infliximab,Musculoskeletal disorder,DS
189069732,Infliximab,Mobility decreased,OT
189069732,Infliximab,Mobility decreased,HO
189069732,Infliximab,Mobility decreased,DS
189069732,Infliximab,Loss of personal independence in daily activities,OT
189069732,Infliximab,Loss of personal independence in daily activities,HO
189069732,Infliximab,Loss of personal independence in daily activities,DS
189069732,Infliximab,Joint swelling,OT
189069732,Infliximab,Joint swelling,HO
189069732,Infliximab,Joint swelling,DS
189069732,Infliximab,Joint injury,OT
189069732,Infliximab,Joint injury,HO
189069732,Infliximab,Joint injury,DS
189069732,Infliximab,Insomnia,OT
189069732,Infliximab,Insomnia,HO
189069732,Infliximab,Insomnia,DS
189069732,Infliximab,Infusion related reaction,OT
189069732,Infliximab,Infusion related reaction,HO
189069732,Infliximab,Infusion related reaction,DS
189069732,Infliximab,Inflammation,OT
189069732,Infliximab,Inflammation,HO
189069732,Infliximab,Inflammation,DS
189069732,Infliximab,Hypertension,OT
189069732,Infliximab,Hypertension,HO
189069732,Infliximab,Hypertension,DS
189069732,Infliximab,Hypersensitivity,OT
189069732,Infliximab,Hypersensitivity,HO
189069732,Infliximab,Hypersensitivity,DS
189069732,Infliximab,Hypercalcaemia,OT
189069732,Infliximab,Hypercalcaemia,HO
189069732,Infliximab,Hypercalcaemia,DS
189069732,Infliximab,Headache,OT
189069732,Infliximab,Headache,HO
189069732,Infliximab,Headache,DS
189069732,Infliximab,Granuloma,OT
189069732,Infliximab,Granuloma,HO
189069732,Infliximab,Granuloma,DS
189069732,Infliximab,General physical health deterioration,OT
189069732,Infliximab,General physical health deterioration,HO
189069732,Infliximab,General physical health deterioration,DS
189069732,Infliximab,Gastric disorder,OT
189069732,Infliximab,Gastric disorder,HO
189069732,Infliximab,Gastric disorder,DS
189069732,Infliximab,Fear of injection,OT
189069732,Infliximab,Fear of injection,HO
189069732,Infliximab,Fear of injection,DS
189069732,Infliximab,Fatigue,OT
189069732,Infliximab,Fatigue,HO
189069732,Infliximab,Fatigue,DS
189069732,Infliximab,Erythema,OT
189069732,Infliximab,Erythema,HO
189069732,Infliximab,Erythema,DS
189069732,Infliximab,Enthesopathy,OT
189069732,Infliximab,Enthesopathy,HO
189069732,Infliximab,Enthesopathy,DS
189069732,Infliximab,Drug tolerance decreased,OT
189069732,Infliximab,Drug tolerance decreased,HO
189069732,Infliximab,Drug tolerance decreased,DS
189069732,Infliximab,Drug tolerance,OT
189069732,Infliximab,Drug tolerance,HO
189069732,Infliximab,Drug tolerance,DS
189069732,Infliximab,Drug intolerance,OT
189069732,Infliximab,Drug intolerance,HO
189069732,Infliximab,Drug intolerance,DS
189069732,Infliximab,Drug ineffective,OT
189069732,Infliximab,Drug ineffective,HO
189069732,Infliximab,Drug ineffective,DS
189069732,Infliximab,Drug hypersensitivity,OT
189069732,Infliximab,Drug hypersensitivity,HO
189069732,Infliximab,Drug hypersensitivity,DS
189069732,Infliximab,Drug eruption,OT
189069732,Infliximab,Drug eruption,HO
189069732,Infliximab,Drug eruption,DS
189069732,Infliximab,Diarrhoea,OT
189069732,Infliximab,Diarrhoea,HO
189069732,Infliximab,Diarrhoea,DS
189069732,Infliximab,Decreased appetite,OT
189069732,Infliximab,Decreased appetite,HO
189069732,Infliximab,Decreased appetite,DS
189069732,Infliximab,Contraindicated product administered,OT
189069732,Infliximab,Contraindicated product administered,HO
189069732,Infliximab,Contraindicated product administered,DS
189069732,Infliximab,Condition aggravated,OT
189069732,Infliximab,Condition aggravated,HO
189069732,Infliximab,Condition aggravated,DS
189069732,Infliximab,C-reactive protein increased,OT
189069732,Infliximab,C-reactive protein increased,HO
189069732,Infliximab,C-reactive protein increased,DS
189069732,Infliximab,C-reactive protein abnormal,OT
189069732,Infliximab,C-reactive protein abnormal,HO
189069732,Infliximab,C-reactive protein abnormal,DS
189069732,Infliximab,Blood pressure systolic increased,OT
189069732,Infliximab,Blood pressure systolic increased,HO
189069732,Infliximab,Blood pressure systolic increased,DS
189069732,Infliximab,Blood parathyroid hormone decreased,OT
189069732,Infliximab,Blood parathyroid hormone decreased,HO
189069732,Infliximab,Blood parathyroid hormone decreased,DS
189069732,Infliximab,Blood creatinine increased,OT
189069732,Infliximab,Blood creatinine increased,HO
189069732,Infliximab,Blood creatinine increased,DS
189069732,Infliximab,Basal cell carcinoma,OT
189069732,Infliximab,Basal cell carcinoma,HO
189069732,Infliximab,Basal cell carcinoma,DS
189069732,Infliximab,Aspartate aminotransferase increased,OT
189069732,Infliximab,Aspartate aminotransferase increased,HO
189069732,Infliximab,Aspartate aminotransferase increased,DS
189069732,Infliximab,Arthropathy,OT
189069732,Infliximab,Arthropathy,HO
189069732,Infliximab,Arthropathy,DS
189069732,Infliximab,Arthritis,OT
189069732,Infliximab,Arthritis,HO
189069732,Infliximab,Arthritis,DS
189069732,Infliximab,Arthralgia,OT
189069732,Infliximab,Arthralgia,HO
189069732,Infliximab,Arthralgia,DS
189069732,Infliximab,Alopecia,OT
189069732,Infliximab,Alopecia,HO
189069732,Infliximab,Alopecia,DS
189069732,Infliximab,Alanine aminotransferase increased,OT
189069732,Infliximab,Alanine aminotransferase increased,HO
189069732,Infliximab,Alanine aminotransferase increased,DS
189069732,Infliximab,Alanine aminotransferase abnormal,OT
189069732,Infliximab,Alanine aminotransferase abnormal,HO
189069732,Infliximab,Alanine aminotransferase abnormal,DS
189069732,Infliximab,Adverse event,OT
189069732,Infliximab,Adverse event,HO
189069732,Infliximab,Adverse event,DS
189069732,Infliximab,Abdominal discomfort,OT
189069732,Infliximab,Abdominal discomfort,HO
189069732,Infliximab,Abdominal discomfort,DS
189069732,Infliximab,Urticaria,OT
189069732,Infliximab,Urticaria,HO
189069732,Infliximab,Urticaria,DS
189069732,Infliximab,Ulcer,OT
189069732,Infliximab,Ulcer,HO
189069732,Infliximab,Ulcer,DS
189069732,Infliximab,Treatment failure,OT
189069732,Infliximab,Treatment failure,HO
189069732,Infliximab,Treatment failure,DS
189069732,Infliximab,Tongue disorder,OT
189069732,Infliximab,Tongue disorder,HO
189069732,Infliximab,Tongue disorder,DS
189069732,Infliximab,Therapy non-responder,OT
189069732,Infliximab,Therapy non-responder,HO
189069732,Infliximab,Therapy non-responder,DS
189069732,Infliximab,Therapeutic product effect incomplete,OT
189069732,Infliximab,Therapeutic product effect incomplete,HO
189069732,Infliximab,Therapeutic product effect incomplete,DS
189069732,Infliximab,Therapeutic product effect decreased,OT
189069732,Infliximab,Therapeutic product effect decreased,HO
189069732,Infliximab,Therapeutic product effect decreased,DS
189069732,Infliximab,Tenosynovitis,OT
189069732,Infliximab,Tenosynovitis,HO
189069732,Infliximab,Tenosynovitis,DS
189069732,Infliximab,Tendonitis,OT
189069732,Infliximab,Tendonitis,HO
189069732,Infliximab,Tendonitis,DS
189069732,Infliximab,Synovitis,OT
189069732,Infliximab,Synovitis,HO
189069732,Infliximab,Synovitis,DS
189069732,Infliximab,Skin ulcer,OT
189069732,Infliximab,Skin ulcer,HO
189069732,Infliximab,Skin ulcer,DS
189069732,Infliximab,Skin necrosis,OT
189069732,Infliximab,Skin necrosis,HO
189069732,Infliximab,Skin necrosis,DS
189069732,Infliximab,Rheumatoid nodule,OT
189069732,Infliximab,Rheumatoid nodule,HO
189069732,Infliximab,Rheumatoid nodule,DS
189069732,Infliximab,Rheumatoid arthritis,OT
189069732,Infliximab,Rheumatoid arthritis,HO
189069732,Infliximab,Rheumatoid arthritis,DS
189069732,Infliximab,Red blood cell sedimentation rate increased,OT
189069732,Infliximab,Red blood cell sedimentation rate increased,HO
189069732,Infliximab,Red blood cell sedimentation rate increased,DS
189069732,Infliximab,Red blood cell sedimentation rate,OT
189069732,Infliximab,Red blood cell sedimentation rate,HO
189069732,Infliximab,Red blood cell sedimentation rate,DS
189069732,Infliximab,Rash pruritic,OT
189069732,Infliximab,Rash pruritic,HO
189069732,Infliximab,Rash pruritic,DS
189069732,Infliximab,Rash,OT
189069732,Infliximab,Rash,HO
189069732,Infliximab,Rash,DS
189069732,Infliximab,Psoriatic arthropathy,OT
189069732,Infliximab,Psoriatic arthropathy,HO
189069732,Infliximab,Psoriatic arthropathy,DS
189069732,Infliximab,Product use issue,OT
189069732,Infliximab,Product use issue,HO
189069732,Infliximab,Product use issue,DS
189069732,Infliximab,Peripheral swelling,OT
189069732,Infliximab,Peripheral swelling,HO
189069732,Infliximab,Peripheral swelling,DS
189069732,Infliximab,Panniculitis,OT
189069732,Infliximab,Panniculitis,HO
189069732,Infliximab,Panniculitis,DS
189069732,Infliximab,Pain,OT
189069732,Infliximab,Pain,HO
189069732,Infliximab,Pain,DS
189069732,Infliximab,Overdose,OT
189069732,Infliximab,Overdose,HO
189069732,Infliximab,Overdose,DS
189069732,Infliximab,Osteomyelitis,OT
189069732,Infliximab,Osteomyelitis,HO
189069732,Infliximab,Osteomyelitis,DS
189069732,Infliximab,Off label use,OT
189069732,Infliximab,Off label use,HO
189069732,Infliximab,Off label use,DS
189069732,Infliximab,Nausea,OT
189069732,Infliximab,Nausea,HO
189069732,Infliximab,Nausea,DS
189069732,Infliximab,Musculoskeletal stiffness,OT
189069732,Infliximab,Musculoskeletal stiffness,HO
189069732,Infliximab,Musculoskeletal stiffness,DS
189069732,Infliximab,Musculoskeletal disorder,OT
189069732,Infliximab,Musculoskeletal disorder,HO
189069732,Infliximab,Musculoskeletal disorder,DS
189069732,Infliximab,Mobility decreased,OT
189069732,Infliximab,Mobility decreased,HO
189069732,Infliximab,Mobility decreased,DS
189069732,Infliximab,Loss of personal independence in daily activities,OT
189069732,Infliximab,Loss of personal independence in daily activities,HO
189069732,Infliximab,Loss of personal independence in daily activities,DS
189069732,Infliximab,Joint swelling,OT
189069732,Infliximab,Joint swelling,HO
189069732,Infliximab,Joint swelling,DS
189069732,Infliximab,Joint injury,OT
189069732,Infliximab,Joint injury,HO
189069732,Infliximab,Joint injury,DS
189069732,Infliximab,Insomnia,OT
189069732,Infliximab,Insomnia,HO
189069732,Infliximab,Insomnia,DS
189069732,Infliximab,Infusion related reaction,OT
189069732,Infliximab,Infusion related reaction,HO
189069732,Infliximab,Infusion related reaction,DS
189069732,Infliximab,Inflammation,OT
189069732,Infliximab,Inflammation,HO
189069732,Infliximab,Inflammation,DS
189069732,Infliximab,Hypertension,OT
189069732,Infliximab,Hypertension,HO
189069732,Infliximab,Hypertension,DS
189069732,Infliximab,Hypersensitivity,OT
189069732,Infliximab,Hypersensitivity,HO
189069732,Infliximab,Hypersensitivity,DS
189069732,Infliximab,Hypercalcaemia,OT
189069732,Infliximab,Hypercalcaemia,HO
189069732,Infliximab,Hypercalcaemia,DS
189069732,Infliximab,Headache,OT
189069732,Infliximab,Headache,HO
189069732,Infliximab,Headache,DS
189069732,Infliximab,Granuloma,OT
189069732,Infliximab,Granuloma,HO
189069732,Infliximab,Granuloma,DS
189069732,Infliximab,General physical health deterioration,OT
189069732,Infliximab,General physical health deterioration,HO
189069732,Infliximab,General physical health deterioration,DS
189069732,Infliximab,Gastric disorder,OT
189069732,Infliximab,Gastric disorder,HO
189069732,Infliximab,Gastric disorder,DS
189069732,Infliximab,Fear of injection,OT
189069732,Infliximab,Fear of injection,HO
189069732,Infliximab,Fear of injection,DS
189069732,Infliximab,Fatigue,OT
189069732,Infliximab,Fatigue,HO
189069732,Infliximab,Fatigue,DS
189069732,Infliximab,Erythema,OT
189069732,Infliximab,Erythema,HO
189069732,Infliximab,Erythema,DS
189069732,Infliximab,Enthesopathy,OT
189069732,Infliximab,Enthesopathy,HO
189069732,Infliximab,Enthesopathy,DS
189069732,Infliximab,Drug tolerance decreased,OT
189069732,Infliximab,Drug tolerance decreased,HO
189069732,Infliximab,Drug tolerance decreased,DS
189069732,Infliximab,Drug tolerance,OT
189069732,Infliximab,Drug tolerance,HO
189069732,Infliximab,Drug tolerance,DS
189069732,Infliximab,Drug intolerance,OT
189069732,Infliximab,Drug intolerance,HO
189069732,Infliximab,Drug intolerance,DS
189069732,Infliximab,Drug ineffective,OT
189069732,Infliximab,Drug ineffective,HO
189069732,Infliximab,Drug ineffective,DS
189069732,Infliximab,Drug hypersensitivity,OT
189069732,Infliximab,Drug hypersensitivity,HO
189069732,Infliximab,Drug hypersensitivity,DS
189069732,Infliximab,Drug eruption,OT
189069732,Infliximab,Drug eruption,HO
189069732,Infliximab,Drug eruption,DS
189069732,Infliximab,Diarrhoea,OT
189069732,Infliximab,Diarrhoea,HO
189069732,Infliximab,Diarrhoea,DS
189069732,Infliximab,Decreased appetite,OT
189069732,Infliximab,Decreased appetite,HO
189069732,Infliximab,Decreased appetite,DS
189069732,Infliximab,Contraindicated product administered,OT
189069732,Infliximab,Contraindicated product administered,HO
189069732,Infliximab,Contraindicated product administered,DS
189069732,Infliximab,Condition aggravated,OT
189069732,Infliximab,Condition aggravated,HO
189069732,Infliximab,Condition aggravated,DS
189069732,Infliximab,C-reactive protein increased,OT
189069732,Infliximab,C-reactive protein increased,HO
189069732,Infliximab,C-reactive protein increased,DS
189069732,Infliximab,C-reactive protein abnormal,OT
189069732,Infliximab,C-reactive protein abnormal,HO
189069732,Infliximab,C-reactive protein abnormal,DS
189069732,Infliximab,Blood pressure systolic increased,OT
189069732,Infliximab,Blood pressure systolic increased,HO
189069732,Infliximab,Blood pressure systolic increased,DS
189069732,Infliximab,Blood parathyroid hormone decreased,OT
189069732,Infliximab,Blood parathyroid hormone decreased,HO
189069732,Infliximab,Blood parathyroid hormone decreased,DS
189069732,Infliximab,Blood creatinine increased,OT
189069732,Infliximab,Blood creatinine increased,HO
189069732,Infliximab,Blood creatinine increased,DS
189069732,Infliximab,Basal cell carcinoma,OT
189069732,Infliximab,Basal cell carcinoma,HO
189069732,Infliximab,Basal cell carcinoma,DS
189069732,Infliximab,Aspartate aminotransferase increased,OT
189069732,Infliximab,Aspartate aminotransferase increased,HO
189069732,Infliximab,Aspartate aminotransferase increased,DS
189069732,Infliximab,Arthropathy,OT
189069732,Infliximab,Arthropathy,HO
189069732,Infliximab,Arthropathy,DS
189069732,Infliximab,Arthritis,OT
189069732,Infliximab,Arthritis,HO
189069732,Infliximab,Arthritis,DS
189069732,Infliximab,Arthralgia,OT
189069732,Infliximab,Arthralgia,HO
189069732,Infliximab,Arthralgia,DS
189069732,Infliximab,Alopecia,OT
189069732,Infliximab,Alopecia,HO
189069732,Infliximab,Alopecia,DS
189069732,Infliximab,Alanine aminotransferase increased,OT
189069732,Infliximab,Alanine aminotransferase increased,HO
189069732,Infliximab,Alanine aminotransferase increased,DS
189069732,Infliximab,Alanine aminotransferase abnormal,OT
189069732,Infliximab,Alanine aminotransferase abnormal,HO
189069732,Infliximab,Alanine aminotransferase abnormal,DS
189069732,Infliximab,Adverse event,OT
189069732,Infliximab,Adverse event,HO
189069732,Infliximab,Adverse event,DS
189069732,Infliximab,Abdominal discomfort,OT
189069732,Infliximab,Abdominal discomfort,HO
189069732,Infliximab,Abdominal discomfort,DS
192796412,Infliximab,Off label use,HO
192796412,Infliximab,Off label use,OT
192796412,Infliximab,Intentional product use issue,HO
192796412,Infliximab,Intentional product use issue,OT
192796412,Infliximab,Inappropriate schedule of product administration,HO
192796412,Infliximab,Inappropriate schedule of product administration,OT
192796412,Infliximab,Hypersensitivity,HO
192796412,Infliximab,Hypersensitivity,OT
192796412,Infliximab,Heart rate decreased,HO
192796412,Infliximab,Heart rate decreased,OT
192796412,Infliximab,Condition aggravated,HO
192796412,Infliximab,Condition aggravated,OT
192796412,Infliximab,Body temperature decreased,HO
192796412,Infliximab,Body temperature decreased,OT
192796412,Infliximab,Blood pressure diastolic increased,HO
192796412,Infliximab,Blood pressure diastolic increased,OT
192796412,Infliximab,Off label use,HO
192796412,Infliximab,Off label use,OT
192796412,Infliximab,Intentional product use issue,HO
192796412,Infliximab,Intentional product use issue,OT
192796412,Infliximab,Inappropriate schedule of product administration,HO
192796412,Infliximab,Inappropriate schedule of product administration,OT
192796412,Infliximab,Hypersensitivity,HO
192796412,Infliximab,Hypersensitivity,OT
192796412,Infliximab,Heart rate decreased,HO
192796412,Infliximab,Heart rate decreased,OT
192796412,Infliximab,Condition aggravated,HO
192796412,Infliximab,Condition aggravated,OT
192796412,Infliximab,Body temperature decreased,HO
192796412,Infliximab,Body temperature decreased,OT
192796412,Infliximab,Blood pressure diastolic increased,HO
192796412,Infliximab,Blood pressure diastolic increased,OT
195113061,Infliximab,Neuropathy peripheral,OT
195113061,Infliximab,Drug ineffective,OT
195113061,Infliximab,Neuropathy peripheral,OT
195113061,Infliximab,Drug ineffective,OT
195449911,Infliximab,Syncope,HO
195449911,Infliximab,Pulmonary embolism,HO
195449911,Infliximab,Microcytic anaemia,HO
195449911,Infliximab,Iron deficiency,HO
195449911,Infliximab,Factor V Leiden mutation,HO
195449911,Infliximab,Colitis ulcerative,HO
195449911,Infliximab,Cardiac ventricular thrombosis,HO
195449911,Infliximab,Bacteraemia,HO
195449911,Infliximab,Factor II mutation,HO
195779201,Infliximab,Condition aggravated,OT
195779201,Infliximab,Cardiac valve disease,OT
196148201,Infliximab,Off label use,OT
196148201,Infliximab,Faecal calprotectin increased,OT
196148201,Infliximab,Condition aggravated,OT
196148201,Infliximab,Colitis,OT
196148201,Infliximab,Bone pain,OT
196148201,Infliximab,Arthralgia,OT
196148201,Infliximab,Off label use,OT
196148201,Infliximab,Faecal calprotectin increased,OT
196148201,Infliximab,Condition aggravated,OT
196148201,Infliximab,Colitis,OT
196148201,Infliximab,Bone pain,OT
196148201,Infliximab,Arthralgia,OT
196323531,Infliximab,Oropharyngeal pain,OT
196323531,Infliximab,Off label use,OT
196323531,Infliximab,Intentional product use issue,OT
196323531,Infliximab,Inappropriate schedule of product administration,OT
196323531,Infliximab,Heart rate decreased,OT
196323531,Infliximab,Eye infection bacterial,OT
196323531,Infliximab,Erythema of eyelid,OT
196323531,Infliximab,C-reactive protein increased,OT
196323531,Infliximab,Blood pressure diastolic decreased,OT
196323531,Infliximab,Blepharitis,OT
197101921,Infliximab,Malaise,OT
197101921,Infliximab,Condition aggravated,OT
197318471,Infliximab,Rectal haemorrhage,HO
197318471,Infliximab,Rectal haemorrhage,OT
197318471,Infliximab,Frequent bowel movements,HO
197318471,Infliximab,Frequent bowel movements,OT
197318471,Infliximab,Decreased activity,HO
197318471,Infliximab,Decreased activity,OT
197318471,Infliximab,Colitis ulcerative,HO
197318471,Infliximab,Colitis ulcerative,OT
197318471,Infliximab,Colitis,HO
197318471,Infliximab,Colitis,OT
197372041,Infliximab Pfizer (Unknown),Hemianopia homonymous,HO
197372041,Infliximab Pfizer (Unknown),Generalised tonic-clonic seizure,HO
197372041,Infliximab Pfizer (Unknown),Encephalitis,HO
197372041,Infliximab Pfizer (Unknown),Anti-myelin-associated glycoprotein antibodies positive,HO
197591281,Infliximab,Death,DE
197942641,Infliximab,Upper limb fracture,OT
197942641,Infliximab,Inappropriate schedule of product administration,OT
197942641,Infliximab,Condition aggravated,OT
197997561,Infliximab,Vanishing bile duct syndrome,OT
197997561,Infliximab,Off label use,OT
197997561,Infliximab,Drug-induced liver injury,OT
198060971,Infliximab,Swelling face,OT
198060971,Infliximab,Red blood cell count increased,OT
198060971,Infliximab,Psoriatic arthropathy,OT
198060971,Infliximab,Off label use,OT
198060971,Infliximab,Mean cell haemoglobin decreased,OT
198060971,Infliximab,Heart rate irregular,OT
198060971,Infliximab,Haemoglobin decreased,OT
198060971,Infliximab,Ear discomfort,OT
198060971,Infliximab,Condition aggravated,OT
198060971,Infliximab,Body temperature fluctuation,OT
198060971,Infliximab,Blood triglycerides increased,OT
198060971,Infliximab,Blood cholesterol increased,OT
198060971,Infliximab,Swelling face,OT
198060971,Infliximab,Red blood cell count increased,OT
198060971,Infliximab,Psoriatic arthropathy,OT
198060971,Infliximab,Off label use,OT
198060971,Infliximab,Mean cell haemoglobin decreased,OT
198060971,Infliximab,Heart rate irregular,OT
198060971,Infliximab,Haemoglobin decreased,OT
198060971,Infliximab,Ear discomfort,OT
198060971,Infliximab,Condition aggravated,OT
198060971,Infliximab,Body temperature fluctuation,OT
198060971,Infliximab,Blood triglycerides increased,OT
198060971,Infliximab,Blood cholesterol increased,OT
198193481,Infliximab,Weight fluctuation,OT
198193481,Infliximab,Therapeutic response shortened,OT
198193481,Infliximab,Therapeutic product effect incomplete,OT
198193481,Infliximab,Sneezing,OT
198193481,Infliximab,Rhinorrhoea,OT
198193481,Infliximab,Inappropriate schedule of product administration,OT
198193481,Infliximab,Heart rate irregular,OT
198193481,Infliximab,Cough,OT
198193481,Infliximab,Contusion,OT
198193481,Infliximab,Condition aggravated,OT
198193481,Infliximab,Back pain,OT
198193481,Infliximab,Arthralgia,OT
198594531,Infliximab (Unknown),Off label use,NULL
198594531,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198696841,Infliximab,Weight decreased,DE
198696841,Infliximab,Weight decreased,OT
198696841,Infliximab,Megacolon,DE
198696841,Infliximab,Megacolon,OT
198696841,Infliximab,Condition aggravated,DE
198696841,Infliximab,Condition aggravated,OT
198696891,Infliximab,Weight decreased,HO
198696891,Infliximab,Weight decreased,OT
198696891,Infliximab,Therapeutic product effect decreased,HO
198696891,Infliximab,Therapeutic product effect decreased,OT
198696891,Infliximab,Sinus congestion,HO
198696891,Infliximab,Sinus congestion,OT
198696891,Infliximab,Product use issue,HO
198696891,Infliximab,Product use issue,OT
198696891,Infliximab,Off label use,HO
198696891,Infliximab,Off label use,OT
198696891,Infliximab,Intestinal obstruction,HO
198696891,Infliximab,Intestinal obstruction,OT
198696891,Infliximab,Incorrect dose administered,HO
198696891,Infliximab,Incorrect dose administered,OT
198696891,Infliximab,Inappropriate schedule of product administration,HO
198696891,Infliximab,Inappropriate schedule of product administration,OT
198696891,Infliximab,Fatigue,HO
198696891,Infliximab,Fatigue,OT
198696891,Infliximab,Dyspepsia,HO
198696891,Infliximab,Dyspepsia,OT
198696891,Infliximab,Condition aggravated,HO
198696891,Infliximab,Condition aggravated,OT
198696891,Infliximab,Chest pain,HO
198696891,Infliximab,Chest pain,OT
198696891,Infliximab,Chest discomfort,HO
198696891,Infliximab,Chest discomfort,OT
198696891,Infliximab,Arthralgia,HO
198696891,Infliximab,Arthralgia,OT
198714621,Infliximab Pfizer (Unknown),Suicidal ideation,OT
198714621,Infliximab Pfizer (Unknown),Suicidal ideation,HO
198714621,Infliximab Pfizer (Unknown),Product preparation issue,OT
198714621,Infliximab Pfizer (Unknown),Product preparation issue,HO
198714621,Infliximab Pfizer (Unknown),Peripheral swelling,OT
198714621,Infliximab Pfizer (Unknown),Peripheral swelling,HO
198714621,Infliximab Pfizer (Unknown),Pain in extremity,OT
198714621,Infliximab Pfizer (Unknown),Pain in extremity,HO
198714621,Infliximab Pfizer (Unknown),Pain,OT
198714621,Infliximab Pfizer (Unknown),Pain,HO
198714621,Infliximab Pfizer (Unknown),Intentional product misuse,OT
198714621,Infliximab Pfizer (Unknown),Intentional product misuse,HO
198714621,Infliximab Pfizer (Unknown),Incorrect dose administered,OT
198714621,Infliximab Pfizer (Unknown),Incorrect dose administered,HO
198714621,Infliximab Pfizer (Unknown),Feeding disorder,OT
198714621,Infliximab Pfizer (Unknown),Feeding disorder,HO
198714621,Infliximab Pfizer (Unknown),Expired product administered,OT
198714621,Infliximab Pfizer (Unknown),Expired product administered,HO
198714621,Infliximab Pfizer (Unknown),Diarrhoea,OT
198714621,Infliximab Pfizer (Unknown),Diarrhoea,HO
198714621,Infliximab Pfizer (Unknown),Dehydration,OT
198714621,Infliximab Pfizer (Unknown),Dehydration,HO
198714621,Infliximab Pfizer (Unknown),Blood potassium decreased,OT
198714621,Infliximab Pfizer (Unknown),Blood potassium decreased,HO
198714621,Infliximab Pfizer (Unknown),Asthenia,OT
198714621,Infliximab Pfizer (Unknown),Asthenia,HO
198714621,Infliximab Pfizer (Unknown),Anal incontinence,OT
198714621,Infliximab Pfizer (Unknown),Anal incontinence,HO
199064171,Infliximab,Rheumatoid arthritis,OT
199064171,Infliximab,Pain,OT
199064171,Infliximab,Joint swelling,OT
199064171,Infliximab,Cystitis,OT
199064171,Infliximab,Arthralgia,OT
168860514,Infliximab,Urinary tract infection,OT
168860514,Infliximab,Sense of oppression,OT
168860514,Infliximab,Pyrexia,OT
168860514,Infliximab,Psoriasis,OT
168860514,Infliximab,Product use issue,OT
168860514,Infliximab,Pain,OT
168860514,Infliximab,Off label use,OT
168860514,Infliximab,Kidney infection,OT
168860514,Infliximab,Intentional product use issue,OT
168860514,Infliximab,Infusion site hypoaesthesia,OT
168860514,Infliximab,Heart rate abnormal,OT
168860514,Infliximab,Fatigue,OT
168860514,Infliximab,Drug level below therapeutic,OT
168860514,Infliximab,Disease recurrence,OT
168860514,Infliximab,Discomfort,OT
168860514,Infliximab,Depressed mood,OT
168860514,Infliximab,Condition aggravated,OT
168860514,Infliximab,Blood pressure increased,OT
168860514,Infliximab,Blood pressure fluctuation,OT
168860514,Infliximab,Bacterial vaginosis,OT
168860514,Infliximab,Arthralgia,OT
168860514,Infliximab,Anxiety,OT
168860514,Infliximab,Anal incontinence,OT
168860514,Infliximab,Anal abscess,OT
168860514,Infliximab,Acne,OT
168860514,Infliximab,Abscess,OT
168860514,Infliximab,Abdominal discomfort,OT
168860514,Infliximab,Urinary tract infection,OT
168860514,Infliximab,Sense of oppression,OT
168860514,Infliximab,Pyrexia,OT
168860514,Infliximab,Psoriasis,OT
168860514,Infliximab,Product use issue,OT
168860514,Infliximab,Pain,OT
168860514,Infliximab,Off label use,OT
168860514,Infliximab,Kidney infection,OT
168860514,Infliximab,Intentional product use issue,OT
168860514,Infliximab,Infusion site hypoaesthesia,OT
168860514,Infliximab,Heart rate abnormal,OT
168860514,Infliximab,Fatigue,OT
168860514,Infliximab,Drug level below therapeutic,OT
168860514,Infliximab,Disease recurrence,OT
168860514,Infliximab,Discomfort,OT
168860514,Infliximab,Depressed mood,OT
168860514,Infliximab,Condition aggravated,OT
168860514,Infliximab,Blood pressure increased,OT
168860514,Infliximab,Blood pressure fluctuation,OT
168860514,Infliximab,Bacterial vaginosis,OT
168860514,Infliximab,Arthralgia,OT
168860514,Infliximab,Anxiety,OT
168860514,Infliximab,Anal incontinence,OT
168860514,Infliximab,Anal abscess,OT
168860514,Infliximab,Acne,OT
168860514,Infliximab,Abscess,OT
168860514,Infliximab,Abdominal discomfort,OT
170896045,Infliximab,Weight increased,HO
170896045,Infliximab,Weight increased,OT
170896045,Infliximab,Sneezing,HO
170896045,Infliximab,Sneezing,OT
170896045,Infliximab,Rhinorrhoea,HO
170896045,Infliximab,Rhinorrhoea,OT
170896045,Infliximab,Pruritus,HO
170896045,Infliximab,Pruritus,OT
170896045,Infliximab,Productive cough,HO
170896045,Infliximab,Productive cough,OT
170896045,Infliximab,Product use issue,HO
170896045,Infliximab,Product use issue,OT
170896045,Infliximab,Pharyngeal paraesthesia,HO
170896045,Infliximab,Pharyngeal paraesthesia,OT
170896045,Infliximab,Palpitations,HO
170896045,Infliximab,Palpitations,OT
170896045,Infliximab,Off label use,HO
170896045,Infliximab,Off label use,OT
170896045,Infliximab,Nausea,HO
170896045,Infliximab,Nausea,OT
170896045,Infliximab,Nasal congestion,HO
170896045,Infliximab,Nasal congestion,OT
170896045,Infliximab,Malaise,HO
170896045,Infliximab,Malaise,OT
170896045,Infliximab,Intestinal stenosis,HO
170896045,Infliximab,Intestinal stenosis,OT
170896045,Infliximab,Intentional product use issue,HO
170896045,Infliximab,Intentional product use issue,OT
170896045,Infliximab,Influenza like illness,HO
170896045,Infliximab,Influenza like illness,OT
170896045,Infliximab,Influenza,HO
170896045,Infliximab,Influenza,OT
170896045,Infliximab,Inappropriate schedule of product administration,HO
170896045,Infliximab,Inappropriate schedule of product administration,OT
170896045,Infliximab,Hot flush,HO
170896045,Infliximab,Hot flush,OT
170896045,Infliximab,Herpes zoster,HO
170896045,Infliximab,Herpes zoster,OT
170896045,Infliximab,Heart rate irregular,HO
170896045,Infliximab,Heart rate irregular,OT
170896045,Infliximab,Erythema,HO
170896045,Infliximab,Erythema,OT
170896045,Infliximab,Dyspnoea,HO
170896045,Infliximab,Dyspnoea,OT
170896045,Infliximab,Drug hypersensitivity,HO
170896045,Infliximab,Drug hypersensitivity,OT
170896045,Infliximab,Dizziness,HO
170896045,Infliximab,Dizziness,OT
170896045,Infliximab,Cough,HO
170896045,Infliximab,Cough,OT
170896045,Infliximab,Condition aggravated,HO
170896045,Infliximab,Condition aggravated,OT
170896045,Infliximab,Blood pressure fluctuation,HO
170896045,Infliximab,Blood pressure fluctuation,OT
170896045,Infliximab,Abdominal pain upper,HO
170896045,Infliximab,Abdominal pain upper,OT
170896045,Infliximab,Weight increased,HO
170896045,Infliximab,Weight increased,OT
170896045,Infliximab,Sneezing,HO
170896045,Infliximab,Sneezing,OT
170896045,Infliximab,Rhinorrhoea,HO
170896045,Infliximab,Rhinorrhoea,OT
170896045,Infliximab,Pruritus,HO
170896045,Infliximab,Pruritus,OT
170896045,Infliximab,Productive cough,HO
170896045,Infliximab,Productive cough,OT
170896045,Infliximab,Product use issue,HO
170896045,Infliximab,Product use issue,OT
170896045,Infliximab,Pharyngeal paraesthesia,HO
170896045,Infliximab,Pharyngeal paraesthesia,OT
170896045,Infliximab,Palpitations,HO
170896045,Infliximab,Palpitations,OT
170896045,Infliximab,Off label use,HO
170896045,Infliximab,Off label use,OT
170896045,Infliximab,Nausea,HO
170896045,Infliximab,Nausea,OT
170896045,Infliximab,Nasal congestion,HO
170896045,Infliximab,Nasal congestion,OT
170896045,Infliximab,Malaise,HO
170896045,Infliximab,Malaise,OT
170896045,Infliximab,Intestinal stenosis,HO
170896045,Infliximab,Intestinal stenosis,OT
170896045,Infliximab,Intentional product use issue,HO
170896045,Infliximab,Intentional product use issue,OT
170896045,Infliximab,Influenza like illness,HO
170896045,Infliximab,Influenza like illness,OT
170896045,Infliximab,Influenza,HO
170896045,Infliximab,Influenza,OT
170896045,Infliximab,Inappropriate schedule of product administration,HO
170896045,Infliximab,Inappropriate schedule of product administration,OT
170896045,Infliximab,Hot flush,HO
170896045,Infliximab,Hot flush,OT
170896045,Infliximab,Herpes zoster,HO
170896045,Infliximab,Herpes zoster,OT
170896045,Infliximab,Heart rate irregular,HO
170896045,Infliximab,Heart rate irregular,OT
170896045,Infliximab,Erythema,HO
170896045,Infliximab,Erythema,OT
170896045,Infliximab,Dyspnoea,HO
170896045,Infliximab,Dyspnoea,OT
170896045,Infliximab,Drug hypersensitivity,HO
170896045,Infliximab,Drug hypersensitivity,OT
170896045,Infliximab,Dizziness,HO
170896045,Infliximab,Dizziness,OT
170896045,Infliximab,Cough,HO
170896045,Infliximab,Cough,OT
170896045,Infliximab,Condition aggravated,HO
170896045,Infliximab,Condition aggravated,OT
170896045,Infliximab,Blood pressure fluctuation,HO
170896045,Infliximab,Blood pressure fluctuation,OT
170896045,Infliximab,Abdominal pain upper,HO
170896045,Infliximab,Abdominal pain upper,OT
172155877,Infliximab,Vomiting,OT
172155877,Infliximab,Treatment failure,OT
172155877,Infliximab,Thyroxine decreased,OT
172155877,Infliximab,Thyroid disorder,OT
172155877,Infliximab,Therapeutic product effect incomplete,OT
172155877,Infliximab,Therapeutic product effect decreased,OT
172155877,Infliximab,Synovitis,OT
172155877,Infliximab,Skin reaction,OT
172155877,Infliximab,Rheumatoid arthritis,OT
172155877,Infliximab,Pneumonia,OT
172155877,Infliximab,Pain in extremity,OT
172155877,Infliximab,Off label use,OT
172155877,Infliximab,Nephrolithiasis,OT
172155877,Infliximab,Musculoskeletal discomfort,OT
172155877,Infliximab,Mobility decreased,OT
172155877,Infliximab,Memory impairment,OT
172155877,Infliximab,Localised infection,OT
172155877,Infliximab,Liver disorder,OT
172155877,Infliximab,Limb discomfort,OT
172155877,Infliximab,Leukopenia,OT
172155877,Infliximab,Intestinal polyp,OT
172155877,Infliximab,Intentional product use issue,OT
172155877,Infliximab,Insomnia,OT
172155877,Infliximab,Hypertension,OT
172155877,Infliximab,Hypersensitivity,OT
172155877,Infliximab,Hepatic enzyme increased,OT
172155877,Infliximab,Glaucoma,OT
172155877,Infliximab,Gait inability,OT
172155877,Infliximab,Drug intolerance,OT
172155877,Infliximab,Drug ineffective,OT
172155877,Infliximab,Drug hypersensitivity,OT
172155877,Infliximab,Diverticulitis,OT
172155877,Infliximab,Contraindicated product administered,OT
172155877,Infliximab,Condition aggravated,OT
172155877,Infliximab,Colitis microscopic,OT
172155877,Infliximab,C-reactive protein increased,OT
172155877,Infliximab,C-reactive protein abnormal,OT
172155877,Infliximab,Bronchitis,OT
172155877,Infliximab,Bone erosion,OT
172155877,Infliximab,Back pain,OT
172155877,Infliximab,Arthralgia,OT
172155877,Infliximab,Alopecia,OT
172155877,Infliximab,Adverse event,OT
173131734,Infliximab,Off label use,OT
173131734,Infliximab,Neutrophil count decreased,OT
173131734,Infliximab,Maternal exposure during pregnancy,OT
173131734,Infliximab,Lymphocyte count decreased,OT
173131734,Infliximab,Intentional product use issue,OT
173131734,Infliximab,Inappropriate schedule of product administration,OT
173131734,Infliximab,Illness,OT
173131734,Infliximab,Headache,OT
173131734,Infliximab,Drug level above therapeutic,OT
173131734,Infliximab,Cystitis,OT
173131734,Infliximab,Condition aggravated,OT
173131734,Infliximab,Clostridium difficile infection,OT
173131734,Infliximab,Chest pain,OT
173131734,Infliximab,C-reactive protein increased,OT
173131734,Infliximab,Aspartate aminotransferase increased,OT
173131734,Infliximab,Arthralgia,OT
173131734,Infliximab,Alanine aminotransferase increased,OT
173131734,Infliximab,Abdominal pain,OT
173131734,Infliximab,Abdominal distension,OT
173131734,Infliximab,Off label use,OT
173131734,Infliximab,Neutrophil count decreased,OT
173131734,Infliximab,Maternal exposure during pregnancy,OT
173131734,Infliximab,Lymphocyte count decreased,OT
173131734,Infliximab,Intentional product use issue,OT
173131734,Infliximab,Inappropriate schedule of product administration,OT
173131734,Infliximab,Illness,OT
173131734,Infliximab,Headache,OT
173131734,Infliximab,Drug level above therapeutic,OT
173131734,Infliximab,Cystitis,OT
173131734,Infliximab,Condition aggravated,OT
173131734,Infliximab,Clostridium difficile infection,OT
173131734,Infliximab,Chest pain,OT
173131734,Infliximab,C-reactive protein increased,OT
173131734,Infliximab,Aspartate aminotransferase increased,OT
173131734,Infliximab,Arthralgia,OT
173131734,Infliximab,Alanine aminotransferase increased,OT
173131734,Infliximab,Abdominal pain,OT
173131734,Infliximab,Abdominal distension,OT
176052184,Infliximab,Weight increased,OT
176052184,Infliximab,Pyrexia,OT
176052184,Infliximab,Product use issue,OT
176052184,Infliximab,Oropharyngeal discomfort,OT
176052184,Infliximab,Off label use,OT
176052184,Infliximab,Malaise,OT
176052184,Infliximab,Intentional product use issue,OT
176052184,Infliximab,Insomnia,OT
176052184,Infliximab,Inappropriate schedule of product administration,OT
176052184,Infliximab,Heart rate irregular,OT
176052184,Infliximab,Dyspnoea,OT
176052184,Infliximab,Diarrhoea,OT
176052184,Infliximab,Cannabinoid hyperemesis syndrome,OT
176052184,Infliximab,Body temperature decreased,OT
176052184,Infliximab,Blood pressure fluctuation,OT
176052184,Infliximab,Administration site swelling,OT
176052184,Infliximab,Abdominal pain upper,OT
176052184,Infliximab,Weight increased,OT
176052184,Infliximab,Pyrexia,OT
176052184,Infliximab,Product use issue,OT
176052184,Infliximab,Oropharyngeal discomfort,OT
176052184,Infliximab,Off label use,OT
176052184,Infliximab,Malaise,OT
176052184,Infliximab,Intentional product use issue,OT
176052184,Infliximab,Insomnia,OT
176052184,Infliximab,Inappropriate schedule of product administration,OT
176052184,Infliximab,Heart rate irregular,OT
176052184,Infliximab,Dyspnoea,OT
176052184,Infliximab,Diarrhoea,OT
176052184,Infliximab,Cannabinoid hyperemesis syndrome,OT
176052184,Infliximab,Body temperature decreased,OT
176052184,Infliximab,Blood pressure fluctuation,OT
176052184,Infliximab,Administration site swelling,OT
176052184,Infliximab,Abdominal pain upper,OT
176584614,Infliximab,Psoriasis,OT
176584614,Infliximab,Off label use,OT
176584614,Infliximab,Intentional product use issue,OT
176584614,Infliximab,Incorrect dose administered,OT
176584614,Infliximab,Condition aggravated,OT
176584614,Infliximab,Blood pressure increased,OT
176584614,Infliximab,Blood pressure fluctuation,OT
176584614,Infliximab,Arthralgia,OT
176584614,Infliximab,Psoriasis,OT
176584614,Infliximab,Off label use,OT
176584614,Infliximab,Intentional product use issue,OT
176584614,Infliximab,Incorrect dose administered,OT
176584614,Infliximab,Condition aggravated,OT
176584614,Infliximab,Blood pressure increased,OT
176584614,Infliximab,Blood pressure fluctuation,OT
176584614,Infliximab,Arthralgia,OT
176584614,Infliximab,Psoriasis,OT
176584614,Infliximab,Off label use,OT
176584614,Infliximab,Intentional product use issue,OT
176584614,Infliximab,Incorrect dose administered,OT
176584614,Infliximab,Condition aggravated,OT
176584614,Infliximab,Blood pressure increased,OT
176584614,Infliximab,Blood pressure fluctuation,OT
176584614,Infliximab,Arthralgia,OT
176862344,Infliximab,Wheezing,OT
176862344,Infliximab,Weight decreased,OT
176862344,Infliximab,Product use issue,OT
176862344,Infliximab,Pain,OT
176862344,Infliximab,Oxygen saturation decreased,OT
176862344,Infliximab,Off label use,OT
176862344,Infliximab,Inappropriate schedule of product administration,OT
176862344,Infliximab,Herpes zoster,OT
176862344,Infliximab,Drug level decreased,OT
176862344,Infliximab,Drug ineffective,OT
176862344,Infliximab,Cough,OT
176862344,Infliximab,C-reactive protein increased,OT
177566974,Infliximab,Wound,OT
177566974,Infliximab,Weight decreased,OT
177566974,Infliximab,Swelling,OT
177566974,Infliximab,Rhinorrhoea,OT
177566974,Infliximab,Pyrexia,OT
177566974,Infliximab,Pruritus,OT
177566974,Infliximab,Productive cough,OT
177566974,Infliximab,Pain in extremity,OT
177566974,Infliximab,Oxygen saturation decreased,OT
177566974,Infliximab,Oxygen saturation abnormal,OT
177566974,Infliximab,Oropharyngeal pain,OT
177566974,Infliximab,Off label use,OT
177566974,Infliximab,Nausea,OT
177566974,Infliximab,Nasopharyngitis,OT
177566974,Infliximab,Malaise,OT
177566974,Infliximab,Localised infection,OT
177566974,Infliximab,Intentional product use issue,OT
177566974,Infliximab,Inappropriate schedule of product administration,OT
177566974,Infliximab,Headache,OT
177566974,Infliximab,Fungal infection,OT
177566974,Infliximab,Foot deformity,OT
177566974,Infliximab,Fatigue,OT
177566974,Infliximab,Diarrhoea,OT
177566974,Infliximab,Cough,OT
177566974,Infliximab,C-reactive protein increased,OT
177566974,Infliximab,Blood pressure increased,OT
177566974,Infliximab,Blood pressure fluctuation,OT
177566974,Infliximab,Abscess limb,OT
177566974,Infliximab,Abdominal discomfort,OT
177623133,Infliximab,White blood cells urine positive,HO
177623133,Infliximab,White blood cells urine positive,OT
177623133,Infliximab,Weight decreased,HO
177623133,Infliximab,Weight decreased,OT
177623133,Infliximab,Vomiting,HO
177623133,Infliximab,Vomiting,OT
177623133,Infliximab,Visual impairment,HO
177623133,Infliximab,Visual impairment,OT
177623133,Infliximab,Therapeutic response shortened,HO
177623133,Infliximab,Therapeutic response shortened,OT
177623133,Infliximab,Red cell distribution width increased,HO
177623133,Infliximab,Red cell distribution width increased,OT
177623133,Infliximab,Rectal haemorrhage,HO
177623133,Infliximab,Rectal haemorrhage,OT
177623133,Infliximab,Rash pruritic,HO
177623133,Infliximab,Rash pruritic,OT
177623133,Infliximab,Pyrexia,HO
177623133,Infliximab,Pyrexia,OT
177623133,Infliximab,Protein urine present,HO
177623133,Infliximab,Protein urine present,OT
177623133,Infliximab,Product use issue,HO
177623133,Infliximab,Product use issue,OT
177623133,Infliximab,Proctalgia,HO
177623133,Infliximab,Proctalgia,OT
177623133,Infliximab,Pain,HO
177623133,Infliximab,Pain,OT
177623133,Infliximab,Off label use,HO
177623133,Infliximab,Off label use,OT
177623133,Infliximab,Nausea,HO
177623133,Infliximab,Nausea,OT
177623133,Infliximab,Mucous stools,HO
177623133,Infliximab,Mucous stools,OT
177623133,Infliximab,Migraine with aura,HO
177623133,Infliximab,Migraine with aura,OT
177623133,Infliximab,Malaise,HO
177623133,Infliximab,Malaise,OT
177623133,Infliximab,Lacrimation increased,HO
177623133,Infliximab,Lacrimation increased,OT
177623133,Infliximab,Intentional product use issue,HO
177623133,Infliximab,Intentional product use issue,OT
177623133,Infliximab,Infection,HO
177623133,Infliximab,Infection,OT
177623133,Infliximab,Inappropriate schedule of product administration,HO
177623133,Infliximab,Inappropriate schedule of product administration,OT
177623133,Infliximab,Hypokalaemia,HO
177623133,Infliximab,Hypokalaemia,OT
177623133,Infliximab,Heart rate irregular,HO
177623133,Infliximab,Heart rate irregular,OT
177623133,Infliximab,Heart rate increased,HO
177623133,Infliximab,Heart rate increased,OT
177623133,Infliximab,Haemoglobin urine present,HO
177623133,Infliximab,Haemoglobin urine present,OT
177623133,Infliximab,Gastrointestinal pain,HO
177623133,Infliximab,Gastrointestinal pain,OT
177623133,Infliximab,Frequent bowel movements,HO
177623133,Infliximab,Frequent bowel movements,OT
177623133,Infliximab,Fatigue,HO
177623133,Infliximab,Fatigue,OT
177623133,Infliximab,Fall,HO
177623133,Infliximab,Fall,OT
177623133,Infliximab,Faeces discoloured,HO
177623133,Infliximab,Faeces discoloured,OT
177623133,Infliximab,Faecal calprotectin increased,HO
177623133,Infliximab,Faecal calprotectin increased,OT
177623133,Infliximab,Extra dose administered,HO
177623133,Infliximab,Extra dose administered,OT
177623133,Infliximab,Exfoliative rash,HO
177623133,Infliximab,Exfoliative rash,OT
177623133,Infliximab,Drug level above therapeutic,HO
177623133,Infliximab,Drug level above therapeutic,OT
177623133,Infliximab,Drug ineffective,HO
177623133,Infliximab,Drug ineffective,OT
177623133,Infliximab,Diarrhoea haemorrhagic,HO
177623133,Infliximab,Diarrhoea haemorrhagic,OT
177623133,Infliximab,Diarrhoea,HO
177623133,Infliximab,Diarrhoea,OT
177623133,Infliximab,Defaecation urgency,HO
177623133,Infliximab,Defaecation urgency,OT
177623133,Infliximab,Decreased appetite,HO
177623133,Infliximab,Decreased appetite,OT
177623133,Infliximab,Contusion,HO
177623133,Infliximab,Contusion,OT
177623133,Infliximab,Constipation,HO
177623133,Infliximab,Constipation,OT
177623133,Infliximab,Condition aggravated,HO
177623133,Infliximab,Condition aggravated,OT
177623133,Infliximab,Colitis ulcerative,HO
177623133,Infliximab,Colitis ulcerative,OT
177623133,Infliximab,Cardiovascular disorder,HO
177623133,Infliximab,Cardiovascular disorder,OT
177623133,Infliximab,Body temperature increased,HO
177623133,Infliximab,Body temperature increased,OT
177623133,Infliximab,Blood pressure increased,HO
177623133,Infliximab,Blood pressure increased,OT
177623133,Infliximab,Blood pressure fluctuation,HO
177623133,Infliximab,Blood pressure fluctuation,OT
177623133,Infliximab,Blood iron decreased,HO
177623133,Infliximab,Blood iron decreased,OT
177623133,Infliximab,Blindness,HO
177623133,Infliximab,Blindness,OT
177623133,Infliximab,Anaemia,HO
177623133,Infliximab,Anaemia,OT
177623133,Infliximab,Abdominal tenderness,HO
177623133,Infliximab,Abdominal tenderness,OT
177623133,Infliximab,Abdominal pain,HO
177623133,Infliximab,Abdominal pain,OT
177623133,Infliximab,Abdominal distension,HO
177623133,Infliximab,Abdominal distension,OT
177623133,Infliximab,Abdominal discomfort,HO
177623133,Infliximab,Abdominal discomfort,OT
177623133,Infliximab,White blood cells urine positive,HO
177623133,Infliximab,White blood cells urine positive,OT
177623133,Infliximab,Weight decreased,HO
177623133,Infliximab,Weight decreased,OT
177623133,Infliximab,Vomiting,HO
177623133,Infliximab,Vomiting,OT
177623133,Infliximab,Visual impairment,HO
177623133,Infliximab,Visual impairment,OT
177623133,Infliximab,Therapeutic response shortened,HO
177623133,Infliximab,Therapeutic response shortened,OT
177623133,Infliximab,Red cell distribution width increased,HO
177623133,Infliximab,Red cell distribution width increased,OT
177623133,Infliximab,Rectal haemorrhage,HO
177623133,Infliximab,Rectal haemorrhage,OT
177623133,Infliximab,Rash pruritic,HO
177623133,Infliximab,Rash pruritic,OT
177623133,Infliximab,Pyrexia,HO
177623133,Infliximab,Pyrexia,OT
177623133,Infliximab,Protein urine present,HO
177623133,Infliximab,Protein urine present,OT
177623133,Infliximab,Product use issue,HO
177623133,Infliximab,Product use issue,OT
177623133,Infliximab,Proctalgia,HO
177623133,Infliximab,Proctalgia,OT
177623133,Infliximab,Pain,HO
177623133,Infliximab,Pain,OT
177623133,Infliximab,Off label use,HO
177623133,Infliximab,Off label use,OT
177623133,Infliximab,Nausea,HO
177623133,Infliximab,Nausea,OT
177623133,Infliximab,Mucous stools,HO
177623133,Infliximab,Mucous stools,OT
177623133,Infliximab,Migraine with aura,HO
177623133,Infliximab,Migraine with aura,OT
177623133,Infliximab,Malaise,HO
177623133,Infliximab,Malaise,OT
177623133,Infliximab,Lacrimation increased,HO
177623133,Infliximab,Lacrimation increased,OT
177623133,Infliximab,Intentional product use issue,HO
177623133,Infliximab,Intentional product use issue,OT
177623133,Infliximab,Infection,HO
177623133,Infliximab,Infection,OT
177623133,Infliximab,Inappropriate schedule of product administration,HO
177623133,Infliximab,Inappropriate schedule of product administration,OT
177623133,Infliximab,Hypokalaemia,HO
177623133,Infliximab,Hypokalaemia,OT
177623133,Infliximab,Heart rate irregular,HO
177623133,Infliximab,Heart rate irregular,OT
177623133,Infliximab,Heart rate increased,HO
177623133,Infliximab,Heart rate increased,OT
177623133,Infliximab,Haemoglobin urine present,HO
177623133,Infliximab,Haemoglobin urine present,OT
177623133,Infliximab,Gastrointestinal pain,HO
177623133,Infliximab,Gastrointestinal pain,OT
177623133,Infliximab,Frequent bowel movements,HO
177623133,Infliximab,Frequent bowel movements,OT
177623133,Infliximab,Fatigue,HO
177623133,Infliximab,Fatigue,OT
177623133,Infliximab,Fall,HO
177623133,Infliximab,Fall,OT
177623133,Infliximab,Faeces discoloured,HO
177623133,Infliximab,Faeces discoloured,OT
177623133,Infliximab,Faecal calprotectin increased,HO
177623133,Infliximab,Faecal calprotectin increased,OT
177623133,Infliximab,Extra dose administered,HO
177623133,Infliximab,Extra dose administered,OT
177623133,Infliximab,Exfoliative rash,HO
177623133,Infliximab,Exfoliative rash,OT
177623133,Infliximab,Drug level above therapeutic,HO
177623133,Infliximab,Drug level above therapeutic,OT
177623133,Infliximab,Drug ineffective,HO
177623133,Infliximab,Drug ineffective,OT
177623133,Infliximab,Diarrhoea haemorrhagic,HO
177623133,Infliximab,Diarrhoea haemorrhagic,OT
177623133,Infliximab,Diarrhoea,HO
177623133,Infliximab,Diarrhoea,OT
177623133,Infliximab,Defaecation urgency,HO
177623133,Infliximab,Defaecation urgency,OT
177623133,Infliximab,Decreased appetite,HO
177623133,Infliximab,Decreased appetite,OT
177623133,Infliximab,Contusion,HO
177623133,Infliximab,Contusion,OT
177623133,Infliximab,Constipation,HO
177623133,Infliximab,Constipation,OT
177623133,Infliximab,Condition aggravated,HO
177623133,Infliximab,Condition aggravated,OT
177623133,Infliximab,Colitis ulcerative,HO
177623133,Infliximab,Colitis ulcerative,OT
177623133,Infliximab,Cardiovascular disorder,HO
177623133,Infliximab,Cardiovascular disorder,OT
177623133,Infliximab,Body temperature increased,HO
177623133,Infliximab,Body temperature increased,OT
177623133,Infliximab,Blood pressure increased,HO
177623133,Infliximab,Blood pressure increased,OT
177623133,Infliximab,Blood pressure fluctuation,HO
177623133,Infliximab,Blood pressure fluctuation,OT
177623133,Infliximab,Blood iron decreased,HO
177623133,Infliximab,Blood iron decreased,OT
177623133,Infliximab,Blindness,HO
177623133,Infliximab,Blindness,OT
177623133,Infliximab,Anaemia,HO
177623133,Infliximab,Anaemia,OT
177623133,Infliximab,Abdominal tenderness,HO
177623133,Infliximab,Abdominal tenderness,OT
177623133,Infliximab,Abdominal pain,HO
177623133,Infliximab,Abdominal pain,OT
177623133,Infliximab,Abdominal distension,HO
177623133,Infliximab,Abdominal distension,OT
177623133,Infliximab,Abdominal discomfort,HO
177623133,Infliximab,Abdominal discomfort,OT
180771874,Infliximab,Weight decreased,HO
180771874,Infliximab,Urinary tract infection,HO
180771874,Infliximab,Product use issue,HO
180771874,Infliximab,Off label use,HO
180771874,Infliximab,Intentional product use issue,HO
180771874,Infliximab,Infection,HO
180771874,Infliximab,Inappropriate schedule of product administration,HO
180771874,Infliximab,Weight decreased,HO
180771874,Infliximab,Urinary tract infection,HO
180771874,Infliximab,Product use issue,HO
180771874,Infliximab,Off label use,HO
180771874,Infliximab,Intentional product use issue,HO
180771874,Infliximab,Infection,HO
180771874,Infliximab,Inappropriate schedule of product administration,HO
180771874,Infliximab,Weight decreased,HO
180771874,Infliximab,Urinary tract infection,HO
180771874,Infliximab,Product use issue,HO
180771874,Infliximab,Off label use,HO
180771874,Infliximab,Intentional product use issue,HO
180771874,Infliximab,Infection,HO
180771874,Infliximab,Inappropriate schedule of product administration,HO
183777752,Infliximab,Off label use,OT
183777752,Infliximab,Drug ineffective,OT
183777752,Infliximab,Diverticulitis,OT
183777752,Infliximab,Condition aggravated,OT
183777752,Infliximab,Blood pressure fluctuation,OT
183777752,Infliximab,Blood pressure diastolic increased,OT
184574413,Infliximab,Weight increased,OT
184574413,Infliximab,Rash macular,OT
184574413,Infliximab,Product use issue,OT
184574413,Infliximab,Pneumonia,OT
184574413,Infliximab,Pleurisy,OT
184574413,Infliximab,Off label use,OT
184574413,Infliximab,Fistula,OT
184574413,Infliximab,Condition aggravated,OT
184574413,Infliximab,Chest wall mass,OT
184574413,Infliximab,Chest pain,OT
184574413,Infliximab,Blood pressure increased,OT
184574413,Infliximab,Blood pressure fluctuation,OT
184574413,Infliximab,Weight increased,OT
184574413,Infliximab,Rash macular,OT
184574413,Infliximab,Product use issue,OT
184574413,Infliximab,Pneumonia,OT
184574413,Infliximab,Pleurisy,OT
184574413,Infliximab,Off label use,OT
184574413,Infliximab,Fistula,OT
184574413,Infliximab,Condition aggravated,OT
184574413,Infliximab,Chest wall mass,OT
184574413,Infliximab,Chest pain,OT
184574413,Infliximab,Blood pressure increased,OT
184574413,Infliximab,Blood pressure fluctuation,OT
184802653,Infliximab,Tooth infection,OT
184802653,Infliximab,Off label use,OT
184802653,Infliximab,Intentional product use issue,OT
184802653,Infliximab,Hypertension,OT
184802653,Infliximab,Condition aggravated,OT
184802653,Infliximab,Blood pressure increased,OT
184802653,Infliximab,Blood pressure fluctuation,OT
184802653,Infliximab,Arthralgia,OT
184865293,Infliximab,pH urine increased,OT
184865293,Infliximab,Sensation of foreign body,OT
184865293,Infliximab,Rectal haemorrhage,OT
184865293,Infliximab,Paraesthesia,OT
184865293,Infliximab,Oropharyngeal pain,OT
184865293,Infliximab,Off label use,OT
184865293,Infliximab,Nausea,OT
184865293,Infliximab,Nasal discomfort,OT
184865293,Infliximab,Magnetic resonance imaging abnormal,OT
184865293,Infliximab,Intentional product use issue,OT
184865293,Infliximab,Inappropriate schedule of product administration,OT
184865293,Infliximab,Hypoaesthesia,OT
184865293,Infliximab,Headache,OT
184865293,Infliximab,Haemoglobinuria,OT
184865293,Infliximab,Feeling abnormal,OT
184865293,Infliximab,Fatigue,OT
184865293,Infliximab,Dizziness,OT
184865293,Infliximab,Chills,OT
184865293,Infliximab,pH urine increased,OT
184865293,Infliximab,Sensation of foreign body,OT
184865293,Infliximab,Rectal haemorrhage,OT
184865293,Infliximab,Paraesthesia,OT
184865293,Infliximab,Oropharyngeal pain,OT
184865293,Infliximab,Off label use,OT
184865293,Infliximab,Nausea,OT
184865293,Infliximab,Nasal discomfort,OT
184865293,Infliximab,Magnetic resonance imaging abnormal,OT
184865293,Infliximab,Intentional product use issue,OT
184865293,Infliximab,Inappropriate schedule of product administration,OT
184865293,Infliximab,Hypoaesthesia,OT
184865293,Infliximab,Headache,OT
184865293,Infliximab,Haemoglobinuria,OT
184865293,Infliximab,Feeling abnormal,OT
184865293,Infliximab,Fatigue,OT
184865293,Infliximab,Dizziness,OT
184865293,Infliximab,Chills,OT
184865293,Infliximab,pH urine increased,OT
184865293,Infliximab,Sensation of foreign body,OT
184865293,Infliximab,Rectal haemorrhage,OT
184865293,Infliximab,Paraesthesia,OT
184865293,Infliximab,Oropharyngeal pain,OT
184865293,Infliximab,Off label use,OT
184865293,Infliximab,Nausea,OT
184865293,Infliximab,Nasal discomfort,OT
184865293,Infliximab,Magnetic resonance imaging abnormal,OT
184865293,Infliximab,Intentional product use issue,OT
184865293,Infliximab,Inappropriate schedule of product administration,OT
184865293,Infliximab,Hypoaesthesia,OT
184865293,Infliximab,Headache,OT
184865293,Infliximab,Haemoglobinuria,OT
184865293,Infliximab,Feeling abnormal,OT
184865293,Infliximab,Fatigue,OT
184865293,Infliximab,Dizziness,OT
184865293,Infliximab,Chills,OT
185915133,Infliximab,Maternal exposure during pregnancy,OT
185915133,Infliximab,Drug ineffective,OT
185915133,Infliximab,Crohn's disease,OT
189543442,Infliximab,Hodgkin's disease,OT
190603735,Infliximab,Therapeutic response unexpected,OT
190603735,Infliximab,Off label use,OT
190603735,Infliximab,Intentional product misuse,OT
190603735,Infliximab,Drug ineffective,OT
190603735,Infliximab,Crohn's disease,OT
192218832,Infliximab,Weight increased,OT
192218832,Infliximab,Skin lesion,OT
192218832,Infliximab,Pyrexia,OT
192218832,Infliximab,Purulent discharge,OT
192218832,Infliximab,Pain,OT
192218832,Infliximab,Off label use,OT
192218832,Infliximab,Impaired quality of life,OT
192218832,Infliximab,Heart rate decreased,OT
192218832,Infliximab,Haemorrhage,OT
192218832,Infliximab,Drug level above therapeutic,OT
192218832,Infliximab,Chills,OT
192218832,Infliximab,Abscess,OT
193496215,Infliximab Pfizer (Unknown),Liver function test decreased,HO
193496215,Infliximab Pfizer (Unknown),Liver function test decreased,OT
193496215,Infliximab Pfizer (Unknown),Interstitial lung disease,HO
193496215,Infliximab Pfizer (Unknown),Interstitial lung disease,OT
193496215,Infliximab Pfizer (Unknown),Dyspnoea,HO
193496215,Infliximab Pfizer (Unknown),Dyspnoea,OT
193496215,Infliximab Pfizer (Unknown),Drug ineffective,HO
193496215,Infliximab Pfizer (Unknown),Drug ineffective,OT
193496215,Infliximab Pfizer (Unknown),Disease recurrence,HO
193496215,Infliximab Pfizer (Unknown),Disease recurrence,OT
193496215,Infliximab Pfizer (Unknown),Cough,HO
193496215,Infliximab Pfizer (Unknown),Cough,OT
193496215,Infliximab Pfizer (Unknown),Liver function test decreased,HO
193496215,Infliximab Pfizer (Unknown),Liver function test decreased,OT
193496215,Infliximab Pfizer (Unknown),Interstitial lung disease,HO
193496215,Infliximab Pfizer (Unknown),Interstitial lung disease,OT
193496215,Infliximab Pfizer (Unknown),Dyspnoea,HO
193496215,Infliximab Pfizer (Unknown),Dyspnoea,OT
193496215,Infliximab Pfizer (Unknown),Drug ineffective,HO
193496215,Infliximab Pfizer (Unknown),Drug ineffective,OT
193496215,Infliximab Pfizer (Unknown),Disease recurrence,HO
193496215,Infliximab Pfizer (Unknown),Disease recurrence,OT
193496215,Infliximab Pfizer (Unknown),Cough,HO
193496215,Infliximab Pfizer (Unknown),Cough,OT
193820912,Infliximab,Weight increased,HO
193820912,Infliximab,Weight increased,OT
193820912,Infliximab,Therapeutic product effect incomplete,HO
193820912,Infliximab,Therapeutic product effect incomplete,OT
193820912,Infliximab,Pneumonia,HO
193820912,Infliximab,Pneumonia,OT
193820912,Infliximab,Off label use,HO
193820912,Infliximab,Off label use,OT
193820912,Infliximab,Malaise,HO
193820912,Infliximab,Malaise,OT
193820912,Infliximab,Inappropriate schedule of product administration,HO
193820912,Infliximab,Inappropriate schedule of product administration,OT
193820912,Infliximab,Heart rate decreased,HO
193820912,Infliximab,Heart rate decreased,OT
193820912,Infliximab,Gastrointestinal bacterial overgrowth,HO
193820912,Infliximab,Gastrointestinal bacterial overgrowth,OT
193820912,Infliximab,Diarrhoea,HO
193820912,Infliximab,Diarrhoea,OT
193820912,Infliximab,Condition aggravated,HO
193820912,Infliximab,Condition aggravated,OT
193820912,Infliximab,Blood pressure increased,HO
193820912,Infliximab,Blood pressure increased,OT
193820912,Infliximab,Blood pressure decreased,HO
193820912,Infliximab,Blood pressure decreased,OT
193820912,Infliximab,Arthralgia,HO
193820912,Infliximab,Arthralgia,OT
193820912,Infliximab,Abnormal faeces,HO
193820912,Infliximab,Abnormal faeces,OT
193820912,Infliximab,Weight increased,HO
193820912,Infliximab,Weight increased,OT
193820912,Infliximab,Therapeutic product effect incomplete,HO
193820912,Infliximab,Therapeutic product effect incomplete,OT
193820912,Infliximab,Pneumonia,HO
193820912,Infliximab,Pneumonia,OT
193820912,Infliximab,Off label use,HO
193820912,Infliximab,Off label use,OT
193820912,Infliximab,Malaise,HO
193820912,Infliximab,Malaise,OT
193820912,Infliximab,Inappropriate schedule of product administration,HO
193820912,Infliximab,Inappropriate schedule of product administration,OT
193820912,Infliximab,Heart rate decreased,HO
193820912,Infliximab,Heart rate decreased,OT
193820912,Infliximab,Gastrointestinal bacterial overgrowth,HO
193820912,Infliximab,Gastrointestinal bacterial overgrowth,OT
193820912,Infliximab,Diarrhoea,HO
193820912,Infliximab,Diarrhoea,OT
193820912,Infliximab,Condition aggravated,HO
193820912,Infliximab,Condition aggravated,OT
193820912,Infliximab,Blood pressure increased,HO
193820912,Infliximab,Blood pressure increased,OT
193820912,Infliximab,Blood pressure decreased,HO
193820912,Infliximab,Blood pressure decreased,OT
193820912,Infliximab,Arthralgia,HO
193820912,Infliximab,Arthralgia,OT
193820912,Infliximab,Abnormal faeces,HO
193820912,Infliximab,Abnormal faeces,OT
194566872,Infliximab,Intestinal obstruction,HO
194566872,Infliximab,Intestinal obstruction,OT
194566872,Infliximab,COVID-19,HO
194566872,Infliximab,COVID-19,OT
194566872,Infliximab,Abdominal pain,HO
194566872,Infliximab,Abdominal pain,OT
194595022,Infliximab,Steroid dependence,HO
194595022,Infliximab,Steroid dependence,OT
194595022,Infliximab,Off label use,HO
194595022,Infliximab,Off label use,OT
194595022,Infliximab,Drug ineffective,HO
194595022,Infliximab,Drug ineffective,OT
194595022,Infliximab,Steroid dependence,HO
194595022,Infliximab,Steroid dependence,OT
194595022,Infliximab,Off label use,HO
194595022,Infliximab,Off label use,OT
194595022,Infliximab,Drug ineffective,HO
194595022,Infliximab,Drug ineffective,OT
194941511,Infliximab,Drug ineffective,HO
194941511,Infliximab,Drug ineffective,HO
195894411,Infliximab,Weight decreased,OT
195894411,Infliximab,Vertigo,OT
195894411,Infliximab,Uveitis,OT
195894411,Infliximab,Therapeutic response shortened,OT
195894411,Infliximab,Systemic viral infection,OT
195894411,Infliximab,Off label use,OT
195894411,Infliximab,Influenza,OT
195894411,Infliximab,Eye infection,OT
195894411,Infliximab,Dizziness,OT
195894411,Infliximab,Conjunctivitis,OT
195894411,Infliximab,Condition aggravated,OT
195894411,Infliximab,Cardiac disorder,OT
195894411,Infliximab,Blood pressure increased,OT
195894411,Infliximab,Arthralgia,OT
196098621,Infliximab,Upper respiratory tract infection,OT
196098621,Infliximab,Therapeutic response shortened,OT
196098621,Infliximab,Therapeutic product effect incomplete,OT
196098621,Infliximab,Spinal osteoarthritis,OT
196098621,Infliximab,Retching,OT
196098621,Infliximab,Peripheral swelling,OT
196098621,Infliximab,Osteoarthritis,OT
196098621,Infliximab,Off label use,OT
196098621,Infliximab,Nausea,OT
196098621,Infliximab,Nasopharyngitis,OT
196098621,Infliximab,Intervertebral disc space narrowing,OT
196098621,Infliximab,Intervertebral disc protrusion,OT
196098621,Infliximab,Intentional product use issue,OT
196098621,Infliximab,Hypertension,OT
196098621,Infliximab,Heart rate decreased,OT
196098621,Infliximab,Dysphonia,OT
196098621,Infliximab,Cough,OT
196098621,Infliximab,Condition aggravated,OT
196098621,Infliximab,Cervical spinal stenosis,OT
196098621,Infliximab,Carpal tunnel syndrome,OT
196098621,Infliximab,Body temperature decreased,OT
196098621,Infliximab,Blood pressure fluctuation,OT
196098621,Infliximab,Abdominal pain upper,OT
196098621,Infliximab,Upper respiratory tract infection,OT
196098621,Infliximab,Therapeutic response shortened,OT
196098621,Infliximab,Therapeutic product effect incomplete,OT
196098621,Infliximab,Spinal osteoarthritis,OT
196098621,Infliximab,Retching,OT
196098621,Infliximab,Peripheral swelling,OT
196098621,Infliximab,Osteoarthritis,OT
196098621,Infliximab,Off label use,OT
196098621,Infliximab,Nausea,OT
196098621,Infliximab,Nasopharyngitis,OT
196098621,Infliximab,Intervertebral disc space narrowing,OT
196098621,Infliximab,Intervertebral disc protrusion,OT
196098621,Infliximab,Intentional product use issue,OT
196098621,Infliximab,Hypertension,OT
196098621,Infliximab,Heart rate decreased,OT
196098621,Infliximab,Dysphonia,OT
196098621,Infliximab,Cough,OT
196098621,Infliximab,Condition aggravated,OT
196098621,Infliximab,Cervical spinal stenosis,OT
196098621,Infliximab,Carpal tunnel syndrome,OT
196098621,Infliximab,Body temperature decreased,OT
196098621,Infliximab,Blood pressure fluctuation,OT
196098621,Infliximab,Abdominal pain upper,OT
196240401,Infliximab,Weight decreased,OT
196240401,Infliximab,Urine abnormality,OT
196240401,Infliximab,Pruritus,OT
196240401,Infliximab,Off label use,OT
196240401,Infliximab,Nausea,OT
196240401,Infliximab,Myalgia,OT
196240401,Infliximab,Malaise,OT
196240401,Infliximab,Infusion site extravasation,OT
196240401,Infliximab,Inappropriate schedule of product administration,OT
196240401,Infliximab,Hand dermatitis,OT
196240401,Infliximab,Drug level abnormal,OT
196240401,Infliximab,Cough,OT
196240401,Infliximab,Blood pressure increased,OT
196240401,Infliximab,Acne,OT
196581263,Infliximab (Unknown),Vertigo,HO
196581263,Infliximab (Unknown),Treatment failure,HO
196581263,Infliximab (Unknown),Product use in unapproved indication,HO
196581263,Infliximab (Unknown),Off label use,HO
196581263,Infliximab (Unknown),Nausea,HO
196581263,Infliximab (Unknown),Headache,HO
196581263,Infliximab (Unknown),Drug resistance,HO
196581263,Infliximab (Unknown),Drug intolerance,HO
196581263,Infliximab (Unknown),Colitis ulcerative,HO
196805571,Infliximab,Off label use,OT
196805571,Infliximab,Off label use,DE
196805571,Infliximab,Injection site mass,OT
196805571,Infliximab,Injection site mass,DE
196805571,Infliximab,Injection site extravasation,OT
196805571,Infliximab,Injection site extravasation,DE
196805571,Infliximab,Headache,OT
196805571,Infliximab,Headache,DE
196805571,Infliximab,Haematoma,OT
196805571,Infliximab,Haematoma,DE
196805571,Infliximab,Food poisoning,OT
196805571,Infliximab,Food poisoning,DE
196805571,Infliximab,Cataract,OT
196805571,Infliximab,Cataract,DE
196805571,Infliximab,Cardiac arrest,OT
196805571,Infliximab,Cardiac arrest,DE
197390531,Infliximab,Weight increased,OT
197390531,Infliximab,Furuncle,OT
197390531,Infliximab,Escherichia infection,OT
197390531,Infliximab,Drug ineffective,OT
197390531,Infliximab,Cushingoid,OT
197390531,Infliximab,Colitis ulcerative,OT
197390531,Infliximab,Central obesity,OT
197390531,Infliximab,Cellulitis,OT
197390531,Infliximab,Cataract,OT
197390531,Infliximab,Bacterial vulvovaginitis,OT
197390531,Infliximab,Bacillus infection,OT
197521442,Infliximab,Product use issue,HO
197521442,Infliximab,Product use issue,OT
197521442,Infliximab,Product use in unapproved indication,HO
197521442,Infliximab,Product use in unapproved indication,OT
197521442,Infliximab,Off label use,HO
197521442,Infliximab,Off label use,OT
197521442,Infliximab,Labelled drug-disease interaction medication error,HO
197521442,Infliximab,Labelled drug-disease interaction medication error,OT
197521442,Infliximab,Haematuria,HO
197521442,Infliximab,Haematuria,OT
197521442,Infliximab,Contraindicated product administered,HO
197521442,Infliximab,Contraindicated product administered,OT
197521442,Infliximab,Acute kidney injury,HO
197521442,Infliximab,Acute kidney injury,OT
197521442,Infliximab,Product use issue,HO
197521442,Infliximab,Product use issue,OT
197521442,Infliximab,Product use in unapproved indication,HO
197521442,Infliximab,Product use in unapproved indication,OT
197521442,Infliximab,Off label use,HO
197521442,Infliximab,Off label use,OT
197521442,Infliximab,Labelled drug-disease interaction medication error,HO
197521442,Infliximab,Labelled drug-disease interaction medication error,OT
197521442,Infliximab,Haematuria,HO
197521442,Infliximab,Haematuria,OT
197521442,Infliximab,Contraindicated product administered,HO
197521442,Infliximab,Contraindicated product administered,OT
197521442,Infliximab,Acute kidney injury,HO
197521442,Infliximab,Acute kidney injury,OT
197521442,Infliximab,Product use issue,HO
197521442,Infliximab,Product use issue,OT
197521442,Infliximab,Product use in unapproved indication,HO
197521442,Infliximab,Product use in unapproved indication,OT
197521442,Infliximab,Off label use,HO
197521442,Infliximab,Off label use,OT
197521442,Infliximab,Labelled drug-disease interaction medication error,HO
197521442,Infliximab,Labelled drug-disease interaction medication error,OT
197521442,Infliximab,Haematuria,HO
197521442,Infliximab,Haematuria,OT
197521442,Infliximab,Contraindicated product administered,HO
197521442,Infliximab,Contraindicated product administered,OT
197521442,Infliximab,Acute kidney injury,HO
197521442,Infliximab,Acute kidney injury,OT
197602931,Infliximab,Off label use,OT
197602931,Infliximab,Gastrointestinal pain,OT
197602931,Infliximab,Drug ineffective,OT
197602931,Infliximab,Condition aggravated,OT
197760871,Infliximab,Weight increased,OT
197760871,Infliximab,Weight increased,HO
197760871,Infliximab,Pruritus,OT
197760871,Infliximab,Pruritus,HO
197760871,Infliximab,Off label use,OT
197760871,Infliximab,Off label use,HO
197760871,Infliximab,Myocardial infarction,OT
197760871,Infliximab,Myocardial infarction,HO
197760871,Infliximab,Heart rate irregular,OT
197760871,Infliximab,Heart rate irregular,HO
197760871,Infliximab,Heart rate increased,OT
197760871,Infliximab,Heart rate increased,HO
197760871,Infliximab,Dizziness,OT
197760871,Infliximab,Dizziness,HO
197760871,Infliximab,Coronary artery occlusion,OT
197760871,Infliximab,Coronary artery occlusion,HO
197760871,Infliximab,Cardiac disorder,OT
197760871,Infliximab,Cardiac disorder,HO
197760871,Infliximab,Blood pressure fluctuation,OT
197760871,Infliximab,Blood pressure fluctuation,HO
197869471,Infliximab,Weight increased,OT
197869471,Infliximab,Blood pressure systolic increased,OT
197886851,Infliximab,Off label use,OT
197886851,Infliximab,Intentional product use issue,OT
197886851,Infliximab,Heart rate irregular,OT
197886851,Infliximab,Dyspnoea,OT
197886851,Infliximab,Condition aggravated,OT
197886851,Infliximab,Abdominal pain upper,OT
198059931,Infliximab,Off label use,OT
198059931,Infliximab,Off label use,HO
198059931,Infliximab,Intentional product use issue,OT
198059931,Infliximab,Intentional product use issue,HO
198059931,Infliximab,Inappropriate schedule of product administration,OT
198059931,Infliximab,Inappropriate schedule of product administration,HO
198059931,Infliximab,Blood pressure fluctuation,OT
198059931,Infliximab,Blood pressure fluctuation,HO
198059931,Infliximab,Abscess,OT
198059931,Infliximab,Abscess,HO
198059931,Infliximab,Off label use,OT
198059931,Infliximab,Off label use,HO
198059931,Infliximab,Intentional product use issue,OT
198059931,Infliximab,Intentional product use issue,HO
198059931,Infliximab,Inappropriate schedule of product administration,OT
198059931,Infliximab,Inappropriate schedule of product administration,HO
198059931,Infliximab,Blood pressure fluctuation,OT
198059931,Infliximab,Blood pressure fluctuation,HO
198059931,Infliximab,Abscess,OT
198059931,Infliximab,Abscess,HO
198294481,Infliximab,Product use issue,OT
198294481,Infliximab,Off label use,OT
198294481,Infliximab,Intentional product use issue,OT
198294481,Infliximab,Inappropriate schedule of product administration,OT
198294481,Infliximab,Hypotension,OT
198294481,Infliximab,Eye infection,OT
198294481,Infliximab,Condition aggravated,OT
198368452,Infliximab,Pulmonary mucormycosis,OT
198368452,Infliximab,Off label use,OT
198408351,Infliximab,Urinary tract infection bacterial,OT
198408351,Infliximab,Off label use,OT
198408351,Infliximab,Lower respiratory tract infection,OT
198408351,Infliximab,Intentional product use issue,OT
198408351,Infliximab,Drug level below therapeutic,OT
198408351,Infliximab,Drug ineffective,OT
198408351,Infliximab,Cough,OT
198408351,Infliximab,Condition aggravated,OT
198450711,Infliximab,Drug ineffective,OT
198450711,Infliximab,Colitis ulcerative,OT
198476181,Infliximab,Off label use,OT
198476181,Infliximab,Injury,OT
198476181,Infliximab,Inappropriate schedule of product administration,OT
198476181,Infliximab,Foot fracture,OT
198715761,Infliximab,Haemophagocytic lymphohistiocytosis,DE
198715761,Infliximab,Haemophagocytic lymphohistiocytosis,HO
198729211,Infliximab,Off label use,OT
198729211,Infliximab,Inappropriate schedule of product administration,OT
198729211,Infliximab,Heart rate decreased,OT
198729211,Infliximab,Condition aggravated,OT
198729211,Infliximab,Blood pressure fluctuation,OT
198729211,Infliximab,Blood pressure diastolic decreased,OT
198785571,Infliximab (Unknown),Off label use,NULL
198785571,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198785571,Infliximab (Unknown),Off label use,NULL
198785571,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198785571,Infliximab (Unknown),Off label use,NULL
198785571,Infliximab (Unknown),Drug effective for unapproved indication,NULL
198785571,Infliximab (Unknown),Off label use,NULL
198785571,Infliximab (Unknown),Drug effective for unapproved indication,NULL
